Drug.Name,Synonyms,ChEMBL ID,IDs,referenced_datasets,MOA,repurposing_target,Indication,Disease Area,Phase(RepHub),merge_issues,Type,Phase(ChEMBL),Inchi Key,SMILES
BDF00016096,AOB2221;BDF00016096,,GDSC1:1530;GDSC2:1620,gdsc,,,,,,,,NA,,
TEMSIROLIMUS,AY-22989;CCI-779;TEMSIROLIMUS,CHEMBL1201182;CHEMBL413,BRD:BRD-BRD-K42898655-001-01-8;BRD:BRD-K42898655-001-01-8;CTRP:660358;GDSC1:1016;GDSC1:3;GDSC2:1084,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,RENAL CELL CARCINOMA (RCC),,LAUNCHED,,Small molecule,Approved,CBPNZQVSJQDFBE-FUXHJELOSA-N;QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
PFI3,PFI 3;PFI3,,GDSC2:1620,gdsc,,,,,,,,NA,,
WY-090217,RAPAMUNE;RAPAMYCIN;SIROLIMUS;WY-090217,CHEMBL2107380;CHEMBL413,BRD:BRD-A79768653-001-12-0;BRD:BRD-BRD-A79768653-001-12-0;BRD:BRD-BRD-K84937637-001-09-9;BRD:BRD-K84937637-001-09-9;CTRP:56703;GDSC1:3;GDSC2:1084,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,FGF2;FKBP1A;MTOR,"ORGAN REJECTION, LYMPHANGIOLEIOMYOMATOSIS",,LAUNCHED,,Small molecule,Approved,QFJCIRLUMZQUOT-HPLJOQBZSA-N;YYSFXUWWPNHNAZ-PKJQJFMNSA-N,CCOCCO[C@@H]1CC[C@@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC;CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C;COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O
(+)-CAMPTOTHECIN,(+)-CAMPTOTHECIN,,GDSC2:1003,gdsc,,,,,,,,NA,,
(+)-IRINOTECAN,(+)-IRINOTECAN,,GDSC2:1088,gdsc,,,,,,,,NA,,
(+)-JQ-1,(+)-JQ-1,,GDSC1:1218;GDSC1:163;GDSC2:2172,gdsc,,,,,,,,NA,,
(5Z)-7-OXOZEAENOL,(5Z)-7-OXOZEAENOL,,GDSC1:1242,gdsc,,,,,,,,NA,,
R(-)-APOMORPHINE,(R)-(-)-APOMORPHINE;R(-)-APOMORPHINE,,BRD:BRD-BRD-K76022557-003-02-7;BRD:BRD-K76022557-003-02-7,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C;CALY;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR5A,PARKINSON'S DISEASE,,LAUNCHED,"Multiple values for repurposing_target: {'ADRA2A;ADRA2B;ADRA2C;CALY;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR5A', 'DRD2;HTR5A'}, taking the union",,NA,,CN1CCC2CCCC-3C2[C@H]1CC1CCC(O)C(O)C-31;CN1CCC2CCCC-3C2C1CC1CCC(O)C(O)C-31
ROLIPRAM-R(-),(R)-(-)-ROLIPRAM;ROLIPRAM-R(-),,BRD:BRD-BRD-K75516118-001-03-3;BRD:BRD-K75516118-001-03-3,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4C;PDE4D;PDE5A,,,PRECLINICAL,,,NA,,COC1CCC(CC1OC1CCCC1)[C@@H]1CNC(=O)C1
BACLOFEN-(R),(R)-BACLOFEN;BACLOFEN-(R),CHEMBL301742,BRD:BRD-BRD-K62353271-001-04-7;BRD:BRD-K62353271-001-04-7,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABBR1;GABBR2,,,PRECLINICAL,,Small molecule,Phase 3,KPYSYYIEGFHWSV-QMMMGPOBSA-N,NC[C@H](CC(=O)O)C1CCC(CL)CC1;NC[C@H](CC(O)=O)C1CCC(CL)CC1
(RAC)-TAVAPADON,(RAC)-TAVAPADON,,BRD:BRD-K00090657-001-01-9,rep_single_dose,,,,,,,,NA,,
"1,12-BESM","1,12-BESM",CHEMBL18794,BRD:BRD-BRD-K04603573-376-01-3;BRD:BRD-K04603573-376-01-3,rep_primary;rep_single_dose,POLYAMINE BIOSYNTHESIS INHIBITOR,,,,PHASE 2,,Small molecule,NA,PGMIWVSHZMWSSI-UHFFFAOYSA-N,CCNCCCNCCCCNCCCNCC
"1,3-DIPROPYL-8-PHENYLXANTHINE","1,3-DIPROPYL-8-PHENYLXANTHINE",,BRD:BRD-BRD-K41853443-001-02-9;BRD:BRD-K41853443-001-02-9,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CCCN1C2[NH]C(NC2C(=O)N(CCC)C1=O)-C1CCCCC1
"1,4-BUTANEDIOL","1,4-BUTANEDIOL",CHEMBL171623,BRD:BRD-K22346679-001-06-3,rep_single_dose,"BENZODIAZEPINE RECEPTOR AGONIST, GAMMA HYDROXYBUTYRIC ACID AGONIST",MAN1B1;PLA2G2A;PLA2G2E,,,,,Small molecule,NA,WERYXYBDKMZEQL-UHFFFAOYSA-N,OCCCCO
"1,5-DICAFFEOYLQUINIC-ACID","1,5-DICAFFEOYLQUINIC-ACID",,BRD:BRD-BRD-K53083666-001-01-0;BRD:BRD-K53083666-001-01-0,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\C2CCC(O)C(O)C2)[C@@H]1O)(OC(=O)\C=C\C1CCC(O)C(O)C1)C(O)=O
"1-((Z)-3-CHLOROALLYL)-1,3,5,7-TETRAAZAADAMANTAN-1-IUM","1-((Z)-3-CHLOROALLYL)-1,3,5,7-TETRAAZAADAMANTAN-1-IUM",,BRD:BRD-BRD-K88956297-003-01-9;BRD:BRD-K88956297-003-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CL\C=C/C[N+]12CN3CN(CN(C3)C1)C2
"1-(1,2-DIPHENYLETHYL)PIPERIDINE-(+/-)","1-(1,2-DIPHENYLETHYL)PIPERIDINE-(+/-)",,BRD:BRD-A86415025-050-01-0;BRD:BRD-BRD-A86415025-050-01-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,C(C(N1CCCCC1)C1CCCCC1)C1CCCCC1
1-ACETYL-4-METHYLPIPERAZINE,1-ACETYL-4-METHYLPIPERAZINE,,BRD:BRD-BRD-K96055017-003-02-7;BRD:BRD-K96055017-003-02-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C(C)=O
1-AZAKENPAULLONE,1-AZAKENPAULLONE,,BRD:BRD-BRD-K03273112-001-01-8;BRD:BRD-K03273112-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,CCNB1;CDK1;CDK5;GSK3B,,,PRECLINICAL,,,NA,,BRC1CCC2[NH]C-3C(CC(=O)NC4CCCNC-34)C2C1
1-DEOXYMANNOJIRIMYCIN,1-DEOXYMANNOJIRIMYCIN,CHEMBL84844,BRD:BRD-BRD-K89665618-003-02-5;BRD:BRD-K89665618-003-02-5,rep_primary;rep_single_dose,ALPHA MANNOSIDASE INHIBITOR,MAN2A1,,,PRECLINICAL,,Small molecule,NA,LXBIFEVIBLOUGU-KVTDHHQDSA-N,OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O
1-EBIO,1-EBIO,,BRD:BRD-BRD-K70586315-001-02-4;BRD:BRD-K70586315-001-02-4,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNN1;KCNN2;KCNN3;KCNN4,,,PRECLINICAL,,,NA,,CCN1C2CCCCC2[NH]C1=O
1-ETHYL-2-PYRROLIDONE,1-ETHYL-2-PYRROLIDONE,,BRD:BRD-BRD-K08288352-001-03-6;BRD:BRD-K08288352-001-03-6,rep_primary;rep_single_dose,TRANSDERMAL ABSORPTION-ENHANCING COMPOUND,,,,PRECLINICAL,,,NA,,CCN1CCCC1=O
1-HEXADECANOL,1-HEXADECANOL,,BRD:BRD-BRD-K37203094-001-02-5;BRD:BRD-K37203094-001-02-5,rep_primary;rep_single_dose,,,COSMETIC,,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCCO
1-NAPHTHYL-PP1,1-NAPHTHYL-PP1,,BRD:BRD-BRD-K29542628-001-03-9;BRD:BRD-K29542628-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,SRC INHIBITOR,SRC,,,PRECLINICAL,,,NA,,CC(C)(C)N1NC(-C2CCCC3CCCCC23)C2C(N)NCNC12
1-OCTANOL,1-OCTANOL,CHEMBL26215,BRD:BRD-BRD-K09338665-001-07-1;BRD:BRD-K09338665-001-07-1,rep_primary;rep_single_dose,,GJA1;GJA10;GJA3;GJA4;GJA5;GJA8;GJA9;GJB1;GJB2;GJB3;GJB4;GJB5;GJB6;GJB7;GJC1;GJC2;GJC3;GJD2;GJD3;GJD4;GJE1,,,PHASE 2,,Small molecule,Phase 2,KBPLFHHGFOOTCA-UHFFFAOYSA-N,CCCCCCCCO
1-PHENYLBIGUANIDE,1-PHENYLBIGUANIDE,CHEMBL13791,BRD:BRD-BRD-K31491153-003-05-9;BRD:BRD-K31491153-003-05-9,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR3A;HTR3B,,,PRECLINICAL,,Small molecule,NA,CUQCMXFWIMOWRP-UHFFFAOYSA-N,N=C(N)NC(=N)NC1CCCCC1;NC(=N)NC(=N)NC1CCCCC1
10-DEACETYLBACCATIN,10-DEACETYLBACCATIN,,BRD:BRD-BRD-K96631475-001-02-4;BRD:BRD-BRD-K96631475-001-04-0;BRD:BRD-K96631475-001-02-4;BRD:BRD-K96631475-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,ANTITUMOR AGENT,,,,PRECLINICAL,,,NA,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2CCCCC2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C
10-DEBC,10-DEBC,,BRD:BRD-BRD-K70792160-003-04-6;BRD:BRD-K70792160-003-04-6,rep_primary;rep_single_dose,AKT INHIBITOR,PIM1,,,PRECLINICAL,,,NA,,CCN(CC)CCCCN1C2CCCCC2OC2CCC(CL)CC12
10-HYDROXYCAMPTOTHECIN,10-HYDROXYCAMPTOTHECIN,CHEMBL273862,BRD:BRD-BRD-K63784565-001-06-2;BRD:BRD-K63784565-001-06-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PRECLINICAL,,Small molecule,Phase 3,HAWSQZCWOQZXHI-FQEVSTJZSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1-C3NC4CCC(O)CC4CC3CN1C2=O;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3CC(O)CCC3NC2-1
10058-F4,10058-F4,,BRD:BRD-BRD-K49460120-001-02-5;BRD:BRD-K49460120-001-02-5,rep_primary;rep_single_dose,C-MYC INHIBITOR,,,,PRECLINICAL,,,NA,,CCC1CCC(CC1)\C=C1\SC(=S)NC1=O
1035270-39-3,1035270-39-3,,GDSC2:1786,gdsc,,,,,,,,NA,,
1044870-39-4,1044870-39-4,,GDSC2:1625,gdsc,,,,,,,,NA,,
1080622-86-1,1080622-86-1,,GDSC1:152,gdsc,,,,,,,,NA,,
12-O-TETRADECANOYLPHORBOL-13-ACETATE,12-O-TETRADECANOYLPHORBOL-13-ACETATE,,BRD:BRD-BRD-K68552125-001-05-3;BRD:BRD-K68552125-001-05-3,rep_multi_dose;rep_primary;rep_single_dose,PKC ACTIVATOR,KCNT2;TRPV4,,,PHASE 2,,,NA,,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O
1400W,1400W,CHEMBL107251,BRD:BRD-BRD-K30237152-300-02-5;BRD:BRD-K30237152-300-02-5,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1;NOS2;NOS3,,,PRECLINICAL,,Small molecule,NA,RODUKNYOEVZQPR-UHFFFAOYSA-N,CC(=N)NCC1CCCC(CN)C1
"16,16-DIMETHYLPROSTAGLANDIN-E2","16,16-DIMETHYLPROSTAGLANDIN-E2",,BRD:BRD-BRD-K92301463-001-05-5;BRD:BRD-K92301463-001-05-5,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,HPGD,,,PHASE 2,,,NA,,CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
16-BETA-BROMOANDROSTERONE,16-BETA-BROMOANDROSTERONE,,CTRP:411726,ctrp,,,,,,,,NA,,
17-AAG,17-AAG,CHEMBL109480,GDSC1:1026,gdsc,,,,,,,Small molecule,Phase 3,AYUNIORJHRXIBJ-TXHRRWQRSA-N,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O
17-ALPHA-METHYLTESTOSTERONE,17-ALPHA-METHYLTESTOSTERONE,,BRD:BRD-BRD-K84036904-001-08-8;BRD:BRD-K84036904-001-08-8,rep_primary;rep_single_dose,AROMATASE INHIBITOR,AR,,,LAUNCHED,,,NA,,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
17-HYDROXYPROGESTERONE-CAPROATE,17-HYDROXYPROGESTERONE-CAPROATE,,BRD:BRD-A29731977-001-04-5;BRD:BRD-BRD-A29731977-001-04-5,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,AR;ESR1;ESR2;NR1H4;NR1I2;NR3C1;PGR,,,LAUNCHED,,,NA,,CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O
17-PA,17-PA,,BRD:BRD-K07395323-001-02-9,rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,,,,,,,NA,,
1E-1-(2-HYDROXY-5-METHYLPHENYL)-1-DODECANONE-OXIME,1E-1-(2-HYDROXY-5-METHYLPHENYL)-1-DODECANONE OXIME;1E-1-(2-HYDROXY-5-METHYLPHENYL)-1-DODECANONE-OXIME,,BRD:BRD-A37752546-001-01-9;BRD:BRD-A37752546-001-02-9;BRD:BRD-BRD-A37752546-001-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCCCCCCC([N+][O-])C1CC(C)CCC1O
"1S,2R-PHENYLPROPANOLAMINE","1S,2R-PHENYLPROPANOLAMINE",,BRD:BRD-BRD-K27853494-003-04-7;BRD:BRD-K27853494-003-04-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA2A;ADRB1;ADRB2;DRD1,,,WITHDRAWN,,,NA,,C[C@@H](N)[C@@H](O)C1CCCCC1
"1S,3R-RSL-3","1S,3R-RSL-3",,CTRP:609060,ctrp,,,,,,,,NA,,
2'-C-METHYLGUANOSINE,2'-C-METHYLGUANOSINE,CHEMBL418899,BRD:BRD-BRD-K78092779-001-01-6;BRD:BRD-K78092779-001-01-6,rep_primary;rep_single_dose,HCV INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,NVKAMPJSWMHVDK-GITKWUPZSA-N,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1CNC2C(=O)[NH]C(N)NC21;C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1CNC2C(O)NC(N)NC12
2'-MECCPA,2'-MECCPA,,BRD:BRD-BRD-K63932022-001-01-5;BRD:BRD-K63932022-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,,,PRECLINICAL,,,NA,,C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1CNC2C(NC3CCCC3)NC(CL)NC12
"2,3-DCPE","2,3-DCPE",,BRD:BRD-BRD-K61734568-003-02-1;BRD:BRD-K61734568-003-02-1,rep_multi_dose;rep_primary;rep_single_dose,BCL-XL DOWNREGULATOR,BCL2L1,,,PRECLINICAL,,,NA,,OCCNCCCOC1CCCC(CL)C1CL
"2,4-DIHYDROXYPYRIMIDINE-5-CARBOXYLIC ACID","2,4-DIHYDROXYPYRIMIDINE-5-CARBOXYLIC ACID",,BRD:BRD-K00078070-001-02-9,rep_single_dose,,,,,,,,NA,,
"2,4-DINITROPHENOL","2,4-DINITROPHENOL",CHEMBL273386,BRD:BRD-BRD-K21910317-001-12-3;BRD:BRD-K21910317-001-12-3,rep_primary;rep_single_dose,ATP SYNTHASE INHIBITOR,APP,,,PRECLINICAL,,Small molecule,Phase 2,UFBJCMHMOXMLKC-UHFFFAOYSA-N,O=[N+]([O-])C1CCC(O)C([N+](=O)[O-])C1;OC1CCC(CC1[N+]([O-])=O)[N+]([O-])=O
"2,6-DIMETHYLPIPERIDINE","2,6-DIMETHYLPIPERIDINE",CHEMBL2104431,BRD:BRD-A21276153-001-01-1;BRD:BRD-BRD-A21276153-001-01-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,SDGKUVSVPIIUCF-UHFFFAOYSA-N,CC1CCCC(C)N1
2-(3-MERCAPTOPROPYL)PENTANEDIOIC-ACID,2-(3-MERCAPTOPROPYL)PENTANEDIOIC ACID;2-(3-MERCAPTOPROPYL)PENTANEDIOIC-ACID,,BRD:BRD-A66788520-001-01-7;BRD:BRD-BRD-A66788520-001-01-7,rep_primary;rep_single_dose,GLUTAMATE CARBOXYPEPTIDASE INHIBITOR,FOLH1,,,PHASE 1,,,NA,,OC(=O)CCC(CCCS)C(O)=O
2-AMINOBENZENESULFONAMIDE,2-AMINOBENZENESULFONAMIDE,,BRD:BRD-BRD-K32681104-001-11-6;BRD:BRD-K32681104-001-11-6,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA12;CA14;CA2;CA6;CA9,,,PRECLINICAL,,,NA,,NC1CCCCC1S(N)(=O)=O
2-BENZYL-4-CHLOROPHENOL,2-BENZYL-4-CHLOROPHENOL,,BRD:BRD-K83982397-001-06-9,rep_single_dose,,,,,,,,NA,,
2-BFI,2-BFI,,BRD:BRD-BRD-K22745370-003-02-3;BRD:BRD-K22745370-003-02-3,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR LIGAND,ADRA2A;ADRA2B;ADRA2C;MAOA;MAOB,,,PRECLINICAL,,,NA,,C1CN=C(N1)C1CC2CCCCC2O1
2-CHLORO-N6-CYCLOPENTYLADENOSINE,2-CHLORO-N6-CYCLOPENTYLADENOSINE,,BRD:BRD-BRD-K70088346-001-01-6;BRD:BRD-K70088346-001-01-6,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(NC3CCCC3)NC(CL)NC12
2-CHLOROADENOSINE,2-CHLOROADENOSINE,,BRD:BRD-BRD-K79511609-001-20-0;BRD:BRD-K79511609-001-20-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B,,,PRECLINICAL,,,NA,,NC1NC(CL)NC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
2-CHLOROPYRAZINE,2-CHLOROPYRAZINE,,BRD:BRD-BRD-K84075000-001-05-5;BRD:BRD-K84075000-001-05-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CLC1CNCCN1
2-CMDO,2-CMDO,,BRD:BRD-BRD-K92588747-051-02-7;BRD:BRD-K92588747-051-02-7,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD4,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1=CC2CCCCC2OC2CCC(CL)CC12
2-CYANOPYRIMIDINE,2-CYANOPYRIMIDINE,,BRD:BRD-BRD-K95015809-001-02-8;BRD:BRD-K95015809-001-02-8,rep_primary;rep_single_dose,CATHEPSIN INHIBITOR,,,,PRECLINICAL,,,NA,,N#CC1NCCCN1
2-DEOXYGLUCOSE,2-DEOXYGLUCOSE,,BRD:BRD-BRD-K97808269-001-02-7;BRD:BRD-K97808269-001-02-7,rep_primary;rep_single_dose,GLYCOLYSIS INHIBITOR,SLC2A1;SLC2A2;SLC2A3;SLC2A4,,,PHASE 2,,,NA,,OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O
2-ETHOXYBENZOIC-ACID,2-ETHOXYBENZOIC-ACID,,BRD:BRD-BRD-K04843302-001-02-5;BRD:BRD-K04843302-001-02-5,rep_primary;rep_single_dose,ANALGESIC AGENT,,,,PHASE 1,,,NA,,CCOC1CCCCC1C(O)=O
"2-ETHYL-1,3-HEXANEDIOL","2-ETHYL-1,3-HEXANEDIOL",,BRD:BRD-A55455283-001-01-3;BRD:BRD-BRD-A55455283-001-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCC(O)C(CC)CO
2-ETHYLHEXYL 4-(DIMETHYLAMINO)BENZOATE,2-ETHYLHEXYL 4-(DIMETHYLAMINO)BENZOATE,,BRD:BRD-A49924714-001-08-9,rep_single_dose,,,,,,,,NA,,
2-FLUORO-2-DEOXY-D-GALACTOSE,2-FLUORO-2-DEOXY-D-GALACTOSE,,BRD:BRD-A53037300-001-01-0;BRD:BRD-BRD-A53037300-001-01-0,rep_primary;rep_single_dose,,LCT,,,PHASE 1,,,NA,,OCC1OC(O)C(F)C(O)C1O
2-FLUOROFUCOSE,2-FLUOROFUCOSE,CHEMBL4297429,BRD:BRD-K00004677-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,SQTFKIKSQNCWGJ-KCDKBNATSA-N,C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O
2-HYDROXYETHYL-SALICYLATE,2-HYDROXYETHYL-SALICYLATE,,BRD:BRD-BRD-K41866823-001-01-3;BRD:BRD-K41866823-001-01-3,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,OCCOC(=O)C1CCCCC1O
2-HYDROXYFLUTAMIDE,2-HYDROXYFLUTAMIDE,CHEMBL491,BRD:BRD-BRD-K82027074-001-07-5;BRD:BRD-K82027074-001-07-5,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,YPQLFJODEKMJEF-UHFFFAOYSA-N,CC(C)(O)C(=O)NC1CCC([N+](=O)[O-])C(C(F)(F)F)C1;CC(C)(O)C(=O)NC1CCC(C(C1)C(F)(F)F)[N+]([O-])=O
2-HYDROXYSACLOFEN,2-HYDROXYSACLOFEN,,BRD:BRD-A27924917-001-03-3;BRD:BRD-BRD-A27924917-001-03-3,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1;GABBR2,,,PRECLINICAL,,,NA,,NCC(O)(CS(O)(=O)=O)C1CCC(CL)CC1
2-IMINOBIOTIN,2-IMINOBIOTIN,CHEMBL1233598,BRD:BRD-BRD-K07954936-001-01-3;BRD:BRD-K07954936-001-01-3,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1;NOS2,,,PHASE 2,,Small molecule,Phase 2,WWVANQJRLPIHNS-ZKWXMUAHSA-N,N=C1N[C@H]2[C@H](CS[C@H]2CCCCC(=O)O)N1;OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12
2-IODOHIPPURIC-ACID,2-IODOHIPPURIC-ACID,,BRD:BRD-BRD-K56634222-001-03-0;BRD:BRD-K56634222-001-03-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)CNC(=O)C1CCCCC1I
2-IODOMELATONIN,2-IODOMELATONIN,CHEMBL289233,BRD:BRD-BRD-K25649279-001-02-0;BRD:BRD-K25649279-001-02-0,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,MTNR1A;MTNR1B;NQO2,,,PRECLINICAL,,Small molecule,NA,FJDDSMSDZHURBJ-UHFFFAOYSA-N,COC1CCC2[NH]C(I)C(CCNC(C)=O)C2C1
2-METHOXYESTRADIOL,2-METHOXYESTRADIOL,CHEMBL299613,BRD:BRD-BRD-K44408410-001-17-6;BRD:BRD-K44408410-001-17-6,rep_multi_dose;rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,COMT;CYP19A1;CYP1A1;CYP1B1;HIF1A;TUBB,,,PHASE 2,,Small molecule,Phase 2,CQOQDQWUFQDJMK-SSTWWWIQSA-N,COC1CC2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCC2CC1O;COC1CC2C(CC1O)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12
2-METHYL-5-HYDROXYTRYPTAMINE,2-METHYL-5-HYDROXYTRYPTAMINE,,BRD:BRD-BRD-K64137799-003-02-5;BRD:BRD-K64137799-003-02-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1B;HTR1D;HTR1E;HTR1F;HTR3A;HTR3B;HTR6,,,PRECLINICAL,,,NA,,CC1[NH]C2CCC(O)CC2C1CCN
2-METHYLIMIDAZOLE,2-METHYLIMIDAZOLE,,BRD:BRD-K68534611-001-07-8,rep_single_dose,CHOLESTEROL INHIBITOR,,,,,,,NA,,
2-OCTYLDODECAN-1-OL,2-OCTYLDODECAN-1-OL,,BRD:BRD-A51407134-001-01-9;BRD:BRD-BRD-A51407134-001-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCCCCCC(CO)CCCCCCCC
2-OLEOYLGLYCEROL,2-OLEOYLGLYCEROL,,BRD:BRD-BRD-K77087341-001-02-4;BRD:BRD-K77087341-001-02-4,rep_primary;rep_single_dose,GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR LIGAND,GPR119,,,PHASE 1,,,NA,,CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO
2-OXOGLUTARIC-ACID,2-OXOGLUTARIC-ACID,,BRD:BRD-BRD-K89712525-001-02-1;BRD:BRD-K89712525-001-02-1,rep_primary;rep_single_dose,,OXGR1,,,PRECLINICAL,,,NA,,OC(=O)CCC(=O)C(O)=O
2-PHENYLMELATONIN,2-PHENYLMELATONIN,,BRD:BRD-BRD-K41869275-001-02-8;BRD:BRD-K41869275-001-02-8,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,MTNR1A;MTNR1B,,,PRECLINICAL,,,NA,,COC1CCC2[NH]C(C(CCNC(C)=O)C2C1)-C1CCCCC1
2-PMDQ,2-PMDQ,,BRD:BRD-A04661934-001-02-9;BRD:BRD-BRD-A04661934-001-02-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A,,,PRECLINICAL,,,NA,,O=C1NC2CCCCC2C2=NC(CN3CCN(CC3)C3CCCCC3)CN12
2-PYRIDYLETHYLAMINE,2-PYRIDYLETHYLAMINE,,BRD:BRD-BRD-K17874705-300-03-2;BRD:BRD-K17874705-300-03-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH1,,,PRECLINICAL,,,NA,,NCCC1CCCCN1
2-TEDC,2-TEDC,,BRD:BRD-BRD-K89072800-001-01-8;BRD:BRD-K89072800-001-01-8,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX12,,,PRECLINICAL,,,NA,,OC1CCC(\C=C(/C#N)C(=O)OCCC2CCCS2)CC1O
2-THIOURACIL,2-THIOURACIL,,BRD:BRD-BRD-K58819470-001-05-9;BRD:BRD-K58819470-001-05-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC1CCNC(S)N1
2-[1-(4-PIPERONYL)PIPERAZINYL]BENZOTHIAZOLE,2-[1-(4-PIPERONYL)PIPERAZINYL]BENZOTHIAZOLE,,BRD:BRD-BRD-K91868854-001-03-6;BRD:BRD-K91868854-001-03-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR4,,,PRECLINICAL,,,NA,,C(N1CCN(CC1)C1NC2CCCCC2S1)C1CCC2OCOC2C1
20-HETE,20-HETE,,BRD:BRD-K00005345-001-01-9,rep_single_dose,ION CHANNEL ANTAGONIST,,,,,,,NA,,
20-HYDROXYECDYSONE,20-HYDROXYECDYSONE,CHEMBL224128,BRD:BRD-BRD-K28343777-001-01-6;BRD:BRD-K28343777-001-01-6,rep_primary;rep_single_dose,ECDYSONE RECEPTOR MODULATOR,,,,PRECLINICAL,,Small molecule,Phase 2,NKDFYOWSKOHCCO-YPVLXUMRSA-N,CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C;CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C
212631-79-3,212631-79-3,,GDSC1:1015,gdsc,,,,,,,,NA,,
284461-73-0,284461-73-0,,GDSC1:30;GDSC2:1085,gdsc,,,,,,,,NA,,
3'-FLUOROBENZYLSPIPERONE,3'-FLUOROBENZYLSPIPERONE,,BRD:BRD-BRD-K45662124-050-01-5;BRD:BRD-K45662124-050-01-5,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR LIGAND,DRD2,,,PRECLINICAL,,,NA,,FC1CCC(CC1)C(=O)CCCN1CCC2(CC1)N(CN(CC1CCCC(F)C1)C2=O)C1CCCCC1
"3,3'-DICHLOROBENZALDAZINE","3,3'-DICHLOROBENZALDAZINE",,BRD:BRD-BRD-K82903013-001-01-4;BRD:BRD-K82903013-001-01-4,rep_primary;rep_single_dose,"GLUTAMATE RECEPTOR ALLOSTERIC LIGAND, GLUTAMATE RECEPTOR MODULATOR",GRM5,,,PRECLINICAL,"Multiple values for MOA: {'GLUTAMATE RECEPTOR ALLOSTERIC LIGAND', 'GLUTAMATE RECEPTOR ALLOSTERIC LIGAND, GLUTAMATE RECEPTOR MODULATOR'}, defaulting to 'GLUTAMATE RECEPTOR ALLOSTERIC LIGAND, GLUTAMATE RECEPTOR MODULATOR'",,NA,,CLC1CCCC(C1)\C=N\N=C\C1CCCC(CL)C1
"3,3'-DIINDOLYLMETHANE","3,3'-DIINDOLYLMETHANE",CHEMBL446452,BRD:BRD-BRD-K37846922-001-09-4;BRD:BRD-K37846922-001-09-4,rep_primary;rep_single_dose,"CHK INHIBITOR, CYTOCHROME P450 ACTIVATOR, INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",AR;HIF1A;IFNG;PI3,,,PHASE 3,,Small molecule,Phase 3,VFTRKSBEFQDZKX-UHFFFAOYSA-N,C(C1C[NH]C2CCCCC12)C1C[NH]C2CCCCC12;C1CCC2C(CC3C[NH]C4CCCCC34)C[NH]C2C1
"3,4-DCPG-(R)","3,4-DCPG-(R)",,BRD:BRD-K06204668-001-03-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,,,,NA,,
"3,5-DHPG-(S)","3,5-DHPG-(S)",,BRD:BRD-K57796080-001-04-9,rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM1,,,,,,NA,,
3-(4-METHYLBENZYLIDENE)CAMPHOR,3-(4-METHYLBENZYLIDENE)CAMPHOR,,BRD:BRD-A55464252-001-01-2;BRD:BRD-BRD-A55464252-001-01-2,rep_primary;rep_single_dose,ENDOCRINE DISRUPTOR,,SUNSCREEN LOTION,,LAUNCHED,,,NA,,CC1CCC(CC1)\C=C1\C2CCC(C)(C1=O)C2(C)C
3-ALPHA-BIS-(4-FLUOROPHENYL)-METHOXYTROPANE,3-ALPHA-BIS-(4-FLUOROPHENYL)-METHOXYTROPANE,,BRD:BRD-A85216385-003-02-4;BRD:BRD-BRD-A85216385-003-02-4,rep_primary;rep_single_dose,DOPAMINE UPTAKE INHIBITOR,CHRM1;SLC6A2;SLC6A3;SLC6A4,,,PRECLINICAL,,,NA,,CN1C2CCC1CC(C2)OC(C1CCC(F)CC1)C1CCC(F)CC1
3-ALPHA-HYDROXY-5-BETA-ANDROSTAN-17-ONE,3-ALPHA-HYDROXY-5-BETA-ANDROSTAN-17-ONE,,BRD:BRD-A43598550-001-09-4;BRD:BRD-BRD-A43598550-001-09-4,rep_primary;rep_single_dose,,HSD17B11;IGHG2;SULT2A1,,,PRECLINICAL,,,NA,,C[C@]12CCC3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O
3-AMINO-BENZAMIDE,3-AMINO-BENZAMIDE,CHEMBL81977,BRD:BRD-BRD-K08703257-001-12-1;BRD:BRD-K08703257-001-12-1;BRD:BRD-K08703257-001-13-9,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PHASE 2,,Small molecule,NA,GSCPDZHWVNUUFI-UHFFFAOYSA-N,NC(=O)C1CCCC(N)C1
3-AQC,3-AQC,,BRD:BRD-BRD-K38370968-050-01-3;BRD:BRD-K38370968-050-01-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR3A,,,PRECLINICAL,,,NA,,C=CCN1CCN(CC1)C1NC2CCCCC2NC1C#N
3-BROMO-7-NITROINDAZOLE,3-BROMO-7-NITROINDAZOLE,,BRD:BRD-BRD-K24689407-001-06-3;BRD:BRD-K24689407-001-06-3,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1;NOS2;NOS3,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCCC2C(BR)N[NH]C12
3-BROMOPYRUVATE,3-BROMOPYRUVATE,,BRD:BRD-BRD-K92980438-001-03-3;BRD:BRD-K92980438-001-03-3,rep_primary;rep_single_dose,HEXOKINASE INHIBITOR,HK2,,,PRECLINICAL,,,NA,,OC(=O)C(=O)CBR
3-CARBOXY-4-HYDROXYPHENYLGLYCINE-(R),3-CARBOXY-4-HYDROXYPHENYLGLYCINE-(R),,BRD:BRD-BRD-K76592088-001-02-1;BRD:BRD-K76592088-001-02-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C,,,PRECLINICAL,,,NA,,N[C@@H](C(O)=O)C1CCC(O)C(C1)C(O)=O
3-CARBOXY-4-HYDROXYPHENYLGLYCINE-(S),3-CARBOXY-4-HYDROXYPHENYLGLYCINE-(S),,BRD:BRD-BRD-K61585876-001-01-0;BRD:BRD-K61585876-001-01-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1;GRM5,,,PRECLINICAL,,,NA,,N[C@H](C(O)=O)C1CCC(O)C(C1)C(O)=O
3-CL-AHPC,3-CL-AHPC,,CTRP:660796,ctrp,,,,,,,,NA,,
3-CPMT,3-CPMT,,BRD:BRD-A51713165-003-02-6;BRD:BRD-BRD-A51713165-003-02-6,rep_primary;rep_single_dose,DOPAMINE REUPTAKE INHIBITOR,,,,PRECLINICAL,,,NA,,CN1C2CCC1CC(C2)OC(C1CCCCC1)C1CCC(CL)CC1
3-DEAZAADENOSINE,3-DEAZAADENOSINE,,BRD:BRD-A79431551-001-01-1;BRD:BRD-BRD-A79431551-001-01-1,rep_primary;rep_single_dose,ADENOSYLHOMOCYSTEINASE INHIBITOR,AHCY,,,PHASE 2,,,NA,,NC1NCCC2N(CNC12)[C@@H]1O[C@H](CO)C(O)C1O
3-DEAZANEPLANOCIN-A,3-DEAZANEPLANOCIN-A,,BRD:BRD-BRD-K77791657-001-01-1;BRD:BRD-BRD-K77791657-003-01-7;BRD:BRD-K77791657-001-01-1;BRD:BRD-K77791657-003-01-7,rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PRECLINICAL,,,NA,,NC1NCCC2N(CNC12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O
3-DEAZAURIDINE,3-DEAZAURIDINE,,BRD:BRD-A26105646-001-06-1;BRD:BRD-BRD-A26105646-001-06-1,rep_primary;rep_single_dose,CYTIDINE DEAMINASE INHIBITOR,,,,PRECLINICAL,,,NA,,OCC1OC(C(O)C1O)N1C=CC(=O)CC1=O
3-HYDROXY-3-PHENYLPENTANAMIDE,3-HYDROXY-3-PHENYLPENTANAMIDE,,BRD:BRD-A66143912-001-01-1;BRD:BRD-BRD-A66143912-001-01-1,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,,,,PHASE 1,,,NA,,CCC(O)(CC(N)=O)C1CCCCC1
3-INDOLEBUTYRIC-ACID,3-INDOLEBUTYRIC-ACID,,BRD:BRD-BRD-K43187796-001-02-3;BRD:BRD-K43187796-001-02-3,rep_primary;rep_single_dose,,B2M;HLA-A;TRAC;TRBC1,,,PRECLINICAL,,,NA,,OC(=O)CCCC1C[NH]C2CCCCC12
3-MATIDA,3-MATIDA,,BRD:BRD-A87125127-001-03-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1,,,,,,NA,,
3-METHYL-GABA,3-METHYL-GABA,,BRD:BRD-K01825682-074-02-9,rep_single_dose,GABA AMINOTRANSFERASE ACTIVATOR,ABAT,,,,,,NA,,
3-METHYLADENINE,3-METHYLADENINE,CHEMBL292268,BRD:BRD-BRD-K81647657-001-04-3;BRD:BRD-K81647657-001-04-3,rep_primary;rep_single_dose,PI3K INHIBITOR,PI3,,,PRECLINICAL,,Small molecule,NA,FSASIHFSFGAIJM-UHFFFAOYSA-N,CN1CNC(=N)C2NC[NH]C12;CN1CNC(N)C2NCNC1-2
3-MPPI,3-MPPI,,BRD:BRD-BRD-K62581435-001-03-8;BRD:BRD-K62581435-001-03-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR LIGAND,ADRA1A,,,PRECLINICAL,,,NA,,COC1CCCCC1N1CCN(CCN2C(=O)[NH]C3C4CCCCC4[NH]C3C2=O)CC1
3PO,3PO,,BRD:BRD-K58413118-001-01-8,rep_single_dose,PHOSPHOFRUCTOKINASE INHIBITOR,PFKFB3,,,,,,NA,,
"4,4-PENTAMETHYLENEPIPERIDINE","4,4-PENTAMETHYLENEPIPERIDINE",,BRD:BRD-BRD-K49545903-003-01-4;BRD:BRD-K49545903-003-01-4,rep_primary;rep_single_dose,M2 CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,C1CCC2(CC1)CCNCC2
"4,5,6,7-TETRABROMOBENZOTRIAZOLE","4,5,6,7-TETRABROMOBENZOTRIAZOLE",CHEMBL177820,BRD:BRD-BRD-K97118047-001-03-8;BRD:BRD-K97118047-001-03-8,rep_primary;rep_single_dose,CASEIN KINASE INHIBITOR,AKT1;CHEK1;CSNK2A1;GSK3B;LCK;MAP2K1;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;PRKCA;ROCK1;RPS6KB1;SGK1,,,PRECLINICAL,,Small molecule,NA,OMZYUVOATZSGJY-UHFFFAOYSA-N,BRC1C(BR)C(BR)C2[NH]NNC2C1BR
4-(4-FLUOROBENZOYL)-1-(4-PHENYLBUTYL)-PIPERIDINE,4-(4-FLUOROBENZOYL)-1-(4-PHENYLBUTYL)-PIPERIDINE,,BRD:BRD-BRD-K47337578-034-02-5;BRD:BRD-K47337578-034-02-5,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A,,,PRECLINICAL,,,NA,,FC1CCC(CC1)C(=O)C1CCN(CCCCC2CCCCC2)CC1
4-(AMINOMETHYL)BENZOIC-ACID,4-(AMINOMETHYL)BENZOIC-ACID,,BRD:BRD-K00003517-001-01-9,rep_single_dose,HEMOSTATIC AGENT,,,,,,,NA,,
"4-ACETYL-1,1-DIMETHYLPIPERAZINIUM","4-ACETYL-1,1-DIMETHYLPIPERAZINIUM",,BRD:BRD-BRD-K97019106-005-02-9;BRD:BRD-K97019106-005-02-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CC(=O)N1CC[N+](C)(C)CC1
4-AMINOHIPPURIC-ACID,4-AMINOHIPPURIC-ACID,,BRD:BRD-BRD-K65544384-001-15-8;BRD:BRD-K65544384-001-15-8,rep_primary;rep_single_dose,,SLC22A6,,,LAUNCHED,,,NA,,NC1CCC(CC1)C(=O)NCC(O)=O
4-CHLOROPHENYLGUANIDINE,4-CHLOROPHENYLGUANIDINE,,BRD:BRD-BRD-K39160765-003-02-9;BRD:BRD-K39160765-003-02-9,rep_multi_dose;rep_primary;rep_single_dose,UROKINASE INHIBITOR,PLAUR,,,PRECLINICAL,,,NA,,NC(=N)NC1CCC(CL)CC1
4-CMTB,4-CMTB,,BRD:BRD-A54139254-001-09-2;BRD:BRD-BRD-A54139254-001-09-2,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,FFAR2,,,PRECLINICAL,,,NA,,CC(C)C(C(=O)NC1NCCS1)C1CCC(CL)CC1
4-CPA,4-CPA,,BRD:BRD-K00078770-001-02-9,rep_single_dose,,,,,,,,NA,,
4-DAMP,4-DAMP,CHEMBL76897,BRD:BRD-K29313239-005-10-9,rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,,,,,Small molecule,NA,WWJHRSCUAQPFQO-UHFFFAOYSA-M,C[N+]1(C)CCC(OC(=O)C(C2CCCCC2)C2CCCCC2)CC1.[I-]
4-GALACTOSYLLACTOSE,4-GALACTOSYLLACTOSE,,BRD:BRD-A32796301-001-01-6;BRD:BRD-BRD-A32796301-001-01-6,rep_primary;rep_single_dose,,AMY2B,,,PRECLINICAL,,,NA,,OC[C@H]1O[C@@H](O[C@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
4-HQN,4-HQN,,BRD:BRD-BRD-K91758890-001-10-0;BRD:BRD-K91758890-001-10-0,rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PRECLINICAL,,,NA,,OC1NCNC2CCCCC12
4-HYDROXY-PHENAZONE,4-HYDROXY-PHENAZONE,,BRD:BRD-BRD-K49759007-001-11-9;BRD:BRD-K49759007-001-11-9,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC1C(O)C(=O)N(-C2CCCCC2)N1C
4-IBP,4-IBP,,BRD:BRD-BRD-K62537556-001-02-5;BRD:BRD-K62537556-001-02-5,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,SIGMAR1,,,PRECLINICAL,,,NA,,IC1CCC(CC1)C(=O)NC1CCN(CC2CCCCC2)CC1
4-IODO-6-PHENYLPYRIMIDINE,4-IODO-6-PHENYLPYRIMIDINE,,BRD:BRD-BRD-K25690923-001-02-4;BRD:BRD-K25690923-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,MACROPHAGE MIGRATION INHIBITING FACTOR INHIBITOR,MIF,,,PRECLINICAL,,,NA,,IC1CC(NCN1)-C1CCCCC1
4-IODO-L-PHENYLALANINE,4-IODO-L-PHENYLALANINE,,BRD:BRD-BRD-K66664625-001-01-2;BRD:BRD-K66664625-001-01-2,rep_primary;rep_single_dose,,DPP4,,,PRECLINICAL,,,NA,,N[C@H](CC1CCC(I)CC1)C(O)=O
4-METHYLGENISTEIN,4-METHYLGENISTEIN,,BRD:BRD-BRD-K73303757-001-21-6;BRD:BRD-K73303757-001-21-6,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,CYP19A1;ESRRA;ESRRB;ESRRG;FASN,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-C1COC2CC(O)CC(O)C2C1=O
4-METHYLHISTAMINE,4-METHYLHISTAMINE,CHEMBL275443,BRD:BRD-BRD-K70821460-300-02-4;BRD:BRD-K70821460-300-02-4,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH4,,,PRECLINICAL,,Small molecule,NA,UGYXPZQILZRKJJ-UHFFFAOYSA-N,CC1NC[NH]C1CCN
4-MU-8C,4-MU-8C,,BRD:BRD-BRD-K81316007-001-01-8;BRD:BRD-K81316007-001-01-8,rep_primary;rep_single_dose,IRE1 INHIBITOR,ERN1,,,PRECLINICAL,,,NA,,CC1CC(=O)OC2C(C=O)C(O)CCC12
4-P-PDOT,4-P-PDOT,,BRD:BRD-A67482312-001-02-6;BRD:BRD-BRD-A67482312-001-02-6,rep_primary;rep_single_dose,MELATONIN RECEPTOR ANTAGONIST,MTNR1A;MTNR1B,,,PRECLINICAL,,,NA,,CCC(=O)NC1CC(C2CCCCC2)C2CCCCC2C1
4-PHENOLSULFONIC-ACID,4-PHENOLSULFONIC-ACID,,BRD:BRD-BRD-K41024817-325-01-0;BRD:BRD-K41024817-325-01-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC1CCC(CC1)S(O)(=O)=O
"4-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE","4-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE",,BRD:BRD-A40504327-003-02-9,rep_single_dose,DOPAMINE RELEASE INHIBITOR,,,,,,,NA,,
4-PPBP,4-PPBP,,BRD:BRD-BRD-K78061844-050-01-9;BRD:BRD-K78061844-050-01-9,rep_primary;rep_single_dose,SIGMA RECEPTOR LIGAND,SIGMAR1,,,PRECLINICAL,,,NA,,C(CCC1CCCCC1)CN1CCC(CC1)C1CCCCC1
4-PYRIMIDINECARBONITRILE,4-PYRIMIDINECARBONITRILE,,BRD:BRD-BRD-K04552268-001-02-4;BRD:BRD-K04552268-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,N#CC1CCNCN1
4BP-TQS,4BP-TQS,,BRD:BRD-A18598741-001-02-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,CHRNA7,,,,,,NA,,
4E1RCAT,4E1RCAT,,BRD:BRD-BRD-K67173685-001-06-9;BRD:BRD-K67173685-001-06-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,EIF4E;EIF4G1,,,PRECLINICAL,,,NA,,OC(=O)C1CCC(CC1)N1C(=O)C(\C=C1C1CCCCC1)=C\C1CCC(O1)-C1CCC(CC1)[N+]([O-])=O
4SC-202,4SC-202,CHEMBL4283683,BRD:BRD-BRD-K11773281-075-02-4;BRD:BRD-K11773281-075-02-4,rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1,,,PHASE 1,,Small molecule,Phase 2,PRXXYMVLYKJITB-IZZDOVSWSA-N,CN1CC(-C2CCC(S(=O)(=O)N3CCC(/C=C/C(=O)NC4CCCCC4N)C3)CC2)CN1;CN1CC(CN1)-C1CCC(CC1)S(=O)(=O)N1CCC(\C=C\C(=O)NC2CCCCC2N)C1
5'-CHLORO-5'-DEOXY-ENBA-(+/-),5'-CHLORO-5'-DEOXY-ENBA-(+/-),,BRD:BRD-A13598753-001-01-2;BRD:BRD-BRD-A13598753-001-01-2,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,,,PRECLINICAL,,,NA,,O[C@@H]1[C@@H](CCL)O[C@H]([C@@H]1O)N1CNC2C(NC3CC4CCC3C4)NCNC12
"5,7-DICHLOROKYNURENIC-ACID","5,7-DICHLOROKYNURENIC-ACID",,BRD:BRD-BRD-K60287130-001-05-7;BRD:BRD-K60287130-001-05-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GLRA2;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PRECLINICAL,,,NA,,OC(=O)C1CC(O)C2C(CL)CC(CL)CC2N1
"5-AMINO-3-D-RIBOFURANOSYLTHIAZOLO[4,5-D]PYRIMIDIN-2,7(3H,6H)-DIONE","5-AMINO-3-D-RIBOFURANOSYLTHIAZOLO[4,5-D]PYRIMIDIN-2,7(3H,6H)-DIONE",,BRD:BRD-BRD-K87535339-001-01-6;BRD:BRD-K87535339-001-01-6,rep_primary;rep_single_dose,,TLR7,,,PRECLINICAL,,,NA,,NC1NC2N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C(=O)SC2C(=O)[NH]1
5-AMINOLEVULINIC-ACID,5-AMINOLEVULINIC-ACID,,BRD:BRD-BRD-K57631554-003-06-2;BRD:BRD-K57631554-003-06-2,rep_primary;rep_single_dose,OXIDIZING AGENT,ALAD,,,LAUNCHED,,,NA,,NCC(=O)CCC(O)=O
DECITABINE,5-AZA-2'-DEOXYCYTIDINE;DECITABINE,CHEMBL1201129,BRD:BRD-BRD-K79254416-001-22-6;BRD:BRD-K79254416-001-07-7;BRD:BRD-K79254416-001-21-8;BRD:BRD-K79254416-001-22-6;CTRP:347775,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,HYPOMETHYLATING AGENT WITH DNA INCORPORATION,DNMT1;DNMT3A,"MYELODYSPLASTIC DISEASES (MDS), ANEMIA, CHRONIC MYELOID LEUKEMIA (CML)",,LAUNCHED,"Multiple values for MOA: {'DNA METHYLTRANSFERASE INHIBITOR', 'HYPOMETHYLATING AGENT WITH DNA INCORPORATION'}, defaulting to 'HYPOMETHYLATING AGENT WITH DNA INCORPORATION'
Multiple values for repurposing_target: {'DNMT1;DNMT3A', 'DNMT1'}, taking the union",Small molecule,Approved,XAUDJQYHKZQPEU-KVQBGUIXSA-N,NC1NCN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)N1
AZACYTIDINE,5-AZACITIDINE;AZACITIDINE;AZACYTIDINE,CHEMBL1489,BRD:BRD-BRD-K03406345-001-27-8;BRD:BRD-K03406345-001-21-1;BRD:BRD-K03406345-001-26-0;BRD:BRD-K03406345-001-27-8;CTRP:26874,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,HYPOMETHYLATING AGENT WITH DNA/RNA INCORPORATION,DNMT1;DNMT3A,"MYELODYSPLASTIC DISEASES (MDS), ANEMIA, CHRONIC MYELOMONOCYTIC LEUKEMIA (CMMOL)",,LAUNCHED,"Multiple values for MOA: {'HYPOMETHYLATING AGENT WITH DNA/RNA INCORPORATION', 'DNA METHYLTRANSFERASE INHIBITOR'}, defaulting to 'HYPOMETHYLATING AGENT WITH DNA/RNA INCORPORATION'
Multiple values for repurposing_target: {'DNMT1;DNMT3A', 'DNMT1'}, taking the union",Small molecule,Approved,NMUSYJAQQFHJEW-KVTDHHQDSA-N,NC1NCN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(=O)N1
5-BDBD,5-BDBD,,BRD:BRD-BRD-K33690734-001-01-5;BRD:BRD-K33690734-001-01-5,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX4,,,PRECLINICAL,,,NA,,BRC1CCCC(C1)C1=NCC(=O)NC2C1OC1CCCCC21
5-CARBOXAMIDOTRYPTAMINE,5-CARBOXAMIDOTRYPTAMINE,,BRD:BRD-BRD-K92382976-050-01-1;BRD:BRD-K92382976-050-01-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR5A;HTR6;HTR7,,,PRECLINICAL,,,NA,,NCCC1C[NH]C2CCC(CC12)C(N)=O
5-FLUORO-3-PYRIDYL-METHANOL,5-FLUORO-3-PYRIDYL-METHANOL,,BRD:BRD-BRD-K73381198-001-01-1;BRD:BRD-K73381198-001-01-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OCC1CNCC(F)C1
5-FLUOROPYRIMIDINE,5-FLUOROPYRIMIDINE,,BRD:BRD-K00004679-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,,NA,,
FLUOROURACIL,5-FLUOROURACIL;5-FU;FLUOROURACIL,CHEMBL185,BRD:BRD-BRD-K24844714-001-24-5;BRD:BRD-K24844714-001-24-5;BRD:BRD-U00115293-001-01-9;CTRP:25344;GDSC1:179;GDSC2:1073,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose, INHIBITOR OF THYMIDYLATE SYNTHASE;PYRIMIDINE ANALOG,DPYD;TYMS,"COLORECTAL CANCER, BREAST CANCER, PANCREATIC CANCER, GASTRIC ADENOCARCINOMA",,LAUNCHED,"Multiple values for MOA: {'THYMIDYLATE SYNTHASE INHIBITOR', 'PYRIMIDINE ANALOG; INHIBITOR OF THYMIDYLATE SYNTHASE'}, defaulting to 'PYRIMIDINE ANALOG; INHIBITOR OF THYMIDYLATE SYNTHASE'
Multiple values for repurposing_target: {'TYMS', 'DPYD;TYMS'}, taking the union
Multiple values for structure_id: {'U00115293', 'K24844714'}, defaulting to None",Small molecule,Approved,GHASVSINZRGABV-UHFFFAOYSA-N,FC1C[NH]C(=O)[NH]C1=O;O=C1[NH]CC(F)C(=O)[NH]1
5-HMF,5-HMF,,BRD:BRD-BRD-K86799112-001-02-0;BRD:BRD-K86799112-001-02-0,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,OCC1CCC(C=O)O1
5-HYDROXYECTOINE,5-HYDROXYECTOINE,,BRD:BRD-BRD-K03871161-001-01-9;BRD:BRD-K03871161-001-01-9;BRD:BRD-K03871161-001-02-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,O[C@H]1CNC(=C)N[C@@H]1C(O)=O
5-HYDROXYMETHYL-TOLTERODINE,5-HYDROXYMETHYL-TOLTERODINE,,BRD:BRD-BRD-K24603946-001-02-1;BRD:BRD-K24603946-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM3,,,PHASE 1,,,NA,,CC(C)N(CC[C@H](C1CCCCC1)C1CC(CO)CCC1O)C(C)C
5-HYDROXYTRYPTOPHAN,5-HYDROXYTRYPTOPHAN,CHEMBL350221,BRD:BRD-A73930134-001-03-0;BRD:BRD-BRD-A73930134-001-03-0,rep_primary;rep_single_dose,NEUROTRANSMITTER,SLC36A1;SLC36A2,INSOMNIA,,LAUNCHED,,Small molecule,Approved,LDCYZAJDBXYCGN-VIFPVBQESA-N,N[C@@H](CC1C[NH]C2CCC(O)CC12)C(=O)O;NC(CC1C[NH]C2CCC(O)CC12)C(O)=O
5-IODO-A-85380,5-IODO-A-85380,,BRD:BRD-BRD-K90065682-300-02-6;BRD:BRD-K90065682-300-02-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PHASE 2,,,NA,,IC1CNCC(OC[C@@H]2CCN2)C1
5-METHYLFURMETHIODIDE,5-METHYLFURMETHIODIDE,CHEMBL1316369,BRD:BRD-BRD-K45437867-005-03-3;BRD:BRD-K45437867-005-03-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4,,,PRECLINICAL,,Small molecule,NA,IHTCZSNKQINGDD-UHFFFAOYSA-M,CC1CCC(C[N+](C)(C)C)O1;CC1CCC(C[N+](C)(C)C)O1.[I-]
5-METHYLHYDANTOIN-(L),5-METHYLHYDANTOIN-(L),,BRD:BRD-BRD-K56033645-001-07-5;BRD:BRD-K56033645-001-07-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C[C@@H]1NC(=O)NC1=O
5-OCTANOYLSALICYLIC-ACID,5-OCTANOYLSALICYLIC-ACID,,BRD:BRD-K00004681-001-01-9,rep_single_dose,PROTEIN KINASE ACTIVATOR,,,,,,,NA,,
5XE,5XE,,GDSC2:1852,gdsc,,,,,,,,NA,,
5Z-7-OXOZEAENOL,5Z-7-OXOZEAENOL,,GDSC1:1242,gdsc,,,,,,,,NA,,
"6,7-DEHYDRO-17-ACETOXY-PROGESTERONE","6,_7-DEHYDRO-17-ACETOXY-PROGESTERONE;6,7-DEHYDRO-17-ACETOXY-PROGESTERONE",,BRD:BRD-BRD-K48329353-001-01-3;BRD:BRD-K48329353-001-01-3,rep_primary;rep_single_dose,STEROIDAL PROGESTIN,,,,PRECLINICAL,,,NA,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
6-AMINOPENICILLANIC-ACID,6-AMINOPENICILLANIC-ACID,,BRD:BRD-K30284967-001-02-9,rep_single_dose,,,,,,,,NA,,
6-BENZYLAMINOPURINE,6-BENZYLAMINOPURINE,CHEMBL228862,BRD:BRD-BRD-K62929068-001-16-5;BRD:BRD-K62929068-001-16-5,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ACTIVATOR,,,,PRECLINICAL,,Small molecule,NA,NWBJYWHLCVSVIJ-UHFFFAOYSA-N,C1CCC(CNC2NCNC3[NH]CNC23)CC1;N(CC1CCCCC1)C1NCNC2NC[NH]C12
6-CHLOROMELATONIN,6-CHLOROMELATONIN,,BRD:BRD-BRD-K34663752-001-09-1;BRD:BRD-K34663752-001-09-1,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,MTNR1A;MTNR1B,,,PRECLINICAL,,,NA,,COC1CC2C(CCNC(C)=O)C[NH]C2CC1CL
6-DIAZO-5-OXO-L-NORLEUCINE,6-DIAZO-5-OXO-L-NOR-LEUCINE;6-DIAZO-5-OXO-L-NORLEUCINE,CHEMBL97485,BRD:BRD-K84924563-001-04-9,rep_single_dose,"GLUTAMATE RECEPTOR ANTAGONIST, GLUTAMINASE INHIBITOR",,,,,,Small molecule,NA,YCWQAMGASJSUIP-YFKPBYRVSA-N,[N-]=[N+]=CC(=O)CC[C@H](N)C(=O)O
6-IODO-NORDIHYDROCAPSAICIN,6-IODO-NORDIHYDROCAPSAICIN,,BRD:BRD-BRD-K49236613-001-02-3;BRD:BRD-K49236613-001-02-3,rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PRECLINICAL,,,NA,,CCCCCCCCC(=O)NCC1CC(OC)C(O)CC1I
6-THIO-2'-DEOXYGUANOSINE,6-THIO-2'-DEOXYGUANOSINE,CHEMBL3250476,BRD:BRD-K00091271-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,SCVJRXQHFJXZFZ-KVQBGUIXSA-N,NC1NC2C(NCN2[C@H]2C[C@H](O)[C@@H](CO)O2)C(=S)[NH]1
681640,681640,,GDSC1:1046;GDSC2:1046,gdsc,,,,,,,,NA,,
"7,8,9,10-TETRAHYDROAZEPINO[2,1-B]QUINAZOLIN-12(6H)-ONE","7,8,9,10-TETRAHYDROAZEPINO[2,1-B]QUINAZOLIN-12(6H)-ONE",,BRD:BRD-BRD-K77756533-001-01-4;BRD:BRD-K77756533-001-01-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,O=C1N2CCCCC=C2NC2CCCCC12
7-AMINOCEPHALOSPORANIC-ACID,7-AMINOCEPHALOSPORANIC-ACID,,BRD:BRD-BRD-K65377893-001-07-4;BRD:BRD-K65377893-001-07-4,rep_multi_dose;rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,,,PRECLINICAL,,,NA,,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O
7-CHLOROKYNURENIC-ACID,7-CHLOROKYNURENIC-ACID,,BRD:BRD-BRD-K84214706-001-05-7;BRD:BRD-K84214706-001-05-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C,,,PRECLINICAL,,,NA,,OC(=O)C1CC(O)C2CCC(CL)CC2N1
7-ETHYL-10-HYDROXY-CAMPTOTHECIN,7-ETHYL-10-HYDROXY-CAMPTOTHECIN,CHEMBL837,GDSC1:1494,gdsc,,,,,,,Small molecule,Phase 2,FJHBVJOVLFPMQE-QFIPXVFZSA-N,CCC1C2C(NC3CCC(O)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC
7-HYDROXY-DPAT,7-HYDROXY-DPAT,,BRD:BRD-A18795974-004-07-3;BRD:BRD-BRD-A18795974-004-07-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2;DRD3,,,PRECLINICAL,,,NA,,CCCN(CCC)C1CCC2CCC(O)CC2C1
7-HYDROXYSTAUROSPORINE,7-HYDROXYSTAUROSPORINE,CHEMBL574737,BRD:BRD-BRD-K45293975-001-02-0;BRD:BRD-K45293975-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, CHK INHIBITOR, PKC INHIBITOR",CDK1;CHEK1;CHEK2;GSK3B;LCK;MAPK14;MARK1;MARK3;PDPK1;PRKCA;PRKCB;PRKCD;PRKCE;PRKCG,,,PHASE 2,"Multiple values for repurposing_target: {'CDK1;CHEK1;CHEK2;GSK3B;LCK;MAPK14;MARK1;MARK3;PDPK1;PRKCA;PRKCB;PRKCD;PRKCE;PRKCG', 'CHEK1;MARK3;PDPK1'}, taking the union",Small molecule,Phase 2,PBCZSGKMGDDXIJ-KRUBCLEUSA-N,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3CCCCC3C3C4[C@H](O)NC(=O)C4C4C5CCCCC5N2C4C13;CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)C(=O)N[C@H]4O
7-KETO-DHEA,7-KETO-DHEA,,BRD:BRD-BRD-K07785030-001-01-6;BRD:BRD-K07785030-001-01-6,rep_primary;rep_single_dose,STEROID,,,,LAUNCHED,,,NA,,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1
7-METHOXYTACRINE,7-METHOXYTACRINE,,BRD:BRD-BRD-K53156626-001-01-3;BRD:BRD-K53156626-001-01-3,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,PHASE 2,,,NA,,COC1CCC2NC3CCCCC3C(N)C2C1
7-METHYLXANTHINE,7-METHYLXANTHINE,CHEMBL321248,BRD:BRD-BRD-K41592905-001-01-6;BRD:BRD-K41592905-001-01-6,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,PHASE 2,,Small molecule,Phase 2,PFWLFWPASULGAN-UHFFFAOYSA-N,CN1CNC2[NH]C(=O)[NH]C(=O)C21;CN1CNC2NC(O)NC(O)C12
7-NITROINDAZOLE,7-NITROINDAZOLE,CHEMBL247378,BRD:BRD-BRD-K04430056-001-17-7;BRD:BRD-BRD-K04430056-236-02-1;BRD:BRD-K04430056-001-17-7;BRD:BRD-K04430056-236-02-1,rep_multi_dose;rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1;NOS2;NOS3,,,PRECLINICAL,,Small molecule,NA,PQCAUHUKTBHUSA-UHFFFAOYSA-N,[O-][N+](=O)C1CCCC2CN[NH]C12;O=[N+]([O-])C1CCCC2CN[NH]C12
8-BROMO-CAMP,8-BROMO-CAMP,,BRD:BRD-A09554849-236-07-6;BRD:BRD-BRD-A09554849-236-07-6,rep_primary;rep_single_dose,PKA ACTIVATOR,,,,PRECLINICAL,,,NA,,NC1NCNC2N([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)C(BR)NC12
8-BROMO-CGMP,8-BROMO-CGMP,,BRD:BRD-A00077618-236-07-6;BRD:BRD-BRD-A00077618-236-07-6,rep_multi_dose;rep_primary;rep_single_dose,PKA ACTIVATOR,PRKG1,,,PRECLINICAL,,,NA,,NC1NC(O)C2NC(BR)N([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)C2N1
8-HYDROXY-DPAT,8-HYDROXY-DPAT,,BRD:BRD-A48015106-004-08-9;BRD:BRD-BRD-A48015106-004-08-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,CDK1;CHEK1;CHEK2;GSK3B;HTR5A;HTR7;LCK;MAPK14;MARK1;PDPK1;PRKCA;PRKCB;PRKCD;PRKCE;PRKCG,,,PRECLINICAL,,,NA,,CCCN(CCC)C1CCC2CCCC(O)C2C1
8-HYDROXY-PIPAT,8-HYDROXY-PIPAT,,BRD:BRD-A60594020-034-01-1;BRD:BRD-BRD-A60594020-034-01-1,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR LIGAND,DRD2;DRD3,,,PRECLINICAL,,,NA,,CCCN(C\C=C\I)C1CCC2CCCC(O)C2C1
8-M-PDOT,8-M-PDOT,,BRD:BRD-A07232941-001-02-7;BRD:BRD-BRD-A07232941-001-02-7,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,MTNR1A;MTNR1B,,,PRECLINICAL,,,NA,,CCC(=O)NC1CCC2CCCC(OC)C2C1
9-??-D-ARABINOFURANOSYL GUANINE,9-??-D-ARABINOFURANOSYL GUANINE,,GDSC1:427,gdsc,,,,,,,,NA,,
9-AMINOACRIDINE,9-AMINOACRIDINE,CHEMBL43184,BRD:BRD-BRD-K00535541-001-05-5;BRD:BRD-BRD-K00535541-001-06-3;BRD:BRD-K00535541-001-05-5;BRD:BRD-K00535541-001-06-3,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,XJGFWWJLMVZSIG-UHFFFAOYSA-N,NC1C2CCCCC2NC2CCCCC12
9-AMINOCAMPTOTHECIN,9-AMINOCAMPTOTHECIN,CHEMBL274070,BRD:BRD-BRD-K09291936-001-13-3;BRD:BRD-K09291936-001-13-3,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 2,,Small molecule,Phase 2,FUXVKZWTXQUGMW-FQEVSTJZSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1-C3NC4CCCC(N)C4CC3CN1C2=O;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3C(N)CCCC3NC2-1
9-ANTHRACENECARBOXYLIC-ACID,9-ANTHRACENECARBOXYLIC-ACID,,BRD:BRD-K62607075-001-04-9,rep_single_dose,,ANO1;CLCN1,,,,,,NA,,
9-ING-41,9-ING-41,CHEMBL483465,BRD:BRD-K00091104-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,FARXPFGGGGLENU-UHFFFAOYSA-N,CN1CC(C2=C(C3COC4CCC(F)CC34)C(=O)NC2=O)C2CC3C(CC21)OCO3
944328-88-5,944328-88-5,,GDSC1:151,gdsc,,,,,,,,NA,,
968,968,,CTRP:660080,ctrp,,,,,,,,NA,,
A-1065-5,A-1065-5,,GDSC1:299;GDSC2:1594,gdsc,,,,,,,,NA,,
A-1070722,A-1070722,,BRD:BRD-BRD-K70329400-001-02-5;BRD:BRD-K70329400-001-02-5,rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3A;GSK3B,,,PRECLINICAL,,,NA,,COC1CCC2C(NC(=O)NC3CCCC(N3)C(F)(F)F)CCNC2C1
A-1120,A-1120,,BRD:BRD-K59060513-001-02-5,rep_single_dose,RETINOID RECEPTOR LIGAND,RBP4,,,,,,NA,,
A-1331852,A-1331852,,BRD:BRD-U00114866-001-01-9,oncref_1,INHIBITOR OF BCL-XL (BCL2L1),BCL2L1,,,,,,NA,,
A-154475,A-154475,CHEMBL603469,GDSC1:1024,gdsc,,,,,,,Small molecule,Phase 3,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)CNC4=O
A-317491,A-317491,CHEMBL596234,BRD:BRD-BRD-K38019854-323-01-4;BRD:BRD-K38019854-323-01-4,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX3,,,PRECLINICAL,,Small molecule,NA,VQGBOYBIENNKMI-LJAQVGFWSA-N,O=C(O)C1CC(C(=O)O)C(C(=O)N(CC2CCCC(OC3CCCCC3)C2)[C@H]2CCCC3CCCCC32)CC1C(=O)O;OC(=O)C1CC(C(O)=O)C(CC1C(O)=O)C(=O)N(CC1CCCC(OC2CCCCC2)C1)[C@H]1CCCC2CCCCC12
A-33903,A-33903,,BRD:BRD-A40302156-001-01-9;BRD:BRD-BRD-A40302156-001-01-9,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CC(=O)NC1C(=O)NC2CCCCC2C(=N1)C1CCCCC1
A-366,A-366,,BRD:BRD-BRD-K06182768-001-02-3;BRD:BRD-K06182768-001-02-3,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT1;EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(CC1OCCCN1CCCC1)N=C(N)C21CCC1
A-381393,A-381393,,BRD:BRD-K00005339-001-01-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,,,,NA,,
A-412997,A-412997,,BRD:BRD-BRD-K62066682-300-01-0;BRD:BRD-K62066682-300-01-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD4,,,PRECLINICAL,,,NA,,CC1CCCC(NC(=O)CN2CCC(CC2)C2CCCCN2)C1
A-438079,A-438079,,BRD:BRD-K13223831-003-02-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX7,,,,,,NA,,
A-443654,A-443654,CHEMBL379300,GDSC1:86,gdsc,,,,,,,Small molecule,NA,YWTBGJGMTBHQTM-IBGZPJMESA-N,CC1N[NH]C2CCC(-C3CNCC(OC[C@@H](N)CC4C[NH]C5CCCCC45)C3)CC12
A485,A-485;A485,CHEMBL4282264,BRD:BRD-K30233223-001-04-9;BRD:BRD-K30233223-001-08-9,oncref_2;rep_single_dose,HISTONE ACETYLTRANSFERASE INHIBITOR,CREBBP;EP300,,,,"Multiple values for MOA: {'HISTONE ACETYLTRANSFERASE INHIBITOR', 'INHIBITOR OF EP300/CREBBP HAT'}, defaulting to 'HISTONE ACETYLTRANSFERASE INHIBITOR'",Small molecule,NA,VRVJKILQRBSEAG-LFPIHBKWSA-N,CNC(=O)NC1CCC2C(C1)CC[C@@]21OC(=O)N(CC(=O)N(CC2CCC(F)CC2)[C@@H](C)C(F)(F)F)C1=O
A-582941,A-582941,,BRD:BRD-K79743788-001-02-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,CHRNA7,,,,,,NA,,
A61603,A-61603;A61603,,BRD:BRD-A83650191-004-02-8;BRD:BRD-BRD-A83650191-004-02-8;BRD:BRD-BRD-K13142315-004-01-2;BRD:BRD-K13142315-004-01-2,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D,,,PRECLINICAL,"Multiple values for SMILES: {'CS(=O)(=O)NC1C(O)CCC2C(CCCC12)=C1NCCN1', 'CS(=O)(=O)NC1C(O)CCC2C(CCCC12)C1=NCCN1'}, defaulting to 'CS(=O)(=O)NC1C(O)CCC2C(CCCC12)C1=NCCN1'
Multiple values for repurposing_target: {'ADRA1A', 'ADRA1A;ADRA1B;ADRA1D'}, taking the union
Multiple values for structure_id: {'K13142315', 'A83650191'}, defaulting to None",,NA,,CS(=O)(=O)NC1C(O)CCC2C(CCCC12)C1=NCCN1
A-674563,A-674563,,BRD:BRD-BRD-K78177893-001-02-4;BRD:BRD-K78177893-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,AKT1;PKIA;PRKACA,,,PRECLINICAL,,,NA,,CC1N[NH]C2CCC(CC12)-C1CNCC(OC[C@@H](N)CC2CCCCC2)C1
A-7,A-7,,BRD:BRD-BRD-K03301001-003-02-5;BRD:BRD-K03301001-003-02-5,rep_primary;rep_single_dose,CALMODULIN ANTAGONIST,,,,PRECLINICAL,,,NA,,NCCCCCCCCCCNS(=O)(=O)C1CCCC2C(CL)CCCC12
A-769662,A-769662,,BRD:BRD-BRD-K41918892-001-05-9;BRD:BRD-K41918892-001-05-9,rep_primary;rep_single_dose,AMPK ACTIVATOR,,,,PRECLINICAL,,,NA,,OC1CCCCC1-C1CCC(CC1)-C1CSC2[NH]C(=O)C(C#N)C(O)C12
A-770041,A-770041,,GDSC1:55,gdsc,,,,,,,,NA,,
A-784168,A-784168,,BRD:BRD-K87665527-001-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPV1,,,,,,NA,,
A-803467,A-803467,,BRD:BRD-BRD-K28570407-001-02-0;BRD:BRD-K28570407-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A,,,PRECLINICAL,,,NA,,COC1CC(NC(=O)C2CCC(O2)-C2CCC(CL)CC2)CC(OC)C1
A-804598,A-804598,,BRD:BRD-K76894955-001-02-1;BRD:BRD-K94313941-001-03-9;CTRP:661033,ctrp;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX7,,,,"Multiple values for structure_id: {'K76894955', 'K94313941'}, defaulting to None",,NA,,
A-83-01,A-83-01,,GDSC1:477,gdsc,,,,,,,,NA,,
A-839977,A-839977,,BRD:BRD-K60427831-001-02-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX7,,,,,,NA,,
A-867744,A-867744,,BRD:BRD-BRD-K33059059-001-01-0;BRD:BRD-K33059059-001-01-0,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATOR,CHRNA3;CHRNA4;CHRNA7,,,PRECLINICAL,,,NA,,CCC(=O)C1CC(-C2CCC(CL)CC2)N(C1C)-C1CCC(CC1)S(N)(=O)=O
A-887826,A-887826,,BRD:BRD-K20239555-001-02-9,rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A,,,,,,NA,,
A922500,A-922500;A922500,,BRD:BRD-BRD-K28861668-001-01-9;BRD:BRD-BRD-K81614372-001-02-1;BRD:BRD-K28861668-001-01-9;BRD:BRD-K81614372-001-02-1,rep_primary;rep_single_dose,DIACYLGLYCEROL O ACYLTRANSFERASE INHIBITOR,DGAT1,,,PRECLINICAL,"Multiple values for SMILES: {'OC(=O)[C@@H]1CCC[C@H]1C(=O)C1CCC(CC1)-C1CCC(NC(=O)NC2CCCCC2)CC1', 'OC(=O)[C@H]1CCC[C@H]1C(=O)C1CCC(CC1)-C1CCC(NC(=O)NC2CCCCC2)CC1'}, defaulting to 'OC(=O)[C@@H]1CCC[C@H]1C(=O)C1CCC(CC1)-C1CCC(NC(=O)NC2CCCCC2)CC1'
Multiple values for structure_id: {'K28861668', 'K81614372'}, defaulting to None",,NA,,OC(=O)[C@@H]1CCC[C@H]1C(=O)C1CCC(CC1)-C1CCC(NC(=O)NC2CCCCC2)CC1
A-939572,A-939572,,BRD:BRD-K99308908-001-02-9,oncref_1;rep_single_dose,INHIBITOR OF STEAROYL-COA DESATURASE 1,SCD,,,,"Multiple values for MOA: {'INHIBITOR OF STEAROYL-COA DESATURASE 1', 'STEAROYL-COA DESATURASE INHIBITOR'}, defaulting to 'INHIBITOR OF STEAROYL-COA DESATURASE 1'",,NA,,
A-967079,A-967079,CHEMBL3697701,BRD:BRD-BRD-K70744942-001-01-2;BRD:BRD-K70744942-001-01-2,rep_primary;rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPA1,,,PRECLINICAL,,Small molecule,NA,HKROEBDHHKMNBZ-CHBKHGQFSA-N,CCC(=N/O)\C(C)=C\C1CCC(F)CC1;CCC(=N\O)/C(C)=C/C1CCC(F)CC1
A-987306,A-987306,,BRD:BRD-K68982262-001-02-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ADORA1;AVPR1A;CCR1;CHRM1;CHRM2;CHRM3;CHRM4;DRD3;HTR1A;HTR1B;HTR2A;HTR2B;HTR3A;TACR2,,,,,,NA,,
A12B4C3,A12B4C3,,BRD:BRD-A30000356-001-02-9,rep_single_dose,POLYNUCLEOTIDE KINASE/PHOSPHATASE INHIBITOR,PNKP,,,,,,NA,,
A205804,A205804,,BRD:BRD-BRD-K77627880-001-04-0;BRD:BRD-K77627880-001-04-0,rep_primary;rep_single_dose,ICAM1 EXPRESSION INHIBITOR,ICAM1;SELE,,,PRECLINICAL,,,NA,,CC1CCC(SC2CNCC3SC(CC23)C(N)=O)CC1
A66,A66,,BRD:BRD-BRD-K49055432-001-04-2;BRD:BRD-K49055432-001-04-2,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA,,,PRECLINICAL,,,NA,,CC1NC(NC(=O)N2CCC[C@H]2C(N)=O)SC1-C1CSC(N1)C(C)(C)C
A740003,A740003,,BRD:BRD-A78952587-001-01-5;BRD:BRD-BRD-A78952587-001-01-5,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX7,,,PRECLINICAL,,,NA,,COC1CCC(CC(=O)NC(N\C(NC2CCCC3NCCCC23)=N\C#N)C(C)(C)C)CC1OC
A77636,A77636,,BRD:BRD-K72226571-003-02-9,rep_single_dose,DOPAMINE RECEPTOR AGONIST,CALY,,,,,,NA,,
AA-COCF3,AA-COCF3,,CTRP:411724,ctrp,,,,,,,,NA,,
AAI101,AAI101,,BRD:BRD-K00003450-001-01-9,rep_single_dose,LACTAMASE INHIBITOR,,,,,,,NA,,
AB-423,AB-423,,BRD:BRD-K00003109-001-01-9,rep_single_dose,HBV CAPSID ASSEMBLY INHIBITOR,,,,,,,NA,,
AB-680,AB-680,CHEMBL4471306,BRD:BRD-K00090628-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,MFYLCAMJNGIULC-KCVUFLITSA-N,C[C@H](NC1CC(CL)NC2C1CNN2[C@@H]1O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]1O)C1CCCCC1F
AB1010,AB1010,CHEMBL1908391,GDSC1:292,gdsc,,,,,,,Small molecule,Approved,WJEOLQLKVOPQFV-UHFFFAOYSA-N,CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NC(-C2CCCNC2)CS1
AB928,AB928,CHEMBL4740383,BRD:BRD-K00091111-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,BUXIAWLTBSXYSW-UHFFFAOYSA-N,CC1C(C#N)CCCC1-C1CC(-C2CN(CC3CCCC(C(C)(C)O)N3)NN2)NC(N)N1
ABACAVIR,ABACAVIR,CHEMBL1380,BRD:BRD-BRD-K17443395-065-02-2;BRD:BRD-K17443395-065-02-2,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,MCGSCOLBFJQGHM-SCZZXKLOSA-N,NC1NC(NC2CC2)C2NCN([C@@H]3C[C@H](CO)C=C3)C2N1;NC1NC(NC2CC2)C2NCN([C@H]3C=C[C@@H](CO)C3)C2N1
ABAFUNGIN,ABAFUNGIN,CHEMBL3989547,BRD:BRD-BRD-K77432251-001-01-2;BRD:BRD-K77432251-001-01-2,rep_primary;rep_single_dose,STEROL METHYLTRANSFERASE INHIBITOR,,,,PHASE 3,,Small molecule,Unknown,TYBHXIFFPVFXQW-UHFFFAOYSA-N,CC1CCC(OC2CCCCC2-C2CSC(N=C3NCCCN3)N2)C(C)C1
ABAMETAPIR,ABAMETAPIR,CHEMBL2205807,BRD:BRD-BRD-K65498798-001-01-7;BRD:BRD-K65498798-001-01-7,rep_primary;rep_single_dose,METALLOPROTEINASE INHIBITOR,MMP9,,,PHASE 3,,Small molecule,Approved,PTRATZCAGVBFIQ-UHFFFAOYSA-N,CC1CCC(-C2CCC(C)CN2)NC1;CC1CCC(NC1)-C1CCC(C)CN1
ABARELIX,ABARELIX,CHEMBL1252,BRD:BRD-K00003158-001-01-9,rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,GNRHR,,,,,Protein,Approved,AIWRTTMUVOZGPW-HSPKUQOVSA-N,CC(=O)N[C@H](CC1CCC2CCCCC2C1)C(=O)N[C@H](CC1CCC(CL)CC1)C(=O)N[C@H](CC1CCCNC1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](CC1CCC(O)CC1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
ABBV-744,ABBV-744,CHEMBL4297454,BRD:BRD-K00003108-001-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,Small molecule,Phase 1,OEDSFMUSNZDJFD-UHFFFAOYSA-N,CCNC(=O)C1CC2C(-C3CC(C(C)(C)O)CCC3OC3C(C)CC(F)CC3C)CN(C)C(=O)C2[NH]1
ABC-294640,ABC-294640,CHEMBL2158685,BRD:BRD-A70814879-001-01-2;BRD:BRD-BRD-A70814879-001-01-2,rep_primary;rep_single_dose,SPHINGOSINE KINASE INHIBITOR,SPHK2,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,CAOTVXGYTWCKQE-UHFFFAOYSA-N,CLC1CCC(CC1)C12CC3CC(CC(C3)(C1)C(=O)NCC1CCNCC1)C2;O=C(NCC1CCNCC1)C12CC3CC(C1)CC(C1CCC(CL)CC1)(C3)C2
LY2835219,ABEMACICLIB;LY2835219,CHEMBL3301610,BRD:BRD-BRD-K33622447-066-01-9;BRD:BRD-K33622447-001-03-9;BRD:BRD-K33622447-066-01-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF CDK4 AND CDK6,CDK4;CDK6,BREAST CANCER,,LAUNCHED,"Multiple values for MOA: {'CDK INHIBITOR', 'INHIBITOR OF CDK4 AND CDK6'}, defaulting to 'INHIBITOR OF CDK4 AND CDK6'",Small molecule,Approved,UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(CC2CCC(NC3NCC(F)C(-C4CC(F)C5NC(C)N(C(C)C)C5C4)N3)NC2)CC1;CCN1CCN(CC2CCC(NC3NCC(F)C(N3)-C3CC(F)C4NC(C)N(C(C)C)C4C3)NC2)CC1
ABIRATERONE,ABIRATERONE,CHEMBL254328,BRD:BRD-BRD-K50071428-001-03-3;BRD:BRD-K50071428-001-03-3;CTRP:660363,ctrp;rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN BIOSYNTHESIS INHIBITOR,CYP11B1;CYP17A1,PROSTATE CANCER,,LAUNCHED,,Small molecule,Approved,GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(C3CCCNC3)=CC[C@@H]12;C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2C1CCCNC1
ABIRATERONE-ACETATE,ABIRATERONE-ACETATE,,BRD:BRD-BRD-K24048528-001-01-7;BRD:BRD-BRD-K24048528-001-02-5;BRD:BRD-K24048528-001-01-7;BRD:BRD-K24048528-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN BIOSYNTHESIS INHIBITOR,CYP17A1,PROSTATE CANCER,,LAUNCHED,,,NA,,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C4CCCNC4)[C@@H]3CC=C2C1
ABITREXATE,ABITREXATE,CHEMBL3244648;CHEMBL34259,GDSC1:1008,gdsc,,,,,,,Small molecule,Approved,DASQOOZCTWOQPA-GXKRWWSZSA-L;FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])CC1.[NA+].[NA+];CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1
ASCIMINIB,ABL001;ASCIMINIB,CHEMBL4208229,BRD:BRD-K00003456-001-01-9,oncref_1;rep_single_dose,ALLOSTERIC INHIBITOR OF ABL1,ABL1,,,,"Multiple values for MOA: {'BCR-ABL KINASE INHIBITOR', 'ALLOSTERIC INHIBITOR OF ABL1'}, defaulting to 'ALLOSTERIC INHIBITOR OF ABL1'",Small molecule,Approved,VOVZXURTCKPRDQ-CQSZACIVSA-N,O=C(NC1CCC(OC(F)(F)CL)CC1)C1CNC(N2CC[C@@H](O)C2)C(-C2CC[NH]N2)C1
ABRAXANE,ABRAXANE,CHEMBL428647,GDSC1:11;GDSC2:1080,gdsc,,,,,,,Small molecule,Approved,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)C3CCCCC3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4CCCCC4)C4CCCCC4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
ABT 263,ABT 263,,GDSC1:1011;GDSC2:1011,gdsc,,,,,,,,NA,,
ABT 869,ABT 869,,GDSC1:277,gdsc,,,,,,,,NA,,
ABT 888,ABT 888,,GDSC1:1018,gdsc,,,,,,,,NA,,
ABT-072,ABT-072,CHEMBL4076467,BRD:BRD-K00004730-001-01-9,rep_single_dose,RNA POLYMERASE INHIBITOR,,,,,,Small molecule,Phase 2,XMZSTQYSBYEENY-RMKNXTFCSA-N,COC1C(/C=C/C2CCC(NS(C)(=O)=O)CC2)CC(-N2CCC(=O)[NH]C2=O)CC1C(C)(C)C
VENETOCLAX,ABT-199;VENETOCLAX,CHEMBL3137309,BRD:BRD-BRD-K62391742-001-03-0;BRD:BRD-K62391742-001-03-0;BRD:BRD-K62391742-001-07-1;BRD:BRD-K62391742-001-09-7;CTRP:666541;GDSC1:412;GDSC2:1909,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF BCL2,BCL2,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),,LAUNCHED,"Multiple values for MOA: {'BCL INHIBITOR', 'INHIBITOR OF BCL2'}, defaulting to 'INHIBITOR OF BCL2'",Small molecule,Approved,LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(CN2CCN(C3CCC(C(=O)NS(=O)(=O)C4CCC(NCC5CCOCC5)C([N+](=O)[O-])C4)C(OC4CNC5[NH]CCC5C4)C3)CC2)=C(C2CCC(CL)CC2)C1;CC1(C)CCC(CN2CCN(CC2)C2CCC(C(=O)NS(=O)(=O)C3CCC(NCC4CCOCC4)C(C3)[N+]([O-])=O)C(OC3CNC4[NH]CCC4C3)C2)=C(C1)C1CCC(CL)CC1
ABT-202,ABT-202,,BRD:BRD-A29844814-300-01-5;BRD:BRD-BRD-A29844814-300-01-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PHASE 1,,,NA,,NC1CCN(C1)C1CCCNC1
ABT-239,ABT-239,,BRD:BRD-BRD-K22749967-046-02-3;BRD:BRD-K22749967-046-02-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1;HRH2;HRH3,,,PHASE 1,,,NA,,C[C@@H]1CCCN1CCC1CC2CC(CCC2O1)-C1CCC(CC1)C#N
NAVITOCLAX,ABT-263;NAVITOCLAX,CHEMBL443684,BRD:BRD-BRD-K82746043-001-15-1;BRD:BRD-K82746043-001-15-1;BRD:BRD-K82746043-001-19-3;BRD:BRD-K82746043-001-24-9;CTRP:362342;GDSC1:1011;GDSC2:1011,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF BCL-XL/BCL2,BCL2;BCL2L1;BCL2L2,,,PHASE 2,"Multiple values for MOA: {'BCL INHIBITOR', 'INHIBITOR OF BCL-XL/BCL2'}, defaulting to 'INHIBITOR OF BCL-XL/BCL2'
Multiple values for repurposing_target: {'BCL2;BCL2L1;BCL2L2', 'BCL2;BCL2L1'}, taking the union",Small molecule,Phase 3,JLYAXFNOILIKPP-KXQOOQHDSA-N,CC1(C)CCC(=C(CN2CCN(CC2)C2CCC(CC2)C(=O)NS(=O)(=O)C2CCC(N[C@H](CCN3CCOCC3)CSC3CCCCC3)C(C2)S(=O)(=O)C(F)(F)F)C1)C1CCC(CL)CC1;CC1(C)CCC(C2CCC(CL)CC2)=C(CN2CCN(C3CCC(C(=O)NS(=O)(=O)C4CCC(N[C@H](CCN5CCOCC5)CSC5CCCCC5)C(S(=O)(=O)C(F)(F)F)C4)CC3)CC2)C1
ABT-418 (HYDROCHLORIDE),ABT-418 (HYDROCHLORIDE),,BRD:BRD-K00075715-003-02-9,rep_single_dose,,,,,,,,NA,,
ABT-491,ABT-491,,BRD:BRD-BRD-K97233161-003-01-5;BRD:BRD-K97233161-003-01-5,rep_primary;rep_single_dose,PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST,PTAFR,,,PHASE 1,,,NA,,CN(C)C(=O)N1CC(C(=O)C2CCC(CN3C(C)NC4CNCCC34)C(F)C2)C2C(CCCC12)C#C
ABT-639,ABT-639,CHEMBL3590674,BRD:BRD-BRD-K11792081-001-01-4;BRD:BRD-K11792081-001-01-4,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1G;CACNA1H;CACNA1I,,,PHASE 2,,Small molecule,Phase 2,AGPIHNZOZNKRGT-CYBMUJFWSA-N,FC1CCCCC1NS(=O)(=O)C1CC(C(=O)N2CCN3CCC[C@@H]3C2)C(CL)CC1F;O=C(C1CC(S(=O)(=O)NC2CCCCC2F)C(F)CC1CL)N1CCN2CCC[C@@H]2C1
ABT-702,ABT-702,,BRD:BRD-BRD-K36021395-300-02-4;BRD:BRD-K36021395-300-02-4,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE KINASE INHIBITOR,ADK,,,PRECLINICAL,,,NA,,NC1NCNC2NC(CC(-C3CCCC(BR)C3)C12)-C1CCC(NC1)N1CCOCC1
ABT-724,ABT-724,CHEMBL440687,BRD:BRD-BRD-K37714784-305-02-1;BRD:BRD-K37714784-305-02-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD4,,,PHASE 2,,Small molecule,NA,FRPJGTNLZNXQEX-UHFFFAOYSA-N,C(N1CCN(CC1)C1CCCCN1)C1NC2CCCCC2[NH]1;C1CCC(N2CCN(CC3NC4CCCCC4[NH]3)CC2)NC1
ABT-737,ABT-737,CHEMBL376408,BRD:BRD-BRD-K56301217-001-07-4;BRD:BRD-K56301217-001-07-4;CTRP:411738,ctrp;rep_multi_dose;rep_primary;rep_single_dose,BCL INHIBITOR,BCL2;BCL2L1;BCL2L2,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,HPLNQCPCUACXLM-PGUFJCEWSA-N,CN(C)CC[C@H](CSC1CCCCC1)NC1CCC(CC1[N+]([O-])=O)S(=O)(=O)NC(=O)C1CCC(CC1)N1CCN(CC2CCCCC2-C2CCC(CL)CC2)CC1;CN(C)CC[C@H](CSC1CCCCC1)NC1CCC(S(=O)(=O)NC(=O)C2CCC(N3CCN(CC4CCCCC4-C4CCC(CL)CC4)CC3)CC2)CC1[N+](=O)[O-]
ABT-751,ABT-751,CHEMBL20684,BRD:BRD-BRD-K91623615-001-05-0;BRD:BRD-K91623615-001-05-0,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,,,PHASE 2,,Small molecule,Phase 2,URCVCIZFVQDVPM-UHFFFAOYSA-N,COC1CCC(CC1)S(=O)(=O)NC1CCCNC1NC1CCC(O)CC1;COC1CCC(S(=O)(=O)NC2CCCNC2NC2CCC(O)CC2)CC1
ABT-869,ABT-869,CHEMBL223360,GDSC1:277,gdsc,,,,,,,Small molecule,Phase 3,MPVGZUGXCQEXTM-UHFFFAOYSA-N,CC1CCC(F)C(NC(=O)NC2CCC(-C3CCCC4[NH]NC(N)C34)CC2)C1
ABT-888,ABT-888,CHEMBL506871,GDSC1:1018,gdsc,,,,,,,Small molecule,Phase 3,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,C[C@]1(C2NC3C(C(N)=O)CCCC3[NH]2)CCCN1
ABT263,ABT263,,GDSC1:1011;GDSC2:1011,gdsc,,,,,,,,NA,,
ABT737,ABT737,,GDSC2:1910,gdsc,,,,,,,,NA,,
ABT888,ABT888,,GDSC1:1018,gdsc,,,,,,,,NA,,
ABX-1431,ABX-1431,CHEMBL3945728,BRD:BRD-K00004603-001-01-9,rep_single_dose,MONOACYLGLYCEROL LIPASE INHIBITOR,,,,,,Small molecule,Phase 2,SQZJGTOZFRNWCX-UHFFFAOYSA-N,O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(CC2CCC(C(F)(F)F)CC2N2CCCC2)CC1
ABX464,ABX464,CHEMBL4297344,BRD:BRD-K00003394-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 2,OZOGDCZJYVSUBR-UHFFFAOYSA-N,FC(F)(F)OC1CCC(NC2CCC3CCCC(CL)C3N2)CC1
AC 220,AC 220,,GDSC1:254,gdsc,,,,,,,,NA,,
AC-186,AC-186,,BRD:BRD-BRD-K53788420-001-01-1;BRD:BRD-K53788420-001-01-1,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR2,,,PRECLINICAL,,,NA,,OC1CCC(CC1)C1(CCC(F)(F)CC1)C1CCCCC1F
AC-220,AC-220,CHEMBL576982,GDSC1:254,gdsc,,,,,,,Small molecule,Phase 3,CVWXJKQAOSCOAB-UHFFFAOYSA-N,CC(C)(C)C1CC(NC(=O)NC2CCC(-C3CN4C(N3)SC3CC(OCCN5CCOCC5)CCC34)CC2)NO1
AC-261066,AC-261066,,BRD:BRD-K31144453-001-03-9,rep_single_dose,RETINOID RECEPTOR AGONIST,RARB,,,,,,NA,,
AC-264613,AC-264613,,BRD:BRD-BRD-K81548480-001-01-2;BRD:BRD-K81548480-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,PAR AGONIST,F2RL1,,,PRECLINICAL,,,NA,,C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)C1CCCCC1)C1CCCC(BR)C1
AC-55541,AC-55541,,BRD:BRD-A27911617-001-01-7;BRD:BRD-BRD-A27911617-001-01-7,rep_primary;rep_single_dose,PARP INHIBITOR,PARP2,,,PRECLINICAL,,,NA,,C\C(=N/NC(=O)C(NC(=O)C1CCCCC1)C1N[NH]C(=O)C2CCCCC12)C1CCCC(BR)C1
AC-55649,AC-55649,,BRD:BRD-BRD-K93176058-001-03-6;BRD:BRD-K93176058-001-03-6,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB,,,PRECLINICAL,,,NA,,CCCCCCCCC1CCC(CC1)-C1CCC(CC1)C(O)=O
AC-710,AC-710,,BRD:BRD-BRD-K15819326-001-01-6;BRD:BRD-K15819326-001-01-6,rep_primary;rep_single_dose,PDGFR TYROSINE KINASE RECEPTOR INHIBITOR,CSF1R;FLT3;KIT;PDGFRA;PDGFRB,,,PRECLINICAL,,,NA,,CCN1C(C)(C)CC(CC1(C)C)OC1CCC(NC1)C(=O)NC1CCC(NC(=O)NC2CC(ON2)C(C)(C)C)CC1
AC-7954-(+/-),AC-7954-(+/-),,BRD:BRD-A49544621-003-02-8;BRD:BRD-BRD-A49544621-003-02-8,rep_primary;rep_single_dose,UROTENSIN RECEPTOR AGONIST,UTS2R,,,PRECLINICAL,,,NA,,CN(C)CCC1(CC2CCCCC2C(=O)O1)C1CCC(CL)CC1
AC-DE,AC-DE,,GDSC2:1911,gdsc,,,,,,,,NA,,
AC1L1GQE,AC1L1GQE,,GDSC1:288,gdsc,,,,,,,,NA,,
AC1NDSS5,AC1NDSS5,,BRD:BRD-BRD-K10226125-245-01-5;BRD:BRD-K10226125-245-01-5,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,CCCCCCCCCCCCCCCCCC[S+](CCC)C1CCCCC1C(=O)OCC
AC220,AC220,CHEMBL2105709;CHEMBL576982,GDSC1:254,gdsc,,,,,,,Small molecule,Phase 3,CVWXJKQAOSCOAB-UHFFFAOYSA-N;DHYPGRVMIOATAE-UHFFFAOYSA-N,CC(C)(C)C1CC(NC(=O)NC2CCC(-C3CN4C(N3)SC3CC(OCCN5CCOCC5)CCC34)CC2)NO1;CC(C)(C)C1CC(NC(=O)NC2CCC(-C3CN4C(N3)SC3CC(OCCN5CCOCC5)CCC34)CC2)NO1.CL.CL
AC260584,AC260584,,BRD:BRD-K00004583-001-01-9,rep_single_dose,CHOLINERGIC RECEPTOR AGONIST,,,,,,,NA,,
AC55649,AC55649,,CTRP:375487,ctrp,,,,,,,,NA,,
ACADESINE,ACADESINE,CHEMBL1551724,BRD:BRD-BRD-K53448858-001-07-0;BRD:BRD-K53448858-001-07-0,rep_primary;rep_single_dose,AMPK ACTIVATOR,,,,PHASE 3,,Small molecule,Phase 3,RTRQQBHATOEIAF-UUOKFMHZSA-N,NC(=O)C1NCN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1N
ACALABRUTINIB,ACALABRUTINIB,CHEMBL3707348,BRD:BRD-BRD-K64034691-001-01-9;BRD:BRD-K64034691-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK,,,PHASE 3,,Small molecule,Approved,WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1C1NC(-C2CCC(C(=O)NC3CCCCN3)CC2)C2C(N)NCCN12;CC#CC(=O)N1CCC[C@H]1C1NC(-C2CCC(CC2)C(=O)NC2CCCCN2)C2C(N)NCCN12
ACALISIB,ACALISIB,CHEMBL4303323,BRD:BRD-BRD-K92517771-001-01-2;BRD:BRD-K92517771-001-01-2,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CB;PIK3CD,,,PHASE 1,,Small molecule,Phase 2,DOCINCLJNAXZQF-LBPRGKRZSA-N,C[C@H](NC1NCNC2[NH]CNC12)C1NC2CCC(F)CC2C(=O)N1-C1CCCCC1
ACAMPROSATE,ACAMPROSATE,CHEMBL1201293,BRD:BRD-BRD-K26262077-238-01-5;BRD:BRD-K26262077-238-01-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;GRM5,ABSTINENCE FROM ALCOHOL,,LAUNCHED,,Small molecule,Approved,AFCGFAGUEYAMAO-UHFFFAOYSA-N,CC(=O)NCCCS(=O)(=O)O;CC(=O)NCCCS(O)(=O)=O
ACARBOSE,ACARBOSE,CHEMBL1566;CHEMBL404271,BRD:BRD-BRD-K44276885-001-07-4;BRD:BRD-K44276885-001-07-4,rep_primary;rep_single_dose,GLUCOSIDASE INHIBITOR,AMY2A;GAA;MGAM;SI,DIABETES MELLITUS,,LAUNCHED,,Oligosaccharide;Small molecule,Approved,XUFXOAAUWZOOIT-SXARVLRPSA-N;XUFXOAAUWZOOIT-UGEKTDRHSA-N,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O;C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O;C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
ACDPP,ACDPP,,BRD:BRD-BRD-K68633617-003-02-9;BRD:BRD-K68633617-003-02-9,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PRECLINICAL,,,NA,,CN(C)C1NC(N)C(NC1CL)C(=O)NC1CCCNC1
ACEBILUSTAT,ACEBILUSTAT,CHEMBL4297604,BRD:BRD-K00003255-001-01-9,rep_single_dose,LEUKOTRIENE INHIBITOR,,,,,,Small molecule,Phase 2,GERJIEKMNDGSCS-DQEYMECFSA-N,O=C(O)C1CCC(CN2C[C@@H]3C[C@H]2CN3CC2CCC(OC3CCC(-C4NCCO4)CC3)CC2)CC1
ACEBUTOLOL,ACEBUTOLOL,CHEMBL642,BRD:BRD-A29260609-003-26-0;BRD:BRD-BRD-A29260609-003-26-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,"HYPERTENSION, VENTRICULAR ARRHYTHMIAS",,LAUNCHED,,Small molecule,Approved,GOEMGAFJFRBGGG-UHFFFAOYSA-N,CCCC(=O)NC1CCC(OCC(O)CNC(C)C)C(C(C)=O)C1;CCCC(=O)NC1CCC(OCC(O)CNC(C)C)C(C1)C(C)=O
ACECAINIDE,ACECAINIDE,CHEMBL1097,BRD:BRD-BRD-K07753030-003-17-6;BRD:BRD-K07753030-003-17-6,rep_primary;rep_single_dose,POLARIZATION INHIBITOR,SCN5A,,,PHASE 3,,Small molecule,Unknown,KEECCEWTUVWFCV-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1CCC(NC(C)=O)CC1
ACECLIDINE,ACECLIDINE,CHEMBL20835,BRD:BRD-A32673558-003-03-9;BRD:BRD-BRD-A32673558-003-03-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,GLAUCOMA,,LAUNCHED,,Small molecule,Phase 2,WRJPSSPFHGNBMG-UHFFFAOYSA-N,CC(=O)OC1CN2CCC1CC2
ACECLOFENAC,ACECLOFENAC,CHEMBL93645,BRD:BRD-BRD-K68538666-001-12-3;BRD:BRD-K68538666-001-12-3,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGS2,"RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, OSTEOARTHRITIS, PERIARTHRITIS, LUMBAGO, ISCHIADYNIA",,LAUNCHED,,Small molecule,Approved,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,O=C(O)COC(=O)CC1CCCCC1NC1C(CL)CCCC1CL;OC(=O)COC(=O)CC1CCCCC1NC1C(CL)CCCC1CL
ACEDAPSONE,ACEDAPSONE,CHEMBL154166,BRD:BRD-BRD-K97417064-001-02-4;BRD:BRD-K97417064-001-02-4,rep_primary;rep_single_dose,,,LEPROSY,,LAUNCHED,,Small molecule,Unknown,AMTPYFGPPVFBBI-UHFFFAOYSA-N,CC(=O)NC1CCC(CC1)S(=O)(=O)C1CCC(NC(C)=O)CC1;CC(=O)NC1CCC(S(=O)(=O)C2CCC(NC(C)=O)CC2)CC1
ACEDOBEN,ACEDOBEN,CHEMBL112687,BRD:BRD-BRD-K47195926-001-06-6;BRD:BRD-K47195926-001-06-6,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,QCXJEYYXVJIFCE-UHFFFAOYSA-N,CC(=O)NC1CCC(C(=O)O)CC1;CC(=O)NC1CCC(CC1)C(O)=O
ACEFYLLINE,ACEFYLLINE,CHEMBL70246,BRD:BRD-BRD-K44004064-001-07-3;BRD:BRD-K44004064-001-07-3,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,ASTHMA,,LAUNCHED,,Small molecule,Approved,HCYFGRCYSCXKNQ-UHFFFAOYSA-N,CN1C(=O)C2C(NCN2CC(=O)O)N(C)C1=O;CN1C2NCN(CC(O)=O)C2C(=O)N(C)C1=O
ACEGLUTAMIDE,ACEGLUTAMIDE,,BRD:BRD-BRD-K13619941-213-01-8;BRD:BRD-K13619941-213-01-8,rep_primary;rep_single_dose,,,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,,NA,,CC(=O)N[C@@H](CCC(N)=O)C(O)=O
ACELARIN,ACELARIN,CHEMBL3126004,BRD:BRD-K00003531-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Phase 3,NHTKGYOMICWFQZ-KKQYNPQSSA-N,C[C@H](NP(=O)(OC[C@H]1O[C@@H](N2CCC(N)NC2=O)C(F)(F)[C@@H]1O)OC1CCCCC1)C(=O)OCC1CCCCC1
ACEMETACIN,ACEMETACIN,CHEMBL189171,BRD:BRD-BRD-K67563174-001-17-6;BRD:BRD-K67563174-001-17-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,OSTEOARTHRITIS,,LAUNCHED,,Small molecule,Approved,FSQKKOOTNAMONP-UHFFFAOYSA-N,COC1CCC2C(C1)C(CC(=O)OCC(=O)O)C(C)N2C(=O)C1CCC(CL)CC1;COC1CCC2N(C(=O)C3CCC(CL)CC3)C(C)C(CC(=O)OCC(O)=O)C2C1
ACENEURAMIC-ACID,ACENEURAMIC-ACID,,BRD:BRD-BRD-K36262466-001-06-3;BRD:BRD-K36262466-001-06-3,rep_primary;rep_single_dose,,AZGP1;CES1;MBL2;REG1A;SELE;SELP;SIGLEC1,,,PHASE 3,,,NA,,CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
ACENOCOUMAROL,ACENOCOUMAROL,CHEMBL397420,BRD:BRD-A65051990-001-12-9;BRD:BRD-BRD-A65051990-001-12-9,rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,VKORC1,DEEP VEIN THROMBOSIS (DVT),,LAUNCHED,,Small molecule,Approved,VABCILAOYCMVPS-UHFFFAOYSA-N,CC(=O)CC(C1CCC([N+](=O)[O-])CC1)C1C(O)C2CCCCC2OC1=O;CC(=O)CC(C1CCC(CC1)[N+]([O-])=O)C1C(O)C2CCCCC2OC1=O
ACEPROMAZINE,ACEPROMAZINE,CHEMBL39560,BRD:BRD-BRD-K37814297-050-09-6;BRD:BRD-K37814297-050-09-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;DRD1;DRD2;HTR1A;HTR2A,SEDATIVE,,LAUNCHED,,Small molecule,Unknown,NOSIYYJFMPDDSA-UHFFFAOYSA-N,CC(=O)C1CCC2C(C1)N(CCCN(C)C)C1CCCCC1S2;CN(C)CCCN1C2CCCCC2SC2CCC(CC12)C(C)=O
ACESULFAME-POTASSIUM,ACESULFAME-POTASSIUM,,BRD:BRD-BRD-K50850824-237-04-8;BRD:BRD-K50850824-237-04-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 3,,,NA,,CC1=CC(=O)NS(=O)(=O)O1
ACETALAX,ACETALAX,,GDSC2:1804,gdsc,,,,,,,,NA,,
ACETANILIDE,ACETANILIDE,CHEMBL269644,BRD:BRD-BRD-K11094367-001-10-1;BRD:BRD-K11094367-001-10-1,rep_primary;rep_single_dose,HYDROGEN PEROXIDE DECOMPOSITION INHIBITOR,,,,PRECLINICAL,,Small molecule,Unknown,FZERHIULMFGESH-UHFFFAOYSA-N,CC(=O)NC1CCCCC1
ACETARSOL,ACETARSOL,CHEMBL1330792,BRD:BRD-BRD-K99048103-001-18-4;BRD:BRD-K99048103-001-18-4,rep_primary;rep_single_dose,,,DIARRHEA,,LAUNCHED,,Small molecule,Approved,ODFJOVXVLFUVNQ-UHFFFAOYSA-N,CC(=O)NC1CC([AS](=O)(O)O)CCC1O;CC(=O)NC1CC(CCC1O)[AS](O)(O)=O
ACETAZOLAMIDE,ACETAZOLAMIDE,CHEMBL20,BRD:BRD-BRD-K43457670-001-27-8;BRD:BRD-K43457670-001-27-8,rep_multi_dose;rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,AQP1;CA1;CA12;CA14;CA2;CA3;CA4;CA7,GLAUCOMA,,LAUNCHED,,Small molecule,Approved,BZKPWHYZMXOIDC-UHFFFAOYSA-N,CC(=O)NC1NNC(S(N)(=O)=O)S1;CC(=O)NC1NNC(S1)S(N)(=O)=O
ACETOHEXAMIDE,ACETOHEXAMIDE,CHEMBL1589,BRD:BRD-BRD-K52960356-001-15-5;BRD:BRD-K52960356-001-15-5,rep_primary;rep_single_dose,ATP CHANNEL BLOCKER,ABCC8;KCNJ1;KCNJ10;KCNJ11,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,VGZSUPCWNCWDAN-UHFFFAOYSA-N,CC(=O)C1CCC(CC1)S(=O)(=O)NC(=O)NC1CCCCC1;CC(=O)C1CCC(S(=O)(=O)NC(=O)NC2CCCCC2)CC1
ACETOHYDROXAMIC-ACID,ACETOHYDROXAMIC-ACID,CHEMBL734,BRD:BRD-BRD-K21615095-001-08-4;BRD:BRD-K21615095-001-08-4,rep_primary;rep_single_dose,UREASE INHIBITOR,MMP12,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,RRUDCFGSUDOHDG-UHFFFAOYSA-N,CC(=O)NO
ACETOPHENAZINE,ACETOPHENAZINE,CHEMBL1085,BRD:BRD-BRD-K42938903-332-01-1;BRD:BRD-K42938903-332-01-1,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2,PSYCHOSIS,,LAUNCHED,,Small molecule,Approved,WNTYBHLDCKXEOT-UHFFFAOYSA-N,CC(=O)C1CCC2C(C1)N(CCCN1CCN(CCO)CC1)C1CCCCC1S2;CC(=O)C1CCC2SC3CCCCC3N(CCCN3CCN(CCO)CC3)C2C1
ACETRIAZOIC-ACID,ACETRIAZOIC-ACID,,BRD:BRD-BRD-K46416130-001-07-7;BRD:BRD-K46416130-001-07-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(=O)NC1C(I)CC(I)C(C(O)=O)C1I
ACETYL-11-KETO-BETA-BOSWELLIC-ACID,ACETYL-11-KETO-BETA-BOSWELLIC-ACID,,BRD:BRD-A44696962-001-01-4;BRD:BRD-BRD-A44696962-001-01-4,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,HSD11B1;HSD11B2,,,PHASE 2,,,NA,,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)C4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)(C5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C
ACETYL-FARNESYL-CYSTEINE,ACETYL-FARNESYL-CYSTEINE,,BRD:BRD-BRD-K79437791-001-05-7;BRD:BRD-K79437791-001-05-7,rep_primary;rep_single_dose,METHYLTRANSFERASE INHIBITOR,PPARG,ACNE VULGARIS (AV),,LAUNCHED,,,NA,,CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O
ACETYL-L-LEUCINE,ACETYL-L-LEUCINE,CHEMBL56021,BRD:BRD-BRD-K27406233-001-07-7;BRD:BRD-K27406233-001-07-7,rep_primary;rep_single_dose,,,VERTIGO,,LAUNCHED,,Small molecule,Phase 3,WXNXCEHXYPACJF-ZETCQYMHSA-N,CC(=O)N[C@@H](CC(C)C)C(=O)O;CC(C)C[C@H](NC(C)=O)C(O)=O
ACETYLCHOLINE,ACETYLCHOLINE,CHEMBL1184;CHEMBL667,BRD:BRD-BRD-K82381502-003-23-1;BRD:BRD-K82381502-003-23-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,ACHE;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;CHRNA2,"DROWSINESS, FATIGUE, HEADACHE, INDIGESTION, CHEST CONGESTION",,LAUNCHED,,Small molecule,Approved,JUGOREOARAHOCO-UHFFFAOYSA-M;OIPILFWXSMYKGL-UHFFFAOYSA-N,CC(=O)OCC[N+](C)(C)C;CC(=O)OCC[N+](C)(C)C.[CL-]
ACETYLCYSTEINE,ACETYLCYSTEINE,CHEMBL600,BRD:BRD-BRD-K59058747-001-18-3;BRD:BRD-BRD-K59058747-001-20-9;BRD:BRD-K59058747-001-18-3;BRD:BRD-K59058747-001-20-9,rep_multi_dose;rep_primary;rep_single_dose,MUCOLYTIC AGENT,ACY1;CHUK;GRIN1;GRIN2A;GRIN2B;GRIN2D;GRIN3A;GSS;IKBKB;RELA;SLC7A11,"ACETAMINOPHEN OVERDOSE, HEPATIC INJURY",,LAUNCHED,,Small molecule,Approved,PWKSKIMOESPYIA-BYPYZUCNSA-N,CC(=O)N[C@@H](CS)C(=O)O;CC(=O)N[C@@H](CS)C(O)=O
ACETYLSALICYLSALICYLIC-ACID,ACETYLSALICYLSALICYLIC-ACID,,BRD:BRD-BRD-K46585355-001-14-3;BRD:BRD-K46585355-001-14-3,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,PRECLINICAL,,,NA,,CC(=O)OC1CCCCC1C(=O)OC1CCCCC1C(O)=O
ACETYLSPIRAMYCIN,ACETYLSPIRAMYCIN,CHEMBL453514,BRD:BRD-K00004968-001-01-9,rep_single_dose,OTHER ANTIBIOTIC,,,,,,Small molecule,Approved,ACTOXUHEUCPTEW-CEUOBAOPSA-N,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
ACEXAMIC-ACID,ACEXAMIC-ACID,,BRD:BRD-BRD-K72215350-001-06-5;BRD:BRD-K72215350-001-06-5,rep_primary;rep_single_dose,5 ALPHA REDUCTASE INHIBITOR,GAST,WOUND HEALING,,LAUNCHED,,,NA,,CC(=O)NCCCCCC(O)=O
ACHP,ACHP,,GDSC1:290,gdsc,,,,,,,,NA,,
ACIFRAN,ACIFRAN,CHEMBL278488,BRD:BRD-A29520968-001-02-7;BRD:BRD-BRD-A29520968-001-02-7,rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,HCAR2;HCAR3,,,PHASE 3,,Small molecule,Unknown,DFDGRKNOFOJBAJ-UHFFFAOYSA-N,CC1(C2CCCCC2)OC(C(=O)O)=CC1=O;CC1(OC(=CC1=O)C(O)=O)C1CCCCC1
ACIPIMOX,ACIPIMOX,CHEMBL345714,BRD:BRD-BRD-K63736853-001-04-8;BRD:BRD-K63736853-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,HCAR2,HYPERLIPIDEMIA,,LAUNCHED,,Small molecule,Approved,DJQOOSBJCLSSEY-UHFFFAOYSA-N,CC1CNC(C(=O)O)C[N+]1[O-];CC1CNC(C[N+]1[O-])C(O)=O
ACITAZANOLAST,ACITAZANOLAST,CHEMBL2104654,BRD:BRD-BRD-K74236708-001-01-9;BRD:BRD-K74236708-001-01-9,rep_primary;rep_single_dose,MEDIATOR RELEASE INHIBITOR,,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Unknown,VWQZJJZGISNFOE-UHFFFAOYSA-N,O=C(O)C(=O)NC1CCCC(-C2NNN[NH]2)C1;OC(=O)C(=O)NC1CCCC(C1)-C1NNN[NH]1
ACITRETIN,ACITRETIN,CHEMBL1131,BRD:BRD-BRD-K62012036-001-14-4;BRD:BRD-K62012036-001-14-4,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB;RARG;RBP1;RXRA;RXRB;RXRG;STAT3,PSORIASIS,,LAUNCHED,,Small molecule,Approved,IHUNBGSDBOWDMA-AQFIFDHZSA-N,COC1CC(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)C1C;COC1CC(C)C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)C1C
ACIVICIN,ACIVICIN,CHEMBL1231101,BRD:BRD-BRD-K13050541-001-01-9;BRD:BRD-K13050541-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,"GAMMA GLUTAMYLTRANSFERASE INHIBITOR, GAMMA GLUTAMYLTRANSFERASE INHIBITORS",CTPS1,,,PHASE 2,"Multiple values for MOA: {'GAMMA GLUTAMYLTRANSFERASE INHIBITOR, GAMMA GLUTAMYLTRANSFERASE INHIBITORS', 'GAMMA GLUTAMYLTRANSFERASE INHIBITORS'}, defaulting to 'GAMMA GLUTAMYLTRANSFERASE INHIBITOR, GAMMA GLUTAMYLTRANSFERASE INHIBITORS'",Small molecule,Unknown,QAWIHIJWNYOLBE-OKKQSCSOSA-N,N[C@H]([C@@H]1CC(CL)=NO1)C(O)=O;N[C@H](C(=O)O)[C@@H]1CC(CL)=NO1
ACLIDINIUM,ACLIDINIUM,CHEMBL1194325,BRD:BRD-BRD-K74363950-004-01-0;BRD:BRD-K74363950-004-01-0,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,"BRONCHITIS, EMPHYSEMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",,LAUNCHED,,Small molecule,Approved,ASMXXROZKSBQIH-VITNCHFBSA-N,O=C(O[C@H]1C[N+]2(CCCOC3CCCCC3)CCC1CC2)C(O)(C1CCCS1)C1CCCS1;OC(C(=O)O[C@H]1C[N+]2(CCCOC3CCCCC3)CCC1CC2)(C1CCCS1)C1CCCS1
ACOLBIFENE,ACOLBIFENE,CHEMBL68055,BRD:BRD-K00004720-001-01-9,rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,DUYNJNWVGIWJRI-LJAQVGFWSA-N,CC1=C(C2CCC(O)CC2)[C@H](C2CCC(OCCN3CCCCC3)CC2)OC2CC(O)CCC21
ACOZIBOROLE,ACOZIBOROLE,CHEMBL2347704,BRD:BRD-K00003303-001-01-9,rep_single_dose,ANTITRYPANOSOMAL,,,,,,Small molecule,Phase 2,PTYGDEXEGLDNAZ-UHFFFAOYSA-N,CC1(C)OB(O)C2CC(NC(=O)C3CCC(F)CC3C(F)(F)F)CCC21
ACPC,ACPC,,BRD:BRD-BRD-K66465025-001-05-1;BRD:BRD-K66465025-001-05-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,NC1(CC1)C(O)=O
ACRIVASTINE,ACRIVASTINE,CHEMBL1224,BRD:BRD-BRD-K50163129-001-01-4;BRD:BRD-K50163129-001-01-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,PWACSDKDOHSSQD-IUTFFREVSA-N,CC1CCC(/C(=C\CN2CCCC2)C2CCCC(/C=C/C(=O)O)N2)CC1;CC1CCC(CC1)C(=C/CN1CCCC1)\C1CCCC(\C=C\C(O)=O)N1
ACRIZANIB,ACRIZANIB,,BRD:BRD-K00093439-001-01-9,rep_single_dose,,,,,,,,NA,,
ACRYLATE,ACRYLATE,,BRD:BRD-M00184283-001-01-1,rep_single_dose,MUCUS PROTECTING AGENT,,,,,,,NA,,
ACT-132577,ACT-132577,CHEMBL2165326,BRD:BRD-K34843150-001-03-0,rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA;EDNRB,,,,,Small molecule,Phase 3,DKULOVKANLVDEA-UHFFFAOYSA-N,NS(=O)(=O)NC1NCNC(OCCOC2NCC(BR)CN2)C1-C1CCC(BR)CC1
ACT-462206,ACT-462206,CHEMBL3597952,BRD:BRD-BRD-K19781342-001-01-4;BRD:BRD-K19781342-001-01-4,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,PHASE 1,,Small molecule,Phase 1,NHPQGZOBHSVTAQ-IBGZPJMESA-N,COC1CCC(CC1)S(=O)(=O)N1CCC[C@H]1C(=O)NC1CC(C)CC(C)C1;COC1CCC(S(=O)(=O)N2CCC[C@H]2C(=O)NC2CC(C)CC(C)C2)CC1
ACT-709478,ACT-709478,CHEMBL4217292,BRD:BRD-K00003538-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,LSYANGLAZUZYFX-UHFFFAOYSA-N,N#CC1CCC(CN2CCC(NC(=O)CC3CCC(C4(C(F)(F)F)CC4)CC3)N2)NC1
ACTARIT,ACTARIT,CHEMBL1885632,BRD:BRD-BRD-K33483813-001-10-0;BRD:BRD-K33483813-001-10-0,rep_primary;rep_single_dose,INTERLEUKIN RECEPTOR AGONIST,,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Unknown,MROJXXOCABQVEF-UHFFFAOYSA-N,CC(=O)NC1CCC(CC(=O)O)CC1;CC(=O)NC1CCC(CC(O)=O)CC1
ACTB-1003,ACTB-1003,,BRD:BRD-BRD-K35936936-001-01-6;BRD:BRD-K35936936-001-01-6,rep_primary;rep_single_dose,"FGFR INHIBITOR, VEGFR INHIBITOR",KDR;TEK,,,PHASE 1,,,NA,,COCC1C(CN2CCOCC2)N2NCNC(N)C2C1-C1CCC(NC(=O)NC2CC(CCC2F)C(F)(F)F)C(F)C1
ACTD,ACTD,,GDSC2:1911,gdsc,,,,,,,,NA,,
ACTINOMYCIN D,ACTINOMYCIN D,CHEMBL1554,GDSC2:1811;GDSC2:1911,gdsc,,,,,,,Protein,Approved,RJURFGZVJUQBHK-IIXSONLDSA-N,CC1C2OC3C(C)CCC(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)C3NC-2C(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)C(N)C1=O
ACTINOMYCIN-D,ACTINOMYCIN-D,CHEMBL1554,BRD:BRD-A42383464-001-06-3;BRD:BRD-BRD-A42383464-001-06-3,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,"WILM'S TUMOR, EWING'S SARCOMA, RHABDOMYOSARCOMA, TESTICULAR CARCINOMA",,LAUNCHED,,Protein,Approved,RJURFGZVJUQBHK-IIXSONLDSA-N,CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)C2CCC(C)C3OC4C(C)C(=O)C(N)C(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)C4NC23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O;CC(C)C1NC(=O)C(NC(=O)C2CCC(C)C3OC4C(C)C(=O)C(N)C(C(=O)NC5C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C6CCCN6C(=O)C(NC5=O)C(C)C)C4NC23)C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C1=O;CC1C2OC3C(C)CCC(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)C3NC-2C(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)C(N)C1=O
ACTINONIN,ACTINONIN,CHEMBL308333,BRD:BRD-K24621118-001-04-9,rep_single_dose,,,,,,,Small molecule,NA,XJLATMLVMSFZBN-VYDXJSESSA-N,CCCCC[C@H](CC(=O)NO)C(=O)N[C@H](C(=O)N1CCC[C@H]1CO)C(C)C
ACTINOQUINOL,ACTINOQUINOL,CHEMBL1356732,BRD:BRD-BRD-K08837089-236-01-6;BRD:BRD-K08837089-236-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,YAMVZYRZAMBCED-UHFFFAOYSA-N,CCOC1CCC(C2CCCNC12)S(O)(=O)=O;CCOC1CCC(S(=O)(=O)O)C2CCCNC12
ACUMAPIMOD,ACUMAPIMOD,CHEMBL3545226,BRD:BRD-K00003220-001-01-9,rep_single_dose,P38 MAPK INHIBITOR,,,,,,Small molecule,Phase 2,,
ACY-1215,ACY-1215,CHEMBL2364628,BRD:BRD-BRD-K82928847-001-04-7;BRD:BRD-K82928847-001-04-7;GDSC1:264,gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC6;HDAC8,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,QGZYDVAGYRLSKP-UHFFFAOYSA-N,O=C(CCCCCCNC(=O)C1CNC(N(C2CCCCC2)C2CCCCC2)NC1)NO;ONC(=O)CCCCCCNC(=O)C1CNC(NC1)N(C1CCCCC1)C1CCCCC1
ACYCLOVIR,ACYCLOVIR,CHEMBL1200380;CHEMBL184,BRD:BRD-BRD-K32318651-001-23-7;BRD:BRD-BRD-K32318651-001-24-5;BRD:BRD-K32318651-001-23-7;BRD:BRD-K32318651-001-24-5,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,PNP,"GENITIAL HERPES, SHINGLES, CHICKEN POX",,LAUNCHED,,Small molecule,Approved,MKUXAQIIEYXACX-UHFFFAOYSA-N;RMLUKZWYIKEASN-UHFFFAOYSA-M,NC1NC([O-])C2NCN(COCCO)C2N1.[NA+];NC1NC2C(NCN2COCCO)C(=O)[NH]1;NC1NC2N(COCCO)CNC2C(=O)[NH]1
AD-5467,AD-5467,,BRD:BRD-A80280426-001-03-8;BRD:BRD-BRD-A80280426-001-03-8,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,,,PHASE 2,,,NA,,CC(C)C1OC2C(CCCC2N(CC(O)=O)C1=S)C(C)C
MRTX-849,ADAGRASIB;MRTX-849,CHEMBL4594350,BRD:BRD-K00029445-001-03-9,oncref_1,INHIBITOR OF KRAS-G12C,KRAS,,,,,Small molecule,Phase 3,PEMUGDMSUDYLHU-ZEQRLZLVSA-N,C=C(F)C(=O)N1CCN(C2NC(OC[C@@H]3CCCN3C)NC3C2CCN(C2CCCC4CCCC(CL)C24)C3)C[C@@H]1CC#N
ADAPALENE,ADAPALENE,CHEMBL1265,BRD:BRD-BRD-K33127281-001-05-6;BRD:BRD-K33127281-001-05-6,rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB;RARG;RXRA;RXRB;RXRG,ACNE VULGARIS (AV),,LAUNCHED,,Small molecule,Approved,LZCDAPDGXCYOEH-UHFFFAOYSA-N,COC1CCC(-C2CCC3CC(C(=O)O)CCC3C2)CC1C12CC3CC(CC(C3)C1)C2;COC1CCC(CC1C12CC3CC(CC(C3)C1)C2)-C1CCC2CC(CCC2C1)C(O)=O
ADAPREV,ADAPREV,,BRD:BRD-A73427433-240-01-3;BRD:BRD-BRD-A73427433-240-01-3,rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,AKR1B1;GPI;HK1;IGF2R;M6PR;PYGM,,,PHASE 3,"Multiple values for repurposing_target: {'IGF2R;M6PR', 'AKR1B1;GPI;HK1;IGF2R;M6PR;PYGM'}, taking the union",,NA,,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O
ADAPTAVIR,ADAPTAVIR,,BRD:BRD-BRD-K37151368-001-01-7;BRD:BRD-K37151368-001-01-7,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR5,,,PHASE 2,,,NA,,C[C@@H](O)[C@H](NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O
ADAROTENE,ADAROTENE,CHEMBL442016,BRD:BRD-BRD-K00152668-001-01-5;BRD:BRD-K00152668-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARB;RARG,,,PHASE 1,,Small molecule,NA,QAWBIEIZDDIEMW-FPYGCLRLSA-N,O=C(O)/C=C/C1CCC(-C2CCC(O)C(C34CC5CC(CC(C5)C3)C4)C2)CC1;OC(=O)\C=C\C1CCC(CC1)-C1CCC(O)C(C1)C12CC3CC(CC(C3)C1)C2
ADATANSERIN,ADATANSERIN,CHEMBL2111138,BRD:BRD-BRD-K67789209-001-01-0;BRD:BRD-K67789209-001-01-0,rep_primary;rep_single_dose,"SEROTONIN RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR1A;HTR2A,,,PHASE 2,,Small molecule,Unknown,HPFLVTSWRFCPCV-UHFFFAOYSA-N,O=C(NCCN1CCN(C2NCCCN2)CC1)C12CC3CC(CC(C3)C1)C2;O=C(NCCN1CCN(CC1)C1NCCCN1)C12CC3CC(CC(C3)C1)C2
ADAVIVINT,ADAVIVINT,CHEMBL4297639,BRD:BRD-K00003499-001-01-9,rep_single_dose,WNT PATHWAY INHIBITOR,,,,,,Small molecule,Phase 3,AQDWDWAYVBQMAM-UHFFFAOYSA-N,CC(C)CC(=O)NC1CNCC(-C2CCC3[NH]NC(-C4NC5CNCC(-C6CCCC(F)C6)C5[NH]4)C3C2)C1
MK-1775,ADAVOSERTIB;MK-1775,CHEMBL1976040,BRD:BRD-BRD-K54256913-001-08-7;BRD:BRD-K54256913-001-08-7;BRD:BRD-U00115430-001-01-9;CTRP:418167;GDSC2:1179,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,WEE1 KINASE INHIBITOR,WEE1,,,PHASE 2,"Multiple values for MOA: {'WEE1 KINASE INHIBITOR', 'INHIBITOR OF WEE1'}, defaulting to 'WEE1 KINASE INHIBITOR'
Multiple values for structure_id: {'K54256913', 'U00115430'}, defaulting to None",Small molecule,Phase 2,BKWJAKQVGHWELA-UHFFFAOYSA-N,C=CCN1C(=O)C2CNC(NC3CCC(N4CCN(C)CC4)CC3)NC2N1-C1CCCC(C(C)(C)O)N1;CN1CCN(CC1)C1CCC(NC2NCC3C(N2)N(-C2CCCC(N2)C(C)(C)O)N(CC=C)C3=O)CC1
IMEPITOIN,ADD-233089;IMEPITOIN,,BRD:BRD-BRD-K43055376-001-01-2;BRD:BRD-K43055376-001-01-2;BRD:BRD-K43055376-001-04-9,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,,,,PHASE 1,,,NA,,CLC1CCC(CC1)N1CC(=NC1=O)N1CCOCC1
ADEFOVIR,ADEFOVIR,CHEMBL484,BRD:BRD-BRD-K77484724-001-02-0;BRD:BRD-K77484724-001-02-0,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,HEPATITIS B,,LAUNCHED,,Small molecule,Phase 3,SUPKOOSCJHTBAH-UHFFFAOYSA-N,NC1NCNC2C1NCN2CCOCP(=O)(O)O;NC1NCNC2N(CCOCP(O)(O)=O)CNC12
ADEFOVIR-DIPIVOXIL,ADEFOVIR-DIPIVOXIL,,BRD:BRD-BRD-K96159438-001-06-3;BRD:BRD-K96159438-001-06-3,rep_multi_dose;rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,HEPATITIS B,,LAUNCHED,,,NA,,CC(C)(C)C(=O)OCOP(=O)(COCCN1CNC2C(N)NCNC12)OCOC(=O)C(C)(C)C
ADELMIDROL,ADELMIDROL,CHEMBL2105967,BRD:BRD-K78097265-001-02-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Phase 2,PAHZPHDAJQIETD-UHFFFAOYSA-N,O=C(CCCCCCCC(=O)NCCO)NCCO
ADENINE,ADENINE,CHEMBL226345,BRD:BRD-BRD-K26060080-065-05-6;BRD:BRD-K26060080-065-05-6,rep_primary;rep_single_dose,PROTEIN SYNTHESIS STIMULANT,ACACB;ACP1;APRT;MTAP;PECR;SRPK2,,,PRECLINICAL,,Small molecule,Phase 3,GFFGJBXGBJISGV-UHFFFAOYSA-N,NC1[NH]CNC2NCNC1-2;NC1NCNC2[NH]CNC12
ADENOSINE,ADENOSINE,CHEMBL477,BRD:BRD-BRD-K01577834-001-15-1;BRD:BRD-K01577834-001-15-1,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3;PI4K2A;PI4K2B;TRPM4,WOLFF-PARKINSON-WHITE SYNDROME (WPW),,LAUNCHED,,Small molecule,Approved,OIRDTQYFTABQOQ-KQYNXXCUSA-N,NC1NCNC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O;NC1NCNC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ADENOSINE-PHOSPHATE,ADENOSINE-PHOSPHATE,,BRD:BRD-A10111329-001-04-6;BRD:BRD-BRD-A10111329-001-04-6,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ACSL1;ACSS1;ACSS2;ADCY1;ADK;CREB1;FBP1;HINT1;PDE4B;PDE4D;PIM1;PRKAA1;PRKAB1;PRKAB2;PYGL;TRPM4,,,LAUNCHED,,,NA,,NC1NCNC2N(CNC12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O
ADENOSINE-TRIPHOSPHATE,ADENOSINE-TRIPHOSPHATE,,BRD:BRD-A31990649-304-02-3;BRD:BRD-BRD-A31990649-304-02-3,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ABCA1;ABCB1;ABCB11;ABCC2;ABCC8;ABCC9;ABCG1;ABL1;ABL2;ACSL1;ACSS1;ACSS2;ACVR1;ACVR1B;ACVRL1;ADCY1;ADRBK1;ADRBK2;AFG3L2;AKT1;ALK;AMHR2;APAF1;ARAF;ASNA1;ASNS;ASS1;CDK15;GPR17;ITPR1;NAE1;NT5C2;P2RY1;P2RY11;P2RY13;P2RY2;P2RY4;PRKAA1;RYR1;RYR2;RYR3;SLC25A4;TNK2;TRPM4;TRPM7,,,PHASE 2,,,NA,,NC1NCNC2N(CNC12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O
ADIPHENINE,ADIPHENINE,CHEMBL353846,BRD:BRD-BRD-K60907894-003-23-5;BRD:BRD-K60907894-003-23-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA1,SPASMS,,LAUNCHED,,Small molecule,Unknown,JGOAIQNSOGZNBX-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C(C1CCCCC1)C1CCCCC1
ADIPIC-ACID,ADIPIC-ACID,,BRD:BRD-BRD-K10656395-001-02-1;BRD:BRD-K10656395-001-02-1,rep_primary;rep_single_dose,SOLUTE CARRIER FAMILY MEMBER INHIBITOR,SLC22A6,,,PRECLINICAL,,,NA,,OC(=O)CCCCC(O)=O
ADIPORON,ADIPORON,,BRD:BRD-BRD-K68810443-001-01-9;BRD:BRD-K68810443-001-01-9,rep_primary;rep_single_dose,ADIPONECTIN RECEPTOR AGONIST,ADIPOR1;ADIPOR2,,,PRECLINICAL,,,NA,,O=C(COC1CCC(CC1)C(=O)C1CCCCC1)NC1CCN(CC2CCCCC2)CC1
ADL5859,ADL5859,,BRD:BRD-BRD-K39624409-003-02-6;BRD:BRD-K39624409-003-02-6,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRD1,,,PHASE 2,,,NA,,CCN(CC)C(=O)C1CCC(CC1)C1=CC2(CCNCC2)OC2CCCC(O)C12
ADOMEGLIVANT,ADOMEGLIVANT,CHEMBL3707351,BRD:BRD-K00003302-001-01-9,rep_single_dose,GLUCAGON RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,FASLTMSUPQDLIB-MHZLTWQESA-N,CC1CC(O[C@@H](CCC(F)(F)F)C2CCC(C(=O)NCCC(=O)O)CC2)CC(C)C1-C1CCC(C(C)(C)C)CC1
ADOPRAZINE,ADOPRAZINE,CHEMBL221692,BRD:BRD-BRD-K34870043-001-01-8;BRD:BRD-K34870043-001-01-8,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR AGONIST",DRD2;HTR1A,,,PHASE 2,,Small molecule,Phase 1,IUVSEUFHPNITEQ-UHFFFAOYSA-N,FC1CCC(-C2CNCC(CN3CCN(C4CCCC5C4OCCO5)CC3)C2)CC1;FC1CCC(CC1)-C1CNCC(CN2CCN(CC2)C2CCCC3OCCOC23)C1
ADRAFINIL,ADRAFINIL,CHEMBL93077,BRD:BRD-A90926615-001-01-9;BRD:BRD-BRD-A90926615-001-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,FATIGUE,,LAUNCHED,,Small molecule,Unknown,CGNMLOKEMNBUAI-UHFFFAOYSA-N,O=C(C[S+]([O-])C(C1CCCCC1)C1CCCCC1)NO;ONC(=O)CS(=O)C(C1CCCCC1)C1CCCCC1
ADRENALONE,ADRENALONE,CHEMBL2103996,BRD:BRD-BRD-K82343404-003-02-4;BRD:BRD-K82343404-003-02-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A,HEMORRHAGE,,LAUNCHED,,Small molecule,Unknown,PZMVOUYYNKPMSI-UHFFFAOYSA-N,CNCC(=O)C1CCC(O)C(O)C1
ADRENOSTERONE,ADRENOSTERONE,,BRD:BRD-BRD-K17368287-001-18-3;BRD:BRD-K17368287-001-18-3,rep_primary;rep_single_dose,11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR,HSD11B1;HSD11B2,,,PRECLINICAL,,,NA,,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
ADRIABLASTIN,ADRIABLASTIN,CHEMBL53463,GDSC1:133,gdsc,,,,,,,Small molecule,Approved,AOJJSUZBOXZQNB-TZSSRYMLSA-N,COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
HYDROXYDAUNORUBICIN,ADRIAMYCIN;DOXORUBICIN;HYDROXYDAUNORUBICIN,CHEMBL2354444;CHEMBL359744;CHEMBL53463,BRD:BRD-BRD-K92093830-003-30-8;BRD:BRD-K00094013-003-39-9;BRD:BRD-K92093830-003-30-8;CTRP:36599;GDSC1:133,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,DNA INTERCALATOR/INHIBITOR OF TOPOISOMERASE,TOP2A;TOP2B,"ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ACUTE MYELOID LEUKEMIA (AML), WILM'S TUMOR, BREAST CANCER, OVARIAN CANCER, HODGKIN'S LYMPHOMA, BLADDER CANCER, MULTIPLE MYELOMA",,LAUNCHED,"Multiple values for MOA: {'DNA INTERCALATOR/INHIBITOR OF TOPOISOMERASE', 'TOPOISOMERASE INHIBITOR'}, defaulting to 'DNA INTERCALATOR/INHIBITOR OF TOPOISOMERASE'
Multiple values for repurposing_target: {'TOP2A', 'TOP2A;TOP2B'}, taking the union
Multiple values for structure_id: {'K92093830', 'K00094013'}, defaulting to None",Small molecule,Approved,AOJJSUZBOXZQNB-TZSSRYMLSA-N;KMSKQZKKOZQFFG-YXRRJAAWSA-N;MWWSFMDVAYGXBV-RUELKSSGSA-N,COC1CCCC2C(=O)C3C(O)C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4C(O)C3C(=O)C12)C(=O)CO;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.CL;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1
ADRIFORANT (HYDROCHLORIDE),ADRIFORANT (HYDROCHLORIDE),,BRD:BRD-K00075632-305-02-9,rep_single_dose,,,,,,,,NA,,
ADX-10059,ADX-10059,CHEMBL3545036,BRD:BRD-BRD-K77911775-003-01-8;BRD:BRD-K77911775-003-01-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATOR,GRM5,,,PHASE 2,,Small molecule,Phase 2,MEDCLNYIYBERKO-UHFFFAOYSA-N,CC1CC(C)C(N)C(C#CC2CCCC(F)C2)N1;CC1CC(C)C(N)C(N1)C#CC1CCCC(F)C1
ADX-47273,ADX-47273,,BRD:BRD-BRD-K56543881-001-02-7;BRD:BRD-K56543881-001-02-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,GRM5,,,PRECLINICAL,,,NA,,FC1CCC(CC1)C(=O)N1CCC[C@@H](C1)C1NC(NO1)-C1CCC(F)CC1
AEE788,AEE788,CHEMBL587723,BRD:BRD-BRD-K40718343-001-02-6;BRD:BRD-K40718343-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, VEGFR INHIBITOR",EGFR;ERBB2;ERBB4;FGFR2;FGFR3;KDR,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,OONFNUWBHFSNBT-HXUWFJFHSA-N,CCN1CCN(CC2CCC(-C3CC4C(N[C@H](C)C5CCCCC5)NCNC4[NH]3)CC2)CC1;CCN1CCN(CC2CCC(CC2)-C2CC3C(N[C@H](C)C4CCCCC4)NCNC3[NH]2)CC1
AEG3482,AEG3482,,BRD:BRD-BRD-K77634909-001-03-5;BRD:BRD-K77634909-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,HSP INDUCER,,,,PRECLINICAL,,,NA,,NS(=O)(=O)C1NN2CC(NC2S1)-C1CCCCC1
AF38469,AF38469,,BRD:BRD-BRD-K47816470-001-01-8;BRD:BRD-K47816470-001-01-8,rep_primary;rep_single_dose,SORTILIN INHIBITOR,SORT1,,,PRECLINICAL,,,NA,,CC1CCCC(NC(=O)C2CCC(CC2C(O)=O)C(F)(F)F)N1
AFALANINE,AFALANINE,CHEMBL134570,BRD:BRD-BRD-K53205568-001-02-6;BRD:BRD-K53205568-001-02-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2,,,PHASE 3,,Small molecule,Unknown,CBQJSKKFNMDLON-UHFFFAOYSA-N,CC(=O)N[C@@H](CC1CCCCC1)C(O)=O;CC(=O)NC(CC1CCCCC1)C(=O)O
AFAMELANOTIDE,AFAMELANOTIDE,CHEMBL441738,BRD:BRD-K00003330-001-01-9,rep_single_dose,MELANOCYTE-STIMULATING HORMONE MIMETIC,,,,,,Protein,Approved,UAHFGYDRQSXQEB-LEBBXHLNSA-N,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1C[NH]CN1)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C
BIBW2992,AFATINIB;BIBW2992,CHEMBL1173655,BRD:BRD-BRD-K66175015-001-09-0;BRD:BRD-K66175015-001-01-7;BRD:BRD-K66175015-001-09-0;CTRP:606135;GDSC1:1032;GDSC1:1377;GDSC2:1032,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF EGFR, ERBB2, AND ERBB4",EGFR;ERBB2;ERBB4,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,"Multiple values for MOA: {'EGFR INHIBITOR', 'INHIBITOR OF EGFR, ERBB2, AND ERBB4'}, defaulting to 'INHIBITOR OF EGFR, ERBB2, AND ERBB4'",Small molecule,Approved,ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C/C=C/C(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1O[C@H]1CCOC1;CN(C)C\C=C\C(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1O[C@H]1CCOC1
AFLOQUALONE,AFLOQUALONE,CHEMBL2105918,BRD:BRD-BRD-K69247067-001-01-8;BRD:BRD-K69247067-001-01-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,SEDATIVE,,LAUNCHED,,Small molecule,Unknown,VDOSWXIDETXFET-UHFFFAOYSA-N,CC1CCCCC1-N1C(CF)NC2CCC(N)CC2C1=O
AFN-1252,AFN-1252,CHEMBL1652621,BRD:BRD-BRD-K23791635-001-01-3;BRD:BRD-K23791635-001-01-3,rep_primary;rep_single_dose,FABI INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,QXTWSUQCXCWEHF-JXMROGBWSA-N,CC1C(CN(C)C(=O)/C=C/C2CNC3C(C2)CCC(=O)N3)OC2CCCCC12;CN(CC1OC2CCCCC2C1C)C(=O)\C=C\C1=CNC2=NC(=O)CCC2=C1
AFOBAZOLE,AFOBAZOLE,CHEMBL3707307,BRD:BRD-BRD-K37793595-003-01-7;BRD:BRD-K37793595-003-01-7,rep_multi_dose;rep_primary;rep_single_dose,ANXIOLYTIC,,ANXIETY,,LAUNCHED,,Small molecule,Phase 3,WWNUCVSRRUDYPP-UHFFFAOYSA-N,CCOC1CCC2[NH]C(SCCN3CCOCC3)NC2C1;CCOC1CCC2NC(SCCN3CCOCC3)[NH]C2C1
AFOXOLANER,AFOXOLANER,CHEMBL2219412;CHEMBL4298144,BRD:BRD-K00084836-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,OXDDDHGGRFRLEE-QHCPKHFHSA-N;OXDDDHGGRFRLEE-UHFFFAOYSA-N,O=C(CNC(=O)C1CCC(C2=NO[C@@](C3CC(CL)CC(C(F)(F)F)C3)(C(F)(F)F)C2)C2CCCCC12)NCC(F)(F)F;O=C(CNC(=O)C1CCC(C2=NOC(C3CC(CL)CC(C(F)(F)F)C3)(C(F)(F)F)C2)C2CCCCC12)NCC(F)(F)F
AFURESERTIB,AFURESERTIB,CHEMBL2219422,GDSC2:1912,gdsc,,,,,,,Small molecule,Phase 2,AFJRDFWMXUECEW-LBPRGKRZSA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCCC(F)C2)SC1CL
AG-014699,AG-014699,CHEMBL1173055;CHEMBL2105733,GDSC1:1175,gdsc,,,,,,,Small molecule,Approved,FCCGJTKEKXUBFZ-UHFFFAOYSA-N;HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCC1CCC(-C2[NH]C3CC(F)CC4C3C2CCNC4=O)CC1;CNCC1CCC(-C2[NH]C3CC(F)CC4C3C2CCNC4=O)CC1.O=P(O)(O)O
AG-1024,AG-1024,,BRD:BRD-BRD-K08310154-001-03-8;BRD:BRD-K08310154-001-03-8,rep_primary;rep_single_dose,INSULIN GROWTH FACTOR RECEPTOR INHIBITOR,IGF1R,,,PRECLINICAL,,,NA,,CC(C)(C)C1CC(C=C(C#N)C#N)CC(BR)C1O
AG-13736,AG-13736,CHEMBL1289926,GDSC1:1021;GDSC2:1021,gdsc,,,,,,,Small molecule,Approved,RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)C1CCCCC1SC1CCC2C(/C=C/C3CCCCN3)N[NH]C2C1
AG-14361,AG-14361,,BRD:BRD-BRD-K00615600-001-12-9;BRD:BRD-K00615600-001-12-9,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PRECLINICAL,,,NA,,CN(C)CC1CCC(CC1)-C1NC2CCCC3C(=O)NCCN1C23
AG-14447,AG-14447,CHEMBL1173055,GDSC1:1175,gdsc,,,,,,,Small molecule,Approved,HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCC1CCC(-C2[NH]C3CC(F)CC4C3C2CCNC4=O)CC1
AG-14699,AG-14699,CHEMBL2105733,GDSC1:1175,gdsc,,,,,,,Small molecule,Phase 1,FCCGJTKEKXUBFZ-UHFFFAOYSA-N,CNCC1CCC(-C2[NH]C3CC(F)CC4C3C2CCNC4=O)CC1.O=P(O)(O)O
AG-270,AG-270,CHEMBL4802164,BRD:BRD-U00115411-001-01-9,oncref_1,INHIBITOR OF METHIONINE ADENOSYLTRANSFERASE 2A,MAT2A,,,,,Unknown,Phase 1,,
AG-490,AG-490,,BRD:BRD-BRD-K47105409-001-14-5;BRD:BRD-K47105409-001-14-5,rep_primary;rep_single_dose,"EGFR INHIBITOR, JAK INHIBITOR",EGFR;JAK2;JAK3,,,PRECLINICAL,,,NA,,OC1CCC(CC1O)\C=C(/C#N)C(=O)NCC1CCCCC1
AG-556,AG-556,,BRD:BRD-K81048131-001-03-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,,NA,,
AGI-24512,AGI-24512,,BRD:BRD-K27773864-001-02-9,oncref_2,INHIBITOR OF MAT2A,MAT2A,,,,,,NA,,
AGI-5198,AGI-5198,,BRD:BRD-A56371469-001-03-3;BRD:BRD-BRD-A56371469-001-03-3;GDSC2:1913,gdsc;rep_primary;rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,IDH1,,,PRECLINICAL,,,NA,,CC1NCCN1CC(=O)N(C(C(=O)NC1CCCCC1)C1CCCCC1C)C1CCCC(F)C1
AGI-6780,AGI-6780,,BRD:BRD-BRD-K04691817-001-01-8;BRD:BRD-K04691817-001-01-8;GDSC1:562;GDSC2:1634,gdsc;rep_primary;rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,IDH2,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCCC(NC(=O)NC2CC(CCC2-C2CCSC2)S(=O)(=O)NC2CC2)C1
AGK-2,AGK-2,,CTRP:411716,ctrp,,,,,,,,NA,,
AGMATINE,AGMATINE,CHEMBL58343,BRD:BRD-BRD-K49738308-065-04-9;BRD:BRD-K49738308-065-04-9,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,ADRA2C;ASIC3;CACNA1B;CHRNA1;GRIN1;KCNJ1;NISCH,,,PHASE 3,,Small molecule,NA,QYPPJABKJHAVHS-UHFFFAOYSA-N,NCCCCN=C(N)N;NCCCCNC(N)=N
AGN-192403,AGN-192403,,BRD:BRD-A18074780-003-02-0;BRD:BRD-BRD-A18074780-003-02-0,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR LIGAND,NISCH,,,PRECLINICAL,,,NA,,CC(C)[C@@H]1C2CCC(C2)[C@H]1N
AGN-194310,AGN-194310,,BRD:BRD-BRD-K70262971-001-01-9;BRD:BRD-K70262971-001-01-9,rep_primary;rep_single_dose,RETINOID RECEPTOR ANTAGONIST,RXRA;RXRB;RXRG,,,PHASE 3,,,NA,,CCC1CCC(CC1)C1=CC(C)(C)SC2CCC(CC12)C#CC1CCC(CC1)C(O)=O
AGN-195183,AGN-195183,CHEMBL107430,BRD:BRD-BRD-K32533226-001-01-3;BRD:BRD-K32533226-001-01-3,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,PNAWUIKCVQSLFG-UHFFFAOYSA-N,CC1(C)CCC(C)(C)C2C(CL)C(O)C(CC12)C(=O)NC1CC(F)C(C(O)=O)C(F)C1;CC1(C)CCC(C)(C)C2C1CC(C(=O)NC1CC(F)C(C(=O)O)C(F)C1)C(O)C2CL
AGOMELATINE,AGOMELATINE,CHEMBL10878,BRD:BRD-BRD-K84698278-001-03-4;BRD:BRD-K84698278-001-03-4,rep_primary;rep_single_dose,"MELATONIN RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR2A;HTR2B;HTR2C;MTNR1A;MTNR1B,DEPRESSION,,LAUNCHED,,Small molecule,Approved,YJYPHIXNFHFHND-UHFFFAOYSA-N,COC1CCC2CCCC(CCNC(C)=O)C2C1
AGP-103,AGP-103,,BRD:BRD-BRD-K91495480-001-02-2;BRD:BRD-K91495480-001-02-2,rep_primary;rep_single_dose,MEMBRANE PERMEABILITY INHIBITOR,,,,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCCCCCCCC(O)=O
AH-7614,AH-7614,,BRD:BRD-BRD-K10852420-001-02-5;BRD:BRD-K10852420-001-02-5,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR ANTAGONIST,FFAR4,,,PRECLINICAL,,,NA,,CC1CCC(CC1)S(=O)(=O)NC1C2CCCCC2OC2CCCCC12
AH11110,AH11110,,BRD:BRD-A64808605-003-02-7;BRD:BRD-BRD-A64808605-003-02-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR LIGAND,ADRA1B,,,PRECLINICAL,,,NA,,OC(COC1CCCCC1-C1CCCCC1)CC(=N)N1CCCCC1
AH6809,AH6809,,BRD:BRD-BRD-K59339270-001-02-6;BRD:BRD-K59339270-001-02-6,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGDR;PTGER1;PTGER2;PTGER3,,,PRECLINICAL,,,NA,,CC(C)OC1CCC2C(C1)OC1CCC(CC1C2=O)C(O)=O
AI-10-49,AI-10-49,,BRD:BRD-K89899948-001-01-7,rep_single_dose,CORE BINDING FACTOR INHIBITOR,CBFB,,,,,,NA,,
AICA RIBONUCLEOTIDE,AICA RIBONUCLEOTIDE,,GDSC1:1001,gdsc,,,,,,,,NA,,
AICAR,AICAR,,GDSC1:1001,gdsc,,,,,,,,NA,,
AIM-100,AIM-100,,BRD:BRD-BRD-K85139301-001-01-3;BRD:BRD-K85139301-001-01-3,rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,TNK2,,,PRECLINICAL,,,NA,,C(NC1NCNC2OC(C(-C3CCCCC3)C12)-C1CCCCC1)[C@@H]1CCCO1
AJ76-(+),AJ76-(+),,BRD:BRD-BRD-K76677554-003-02-1;BRD:BRD-K76677554-003-02-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;DRD4,,,PRECLINICAL,,,NA,,CCCN[C@@H]1CCC2C(OC)CCCC2[C@@H]1C
AJMALINE,AJMALINE,CHEMBL2105617,BRD:BRD-A48300215-001-04-8;BRD:BRD-BRD-A48300215-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN5A,WOLFF-PARKINSON-WHITE SYNDROME (WPW),,LAUNCHED,,Small molecule,Phase 3,CJDRUOGAGYHKKD-FUIWMBJSSA-N,CC[C@H]1C2CC3[C@@H]4N(C)C5CCCCC5[C@]44C[C@@H](C2C4O)N3[C@@H]1O;CCC1C2CC3C4N(C)C5CCCCC5C45CC(C2[C@H]5O)N3C1O
AK-55409,AK-55409,,GDSC1:1066;GDSC1:156;GDSC2:2169,gdsc,,,,,,,,NA,,
AK-7,AK-7,,BRD:BRD-BRD-K09143580-001-01-0;BRD:BRD-K09143580-001-01-0,rep_primary;rep_single_dose,SIRT INHIBITOR,SIRT2,,,PRECLINICAL,,,NA,,BRC1CCCC(NC(=O)C2CCCC(C2)S(=O)(=O)N2CCCCCC2)C1
AK161197,AK161197,,GDSC2:1622,gdsc,,,,,,,,NA,,
AK162157,AK162157,,GDSC2:1634,gdsc,,,,,,,,NA,,
AK175551,AK175551,,GDSC2:1618,gdsc,,,,,,,,NA,,
AK175558,AK175558,,GDSC2:1627,gdsc,,,,,,,,NA,,
AK176060,AK176060,,GDSC1:1230,gdsc,,,,,,,,NA,,
AK298746,AK298746,,GDSC2:1621,gdsc,,,,,,,,NA,,
AKBA,AKBA,CHEMBL237111,BRD:BRD-BRD-K54907283-001-01-2;BRD:BRD-K54907283-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5,,,PHASE 3,,Small molecule,Unknown,HMMGKOVEOFBCAU-BCDBGHSCSA-N,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C;CC(=O)O[C@@H]1CC[C@@]2(C)[C@@H](CC[C@]3(C)[C@@H]2C(=O)C=C2[C@@H]4[C@@H](C)[C@H](C)CC[C@]4(C)CC[C@]23C)[C@@]1(C)C(=O)O
AKLOMIDE,AKLOMIDE,CHEMBL1450565,BRD:BRD-BRD-K26807903-001-04-3;BRD:BRD-K26807903-001-04-3,rep_primary;rep_single_dose,,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,GFGSZUNNBQXGMK-UHFFFAOYSA-N,NC(=O)C1CCC([N+](=O)[O-])CC1CL;NC(=O)C1CCC(CC1CL)[N+]([O-])=O
AKT INHIBITOR VIII,AKT INHIBITOR VIII,,GDSC1:171;GDSC1:228,gdsc,,,,,,,,NA,,
AKTI-1/2,AKTI-1/2,,GDSC1:171;GDSC1:228,gdsc,,,,,,,,NA,,
AL-39256,AL-39256,CHEMBL14762,GDSC1:110,gdsc,,,,,,,Small molecule,Phase 2,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,CC[C@H](CO)NC1NC(NCC2CCCCC2)C2NCN(C(C)C)C2N1
AL-8697,AL-8697,,BRD:BRD-BRD-K44731351-001-01-6;BRD:BRD-K44731351-001-01-6,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PRECLINICAL,,,NA,,CC1C(F)CC(CC1-C1C(F)CN2C(NNC2C1F)C(C)(C)C)C(=O)NC1CC1
ALACEPRIL,ALACEPRIL,CHEMBL2103775,BRD:BRD-BRD-K51784806-001-01-6;BRD:BRD-K51784806-001-01-6,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,HYPERTENSION,,LAUNCHED,,Small molecule,Unknown,FHHHOYXPRDYHEZ-COXVUDFISA-N,C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1CCCCC1)C(O)=O;CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1CCCCC1)C(=O)O
ALAFOSFALIN,ALAFOSFALIN,CHEMBL3989665,BRD:BRD-BRD-K80403280-001-02-1;BRD:BRD-K80403280-001-02-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,BHAYDBSYOBONRV-IUYQGCFVSA-N,C[C@H](N)C(=O)N[C@@H](C)P(=O)(O)O;C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O
ALAGEBRIUM,ALAGEBRIUM,CHEMBL2111081,BRD:BRD-BRD-K96029467-003-01-9;BRD:BRD-K96029467-003-01-9,rep_primary;rep_single_dose,GLYCOSYLATION INHIBITOR,,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,LYLFQLCLUXOFOL-UHFFFAOYSA-N,CC1SC[N+](CC(=O)C2CCCCC2)C1C
ALANOSINE,ALANOSINE,CHEMBL452715,BRD:BRD-K00004718-001-01-9,rep_single_dose,ANTIMETABOLITE,,,,,,Small molecule,Phase 2,MLFKVJCWGUZWNV-REOHCLBHSA-N,N[C@@H](CN(O)N=O)C(=O)O
ALANTOLACTONE,ALANTOLACTONE,CHEMBL136356,BRD:BRD-K53731810-001-05-9,rep_single_dose,"APOPTOSIS STIMULANT, STAT INHIBITOR",STAT3,,,,,Small molecule,NA,PXOYOCNNSUAQNS-AGNJHWRGSA-N,C=C1C(=O)O[C@@H]2C[C@@]3(C)CCC[C@H](C)C3=C[C@H]12
ALAPROCLATE,ALAPROCLATE,CHEMBL251941;CHEMBL36591,BRD:BRD-A14966924-003-07-7;BRD:BRD-BRD-A14966924-003-07-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,SLC6A4,,,PHASE 2,,Small molecule,Unknown,FZSPJBYOKQPKCD-UHFFFAOYSA-N;FZSPJBYOKQPKCD-VIFPVBQESA-N,C[C@H](N)C(=O)OC(C)(C)CC1CCC(CL)CC1;CC(N)C(=O)OC(C)(C)CC1CCC(CL)CC1
ALARELIN,ALARELIN,,BRD:BRD-BRD-K42140276-402-01-4;BRD:BRD-K42140276-402-01-4,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,GNRH1,,,LAUNCHED,,,NA,,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CNC[NH]1)NC(=O)[C@@H]1CCC(=O)N1
ALBENDAZOLE,ALBENDAZOLE,CHEMBL1483,BRD:BRD-BRD-K79131256-001-17-9;BRD:BRD-K79131256-001-17-9,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBA1A;TUBB;TUBB4B,"CYSTIC HYDATID DISEASE, PARENCHYMAL NEUROCYSTICERCOSIS",,LAUNCHED,,Small molecule,Approved,HXHWSAZORRCQMX-UHFFFAOYSA-N,CCCSC1CCC2[NH]C(NC(=O)OC)NC2C1
ALBENDAZOLE-OXIDE,ALBENDAZOLE-OXIDE,,BRD:BRD-A67060370-001-02-9;BRD:BRD-BRD-A67060370-001-02-9,rep_primary;rep_single_dose,ANTHELMINTIC AGENT,,"CYSTIC HYDATID DISEASE, PARENCHYMAL NEUROCYSTICERCOSIS",,LAUNCHED,,,NA,,CCCS(=O)C1CCC2NC(NC(=O)OC)[NH]C2C1
ALBUTEROL,ALBUTEROL,CHEMBL714,BRD:BRD-A88254928-001-07-9;BRD:BRD-BRD-A88254928-001-07-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2,ASTHMA,,LAUNCHED,,Small molecule,Approved,NDAUXUAQIAJITI-UHFFFAOYSA-N,CC(C)(C)NCC(O)C1CCC(O)C(CO)C1
ALCAFTADINE,ALCAFTADINE,CHEMBL1201747,BRD:BRD-BRD-K55991142-001-01-6;BRD:BRD-K55991142-001-01-6,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,MWTBKTRZPHJQLH-UHFFFAOYSA-N,CN1CCC(=C2C3CCCCC3CCN3C(C=O)CNC32)CC1;CN1CCC(CC1)=C1C2NCC(C=O)N2CCC2CCCCC12
ALCLOFENAC,ALCLOFENAC,CHEMBL94081,BRD:BRD-BRD-K47492008-001-02-7;BRD:BRD-K47492008-001-02-7,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Approved,ARHWPKZXBHOEEE-UHFFFAOYSA-N,C=CCOC1CCC(CC(=O)O)CC1CL;OC(=O)CC1CCC(OCC=C)C(CL)C1
ALCLOMETASONE-DIPROPIONATE,ALCLOMETASONE-DIPROPIONATE,,BRD:BRD-A17407635-001-04-0;BRD:BRD-BRD-A17407635-001-04-0,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,CYP3A4;NR3C1;SERPINA6,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](CL)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
ALCURONIUM,ALCURONIUM,CHEMBL1180293;CHEMBL3305985,BRD:BRD-A84907376-300-03-8;BRD:BRD-BRD-A84907376-300-03-8,rep_primary;rep_single_dose,MUSCLE RELAXANT,CHRM1;CHRM2;CHRM3;CHRM4;CHRNA7,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,MUQUYTSLDVKIOF-BAURZYLOSA-N;MUQUYTSLDVKIOF-CHJKCJHBSA-N,C=CC[N@@+]12CC[C@@]34C5CCCCC5N5/C=C6/[C@H]7C[C@H]8[C@@]9(CC[N@@+]8(CC=C)C/C7=C/CO)C7CCCCC7N(/C=C(/[C@@H](C[C@@H]31)/C(=C\CO)C2)[C@H]54)[C@@H]69;C=CC[N+]12CC[C@@]34C5CCCCC5N5/C=C6/[C@H]7C[C@H]8[C@@]9(CC[N@@+]8(CC=C)C/C7=C/CO)C7CCCCC7N(/C=C(/[C@@H](C[C@@H]31)/C(=C\CO)C2)[C@H]54)[C@@H]69;OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)C1CCCCC41)C1CCCCC21
ALDA-1,ALDA-1,,BRD:BRD-BRD-K06890060-001-09-1;BRD:BRD-K06890060-001-09-1,rep_primary;rep_single_dose,ALDEHYDE DEHYDROGENASE ACTIVATOR,ALDH2,,,PRECLINICAL,,,NA,,CLC1CCCC(CL)C1C(=O)NCC1CCC2OCOC2C1
ALECENSA,ALECENSA,CHEMBL1738797;CHEMBL3707320,GDSC1:281,gdsc,,,,,,,Small molecule,Approved,GYABBVHSRIHYJR-UHFFFAOYSA-N;KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCC1CC2C(CC1N1CCC(N3CCOCC3)CC1)C(C)(C)C1[NH]C3CC(C#N)CCC3C1C2=O;CCC1CC2C(CC1N1CCC(N3CCOCC3)CC1)C(C)(C)C1[NH]C3CC(C#N)CCC3C1C2=O.CL
ALECTINIB,ALECTINIB,CHEMBL1738797,BRD:BRD-BRD-K11267252-001-04-4;BRD:BRD-K11267252-001-04-4;GDSC1:281,gdsc;rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK;MET,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,,Small molecule,Approved,KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCC1CC2C(=O)C3C([NH]C4CC(CCC34)C#N)C(C)(C)C2CC1N1CCC(CC1)N1CCOCC1;CCC1CC2C(CC1N1CCC(N3CCOCC3)CC1)C(C)(C)C1[NH]C3CC(C#N)CCC3C1C2=O
ALEGLITAZAR,ALEGLITAZAR,CHEMBL519504,BRD:BRD-K00076061-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,DAYKLWSKQJBGCS-NRFANRHFSA-N,CO[C@@H](CC1CCC(OCCC2NC(-C3CCCCC3)OC2C)C2CCSC12)C(=O)O
ALENDRONATE,ALENDRONATE,CHEMBL870,BRD:BRD-BRD-K75527158-360-04-9;BRD:BRD-K75527158-360-04-9,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,ATP6V1A;FDPS;PTPN4;PTPRE;PTPRS,OSTEOPOROSIS,,LAUNCHED,,Small molecule,Approved,OGSPWJRAVKPPFI-UHFFFAOYSA-N,NCCCC(O)(P(=O)(O)O)P(=O)(O)O;NCCCC(O)(P(O)(O)=O)P(O)(O)=O
ALEXIDINE,ALEXIDINE,CHEMBL1195210,BRD:BRD-A27883417-300-01-6;BRD:BRD-BRD-A27883417-300-01-6,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHATIDYLGLYCEROPHOSPHATASE INHIBITOR,PTPMT1,,,PRECLINICAL,,Small molecule,Unknown,LFVVNPBBFUSSHL-UHFFFAOYSA-N,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC;CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC
ALFACALCIDOL,ALFACALCIDOL,CHEMBL1601669,BRD:BRD-BRD-K49522529-001-02-9;BRD:BRD-BRD-K49522529-001-03-7;BRD:BRD-K49522529-001-02-9;BRD:BRD-K49522529-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,CYP27B1;VDR,VITAMIN D DEFICIENCY,,LAUNCHED,,Small molecule,Approved,OFHCOWSQAMBJIW-AVJTYSNKSA-N,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O;CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C
ALFADOLONE-ACETATE,ALFADOLONE-ACETATE,,BRD:BRD-BRD-K51751936-001-09-1;BRD:BRD-K51751936-001-09-1,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,,,,PHASE 2,,,NA,,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
ALFAXALONE,ALFAXALONE,CHEMBL190279,BRD:BRD-BRD-K41445866-001-18-8;BRD:BRD-K41445866-001-18-8,rep_primary;rep_single_dose,"CHLORIDE CHANNEL AGONIST, BENZODIAZEPINE RECEPTOR AGONIST",GABBR1,GENERAL ANAESTHETIC,,LAUNCHED,"Multiple values for MOA: {'BENZODIAZEPINE RECEPTOR AGONIST, CHLORIDE CHANNEL AGONIST', 'CHLORIDE CHANNEL AGONIST, BENZODIAZEPINE RECEPTOR AGONIST'}, defaulting to 'CHLORIDE CHANNEL AGONIST, BENZODIAZEPINE RECEPTOR AGONIST'",Small molecule,Unknown,DUHUCHOQIDJXAT-OLVMNOGESA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
ALFUZOSIN,ALFUZOSIN,CHEMBL709,BRD:BRD-A09056319-003-07-7;BRD:BRD-BRD-A09056319-003-07-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;KCNH2,BENIGN PROSTATIC HYPERPLASIA (BPH),,LAUNCHED,,Small molecule,Approved,WNMJYKCGWZFFKR-UHFFFAOYSA-N,COC1CC2NC(N(C)CCCNC(=O)C3CCCO3)NC(N)C2CC1OC;COC1CC2NC(NC(N)C2CC1OC)N(C)CCCNC(=O)C1CCCO1
ALGESTONE-ACETOPHENIDE,ALGESTONE-ACETOPHENIDE,,BRD:BRD-A41774846-001-01-4;BRD:BRD-BRD-A41774846-001-01-4,rep_primary;rep_single_dose,,,CONTRACEPTIVE,,LAUNCHED,,,NA,,CC(=O)[C@@]12OC(C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)C1CCCCC1
ALIBENDOL,ALIBENDOL,CHEMBL2105999,BRD:BRD-BRD-K60102752-001-02-2;BRD:BRD-K60102752-001-02-2,rep_primary;rep_single_dose,ANTISPASMODIC,,BILE STIMULATION,,LAUNCHED,,Small molecule,Unknown,UMJHTFHIQDEGKB-UHFFFAOYSA-N,C=CCC1CC(OC)C(O)C(C(=O)NCCO)C1;COC1CC(CC=C)CC(C(=O)NCCO)C1O
ALICAPISTAT,ALICAPISTAT,,BRD:BRD-K00091073-001-01-9,rep_single_dose,,,,,,,,NA,,
ALIMEMAZINE,ALIMEMAZINE,CHEMBL829,BRD:BRD-A49225603-045-10-0;BRD:BRD-BRD-A49225603-045-10-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH1,SEDATIVE,,LAUNCHED,,Small molecule,Approved,ZZHLYYDVIOPZBE-UHFFFAOYSA-N,CC(CN(C)C)CN1C2CCCCC2SC2CCCCC12;CC(CN(C)C)CN1C2CCCCC2SC2CCCCC21
ALINIDINE,ALINIDINE,CHEMBL278581,BRD:BRD-K00004709-001-01-9,rep_single_dose,BRADYCARDIC EFFECT,,,,,,Small molecule,Unknown,OXTYVEUAQHPPMV-UHFFFAOYSA-N,C=CCN(C1=NCCN1)C1C(CL)CCCC1CL
ALISERTIB,ALISERTIB,CHEMBL483158,BRD:BRD-BRD-K75295174-001-05-0;BRD:BRD-K75295174-001-05-0;CTRP:636711;GDSC1:431;GDSC2:1051,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA,,,PHASE 3,,Small molecule,Phase 3,ZLHFILGSQDJULK-UHFFFAOYSA-N,COC1CC(NC2NCC3C(N2)-C2CCC(CL)CC2C(C2C(F)CCCC2OC)=NC3)CCC1C(=O)O;COC1CC(NC2NCC3CN=C(C4CC(CL)CCC4-C3N2)C2C(F)CCCC2OC)CCC1C(O)=O
ALISERTIB:NAVITOCLAX (2:1 MOL/MOL),ALISERTIB:NAVITOCLAX (2:1 MOL/MOL),,CTRP:660282,ctrp,,,,,,,,NA,,
ALISKIREN-HEMIFUMARATE,ALISKIREN-HEMIFUMARATE,,BRD:BRD-BRD-K30020243-051-02-5;BRD:BRD-K30020243-051-02-5,rep_primary;rep_single_dose,RENIN INHIBITOR,REN,HYPERTENSION,,LAUNCHED,,,NA,,COCCCOC1CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)CCC1OC
ALISPORIVIR,ALISPORIVIR,CHEMBL1651956,BRD:BRD-K00003135-001-01-9,rep_single_dose,CYCLOPHILIN INHIBITOR,,,,,,Protein,Phase 3,OLROWHGDTNFZBH-XEMWPYQTSA-N,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(CC)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
ALIZAPRIDE,ALIZAPRIDE,CHEMBL290194,BRD:BRD-A03061970-003-07-3;BRD:BRD-BRD-A03061970-003-07-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2,NAUSEA,,LAUNCHED,,Small molecule,Phase 3,KSEYRUGYKHXGFW-UHFFFAOYSA-N,C=CCN1CCCC1CNC(=O)C1CC2NN[NH]C2CC1OC;COC1CC2[NH]NNC2CC1C(=O)NCC1CCCN1CC=C
ALIZARIN,ALIZARIN,,BRD:BRD-BRD-K73191876-001-11-2;BRD:BRD-K73191876-001-11-2,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC1CCC2C(=O)C3CCCCC3C(=O)C2C1O
ALK2-IN-1,ALK2-IN-1,,BRD:BRD-K00091120-001-01-9,rep_single_dose,,,,,,,,NA,,
ALLANTOIN,ALLANTOIN,CHEMBL593429,BRD:BRD-A96407378-001-15-1;BRD:BRD-BRD-A96407378-001-15-1,rep_primary;rep_single_dose,COSMETIC,,SKIN PROTECTANT,,LAUNCHED,,Small molecule,Phase 2,POJWUDADGALRAB-UHFFFAOYSA-N,NC(=O)NC1NC(=O)NC1=O
ALLICIN,ALLICIN,CHEMBL359965,BRD:BRD-A60402836-001-01-0,rep_single_dose,CYTOKINE PRODUCTION INHIBITOR,TRPA1;TRPV1,,,,,Small molecule,Phase 2,JDLKFOPOAOFWQN-UHFFFAOYSA-N,C=CCS[S+]([O-])CC=C
ALLOPURINOL,ALLOPURINOL,CHEMBL1467,BRD:BRD-BRD-K86307448-001-17-5;BRD:BRD-BRD-K86307448-001-19-1;BRD:BRD-K86307448-001-17-5;BRD:BRD-K86307448-001-19-1,rep_primary;rep_single_dose,XANTHINE OXIDASE INHIBITOR,XDH,"GOUT, KIDNEY STONES",,LAUNCHED,,Small molecule,Approved,OFCNXPDARWKPPY-UHFFFAOYSA-N,O=C1[NH]CNC2[NH]NCC12;OC1NCNC2[NH]NCC12
ALLOPURINOL-RIBOSIDE,ALLOPURINOL-RIBOSIDE,,BRD:BRD-A93407926-001-01-1;BRD:BRD-BRD-A93407926-001-01-1;BRD:BRD-K00004728-001-01-9,rep_primary;rep_single_dose,"ANTI-LEISHMANIAL AGENT, PHOSPHORYLASE INHIBITOR",,,,PHASE 2,"Multiple values for MOA: {'ANTI-LEISHMANIAL AGENT', 'ANTI-LEISHMANIAL AGENT, PHOSPHORYLASE INHIBITOR'}, defaulting to 'ANTI-LEISHMANIAL AGENT, PHOSPHORYLASE INHIBITOR'
Multiple values for structure_id: {'K00004728', 'A93407926'}, defaulting to None",,NA,,OC[C@H]1O[C@H](C(O)[C@H]1O)N1[NH]CC2C1NCNC2=O
ALLYLISOTHIOCYANATE,ALLYLISOTHIOCYANATE,CHEMBL233248,BRD:BRD-BRD-K33219225-001-01-9;BRD:BRD-K33219225-001-01-9,rep_primary;rep_single_dose,TRPV AGONIST,TRPA1,,,PRECLINICAL,,Small molecule,Phase 1,ZOJBYZNEUISWFT-UHFFFAOYSA-N,C=CCN=C=S
ALLYLTHIOUREA,ALLYLTHIOUREA,CHEMBL1451910,BRD:BRD-BRD-K89634775-001-09-9;BRD:BRD-K89634775-001-09-9,rep_primary;rep_single_dose,NITRIFICATION INHIBITOR,,,,PRECLINICAL,,Small molecule,Unknown,HTKFORQRBXIQHD-UHFFFAOYSA-N,C=CCNC(N)=S;NC(S)=NCC=C
ALMINOPROFEN,ALMINOPROFEN,CHEMBL1765293,BRD:BRD-K00073457-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,FPHLBGOJWPEVME-UHFFFAOYSA-N,C=C(C)CNC1CCC(C(C)C(=O)O)CC1
ALMITRINE,ALMITRINE,CHEMBL1183717,BRD:BRD-BRD-K82677201-001-01-6;BRD:BRD-K82677201-001-01-6,rep_primary;rep_single_dose,NEUROTRANSMITTER AGONIST,ATP1A1,CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),,LAUNCHED,,Small molecule,Approved,OBDOVFRMEYHSQB-UHFFFAOYSA-N,C=CCNC1NC(NCC=C)NC(N2CCN(C(C3CCC(F)CC3)C3CCC(F)CC3)CC2)N1;FC1CCC(CC1)C(N1CCN(CC1)C1NC(NCC=C)NC(NCC=C)N1)C1CCC(F)CC1
ALMOREXANT,ALMOREXANT,CHEMBL455136,BRD:BRD-BRD-K84810405-003-01-1;BRD:BRD-K84810405-003-01-1,rep_multi_dose;rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,PHASE 3,,Small molecule,Phase 3,DKMACHNQISHMDN-RPLLCQBOSA-N,CNC(=O)[C@@H](C1CCCCC1)N1CCC2CC(OC)C(OC)CC2[C@@H]1CCC1CCC(C(F)(F)F)CC1;CNC(=O)[C@H](N1CCC2CC(OC)C(OC)CC2[C@@H]1CCC1CCC(CC1)C(F)(F)F)C1CCCCC1
ALMOTRIPTAN,ALMOTRIPTAN,CHEMBL1505,BRD:BRD-BRD-K67601717-037-02-4;BRD:BRD-K67601717-037-02-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1B;HTR1D,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,WKEMJKQOLOHJLZ-UHFFFAOYSA-N,CN(C)CCC1C[NH]C2CCC(CS(=O)(=O)N3CCCC3)CC12
ALOE-EMODIN,ALOE-EMODIN,CHEMBL40275,BRD:BRD-BRD-K04851519-001-06-8;BRD:BRD-K04851519-001-06-8,rep_primary;rep_single_dose,ANTICANCER AGENT,CASP8,,,PRECLINICAL,,Small molecule,NA,YDQWDHRMZQUTBA-UHFFFAOYSA-N,O=C1C2CCCC(O)C2C(=O)C2C(O)CC(CO)CC21;OCC1CC(O)C2C(=O)C3C(O)CCCC3C(=O)C2C1
ALOFANIB,ALOFANIB,CHEMBL4594436,BRD:BRD-K00073093-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,QUQGQIASFYWKAB-UHFFFAOYSA-N,CC1CC([N+](=O)[O-])C(NS(=O)(=O)C2CCCC(C(=O)O)C2)CC1-C1CCCNC1
ALOGLIPTIN,ALOGLIPTIN,CHEMBL376359,BRD:BRD-BRD-K83003151-057-02-4;BRD:BRD-K83003151-057-02-4,rep_multi_dose;rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,CN1C(=O)CC(N2CCC[C@@H](N)C2)N(CC2CCCCC2C#N)C1=O;CN1C(=O)CC(N2CCCC(N)C2)N(CC2CCCCC2C#N)C1=O
ALOPERINE,ALOPERINE,,BRD:BRD-BRD-K96391852-001-02-8;BRD:BRD-K96391852-001-02-8,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1
ALOSETRON,ALOSETRON,CHEMBL1110,BRD:BRD-BRD-K46742498-003-11-0;BRD:BRD-K46742498-003-11-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A,,,WITHDRAWN,,Small molecule,Approved,JSWZEAMFRNKZNL-UHFFFAOYSA-N,CC1[NH]CNC1CN1CCC2C(C1=O)C1CCCCC1N2C;CC1[NH]CNC1CN1CCC2C(C3CCCCC3N2C)C1=O
ALOVUDINE,ALOVUDINE,CHEMBL105318,BRD:BRD-K00004697-001-01-9,rep_single_dose,DNA SYNTHESIS MARKER,,,,,,Small molecule,Phase 2,UXCAQJAQSWSNPQ-XLPZGREQSA-N,CC1CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)[NH]C1=O
ALOXISTATIN,ALOXISTATIN,CHEMBL63440,BRD:BRD-BRD-K91188791-001-18-3;BRD:BRD-K91188791-001-18-3,rep_primary;rep_single_dose,PROTEASE INHIBITOR,CTSG,,,PHASE 3,,Small molecule,Unknown,SRVFFFJZQVENJC-IHRRRGAJSA-N,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C
BYL-719,ALPELISIB;BYL-719,CHEMBL2396661,BRD:BRD-BRD-K54997624-001-06-0;BRD:BRD-K54997624-001-06-0;BRD:BRD-K54997624-001-10-9;CTRP:668495;GDSC2:1560,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF PI3 KINASE ALPHA,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 3,"Multiple values for MOA: {'PI3K INHIBITOR', 'INHIBITOR OF PI3 KINASE ALPHA'}, defaulting to 'INHIBITOR OF PI3 KINASE ALPHA'
Multiple values for repurposing_target: {'PIK3CA', 'PIK3CA;PIK3CB;PIK3CD;PIK3CG'}, taking the union",Small molecule,Approved,STUWGJZDJHPWGZ-LBPRGKRZSA-N,CC1NC(NC(=O)N2CCC[C@H]2C(N)=O)SC1-C1CCNC(C(C)(C)C(F)(F)F)C1;CC1NC(NC(=O)N2CCC[C@H]2C(N)=O)SC1-C1CCNC(C1)C(C)(C)C(F)(F)F
ALPHA-ASARONE,ALPHA-ASARONE,CHEMBL333306,BRD:BRD-K72536715-001-01-5,rep_single_dose,"CYTOCHROME P450 INHIBITOR, HMGCR INHIBITOR",HMGCR,,,,,Small molecule,NA,RKFAZBXYICVSKP-AATRIKPKSA-N,C/C=C/C1CC(OC)C(OC)CC1OC
ALPHA-GLUCOSYL-HESPERIDIN,ALPHA-GLUCOSYL-HESPERIDIN,,BRD:BRD-K00005238-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
ALPHA-LINOLENIC-ACID,ALPHA-LINOLENIC-ACID,,BRD:BRD-BRD-K33396764-001-08-7;BRD:BRD-K33396764-001-08-7,rep_primary;rep_single_dose,OMEGA 3 FATTY ACID STIMULANT,ELOVL4;FADS1;FADS2;FFAR1;FFAR4;PTGS2;SLC8A1;TRPV1,,,PHASE 3,,,NA,,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
ALPHA-METHYLHISTAMINE-DIHYDROBROMIDE-(R)-(-),ALPHA-METHYLHISTAMINE-DIHYDROBROMIDE-(R)-(-),,BRD:BRD-BRD-K80028314-303-02-6;BRD:BRD-K80028314-303-02-6,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH3,,,PRECLINICAL,,,NA,,C[C@@H](N)CC1C[NH]CN1
ALPHA-METHYLHISTAMINE-DIHYDROBROMIDE-(S)-(+),ALPHA-METHYLHISTAMINE-DIHYDROBROMIDE-(S)-(+),,BRD:BRD-BRD-K28308851-303-01-8;BRD:BRD-K28308851-303-01-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH3,,,PRECLINICAL,,,NA,,C[C@H](N)CC1C[NH]CN1
ALPHA-METHYLSEROTONIN,ALPHA-METHYLSEROTONIN,,BRD:BRD-K01826806-050-02-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR4,,,,,,NA,,
ALPHA-TOCHOPHERYL-ACETATE,ALPHA-TOCHOPHERYL-ACETATE,,BRD:BRD-A61850409-001-10-7;BRD:BRD-BRD-A61850409-001-10-7,rep_primary;rep_single_dose,ANTIOXIDANT,,VITAMIN E DEFICIENCY,,LAUNCHED,,,NA,,CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2C(C)C(OC(C)=O)C(C)C(C)C2O1
ALPIDEM,ALPIDEM,CHEMBL54349,BRD:BRD-BRD-K66896751-001-02-4;BRD:BRD-K66896751-001-02-4,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1,,,WITHDRAWN,,Small molecule,Approved,JRTIDHTUMYMPRU-UHFFFAOYSA-N,CCCN(CCC)C(=O)CC1C(-C2CCC(CL)CC2)NC2CCC(CL)CN12;CCCN(CCC)C(=O)CC1C(NC2CCC(CL)CN12)-C1CCC(CL)CC1
ALPRENOLOL,ALPRENOLOL,CHEMBL266195,BRD:BRD-A00993607-003-24-6;BRD:BRD-BRD-A00993607-003-24-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;HTR1A,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Unknown,PAZJSJFMUHDSTF-UHFFFAOYSA-N,C=CCC1CCCCC1OCC(O)CNC(C)C;CC(C)NCC(O)COC1CCCCC1CC=C
ALPROSTADIL,ALPROSTADIL,CHEMBL495,BRD:BRD-BRD-K52459643-001-17-7;BRD:BRD-K52459643-001-17-7,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,CATSPER1;CATSPER2;CATSPER3;CATSPER4;PTGDR;PTGER1;PTGER2;PTGER4;PTGIR,CONGENITAL HEART DEFECTS,,LAUNCHED,,Small molecule,Approved,GMVPRGQOIOIIMI-DWKJAMRDSA-N,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O;CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
ALRESTATIN,ALRESTATIN,CHEMBL63055,BRD:BRD-BRD-K35498378-001-06-1;BRD:BRD-K35498378-001-06-1,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,,,PRECLINICAL,,Small molecule,Unknown,GCUCIFQCGJIRNT-UHFFFAOYSA-N,O=C(O)CN1C(=O)C2CCCC3CCCC(C23)C1=O;OC(=O)CN1C(=O)C2CCCC3CCCC(C1=O)C23
ALS-8176,ALS-8176,CHEMBL3417258,BRD:BRD-BRD-K21415491-001-01-4,rep_primary,RNA POLYMERASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 2,MJVKYGMNSQJLIN-KYZVSKTDSA-N,CC(C)C(=O)OC[C@@]1(CCL)O[C@@H](N2CCC(N)NC2=O)[C@H](F)[C@@H]1OC(=O)C(C)C;NC1CCN([C@@H]2O[C@@](CO)(CCL)[C@@H](O)[C@H]2F)C(=O)N1
ALTANSERIN,ALTANSERIN,CHEMBL62919,BRD:BRD-BRD-K00610438-003-02-5;BRD:BRD-K00610438-003-02-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A,,,PHASE 2,,Small molecule,Unknown,SMYALUSCZJXWHG-UHFFFAOYSA-N,FC1CCC(CC1)C(=O)C1CCN(CCN2C(=S)[NH]C3CCCCC3C2=O)CC1;O=C(C1CCC(F)CC1)C1CCN(CCN2C(=S)[NH]C3CCCCC3C2=O)CC1
ALTHIAZIDE,ALTHIAZIDE,CHEMBL599870,BRD:BRD-A56675431-001-12-3;BRD:BRD-BRD-A56675431-001-12-3,rep_primary;rep_single_dose,DIURETIC,,HYPERTENSION,,LAUNCHED,,Small molecule,Unknown,VGLGVJVUHYTIIU-UHFFFAOYSA-N,C=CCSCC1NC2CC(CL)C(S(N)(=O)=O)CC2S(=O)(=O)N1;NS(=O)(=O)C1CC2C(NC(CSCC=C)NS2(=O)=O)CC1CL
ALTINICLINE,ALTINICLINE,CHEMBL111659,BRD:BRD-BRD-K52681925-050-01-6;BRD:BRD-K52681925-050-01-6,rep_primary;rep_single_dose,NICOTINIC RECEPTOR AGONIST,CHRNA4;CHRNB2,,,PHASE 2,,Small molecule,Unknown,NUPUDYKEEJNZRG-LBPRGKRZSA-N,C#CC1CNCC([C@@H]2CCCN2C)C1;CN1CCC[C@H]1C1CNCC(C1)C#C
ALTIRATINIB,ALTIRATINIB,CHEMBL3545365,BRD:BRD-BRD-K78627070-001-01-5;BRD:BRD-K78627070-001-01-5,rep_primary;rep_single_dose,"MET INHIBITOR, VEGFR INHIBITOR",KDR;MET;TEK,,,PHASE 1,"Multiple values for MOA: {'VEGFR INHIBITOR, MET INHIBITOR', 'MET INHIBITOR, VEGFR INHIBITOR'}, defaulting to 'MET INHIBITOR, VEGFR INHIBITOR'",Small molecule,Phase 1,GNNDEPIMDAZHRQ-UHFFFAOYSA-N,FC1CCC(NC(=O)C2(CC2)C(=O)NC2CC(F)C(OC3CCNC(NC(=O)C4CC4)C3)CC2F)CC1;O=C(NC1CC(OC2CC(F)C(NC(=O)C3(C(=O)NC4CCC(F)CC4)CC3)CC2F)CCN1)C1CC1
ALTRENOGEST,ALTRENOGEST,CHEMBL1315492,BRD:BRD-BRD-K14619660-001-01-5;BRD:BRD-K14619660-001-01-5,rep_primary;rep_single_dose,PROGESTOGEN HORMONE,PGR,ESTRUS,,LAUNCHED,,Small molecule,Unknown,VWAUPFMBXBWEQY-ANULTFPQSA-N,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C;C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21C
ALTRETAMINE,ALTRETAMINE,CHEMBL1455,BRD:BRD-BRD-K67043667-001-26-4;BRD:BRD-K67043667-001-26-4,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,OVARIAN CANCER,,LAUNCHED,,Small molecule,Approved,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,CN(C)C1NC(N(C)C)NC(N(C)C)N1;CN(C)C1NC(NC(N1)N(C)C)N(C)C
ALVERINE,ALVERINE,CHEMBL253371,BRD:BRD-BRD-K89055274-048-22-7;BRD:BRD-K89055274-048-22-7,rep_primary;rep_single_dose,MUSCLE RELAXANT,HTR1A,"IRRITABLE BOWEL SYNDROME, DIVERTICULAR DISEASE",,LAUNCHED,,Small molecule,Approved,ZPFXAOWNKLFJDN-UHFFFAOYSA-N,CCN(CCCC1CCCCC1)CCCC1CCCCC1
ALVESPIMYCIN,ALVESPIMYCIN,CHEMBL383824,BRD:BRD-BRD-K83988098-001-02-0;BRD:BRD-BRD-K83988098-003-03-4;BRD:BRD-K83988098-001-02-0;BRD:BRD-K83988098-003-03-4,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PHASE 2,,Small molecule,Phase 2,KUFRQPKVAWMTJO-LMZWQJSESA-N,CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O;CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O
ALVIMOPAN,ALVIMOPAN,CHEMBL270190,BRD:BRD-BRD-K07857022-002-01-1;BRD:BRD-K07857022-002-01-1,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,POSTOPERATIVE ILEUS,,LAUNCHED,,Small molecule,Approved,UPNUIXSCZBYVBB-JVFUWBCBSA-N,C[C@H]1CN(C[C@H](CC2CCCCC2)C(=O)NCC(=O)O)CC[C@@]1(C)C1CCCC(O)C1;C[C@H]1CN(C[C@H](CC2CCCCC2)C(=O)NCC(O)=O)CC[C@@]1(C)C1CCCC(O)C1
ALVOCIDIB,ALVOCIDIB,CHEMBL428690,BRD:BRD-BRD-K87909389-003-03-4;BRD:BRD-K87909389-003-03-4;CTRP:687720,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK4;CDK5;CDK6;CDK7;CDK8;CDK9;EGFR;PYGM,,,PHASE 2,,Small molecule,Phase 3,BIIVYFLTOXDAOV-YVEFUNNKSA-N,CN1CC[C@@H]([C@H](O)C1)C1C(O)CC(O)C2C1OC(CC2=O)-C1CCCCC1CL;CN1CC[C@H](C2C(O)CC(O)C3C(=O)CC(-C4CCCCC4CL)OC23)[C@H](O)C1
ALX-40-4C,ALX-40-4C,,BRD:BRD-K00003337-019-01-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,,NA,,
ALX-5407,ALX-5407,,BRD:BRD-BRD-K53979406-003-02-8;BRD:BRD-K53979406-003-02-8,rep_primary;rep_single_dose,"GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR",SLC6A9,,,PHASE 1,"Multiple values for MOA: {'GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR', 'GLYCINE TRANSPORTER 1 INHIBITOR'}, defaulting to 'GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR'",,NA,,CN(CC[C@@H](OC1CCC(CC1)-C1CCCCC1)C1CCC(F)CC1)CC(O)=O
AM-1241,AM-1241,,BRD:BRD-A66116161-001-02-3;BRD:BRD-BRD-A66116161-001-02-3,rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR1;CNR2,,,PRECLINICAL,,,NA,,CN1CCCCC1CN1CC(C(=O)C2CC(CCC2I)[N+]([O-])=O)C2CCCCC12
AM-24,AM-24,,BRD:BRD-BRD-K59013864-001-01-1;BRD:BRD-K59013864-001-01-1,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5,,,PHASE 2,,,NA,,OC1C(I)CC(I)CC1I
AM-251,AM-251,,BRD:BRD-BRD-K92000912-001-12-6;BRD:BRD-K92000912-001-12-6,rep_multi_dose;rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1;GPR18;GPR55,,,PRECLINICAL,,,NA,,CC1C(NN(C1-C1CCC(I)CC1)-C1CCC(CL)CC1CL)C(=O)NN1CCCCC1
AM-281,AM-281,,BRD:BRD-BRD-K59419204-001-02-7;BRD:BRD-K59419204-001-02-7,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1;CNR2;GPR55,,,PRECLINICAL,,,NA,,CC1C(NN(C1-C1CCC(I)CC1)-C1CCC(CL)CC1CL)C(=O)NN1CCOCC1
AM-404,AM-404,,BRD:BRD-BRD-K55462201-001-07-3;BRD:BRD-K55462201-001-07-3,rep_multi_dose;rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, FAAH INHIBITOR, TRPV ANTAGONIST",CNR1;CNR2;FAAH;TRPV1,,,PRECLINICAL,,,NA,,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1CCC(O)CC1
AM-580,AM-580,,BRD:BRD-BRD-K06854232-001-19-9;BRD:BRD-K06854232-001-19-9;CTRP:58455,ctrp;rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA,,,PRECLINICAL,,,NA,,CC1(C)CCC(C)(C)C2CC(CCC12)C(=O)NC1CCC(CC1)C(O)=O
AM-630,AM-630,,BRD:BRD-BRD-K63533170-001-02-9;BRD:BRD-K63533170-001-02-9,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1;CNR2,,,PRECLINICAL,,,NA,,COC1CCC(CC1)C(=O)C1C(C)N(CCN2CCOCC2)C2CC(I)CCC12
AM-92016,AM-92016,,BRD:BRD-A11813248-003-02-4;BRD:BRD-BRD-A11813248-003-02-4,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,GRIN1,,,PRECLINICAL,,,NA,,CN(CCC1CCC(CL)C(CL)C1)CC(O)COC1CCC(NS(C)(=O)=O)CC1
AM211,AM211,CHEMBL2181753,BRD:BRD-K00003152-001-01-9,rep_single_dose,PROSTAGLANDIN INHIBITOR,,,,,,Small molecule,Phase 1,OPXIRFWNLBDKQB-UHFFFAOYSA-N,CCN(CC1CC(C(F)(F)F)CCC1-C1CC(CC(=O)O)CCC1OC)C(=O)NCC1CCCCC1
AM679,AM679,,BRD:BRD-BRD-K88443722-001-01-7;BRD:BRD-K88443722-001-01-7,rep_primary;rep_single_dose,"CANNABINOID RECEPTOR AGONIST, LIPOXYGENASE INHIBITOR",ALOX5AP;CNR1;CNR2,,,PRECLINICAL,,,NA,,COC1CNC(NC1)-C1CCC(CN2C(CC(C)(C)C(O)=O)C(SC(C)(C)C)C3CC(OC[C@@H]4CC5CCCCC5N4C(C)=O)CCC23)CC1
AMANTADINE,AMANTADINE,CHEMBL660,BRD:BRD-BRD-K70330367-003-07-9;BRD:BRD-K70330367-003-07-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,DRD2;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A,"INFLUENZA A VIRUS INFECTION, PARKINSON'S DISEASE",,LAUNCHED,,Small molecule,Approved,DKNWSYNQZKUICI-UHFFFAOYSA-N,NC12CC3CC(CC(C3)C1)C2
AMBAZONE,AMBAZONE,CHEMBL2103762,BRD:BRD-BRD-K11244467-001-08-5;BRD:BRD-K11244467-001-08-5,rep_multi_dose;rep_primary;rep_single_dose,DNA DAMAGE INDUCER,,,,PHASE 1,,Small molecule,Unknown,MLMFUKWWZIZRHX-VFWKFLPVSA-N,N=C(N)NN=C1C=CC(=NNC(N)=S)C=C1;NC(=N)N=NC1CCC(NNC(S)=N)CC1
AMBENONIUM,AMBENONIUM,CHEMBL1652,BRD:BRD-BRD-K11292736-300-02-8;BRD:BRD-K11292736-300-02-8,rep_primary;rep_single_dose,CHOLINESTERASE INHIBITOR,ACHE,MYASTHENIA GRAVIS,,LAUNCHED,,Small molecule,Approved,OMHBPUNFVFNHJK-UHFFFAOYSA-P,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1CCCCC1CL)CC1CCCCC1CL
AMBRISENTAN,AMBRISENTAN,CHEMBL1111,BRD:BRD-BRD-K41185545-001-02-3;BRD:BRD-K41185545-001-02-3,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA;EDNRB,PULMONARY ARTERIAL HYPERTENSION (PAH),,LAUNCHED,,Small molecule,Approved,OUJTZYPIHDYQMC-LJQANCHMSA-N,COC([C@H](OC1NC(C)CC(C)N1)C(O)=O)(C1CCCCC1)C1CCCCC1;COC(C1CCCCC1)(C1CCCCC1)[C@H](OC1NC(C)CC(C)N1)C(=O)O
AMBROXOL,AMBROXOL,CHEMBL153479,BRD:BRD-BRD-K56558538-003-11-9;BRD:BRD-K56558538-003-11-9,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,CYP3A4,BRONCHITIS,,LAUNCHED,,Small molecule,Phase 3,JBDGDEWWOUBZPM-XYPYZODXSA-N,NC1C(BR)CC(BR)CC1CN[C@H]1CC[C@H](O)CC1
AMCASERTIB,AMCASERTIB,CHEMBL3707349,BRD:BRD-K00003244-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 2,QDWKGEFGLQMDAM-ULJHMMPZSA-N,CCN(CC)CCNC(=O)C1C(C)[NH]C(/C=C2\C(=O)NC3CCC(-C4CSC(-C5CCCCC5)N4)CC32)C1C
AMCINONIDE,AMCINONIDE,CHEMBL1200732,BRD:BRD-A36010170-001-04-0;BRD:BRD-BRD-A36010170-001-04-0,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,ANXA1;NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Approved,ILKJAFIWWBXGDU-MOGDOJJUSA-N,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C;CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C
AMD-3465,AMD-3465,,BRD:BRD-K03019184-439-02-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR4,,,,,,NA,,
AMD11070,AMD11070,CHEMBL518924,BRD:BRD-BRD-K42948882-305-01-1;BRD:BRD-K42948882-305-01-1,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR5;CXCR4,,,PHASE 1/PHASE 2,"Multiple values for repurposing_target: {'CCR5;CXCR4', 'CXCR4'}, taking the union",Small molecule,Phase 3,WVLHHLRVNDMIAR-IBGZPJMESA-N,NCCCCN(CC1NC2CCCCC2[NH]1)[C@H]1CCCC2CCCNC12;NCCCCN(CC1NC2CCCCC2[NH]1)[C@H]1CCCC2CCCNC21
AMELTOLIDE,AMELTOLIDE,CHEMBL22916,BRD:BRD-BRD-K48173020-001-01-8;BRD:BRD-K48173020-001-01-8,rep_primary;rep_single_dose,ANTICONVULSANT,,,,PRECLINICAL,,Small molecule,Unknown,HZIWGOAXOBPQGY-UHFFFAOYSA-N,CC1CCCC(C)C1NC(=O)C1CCC(N)CC1
AMENAMEVIR,AMENAMEVIR,CHEMBL4297592,BRD:BRD-K00004966-001-01-9,rep_single_dose,HELICASE PRIMASE INHIBITOR,,,,,,Small molecule,Phase 3,MNHNIVNAFBSLLX-UHFFFAOYSA-N,CC1CCCC(C)C1N(CC(=O)NC1CCC(-C2NCON2)CC1)C(=O)C1CCS(=O)(=O)CC1
AMETANTRONE,AMETANTRONE,CHEMBL49442,BRD:BRD-K00004726-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Unknown,FFGSXKJJVBXWCY-UHFFFAOYSA-N,O=C1C2CCCCC2C(=O)C2C(NCCNCCO)CCC(NCCNCCO)C21
AMETHOPTERIN,AMETHOPTERIN,CHEMBL34259,GDSC1:1008,gdsc,,,,,,,Small molecule,Approved,FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1
AMEZINIUM,AMEZINIUM,CHEMBL2110922,BRD:BRD-BRD-K51387999-067-01-6;BRD:BRD-K51387999-067-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,,,LAUNCHED,,Small molecule,Unknown,VXROHTDSRBRJLN-UHFFFAOYSA-O,COC1CC(N)CN[N+]1-C1CCCCC1
AMFENAC,AMFENAC,CHEMBL25146,BRD:BRD-BRD-K82122102-323-01-1;BRD:BRD-K82122102-323-01-1,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,SOYCMDCMZDHQFP-UHFFFAOYSA-N,NC1C(CC(=O)O)CCCC1C(=O)C1CCCCC1;NC1C(CC(O)=O)CCCC1C(=O)C1CCCCC1
AMFEPRAMONE,AMFEPRAMONE,CHEMBL1194666,BRD:BRD-A37288617-003-02-2;BRD:BRD-BRD-A37288617-003-02-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,SLC6A2;SLC6A3,OBESITY,,LAUNCHED,,Small molecule,Approved,XXEPPPIWZFICOJ-UHFFFAOYSA-N,CCN(CC)C(C)C(=O)C1CCCCC1
AMFLUTIZOLE,AMFLUTIZOLE,CHEMBL2106558,BRD:BRD-BRD-K50813454-001-01-9;BRD:BRD-K50813454-001-01-9,rep_primary;rep_single_dose,XANTHINE OXIDASE INHIBITOR,XDH,,,PHASE 2,,Small molecule,Unknown,KVMCEGAWQYTFKC-UHFFFAOYSA-N,NC1C(-C2CCCC(C(F)(F)F)C2)NSC1C(=O)O;NC1C(SNC1-C1CCCC(C1)C(F)(F)F)C(O)=O
AMG 333,AMG 333,,BRD:BRD-K00079528-001-02-9,rep_single_dose,,,,,,,,NA,,
SOVILNESIB,AMG 650;SOVILNESIB,,BRD:BRD-K00126785-001-01-9;BRD:BRD-U00114870-001-01-9,oncref_1;oncref_2,INHIBITOR OF KIF18A,KIF18A,,,,"Multiple values for structure_id: {'U00114870', 'K00126785'}, defaulting to None",,NA,,
AMG 706,AMG 706,CHEMBL2107357;CHEMBL572881,GDSC1:1029,gdsc,,,,,,,Small molecule,Phase 3,ONDPWWDPQDCQNJ-UHFFFAOYSA-N;RAHBGWKEPAQNFF-UHFFFAOYSA-N,CC1(C)CNC2CC(NC(=O)C3CCCNC3NCC3CCNCC3)CCC21;CC1(C)CNC2CC(NC(=O)C3CCCNC3NCC3CCNCC3)CCC21.O=P(O)(O)O.O=P(O)(O)O
AMG-176,AMG-176,CHEMBL4446378,BRD:BRD-K43900408-001-02-9,rep_single_dose,MCL1 INHIBITOR,,,,,,Small molecule,Phase 1,JQNINBDKGLWYMU-GEAQBIRJSA-N,CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2CCC3C(C2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCC2CC(CL)CCC21)CO3
AMG-208,AMG-208,CHEMBL496102,BRD:BRD-BRD-K32285926-001-02-1;BRD:BRD-K32285926-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,MET,,,PHASE 1,,Small molecule,Phase 2,HEAIZQNMNCHNFD-UHFFFAOYSA-N,COC1CCC2C(OCC3NNC4CCC(-C5CCCCC5)NN34)CCNC2C1;COC1CCC2C(OCC3NNC4CCC(NN34)-C3CCCCC3)CCNC2C1
AMG-232,AMG-232,CHEMBL3125702,BRD:BRD-BRD-K64925568-001-01-8;BRD:BRD-K64925568-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,MDM INHIBITOR,MDM2,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,DRLCSJFKKILATL-YWCVFVGNSA-N,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)C1CCCC(CL)C1)C1CCC(CL)CC1;CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](C2CCCC(CL)C2)[C@H]1C1CCC(CL)CC1
AMG319,AMG-319;AMG319,CHEMBL3545048,BRD:BRD-A58947127-001-01-6;BRD:BRD-BRD-A58947127-001-01-6;BRD:BRD-BRD-K21077415-001-01-5;BRD:BRD-K21077415-001-01-5;GDSC2:2045,gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CD,,,PHASE 2,"Multiple values for SMILES: {'C[C@H](NC1NCNC2[NH]CNC12)C1CC2CCC(F)CC2NC1-C1CCCCN1', 'CC(NC1NCNC2NC[NH]C12)C1CC2CCC(F)CC2NC1-C1CCCCN1'}, defaulting to 'C[C@H](NC1NCNC2[NH]CNC12)C1CC2CCC(F)CC2NC1-C1CCCCN1'
Multiple values for structure_id: {'A58947127', 'K21077415'}, defaulting to None",Small molecule,Phase 2,,C[C@H](NC1NCNC2[NH]CNC12)C1CC2CCC(F)CC2NC1-C1CCCCN1
AMG-337,AMG-337,CHEMBL3545212,BRD:BRD-BRD-K27061362-001-01-6;BRD:BRD-K27061362-001-01-6,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MET,MET,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF MET', 'MET INHIBITOR'}, defaulting to 'INHIBITOR OF MET'",Small molecule,Phase 2,,COCCOC1CNC2CCN([C@H](C)C3NNC4C(F)CC(CN34)-C3CNN(C)C3)C(=O)C2C1
AMG-397,AMG-397,CHEMBL4650225,BRD:BRD-K00108790-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,BJTFTQIBRVBSBH-VCQPVEJUSA-N,CO[C@]1(CN2CCN3CCCC[C@@H]3C2)/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2CCC3C(C2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCC2CC(CL)CCC21)CO3
AMG-487,AMG-487,,BRD:BRD-BRD-K90239174-001-01-8;BRD:BRD-K90239174-001-01-8,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,PHASE 2,,,NA,,CCOC1CCC(CC1)-N1C(NC2NCCCC2C1=O)[C@@H](C)N(CC1CCCNC1)C(=O)CC1CCC(OC(F)(F)F)CC1
AMG-487-(+/-),AMG-487-(+/-),,BRD:BRD-A01307728-001-01-4;BRD:BRD-BRD-A01307728-001-01-4,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR3,,,PHASE 2,,,NA,,CCOC1CCC(CC1)-N1C(NC2NCCCC2C1=O)C(C)N(CC1CCCNC1)C(=O)CC1CCC(OC(F)(F)F)CC1
SOTORASIB,AMG-510;SOTORASIB,CHEMBL4535757,BRD:BRD-K00010385-001-01-9;BRD:BRD-K00010385-001-04-9,oncref_1;rep_single_dose,INHIBITOR OF KRAS-G12C,KRAS,,,,"Multiple values for MOA: {'INHIBITOR OF KRAS-G12C', 'K-RAS INHIBITOR'}, defaulting to 'INHIBITOR OF KRAS-G12C'",Small molecule,Approved,NXQKSXLFSAEQCZ-SFHVURJKSA-N,C=CC(=O)N1CCN(C2NC(=O)N(-C3C(C)CCNC3C(C)C)C3NC(-C4C(O)CCCC4F)C(F)CC23)[C@@H](C)C1
AMG-517,AMG-517,CHEMBL229430,BRD:BRD-BRD-K34185671-001-02-8;BRD:BRD-K34185671-001-02-8,rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PHASE 1,,Small molecule,Phase 1,YUTIXVXZQIQWGY-UHFFFAOYSA-N,CC(=O)NC1NC2C(OC3CC(-C4CCC(C(F)(F)F)CC4)NCN3)CCCC2S1;CC(=O)NC1NC2C(OC3CC(NCN3)-C3CCC(CC3)C(F)(F)F)CCCC2S1
AMG-548,AMG-548,CHEMBL585902,BRD:BRD-BRD-K86673452-001-01-7;BRD:BRD-K86673452-001-01-7,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK11;MAPK12;MAPK13;MAPK14,,,PHASE 1,,Small molecule,Phase 1,RQVKVJIRFKVPBF-VWLOTQADSA-N,CN1C(NC[C@@H](N)CC2CCCCC2)NC(-C2CCNCC2)C(-C2CCC3CCCCC3C2)C1=O
AMG-706,AMG-706,CHEMBL572881,GDSC1:1029,gdsc,,,,,,,Small molecule,Phase 3,RAHBGWKEPAQNFF-UHFFFAOYSA-N,CC1(C)CNC2CC(NC(=O)C3CCCNC3NCC3CCNCC3)CCC21
AMG-837,AMG-837,,BRD:BRD-BRD-K43802723-340-01-9;BRD:BRD-K43802723-340-01-9,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,FFAR1,,,PHASE 1,,,NA,,CC#C[C@@H](CC(O)=O)C1CCC(OCC2CCCC(C2)-C2CCC(CC2)C(F)(F)F)CC1
AMG-925,AMG-925,,BRD:BRD-BRD-K97452254-001-01-3;BRD:BRD-K97452254-001-01-3,rep_primary;rep_single_dose,"CDK INHIBITOR, FLT3 INHIBITOR",CDK4;CDK6;FLT3,,,PHASE 1,,,NA,,C[C@H]1CC[C@@H](CC1)N1C2CNCCC2C2CNC(NC3CCC4CN(CCC4N3)C(=O)CO)NC12
AMG-9810,AMG-9810,,BRD:BRD-BRD-K01995783-001-01-6;BRD:BRD-K01995783-001-01-6,rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PRECLINICAL,,,NA,,CC(C)(C)C1CCC(CC1)\C=C\C(=O)NC1CCC2OCCOC2C1
AMG-PERK-44,AMG-PERK-44,,BRD:BRD-BRD-K04374714-003-01-1;BRD:BRD-K04374714-003-01-1,rep_primary;rep_single_dose,PERK INHIBITOR,EIF2AK4,,,PRECLINICAL,,,NA,,CC1CCC2CC(CCC2N1)-C1C(C)CCC(C(=O)C2C(-C3CCCCC3)N(C)N(-C3CCCCC3)C2=O)C1N
AMG458,AMG458,,BRD:BRD-BRD-K21782625-001-02-4;BRD:BRD-BRD-K21782625-001-03-2;BRD:BRD-K21782625-001-02-4;BRD:BRD-K21782625-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,MET INHIBITOR,MET,,,PRECLINICAL,,,NA,,COC1CCC2C(OC3CCC(NC(=O)C4C(C)N(CC(C)(C)O)N(-C5CCCCC5)C4=O)NC3)CCNC2C1
AMG706,AMG706,,GDSC1:1029,gdsc,,,,,,,,NA,,
AMG900,AMG900,CHEMBL2140408,BRD:BRD-BRD-K21728777-001-02-3;BRD:BRD-K21728777-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC,,,PHASE 1,,Small molecule,Phase 1,IVUGFMLRJOCGAS-UHFFFAOYSA-N,CC1CSC(-C2NNC(NC3CCC(OC4NCCCC4-C4CCNC(N)N4)CC3)C3CCCCC23)C1;CC1CSC(C1)-C1NNC(NC2CCC(OC3NCCCC3-C3CCNC(N)N3)CC2)C2CCCCC12
AMI-1,AMI-1,,BRD:BRD-K75114721-304-02-6,rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT1,,,,,,NA,,
AMIBEGRON,AMIBEGRON,CHEMBL1193948,BRD:BRD-BRD-K24610819-003-01-8;BRD:BRD-K24610819-003-01-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB3,,,PHASE 3,,Small molecule,Phase 3,RDJQCOBTKKAQAH-FPOVZHCZSA-N,CCOC(=O)COC1CCC2C(C1)C[C@@H](NC[C@H](O)C1CCCC(CL)C1)CC2;CCOC(=O)COC1CCC2CC[C@@H](CC2C1)NC[C@H](O)C1CCCC(CL)C1
AMIDOPYRINE,AMIDOPYRINE,CHEMBL288470,BRD:BRD-BRD-K12568846-001-14-6;BRD:BRD-K12568846-001-14-6,rep_primary;rep_single_dose,ANALGESIC AGENT,,DERMATITIS HERPETIFORMIS (DH),,LAUNCHED,,Small molecule,Approved,RMMXTBMQSGEXHJ-UHFFFAOYSA-N,CC1C(N(C)C)C(=O)N(-C2CCCCC2)N1C;CN(C)C1C(C)N(C)N(-C2CCCCC2)C1=O
AMIFAMPRIDINE,AMIFAMPRIDINE,CHEMBL354077,BRD:BRD-BRD-K80262108-001-07-0;BRD:BRD-K80262108-001-07-0,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,,LAMBERT-EATON MYASTHENIC SYNDROME (LEMS),,LAUNCHED,,Small molecule,Approved,OYTKINVCDFNREN-UHFFFAOYSA-N,NC1CCNCC1N
AMIFOSTINE,AMIFOSTINE,CHEMBL1006,BRD:BRD-K73947551-001-04-4,rep_single_dose,REDUCING AGENT,ALPPL2;ENPP1,,,,,Small molecule,Approved,JKOQGQFVAUAYPM-UHFFFAOYSA-N,NCCCNCCSP(=O)(O)O
AMIKACIN,AMIKACIN,CHEMBL177,BRD:BRD-A30051119-002-01-8;BRD:BRD-BRD-A30051119-002-01-8,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,LKCWBDHBTVXHDL-RMDFUYIESA-N,NCC[C@@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)C1O;NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O;NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
AMILORIDE,AMILORIDE,CHEMBL945,BRD:BRD-BRD-K97181089-003-24-7;BRD:BRD-K97181089-003-24-7,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,AOC1;ASIC1;ASIC2;ASIC3;PKD2;PKD2L1;PLAU;SCNN1A;SCNN1B;SCNN1D;SCNN1G;SLC9A1;TRPC7;TRPV2,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,XSDQTOBWRPYKKA-UHFFFAOYSA-N,N=C(N)NC(=O)C1NC(CL)C(N)NC1N;NC(=N)NC(=O)C1NC(CL)C(N)NC1N
AMINEPTINE,AMINEPTINE,CHEMBL1697712;CHEMBL418995,BRD:BRD-BRD-K24219278-001-01-6;BRD:BRD-K24219278-001-01-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,SLC6A2;SLC6A4,,,WITHDRAWN,,Small molecule,Approved,ONNOFKFOZAJDHT-UHFFFAOYSA-N;VDPUXONTAVMIKZ-UHFFFAOYSA-N,CL.O=C(O)CCCCCCNC1C2CCCCC2CCC2CCCCC21;O=C(O)CCCCCCNC1C2CCCCC2CCC2CCCCC21;OC(=O)CCCCCCNC1C2CCCCC2CCC2CCCCC12
AMINOCAPROIC-ACID,AMINOCAPROIC-ACID,,BRD:BRD-BRD-K64931368-003-01-4;BRD:BRD-K64931368-003-01-4,rep_primary;rep_single_dose,PLASMINOGEN ACTIVATOR INHIBITOR,LPA;PLAT;PLG,FIBRINOLYTIC BLEEDING,,LAUNCHED,,,NA,,NCCCCCC(O)=O
AMINOGLUTETHIMIDE,AMINOGLUTETHIMIDE,CHEMBL488,BRD:BRD-A25234499-001-18-3;BRD:BRD-A25234499-001-19-1;BRD:BRD-BRD-A25234499-001-18-3,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR ANTAGONIST,CYP11A1;CYP19A1,"CUSHING'S SYNDROME, BREAST CANCER",,LAUNCHED,,Small molecule,Approved,ROBVIMPUHSLWNV-UHFFFAOYSA-N,CCC1(C2CCC(N)CC2)CCC(=O)NC1=O;CCC1(CCC(=O)NC1=O)C1CCC(N)CC1
AMINOGUANIDINE,AMINOGUANIDINE,CHEMBL225304,BRD:BRD-BRD-K25114078-003-08-1;BRD:BRD-K25114078-003-08-1,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,AKR1B1;NOS2;TIMP3,,,PHASE 3,"Multiple values for repurposing_target: {'AKR1B1;NOS2;TIMP3', 'NOS2'}, taking the union",Small molecule,Phase 1,HAMNKKUPIHEESI-UHFFFAOYSA-N,N=C(N)NN;NNC(N)=N
AMINOHYDROXYBUTYRIC-ACID,AMINOHYDROXYBUTYRIC-ACID,,BRD:BRD-A40777960-001-04-2;BRD:BRD-BRD-A40777960-001-04-2,rep_primary;rep_single_dose,,,EPILEPSY,,LAUNCHED,,,NA,,NCC(O)CC(O)=O
AMINOLEVULINIC-ACID-BENZYL-ESTER,AMINOLEVULINIC-ACID-BENZYL-ESTER,,BRD:BRD-BRD-K59998349-003-01-4;BRD:BRD-K59998349-003-01-4,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,NCC(=O)CCC(=O)OCC1CCCCC1
AMINOMETHYLTRANSFERASE,AMINOMETHYLTRANSFERASE,,BRD:BRD-A28318179-003-08-5;BRD:BRD-BRD-A28318179-003-08-5,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS2,,,PRECLINICAL,,,NA,,CC1CCN=C(N)S1
AMINOPENTAMIDE,AMINOPENTAMIDE,CHEMBL92915,BRD:BRD-A69917777-065-02-2;BRD:BRD-BRD-A69917777-065-02-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,"ACUTE ABDOMINAL VISCERAL SPASM, HYPERTROPHIC GASTRITIS (GHG), NAUSEA",,LAUNCHED,,Small molecule,Unknown,NARHAGIVSFTMIG-UHFFFAOYSA-N,CC(CC(C(N)=O)(C1CCCCC1)C1CCCCC1)N(C)C
AMINOPHYLLINE,AMINOPHYLLINE,CHEMBL1370561,BRD:BRD-BRD-K97799481-230-01-7,rep_primary,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3;HDAC2;PDE3A;PDE3B;PDE4A;PDE4B;PDE4C;PDE4D,"ASTHMA, BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,FQPFAHBPWDRTLU-UHFFFAOYSA-N,CN1C(=O)C2[NH]CNC2N(C)C1=O.CN1C(=O)C2[NH]CNC2N(C)C1=O.NCCN;CN1C2NC[NH]C2C(=O)N(C)C1=O
AMINOPURVALANOL-A,AMINOPURVALANOL-A,,BRD:BRD-BRD-K07762753-001-04-4;BRD:BRD-K07762753-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, TYROSINE KINASE INHIBITOR",CDK1;CDK2;CDK5;CDK6,,,PRECLINICAL,,,NA,,CC(C)[C@H](CO)NC1NC(NC2CC(N)CC(CL)C2)C2NCN(C(C)C)C2N1
AMINOSALICYLATE,AMINOSALICYLATE,CHEMBL1169,BRD:BRD-BRD-K80267133-001-17-7;BRD:BRD-BRD-K80267133-001-19-3;BRD:BRD-K80267133-001-17-7;BRD:BRD-K80267133-001-19-3;BRD:BRD-K80267133-325-22-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,ALOX5;CHUK;PLA2G2E;PTGS1;PTGS2,"INFLAMMATORY BOWEL DISEASE, ULCERATIVE COLITIS",,LAUNCHED,,Small molecule,Approved,WUBBRNOQWQTFEX-UHFFFAOYSA-N,NC1CCC(C(=O)O)C(O)C1;NC1CCC(C(O)=O)C(O)C1
AMINOTHIAZOLE,AMINOTHIAZOLE,CHEMBL344760,BRD:BRD-BRD-K13421763-001-06-2;BRD:BRD-K13421763-001-06-2,rep_primary;rep_single_dose,CYCLIN D INHIBITOR,NOS2,,,PRECLINICAL,,Small molecule,Unknown,RAIPHJJURHTUIC-UHFFFAOYSA-N,NC1NCCS1
AMIODARONE,AMIODARONE,CHEMBL1083993;CHEMBL633,BRD:BRD-BRD-K17561142-003-32-5;BRD:BRD-K17561142-003-32-5,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,ADRB1;CACNA1H;CACNA2D2;KCNA7;KCNH2,VENTRICULAR ARRHYTHMIAS,,LAUNCHED,,Small molecule,Approved,ITPDYQOUSLNIHG-UHFFFAOYSA-N;IYIKLHRQXLHMJQ-UHFFFAOYSA-N,CCCCC1OC2CCCCC2C1C(=O)C1CC(I)C(OCCN(CC)CC)C(I)C1;CCCCC1OC2CCCCC2C1C(=O)C1CC(I)C(OCCN(CC)CC)C(I)C1.CL
AMIPRILOSE,AMIPRILOSE,CHEMBL1316321,BRD:BRD-BRD-K97643133-003-09-3;BRD:BRD-K97643133-003-09-3,rep_primary;rep_single_dose,CD ANTAGONIST,,,,PHASE 3,,Small molecule,Unknown,YXBQLONCIPUQKO-UJPOAAIJSA-N,CN(C)CCCO[C@@H]1[C@H]2OC(C)(C)O[C@H]2O[C@@H]1[C@H](O)CO;CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO
AMISELIMOD,AMISELIMOD,CHEMBL3707375,BRD:BRD-K00003223-003-01-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR,,,,,,Small molecule,Phase 2,JVCPIJKPAKAIIP-UHFFFAOYSA-N,CCCCCCCOC1CCC(CCC(N)(CO)CO)CC1C(F)(F)F
AMISULPRIDE,AMISULPRIDE,CHEMBL243712,BRD:BRD-A60197193-001-14-6;BRD:BRD-BRD-A60197193-001-14-6,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;HTR2A;HTR7,"PSYCHOSIS, BIPOLAR DISORDER, SCHIZOPHRENIA",,LAUNCHED,,Small molecule,Approved,NTJOBXMMWNYJFB-UHFFFAOYSA-N,CCN1CCCC1CNC(=O)C1CC(C(N)CC1OC)S(=O)(=O)CC;CCN1CCCC1CNC(=O)C1CC(S(=O)(=O)CC)C(N)CC1OC
AMITIFADINE,AMITIFADINE,CHEMBL592374,BRD:BRD-A68942014-003-01-7;BRD:BRD-BRD-A68942014-003-01-7,rep_primary;rep_single_dose,SEROTONIN TRANSPORTER (SERT) INHIBITOR,SLC6A2;SLC6A3;SLC6A4,,,PHASE 3,,Small molecule,Phase 2,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,CLC1CCC([C@]23CNC[C@H]2C3)CC1CL;CLC1CCC(CC1CL)C12CC1CNC2
AMITRIPTYLINE,AMITRIPTYLINE,CHEMBL629,BRD:BRD-BRD-K53737926-003-27-8;BRD:BRD-K53737926-003-27-8,rep_primary;rep_single_dose,"NOREPINEPHRINE INHIBITOR, NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONINNOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRB1;ADRB2;ADRB3;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;HRH1;HRH2;HRH4;HTR1A;HTR1B;HTR1D;HTR2A;HTR2C;HTR6;HTR7;KCNA1;KCND2;KCND3;KCNQ2;KCNQ3;NTRK1;NTRK2;OPRD1;OPRK1;OPRM1;SIGMAR1;SLC6A2;SLC6A4,DEPRESSION,,LAUNCHED,"Multiple values for MOA: {'NOREPINEPHRINE INHIBITOR, NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONIN\x80\x93NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)', 'NOREPINEPHRINE INHIBITOR, NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)'}, defaulting to 'NOREPINEPHRINE INHIBITOR, NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONIN\x80\x93NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)'",Small molecule,Approved,KRMDCWKBEZIMAB-UHFFFAOYSA-N,CN(C)CCC=C1C2CCCCC2CCC2CCCCC12;CN(C)CCC=C1C2CCCCC2CCC2CCCCC21
AMLEXANOX,AMLEXANOX,CHEMBL1096,BRD:BRD-BRD-K29530284-001-06-2;BRD:BRD-K29530284-001-06-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR MODULATOR,FGF1;IL3;PDE4A;PDE4B;PDE4C;PDE4D;S100A12;S100A13,"APHTHOUS ULCERS, ASTHMA, CONJUNCTIVITIS, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Approved,SGRYPYWGNKJSDL-UHFFFAOYSA-N,CC(C)C1CCC2OC3NC(N)C(C(=O)O)CC3C(=O)C2C1;CC(C)C1CCC2OC3NC(N)C(CC3C(=O)C2C1)C(O)=O
AMLODIPINE,AMLODIPINE,CHEMBL1491;CHEMBL2111097,BRD:BRD-A22032524-074-06-5;BRD:BRD-BRD-A22032524-074-06-5,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CA1;CACNA1B;CACNA1C;CACNA1D;CACNA1F;CACNA1S;CACNA2D1;CACNA2D3;CACNB1;CACNB2;SMPD1,"HYPERTENSION, CHRONIC STABLE ANGINA, VASOSPASTIC ANGINA, CORONARY ARTERY DISEASE (CAD)",,LAUNCHED,,Small molecule,Approved,HTIQEAQVCYTUBX-KRWDZBQOSA-N;HTIQEAQVCYTUBX-UHFFFAOYSA-N,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1CCCCC1CL;CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1CCCCC1CL;CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1CCCCC1CL)C(=O)OC
AMMONIUM-GLYCYRRHIZINATE,AMMONIUM-GLYCYRRHIZINATE,,BRD:BRD-BRD-K15318383-201-01-5;BRD:BRD-K15318383-201-01-5,rep_primary;rep_single_dose,THROMBIN INHIBITOR,HSD11B1;HSD11B2;SLCO1B1;SLCO1B3,COSMETIC,,LAUNCHED,,,NA,,C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O
AMMONIUM-LACTATE,AMMONIUM-LACTATE,,BRD:BRD-BRD-M29182745-001-01-4;BRD:BRD-M29182745-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,,HCAR1,"XEROSIS CUTIS, ICHTHYOSIS VULGARIS",,LAUNCHED,,,NA,,N.CC(O)C(O)=O
AMMONIUM-PERFLUOROCAPRYLATE,AMMONIUM-PERFLUOROCAPRYLATE,,BRD:BRD-K32531356-001-03-9,rep_single_dose,PIM KINASE INHIBITOR,PIM1,,,,,,NA,,
AMN 107,AMN 107,CHEMBL255863,GDSC1:1013;GDSC2:1013,gdsc,,,,,,,Small molecule,Approved,HHZIURLSWUIHRB-UHFFFAOYSA-N,CC1CN(-C2CC(NC(=O)C3CCC(C)C(NC4NCCC(-C5CCCNC5)N4)C3)CC(C(F)(F)F)C2)CN1
AMN-082,AMN-082,,BRD:BRD-BRD-K23335153-300-02-5;BRD:BRD-K23335153-300-02-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,GRM7,,,PRECLINICAL,,,NA,,C(CNC(C1CCCCC1)C1CCCCC1)NC(C1CCCCC1)C1CCCCC1
AMODIAQUINE,AMODIAQUINE,CHEMBL682,BRD:BRD-BRD-K91290917-300-01-8;BRD:BRD-K91290917-300-01-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HNMT,MALARIA,,LAUNCHED,,Small molecule,Approved,OVCDSSHSILBFBN-UHFFFAOYSA-N,CCN(CC)CC1CC(NC2CCNC3CC(CL)CCC23)CCC1O
AMONAFIDE,AMONAFIDE,CHEMBL428676,BRD:BRD-BRD-K56334280-001-05-1;BRD:BRD-K56334280-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A;TOP2B,,,PHASE 3,,Small molecule,Phase 3,UPALIKSFLSVKIS-UHFFFAOYSA-N,CN(C)CCN1C(=O)C2CCCC3CC(N)CC(C1=O)C23;CN(C)CCN1C(=O)C2CCCC3CC(N)CC(C23)C1=O
AMOROLFINE,AMOROLFINE,CHEMBL489411,BRD:BRD-A37390343-003-03-5;BRD:BRD-BRD-A37390343-003-03-5,rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,,ONYCHOMYCOSIS,,LAUNCHED,,Small molecule,Approved,MQHLMHIZUIDKOO-AYHJJNSGSA-N,CCC(C)(C)C1CCC(CC(C)CN2C[C@@H](C)O[C@@H](C)C2)CC1;CCC(C)(C)C1CCC(CC(C)CN2C[C@H](C)O[C@H](C)C2)CC1
AMOXAPINE,AMOXAPINE,CHEMBL1113,BRD:BRD-BRD-K02265150-001-26-5;BRD:BRD-K02265150-001-26-5,rep_primary;rep_single_dose,NOREPINEPHRINE REPUTAKE INHIBITOR,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;HRH1;HRH4;HTR1A;HTR1B;HTR2A;HTR2B;HTR2C;HTR3A;HTR6;HTR7;SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,QWGDMFLQWFTERH-UHFFFAOYSA-N,CLC1CCC2C(C1)C(N1CCNCC1)=NC1CCCCC1O2;CLC1CCC2OC3CCCCC3N=C(N3CCNCC3)C2C1
AMOXICILLIN,AMOXICILLIN,CHEMBL1082,BRD:BRD-BRD-K55044200-001-14-6;BRD:BRD-BRD-K55044200-001-15-3;BRD:BRD-K55044200-001-14-6;BRD:BRD-K55044200-001-15-3,rep_multi_dose;rep_primary;rep_single_dose,PENICILLIN BINDING PROTEIN INHIBITOR,CYP2C19;SLC15A1;SLC15A2;SLC22A6,"SKIN INFECTIONS, DUODENAL ULCER DISEASE, GONORRHEA, EAR INFECTIONS, THROAT INFECTIONS, GENITOURINARY TRACT INFECTIONS, RESPIRATORY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3CCC(O)CC3)C(=O)N2[C@H]1C(=O)O;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3CCC(O)CC3)C(=O)N2[C@H]1C(O)=O
AMPA-(RS),AMPA-(RS),,BRD:BRD-A34716233-004-03-5;BRD:BRD-BRD-A34716233-004-03-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIN1,,,PRECLINICAL,,,NA,,CC1ONC(O)C1CC(N)C(O)=O
AMPA-(S),AMPA-(S),,BRD:BRD-BRD-K92493880-001-03-0;BRD:BRD-K92493880-001-03-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIA2;GRIN1,,,PRECLINICAL,"Multiple values for repurposing_target: {'GRIA2;GRIN1', 'GRIN1'}, taking the union",,NA,,CC1ONC(O)C1C[C@H](N)C(O)=O
AMPALEX,AMPALEX,CHEMBL136800,BRD:BRD-BRD-K24771047-001-01-6;BRD:BRD-K24771047-001-01-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIA1;GRIA2;GRIA3;GRIA4,,,PHASE 2,,Small molecule,Phase 2,ANDGGVOPIJEHOF-UHFFFAOYSA-N,O=C(C1CCC2NCCNC2C1)N1CCCCC1;O=C(N1CCCCC1)C1CCC2NCCNC2C1
AMPEROZIDE,AMPEROZIDE,CHEMBL1079935,BRD:BRD-BRD-K52397688-003-06-4;BRD:BRD-K52397688-003-06-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,FAAH;HTR2A,PSYCHOSIS,,LAUNCHED,,Small molecule,Unknown,NNAIYOXJNVGUOM-UHFFFAOYSA-N,CCNC(=O)N1CCN(CCCC(C2CCC(F)CC2)C2CCC(F)CC2)CC1
AMPHOTERICIN-B,AMPHOTERICIN-B,,BRD:BRD-BRD-K27352494-001-03-6;BRD:BRD-K27352494-001-03-6,rep_primary;rep_single_dose,MEMBRANE PERMEABILITY ENHANCER,,FUNGAL INFECTION,,LAUNCHED,,,NA,,C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O
AMPICILLIN,AMPICILLIN,CHEMBL174,BRD:BRD-BRD-K68432770-236-23-1;BRD:BRD-K68432770-236-23-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"RESPIRATORY TRACT INFECTIONS, MENINGITIS, BACTERIAL SEPTICEMIA, ENDOCARDITIS, URINARY TRACT INFECTIONS, GASTROINTESTINAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,AVKUERGKIZMTKX-NJBDSQKTSA-N,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3CCCCC3)C(=O)N2[C@H]1C(=O)O;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3CCCCC3)C(=O)N2[C@H]1C(O)=O
AMPRENAVIR,AMPRENAVIR,CHEMBL116,BRD:BRD-BRD-K47827687-001-02-2;BRD:BRD-K47827687-001-02-2,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,YMARZQAQMVYCKC-OEMFJLHTSA-N,CC(C)CN(C[C@@H](O)[C@H](CC1CCCCC1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1CCC(N)CC1
AMPROLIUM,AMPROLIUM,CHEMBL1179735;CHEMBL97350,BRD:BRD-BRD-K90027121-003-01-7;BRD:BRD-K90027121-003-01-7,rep_multi_dose;rep_primary;rep_single_dose,THIAMINE UPTAKE BLOCKER,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,IPZFPROOBOUEIG-UHFFFAOYSA-N;LCTXBFGHZLGBNU-UHFFFAOYSA-M,CCCC1NCC(C[N+]2CCCCC2C)C(N)N1;CCCC1NCC(C[N+]2CCCCC2C)C(N)N1.[CL-]
AMPYRONE,AMPYRONE,CHEMBL1165011,BRD:BRD-K20484910-001-16-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,,,Small molecule,NA,RLFWWDJHLFCNIJ-UHFFFAOYSA-N,CC1C(N)C(=O)N(-C2CCCCC2)N1C
AMRINONE,AMRINONE,CHEMBL12856,BRD:BRD-BRD-K45924332-001-16-8;BRD:BRD-K45924332-001-16-8,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A;PDE3B;PDE4B;TNF,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Approved,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,NC1CC(-C2CCNCC2)C[NH]C1=O;NC1CC(C[NH]C1=O)-C1CCNCC1
AMRUBICIN,AMRUBICIN,CHEMBL1186894,BRD:BRD-BRD-K13843533-001-01-7;BRD:BRD-K13843533-001-01-7,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A;TOP2B,"SMALL CELL LUNG CANCER, SMALL CELL LUNG CANCER",,LAUNCHED,,Small molecule,Phase 3,VJZITPJGSQKZMX-XDPRQOKASA-N,CC(=O)[C@]1(N)CC2C(O)C3C(C(O)C2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)C1CCCCC1C3=O;CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C2C(O)C3C(=O)C4CCCCC4C(=O)C3C(O)C2C1
AMSACRINE,AMSACRINE,CHEMBL43,BRD:BRD-BRD-K68346641-001-01-4;BRD:BRD-BRD-K68346641-001-02-2;BRD:BRD-K68346641-001-01-4;BRD:BRD-K68346641-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,KCNH2;TOP2A,"ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)",,LAUNCHED,,Small molecule,Approved,XCPGHVQEEXUHNC-UHFFFAOYSA-N,COC1CC(NS(C)(=O)=O)CCC1NC1C2CCCCC2NC2CCCCC12
AMTHAMINE,AMTHAMINE,CHEMBL293762,BRD:BRD-BRD-K39670393-303-02-1;BRD:BRD-K39670393-303-02-1,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH2,,,PRECLINICAL,,Small molecule,NA,LHVRFUVVRXGZPV-UHFFFAOYSA-N,CC1NC(N)SC1CCN
AMTOLMETIN-GUACIL,AMTOLMETIN-GUACIL,,BRD:BRD-BRD-K70924353-001-01-2;BRD:BRD-K70924353-001-01-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,,NA,,COC1CCCCC1OC(=O)CNC(=O)CC1CCC(C(=O)C2CCC(C)CC2)N1C
AMUVATINIB,AMUVATINIB,CHEMBL2103851,BRD:BRD-BRD-K66538826-001-07-2;BRD:BRD-K66538826-001-07-2;GDSC1:293,gdsc;rep_primary;rep_single_dose,"FLT3 INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, RAD51 INHIBITOR, RET TYROSINE KINASE INHIBITOR",KIT;MET,,,PHASE 2,,Small molecule,Phase 2,FOFDIMHVKGYHRU-UHFFFAOYSA-N,S=C(NCC1CCC2C(C1)OCO2)N1CCN(C2NCNC3C2OC2CCCCC23)CC1;S=C(NCC1CCC2OCOC2C1)N1CCN(CC1)C1NCNC2C3CCCCC3OC12
AMXT-1501 TETRAHYDROCHLORIDE,AMXT-1501 TETRAHYDROCHLORIDE,,BRD:BRD-K00091067-376-01-9,rep_single_dose,,,,,,,,NA,,
AMYGDALIN,AMYGDALIN,CHEMBL461727,BRD:BRD-BRD-K03504028-001-07-6;BRD:BRD-K03504028-001-07-6,rep_multi_dose;rep_primary;rep_single_dose,CASPASE ACTIVATOR,CASP3,,,PHASE 2,,Small molecule,NA,XUCIJNAGGSZNQT-JHSLDZJXSA-N,N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)C1CCCCC1;OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)C3CCCCC3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
AMYLEINE,AMYLEINE,,BRD:BRD-A09062839-003-10-0;BRD:BRD-BRD-A09062839-003-10-0,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,,NA,,CCC(C)(CN(C)C)OC(=O)C1CCCCC1
AMYLENE-HYDRATE,AMYLENE-HYDRATE,,BRD:BRD-BRD-K93502141-001-01-6;BRD:BRD-K93502141-001-01-6,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,,NA,,CCC(C)(C)O
AMYLOID P-IN-1,AMYLOID P-IN-1,,BRD:BRD-K00090622-001-01-9,rep_single_dose,,,,,,,,NA,,
AMZ30,AMZ30,,BRD:BRD-K00256256-001-06-1,rep_single_dose,PROTEIN PHOSPHATASE INHIBITOR,,,,,,,NA,,
AN2718,AN2718,CHEMBL211538,BRD:BRD-BRD-K21920947-001-02-1;BRD:BRD-K21920947-001-02-1,rep_primary;rep_single_dose,LEUCYL-TRNA SYNTHETASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,HMAFTPZYFJFEHK-UHFFFAOYSA-N,OB1OCC2CC(CL)CCC12;OB1OCC2CC(CL)CCC21
ANA-12,ANA-12,,BRD:BRD-A19609491-001-01-8;BRD:BRD-BRD-A19609491-001-01-8,rep_primary;rep_single_dose,TROPOMYOSIN RECEPTOR KINASE INHIBITOR,NTRK2,,,PRECLINICAL,,,NA,,O=C(NC1CCCCC1C(=O)NC1CCCCNC1=O)C1CC2CCCCC2S1
ANABASINE,ANABASINE,CHEMBL1526229,BRD:BRD-A24284985-001-09-9;BRD:BRD-BRD-A24284985-001-09-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,Small molecule,NA,MTXSIJUGVMTTMU-JTQLQIEISA-N,C1CCC(NC1)C1CCCNC1;C1CNCC([C@@H]2CCCCN2)C1
ANACETRAPIB,ANACETRAPIB,CHEMBL1800807,BRD:BRD-BRD-K44366189-001-01-9;BRD:BRD-K44366189-001-01-9,rep_primary;rep_single_dose,CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR,CETP,,,PHASE 3,,Small molecule,Phase 3,MZZLGJHLQGUVPN-HAWMADMCSA-N,COC1CC(F)C(C(C)C)CC1-C1CCC(C(F)(F)F)CC1CN1C(=O)O[C@H](C2CC(C(F)(F)F)CC(C(F)(F)F)C2)[C@@H]1C;COC1CC(F)C(CC1-C1CCC(CC1CN1[C@H](C)[C@H](OC1=O)C1CC(CC(C1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C
ANAGLIPTIN,ANAGLIPTIN,CHEMBL1929396,BRD:BRD-K05355328-001-02-9,rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,,,,,Small molecule,Phase 3,LDXYBEHACFJIEL-HNNXBMFYSA-N,CC1CC2NCC(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)CN2N1
ANAGRELIDE,ANAGRELIDE,CHEMBL760,BRD:BRD-BRD-K62200014-003-10-5;BRD:BRD-K62200014-003-10-5,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A,"THROMBOCYTHEMIA, MYELOPROLIFERATIVE NEOPLASMS",,LAUNCHED,,Small molecule,Approved,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,CLC1CCC2N=C3NC(=O)CN3CC2C1CL;O=C1CN2CC3C(CCC(CL)C3CL)N=C2N1
ANAMORELIN,ANAMORELIN,CHEMBL2110579,BRD:BRD-BRD-K01174345-001-01-9;BRD:BRD-K01174345-001-01-9,rep_primary;rep_single_dose,GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST,GHSR,,,PHASE 3,,Small molecule,Phase 3,VQPFSIRUEPQQPP-MXBOTTGLSA-N,CN(C)N(C)C(=O)[C@@]1(CC2CCCCC2)CCCN(C(=O)[C@@H](CC2C[NH]C3CCCCC23)NC(=O)C(C)(C)N)C1;CN(C)N(C)C(=O)[C@@]1(CC2CCCCC2)CCCN(C1)C(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)C(C)(C)N
ANANDAMIDE,ANANDAMIDE,CHEMBL15848,BRD:BRD-BRD-K42352790-001-05-3;BRD:BRD-K42352790-001-05-3,rep_multi_dose;rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CACNA1G;CACNA1H;CACNA1I;CNR1;CNR2;GLRA1;GPR18;GPR55;KCNA2;KCNK3;KCNK9;TRPM8;TRPV1,,,PHASE 2,,Small molecule,NA,LGEQQWMQCRIYKG-DOFZRALJSA-N,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCO;CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO
ANASTROZOLE,ANASTROZOLE,CHEMBL1399,BRD:BRD-BRD-K52172416-001-11-4;BRD:BRD-K52172416-001-11-4,rep_multi_dose;rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP19A1,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,YBBLVLTVTVSKRW-UHFFFAOYSA-N,CC(C)(C#N)C1CC(CN2CNCN2)CC(C(C)(C)C#N)C1;CC(C)(C#N)C1CC(CN2CNCN2)CC(C1)C(C)(C)C#N
ANCHUSIN,ANCHUSIN,,GDSC1:170,gdsc,,,,,,,,NA,,
ANDARINE,ANDARINE,,BRD:BRD-BRD-K82164249-001-03-5;BRD:BRD-K82164249-001-03-5,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 1,,,NA,,CC(=O)NC1CCC(OC[C@](C)(O)C(=O)NC2CCC(C(C2)C(F)(F)F)[N+]([O-])=O)CC1
ANDROGRAPHOLIDE,ANDROGRAPHOLIDE,CHEMBL186141,BRD:BRD-A86619021-001-04-8;BRD:BRD-BRD-A86619021-001-04-8,rep_primary;rep_single_dose,TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR,NFKB1,,,PHASE 2,,Small molecule,Phase 3,BOJKULTULYSRAS-OTESTREVSA-N,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CCC12;C=C1CC[C@@H]2[C@](C)(CO)[C@H](O)CC[C@@]2(C)[C@@H]1C/C=C1/C(=O)OC[C@H]1O
ANDROSTENONE,ANDROSTENONE,,BRD:BRD-A64011898-001-01-0;BRD:BRD-BRD-A64011898-001-01-0,rep_primary;rep_single_dose,STEROID,,,,PRECLINICAL,,,NA,,CC12CCC3C(CCC4CC(=O)CCC34C)C1CC=C2
ANDROSTERONE,ANDROSTERONE,CHEMBL87285,BRD:BRD-BRD-K12329651-001-18-8;BRD:BRD-K12329651-001-18-8,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,,,,PRECLINICAL,,Small molecule,NA,QGXBDMJGAMFCBF-HLUDHZFRSA-N,C[C@]12CC[C@@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12;C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O
ANECORTAVE-ACETATE,ANECORTAVE-ACETATE,,BRD:BRD-A53566267-001-01-9;BRD:BRD-BRD-A53566267-001-01-9,rep_primary;rep_single_dose,ANGIOGENESIS INHIBITOR,,MACULAR DEGENERATION,,LAUNCHED,,,NA,,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C
ANETHOLE-TRITHIONE,ANETHOLE-TRITHIONE,,BRD:BRD-BRD-K92490248-001-06-6;BRD:BRD-K92490248-001-06-6,rep_primary;rep_single_dose,GLUTATHIONE TRANSFERASE STIMULANT,,,,LAUNCHED,,,NA,,COC1CCC(CC1)-C1CC(=S)SS1
ANGUIDINE,ANGUIDINE,,BRD:BRD-BRD-K45724504-001-01-6;BRD:BRD-K45724504-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,SLC5A1,,,PHASE 2,,,NA,,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1
ANIDULAFUNGIN,ANIDULAFUNGIN,CHEMBL1631577;CHEMBL264241,BRD:BRD-A75305484-001-01-3;BRD:BRD-BRD-A75305484-001-01-3,rep_primary;rep_single_dose,"FUNGAL 1,3-BETA-D-GLUCAN SYNTHASE INHIBITOR",,"CANDIDEMIA, FUNGAL INFECTION, ESOPHAGEAL CANDIDIASIS",,LAUNCHED,,Small molecule,Approved,JHVAMHSQVVQIOT-MFAJLEFUSA-N;JHVAMHSQVVQIOT-ODOSRWJUSA-N,CCCCCOC1CCC(-C2CCC(-C3CCC([14C](=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)C5CCC(O)CC5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@H](C)O)NC4=O)CC3)CC2)CC1;CCCCCOC1CCC(-C2CCC(-C3CCC(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)C5CCC(O)CC5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)CC3)CC2)CC1;CCCCCOC1CCC(CC1)-C1CCC(CC1)-C1CCC(CC1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(NC(=O)C(NC(=O)C2CC(O)CN2C(=O)C(NC1=O)C(C)O)C(O)C(O)C1CCC(O)CC1)C(C)O
ANIRACETAM,ANIRACETAM,CHEMBL36994,BRD:BRD-BRD-K88611939-001-22-4;BRD:BRD-K88611939-001-22-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,DRD2;GRIA1;GRIA2;GRIA3;GRIA4;HTR2A,,,LAUNCHED,,Small molecule,Unknown,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,COC1CCC(C(=O)N2CCCC2=O)CC1;COC1CCC(CC1)C(=O)N1CCCC1=O
ANISINDIONE,ANISINDIONE,CHEMBL712,BRD:BRD-BRD-K47458712-001-20-7;BRD:BRD-K47458712-001-20-7,rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,GGCX,DEEP VEIN THROMBOSIS (DVT),,LAUNCHED,,Small molecule,Approved,XRCFXMGQEVUZFC-UHFFFAOYSA-N,COC1CCC(C2C(=O)C3CCCCC3C2=O)CC1;COC1CCC(CC1)C1C(=O)C2CCCCC2C1=O
ANISODAMINE,ANISODAMINE,CHEMBL2165224,BRD:BRD-A29623586-001-01-3;BRD:BRD-BRD-A29623586-001-01-3,rep_primary;rep_single_dose,LIPID PEROXIDASE INHIBITOR,ADRA1A,,,PHASE 3,,Small molecule,Phase 3,WTQYWNWRJNXDEG-RBZJEDDUSA-N,CN1[C@H]2C[C@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@@H]1[C@@H](O)C2;CN1C2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)C1CCCCC1
ANISOMYCIN,ANISOMYCIN,CHEMBL423192,BRD:BRD-BRD-K91370081-001-25-1;BRD:BRD-K91370081-001-25-1,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,NHP2L1;RPL10L;RPL11;RPL13A;RPL15;RPL19;RPL23;RPL23A;RPL26L1;RPL3;RPL37;RPL8;RSL24D1,,,PRECLINICAL,,Small molecule,NA,YKJYKKNCCRKFSL-RDBSUJKOSA-N,COC1CCC(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)CC1
ANISOTROPINE,ANISOTROPINE,CHEMBL1186610,BRD:BRD-A06771424-004-01-7;BRD:BRD-BRD-A06771424-004-01-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,XGGHHHBGPSNXFE-ZSHCYNCHSA-N,CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C;CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C
ANLOTINIB,ANLOTINIB,CHEMBL4303201,BRD:BRD-BRD-K36949735-001-01-1;BRD:BRD-K36949735-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,"VEGFR INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR",KDR;PDGFRB,,,PHASE 2/PHASE 3,"Multiple values for MOA: {'PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR', 'VEGFR INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR'}, defaulting to 'VEGFR INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR'",Small molecule,Phase 3,KSMZEXLVHXZPEF-UHFFFAOYSA-N,COC1CC2C(OC3CCC4[NH]C(C)CC4C3F)CCNC2CC1OCC1(N)CC1
ANPIRTOLINE,ANPIRTOLINE,CHEMBL1316374,BRD:BRD-BRD-K55424922-003-02-8;BRD:BRD-K55424922-003-02-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1B,,,PHASE 1,,Small molecule,Unknown,GGALEXMXDMUMDM-UHFFFAOYSA-N,CLC1CCCC(SC2CCNCC2)N1
ANR-94,ANR-94,,BRD:BRD-BRD-K31170746-001-01-6;BRD:BRD-K31170746-001-01-6,rep_primary;rep_single_dose,"A1 ADENOSINE RECEPTOR ANTAGONIST, ADENOSINE RECEPTOR ANTAGONIST",ADORA2A,,,PRECLINICAL,"Multiple values for MOA: {'A1 ADENOSINE RECEPTOR ANTAGONIST', 'A1 ADENOSINE RECEPTOR ANTAGONIST, ADENOSINE RECEPTOR ANTAGONIST'}, defaulting to 'A1 ADENOSINE RECEPTOR ANTAGONIST, ADENOSINE RECEPTOR ANTAGONIST'",,NA,,CCOC1NC2C(N)NCNC2N1CC
ANSOFAXINE HYDROCHLORIDE,ANSOFAXINE HYDROCHLORIDE,,BRD:BRD-K00075778-003-02-9,rep_single_dose,,,,,,,,NA,,
ANTAGONIST-G,ANTAGONIST-G,,BRD:BRD-BRD-K25863791-001-01-8;BRD:BRD-K25863791-001-01-8,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,MAPK8,,,PHASE 1,,,NA,,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CCCCC1)N(C)C(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O
ANTALARMIN,ANTALARMIN,CHEMBL296641,BRD:BRD-BRD-K01363385-003-01-5;BRD:BRD-K01363385-003-01-5,rep_primary;rep_single_dose,"CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST",CRHR1,,,PRECLINICAL,"Multiple values for MOA: {'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST', 'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST'}, defaulting to 'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST'",Small molecule,NA,IXPROWGEHNVJOY-UHFFFAOYSA-N,CCCCN(CC)C1NC(C)NC2C1C(C)C(C)N2-C1C(C)CC(C)CC1C;CCCCN(CC)C1NC(C)NC2N(C(C)C(C)C12)-C1C(C)CC(C)CC1C
ANTAZOLINE,ANTAZOLINE,CHEMBL1305,BRD:BRD-BRD-K99300445-003-21-6;BRD:BRD-K99300445-003-21-6,rep_primary;rep_single_dose,ANTIHISTAMINE,HRH1,"CONJUNCTIVITIS, NASAL CONGESTION",,LAUNCHED,,Small molecule,Approved,REYFJDPCWQRWAA-UHFFFAOYSA-N,C(N(CC1CCCCC1)C1CCCCC1)C1=NCCN1;C1CCC(CN(CC2=NCCN2)C2CCCCC2)CC1
ANTHRANILIC-ACID,ANTHRANILIC-ACID,,BRD:BRD-BRD-K75167327-001-01-6,rep_primary,,,,,PRECLINICAL,,,NA,,OC(=O)C1CCCCC1NC(=O)C12CC3CC(CC(C3)C1)C2
ANTHRAQUINONE,ANTHRAQUINONE,CHEMBL55659,BRD:BRD-K15957397-001-05-9,rep_single_dose,CDC INHIBITOR,CDC25B,,,,,Small molecule,NA,RZVHIXYEVGDQDX-UHFFFAOYSA-N,O=C1C2CCCCC2C(=O)C2CCCCC21
ANTIMONYL,ANTIMONYL,,BRD:BRD-A74328360-409-02-8,rep_single_dose,,,,,,,,NA,,
ANTINEOPLASTON A10,ANTINEOPLASTON A10,CHEMBL1980825,BRD:BRD-K00091100-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,OQGRFQCUGLKSAV-JTQLQIEISA-N,O=C1CC[C@H](NC(=O)CC2CCCCC2)C(=O)N1
AOB2313,AOB2313,,GDSC2:1629,gdsc,,,,,,,,NA,,
AOB3540,AOB3540,,GDSC2:1622,gdsc,,,,,,,,NA,,
AOB3680,AOB3680,,GDSC2:1627,gdsc,,,,,,,,NA,,
AOB5560,AOB5560,,GDSC2:1617,gdsc,,,,,,,,NA,,
AP-18,AP-18,,BRD:BRD-K32143970-001-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPA1,,,,,,NA,,
AP-24534,AP-24534,CHEMBL1171837,GDSC1:155,gdsc,,,,,,,Small molecule,Approved,PHXJVRSECIGDHY-UHFFFAOYSA-N,CC1CCC(C(=O)NC2CCC(CN3CCN(C)CC3)C(C(F)(F)F)C2)CC1C#CC1CNC2CCCNN12
AP1903,AP1903,CHEMBL269259,BRD:BRD-BRD-K28383148-001-01-4;BRD:BRD-K28383148-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,,MTOR,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,GQLCLPLEEOUJQC-ZTQDTCGGSA-N,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1CCC(OC)C(OC)C1)C1CCCC(OCC(=O)NCCNC(=O)COC2CCCC([C@@H](CCC3CCC(OC)C(OC)C3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)C3CC(OC)C(OC)C(OC)C3)C2)C1)C1CC(OC)C(OC)C(OC)C1;CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1CCC(OC)C(OC)C1)C1CCCC(OCC(=O)NCCNC(=O)COC2CCCC(C2)[C@@H](CCC2CCC(OC)C(OC)C2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)C2CC(OC)C(OC)C(OC)C2)C1)C1CC(OC)C(OC)C(OC)C1
AP24534,AP24534,CHEMBL1171837,GDSC1:155,gdsc,,,,,,,Small molecule,Approved,PHXJVRSECIGDHY-UHFFFAOYSA-N,CC1CCC(C(=O)NC2CCC(CN3CCN(C)CC3)C(C(F)(F)F)C2)CC1C#CC1CNC2CCCNN12
AP26113,AP26113,CHEMBL3545311,BRD:BRD-BRD-K56032964-001-02-1;BRD:BRD-K56032964-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK;EGFR,,,PHASE 2,,Small molecule,Approved,AILRADAXUVEEIR-UHFFFAOYSA-N,COC1CC(CCC1NC1NCC(CL)C(NC2CCCCC2P(C)(C)=O)N1)N1CCC(CC1)N(C)C;COC1CC(N2CCC(N3CCN(C)CC3)CC2)CCC1NC1NCC(CL)C(NC2CCCCC2P(C)(C)=O)N1
APABETALONE,APABETALONE,CHEMBL2393130,BRD:BRD-BRD-K20001883-001-02-7;BRD:BRD-K20001883-001-02-7;GDSC2:1625,gdsc;rep_primary;rep_single_dose,APOLIPOPROTEIN EXPRESSION ENHANCER,BRD3,,,PHASE 3,,Small molecule,Phase 3,NETXMUIMUZJUTB-UHFFFAOYSA-N,COC1CC(OC)C2C(=O)[NH]C(-C3CC(C)C(OCCO)C(C)C3)NC2C1;COC1CC(OC)C2C(C1)[NH]C(NC2=O)-C1CC(C)C(OCCO)C(C)C1
APAFANT,APAFANT,CHEMBL280164,BRD:BRD-BRD-K28115081-001-02-7;BRD:BRD-K28115081-001-02-7,rep_primary;rep_single_dose,PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST,PTAFR,,,PHASE 3,,Small molecule,Unknown,JGPJQFOROWSRRS-UHFFFAOYSA-N,CC1NNC2CN=C(C3CC(CCC(=O)N4CCOCC4)SC3-N12)C1CCCCC1CL;CC1NNC2N1-C1SC(CCC(=O)N3CCOCC3)CC1C(C1CCCCC1CL)=NC2
APALUTAMIDE,APALUTAMIDE,CHEMBL3183409,BRD:BRD-BRD-K91308639-001-02-7;BRD:BRD-K91308639-001-02-7,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,,PROSTATE CANCER,,LAUNCHED,,Small molecule,Approved,HJBWBFZLDZWPHF-UHFFFAOYSA-N,CNC(=O)C1CCC(CC1F)N1C(=S)N(C(=O)C11CCC1)C1CNC(C#N)C(C1)C(F)(F)F;CNC(=O)C1CCC(N2C(=S)N(C3CNC(C#N)C(C(F)(F)F)C3)C(=O)C23CCC3)CC1F
APARARENONE,APARARENONE,CHEMBL3545392,BRD:BRD-K00003492-001-01-9,rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,,
APATINIB,APATINIB,CHEMBL3186534,BRD:BRD-BRD-K25244359-066-03-4;BRD:BRD-K25244359-066-03-4,rep_multi_dose;rep_primary;rep_single_dose,RET TYROSINE KINASE INHIBITOR,CSK;KDR;KIT;RET,,,PHASE 3,,Small molecule,Phase 3,WPEWQEMJFLWMLV-UHFFFAOYSA-N,N#CC1(C2CCC(NC(=O)C3CCCNC3NCC3CCNCC3)CC2)CCCC1;O=C(NC1CCC(CC1)C1(CCCC1)C#N)C1CCCNC1NCC1CCNCC1
APC-100,APC-100,CHEMBL37676,BRD:BRD-BRD-K07449869-001-01-5;BRD:BRD-K07449869-001-01-5,rep_primary;rep_single_dose,"ANTI-INFLAMMATORY AGENT, ANDROGEN RECEPTOR ANTAGONIST",AR,,,PHASE 1/PHASE 2,"Multiple values for MOA: {'ANDROGEN RECEPTOR ANTAGONIST, ANTI-INFLAMMATORY AGENT', 'ANTI-INFLAMMATORY AGENT, ANDROGEN RECEPTOR ANTAGONIST'}, defaulting to 'ANTI-INFLAMMATORY AGENT, ANDROGEN RECEPTOR ANTAGONIST'",Small molecule,Phase 1,SEBPXHSZHLFWRL-UHFFFAOYSA-N,CC1C(C)C2C(C(C)C1O)CCC(C)(C)O2;CC1C(C)C2OC(C)(C)CCC2C(C)C1O
APCK-110,APCK-110,,BRD:BRD-BRD-K72748448-001-01-0;BRD:BRD-K72748448-001-01-0,rep_primary;rep_single_dose,KIT INHIBITOR,KIT;STAT3,,,PRECLINICAL,,,NA,,COC1CC(OC)CC(C1)-C1CCC2C(N[NH]C2N1)-C1CCC(F)CC1
APD597,APD597,,BRD:BRD-BRD-K86226872-001-01-6;BRD:BRD-K86226872-001-01-6,rep_primary;rep_single_dose,GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR AGONIST,GPR119,,,PHASE 1,,,NA,,COC1C(NC2CCC(NC2C)S(C)(=O)=O)NCNC1OC1CCN(CC1)C(=O)OC(C)C
APD668,APD668,,BRD:BRD-BRD-K10859802-001-01-0;BRD:BRD-K10859802-001-01-0,rep_primary;rep_single_dose,GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR AGONIST,GPR119,,,PHASE 1,,,NA,,CC(C)OC(=O)N1CCC(CC1)OC1NCNC2N(NCC12)-C1CCC(CC1F)S(C)(=O)=O
APHIDICOLIN,APHIDICOLIN,CHEMBL29711,BRD:BRD-BRD-K85140930-001-12-7;BRD:BRD-K85140930-001-12-7,rep_multi_dose;rep_primary;rep_single_dose,RNA SYNTHESIS INHIBITOR,,,,PHASE 1,,Small molecule,NA,NOFOAYPPHIUXJR-APNQCZIXSA-N,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO;C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@@]12CC[C@]3(O)CO
API-001,API-001,,BRD:BRD-BRD-K26325692-003-01-3;BRD:BRD-K26325692-003-01-3,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,SIGMAR1,,,PHASE 2,,,NA,,CC1CC(OCCN2CCOCC2)NN1-C1CCC2CCCCC2C1
API-1,API-1,,BRD:BRD-K97840621-001-02-9,rep_single_dose,AKT INHIBITOR,AKT1;AKT2;AKT3,,,,,,NA,,
APICIDIN,APICIDIN,CHEMBL430060,CTRP:61097,ctrp,,,,,,,Protein,NA,JWOGUUIOCYMBPV-GMFLJSBRSA-N,CCC(=O)CCCCC[C@@H]1NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC2CN(OC)C3CCCCC23)NC1=O
APIGENIN,APIGENIN,CHEMBL28,BRD:BRD-BRD-K01493881-001-29-4;BRD:BRD-K01493881-001-29-4,rep_primary;rep_single_dose,"CASEIN KINASE INHIBITOR, CELL PROLIFERATION INHIBITOR",AKR1B1;AR;CDK6;CFTR;CYP19A1;CYP1B1;HSD17B1,,,PRECLINICAL,,Small molecule,NA,KZNIFHPLKGYRTM-UHFFFAOYSA-N,O=C1CC(-C2CCC(O)CC2)OC2CC(O)CC(O)C12;OC1CCC(CC1)-C1CC(=O)C2C(O)CC(O)CC2O1
APITOLISIB,APITOLISIB,CHEMBL1922094,GDSC1:382,gdsc,,,,,,,Small molecule,Phase 2,YOVVNQKCSKSHKT-HNNXBMFYSA-N,CC1C(CN2CCN(C(=O)[C@H](C)O)CC2)SC2C(N3CCOCC3)NC(-C3CNC(N)NC3)NC12
APIXABAN,APIXABAN,CHEMBL231779,BRD:BRD-BRD-K67121414-001-03-3;BRD:BRD-K67121414-001-03-3,rep_primary;rep_single_dose,COAGULATION FACTOR INHIBITOR,F10,"STROKE, SYSTEMIC EMBOLISM, PULMONARY EMBOLISM (PE), ATRIAL FIBRILLATION (AF), DEEP VEIN THROMBOSIS (DVT)",,LAUNCHED,,Small molecule,Approved,QNZCBYKSOIHPEH-UHFFFAOYSA-N,COC1CCC(-N2NC(C(N)=O)C3C2C(=O)N(C2CCC(N4CCCCC4=O)CC2)CC3)CC1;COC1CCC(CC1)-N1NC(C(N)=O)C2CCN(C(=O)C12)C1CCC(CC1)N1CCCCC1=O
APO866,APO866,CHEMBL566757,GDSC1:1248;GDSC2:1248,gdsc,,,,,,,Small molecule,Phase 2,KPBNHDGDUADAGP-VAWYXSNFSA-N,O=C(/C=C/C1CCCNC1)NCCCCC1CCN(C(=O)C2CCCCC2)CC1
APOCYNIN,APOCYNIN,CHEMBL346919,BRD:BRD-BRD-K64990520-001-08-4;BRD:BRD-K64990520-001-08-4,rep_primary;rep_single_dose,NADPH OXIDASE INHIBITOR,NOX4,,,PHASE 1,,Small molecule,Phase 1,DFYRUELUNQRZTB-UHFFFAOYSA-N,COC1CC(C(C)=O)CCC1O;COC1CC(CCC1O)C(C)=O
APOPTOSIS-ACTIVATOR-II,APOPTOSIS-ACTIVATOR-II,,BRD:BRD-BRD-K15164005-001-05-6;BRD:BRD-K15164005-001-05-6,rep_primary;rep_single_dose,CARBOXYLESTERASE INHIBITOR,BCHE;CES1,,,PRECLINICAL,,,NA,,CLC1CCC(CN2C(=O)C(=O)C3CCCCC23)CC1CL
APR-246,APR-246,CHEMBL3186011,BRD:BRD-A09004963-001-01-3;BRD:BRD-BRD-A09004963-001-01-3;GDSC2:1131,gdsc;rep_primary;rep_single_dose,P53 ACTIVATOR,TP53,,,PHASE 1/PHASE 2,,Small molecule,Phase 3,BGBNULCRKBVAKL-UHFFFAOYSA-N,COCC1(CO)C(=O)C2CCN1CC2;COCC1(CO)N2CCC(CC2)C1=O
APRACLONIDINE,APRACLONIDINE,CHEMBL647,BRD:BRD-BRD-K38911213-003-01-6;BRD:BRD-K38911213-003-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA2A;ADRA2B;ADRA2C,"GLAUCOMA, INTRAOCULAR PRESSURE",,LAUNCHED,,Small molecule,Approved,IEJXVRYNEISIKR-UHFFFAOYSA-N,NC1CC(CL)C(N=C2NCCN2)C(CL)C1;NC1CC(CL)C(NC2=NCCN2)C(CL)C1
APRATASTAT,APRATASTAT,CHEMBL206815,BRD:BRD-BRD-K06883221-001-01-9;BRD:BRD-K06883221-001-01-9,rep_primary;rep_single_dose,"MATRIX METALLOPROTEASE INHIBITOR, TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR",ADAM17;MMP1;MMP13;MMP9,,,PHASE 2,,Small molecule,Phase 2,MAVDNGWEBZTACC-HNNXBMFYSA-N,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C1CCC(OCC#CCO)CC1;CC1(C)SCCN(S(=O)(=O)C2CCC(OCC#CCO)CC2)[C@H]1C(=O)NO
APREMILAST,APREMILAST,CHEMBL514800,BRD:BRD-BRD-K93208532-001-02-5;BRD:BRD-K93208532-001-02-5,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4C;PDE4D,"PSORIASIS, PSORIATIC ARTHRITIS",,LAUNCHED,,Small molecule,Approved,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,CCOC1CC([C@@H](CS(C)(=O)=O)N2C(=O)C3CCCC(NC(C)=O)C3C2=O)CCC1OC;CCOC1CC(CCC1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2CCCC(NC(C)=O)C2C1=O
APREPITANT,APREPITANT,CHEMBL1471,BRD:BRD-BRD-K65170927-001-01-6;BRD:BRD-K65170927-001-01-6,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,ATALOFNDEOCMKK-OITMNORJSA-N,C[C@@H](O[C@H]1OCCN(CC2N[NH]C(=O)[NH]2)[C@H]1C1CCC(F)CC1)C1CC(C(F)(F)F)CC(C(F)(F)F)C1;C[C@H](O[C@H]1OCCN(CC2N[NH]C(=O)[NH]2)[C@H]1C1CCC(F)CC1)C1CC(CC(C1)C(F)(F)F)C(F)(F)F
APRICITABINE,APRICITABINE,CHEMBL210651,BRD:BRD-BRD-K55172746-001-01-3;BRD:BRD-K55172746-001-01-3,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,RYMCFYKJDVMSIR-RNFRBKRXSA-N,NC1CCN([C@H]2CO[C@@H](CO)S2)C(=O)N1
APRINDINE,APRINDINE,CHEMBL1213033,BRD:BRD-BRD-K53236343-003-03-7;BRD:BRD-K53236343-003-03-7,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,CALM1;SCN5A,CARDIAC ARRYTHMIA,,LAUNCHED,,Small molecule,Unknown,NZLBHDRPUJLHCE-UHFFFAOYSA-N,CCN(CC)CCCN(C1CC2CCCCC2C1)C1CCCCC1;CCN(CC)CCCN(C1CCCCC1)C1CC2CCCCC2C1
APRONAL,APRONAL,CHEMBL509282,BRD:BRD-K00003524-001-01-9,rep_single_dose,CYTOCHROME P450 MODULATOR,,,,,,Small molecule,Unknown,KSUUMAWCGDNLFK-UHFFFAOYSA-N,C=CCC(C(=O)NC(N)=O)C(C)C
APTIGANEL,APTIGANEL,CHEMBL92484,BRD:BRD-BRD-K63919159-003-07-0;BRD:BRD-K63919159-003-07-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,,,PHASE 3,,Small molecule,Unknown,BFNCJMURTMZBTE-UHFFFAOYSA-N,CCC1CCCC(C1)N(C)C(=N)NC1CCCC2CCCCC12;CCC1CCCC(N(C)C(=N)NC2CCCC3CCCCC23)C1
APTO-253,APTO-253,CHEMBL4297261,BRD:BRD-BRD-K68003372-001-01-6;BRD:BRD-K68003372-001-01-6,rep_primary;rep_single_dose,"KR""""""""UPPEL-LIKE FACTOR EXPRESSION ENHANCER, KRPPEL-LIKE FACTOR EXPRESSION ENHANCER",KLF4,,,PHASE 1,"Multiple values for MOA: {'KR""""""""UPPEL-LIKE FACTOR EXPRESSION ENHANCER, KR\x9cPPEL-LIKE FACTOR EXPRESSION ENHANCER', 'KR""UPPEL-LIKE FACTOR EXPRESSION ENHANCER'}, defaulting to 'KR""""""""UPPEL-LIKE FACTOR EXPRESSION ENHANCER, KR\x9cPPEL-LIKE FACTOR EXPRESSION ENHANCER'",Small molecule,Phase 1,NIRXBXIPHUTNNI-UHFFFAOYSA-N,CC1[NH]C2CCC(F)CC2C1-C1NC2C([NH]1)C1CCCNC1C1NCCCC21;CC1[NH]C2CCC(F)CC2C1-C1NC2C3CCCNC3C3NCCCC3C2[NH]1
APY-29,APY-29,,BRD:BRD-K17511755-001-02-9,rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,ERN1,,,,,,NA,,
APY0201,APY0201,,BRD:BRD-K38627885-001-01-9,rep_single_dose,PHOSPHOINOSITIDE DEPENDENT KINASE INHIBITOR,IL12A;IL12B;PIKFYVE,,,,,,NA,,
APYRAMIDE,APYRAMIDE,,BRD:BRD-K00004738-001-01-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,,,,NA,,
AQ-13,AQ-13,CHEMBL4297695,BRD:BRD-K00003365-300-01-9,rep_single_dose,ANTIMALARIAL AGENT,,,,,,Unknown,Phase 2,,
AQ-RA741,AQ-RA741,,BRD:BRD-BRD-K81729199-001-02-8;BRD:BRD-K81729199-001-02-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM2,,,PRECLINICAL,,,NA,,CCN(CC)CCCCC1CCN(CC(=O)N2C3CCCCC3C(=O)NC3CCCNC23)CC1
AQW-051,AQW-051,,BRD:BRD-K00004705-001-01-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,,,,,,,NA,,
AR 42,AR 42,,GDSC1:272,gdsc,,,,,,,,NA,,
AR-12,AR-12,CHEMBL1650595,BRD:BRD-BRD-K90497590-001-04-2;BRD:BRD-K90497590-001-04-2;GDSC1:167,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PHOSPHOINOSITIDE DEPENDENT KINASE INHIBITOR,PDPK1,,,PHASE 1,,Small molecule,Phase 1,YULUCECVQOCQFQ-UHFFFAOYSA-N,NCC(=O)NC1CCC(-N2NC(C(F)(F)F)CC2-C2CCC3C(CCC4CCCCC43)C2)CC1;NCC(=O)NC1CCC(CC1)-N1NC(CC1-C1CCC2C(CCC3CCCCC23)C1)C(F)(F)F
AR-42,AR-42,CHEMBL191482,BRD:BRD-BRD-K13167095-001-02-9;BRD:BRD-K13167095-001-02-9;GDSC1:272,gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1,,,PHASE 1,,Small molecule,Phase 2,LAMIXXKAWNLXOC-INIZCTEOSA-N,CC(C)[C@H](C(=O)NC1CCC(C(=O)NO)CC1)C1CCCCC1;CC(C)[C@H](C(=O)NC1CCC(CC1)C(=O)NO)C1CCCCC1
AR-9281,AR-9281,,BRD:BRD-K00078154-001-02-9,rep_single_dose,,,,,,,,NA,,
AR-A014418,AR-A014418,,BRD:BRD-BRD-K67860401-001-05-6;BRD:BRD-K67860401-001-05-6,rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3B,,,PRECLINICAL,,,NA,,COC1CCC(CNC(=O)NC2NCC(S2)[N+]([O-])=O)CC1
AR-C155858,AR-C155858,,BRD:BRD-K42325600-001-01-8,rep_single_dose,MONOCARBOXYLATE TRANSPORTER INHIBITOR,SLC16A1;SLC16A7,,,,,,NA,,
AR42,AR42,CHEMBL191482,GDSC1:272,gdsc,,,,,,,Small molecule,Phase 2,LAMIXXKAWNLXOC-INIZCTEOSA-N,CC(C)[C@H](C(=O)NC1CCC(C(=O)NO)CC1)C1CCCCC1
CYTARABINE,ARA-C;CYTARABINE,CHEMBL596186;CHEMBL803,BRD:BRD-BRD-K71847383-001-12-5;BRD:BRD-K71847383-001-12-5;GDSC1:1006;GDSC2:1006,gdsc;oncref_2;rep_primary,RIBONUCLEOTIDE REDUCTASE INHIBITOR,POLA1;POLB;POLD1;POLE,"ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), ACUTE MYELOID LEUKEMIA (AML), NON-HODGKIN LYMPHOMA (NHL)",,LAUNCHED,"Multiple values for MOA: {'RIBONUCLEOTIDE REDUCTASE INHIBITOR', 'PYRIMIDINE NUCLEOSIDE ANALOG'}, defaulting to 'RIBONUCLEOTIDE REDUCTASE INHIBITOR'",Small molecule,Approved,IERHLVCPSMICTF-CCXZUQQUSA-N;UHDGCWIWMRVCDJ-CCXZUQQUSA-N,NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)N1;NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(=O)N1;NC1CCN([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]2O)C(=O)N1
ARA-CYTIDINE,ARA-CYTIDINE,CHEMBL803,GDSC1:1006;GDSC2:1006,gdsc,,,,,,,Small molecule,Approved,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)N1
ARA-G,ARA-G,,GDSC1:427,gdsc,,,,,,,,NA,,
ARABINOSYL CYTOSINE,ARABINOSYL CYTOSINE,CHEMBL803,GDSC1:1006;GDSC2:1006,gdsc,,,,,,,Small molecule,Approved,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)N1
ARAMCHOL,ARAMCHOL,CHEMBL4297262,BRD:BRD-K00004646-001-01-9,rep_single_dose,STEAROYL-COA DESATURASE INHIBITOR,,,,,,Small molecule,Phase 3,SHKXZIQNFMOPBS-OOMQYRRCSA-N,CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@@H](C1)C[C@@H](O)[C@@H]1[C@@H]2C[C@H](O)[C@]2(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]12
ARAVA,ARAVA,CHEMBL960,GDSC2:1578,gdsc,,,,,,,Small molecule,Approved,VHOGYURTWQBHIL-UHFFFAOYSA-N,CC1ONCC1C(=O)NC1CCC(C(F)(F)F)CC1
ARBIDOL,ARBIDOL,CHEMBL1214598,BRD:BRD-BRD-K73881242-003-04-6;BRD:BRD-K73881242-003-04-6,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP3A4,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,Small molecule,Phase 3,KCFYEAOKVJSACF-UHFFFAOYSA-N,CCOC(=O)C1C(CSC2CCCCC2)N(C)C2CC(BR)C(O)C(CN(C)C)C12
ARBUTIN,ARBUTIN,CHEMBL232202,BRD:BRD-BRD-K08037784-001-12-6;BRD:BRD-K08037784-001-12-6,rep_primary;rep_single_dose,MELANIN INHIBITOR,TYR,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,BJRNKVDFDLYUGJ-RMPHRYRLSA-N,OC[C@H]1O[C@@H](OC2CCC(O)CC2)[C@H](O)[C@@H](O)[C@@H]1O
ARC-239,ARC-239,,BRD:BRD-BRD-K93188295-300-02-2;BRD:BRD-K93188295-300-02-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRA2B;ADRA2C,,,PRECLINICAL,,,NA,,COC1CCCCC1N1CCN(CCN2C(=O)C3CCCCC3C(C)(C)C2=O)CC1
ARCTIGENIN,ARCTIGENIN,CHEMBL435734,BRD:BRD-BRD-K53523901-001-04-4;BRD:BRD-K53523901-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,CHUK;MAP2K1,,,PRECLINICAL,,Small molecule,NA,NQWVSMVXKMHKTF-JKSUJKDBSA-N,COC1CC(C[C@@H]2[C@@H](CC3CCC(OC)C(OC)C3)COC2=O)CCC1O;COC1CC(C[C@H]2C(=O)OC[C@@H]2CC2CCC(OC)C(OC)C2)CCC1O
ARCYRIAFLAVIN-A,ARCYRIAFLAVIN-A,,BRD:BRD-BRD-K72726508-001-02-1;BRD:BRD-K72726508-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CCND1;CDK4,,,PRECLINICAL,,,NA,,O=C1NC(=O)C2C1C1C3CCCCC3[NH]C1C1[NH]C3CCCCC3C21
ARDEPARIN,ARDEPARIN,,BRD:BRD-A83644949-236-01-6;BRD:BRD-BRD-A83644949-236-01-6,rep_primary;rep_single_dose,THROMBIN INHIBITOR,SERPINC1;SERPIND1,,,WITHDRAWN,,,NA,,CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O
ARECAIDINE-BUT-2-YNYL-ESTER,ARECAIDINE-BUT-2-YNYL-ESTER,CHEMBL1395412,BRD:BRD-BRD-K63792901-075-02-1;BRD:BRD-K63792901-075-02-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM2,,,PRECLINICAL,,Small molecule,NA,LBFWTPRSXIRKMZ-UHFFFAOYSA-N,CC#CCOC(=O)C1=CCCN(C)C1
ARECAIDINE-PROPARGYL-ESTER,ARECAIDINE-PROPARGYL-ESTER,,BRD:BRD-BRD-K23922020-075-02-9;BRD:BRD-K23922020-075-02-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4,,,PRECLINICAL,,,NA,,CN1CCC=C(C1)C(=O)OCC#C
ARECOLINE,ARECOLINE,CHEMBL7303,BRD:BRD-BRD-K88646909-004-16-2;BRD:BRD-K88646909-004-16-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4,,,PHASE 1,,Small molecule,Unknown,HJJPJSXJAXAIPN-UHFFFAOYSA-N,COC(=O)C1=CCCN(C)C1
ARGATROBAN,ARGATROBAN,CHEMBL1166,BRD:BRD-A48261811-001-08-1;BRD:BRD-BRD-A48261811-001-08-1,rep_primary;rep_single_dose,THROMBIN INHIBITOR,F2,HEPARIN-INDUCED THROMBOCYTOPENIA (HIT),,LAUNCHED,,Small molecule,Approved,KXNPVXPOPUZYGB-IOVMHBDKSA-N,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1CCCC2CC(C)CNC12;CC1CNC2C(CCCC2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1
ARGIRELINE,ARGIRELINE,,BRD:BRD-K00003332-001-01-9,rep_single_dose,NEUROTRANSMITTER RELEASE INHIBITOR,,,,,,,NA,,
ARGLABIN,ARGLABIN,CHEMBL2206431,BRD:BRD-BRD-K62734952-001-01-0;BRD:BRD-K62734952-001-01-0,rep_primary;rep_single_dose,FARNESYLTRANSFERASE INHIBITOR,FNTA;NFKB1,,,LAUNCHED,,Small molecule,NA,UVJYAKBJSGRTHA-CUZKYEQNSA-N,C=C1C(=O)O[C@@H]2[C@H]3C(C)=CC[C@@]34O[C@@]4(C)CC[C@@H]12;CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13
ARIMOCLOMOL (MALEATE),ARIMOCLOMOL (MALEATE),,BRD:BRD-K00090627-050-01-9,rep_single_dose,,,,,,,,NA,,
ARIPIPRAZOLE,ARIPIPRAZOLE,CHEMBL1112,BRD:BRD-BRD-K70358946-001-15-7;BRD:BRD-K70358946-001-15-7,rep_multi_dose;rep_primary;rep_single_dose,"SEROTONIN RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HTR1A;HTR1B;HTR1D;HTR1E;HTR2A;HTR2C;HTR3A;HTR6;HTR7,"DEPRESSION, SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,CEUORZQYGODEFX-UHFFFAOYSA-N,CLC1CCCC(N2CCN(CCCCOC3CCC4CCC(=O)NC4C3)CC2)C1CL;O=C1CCC2CCC(OCCCCN3CCN(C4CCCC(CL)C4CL)CC3)CC2N1
ARIPIPRAZOLE-LAUROXIL,ARIPIPRAZOLE-LAUROXIL,,BRD:BRD-K00004574-001-01-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,,,,,,,NA,,
ARMODAFINIL,ARMODAFINIL,CHEMBL1201192,BRD:BRD-BRD-K87278688-001-01-0;BRD:BRD-K87278688-001-01-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,SLC6A3,"OBSTRUCTIVE SLEEP APNEA, NARCOLEPSY, SHIFT WORK DISORDER (SWD)",,LAUNCHED,,Small molecule,Approved,YFGHCGITMMYXAQ-LJQANCHMSA-N,NC(=O)C[S@@](=O)C(C1CCCCC1)C1CCCCC1;NC(=O)C[S@@+]([O-])C(C1CCCCC1)C1CCCCC1
AROFYLLINE,AROFYLLINE,CHEMBL1598450,BRD:BRD-BRD-K33852358-001-09-9;BRD:BRD-K33852358-001-09-9,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A,,,PHASE 3,,Small molecule,Unknown,GVTLDPJNRVMCAL-UHFFFAOYSA-N,CCCN1C(=O)C2[NH]CNC2N(-C2CCC(CL)CC2)C1=O;CCCN1C(=O)N(-C2CCC(CL)CC2)C2[NH]CNC2C1=O
AROTINOLOL,AROTINOLOL,CHEMBL93298,BRD:BRD-A28044053-001-01-7;BRD:BRD-BRD-A28044053-001-01-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB3,"HYPERTENSION, TREMORS",,LAUNCHED,,Small molecule,Phase 3,BHIAIPWSVYSKJS-UHFFFAOYSA-N,CC(C)(C)NCC(O)CSC1NC(-C2CCC(C(N)=O)S2)CS1;CC(C)(C)NCC(O)CSC1NC(CS1)-C1CCC(S1)C(N)=O
ARQ-092,ARQ-092,CHEMBL4297188,BRD:BRD-BRD-K60171656-001-01-6;BRD:BRD-K60171656-001-01-6,rep_primary;rep_single_dose,AKT INHIBITOR,AKT2,,,PHASE 1,,Small molecule,Phase 2,HNFMVVHMKGFCMB-UHFFFAOYSA-N,NC1NCCCC1-C1NC2CCC(-C3CCCCC3)NC2N1-C1CCC(C2(N)CCC2)CC1;NC1NCCCC1-C1NC2CCC(NC2N1-C1CCC(CC1)C1(N)CCC1)-C1CCCCC1
ARQ-621,ARQ-621,CHEMBL4303449,BRD:BRD-BRD-K43436647-001-01-7;BRD:BRD-K43436647-001-01-7,rep_primary;rep_single_dose,KINESIN-LIKE SPINDLE PROTEIN INHIBITOR,KIF11,,,PHASE 1,,Small molecule,Phase 1,UPJSUQWHUVLLNW-XMMPIXPASA-N,C#CC[C@H](C1NC2CC(CL)CCC2C(=O)N1NC1CCCCC1)N(CCCN)C(=O)C1CCCC(CL)C1F;NCCCN([C@H](CC#C)C1NC2CC(CL)CCC2C(=O)N1NC1CCCCC1)C(=O)C1CCCC(CL)C1F
ARRANON,ARRANON,CHEMBL1201112,GDSC2:1814,gdsc,,,,,,,Small molecule,Approved,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,COC1NC(N)NC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
MEK162,ARRY-162;BINIMETINIB;MEK162,CHEMBL3187723,BRD:BRD-BRD-K82244583-001-01-3;BRD:BRD-K82244583-001-01-3;BRD:BRD-K82244583-001-02-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MEK1 AND MEK2,MAP2K1;MAP2K2,,,PHASE 3,"Multiple values for MOA: {'MEK INHIBITOR', 'INHIBITOR OF MEK1 AND MEK2'}, defaulting to 'INHIBITOR OF MEK1 AND MEK2'",Small molecule,Approved,ACWZRVQXLIRSDF-UHFFFAOYSA-N,CN1CNC2C(F)C(NC3CCC(BR)CC3F)C(C(=O)NOCCO)CC21;CN1CNC2C(F)C(NC3CCC(BR)CC3F)C(CC12)C(=O)NOCCO
ARRY-334543,ARRY-334543,CHEMBL2103842;CHEMBL2105679,BRD:BRD-BRD-K46386702-001-02-1;BRD:BRD-K46386702-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,ERBB2,,,PHASE 2,,Small molecule,Phase 2,QSUPQMGDXOHVLK-FFXKMJQXSA-N;UWXSAYUXVSFDBQ-CYBMUJFWSA-N,C[C@@H]1COC(NC2CCC3NCNC(NC4CCC(OCC5NCCS5)C(CL)C4)C3C2)=N1;C[C@@H]1COC(NC2CCC3NCNC(NC4CCC(OCC5NCCS5)C(CL)C4)C3C2)=N1.CC1CCC(S(=O)(=O)O)CC1.CC1CCC(S(=O)(=O)O)CC1
TUCATINIB,ARRY-380;IRBINITINIB;ONT-380;TUCATINIB,CHEMBL3989868,BRD:BRD-BRD-K26026438-001-01-0;BRD:BRD-K26026438-001-01-0,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF ERBB2 (HER2),ERBB2,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF ERBB2 (HER2)', 'EGFR INHIBITOR'}, defaulting to 'INHIBITOR OF ERBB2 (HER2)'",Small molecule,Approved,SDEAXTCZPQIFQM-UHFFFAOYSA-N,CC1CC(NC2NCNC3CCC(NC4=NC(C)(C)CO4)CC23)CCC1OC1CCN2NCNC2C1
ARRY-520,ARRY-520,CHEMBL2347655,GDSC1:474,gdsc,,,,,,,Small molecule,Phase 2,LLXISKGBWFTGEI-FQEVSTJZSA-N,CON(C)C(=O)N1N=C(C2CC(F)CCC2F)S[C@@]1(CCCN)C1CCCCC1
ARRY-886,ARRY-886,CHEMBL1614701,GDSC1:1062;GDSC1:1498,gdsc,,,,,,,Small molecule,Approved,CYOHGALHFOKKQC-UHFFFAOYSA-N,CN1CNC2C(F)C(NC3CCC(BR)CC3CL)C(C(=O)NOCCO)CC21
ARS-1620,ARS-1620,,BRD:BRD-K96889205-001-08-9,oncref_1,INHIBITOR OF KRAS-G12C,KRAS,,,,,,NA,,
ARS-1630,ARS-1630,,BRD:BRD-U00115351-001-01-9,oncref_1,LESS ACTIVE ENANTIOMER OF KRAS-G12C INHIBITOR ARS-1620,KRAS,,,,,,NA,,
ARS-853,ARS-853,,BRD:BRD-K65313170-001-02-9,oncref_1,INHIBITOR OF KRAS-G12C,KRAS,,,,,,NA,,
ARSANILIC-ACID,ARSANILIC-ACID,,BRD:BRD-BRD-K24179883-001-16-7;BRD:BRD-K24179883-001-16-7,rep_primary;rep_single_dose,,LYZ,,,PHASE 1,,,NA,,NC1CCC(CC1)[AS](O)(O)=O
ART558,ART558,,BRD:BRD-K00126476-001-01-9,oncref_2,INHIBITOR OF DNA POLGAMMA,POLQ,,,,,,NA,,
ARTELINIC ACID,ARTELINIC ACID,CHEMBL1208264,BRD:BRD-K00073067-001-02-9,rep_single_dose,,,,,,,Small molecule,NA,UVNHKOOJXSALHN-LBIQBRDBSA-N,C[C@@H]1[C@H](OCC2CCC(C(=O)O)CC2)O[C@@H]2O[C@@]3(C)CC[C@@H]4[C@@H](C)CC[C@@H]1[C@]24OO3
ARTEMISININ,ARTEMISININ,CHEMBL567597,BRD:BRD-BRD-K13112821-001-17-4;BRD:BRD-K13112821-001-17-4,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,CYP2B6,MALARIA,,LAUNCHED,,Small molecule,Approved,BLUAFEHZUWYNDE-DKGJTOOQSA-N,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4;C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4
ARTESUNATE,ARTESUNATE,CHEMBL361497,BRD:BRD-BRD-K54634444-001-05-9;BRD:BRD-K54634444-001-05-9,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,MALARIA,,LAUNCHED,,Small molecule,Approved,FIHJKUPKCHIPAT-AHIGJZGOSA-N,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4;C[C@H]1[C@H](OC(=O)CCC(=O)O)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3
ARTICAINE,ARTICAINE,CHEMBL1093,BRD:BRD-A70514680-003-11-2;BRD:BRD-BRD-A70514680-003-11-2,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,QTGIAADRBBLJGA-UHFFFAOYSA-N,CCCNC(C)C(=O)NC1C(C)CSC1C(=O)OC
VEPDEGESTRANT,ARV-471;VEPDEGESTRANT,CHEMBL5095210,BRD:BRD-U00114869-001-01-9,oncref_1,PROTAC DEGRADER OF ESTROGEN RECEPTOR 1,ESR1,,,,,Unknown,Phase 1,TZZDVPMABRWKIZ-XMOGEVODSA-N,O=C1CC[C@H](N2CC3CC(N4CCN(CC5CCN(C6CCC([C@@H]7C8CCC(O)CC8CC[C@@H]7C7CCCCC7)CC6)CC5)CC4)CCC3C2=O)C(=O)N1
ARV-825,ARV-825,,BRD:BRD-A00047421-001-01-7,rep_single_dose,BROMODOMAIN INHIBITOR,BRD4,,,,,,NA,,
AS-1269574,AS-1269574,,BRD:BRD-BRD-K07656463-001-01-5;BRD:BRD-K07656463-001-01-5,rep_primary;rep_single_dose,GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR AGONIST,GPR119,,,PRECLINICAL,,,NA,,CC1CC(NCCO)NC(N1)-C1CCC(BR)CC1
AS-1892802,AS-1892802,,BRD:BRD-BRD-K27051047-001-01-0;BRD:BRD-K27051047-001-01-0,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1,,,PRECLINICAL,,,NA,,OC[C@@H](NC(=O)NC1CCC(CC1)-C1CCNCC1)C1CCCCC1
AS-1949490,AS-1949490,,BRD:BRD-BRD-K61936403-001-01-7;BRD:BRD-K61936403-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,SHIP2 PHOSPHATASE INHIBITOR,INPP5D,,,PRECLINICAL,,,NA,,C[C@H](NC(=O)C1SCCC1OCC1CCC(CL)CC1)C1CCCCC1
AS-2034178,AS-2034178,,BRD:BRD-BRD-K75254015-001-01-9;BRD:BRD-K75254015-001-01-9,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,FFAR1,,,PRECLINICAL,,,NA,,OC(=O)CCC1CCC(NCC2CCCC3N(CCOC4CCCCC4)CCCC23)CC1F
AS-2444697,AS-2444697,,BRD:BRD-K73565918-003-02-9,rep_single_dose,INTERLEUKIN INHIBITOR,IRAK4,,,,,,NA,,
AS-252424,AS-252424,,BRD:BRD-K14988953-001-04-4,rep_single_dose,PI3K INHIBITOR,PIK3CG,,,,,,NA,,
AS-604850,AS-604850,,BRD:BRD-BRD-K63915849-001-03-7;BRD:BRD-K63915849-001-03-7,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CG,,,PRECLINICAL,,,NA,,FC1(F)OC2CCC(CC2O1)\C=C1/SC(=O)NC1=O
AS-605240,AS-605240,,GDSC1:224,gdsc,,,,,,,,NA,,
AS-703026,AS-703026,CHEMBL2107832,BRD:BRD-BRD-K89014967-001-04-3;BRD:BRD-K89014967-001-04-3,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1;MAP2K2,,,PHASE 2,,Small molecule,Phase 2,VIUAUNHCRHHYNE-JTQLQIEISA-N,O=C(NC[C@H](O)CO)C1CCNCC1NC1CCC(I)CC1F;OC[C@@H](O)CNC(=O)C1CCNCC1NC1CCC(I)CC1F
AS-77,AS-77,,BRD:BRD-BRD-K62427771-001-01-0;BRD:BRD-K62427771-001-01-0,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNA3;KCNA5;KCNN4,,,PRECLINICAL,,,NA,,O=C1CCC2C(OCCCCOC3CCCCC3)C3CCOC3CC2O1
AS601245,AS601245,,GDSC1:207,gdsc,,,,,,,,NA,,
AS605240,AS605240,,GDSC1:224,gdsc,,,,,,,,NA,,
ASA-404,ASA-404,CHEMBL71263,BRD:BRD-BRD-K27938825-001-02-4;BRD:BRD-K27938825-001-02-4,rep_primary;rep_single_dose,ANGIOGENESIS INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,XGOYIMQSIKSOBS-UHFFFAOYSA-N,CC1CCC2C(=O)C3CCCC(CC(=O)O)C3OC2C1C;CC1CCC2C(OC3C(CC(O)=O)CCCC3C2=O)C1C
ASAPIPRANT,ASAPIPRANT,CHEMBL3545043,BRD:BRD-K00003230-001-01-9,rep_single_dose,PROSTAGLANDIN INHIBITOR,,,,,,Small molecule,Phase 3,ZMZNWNTZRWXTJU-UHFFFAOYSA-N,CC(C)OC1CCC(S(=O)(=O)N2CCN(C3CCC(-C4NCCO4)C(OCC(=O)O)C3)CC2)CC1
ASARALDEHYDE,ASARALDEHYDE,CHEMBL1164301,BRD:BRD-BRD-K88219015-001-10-8;BRD:BRD-K88219015-001-10-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,,,PRECLINICAL,,Small molecule,NA,IAJBQAYHSQIQRE-UHFFFAOYSA-N,COC1CC(OC)C(C=O)CC1OC;COC1CC(OC)C(OC)CC1C=O
ASC-J9,ASC-J9,,BRD:BRD-BRD-K30331124-001-01-7;BRD:BRD-K30331124-001-01-7;BRD:BRD-K30331124-001-04-9,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ENHANCER,AR,,,PHASE 2,,,NA,,COC1CCC(CC1OC)\C=C\C(=O)CC(=O)\C=C\C1CCC(OC)C(OC)C1
ASCOMYCIN,ASCOMYCIN,CHEMBL8597,BRD:BRD-K88882192-001-03-3,rep_single_dose,CALCINEURIN INHIBITOR,FKBP1A,,,,,Small molecule,NA,ZDQSOHOQTUFQEM-NURRSENYSA-N,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
ASCORBIC-ACID,ASCORBIC-ACID,,BRD:BRD-A85242401-001-12-3;BRD:BRD-BRD-A85242401-001-12-3,rep_primary;rep_single_dose,ANTIOXIDANT,ALKBH2;ALKBH3;BBOX1;DBH;EGLN1;EGLN2;EGLN3;KDM5D;LCT;OGFOD1;OGFOD2;P3H1;P3H2;P3H3;P4HA1;P4HTM;PAM;PHYH;PLOD1;PLOD2;PLOD3;SLC23A1;SLC23A2;TMLHE,SCURVY,,LAUNCHED,,,NA,,OC[C@H](O)[C@H]1OC(=O)C(=O)C1O
ASENAPINE,ASENAPINE,CHEMBL3187365,BRD:BRD-BRD-K95260951-050-03-1;BRD:BRD-K95260951-050-03-1,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;DRD1;DRD2;DRD3;DRD4;HRH1;HRH2;HTR1A;HTR1B;HTR1D;HTR1E;HTR2A;HTR2B;HTR2C;HTR5A;HTR6;HTR7,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,VSWBSWWIRNCQIJ-UHFFFAOYSA-N,CN1C[C@H]2[C@H](C1)C1CC(CL)CCC1OC1CCCCC21;CN1C[C@H]2[C@H](C1)C1CC(CL)CCC1OC1CCCCC21.CN1C[C@@H]2[C@@H](C1)C1CC(CL)CCC1OC1CCCCC21;CN1CC2C3CCCCC3OC3CCC(CL)CC3C2C1
ASIATIC-ACID,ASIATIC-ACID,,BRD:BRD-BRD-K35079116-001-02-5;BRD:BRD-BRD-K35079116-001-03-3;BRD:BRD-K35079116-001-02-5;BRD:BRD-K35079116-001-03-3,rep_primary;rep_single_dose,APOPTOSIS STIMULANT,PYGM,,,PRECLINICAL,,,NA,,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O
ASIMADOLINE,ASIMADOLINE,CHEMBL1190199,BRD:BRD-K00003477-001-01-9,rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1,,,,,Small molecule,Phase 3,JHLHNYVMZCADTC-LOSJGSFVSA-N,CN(C(=O)C(C1CCCCC1)C1CCCCC1)[C@H](CN1CC[C@H](O)C1)C1CCCCC1
ASIVATREP,ASIVATREP,CHEMBL3707398,BRD:BRD-K00003138-001-01-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,,,,,,Small molecule,Phase 3,,
ASP-2535,ASP-2535,,BRD:BRD-BRD-K07150325-001-01-7;BRD:BRD-K07150325-001-01-7,rep_primary;rep_single_dose,GLYCINE TRANSPORTER INHIBITOR,SLC6A9,,,PHASE 1,,,NA,,CC(C)C1NNC(-C2CCC(NC2)-C2CCCCC2)N1-C1CCCC2NONC12
ASP-2689,ASP-2689,CHEMBL576982,GDSC1:254,gdsc,,,,,,,Small molecule,Phase 3,CVWXJKQAOSCOAB-UHFFFAOYSA-N,CC(C)(C)C1CC(NC(=O)NC2CCC(-C3CN4C(N3)SC3CC(OCCN5CCOCC5)CCC34)CC2)NO1
ASP-4130,ASP-4130,CHEMBL1289494,GDSC1:312,gdsc,,,,,,,Small molecule,Approved,SPMVMDHWKHCIDT-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)NC4CC(C)ON4)C(CL)C3)C2CC1OC
ASP-6537,ASP-6537,,BRD:BRD-K82239282-001-02-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,,,,NA,,
ASP-7487,ASP-7487,CHEMBL1091644,GDSC1:185;GDSC2:1510,gdsc,,,,,,,Small molecule,Phase 3,PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@]1(O)C[C@@H](C2NC(-C3CCC4CCC(-C5CCCCC5)NC4C3)C3C(N)NCCN32)C1
ASP-9521,ASP-9521,,BRD:BRD-K00003301-001-01-9,rep_single_dose,ALDO-KETO REDUCTASE INHIBITOR,,,,,,,NA,,
ASP3026,ASP3026,CHEMBL3545360,BRD:BRD-BRD-K06542892-001-01-9;BRD:BRD-K06542892-001-01-9,rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK,,,PHASE 1,,Small molecule,Phase 1,MGGBYMDAPCCKCT-UHFFFAOYSA-N,COC1CC(CCC1NC1NCNC(NC2CCCCC2S(=O)(=O)C(C)C)N1)N1CCC(CC1)N1CCN(C)CC1;COC1CC(N2CCC(N3CCN(C)CC3)CC2)CCC1NC1NCNC(NC2CCCCC2S(=O)(=O)C(C)C)N1
ASP5878,ASP5878,CHEMBL4594428,BRD:BRD-K00091280-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,VDZZYOJYLLNBTD-UHFFFAOYSA-N,COC1CC(OC)C(F)C(COC2CNC(NC3CNN(CCO)C3)NC2)C1F
ASPARTAME,ASPARTAME,CHEMBL171679,BRD:BRD-BRD-K78841970-001-13-8;BRD:BRD-K78841970-001-13-8,rep_primary;rep_single_dose,,TAS1R2;TRPV1,,,LAUNCHED,,Small molecule,Phase 3,IAOZJIPTCAWIRG-QWRGUYRKSA-N,COC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CC(=O)O;COC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](N)CC(O)=O
ASPIRIN,ASPIRIN,CHEMBL25,BRD:BRD-BRD-K11433652-001-17-0;BRD:BRD-K11433652-001-17-0,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,AKR1C1;ASIC3;EDNRA;HSPA5;IKBKB;NFKB1;NFKB2;NFKBIA;PRKAA1;PRKAA2;PRKAB1;PRKAB2;PRKAG1;PRKAG2;PRKAG3;PTGS1;PTGS2;RPS6KA3;TP53,"HEADACHE, FEVER, TOOTHACHE, MUSCLE PAIN",,LAUNCHED,,Small molecule,Approved,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,CC(=O)OC1CCCCC1C(=O)O;CC(=O)OC1CCCCC1C(O)=O
AST-1306,AST-1306,CHEMBL1947204,BRD:BRD-BRD-K26838195-075-04-9;BRD:BRD-K26838195-075-04-9;GDSC1:381,gdsc;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2,,,PHASE 1,,Small molecule,Phase 2,MVZGYPSXNDCANY-UHFFFAOYSA-N,C=CC(=O)NC1CCC2NCNC(NC3CCC(OCC4CCCC(F)C4)C(CL)C3)C2C1;FC1CCCC(COC2CCC(NC3NCNC4CCC(NC(=O)C=C)CC34)CC2CL)C1
ASTEMIZOLE,ASTEMIZOLE,CHEMBL296419,BRD:BRD-BRD-K37249724-001-25-7;BRD:BRD-K37249724-001-25-7,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1;KCNH1;KCNH2,,,WITHDRAWN,,Small molecule,Approved,GXDALQBWZGODGZ-UHFFFAOYSA-N,COC1CCC(CCN2CCC(CC2)NC2NC3CCCCC3N2CC2CCC(F)CC2)CC1;COC1CCC(CCN2CCC(NC3NC4CCCCC4N3CC3CCC(F)CC3)CC2)CC1
ASTILBIN,ASTILBIN,CHEMBL486017,BRD:BRD-K44845912-001-02-9,rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",,,,,,Small molecule,NA,ZROGCCBNZBKLEL-MPRHSVQHSA-N,C[C@@H]1O[C@@H](O[C@H]2C(=O)C3C(O)CC(O)CC3O[C@@H]2C2CCC(O)C(O)C2)[C@H](O)[C@H](O)[C@H]1O
ASTRAGALOSIDE-A,ASTRAGALOSIDE-A,,BRD:BRD-BRD-K08188887-001-02-4;BRD:BRD-K08188887-001-02-4,rep_primary;rep_single_dose,"ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT",,,,PRECLINICAL,"Multiple values for MOA: {'ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT', 'ANTIINFLAMMATORY AGENT'}, defaulting to 'ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT'",,NA,,CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C
ASTX660,ASTX660,CHEMBL4173974,BRD:BRD-K00003508-001-01-9,rep_single_dose,APOPTOSIS INHIBITOR,,,,,,Small molecule,Phase 1,YCXOHEXZVKOGEV-DNRQZRRGSA-N,C[C@@H]1CN(CC(=O)N2CC(C)(C)C3NC(CO)C(CC4CCC(F)CC4)CC32)[C@@H](CN2CCOC[C@H]2C)CN1
ASUNAPREVIR,ASUNAPREVIR,CHEMBL2105735,BRD:BRD-BRD-K87028197-001-01-3;BRD:BRD-K87028197-001-01-3,rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,XRWSZZJLZRKHHD-WVWIJVSJSA-N,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2NCC(OC)C3CCC(CL)CC23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1;COC1CNC(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2CC(CL)CCC12
ASYMMETRICAL-DIMETHYLARGININE,ASYMMETRICAL-DIMETHYLARGININE,,BRD:BRD-BRD-K36269323-300-02-6;BRD:BRD-K36269323-300-02-6,rep_multi_dose;rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS2;NOS3,,,PHASE 1,,,NA,,CN(C)C(=N)NCCC[C@H](N)C(O)=O
AT-1015,AT-1015,,BRD:BRD-K06496777-003-02-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A,,,,,,NA,,
AT-406,AT-406,CHEMBL2158051,BRD:BRD-K83030136-001-02-9;CTRP:710154,ctrp;rep_single_dose,IAP ANTAGONIST,,,,,,Small molecule,Phase 3,LSXUTRRVVSPWDZ-MKKUMYSQSA-N,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)CC[C@H]2CC[C@@H](C(=O)NC(C3CCCCC3)C3CCCCC3)N2C1=O
AT-7519,AT-7519,CHEMBL445813,BRD:BRD-BRD-K13390322-001-06-3;BRD:BRD-K13390322-001-06-3;GDSC1:219,gdsc;rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK4;CDK5;CDK6;CDK9,,,PHASE 2,,Small molecule,Phase 2,OVPNQJVDAFNBDN-UHFFFAOYSA-N,CLC1CCCC(CL)C1C(=O)NC1C[NH]NC1C(=O)NC1CCNCC1;O=C(NC1CCNCC1)C1N[NH]CC1NC(=O)C1C(CL)CCCC1CL
AT-9283,AT-9283,CHEMBL495727,BRD:BRD-BRD-K24576554-001-04-8;BRD:BRD-K24576554-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,"AURORA KINASE INHIBITOR, JAK INHIBITOR",AURKA;AURKB;JAK2;JAK3;RPS6KA6;STK17A,,,PHASE 2,,Small molecule,Phase 2,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,O=C(NC1C[NH]NC1-C1NC2CCC(CN3CCOCC3)CC2[NH]1)NC1CC1;O=C(NC1CC1)NC1C[NH]NC1-C1NC2CC(CN3CCOCC3)CCC2[NH]1
AT13148,AT13148,CHEMBL3544960,BRD:BRD-BRD-K32127727-001-04-2;BRD:BRD-K32127727-001-04-2;GDSC2:2170,gdsc;rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,AKT1;AKT2;AKT3;ROCK1;ROCK2;SGK3,,,PHASE 1,,Small molecule,Phase 1,IIRWNGPLJQXWFJ-KRWDZBQOSA-N,NC[C@@](O)(C1CCC(CL)CC1)C1CCC(-C2CN[NH]C2)CC1;NC[C@@](O)(C1CCC(CL)CC1)C1CCC(CC1)-C1CN[NH]C1
AT13387,AT13387,CHEMBL1214827,BRD:BRD-BRD-K58435339-001-03-0;BRD:BRD-K58435339-001-03-0;CTRP:688229,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"HSP ANTAGONIST, HSP INHIBITOR",HSP90AA1,,,PHASE 2,"Multiple values for MOA: {'HSP ANTAGONIST', 'HSP ANTAGONIST, HSP INHIBITOR'}, defaulting to 'HSP ANTAGONIST, HSP INHIBITOR'",Small molecule,Phase 2,IFRGXKKQHBVPCQ-UHFFFAOYSA-N,CC(C)C1CC(C(=O)N2CC3CCC(CN4CCN(C)CC4)CC3C2)C(O)CC1O
AT7519,AT7519,CHEMBL445813,GDSC1:219,gdsc,,,,,,,Small molecule,Phase 2,OVPNQJVDAFNBDN-UHFFFAOYSA-N,O=C(NC1CCNCC1)C1N[NH]CC1NC(=O)C1C(CL)CCCC1CL
AT7867,AT7867,,BRD:BRD-BRD-K12040459-001-06-0;BRD:BRD-K12040459-001-06-0;CTRP:660409;GDSC1:356,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,AKT2;GSK3B;PKIA;PRKACA,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)C1(CCNCC1)C1CCC(CC1)-C1CN[NH]C1
ATALUREN,ATALUREN,CHEMBL256997,BRD:BRD-BRD-K94830329-001-03-0;BRD:BRD-K94830329-001-03-0,rep_primary;rep_single_dose,"CFTR CHANNEL AGONIST, DYSTROPHIN STIMULANT",DMD,"DUCHENNE MUSCULAR DYSTROPHY (DMD), CYSTIC FIBROSIS",,LAUNCHED,,Small molecule,Approved,OOUGLTULBSNHNF-UHFFFAOYSA-N,O=C(O)C1CCCC(-C2NOC(-C3CCCCC3F)N2)C1;OC(=O)C1CCCC(C1)-C1NOC(N1)-C1CCCCC1F
S8993,ATAMPARIB;RBN-2397;S8993,CHEMBL5095043,BRD:BRD-K00090629-001-01-9;BRD:BRD-K00090629-001-02-9,oncref_2;rep_single_dose,INHIBITOR OF PARP7,PARP7,,,,,Small molecule,Phase 1,UQZCQKXJAXKZQH-LBPRGKRZSA-N,C[C@@H](COCCC(=O)N1CCN(C2NCC(C(F)(F)F)CN2)CC1)NC1CN[NH]C(=O)C1C(F)(F)F
ATAZANAVIR,ATAZANAVIR,CHEMBL1163,BRD:BRD-BRD-K09757388-065-04-0;BRD:BRD-K09757388-065-04-0,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,AXRYRYVKAWYZBR-GASGPIRDSA-N,COC(=O)N[C@H](C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)CN(CC1CCC(-C2CCCCN2)CC1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C;COC(=O)N[C@H](C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)CN(CC1CCC(CC1)-C1CCCCN1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
ATB-346,ATB-346,CHEMBL4211107,BRD:BRD-A52551912-001-02-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGER2,,,,,Small molecule,Phase 2,YCNMAPLPQYQJFC-UHFFFAOYSA-N,COC1CCC2CC(C(C)C(=O)OC3CCC(C(N)=S)CC3)CCC2C1
ATENOLOL-(+),ATENOLOL-(+),,BRD:BRD-K68075732-001-11-8,rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,,,,NA,,
ATENOLOL-(+/-),ATENOLOL-(+/-),,BRD:BRD-A20239487-001-24-9;BRD:BRD-BRD-A20239487-001-24-9,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;LTF;PLA2G2E,"HYPERTENSION, ANGINA PECTORIS",,LAUNCHED,"Multiple values for repurposing_target: {'ADRB1;ADRB2', 'ADRB1;ADRB2;LTF;PLA2G2E'}, taking the union",,NA,,CC(C)NCC(O)COC1CCC(CC(N)=O)CC1
ATENOLOL-(-),ATENOLOL-(-),,BRD:BRD-BRD-K44993696-001-12-3;BRD:BRD-K44993696-001-12-3,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,PHASE 2,,,NA,,CC(C)NC[C@H](O)COC1CCC(CC(N)=O)CC1
ATGLISTATIN,ATGLISTATIN,,BRD:BRD-BRD-K43363084-001-01-3;BRD:BRD-K43363084-001-01-3,rep_primary;rep_single_dose,ADIPOSE TRIGLYCERIDE LIPASE INHIBITOR,,,,PRECLINICAL,,,NA,,CN(C)C(=O)NC1CCCC(C1)-C1CCC(CC1)N(C)C
ATICAPRANT,ATICAPRANT,CHEMBL1921847,BRD:BRD-K00003342-001-01-9,rep_single_dose,OPIOID RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,ZHPMYDSXGRRERG-DEOSSOPVSA-N,CC1CC(C)CC([C@@H]2CCCN2CC2CCC(OC3CCC(C(N)=O)CC3F)CC2)C1
ATIPAMEZOLE,ATIPAMEZOLE,CHEMBL353972,BRD:BRD-BRD-K39252998-003-01-5;BRD:BRD-K39252998-003-01-5,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,REVERSE SEDATIVE,,LAUNCHED,,Small molecule,Phase 1,HSWPZIDYAHLZDD-UHFFFAOYSA-N,CCC1(C2C[NH]CN2)CC2CCCCC2C1;CCC1(CC2CCCCC2C1)C1CNC[NH]1
ATIPRIMOD,ATIPRIMOD,CHEMBL103735,BRD:BRD-BRD-K38527262-300-01-0;BRD:BRD-K38527262-300-01-0,rep_multi_dose;rep_primary;rep_single_dose,"JAK INHIBITOR, STAT INHIBITOR",JAK2;STAT3,,,PHASE 2,,Small molecule,Phase 2,SERHTTSLBVGRBY-UHFFFAOYSA-N,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1
ATIZORAM,ATIZORAM,CHEMBL1229569,BRD:BRD-BRD-K76614248-001-01-2;BRD:BRD-K76614248-001-01-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4C;PDE4D,,,PHASE 2,,Small molecule,Unknown,LITNEAPWQHVPOK-FFSVYQOJSA-N,COC1CCC(C2CNC(=O)NC2)CC1O[C@H]1C[C@@H]2CC[C@H]1C2;COC1CCC(CC1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1
KU-55933,ATM KINASE INHIBITOR;KU-55933,CHEMBL222102,BRD:BRD-BRD-K25311561-001-10-7;BRD:BRD-K25311561-001-10-7;BRD:BRD-K25311561-001-15-9;CTRP:58339;GDSC1:1030;GDSC2:1030,ctrp;gdsc;oncref_2;rep_primary;rep_single_dose,ATM KINASE INHIBITOR,ATM;PRKDC,,,PRECLINICAL,"Multiple values for MOA: {'INHIBITOR OF ATM', 'ATM KINASE INHIBITOR'}, defaulting to 'ATM KINASE INHIBITOR'
Multiple values for repurposing_target: {'ATM', 'ATM;PRKDC'}, taking the union",Small molecule,NA,XRKYMMUGXMWDAO-UHFFFAOYSA-N,O=C1CC(-C2CCCC3C2SC2CCCCC2S3)OC(N2CCOCC2)C1;O=C1CC(OC(C1)-C1CCCC2SC3CCCCC3SC12)N1CCOCC1
ATN-161,ATN-161,CHEMBL4297456,BRD:BRD-BRD-K00521308-019-01-9;BRD:BRD-K00521308-019-01-9,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGA5;ITGAV;ITGB1;ITGB3,,,PHASE 2,,Protein,Phase 2,MMHDBUJXLOFTLC-WOYTXXSLSA-N,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1C[NH]CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O;CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1CNC[NH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O
ATOMOXETINE,ATOMOXETINE,CHEMBL641,BRD:BRD-BRD-K20141153-003-13-7;BRD:BRD-K20141153-003-13-7,rep_primary;rep_single_dose,NOREPINEPHRINE TRANSPORTER INHIBITOR,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;SLC6A2;SLC6A3;SLC6A4,ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),,LAUNCHED,,Small molecule,Approved,VHGCDTVCOLNTBX-QGZVFWFLSA-N,CNCC[C@@H](OC1CCCCC1C)C1CCCCC1
ATORVASTATIN,ATORVASTATIN,CHEMBL1487,BRD:BRD-BRD-K69726342-238-02-4;BRD:BRD-K69726342-238-02-4;BRD:BRD-K69726342-238-05-9,rep_multi_dose;rep_primary;rep_single_dose,HMGCR INHIBITOR,AHR;DPP4;HMGCR,"STROKE, HEART ATTACK",,LAUNCHED,,Small molecule,Approved,XUKUURHRXDUEBC-KAYWLYCHSA-N,CC(C)C1C(C(=O)NC2CCCCC2)C(-C2CCCCC2)C(-C2CCC(F)CC2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O;CC(C)C1C(C(=O)NC2CCCCC2)C(C(-C2CCC(F)CC2)N1CC[C@@H](O)C[C@@H](O)CC(O)=O)-C1CCCCC1
ATOVAQUONE,ATOVAQUONE,CHEMBL1450,BRD:BRD-A19795905-001-08-0;BRD:BRD-BRD-A19795905-001-08-0,rep_primary;rep_single_dose,MITOCHONDRIAL ELECTRON TRANSPORT INHIBITOR,DHODH,PNEUMONIA,,LAUNCHED,,Small molecule,Approved,KUCQYCKVKVOKAY-CTYIDZIISA-N,CLC1CCC(CC1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)C2CCCCC2C1=O;O=C1C(O)=C([C@H]2CC[C@H](C3CCC(CL)CC3)CC2)C(=O)C2CCCCC21
ATPA,ATPA,,BRD:BRD-A65145453-001-06-1;BRD:BRD-BRD-A65145453-001-06-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIA2;GRIK1,,,PRECLINICAL,,,NA,,CC(C)(C)C1ONC(O)C1CC(N)C(O)=O
ATR INHIBITOR 2,ATR INHIBITOR 2,,BRD:BRD-K00091072-001-01-9,rep_single_dose,,,,,,,,NA,,
ATRA,ATRA,,GDSC1:1009,gdsc,,,,,,,,NA,,
ATRACTYLENOLIDE-I,ATRACTYLENOLIDE-I,,BRD:BRD-K00003732-001-01-9,rep_single_dose,JAK INHIBITOR,,,,,,,NA,,
ATRALIN,ATRALIN,CHEMBL38,GDSC1:1009,gdsc,,,,,,,Small molecule,Approved,SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
ATRASENTAN,ATRASENTAN,CHEMBL9194,BRD:BRD-BRD-K16295392-003-01-3;BRD:BRD-K16295392-003-01-3,rep_multi_dose;rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,PHASE 3,,Small molecule,Phase 3,MOTJMGVDPWRKOC-QPVYNBJUSA-N,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1CCC(OC)CC1)C(O)=O)C1CCC2OCOC2C1;CCCCN(CCCC)C(=O)CN1C[C@H](C2CCC3C(C2)OCO3)[C@@H](C(=O)O)[C@@H]1C1CCC(OC)CC1
ATRIANCE,ATRIANCE,CHEMBL1201112,GDSC2:1814,gdsc,,,,,,,Small molecule,Approved,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,COC1NC(N)NC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
ATROPINE,ATROPINE,CHEMBL1331216;CHEMBL2146146;CHEMBL517712,BRD:BRD-A27290375-330-01-1;BRD:BRD-BRD-A27290375-330-01-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,"CYCLOPLEGIA, MYDRIASIS, AMBLYOPIA",,LAUNCHED,,Small molecule,Approved,RKUNBYITZUJHSG-FXUDXRNXSA-N;RKUNBYITZUJHSG-SPUOUPEWSA-N;VJFQPODMEGSXHC-RIMUKSHESA-N,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)C1CCCCC1)C2;CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)C1CCCCC1)C2;CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)C1CCCCC1)C2.O=S(=O)(O)O;CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1CCCCC1
ATROPINE-OXIDE,ATROPINE-OXIDE,,BRD:BRD-K00004526-001-01-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,,,,,,NA,,
ATUVECICLIB,ATUVECICLIB,CHEMBL4439321,BRD:BRD-K00003144-001-01-9,rep_single_dose,CDK9 INHIBITOR,,,,,,Small molecule,Phase 1,ACWKGTGIJRCOOM-HHHXNRCGSA-N,COC1CC(F)CCC1-C1NCNC(NC2CCCC(C[S@](C)(=N)=O)C2)N1
AURANOFIN,AURANOFIN,CHEMBL1366,BRD:BRD-BRD-K45995181-001-04-6;BRD:BRD-K45995181-001-04-6,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,IKBKB;PRDX5;TRPA1,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Approved,,CCP(CC)(CC)[AU]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O;CCP(CC)(CC)=[AU]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
AURORA-A-INHIBITOR-I,AURORA-A-INHIBITOR-I,,BRD:BRD-BRD-K53561341-001-07-5;BRD:BRD-K53561341-001-07-5,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA,,,PRECLINICAL,,,NA,,CCN1CCN(CC1)C(=O)CC1CCC(NC2NCC(F)C(NC3CCC(CC3)C(=O)NC3CCCCC3CL)N2)CC1
AUSTOCYSTIN D,AUSTOCYSTIN D,CHEMBL1966436,CTRP:416775,ctrp,,,,,,,Small molecule,NA,VXTQFTUOAJRUDO-IFMALSPDSA-N,CC(C)(O)CCC1CCC(O)C2C(=O)C3C(O)C4C(CC3OC12)O[C@H]1OC=C[C@@]41O
AUT-1,AUT-1,,BRD:BRD-K00005330-001-01-9,rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,,,,,,,NA,,
AUTOTAXIN-MODULATOR-1,AUTOTAXIN-MODULATOR-1,,BRD:BRD-A94640958-001-01-7;BRD:BRD-BRD-A94640958-001-01-7,rep_primary;rep_single_dose,AUTOTAXIN INHIBITOR,ENPP2,,,PRECLINICAL,,,NA,,C[C@@H](N1C2CCC1CC(C2)C(O)=O)C1CCC2CCC(O[C@H]3CC[C@H](CC3)C(F)(F)F)C(C2C1)C(F)(F)F
AUY,AUY,,GDSC1:194;GDSC2:1559,gdsc,,,,,,,,NA,,
AUY922,AUY922,,GDSC1:194;GDSC2:1559,gdsc,,,,,,,,NA,,
AV 951,AV 951,,GDSC1:312,gdsc,,,,,,,,NA,,
AV-412,AV-412,CHEMBL5095024,BRD:BRD-BRD-K23190681-001-01-1;BRD:BRD-K23190681-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,EGFR;ERBB2,,,PHASE 1,,Small molecule,Phase 1,BRZCZOWSDKKGGK-UHFFFAOYSA-N,C=CC(=O)NC1CC(C#CC(C)(C)N2CCN(C)CC2)CC2NCNC(NC3CCC(F)C(CL)C3)C12.CC1CCC(S(=O)(=O)O)CC1.CC1CCC(S(=O)(=O)O)CC1;CN1CCN(CC1)C(C)(C)C#CC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1NC(=O)C=C
AV-608,AV-608,,BRD:BRD-BRD-K96615647-001-01-2;BRD:BRD-K96615647-001-01-2,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,,,PHASE 2,,,NA,,FC(F)(F)C1CC(CC(C1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1CC1CCC(CL)CC1)NC(=O)C1CCNC2CCCCC12
AV-951,AV-951,CHEMBL1289494;CHEMBL2105756,GDSC1:312,gdsc,,,,,,,Small molecule,Approved,RQXMKRRBJITKRN-UHFFFAOYSA-N;SPMVMDHWKHCIDT-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)NC4CC(C)ON4)C(CL)C3)C2CC1OC;COC1CC2NCCC(OC3CCC(NC(=O)NC4CC(C)ON4)C(CL)C3)C2CC1OC.CL.O
AVACOPAN,AVACOPAN,CHEMBL3989871,BRD:BRD-K00003256-001-01-9,rep_single_dose,COMPLEMENT INHIBITOR,,,,,,Small molecule,Approved,PUKBOVABABRILL-YZNIXAGQSA-N,CC1CCC(NC(=O)[C@H]2CCCN(C(=O)C3C(C)CCCC3F)[C@H]2C2CCC(NC3CCCC3)CC2)CC1C(F)(F)F
AVADOMIDE,AVADOMIDE,CHEMBL3989934,BRD:BRD-A88644406-001-02-9,rep_single_dose,ANTITUMOR AGENT,,,,,,Small molecule,Phase 2,RSNPAKAFCAAMBH-UHFFFAOYSA-N,CC1NC2CCCC(N)C2C(=O)N1C1CCC(=O)NC1=O
AVAGACESTAT,AVAGACESTAT,CHEMBL1090771,BRD:BRD-BRD-K83720053-001-03-8;BRD:BRD-K83720053-001-03-8;GDSC1:1072;GDSC1:205,gdsc;rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,PSEN1,,,PHASE 2,,Small molecule,Phase 2,XEAOPVUAMONVLA-QGZVFWFLSA-N,NC(=O)[C@@H](CCC(F)(F)F)N(CC1CCC(-C2NCON2)CC1F)S(=O)(=O)C1CCC(CL)CC1;NC(=O)[C@@H](CCC(F)(F)F)N(CC1CCC(CC1F)-C1NCON1)S(=O)(=O)C1CCC(CL)CC1
AVANAFIL,AVANAFIL,CHEMBL1963681,BRD:BRD-BRD-K65781196-001-03-0;BRD:BRD-K65781196-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,ERECTILE DYSFUNCTION,,LAUNCHED,,Small molecule,Approved,WEAJZXNPAWBCOA-INIZCTEOSA-N,COC1CCC(CNC2NC(N3CCC[C@H]3CO)NCC2C(=O)NCC2NCCCN2)CC1CL;COC1CCC(CNC2NC(NCC2C(=O)NCC2NCCCN2)N2CCC[C@H]2CO)CC1CL
AVAPRITINIB,AVAPRITINIB,CHEMBL4204794,BRD:BRD-K00003419-001-01-9,rep_single_dose,KIT INHIBITOR,,,,,,Small molecule,Approved,DWYRIWUZIJHQKQ-SANMLTNESA-N,CN1CC(-C2CC3C(N4CCN(C5NCC([C@@](C)(N)C6CCC(F)CC6)CN5)CC4)NCNN3C2)CN1
AVASIMIBE,AVASIMIBE,CHEMBL101309,BRD:BRD-BRD-K67901620-001-02-0;BRD:BRD-K67901620-001-02-0,rep_primary;rep_single_dose,ACAT INHIBITOR,CES1,,,PHASE 3,,Small molecule,Unknown,PTQXTEKSNBVPQJ-UHFFFAOYSA-N,CC(C)C1CC(C(C)C)C(CC(=O)NS(=O)(=O)OC2C(C(C)C)CCCC2C(C)C)C(C(C)C)C1;CC(C)C1CC(C(C)C)C(CC(=O)NS(=O)(=O)OC2C(CCCC2C(C)C)C(C)C)C(C1)C(C)C
AVATROMBOPAG,AVATROMBOPAG,CHEMBL2103883,BRD:BRD-BRD-K68544925-001-01-1;BRD:BRD-K68544925-001-01-1,rep_primary;rep_single_dose,THROMBOPOIETIN RECEPTOR AGONIST,MPL,THROMBOCYTOPENIA,,LAUNCHED,,Small molecule,Approved,OFZJKCQENFPZBH-UHFFFAOYSA-N,O=C(NC1NC(-C2CC(CL)CS2)C(N2CCN(C3CCCCC3)CC2)S1)C1CNC(N2CCC(C(=O)O)CC2)C(CL)C1;OC(=O)C1CCN(CC1)C1NCC(CC1CL)C(=O)NC1NC(-C2CC(CL)CS2)C(S1)N1CCN(CC1)C1CCCCC1
AVE-0991,AVE-0991,,BRD:BRD-K36154108-001-01-7,rep_single_dose,ANGIOTENSIN RECEPTOR AGONIST,MRGPRX1,,,,,,NA,,
AVE-3085,AVE-3085,,BRD:BRD-K00004734-001-01-9,rep_single_dose,NITRIC OXIDE SYNTHASE STIMULANT,,,,,,,NA,,
AVEX-73,AVEX-73,,BRD:BRD-K00003435-003-01-9,rep_single_dose,SIGMA RECEPTOR AGONIST,,,,,,,NA,,
AVIBACTAM,AVIBACTAM,CHEMBL1689063,BRD:BRD-BRD-K85882401-323-01-5;BRD:BRD-K85882401-323-01-5,rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,"INTRA-ABDOMINAL INFECTIONS, URINARY TRACT INFECTIONS, PYELONEPHRITIS, INTRA-ABDOMINAL INFECTIONS, URINARY TRACT INFECTIONS, PYELONEPHRITIS, INTRA-ABDOMINAL INFECTIONS, URINARY TRACT INFECTIONS, PYELONEPHRITIS",,LAUNCHED,,Small molecule,Approved,NDCUAPJVLWFHHB-UHNVWZDZSA-N,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O;NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O
AVICIN D,AVICIN D,CHEMBL508651,CTRP:688975,ctrp,,,,,,,Small molecule,NA,HKEDBKXRDHFCFB-LUAQNYIXSA-N,C=C[C@](C)(O)CC/C=C(\CO)C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@](C)(C=C)CC/C=C(\CO)C(=O)O[C@H]2C[C@]3(C(=O)O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H](C)[C@H](O[C@@H]5O[C@@H](CO)[C@H](O)[C@H]5O)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]4O)[C@H](O)C[C@]4(C)C(=CC[C@@H]5[C@@]6(C)CC[C@H](O[C@@H]7O[C@H](CO[C@@H]8O[C@H](C)[C@H](O)[C@H](O)[C@H]8O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7NC(C)=O)C(C)(C)[C@@H]6CC[C@]54C)[C@@H]3CC2(C)C)O[C@@H]1C
AVITA,AVITA,CHEMBL38,GDSC1:1009,gdsc,,,,,,,Small molecule,Approved,SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
AVITINIB,AVITINIB,CHEMBL4297865,BRD:BRD-K00003294-050-01-9,rep_single_dose,EGFR INHIBITOR,,,,,,Small molecule,Phase 3,UOFYSRZSLXWIQB-UHFFFAOYSA-N,C=CC(=O)NC1CCCC(OC2NC(NC3CCC(N4CCN(C)CC4)C(F)C3)NC3[NH]CCC23)C1
AVL-292,AVL-292,CHEMBL3301600;CHEMBL3301625,BRD:BRD-BRD-K87782578-001-01-4;BRD:BRD-K87782578-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK;YES1,,,PHASE 2,,Small molecule,Phase 2,ABSXPNGWJFAPRT-UHFFFAOYSA-N;KXBDTLQSDKGAEB-UHFFFAOYSA-N,C=CC(=O)NC1CCCC(NC2NC(NC3CCC(OCCOC)CC3)NCC2F)C1;C=CC(=O)NC1CCCC(NC2NC(NC3CCC(OCCOC)CC3)NCC2F)C1.O=S(=O)(O)C1CCCCC1;COCCOC1CCC(NC2NCC(F)C(NC3CCCC(NC(=O)C=C)C3)N2)CC1
AVN-492,AVN-492,,BRD:BRD-K00003436-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,,NA,,
AVN-944,AVN-944,CHEMBL3349001,BRD:BRD-BRD-K62196610-001-01-6;BRD:BRD-K62196610-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR,IMPDH1;IMPDH2,,,PHASE 2,,Small molecule,Phase 2,GYCPCOJTCINIFZ-OXJNMPFZSA-N,CC[C@H](CC#N)OC(=O)N[C@@H](C)C1CCCC(NC(=O)NC2CCC(-C3CNCO3)C(OC)C2)C1
AVOBENZONE,AVOBENZONE,CHEMBL1200522,BRD:BRD-BRD-K14401183-001-10-7;BRD:BRD-K14401183-001-10-7,rep_primary;rep_single_dose,"TOPICAL SUNSCREEN AGENT, UV BLOCKER",TYR,"COSMETIC, SUNSCREEN LOTION",,LAUNCHED,"Multiple values for MOA: {'TOPICAL SUNSCREEN AGENT, UV BLOCKER', 'UV BLOCKER'}, defaulting to 'TOPICAL SUNSCREEN AGENT, UV BLOCKER'",Small molecule,Approved,XNEFYCZVKIDDMS-UHFFFAOYSA-N,COC1CCC(C(=O)CC(=O)C2CCC(C(C)(C)C)CC2)CC1;COC1CCC(CC1)C(=O)CC(=O)C1CCC(CC1)C(C)(C)C
AVORALSTAT,AVORALSTAT,CHEMBL4297502,BRD:BRD-K00003224-001-01-9,rep_single_dose,KALLIKREIN INHIBITOR,,,,,,Small molecule,Phase 3,TUWMKPVJGGWGNL-UHFFFAOYSA-N,C=CC1CC(C(=O)NC2CCC(C(=N)N)CC2)C(-C2CCC(C(=O)NCC3CC3)NC2C(=O)O)CC1OC
AVRAINVILLAMIDE,AVRAINVILLAMIDE,CHEMBL2042025,CTRP:411856,ctrp,,,,,,,Small molecule,NA,ALXLLOQTGLPCFG-ATANMQQVSA-N,CC1(C)C=CC2C(CCC3C2[N+]([O-])=C2C3=C[C@@]34NC(=O)[C@]5(CCCN5C3=O)C[C@H]4C2(C)C)O1
AX-024,AX-024,,BRD:BRD-K00003479-003-01-9,rep_single_dose,CYTOKINE PRODUCTION INHIBITOR,,,,,,,NA,,
AXITINIB,AXITINIB,CHEMBL1289926,BRD:BRD-BRD-K29905972-001-06-3;BRD:BRD-K29905972-001-06-3;CTRP:348990;GDSC1:1021;GDSC2:1021,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",CSF1;FLT1;FLT4;KDR;PLK4,RENAL CELL CARCINOMA (RCC),,LAUNCHED,,Small molecule,Approved,RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)C1CCCCC1SC1CCC2C(/C=C/C3CCCCN3)N[NH]C2C1;CNC(=O)C1CCCCC1SC1CCC2C(\C=C\C3CCCCN3)N[NH]C2C1
AY-9944,AY-9944,,BRD:BRD-BRD-K77012840-300-01-6;BRD:BRD-K77012840-300-01-6,rep_primary;rep_single_dose,HEDGEHOG PATHWAY MODULATOR,,,,PRECLINICAL,,,NA,,CLC1CCCCC1CNC[C@H]1CC[C@H](CNCC2CCCCC2CL)CC1
BRD-K05804044-001-18-5,AZ 628;AZ-628;BRD-K05804044-001-18-5,,BRD:BRD-BRD-K05804044-001-06-0;BRD:BRD-K05804044-001-06-0;BRD:BRD-K05804044-001-18-5;BRD:BRD-K05804044-001-19-3;GDSC1:29,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF BRAF AND CRAF (RAF1),BRAF;RAF1,,,PRECLINICAL,"Multiple values for MOA: {'INHIBITOR OF BRAF AND CRAF (RAF1)', 'RAF INHIBITOR'}, defaulting to 'INHIBITOR OF BRAF AND CRAF (RAF1)'",,NA,,CC1CCC(NC(=O)C2CCCC(C2)C(C)(C)C#N)CC1NC1CCC2NCN(C)C(=O)C2C1
AZ 960,AZ 960,,GDSC2:1250,gdsc,,,,,,,,NA,,
AZ-10353926,AZ-10353926,CHEMBL217092,GDSC1:38,gdsc,,,,,,,Small molecule,Phase 3,OUKYUETWWIPKQR-UHFFFAOYSA-N,CN1CCN(CCOC2CC(OC3CCOCC3)C3C(NC4C(CL)CCC5C4OCO5)NCNC3C2)CC1
AZ-10417808,AZ-10417808,,BRD:BRD-BRD-K36258877-001-03-1;BRD:BRD-K36258877-001-03-1,rep_primary;rep_single_dose,CASPASE INHIBITOR,CASP3,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CC(C(=O)NCC=C)C2NC(NC3CCC(CL)C(CL)C3)[NH]C(=O)C2C1
AZ-10606120,AZ-10606120,,BRD:BRD-K09907507-300-02-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX7,,,,,,NA,,
AZ-12080282,AZ-12080282,,BRD:BRD-BRD-K05973499-300-01-0;BRD:BRD-K05973499-300-01-0,rep_primary;rep_single_dose,HEDGEHOG PATHWAY INHIBITOR,DHH,,,PRECLINICAL,,,NA,,CC1CCC(CC1NC(=O)C1CCC(OCC2CCCCN2)CC1)-C1NCC[NH]1
AZ-3146,AZ-3146,,CTRP:660087,ctrp,,,,,,,,NA,,
AZ-7371,AZ-7371,CHEMBL3109802,BRD:BRD-K14661019-001-02-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Phase 2,VDRYGTNDKXIPSK-UHFFFAOYSA-N,COC1NCNC(CN2CC(C(=O)NCCO)C3NCC(C)CC32)C1C
AZ-960,AZ-960,,GDSC2:1250,gdsc,,,,,,,,NA,,
AZ191,AZ191,,BRD:BRD-BRD-K80935598-001-01-1;BRD:BRD-K80935598-001-01-1,rep_primary;rep_single_dose,DYRK INHIBITOR,DYRK1B,,,PRECLINICAL,,,NA,,COC1CC(CCC1NC1NCCC(N1)-C1CN(C)C2CNCCC12)N1CCN(C)CC1
AZ20,AZ20,,BRD:BRD-BRD-K42436189-001-01-2;BRD:BRD-K42436189-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,ATR KINASE INHIBITOR,ATR;MTOR,,,PRECLINICAL,,,NA,,C[C@@H]1COCCN1C1CC(NC(N1)-C1CCCC2[NH]CCC12)C1(CC1)S(C)(=O)=O
AZ3146,AZ3146,,BRD:BRD-BRD-K59146805-001-03-7;BRD:BRD-K59146805-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,MONOPOLAR SPINDLE 1 KINASE INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CC(OC2CCN(C)CC2)CCC1NC1NCC2N(C)C(=O)N(C3CCCC3)C2N1
AZ505,AZ505,,BRD:BRD-BRD-K76244476-362-02-5;BRD:BRD-K76244476-362-02-5,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,SMYD2,,,PRECLINICAL,,,NA,,OC1CCC(CCNCCN(C2CCCCC2)C(=O)CCNCCC2CCC(CL)C(CL)C2)C2OCC(=O)NC12
AZ6102,AZ6102,,GDSC2:2109,gdsc,,,,,,,,NA,,
AZ628,AZ628,,GDSC1:29,gdsc,,,,,,,,NA,,
AZ7550,AZ7550,,BRD:BRD-K00003515-003-01-9,rep_single_dose,INSULIN GROWTH FACTOR RECEPTOR INHIBITOR,,,,,,,NA,,
AZ960,AZ960,,BRD:BRD-BRD-K64888243-001-03-7;BRD:BRD-K64888243-001-03-7;GDSC2:1250,gdsc;rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK2,,,PRECLINICAL,,,NA,,C[C@H](NC1NC(NC2CC(C)[NH]N2)C(F)CC1C#N)C1CCC(F)CC1
AZACYCLONOL,AZACYCLONOL,CHEMBL127508,BRD:BRD-BRD-K97061094-001-21-4;BRD:BRD-K97061094-001-21-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,,,PRECLINICAL,,Small molecule,Unknown,ZMISODWVFHHWNR-UHFFFAOYSA-N,OC(C1CCCCC1)(C1CCCCC1)C1CCNCC1;OC(C1CCNCC1)(C1CCCCC1)C1CCCCC1
AZAGUANINE-8,AZAGUANINE-8,,BRD:BRD-K53114651-001-12-7,rep_single_dose,PURINE ANTAGONIST,PNP,,,,,,NA,,
AZALOMYCIN-B,AZALOMYCIN-B,,BRD:BRD-BRD-K96104201-001-01-5;BRD:BRD-K96104201-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,,,PRECLINICAL,,,NA,,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1
AZAPERONE,AZAPERONE,CHEMBL340211,BRD:BRD-BRD-K45861246-001-13-4;BRD:BRD-K45861246-001-13-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3,SEDATIVE,,LAUNCHED,,Small molecule,Unknown,XTKDAFGWCDAMPY-UHFFFAOYSA-N,FC1CCC(CC1)C(=O)CCCN1CCN(CC1)C1CCCCN1;O=C(CCCN1CCN(C2CCCCN2)CC1)C1CCC(F)CC1
AZAPROPAZONE,AZAPROPAZONE,CHEMBL1565476,BRD:BRD-A70182876-001-11-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,,,,,Small molecule,Approved,MPHPHYZQRGLTBO-UHFFFAOYSA-N,CCCC1C(=O)N2C(N(C)C)=NC3CCC(C)CC3N2C1=O
AZASERINE,AZASERINE,CHEMBL1095699,BRD:BRD-K47464228-001-14-9,rep_single_dose,PURINE ANTAGONIST,,,,,,Small molecule,Unknown,MZZGOOYMKKIOOX-VKHMYHEASA-N,[N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O
AZASETRON,AZASETRON,CHEMBL1598608,BRD:BRD-A44133049-003-07-8;BRD:BRD-BRD-A44133049-003-07-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A;HTR3B,GENITIAL HERPES,,LAUNCHED,,Small molecule,Phase 2,WUKZPHOXUVCQOR-UHFFFAOYSA-N,CN1C(=O)COC2C(C(=O)NC3CN4CCC3CC4)CC(CL)CC21;CN1C(=O)COC2C1CC(CL)CC2C(=O)NC1CN2CCC1CC2
AZATADINE,AZATADINE,CHEMBL946,BRD:BRD-BRD-K77821588-364-01-2;BRD:BRD-K77821588-364-01-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,SEBMTIQKRHYNIT-UHFFFAOYSA-N,CN1CCC(=C2C3CCCCC3CCC3CCCNC32)CC1;CN1CCC(CC1)=C1C2CCCCC2CCC2CCCNC12
AZATHIOPRINE,AZATHIOPRINE,CHEMBL1542,BRD:BRD-BRD-K32821942-001-21-3;BRD:BRD-K32821942-001-21-3,rep_multi_dose;rep_primary;rep_single_dose,DEHYDROGENASE INHIBITOR,HPRT1;IMPDH1;PPAT,"RENAL HOMOTRANSPLANTATION, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,LMEKQMALGUDUQG-UHFFFAOYSA-N,CN1CNC([N+](=O)[O-])C1SC1NCNC2[NH]CNC12;CN1CNC(C1SC1[NH]CNC2NCNC12)[N+]([O-])=O
AZD 2171,AZD 2171,,GDSC2:1922,gdsc,,,,,,,,NA,,
AZD 4017,AZD 4017,CHEMBL2153191,BRD:BRD-K00074831-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,NCDZABJPWMBMIQ-INIZCTEOSA-N,CCCSC1NC(N2CCC[C@@H](CC(=O)O)C2)CCC1C(=O)NC1CCCCC1
AZD 6094,AZD 6094,,GDSC2:1936,gdsc,,,,,,,,NA,,
AZD 6482,AZD 6482,CHEMBL2165191,GDSC1:1066;GDSC1:156;GDSC2:2169,gdsc,,,,,,,Small molecule,Phase 2,IRTDIKMSKMREGO-OAHLLOKOSA-N,CC1CC([C@@H](C)NC2CCCCC2C(=O)O)C2NC(N3CCOCC3)CC(=O)N2C1
AZD 6738,AZD 6738,CHEMBL4285417,GDSC2:1917,gdsc,,,,,,,Small molecule,Phase 3,OHUHVTCQTUDPIJ-JYCIKRDWSA-N,C[C@@H]1COCCN1C1CC(C2([S@](C)(=N)=O)CC2)NC(-C2CC[NH]C3NCCC2-3)N1
AZD 7762,AZD 7762,CHEMBL2041933,GDSC1:1022;GDSC2:1022,gdsc,,,,,,,Small molecule,Phase 1,IAYGCINLNONXHY-LBPRGKRZSA-N,NC(=O)NC1CC(-C2CCCC(F)C2)SC1C(=O)N[C@H]1CCCNC1
AZD 8186,AZD 8186,CHEMBL3408248,GDSC2:1918,gdsc,,,,,,,Small molecule,Phase 1,LMJFJIDLEAWOQJ-CQSZACIVSA-N,C[C@@H](NC1CC(F)CC(F)C1)C1CC(C(=O)N(C)C)CC2C(=O)CC(N3CCOCC3)OC12
AZD 9291,AZD 9291,,GDSC2:1919,gdsc,,,,,,,,NA,,
AZD-0364,AZD-0364,,BRD:BRD-K00091078-001-01-9,rep_single_dose,,,,,,,,NA,,
AZD-0530,AZD-0530,CHEMBL217092,GDSC1:38,gdsc,,,,,,,Small molecule,Phase 3,OUKYUETWWIPKQR-UHFFFAOYSA-N,CN1CCN(CCOC2CC(OC3CCOCC3)C3C(NC4C(CL)CCC5C4OCO5)NCNC3C2)CC1
AZD-2171,AZD-2171,CHEMBL491473,GDSC2:1922,gdsc,,,,,,,Small molecule,Phase 3,XXJWYDDUDKYVKI-UHFFFAOYSA-N,COC1CC2C(OC3CCC4[NH]C(C)CC4C3F)NCNC2CC1OCCCN1CCCC1
OLAPARIB,AZD-2281;KU0059436;MK-7339;OLAPARIB,CHEMBL521686,BRD:BRD-BRD-K02113016-001-15-4;BRD:BRD-K02113016-001-02-2;BRD:BRD-K02113016-001-15-4;BRD:BRD-K02113016-001-19-6;CTRP:411867;GDSC1:1017;GDSC1:1495;GDSC2:1017,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF PARP1 AND PARP2,PARP1;PARP2,OVARIAN CANCER,,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF PARP1 AND PARP2', 'PARP INHIBITOR'}, defaulting to 'INHIBITOR OF PARP1 AND PARP2'",Small molecule,Approved,FDLYAMZZIXQODN-UHFFFAOYSA-N,FC1CCC(CC2N[NH]C(=O)C3CCCCC23)CC1C(=O)N1CCN(CC1)C(=O)C1CC1;O=C(C1CC(CC2N[NH]C(=O)C3CCCCC23)CCC1F)N1CCN(C(=O)C2CC2)CC1
AZD-6094,AZD-6094,CHEMBL3334567,GDSC2:1936,gdsc,,,,,,,Small molecule,Phase 3,XYDNMOZJKOGZLS-NSHDSACASA-N,C[C@@H](C1CCC2NCCN2C1)N1NNC2NCC(-C3CNN(C)C3)NC21
AZD-6244,AZD-6244,CHEMBL1614701,GDSC1:1062;GDSC1:1498,gdsc,,,,,,,Small molecule,Approved,CYOHGALHFOKKQC-UHFFFAOYSA-N,CN1CNC2C(F)C(NC3CCC(BR)CC3CL)C(C(=O)NOCCO)CC21
AZD-6482,AZD-6482,CHEMBL2165191,GDSC1:1066;GDSC1:156;GDSC2:2169,gdsc,,,,,,,Small molecule,Phase 2,IRTDIKMSKMREGO-OAHLLOKOSA-N,CC1CC([C@@H](C)NC2CCCCC2C(=O)O)C2NC(N3CCOCC3)CC(=O)N2C1
AZD-6738,AZD-6738,CHEMBL4285417,GDSC2:1917,gdsc,,,,,,,Small molecule,Phase 3,OHUHVTCQTUDPIJ-JYCIKRDWSA-N,C[C@@H]1COCCN1C1CC(C2([S@](C)(=N)=O)CC2)NC(-C2CC[NH]C3NCCC2-3)N1
AZD-7648,AZD-7648,CHEMBL4650446,BRD:BRD-K00091088-001-01-9,rep_single_dose,,,,,,,Unknown,Phase 1,,
AZD-7762,AZD-7762,CHEMBL2041933,GDSC1:1022;GDSC2:1022,gdsc,,,,,,,Small molecule,Phase 1,IAYGCINLNONXHY-LBPRGKRZSA-N,NC(=O)NC1CC(-C2CCCC(F)C2)SC1C(=O)N[C@H]1CCCNC1
AZD-8055,AZD-8055,CHEMBL1801204,GDSC1:1059;GDSC2:1059,gdsc,,,,,,,Small molecule,Phase 1,KVLFRAWTRWDEDF-IRXDYDNUSA-N,COC1CCC(-C2CCC3C(N4CCOC[C@@H]4C)NC(N4CCOC[C@@H]4C)NC3N2)CC1CO
AZD-8186,AZD-8186,CHEMBL3408248,GDSC2:1918,gdsc,,,,,,,Small molecule,Phase 1,LMJFJIDLEAWOQJ-CQSZACIVSA-N,C[C@@H](NC1CC(F)CC(F)C1)C1CC(C(=O)N(C)C)CC2C(=O)CC(N3CCOCC3)OC12
AZD-9291,AZD-9291,CHEMBL3353410,GDSC2:1919,gdsc,,,,,,,Small molecule,Approved,DUYJMQONPNNFPI-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCCC(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C
AZD0156,AZD0156,CHEMBL4297899,BRD:BRD-K69555850-001-02-9,rep_single_dose,ATM KINASE INHIBITOR,,,,,,Unknown,Phase 1,,
AZD0530,AZD0530,CHEMBL217092,GDSC1:38,gdsc,,,,,,,Small molecule,Phase 3,OUKYUETWWIPKQR-UHFFFAOYSA-N,CN1CCN(CCOC2CC(OC3CCOCC3)C3C(NC4C(CL)CCC5C4OCO5)NCNC3C2)CC1
AZD1080,AZD1080,,BRD:BRD-BRD-K61041538-001-03-0;BRD:BRD-K61041538-001-03-0,rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3A;GSK3B,,,PHASE 1,,,NA,,OC1[NH]C2CCC(CC2C1-C1CCC(CN2CCOCC2)CN1)C#N
AZD1208,AZD1208,,BRD:BRD-BRD-K21908111-001-01-8;BRD:BRD-K21908111-001-01-8,rep_primary;rep_single_dose,PIM KINASE INHIBITOR,PIM1;PIM2;PIM3,,,PHASE 1,,,NA,,N[C@@H]1CCCN(C1)C1C(CCCC1-C1CCCCC1)\C=C1/SC(=O)NC1=O
AZD1283,AZD1283,,BRD:BRD-BRD-K77060810-001-01-5;BRD:BRD-K77060810-001-01-5,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RY12,,,PRECLINICAL,,,NA,,CCOC(=O)C1CC(C#N)C(NC1C)N1CCC(CC1)C(=O)NS(=O)(=O)CC1CCCCC1
AZD1390,AZD1390,CHEMBL4594429,BRD:BRD-K00003509-001-01-9,rep_single_dose,ATM KINASE INHIBITOR,,,,,,Small molecule,Phase 1,VQSZIPCGAGVRRP-UHFFFAOYSA-N,CC(C)N1C(=O)N(C)C2CNC3CC(F)C(-C4CCC(OCCCN5CCCCC5)NC4)CC3C21
AZD1446,AZD1446,CHEMBL2179529,BRD:BRD-A44188509-001-01-2;BRD:BRD-BRD-A44188509-001-01-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA4;CHRNB2,,,PHASE 2,,Small molecule,Phase 2,GTUIQNHJSXQMKW-UHFFFAOYSA-N,CLC1CCC(O1)C(=O)N1CC2CNCC2C1;O=C(C1CCC(CL)O1)N1CC2CNCC2C1
AZD1480,AZD1480,CHEMBL1231124,BRD:BRD-BRD-K65928735-001-04-3;BRD:BRD-K65928735-001-04-3;CTRP:660306,ctrp;rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3,,,PHASE 1,,Small molecule,Phase 2,PDOQBOJDRPLBQU-QMMMGPOBSA-N,C[C@H](NC1NCC(CL)C(NC2CC(C)[NH]N2)N1)C1NCC(F)CN1;CC1CC(NC2NC(N[C@@H](C)C3NCC(F)CN3)NCC2CL)[NH]N1
AZD1775,AZD1775,CHEMBL1976040,GDSC2:1179,gdsc,,,,,,,Small molecule,Phase 2,BKWJAKQVGHWELA-UHFFFAOYSA-N,C=CCN1C(=O)C2CNC(NC3CCC(N4CCN(C)CC4)CC3)NC2N1-C1CCCC(C(C)(C)O)N1
AZD1940,AZD1940,,BRD:BRD-K00075152-001-02-9,rep_single_dose,,,,,,,,NA,,
AZD1981,AZD1981,CHEMBL1914489,BRD:BRD-BRD-K83186168-001-01-8;BRD:BRD-K83186168-001-01-8,rep_primary;rep_single_dose,CRTH RECEPTOR ANTAGONIST,PTGDR2,,,PHASE 2,,Small molecule,Phase 2,JWYIGNODXSRKGP-UHFFFAOYSA-N,CC(=O)NC1CCCC2C1C(SC1CCC(CL)CC1)C(C)N2CC(=O)O;CC(=O)NC1CCCC2N(CC(O)=O)C(C)C(SC3CCC(CL)CC3)C12
VISTUSERTIB,AZD2014;VISTUSERTIB,CHEMBL2336325,BRD:BRD-BRD-K99113996-001-02-0;BRD:BRD-K99113996-001-02-0;BRD:BRD-K99113996-001-03-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MTOR,MTOR,,,PHASE 2,"Multiple values for MOA: {'MTOR INHIBITOR', 'INHIBITOR OF MTOR'}, defaulting to 'INHIBITOR OF MTOR'",Small molecule,Phase 2,JUSFANSTBFGBAF-IRXDYDNUSA-N,CNC(=O)C1CCCC(-C2CCC3C(N4CCOC[C@@H]4C)NC(N4CCOC[C@@H]4C)NC3N2)C1;CNC(=O)C1CCCC(C1)-C1CCC2C(NC(NC2N1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C
AZD2098,AZD2098,,BRD:BRD-K00076909-001-02-9,rep_single_dose,,,,,,,,NA,,
AZD2171,AZD2171,CHEMBL491473,GDSC2:1922,gdsc,,,,,,,Small molecule,Phase 3,XXJWYDDUDKYVKI-UHFFFAOYSA-N,COC1CC2C(OC3CCC4[NH]C(C)CC4C3F)NCNC2CC1OCCCN1CCCC1
AZD2281,AZD2281,CHEMBL521686,GDSC1:1017;GDSC1:1495;GDSC2:1017,gdsc,,,,,,,Small molecule,Approved,FDLYAMZZIXQODN-UHFFFAOYSA-N,O=C(C1CC(CC2N[NH]C(=O)C3CCCCC23)CCC1F)N1CCN(C(=O)C2CC2)CC1
AZD2461,AZD2461,CHEMBL4098253,BRD:BRD-BRD-K85014146-001-02-5;BRD:BRD-K85014146-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,HYNBNUYQTQIHJK-UHFFFAOYSA-N,COC1CCN(C(=O)C2CC(CC3N[NH]C(=O)C4CCCCC34)CCC2F)CC1;COC1CCN(CC1)C(=O)C1CC(CC2N[NH]C(=O)C3CCCCC23)CCC1F
AZD2858,AZD2858,,BRD:BRD-BRD-K85849709-001-01-5;BRD:BRD-K85849709-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3B,,,PRECLINICAL,,,NA,,CN1CCN(CC1)S(=O)(=O)C1CCC(CC1)-C1CNC(N)C(N1)C(=O)NC1CCCNC1
AZD3264,AZD3264,,BRD:BRD-K14287049-001-01-3,rep_single_dose,IKK INHIBITOR,IKBKB,,,,,,NA,,
AZD3463,AZD3463,,BRD:BRD-BRD-K24593301-001-02-3;BRD:BRD-K24593301-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,"ALK TYROSINE KINASE RECEPTOR INHIBITOR, INSULIN GROWTH FACTOR RECEPTOR INHIBITOR",ALK;IGF1R,,,PRECLINICAL,,,NA,,COC1CC(CCC1NC1NCC(CL)C(N1)-C1C[NH]C2CCCCC12)N1CCC(N)CC1
AZD3514,AZD3514,CHEMBL2346976,BRD:BRD-BRD-K84996356-001-01-1;BRD:BRD-K84996356-001-01-1,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 1,,Small molecule,Phase 1,JMEYDSHPKCSIJC-UHFFFAOYSA-N,CC(=O)N1CCN(CCOC2CCC(C3CCN(C4=NN5C(NNC5C(F)(F)F)CC4)CC3)CC2)CC1;CC(=O)N1CCN(CCOC2CCC(CC2)C2CCN(CC2)C2=NN3C(CC2)NNC3C(F)(F)F)CC1
AZD3759,AZD3759,CHEMBL3623290,BRD:BRD-BRD-K41626799-001-01-1;BRD:BRD-K41626799-001-01-1;GDSC2:1915,gdsc;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PHASE 1,,Small molecule,Phase 2,MXDSJQHFFDGFDK-CYBMUJFWSA-N,COC1CC2NCNC(NC3CCCC(CL)C3F)C2CC1OC(=O)N1CCN(C)C[C@H]1C
AZD3839,AZD3839,CHEMBL2177913,BRD:BRD-K00004606-001-01-9,rep_single_dose,BETA-SECRETASE INHIBITOR,BACE1,,,,,Small molecule,Phase 1,MRXBCEQZNKUUIP-DEOSSOPVSA-N,NC1=N[C@@](C2CCCC(-C3CNCNC3)C2)(C2CCNC(C(F)F)C2)C2CCCC(F)C21
AZD3965,AZD3965,CHEMBL3335793,BRD:BRD-BRD-K25210703-001-01-9;BRD:BRD-K25210703-001-01-9,rep_primary;rep_single_dose,MONOCARBOXYLATE TRANSPORTER INHIBITOR,SLC16A1,,,PHASE 1,,Small molecule,Phase 1,PRNXOFBDXNTIFG-FQEVSTJZSA-N,CC(C)N1C2SC(CC3C(C)[NH]NC3C(F)(F)F)C(C(=O)N3C[C@](C)(O)CO3)C2C(=O)N(C)C1=O;CC1[NH]NC(C(F)(F)F)C1CC1SC2C(C1C(=O)N1C[C@](C)(O)CO1)C(=O)N(C)C(=O)N2C(C)C
AZD3988,AZD3988,,BRD:BRD-BRD-K73984371-001-01-1;BRD:BRD-K73984371-001-01-1,rep_primary;rep_single_dose,DIACYLGLYCEROL KINASE INHIBITOR,DGAT1,,,PRECLINICAL,,,NA,,OC(=O)C[C@H]1CC[C@@H](CC1)C1CCC(NC(=O)C2NNC(NC3CCC(F)C(F)C3)O2)CC1
AZD4282,AZD4282,,BRD:BRD-BRD-K72369578-001-04-1;BRD:BRD-K72369578-001-04-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,AGXT;AGXT2;ALAS1;ALAS2;BAAT;GARS;GATM;GCAT;GCSH;GLDC;GLRA1;GLRA2;GLRA3;GLRB;GLYAT;GLYATL1;GLYATL2;GNMT;GPR18;GPRC6A;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3B;GSS;PIPOX;SHMT1;SHMT2;SLC32A1;SLC36A1;SLC6A5;SLC6A9,,,PHASE 1,,,NA,,NCC(O)=O
AZD4547,AZD4547,CHEMBL3184679,BRD:BRD-BRD-K28392481-001-05-1;BRD:BRD-K28392481-001-05-1;CTRP:660325;GDSC2:1786,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,FGFR INHIBITOR,FGFR1;FGFR2;FGFR3;FGFR4;IGF1R;KDR,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,VRQMAABPASPXMW-UHFFFAOYSA-N,COC1CC(CCC2CC(NC(=O)C3CCC(CC3)N3C[C@H](C)N[C@H](C)C3)N[NH]2)CC(OC)C1;COC1CC(CCC2CC(NC(=O)C3CCC(N4CC(C)NC(C)C4)CC3)N[NH]2)CC(OC)C1
AZD4573,AZD4573,CHEMBL4462530,BRD:BRD-K00003106-001-01-9,rep_single_dose,CDK9 INHIBITOR,,,,,,Small molecule,Phase 2,AVIWDYSJSPOOAR-LSDHHAIUSA-N,CC(=O)N[C@@H]1CCC[C@H](C(=O)NC2CC(-C3CNN4C3CC(C)(C)C4)C(CL)CN2)C1
AZD4635,AZD4635,CHEMBL4594442,BRD:BRD-K00003443-001-01-9,rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,NCWQLHHDGDXIJN-UHFFFAOYSA-N,CC1CC(-C2NNC(N)NC2-C2CCC(F)CC2)CC(CL)N1
AZD5069,AZD5069,,BRD:BRD-BRD-K34801930-001-01-9;BRD:BRD-K00003297-001-01-9,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR2,,,PHASE 2,,,NA,,C[C@H](NC1CC(NS(=O)(=O)N2CCC2)NC(SCC2CCCC(F)C2F)N1)[C@@H](O)CO
AZD5153,AZD5153,CHEMBL4078100,BRD:BRD-K00003528-457-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,Small molecule,Phase 1,RSMYFSPOTCDHHJ-GOSISDBHSA-N,COC1NNC2CCC(N3CCC(C4CCC(OCCN5CCN(C)C(=O)[C@H]5C)CC4)CC3)NN12
SARUPARIB,AZD5305;SARUPARIB,CHEMBL5095220,BRD:BRD-K00126470-001-01-9,oncref_2,INHIBITOR OF PARP1,PARP1;PARP2,,,,,Small molecule,Phase 2,WQAVGRAETZEADU-UHFFFAOYSA-N,CCC1CC2NCC(CN3CCN(C4CCC(C(=O)NC)NC4)CC3)CC2[NH]C1=O
CAPIVASERTIB,AZD5363;CAPIVASERTIB,CHEMBL2325741,BRD:BRD-BRD-K99023089-001-03-7;BRD:BRD-K99023089-001-03-7;BRD:BRD-K99023089-001-06-9;GDSC2:1916,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF AKT1, AKT2, AND AKT3",AKT1;AKT2;AKT3,,,PHASE 2,"Multiple values for MOA: {'AKT INHIBITOR', 'INHIBITOR OF AKT1, AKT2, AND AKT3'}, defaulting to 'INHIBITOR OF AKT1, AKT2, AND AKT3'",Small molecule,Phase 3,JDUBGYFRJFOXQC-KRWDZBQOSA-N,NC1(C(=O)N[C@@H](CCO)C2CCC(CL)CC2)CCN(C2NC[NH]C3NCCC2-3)CC1;NC1(CCN(CC1)C1NCNC2[NH]CCC12)C(=O)N[C@@H](CCO)C1CCC(CL)CC1
AZD5423,AZD5423,CHEMBL4072756,BRD:BRD-K00076418-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,FCNQMDSJHADDFT-WNSKOXEYSA-N,COC1CCCC([C@@H](OC2CCC3C(CNN3-C3CCC(F)CC3)C2)[C@H](C)NC(=O)C(F)(F)F)C1
AZD5438,AZD5438,,BRD:BRD-BRD-K72414522-001-06-7;BRD:BRD-K72414522-001-06-7,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,KCNH2,,,PHASE 1,,,NA,,CC(C)N1C(C)NCC1-C1CCNC(NC2CCC(CC2)S(C)(=O)=O)N1
AZD5582,AZD5582,,BRD:BRD-K88767641-001-01-7;GDSC2:1617,gdsc;rep_single_dose,XIAP INHIBITOR,BIRC2;BIRC3;XIAP,,,,,,NA,,
AZD5991,AZD5991,CHEMBL4297482,BRD:BRD-K00005264-001-01-9;BRD:BRD-K00005264-001-02-9,oncref_1;rep_single_dose,INHIBITOR OF MCL1,MCL1,,,,"Multiple values for MOA: {'INHIBITOR OF MCL1', 'MCL1 INHIBITOR'}, defaulting to 'INHIBITOR OF MCL1'",Small molecule,Phase 1,KBQCEQAXHPIRTF-UHFFFAOYSA-N,CC1C2C(NN1C)CSCC1CC(N(C)N1)CSC1CC(C3CCCCC3C1)OCCCC1C(C(=O)O)N(C)C3C-2C(CL)CCC13
AZD6094,AZD6094,CHEMBL3334567,GDSC2:1936,gdsc,,,,,,,Small molecule,Phase 3,XYDNMOZJKOGZLS-NSHDSACASA-N,C[C@@H](C1CCC2NCCN2C1)N1NNC2NCC(-C3CNN(C)C3)NC21
AZD6244,AZD6244,CHEMBL1614701,GDSC1:1062;GDSC1:1498,gdsc,,,,,,,Small molecule,Approved,CYOHGALHFOKKQC-UHFFFAOYSA-N,CN1CNC2C(F)C(NC3CCC(BR)CC3CL)C(C(=O)NOCCO)CC21
AZD6482,AZD6482,CHEMBL2165191,BRD:BRD-BRD-K58772419-001-07-0;BRD:BRD-K58772419-001-07-0;CTRP:639390;GDSC1:1066;GDSC1:156;GDSC2:2169,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 1,,Small molecule,Phase 2,IRTDIKMSKMREGO-OAHLLOKOSA-N,C[C@@H](NC1CCCCC1C(O)=O)C1CC(C)CN2C1NC(CC2=O)N1CCOCC1;CC1CC([C@@H](C)NC2CCCCC2C(=O)O)C2NC(N3CCOCC3)CC(=O)N2C1
CERALASERTIB,AZD6738;CERALASERTIB,CHEMBL4285417,BRD:BRD-A36013532-001-01-3;BRD:BRD-BRD-A36013532-001-01-3;GDSC2:1917,gdsc;oncref_1;rep_primary;rep_single_dose,INHIBITOR OF ATR KINASE,ATR,,,PHASE 1/PHASE 2,"Multiple values for MOA: {'ATR KINASE INHIBITOR', 'INHIBITOR OF ATR KINASE'}, defaulting to 'INHIBITOR OF ATR KINASE'",Small molecule,Phase 3,OHUHVTCQTUDPIJ-JYCIKRDWSA-N,C[C@@H]1COCCN1C1CC(C2([S@](C)(=N)=O)CC2)NC(-C2CC[NH]C3NCCC2-3)N1;C[C@@H]1COCCN1C1CC(NC(N1)-C1CCNC2[NH]CCC12)C1(CC1)S(C)(=N)=O
AZD6765,AZD6765,CHEMBL467084,BRD:BRD-A94033181-001-01-4;BRD:BRD-BRD-A94033181-001-01-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,,,PHASE 2,,Small molecule,Phase 2,FWUQWDCOOWEXRY-ZDUSSCGKSA-N,N[C@@H](CC1CCCCN1)C1CCCCC1;NC(CC1CCCCN1)C1CCCCC1
AZD7545,AZD7545,,BRD:BRD-A87435144-001-01-6;BRD:BRD-BRD-A87435144-001-01-6;CTRP:411814,ctrp;rep_primary;rep_single_dose,PYRUVATE DEHYDROGENASE KINASE INHIBITOR,PDK1,,,PHASE 1,,,NA,,CN(C)C(=O)C1CCC(CC1)S(=O)(=O)C1CCC(NC(=O)C(C)(O)C(F)(F)F)C(CL)C1
AZD7594,AZD7594,CHEMBL3666807,BRD:BRD-K00003100-001-01-9,rep_single_dose,GLUCOCORTICOID RECEPTOR MODULATOR,,,,,,Small molecule,Phase 2,ZZWJKLGCDHYVMB-BWGXUDETSA-N,C[C@H](NC(=O)C(C)(F)F)[C@H](OC1CCC2C(CNN2-C2CCCC(C(=O)N[C@@H]3CCOC3)C2)C1)C1CCC2C(C1)OCCO2
AZD7687,AZD7687,CHEMBL4297354,BRD:BRD-BRD-K31495718-001-01-1;BRD:BRD-K31495718-001-01-1,rep_primary;rep_single_dose,DIACYLGLYCEROL O ACYLTRANSFERASE INHIBITOR,DGAT1,,,PHASE 1,,Small molecule,Phase 1,YXFNPRHZMOGREC-UHFFFAOYSA-N,CC1NC(C)C(-C2CCC(C3CCC(CC(=O)O)CC3)CC2)NC1C(N)=O;CC1NC(C)C(NC1C(N)=O)-C1CCC(CC1)[C@H]1CC[C@H](CC(O)=O)CC1
AZD7762,AZD7762,CHEMBL2041933,BRD:BRD-BRD-K86525559-001-04-5;BRD:BRD-BRD-K86525559-001-07-8;BRD:BRD-K86525559-001-04-5;BRD:BRD-K86525559-001-07-8;BRD:BRD-K86525559-003-11-9;CTRP:660777;GDSC1:1022;GDSC2:1022,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF CHEK1,CHEK1;CHEK2,,,PHASE 1,"Multiple values for MOA: {'INHIBITOR OF CHEK1', 'CHK INHIBITOR'}, defaulting to 'INHIBITOR OF CHEK1'
Multiple values for repurposing_target: {'CHEK1;CHEK2', 'CHEK1'}, taking the union",Small molecule,Phase 1,IAYGCINLNONXHY-LBPRGKRZSA-N,NC(=O)NC1CC(-C2CCCC(F)C2)SC1C(=O)N[C@H]1CCCNC1;NC(=O)NC1CC(SC1C(=O)N[C@H]1CCCNC1)-C1CCCC(F)C1
AZD7986,AZD7986,CHEMBL3900409,BRD:BRD-K00003398-001-01-9,rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,,,,,,Small molecule,Phase 3,AEXFXNFMSAAELR-RXVVDRJESA-N,CN1C(=O)OC2CCC(-C3CCC(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)CC3)CC21
AZD8055,AZD8055,CHEMBL1801204,BRD:BRD-BRD-K69932463-001-10-6;BRD:BRD-K69932463-001-10-6;CTRP:609639;GDSC1:1059;GDSC2:1059,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PHASE 1,,Small molecule,Phase 1,KVLFRAWTRWDEDF-IRXDYDNUSA-N,COC1CCC(-C2CCC3C(N4CCOC[C@@H]4C)NC(N4CCOC[C@@H]4C)NC3N2)CC1CO;COC1CCC(CC1CO)-C1CCC2C(NC(NC2N1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C
AZD8186,AZD8186,CHEMBL3408248,BRD:BRD-BRD-K47289408-001-01-5;BRD:BRD-K47289408-001-01-5;GDSC2:1918,gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CB;PIK3CD,,,PHASE 1,,Small molecule,Phase 1,LMJFJIDLEAWOQJ-CQSZACIVSA-N,C[C@@H](NC1CC(F)CC(F)C1)C1CC(C(=O)N(C)C)CC2C(=O)CC(N3CCOCC3)OC12;C[C@@H](NC1CC(F)CC(F)C1)C1CC(CC2C1OC(CC2=O)N1CCOCC1)C(=O)N(C)C
AZD8329,AZD8329,,BRD:BRD-K00091077-001-01-9,rep_single_dose,,,,,,,,NA,,
AZD8330,AZD8330,CHEMBL3182621,BRD:BRD-BRD-K37687095-001-06-9;BRD:BRD-K37687095-001-06-9,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP3K1,,,PHASE 1,,Small molecule,Phase 1,RWEVIPRMPFNTLO-UHFFFAOYSA-N,CC1CC(C(=O)NOCCO)C(NC2CCC(I)CC2F)N(C)C1=O
AZD8797,AZD8797,,BRD:BRD-K03336321-001-02-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,,NA,,
AZD8835,AZD8835,CHEMBL3894518,BRD:BRD-BRD-K82894950-001-01-0;BRD:BRD-K82894950-001-01-0,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CD,,,PHASE 1,,Small molecule,Phase 1,ZGRDYKFVDCFJCZ-UHFFFAOYSA-N,CCN1NC(C2CCN(C(=O)CCO)CC2)NC1-C1CNC(N)C(-C2NNC(C(C)(C)C)O2)N1;CCN1NC(NC1-C1CNC(N)C(N1)-C1NNC(O1)C(C)(C)C)C1CCN(CC1)C(=O)CCO
AZD8931,AZD8931,CHEMBL2408045,BRD:BRD-BRD-K98572433-001-02-9;BRD:BRD-K98572433-001-02-9;GDSC2:1549,gdsc;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2;ERBB3,,,PHASE 2,,Small molecule,Phase 2,DFJSJLGUIXFDJP-UHFFFAOYSA-N,CNC(=O)CN1CCC(CC1)OC1CC2C(NC3CCCC(CL)C3F)NCNC2CC1OC;CNC(=O)CN1CCC(OC2CC3C(NC4CCCC(CL)C4F)NCNC3CC2OC)CC1
AZD9056,AZD9056,CHEMBL3545108,BRD:BRD-K13699028-003-02-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,HSQAARMBHJCUOK-UHFFFAOYSA-N,O=C(NCC12CC3CC(CC(C3)C1)C2)C1CC(CCCNCCCO)CCC1CL
AZD9272,AZD9272,,BRD:BRD-BRD-K61043483-001-01-5;BRD:BRD-K61043483-001-01-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PRECLINICAL,,,NA,,FC1CCC(NC1)-C1NOC(N1)-C1CC(F)CC(C1)C#N
AZD9291,AZD9291,CHEMBL3353410,GDSC2:1919,gdsc,,,,,,,Small molecule,Approved,DUYJMQONPNNFPI-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCCC(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C
AZD9496,AZD9496,CHEMBL3623004,BRD:BRD-BRD-K73235735-001-02-7;BRD:BRD-K73235735-001-02-7,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,,,PHASE 1,,Small molecule,Phase 1,DFBDRVGWBHBJNR-BBNFHIFMSA-N,C[C@@H]1CC2C([NH]C3CCCCC23)[C@@H](C2C(F)CC(/C=C/C(=O)O)CC2F)N1CC(C)(C)F;C[C@@H]1CC2C([NH]C3CCCCC23)[C@H](N1CC(C)(C)F)C1C(F)CC(\C=C\C(O)=O)CC1F
AZD9668,AZD9668,CHEMBL3617964,BRD:BRD-BRD-K31476763-001-01-5;BRD:BRD-K31476763-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,ELASTASE INHIBITOR,ELANE,,,PHASE 2,,Small molecule,Phase 2,QNQZWEGMKJBHEM-UHFFFAOYSA-N,CC1C(-C2CCNN2C)CC(C(=O)NCC2CCC(S(C)(=O)=O)CN2)C(=O)N1-C1CCCC(C(F)(F)F)C1;CC1C(CC(C(=O)NCC2CCC(CN2)S(C)(=O)=O)C(=O)N1-C1CCCC(C1)C(F)(F)F)-C1CCNN1C
AZELAIC-ACID,AZELAIC-ACID,,BRD:BRD-BRD-K08976401-001-18-5;BRD:BRD-K08976401-001-18-5,rep_primary;rep_single_dose,TYROSINASE INHIBITOR,AKR1D1;SRD5A2;TYR,ROSACEA,,LAUNCHED,,,NA,,OC(=O)CCCCCCCC(O)=O
AZELASTINE,AZELASTINE,CHEMBL639,BRD:BRD-A68888262-003-15-1;BRD:BRD-BRD-A68888262-003-15-1,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,MBUVEWMHONZEQD-UHFFFAOYSA-N,CN1CCCC(CC1)N1NC(CC2CCC(CL)CC2)C2CCCCC2C1=O;CN1CCCC(N2NC(CC3CCC(CL)CC3)C3CCCCC3C2=O)CC1
AZELIRAGON,AZELIRAGON,CHEMBL3989929,BRD:BRD-BRD-K51899933-001-02-6;BRD:BRD-K51899933-001-02-6,rep_primary;rep_single_dose,RAGE RECEPTOR ANTAGONIST,AGER,,,PHASE 3,,Small molecule,Phase 3,KJNNWYBAOPXVJY-UHFFFAOYSA-N,CCCCC1NC(-C2CCC(OCCCN(CC)CC)CC2)CN1-C1CCC(OC2CCC(CL)CC2)CC1;CCCCC1NC(CN1-C1CCC(OC2CCC(CL)CC2)CC1)-C1CCC(OCCCN(CC)CC)CC1
AZELNIDIPINE,AZELNIDIPINE,CHEMBL1275868,BRD:BRD-A01098288-001-02-9;BRD:BRD-BRD-A01098288-001-02-9,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,ZKFQEACEUNWPMT-UHFFFAOYSA-N,CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1CCCCC1)C1CCCCC1;CC1=C(C(=O)OC(C)C)C(C2CCCC([N+](=O)[O-])C2)C(C(=O)OC2CN(C(C3CCCCC3)C3CCCCC3)C2)=C(N)N1
AZILSARTAN,AZILSARTAN,CHEMBL57242,BRD:BRD-BRD-K81074237-001-02-3;BRD:BRD-K81074237-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1;AGTR2,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,KGSXMPPBFPAXLY-UHFFFAOYSA-N,CCOC1NC2CCCC(C(=O)O)C2N1CC1CCC(-C2CCCCC2-C2NOC(=O)[NH]2)CC1;CCOC1NC2CCCC(C(O)=O)C2N1CC1CCC(CC1)-C1CCCCC1-C1NC(=O)O[NH]1
AZILSARTAN-MEDOXOMIL,AZILSARTAN-MEDOXOMIL,,BRD:BRD-BRD-K25723200-001-02-7;BRD:BRD-K25723200-001-02-7,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1;AGTR2,HYPERTENSION,,LAUNCHED,,,NA,,CCOC1NC2CCCC(C(=O)OCC3OC(=O)OC3C)C2N1CC1CCC(CC1)-C1CCCCC1-C1NC(=O)O[NH]1
AZIMILIDE,AZIMILIDE,CHEMBL123558,BRD:BRD-BRD-K38913877-300-01-9;BRD:BRD-K38913877-300-01-9,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNA5;KCNE1;KCNH2;KCNQ1,,,PHASE 3,,Small molecule,Phase 3,MREBEPTUUMTTIA-PCLIKHOPSA-N,CN1CCN(CCCCN2C(=O)CN(/N=C/C3CCC(-C4CCC(CL)CC4)O3)C2=O)CC1;CN1CCN(CCCCN2C(=O)CN(\N=C\C3CCC(O3)-C3CCC(CL)CC3)C2=O)CC1
AZITHROMYCIN,AZITHROMYCIN,CHEMBL529,BRD:BRD-BRD-K74501079-001-18-1;BRD:BRD-K74501079-001-18-1,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,MLNR,"PELVIC INFLAMMATORY DISEASE, PNEUMONIA",,LAUNCHED,,Small molecule,Approved,MQTOSJVFKKJCRP-BICOPXKESA-N,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
AZLOCILLIN,AZLOCILLIN,CHEMBL1537,BRD:BRD-A46717658-236-02-5;BRD:BRD-BRD-A46717658-236-02-5,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"GRAM-POSITIVE BACTERIAL INFECTIONS, GRAM-NEGATIVE BACTERIAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,JTWOMNBEOCYFNV-NFFDBFGFSA-N,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C3CCCCC3)C(=O)N2[C@H]1C(=O)O;CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)C3CCCCC3)C(=O)N2[C@H]1C(O)=O;CC1(C)SC2C(NC(=O)[C@H](NC(=O)N3CCNC3=O)C3CCCCC3)C(=O)N2C1C(O)=O
AZM-475271,AZM-475271,CHEMBL3545150,BRD:BRD-K51329597-001-02-9,rep_single_dose,SRC INHIBITOR,SRC,,,,,Small molecule,Phase 2,,
AZODICARBONAMIDE,AZODICARBONAMIDE,,BRD:BRD-BRD-K87036601-001-01-6;BRD:BRD-K87036601-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,PHASE 2,,,NA,,NC(=O)\N=N\C(N)=O
AZOMYCIN-(2-NITROIMIDAZOLE),AZOMYCIN-(2-NITROIMIDAZOLE),,BRD:BRD-BRD-K26824830-001-02-0;BRD:BRD-K26824830-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1NCC[NH]1
AZOSEMIDE,AZOSEMIDE,CHEMBL1097235,BRD:BRD-BRD-K68770713-001-01-8;BRD:BRD-K68770713-001-01-8,rep_primary;rep_single_dose,ELECTROLYTE REABSORPTION INHIBITOR,SLC12A1;SLC12A2,EDEMA,,LAUNCHED,,Small molecule,Phase 3,HMEDEBAJARCKCT-UHFFFAOYSA-N,NS(=O)(=O)C1CC(-C2NNN[NH]2)C(NCC2CCCS2)CC1CL
AZTREONAM,AZTREONAM,CHEMBL158,BRD:BRD-BRD-K62607865-001-09-7;BRD:BRD-K62607865-001-09-7,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"URINARY TRACT INFECTIONS, RESPIRATORY TRACT INFECTIONS, BACTERIAL SEPTICEMIA, SKIN INFECTIONS, INTRA-ABDOMINAL INFECTIONS, GYNECOLOGIC INFECTIONS",,LAUNCHED,,Small molecule,Approved,WZPBZJONDBGPKJ-VEHQQRBSSA-N,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)C2CSC(N)N2)C(=O)N1S(=O)(=O)O;C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2CSC(N)N2)C(=O)N1S(O)(=O)=O
B02,B02,,CTRP:122255,ctrp,,,,,,,,NA,,
BACAMPICILLIN,BACAMPICILLIN,CHEMBL1583,BRD:BRD-A41698174-003-12-0;BRD:BRD-BRD-A41698174-003-12-0,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"GRAM-POSITIVE BACTERIAL INFECTIONS, GRAM-NEGATIVE BACTERIAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,PFOLLRNADZZWEX-FFGRCDKISA-N,CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)C1CCCCC1)C2=O;CCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)C3CCCCC3)[C@H]2SC1(C)C
BADGE,BADGE,,BRD:BRD-A16694057-001-06-8;BRD:BRD-BRD-A16694057-001-06-8,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARG,,,PRECLINICAL,,,NA,,CC(C)(C1CCC(OCC2CO2)CC1)C1CCC(OCC2CO2)CC1
BAFETINIB,BAFETINIB,CHEMBL206834,BRD:BRD-A75975749-001-01-4;BRD:BRD-BRD-A75975749-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,"BCR-ABL KINASE INHIBITOR, LYN TYROSINE KINASE INHIBITOR",ABL1;BCR;LYN,,,PHASE 2,,Small molecule,Phase 2,ZGBAJMQHJDFTQJ-DEOSSOPVSA-N,CC1CCC(NC(=O)C2CCC(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)C2)CC1NC1NCCC(-C2CNCNC2)N1;CN(C)C1CCN(CC2CCC(CC2C(F)(F)F)C(=O)NC2CCC(C)C(NC3NCC(CN3)-C3CNCNC3)C2)C1
BAFILOMYCIN A1,BAFILOMYCIN A1,CHEMBL290814,CTRP:467037,ctrp,,,,,,,Small molecule,NA,XDHNQDDQEHDUTM-JQWOJBOSSA-N,CO/C1=C\C(C)=C\[C@@H](C)[C@@H](O)[C@@H](C)C/C(C)=C/C=C/[C@H](OC)[C@@H]([C@@H](C)[C@@H](O)[C@H](C)[C@@]2(O)C[C@@H](O)[C@H](C)[C@@H](C(C)C)O2)OC1=O
BAFILOMYCIN-A1,BAFILOMYCIN-A1,,BRD:BRD-K00010387-001-01-9,rep_single_dose,ATPASE INHIBITOR,,,,,,,NA,,
BAG-956,BAG-956,,BRD:BRD-BRD-K00652956-001-01-5;BRD:BRD-K00652956-001-01-5,rep_primary;rep_single_dose,PHOSPHOINOSITIDE DEPENDENT KINASE INHIBITOR,PIK3CG,,,PRECLINICAL,,,NA,,CC1NC2CNC3CCC(CC3C2N1-C1CCC(CC1)C(C)(C)C#N)C#CC1CCCNC1
BAICALEIN,BAICALEIN,CHEMBL8260,BRD:BRD-BRD-K72327355-001-14-7;BRD:BRD-K72327355-001-14-7,rep_multi_dose;rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5;GLO1;PREP;SELL;SELP;TNF;XDH,,,PRECLINICAL,,Small molecule,Phase 2,FXNFHKRTJBSTCS-UHFFFAOYSA-N,O=C1CC(-C2CCCCC2)OC2CC(O)C(O)C(O)C12;OC1CC2OC(CC(=O)C2C(O)C1O)-C1CCCCC1
BAICALIN,BAICALIN,CHEMBL485818,BRD:BRD-BRD-K49962337-001-01-1;BRD:BRD-BRD-K49962337-001-02-9;BRD:BRD-K49962337-001-01-1;BRD:BRD-K49962337-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,BETA GLUCURONIDASE INHIBITOR,PREP,,,LAUNCHED,,Small molecule,NA,IKIIZLYTISPENI-ZFORQUDYSA-N,O[C@H]1[C@H](OC2CC3OC(CC(=O)C3C(O)C2O)-C2CCCCC2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O;O=C(O)[C@H]1O[C@@H](OC2CC3OC(-C4CCCCC4)CC(=O)C3C(O)C2O)[C@H](O)[C@@H](O)[C@@H]1O
BAKUCHIOL,BAKUCHIOL,CHEMBL262344,BRD:BRD-BRD-K09785578-001-01-2;BRD:BRD-K09785578-001-01-2,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,HIF1A,,,PHASE 2,,Small molecule,Phase 1,LFYJSSARVMHQJB-QIXNEVBVSA-N,C=C[C@@](C)(/C=C/C1CCC(O)CC1)CCC=C(C)C;CC(C)=CCC[C@@](C)(C=C)\C=C\C1CCC(O)CC1
BALAGLITAZONE,BALAGLITAZONE,CHEMBL2103991,BRD:BRD-A00147595-001-01-5;BRD:BRD-BRD-A00147595-001-01-5,rep_primary;rep_single_dose,"INSULIN SENSITIZER, PPAR RECEPTOR PARTIAL AGONIST",PPARG,,,PHASE 3,,Small molecule,Phase 3,IETKPTYAGKZLKY-UHFFFAOYSA-N,CN1C(COC2CCC(CC3SC(=O)NC3=O)CC2)NC2CCCCC2C1=O
BALAPIRAVIR,BALAPIRAVIR,CHEMBL550936,BRD:BRD-BRD-K47976015-001-01-2;BRD:BRD-K47976015-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,VKXWOLCNTHXCLF-DXEZIKHYSA-N,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1CCC(N)NC1=O)N=[N+]=[N-];CC(C)C(=O)OC[C@@]1(N=[N+]=[N-])O[C@@H](N2CCC(N)NC2=O)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C
BALICATIB,BALICATIB,CHEMBL371064,BRD:BRD-BRD-K27204852-001-01-9;BRD:BRD-K27204852-001-01-9,rep_primary;rep_single_dose,CATHEPSIN INHIBITOR,CTSK,,,PHASE 2,,Small molecule,Phase 2,LLCRBOWRJOUJAE-UHFFFAOYSA-N,CCCN1CCN(C2CCC(C(=O)NC3(C(=O)NCC#N)CCCCC3)CC2)CC1;CCCN1CCN(CC1)C1CCC(CC1)C(=O)NC1(CCCCC1)C(=O)NCC#N
BALOFLOXACIN,BALOFLOXACIN,CHEMBL1210954,BRD:BRD-A47790386-001-03-6;BRD:BRD-BRD-A47790386-001-03-6,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Unknown,MGQLHRYJBWGORO-UHFFFAOYSA-N,CNC1CCCN(C1)C1C(F)CC2C(C1OC)N(CC(C(O)=O)C2=O)C1CC1;CNC1CCCN(C2C(F)CC3C(=O)C(C(=O)O)CN(C4CC4)C3C2OC)C1
BALOVAPTAN,BALOVAPTAN,CHEMBL4297183,BRD:BRD-K00091279-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,GMPZPHGHNDMRKL-RZDIXWSQSA-N,CN1CC2CC(CL)CCC2-N2C(NNC2[C@H]2CC[C@H](OC3CCCCN3)CC2)C1
BALOXAVIR,BALOXAVIR,CHEMBL4297215,BRD:BRD-K00003496-001-01-9,rep_single_dose,ENDONUCLEASE INHIBITOR,,,,,,Small molecule,Phase 2,FIDLLEYNNRGVFR-CTNGQTDRSA-N,O=C1C2C(O)C(=O)CCN2N([C@@H]2C3CCCCC3SCC3C2CCC(F)C3F)[C@@H]2COCCN12
BALOXAVIR-MARBOXIL,BALOXAVIR-MARBOXIL,,BRD:BRD-K00003495-001-01-9,rep_single_dose,ENDONUCLEASE INHIBITOR,,,,,,,NA,,
BALSALAZIDE,BALSALAZIDE,CHEMBL1201346,BRD:BRD-BRD-K41410256-304-02-2;BRD:BRD-K41410256-304-02-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,ALOX5;PPARG;PTGS1;PTGS2,ULCERATIVE COLITIS,,LAUNCHED,,Small molecule,Approved,IPOKCKJONYRRHP-FMQUCBEESA-N,O=C(O)CCNC(=O)C1CCC(/N=N/C2CCC(O)C(C(=O)O)C2)CC1;OC(=O)CCNC(=O)C1CCC(CC1)N=NC1CCC(O)C(C1)C(O)=O
BAM7,BAM7,,BRD:BRD-BRD-K07442505-001-03-6;BRD:BRD-K07442505-001-03-6;GDSC1:552,gdsc;rep_multi_dose;rep_primary;rep_single_dose,BAX ACTIVATOR,BAX,,,PRECLINICAL,,,NA,,CCOC1CCCCC1N\N=C1C(=O)N(N=C\1C)C1NC(CS1)-C1CCCCC1
BAMAQUIMAST,BAMAQUIMAST,CHEMBL2105906,BRD:BRD-K00003411-001-01-9,rep_single_dose,PROTON PUMP INHIBITOR,,,,,,Small molecule,Unknown,HNQSZPBGDAJIJO-UHFFFAOYSA-N,CCCN1C(=O)C(CCCOC(=O)NC)NC2CCCCC21
BAMBUTEROL,BAMBUTEROL,CHEMBL521589,BRD:BRD-A17462676-003-11-6;BRD:BRD-BRD-A17462676-003-11-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2;BCHE,ASTHMA,,LAUNCHED,,Small molecule,Phase 3,ANZXOIAKUNOVQU-UHFFFAOYSA-N,CN(C)C(=O)OC1CC(OC(=O)N(C)C)CC(C(O)CNC(C)(C)C)C1;CN(C)C(=O)OC1CC(OC(=O)N(C)C)CC(C1)C(O)CNC(C)(C)C
BAN-ORL-24,BAN-ORL-24,,BRD:BRD-BRD-K47049295-300-01-5;BRD:BRD-K47049295-300-01-5,rep_multi_dose;rep_primary;rep_single_dose,NOCICEPTIN/ORPHANIN FQ RECEPTOR ANTAGONIST,OPRL1,,,PRECLINICAL,,,NA,,O=C(NCCCN1CCC2(CC1)OCC1CCCCC21)[C@H]1CCCN1CC1CCCCC1
BANOXANTRONE,BANOXANTRONE,CHEMBL117391,BRD:BRD-K00003159-300-01-9,rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,,,,,Small molecule,Unknown,YZBAXVICWUUHGG-UHFFFAOYSA-N,C[N+](C)([O-])CCNC1CCC(NCC[N+](C)(C)[O-])C2C1C(=O)C1C(O)CCC(O)C1C2=O
BARASERTIB,BARASERTIB,CHEMBL215152;CHEMBL415049,BRD:BRD-BRD-K31928526-001-02-1;BRD:BRD-K31928526-001-02-1;CTRP:601923,ctrp;rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,GBJVVSCPOBPEIT-UHFFFAOYSA-N;QYZOGCMHVIGURT-UHFFFAOYSA-N,CCN(CCCOC1CCC2C(NC3CC(CC(=O)NC4CCCC(F)C4)[NH]N3)NCNC2C1)CCOP(=O)(O)O;CCN(CCCOC1CCC2C(NC3CC(CC(=O)NC4CCCC(F)C4)[NH]N3)NCNC2C1)CCOP(O)(O)=O;CCN(CCO)CCCOC1CCC2C(NC3CC(CC(=O)NC4CCCC(F)C4)[NH]N3)NCNC2C1
BARASERTIB-HQPA,BARASERTIB-HQPA,,BRD:BRD-BRD-K63923597-001-10-0;BRD:BRD-K63923597-001-10-0,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKB,,,PHASE 2/PHASE 3,,,NA,,CCN(CCO)CCCOC1CCC2C(NC3CC(CC(=O)NC4CCCC(F)C4)[NH]N3)NCNC2C1
BARBITAL,BARBITAL,CHEMBL2105904;CHEMBL444,BRD:BRD-BRD-K83359602-001-02-3;BRD:BRD-K83359602-001-02-3,rep_primary;rep_single_dose,SEDATIVE,CHRNA4;CHRNA7;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GRIA2;GRIK2,"SEDATIVE, SEIZURES",,LAUNCHED,,Small molecule,Approved,FTOAOBMCPZCFFF-UHFFFAOYSA-N;RGHFKWPGWBFQLN-UHFFFAOYSA-M,CCC1(CC)C(=O)[N-]C(=O)NC1=O.[NA+];CCC1(CC)C(=O)NC(=O)NC1=O
BARDOXOLONE,BARDOXOLONE,CHEMBL1093059,BRD:BRD-BRD-K20545304-001-01-6;BRD:BRD-K20545304-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",NOS2;PPARG,,,PHASE 1,"Multiple values for MOA: {'NUCLEAR FACTOR ERYTHROID DERIVED, LIKE (NRF2) ACTIVATOR', 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'}, defaulting to 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'",Small molecule,Phase 1,TXGZJQLMVSIZEI-UQMAOPSPSA-N,CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1;CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O
BARDOXOLONE METHYL,BARDOXOLONE METHYL,CHEMBL1762621,CTRP:660318,ctrp,,,,,,,Small molecule,Phase 3,WPTTVJLTNAWYAO-KPOXMGGZSA-N,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
BARDOXOLONE-METHYL,BARDOXOLONE-METHYL,CHEMBL1762621,BRD:BRD-BRD-K69694239-001-02-2;BRD:BRD-K69694239-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",PPARG;STAT3,,,PHASE 3,"Multiple values for MOA: {'NUCLEAR FACTOR ERYTHROID DERIVED, LIKE (NRF2) ACTIVATOR', 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'}, defaulting to 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'",Small molecule,Phase 3,WPTTVJLTNAWYAO-KPOXMGGZSA-N,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2
BARICITINIB,BARICITINIB,CHEMBL2105759,BRD:BRD-BRD-K53581288-001-02-9;BRD:BRD-K53581288-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2,,,PHASE 3,,Small molecule,Approved,XUZMWHLSFXCVMG-UHFFFAOYSA-N,CCS(=O)(=O)N1CC(CC#N)(C1)N1CC(CN1)-C1NCNC2[NH]CCC12;CCS(=O)(=O)N1CC(CC#N)(N2CC(-C3NCNC4[NH]CCC34)CN2)C1
BARNIDIPINE,BARNIDIPINE,CHEMBL2103761,BRD:BRD-BRD-K78781788-003-01-9;BRD:BRD-K78781788-003-01-9,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,HYPERTENSION,,LAUNCHED,,Small molecule,Unknown,VXMOONUMYLCFJD-DHLKQENFSA-N,COC(=O)C1=C(C)NC(C)=C([C@H]1C1CCCC(C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2CCCCC2)C1;COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(CC3CCCCC3)C2)[C@H]1C1CCCC([N+](=O)[O-])C1
BASIMGLURANT,BASIMGLURANT,CHEMBL3301626,BRD:BRD-BRD-K62387885-001-01-9;BRD:BRD-K62387885-001-01-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PHASE 2,,Small molecule,Phase 2,UPZWINBEAHDTLA-UHFFFAOYSA-N,CC1NC(C#CC2CCNC(CL)C2)C(C)N1-C1CCC(F)CC1
BASMISANIL,BASMISANIL,CHEMBL3681419,BRD:BRD-K00003221-001-01-9,rep_single_dose,GABA RECEPTOR INVERSE AGONIST,,,,,,Small molecule,Phase 2,VCGRFBXVSFAGGA-UHFFFAOYSA-N,CC1ONC(-C2CCC(F)CC2)C1COC1CCC(C(=O)N2CCS(=O)(=O)CC2)CN1
BATABULIN,BATABULIN,CHEMBL79280,BRD:BRD-K00091286-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,ROZCIVXTLACYNY-UHFFFAOYSA-N,COC1CCC(NS(=O)(=O)C2C(F)C(F)C(F)C(F)C2F)CC1F
BATEFENTEROL,BATEFENTEROL,CHEMBL3039518,BRD:BRD-K00003148-001-01-9,rep_single_dose,"ACETYLCHOLINE RECEPTOR ANTAGONIST, ADRENERGIC RECEPTOR AGONIST",,,,,,Small molecule,Phase 2,URWYQGVSPQJGGB-DHUJRADRSA-N,COC1CC(NC(=O)CCN2CCC(OC(=O)NC3CCCCC3-C3CCCCC3)CC2)C(CL)CC1CNC[C@H](O)C1CCC(O)C2[NH]C(=O)CCC12
BATIMASTAT,BATIMASTAT,CHEMBL279786,BRD:BRD-BRD-K82818427-001-02-2;BRD:BRD-BRD-K82818427-001-04-8;BRD:BRD-K82818427-001-02-2;BRD:BRD-K82818427-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,ADAM28;ADAMTS5;MMP12;MMP16;MMP2;MMP8,,,PHASE 3,,Small molecule,Unknown,XFILPEOLDIKJHX-QYZOEREBSA-N,CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC(C)C)[C@H](CSC1CCCS1)C(=O)NO
TNO155,BATOPROTAFIB;TNO155,CHEMBL4650521,BRD:BRD-K00084310-001-02-9,oncref_1,INHIBITOR OF SHP2,PTPN11,,,,,Small molecule,Phase 1,UCJZOKGUEJUNIO-IINYFYTJSA-N,C[C@@H]1OCC2(CCN(C3CNC(SC4CCNC(N)C4CL)C(N)N3)CC2)[C@@H]1N
BAVISANT,BAVISANT,CHEMBL2103862,BRD:BRD-BRD-K79595931-312-01-3;BRD:BRD-K79595931-312-01-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH3,,,PHASE 2,,Small molecule,Phase 2,BGBVSGSIXIIREO-UHFFFAOYSA-N,O=C(C1CCC(CN2CCOCC2)CC1)N1CCN(C2CC2)CC1;O=C(N1CCN(CC1)C1CC1)C1CCC(CN2CCOCC2)CC1
BAX CHANNEL BLOCKER,BAX CHANNEL BLOCKER,,CTRP:18311,ctrp,,,,,,,,NA,,
BAX-CHANNEL-BLOCKER,BAX-CHANNEL-BLOCKER,,BRD:BRD-A18763547-300-05-5;BRD:BRD-BRD-A18763547-300-05-5,rep_primary;rep_single_dose,CYTOCHROME C RELEASE INHIBITOR,BAX,,,PRECLINICAL,,,NA,,OC(CN1CCNCC1)CN1C2CCC(BR)CC2C2CC(BR)CCC12
BAY 2416964,BAY 2416964,,BRD:BRD-K00091085-001-01-9,rep_single_dose,,,,,,,,NA,,
BAY 43-9006,BAY 43-9006,CHEMBL1336,GDSC1:30;GDSC2:1085,gdsc,,,,,,,Small molecule,Approved,MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C(F)(F)F)C3)CC2)CCN1
BAY 869766,BAY 869766,CHEMBL1236682,GDSC1:1014;GDSC1:1526,gdsc,,,,,,,Small molecule,Phase 2,RDSACQWTXKSHJT-NSHDSACASA-N,COC1CC(F)C(F)C(NC2CCC(I)CC2F)C1NS(=O)(=O)C1(C[C@H](O)CO)CC1
BAY-11-7082,BAY-11-7082,,BRD:BRD-BRD-K15025317-001-15-1;BRD:BRD-K15025317-001-15-1,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,RELA,,,PRECLINICAL,,,NA,,CC1CCC(CC1)S(=O)(=O)\C=C\C#N
BAY-11-7085,BAY-11-7085,CHEMBL270299,BRD:BRD-BRD-K48684885-001-04-2;BRD:BRD-K48684885-001-04-2,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,NFKBIA,,,PRECLINICAL,,Small molecule,NA,VHKZGNPOHPFPER-ONNFQVAWSA-N,CC(C)(C)C1CCC(CC1)S(=O)(=O)\C=C\C#N;CC(C)(C)C1CCC(S(=O)(=O)/C=C/C#N)CC1
BAY-1251152,BAY-1251152,,BRD:BRD-K00003533-001-01-9,rep_single_dose,CDK9 INHIBITOR,,,,,,,NA,,
BAY-1436032,BAY-1436032,,BRD:BRD-K00003359-001-01-9,rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,,,,,,,NA,,
ELIMUSERTIB,BAY-1895344;ELIMUSERTIB,CHEMBL4647810,BRD:BRD-K00003422-003-01-9;BRD:BRD-U00115418-001-01-9,oncref_1;rep_single_dose,INHIBITOR OF ATR KINASE,ATR,,,,"Multiple values for MOA: {'ATR KINASE INHIBITOR', 'INHIBITOR OF ATR KINASE'}, defaulting to 'INHIBITOR OF ATR KINASE'
Multiple values for structure_id: {'U00115418', 'K00003422'}, defaulting to None",Small molecule,Phase 1,YBXRSCXGRPSTMW-CYBMUJFWSA-N,C[C@@H]1COCCN1C1CC(-C2CCNN2C)C2CCNC(-C3CCN[NH]3)C2N1
BAY-2402234,BAY-2402234,,BRD:BRD-K22379844-001-04-9,rep_single_dose,DIHYDROOROTATE DEHYDROGENASE INHIBITOR,,,,,,,NA,,
BAY-293,BAY-293,CHEMBL4535474,BRD:BRD-U00115412-001-01-9,oncref_1,INHIBITOR OF THE KRAS-SOS1 INTERACTION,KRAS;SOS1,,,,,Unknown,NA,WEGLOYDTDILXDA-OAHLLOKOSA-N,CNCC1CCCCC1-C1CSC([C@@H](C)NC2NC(C)NC3CC(OC)C(OC)CC23)C1
BAY-41-2272,BAY-41-2272,,BRD:BRD-BRD-K32033120-001-01-1;BRD:BRD-K32033120-001-01-1,rep_primary;rep_single_dose,GUANYLYL CYCLASE ACTIVATOR,GUCY1A3;GUCY1B3,,,PRECLINICAL,,,NA,,NC1NC(NCC1C1CC1)-C1NN(CC2CCCCC2F)C2NCCCC12
BAY-60-6583,BAY-60-6583,,BRD:BRD-K32952627-001-02-9,rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,,,,NA,,
BAY-60-7550,BAY-60-7550,,BRD:BRD-K86932920-001-02-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE2A,,,,,,NA,,
BAY-61-3606,BAY-61-3606,,BRD:BRD-K53281329-300-01-5;GDSC1:178,gdsc;rep_single_dose,SYK INHIBITOR,SYK,,,,,,NA,,
BAY-613606,BAY-613606,,GDSC1:178,gdsc,,,,,,,,NA,,
BAY-6888,BAY-6888,,BRD:BRD-K85565846-001-02-9,oncref_2,INHIBITOR OF CSNK1A1 AND CSNK1D,CSNK1A1;CSNK1D,,,,,,NA,,
BAY-8002,BAY-8002,,BRD:BRD-K00005331-001-01-9,oncref_1;rep_single_dose,INHIBITOR OF MONOCARBOXYLATE TRANSPORTER 1,SLC16A1,,,,"Multiple values for MOA: {'INHIBITOR OF MONOCARBOXYLATE TRANSPORTER 1', 'MONOCARBOXYLATE TRANSPORTER INHIBITOR'}, defaulting to 'INHIBITOR OF MONOCARBOXYLATE TRANSPORTER 1'",,NA,,
BAY-85-8050,BAY-85-8050,,BRD:BRD-A11731518-001-01-7;BRD:BRD-BRD-A11731518-001-01-7,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,NC(CC(F)C(O)=O)C(O)=O
BAY-85-8501,BAY-85-8501,,BRD:BRD-K00077971-001-02-9,rep_single_dose,,,,,,,,NA,,
BAY-86-9766,BAY-86-9766,CHEMBL1236682,GDSC1:1014;GDSC1:1526,gdsc,,,,,,,Small molecule,Phase 2,RDSACQWTXKSHJT-NSHDSACASA-N,COC1CC(F)C(F)C(NC2CCC(I)CC2F)C1NS(=O)(=O)C1(C[C@H](O)CO)CC1
BAY-87-2243,BAY-87-2243,,BRD:BRD-BRD-K70463136-001-01-5;BRD:BRD-K70463136-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,HIF1A,,,PHASE 1,,,NA,,CC1CC(NN1CC1CCNC(C1)N1CCN(CC1)C1CC1)-C1NC(NO1)-C1CCC(OC(F)(F)F)CC1
BAY-876,BAY-876,CHEMBL4448899,BRD:BRD-K00103299-001-01-9,oncref_1,INHIBITOR OF GLUT1,SLC2A1,,,,,Unknown,NA,BKLJDIJJOOQUFG-UHFFFAOYSA-N,CC1C(NC(=O)C2CC(C(N)=O)NC3CC(F)CCC23)C(C(F)(F)F)NN1CC1CCC(C#N)CC1
BAY-K-8644-(+/-),BAY-K-8644-(+/-),,BRD:BRD-A05457250-001-08-4;BRD:BRD-BRD-A05457250-001-08-4,rep_primary;rep_single_dose,"L-TYPE CALCIUM CHANNEL ACTIVATOR, L-TYPE CALCIUM CHANNEL BLOCKER",,,,PRECLINICAL,"Multiple values for MOA: {'L-TYPE CALCIUM CHANNEL ACTIVATOR, L-TYPE CALCIUM CHANNEL BLOCKER', 'L-TYPE CALCIUM CHANNEL ACTIVATOR'}, defaulting to 'L-TYPE CALCIUM CHANNEL ACTIVATOR, L-TYPE CALCIUM CHANNEL BLOCKER'",,NA,,COC(=O)C1=C(C)NC(C)=C(C1C1CCCCC1C(F)(F)F)[N+]([O-])=O
BAY-K-8644-(S)-(-),BAY-K-8644-(S)-(-),,BRD:BRD-BRD-K14329163-001-03-9;BRD:BRD-K14329163-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,L-TYPE CALCIUM CHANNEL ACTIVATOR,CACNA1C,,,PRECLINICAL,,,NA,,COC(=O)C1=C(C)NC(C)=C([C@H]1C1CCCCC1C(F)(F)F)[N+]([O-])=O
BAY-W-9798,BAY-W-9798,,BRD:BRD-BRD-K44471774-001-01-8;BRD:BRD-K44471774-001-01-8,rep_primary;rep_single_dose,ANTIOXIDANT,,,,PHASE 2,,,NA,,COC(=O)C1=C(C)N(C)C(C)=C(C1C1CCC(CC1)C(F)(F)F)C(=O)OC
BAY1125976,BAY1125976,CHEMBL4751394,BRD:BRD-K00003357-001-01-9,rep_single_dose,AKT INHIBITOR,,,,,,Small molecule,Phase 1,JBGYKRAZYDNCNV-UHFFFAOYSA-N,NC(=O)C1CCC2NC(-C3CCC(C4(N)CCC4)CC3)C(-C3CCCCC3)N2N1
ROGARATINIB,BAY1163877;ROGARATINIB,CHEMBL3963485,BRD:BRD-K00003358-001-01-9;BRD:BRD-K00003358-001-03-9,oncref_1;rep_single_dose,"INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4",FGFR1;FGFR2;FGFR3;FGFR4,,,,"Multiple values for MOA: {'FGFR INHIBITOR', 'INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4'}, defaulting to 'INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4'",Small molecule,Phase 2,HNLRRJSKGXOYNO-UHFFFAOYSA-N,COCC1C(-C2CC3CC(C)CC(OC)C3S2)C2C(N)NCNN2C1CN1CCNC(=O)C1
BAY1217389,BAY1217389,,BRD:BRD-K00003143-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,,NA,,
BAYER IKKB INHIBITOR,BAYER IKKB INHIBITOR,,GDSC1:290,gdsc,,,,,,,,NA,,
BAZ2-ICR,BAZ2-ICR,,BRD:BRD-K66830666-001-02-7,rep_single_dose,BROMODOMAIN INHIBITOR,ZNF215,,,,,,NA,,
BAZEDOXIFENE,BAZEDOXIFENE,CHEMBL46740,BRD:BRD-BRD-K90195324-003-02-5;BRD:BRD-K90195324-003-02-5,rep_primary;rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),ESR1;ESR2,"OSTEOPOROSIS, MENOPAUSE",,LAUNCHED,,Small molecule,Approved,UCJGJABZCDBEDK-UHFFFAOYSA-N,CC1C(-C2CCC(O)CC2)N(CC2CCC(OCCN3CCCCCC3)CC2)C2CCC(O)CC12
IACS-13909,BBP-398;IACS-13909,,BRD:BRD-U00115413-001-01-9,oncref_1,INHIBITOR OF SHP2,PTPN11,,,,,,NA,,
BC-11,BC-11,,BRD:BRD-K14646328-004-02-9,rep_single_dose,UROKINASE INHIBITOR,PLAU,,,,,,NA,,
BCI-540,BCI-540,,BRD:BRD-BRD-K23672206-001-01-4;BRD:BRD-K23672206-001-01-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,,,,PHASE 2,,,NA,,CC1OC2NC3CCCCC3C(NC(=O)CN3CCCC3=O)C2C1C
BCL-LZH-4,BCL-LZH-4,,CTRP:688516,ctrp,,,,,,,,NA,,
BCTC,BCTC,,BRD:BRD-K66541497-001-02-9,rep_single_dose,TRPV ANTAGONIST,TRPV1,,,,,,NA,,
BCX-1470,BCX-1470,,BRD:BRD-BRD-K90472149-066-01-0;BRD:BRD-K90472149-066-01-0,rep_primary;rep_single_dose,"COMPLEMENT INHIBITOR, SERINE PROTEASE INHIBITOR",CFD,,,PHASE 1,"Multiple values for MOA: {'SERINE PROTEASE INHIBITOR, COMPLEMENT INHIBITOR', 'COMPLEMENT INHIBITOR, SERINE PROTEASE INHIBITOR'}, defaulting to 'COMPLEMENT INHIBITOR, SERINE PROTEASE INHIBITOR'",,NA,,NC(=N)C1CC2CCC(OC(=O)C3CCCS3)CC2S1
BD-1008,BD-1008,,BRD:BRD-BRD-K17008822-303-02-1;BRD:BRD-K17008822-303-02-1,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CN(CCN1CCCC1)CCC1CCC(CL)C(CL)C1
BD-1047,BD-1047,,BRD:BRD-BRD-K36864847-303-02-5;BRD:BRD-K36864847-303-02-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,SIGMAR1,,,PRECLINICAL,,,NA,,CN(C)CCN(C)CCC1CCC(CL)C(CL)C1
BD-1063,BD-1063,,BRD:BRD-BRD-K29668683-300-02-2;BRD:BRD-K29668683-300-02-2,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,SIGMAR1,,,PRECLINICAL,,,NA,,CN1CCN(CCC2CCC(CL)C(CL)C2)CC1
BDP-00009066,BDP-00009066,,GDSC2:1866,gdsc,,,,,,,,NA,,
BEBT-908,BEBT-908,,BRD:BRD-K00003291-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,,NA,,
BEC,BEC,,CTRP:60679,ctrp,,,,,,,,NA,,
BECLABUVIR,BECLABUVIR,CHEMBL3126842,BRD:BRD-K00003128-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 3,ZTTKEBYSXUCBSE-VSBZUFFNSA-N,COC1CCC2C(C1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)CN1C-2C(C2CCCCC2)C2CCC(C(=O)NS(=O)(=O)N(C)C)CC21
BECLAMIDE,BECLAMIDE,CHEMBL64195,BRD:BRD-BRD-K44824027-001-02-1;BRD:BRD-K44824027-001-02-1,rep_primary;rep_single_dose,ANTICONVULSANT,,"SEDATIVE, SEIZURES",,LAUNCHED,,Small molecule,Approved,JPYQFYIEOUVJDU-UHFFFAOYSA-N,CLCCC(=O)NCC1CCCCC1;O=C(CCCL)NCC1CCCCC1
BECLOMETHASONE,BECLOMETHASONE,CHEMBL1200500;CHEMBL1586,BRD:BRD-A73385064-001-01-5;BRD:BRD-BRD-A73385064-001-01-5,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,KUVIULQEHSCUHY-XYWKZLDCSA-N;NBMKJKDGKREAPL-DVTGEIKXSA-N,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(CL)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(CL)C(O)CC2(C)C1(O)C(=O)CO;CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(CL)[C@@H](O)C[C@@]21C
BECLOMETHASONE-DIPROPIONATE,BECLOMETHASONE-DIPROPIONATE,,BRD:BRD-BRD-K97810537-001-12-8;BRD:BRD-BRD-K97810537-001-13-6;BRD:BRD-K97810537-001-12-8;BRD:BRD-K97810537-001-13-6,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,GPR97;NR3C1,ALLERGIC RHINITIS,,LAUNCHED,,,NA,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(CL)[C@@H](O)C[C@]12C
BEDAQUILINE,BEDAQUILINE,CHEMBL376488,BRD:BRD-BRD-K90817094-001-02-6;BRD:BRD-K90817094-001-02-6,rep_primary;rep_single_dose,ATPASE INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,QUIJNHUBAXPXFS-XLJNKUFUSA-N,COC1NC2CCC(BR)CC2CC1[C@@H](C1CCCCC1)[C@@](O)(CCN(C)C)C1CCCC2CCCCC12
BEFURALINE,BEFURALINE,CHEMBL1076256,BRD:BRD-BRD-K99077012-001-01-9;BRD:BRD-K99077012-001-01-9,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,SRIJFPBZWUFLFD-UHFFFAOYSA-N,O=C(C1CC2CCCCC2O1)N1CCN(CC2CCCCC2)CC1;O=C(N1CCN(CC2CCCCC2)CC1)C1CC2CCCCC2O1
BEGACESTAT,BEGACESTAT,CHEMBL463981,BRD:BRD-BRD-K58319700-001-01-1;BRD:BRD-K58319700-001-01-1,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,PSEN1,,,PHASE 1,,Small molecule,Phase 1,PSXOKXJMVRSARX-SCSAIBSYSA-N,O=S(=O)(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)C1CCC(CL)S1;OC[C@@H](NS(=O)(=O)C1CCC(CL)S1)C(C(F)(F)F)C(F)(F)F
BEKANAMYCIN,BEKANAMYCIN,CHEMBL176,BRD:BRD-BRD-K73425385-065-04-8;BRD:BRD-K73425385-065-04-8,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Phase 3,SKKLOUVUUNMCJE-FQSMHNGLSA-N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O;NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O
BELINOSTAT,BELINOSTAT,CHEMBL408513,BRD:BRD-BRD-K17743125-001-08-4;BRD:BRD-K17743125-001-08-4;CTRP:60225;GDSC1:274,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC10;HDAC11;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9,PERIPHERAL T-CELL LYMPHOMA (PTCL),,LAUNCHED,,Small molecule,Approved,NCNRHFGMJRPRSK-MDZDMXLPSA-N,O=C(/C=C/C1CCCC(S(=O)(=O)NC2CCCCC2)C1)NO;ONC(=O)\C=C\C1CCCC(C1)S(=O)(=O)NC1CCCCC1
BELIZATINIB,BELIZATINIB,,BRD:BRD-K00003245-001-01-9,rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,,,,,,,NA,,
BELOTECAN,BELOTECAN,CHEMBL2111084,BRD:BRD-K00003160-003-01-9,rep_single_dose,TOPOISOMERASE INHIBITOR,,,,,,Small molecule,Phase 3,LNHWXBUNXOXMRL-VWLOTQADSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2C-1NC1CCCCC1C2CCNC(C)C
RG6185,BELVARAFENIB;GDC5573;HM95573;RG6185,CHEMBL3977543,BRD:BRD-K00091122-001-01-9;BRD:BRD-U00115427-001-01-9,oncref_1;rep_single_dose,"INHIBITOR OF BRAF, BRAF-V600E, AND CRAF",BRAF;CRAF,,,,"Multiple values for structure_id: {'K00091122', 'U00115427'}, defaulting to None",Small molecule,Phase 2,KVCQTKNUUQOELD-UHFFFAOYSA-N,CC1CCC2C(NC3CCCC(CL)C3F)NCCC2C1NC(=O)C1CSC2C(N)NCNC12
BELZUTIFAN,BELZUTIFAN,CHEMBL4585668,BRD:BRD-K00091288-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,LOMMPXLFBTZENJ-ZACQAIPSSA-N,CS(=O)(=O)C1CCC(OC2CC(F)CC(C#N)C2)C2C1[C@H](O)[C@H](F)[C@@H]2F
BEMEGRIDE,BEMEGRIDE,CHEMBL1214192,BRD:BRD-BRD-K14993104-001-05-9;BRD:BRD-K14993104-001-05-9,rep_primary;rep_single_dose,CHEMORECEPTOR AGONIST,GABRA1,POISON ANTIDOTE,,LAUNCHED,,Small molecule,Unknown,ORRZGUBHBVWWOP-UHFFFAOYSA-N,CCC1(C)CC(=O)NC(=O)C1
BEMESETRON,BEMESETRON,CHEMBL2107804,BRD:BRD-A85587465-001-03-3;BRD:BRD-BRD-A85587465-001-03-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A;HTR3B,,,PHASE 3,,Small molecule,Unknown,MNJNPLVXBISNSX-WDNDVIMCSA-N,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C1CC(CL)CC(CL)C1)C2;CN1C2CCC1CC(C2)OC(=O)C1CC(CL)CC(CL)C1
ETC-1002,BEMPEDOIC-ACID;ETC-1002,CHEMBL3545313,BRD:BRD-BRD-K63177377-001-01-8;BRD:BRD-K63177377-001-01-8,rep_primary;rep_single_dose,AMPK INHIBITOR,ACLY,,,PHASE 3,,Small molecule,Approved,HYHMLYSLQUKXKP-UHFFFAOYSA-N,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O;CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
BENACTYZINE,BENACTYZINE,CHEMBL70352,BRD:BRD-K85030058-003-16-9,rep_single_dose,BUTYRYLCHOLINESTERASE INHIBITOR,,,,,,Small molecule,Unknown,IVQOFBKHQCTVQV-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C(O)(C1CCCCC1)C1CCCCC1
BENAXIBINE,BENAXIBINE,CHEMBL490070,BRD:BRD-A90642009-001-03-2;BRD:BRD-BRD-A90642009-001-03-2,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Unknown,HLDUHCYBUVVDOT-GZBOUJLJSA-N,O=C(O)C1CCC(NC2OC[C@@H](O)[C@H](O)[C@H]2O)CC1;OC1COC(NC2CCC(CC2)C(O)=O)C(O)C1O
BENAZEPRIL,BENAZEPRIL,CHEMBL838,BRD:BRD-BRD-K49807096-003-15-5;BRD:BRD-K49807096-003-15-5,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,XPCFTKFZXHTYIP-PMACEKPBSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]1CCC2CCCCC2N(CC(=O)O)C1=O;CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]1CCC2CCCCC2N(CC(O)=O)C1=O
BENDAMUSTINE,BENDAMUSTINE,CHEMBL487253,BRD:BRD-BRD-K17068645-003-04-2;BRD:BRD-K17068645-003-04-2;CTRP:374755,ctrp;rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,"CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), NON-HODGKIN LYMPHOMA (NHL)",,LAUNCHED,,Small molecule,Approved,YTKUWDBFDASYHO-UHFFFAOYSA-N,CN1C(CCCC(=O)O)NC2CC(N(CCCL)CCCL)CCC21;CN1C(CCCC(O)=O)NC2CC(CCC12)N(CCCL)CCCL
BENDAZAC,BENDAZAC,CHEMBL1089221,BRD:BRD-BRD-K19515365-001-02-6;BRD:BRD-K19515365-001-02-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"MUSCLE PAIN, JOINT PAIN",,LAUNCHED,,Small molecule,Approved,BYFMCKSPFYVMOU-UHFFFAOYSA-N,O=C(O)COC1NN(CC2CCCCC2)C2CCCCC12;OC(=O)COC1NN(CC2CCCCC2)C2CCCCC12
BENDAZOL,BENDAZOL,CHEMBL355063,BRD:BRD-K60379054-001-09-9,rep_single_dose,NITRIC OXIDE SYNTHASE STIMULANT,,,,,,Small molecule,Unknown,YTLQFZVCLXFFRK-UHFFFAOYSA-N,C1CCC(CC2NC3CCCCC3[NH]2)CC1
BENDROFLUMETHIAZIDE,BENDROFLUMETHIAZIDE,CHEMBL1684,BRD:BRD-A80017228-001-25-7;BRD:BRD-BRD-A80017228-001-25-7,rep_multi_dose;rep_primary;rep_single_dose,SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR,CA1;CA2;CA4;KCNMA1;SLC12A1;SLC12A3,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,HDWIHXWEUNVBIY-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1C(F)(F)F)NC(CC1CCCCC1)NS2(=O)=O;NS(=O)(=O)C1CC2C(NC(CC3CCCCC3)NS2(=O)=O)CC1C(F)(F)F
BENETHAMINE,BENETHAMINE,,BRD:BRD-BRD-K13473780-001-02-1;BRD:BRD-K13473780-001-02-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C(CC1CCCCC1)NCC1CCCCC1
BENFLUOREX,BENFLUOREX,CHEMBL400599,BRD:BRD-A22305049-003-13-6;BRD:BRD-BRD-A22305049-003-13-6,rep_primary;rep_single_dose,GLUCONEOGENESIS INHIBITOR,HMGCR,,,WITHDRAWN,,Small molecule,Approved,CJAVTWRYCDNHSM-UHFFFAOYSA-N,CC(CC1CCCC(C(F)(F)F)C1)NCCOC(=O)C1CCCCC1;CC(CC1CCCC(C1)C(F)(F)F)NCCOC(=O)C1CCCCC1
BENFLURALIN,BENFLURALIN,CHEMBL1256668,BRD:BRD-BRD-K33903083-001-03-5;BRD:BRD-K33903083-001-03-5,rep_primary;rep_single_dose,,CYP1A1;CYP1A2;CYP2B6;CYP3A4;ESR1;MMP1;SULT2A1;UGT1A1,,,PHASE 3,,Small molecule,NA,SMDHCQAYESWHAE-UHFFFAOYSA-N,CCCCN(CC)C1C([N+](=O)[O-])CC(C(F)(F)F)CC1[N+](=O)[O-];CCCCN(CC)C1C(CC(CC1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O
BENFOTIAMINE,BENFOTIAMINE,CHEMBL1491875;CHEMBL3183549,BRD:BRD-BRD-K07359318-001-03-9;BRD:BRD-K07359318-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,ANTIOXIDANT,AGER,LUMBAGO,,LAUNCHED,,Small molecule,Phase 3,BTNNPSLJPBRMLZ-GHRIWEEISA-N;BTNNPSLJPBRMLZ-UHFFFAOYSA-N,C/C(=C(/CCOP(=O)(O)O)SC(=O)C1CCCCC1)N(C=O)CC1CNC(C)NC1N;C\C(N(CC1CNC(C)NC1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)C1CCCCC1;C\C(N(CC1CNC(C)NC1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)C1CCCCC1;CC(=C(CCOP(=O)(O)O)SC(=O)C1CCCCC1)N(C=O)CC1CNC(C)NC1N
BENIDIPINE,BENIDIPINE,CHEMBL2074972;CHEMBL2105555;CHEMBL2218858,BRD:BRD-BRD-K97181463-003-01-1;BRD:BRD-K97181463-003-01-1,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1G,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,QZVNQOLPLYWLHQ-GEPVFLLWSA-N;QZVNQOLPLYWLHQ-UHFFFAOYSA-N;QZVNQOLPLYWLHQ-ZEQKJWHPSA-N,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1CCCC(C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2CCCCC2)C1;COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(CC3CCCCC3)C2)[C@@H]1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(CC3CCCCC3)C2)C1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(CC3CCCCC3)C2)C1C1CCCC([N+](=O)[O-])C1
BENPERIDOL,BENPERIDOL,CHEMBL297302,BRD:BRD-BRD-K79425933-001-09-3;BRD:BRD-K79425933-001-09-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,FEBOTPHFXYHVPL-UHFFFAOYSA-N,FC1CCC(CC1)C(=O)CCCN1CCC(CC1)N1C2CCCCC2[NH]C1=O;O=C(CCCN1CCC(N2C(=O)[NH]C3CCCCC32)CC1)C1CCC(F)CC1
BENPROPERINE,BENPROPERINE,CHEMBL2105910,BRD:BRD-A42423104-001-01-4;BRD:BRD-BRD-A42423104-001-01-4,rep_primary;rep_single_dose,ANTITUSSIVE,SCN5A,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Unknown,JTUQXGZRVLWBCR-UHFFFAOYSA-N,CC(COC1CCCCC1CC1CCCCC1)N1CCCCC1
BENSERAZIDE,BENSERAZIDE,CHEMBL1096979,BRD:BRD-A61194565-003-27-0;BRD:BRD-BRD-A61194565-003-27-0,rep_primary;rep_single_dose,DOPA DECARBOXYLASE INHIBITOR,DDC,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,BNQDCRGUHNALGH-UHFFFAOYSA-N,NC(CO)C(=O)NNCC1CCC(O)C(O)C1O
BENTAZEPAM,BENTAZEPAM,CHEMBL1521495,BRD:BRD-BRD-K89490285-001-08-1;BRD:BRD-K89490285-001-08-1,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,,"ANXIETY, SEDATIVE, MUSCLE RELAXANT",,LAUNCHED,,Small molecule,Unknown,AIZFEOPQVZBNGH-UHFFFAOYSA-N,O=C1CN=C(C2C3CCCCC3SC2N1)C1CCCCC1;O=C1CN=C(C2CCCCC2)C2C(SC3C2CCCC3)N1
BENTIROMIDE,BENTIROMIDE,CHEMBL1200368,BRD:BRD-BRD-K58794715-001-01-8;BRD:BRD-K58794715-001-01-8,rep_primary;rep_single_dose,,HPN,PANCREAS DIAGNOSTIC AGENT,,LAUNCHED,,Small molecule,Approved,SPPTWHFVYKCNNK-FQEVSTJZSA-N,O=C(O)C1CCC(NC(=O)[C@H](CC2CCC(O)CC2)NC(=O)C2CCCCC2)CC1;OC(=O)C1CCC(NC(=O)[C@H](CC2CCC(O)CC2)NC(=O)C2CCCCC2)CC1
BENURESTAT,BENURESTAT,CHEMBL2105796,BRD:BRD-BRD-K88553858-001-02-7;BRD:BRD-K88553858-001-02-7,rep_primary;rep_single_dose,UREASE INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,JFZGBMJPJZDNNT-UHFFFAOYSA-N,O=C(CNC(=O)C1CCC(CL)CC1)NO;ONC(=O)CNC(=O)C1CCC(CL)CC1
BENZAMIL,BENZAMIL,CHEMBL212579,BRD:BRD-BRD-K87158025-001-01-6;BRD:BRD-K87158025-001-01-6,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,ASIC1;PKD2L1;SCNN1A;SCNN1B;SCNN1D;SCNN1G;SLC8A1,,,PHASE 2,,Small molecule,NA,KXDROGADUISDGY-UHFFFAOYSA-N,N/C(=N\C(=O)C1NC(CL)C(N)NC1N)NCC1CCCCC1;NC(NCC1CCCCC1)=NC(=O)C1NC(CL)C(N)NC1N
BENZBROMARONE,BENZBROMARONE,CHEMBL388590,BRD:BRD-BRD-K11717138-001-30-3;BRD:BRD-K11717138-001-30-3,rep_primary;rep_single_dose,CHLORIDE CHANNEL BLOCKER,ABCC1,GOUT,,LAUNCHED,,Small molecule,Approved,WHQCHUCQKNIQEC-UHFFFAOYSA-N,CCC1OC2CCCCC2C1C(=O)C1CC(BR)C(O)C(BR)C1
BENZETHONIUM,BENZETHONIUM,CHEMBL1182210,BRD:BRD-BRD-K72723676-003-17-8;BRD:BRD-K72723676-003-17-8,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A,FIRST-AID ANTISEPTIC,,LAUNCHED,,Small molecule,Unknown,SIYLLGKDQZGJHK-UHFFFAOYSA-N,CC(C)(C)CC(C)(C)C1CCC(OCCOCC[N+](C)(C)CC2CCCCC2)CC1
BENZNIDAZOLE,BENZNIDAZOLE,CHEMBL110,BRD:BRD-BRD-K56156805-001-09-6;BRD:BRD-K56156805-001-09-6,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,CHAGAS DISEASE,,LAUNCHED,,Small molecule,Approved,CULUWZNBISUWAS-UHFFFAOYSA-N,[O-][N+](=O)C1NCCN1CC(=O)NCC1CCCCC1;O=C(CN1CCNC1[N+](=O)[O-])NCC1CCCCC1
BENZOCAINE,BENZOCAINE,CHEMBL278172,BRD:BRD-BRD-K75466013-001-14-4;BRD:BRD-K75466013-001-14-4,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A,FIRST-AID ANTISEPTIC,,LAUNCHED,,Small molecule,Approved,BLFLLBZGZJTVJG-UHFFFAOYSA-N,CCOC(=O)C1CCC(N)CC1
BENZOFENAC,BENZOFENAC,,BRD:BRD-BRD-K26556907-001-01-8;BRD:BRD-K26556907-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,OC(=O)CC1CCC(OCC2CCCCC2)C(CL)C1
BENZOIC-ACID,BENZOIC-ACID,,BRD:BRD-BRD-K53397409-001-12-3;BRD:BRD-K53397409-001-12-3,rep_primary;rep_single_dose,FOOD PRESERVATIVE,DAO;HRSP12;PRDX5;RAB9A,TINEA PEDIS,,LAUNCHED,,,NA,,OC(=O)C1CCCCC1
BENZOIN,BENZOIN,CHEMBL190677,BRD:BRD-A55748233-001-08-7;BRD:BRD-BRD-A55748233-001-08-7,rep_primary;rep_single_dose,,CES1,,,PRECLINICAL,,Small molecule,Approved,ISAOCJYIOMOJEB-UHFFFAOYSA-N,O=C(C1CCCCC1)C(O)C1CCCCC1;OC(C(=O)C1CCCCC1)C1CCCCC1
BENZONATATE,BENZONATATE,CHEMBL1374379,BRD:BRD-BRD-K91699951-001-10-2;BRD:BRD-K91699951-001-10-2,rep_primary;rep_single_dose,LOCAL ANESTHETIC,SCN5A,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Approved,MAFMQEKGGFWBAB-UHFFFAOYSA-N,CCCCNC1CCC(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)CC1;CCCCNC1CCC(CC1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
BENZOQUINONIUM-DIBROMIDE,BENZOQUINONIUM-DIBROMIDE,,BRD:BRD-BRD-K18772613-303-02-4;BRD:BRD-K18772613-303-02-4,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRNA1,,,PRECLINICAL,,,NA,,CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)CC2CCCCC2)=CC1=O)CC1CCCCC1
BENZOTRIPT,BENZOTRIPT,CHEMBL63544,BRD:BRD-A87983072-001-01-1;BRD:BRD-BRD-A87983072-001-01-1,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKAR;CCKBR,,,PHASE 1,,Small molecule,Unknown,QJERBBQXOMUURJ-INIZCTEOSA-N,O=C(N[C@@H](CC1C[NH]C2CCCCC12)C(=O)O)C1CCC(CL)CC1;OC(=O)C(CC1C[NH]C2CCCCC12)NC(=O)C1CCC(CL)CC1
BENZOXIQUINE,BENZOXIQUINE,CHEMBL1170610,BRD:BRD-BRD-K70327191-001-02-2;BRD:BRD-K70327191-001-02-2,rep_primary;rep_single_dose,ANTIINFECTIVE DRUG,,,,PRECLINICAL,,Small molecule,Unknown,BHKPHCKISVSDGV-UHFFFAOYSA-N,O=C(OC1CCCC2CCCNC12)C1CCCCC1
BENZOYLPAS,BENZOYLPAS,CHEMBL1487804,BRD:BRD-BRD-K20431737-001-08-1;BRD:BRD-K20431737-001-08-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,GNZCRYWFWKFIDM-UHFFFAOYSA-N,O=C(NC1CCC(C(=O)O)C(O)C1)C1CCCCC1;OC(=O)C1CCC(NC(=O)C2CCCCC2)CC1O
BENZOYLSTAUROSPORINE,BENZOYLSTAUROSPORINE,,GDSC1:153,gdsc,,,,,,,,NA,,
BENZO[D]THIAZOLE-2(3H)-THIONE,BENZO[D]THIAZOLE-2(3H)-THIONE,,BRD:BRD-BRD-K55160477-001-04-7;BRD:BRD-K55160477-001-04-7,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,SC1NC2CCCCC2S1
BENZTHIAZIDE,BENZTHIAZIDE,CHEMBL1201039,BRD:BRD-BRD-K21450440-001-14-6;BRD:BRD-K21450440-001-14-6,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA2;CA4;CA9;SLC12A3,"HYPERTENSION, EDEMA",,LAUNCHED,,Small molecule,Approved,NDTSRXAMMQDVSW-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1CL)N=C(CSCC1CCCCC1)NS2(=O)=O
BENZTROPINE-MESYLATE,BENZTROPINE-MESYLATE,,BRD:BRD-BRD-K48061146-066-01-7;BRD:BRD-K48061146-066-01-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;HRH1;SLC6A3,"EXTRAPYRAMIDAL SYMPTOMS (EPS), PARKINSON'S DISEASE",,LAUNCHED,,,NA,,CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(C1CCCCC1)C1CCCCC1
BENZYDAMINE,BENZYDAMINE,CHEMBL12610,BRD:BRD-BRD-K28542495-003-13-5;BRD:BRD-K28542495-003-13-5,rep_multi_dose;rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,,"MOUTH INFLAMMATION, THROAT INFLAMMATION",,LAUNCHED,,Small molecule,Approved,CNBGNNVCVSKAQZ-UHFFFAOYSA-N,CN(C)CCCOC1NN(CC2CCCCC2)C2CCCCC12
BENZYLDIMETHYLHEXADECYLAMMONIUM,BENZYLDIMETHYLHEXADECYLAMMONIUM,,BRD:BRD-BRD-K23403298-003-01-9;BRD:BRD-K23403298-003-01-9,rep_multi_dose;rep_primary;rep_single_dose,CATIONIC SURFACTANT,,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCCCCC[N+](C)(C)CC1CCCCC1
BENZYLDIMETHYLOCTYLAMMONIUM,BENZYLDIMETHYLOCTYLAMMONIUM,,BRD:BRD-BRD-K11576103-003-01-1;BRD:BRD-K11576103-003-01-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCCC[N+](C)(C)CC1CCCCC1
BENZYLPENICILLIN,BENZYLPENICILLIN,CHEMBL29,BRD:BRD-BRD-K55191674-237-18-3;BRD:BRD-K55191674-237-18-3,rep_primary;rep_single_dose,PENICILLIN BINDING PROTEIN INHIBITOR,,"CELLUITIS, MENINGITIS, ENDOCARDITIS, SYPHILIS, PNEUMONIA, BACTERIAL SEPTICEMIA",,LAUNCHED,,Small molecule,Approved,JGSARLDLIJGVTE-MBNYWOFBSA-N,CC1(C)S[C@@H]2[C@H](NC(=O)CC3CCCCC3)C(=O)N2[C@H]1C(=O)O;CC1(C)S[C@@H]2[C@H](NC(=O)CC3CCCCC3)C(=O)N2[C@H]1C(O)=O
BEPHENIUM-HYDROXYNAPHTHOATE,BEPHENIUM-HYDROXYNAPHTHOATE,,BRD:BRD-BRD-K47878171-086-06-0;BRD:BRD-K47878171-086-06-0,rep_multi_dose;rep_primary;rep_single_dose,ANTHELMINTIC AGENT,,ASCARIASIS,,LAUNCHED,,,NA,,C[N+](C)(CCOC1CCCCC1)CC1CCCCC1
BEPOTASTINE,BEPOTASTINE,CHEMBL1201758,BRD:BRD-BRD-K98624455-074-02-8;BRD:BRD-K98624455-074-02-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,YWGDOWXRIALTES-NRFANRHFSA-N,O=C(O)CCCN1CCC(O[C@@H](C2CCC(CL)CC2)C2CCCCN2)CC1;OC(=O)CCCN1CCC(CC1)O[C@@H](C1CCC(CL)CC1)C1CCCCN1
BEPRIDIL,BEPRIDIL,CHEMBL1008,BRD:BRD-A91008255-003-24-8;BRD:BRD-BRD-A91008255-003-24-8,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,ATP1A1;CACNA1A;CACNA1H;CACNA2D2;CALM1;KCNQ1;KCNQ4;PDE1A;PDE1B;TNNC1,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Approved,UIEATEWHFDRYRU-UHFFFAOYSA-N,CC(C)COCC(CN(CC1CCCCC1)C1CCCCC1)N1CCCC1
BERBERINE,BERBERINE,CHEMBL295124,BRD:BRD-BRD-K14796088-003-26-8;BRD:BRD-K14796088-003-26-8,rep_multi_dose;rep_primary;rep_single_dose,LDL RECEPTOR ACTIVATOR,LDLR,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,YBHILYKTIRIUTE-UHFFFAOYSA-N,COC1CCC2CC3-C4CC5OCOC5CC4CC[N+]3CC2C1OC;COC1CCC2CC3[N+](CC2C1OC)CCC1CC2C(CC1-3)OCO2
BERGAPTEN,BERGAPTEN,CHEMBL24171,BRD:BRD-BRD-K12968785-001-13-3;BRD:BRD-K12968785-001-13-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Approved,BGEBZHIAGXMEMV-UHFFFAOYSA-N,COC1C2CCOC2CC2OC(=O)CCC12
BERGENIN,BERGENIN,CHEMBL273019,BRD:BRD-BRD-K04176066-001-08-3;BRD:BRD-K04176066-001-08-3,rep_primary;rep_single_dose,INTERLEUKIN INHIBITOR,IL1B;TNF,,,PRECLINICAL,,Small molecule,Unknown,YWJXCIXBAKGUKZ-HJJNZUOJSA-N,COC1C(O)CC2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3C2C1O;COC1C(O)CC2C(C1O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1OC2=O
BERZOSERTIB,BERZOSERTIB,CHEMBL3989870,GDSC2:1613,gdsc,,,,,,,Small molecule,Phase 2,JZCWLJDSIRUGIN-UHFFFAOYSA-N,CNCC1CCC(-C2CC(-C3NC(-C4CCC(S(=O)(=O)C(C)C)CC4)CNC3N)ON2)CC1
BESIFLOXACIN,BESIFLOXACIN,CHEMBL1201760,BRD:BRD-BRD-K10196357-003-02-0;BRD:BRD-K10196357-003-02-0,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,QFFGVLORLPOAEC-SNVBAGLBSA-N,N[C@@H]1CCCCN(C1)C1C(F)CC2C(C1CL)N(CC(C(O)=O)C2=O)C1CC1;N[C@@H]1CCCCN(C2C(F)CC3C(=O)C(C(=O)O)CN(C4CC4)C3C2CL)C1
BET-BAY-002,BET-BAY-002,,BRD:BRD-BRD-K72735080-001-01-0;BRD:BRD-K72735080-001-01-0,rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,,,,PRECLINICAL,,,NA,,CC1NNC(C[C@@H]2C=C(C3CCC(CL)CC3)C3CCCCC3-N3C(C)NNC23)O1
BETA-AMYLOID-SYNTHESIS-INHIBITOR,BETA-AMYLOID-SYNTHESIS-INHIBITOR,,BRD:BRD-BRD-K38687824-001-02-5;BRD:BRD-K38687824-001-02-5,rep_primary;rep_single_dose,BETA AMYLOID SYNTHESIS INHIBITOR,APP,,,PRECLINICAL,,,NA,,OC1CCCC(NC2CCC(NC3CCCC(O)C3)NN2)C1
BETA-CCB,BETA-CCB,,BRD:BRD-BRD-K87349602-001-03-8;BRD:BRD-K87349602-001-03-8,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR LIGAND,GABRA1;GABRG2,,,LAUNCHED,,,NA,,CCCCOC(=O)C1CC2C(CN1)[NH]C1CCCCC21
BETA-FUNALTREXAMINE,BETA-FUNALTREXAMINE,,BRD:BRD-BRD-K95110148-003-01-5;BRD:BRD-K95110148-003-01-5,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,,,PRECLINICAL,,,NA,,COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3CC4CCC(O)C5O[C@@H]1[C@]2(CCN3CC1CC1)C45
BETA-GLYCEROPHOSPHORIC-ACID,BETA-GLYCEROPHOSPHORIC-ACID,,BRD:BRD-BRD-K39061174-001-01-0;BRD:BRD-K39061174-001-01-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OCC(CO)OP(O)(O)=O
BETA-HYDROXY-BETA-METHYLBUTYRATE,BETA-HYDROXY-BETA-METHYLBUTYRATE,,BRD:BRD-BRD-M02899238-238-01-6;BRD:BRD-M02899238-238-01-6,rep_primary;rep_single_dose,PROTEIN SYNTHESIS STIMULANT,MTOR,,,PHASE 2/PHASE 3,,,NA,,CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O
BETA-HYDROXYBUTYRATE,BETA-HYDROXYBUTYRATE,CHEMBL1162496,BRD:BRD-A41387824-001-06-0,rep_single_dose,,HCAR2,,,,,Small molecule,Phase 1,WHBMMWSBFZVSSR-UHFFFAOYSA-N,CC(O)CC(=O)O
BETA-LAPACHONE,BETA-LAPACHONE,CHEMBL15192,BRD:BRD-BRD-K28061410-001-06-6;BRD:BRD-K28061410-001-06-6,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 2,,Small molecule,Phase 2,QZPQTZZNNJUOLS-UHFFFAOYSA-N,CC1(C)CCC2=C(O1)C1CCCCC1C(=O)C2=O
BETA-NAPHTHOL,BETA-NAPHTHOL,,BRD:BRD-BRD-K21164796-001-02-8;BRD:BRD-K21164796-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC1CCC2CCCCC2C1
BETAHISTINE,BETAHISTINE,CHEMBL24441;CHEMBL4298035,BRD:BRD-BRD-K91315211-300-05-7;BRD:BRD-K91315211-300-05-7,rep_primary;rep_single_dose,"HISTAMINE RECEPTOR AGONIST, HISTAMINE RECEPTOR ANTAGONIST",HRH1;HRH3,MENIERE'S DISEASE,,LAUNCHED,,Small molecule;Unknown,Approved,;UUQMNUMQCIQDMZ-UHFFFAOYSA-N,CNCCC1CCCCN1
BETAINE,BETAINE,CHEMBL95889,BRD:BRD-BRD-K12014493-001-02-2;BRD:BRD-K12014493-001-02-2,rep_primary;rep_single_dose,NITRIC OXIDE DONOR,,HOMOCYSTINURIA,,LAUNCHED,,Small molecule,Approved,KWIUHFFTVRNATP-UHFFFAOYSA-O,C[N+](C)(C)CC(=O)O;C[N+](C)(C)CC(O)=O
BETAMETHASONE,BETAMETHASONE,CHEMBL632,BRD:BRD-A02180903-001-04-5;BRD:BRD-BRD-A02180903-001-04-5,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Approved,UREBDLICKHMUKA-DVTGEIKXSA-N,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO;C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
BETAMETHASONE-ACETATE,BETAMETHASONE-ACETATE,,BRD:BRD-A92177080-001-02-1;BRD:BRD-BRD-A92177080-001-02-1,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O
BETAMETHASONE-BUTYRATE-PROPIONATE,BETAMETHASONE-BUTYRATE-PROPIONATE,,BRD:BRD-K00004736-001-01-9,rep_single_dose,,,,,,,,NA,,
BETAMETHASONE-DIPROPIONATE,BETAMETHASONE-DIPROPIONATE,,BRD:BRD-BRD-K58148589-001-03-6;BRD:BRD-K58148589-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
BETAMETHASONE-PHOSPHATE,BETAMETHASONE-PHOSPHATE,,BRD:BRD-K00005349-304-01-9,rep_single_dose,,,,,,,,NA,,
BETAMETHASONE-VALERATE,BETAMETHASONE-VALERATE,,BRD:BRD-BRD-K34032314-001-04-1;BRD:BRD-K34032314-001-04-1,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO
BETAMIPRON,BETAMIPRON,CHEMBL1231530,BRD:BRD-BRD-K82142815-001-19-1;BRD:BRD-K82142815-001-19-1,rep_primary;rep_single_dose,PANIPENEM UPTAKE INHIBITOR,,RENAL TOXICITY,,LAUNCHED,,Small molecule,Unknown,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,O=C(O)CCNC(=O)C1CCCCC1;OC(=O)CCNC(=O)C1CCCCC1
BETAXOLOL,BETAXOLOL,CHEMBL1201274;CHEMBL1691;CHEMBL423,BRD:BRD-A02759312-003-24-5;BRD:BRD-BRD-A02759312-003-24-5;BRD:BRD-BRD-K17498618-344-02-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,"INTRAOCULAR PRESSURE, GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,,Small molecule,Approved,CHDPSNLJFOQTRK-UHFFFAOYSA-N;NWIUTZDMDHAVTP-KRWDZBQOSA-N;NWIUTZDMDHAVTP-UHFFFAOYSA-N,CC(C)NC[C@H](O)COC1CCC(CCOCC2CC2)CC1;CC(C)NCC(O)COC1CCC(CCOCC2CC2)CC1;CC(C)NCC(O)COC1CCC(CCOCC2CC2)CC1.CL;COC1CCC(C[C@@H]2C3CC(OC)C(OC)CC3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCC3CC(OC)C(OC)CC3[C@H]2CC2CCC(OC)C(OC)C2)CC1OC
BETAZOLE,BETAZOLE,CHEMBL1201323,BRD:BRD-BRD-K20075662-300-04-0;BRD:BRD-K20075662-300-04-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH2,GASTRIC HYPERSECRETION DIAGNOSTIC,,LAUNCHED,,Small molecule,Approved,JXDFEQONERDKSS-UHFFFAOYSA-N,NCCC1CC[NH]N1
BETHANECHOL,BETHANECHOL,CHEMBL1482,BRD:BRD-A99833829-003-27-1;BRD:BRD-BRD-A99833829-003-27-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4,URINARY RETENTION,,LAUNCHED,,Small molecule,Approved,NZUPCNDJBJXXRF-UHFFFAOYSA-O,CC(C[N+](C)(C)C)OC(N)=O
BETP,BETP,,BRD:BRD-A60153876-001-01-0;BRD:BRD-BRD-A60153876-001-01-0,rep_primary;rep_single_dose,GLUCAGON-LIKE PEPTIDE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GLP1R,,,PRECLINICAL,,,NA,,CCS(=O)C1NC(CC(N1)C(F)(F)F)-C1CCCC(OCC2CCCCC2)C1
BETRIXABAN,BETRIXABAN,CHEMBL512351,BRD:BRD-BRD-K45275534-001-01-3;BRD:BRD-K45275534-001-01-3,rep_primary;rep_single_dose,COAGULATION FACTOR INHIBITOR,KCNH2,DEEP VEIN THROMBOSIS (DVT),,LAUNCHED,,Small molecule,Approved,XHOLNRLADUSQLD-UHFFFAOYSA-N,COC1CCC(NC(=O)C2CCC(C(=N)N(C)C)CC2)C(C(=O)NC2CCC(CL)CN2)C1;COC1CCC(NC(=O)C2CCC(CC2)C(=N)N(C)C)C(C1)C(=O)NC1CCC(CL)CN1
BETULINIC ACID,BETULINIC ACID,CHEMBL269277,CTRP:23256,ctrp,,,,,,,Small molecule,Phase 1,QGJZLNKBHJESQX-FZFNOLFKSA-N,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
BETULINIC-ACID,BETULINIC-ACID,,BRD:BRD-BRD-K45401373-001-20-9;BRD:BRD-BRD-K45401373-001-22-5;BRD:BRD-K45401373-001-20-9;BRD:BRD-K45401373-001-22-5,rep_multi_dose;rep_primary;rep_single_dose,"APOPTOSIS STIMULANT, NFKB PATHWAY INHIBITOR",GPBAR1,,,PHASE 1/PHASE 2,,,NA,,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O
BEVANTOLOL,BEVANTOLOL,CHEMBL314010,BRD:BRD-A18233884-003-02-7;BRD:BRD-BRD-A18233884-003-02-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRB1;ADRB2,"ANGINA PECTORIS, HYPERTENSION",,LAUNCHED,,Small molecule,Phase 2,HXLAFSUPPDYFEO-UHFFFAOYSA-N,COC1CCC(CCNCC(O)COC2CCCC(C)C2)CC1OC
BEVENOPRAN,BEVENOPRAN,CHEMBL3039511,BRD:BRD-K00004680-001-01-9,rep_single_dose,OPIOID RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,ZGCYVRNZWGUXNQ-UHFFFAOYSA-N,COC1CC(CNCCC2CCOCC2)CCC1OC1CNC(C(N)=O)CN1
BEVIRIMAT-DIMEGLUMINE,BEVIRIMAT-DIMEGLUMINE,,BRD:BRD-BRD-K16898998-001-01-6;BRD:BRD-K16898998-001-01-6,rep_primary;rep_single_dose,HIV CAPSID ASSEMBLY INHIBITOR,,,,PHASE 2,,,NA,,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O
BEXAGLIFLOZIN,BEXAGLIFLOZIN,CHEMBL1808388,BRD:BRD-K00003246-001-01-9,rep_single_dose,SOLUTE CARRIER FAMILY MEMBER INHIBITOR,,,,,,Small molecule,Phase 3,BTCRKOKVYTVOLU-SJSRKZJXSA-N,OC[C@H]1O[C@@H](C2CCC(CL)C(CC3CCC(OCCOC4CC4)CC3)C2)[C@H](O)[C@@H](O)[C@@H]1O
BEXAROTENE,BEXAROTENE,CHEMBL1023,BRD:BRD-BRD-K92441787-001-04-1;BRD:BRD-K92441787-001-04-1;CTRP:374747;GDSC1:186,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RXRA;RXRB;RXRG,CUTANEOUS T-CELL LYMPHOMA (CTCL),,LAUNCHED,,Small molecule,Approved,NAVMQTYZDKMPEU-UHFFFAOYSA-N,C=C(C1CCC(C(=O)O)CC1)C1CC2C(CC1C)C(C)(C)CCC2(C)C;CC1CC2C(CC1C(=C)C1CCC(CC1)C(O)=O)C(C)(C)CCC2(C)C
BEXAROTENUM,BEXAROTENUM,,GDSC1:186,gdsc,,,,,,,,NA,,
BEZ235,BEZ235,CHEMBL1879463,GDSC1:1057;GDSC2:1057,gdsc,,,,,,,Small molecule,Phase 3,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,CN1C(=O)N(-C2CCC(C(C)(C)C#N)CC2)C2C3CC(-C4CNC5CCCCC5C4)CCC3NCC21
BEZAFIBRATE,BEZAFIBRATE,CHEMBL264374,BRD:BRD-BRD-K46018455-001-27-6;BRD:BRD-K46018455-001-27-6,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA;PPARD;PPARG,CHOLESTEROL,,LAUNCHED,,Small molecule,Approved,IIBYAHWJQTYFKB-UHFFFAOYSA-N,CC(C)(OC1CCC(CCNC(=O)C2CCC(CL)CC2)CC1)C(=O)O;CC(C)(OC1CCC(CCNC(=O)C2CCC(CL)CC2)CC1)C(O)=O
PITOLISANT,BF2.649;PITOLISANT,CHEMBL462605,BRD:BRD-BRD-K21673112-003-01-3;BRD:BRD-K21673112-003-01-3,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH3,,,PHASE 3,,Small molecule,Approved,NNACHAUCXXVJSP-UHFFFAOYSA-N,CLC1CCC(CCCOCCCN2CCCCC2)CC1
BFH772,BFH772,CHEMBL4080062,BRD:BRD-K00003368-001-01-9,rep_single_dose,VEGFR INHIBITOR,,,,,,Small molecule,Phase 2,JNLSTLQFDDAULK-UHFFFAOYSA-N,O=C(NC1CCCC(C(F)(F)F)C1)C1CCCC2CC(OC3CC(CO)NCN3)CCC12
NVP-BGJ398,BGJ398;INFIGRATINIB;NVP-BGJ398,CHEMBL1852688,BRD:BRD-BRD-K42728290-001-09-1;BRD:BRD-K42728290-001-09-1;BRD:BRD-U00115288-001-01-9,oncref_1;rep_primary;rep_single_dose,"INHIBITOR OF FGFR1, FGFR2, AND FGFR3",FGFR1;FGFR2;FGFR3;FGFR4;KDR,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF FGFR1, FGFR2, AND FGFR3', 'FGFR INHIBITOR'}, defaulting to 'INHIBITOR OF FGFR1, FGFR2, AND FGFR3'
Multiple values for repurposing_target: {'FGFR1;FGFR2;FGFR3', 'FGFR1;FGFR2;FGFR3;FGFR4;KDR'}, taking the union
Multiple values for structure_id: {'U00115288', 'K42728290'}, defaulting to None",Small molecule,Approved,QADPYRIHXKWUSV-UHFFFAOYSA-N,CCN1CCN(C2CCC(NC3CC(N(C)C(=O)NC4C(CL)C(OC)CC(OC)C4CL)NCN3)CC2)CC1;CCN1CCN(CC1)C1CCC(NC2CC(NCN2)N(C)C(=O)NC2C(CL)C(OC)CC(OC)C2CL)CC1
BGP-15,BGP-15,CHEMBL4747845,BRD:BRD-K00003393-300-01-9,rep_single_dose,PARP INHIBITOR,,,,,,Small molecule,Phase 2,MVLOQULXIYSERZ-UHFFFAOYSA-N,N=C(NOCC(O)CN1CCCCC1)C1CCCNC1
BGT226,BGT226,CHEMBL3545096,BRD:BRD-BRD-K29415052-050-04-8;BRD:BRD-K29415052-050-04-8,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,MTOR;PIK3CA;PIK3CB;PIK3CG,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,YUXMAKUNSXIEKN-BTJKTKAUSA-N,COC1CCC(-C2CCC3NCC4C(C3C2)N(-C2CCC(N3CCNCC3)C(C(F)(F)F)C2)C(=O)N4C)CN1.O=C(O)/C=C\C(=O)O;COC1CCC(CN1)-C1CCC2NCC3N(C)C(=O)N(-C4CCC(N5CCNCC5)C(C4)C(F)(F)F)C3C2C1
BHG712,BHG712,,GDSC1:295,gdsc,,,,,,,,NA,,
BHQ,BHQ,,BRD:BRD-K95603879-001-08-9,rep_single_dose,ATPASE INHIBITOR,ATP2A1,,,,,,NA,,
BI-0319,BI-0319,,BRD:BRD-K00127345-001-01-9,oncref_2,PROTAC DEGRADER OF PTK2,PTK2;VHL,,,,,,NA,,
BI-224436,BI-224436,,BRD:BRD-BRD-K53422148-001-01-8;BRD:BRD-K53422148-001-01-8,rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,,,,PHASE 1,,,NA,,CC1NC2CCCCC2C(-C2CCC3OCCC4CCNC2C34)C1[C@H](OC(C)(C)C)C(O)=O
BI-2536,BI-2536,CHEMBL513909,BRD:BRD-BRD-K64890080-001-13-8;BRD:BRD-K64890080-001-13-8;CTRP:347813;GDSC1:60;GDSC2:1086,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,PLK INHIBITOR,BRD4;PLK1;PLK2;PLK3,,,PHASE 2,,Small molecule,Phase 2,XQVVPGYIWAGRNI-JOCHJYFZSA-N,CC[C@@H]1C(=O)N(C)C2CNC(NC3CCC(C(=O)NC4CCN(C)CC4)CC3OC)NC2N1C1CCCC1;CC[C@H]1N(C2CCCC2)C2NC(NC3CCC(CC3OC)C(=O)NC3CCN(C)CC3)NCC2N(C)C1=O
BI-2852,BI-2852,,BRD:BRD-K00006885-001-03-9,oncref_1,INHIBITOR OF KRAS,KRAS,,,,,,NA,,
COMPOUND I-6,BI-3406;COMPOUND I-6,,BRD:BRD-U00115414-001-01-9,oncref_1;oncref_2,INHIBITOR OF THE KRAS-SOS1 INTERACTION,KRAS;SOS1,,,,,,NA,,
BI-3663,BI-3663,,BRD:BRD-U00115415-001-01-9,oncref_1,PROTAC DEGRADER OF PTK2,PTK2,,,,,,NA,,
BI-3802,BI-3802,,BRD:BRD-K00126481-001-03-9,oncref_2,BCL6-POLYMERIZER,BCL6,,,,,,NA,,
BI-409306,BI-409306,CHEMBL4206492,BRD:BRD-K00003120-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Phase 2,BZTIJCSHNVZMES-UHFFFAOYSA-N,O=C1[NH]C(CC2CCCCN2)NC2C1CNN2C1CCOCC1
BI-4206,BI-4206,,BRD:BRD-U00115416-001-01-9,oncref_1,INACTIVE STEREOISOMER OF PTK2 DEGRADER BI-0319,PTK2,,,,,,NA,,
BI-5521,BI-5521,,BRD:BRD-K00126784-001-01-9,oncref_2,INHIBITOR OF GSK3,GSK3A;GSK3B,,,,,,NA,,
BI-78D3,BI-78D3,,BRD:BRD-BRD-K73982490-001-02-9;BRD:BRD-K73982490-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,JNK INHIBITOR,MAPK8,,,PRECLINICAL,,,NA,,OC1NNC(SC2NCC(S2)[N+]([O-])=O)N1-C1CCC2OCCOC2C1
BI-847325,BI-847325,,BRD:BRD-BRD-K37492701-001-02-9;BRD:BRD-K37492701-001-02-9,rep_primary;rep_single_dose,"AURORA KINASE INHIBITOR, MEK INHIBITOR",AURKA;AURKB;AURKC;MAP2K1;MAP2K2,,,PHASE 1,"Multiple values for MOA: {'MEK INHIBITOR, AURORA KINASE INHIBITOR', 'AURORA KINASE INHIBITOR, MEK INHIBITOR'}, defaulting to 'AURORA KINASE INHIBITOR, MEK INHIBITOR'",,NA,,CCNC(=O)C#CC1CCC2C(NC(=O)\C2=C(\NC2CCC(CN(C)C)CC2)C2CCCCC2)C1
BI-97C1,BI-97C1,,GDSC2:1849,gdsc,,,,,,,,NA,,
BI-9930,BI-9930,,BRD:BRD-U00115432-001-01-9,oncref_1,INACTIVE REGIOISOMER OF SOS1 ACTIVATOR VUBI1,SOS1,,,,,,NA,,
BI-D1870,BI-D1870,,BRD:BRD-A81370665-001-03-6;BRD:BRD-BRD-A81370665-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,RIBOSOMAL PROTEIN INHIBITOR,RPS6KA1;RPS6KA2;RPS6KA3;RPS6KA6,,,PRECLINICAL,,,NA,,CC(C)CCN1C(C)C(=O)N(C)C2CNC(NC3CC(F)C(O)C(F)C3)NC12
BIA-10-2474,BIA-10-2474,,BRD:BRD-K00004735-001-01-9,rep_single_dose,FATTY ACID HYDROLASE INHIBITOR,,,,,,,NA,,
BIAPENEM,BIAPENEM,CHEMBL285347,BRD:BRD-A80321291-001-03-2;BRD:BRD-BRD-A80321291-001-03-2,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"BACTERIAL SEPTICEMIA, PNEUMONIA, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Phase 1,MRMBZHPJVKCOMA-YJFSRANCSA-N,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN4CNC[N+]4C3)=C(N2C1=O)C(O)=O;C[C@@H](O)[C@H]1C(=O)N2C(C(=O)[O-])=C(SC3CN4CNC[N+]4C3)[C@H](C)[C@H]12
BIBF-1120,BIBF-1120,CHEMBL502835,GDSC1:380,gdsc,,,,,,,Small molecule,Approved,XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)C1CCC2C(C1)NC(=O)/C2=C(\NC1CCC(N(C)C(=O)CN2CCN(C)CC2)CC1)C1CCCCC1
BIBN4096,BIBN4096,,BRD:BRD-BRD-K43927145-001-01-2;BRD:BRD-K43927145-001-01-2,rep_primary;rep_single_dose,CALCITONIN ANTAGONIST,CALCA;CALCRL;RAMP1,,,PHASE 2,,,NA,,NCCCC[C@H](NC(=O)[C@@H](CC1CC(BR)C(O)C(BR)C1)NC(=O)N1CCC(CC1)N1CC2CCCCC2NC1=O)C(=O)N1CCN(CC1)C1CCNCC1
BIBR-1532,BIBR-1532,,BRD:BRD-BRD-K04623885-001-07-5;BRD:BRD-K04623885-001-07-5;CTRP:417982;GDSC2:2043,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,TELOMERASE INHIBITOR,TERT,,,PRECLINICAL,,,NA,,C\C(=C/C(=O)NC1CCCCC1C(O)=O)C1CCC2CCCCC2C1
BIBU-1361,BIBU-1361,,BRD:BRD-BRD-K49294207-300-03-8;BRD:BRD-K49294207-300-03-8,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,CCN(CC)CC1CCN(CC1)C1NCC2NCNC(NC3CCC(F)C(CL)C3)C2N1
BIBX-1382,BIBX-1382,CHEMBL258940,BRD:BRD-BRD-K70914287-300-02-8;BRD:BRD-K70914287-300-02-8,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2,,,PHASE 1,,Small molecule,Phase 1,FTFRZXFNZVCRSK-UHFFFAOYSA-N,CN1CCC(CC1)NC1NCC2NCNC(NC3CCC(F)C(CL)C3)C2N1;CN1CCC(NC2NCC3NCNC(NC4CCC(F)C(CL)C4)C3N2)CC1
BICALUTAMIDE,BICALUTAMIDE,CHEMBL409,BRD:BRD-A29485665-001-12-8;BRD:BRD-BRD-A29485665-001-12-8;GDSC1:150;GDSC1:1502,gdsc;rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,PROSTATE CANCER,,LAUNCHED,,Small molecule,Approved,LKJPYSCBVHEWIU-UHFFFAOYSA-N,CC(O)(CS(=O)(=O)C1CCC(F)CC1)C(=O)NC1CCC(C#N)C(C(F)(F)F)C1;CC(O)(CS(=O)(=O)C1CCC(F)CC1)C(=O)NC1CCC(C#N)C(C1)C(F)(F)F
BICIFADINE,BICIFADINE,CHEMBL511099,BRD:BRD-A24208517-003-01-8;BRD:BRD-BRD-A24208517-003-01-8,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST",DRD2;SLC6A2;SLC6A4,,,PHASE 3,"Multiple values for MOA: {'SEROTONIN RECEPTOR ANTAGONIST, DOPAMINE REUPTAKE INHIBITOR', 'DOPAMINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST'",Small molecule,Phase 3,OFYVIGTWSQPCLF-UHFFFAOYSA-N,CC1CCC(C23CNCC2C3)CC1;CC1CCC(CC1)C12CC1CNC2
BICTEGRAVIR,BICTEGRAVIR,CHEMBL3989866,BRD:BRD-K00003247-001-01-9,rep_single_dose,HIV INTEGRASE INHIBITOR,,,,,,Small molecule,Approved,SOLUWJRYJLAZCX-LYOVBCGYSA-N,O=C(NCC1C(F)CC(F)CC1F)C1CN2C(C(O)C1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2
BICUCULLINE-(+),BICUCULLINE-(+),,BRD:BRD-A07870296-001-07-4;BRD:BRD-BRD-A07870296-001-07-4,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;KCNN1,,,PRECLINICAL,,,NA,,CN1CCC2CC3OCOC3CC2C1[C@@H]1OC(=O)C2C1CCC1OCOC21
BICUCULLINE-METHOCHLORIDE-(-),BICUCULLINE-METHOCHLORIDE-(-),,BRD:BRD-A57798559-004-02-3;BRD:BRD-BRD-A57798559-004-02-3,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,C[N+]1(C)CCC2CC3OCOC3CC2C1[C@@H]1OC(=O)C2C1CCC1OCOC21
BICYCLOL,BICYCLOL,CHEMBL482035,BRD:BRD-BRD-K16546375-001-01-4;BRD:BRD-K16546375-001-01-4,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,HSPA1A;HSPB1,,,LAUNCHED,,Small molecule,Phase 3,KXMTXZACPVCDMH-UHFFFAOYSA-N,COC(=O)C1CC(OC)C2C(C1-C1C(CO)CC(OC)C3C1OCO3)OCO2;COC(=O)C1CC(OC)C2OCOC2C1-C1C2OCOC2C(OC)CC1CO
BIFEMELANE,BIFEMELANE,CHEMBL1192517,BRD:BRD-BRD-K18779551-003-07-8;BRD:BRD-K18779551-003-07-8,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RELEASE ENHANCER,MAOA;MAOB,"GLAUCOMA, SENILE DEMENTIA",,LAUNCHED,,Small molecule,Unknown,QSQQPMHPCBLLGX-UHFFFAOYSA-N,CNCCCCOC1CCCCC1CC1CCCCC1
BIFENDATE,BIFENDATE,CHEMBL105184,BRD:BRD-BRD-K26581543-001-01-6;BRD:BRD-K26581543-001-01-6,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Phase 1,JMZOMFYRADAWOG-UHFFFAOYSA-N,COC(=O)C1CC(OC)C2C(C1-C1C(C(=O)OC)CC(OC)C3C1OCO3)OCO2;COC(=O)C1CC(OC)C2OCOC2C1-C1C2OCOC2C(OC)CC1C(=O)OC
BIFONAZOLE,BIFONAZOLE,CHEMBL277535,BRD:BRD-A94543220-001-24-7;BRD:BRD-BRD-A94543220-001-24-7,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,CYP2B6,"TINEA PEDIS, TINEA CRURIS",,LAUNCHED,,Small molecule,Approved,OCAPBUJLXMYKEJ-UHFFFAOYSA-N,C1CCC(-C2CCC(C(C3CCCCC3)N3CCNC3)CC2)CC1;C1CN(CN1)C(C1CCCCC1)C1CCC(CC1)-C1CCCCC1
BIIB-057,BIIB-057,CHEMBL3545138,GDSC2:1631,gdsc,,,,,,,Small molecule,Phase 1,,
BIIB021,BIIB021,CHEMBL467399,BRD:BRD-BRD-K51967704-001-03-6;BRD:BRD-K51967704-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PHASE 2,,Small molecule,Phase 2,QULDDKSCVCJTPV-UHFFFAOYSA-N,COC1C(C)CNC(CN2CNC3C(CL)NC(N)NC23)C1C;COC1C(C)CNC(CN2CNC3C(CL)NC(N)NC32)C1C
BIIB068,BIIB068,CHEMBL4650450,BRD:BRD-K00091113-001-01-9,rep_single_dose,,,,,,,Unknown,Phase 1,,
BILASTINE,BILASTINE,CHEMBL1742423,BRD:BRD-BRD-K51937257-001-01-4;BRD:BRD-K51937257-001-01-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,ACCMWZWAEFYUGZ-UHFFFAOYSA-N,CCOCCN1C(C2CCN(CCC3CCC(C(C)(C)C(=O)O)CC3)CC2)NC2CCCCC21;CCOCCN1C(NC2CCCCC12)C1CCN(CCC2CCC(CC2)C(C)(C)C(O)=O)CC1
BILOBALIDE,BILOBALIDE,CHEMBL133266,BRD:BRD-A41714661-001-02-0;BRD:BRD-BRD-A41714661-001-02-0,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GLRA1;GLRA2;GLRB;HTR3A;HTR3B,,,PRECLINICAL,,Small molecule,NA,MOLPUWBMSBJXER-YKFMWRJQSA-N,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)C123;CC(C)(C)[C@]1(O)CC2OC(=O)CC23C(=O)OC2OC(=O)[C@H](O)C231
BIMATOPROST,BIMATOPROST,CHEMBL1200963,BRD:BRD-A45153512-001-01-0;BRD:BRD-BRD-A45153512-001-01-0,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,AKR1C3;PTGER1;PTGER3;PTGFR,"INTRAOCULAR PRESSURE, GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,,Small molecule,Approved,AQOKCDNYWBIDND-FTOWTWDKSA-N,CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O;CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCC1CCCCC1
BIMOSIAMOSE,BIMOSIAMOSE,CHEMBL1215923,BRD:BRD-K00077698-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,RYWCQJDEHXJHRI-XJMXIVSISA-N,O=C(O)CC1CCCC(-C2CC(CCCCCCC3CCC(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)C(-C4CCCC(CC(=O)O)C4)C3)CCC2O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)C1
BIMU-8,BIMU-8,,BRD:BRD-A62743154-003-01-5;BRD:BRD-BRD-A62743154-003-01-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR4,,,PRECLINICAL,,,NA,,CC(C)N1C2CCCCC2N(C(=O)NC2C[C@@H]3CC[C@H](C2)N3C)C1=O
BINA,BINA,,BRD:BRD-A13293292-001-02-6;BRD:BRD-BRD-A13293292-001-02-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM2,,,PRECLINICAL,,,NA,,CC1C2C(=O)C(CC2CC(OCC2CCCC(C2)-C2CCC(CC2)C(O)=O)C1C)C1CCCC1
BINDARIT,BINDARIT,CHEMBL2107549,BRD:BRD-BRD-K36467523-001-02-8;BRD:BRD-K36467523-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,CCL2;CCL7;CCL8,,,PHASE 2,,Small molecule,Phase 2,MTHORRSSURHQPZ-UHFFFAOYSA-N,CC(C)(OCC1NN(CC2CCCCC2)C2CCCCC12)C(=O)O;CC(C)(OCC1NN(CC2CCCCC2)C2CCCCC12)C(O)=O
BIO-1211,BIO-1211,,BRD:BRD-BRD-K03399463-001-01-6;BRD:BRD-K03399463-001-01-6,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGA4;ITGB1,,,PHASE 2,,,NA,,CC(C)C[C@H](NC(=O)CC1CCC(NC(=O)NC2CCCCC2C)CC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O
BIO-5192,BIO-5192,,BRD:BRD-BRD-K21318844-001-01-4;BRD:BRD-K21318844-001-01-4,rep_primary;rep_single_dose,INTEGRIN INHIBITOR,ITGA4;ITGB1,,,PRECLINICAL,,,NA,,CC(C)C[C@H](N(C)C(=O)CC1CCC(NC(=O)NC2CCCCC2C)CC1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)C1CC(CL)CC(CL)C1)C(O)=O
BIOTIN,BIOTIN,CHEMBL857,BRD:BRD-BRD-K89210380-001-13-7;BRD:BRD-K89210380-001-13-7,rep_primary;rep_single_dose,VITAMIN B,ACACA;ACACB;HLCS;MCCC1;MCCC2;PC;PCCA;PCCB;SLC5A6,,,LAUNCHED,,Small molecule,Approved,YBJHBAHKTGYVGT-ZKWXMUAHSA-N,O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21;OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12
BIPENAMOL,BIPENAMOL,CHEMBL310160,BRD:BRD-BRD-K47690382-001-03-0;BRD:BRD-K47690382-001-03-0,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,CTSC,,,PHASE 2,,Small molecule,Unknown,HLAFSNJRKZLMPT-UHFFFAOYSA-N,NCC1CCCCC1SC1CCCCC1CO
BIPERIDEN,BIPERIDEN,CHEMBL1101,BRD:BRD-A00546892-001-02-6;BRD:BRD-BRD-A00546892-001-02-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;CHRNA2,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,YSXKPIUOCJLQIE-UHFFFAOYSA-N,OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1CCCCC1;OC(CCN1CCCCC1)(C1CCCCC1)C1CC2C=CC1C2
BIRABRESIB,BIRABRESIB,CHEMBL3581647,GDSC2:1626,gdsc,,,,,,,Small molecule,Phase 2,GNMUEVRJHCWKTO-FQEVSTJZSA-N,CC1SC2C(C1C)C(C1CCC(CL)CC1)=N[C@@H](CC(=O)NC1CCC(O)CC1)C1NNC(C)N1-2
BIRB 796,BIRB 796,,GDSC1:1042;GDSC2:1042,gdsc,,,,,,,,NA,,
BIRB-796,BIRB-796,CHEMBL103667,CTRP:660412;GDSC1:1042;GDSC2:1042,ctrp;gdsc,,,,,,,Small molecule,Phase 2,MVCOAUNKQVWQHZ-UHFFFAOYSA-N,CC1CCC(-N2NC(C(C)(C)C)CC2NC(=O)NC2CCC(OCCN3CCOCC3)C3CCCCC23)CC1
BIRINAPANT,BIRINAPANT,CHEMBL3039522,BRD:BRD-BRD-K71221037-001-01-6;BRD:BRD-K71221037-001-01-6;CTRP:660778,ctrp;rep_multi_dose;rep_primary;rep_single_dose,XIAP INHIBITOR,BIRC2;XIAP,,,PHASE 2,,Small molecule,Phase 2,PKWRMUKBEYJEIX-DXXQBUJASA-N,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1C(-C2[NH]C3CC(F)CCC3C2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[NH]C2CC(F)CCC12;CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1C([NH]C2CC(F)CCC12)-C1[NH]C2CC(F)CCC2C1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC
BIRT-377,BIRT-377,,BRD:BRD-BRD-K64880136-001-02-6;BRD:BRD-K64880136-001-02-6,rep_primary;rep_single_dose,LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN NEGATIVE MODULATOR,ICAM1,,,PRECLINICAL,,,NA,,CN1C(=O)N(C(=O)[C@@]1(C)CC1CCC(BR)CC1)C1CC(CL)CC(CL)C1
BIS(MALTOLATO)OXOVANADIUM(IV),BIS(MALTOLATO)OXOVANADIUM(IV),CHEMBL286447,BRD:BRD-BRD-K16180792-001-01-7;BRD:BRD-K16180792-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE PHOSPHATASE INHIBITOR,PTPN1,,,PHASE 2,,Small molecule,NA,,CC1OCCC(=O)C1O[V](=O)OC1C(C)OCCC1=O
BISACODYL,BISACODYL,CHEMBL942,BRD:BRD-BRD-K39987650-001-24-1;BRD:BRD-K39987650-001-24-1,rep_multi_dose;rep_primary;rep_single_dose,LAXATIVE,,CONSTIPATION,,LAUNCHED,,Small molecule,Approved,KHOITXIGCFIULA-UHFFFAOYSA-N,CC(=O)OC1CCC(C(C2CCC(OC(C)=O)CC2)C2CCCCN2)CC1;CC(=O)OC1CCC(CC1)C(C1CCC(OC(C)=O)CC1)C1CCCCN1
BISANTRENE,BISANTRENE,CHEMBL139554;CHEMBL25336,BRD:BRD-K00003395-001-01-9,rep_single_dose,TOPOISOMERASE INHIBITOR,,,,,,Small molecule,Phase 3,NJSMWLQOCQIOPE-JEGUCOMDSA-N;NJSMWLQOCQIOPE-OCHFTUDZSA-N,C(=N/NC1=NCCN1)\C1C2CCCCC2C(/C=N/NC2=NCCN2)C2CCCCC12;C(=N\NC1=NCCN1)\C1C2CCCCC2C(/C=N\NC2=NCCN2)C2CCCCC12
BISINDOLYLMALEIMIDE-IX,BISINDOLYLMALEIMIDE-IX,,BRD:BRD-BRD-K06543683-066-02-1;BRD:BRD-K06543683-066-02-1,rep_multi_dose;rep_primary;rep_single_dose,PKC INHIBITOR,AKT1;GSK3B;LCK;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;PRKCA;ROCK1;RPS6KB1;SIRT1,,,PRECLINICAL,,,NA,,CN1CC(C2=C(C(=O)NC2=O)C2CN(CCCSC(N)=N)C3CCCCC23)C2CCCCC12
BISMUTH(III)-TRIFLUOROMETHANESULFONATE,BISMUTH(III)-TRIFLUOROMETHANESULFONATE,,BRD:BRD-BRD-M56276249-001-01-1;BRD:BRD-M56276249-001-01-1,rep_primary;rep_single_dose,DIRECT SUBSTITUTION CATALYST,,,,PRECLINICAL,,,NA,,[BI].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F
BISMUTH-OXALATE,BISMUTH-OXALATE,,BRD:BRD-BRD-M02179497-001-01-1;BRD:BRD-M02179497-001-01-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,[BI].[BI].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O
BISMUTH-SUBCITRATE-POTASSIUM,BISMUTH-SUBCITRATE-POTASSIUM,,BRD:BRD-A03880619-001-01-0;BRD:BRD-BRD-A03880619-001-01-0,rep_primary;rep_single_dose,,,DUODENAL ULCER DISEASE,,LAUNCHED,,,NA,,OC(=O)CC(O)(CC(=O)O[BI]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O
BISMUTH-SUBSALICYLATE,BISMUTH-SUBSALICYLATE,,BRD:BRD-K80528473-001-03-0,rep_single_dose,ANTACID,,,,,,,NA,,
BISOPROLOL,BISOPROLOL,CHEMBL645,BRD:BRD-A89175223-051-14-8;BRD:BRD-BRD-A89175223-051-14-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,VHYCDWMUTMEGQY-UHFFFAOYSA-N,CC(C)NCC(O)COC1CCC(COCCOC(C)C)CC1
BISPHENOL-A,BISPHENOL-A,,BRD:BRD-BRD-K41494493-001-13-8;BRD:BRD-K41494493-001-13-8,rep_primary;rep_single_dose,SYNTHETIC ESTROGEN,AR;ESR1;ESR2;ESRRG;PPARG,,,PHASE 1,,,NA,,CC(C)(C1CCC(O)CC1)C1CCC(O)CC1
BITHIONOL,BITHIONOL,CHEMBL290106,BRD:BRD-BRD-K39120595-304-04-7;BRD:BRD-K39120595-304-04-7,rep_primary;rep_single_dose,AUTOTAXIN INHIBITOR,ESR1;ESR2;MCL1,,,WITHDRAWN,,Small molecule,Approved,JFIOVJDNOJYLKP-UHFFFAOYSA-N,OC1C(CL)CC(CL)CC1SC1CC(CL)CC(CL)C1O
BITOPERTIN,BITOPERTIN,CHEMBL1169880;CHEMBL1171829,BRD:BRD-BRD-K13756951-001-01-4;BRD:BRD-K13756951-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,"GLYCINE TRANSPORTER INHIBITOR, GLYT-1 INHIBITOR",SLC6A5;SLC6A9,,,PHASE 3,,Small molecule,Phase 3,YUUGYIUSCYNSQR-GFCCVEGCSA-N;YUUGYIUSCYNSQR-LBPRGKRZSA-N,C[C@@H](OC1CCC(S(C)(=O)=O)CC1C(=O)N1CCN(C2NCC(C(F)(F)F)CC2F)CC1)C(F)(F)F;C[C@H](OC1CCC(CC1C(=O)N1CCN(CC1)C1NCC(CC1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F;C[C@H](OC1CCC(S(C)(=O)=O)CC1C(=O)N1CCN(C2NCC(C(F)(F)F)CC2F)CC1)C(F)(F)F
BIVALIRUDIN,BIVALIRUDIN,CHEMBL2103749,BRD:BRD-BRD-K73504359-001-01-3;BRD:BRD-K73504359-001-01-3,rep_primary;rep_single_dose,THROMBIN INHIBITOR,F2,ANGINA PECTORIS,,LAUNCHED,,Protein,Approved,OIRCOABEOLEUMC-GEJPAHFPSA-N,[2H]N[C@@H](CC1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1CCC(O)CC1)C(=O)N[C@@H](CC(C)C)C(O)=O;CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCC(O)CC1)C(=O)N[C@@H](CC(C)C)C(=O)O;CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1CCC(O)CC1)C(=O)N[C@@H](CC(C)C)C(O)=O
BIX 02189,BIX 02189,,GDSC1:279,gdsc,,,,,,,,NA,,
BIX-01294,BIX-01294,,BRD:BRD-BRD-K26818574-305-04-3;BRD:BRD-BRD-K26818574-305-07-6;BRD:BRD-K26818574-305-04-3;BRD:BRD-K26818574-305-07-6;CTRP:53705,ctrp;rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT1;EHMT2,,,PRECLINICAL,,,NA,,COC1CC2NC(NC(NC3CCN(CC4CCCCC4)CC3)C2CC1OC)N1CCCN(C)CC1
BIX-02188,BIX-02188,,BRD:BRD-BRD-K20290250-001-01-3;BRD:BRD-BRD-K20290250-001-02-1;BRD:BRD-K20290250-001-01-3;BRD:BRD-K20290250-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K5,,,PRECLINICAL,,,NA,,CN(C)CC1CCCC(N\C(C2CCCCC2)=C2/C(=O)NC3CC(CCC23)C(N)=O)C1
BIX-02189,BIX-02189,,BRD:BRD-BRD-K73368362-001-07-5;BRD:BRD-K73368362-001-07-5,rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K5;MAPK7,,,PRECLINICAL,,,NA,,CN(C)CC1CCCC(N\C(C2CCCCC2)=C2/C(=O)NC3CC(CCC23)C(=O)N(C)C)C1
BIX02189,BIX02189,,GDSC1:279,gdsc,,,,,,,,NA,,
BIX02565,BIX02565,,BRD:BRD-K00126783-001-01-9,oncref_2,INHIBITOR OF RSK2,ADRA1A;ADRA1B;ADRA2A;ADRB2;LRRK2;NISCH;PRKD1;RSK1;RSK2;RSK3,,,,,,NA,,
BKM120,BKM120,,GDSC2:1873,gdsc,,,,,,,,NA,,
BL-5583,BL-5583,,BRD:BRD-BRD-K75282704-001-02-4;BRD:BRD-K75282704-001-02-4,rep_primary;rep_single_dose,HYPERCALCAEMIC AGENT,,,,PRECLINICAL,,,NA,,OC(=O)C1CC2CCCCC2S1
BLEBBISTATIN,BLEBBISTATIN,,CTRP:50140,ctrp,,,,,,,,NA,,
BLEBBISTATIN-(+/-),BLEBBISTATIN-(+/-),,BRD:BRD-A75817871-001-06-7;BRD:BRD-BRD-A75817871-001-06-7,rep_primary;rep_single_dose,ATPASE INHIBITOR,MYH14;MYH2,,,PRECLINICAL,"Multiple values for repurposing_target: {'MYH14;MYH2', 'MYH2'}, taking the union",,NA,,CC1CCC2N=C3N(CCC3(O)C(=O)C2C1)C1CCCCC1
BLEBBISTATIN-(-),BLEBBISTATIN-(-),,BRD:BRD-BRD-K61295575-001-03-6;BRD:BRD-K61295575-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,,,,PRECLINICAL,,,NA,,CC1CCC2N=C3N(CC[C@@]3(O)C(=O)C2C1)C1CCCCC1
BLEOMYCIN,BLEOMYCIN,CHEMBL403664,GDSC1:190,gdsc,,,,,,,Small molecule,Approved,OYVAGSVQBOHSSS-UAPAGMARSA-O,CC1C(N)NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)NC1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCC1NC(-C2NC(C(=O)NCCC[S+](C)C)CS2)CS1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)C1C[NH]CN1
BLEOMYCIN (50 UM),BLEOMYCIN (50 UM),,GDSC1:1378,gdsc,,,,,,,,NA,,
BLEOMYCIN A2,BLEOMYCIN A2,,CTRP:639531,ctrp,,,,,,,,NA,,
BLONANSERIN,BLONANSERIN,CHEMBL178803,BRD:BRD-BRD-K25943794-001-02-3;BRD:BRD-K25943794-001-02-3,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",DRD2;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Phase 3,XVGOZDAJGBALKS-UHFFFAOYSA-N,CCN1CCN(C2CC(-C3CCC(F)CC3)C3C(N2)CCCCCC3)CC1;CCN1CCN(CC1)C1CC(-C2CCC(F)CC2)C2CCCCCCC2N1
BLU9931,BLU9931,,BRD:BRD-K72898849-001-01-8,rep_single_dose,FGFR INHIBITOR,FGFR4,,,,,,NA,,
BLZ945,BLZ945,CHEMBL4227505,BRD:BRD-K83157152-001-02-9,rep_single_dose,CSF1R INHIBITOR,,,,,,Small molecule,Phase 2,ADZBMFGQQWPHMJ-RHSMWYFYSA-N,CNC(=O)C1CC(OC2CCC3NC(N[C@@H]4CCCC[C@H]4O)SC3C2)CCN1
BML-190,BML-190,,BRD:BRD-BRD-K94379058-001-06-8;BRD:BRD-K94379058-001-06-8,rep_primary;rep_single_dose,CANNABINOID RECEPTOR INVERSE AGONIST,CNR2,,,PRECLINICAL,,,NA,,COC1CCC2N(C(=O)C3CCC(CL)CC3)C(C)C(CC(=O)N3CCOCC3)C2C1
BML-284,BML-284,,BRD:BRD-BRD-K42624714-001-04-1;BRD:BRD-K42624714-001-04-1,rep_primary;rep_single_dose,WNT AGONIST,,,,PRECLINICAL,,,NA,,COC1CCCC(C1)-C1CC(NCC2CCC3OCOC3C2)NC(N)N1
BMN 973,BMN 973,,GDSC1:1259;GDSC2:1259,gdsc,,,,,,,,NA,,
BMN-673,BMN-673,CHEMBL3137320,GDSC1:1259;GDSC2:1259,gdsc,,,,,,,Small molecule,Approved,HWGQMRYQVZSGDQ-HZPDHXFCSA-N,CN1NCNC1[C@H]1C2N[NH]C(=O)C3CC(F)CC(C23)N[C@@H]1C1CCC(F)CC1
BMS 536924,BMS 536924,,GDSC1:1091;GDSC1:62;GDSC2:1091,gdsc,,,,,,,,NA,,
BMS 708163,BMS 708163,CHEMBL1090771,GDSC1:1072;GDSC1:205,gdsc,,,,,,,Small molecule,Phase 2,XEAOPVUAMONVLA-QGZVFWFLSA-N,NC(=O)[C@@H](CCC(F)(F)F)N(CC1CCC(-C2NCON2)CC1F)S(=O)(=O)C1CCC(CL)CC1
BMS 754807,BMS 754807,CHEMBL575448,GDSC1:184,gdsc,,,,,,,Small molecule,Phase 2,LQVXSNNAFNGRAH-QHCPKHFHSA-N,C[C@@]1(C(=O)NC2CCC(F)NC2)CCCN1C1NC(NC2CC(C3CC3)N[NH]2)C2CCCN2N1
BMS-181339-01,BMS-181339-01,CHEMBL428647,GDSC1:11;GDSC2:1080,gdsc,,,,,,,Small molecule,Approved,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)C3CCCCC3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4CCCCC4)C4CCCCC4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
BMS-182874,BMS-182874,CHEMBL267458,BRD:BRD-K56509348-003-04-9,rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,,,Small molecule,NA,MJRGSRRZKSJHOE-UHFFFAOYSA-N,CC1NOC(NS(=O)(=O)C2CCCC3C(N(C)C)CCCC23)C1C
BMS-191011,BMS-191011,,BRD:BRD-BRD-K95609758-001-03-7;BRD:BRD-K95609758-001-03-7,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNMA1,,,PRECLINICAL,,,NA,,OC1CCC(CL)CC1CN1NC(OC1=O)-C1CCC(CC1)C(F)(F)F
BMS-191095,BMS-191095,CHEMBL11594,BRD:BRD-BRD-K01231377-001-01-8;BRD:BRD-K01231377-001-01-8,rep_primary;rep_single_dose,"KATP ACTIVATOR, POTASSIUM CHANNEL AGONIST",,,,PHASE 1,,Small molecule,NA,SMIKIPXIDLITMP-LEWJYISDSA-N,CC1(C)OC2CCC(C#N)CC2[C@H](N(CC2NCC[NH]2)C2CCC(CL)CC2)[C@H]1O;CC1(C)OC2CCC(CC2[C@@H]([C@H]1O)N(CC1NCC[NH]1)C1CCC(CL)CC1)C#N
BMS-195614,BMS-195614,,CTRP:660228,ctrp,,,,,,,,NA,,
BMS-207940,BMS-207940,,BRD:BRD-K00004634-001-01-9,rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,,,,,,,NA,,
BMS-214662,BMS-214662,CHEMBL351706,BRD:BRD-K00003203-001-01-9,rep_single_dose,FARNESYLTRANSFERASE INHIBITOR,,,,,,Small molecule,Phase 1,OLCWFLWEHWLBTO-HSZRJFAPSA-N,N#CC1CCC2C(C1)CN(S(=O)(=O)C1CCCS1)[C@H](CC1CCCCC1)CN2CC1C[NH]CN1
BMS-265246,BMS-265246,,BRD:BRD-BRD-K62814476-001-03-3;BRD:BRD-K62814476-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2,,,PRECLINICAL,,,NA,,CCCCOC1C(CNC2[NH]NCC12)C(=O)C1C(F)CC(C)CC1F
BMS-270394,BMS-270394,,CTRP:660321,ctrp,,,,,,,,NA,,
BMS-299897,BMS-299897,,BRD:BRD-BRD-K02950022-001-02-9;BRD:BRD-K02950022-001-02-9,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,PHASE 1,,,NA,,C[C@@H](N(C1CC(F)CCC1F)S(=O)(=O)C1CCC(CL)CC1)C1CCC(F)CC1CCCC(O)=O
BMS-309403,BMS-309403,,BRD:BRD-BRD-K87956243-001-01-9;BRD:BRD-K87956243-001-01-9,rep_primary;rep_single_dose,FATTY ACID BINDING PROTEIN INHIBITOR,FABP4,,,PRECLINICAL,,,NA,,CCC1C(C(NN1-C1CCCCC1-C1CCCC(OCC(O)=O)C1)-C1CCCCC1)-C1CCCCC1
BMS-345541,BMS-345541,CHEMBL249697,BRD:BRD-BRD-K13566078-001-02-3;BRD:BRD-K13566078-001-02-3;CTRP:622911;GDSC1:203;GDSC2:1249,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,IKK INHIBITOR,CHUK;IKBKB,,,PRECLINICAL,,Small molecule,NA,PSPFQEBFYXJZEV-UHFFFAOYSA-N,CC1CCC2NC(NCCN)C3NCC(C)N3C2C1;CC1CNC2C(NCCN)NC3CCC(C)CC3N12
BMS-354825,BMS-354825,CHEMBL1421,GDSC1:51;GDSC2:1079,gdsc,,,,,,,Small molecule,Approved,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,CC1NC(NC2NCC(C(=O)NC3C(C)CCCC3CL)S2)CC(N2CCN(CCO)CC2)N1
BMS-354825-03,BMS-354825-03,CHEMBL1421,GDSC1:51;GDSC2:1079,gdsc,,,,,,,Small molecule,Approved,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,CC1NC(NC2NCC(C(=O)NC3C(C)CCCC3CL)S2)CC(N2CCN(CCO)CC2)N1
BMS-387032,BMS-387032,CHEMBL296468,BRD:BRD-BRD-K43389698-001-09-9;BRD:BRD-K43389698-001-09-9,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, CELL CYCLE INHIBITOR, MCL1 INHIBITOR",CDK2;CDK7;CDK9,,,PHASE 1,,Small molecule,Phase 1,OUSFTKFNBAZUKL-UHFFFAOYSA-N,CC(C)(C)C1CNC(CSC2CNC(NC(=O)C3CCNCC3)S2)O1
BMS-470539,BMS-470539,,BRD:BRD-K22000702-300-02-9,rep_single_dose,MELANOCORTIN RECEPTOR AGONIST,MC1R,,,,,,NA,,
BMS-509744,BMS-509744,,GDSC1:63,gdsc,,,,,,,,NA,,
BMS-536924,BMS-536924,,BRD:BRD-K34581968-001-04-6;CTRP:411859;GDSC1:1091;GDSC1:62;GDSC2:1091,ctrp;gdsc;rep_single_dose,IGF-1 INHIBITOR,AKT1;CCNE1;CDK2;CYP3A4;ERBB2;IGF1R;KDR;LCK;MAPK1;MET;PDGFRA;PDGFRB,,,,,,NA,,
BMS-566419,BMS-566419,,BRD:BRD-K56932272-001-02-9,rep_single_dose,INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR,IMPDH1;IMPDH2,,,,,,NA,,
BMS-582949,BMS-582949,CHEMBL1230065,BRD:BRD-K00003168-003-01-9,rep_single_dose,P38 MAPK INHIBITOR,,,,,,Small molecule,Phase 2,GDTQLZHHDRRBEB-UHFFFAOYSA-N,CCCNC(=O)C1CN2NCNC(NC3CC(C(=O)NC4CC4)CCC3C)C2C1C
BMS-587101,BMS-587101,,BRD:BRD-BRD-K20093108-001-02-3;BRD:BRD-K20093108-001-02-3,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGAL;ITGB2,,,PHASE 2,,,NA,,CN1C(=O)N(C(=O)[C@]11CN(CC2CC(CS2)C(O)=O)C[C@H]1C1CCC(CC1)C#N)C1CC(CL)CC(CL)C1
BMS-599626,BMS-599626,CHEMBL1645462,BRD:BRD-BRD-K07106112-003-03-8;BRD:BRD-K07106112-003-03-8,rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, PROTEIN TYROSINE KINASE INHIBITOR",EGFR;ERBB2;ERBB4,,,PHASE 1,,Small molecule,Phase 1,LUJZZYWHBDHDQX-QFIPXVFZSA-N,CC1C(NC(=O)OC[C@@H]2COCCN2)CN2NCNC(NC3CCC4C(CNN4CC4CCCC(F)C4)C3)C12;CC1C(NC(=O)OC[C@@H]2COCCN2)CN2NCNC(NC3CCC4N(CC5CCCC(F)C5)NCC4C3)C12
BMS-626529,BMS-626529,CHEMBL3301620,BRD:BRD-BRD-K97883416-001-01-4;BRD:BRD-K97883416-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,HIV ATTACHMENT INHIBITOR,,,,PHASE 3,,Small molecule,Phase 1,QRPZBKAMSFHVRW-UHFFFAOYSA-N,COC1CNC(-N2CNC(C)N2)C2[NH]CC(C(=O)C(=O)N3CCN(C(=O)C4CCCCC4)CC3)C12;COC1CNC(-N2CNC(C)N2)C2[NH]CC(C(=O)C(=O)N3CCN(CC3)C(=O)C3CCCCC3)C12
BMS-626531,BMS-626531,,BRD:BRD-K00004550-001-01-9,rep_single_dose,P38 MAPK INHIBITOR,,,,,,,NA,,
BMS-649,BMS-649,,BRD:BRD-BRD-K25991633-001-01-9;BRD:BRD-K25991633-001-01-9,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RXRA,,,PRECLINICAL,,,NA,,CC1(C)CCC(C)(C)C2CC(CCC12)C1(OCCO1)C1CCC(CC1)C(O)=O
BMS-688521,BMS-688521,,BRD:BRD-BRD-K85649978-001-02-1;BRD:BRD-K85649978-001-02-1,rep_primary;rep_single_dose,"LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN RECEPTOR ANTAGONIST, ICAM1 ANTAGONIST",ICAM1,,,PRECLINICAL,"Multiple values for MOA: {'ICAM1 ANTAGONIST, LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN RECEPTOR ANTAGONIST', 'LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN RECEPTOR ANTAGONIST, ICAM1 ANTAGONIST'}, defaulting to 'LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN RECEPTOR ANTAGONIST, ICAM1 ANTAGONIST'",,NA,,CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1C1CCC(CC1)C#N)C1CCC(CN1)C(O)=O)C1CC(CL)CC(CL)C1
BMS-690514,BMS-690514,CHEMBL3545396,BRD:BRD-BRD-K76239644-001-01-8;BRD:BRD-K76239644-001-01-8;BRD:BRD-K76239644-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, VEGFR INHIBITOR",EGFR;ERBB2;FLT3;KDR,,,PHASE 2,,Small molecule,Phase 2,CSGQVNMSRKWUSH-IAGOWNOFSA-N,COC1CCCC(NC2NCNN3CCC(CN4CC[C@@H](N)[C@H](O)C4)C23)C1
BMS-707035,BMS-707035,CHEMBL486226,BRD:BRD-BRD-K49555808-001-03-9;BRD:BRD-K49555808-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,VNIWZCGZPBJWBI-UHFFFAOYSA-N,CN1C(N2CCCCS2(=O)=O)NC(C(=O)NCC2CCC(F)CC2)C(O)C1=O;CN1C(NC(C(=O)NCC2CCC(F)CC2)C(O)C1=O)N1CCCCS1(=O)=O
BMS-708163,BMS-708163,CHEMBL1090771,GDSC1:1072;GDSC1:205,gdsc,,,,,,,Small molecule,Phase 2,XEAOPVUAMONVLA-QGZVFWFLSA-N,NC(=O)[C@@H](CCC(F)(F)F)N(CC1CCC(-C2NCON2)CC1F)S(=O)(=O)C1CCC(CL)CC1
BMS-722782,BMS-722782,CHEMBL109480,GDSC1:1026,gdsc,,,,,,,Small molecule,Phase 3,AYUNIORJHRXIBJ-TXHRRWQRSA-N,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O
BMS-754807,BMS-754807,CHEMBL575448,BRD:BRD-BRD-K13049116-001-05-7;BRD:BRD-K13049116-001-04-0;BRD:BRD-K13049116-001-05-7;CTRP:417981;GDSC1:184;GDSC2:2171,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF IGF1R AND INSR,AKT1;IGF1R;INSR,,,PHASE 2,"Multiple values for MOA: {'IGF-1 INHIBITOR', 'INHIBITOR OF IGF1R AND INSR'}, defaulting to 'INHIBITOR OF IGF1R AND INSR'
Multiple values for repurposing_target: {'IGF1R;INSR', 'AKT1;IGF1R'}, taking the union",Small molecule,Phase 2,LQVXSNNAFNGRAH-QHCPKHFHSA-N,C[C@]1(CCCN1C1NC(NC2CC(N[NH]2)C2CC2)C2CCCN2N1)C(=O)NC1CCC(F)NC1;C[C@@]1(C(=O)NC2CCC(F)NC2)CCCN1C1NC(NC2CC(C3CC3)N[NH]2)C2CCCN2N1
BMS-770767,BMS-770767,CHEMBL4802167,BRD:BRD-K00004655-001-01-9,rep_single_dose,11-BETA-HSD1 INHIBITOR,,,,,,Unknown,Phase 2,,
BMS-777607,BMS-777607,CHEMBL460702,BRD:BRD-BRD-K40738845-001-05-0;BRD:BRD-K40738845-001-05-0,rep_primary;rep_single_dose,"AXL KINASE INHIBITOR, C-MET INHIBITOR, FLT3 INHIBITOR, HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR, MACROPHAGE MIGRATION INHIBITING FACTOR INHIBITOR, TYROSINE KINASE INHIBITOR",AXL;MERTK;MET;MST1R;TYRO3,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,VNBRGSXVFBYQNN-UHFFFAOYSA-N,CCOC1CCN(-C2CCC(F)CC2)C(=O)C1C(=O)NC1CCC(OC2CCNC(N)C2CL)C(F)C1
BMS-779788,BMS-779788,CHEMBL3545418,BRD:BRD-K00003305-001-01-9,rep_single_dose,LXR AGONIST,,,,,,Small molecule,Phase 1,,
BMS-806,BMS-806,,BRD:BRD-BRD-K55773932-001-02-0;BRD:BRD-K55773932-001-02-0,rep_primary;rep_single_dose,HIV ATTACHMENT INHIBITOR,,,,PHASE 1,,,NA,,COC1CC[NH]C2NCC(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)C3CCCCC3)C12
BMS-813160,BMS-813160,CHEMBL4594419,BRD:BRD-K00003512-001-01-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,CMVHFGNTABZQJU-HCXYKTFWSA-N,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](NC2NCNC3CC(C(C)(C)C)NN23)C1=O
BMS-817378,BMS-817378,CHEMBL3545050,BRD:BRD-BRD-K81026553-234-01-8;BRD:BRD-K81026553-234-01-8,rep_primary;rep_single_dose,"C-MET INHIBITOR, VEGFR INHIBITOR",KDR;MET,,,PHASE 1,,Small molecule,Phase 1,,NC1NCCC(OC2CCC(NC(=O)C3CN(COP(O)(O)=O)CC(-C4CCC(F)CC4)C3=O)CC2F)C1CL
BMS-833923,BMS-833923,CHEMBL3545403,BRD:BRD-BRD-K33245965-001-03-4;BRD:BRD-K33245965-001-03-4,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,SMO,,,PHASE 2,,Small molecule,Phase 2,KLRRGBHZCJLIEL-UHFFFAOYSA-N,CNCC1CCC(C)C(NC(=O)C2CCC(NC3NC(-C4CCCCC4)C4CCCCC4N3)CC2)C1
BMS-863233,BMS-863233,CHEMBL3544943;CHEMBL3544944,BRD:BRD-BRD-K12511835-003-02-0;BRD:BRD-K12511835-003-02-0,rep_primary;rep_single_dose,CDC INHIBITOR,CDC7;PIM1,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,JJWLXRKVUJDJKG-UHFFFAOYSA-N;UNDKJUKLBNARIZ-UHFFFAOYSA-N,CL.O=C1[NH]C(C2CCCN2)NC2C1OC1CCC(CL)CC12;CLC1CCC2OC3C(NC([NH]C3=O)[C@@H]3CCCN3)C2C1;O=C1[NH]C(C2CCCN2)NC2C1OC1CCC(CL)CC12
BMS-906024,BMS-906024,CHEMBL4297269,BRD:BRD-K29343434-001-02-9,rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,,,Small molecule,Phase 2,AYOUDDAETNMCBW-GSHUGGBRSA-N,CN1C(=O)[C@@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)N=C(C2CCCCC2)C2CCCCC21
BMS-907351,BMS-907351,CHEMBL2103868;CHEMBL2105717,GDSC1:249,gdsc,,,,,,,Small molecule,Approved,HFCFMRYTXDINDK-WNQIDUERSA-N;ONIQOQHATWINJY-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC;COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC.O=C(O)C[C@H](O)C(=O)O
BMS-911543,BMS-911543,CHEMBL3545215,BRD:BRD-K00003189-001-01-9,rep_single_dose,JAK INHIBITOR,,,,,,Small molecule,Phase 2,JCINBYQJBYJGDM-UHFFFAOYSA-N,CCN1C(C(=O)N(C2CC2)C2CC2)CC2C3C(NCN3C)C(NC3CC(C)N(C)N3)NC21
RIMEGEPANT,BMS-927711;RIMEGEPANT,CHEMBL2178422,BRD:BRD-BRD-K55781385-001-01-7;BRD:BRD-K55781385-001-01-7,rep_primary;rep_single_dose,CALCITONIN ANTAGONIST,CALCA,,,PHASE 2,,Small molecule,Approved,KRNAOFGYEFKHPB-ANJVHQHFSA-N,N[C@@H]1C2CCCNC2[C@H](OC(=O)N2CCC(N3C(=O)[NH]C4NCCCC43)CC2)CC[C@H]1C1CCCC(F)C1F;N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C3CCCNC3[NH]C2=O)C2NCCCC12)C1CCCC(F)C1F
BMS-935177,BMS-935177,,BRD:BRD-K00004721-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,,NA,,
BMS-983970,BMS-983970,,BRD:BRD-BRD-K22316123-001-01-9;BRD:BRD-K22316123-001-01-9,rep_primary;rep_single_dose,NOTCH SIGNALING INHIBITOR,,,,PHASE 1,,,NA,,NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(C2CCCCC2)C2CCCC(F)C2NC1=O
BMS-986020,BMS-986020,CHEMBL4297270,BRD:BRD-BRD-K23952234-236-01-8;BRD:BRD-K00004586-001-01-9,rep_primary;rep_single_dose,LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST,LPAR1,,,PHASE 2,,Small molecule,Phase 2,GQBRZBHEPUQRPL-LJQANCHMSA-N,C[C@@H](OC(=O)NC1C(C)NOC1-C1CCC(CC1)-C1CCC(CC(O)=O)CC1)C1CCCCC1;CC1NOC(-C2CCC(-C3CCC(C4(C(=O)O)CC4)CC3)CC2)C1NC(=O)O[C@H](C)C1CCCCC1
BMS-986142,BMS-986142,CHEMBL3900554,BRD:BRD-K00004591-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Phase 2,ZRYMMWAJAFUANM-INIZCTEOSA-N,CC1C(-C2C(F)CC(C(N)=O)C3[NH]C4C(C23)CC[C@H](C(C)(C)O)C4)CCCC1-N1C(=O)C2CCCC(F)C2N(C)C1=O
BMS-986158,BMS-986158,CHEMBL4297458,BRD:BRD-K00003423-001-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,Small molecule,Phase 1,KGERZPVQIRYWRK-GDLZYMKVSA-N,CC1NNN(C)C1-C1CNC2C3CCC(C(C)(C)O)CC3N([C@H](C3CCCCC3)C3CCOCC3)C2C1
BMS-986165,BMS-986165,CHEMBL4435170,BRD:BRD-K00091094-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,BZZKEPGENYLQSC-FIBGUPNXSA-N,[2H]C([2H])([2H])NC(=O)C1NNC(NC(=O)C2CC2)CC1NC1CCCC(-C2NCN(C)N2)C1OC
BMS-986195,BMS-986195,CHEMBL4297674,BRD:BRD-K00003110-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Phase 2,VJPPLCNBDLZIFG-ZDUSSCGKSA-N,CC#CC(=O)N[C@H]1CCCN(C2C(F)CC(C(N)=O)C3[NH]C(C)C(C)C23)C1
BMS-986205,BMS-986205,CHEMBL4297598,BRD:BRD-K00003418-001-01-9,rep_single_dose,"INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",,,,,,Small molecule,Phase 3,KRTIYQIPSAGSBP-KLAILNCOSA-N,C[C@@H](C(=O)NC1CCC(CL)CC1)C1CCC(C2CCNC3CCC(F)CC23)CC1
BMS-CCR2-22,BMS-CCR2-22,,BRD:BRD-BRD-K15119094-001-01-1;BRD:BRD-K15119094-001-01-1,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR2,,,PRECLINICAL,,,NA,,CSC1CCC(CC1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)C1CC(CCC1NC(=O)NC(C)C)C(F)(F)F
BMS345541,BMS345541,,GDSC1:203,gdsc,,,,,,,,NA,,
BMS754807,BMS754807,CHEMBL575448,GDSC1:184,gdsc,,,,,,,Small molecule,Phase 2,LQVXSNNAFNGRAH-QHCPKHFHSA-N,C[C@@]1(C(=O)NC2CCC(F)NC2)CCCN1C1NC(NC2CC(C3CC3)N[NH]2)C2CCCN2N1
XL184,BMS907351;CABOZANTINIB;XL184,CHEMBL2103868;CHEMBL2105717,BRD:BRD-BRD-K51544265-001-04-2;BRD:BRD-K51544265-001-04-2;BRD:BRD-K51544265-001-10-9;CTRP:660840;GDSC1:249,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,"RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR",AXL;KDR;MET;RET;VEGFRS,MEDULLARY THYROID CANCER (MTC),,LAUNCHED,"Multiple values for MOA: {'RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR', 'INHIBITOR OF RECEPTOR TYROSINE KINASES'}, defaulting to 'RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR'
Multiple values for repurposing_target: {'KDR;MET;RET', 'AXL;KDR;MET;RET;VEGFRS'}, taking the union
Multiple values for repurposing_target: {'KDR;MET;RET', 'KDR;MET'}, taking the union",Small molecule,Approved,HFCFMRYTXDINDK-WNQIDUERSA-N;ONIQOQHATWINJY-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC;COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC.O=C(O)C[C@H](O)C(=O)O;COC1CC2NCCC(OC3CCC(NC(=O)C4(CC4)C(=O)NC4CCC(F)CC4)CC3)C2CC1OC
BMY-14802,BMY-14802,CHEMBL60859,BRD:BRD-A15435692-003-02-3;BRD:BRD-BRD-A15435692-003-02-3,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,HTR1A,,,PHASE 2,,Small molecule,NA,ZXUYYZPJUGQHLQ-UHFFFAOYSA-N,OC(CCCN1CCN(C2NCC(F)CN2)CC1)C1CCC(F)CC1;OC(CCCN1CCN(CC1)C1NCC(F)CN1)C1CCC(F)CC1
BMY-45778,BMY-45778,,BRD:BRD-BRD-K84895041-001-02-4;BRD:BRD-K84895041-001-02-4,rep_primary;rep_single_dose,IP1 PROSTACYCLIN RECEPTOR AGONIST,PTGIR,,,PRECLINICAL,,,NA,,OC(=O)COC1CCCC(C1)-C1OCNC1-C1NC(C(O1)-C1CCCCC1)-C1CCCCC1
BMY-7378,BMY-7378,CHEMBL13647,BRD:BRD-BRD-K31054881-300-04-7;BRD:BRD-K31054881-300-04-7,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;HTR1A,,,PRECLINICAL,,Small molecule,NA,AYYCFGDXLUPJAQ-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1
BNC105,BNC105,,BRD:BRD-BRD-K20468903-001-01-6;BRD:BRD-K20468903-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,PHASE 2,,,NA,,COC1CCC2C(C(=O)C3CC(OC)C(OC)C(OC)C3)C(C)OC2C1O
BNTX,BNTX,CHEMBL252172,BRD:BRD-A55484088-050-02-5;BRD:BRD-BRD-A55484088-050-02-5,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,,,PRECLINICAL,,Small molecule,NA,WXOUFNFMPVMGFZ-BDQAUFNLSA-N,O=C1/C(=C/C2CCCCC2)C[C@@]2(O)[C@H]3CC4CCC(O)C5C4[C@@]2(CCN3CC2CC2)[C@H]1O5;OC1CCC2CC3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C(=O)\C(C[C@@]35O)=C\C1CCCCC1
BOCEPREVIR,BOCEPREVIR,CHEMBL218394,BRD:BRD-A09735281-001-02-5;BRD:BRD-BRD-A09735281-001-02-5,rep_primary;rep_single_dose,HCV INHIBITOR,CMA1;CTSA;CTSF;CTSK;CTSL;CTSS,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,LHHCSNFAOIFYRV-DOVBMPENSA-N,CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C
BOPINDOLOL,BOPINDOLOL,CHEMBL357995,BRD:BRD-A07563059-035-01-3;BRD:BRD-BRD-A07563059-035-01-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3;HTR1A;HTR1B,"HYPERTENSION, CORONARY ARTERY DISEASE (CAD)",,LAUNCHED,,Small molecule,Unknown,UUOJIACWOAYWEZ-UHFFFAOYSA-N,CC1CC2C(OCC(CNC(C)(C)C)OC(=O)C3CCCCC3)CCCC2[NH]1
BORNYL-ACETATE,BORNYL-ACETATE,,BRD:BRD-A41385909-001-01-3;BRD:BRD-BRD-A41385909-001-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(=O)OC1CC2CCC1(C)C2(C)C
BORONOPHENYLALANINE,BORONOPHENYLALANINE,,BRD:BRD-BRD-K50122911-001-01-2;BRD:BRD-K50122911-001-01-2,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,N[C@@H](CC1CCC(CC1)B(O)O)C(O)=O
BORTEZOMIB,BORTEZOMIB,CHEMBL325041,BRD:BRD-BRD-K50691590-001-04-8;BRD:BRD-BRD-K88510285-001-11-1;BRD:BRD-BRD-K88510285-001-22-8;BRD:BRD-K88510285-001-11-1;BRD:BRD-K88510285-001-17-8;BRD:BRD-K88510285-001-22-8;CTRP:411737;GDSC1:104;GDSC2:1191,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"NFKB PATHWAY INHIBITOR, PROTEASOME INHIBITOR",PSMA1;PSMA2;PSMA3;PSMA4;PSMA5;PSMA6;PSMA7;PSMA8;PSMB1;PSMB10;PSMB11;PSMB2;PSMB3;PSMB4;PSMB5;PSMB6;PSMB7;PSMB8;PSMB9;PSMD1;PSMD2;RELA,"MULTIPLE MYELOMA, MANTLE CELL LYMPHOMA (MCL)",,LAUNCHED,,Small molecule,Approved,GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1CNCCN1)B(O)O
BOS-172722,BOS-172722,,BRD:BRD-K00003111-001-01-9,rep_single_dose,MONOPOLAR SPINDLE 1 KINASE INHIBITOR,,,,,,,NA,,
BOSENTAN,BOSENTAN,CHEMBL957,BRD:BRD-BRD-K74763371-002-04-0;BRD:BRD-K74763371-002-04-0,rep_multi_dose;rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA;EDNRB,PULMONARY ARTERIAL HYPERTENSION (PAH),,LAUNCHED,,Small molecule,Approved,GJPICJJJRGTNOD-UHFFFAOYSA-N,COC1CCCCC1OC1C(NS(=O)(=O)C2CCC(C(C)(C)C)CC2)NC(-C2NCCCN2)NC1OCCO;COC1CCCCC1OC1C(NS(=O)(=O)C2CCC(CC2)C(C)(C)C)NC(NC1OCCO)-C1NCCCN1
BOSULIF,BOSULIF,CHEMBL288441,GDSC1:1019,gdsc,,,,,,,Small molecule,Approved,UBPYILGKFZZVDX-UHFFFAOYSA-N,COC1CC(NC2C(C#N)CNC3CC(OCCCN4CCN(C)CC4)C(OC)CC23)C(CL)CC1CL
BOSUTINIB,BOSUTINIB,CHEMBL288441,BRD:BRD-BRD-K99964838-001-11-9;BRD:BRD-K99964838-001-11-9;CTRP:660346;GDSC1:1019,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"ABL KINASE INHIBITOR, BCR-ABL KINASE INHIBITOR, SRC INHIBITOR",ABL1;BCR;CAMK1D;CAMK2G;CDK2;FRK;FYN;HCK;LYN;MAP2K1;MAP2K2;MAP3K2;MAP4K5;SRC;STK10;STK24;STK4;TNK2;TXK,CHRONIC MYELOID LEUKEMIA (CML),,LAUNCHED,,Small molecule,Approved,UBPYILGKFZZVDX-UHFFFAOYSA-N,COC1CC(NC2C(C#N)CNC3CC(OCCCN4CCN(C)CC4)C(OC)CC23)C(CL)CC1CL;COC1CC(NC2C(CNC3CC(OCCCN4CCN(C)CC4)C(OC)CC23)C#N)C(CL)CC1CL
BP-554,BP-554,,BRD:BRD-BRD-K45479396-050-01-5;BRD:BRD-K45479396-050-01-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PRECLINICAL,,,NA,,C(COC1CCC2OCOC2C1)CN1CCN(CC1)C1CCCCC1
BP-897,BP-897,CHEMBL25236,BRD:BRD-BRD-K17378184-300-05-9;BRD:BRD-K17378184-300-05-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA1D;ADRA2A;DRD1;DRD2;DRD3;DRD4;HTR1A;HTR2B,,,PHASE 2,,Small molecule,NA,MNHDKMDLOJSCGN-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CCCCNC(=O)C2CCC3CCCCC3C2)CC1
BPD-00008900,BPD-00008900,,GDSC2:1998,gdsc,,,,,,,,NA,,
BQ-123,BQ-123,CHEMBL1269102,BRD:BRD-A59961917-001-01-0;BRD:BRD-BRD-A59961917-001-01-0,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,PHASE 2,,Protein,Phase 2,VYCMAAOURFJIHD-AOYLRGCGSA-N,CC(C)C[C@@H]1NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CC2C[NH]C3CCCCC23)NC1=O;CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(CC2C[NH]C3CCCCC23)NC1=O)C(C)C
BQ-788,BQ-788,,BRD:BRD-K02490038-236-03-8,rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRB,,,,,,NA,,
BQU57,BQU57,,BRD:BRD-A40257118-001-02-0,rep_single_dose,RAS GTPASE INHIBITOR,RALA;RALB,,,,,,NA,,
BRD-A02303741,BRD-A02303741,,CTRP:659371,ctrp,,,,,,,,NA,,
BRD-A02303741:CARBOPLATIN (1:1 MOL/MOL),BRD-A02303741:CARBOPLATIN (1:1 MOL/MOL),,CTRP:660271,ctrp,,,,,,,,NA,,
BRD-A02303741:NAVITOCLAX (2:1 MOL/MOL),BRD-A02303741:NAVITOCLAX (2:1 MOL/MOL),,CTRP:660268,ctrp,,,,,,,,NA,,
BRD-A05715709,BRD-A05715709,,CTRP:660342,ctrp,,,,,,,,NA,,
BRD-A71883111,BRD-A71883111,,CTRP:660145,ctrp,,,,,,,,NA,,
BRD-A86708339,BRD-A86708339,,CTRP:687769,ctrp,,,,,,,,NA,,
BRD-A94377914,BRD-A94377914,,CTRP:61724,ctrp,,,,,,,,NA,,
BRD-K01737880,BRD-K01737880,,CTRP:438345,ctrp,,,,,,,,NA,,
BRD-K02251932,BRD-K02251932,,CTRP:442141,ctrp,,,,,,,,NA,,
BRD-K02492147,BRD-K02492147,,CTRP:415688,ctrp,,,,,,,,NA,,
BRD-K03536150,BRD-K03536150,,CTRP:686134,ctrp,,,,,,,,NA,,
BRD-K03911514,BRD-K03911514,,CTRP:660424,ctrp,,,,,,,,NA,,
BRD-K04800985,BRD-K04800985,,CTRP:435086,ctrp,,,,,,,,NA,,
BRD-K07442505,BRD-K07442505,,CTRP:660229,ctrp,,,,,,,,NA,,
BRD-K09344309,BRD-K09344309,,CTRP:439882,ctrp,,,,,,,,NA,,
BRD-K09587429,BRD-K09587429,,CTRP:416842,ctrp,,,,,,,,NA,,
BRD-K11533227,BRD-K11533227,,CTRP:389297,ctrp,,,,,,,,NA,,
BRD-K13185470,BRD-K13185470,,CTRP:660839,ctrp,,,,,,,,NA,,
BRD-K13999467,BRD-K13999467,,CTRP:410270,ctrp,,,,,,,,NA,,
BRD-K14844214,BRD-K14844214,,CTRP:402775,ctrp,,,,,,,,NA,,
BRD-K16130065,BRD-K16130065,,CTRP:660425,ctrp,,,,,,,,NA,,
BRD-K16147474,BRD-K16147474,,CTRP:447732,ctrp,,,,,,,,NA,,
BRD-K17060750,BRD-K17060750,,CTRP:600054,ctrp,,,,,,,,NA,,
BRD-K19103580,BRD-K19103580,,CTRP:436211,ctrp,,,,,,,,NA,,
BRD-K20514654,BRD-K20514654,,CTRP:651304,ctrp,,,,,,,,NA,,
BRD-K24690302,BRD-K24690302,,CTRP:641721,ctrp,,,,,,,,NA,,
BRD-K26531177,BRD-K26531177,,CTRP:42319,ctrp,,,,,,,,NA,,
BRD-K27188169,BRD-K27188169,,CTRP:660798,ctrp,,,,,,,,NA,,
BRD-K27188169:NAVITOCLAX (2:1 MOL/MOL),BRD-K27188169:NAVITOCLAX (2:1 MOL/MOL),,CTRP:665818,ctrp,,,,,,,,NA,,
BRD-K27224038,BRD-K27224038,,CTRP:397964,ctrp,,,,,,,,NA,,
BRD-K27986637,BRD-K27986637,,CTRP:452570,ctrp,,,,,,,,NA,,
BRD-K28456706,BRD-K28456706,,CTRP:651642,ctrp,,,,,,,,NA,,
BRD-K29086754,BRD-K29086754,,CTRP:448891,ctrp,,,,,,,,NA,,
BRD-K29313308,BRD-K29313308,,CTRP:634814,ctrp,,,,,,,,NA,,
BRD-K30019337,BRD-K30019337,,CTRP:437263,ctrp,,,,,,,,NA,,
BRD-K30748066,BRD-K30748066,,CTRP:689506,ctrp,,,,,,,,NA,,
BRD-K33199242,BRD-K33199242,,CTRP:449707,ctrp,,,,,,,,NA,,
BRD-K33514849,BRD-K33514849,,CTRP:401251,ctrp,,,,,,,,NA,,
BRD-K34099515,BRD-K34099515,,CTRP:660064,ctrp,,,,,,,,NA,,
BRD-K34222889,BRD-K34222889,,CTRP:688888,ctrp,,,,,,,,NA,,
BRD-K34485477,BRD-K34485477,,CTRP:446716,ctrp,,,,,,,,NA,,
BRD-K35604418,BRD-K35604418,,CTRP:660230,ctrp,,,,,,,,NA,,
BRD-K37390332,BRD-K37390332,,CTRP:463198,ctrp,,,,,,,,NA,,
BRD-K41334119,BRD-K41334119,,CTRP:446546,ctrp,,,,,,,,NA,,
BRD-K41597374,BRD-K41597374,,CTRP:404452,ctrp,,,,,,,,NA,,
BRD-K42260513,BRD-K42260513,,CTRP:687715,ctrp,,,,,,,,NA,,
BRD-K44224150,BRD-K44224150,,CTRP:438564,ctrp,,,,,,,,NA,,
BRD-K45681478,BRD-K45681478,,CTRP:142931,ctrp,,,,,,,,NA,,
BRD-K48334597,BRD-K48334597,,CTRP:431987,ctrp,,,,,,,,NA,,
BRD-K48477130,BRD-K48477130,,CTRP:649754,ctrp,,,,,,,,NA,,
BRD-K49290616,BRD-K49290616,,CTRP:414479,ctrp,,,,,,,,NA,,
BRD-K50799972,BRD-K50799972,,CTRP:596868,ctrp,,,,,,,,NA,,
BRD-K51490254,BRD-K51490254,,CTRP:616355,ctrp,,,,,,,,NA,,
BRD-K51831558,BRD-K51831558,,CTRP:687661,ctrp,,,,,,,,NA,,
BRD-K52037352,BRD-K52037352,,CTRP:450415,ctrp,,,,,,,,NA,,
BRD-K55116708,BRD-K55116708,,CTRP:444779,ctrp,,,,,,,,NA,,
BRD-K55473186,BRD-K55473186,,CTRP:651306,ctrp,,,,,,,,NA,,
BRD-K58730230,BRD-K58730230,,CTRP:660797,ctrp,,,,,,,,NA,,
BRD-K61166597,BRD-K61166597,,CTRP:348633,ctrp,,,,,,,,NA,,
BRD-K63431240,BRD-K63431240,,CTRP:404566,ctrp,,,,,,,,NA,,
BRD-K64610608,BRD-K64610608,,CTRP:438776,ctrp,,,,,,,,NA,,
BRD-K66453893,BRD-K66453893,,CTRP:387472,ctrp,,,,,,,,NA,,
BRD-K66532283,BRD-K66532283,,CTRP:376693,ctrp,,,,,,,,NA,,
BRD-K70511574,BRD-K70511574,,CTRP:648987,ctrp,,,,,,,,NA,,
BRD-K71781559,BRD-K71781559,,CTRP:425733,ctrp,,,,,,,,NA,,
BRD-K71935468,BRD-K71935468,,CTRP:58566,ctrp,,,,,,,,NA,,
BRD-K75293299,BRD-K75293299,,CTRP:438691,ctrp,,,,,,,,NA,,
BRD-K78574327,BRD-K78574327,,CTRP:435898,ctrp,,,,,,,,NA,,
BRD-K79669418,BRD-K79669418,,CTRP:660139,ctrp,,,,,,,,NA,,
BRD-K80183349,BRD-K80183349,,CTRP:376307,ctrp,,,,,,,,NA,,
BRD-K84807411,BRD-K84807411,,CTRP:437906,ctrp,,,,,,,,NA,,
BRD-K85133207,BRD-K85133207,,CTRP:616408,ctrp,,,,,,,,NA,,
BRD-K86535717,BRD-K86535717,,CTRP:429535,ctrp,,,,,,,,NA,,
BRD-K88742110,BRD-K88742110,,CTRP:606670,ctrp,,,,,,,,NA,,
BRD-K90370028,BRD-K90370028,,CTRP:362207,ctrp,,,,,,,,NA,,
BRD-K92856060,BRD-K92856060,,CTRP:119769,ctrp,,,,,,,,NA,,
BRD-K94991378,BRD-K94991378,,CTRP:53556,ctrp,,,,,,,,NA,,
BRD-K96431673,BRD-K96431673,,CTRP:417262,ctrp,,,,,,,,NA,,
BRD-K96970199,BRD-K96970199,,CTRP:410703,ctrp,,,,,,,,NA,,
BRD-K97651142,BRD-K97651142,,CTRP:660135,ctrp,,,,,,,,NA,,
BRD-K99006945,BRD-K99006945,,CTRP:687395,ctrp,,,,,,,,NA,,
BRD-K99584050,BRD-K99584050,,CTRP:660140,ctrp,,,,,,,,NA,,
BRD-M00053801,BRD-M00053801,,CTRP:660890,ctrp,,,,,,,,NA,,
BRD1812,BRD1812,,CTRP:418162,ctrp,,,,,,,,NA,,
BRD1835,BRD1835,,CTRP:404070,ctrp,,,,,,,,NA,,
BRD4132,BRD4132,,CTRP:3588,ctrp,,,,,,,,NA,,
BRD4770,BRD4770,,BRD:BRD-BRD-K72264770-001-03-2;BRD:BRD-K72264770-001-03-2,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT2,,,PRECLINICAL,,,NA,,COC(=O)C1CCC2N(CCCC3CCCCC3)C(NC(=O)C3CCCCC3)NC2C1
BRD6340,BRD6340,,CTRP:12877,ctrp,,,,,,,,NA,,
BRD8899,BRD8899,,CTRP:608062,ctrp,,,,,,,,NA,,
BRD8958,BRD8958,,CTRP:418163,ctrp,,,,,,,,NA,,
BRD9647,BRD9647,,CTRP:37479,ctrp,,,,,,,,NA,,
BRD9876,BRD9876,,BRD:BRD-K89329876-001-08-9;CTRP:19153,ctrp;rep_single_dose,KINESIN INHIBITOR,KIF11,,,,,,NA,,
BRD9876:MK-1775 (4:1 MOL/MOL),BRD9876:MK-1775 (4:1 MOL/MOL),,CTRP:689136,ctrp,,,,,,,,NA,,
BREFELDIN A,BREFELDIN A,CHEMBL19980,CTRP:411714,ctrp,,,,,,,Small molecule,NA,KQNZDYYTLMIZCT-KQPMLPITSA-N,C[C@H]1CCC/C=C/[C@@H]2C[C@H](O)C[C@H]2[C@H](O)/C=C/C(=O)O1
BREFELDIN-A,BREFELDIN-A,,BRD:BRD-BRD-K77841042-001-14-1;BRD:BRD-K77841042-001-14-1,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,ARF1;CYTH2,,,PRECLINICAL,,,NA,,C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1
BREMELANOTIDE,BREMELANOTIDE,CHEMBL2070241,BRD:BRD-BRD-K06328344-015-01-7;BRD:BRD-K06328344-015-01-7,rep_primary;rep_single_dose,MELANOCORTIN RECEPTOR AGONIST,MC1R;MC2R;MC3R;MC4R;MC5R,,,PHASE 3,,Protein,Approved,FFHBJDQSGDNCIV-MFVUMRCOSA-N,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CC2CCCCC2)NC(=O)[C@H](CC2C[NH]CN2)NC1=O;CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2CCCCC2)NC(=O)[C@H](CC2CNC[NH]2)NC1=O)C(O)=O
BREQUINAR,BREQUINAR,CHEMBL38434,BRD:BRD-BRD-K96123349-236-02-8;BRD:BRD-K96123349-236-02-8,rep_multi_dose;rep_primary;rep_single_dose,DIHYDROOROTATE DEHYDROGENASE INHIBITOR,DHODH,,,PHASE 2,,Small molecule,Phase 2,PHEZJEYUWHETKO-UHFFFAOYSA-N,CC1C(-C2CCC(-C3CCCCC3F)CC2)NC2CCC(F)CC2C1C(=O)O;CC1C(NC2CCC(F)CC2C1C(O)=O)-C1CCC(CC1)-C1CCCCC1F
BRETAZENIL,BRETAZENIL,CHEMBL366947,BRD:BRD-BRD-K96936751-001-01-4;BRD:BRD-K96936751-001-01-4,rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR PARTIAL AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6,,,PHASE 2,,Small molecule,Unknown,LWUDDYHYYNNIQI-ZDUSSCGKSA-N,CC(C)(C)OC(=O)C1NCN-2C1[C@@H]1CCCN1C(=O)C1C(BR)CCCC-21;CC(C)(C)OC(=O)C1NCN2C1[C@@H]1CCCN1C(=O)C1C(BR)CCCC1-2
BREXPIPRAZOLE,BREXPIPRAZOLE,CHEMBL2105760,BRD:BRD-BRD-K00911143-001-01-9;BRD:BRD-K00911143-001-01-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR PARTIAL AGONIST,DRD2,"DEPRESSION, SCHIZOPHRENIA",,LAUNCHED,,Small molecule,Approved,ZKIAIYBUSXZPLP-UHFFFAOYSA-N,O=C1CCC2CCC(OCCCCN3CCN(C4CCCC5SCCC45)CC3)CC2[NH]1;O=C1CCC2CCC(OCCCCN3CCN(CC3)C3CCCC4SCCC34)CC2[NH]1
BRICICLIB,BRICICLIB,CHEMBL1206245,BRD:BRD-BRD-K05531427-001-01-7;BRD:BRD-K05531427-001-01-7,rep_primary;rep_single_dose,CYCLIN D INHIBITOR,CCND1,,,PHASE 1,,Small molecule,Phase 1,LXENKEWVEVKKGV-BQYQJAHWSA-N,COC1CC(OC)C(/C=C/S(=O)(=O)CC2CCC(OC)C(OP(=O)(O)O)C2)C(OC)C1;COC1CC(OC)C(\C=C\S(=O)(=O)CC2CCC(OC)C(OP(O)(O)=O)C2)C(OC)C1
BRIGATINIB,BRIGATINIB,CHEMBL3545311,BRD:BRD-BRD-K56981171-001-01-0;BRD:BRD-K56981171-001-01-0;BRD:BRD-K56981171-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,"ALK TYROSINE KINASE RECEPTOR INHIBITOR, EGFR INHIBITOR",ALK;EGFR,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,,Small molecule,Approved,AILRADAXUVEEIR-UHFFFAOYSA-N,COC1CC(CCC1NC1NCC(CL)C(NC2CCCCC2P(C)(C)=O)N1)N1CCC(CC1)N1CCN(C)CC1;COC1CC(N2CCC(N3CCN(C)CC3)CC2)CCC1NC1NCC(CL)C(NC2CCCCC2P(C)(C)=O)N1
BRILLIANT-GREEN,BRILLIANT-GREEN,,BRD:BRD-BRD-K60348325-065-09-9;BRD:BRD-K60348325-065-09-9,rep_multi_dose;rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CCN(CC)C1CCC(CC1)C(C1CCCCC1)=C1C=CC(C=C1)=[N+](CC)CC
BRIMONIDINE,BRIMONIDINE,CHEMBL844,BRD:BRD-BRD-K68264559-045-02-4;BRD:BRD-BRD-K68264559-045-04-0;BRD:BRD-K68264559-045-02-4;BRD:BRD-K68264559-045-04-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,"INTRAOCULAR PRESSURE, GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,,Small molecule,Approved,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRC1C(NC2=NCCN2)CCC2NCCNC12
BRINCIDOFOVIR,BRINCIDOFOVIR,CHEMBL203321,BRD:BRD-K00004672-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Approved,WXJFKKQWPMNTIM-VWLOTQADSA-N,CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)CN1CCC(N)NC1=O
BRINZOLAMIDE,BRINZOLAMIDE,CHEMBL220491,BRD:BRD-BRD-K74913225-001-12-4;BRD:BRD-K74913225-001-12-4,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA14;CA2;CA4;CA5A;CA7,"INTRAOCULAR PRESSURE, GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,,Small molecule,Approved,HCRKCZRJWPKOAR-JTQLQIEISA-N,CCN[C@H]1CN(CCCOC)S(=O)(=O)C2SC(CC12)S(N)(=O)=O;CCN[C@H]1CN(CCCOC)S(=O)(=O)C2SC(S(N)(=O)=O)CC21
BRIVANIB,BRIVANIB,CHEMBL377300,BRD:BRD-BRD-K28428262-001-04-1;BRD:BRD-K28428262-001-04-1;CTRP:606246,ctrp;rep_primary;rep_single_dose,"FGFR INHIBITOR, VEGFR INHIBITOR",CYP3A4;FGFR1;FLT1;KCNH2;KDR,,,PHASE 3,,Small molecule,Phase 3,WCWUXEGQKLTGDX-LLVKDONJSA-N,C[C@@H](O)COC1CN2NCNC(OC3CCC4[NH]C(C)CC4C3F)C2C1C;CC1CC2C(F)C(OC3NCNN4CC(OC[C@@H](C)O)C(C)C34)CCC2[NH]1
"BRIVANIB, BMS-540215","BRIVANIB, BMS-540215",,GDSC1:376,gdsc,,,,,,,,NA,,
BRIVANIB-ALANINATE,BRIVANIB-ALANINATE,,BRD:BRD-BRD-K57187269-001-02-4;BRD:BRD-K57187269-001-02-4,rep_primary;rep_single_dose,"FGFR INHIBITOR, VEGFR INHIBITOR",FGFR3,,,PHASE 3,,,NA,,C[C@H](COC1CN2NCNC(OC3CCC4[NH]C(C)CC4C3F)C2C1C)OC(=O)[C@H](C)N
BRIVARACETAM,BRIVARACETAM,CHEMBL607400,BRD:BRD-BRD-K00634421-001-01-0;BRD:BRD-K00634421-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,SV2A,SEIZURES,,LAUNCHED,,Small molecule,Approved,MSYKRHVOOPPJKU-BDAKNGLRSA-N,CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1;CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
BRIVUDINE,BRIVUDINE,CHEMBL31634,BRD:BRD-A63675168-001-01-6;BRD:BRD-BRD-A63675168-001-01-6,rep_primary;rep_single_dose,DNA DIRECTED DNA POLYMERASE INHIBITOR,,SHINGLES,,LAUNCHED,,Small molecule,Phase 2,ODZBBRURCPAEIQ-PIXDULNESA-N,O=C1[NH]C(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CC1/C=C/BR;OC[C@H]1O[C@H](CC1O)N1CC(\C=C\BR)C(=O)[NH]C1=O
BRL-15572,BRL-15572,CHEMBL534232,BRD:BRD-A51829654-003-07-7;BRD:BRD-BRD-A51829654-003-07-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR6,,,PRECLINICAL,,Small molecule,NA,QJHCTHPYUOXOGM-UHFFFAOYSA-N,OC(CN1CCN(C2CCCC(CL)C2)CC1)C(C1CCCCC1)C1CCCCC1;OC(CN1CCN(CC1)C1CCCC(CL)C1)C(C1CCCCC1)C1CCCCC1
BRL-26314,BRL-26314,,BRD:BRD-A57806482-001-01-4;BRD:BRD-BRD-A57806482-001-01-4,rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,LPL,,,PHASE 1,,,NA,,OC(=O)C(CC1CCCCC1)NCC1CCC(CL)CC1
BRL-37344,BRL-37344,,BRD:BRD-BRD-K07507905-236-02-6;BRD:BRD-K07507905-236-02-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3,,,PHASE 2,,,NA,,C[C@H](CC1CCC(OCC(O)=O)CC1)NC[C@H](O)C1CCCC(CL)C1
BRL-44408,BRL-44408,,BRD:BRD-K01825677-050-02-9,rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRA2B;ADRA2C,,,,,,NA,,
BRL-50481,BRL-50481,,BRD:BRD-BRD-K84266862-001-03-2;BRD:BRD-K84266862-001-03-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE7A;PDE7B,,,PRECLINICAL,,,NA,,CN(C)S(=O)(=O)C1CC(CCC1C)[N+]([O-])=O
BRL-52537,BRL-52537,,BRD:BRD-A37347161-003-02-6;BRD:BRD-BRD-A37347161-003-02-6,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1,,,PRECLINICAL,,,NA,,CLC1CCC(CC(=O)N2CCCCC2CN2CCCC2)CC1CL
BRL-54443,BRL-54443,,BRD:BRD-BRD-K17868609-001-05-0;BRD:BRD-K17868609-001-05-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1E;HTR1F,,,PRECLINICAL,,,NA,,CN1CCC(CC1)C1C[NH]C2CCC(O)CC12
COMPOUND 14,BRM/BRG1 ATP INHIBITOR-1;COMPOUND 14,,BRD:BRD-K00103294-001-02-9,oncref_2,SWI/SNF ATPASE INHIBITOR,SMARCA2;SMARCA4,,,,,,NA,,
BROFAROMINE,BROFAROMINE,CHEMBL160347,BRD:BRD-K00076468-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,WZXHSWVDAYOFPE-UHFFFAOYSA-N,COC1CC(BR)C2OC(C3CCNCC3)CC2C1
BROMANTAN,BROMANTAN,,BRD:BRD-BRD-K86358349-001-02-0;BRD:BRD-K86358349-001-02-0,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, SEROTONIN REUPTAKE INHIBITOR",,NEURASTHENIA,,LAUNCHED,,,NA,,BRC1CCC(NC2C3CC4CC(C3)CC2C4)CC1
BROMEBRIC-ACID,BROMEBRIC-ACID,,BRD:BRD-K17874929-236-02-0,rep_single_dose,"DNA SYNTHESIS INHIBITOR, PURINE ANTAGONIST",,,,,,,NA,,
BROMFENAC,BROMFENAC,CHEMBL1077,BRD:BRD-BRD-K47679368-236-01-7;BRD:BRD-K47679368-236-01-7,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,WITHDRAWN,,Small molecule,Approved,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,NC1C(CC(=O)O)CCCC1C(=O)C1CCC(BR)CC1;NC1C(CC(O)=O)CCCC1C(=O)C1CCC(BR)CC1
BROMHEXINE,BROMHEXINE,CHEMBL253376,BRD:BRD-BRD-K47631482-003-06-2;BRD:BRD-K47631482-003-06-2,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,CHEST CONGESTION,,LAUNCHED,,Small molecule,Approved,OJGDCBLYJGHCIH-UHFFFAOYSA-N,CN(CC1CC(BR)CC(BR)C1N)C1CCCCC1
BROMINDIONE,BROMINDIONE,CHEMBL288496,BRD:BRD-K50490982-001-09-9,rep_single_dose,ANTICOAGULANT,,,,,,Small molecule,Unknown,NPUZIGSOEWMFKK-UHFFFAOYSA-N,O=C1C2CCCCC2C(=O)C1C1CCC(BR)CC1
BROMISOVAL,BROMISOVAL,CHEMBL1515611,BRD:BRD-K00003522-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Unknown,CMCCHHWTTBEZNM-UHFFFAOYSA-N,CC(C)C(BR)C(=O)NC(N)=O
BROMOCRIPTINE,BROMOCRIPTINE,CHEMBL493,BRD:BRD-BRD-K14496212-066-04-8;BRD:BRD-K14496212-066-04-8,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR6;HTR7,"HYPERPROLACTINEMIA, PARKINSON'S DISEASE, ACROMEGALY",,LAUNCHED,,Small molecule,Approved,OZVBMTJYIDMWIL-AYFBDAFISA-N,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4CC5C(BR)[NH]C6CCCC(C4=C3)C56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4C5CCCC6[NH]C(BR)C(C56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
BROMOPRIDE,BROMOPRIDE,CHEMBL399510,BRD:BRD-BRD-K73642618-001-13-3;BRD:BRD-K73642618-001-13-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2,"NAUSEA, VOMITING, GASTROESOPHAGEAL REFLUX DISEASE (GERD)",,LAUNCHED,,Small molecule,Phase 3,GIYAQDDTCWHPPL-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1CC(BR)C(N)CC1OC
BROMOSPORINE,BROMOSPORINE,,BRD:BRD-BRD-K44665581-001-01-8;BRD:BRD-K44665581-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,,,,PRECLINICAL,,,NA,,CCOC(=O)NC1CC(NN2C(C)NNC12)-C1CCC(C)C(NS(C)(=O)=O)C1
BROMPERIDOL,BROMPERIDOL,CHEMBL28218,BRD:BRD-BRD-K78643075-001-11-6;BRD:BRD-K78643075-001-11-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,RKLNONIVDFXQRX-UHFFFAOYSA-N,O=C(CCCN1CCC(O)(C2CCC(BR)CC2)CC1)C1CCC(F)CC1;OC1(CCN(CCCC(=O)C2CCC(F)CC2)CC1)C1CCC(BR)CC1
BROMPHENIRAMINE,BROMPHENIRAMINE,CHEMBL1201287;CHEMBL811,BRD:BRD-A68723818-050-32-5;BRD:BRD-BRD-A68723818-050-32-5,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;HRH1,"ALLERGIC RHINITIS, COMMON COLD",,LAUNCHED,,Small molecule,Approved,ZDIGNSYAACHWNL-HNNXBMFYSA-N;ZDIGNSYAACHWNL-UHFFFAOYSA-N,CN(C)CC[C@@H](C1CCC(BR)CC1)C1CCCCN1;CN(C)CCC(C1CCC(BR)CC1)C1CCCCN1
BRONOPOL,BRONOPOL,CHEMBL1408862,BRD:BRD-K33457401-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,LVDKZNITIUWNER-UHFFFAOYSA-N,O=[N+]([O-])C(BR)(CO)CO
BROPIRIMINE,BROPIRIMINE,CHEMBL37387,BRD:BRD-BRD-K17500877-001-02-1;BRD:BRD-K17500877-001-02-1,rep_primary;rep_single_dose,INTERFERON INDUCER,,,,PHASE 3,,Small molecule,Unknown,CIUUIPMOFZIWIZ-UHFFFAOYSA-N,NC1NC(-C2CCCCC2)C(BR)C(=O)[NH]1;NC1NC(=O)C(BR)C(-C2CCCCC2)[NH]1
BROXALDINE,BROXALDINE,CHEMBL2104247,BRD:BRD-BRD-K36222532-001-01-8;BRD:BRD-K36222532-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,IJTPLVAAROHGGB-UHFFFAOYSA-N,CC1CCC2C(BR)CC(BR)C(OC(=O)C3CCCCC3)C2N1
BROXATEROL,BROXATEROL,CHEMBL2105475,BRD:BRD-A08316590-001-01-3;BRD:BRD-BRD-A08316590-001-01-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,,,PHASE 3,,Small molecule,Unknown,JBRBWHCVRGURBA-UHFFFAOYSA-N,CC(C)(C)NCC(O)C1CC(BR)NO1
BROXURIDINE,BROXURIDINE,CHEMBL222280,BRD:BRD-BRD-K79095980-001-09-6;BRD:BRD-K79095980-001-09-6,rep_primary;rep_single_dose,ANTIMETABOLITE,,,,PHASE 2,,Small molecule,Phase 2,WOVKYSAHUYNSMH-RRKCRQDMSA-N,O=C1[NH]C(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CC1BR;OC[C@H]1O[C@H](C[C@@H]1O)N1CC(BR)C(=O)[NH]C1=O
BROXYQUINOLINE,BROXYQUINOLINE,CHEMBL223448,BRD:BRD-BRD-K23301018-001-11-7;BRD:BRD-K23301018-001-11-7,rep_multi_dose;rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,,,PHASE 1,,Small molecule,Unknown,ZDASUJMDVPTNTF-UHFFFAOYSA-N,OC1C(BR)CC(BR)C2CCCNC12
BRUCEANTIN,BRUCEANTIN,CHEMBL509895,BRD:BRD-A36057565-001-01-0;BRD:BRD-BRD-A36057565-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,,,PHASE 2,,Small molecule,NA,IRQXZTBHNKVIRL-GOTQHHPNSA-N,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O;COC(=O)[C@@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)/C=C(\C)C(C)C)[C@@H]24
BRUCINE,BRUCINE,CHEMBL501756,BRD:BRD-A41995253-001-04-5;BRD:BRD-BRD-A41995253-001-04-5,rep_primary;rep_single_dose,GLYCINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,,,PRECLINICAL,,Small molecule,Unknown,RRKTZKIUPZVBMF-IBTVXLQLSA-N,COC1CC2C(CC1OC)[C@@]13CCN4CC5=CCO[C@H]6CC(=O)N2[C@H]1[C@H]6[C@H]5C[C@H]43;COC1CC2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)C2CC1OC
BRYOSTATIN,BRYOSTATIN,CHEMBL449158,GDSC1:197,gdsc,,,,,,,Small molecule,Phase 2,MJQUEDHRCUIRLF-TVIXENOKSA-N,CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)C[C@H]2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C/C(=C/C(=O)OC)C[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3
BRYOSTATIN 1,BRYOSTATIN 1,CHEMBL449158,GDSC1:197,gdsc,,,,,,,Small molecule,Phase 2,MJQUEDHRCUIRLF-TVIXENOKSA-N,CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)C[C@H]2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C/C(=C/C(=O)OC)C[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3
BS-181,BS-181,,BRD:BRD-BRD-K31313613-003-04-2;BRD:BRD-K31313613-003-04-2,rep_primary;rep_single_dose,CDK INHIBITOR,CDK7,,,PRECLINICAL,,,NA,,CC(C)C1CNN2C(NCC3CCCCC3)CC(NCCCCCCN)NC12
BSJ-03-123,BSJ-03-123,,BRD:BRD-K00126486-001-01-9,oncref_2,PROTAC DEGRADER OF CDK6,CDK6;CRBN,,,,,,NA,,
BSJ-4-116,BSJ-4-116,,BRD:BRD-U00115417-001-01-9,oncref_1,IMID-BASED DEGRADER OF CDK12,CDK12,,,,,,NA,,
BT-11,BT-11,,BRD:BRD-K00003444-001-01-9,rep_single_dose,CAMP STIMULANT,,,,,,,NA,,
BTB06584,BTB06584,,BRD:BRD-K37933329-001-03-9,rep_single_dose,ATPASE INHIBITOR,ATP5F1,,,,,,NA,,
BTB1,BTB1,,BRD:BRD-BRD-K89000287-001-01-1;BRD:BRD-K89000287-001-01-1,rep_primary;rep_single_dose,MITOTIC KINESIN INHIBITOR,KIF18A,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CC(CL)CCC1S(=O)(=O)C1CCCCC1
BTK-IN-1,BTK-IN-1,,BRD:BRD-K00003437-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,,NA,,
BTS,BTS,,BRD:BRD-BRD-K64178227-001-09-0;BRD:BRD-K64178227-001-09-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC1CCC(CC1)S(=O)(=O)NCC1CCCCC1
BTS-54505,BTS-54505,,BRD:BRD-A68304895-003-02-2;BRD:BRD-BRD-A68304895-003-02-2,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE REUPTAKE INHIBITOR,SLC6A2;SLC6A3;SLC6A4,,,WITHDRAWN,,,NA,,CC(C)CC(N)C1(CCC1)C1CCC(CL)CC1
BTS-71321,BTS-71321,,BRD:BRD-K00010938-001-01-9,rep_single_dose,,,,,,,,NA,,
BTS-72664,BTS-72664,,BRD:BRD-A65793993-001-01-6;BRD:BRD-BRD-A65793993-001-01-6,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1,,,PHASE 1,,,NA,,CC(OC1CCC(CL)CC1)C1CCNC2NCNN12
BTT-3033,BTT-3033,,BRD:BRD-BRD-K01492390-001-01-9;BRD:BRD-K01492390-001-01-9,rep_primary;rep_single_dose,INTEGRIN INHIBITOR,ITGA2;ITGB1,,,PRECLINICAL,,,NA,,CN(C1CCC(NC(=O)NC2CCCCC2)CC1)S(=O)(=O)C1CNN(C1)-C1CCC(F)CC1
BTZ043-RACEMATE,BTZ043-RACEMATE,,BRD:BRD-A53037217-001-02-0;BRD:BRD-BRD-A53037217-001-02-0,rep_primary;rep_single_dose,DPRE1 INHIBITOR,,,,PRECLINICAL,,,NA,,CC1COC2(CCN(CC2)C2NC(=O)C3CC(CC([N+]([O-])=O)C3S2)C(F)(F)F)O1
BU-224,BU-224,,BRD:BRD-BRD-K55344148-003-02-6;BRD:BRD-K55344148-003-02-6,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR LIGAND,MAOA;MAOB,,,PRECLINICAL,,,NA,,C1CN=C(N1)C1CCC2CCCCC2N1
BU-239,BU-239,,BRD:BRD-BRD-K11696279-003-02-3;BRD:BRD-K11696279-003-02-3,rep_primary;rep_single_dose,"IMIDAZOLINE RECEPTOR LIGAND, IMIDAZOLINE RECEPTOR AGONIST",,,,PRECLINICAL,"Multiple values for MOA: {'IMIDAZOLINE RECEPTOR AGONIST, IMIDAZOLINE RECEPTOR LIGAND', 'IMIDAZOLINE RECEPTOR LIGAND, IMIDAZOLINE RECEPTOR AGONIST'}, defaulting to 'IMIDAZOLINE RECEPTOR LIGAND, IMIDAZOLINE RECEPTOR AGONIST'",,NA,,C1CN=C(N1)C1CNC2CCCCC2N1
BU226,BU226,,BRD:BRD-BRD-K56115039-003-02-1;BRD:BRD-K56115039-003-02-1,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR LIGAND,,,,PRECLINICAL,,,NA,,C1CN=C(N1)C1CC2CCCCC2CN1
BUCETIN,BUCETIN,CHEMBL1697856,BRD:BRD-A88684804-001-04-3;BRD:BRD-BRD-A88684804-001-04-3,rep_primary;rep_single_dose,ANALGESIC AGENT,,,,WITHDRAWN,,Small molecule,Approved,LIAWQASKBFCRNR-UHFFFAOYSA-N,CCOC1CCC(NC(=O)CC(C)O)CC1
BUCILLAMINE,BUCILLAMINE,CHEMBL80830,BRD:BRD-BRD-K24697665-001-01-4;BRD:BRD-K24697665-001-01-4,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Phase 3,VUAFHZCUKUDDBC-BYPYZUCNSA-N,CC(C)(S)C(=O)N[C@@H](CS)C(=O)O;CC(C)(S)C(=O)N[C@@H](CS)C(O)=O
BUCLADESINE,BUCLADESINE,CHEMBL485980,BRD:BRD-A15931911-001-03-8;BRD:BRD-A94624445-236-17-0;BRD:BRD-BRD-A15931911-001-03-8;BRD:BRD-BRD-A94624445-236-17-0,rep_multi_dose;rep_primary;rep_single_dose,"ADENOSINE RECEPTOR AGONIST, CAMP STIMULANT",PRKACA,SKIN ULCER,,LAUNCHED,"Multiple values for structure_id: {'A15931911', 'A94624445'}, defaulting to None",Small molecule,Unknown,CJGYSWNGNKCJSB-YVLZZHOMSA-N,CCCC(=O)NC1NCNC2C1NCN2[C@@H]1O[C@@H]2COP(=O)(O)O[C@H]2[C@H]1OC(=O)CCC;CCCC(=O)NC1NCNC2N(CNC12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC;CCCC(=O)NC1NCNC2N(CNC12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC
BUCLIZINE,BUCLIZINE,CHEMBL1201271,BRD:BRD-A91444184-300-01-9;BRD:BRD-BRD-A91444184-300-01-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,CHRM1;HRH1,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,MOYGZHXDRJNJEP-UHFFFAOYSA-N,CC(C)(C)C1CCC(CN2CCN(C(C3CCCCC3)C3CCC(CL)CC3)CC2)CC1;CC(C)(C)C1CCC(CN2CCN(CC2)C(C2CCCCC2)C2CCC(CL)CC2)CC1
BUDIPINE,BUDIPINE,CHEMBL334491,BRD:BRD-BRD-K18324993-001-01-6;BRD:BRD-K18324993-001-01-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Unknown,QIHLUZAFSSMXHQ-UHFFFAOYSA-N,CC(C)(C)N1CCC(C2CCCCC2)(C2CCCCC2)CC1;CC(C)(C)N1CCC(CC1)(C1CCCCC1)C1CCCCC1
BUFEXAMAC,BUFEXAMAC,CHEMBL94394,BRD:BRD-BRD-K36660044-001-24-2;BRD:BRD-K36660044-001-24-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,HDAC10;HDAC6,,,WITHDRAWN,,Small molecule,Approved,MXJWRABVEGLYDG-UHFFFAOYSA-N,CCCCOC1CCC(CC(=O)NO)CC1
BUFLOMEDIL,BUFLOMEDIL,CHEMBL188921,BRD:BRD-BRD-K19462402-003-24-6;BRD:BRD-K19462402-003-24-6,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, CALCIUM CHANNEL BLOCKER",ADRA1A,PERIPHERAL ARTERY DISEASE (PAD),,LAUNCHED,,Small molecule,Approved,OWYLAEYXIQKAOL-UHFFFAOYSA-N,COC1CC(OC)C(C(=O)CCCN2CCCC2)C(OC)C1
BUMETANIDE,BUMETANIDE,CHEMBL1072,BRD:BRD-BRD-K38197229-001-29-9;BRD:BRD-K38197229-001-29-9,rep_multi_dose;rep_primary;rep_single_dose,SOLUTE CARRIER FAMILY MEMBER INHIBITOR,CFTR;GPR35;SLC12A1;SLC12A2;SLC12A4;SLC12A5,"EDEMA, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,MAEIEVLCKWDQJH-UHFFFAOYSA-N,CCCCNC1CC(C(=O)O)CC(S(N)(=O)=O)C1OC1CCCCC1;CCCCNC1CC(CC(C1OC1CCCCC1)S(N)(=O)=O)C(O)=O
BUNAZOSIN,BUNAZOSIN,CHEMBL188185,BRD:BRD-BRD-K35034482-001-01-8;BRD:BRD-K35034482-001-01-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A,"GLAUCOMA, INTRAOCULAR PRESSURE",,LAUNCHED,,Small molecule,Phase 3,RHLJLALHBZGAFM-UHFFFAOYSA-N,CCCC(=O)N1CCCN(C2NC(N)C3CC(OC)C(OC)CC3N2)CC1;CCCC(=O)N1CCCN(CC1)C1NC(N)C2CC(OC)C(OC)CC2N1
BUPARLISIB,BUPARLISIB,CHEMBL2017974,BRD:BRD-BRD-K42191735-001-05-3;BRD:BRD-K42191735-001-05-3;GDSC2:1873,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CG,,,PHASE 3,,Small molecule,Phase 3,CWHUFRVAEUJCEF-UHFFFAOYSA-N,NC1CC(C(CN1)-C1CC(NC(N1)N1CCOCC1)N1CCOCC1)C(F)(F)F;NC1CC(C(F)(F)F)C(-C2CC(N3CCOCC3)NC(N3CCOCC3)N2)CN1
BUPARVAQUONE,BUPARVAQUONE,CHEMBL292009,BRD:BRD-A07947329-001-01-4;BRD:BRD-BRD-A07947329-001-01-4,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,,,LAUNCHED,,Small molecule,Unknown,KLLIVCPQDTYMLC-HDJSIYSDSA-N,CC(C)(C)[C@H]1CC[C@H](CC2=C(O)C(=O)C3CCCCC3C2=O)CC1;CC(C)(C)C1CCC(CC2C(=O)C(=O)C3CCCCC3C2=O)CC1
BUPHENINE,BUPHENINE,CHEMBL114655,BRD:BRD-A36267905-003-18-4;BRD:BRD-BRD-A36267905-003-18-4,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,RAYNAUD'S DISEASE,,LAUNCHED,,Small molecule,Unknown,PTGXAUBQBSGPKF-UHFFFAOYSA-N,CC(CCC1CCCCC1)NC(C)C(O)C1CCC(O)CC1
BUPICOMIDE,BUPICOMIDE,CHEMBL2106646,BRD:BRD-BRD-K51700582-001-01-2;BRD:BRD-K51700582-001-01-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1,,,PHASE 1,,Small molecule,Unknown,VKSPIPWLHGKJQO-UHFFFAOYSA-N,CCCCC1CCC(C(N)=O)NC1;CCCCC1CCC(NC1)C(N)=O
BUPIVACAINE,BUPIVACAINE,CHEMBL1098;CHEMBL1201193,BRD:BRD-A01636364-003-15-1;BRD:BRD-BRD-A01636364-003-15-1,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,KCNA5;PTGER1;SCN10A;SCN4A,"PERIPHERAL NERVE BLOCK, CAUDAL EPIDURAL BLOCK, LUMBAR EPIDURAL BLOCK",,LAUNCHED,,Small molecule,Approved,LEBVLXFERQHONN-INIZCTEOSA-N;LEBVLXFERQHONN-UHFFFAOYSA-N,CCCCN1CCCC[C@H]1C(=O)NC1C(C)CCCC1C;CCCCN1CCCCC1C(=O)NC1C(C)CCCC1C
BUPRANOLOL,BUPRANOLOL,CHEMBL305380,BRD:BRD-A48420483-001-02-3;BRD:BRD-BRD-A48420483-001-02-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,"HYPERTENSION, GLAUCOMA",,LAUNCHED,,Small molecule,Unknown,HQIRNZOQPUAHHV-UHFFFAOYSA-N,CC1CCC(CL)C(OCC(O)CNC(C)(C)C)C1
BUPROPION,BUPROPION,CHEMBL894,BRD:BRD-A05186015-003-19-8;BRD:BRD-BRD-A05186015-003-19-8,rep_primary;rep_single_dose,DOPAMINE UPTAKE INHIBITOR,CHRNA3;SLC6A2;SLC6A3,DEPRESSION,,LAUNCHED,,Small molecule,Approved,SNPPWIUOZRMYNY-UHFFFAOYSA-N,CC(NC(C)(C)C)C(=O)C1CCCC(CL)C1
BURAMATE,BURAMATE,CHEMBL2103933,BRD:BRD-K30360804-001-02-9,rep_single_dose,ANTIEPILEPTIC,,,,,,Small molecule,Unknown,YFLRYAVDPKONNX-UHFFFAOYSA-N,O=C(NCC1CCCCC1)OCCO
BURIXAFOR (HYDROBROMIDE),BURIXAFOR (HYDROBROMIDE),,BRD:BRD-K00091136-303-01-9,rep_single_dose,,,,,,,,NA,,
BUSERELIN,BUSERELIN,CHEMBL2110824,BRD:BRD-K00003161-015-01-9,rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR AGONIST,,,,,,Protein,Approved,CUWODFFVMXJOKD-UVLQAERKSA-N,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CNC[NH]1)NC(=O)[C@@H]1CCC(=O)N1
BUSPIRONE,BUSPIRONE,CHEMBL49,BRD:BRD-BRD-K93461745-003-25-0;BRD:BRD-K93461745-003-25-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,DRD2;HTR1A,GENERALIZED ANXIETY DISORDER (GAD),,LAUNCHED,,Small molecule,Approved,QWCRAEMEVRGPNT-UHFFFAOYSA-N,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(C2NCCCN2)CC1;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1NCCCN1
BUSULFAN,BUSULFAN,CHEMBL820,BRD:BRD-BRD-K23204545-001-16-4;BRD:BRD-K23204545-001-16-4,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,CHRONIC MYELOID LEUKEMIA (CML),,LAUNCHED,,Small molecule,Approved,COVZYZSDYWQREU-UHFFFAOYSA-N,CS(=O)(=O)OCCCCOS(C)(=O)=O
BUTABINDIDE,BUTABINDIDE,,BRD:BRD-K40581315-034-02-9,rep_single_dose,TRIPEPTIDYL PEPTIDASE INHIBITOR,TPP2,,,,,,NA,,
BUTACAINE,BUTACAINE,CHEMBL129529,BRD:BRD-BRD-K99622919-001-23-0;BRD:BRD-K99622919-001-23-0,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Unknown,HQFWVSGBVLEQGA-UHFFFAOYSA-N,CCCCN(CCCC)CCCOC(=O)C1CCC(N)CC1
BUTACLAMOL,BUTACLAMOL,CHEMBL479587;CHEMBL8514,BRD:BRD-BRD-K23082237-003-01-5;BRD:BRD-K23082237-003-01-5,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR2A,,,PHASE 2,,Small molecule,Unknown,ZZJYIKPMDIWRSN-HWBMXIPRSA-N;ZZJYIKPMDIWRSN-RQTOMXEWSA-N,CC(C)(C)[C@]1(O)CCN2C[C@@H]3C4CCCCC4CCC4CCCC(C43)[C@H]2C1;CC(C)(C)[C@]1(O)CCN2C[C@H]3C4CCCCC4CCC4CCCC(C43)[C@@H]2C1;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3C4CCCCC4CCC4CCCC([C@H]2C1)C34
BUTALBITAL,BUTALBITAL,CHEMBL454,BRD:BRD-BRD-K71350836-001-02-4;BRD:BRD-K71350836-001-02-4,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,CHRNA4;CHRNA7;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIA2;GRIK2,"HEADACHE, MUSCLE RELAXANT",,LAUNCHED,,Small molecule,Approved,UZVHFVZFNXBMQJ-UHFFFAOYSA-N,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O;CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O
BUTAMBEN,BUTAMBEN,CHEMBL127516,BRD:BRD-BRD-K27217864-001-22-3;BRD:BRD-K27217864-001-22-3,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,,,,WITHDRAWN,,Small molecule,Approved,IUWVALYLNVXWKX-UHFFFAOYSA-N,CCCCOC(=O)C1CCC(N)CC1
BUTAPROST,BUTAPROST,CHEMBL271896,BRD:BRD-K00004715-001-01-9,rep_single_dose,PROSTAGLANDIN RECEPTOR AGONIST,,,,,,Small molecule,Unknown,XRISENIKJUKIHD-LHQZMKCDSA-N,CCCC1([C@H](O)C/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCCCCCC(=O)OC)CCC1
BUTEIN,BUTEIN,CHEMBL128000,BRD:BRD-BRD-K17497770-001-03-6;BRD:BRD-K17497770-001-03-6,rep_primary;rep_single_dose,"EGFR INHIBITOR, SRC INHIBITOR",ACE,,,PRECLINICAL,,Small molecule,NA,AYMYWHCQALZEGT-ORCRQEGFSA-N,O=C(/C=C/C1CCC(O)C(O)C1)C1CCC(O)CC1O;OC1CCC(C(=O)\C=C\C2CCC(O)C(O)C2)C(O)C1
BUTENAFINE,BUTENAFINE,CHEMBL990,BRD:BRD-BRD-K90630139-003-05-9;BRD:BRD-K90630139-003-05-9,rep_primary;rep_single_dose,FUNGAL SQUALENE EPOXIDASE INHIBITOR,SQLE,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,CN(CC1CCC(C(C)(C)C)CC1)CC1CCCC2CCCCC12;CN(CC1CCC(CC1)C(C)(C)C)CC1CCCC2CCCCC12
BUTHIONINE-SULFOXIMINE,BUTHIONINE-SULFOXIMINE,,BRD:BRD-A47706533-001-02-6;BRD:BRD-BRD-A47706533-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,GLUTATHIONE TRANSFERASE INHIBITOR,GCLM,,,PHASE 1,,,NA,,CCCCS(=N)(=O)CC[C@H](N)C(O)=O
BUTIBUFEN,BUTIBUFEN,CHEMBL454450,BRD:BRD-A46136514-001-01-2;BRD:BRD-BRD-A46136514-001-01-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,WITHDRAWN,,Small molecule,Unknown,UULSXYSSHHRCQK-UHFFFAOYSA-N,CCC(C(=O)O)C1CCC(CC(C)C)CC1;CCC(C(O)=O)C1CCC(CC(C)C)CC1
BUTOCONAZOLE,BUTOCONAZOLE,CHEMBL1295,BRD:BRD-A16665823-001-02-0;BRD:BRD-BRD-A16665823-001-02-0,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,VULVOVAGINAL CANDIDIASIS,,LAUNCHED,,Small molecule,Approved,SWLMUYACZKCSHZ-UHFFFAOYSA-N,CLC1CCC(CCC(CN2CCNC2)SC2C(CL)CCCC2CL)CC1
BUTOFILOLOL,BUTOFILOLOL,CHEMBL157443,BRD:BRD-A27274504-001-01-6;BRD:BRD-BRD-A27274504-001-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,PHASE 2,,Small molecule,Unknown,NMBNQRJDEPOXCP-UHFFFAOYSA-N,CCCC(=O)C1CC(F)CCC1OCC(O)CNC(C)(C)C
BUTORPHANOL-(+)-TARTRATE,BUTORPHANOL-(+)-TARTRATE,,BRD:BRD-BRD-K42417338-045-01-9;BRD:BRD-K42417338-045-01-9,rep_primary;rep_single_dose,"OPIOID RECEPTOR AGONIST, OPIOID RECEPTOR ANTAGONIST",OPRD1;OPRK1;OPRM1,"MUSCLE PAIN, HEADACHE, ABDOMINAL PAIN",,LAUNCHED,,,NA,,OC1CCC2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)C2C1
BUTYL-PARABEN,BUTYL-PARABEN,,BRD:BRD-BRD-K08287586-001-14-3;BRD:BRD-K08287586-001-14-3,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,PRECLINICAL,,,NA,,CCCCOC(=O)C1CCC(O)CC1
BUTYLATED-HYDROXYANISOLE,BUTYLATED-HYDROXYANISOLE,,BRD:BRD-BRD-K93035859-001-07-6;BRD:BRD-K93035859-001-07-6,rep_primary;rep_single_dose,ANTIOXIDANT,,,,PRECLINICAL,,,NA,,COC1CCC(O)C(C1)C(C)(C)C
BUTYLATED-HYDROXYTOLUENE,BUTYLATED-HYDROXYTOLUENE,,BRD:BRD-BRD-K53153417-001-10-4;BRD:BRD-K53153417-001-10-4,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA2,,,PHASE 1,,,NA,,CC1CC(C(O)C(C1)C(C)(C)C)C(C)(C)C
BUTYLIDENEPHTHALIDE,BUTYLIDENEPHTHALIDE,,BRD:BRD-K02260986-001-03-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,,,,NA,,
BUTYLPHTHALIDE,BUTYLPHTHALIDE,,BRD:BRD-A59378440-001-01-3;BRD:BRD-BRD-A59378440-001-01-3,rep_primary;rep_single_dose,POTASSIUM CHANNEL ANTAGONIST,KCNK2,STROKE,,LAUNCHED,,,NA,,CCCCC1OC(=O)C2CCCCC12
BUTYLSCOPOLAMINE-BROMIDE,BUTYLSCOPOLAMINE-BROMIDE,,BRD:BRD-A53951045-004-01-6;BRD:BRD-BRD-A53951045-004-01-6,rep_multi_dose;rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,,ABDOMINAL PAIN,,LAUNCHED,,,NA,,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)C1CCCCC1
BVD-523,BVD-523,CHEMBL3590106,BRD:BRD-BRD-K28965160-001-01-1;BRD:BRD-K28965160-001-01-1;GDSC2:1908;GDSC2:2047,gdsc;rep_multi_dose;rep_primary;rep_single_dose,MAP KINASE INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,KSERXGMCDHOLSS-LJQANCHMSA-N,CC(C)NC1CC(-C2C[NH]C(C(=O)N[C@H](CO)C3CCCC(CL)C3)C2)C(CL)CN1;CC(C)NC1CC(-C2C[NH]C(C2)C(=O)N[C@H](CO)C2CCCC(CL)C2)C(CL)CN1
BVT-2733,BVT-2733,,BRD:BRD-BRD-K01742705-001-01-7;BRD:BRD-K01742705-001-01-7,rep_primary;rep_single_dose,11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR,HSD17B1,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C(=O)CC1CSC(NS(=O)(=O)C2CCCC(CL)C2C)N1
BVT-948,BVT-948,,BRD:BRD-BRD-K68567222-001-01-2;BRD:BRD-K68567222-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE PHOSPHATASE INHIBITOR,PTPN1;PTPN11;PTPN2,,,PRECLINICAL,,,NA,,CC1(C)C(=O)NC2=C1C(=O)C(=O)C1CCCCC21;CC1(C)C2C(=NC1=O)C1CCCCC1C(=O)C2=O
BW-180C,BW-180C,,BRD:BRD-BRD-K57927309-001-01-7;BRD:BRD-K57927309-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRD1;OPRM1,,,PHASE 2,,,NA,,CC(C)C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1CCC(O)CC1)C(O)=O
BW-348U87,BW-348U87,,BRD:BRD-K00004593-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,,NA,,
BW-373U86,BW-373U86,,BRD:BRD-BRD-K74990253-001-02-8;BRD:BRD-K74990253-001-02-8,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRD1,,,PRECLINICAL,,,NA,,CCN(CC)C(=O)C1CCC(CC1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)C1CCCC(O)C1
BW-616U,BW-616U,,BRD:BRD-BRD-K07061232-001-01-8;BRD:BRD-K07061232-001-01-8,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA,,,PRECLINICAL,,,NA,,CNC(=O)C1CCC2C(=O)C3CCCCC3S(=O)(=O)C2C1
BW-723C86,BW-723C86,CHEMBL1255834,BRD:BRD-A17428743-003-09-0;BRD:BRD-BRD-A17428743-003-09-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,Small molecule,NA,ALFGDCNSEBJYSP-UHFFFAOYSA-N,CC(N)CC1C[NH]C2CCC(OCC3CCCS3)CC12
BW-A4C,BW-A4C,,BRD:BRD-BRD-K80194255-001-01-9;BRD:BRD-K80194255-001-01-9,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5,,,PHASE 1,,,NA,,CC(=O)N(O)C\C=C\C1CCCC(OC2CCCCC2)C1
BW-B70C,BW-B70C,,BRD:BRD-A55946879-001-04-9,rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5,,,,,,NA,,
BX-795,BX-795,CHEMBL577784,BRD:BRD-K47983010-001-15-3;GDSC1:1037,gdsc;rep_single_dose,IKK INHIBITOR,CDK2;CHEK1;GSK3B;KDR;PDK1;PDPK1,,,,,Small molecule,NA,VAVXGGRQQJZYBL-UHFFFAOYSA-N,O=C(NCCCNC1NC(NC2CCCC(NC(=O)N3CCCC3)C2)NCC1I)C1CCCS1
BX-912,BX-912,,BRD:BRD-BRD-K49669041-001-08-4;BRD:BRD-K49669041-001-08-4;GDSC1:222,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PYRUVATE DEHYDROGENASE KINASE INHIBITOR,CDK2;CHEK1;GSK3B;KDR;PDK1;PDPK1,,,PRECLINICAL,,,NA,,BRC1CNC(NC2CCCC(NC(=O)N3CCCC3)C2)NC1NCCC1C[NH]CN1
BX795,BX795,,GDSC1:1037,gdsc,,,,,,,,NA,,
BYK-204165,BYK-204165,,BRD:BRD-BRD-K61665160-001-01-5;BRD:BRD-K61665160-001-01-5,rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PRECLINICAL,,,NA,,CN1CCCC1\C=C1/C(=O)NC(=O)C2CCCCC12
BYL719,BYL719,CHEMBL2396661,GDSC2:1560,gdsc,,,,,,,Small molecule,Approved,STUWGJZDJHPWGZ-LBPRGKRZSA-N,CC1NC(NC(=O)N2CCC[C@H]2C(N)=O)SC1-C1CCNC(C(C)(C)C(F)(F)F)C1
C-021,C-021,,BRD:BRD-BRD-K98179423-300-01-3;BRD:BRD-K98179423-300-01-3,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR4,,,PRECLINICAL,,,NA,,COC1CC2NC(NC(NC3CCCCCC3)C2CC1OC)N1CCC(CC1)N1CCCCC1
C-1,C-1,CHEMBL2108955,BRD:BRD-BRD-K72462751-001-02-7;BRD:BRD-K72462751-001-02-7,rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,PRKCA,,,PRECLINICAL,,Antibody,Phase 3,,O=S(=O)(N1CCNCC1)C1CCCC2CNCCC12
C-75,C-75,,GDSC1:435,gdsc,,,,,,,,NA,,
C-751,C-751,,BRD:BRD-BRD-K15337272-001-01-3;BRD:BRD-K15337272-001-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCOC(=O)C1C[NH]CN1
C11-ACETATE,C11-ACETATE,,BRD:BRD-K83914624-415-01-3,rep_single_dose,,ABAT;ACE;AKR1C3;CA2;CELA1;ESR2;FFAR2;FFAR3;HPRT1;LTA4H;MMP12;NOS1;NOS3;PLA2G1B;PTPN1;SOD1;TXN,,,,,,NA,,
C188-9,C188-9,,BRD:BRD-K00003114-001-01-9,rep_single_dose,STAT INHIBITOR,,,,,,,NA,,
C225,C225,CHEMBL1201577,GDSC1:1114,gdsc,,,,,,,Antibody,Approved,,
C34,C34,,BRD:BRD-BRD-K43167535-001-01-3;BRD:BRD-K43167535-001-01-3,rep_primary;rep_single_dose,TOLL-LIKE RECEPTOR INHIBITOR,TLR4,,,PRECLINICAL,,,NA,,CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O
WNT-C59,C59;WNT-C59,,BRD:BRD-BRD-K78455053-001-01-2;BRD:BRD-K78455053-001-01-2;BRD:BRD-K78455053-001-05-9;GDSC1:574;GDSC2:1622,gdsc;oncref_2;rep_primary;rep_single_dose,PORCUPINE INHIBITOR,PORCN,,,PRECLINICAL,"Multiple values for MOA: {'PORCUPINE INHIBITOR', 'INHBITOR OF PORCN'}, defaulting to 'PORCUPINE INHIBITOR'",,NA,,CC1CC(CCN1)-C1CCC(CC(=O)NC2CCC(CC2)-C2CCCNC2)CC1
C6-CERAMIDE,C6-CERAMIDE,,CTRP:44554,ctrp,,,,,,,,NA,,
C646,C646,,BRD:BRD-BRD-K73383190-001-02-3;BRD:BRD-BRD-K73383190-001-03-1;BRD:BRD-K73383190-001-02-3;BRD:BRD-K73383190-001-03-1,rep_primary;rep_single_dose,HISTONE ACETYLTRANSFERASE INHIBITOR,EP300,,,PRECLINICAL,,,NA,,CC1=NN(C(=O)C1=CC1CCC(O1)-C1CC(C)C(C)CC1[N+]([O-])=O)C1CCC(CC1)C(O)=O
CA-4948,CA-4948,CHEMBL4783351,BRD:BRD-K00003511-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 1,SJHNWSAWWOAWJH-MRXNPFEDSA-N,CC1CC(-C2NC(C(=O)NC3CC4OC(N5CCOCC5)NC4NC3N3CC[C@@H](O)C3)CO2)CCN1
CABAGIN,CABAGIN,,BRD:BRD-K41504985-003-02-9,rep_single_dose,,,,,,,,NA,,
CABALETTA,CABALETTA,CHEMBL1236395,BRD:BRD-BRD-K54028654-001-02-6;BRD:BRD-K54028654-001-02-6,rep_primary;rep_single_dose,PHARMACOLOGICAL CHAPERONE,,,,PHASE 2,,Small molecule,Phase 3,HDTRYLNUVZCQOY-LIZSDCNHSA-N,OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
CABAZITAXEL,CABAZITAXEL,CHEMBL1201748,BRD:BRD-BRD-K06858286-001-01-3;BRD:BRD-K06858286-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE INHIBITOR,TUBA4A;TUBB;TUBB1,PROSTATE CANCER,,LAUNCHED,,Small molecule,Approved,BMQGVNUXMIRLCK-OAGWZNDDSA-N,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)C3CCCCC3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C;CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)C2CCCCC2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3CCCCC3)C(C)=C1C2(C)C
CABERGOLINE,CABERGOLINE,CHEMBL1201087,BRD:BRD-BRD-K86882815-001-03-2;BRD:BRD-K86882815-001-03-2,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR7,HYPERPROLACTINEMIA,,LAUNCHED,,Small molecule,Approved,KORNTPPJEAJQIU-KJXAQDMKSA-N,C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3CCCC4[NH]CC(C34)C[C@H]21;CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3C[NH]C4CCCC2C34)N(CC=C)C1
CABOTEGRAVIR,CABOTEGRAVIR,CHEMBL2403238,BRD:BRD-BRD-K76819217-001-02-2;BRD:BRD-K76819217-001-02-2,rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,,,,PHASE 2/PHASE 3,,Small molecule,Approved,WCWSTNLSLKSJPK-LKFCYVNXSA-N,C[C@H]1CO[C@@H]2CN3CC(C(=O)NCC4CCC(F)CC4F)C(=O)C(O)C3C(=O)N12
CACCINH-A01,CACCINH-A01,,BRD:BRD-A90751343-001-02-9,rep_single_dose,CALCIUM-ACTIVATED CHLORIDE CHANNEL INHIBITOR,CLCA1,,,,,,NA,,
CADAZOLID,CADAZOLID,CHEMBL3707376,BRD:BRD-K00003370-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Phase 3,XWFCFMXQTBGXQW-GOSISDBHSA-N,O=C(O)C1CN(C2CC2)C2CC(N3CCC(O)(COC4CCC(N5C[C@H](CO)OC5=O)CC4F)CC3)C(F)CC2C1=O
CAFESTOL,CAFESTOL,CHEMBL1407645,BRD:BRD-BRD-K46741531-001-02-4;BRD:BRD-K46741531-001-02-4,rep_primary;rep_single_dose,PREGNANE X RECEPTOR AGONIST,,,,LAUNCHED,,Small molecule,NA,DNJVYWXIDISQRD-HWUKTEKMSA-N,C[C@@]12CCC3OCCC3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3;C[C@@]12CCC3OCCC3[C@H]1CC[C@@]13C[C@@H](CC[C@H]12)[C@@](O)(CO)C3
CAFFEIC-ACID,CAFFEIC-ACID,,BRD:BRD-BRD-K09900591-001-26-7;BRD:BRD-K09900591-001-26-7,rep_multi_dose;rep_primary;rep_single_dose,"HIV INTEGRASE INHIBITOR, LIPOXYGENASE INHIBITOR, NITRIC OXIDE PRODUCTION INHIBITOR, TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR",ALOX5;MIF,,,PRECLINICAL,,,NA,,OC(=O)\C=C\C1CCC(O)C(O)C1
CAFFEIC-ACID-PHENETHYL-ESTER,CAFFEIC-ACID-PHENETHYL-ESTER,,BRD:BRD-BRD-K96188950-001-16-9;BRD:BRD-K96188950-001-16-9,rep_multi_dose;rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,RELA,,,PRECLINICAL,,,NA,,OC1CCC(\C=C\C(=O)OCCC2CCCCC2)CC1O
CAFFEINE,CAFFEINE,CHEMBL113;CHEMBL1200569,BRD:BRD-BRD-K02404261-001-16-7;BRD:BRD-K02404261-001-16-7,rep_primary;rep_single_dose,"ADENOSINE RECEPTOR ANTAGONIST, PHOSPHODIESTERASE INHIBITOR",ADORA1;ADORA2A;ADORA2B;ADORA3;ATM;ITPR1;ITPR2;ITPR3;PDE10A;PDE11A;PDE1A;PDE1B;PDE1C;PDE2A;PDE3A;PDE3B;PDE4A;PDE4B;PDE4C;PDE4D;PDE5A;PDE6A;PDE6B;PDE6C;PDE7A;PDE7B;PDE8A;PDE8B;PDE9A;PIK3CA;PIK3CB;PIK3CD;PRKDC;RYR1;RYR2;RYR3,"FATIGUE, DROWSINESS, FATIGUE, DROWSINESS",,LAUNCHED,,Small molecule,Approved,RCQXSQPPHJPGOF-UHFFFAOYSA-N;RYYVLZVUVIJVGH-UHFFFAOYSA-N,CN1C(=O)C2C(NCN2C)N(C)C1=O;CN1C(=O)C2C(NCN2C)N(C)C1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O;CN1CNC2N(C)C(=O)N(C)C(=O)C12
CAL-101,CAL-101,CHEMBL2216870,CTRP:660430;GDSC1:238,ctrp;gdsc,,,,,,,Small molecule,Approved,IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](NC1NCNC2[NH]CNC12)C1NC2CCCC(F)C2C(=O)N1-C1CCCCC1
CALCIFEDIOL,CALCIFEDIOL,CHEMBL1040;CHEMBL3544909,BRD:BRD-BRD-K77175907-001-08-0;BRD:BRD-K77175907-001-08-0,rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,,,LAUNCHED,,Small molecule,Approved,JWUBBDSIWDLEOM-DTOXIADCSA-N;WRLFSJXJGJBFJQ-WPUCQFJDSA-N,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C;C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12;C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O
CALCIPOTRIOL,CALCIPOTRIOL,CHEMBL1200666,BRD:BRD-BRD-K56429665-001-09-6;BRD:BRD-K56429665-001-09-6,rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,PSORIASIS,,LAUNCHED,,Small molecule,Approved,LWQQLNNNIPYSNX-UROSTWAQSA-N,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C;C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
CALCITONIN,CALCITONIN,CHEMBL2207138;CHEMBL4594242,BRD:BRD-K00005332-019-01-9,rep_single_dose,CALCITONIN AGONIST,,,,,,Protein,Approved,;CWCXERYKLSEGEZ-KDKHKZEGSA-N,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)[C@H](CC1CNC[NH]1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C
CALCITRIOL,CALCITRIOL,CHEMBL846,BRD:BRD-BRD-K27316855-001-13-3;BRD:BRD-BRD-K27316855-001-19-0;BRD:BRD-K27316855-001-13-3;BRD:BRD-K27316855-001-19-0,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,"HYPOCALCEMIA, HYPOPARATHYROIDISM, OSTEOPOROSIS",,LAUNCHED,,Small molecule,Approved,GMRQFYUYWCNGIN-NKMMMXOESA-N,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C;C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
CALCIUM-GLUCEPTATE,CALCIUM-GLUCEPTATE,,BRD:BRD-BRD-K35952844-238-01-2,rep_primary,,,,,LAUNCHED,,,NA,,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O
CALCIUM-LEVOFOLINATE,CALCIUM-LEVOFOLINATE,,BRD:BRD-BRD-K97009491-238-03-8;BRD:BRD-K97009491-238-03-8;BRD:BRD-K97009491-238-05-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,NC1NC(=O)C2N(C=O)[C@@H](CNC3CCC(CC3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2[NH]1
CALHEX-231,CALHEX-231,,BRD:BRD-K19811997-003-02-9,rep_single_dose,CALCIUM SENSING RECEPTOR NEGATIVE ALLOSTERIC MODULATOR,CASR,,,,,,NA,,
CAMICINAL,CAMICINAL,CHEMBL489095,BRD:BRD-BRD-K23248433-001-01-8;BRD:BRD-K23248433-001-01-8,rep_primary;rep_single_dose,MOTILIN RECEPTOR AGONIST,MLNR,,,PHASE 2,,Small molecule,Phase 3,RZKDEGZIFSJVNA-IBGZPJMESA-N,C[C@H]1CN(CC2CCC(CC(=O)N3CCC(CC3)NC3CCCC(F)C3)CC2)CCN1;C[C@H]1CN(CC2CCC(CC(=O)N3CCC(NC4CCCC(F)C4)CC3)CC2)CCN1
CAMKII-IN-1,CAMKII-IN-1,,BRD:BRD-BRD-K35772771-001-02-1;BRD:BRD-K35772771-001-02-1,rep_primary;rep_single_dose,CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE INHIBITOR,AKT1;CAMK2A;CAMK4;MYLK,,,PRECLINICAL,,,NA,,CC1C(CL)CCCC1S(=O)(=O)NC1NC(NCCC2CCCCC2)NC2CCN(CC3CCCCC3)CC12
CAMOBUCOL,CAMOBUCOL,CHEMBL2104958,BRD:BRD-K00004732-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Unknown,FGBGXESDYFKUFX-UHFFFAOYSA-N,CC(C)(SC1CC(C(C)(C)C)C(O)C(C(C)(C)C)C1)SC1CC(C(C)(C)C)C(OCC(=O)O)C(C(C)(C)C)C1
CAMOSTAT-MESILATE,CAMOSTAT-MESILATE,,BRD:BRD-BRD-K43806473-066-02-1;BRD:BRD-K43806473-066-02-1,rep_primary;rep_single_dose,PROTEASE INHIBITOR,PRSS1,PANCREATITIS,,LAUNCHED,,,NA,,CN(C)C(=O)COC(=O)CC1CCC(OC(=O)C2CCC(NC(N)=N)CC2)CC1
CAMPTOSAR,CAMPTOSAR,CHEMBL1200512;CHEMBL3989514;CHEMBL481,GDSC2:1088,gdsc,,,,,,,Small molecule,Approved,KLEAIHJJLUAXIQ-JDRGBKBRSA-N;OHNBIIZWIUBGTK-NYPSMHOZSA-N;UWKQSNNFCGGAFS-XIFFEERXSA-N,CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC;CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC.CL.O;CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC.CL.O.O.O
CAMPTOTHECIN,CAMPTOTHECIN,CHEMBL65;CHEMBL837,BRD:BRD-BRD-K37890730-001-15-1;BRD:BRD-K37890730-001-15-1;GDSC2:1003,gdsc;rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 3,,Small molecule,Phase 2,FJHBVJOVLFPMQE-QFIPXVFZSA-N;VSJKWCGYPAHWDS-FQEVSTJZSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1-C3NC4CCCCC4CC3CN1C2=O;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3CCCCC3NC2-1;CCC1C2C(NC3CCC(O)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC
CAMPTOTHECINE,CAMPTOTHECINE,CHEMBL65,GDSC2:1003,gdsc,,,,,,,Small molecule,Unknown,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3CCCCC3NC2-1
CAMYLOFINE-CHLORHYDRATE,CAMYLOFINE-CHLORHYDRATE,,BRD:BRD-A91733352-300-04-5;BRD:BRD-BRD-A91733352-300-04-5,rep_multi_dose;rep_primary;rep_single_dose,,,ABDOMINAL PAIN,,LAUNCHED,,,NA,,CCN(CC)CCNC(C(=O)OCCC(C)C)C1CCCCC1
CANAGLIFLOZIN,CANAGLIFLOZIN,CHEMBL2048484;CHEMBL2103841;CHEMBL4594217,BRD:BRD-BRD-K90868879-001-03-8;BRD:BRD-K90868879-001-03-8,rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A1;SLC5A2,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,RCCZPUWDQVUJAB-FVYJGOGTSA-N;VHOFTEAWFCUTOS-TUGBYPPCSA-N;XTNGUQKDFGDXSJ-ZXGKGEBGSA-N,CC1CCC([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1CC1CCC(-C2CCC(F)CC2)S1;CC1CCC([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1CC1CCC(-C2CCC(F)CC2)S1.CC1CCC([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1CC1CCC(-C2CCC(F)CC2)S1.O;CC1CCC([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1CC1CCC(-C2CCC(F)CC2)S1.O;CC1CCC(CC1CC1CCC(S1)-C1CCC(F)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
CANDESARTAN,CANDESARTAN,CHEMBL1014;CHEMBL1016,BRD:BRD-BRD-K84091759-001-07-1;BRD:BRD-K84091759-001-07-1,rep_multi_dose;rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,GHOSNRCGJFBJIB-UHFFFAOYSA-N;HTQMVQVXFRQIKW-UHFFFAOYSA-N,CCOC1NC2CCCC(C(=O)O)C2N1CC1CCC(-C2CCCCC2-C2NNN[NH]2)CC1;CCOC1NC2CCCC(C(=O)OC(C)OC(=O)OC3CCCCC3)C2N1CC1CCC(-C2CCCCC2-C2NN[NH]N2)CC1;CCOC1NC2CCCC(C(O)=O)C2N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
CANDESARTAN-CILEXTIL,CANDESARTAN-CILEXETIL;CANDESARTAN-CILEXTIL,,BRD:BRD-A65671304-001-07-5;BRD:BRD-BRD-A65671304-001-07-5,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1;AGTR2,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,,NA,,CCOC1NC2CCCC(C(=O)OC(C)OC(=O)OC3CCCCC3)C2N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
CANERTINIB,CANERTINIB,CHEMBL31965,BRD:BRD-BRD-K50168500-001-07-9;BRD:BRD-K50168500-001-07-9;CTRP:606138,ctrp;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,AKT1;EGFR;ERBB2;ERBB4,,,PHASE 3,,Small molecule,Phase 3,OMZCMEYTWSXEPZ-UHFFFAOYSA-N,C=CC(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1OCCCN1CCOCC1;FC1CCC(NC2NCNC3CC(OCCCN4CCOCC4)C(NC(=O)C=C)CC23)CC1CL
CANGRELOR,CANGRELOR,CHEMBL1097279;CHEMBL334966,BRD:BRD-K00004669-001-01-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,COWWROCHWNGJHQ-OPKBHZIBSA-J;PAEBIVWUMLRPSK-IDTAVKCVSA-N,CSCCNC1NC(SCCC(F)(F)F)NC2C1NCN2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(CL)(CL)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[NA+].[NA+].[NA+].[NA+];CSCCNC1NC(SCCC(F)(F)F)NC2C1NCN2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(CL)(CL)P(=O)(O)O)[C@@H](O)[C@H]1O
CANRENONE,CANRENONE,CHEMBL1463345,BRD:BRD-A20644369-001-08-6;BRD:BRD-BRD-A20644369-001-08-6,rep_multi_dose;rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,NR3C2,,,WITHDRAWN,,Small molecule,Approved,UJVLDDZCTMKXJK-WNHSNXHDSA-N,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]21CCC(=O)O1;C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1
"CAP-232, TT-232, TLN-232","CAP-232, TT-232, TLN-232",,GDSC1:436,gdsc,,,,,,,,NA,,
CAPADENOSON,CAPADENOSON,CHEMBL3235279,BRD:BRD-BRD-K97025174-001-01-4;BRD:BRD-K97025174-001-01-4,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,,,PHASE 2,,Small molecule,Phase 2,CITWCLNVRIKQAF-UHFFFAOYSA-N,N#CC1C(N)NC(SCC2CSC(-C3CCC(CL)CC3)N2)C(C#N)C1-C1CCC(OCCO)CC1;NC1NC(SCC2CSC(N2)-C2CCC(CL)CC2)C(C#N)C(-C2CCC(OCCO)CC2)C1C#N
CAPECITABINE,CAPECITABINE,CHEMBL1773,BRD:BRD-BRD-K61192372-001-05-5;BRD:BRD-BRD-K61192372-001-08-9;BRD:BRD-K61192372-001-05-5;BRD:BRD-K61192372-001-08-9,rep_multi_dose;rep_primary;rep_single_dose,"DNA SYNTHESIS INHIBITOR, THYMIDYLATE SYNTHASE INHIBITOR",TYMS,"BREAST CANCER, COLORECTAL CANCER",,LAUNCHED,,Small molecule,Approved,GAGWJHPBXLXJQN-UORFTKCHSA-N,CCCCCOC(=O)NC1NC(=O)N([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)CC1F;CCCCCOC(=O)NC1NC(=O)N(CC1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
INC280,CAPMATINIB;INC-280;INC280,CHEMBL3188267,BRD:BRD-BRD-K81016934-001-02-0;BRD:BRD-K81016934-001-02-0;BRD:BRD-K81016934-001-03-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MET,MET,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF MET', 'C-MET INHIBITOR'}, defaulting to 'INHIBITOR OF MET'",Small molecule,Approved,LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)C1CCC(-C2CNC3NCC(CC4CCC5NCCCC5C4)N3N2)CC1F;CNC(=O)C1CCC(CC1F)-C1CNC2NCC(CC3CCC4NCCCC4C3)N2N1
CAPREOMYCIN,CAPREOMYCIN,CHEMBL2218913;CHEMBL2221250,BRD:BRD-A31362467-065-01-3;BRD:BRD-BRD-A31362467-065-01-3,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,Protein,Approved,TUATYNXRYJTQTQ-BVRBKCERSA-N;VCOPTHOUUNAYKQ-DAOVIKHBSA-N,C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1;C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1.O=S(=O)(O)O.O=S(=O)(O)O;CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1;NCCCC(N)CC(=O)NCC1NC(=O)C(CO)NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC1=O)=C/NC(N)=O)C1CCNC(=N)N1
CAPROMORELIN,CAPROMORELIN,CHEMBL113313,BRD:BRD-K00003188-046-01-9,rep_single_dose,GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,KVLLHLWBPNCVNR-SKCUWOTOSA-N,CN1N=C2CCN(C(=O)[C@@H](COCC3CCCCC3)NC(=O)C(C)(C)N)C[C@@]2(CC2CCCCC2)C1=O
CAPRYLIC-ACID,CAPRYLIC-ACID,,BRD:BRD-BRD-K35170555-001-09-5;BRD:BRD-K35170555-001-09-5,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CCCCCCCC(O)=O
CAPSAICIN,CAPSAICIN,CHEMBL294199,BRD:BRD-BRD-K50590187-001-19-9;BRD:BRD-K50590187-001-19-9,rep_multi_dose;rep_primary;rep_single_dose,TRPV AGONIST,CFTR;TRPV1,"MUSCLE PAIN, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,YKPUWZUDDOIDPM-SOFGYWHQSA-N,COC1CC(CNC(=O)CCCC/C=C/C(C)C)CCC1O;COC1CC(CNC(=O)CCCC\C=C\C(C)C)CCC1O
CAPSAZEPINE,CAPSAZEPINE,CHEMBL391997,BRD:BRD-BRD-K44849676-001-10-5;BRD:BRD-K44849676-001-10-5,rep_primary;rep_single_dose,TRPV AGONIST,TRPV1;TRPV4,,,PRECLINICAL,,Small molecule,NA,DRCMAZOSEIMCHM-UHFFFAOYSA-N,OC1CC2C(CC1O)CN(C(=S)NCCC1CCC(CL)CC1)CCC2;OC1CC2CCCN(CC2CC1O)C(=S)NCCC1CCC(CL)CC1
CAPTAMINE,CAPTAMINE,CHEMBL1395579,BRD:BRD-BRD-K81645907-001-01-1;BRD:BRD-K81645907-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,DENMGZODXQRYAR-UHFFFAOYSA-N,CN(C)CCS
CAPTOPRIL,CAPTOPRIL,CHEMBL1560,BRD:BRD-BRD-K54529596-001-26-3;BRD:BRD-K54529596-001-26-3,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE;LTA4H;MMP2;MMP9,"HYPERTENSION, CONGESTIVE HEART FAILURE, MYOCARDIAL INFARCTION, DIABETES MELLITUS, DIABETIC NEPHROPATHY",,LAUNCHED,,Small molecule,Approved,FAKRSMQSSFJEIM-RQJHMYQMSA-N,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O;C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
CARAMIPHEN,CARAMIPHEN,CHEMBL61946,BRD:BRD-BRD-K59895502-001-01-9;BRD:BRD-K59895502-001-01-9,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM2,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Unknown,OFAIGZWCDGNZGT-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCC1;CCN(CC)CCOC(=O)C1(CCCC1)C1CCCCC1
CARAZOLOL,CARAZOLOL,CHEMBL324665,BRD:BRD-A50675490-001-01-0;BRD:BRD-BRD-A50675490-001-01-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,"ANGINA PECTORIS, CARDIAC ARRYTHMIA, HYPERTENSION, MYOCARDIAL INFARCTION",,LAUNCHED,,Small molecule,Unknown,BQXQGZPYHWWCEB-UHFFFAOYSA-N,CC(C)NCC(O)COC1CCCC2[NH]C3CCCCC3C12
CARBACHOL,CARBACHOL,CHEMBL14;CHEMBL965,BRD:BRD-BRD-K75037734-003-13-9;BRD:BRD-K75037734-003-13-9,rep_multi_dose;rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;CHRNA2,INTRAOCULAR PRESSURE,,LAUNCHED,,Small molecule,Approved,AIXAANGOTKPUOY-UHFFFAOYSA-N;VPJXQGSRWJZDOB-UHFFFAOYSA-O,C[N+](C)(C)CCOC(N)=O;C[N+](C)(C)CCOC(N)=O.[CL-]
CARBADOX,CARBADOX,CHEMBL13779,BRD:BRD-BRD-K56735750-001-06-8;BRD:BRD-K56735750-001-06-8,rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,"DYSENTRY, ENTERITIS",,LAUNCHED,,Small molecule,Unknown,OVGGLBAWFMIPPY-WUXMJOGZSA-N,COC(=O)N/N=C/C1C[N+]([O-])C2CCCCC2[N+]1[O-];COC(=O)N\N=C\C1C[N+]([O-])C2CCCCC2[N+]1[O-]
CARBAMAZEPINE,CARBAMAZEPINE,CHEMBL108,BRD:BRD-BRD-K71799949-001-36-4;BRD:BRD-K71799949-001-36-4,rep_primary;rep_single_dose,CARBOXAMIDE ANTIEPILEPTIC,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,FFGPTBGBLSHEPO-UHFFFAOYSA-N,NC(=O)N1C2CCCCC2C=CC2CCCCC12;NC(=O)N1C2CCCCC2C=CC2CCCCC21
CARBARIL,CARBARIL,CHEMBL46917,BRD:BRD-K54208592-001-10-9,rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,,,,,,Small molecule,Approved,CVXBEEMKQHEXEN-UHFFFAOYSA-N,CNC(=O)OC1CCCC2CCCCC12
CARBARSONE,CARBARSONE,CHEMBL1331366,BRD:BRD-K94848716-001-12-9,rep_single_dose,ANTIPROTOZOAL AGENT,,,,,,Small molecule,NA,WWXBHTZSYYGCSG-UHFFFAOYSA-N,NC(=O)NC1CCC([AS](=O)(O)O)CC1
CARBAZOCHROME,CARBAZOCHROME,CHEMBL2051960,BRD:BRD-A11070335-236-02-1;BRD:BRD-BRD-A11070335-236-02-1,rep_primary;rep_single_dose,,,HEMORRHAGE,,LAUNCHED,,Small molecule,Unknown,XSXCZNVKFKNLPR-SDQBBNPISA-N,CN1C(CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O;CN1CC(O)C2=C/C(=N/NC(N)=O)C(=O)C=C21
CARBENDAZIM,CARBENDAZIM,CHEMBL70971,BRD:BRD-BRD-K12906202-001-06-2;BRD:BRD-K12906202-001-06-2,rep_primary;rep_single_dose,"MICROTUBULE INHIBITOR, TUBULIN POLYMERIZATION INHIBITOR",TP53;TUBB,FUNGICIDE,,LAUNCHED,,Small molecule,Phase 1,TWFZGCMQGLPBSX-UHFFFAOYSA-N,COC(=O)NC1NC2CCCCC2[NH]1
CARBENOXOLONE,CARBENOXOLONE,CHEMBL499915,BRD:BRD-A29700858-304-01-8;BRD:BRD-A29700858-304-02-6;BRD:BRD-BRD-A29700858-304-01-8;BRD:BRD-BRD-A29700858-304-02-6,rep_primary;rep_single_dose,11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR,GJA1;GJA10;GJA3;GJA4;GJA5;GJA8;GJA9;GJB1;GJB2;GJB3;GJB4;GJB5;GJB6;GJB7;GJC1;GJC2;GJC3;GJD2;GJD3;GJD4;GJE1;HSD11B1;PANX1;PANX2;PANX3,"PEPTIC ULCER DISEASE (PUD), MOUTH INFLAMMATION",,LAUNCHED,,Small molecule,Approved,OBZHEBDUNPOCJG-WBXJDKIVSA-N,CC1(C)[C@@H](OC(=O)CCC(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12;CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O
CARBETAPENTANE,CARBETAPENTANE,CHEMBL73234,BRD:BRD-BRD-K06181161-048-15-1;BRD:BRD-K06181161-048-15-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM2,"COMMON COLD, NASAL CONGESTION, BRONCHITIS",,LAUNCHED,,Small molecule,Approved,CFJMRBQWBDQYMK-UHFFFAOYSA-N,CCN(CC)CCOCCOC(=O)C1(C2CCCCC2)CCCC1;CCN(CC)CCOCCOC(=O)C1(CCCC1)C1CCCCC1
CARBETOCIN,CARBETOCIN,CHEMBL3301668,BRD:BRD-BRD-K56107812-001-01-7;BRD:BRD-K56107812-001-01-7,rep_primary;rep_single_dose,OXYTOCIN RECEPTOR AGONIST,OXTR,HEMORRHAGE,,LAUNCHED,,Protein,Approved,NSTRIRCPWQHTIA-DTRKZRJBSA-N,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCC(OC)CC2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O;CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCC(OC)CC2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O
CARBIMAZOLE,CARBIMAZOLE,CHEMBL508102,BRD:BRD-BRD-K87156652-001-12-7;BRD:BRD-K87156652-001-12-7,rep_primary;rep_single_dose,ANTITHYROID AGENT,TPO,HYPERTHYROIDISM,,LAUNCHED,,Small molecule,Approved,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CCOC(=O)N1CCN(C)C1=S
CARBINOXAMINE,CARBINOXAMINE,CHEMBL1740361;CHEMBL864,BRD:BRD-A29426959-050-13-2;BRD:BRD-BRD-A29426959-050-13-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, CONJUNCTIVITIS, VASOMOTOR RHINITIS, DERMATOGRAPHISM",,LAUNCHED,,Small molecule,Approved,OJFSXZCBGQGRNV-INIZCTEOSA-N;OJFSXZCBGQGRNV-UHFFFAOYSA-N,CN(C)CCO[C@@H](C1CCC(CL)CC1)C1CCCCN1;CN(C)CCOC(C1CCC(CL)CC1)C1CCCCN1
CARBOPLATIN,CARBOPLATIN,CHEMBL1351,BRD:BRD-BRD-K90947825-001-02-7;BRD:BRD-K90947825-001-02-7;CTRP:26979,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"DNA ALKYLATING AGENT, DNA INHIBITOR",,OVARIAN CANCER,,LAUNCHED,,Small molecule,Approved,,N[PT]1(N)OC(=O)C2(CCC2)C(=O)O1
CARBOPLATIN:ETOPOSIDE (40:17 MOL/MOL),CARBOPLATIN:ETOPOSIDE (40:17 MOL/MOL),,CTRP:660223,ctrp,,,,,,,,NA,,
CARBOPLATIN:UNC0638 (2:1 MOL/MOL),CARBOPLATIN:UNC0638 (2:1 MOL/MOL),,CTRP:660130,ctrp,,,,,,,,NA,,
CARBOXYAMIDOTRIAZOLE,CARBOXYAMIDOTRIAZOLE,CHEMBL95431,BRD:BRD-BRD-K68408772-001-05-4;BRD:BRD-K68408772-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CXCL8,,,PHASE 3,,Small molecule,Phase 3,WNRZHQBJSXRYJK-UHFFFAOYSA-N,NC(=O)C1NNN(CC2CC(CL)C(C(=O)C3CCC(CL)CC3)C(CL)C2)C1N
CARBOXYLOSARTAN,CARBOXYLOSARTAN,,BRD:BRD-BRD-K23533833-001-01-9;BRD:BRD-K23533833-001-01-9,rep_primary;rep_single_dose,ANGIOTENSIN ANTAGONIST,AGTR1,,,PHASE 1,,,NA,,CCCCC1NC(CL)C(C(O)=O)N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
CARBOXYPYRIDINE-DISULFIDE,CARBOXYPYRIDINE-DISULFIDE,,BRD:BRD-BRD-K26530649-001-01-6;BRD:BRD-K26530649-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,OC(=O)C1CCC(SSC2CCC(CN2)C(O)=O)NC1
CARCAINIUM (CHLORIDE),CARCAINIUM (CHLORIDE),,BRD:BRD-K00079286-003-02-9,rep_single_dose,,,,,,,,NA,,
CARDIOGENOL-C,CARDIOGENOL-C,,BRD:BRD-BRD-K99174507-003-02-0;BRD:BRD-K99174507-003-02-0,rep_primary;rep_single_dose,CARDIOMYOGENESIS INDUCER,,,,PRECLINICAL,,,NA,,COC1CCC(NC2NCCC(NCCO)N2)CC1
CARDIONOGEN-1,CARDIONOGEN-1,,BRD:BRD-K50905564-001-08-9,rep_single_dose,WNT SIGNALING INHIBITOR,CTNNB1,,,,,,NA,,
CAREBASTINE,CAREBASTINE,CHEMBL67654,BRD:BRD-BRD-K49554218-001-01-0;BRD:BRD-K49554218-001-01-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,,,PHASE 1,,Small molecule,Unknown,XGHOVGYJHWQGCC-UHFFFAOYSA-N,CC(C)(C(=O)O)C1CCC(C(=O)CCCN2CCC(OC(C3CCCCC3)C3CCCCC3)CC2)CC1;CC(C)(C(O)=O)C1CCC(CC1)C(=O)CCCN1CCC(CC1)OC(C1CCCCC1)C1CCCCC1
CARFILZOMIB,CARFILZOMIB,CHEMBL451887,BRD:BRD-BRD-K15179879-001-03-2;BRD:BRD-K15179879-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,PSMA1;PSMA2;PSMA3;PSMA4;PSMA5;PSMA6;PSMA7;PSMA8;PSMB1;PSMB10;PSMB11;PSMB2;PSMB3;PSMB4;PSMB5;PSMB6;PSMB7;PSMB8;PSMB9,MULTIPLE MYELOMA,,LAUNCHED,,Protein,Approved,BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)C[C@H](NC(=O)[C@H](CCC1CCCCC1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
CARGLUMIC-ACID,CARGLUMIC-ACID,,BRD:BRD-BRD-K60240222-001-01-4;BRD:BRD-K60240222-001-01-4,rep_primary;rep_single_dose,CARBAMOYL PHOSPHATE SYNTHASE ACTIVATOR,CPS1,HYPERAMMONEMIA,,LAUNCHED,,,NA,,NC(=O)N[C@@H](CCC(O)=O)C(O)=O
CARIPORIDE,CARIPORIDE,CHEMBL436559,BRD:BRD-BRD-K21670884-001-01-9;BRD:BRD-K21670884-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,SODIUM/HYDROGEN EXCHANGER INHIBITOR,SLC9A1,,,PHASE 3,,Small molecule,Unknown,IWXNYAIICFKCTM-UHFFFAOYSA-N,CC(C)C1CCC(C(=O)N=C(N)N)CC1S(C)(=O)=O;CC(C)C1CCC(CC1S(C)(=O)=O)C(=O)N=C(N)N
CARIPRAZINE,CARIPRAZINE,CHEMBL2028019,BRD:BRD-BRD-K57764956-001-02-8;BRD:BRD-K57764956-001-02-8,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,KPWSJANDNDDRMB-QAQDUYKDSA-N,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(C3CCCC(CL)C3CL)CC2)CC1;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2CCCC(CL)C2CL)CC1
CARISOPRODOL,CARISOPRODOL,CHEMBL1233,BRD:BRD-A99939097-001-24-2;BRD:BRD-BRD-A99939097-001-24-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CYP2C19,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,OFZCIYFFPZCNJE-UHFFFAOYSA-N,CCCC(C)(COC(N)=O)COC(=O)NC(C)C
CARMOFUR,CARMOFUR,CHEMBL460499,BRD:BRD-BRD-K11630072-001-13-2;BRD:BRD-K11630072-001-13-2,rep_multi_dose;rep_primary;rep_single_dose,THYMIDYLATE SYNTHASE INHIBITOR,TYMS,"BREAST CANCER, COLORECTAL CANCER",,LAUNCHED,,Small molecule,Unknown,AOCCBINRVIKJHY-UHFFFAOYSA-N,CCCCCCNC(=O)N1CC(F)C(=O)[NH]C1=O
CARMOXIROLE,CARMOXIROLE,CHEMBL70159,BRD:BRD-BRD-K82484965-003-03-5;BRD:BRD-K82484965-003-03-5,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2,,,PHASE 2,,Small molecule,Unknown,AFSOIHMEOKEZJF-UHFFFAOYSA-N,O=C(O)C1CCC2[NH]CC(CCCCN3CC=C(C4CCCCC4)CC3)C2C1;OC(=O)C1CCC2[NH]CC(CCCCN3CCC(=CC3)C3CCCCC3)C2C1
CARMUSTINE,CARMUSTINE,CHEMBL513,BRD:BRD-BRD-K36234266-001-09-8;BRD:BRD-K36234266-001-09-8;GDSC2:1807,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"DNA ALKYLATING AGENT, DNA INHIBITOR",GSR,"NON-HODGKIN LYMPHOMA (NHL), HODGKIN'S LYMPHOMA, MULTIPLE MYELOMA, GLIOBLASTOMA, BRAINSTEM GLIOMA, MEDULLOBLASTOMA, ASTROCYTOMA, EPENDYMOMA",,LAUNCHED,,Small molecule,Approved,DLGOEMSEDOSKAD-UHFFFAOYSA-N,[O-][N+]N(CCCL)C(=O)NCCCL;O=NN(CCCL)C(=O)NCCCL
CARNITINE-(D/L),CARNITINE-(D/L),,BRD:BRD-A89594340-003-11-5;BRD:BRD-BRD-A89594340-003-11-5,rep_primary;rep_single_dose,,,,,PHASE 3,,,NA,,C[N+](C)(C)CC(O)CC(O)=O
CAROVERIN,CAROVERIN,,BRD:BRD-K70161083-001-06-9,rep_single_dose,CYTOCHROME P450 INHIBITOR,,,,,,,NA,,
CAROVERINE,CAROVERINE,CHEMBL1729803,BRD:BRD-BRD-K65900713-003-01-0;BRD:BRD-K65900713-003-01-0,rep_primary;rep_single_dose,"CALCIUM CHANNEL BLOCKER, GLUTAMATE RECEPTOR ANTAGONIST",,TINNITUS,,LAUNCHED,"Multiple values for MOA: {'GLUTAMATE RECEPTOR ANTAGONIST, CALCIUM CHANNEL BLOCKER', 'CALCIUM CHANNEL BLOCKER, GLUTAMATE RECEPTOR ANTAGONIST'}, defaulting to 'CALCIUM CHANNEL BLOCKER, GLUTAMATE RECEPTOR ANTAGONIST'",Small molecule,Unknown,MSPRUJDUTKRMLM-UHFFFAOYSA-N,CCN(CC)CCN1C(=O)C(CC2CCC(OC)CC2)NC2CCCCC21;CCN(CC)CCN1C(=O)C(NC2CCCCC12)=CC1CCC(OC)CC1
CAROXAZONE,CAROXAZONE,CHEMBL2104164,BRD:BRD-BRD-K92129045-001-01-6;BRD:BRD-K92129045-001-01-6,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,,,WITHDRAWN,,Small molecule,Unknown,KYCBWEZLKCTALM-UHFFFAOYSA-N,NC(=O)CN1CC2CCCCC2OC1=O
CARPROFEN,CARPROFEN,CHEMBL1316,BRD:BRD-A17411484-001-11-9;BRD:BRD-BRD-A17411484-001-11-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,OSTEOARTHRITIS,,LAUNCHED,,Small molecule,Approved,PUXBGTOOZJQSKH-UHFFFAOYSA-N,CC(C(=O)O)C1CCC2C(C1)[NH]C1CCC(CL)CC12;CC(C(O)=O)C1CCC2C(C1)[NH]C1CCC(CL)CC21
CARSALAM,CARSALAM,CHEMBL1720051,BRD:BRD-BRD-K13238618-001-05-9;BRD:BRD-K13238618-001-05-9,rep_primary;rep_single_dose,ANALGESIC AGENT,,,,PRECLINICAL,,Small molecule,Unknown,OAYRYNVEFFWSHK-UHFFFAOYSA-N,O=C1[NH]C(=O)C2CCCCC2O1
CARTEOLOL,CARTEOLOL,CHEMBL839,BRD:BRD-A42167015-003-10-2;BRD:BRD-BRD-A42167015-003-10-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,"INTRAOCULAR PRESSURE, GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,"Multiple values for repurposing_target: {'ADRB1;ADRB2', 'ADRB1;ADRB2;ADRB3'}, taking the union",Small molecule,Approved,LWAFSWPYPHEXKX-UHFFFAOYSA-N,CC(C)(C)NCC(O)COC1CCCC2C1CCC(=O)N2;CC(C)(C)NCC(O)COC1CCCC2NC(=O)CCC12
CARUMONAM,CARUMONAM,CHEMBL1614658,BRD:BRD-BRD-K71026158-304-01-0;BRD:BRD-K71026158-304-01-0,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"URINARY TRACT INFECTIONS, GRAM-NEGATIVE BACTERIAL INFECTIONS",,LAUNCHED,,Small molecule,Unknown,UIMOJFJSJSIGLV-JNHMLNOCSA-N,NC(=O)OC[C@@H]1[C@H](NC(=O)/C(=N\OCC(=O)O)C2CSC(N)N2)C(=O)N1S(=O)(=O)O;NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\C2CSC(N)N2)C(=O)N1S(O)(=O)=O
CARVEDILOL,CARVEDILOL,CHEMBL723,BRD:BRD-A10977446-001-12-1;BRD:BRD-BRD-A10977446-001-12-1,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3;GJA1;HIF1A;KCNH2;NDUFC2;NPPB;SELE;VCAM1;VEGFA,"MYOCARDIAL INFARCTION, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,OGHNVEJMJSYVRP-UHFFFAOYSA-N,COC1CCCCC1OCCNCC(O)COC1CCCC2[NH]C3CCCCC3C12
CARZENIDE,CARZENIDE,CHEMBL414,BRD:BRD-BRD-K09295674-001-09-8;BRD:BRD-K09295674-001-09-8,rep_primary;rep_single_dose,,CA1;CA12;CA14;CA2;CA6;CA9,,,PRECLINICAL,,Small molecule,Unknown,UCAGLBKTLXCODC-UHFFFAOYSA-N,NS(=O)(=O)C1CCC(C(=O)O)CC1;NS(=O)(=O)C1CCC(CC1)C(O)=O
CASIN,CASIN,,BRD:BRD-A25043798-001-02-9,rep_single_dose,GTPASE INHIBITOR,CDC42,,,,,,NA,,
CASODEX,CASODEX,CHEMBL409,GDSC1:150;GDSC1:1502,gdsc,,,,,,,Small molecule,Approved,LKJPYSCBVHEWIU-UHFFFAOYSA-N,CC(O)(CS(=O)(=O)C1CCC(F)CC1)C(=O)NC1CCC(C#N)C(C(F)(F)F)C1
CASPOFUNGIN,CASPOFUNGIN,CHEMBL499808,BRD:BRD-K00002625-402-02-9,rep_single_dose,"BACTERIAL CELL WALL SYNTHESIS INHIBITOR, FUNGAL 1,3-BETA-D-GLUCAN SYNTHASE INHIBITOR",,,,,,Small molecule,Approved,JYIKNQVWKBUSNH-OGZDCFRISA-N,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)C2CCC(O)CC2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O
CASPOFUNGIN-ACETATE,CASPOFUNGIN-ACETATE,,BRD:BRD-BRD-K49793107-402-02-6;BRD:BRD-K49793107-402-02-6,rep_primary;rep_single_dose,"FUNGAL 1,3-BETA-D-GLUCAN SYNTHASE INHIBITOR",,"CANDIDEMIA, ESOPHAGEAL CANDIDIASIS, ASPERGILLOSIS, PERITONITIS",,LAUNCHED,,,NA,,CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1CCC(O)CC1)[C@H](O)CCN
CASTANOSPERMINE,CASTANOSPERMINE,CHEMBL311226,BRD:BRD-BRD-K20897876-001-10-0;BRD:BRD-K20897876-001-10-0,rep_primary;rep_single_dose,GLUCOSIDASE INHIBITOR,GAA;GBA,,,PHASE 2,,Small molecule,Unknown,JDVVGAQPNNXQDW-TVNFTVLESA-N,O[C@H]1[C@H](O)[C@@H](O)CN2CC[C@H](O)[C@H]12;O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12
CATHARANTHINE,CATHARANTHINE,,BRD:BRD-K92377961-001-03-7,rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,,,,NA,,
CATHEPSIN-INHIBITOR-1,CATHEPSIN-INHIBITOR-1,,BRD:BRD-BRD-K40269473-001-02-2;BRD:BRD-K40269473-001-02-2,rep_primary;rep_single_dose,CATHEPSIN INHIBITOR,CTSB;CTSL;CTSV,,,PRECLINICAL,,,NA,,CN1NC(CC1C(=O)N[C@@H](CC1CCCC(CL)C1)C(=O)NCC#N)C(C)(C)C
CAY10505,CAY10505,,BRD:BRD-BRD-K40366680-001-03-3;BRD:BRD-K40366680-001-03-3,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CG,,,PRECLINICAL,,,NA,,FC1CCC(CC1)-C1CCC(\C=C2\SC(=O)NC2=O)O1
CAY10566,CAY10566,,GDSC1:416,gdsc,,,,,,,,NA,,
CAY10576,CAY10576,,CTRP:622913,ctrp,,,,,,,,NA,,
CAY10594,CAY10594,,CTRP:411824,ctrp,,,,,,,,NA,,
CAY10603,CAY10603,,GDSC1:276,gdsc,,,,,,,,NA,,
CAY10618,CAY10618,,CTRP:632104,ctrp,,,,,,,,NA,,
CB-03-01,CB-03-01,CHEMBL3590187,BRD:BRD-BRD-K41779183-001-01-2;BRD:BRD-K41779183-001-01-2,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,,,PHASE 3,,Small molecule,Approved,GPNHMOZDMYNCPO-PDUMRIMRSA-N,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C;CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO
CB-10-277,CB-10-277,,BRD:BRD-BRD-K59929863-001-01-9;BRD:BRD-K59929863-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,PHASE 1,,,NA,,CN(C)\N=N\C1CCC(CC1)C(O)=O
CB-103,CB-103,CHEMBL1420319,BRD:BRD-K99108507-001-10-9,rep_single_dose,,,,,,,Small molecule,Phase 2,WHIWGRCYMQLLAO-UHFFFAOYSA-N,CC(C)(C)C1CCC(OC2CCC(N)CN2)CC1
CB-5083,CB-5083,CHEMBL3747513,BRD:BRD-BRD-K49048664-001-01-2;BRD:BRD-K49048664-001-01-2,rep_primary;rep_single_dose,VALOSIN-CONTAINING PROTEIN INHIBITOR,VCP,,,PHASE 1,,Small molecule,Phase 1,RDALZZCKQFLGJP-UHFFFAOYSA-N,CC1CC2C(C(N)=O)CCCC2N1-C1NC2C(C(NCC3CCCCC3)N1)COCC2;CC1CC2C(CCCC2N1-C1NC2CCOCC2C(NCC2CCCCC2)N1)C(N)=O
CB-839,CB-839,CHEMBL3639788,BRD:BRD-BRD-K58070273-001-03-3;BRD:BRD-K58070273-001-03-3,rep_primary;rep_single_dose,GLUTAMINASE INHIBITOR,GLS,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,PRAAPINBUWJLGA-UHFFFAOYSA-N,FC(F)(F)OC1CCCC(CC(=O)NC2CCC(CCCCC3NNC(NC(=O)CC4CCCCN4)S3)NN2)C1;O=C(CC1CCCC(OC(F)(F)F)C1)NC1CCC(CCCCC2NNC(NC(=O)CC3CCCCN3)S2)NN1
CBB-1007,CBB-1007,,CTRP:687721,ctrp,,,,,,,,NA,,
CBIPES,CBIPES,,BRD:BRD-BRD-K34675210-003-01-4;BRD:BRD-K34675210-003-01-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM2,,,PRECLINICAL,,,NA,,CCS(=O)(=O)N(CC1CCCNC1)C1CCCC(C1)-C1CCC(CC1)C#N
CBL0137,CBL0137,,BRD:BRD-K00003273-003-01-9,rep_single_dose,HISTONE CHAPERONE INHIBITOR,,,,,,,NA,,
INOBRODIB,CBP/P300-IN-4;CCS1477;INOBRODIB,CHEMBL4785363,BRD:BRD-K00068629-001-02-9;BRD:BRD-K00068629-001-03-9,oncref_2;rep_single_dose,INHIBITOR OF EP300/CREBBP BRD,BRD4;CREBBP;EP300,,,,"Multiple values for Drug.Name: {'CBP/P300-IN-4', 'CCS1477'}, defaulting to 'CBP/P300-IN-4'",Small molecule,Phase 1,SKDNDJWEBPQKCS-CLHVYKLBSA-N,CO[C@H]1CC[C@H](N2C([C@@H]3CCCC(=O)N3C3CCC(F)C(F)C3)NC3CC(-C4C(C)NOC4C)CCC32)CC1
N-CYCLOHEXYL-2-BENZOTHIAZOLESULFENAMIDE,"CBS,-N-CYCLOHEXYL-2-BENZOTHIAZOLESULFENAMIDE;N-CYCLOHEXYL-2-BENZOTHIAZOLESULFENAMIDE",,BRD:BRD-BRD-K64191834-001-03-1;BRD:BRD-K64191834-001-03-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C1CCC(CC1)NSC1NC2CCCCC2S1
CC-115,CC-115,CHEMBL3586573,BRD:BRD-BRD-K16755045-003-01-7;BRD:BRD-K16755045-003-01-7,rep_primary;rep_single_dose,"MTOR INHIBITOR, DNA PROTEIN KINASE INHIBITOR",MTOR,,,PHASE 1,"Multiple values for MOA: {'DNA PROTEIN KINASE INHIBITOR, MTOR INHIBITOR', 'MTOR INHIBITOR, DNA PROTEIN KINASE INHIBITOR'}, defaulting to 'MTOR INHIBITOR, DNA PROTEIN KINASE INHIBITOR'",Small molecule,Phase 2,GMYLVKUGJMYTFB-UHFFFAOYSA-N,CCN1C(=O)CN=C2NC=C(N=C12)C1CCC(NC1C)-C1NNC[NH]1;CCN1C(=O)CNC2NCC(-C3CCC(-C4NC[NH]N4)NC3C)NC21
CC-223,CC-223,CHEMBL3586404,BRD:BRD-K88737571-001-02-2,rep_single_dose,MTOR INHIBITOR,MTOR,,,,,Small molecule,Phase 2,UFKLYTOEMRFKAD-SHTZXODSSA-N,CO[C@H]1CC[C@H](N2C(=O)CNC3NCC(-C4CCC(C(C)(C)O)NC4)NC32)CC1
CC-401,CC-401,CHEMBL1614713,BRD:BRD-BRD-K45746021-003-01-9;BRD:BRD-K45746021-003-01-9,rep_primary;rep_single_dose,JNK INHIBITOR,MAPK8,,,PHASE 1,,Small molecule,Phase 2,XDJCLCLBSGGNKS-UHFFFAOYSA-N,C(CN1CCCCC1)OC1CCCC(C1)-C1N[NH]C2CCC(CC12)-C1NCN[NH]1;C1CC(OCCN2CCCCC2)CC(-C2N[NH]C3CCC(-C4NNC[NH]4)CC23)C1
CC-5013,CC-5013,CHEMBL848,GDSC1:1020,gdsc,,,,,,,Small molecule,Approved,GOTYRUGSSMKFNF-UHFFFAOYSA-N,NC1CCCC2C1CN(C1CCC(=O)NC1=O)C2=O
CC-90003,CC-90003,,BRD:BRD-K00003116-001-01-9,rep_single_dose,MAP KINASE INHIBITOR,,,,,,,NA,,
CC-90011 (BENZENESULFONATE),CC-90011 (BENZENESULFONATE),,BRD:BRD-K00091110-074-01-9,rep_single_dose,,,,,,,,NA,,
CC-92480,CC-92480,CHEMBL4648616,BRD:BRD-K00087010-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,YTINZZFBHWSAGL-NDEPHWFRSA-N,N#CC1CCC(N2CCN(CC3CCC(COC4CCCC5C4CN([C@H]4CCC(=O)NC4=O)C5=O)CC3)CC2)C(F)C1
CC-930,CC-930,CHEMBL1950289,BRD:BRD-BRD-K48213016-001-01-8;BRD:BRD-K48213016-001-01-8,rep_primary;rep_single_dose,JNK INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,IBGLGMOPHJQDJB-IHRRRGAJSA-N,O[C@H]1CC[C@@H](CC1)NC1NCC2NC(NC3C(F)CC(F)CC3F)N([C@H]3CCOC3)C2N1;O[C@H]1CC[C@H](NC2NCC3NC(NC4C(F)CC(F)CC4F)N([C@H]4CCOC4)C3N2)CC1
CC4,CC4,,BRD:BRD-K17751100-001-02-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,CHRNB2,,,,,,NA,,
CCG-1423,CCG-1423,,BRD:BRD-A79726147-001-02-9,rep_single_dose,APOPTOSIS STIMULANT,RHOC;SRF,,,,,,NA,,
CCG-50014,CCG-50014,,BRD:BRD-BRD-K08893438-001-04-9;BRD:BRD-K08893438-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,G PROTEIN SIGNALING INHIBITOR,RGS4;RGS8,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-N1SC(=O)N(CC2CCC(F)CC2)C1=O
CCMI,CCMI,CHEMBL429317,BRD:BRD-BRD-K16338837-001-02-6;BRD:BRD-K16338837-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATOR,CHRNA7,,,PRECLINICAL,,Small molecule,Phase 1,VMAKIACTLSBBIY-BOPFTXTBSA-N,CC1CC(/C(=C/NC2CCC(CL)CC2)C(=O)NC2CCC(CL)CC2)ON1;CC1CC(ON1)C(=CNC1CCC(CL)CC1)C(=O)NC1CCC(CL)CC1
CCMQ,CCMQ,,BRD:BRD-K06159959-001-03-9,rep_single_dose,HOMOQUINOLINIC ACID BINDING INHIBITOR,,,,,,,NA,,
CCR1 ANTAGONIST 9,CCR1 ANTAGONIST 9,,BRD:BRD-K00091272-001-01-9,rep_single_dose,,,,,,,,NA,,
CCR2 ANTAGONIST 3,CCR2 ANTAGONIST 3,,BRD:BRD-K00077266-001-02-9,rep_single_dose,,,,,,,,NA,,
CCT 018159,CCT 018159,,GDSC1:1170,gdsc,,,,,,,,NA,,
CCT-018159,CCT-018159,,GDSC1:1170,gdsc,,,,,,,,NA,,
CCT-031374,CCT-031374,,BRD:BRD-K90999434-004-02-9,rep_single_dose,WNT SIGNALING INHIBITOR,CTNNB1,,,,,,NA,,
CCT007093,CCT007093,,GDSC1:1067,gdsc,,,,,,,,NA,,
CCT018159,CCT018159,,BRD:BRD-BRD-K65503129-001-06-3;BRD:BRD-K65503129-001-06-3;GDSC1:1170,gdsc;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1;HSP90AB1,,,PRECLINICAL,,,NA,,CCC1CC(-C2N[NH]C(C)C2-C2CCC3OCCOC3C2)C(O)CC1O
CCT036477,CCT036477,,CTRP:417663,ctrp,,,,,,,,NA,,
CCT128930,CCT128930,,BRD:BRD-BRD-K76406695-001-02-9;BRD:BRD-K76406695-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,PKIA;PRKACA,,,PRECLINICAL,,,NA,,NC1(CC2CCC(CL)CC2)CCN(CC1)C1NCNC2[NH]CCC12
CCT129202,CCT129202,,BRD:BRD-BRD-K57136142-001-02-4;BRD:BRD-K57136142-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC,,,PRECLINICAL,,,NA,,CN(C)C1CCC(CC1)-C1NC2C(N3CCN(CC(=O)NC4NCCS4)CC3)C(CL)CNC2[NH]1
CCT137690,CCT137690,,BRD:BRD-BRD-K03289018-001-02-7;BRD:BRD-K03289018-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CCC(CC1)-C1NC2C(N3CCN(CC4CC(C)ON4)CC3)C(BR)CNC2[NH]1
CCT196969,CCT196969,,BRD:BRD-K00005244-001-01-9,rep_single_dose,RAF INHIBITOR,,,,,,,NA,,
CCT245737,CCT245737,,BRD:BRD-K00003276-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,,NA,,
CD-1530,CD-1530,,BRD:BRD-BRD-K09619322-001-03-8;BRD:BRD-K09619322-001-03-8;CTRP:375562,ctrp;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARG,,,PRECLINICAL,,,NA,,OC(=O)C1CCC(CC1)-C1CCC2CC(O)C(CC2C1)C12CC3CC(CC(C3)C1)C2
CD-437,CD-437,,BRD:BRD-BRD-K28907958-001-04-3;BRD:BRD-K28907958-001-04-3;CTRP:375256,ctrp;rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARG,,,PRECLINICAL,,,NA,,OC(=O)C1CCC2CC(CCC2C1)-C1CCC(O)C(C1)C12CC3CC(CC(C3)C1)C2
CD532,CD532,,GDSC1:449,gdsc,,,,,,,,NA,,
CDBA,CDBA,,BRD:BRD-A08079565-001-01-8;BRD:BRD-BRD-A08079565-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 3,,,NA,,OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O
CDC-501,CDC-501,CHEMBL848,GDSC1:1020,gdsc,,,,,,,Small molecule,Approved,GOTYRUGSSMKFNF-UHFFFAOYSA-N,NC1CCCC2C1CN(C1CCC(=O)NC1=O)C2=O
CDK1-5-INHIBITOR,CDK1-5-INHIBITOR,,BRD:BRD-BRD-K87932577-001-02-4;BRD:BRD-K87932577-001-02-4,rep_primary;rep_single_dose,"CDK INHIBITOR, GLYCOGEN SYNTHASE KINASE INHIBITOR",CDK1;CDK5;GSK3B,,,PRECLINICAL,,,NA,,NC1N[NH]C2NC3CCCCC3NC12
CDK9 INHIBITOR,CDK9 INHIBITOR,,GDSC1:345,gdsc,,,,,,,,NA,,
CDK9-IN-1,CDK9-IN-1,,GDSC1:345,gdsc,,,,,,,,NA,,
CDK9-IN-6,CDK9-IN-6,,BRD:BRD-BRD-K43914553-001-01-5;BRD:BRD-K43914553-001-01-5,rep_primary;rep_single_dose,CDK INHIBITOR,CDK9,,,PRECLINICAL,,,NA,,COC[C@H](C)N[C@H]1CC[C@@H](CC1)NC1CC(C(CL)CN1)-C1CCCC(NCC2(CCOCC2)C#N)N1
CDPPB,CDPPB,,BRD:BRD-BRD-K02213468-001-02-3;BRD:BRD-K02213468-001-02-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM5,,,PRECLINICAL,,,NA,,O=C(NC1CC(NN1-C1CCCCC1)-C1CCCCC1)C1CCCC(C1)C#N
CE-245677,CE-245677,CHEMBL3545120,BRD:BRD-K00076620-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,,
CE3F4,CE3F4,,BRD:BRD-A47940219-001-01-4;BRD:BRD-BRD-A47940219-001-01-4,rep_primary;rep_single_dose,RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR INHIBITOR,RAPGEF3,,,PRECLINICAL,,,NA,,CC1CCC2C(CC(BR)C(F)C2BR)N1C=O
CEBRANOPADOL,CEBRANOPADOL,CHEMBL2364605,BRD:BRD-BRD-K48141473-001-01-7;BRD:BRD-K48141473-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRL1;OPRM1,,,PHASE 3,,Small molecule,Phase 3,CSMVOZKEWSOFER-RQNOJGIXSA-N,CN(C)[C@]1(C2CCCCC2)CC[C@]2(CC1)OCCC1C3CC(F)CCC3[NH]C12;CN(C)[C@]1(CC[C@@]2(CC1)OCCC1C2[NH]C2CCC(F)CC12)C1CCCCC1
CEDIRANIB,CEDIRANIB,CHEMBL491473,BRD:BRD-BRD-K86930074-001-05-0;BRD:BRD-K86930074-001-05-0;CTRP:606136;GDSC2:1922,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, VEGFR INHIBITOR",CSF1R;FLT1;FLT3;FLT4;KDR;KIT;PDGFRA;PDGFRB,,,PHASE 3,,Small molecule,Phase 3,XXJWYDDUDKYVKI-UHFFFAOYSA-N,COC1CC2C(OC3CCC4[NH]C(C)CC4C3F)NCNC2CC1OCCCN1CCCC1
CEFACLOR,CEFACLOR,CHEMBL1201018;CHEMBL680,BRD:BRD-BRD-K20338176-001-17-7;BRD:BRD-K20338176-001-17-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"PNEUMONIA, SKIN INFECTIONS, URINARY TRACT INFECTIONS, RESPIRATORY TRACT INFECTIONS, TONSILLITIS, PHARYNGITIS",,LAUNCHED,,Small molecule,Approved,QYIYFLOTGYLRGG-GPCCPHFNSA-N;WKJGTOYAEQDNIA-IOOZKYRYSA-N,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CL)CS[C@H]12)C1CCCCC1;N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CL)CS[C@H]12)C1CCCCC1.O;N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CL)=C(N2C1=O)C(O)=O)C1CCCCC1
CEFADROXIL,CEFADROXIL,CHEMBL1644,BRD:BRD-A56858165-001-04-4;BRD:BRD-BRD-A56858165-001-04-4,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,SLC15A1;SLC15A2;SLC22A6;SLC22A8,"URINARY TRACT INFECTIONS, SKIN INFECTIONS, TONSILLITIS, PHARYNGITIS",,LAUNCHED,,Small molecule,Approved,BOEGTKLJZSQCCD-UEKVPHQBSA-N,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3CCC(O)CC3)[C@H]2SC1;CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)C1CCC(O)CC1)C2=O)C(O)=O
CEFAZOLIN,CEFAZOLIN,CHEMBL1435,BRD:BRD-K99750640-236-20-3,rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,PON1,,,,,Small molecule,Approved,MLYYVTUWGNIJIB-BXKDBHETSA-N,CC1NNC(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)CN4CNNN4)[C@H]3SC2)S1
CEFCAPENE-PIVOXIL,CEFCAPENE-PIVOXIL,,BRD:BRD-BRD-K27515606-003-01-3;BRD:BRD-K27515606-003-01-3,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"SKIN INFECTIONS, PNEUMONIA, URINARY TRACT INFECTIONS",,LAUNCHED,,,NA,,CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1CSC(N)N1
CEFDINIR,CEFDINIR,CHEMBL927,BRD:BRD-BRD-K15766189-001-09-8;BRD:BRD-K15766189-001-09-8,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,MPO,"PNEUMONIA, TONSILLITIS, PHARYNGITIS, BRONCHITIS, SKIN INFECTIONS, OTITIS, SINUSITIS",,LAUNCHED,,Small molecule,Approved,RTXOFQZKPXMALH-GHXIOONMSA-N,C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)C3CSC(N)N3)[C@H]2SC1;NC1NC(CS1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
CEFDITOREN-PIVOXIL,CEFDITOREN-PIVOXIL,,BRD:BRD-BRD-K72167406-001-02-1;BRD:BRD-BRD-K72167406-001-03-9;BRD:BRD-K72167406-001-02-1;BRD:BRD-K72167406-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"PNEUMONIA, BRONCHITIS, SKIN INFECTIONS, TONSILLITIS, PHARYNGITIS",,LAUNCHED,,,NA,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/C3SCNC3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1CSC(N)N1
CEFEPIME,CEFEPIME,CHEMBL186,BRD:BRD-A12077521-003-01-5;BRD:BRD-BRD-A12077521-003-01-5,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"PNEUMONIA, URINARY TRACT INFECTIONS, SKIN INFECTIONS, INTRA-ABDOMINAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,HVFLCNVBZFFHBT-ZKDACBOMSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)C1CSC(N)N1;CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFETAMET,CEFETAMET,CHEMBL2103764,BRD:BRD-BRD-K27798832-001-01-5;BRD:BRD-K27798832-001-01-5,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"EAR INFECTIONS, PNEUMONIA, OTITIS, SINUSITIS, BRONCHITIS, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Unknown,MQLRYUCJDNBWMV-GHXIOONMSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)C1CSC(N)N1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFETAMET-PIVOXIL,CEFETAMET-PIVOXIL,,BRD:BRD-BRD-K21372554-003-01-7;BRD:BRD-K21372554-003-01-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,,NA,,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1CSC(N)N1
CEFIDEROCOL,CEFIDEROCOL,CHEMBL3989974,BRD:BRD-K00003257-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Approved,DBPPRLRVDVJOCL-FQRUVTKNSA-N,CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(CCNC(=O)C4CCC(O)C(O)C4CL)CCCC3)CS[C@H]12)C1CSC(N)N1)C(=O)O
CEFIXIME,CEFIXIME,CHEMBL1541,BRD:BRD-BRD-K71059170-001-11-6;BRD:BRD-K71059170-001-11-6,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"URINARY TRACT INFECTIONS, OTITIS, PHARYNGITIS, TONSILLITIS, GONORRHEA, BRONCHITIS",,LAUNCHED,,Small molecule,Approved,OKBVVJOGVLARMR-QSWIMTSFSA-N,C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)C3CSC(N)N3)[C@H]2SC1;NC1NC(CS1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O
CEFMENOXIME,CEFMENOXIME,CHEMBL1201224,BRD:BRD-A20839672-003-01-5;BRD:BRD-BRD-A20839672-003-01-5,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,HJJDBAOLQAWBMH-YCRCPZNHSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC3NNNN3C)CS[C@H]12)C1CSC(N)N1;CO\N=C(\C(=O)NC1C2SCC(CSC3NNNN3C)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFMETAZOLE,CEFMETAZOLE,CHEMBL1201195,BRD:BRD-K48470486-236-11-6,rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,,,Small molecule,Approved,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSC3NNNN3C)CS[C@@H]21
CEFMINOX,CEFMINOX,CHEMBL1276342,BRD:BRD-BRD-K77073709-435-01-2;BRD:BRD-K77073709-435-01-2,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Unknown,JSDXOWVAHXDYCU-VXSYNFHWSA-N,CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSC3NNNN3C)=C(N2C1=O)C(O)=O;CO[C@@]1(NC(=O)CSC[C@@H](N)C(=O)O)C(=O)N2C(C(=O)O)=C(CSC3NNNN3C)CS[C@@H]21
CEFODIZIME,CEFODIZIME,CHEMBL2303613,BRD:BRD-BRD-K22641081-304-01-8;BRD:BRD-K22641081-304-01-8,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"RESPIRATORY TRACT INFECTIONS, SKIN INFECTIONS, GONORRHEA",,LAUNCHED,,Small molecule,Approved,XDZKBRJLTGRPSS-BGZQYGJUSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC3NC(C)C(CC(=O)O)S3)CS[C@H]12)C1CSC(N)N1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3NC(C)C(CC(O)=O)S3)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFONICID,CEFONICID,CHEMBL1601,BRD:BRD-BRD-K34058848-304-03-1;BRD:BRD-K34058848-304-03-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,DYAIAHUQIPBDIP-AXAPSJFSSA-N,O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3NNNN3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)C1CCCCC1;O=C(O)C1=C(CSC2NNNN2CS(=O)(=O)O)CS[C@@H]2[C@H](NC(=O)[C@H](O)C3CCCCC3)C(=O)N12
CEFOPERAZONE,CEFOPERAZONE,CHEMBL507674,BRD:BRD-BRD-K02292852-001-02-1;BRD:BRD-K02292852-001-02-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,GCFBRXLSHGKWDP-XCGNWRKASA-N,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4NNNN4C)CS[C@H]23)C2CCC(O)CC2)C(=O)C1=O;CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSC4NNNN4C)=C(N3C2=O)C(O)=O)C2CCC(O)CC2)C(=O)C1=O
CEFORANIDE,CEFORANIDE,CHEMBL1201046,BRD:BRD-BRD-K37848908-001-05-6;BRD:BRD-K37848908-001-05-6,rep_primary;rep_single_dose,PENICILLIN BINDING PROTEIN INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,SLAYUXIURFNXPG-CRAIPNDOSA-N,NCC1CCCCC1CC(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC3NNNN3CC(=O)O)CS[C@H]12;NCC1CCCCC1CC(=O)N[C@H]1[C@H]2SCC(CSC3NNNN3CC(O)=O)=C(N2C1=O)C(O)=O
CEFOSELIS,CEFOSELIS,CHEMBL2105940,BRD:BRD-BRD-K72339976-065-02-1;BRD:BRD-BRD-K72339976-065-03-9;BRD:BRD-BRD-K72339976-065-04-7;BRD:BRD-K72339976-065-02-1;BRD:BRD-K72339976-065-03-9;BRD:BRD-K72339976-065-04-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,BHXLLRXDAYEMPP-SBGRAJFYSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3CCC(N)N3CCO)CS[C@H]12)C1CSC(N)N1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN3CCC(=N)N3CCO)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFOTAXIME,CEFOTAXIME,CHEMBL1010;CHEMBL1730,BRD:BRD-K78364995-236-18-3,rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,,,Small molecule,Approved,AZZMGZXNTDTSME-JUZDKLSSSA-M;GPRBEKHLDVQUJE-QSWIMTSFSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(C)=O)CS[C@H]12)C1CSC(N)N1.[NA+];CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)C1CSC(N)N1
CEFOTETAN,CEFOTETAN,CHEMBL1201098;CHEMBL474579,BRD:BRD-A78723049-001-01-2;BRD:BRD-BRD-A78723049-001-01-2,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"URINARY TRACT INFECTIONS, RESPIRATORY TRACT INFECTIONS, SKIN INFECTIONS, GYNECOLOGIC INFECTIONS, CHLAMYDIA, INTRA-ABDOMINAL INFECTIONS, BONE AND JOINT INFECTIONS, SURGICAL PROPHYLAXIS",,LAUNCHED,,Small molecule,Approved,SRZNHPXWXCNNDU-IXOPCIAXSA-N;ZQQALMSFFARWPK-GLHLDKNHSA-L,CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSC3NNNN3C)=C(N2C1=O)C(O)=O;CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)[O-])S2)C(=O)N2C(C(=O)[O-])=C(CSC3NNNN3C)CS[C@@H]21.[NA+].[NA+];CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)O)S2)C(=O)N2C(C(=O)O)=C(CSC3NNNN3C)CS[C@@H]21
CEFOTIAM,CEFOTIAM,CHEMBL1296,BRD:BRD-BRD-K02275692-300-02-6;BRD:BRD-K02275692-300-02-6,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"BACTERIAL SEPTICEMIA, BONE AND JOINT INFECTIONS, RESPIRATORY TRACT INFECTIONS, SKIN INFECTIONS, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,QYQDKDWGWDOFFU-IUODEOHRSA-N,CN(C)CCN1NNNC1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CC3CSC(N)N3)[C@H]2SC1;CN(C)CCN1NNNC1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1CSC(N)N1)C2=O)C(O)=O
CEFOXITIN,CEFOXITIN,CHEMBL1200530;CHEMBL996,BRD:BRD-BRD-K70976396-236-26-0;BRD:BRD-K70976396-236-26-0,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"RESPIRATORY TRACT INFECTIONS, URINARY TRACT INFECTIONS, INTRA-ABDOMINAL INFECTIONS, GYNECOLOGIC INFECTIONS, BACTERIAL SEPTICEMIA, BONE AND JOINT INFECTIONS, SKIN INFECTIONS",,LAUNCHED,,Small molecule,Approved,GNWUOVJNSFPWDD-XMZRARIVSA-M;WZOZEZRFJCJXNZ-ZBFHGGJFSA-N,CO[C@]1(NC(=O)CC2CCCS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O;CO[C@@]1(NC(=O)CC2CCCS2)C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@@H]21.[NA+];CO[C@@]1(NC(=O)CC2CCCS2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21
CEFOZOPRAN,CEFOZOPRAN,CHEMBL1276663,BRD:BRD-BRD-K46970505-003-01-9;BRD:BRD-K46970505-003-01-9,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,QDUIJCOKQCCXQY-WHJQOFBOSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3CCN4NCCCC43)CS[C@H]12)C1NSC(N)N1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3CCN4NCCCC34)=C(N2C1=O)C(O)=O)C1NSC(N)N1
CEFPIRAMIDE,CEFPIRAMIDE,CHEMBL1201204,BRD:BRD-BRD-K92872987-001-02-9;BRD:BRD-K92872987-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,PWAUCHMQEXVFJR-PMAPCBKXSA-N,CC1CC(O)C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4NNNN4C)CS[C@H]23)C2CCC(O)CC2)CN1;CC1CC(O)C(CN1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSC3NNNN3C)=C(N2C1=O)C(O)=O)C1CCC(O)CC1
CEFPIROME,CEFPIROME,CHEMBL65794,BRD:BRD-BRD-K56542719-065-01-4;BRD:BRD-K56542719-065-01-4,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,DKOQGJHPHLTOJR-WHRDSVKCSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3CCCC4C3CCC4)CS[C@H]12)C1CSC(N)N1;CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3CCCC4CCCC34)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFPROZIL,CEFPROZIL,CHEMBL276568;CHEMBL3184906;CHEMBL3301800,BRD:BRD-BRD-K24871708-002-04-6;BRD:BRD-K24871708-002-04-6,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"PHARYNGITIS, TONSILLITIS, OTITIS, SINUSITIS, RESPIRATORY TRACT INFECTIONS, SKIN INFECTIONS, BRONCHITIS",,LAUNCHED,,Small molecule,Approved,ALYUMNAHLSSTOU-PFBPGKLMSA-N;WDLWHQDACQUCJR-PBFPGSCMSA-N;WDLWHQDACQUCJR-ZAMMOSSLSA-N,C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3CCC(O)CC3)[C@H]2SC1;C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1CCC(O)CC1)C2=O)C(O)=O;CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3CCC(O)CC3)[C@H]2SC1;CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3CCC(O)CC3)[C@H]2SC1.O
CEFTIBUTEN,CEFTIBUTEN,CHEMBL1605,BRD:BRD-BRD-K11124378-001-04-6;BRD:BRD-K11124378-001-04-6,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"BRONCHITIS, OTITIS, PHARYNGITIS, TONSILLITIS",,LAUNCHED,,Small molecule,Approved,UNJFKXSSGBWRBZ-BJCIPQKHSA-N,NC1NC(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)CS1;NC1NC(CS1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O
CEFTIOFUR,CEFTIOFUR,CHEMBL222913,BRD:BRD-BRD-K82960980-003-01-9;BRD:BRD-BRD-K82960980-003-02-7;BRD:BRD-K82960980-003-01-9;BRD:BRD-K82960980-003-02-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"PNEUMONIA, RESPIRATORY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Unknown,ZBHXIWJRIFEVQY-IHMPYVIRSA-N,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC(=O)C3CCCO3)CS[C@H]12)C1CSC(N)N1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)C3CCCO3)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFTIZOXIM,CEFTIZOXIM,,BRD:BRD-K04301924-236-03-2,rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,,,,NA,,
CEFTOBIPROLE,CEFTOBIPROLE,CHEMBL520642,BRD:BRD-K00003117-001-01-9,rep_single_dose,ANTIINFECTIVE DRUG,,,,,,Small molecule,Phase 3,VOAZJEPQLGBXGO-SDAWRPRTSA-N,NC1NC(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)NS1
CEFTRIAXONE,CEFTRIAXONE,CHEMBL1200995;CHEMBL161;CHEMBL3183968,BRD:BRD-BRD-K96734425-304-01-7;BRD:BRD-K96734425-304-01-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"GONORRHEA, PNEUMONIA, OTITIS, SKIN INFECTIONS, URINARY TRACT INFECTIONS, PELVIC INFLAMMATORY DISEASE, BACTERIAL SEPTICEMIA, BONE AND JOINT INFECTIONS, INTRA-ABDOMINAL INFECTIONS, MENINGITIS, SURGICAL PROPHYLAXIS",,LAUNCHED,,Small molecule,Approved,VAAUVRVFOQPIGI-SPQHTLEESA-N;XMCDZRXQAGFWAK-PMCOHIMVSA-L;YOBPSXOHCHDCMU-VKZZUTNHSA-M,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSC3NC(=O)C([O-])NN3C)CS[C@H]12)C1CSC(N)N1.O.O.O.[NA+].[NA+];CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSC3NC(=O)C(O)NN3C)CS[C@H]12)C1CSC(N)N1.[NA+];CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC3NC(=O)C(O)NN3C)CS[C@H]12)C1CSC(N)N1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC3NC(=O)C(O)NN3C)=C(N2C1=O)C(O)=O)C1CSC(N)N1
CEFUROXIME,CEFUROXIME,CHEMBL1436;CHEMBL2146124,BRD:BRD-BRD-K02733959-236-07-7;BRD:BRD-K02733959-236-07-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,JFPVXVDWJQMJEE-IZRZKJBUSA-N;URDOHUPGIOGTKV-JTBFTWTJSA-M,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@H]12)C1CCCO1.[NA+];CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)C1CCCO1;CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)C1CCCO1
CELECOXIB,CELECOXIB,CHEMBL118,BRD:BRD-BRD-K02637541-001-18-0;BRD:BRD-K02637541-001-18-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,CA12;PDPK1;PTGS2,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, PRIMARY DYSMENORRHEA (PD)",,LAUNCHED,,Small molecule,Approved,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CC1CCC(-C2CC(C(F)(F)F)NN2-C2CCC(S(N)(=O)=O)CC2)CC1;CC1CCC(CC1)-C1CC(NN1-C1CCC(CC1)S(N)(=O)=O)C(F)(F)F
CELGOSIVIR,CELGOSIVIR,CHEMBL2110737,BRD:BRD-K00003204-003-01-9,rep_single_dose,GLUCOSIDASE INHIBITOR,,,,,,Small molecule,Phase 2,HTJGLYIJVSDQAE-VWNXEWBOSA-N,CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O
CELIPROLOL,CELIPROLOL,CHEMBL27810,BRD:BRD-A95602221-003-02-1;BRD:BRD-BRD-A95602221-003-02-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRB1;ADRB2,EHLERS-DANLOS SYNDROME (EDS),,LAUNCHED,,Small molecule,Approved,JOATXPAWOHTVSZ-UHFFFAOYSA-N,CCN(CC)C(=O)NC1CCC(OCC(O)CNC(C)(C)C)C(C(C)=O)C1;CCN(CC)C(=O)NC1CCC(OCC(O)CNC(C)(C)C)C(C1)C(C)=O
CENERIMOD,CENERIMOD,CHEMBL4297505,BRD:BRD-K00003248-001-01-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR,,,,,,Small molecule,Phase 2,KJKKMMMRWISKRF-FQEVSTJZSA-N,CCC1CC(-C2NOC(-C3CC(OC)NC(C4CCCC4)C3)N2)CC(C)C1OC[C@@H](O)CO
CENICRIVIROC,CENICRIVIROC,CHEMBL2110727,BRD:BRD-K00003181-001-01-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,PNDKCRDVVKJPKG-WHERJAGFSA-N,CCCCOCCOC1CCC(-C2CCC3C(C2)/C=C(/C(=O)NC2CCC([S@@+]([O-])CC4CNCN4CCC)CC2)CCCN3CC(C)C)CC1
CENISERTIB,CENISERTIB,CHEMBL1614709;CHEMBL1967878,BRD:BRD-K00075754-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,KSOVGRCOLZZTPF-QMKUDKLTSA-N;KSOVGRCOLZZTPF-UHFFFAOYSA-N,CC1CC(NC2NCC(F)C(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)N2)CCC1N1CCN(C)CC1;CC1CC(NC2NCC(F)C(NC3C4C=CC(C4)C3C(N)=O)N2)CCC1N1CCN(C)CC1
CENOBAMATE,CENOBAMATE,CHEMBL3989949,BRD:BRD-K00003249-001-01-9,rep_single_dose,"GABA RECEPTOR MODULATOR, VOLTAGE-GATED SODIUM CHANNEL BLOCKER",,,,,,Small molecule,Approved,GFHAXPJGXSQLPT-VIFPVBQESA-N,NC(=O)O[C@@H](CN1NCNN1)C1CCCCC1CL
CENTANAFADINE,CENTANAFADINE,CHEMBL3301621,BRD:BRD-K00004588-001-01-9,rep_single_dose,DOPAMINE REUPTAKE INHIBITOR,,,,,,Small molecule,Phase 3,HKHCSWPSUSWGLI-CABCVRRESA-N,C1CCC2CC([C@]34CNC[C@H]3C4)CCC2C1
CENTAZOLONE,CENTAZOLONE,,BRD:BRD-BRD-K31329721-001-08-2;BRD:BRD-K31329721-001-08-2,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,,,,PHASE 1,,,NA,,NN1CNC2CC3CCCCC3CC2C1=O
CENTHAQUIN,CENTHAQUIN,,BRD:BRD-K00004619-001-01-9,rep_single_dose,ANALGESIC AGENT,,,,,,,NA,,
CENTPROPAZINE,CENTPROPAZINE,,BRD:BRD-A28958257-001-01-2;BRD:BRD-BRD-A28958257-001-01-2,rep_primary;rep_single_dose,INOSITOL MONOPHOSPHATASE INHIBITOR,,,,PHASE 3,,,NA,,CCC(=O)C1CCC(OCC(O)CN2CCN(CC2)C2CCCCC2)CC1
CEP-32496,CEP-32496,CHEMBL2029988,BRD:BRD-BRD-K20722021-001-02-1;BRD:BRD-K20722021-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,RAF INHIBITOR,BRAF;RAF1,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,DKNUPRMJNUQNHR-UHFFFAOYSA-N,COC1CC2NCNC(OC3CCCC(NC(=O)NC4CC(C(C)(C)C(F)(F)F)ON4)C3)C2CC1OC;COC1CC2NCNC(OC3CCCC(NC(=O)NC4CC(ON4)C(C)(C)C(F)(F)F)C3)C2CC1OC
CEP-33779,CEP-33779,,BRD:BRD-BRD-K37237504-001-02-7;BRD:BRD-K37237504-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK2,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CCCC(NC2NC3C(CCCN3N2)-C2CCC(CC2)S(C)(=O)=O)C1
CEP-37440,CEP-37440,CHEMBL3545051,BRD:BRD-BRD-K72827473-001-01-0;BRD:BRD-K72827473-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK,,,PHASE 1,,Small molecule,Phase 1,,CNC(=O)C1CCCCC1NC1NC(NC2CCC3C[C@H](CCCC3C2OC)N2CCN(CCO)CC2)NCC1CL
CEP-40783,CEP-40783,CHEMBL4650515,BRD:BRD-K00003396-001-01-9,rep_single_dose,AXL KINASE INHIBITOR,,,,,,Unknown,Early Phase,,
CEP-701,CEP-701,CHEMBL603469,GDSC1:1024,gdsc,,,,,,,Small molecule,Phase 3,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)CNC4=O
CEPHALOMANNINE,CEPHALOMANNINE,CHEMBL305522,BRD:BRD-BRD-K68904758-001-03-5;BRD:BRD-K68904758-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,DBXFAPJCZABTDR-WBYYIXQISA-N,C/C=C(\C)C(=O)N[C@@H](C1CCCCC1)[C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3CCCCC3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C;C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)C3CCCCC3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)C1CCCCC1
CEPHALOSPORIN-C-ZN,CEPHALOSPORIN-C-ZN,,BRD:BRD-A44936478-001-01-1;BRD:BRD-BRD-A44936478-001-01-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,PRECLINICAL,,,NA,,CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[ZN]OC2=O)C3=O
CEPHALOTHIN,CEPHALOTHIN,CHEMBL1632;CHEMBL617,BRD:BRD-BRD-K28210218-236-08-1;BRD:BRD-K28210218-236-08-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"SKIN INFECTIONS, SURGICAL PROPHYLAXIS",,LAUNCHED,,Small molecule,Approved,VUFGUVLLDPOSBC-XRZFDKQNSA-M;XIURVHNZVLADCM-IUODEOHRSA-N,CC(=O)OCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)CC3CCCS3)[C@H]2SC1.[NA+];CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CC3CCCS3)[C@H]2SC1;CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1CCCS1)C2=O)C(O)=O
CEPHAPIRIN,CEPHAPIRIN,CHEMBL1599,BRD:BRD-BRD-K49880111-236-09-2;BRD:BRD-K49880111-236-09-2,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,MASTITIS,,LAUNCHED,,Small molecule,Approved,UQLLWWBDSUHNEB-CZUORRHYSA-N,CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSC3CCNCC3)[C@H]2SC1;CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSC1CCNCC1)C2=O)C(O)=O
CEPHARANTHINE,CEPHARANTHINE,CHEMBL449782,BRD:BRD-BRD-K96194081-001-10-2;BRD:BRD-K96194081-001-10-2,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,YVPXVXANRNDGTA-WDYNHAJCSA-N,COC1CCC2C[C@H]3N(C)CCC4CC(OC)C(OC5C6OCOC6CC6CCN(C)[C@@H](CC7CCC(OC1C2)CC7)C56)CC34;COC1CCC2CC1OC1CCC(CC1)C[C@H]1C3C(CC4C(C3OC3CC5C(CC3OC)CCN(C)[C@@H]5C2)OCO4)CCN1C
CERAMIDE,CERAMIDE,CHEMBL155886,BRD:BRD-BRD-K41707108-001-05-6;BRD:BRD-K41707108-001-05-6,rep_primary;rep_single_dose,"PHOSPHOENOLPYRUVATE CARBOXYLASE ACTIVATOR, SERINE/THREONINE PROTEIN PHOSPHATASE ACTIVATOR",,COSMETIC,,LAUNCHED,,Small molecule,Phase 2,CRJGESKKUOMBCT-VQTJNVASSA-N,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O;CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O
CERANIB-2,CERANIB-2,,CTRP:660078,ctrp,,,,,,,,NA,,
LDK378,CERITINIB;LDK378,CHEMBL2403108,BRD:BRD-BRD-K22149900-001-03-9;BRD:BRD-K22149900-001-03-9;BRD:BRD-K22149900-001-05-4,oncref_1;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK;FLT3;IGF1R;INSR;TSSK1B,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF ALK', 'ALK TYROSINE KINASE RECEPTOR INHIBITOR'}, defaulting to 'ALK TYROSINE KINASE RECEPTOR INHIBITOR'
Multiple values for repurposing_target: {'ALK;FLT3;IGF1R;INSR;TSSK1B', 'ALK'}, taking the union",Small molecule,Approved,VERWOWGGCGHDQE-UHFFFAOYSA-N,CC(C)OC1CC(C2CCNCC2)C(C)CC1NC1NCC(CL)C(NC2CCCCC2S(=O)(=O)C(C)C)N1;CC1CC(NC2NCC(CL)C(NC3CCCCC3S(=O)(=O)C(C)C)N2)C(OC(C)C)CC1C1CCNCC1
CERULENIN,CERULENIN,CHEMBL45627,BRD:BRD-BRD-K52075040-001-09-7;BRD:BRD-K52075040-001-09-7;CTRP:52430,ctrp;rep_primary;rep_single_dose,FATTY ACID SYNTHASE INHIBITOR,FASN,FUNGAL INFECTION,,LAUNCHED,,Small molecule,NA,GVEZIHKRYBHEFX-NQQPLRFYSA-N,C/C=C/C/C=C/CCC(=O)[C@H]1O[C@H]1C(N)=O;C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O
CERULETIDE,CERULETIDE,CHEMBL1201355,BRD:BRD-K00003320-001-01-9,rep_single_dose,CCK RECEPTOR AGONIST,CCKAR,,,,,Protein,Approved,YRALAIOMGQZKOW-HYAOXDFASA-N,CSCC[C@H](NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC1CCC(OS(=O)(=O)O)CC1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
CETIRIZINE,CETIRIZINE,CHEMBL1000;CHEMBL1201191;CHEMBL1607273,BRD:BRD-A42571354-300-12-0;BRD:BRD-BRD-A42571354-300-12-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,PGLIUCLTXOYQMV-UHFFFAOYSA-N;ZKLPARSLTMPFCP-OAQYLSRUSA-N;ZKLPARSLTMPFCP-UHFFFAOYSA-N,CL.CL.O=C(O)COCCN1CCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;O=C(O)COCCN1CCN([C@H](C2CCCCC2)C2CCC(CL)CC2)CC1;O=C(O)COCCN1CCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;OC(=O)COCCN1CCN(CC1)C(C1CCCCC1)C1CCC(CL)CC1
CETRIMONIUM,CETRIMONIUM,CHEMBL1183605,BRD:BRD-BRD-K47079459-004-04-6;BRD:BRD-K47079459-004-04-6,rep_multi_dose;rep_primary;rep_single_dose,,,COSMETIC,,LAUNCHED,,Small molecule,Unknown,RLGQACBPNDBWTB-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC[N+](C)(C)C
CETRORELIX,CETRORELIX,CHEMBL1200490;CHEMBL2103735,BRD:BRD-BRD-K76315403-015-02-5;BRD:BRD-K76315403-015-02-5,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,GNRHR;LHCGR,PREMATURE LUTEINIZING HORMONE SURGES,,LAUNCHED,,Protein,Approved,KFEFLCOCAHJBEA-ANRVCLKPSA-N;SBNPWPIBESPSIF-MHWMIDJBSA-N,CC(=O)N[C@H](CC1CCC2CCCCC2C1)C(=O)N[C@H](CC1CCC(CL)CC1)C(=O)N[C@H](CC1CCCNC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1CCC(O)CC1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O;CC(=O)N[C@H](CC1CCC2CCCCC2C1)C(=O)N[C@H](CC1CCC(CL)CC1)C(=O)N[C@H](CC1CCCNC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1CCC(O)CC1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O;CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1CCCNC1)NC(=O)[C@@H](CC1CCC(CL)CC1)NC(=O)[C@@H](CC1CCC2CCCCC2C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
CETUXIMAB,CETUXIMAB,CHEMBL1201577,GDSC1:1114,gdsc,,,,,,,Antibody,Approved,,
CETYLPYRIDINIUM,CETYLPYRIDINIUM,CHEMBL305906,BRD:BRD-BRD-K87700323-003-05-1;BRD:BRD-K87700323-003-05-1,rep_multi_dose;rep_primary;rep_single_dose,,,"GINGIVITIS, MOUTH INFLAMMATION",,LAUNCHED,,Small molecule,Approved,NEUSVAOJNUQRTM-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC[N+]1CCCCC1
CEVIMELINE,CEVIMELINE,CHEMBL168815;CHEMBL2218917,BRD:BRD-BRD-M98279124-300-01-1;BRD:BRD-M98279124-300-01-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM3,SJOGREN'S SYNDROME,,LAUNCHED,,Small molecule,Approved,JKJRNPOQQPBPOV-UHFFFAOYSA-N;WUTYZMFRCNBCHQ-UHFFFAOYSA-N,C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1;CC1OC2(CS1)CN1CCC2CC1;CC1OC2(CS1)CN1CCC2CC1.CL.O
CEVIPABULIN,CEVIPABULIN,CHEMBL1182714,BRD:BRD-A02473266-001-01-1;BRD:BRD-BRD-A02473266-001-01-1,rep_primary;rep_single_dose,"MICROTUBULE STIMULANT, TUBULIN POLYMERIZATION INHIBITOR",TUBB,,,PHASE 1,,Small molecule,Phase 1,ZUZPCOQWSYNWLU-VIFPVBQESA-N,CNCCCOC1CC(F)C(-C2C(CL)NC3NCNN3C2N[C@@H](C)C(F)(F)F)C(F)C1;CNCCCOC1CC(F)C(C(F)C1)-C1C(CL)NC2NCNN2C1NC(C)C(F)(F)F
CF102,CF102,CHEMBL431733,BRD:BRD-BRD-K52396582-001-06-7;BRD:BRD-K52396582-001-06-7,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 2,,Small molecule,Phase 3,IPSYPUKKXMNCNQ-PFHKOEEOSA-N,CNC(=O)[C@H]1O[C@@H](N2CNC3C(NCC4CCCC(I)C4)NC(CL)NC32)[C@H](O)[C@@H]1O;CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(NCC3CCCC(I)C3)NC(CL)NC12
CFI-400945,CFI-400945,CHEMBL3408947;CHEMBL4297462,BRD:BRD-K27040396-051-02-9,rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,,,,,,Small molecule,Phase 2,AQCDFVLWUWJREO-WQVJSASDSA-N;DADASRPKWOGKCU-FVTQAUBDSA-N,COC1CCC2C(C1)[C@]1(C[C@H]1C1CCC3C(/C=C/C4CCC(CN5C[C@@H](C)O[C@@H](C)C5)CC4)N[NH]C3C1)C(=O)N2;COC1CCC2C(C1)[C@]1(C[C@H]1C1CCC3C(/C=C/C4CCC(CN5C[C@@H](C)O[C@@H](C)C5)CC4)N[NH]C3C1)C(=O)N2.O=C(O)/C=C/C(=O)O
CFI-402257,CFI-402257,CHEMBL4469414,BRD:BRD-K00003409-001-01-9,rep_single_dose,DUAL SPECIFICITY PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Phase 1,PMQUGSPFUBGJCZ-CHOKWEPUSA-N,CC1CC(-C2CNN3C(NC[C@H]4C[C@@](C)(O)C4)CC(OC4CCCNC4)NC23)CCC1C(=O)NC1CC1
CFM-1571,CFM-1571,,BRD:BRD-BRD-K64341947-003-02-4;BRD:BRD-K64341947-003-02-4,rep_primary;rep_single_dose,GUANYLATE CYCLASE ACTIVATOR,,,,PRECLINICAL,,,NA,,COC1CCC(NC(=O)C2CC(OCCCN(C)C)NN2CC2CCCCC2)CC1
CFM-2,CFM-2,,BRD:BRD-BRD-K42859542-001-03-3;BRD:BRD-K42859542-001-03-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,COC1CC2CC(=O)NN=C(C3CCC(N)CC3)C2CC1OC
CFMS RECEPTOR TYROSINE KINASE INHIBITOR,CFMS RECEPTOR TYROSINE KINASE INHIBITOR,,GDSC1:193,gdsc,,,,,,,,NA,,
CFTRINH-172,CFTRINH-172,,BRD:BRD-BRD-K72004355-001-01-9;BRD:BRD-K72004355-001-01-9,rep_primary;rep_single_dose,CHLORIDE CHANNEL BLOCKER,CFTR,,,PRECLINICAL,,,NA,,OC(=O)C1CCC(CC1)\C=C1\SC(=S)N(C1=O)C1CCCC(C1)C(F)(F)F
CG-400549,CG-400549,CHEMBL488937,BRD:BRD-BRD-K48888725-001-01-9;BRD:BRD-K48888725-001-01-9,rep_primary;rep_single_dose,FABI INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,YCLREGRRHGLOAK-UHFFFAOYSA-N,CC1C(N)CCCC1CN1CCC(OCCC2CCCS2)CC1=O
CGH2466,CGH2466,,BRD:BRD-BRD-K82028950-300-02-9;BRD:BRD-K82028950-300-02-9,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,NC1NC(C(S1)-C1CCNCC1)-C1CCC(CL)C(CL)C1
CGK-733,CGK-733,,BRD:BRD-A50737080-001-03-0;BRD:BRD-BRD-A50737080-001-03-0,rep_primary;rep_single_dose,"ATM KINASE INHIBITOR, ATR KINASE INHIBITOR",ATM;ATR,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CC(NC(=S)NC(NC(=O)C(C2CCCCC2)C2CCCCC2)C(CL)(CL)CL)CCC1F
CGM097,CGM097,CHEMBL3601398,BRD:BRD-BRD-K79584249-001-01-3;BRD:BRD-K79584249-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,MDM INHIBITOR,MDM2,,,PHASE 1,,Small molecule,Phase 1,CLRSLRWKONPSRQ-IIPSPAQQSA-N,COC1CC2C(CC1OC(C)C)[C@H](C1CCC(CL)CC1)N(C1CCC(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)CC1)C(=O)C2;COC1CC2CC(=O)N([C@@H](C3CCC(CL)CC3)C2CC1OC(C)C)C1CCC(CC1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1
CGP 60474,CGP 60474,,GDSC1:53,gdsc,,,,,,,,NA,,
CGP-082996,CGP-082996,,GDSC1:54,gdsc,,,,,,,,NA,,
CGP-12177,CGP-12177,CHEMBL420746,BRD:BRD-A40084411-003-07-7;BRD:BRD-BRD-A40084411-003-07-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3,,,PHASE 1,,Small molecule,NA,UMQUQWCJKFOUGV-UHFFFAOYSA-N,CC(C)(C)NCC(O)COC1CCCC2[NH]C(=O)[NH]C12;CC(C)(C)NCC(O)COC1CCCC2[NH]C(O)NC12
CGP-13501,CGP-13501,,BRD:BRD-BRD-K95851186-001-07-8;BRD:BRD-K95851186-001-07-8,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABBR1,,,PRECLINICAL,,,NA,,CC(C)(CC1CC(C(O)C(C1)C(C)(C)C)C(C)(C)C)C=O
CGP-20712A,CGP-20712A,CHEMBL280822,BRD:BRD-A31575449-066-07-8;BRD:BRD-BRD-A31575449-066-07-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB3,,,PRECLINICAL,,Small molecule,NA,GKJZEKSHCJELPL-UHFFFAOYSA-N,CN1CC(C(F)(F)F)NC1-C1CCC(OCC(O)CNCCOC2CCC(O)C(C(N)=O)C2)CC1;CN1CC(NC1-C1CCC(OCC(O)CNCCOC2CCC(O)C(C2)C(N)=O)CC1)C(F)(F)F
CGP-25454A,CGP-25454A,,BRD:BRD-K00003372-003-01-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,,,,NA,,
CGP-37157,CGP-37157,,BRD:BRD-A35623999-001-05-7;BRD:BRD-BRD-A35623999-001-05-7,rep_primary;rep_single_dose,"MITOCHONDRIAL NA+/CA2+ EXCHANGER ANTAGONIST, SODIUM/CALCIUM EXCHANGE INHIBITOR",SLC8A1,,,PRECLINICAL,,,NA,,CLC1CCC2NC(=O)CSC(C3CCCCC3CL)C2C1
CGP-37849,CGP-37849,CHEMBL29811,BRD:BRD-A90272038-001-01-7;BRD:BRD-BRD-A90272038-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PHASE 1,,Small molecule,NA,BDYHNCZIGYIOGJ-DUXPYHPUSA-N,C/C(=C\C(N)C(=O)O)CP(=O)(O)O;C\C(CP(O)(O)=O)=C/C(N)C(O)=O
CGP-39551,CGP-39551,,BRD:BRD-K00004626-001-01-9,rep_single_dose,NMDA RECEPTOR ANTAGONIST,,,,,,,NA,,
CGP-41251,CGP-41251,CHEMBL608533,GDSC1:153,gdsc,,,,,,,Small molecule,Approved,BMGQWWVMWDBQGC-IIFHNQTCSA-N,CO[C@@H]1[C@H](N(C)C(=O)C2CCCCC2)C[C@H]2O[C@]1(C)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)C(=O)NC4
CGP-52411,CGP-52411,,BRD:BRD-BRD-K13087974-001-02-5;BRD:BRD-K13087974-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,O=C1NC(=O)C2CC(NC3CCCCC3)C(NC3CCCCC3)CC12
CGP-53353,CGP-53353,CHEMBL7939,BRD:BRD-BRD-K32292990-001-03-6;BRD:BRD-K32292990-001-03-6,rep_primary;rep_single_dose,"EGFR INHIBITOR, PKC INHIBITOR",EGFR;PRKCB,,,PRECLINICAL,,Small molecule,NA,RONQPWQYDRPRGG-UHFFFAOYSA-N,FC1CCC(NC2CC3C(=O)NC(=O)C3CC2NC2CCC(F)CC2)CC1;O=C1NC(=O)C2CC(NC3CCC(F)CC3)C(NC3CCC(F)CC3)CC21
CGP-54626,CGP-54626,,BRD:BRD-A74208568-003-01-5;BRD:BRD-BRD-A74208568-003-01-5,rep_multi_dose;rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1;GABBR2;KCTD12;KCTD16;KCTD8,,,PRECLINICAL,,,NA,,C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)C1CCC(CL)C(CL)C1
CGP-55845,CGP-55845,,BRD:BRD-A89672324-001-03-0;BRD:BRD-BRD-A89672324-001-03-0,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1;GABBR2;KCTD12;KCTD16;KCTD8,,,PRECLINICAL,,,NA,,C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)C1CCC(CL)C(CL)C1
CGP-57380,CGP-57380,,BRD:BRD-BRD-K42500029-001-03-5;BRD:BRD-K42500029-001-03-5,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,AURKB;LCK;MKNK1;MKNK2;SGK1,,,PRECLINICAL,,,NA,,NC1NCNC2[NH]NC(NC3CCC(F)CC3)C12
CGP-60474,CGP-60474,,BRD:BRD-BRD-K79090631-001-22-3;BRD:BRD-K79090631-001-22-3;GDSC1:53,gdsc;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2,,,PRECLINICAL,,,NA,,OCCCNC1CC(CCN1)-C1CCNC(NC2CCCC(CL)C2)N1
CGP-71683,CGP-71683,,BRD:BRD-BRD-K34321528-003-01-2;BRD:BRD-K34321528-003-01-2,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY5R,,,PRECLINICAL,,,NA,,NC1NC(NC[C@H]2CC[C@H](CNS(=O)(=O)C3CCCC4CCCCC34)CC2)NC2CCCCC12
CGP-74514,CGP-74514,,BRD:BRD-BRD-K56239177-300-01-3;BRD:BRD-K56239177-300-01-3,rep_primary;rep_single_dose,CDK INHIBITOR,CDK1,,,PRECLINICAL,,,NA,,CCN1CNC2C(NC3CCCC(CL)C3)NC(N[C@@H]3CCCC[C@@H]3N)NC12
CGP-78608,CGP-78608,,BRD:BRD-K60946979-003-02-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,,,,NA,,
CGP-7930,CGP-7930,,BRD:BRD-BRD-K65786282-001-07-5;BRD:BRD-K65786282-001-07-5,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABBR1,,,PRECLINICAL,,,NA,,CC(C)(CO)CC1CC(C(O)C(C1)C(C)(C)C)C(C)(C)C
CGP60474,CGP60474,,GDSC1:53,gdsc,,,,,,,,NA,,
CGS-15943,CGS-15943,CHEMBL16687,BRD:BRD-BRD-K49049886-001-08-7;BRD:BRD-K49049886-001-08-7,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,Small molecule,NA,MSJODEOZODDVGW-UHFFFAOYSA-N,NC1NC2CCC(CL)CC2C2NC(-C3CCCO3)NN12;NC1NC2CCC(CL)CC2C2NC(NN12)-C1CCCO1
CGS-20625,CGS-20625,,BRD:BRD-BRD-K68103045-001-02-9;BRD:BRD-K68103045-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,"BENZODIAZEPINE RECEPTOR AGONIST, GABA BENZODIAZEPINE SITE RECEPTOR PARTIAL AGONIST",GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6,,,PHASE 1,,,NA,,COC1CCC(CC1)-N1NC2C3CCCCCC3[NH]CC2C1=O
CGS-21680,CGS-21680,CHEMBL331372,BRD:BRD-BRD-K12614344-003-01-8;BRD:BRD-K12614344-003-01-8,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,Small molecule,NA,PAOANWZGLPPROA-RQXXJAGISA-N,CCNC(=O)[C@H]1O[C@@H](N2CNC3C(N)NC(NCCC4CCC(CCC(=O)O)CC4)NC32)[C@H](O)[C@@H]1O;CCNC(=O)[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1CNC2C(N)NC(NCCC3CCC(CCC(O)=O)CC3)NC12
CGS-9896,CGS-9896,CHEMBL20042,BRD:BRD-BRD-K54093161-001-01-8;BRD:BRD-K54093161-001-01-8,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABRA1;GABRB2;GABRG2,,,PRECLINICAL,,Small molecule,NA,XJMIBNLJFYSGAR-UHFFFAOYSA-N,CLC1CCC(CC1)-N1[NH]C2C(CNC3CCCCC23)C1=O;O=C1C2C=NC3CCCCC3C2=NN1C1CCC(CL)CC1
CH 542802,CH 542802,,GDSC1:281,gdsc,,,,,,,,NA,,
CH-170,CH-170,,BRD:BRD-BRD-K24820488-001-01-7;BRD:BRD-K24820488-001-01-7,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,CC1NC(CN2CNC3N(C)C(=O)N(C)C(=O)C23)NO1
CH-5183284,CH-5183284,,BRD:BRD-BRD-K11683436-001-01-7;BRD:BRD-K11683436-001-01-7,rep_primary;rep_single_dose,FIBROBLAST GROWTH FACTOR INHIBITOR,FGFR1;FGFR2;FGFR3,,,PHASE 1,,,NA,,CC1NC2CCC(CC2[NH]1)-N1NCC(C(=O)C2CC3CCCCC3[NH]2)C1N
CH-55,CH-55,,CTRP:660137,ctrp,,,,,,,,NA,,
CH223191,CH223191,,BRD:BRD-BRD-K22314899-001-02-4;BRD:BRD-K22314899-001-02-4,rep_primary;rep_single_dose,ARYL HYDROCARBON RECEPTOR ANTAGONIST,AHR,,,PRECLINICAL,,,NA,,CC1CC(CCC1NC(=O)C1CCNN1C)\N=N\C1CCCCC1C
CH5132799,CH5132799,CHEMBL1684984,BRD:BRD-BRD-K28352084-001-02-3;BRD:BRD-K28352084-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 1,,Small molecule,Phase 1,JEGHXKRHKHPBJD-UHFFFAOYSA-N,CS(=O)(=O)N1CCC2C(-C3CNC(N)NC3)NC(N3CCOCC3)NC21;CS(=O)(=O)N1CCC2C1NC(NC2-C1CNC(N)NC1)N1CCOCC1
CH5424802,CH5424802,CHEMBL1738797,GDSC1:281,gdsc,,,,,,,Small molecule,Approved,KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCC1CC2C(CC1N1CCC(N3CCOCC3)CC1)C(C)(C)C1[NH]C3CC(C#N)CCC3C1C2=O
CH55,CH55,,BRD:BRD-K71487808-001-02-8,rep_single_dose,RETINOID RECEPTOR BINDER,RARA;RARB,,,,,,NA,,
CHC,CHC,,BRD:BRD-K60302405-001-04-5,rep_single_dose,MONOCARBOXYLATE TRANSPORTER INHIBITOR,SLC16A1,,,,,,NA,,
CHENODEOXYCHOLIC-ACID,CHENODEOXYCHOLIC-ACID,,BRD:BRD-BRD-K18135438-001-14-2;BRD:BRD-BRD-K18135438-001-16-7;BRD:BRD-K18135438-001-14-2;BRD:BRD-K18135438-001-16-7,rep_primary;rep_single_dose,"11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR, FXR AGONIST",HSD11B1;NR1H4,"CEREBRAL CHOLESTEROSIS, GALLSTONES",,LAUNCHED,,,NA,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
CHF5074,CHF5074,,BRD:BRD-BRD-K34508702-001-02-4;BRD:BRD-K34508702-001-02-4,rep_primary;rep_single_dose,GAMMA SECRETASE MODULATOR,PSEN1,,,PHASE 2,,,NA,,OC(=O)C1(CC1)C1CCC(C(F)C1)-C1CCC(CL)C(CL)C1
CHICAGO-SKY-BLUE-6B,CHICAGO-SKY-BLUE-6B,,BRD:BRD-BRD-K56483981-342-06-4;BRD:BRD-K56483981-342-06-4,rep_multi_dose;rep_primary;rep_single_dose,"GLUTAMATE INHIBITOR, MACROPHAGE MIGRATION INHIBITING FACTOR INHIBITOR",MIF,,,PRECLINICAL,,,NA,,COC1CC(CCC1\N=N\C1CCC2C(CC(C(N)C2C1O)S(O)(=O)=O)S(O)(=O)=O)-C1CCC(\N=N\C2CCC3C(CC(C(N)C3C2O)S(O)(=O)=O)S(O)(=O)=O)C(OC)C1
CHIDAMIDE,CHIDAMIDE,CHEMBL3621988,BRD:BRD-BRD-K28537285-001-01-8;BRD:BRD-K28537285-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC10;HDAC3,,,LAUNCHED,,Small molecule,Phase 3,SZMJVTADHFNAIS-BJMVGYQFSA-N,NC1CC(F)CCC1NC(=O)C1CCC(CNC(=O)/C=C/C2CCCNC2)CC1;NC1CCC(F)CC1NC(=O)C1CCC(CNC(=O)\C=C\C2CCCNC2)CC1
CHINIOFON,CHINIOFON,CHEMBL1788402;CHEMBL2104146,BRD:BRD-BRD-K52284881-236-02-4;BRD:BRD-K52284881-236-02-4,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,AMEBIASIS,,LAUNCHED,,Small molecule,Unknown,FNXKBSAUKFCXIK-UHFFFAOYSA-M;ZBJWWKFMHOAPNS-UHFFFAOYSA-N,O=C([O-])O.O=S(=O)(O)C1CC(I)C(O)C2NCCCC12.[NA+];O=S(=O)(O)C1CC(I)C(O)C2NCCCC12;OC1C(I)CC(C2CCCNC12)S(O)(=O)=O
CHIR 99021,CHIR 99021,,GDSC1:1241;GDSC1:154,gdsc,,,,,,,,NA,,
CHIR-124,CHIR-124,,BRD:BRD-BRD-K02241333-001-02-7;BRD:BRD-K02241333-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,CHK INHIBITOR,CHEK1,,,PRECLINICAL,,,NA,,CLC1CCC2[NH]C(=O)C(-C3NC4CCCCC4[NH]3)C(N[C@@H]3CN4CCC3CC4)C2C1
CHIR-98014,CHIR-98014,,BRD:BRD-BRD-K42973005-001-04-0;BRD:BRD-K42973005-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3A;GSK3B,,,PRECLINICAL,,,NA,,NC1NC(NCCNC2NCC(C(N2)-C2CCC(CL)CC2CL)-N2CCNC2)CCC1[N+]([O-])=O
LADUVIGLUSIB,CHIR-99021;CT99021;LADUVIGLUSIB,CHEMBL412142,BRD:BRD-BRD-K16189898-003-03-3;BRD:BRD-K16189898-003-03-3;CTRP:347812;GDSC1:1241;GDSC1:154,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,CDK1;GSK3A;GSK3B;MAPK1,,,PRECLINICAL,"Multiple values for MOA: {'GLYCOGEN SYNTHASE KINASE INHIBITOR', 'INHIBITOR OF GSK3'}, defaulting to 'GLYCOGEN SYNTHASE KINASE INHIBITOR'
Multiple values for repurposing_target: {'CDK1;GSK3A;GSK3B;MAPK1', 'GSK3A;GSK3B'}, taking the union",Small molecule,Unknown,AQGNHMOJWBZFQQ-UHFFFAOYSA-N,CC1C[NH]C(N1)-C1CNC(NCCNC2CCC(CN2)C#N)NC1-C1CCC(CL)CC1CL;CC1CNC(-C2CNC(NCCNC3CCC(C#N)CN3)NC2-C2CCC(CL)CC2CL)[NH]1
CHIR99021,CHIR99021,,GDSC1:1241;GDSC1:154,gdsc,,,,,,,,NA,,
CHLORALOSE,CHLORALOSE,CHEMBL2104181,BRD:BRD-A98174560-001-02-1;BRD:BRD-BRD-A98174560-001-02-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,OJYGBLRPYBAHRT-IPQSZEQASA-N,OC[C@@H](O)[C@H]1O[C@@H]2O[C@H](C(CL)(CL)CL)O[C@@H]2[C@H]1O;OCC(O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(CL)(CL)CL
CHLORAMBUCIL,CHLORAMBUCIL,CHEMBL515,BRD:BRD-BRD-K29458283-001-29-9;BRD:BRD-K29458283-001-29-9;CTRP:25334,ctrp;rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,"CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), HODGKIN'S LYMPHOMA",,LAUNCHED,,Small molecule,Approved,JCKYGMPEJWAADB-UHFFFAOYSA-N,O=C(O)CCCC1CCC(N(CCCL)CCCL)CC1;OC(=O)CCCC1CCC(CC1)N(CCCL)CCCL
CHLORAMPHENICOL,CHLORAMPHENICOL,CHEMBL130,BRD:BRD-BRD-K08111712-001-16-7;BRD:BRD-K08111712-001-16-7,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,CD55,"MENINGITIS, FEVER, CHOLERA",,LAUNCHED,,Small molecule,Approved,WIIZWVCIJKGZOK-RKDXNWHRSA-N,O=C(N[C@H](CO)[C@H](O)C1CCC([N+](=O)[O-])CC1)C(CL)CL;OC[C@@H](NC(=O)C(CL)CL)[C@H](O)C1CCC(CC1)[N+]([O-])=O
CHLORAMPHENICOL-PALMITATE,CHLORAMPHENICOL-PALMITATE,,BRD:BRD-BRD-K96424892-001-02-9;BRD:BRD-K96424892-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,"MENINGITIS, FEVER, CHOLERA",,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(CL)CL)[C@H](O)C1CCC(CC1)[N+]([O-])=O
CHLORAZANIL,CHLORAZANIL,CHEMBL1984344,BRD:BRD-BRD-K21452876-003-01-8;BRD:BRD-K21452876-003-01-8,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,YRZQHIVOIFJEEE-UHFFFAOYSA-N,NC1NCNC(NC2CCC(CL)CC2)N1
CHLORCYCLIZINE,CHLORCYCLIZINE,CHEMBL22150,BRD:BRD-A57133233-003-11-0;BRD:BRD-BRD-A57133233-003-11-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Phase 1,WFNAKBGANONZEQ-UHFFFAOYSA-N,CN1CCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;CN1CCN(CC1)C(C1CCCCC1)C1CCC(CL)CC1
CHLORHEXIDINE,CHLORHEXIDINE,CHEMBL790,BRD:BRD-BRD-K52256627-300-06-6;BRD:BRD-K52256627-300-06-6,rep_multi_dose;rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,,"COSMETIC, SKIN INFECTIONS, GINGIVITIS",,LAUNCHED,,Small molecule,Approved,GHXZTYHSJHQHIJ-UHFFFAOYSA-N,CLC1CCC(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2CCC(CL)CC2)CC1;N=C(NCCCCCCNC(=N)NC(=N)NC1CCC(CL)CC1)NC(=N)NC1CCC(CL)CC1
CHLORIDINE,CHLORIDINE,CHEMBL36,GDSC1:71,gdsc,,,,,,,Small molecule,Approved,WKSAUQYGYAYLPV-UHFFFAOYSA-N,CCC1NC(N)NC(N)C1-C1CCC(CL)CC1
CHLORINDANOL,CHLORINDANOL,CHEMBL1449249,BRD:BRD-BRD-K01653460-001-01-1;BRD:BRD-K01653460-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,ATAJVFBUUIBIEO-UHFFFAOYSA-N,OC1CCC(CL)C2C1CCC2;OC1CCC(CL)C2CCCC12
CHLORINDIONE,CHLORINDIONE,,BRD:BRD-BRD-K61802864-001-08-8;BRD:BRD-K61802864-001-08-8,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)C1C(=O)C2CCCCC2C1=O
CHLORMADINONE-ACETATE,CHLORMADINONE-ACETATE,,BRD:BRD-A01593789-001-03-1;BRD:BRD-BRD-A01593789-001-03-1,rep_primary;rep_single_dose,5 ALPHA REDUCTASE INHIBITOR,PGR,"HYPERMENORRHEA, AMENORRHEA, OLIGOMENORRHEA, POLYMENORRHEA",,LAUNCHED,,,NA,,CC(=O)O[C@@]1(CCC2C3C=C(CL)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O
CHLORMEZANONE,CHLORMEZANONE,CHEMBL1200714,BRD:BRD-A20348246-001-15-8;BRD:BRD-BRD-A20348246-001-15-8,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1;TSPO,,,WITHDRAWN,,Small molecule,Approved,WEQAYVWKMWHEJO-UHFFFAOYSA-N,CN1C(=O)CCS(=O)(=O)C1C1CCC(CL)CC1;CN1C(C2CCC(CL)CC2)S(=O)(=O)CCC1=O
CHLORMIDAZOLE,CHLORMIDAZOLE,CHEMBL152649,BRD:BRD-BRD-K60443845-001-08-6;BRD:BRD-K60443845-001-08-6,rep_multi_dose;rep_primary;rep_single_dose,FUNGAL LANOSTEROL DEMETHYLASE INHIBITOR,,FUNGAL INFECTION,,LAUNCHED,,Small molecule,Unknown,WNAQOLSMVPFGTE-UHFFFAOYSA-N,CC1NC2CCCCC2N1CC1CCC(CL)CC1
CHLOROBUTANOL,CHLOROBUTANOL,CHEMBL1439973,BRD:BRD-BRD-K39495750-001-01-2;BRD:BRD-K39495750-001-01-2,rep_primary;rep_single_dose,,,"ANESTHETIC, SEDATIVE",,LAUNCHED,,Small molecule,Approved,OSASVXMJTNOKOY-UHFFFAOYSA-N,CC(C)(O)C(CL)(CL)CL
CHLOROCRESOL,CHLOROCRESOL,CHEMBL1230222,BRD:BRD-BRD-K89056082-001-07-7;BRD:BRD-K89056082-001-07-7,rep_primary;rep_single_dose,RYANODINE RECEPTOR ACTIVATOR,,FIRST-AID ANTISEPTIC,,LAUNCHED,,Small molecule,Unknown,CFKMVGJGLGKFKI-UHFFFAOYSA-N,CC1CC(O)CCC1CL
CHLOROGENIC-ACID,CHLOROGENIC-ACID,,BRD:BRD-BRD-K47114202-001-14-6;BRD:BRD-K47114202-001-14-6,rep_multi_dose;rep_primary;rep_single_dose,ANTIOXIDANT,SLC37A4,"HEADACHE, CHEST CONGESTION, ALLERGIC RHINITIS",,LAUNCHED,,,NA,,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\C2CCC(O)C(O)C2)[C@@H]1O)C(O)=O
CHLOROPROCAINE,CHLOROPROCAINE,CHEMBL1179047,BRD:BRD-BRD-K86864073-001-01-1;BRD:BRD-K86864073-001-01-1,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,ATP1A1;CHRNA10;GRIN3A;HTR3A;SCN10A;SLC6A3,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,VDANGULDQQJODZ-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1CCC(N)CC1CL
CHLOROPYRAMINE,CHLOROPYRAMINE,CHEMBL1194287,BRD:BRD-BRD-K83257731-003-23-5;BRD:BRD-K83257731-003-23-5,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"EDEMA, CONJUNCTIVITIS, ALLERGIC RHINITIS, ASTHMA",,LAUNCHED,,Small molecule,Unknown,ICKFFNBDFNZJSX-UHFFFAOYSA-N,CN(C)CCN(CC1CCC(CL)CC1)C1CCCCN1
CHLOROQUINE,CHLOROQUINE,CHEMBL1326;CHEMBL76,BRD:BRD-A91699651-316-10-9;BRD:BRD-BRD-A91699651-316-10-9,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,GSTA2;MRGPRX1;TLR9;TNF,"MALARIA, AMEBIASIS",,LAUNCHED,,Small molecule,Approved,AEUAEICGCMSYCQ-UHFFFAOYSA-N;WHTVZRBIWZFKQO-UHFFFAOYSA-N,CCN(CC)CCCC(C)NC1CCNC2CC(CL)CCC12;CCN(CC)CCCC(C)NC1CCNC2CC(CL)CCC12.O=P(O)(O)O
CHLOROTHIAZIDE,CHLOROTHIAZIDE,CHEMBL842,BRD:BRD-BRD-K88682005-001-15-8;BRD:BRD-K88682005-001-15-8,rep_primary;rep_single_dose,DIURETIC,CA1;CA2;CA4;SLC12A3,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,JBMKAUGHUNFTOL-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1CL)N=CNS2(=O)=O
CHLOROTRIANISENE,CHLOROTRIANISENE,CHEMBL1200761,BRD:BRD-BRD-K27062708-001-23-1;BRD:BRD-K27062708-001-23-1,rep_primary;rep_single_dose,ESTROGENIC HORMONE,ESR1;ESR2,"MENOPAUSE, PROSTATE CANCER",,LAUNCHED,,Small molecule,Approved,BFPSDSIWYFKGBC-UHFFFAOYSA-N,COC1CCC(C(CL)=C(C2CCC(OC)CC2)C2CCC(OC)CC2)CC1;COC1CCC(CC1)C(CL)=C(C1CCC(OC)CC1)C1CCC(OC)CC1
CHLOROXINE,CHLOROXINE,CHEMBL1200596,BRD:BRD-BRD-K17075857-001-17-6;BRD:BRD-BRD-K17075857-001-18-4;BRD:BRD-K17075857-001-17-6;BRD:BRD-K17075857-001-18-4,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRK1,"DIARRHEA, INFLAMMATORY BOWEL DISEASE, GIARDIASIS, DANDRUFF",,LAUNCHED,,Small molecule,Approved,WDFKMLRRRCGAKS-UHFFFAOYSA-N,OC1C(CL)CC(CL)C2CCCNC12
CHLOROXOQUINOLINE,CHLOROXOQUINOLINE,,BRD:BRD-BRD-K83335125-001-07-0;BRD:BRD-K83335125-001-07-0,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,OC1CCNC2CC(CL)CCC12
CHLOROXYLENOL,CHLOROXYLENOL,CHEMBL398440,BRD:BRD-BRD-K17223896-001-10-0;BRD:BRD-K17223896-001-10-0,rep_primary;rep_single_dose,ATP SYNTHASE INHIBITOR,,SKIN INFECTIONS,,LAUNCHED,,Small molecule,Approved,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CC1CC(O)CC(C)C1CL
CHLORPHENAMINE,CHLORPHENAMINE,CHEMBL1201353;CHEMBL1659;CHEMBL505,BRD:BRD-A04553218-050-16-2;BRD:BRD-BRD-A04553218-050-16-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1;SLC6A2;SLC6A3;SLC6A4,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,DBAKFASWICGISY-BTJKTKAUSA-N;SOYKEARSMXGVTM-HNNXBMFYSA-N;SOYKEARSMXGVTM-UHFFFAOYSA-N,CN(C)CC[C@@H](C1CCC(CL)CC1)C1CCCCN1;CN(C)CCC(C1CCC(CL)CC1)C1CCCCN1;CN(C)CCC(C1CCC(CL)CC1)C1CCCCN1.O=C(O)/C=C\C(=O)O
CHLORPHENESIN,CHLORPHENESIN,CHEMBL607710,BRD:BRD-A92262698-001-02-5;BRD:BRD-BRD-A92262698-001-02-5,rep_primary;rep_single_dose,MUSCLE RELAXANT,,"MUSCLE RELAXANT, SEDATIVE",,LAUNCHED,,Small molecule,Approved,SKPLBLUECSEIFO-UHFFFAOYSA-N,NC(=O)OCC(O)COC1CCC(CL)CC1;OCC(O)COC1CCC(CL)CC1
CHLORPHENOXAMINE,CHLORPHENOXAMINE,CHEMBL2110774,BRD:BRD-K00003537-001-01-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,KKHPNPMTPORSQE-UHFFFAOYSA-N,CN(C)CCOC(C)(C1CCCCC1)C1CCC(CL)CC1
CHLORPHENSIN-CARBAMATE,CHLORPHENSIN-CARBAMATE,,BRD:BRD-A39230911-001-10-2;BRD:BRD-BRD-A39230911-001-10-2,rep_primary;rep_single_dose,MUSCLE RELAXANT,,,,PRECLINICAL,,,NA,,NC(=O)OCC(O)COC1CCC(CL)CC1
CHLORPROGUANIL,CHLORPROGUANIL,CHEMBL1213553,BRD:BRD-BRD-K25494650-003-01-8;BRD:BRD-K25494650-003-01-8,rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR,MALARIA,,LAUNCHED,,Small molecule,Phase 3,ISZNZKHCRKXXAU-UHFFFAOYSA-N,CC(C)NC(=N)NC(=N)NC1CCC(CL)C(CL)C1
CHLORPROMAZINE,CHLORPROMAZINE,CHEMBL71,BRD:BRD-BRD-K89997465-003-43-0;BRD:BRD-K89997465-003-43-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CALM1;CHRM1;CHRM3;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HRH4;HTR1A;HTR2A;HTR2B;HTR2C;HTR6;HTR7;KCNH2;ORM1;ORM2;SMPD1;TRPC5,"SCHIZOPHRENIA, NAUSEA, VOMITING, ACUTE INTERMITTENT PORPHYRIA (AIP), TETANUS",,LAUNCHED,,Small molecule,Approved,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CN(C)CCCN1C2CCCCC2SC2CCC(CL)CC12;CN(C)CCCN1C2CCCCC2SC2CCC(CL)CC21
CHLORPROPAMIDE,CHLORPROPAMIDE,CHEMBL498,BRD:BRD-BRD-K97746869-001-27-0;BRD:BRD-K97746869-001-27-0,rep_multi_dose;rep_primary;rep_single_dose,ATP CHANNEL BLOCKER,ABCC8;KCNJ10;KCNJ11,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CCCNC(=O)NS(=O)(=O)C1CCC(CL)CC1
CHLORPROPHAM,CHLORPROPHAM,CHEMBL104560,BRD:BRD-BRD-K59590127-001-04-5;BRD:BRD-K59590127-001-04-5,rep_primary;rep_single_dose,ANTIVIRAL,,,,PHASE 1,,Small molecule,NA,CWJSHJJYOPWUGX-UHFFFAOYSA-N,CC(C)OC(=O)NC1CCCC(CL)C1
CHLORPROTHIXENE,CHLORPROTHIXENE,CHEMBL908,BRD:BRD-BRD-K36207157-001-07-0;BRD:BRD-BRD-K36207157-001-09-6;BRD:BRD-K36207157-001-07-0;BRD:BRD-K36207157-001-09-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;HRH1;HTR2A;HTR2B;HTR2C,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CN(C)CC/C=C1/C2CCCCC2SC2CCC(CL)CC21;CN(C)CC\C=C1\C2CCCCC2SC2CCC(CL)CC12
CHLORPYRIFOS,CHLORPYRIFOS,CHEMBL463210,BRD:BRD-BRD-K08303368-001-10-0;BRD:BRD-K08303368-001-10-0,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,LAUNCHED,,Small molecule,Unknown,SBPBAQFWLVIOKP-UHFFFAOYSA-N,CCOP(=S)(OCC)OC1NC(CL)C(CL)CC1CL
CHLORQUINALDOL,CHLORQUINALDOL,CHEMBL224325,BRD:BRD-BRD-K90374350-001-09-2;BRD:BRD-K90374350-001-09-2,rep_multi_dose;rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,FUNGAL INFECTION,,LAUNCHED,,Small molecule,Approved,GPTXWRGISTZRIO-UHFFFAOYSA-N,CC1CCC2C(CL)CC(CL)C(O)C2N1
CHLORTETRACYCLINE,CHLORTETRACYCLINE,CHEMBL404520,BRD:BRD-A25492003-003-14-1;BRD:BRD-BRD-A25492003-003-14-1;BRD:BRD-K00003353-003-01-9,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,CONJUNCTIVITIS,,LAUNCHED,"Multiple values for structure_id: {'K00003353', 'A25492003'}, defaulting to None",Small molecule,Approved,CYDMQBQPVICBEU-XRNKAMNCSA-N,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)C4C(O)CCC(CL)C4[C@@](C)(O)[C@H]3C[C@@H]12;CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4C(O)CCC(CL)C4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O
CHLORTHALIDONE,CHLORTHALIDONE,CHEMBL1055;CHEMBL255014,BRD:BRD-A26384407-001-25-1;BRD:BRD-BRD-A26384407-001-25-1,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA14;CA2;CA4;CA7;SLC12A1;SLC12A3,"HYPERTENSION, EDEMA, CONGESTIVE HEART FAILURE, HEPATIC CIRRHOSIS, NEPHROTIC SYNDROME, ACUTE GLOMERULONEPHRITIS (AGN), CHRONIC RENAL FAILURE",,LAUNCHED,"Multiple values for repurposing_target: {'CA1;CA12;CA14;CA2;CA4;CA7;SLC12A1;SLC12A3', 'CA1;CA12;CA14;CA4;CA7;SLC12A1;SLC12A3'}, taking the union",Small molecule,Approved,JIVPVXMEBJLZRO-CQSZACIVSA-N;JIVPVXMEBJLZRO-UHFFFAOYSA-N,NS(=O)(=O)C1CC([C@]2(O)NC(=O)C3CCCCC32)CCC1CL;NS(=O)(=O)C1CC(C2(O)NC(=O)C3CCCCC32)CCC1CL;NS(=O)(=O)C1CC(CCC1CL)C1(O)NC(=O)C2CCCCC12
CHLORZOXAZONE,CHLORZOXAZONE,CHEMBL1371,BRD:BRD-BRD-K98174813-001-18-0;BRD:BRD-K98174813-001-18-0,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,KCNMA1;KCNN4,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CLC1CCC2OC(=O)[NH]C2C1;O=C1[NH]C2CC(CL)CCC2O1
CHM-1,CHM-1,,CTRP:609674,ctrp,,,,,,,,NA,,
CHOLECALCIFEROL,CHOLECALCIFEROL,CHEMBL1042,BRD:BRD-BRD-K62779383-001-05-5;BRD:BRD-K62779383-001-05-5,rep_multi_dose;rep_primary;rep_single_dose,,VDR,VITAMIN D DEFICIENCY,,LAUNCHED,,Small molecule,Approved,QYSXJUFSXHHAJI-YRZJJWOYSA-N,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12;CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
CHOLIC-ACID,CHOLIC-ACID,,BRD:BRD-BRD-K43164539-001-11-5;BRD:BRD-K43164539-001-11-5,rep_primary;rep_single_dose,BILE ACID,ADH1C;CES1;COX4I1;COX5A;COX5B;COX6A2;COX6B1;COX6C;COX7A1;COX7B;COX7C;COX8A;ESRRG;FABP6;FECH;GPBAR1;MT-CO1;MT-CO2;MT-CO3;PLA2G1B,"BILE ACID SYNTHESIS DISORDERS, PEROXISOMAL DISORDERS, ZELLWEGER SYNDROME",,LAUNCHED,,,NA,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
CHOLINE,CHOLINE,CHEMBL2104095;CHEMBL920,BRD:BRD-BRD-K77300776-001-02-5;BRD:BRD-K77300776-001-02-5,rep_primary;rep_single_dose,ACETYLCHOLINE PRECURSOR,ACHE;BCHE;CHRNA2;PCYT1A;PCYT1B;PHOSPHO1;PLD1;PLD2,,,PHASE 3,,Small molecule,Approved,OEYIOHPDSNJKLS-UHFFFAOYSA-N;UDKCHVLMFQVBAA-UHFFFAOYSA-M,C[N+](C)(C)CCO;C[N+](C)(C)CCO.O=C([O-])C1CCCCC1O
CHOLINE-ALFOSCERATE,CHOLINE-ALFOSCERATE,,BRD:BRD-A72390365-001-15-2;BRD:BRD-BRD-A72390365-001-15-2,rep_primary;rep_single_dose,ACETYLCHOLINE PRECURSOR,GM2A,,,LAUNCHED,,,NA,,C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO
CHR-6494,CHR-6494,,BRD:BRD-BRD-K76259716-019-01-1;BRD:BRD-K76259716-019-01-1,rep_primary;rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,GSG2,,,PRECLINICAL,,,NA,,CCCNC1CCC2NCC(-C3CCC4[NH]NCC4C3)N2N1
CHROMANOL-(+/-),CHROMANOL-(+/-),,BRD:BRD-BRD-M02075109-001-01-1;BRD:BRD-M02075109-001-01-1,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)OC2CCC(CC12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)OC2CCC(CC12)C#N
"CHROMANOL-293B-(-)-[3R,4S]","CHROMANOL-293B-(-)-[3R,4S]",,BRD:BRD-BRD-K27911943-001-02-8;BRD:BRD-K27911943-001-02-8,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)OC2CCC(CC12)C#N
PICOLINIC-ACID,CHROMIUM-PICOLINATE;PICOLINIC-ACID,,BRD:BRD-BRD-K01029106-001-01-4;BRD:BRD-K01029106-001-01-4;BRD:BRD-K01029106-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,"CHELATING AGENT, INSULIN SENSITIZER",,,,PHASE 2,"Multiple values for MOA: {'CHELATING AGENT, INSULIN SENSITIZER', 'CHELATING AGENT'}, defaulting to 'CHELATING AGENT, INSULIN SENSITIZER'",,NA,,O=C(O[CR](OC(=O)C1CCCCN1)OC(=O)C1CCCCN1)C1CCCCN1;OC(=O)C1CCCCN1
CHROMOCARB,CHROMOCARB,CHEMBL83628,BRD:BRD-BRD-K94720315-001-10-4;BRD:BRD-K94720315-001-10-4,rep_multi_dose;rep_primary;rep_single_dose,ANTISPASMODIC,,,,LAUNCHED,,Small molecule,Unknown,RVMGXWBCQGAWBR-UHFFFAOYSA-N,O=C(O)C1CC(=O)C2CCCCC2O1;OC(=O)C1CC(=O)C2CCCCC2O1
CHRYSIN,CHRYSIN,CHEMBL117,BRD:BRD-BRD-K22861715-001-17-4;BRD:BRD-K22861715-001-17-4,rep_primary;rep_single_dose,BREAST CANCER RESISTANCE PROTEIN INHIBITOR,AKR1B1;CDK6;CYP19A1;CYP1B1,,,PHASE 1,,Small molecule,NA,RTIXKCRFFJGDFG-UHFFFAOYSA-N,O=C1CC(-C2CCCCC2)OC2CC(O)CC(O)C12;OC1CC(O)C2C(C1)OC(CC2=O)-C1CCCCC1
CHRYSOPHANIC-ACID,CHRYSOPHANIC-ACID,,BRD:BRD-BRD-K59284035-001-07-9;BRD:BRD-K59284035-001-07-9,rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;MTOR,,,PRECLINICAL,,,NA,,CC1CC(O)C2C(=O)C3C(O)CCCC3C(=O)C2C1
CHUANXIONGZINE,CHUANXIONGZINE,,BRD:BRD-BRD-K25691735-001-09-5;BRD:BRD-K25691735-001-09-5,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CC1NC(C)C(C)NC1C
CI 1040,CI 1040,CHEMBL105442,GDSC1:1015,gdsc,,,,,,,Small molecule,Phase 2,GFMMXOIFOQCCGU-UHFFFAOYSA-N,O=C(NOCC1CC1)C1CCC(F)C(F)C1NC1CCC(I)CC1CL
CI-1033,CI-1033,CHEMBL31965;CHEMBL545315,GDSC1:362,gdsc,,,,,,,Small molecule,Phase 3,JZZFDCXSFTVOJY-UHFFFAOYSA-N;OMZCMEYTWSXEPZ-UHFFFAOYSA-N,C=CC(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1OCCCN1CCOCC1;C=CC(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1OCCCN1CCOCC1.CL.CL
CI-1040,CI-1040,CHEMBL105442,GDSC1:1015,gdsc,,,,,,,Small molecule,Phase 2,GFMMXOIFOQCCGU-UHFFFAOYSA-N,O=C(NOCC1CC1)C1CCC(F)C(F)C1NC1CCC(I)CC1CL
CI-844,CI-844,,BRD:BRD-BRD-K83022601-001-01-0;BRD:BRD-K83022601-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,O(C1CCCCC1)C1CCCNC1
CI-923,CI-923,,BRD:BRD-A50016482-001-01-7;BRD:BRD-BRD-A50016482-001-01-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,CCNC(C)CN1CCC2C(C1)C(=O)OC1CCCCC21
CI-953,CI-953,,BRD:BRD-K00004748-001-01-9,rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,,,,,,,NA,,
CI-966,CI-966,,BRD:BRD-BRD-K67680372-003-02-6;BRD:BRD-K67680372-003-02-6,rep_primary;rep_single_dose,GAT INHIBITOR,SLC6A1,,,PHASE 1,,,NA,,OC(=O)C1=CCCN(CCOC(C2CCC(CC2)C(F)(F)F)C2CCC(CC2)C(F)(F)F)C1
CI-976,CI-976,CHEMBL22373,BRD:BRD-BRD-K88544581-001-06-1;BRD:BRD-K88544581-001-06-1;CTRP:375390,ctrp;rep_primary;rep_single_dose,ACAT INHIBITOR,ACAT1;CES1,,,PHASE 1,,Small molecule,NA,WAFNZAURAWBNDZ-UHFFFAOYSA-N,CCCCCCCCCCC(C)(C)C(=O)NC1C(OC)CC(OC)CC1OC
CIANIDANOL,CIANIDANOL,CHEMBL311498,BRD:BRD-BRD-K58736316-001-09-5;BRD:BRD-K58736316-001-09-5,rep_primary;rep_single_dose,FATTY ACID SYNTHASE INHIBITOR,PTGS1,,,WITHDRAWN,,Small molecule,Approved,PFTAWBLQPZVEMU-DZGCQCFKSA-N,O[C@H]1CC2C(O)CC(O)CC2O[C@@H]1C1CCC(O)C(O)C1;OC1CC(O)C2C(C1)O[C@H](C1CCC(O)C(O)C1)[C@@H](O)C2
CIBENZOLINE,CIBENZOLINE,CHEMBL87045,BRD:BRD-BRD-K34251960-036-01-6;BRD:BRD-K34251960-036-01-6,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,,,,LAUNCHED,,Small molecule,Unknown,IPOBOOXFSRWSHL-UHFFFAOYSA-N,C1C(=C2NCCN2)C1(C1CCCCC1)C1CCCCC1;C1CCC(C2(C3CCCCC3)CC2C2=NCCN2)CC1
CICLESONIDE,CICLESONIDE,CHEMBL2040682,BRD:BRD-BRD-K35245662-001-01-2;BRD:BRD-K35245662-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,LUKZNWIVRBCLON-GXOBDPJESA-N,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1;CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
CICLOPIROX,CICLOPIROX,CHEMBL1413,BRD:BRD-BRD-K13044802-213-20-7;BRD:BRD-K13044802-213-20-7;CTRP:28784,ctrp;rep_multi_dose;rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,ATP1A1,ONYCHOMYCOSIS,,LAUNCHED,,Small molecule,Approved,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CC1CC(C2CCCCC2)N(O)C(=O)C1
CICLOPROFEN,CICLOPROFEN,CHEMBL2104122,BRD:BRD-A94965935-001-01-6,rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,,,Small molecule,Unknown,LRXFKKPEBXIPMW-UHFFFAOYSA-N,CC(C(=O)O)C1CCC2C(C1)CC1CCCCC1-2
CICLOSPORIN,CICLOSPORIN,CHEMBL160,CTRP:55512,ctrp,,,,,,,Protein,Approved,PMATZTZNYRCHOR-CGLBZJNRSA-N,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
CID-16020046,CID-16020046,,BRD:BRD-A59391172-001-07-7;BRD:BRD-BRD-A59391172-001-07-7,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR ANTAGONIST,GPR55,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1[NH]NC2C(=O)N(C(C12)C1CCCC(O)C1)C1CCC(CC1)C(O)=O
CID-2011756,CID-2011756,,BRD:BRD-BRD-K92781136-001-08-9;BRD:BRD-K92781136-001-08-9,rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,PKD1,,,PRECLINICAL,,,NA,,CLC1CCCC(C1)-C1CCC(O1)C(=O)NC1CCC(CN2CCOCC2)CC1
CID-2745687,CID-2745687,,BRD:BRD-K06405316-001-04-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR ANTAGONIST,GPR35,,,,,,NA,,
CID-5458317,CID-5458317,,BRD:BRD-A08840375-001-01-3;BRD:BRD-BRD-A08840375-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,MAP KINASE PHOSPHATASE INHIBITOR,MAPK3,,,PRECLINICAL,,,NA,,O=C1C2CCCCC2C(NC2CCCCC2)\C1=C/C1CCCCC1
CID-5951923,CID-5951923,,CTRP:267119,ctrp,,,,,,,,NA,,
CIDOFOVIR,CIDOFOVIR,CHEMBL152,BRD:BRD-BRD-K96153583-001-05-1;BRD:BRD-K96153583-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,"ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), CYTOMEGALOVIRUS RETINITIS",,LAUNCHED,,Small molecule,Approved,VWFCHDSQECPREK-LURJTMIESA-N,NC1CCN(C[C@@H](CO)OCP(=O)(O)O)C(=O)N1;NC1CCN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N1
CIGLITAZONE,CIGLITAZONE,CHEMBL7002,BRD:BRD-A93000692-001-08-1;BRD:BRD-BRD-A93000692-001-08-1,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARG,,,PHASE 2,,Small molecule,Unknown,YZFWTZACSRHJQD-UHFFFAOYSA-N,CC1(COC2CCC(CC3SC(=O)NC3=O)CC2)CCCCC1
CIL41,CIL41,,CTRP:176181,ctrp,,,,,,,,NA,,
CIL55,CIL55,,CTRP:1788,ctrp,,,,,,,,NA,,
CIL55A,CIL55A,,CTRP:609061,ctrp,,,,,,,,NA,,
CIL56,CIL56,,CTRP:100490,ctrp,,,,,,,,NA,,
CIL70,CIL70,,CTRP:183526,ctrp,,,,,,,,NA,,
CILAZAPRIL,CILAZAPRIL,CHEMBL515606,BRD:BRD-BRD-K65518078-002-01-1;BRD:BRD-K65518078-002-01-1,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,HHHKFGXWKKUNCY-FHWLQOOXSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O;CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O
CILENGITIDE,CILENGITIDE,CHEMBL429876,BRD:BRD-BRD-K57252450-001-02-5;BRD:BRD-K57252450-001-02-5,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGAV;ITGB3,,,PHASE 3,,Protein,Phase 3,AMLYAMJWYAIXIA-VWNVYAMZSA-N,CC(C)[C@@H]1N(C)C(=O)[C@@H](CC2CCCCC2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O;CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC2CCCCC2)C(=O)N1C
CILNIDIPINE,CILNIDIPINE,CHEMBL452076,BRD:BRD-A02743701-001-03-6;BRD:BRD-BRD-A02743701-001-03-6,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1B,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,KJEBULYHNRNJTE-DHZHZOJOSA-N,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/C2CCCCC2)C1C1CCCC([N+](=O)[O-])C1;COCCOC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC\C=C\C1CCCCC1
CILOFEXOR,CILOFEXOR,CHEMBL4297613,BRD:BRD-K00004595-001-01-9,rep_single_dose,FXR AGONIST,,,,,,Small molecule,Phase 3,KZSKGLFYQAYZCO-UHFFFAOYSA-N,O=C(O)C1CCNC(N2CC(O)(C3CCC(OCC4C(-C5C(CL)CCCC5CL)NOC4C4CC4)CC3CL)C2)C1
CILOMILAST,CILOMILAST,CHEMBL511115,BRD:BRD-BRD-K38473998-001-02-0;BRD:BRD-K38473998-001-02-0,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4D,,,PHASE 3,,Small molecule,Phase 3,CFBUZOUXXHZCFB-OYOVHJISSA-N,COC1CCC([C@]2(C#N)CC[C@@H](C(=O)O)CC2)CC1OC1CCCC1;COC1CCC(CC1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N
CILOSTAMIDE,CILOSTAMIDE,CHEMBL34431,BRD:BRD-BRD-K28578425-001-07-0;BRD:BRD-K28578425-001-07-0,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A;PDE3B,,,PRECLINICAL,,Small molecule,Unknown,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CN(C(=O)CCCOC1CCC2[NH]C(=O)CCC2C1)C1CCCCC1;CN(C1CCCCC1)C(=O)CCCOC1CCC2[NH]C(=O)CCC2C1
CILOSTAZOL,CILOSTAZOL,CHEMBL799,BRD:BRD-BRD-K67017579-001-28-1;BRD:BRD-K67017579-001-28-1,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A;PDE3B,CLAUDICATION,,LAUNCHED,,Small molecule,Approved,RRGUKTPIGVIEKM-UHFFFAOYSA-N,O=C1CCC2CC(OCCCCC3NNNN3C3CCCCC3)CCC2N1
CILUPREVIR,CILUPREVIR,CHEMBL297884,BRD:BRD-K00004667-001-01-9,rep_single_dose,SERINE PROTEASE INHIBITOR,,,,,,Small molecule,Phase 2,PJZPDFUUXKKDNB-KNINVFKUSA-N,COC1CCC2C(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)CC(-C3CSC(NC(C)C)N3)NC2C1
CIM-0216,CIM-0216,,BRD:BRD-A75514485-001-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL AGONIST,TRPM3,,,,,,NA,,
CIMATEROL,CIMATEROL,CHEMBL1374751,BRD:BRD-A65440446-001-04-1;BRD:BRD-BRD-A65440446-001-04-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3,,,PRECLINICAL,,Small molecule,Unknown,BUXRLJCGHZZYNE-UHFFFAOYSA-N,CC(C)NCC(O)C1CCC(N)C(C#N)C1;CC(C)NCC(O)C1CCC(N)C(C1)C#N
CIMETIDINE,CIMETIDINE,CHEMBL30,BRD:BRD-BRD-K34157611-001-16-0;BRD:BRD-K34157611-001-16-0;CTRP:26870,ctrp;rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2;SLC29A4;SLC47A1;SLC47A2,"DUODENAL ULCER DISEASE, PEPTIC ULCER DISEASE (PUD), GASTROESOPHAGEAL REFLUX DISEASE (GERD), AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), ZOLLINGER-ELLISON SYNDROME, ENDOCRINE ADENOMA",,LAUNCHED,,Small molecule,Approved,AQIXAKUUQRKLND-UHFFFAOYSA-N,CN/C(=N\CCSCC1NC[NH]C1C)NC#N;CN\C(NCCSCC1NC[NH]C1C)=N/C#N
CIMETROPIUM,CIMETROPIUM,CHEMBL2110773,BRD:BRD-A99899486-004-01-9;BRD:BRD-BRD-A99899486-004-01-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Phase 3,QVVOZYKELHAIPX-WVHCHWADSA-N,C[N+]1(CC2CC2)[C@@H]2C[C@@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@H]1[C@@H]1O[C@@H]12;C[N+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1CCCCC1
CINACALCET,CINACALCET,CHEMBL1201284,BRD:BRD-BRD-K73838513-003-05-5;BRD:BRD-K73838513-003-05-5,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL ACTIVATOR,CASR,"HYPERPARATHYROIDISM, CHRONIC KIDNEY DISEASE (CKD), PARATHYROID CARCINOMA, HYPERCALCEMIA",,LAUNCHED,,Small molecule,Approved,VDHAWDNDOKGFTD-MRXNPFEDSA-N,C[C@@H](NCCCC1CCCC(C(F)(F)F)C1)C1CCCC2CCCCC12;C[C@@H](NCCCC1CCCC(C1)C(F)(F)F)C1CCCC2CCCCC12
CINACIGUAT,CINACIGUAT,CHEMBL1236936,BRD:BRD-BRD-K73440166-001-01-3;BRD:BRD-K73440166-001-01-3,rep_primary;rep_single_dose,GUANYLATE CYCLASE ACTIVATOR,GUCY1A3;GUCY1B3,,,PHASE 2,,Small molecule,Phase 2,WPYWMXNXEZFMAK-UHFFFAOYSA-N,O=C(O)CCCCN(CCC1CCCCC1OCC1CCC(CCC2CCCCC2)CC1)CC1CCC(C(=O)O)CC1;OC(=O)CCCCN(CCC1CCCCC1OCC1CCC(CCC2CCCCC2)CC1)CC1CCC(CC1)C(O)=O
CINALUKAST,CINALUKAST,CHEMBL283754,BRD:BRD-BRD-K53720352-001-03-2;BRD:BRD-K53720352-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,CYSLTR1,,,PHASE 2,,Small molecule,Unknown,BZMKNPGKXJAIDV-VAWYXSNFSA-N,CCC(CC)(CC(=O)NC1CCCC(/C=C/C2NC(C3CCC3)CS2)C1)C(=O)O;CCC(CC)(CC(=O)NC1CCCC(\C=C\C2NC(CS2)C2CCC2)C1)C(O)=O
CINANSERIN,CINANSERIN,CHEMBL18786,BRD:BRD-BRD-K40901640-003-01-6;BRD:BRD-K40901640-003-01-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A,,,PRECLINICAL,,Small molecule,Unknown,RSUVYMGADVXGOU-BUHFOSPRSA-N,CN(C)CCCSC1CCCCC1NC(=O)/C=C/C1CCCCC1;CN(C)CCCSC1CCCCC1NC(=O)\C=C\C1CCCCC1
CINCHOCAINE,CINCHOCAINE,CHEMBL1086,BRD:BRD-BRD-K99121711-003-19-7;BRD:BRD-K99121711-003-19-7,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,CALM1;SCN10A;SCN5A,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,PUFQVTATUTYEAL-UHFFFAOYSA-N,CCCCOC1CC(C(=O)NCCN(CC)CC)C2CCCCC2N1
CINCHONIDINE,CINCHONIDINE,CHEMBL533841,BRD:BRD-BRD-K39079086-001-07-6;BRD:BRD-K39079086-001-07-6,rep_primary;rep_single_dose,P GLYCOPROTEIN INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,KMPWYEUPVWOPIM-KODHJQJWSA-N,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCCCC12;O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C1CCNC2CCCCC12
CINCHONINE,CINCHONINE,CHEMBL2105783;CHEMBL588619,BRD:BRD-K36551084-001-04-9,rep_single_dose,P GLYCOPROTEIN INHIBITOR,CYP2D6,,,,,Small molecule,Unknown,KMPWYEUPVWOPIM-QAMTZSDWSA-N;WBBHOISPYYYBTC-SJFRDBBCSA-N,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C1CCNC2CCCCC12;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C1CCNC2CCCCC12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C1CCNC2CCCCC12.O=S(=O)(O)O
CINCHOPHEN,CINCHOPHEN,CHEMBL348000,BRD:BRD-BRD-K72915123-001-18-1;BRD:BRD-K72915123-001-18-1,rep_primary;rep_single_dose,ANALGESIC AGENT,,GOUT,,LAUNCHED,,Small molecule,Unknown,YTRMTPPVNRALON-UHFFFAOYSA-N,O=C(O)C1CC(-C2CCCCC2)NC2CCCCC12;OC(=O)C1CC(NC2CCCCC12)-C1CCCCC1
CINEPAZET,CINEPAZET,CHEMBL2110784,BRD:BRD-BRD-K00531707-001-01-3;BRD:BRD-K00531707-001-01-3,rep_primary;rep_single_dose,VASODILATOR,,,,LAUNCHED,,Small molecule,Unknown,XDUOTWNXVDBCDY-VOTSOKGWSA-N,CCOC(=O)CN1CCN(C(=O)/C=C/C2CC(OC)C(OC)C(OC)C2)CC1;CCOC(=O)CN1CCN(CC1)C(=O)\C=C\C1CC(OC)C(OC)C(OC)C1
CINEPAZIDE,CINEPAZIDE,CHEMBL1874750,BRD:BRD-BRD-K46839850-050-04-2;BRD:BRD-K46839850-050-04-2,rep_primary;rep_single_dose,CALCIUM CHANNEL ACTIVATOR,,,,WITHDRAWN,,Small molecule,Approved,RCUDFXMNPQNBDU-VOTSOKGWSA-N,COC1CC(/C=C/C(=O)N2CCN(CC(=O)N3CCCC3)CC2)CC(OC)C1OC;COC1CC(CC(OC)C1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1
CINFLUMIDE,CINFLUMIDE,CHEMBL132663,BRD:BRD-BRD-K25154476-001-01-4;BRD:BRD-K25154476-001-01-4,rep_primary;rep_single_dose,MUSCLE RELAXANT,,,,PHASE 2,,Small molecule,Unknown,NCOOUEIQXVWKTO-QPJJXVBHSA-N,FC1CCCC(C1)\C=C\C(=O)NC1CC1;O=C(/C=C/C1CCCC(F)C1)NC1CC1
CINK4,CINK4,,GDSC1:54,gdsc,,,,,,,,NA,,
CINNAMALDEHYDE,CINNAMALDEHYDE,CHEMBL293492,BRD:BRD-K26875402-001-13-9,rep_single_dose,"ALDOSE REDUCTASE INHIBITOR, TRPV AGONIST",TRPA1,,,,,Small molecule,Unknown,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,O=C/C=C/C1CCCCC1
CINNARAZINE,CINNARAZINE,,BRD:BRD-BRD-K07220430-001-18-4;BRD:BRD-BRD-K07220430-001-19-2;BRD:BRD-K07220430-001-18-4;BRD:BRD-K07220430-001-19-2,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,"MENIERE'S DISEASE, NAUSEA, VOMITING, COGAN'S SYNDROME",,LAUNCHED,,,NA,,C(\C=C\C1CCCCC1)N1CCN(CC1)C(C1CCCCC1)C1CCCCC1
CINOBUFOTALIN,CINOBUFOTALIN,CHEMBL517341,BRD:BRD-K00003354-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Phase 1,KBKUJJFDSHBPPA-ZNCGZLKOSA-N,CC(=O)O[C@H]1[C@H]2O[C@]23[C@@H]2CC[C@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]2CC[C@]3(C)[C@H]1C1CCC(=O)OC1
CINOXACIN,CINOXACIN,CHEMBL1208,BRD:BRD-BRD-K14704277-001-22-6;BRD:BRD-K14704277-001-22-6,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,VDUWPHTZYNWKRN-UHFFFAOYSA-N,CCN1NC(C(=O)O)C(=O)C2CC3C(CC21)OCO3;CCN1NC(C(O)=O)C(=O)C2CC3OCOC3CC12
CINOXATE,CINOXATE,CHEMBL2104045,BRD:BRD-BRD-K17828029-001-01-5;BRD:BRD-K17828029-001-01-5,rep_primary;rep_single_dose,,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Approved,CMDKPGRTAQVGFQ-RMKNXTFCSA-N,CCOCCOC(=O)/C=C/C1CCC(OC)CC1;CCOCCOC(=O)\C=C\C1CCC(OC)CC1
CINPA-1,CINPA-1,,BRD:BRD-K24570280-001-07-9,rep_single_dose,CAR ANTAGONIST,NR1H4;NR1I3;PPARG,,,,,,NA,,
CINROMIDE,CINROMIDE,CHEMBL93233,BRD:BRD-BRD-K66241279-001-01-8;BRD:BRD-K66241279-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,Unknown,LDCXGZCEMNMWIL-VOTSOKGWSA-N,CCNC(=O)/C=C/C1CCCC(BR)C1;CCNC(=O)\C=C\C1CCCC(BR)C1
CINTIRORGON,CINTIRORGON,,BRD:BRD-K00003458-001-01-9,rep_single_dose,ROR AGONIST,,,,,,,NA,,
CINTRIAMIDE,CINTRIAMIDE,CHEMBL2107098,BRD:BRD-BRD-K24507548-001-01-8;BRD:BRD-K24507548-001-01-8,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,LRLKZVMLJBNNPE-SNAWJCMRSA-N,COC1CC(/C=C/C(N)=O)CC(OC)C1OC;COC1CC(CC(OC)C1OC)\C=C\C(N)=O
CIPAMFYLLINE,CIPAMFYLLINE,CHEMBL356323,BRD:BRD-K00004625-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Unknown,KSPYMJJKQMWWNB-UHFFFAOYSA-N,NC1NC2C([NH]1)C(=O)N(CC1CC1)C(=O)N2CC1CC1
CIPARGAMIN,CIPARGAMIN,CHEMBL1082723,BRD:BRD-K27811785-001-02-9,rep_single_dose,ANTIMALARIAL AGENT,,,,,,Small molecule,Phase 2,CKLPLPZSUQEDRT-WPCRTTGESA-N,C[C@H]1CC2C([NH]C3CC(CL)C(F)CC23)[C@@]2(N1)C(=O)NC1CCC(CL)CC12
CIPEMASTAT,CIPEMASTAT,CHEMBL115653,BRD:BRD-BRD-K95362002-001-01-1;BRD:BRD-K95362002-001-01-1,rep_primary;rep_single_dose,METALLOPROTEINASE INHIBITOR,ADAM17;MMP1;MMP13;MMP2;MMP3;MMP8;MMP9,,,PHASE 3,,Small molecule,Unknown,GFUITADOEPNRML-SJORKVTESA-N,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C;CN1C(=O)N(C[C@H](C(=O)NO)[C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)C1(C)C
CIPROFIBRATE,CIPROFIBRATE,CHEMBL557555,BRD:BRD-A49358627-001-14-6;BRD:BRD-BRD-A49358627-001-14-6,rep_multi_dose;rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA,HYPERLIPIDEMIA,,LAUNCHED,,Small molecule,Approved,KPSRODZRAIWAKH-UHFFFAOYSA-N,CC(C)(OC1CCC(C2CC2(CL)CL)CC1)C(=O)O;CC(C)(OC1CCC(CC1)C1CC1(CL)CL)C(O)=O
CIPROFLOXACIN,CIPROFLOXACIN,CHEMBL8,BRD:BRD-BRD-K04804440-001-09-5;BRD:BRD-K04804440-001-09-5,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,OTITIS,,LAUNCHED,,Small molecule,Approved,MYSWGUAQZAJSOK-UHFFFAOYSA-N,O=C(O)C1CN(C2CC2)C2CC(N3CCNCC3)C(F)CC2C1=O;OC(=O)C1CN(C2CC2)C2CC(N3CCNCC3)C(F)CC2C1=O
CIPROXIFAN,CIPROXIFAN,CHEMBL14638,BRD:BRD-BRD-K01767299-050-02-1;BRD:BRD-K01767299-050-02-1,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ADRA2A;ADRA2C;HRH3;HRH4;HTR3A,,,PRECLINICAL,,Small molecule,NA,ACQBHJXEAYTHCY-UHFFFAOYSA-N,O=C(C1CC1)C1CCC(OCCCC2C[NH]CN2)CC1;O=C(C1CCC(OCCCC2C[NH]CN2)CC1)C1CC1
CIQ,CIQ,,BRD:BRD-A35425966-001-02-3;BRD:BRD-BRD-A35425966-001-02-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POTENTIATOR,GRIN2C;GRIN2D,,,PRECLINICAL,,,NA,,COC1CCC(OCC2N(CCC3CC(OC)C(OC)CC23)C(=O)C2CCCC(CL)C2)CC1
CIRAZOLINE,CIRAZOLINE,CHEMBL13852,BRD:BRD-BRD-K54142781-003-11-8;BRD:BRD-K54142781-003-11-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A,,,PRECLINICAL,,Small molecule,Unknown,YAORIDZYZDUZCM-UHFFFAOYSA-N,C(OC1CCCCC1C1CC1)C1=NCCN1;C1CCC(C2CC2)C(OCC2=NCCN2)C1
"CIS-9,TRANS-11-CONJUGATED-LINOLEIC-ACID","CIS-9,TRANS-11-CONJUGATED-LINOLEIC-ACID",,BRD:BRD-BRD-K80025777-001-01-4;BRD:BRD-K80025777-001-01-4,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CCCCCC\C=C\C=C/CCCCCCCC(O)=O
CIS-ACONITIC-ACID,CIS-ACONITIC-ACID,,BRD:BRD-K71756122-001-02-5,rep_single_dose,,ACO2,,,,,,NA,,
CIS-ACPD,CIS-ACPD,,BRD:BRD-BRD-M29936662-001-02-0;BRD:BRD-M29936662-001-02-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM2;GRM3;GRM6;GRM7;GRM8,,,PRECLINICAL,,,NA,,N[C@]1(CC[C@@H](C1)C(O)=O)C(O)=O.N[C@@]1(CC[C@H](C1)C(O)=O)C(O)=O
CIS-DDP,CIS-DDP,CHEMBL11359,GDSC1:1005;GDSC2:1005,gdsc,,,,,,,Small molecule,Approved,,
CIS-DIAMMINEPLATINUM(II) DICHLORIDE,CIS-DIAMMINEPLATINUM(II) DICHLORIDE,,GDSC1:1005;GDSC2:1005,gdsc,,,,,,,,NA,,
CIS-UROCANIC-ACID,CIS-UROCANIC ACID;CIS-UROCANIC-ACID,CHEMBL1316726,BRD:BRD-BRD-K25146005-001-01-0;BRD:BRD-BRD-K52670952-003-01-4;BRD:BRD-K25146005-001-01-0;BRD:BRD-K52670952-003-01-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A,,,PHASE 2,"Multiple values for SMILES: {'OC(=O)\\C=C/C1C[NH]CN1', 'OC(=O)\\C=C\\C1C[NH]CN1, OC(=O)\\C=C\\C1C[NH]CN1'}, defaulting to 'OC(=O)\\C=C\\C1C[NH]CN1, OC(=O)\\C=C\\C1C[NH]CN1'
Multiple values for structure_id: {'K25146005', 'K52670952'}, defaulting to None",Small molecule,Phase 1,LOIYMIARKYCTBW-UPHRSURJSA-N,O=C(O)/C=C\C1C[NH]CN1;OC(=O)\C=C\C1C[NH]CN1
CISAPRIDE,CISAPRIDE,CHEMBL1200788;CHEMBL1729,BRD:BRD-A12896037-001-04-3;BRD:BRD-BRD-A12896037-001-04-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A;HTR3A;HTR4;KCNH2,,,WITHDRAWN,,Small molecule,Approved,DCSUBABJRXZOMT-UHFFFAOYSA-N;QBYYXIDJOFZORM-UHFFFAOYSA-N,CO[C@H]1CN(CCCOC2CCC(F)CC2)CC[C@H]1NC(=O)C1CC(CL)C(N)CC1OC;COC1CC(N)C(CL)CC1C(=O)NC1CCN(CCCOC2CCC(F)CC2)CC1OC;COC1CC(N)C(CL)CC1C(=O)NC1CCN(CCCOC2CCC(F)CC2)CC1OC.O;COC1CN(CCCOC2CCC(F)CC2)CCC1NC(=O)C1CC(CL)C(N)CC1OC
CISPLATIN,CISPLATIN,CHEMBL11359;CHEMBL1386;CHEMBL2068237,BRD:BRD-BRD-K69172251-001-08-9;BRD:BRD-K69172251-001-08-9;GDSC1:1005;GDSC2:1005,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"DNA ALKYLATING AGENT, DNA SYNTHESIS INHIBITOR",XIAP,"TESTICULAR CARCINOMA, OVARIAN CANCER, BLADDER CANCER",,LAUNCHED,,Small molecule,Approved,,N[PT](N)(CL)CL
CITALOPRAM,CITALOPRAM,CHEMBL399730;CHEMBL549,BRD:BRD-A47598013-004-16-0;BRD:BRD-BRD-A47598013-004-16-0,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),ADRA1A;CHRM1;HRH1;SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,"Multiple values for repurposing_target: {'ADRA1A;CHRM1;HRH1;SLC6A2;SLC6A3;SLC6A4', 'SLC6A2;SLC6A4'}, taking the union",Small molecule,Approved,WSEQXVZVJXJVFP-HXUWFJFHSA-N;WSEQXVZVJXJVFP-UHFFFAOYSA-N,CN(C)CCC[C@]1(C2CCC(F)CC2)OCC2CC(C#N)CCC21;CN(C)CCCC1(C2CCC(F)CC2)OCC2CC(C#N)CCC21;CN(C)CCCC1(OCC2CC(CCC12)C#N)C1CCC(F)CC1
CITARINOSTAT,CITARINOSTAT,CHEMBL3693786,BRD:BRD-K00003202-001-01-9,rep_single_dose,HDAC INHIBITOR,,,,,,Small molecule,Phase 1,VLIUIBXPEDFJRF-UHFFFAOYSA-N,O=C(CCCCCCNC(=O)C1CNC(N(C2CCCCC2)C2CCCCC2CL)NC1)NO
CITCO,CITCO,,BRD:BRD-BRD-K53263234-001-05-2;BRD:BRD-K53263234-001-05-2,rep_primary;rep_single_dose,CONSTITUTIVE ANDROSTANE RECEPTOR (CAR) AGONIST,NR1I3,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)-C1NC2SCCN2C1\C=N\OCC1CCC(CL)C(CL)C1
CITICOLINE,CITICOLINE,CHEMBL1231700;CHEMBL1256994,BRD:BRD-A91728607-236-11-9;BRD:BRD-BRD-A91728607-236-11-9,rep_primary;rep_single_dose,"MEMBRANE PERMEABILITY ENHANCER, GLUTATHIONE TRANSFERASE STIMULANT",ACHE;SLC1A2,"STROKE, ALZHEIMER'S DISEASE, SENILE DEMENTIA, PARKINSON'S DISEASE, ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD), GLAUCOMA",,LAUNCHED,"Multiple values for MOA: {'GLUTATHIONE TRANSFERASE STIMULANT, MEMBRANE PERMEABILITY ENHANCER', 'MEMBRANE PERMEABILITY ENHANCER, GLUTATHIONE TRANSFERASE STIMULANT'}, defaulting to 'MEMBRANE PERMEABILITY ENHANCER, GLUTATHIONE TRANSFERASE STIMULANT'",Small molecule,Phase 3,RZZPDXZPRHQOCG-OJAKKHQRSA-N;YWAFNFGRBBBSPD-OCMLZEEQSA-M,C[N+](C)(C)CCOP(=O)([O-])OP(=O)([O-])OC[C@H]1O[C@@H](N2CCC(N)NC2=O)[C@H](O)[C@@H]1O.[NA+];C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@H]1O[C@@H](N2CCC(N)NC2=O)[C@H](O)[C@@H]1O;C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(N)NC1=O
CITIOLONE,CITIOLONE,CHEMBL2104457,BRD:BRD-A57957888-001-08-0;BRD:BRD-BRD-A57957888-001-08-0,rep_primary;rep_single_dose,"LIPOTROPIC, MUCOLYTIC AGENT",,,,PRECLINICAL,,Small molecule,Unknown,NRFJZTXWLKPZAV-UHFFFAOYSA-N,CC(=O)NC1CCSC1=O
CJ-033466,CJ-033466,,BRD:BRD-K21306330-001-02-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR4,,,,,,NA,,
CJ-13610,CJ-13610,,BRD:BRD-K00004624-001-01-9,rep_single_dose,LIPOXYGENASE INHIBITOR,,,,,,,NA,,
CK-101,CK-101,CHEMBL4297486,BRD:BRD-K00005246-001-01-9,rep_single_dose,EGFR INHIBITOR,,,,,,Small molecule,Phase 1,IDRGFNPZDVBSSE-UHFFFAOYSA-N,C=CC(=O)NC1CCCC(-C2CCCC3CNC(NC4CCC(N5CCN(CCO)CC5)C(F)C4F)NC23)C1
CK-636,CK-636,,BRD:BRD-BRD-K81572616-001-01-9;BRD:BRD-K81572616-001-01-9,rep_primary;rep_single_dose,ACTIN RELATED PROTEIN INHIBITOR,ACTR2;ACTR3;ARPC1B;ARPC2;ARPC3;ARPC4;ARPC5,,,PRECLINICAL,,,NA,,CC1[NH]C2CCCCC2C1CCNC(=O)C1CCCS1
SB-715992,CK0238273;ISPINESIB;SB-715992,CHEMBL228814;CHEMBL2347651,BRD:BRD-BRD-K64881305-001-03-7;BRD:BRD-K64881305-001-01-1;BRD:BRD-K64881305-001-03-7;GDSC1:208,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF KIF11,KIF11,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF KIF11', 'KINESIN INHIBITOR'}, defaulting to 'INHIBITOR OF KIF11'",Small molecule,Phase 2,MRKSDPIHUJSKRA-HZPIKELBSA-N;QJZRFPJCWMNVAV-HHHXNRCGSA-N,CC(C)[C@@H](N(CCCN)C(=O)C1CCC(C)CC1)C1NC2CC(CL)CCC2C(=O)N1CC1CCCCC1;CC1CCC(C(=O)N(CCCN)[C@@H](C2NC3CC(CL)CCC3C(=O)N2CC2CCCCC2)C(C)C)CC1;CS(=O)(=O)O.CC1CCC(C(=O)N(CCCN)[C@@H](C2NC3CC(CL)CCC3C(=O)N2CC2CCCCC2)C(C)C)CC1
CKD-712,CKD-712,,BRD:BRD-A26458246-004-02-1;BRD:BRD-BRD-A26458246-004-02-1,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,JAK2;STAT1,,,PHASE 1,,,NA,,OC1CC2CCNC(CC3CCCC4CCCCC34)C2CC1O
CKI-7,CKI-7,,BRD:BRD-K34303607-300-01-4,rep_single_dose,CASEIN KINASE INHIBITOR,CSNK1G2,,,,,,NA,,
CL-218872,CL-218872,,BRD:BRD-BRD-K00662280-001-09-4;BRD:BRD-K00662280-001-09-4,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA5;GABRB2;GABRG2,,,PHASE 1,,,NA,,CC1NNC2CCC(NN12)-C1CCCC(C1)C(F)(F)F
CL-225385,CL-225385,,BRD:BRD-BRD-K87573013-001-01-0;BRD:BRD-K87573013-001-01-0,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,O=C(CC#N)C1CCCCC1
CL316243,CL316243,,BRD:BRD-BRD-K06467130-304-02-7;BRD:BRD-K06467130-304-02-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB3;UCP1;UCP2;UCP3,,,PHASE 2,,,NA,,C[C@H](CC1CCC2OC(OC2C1)(C(O)=O)C(O)=O)NC[C@H](O)C1CCCC(CL)C1
CLADRIBINE,CLADRIBINE,CHEMBL1619,BRD:BRD-BRD-K93034159-001-25-8;BRD:BRD-K93034159-001-25-8,rep_multi_dose;rep_primary;rep_single_dose,"ADENOSINE DEAMINASE INHIBITOR, RIBONUCLEOTIDE REDUCTASE INHIBITOR",ADA;PNP;POLA1;POLE;POLE2;POLE3;POLE4;RRM1;RRM2;RRM2B,HAIRY CELL LEUKEMIA,,LAUNCHED,,Small molecule,Approved,PTOAARAWEBMLNO-KVQBGUIXSA-N,NC1NC(CL)NC2C1NCN2[C@H]1C[C@H](O)[C@@H](CO)O1;NC1NC(CL)NC2N(CNC12)[C@H]1C[C@H](O)[C@@H](CO)O1
CLAMIKALANT,CLAMIKALANT,CHEMBL12531,BRD:BRD-K00004576-001-01-9,rep_single_dose,ATP-SENSITIVE POTASSIUM CHANNEL ANTAGONIST,,,,,,Small molecule,Unknown,VXTKXGKPBOLHRY-UHFFFAOYSA-N,CNC(=S)NS(=O)(=O)C1CC(CCNC(=O)C2CC(CL)CCC2OC)CCC1OC
CLANFENUR,CLANFENUR,CHEMBL1876799,BRD:BRD-K62378877-001-05-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Unknown,SRLPZQAEBMZCIJ-UHFFFAOYSA-N,CN(C)C1CCCC(F)C1C(=O)NC(=O)NC1CCC(CL)CC1
CLARITHROMYCIN,CLARITHROMYCIN,CHEMBL1741,BRD:BRD-BRD-K49668410-001-18-8;BRD:BRD-K49668410-001-18-8,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,CYP3A4,"PHARYNGITIS, TONSILLITIS, SINUSITIS, BRONCHITIS, PNEUMONIA, SKIN INFECTIONS, OTITIS",,LAUNCHED,,Small molecule,Approved,AGOYDEPGAOXOCK-KCBOHYOISA-N,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
CLEBOPRIDE,CLEBOPRIDE,CHEMBL325109,BRD:BRD-BRD-K17294426-050-12-3;BRD:BRD-K17294426-050-12-3,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ACHE;DRD2,NAUSEA,,LAUNCHED,,Small molecule,Approved,BVPWJMCABCPUQY-UHFFFAOYSA-N,COC1CC(N)C(CL)CC1C(=O)NC1CCN(CC2CCCCC2)CC1
CLEMASTINE,CLEMASTINE,CHEMBL1626,BRD:BRD-BRD-K30240666-051-15-9;BRD:BRD-K30240666-051-15-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CN1CCC[C@@H]1CCO[C@](C)(C1CCCCC1)C1CCC(CL)CC1
CLEMIZOLE,CLEMIZOLE,CHEMBL1407943,BRD:BRD-BRD-K04704168-003-14-3;BRD:BRD-K04704168-003-14-3,rep_primary;rep_single_dose,HCV INHIBITOR,,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Phase 2,CJXAEXPPLWQRFR-UHFFFAOYSA-N,CLC1CCC(CN2C(CN3CCCC3)NC3CCCCC23)CC1;CLC1CCC(CN2C(CN3CCCC3)NC3CCCCC32)CC1
CLENBUTEROL,CLENBUTEROL,CHEMBL49080,BRD:BRD-A75726477-003-21-3;BRD:BRD-BRD-A75726477-003-21-3,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3;NGF;TNF,"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), ASTHMA",,LAUNCHED,,Small molecule,Approved,STJMRWALKKWQGH-UHFFFAOYSA-N,CC(C)(C)NCC(O)C1CC(CL)C(N)C(CL)C1
CLEVIPREX,CLEVIPREX,CHEMBL1237132,BRD:BRD-A01563671-001-02-7;BRD:BRD-BRD-A01563671-001-02-7,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1F;CACNA1S,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,KPBZROQVTHLCDU-UHFFFAOYSA-N,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1CCCC(CL)C1CL;CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1CCCC(CL)C1CL)C(=O)OC
CLEVUDINE,CLEVUDINE,CHEMBL458875,BRD:BRD-BRD-K18948558-001-01-9;BRD:BRD-K18948558-001-01-9,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,HEPATITIS B,,LAUNCHED,,Small molecule,Phase 3,GBBJCSTXCAQSSJ-XQXXSGGOSA-N,CC1CN([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)C(=O)[NH]C1=O;CC1CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)[NH]C1=O
CLIDINIUM,CLIDINIUM,CHEMBL620,BRD:BRD-A46066006-004-22-6;BRD:BRD-BRD-A46066006-004-22-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM3,"PEPTIC ULCER DISEASE (PUD), IRRITABLE BOWEL SYNDROME, ENTEROCOLITIS",,LAUNCHED,,Small molecule,Approved,HOOSGZJRQIVJSZ-UHFFFAOYSA-N,C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C1CCCCC1)C1CCCCC1;C[N+]12CCC(CC1)C(OC(=O)C(O)(C1CCCCC1)C1CCCCC1)C2
CLIMBAZOLE,CLIMBAZOLE,CHEMBL1437764,BRD:BRD-A61676498-001-06-6;BRD:BRD-BRD-A61676498-001-06-6,rep_primary;rep_single_dose,ENZYME INDUCER,,"DANDRUFF, ECZEMA",,LAUNCHED,,Small molecule,Unknown,OWEGWHBOCFMBLP-UHFFFAOYSA-N,CC(C)(C)C(=O)C(OC1CCC(CL)CC1)N1CCNC1
CLINAFLOXACIN,CLINAFLOXACIN,CHEMBL278255,BRD:BRD-A93964801-003-03-3;BRD:BRD-BRD-A93964801-003-03-3,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,,,PHASE 3,,Small molecule,Unknown,QGPKADBNRMWEQR-UHFFFAOYSA-N,NC1CCN(C1)C1C(F)CC2C(C1CL)N(CC(C(O)=O)C2=O)C1CC1;NC1CCN(C2C(F)CC3C(=O)C(C(=O)O)CN(C4CC4)C3C2CL)C1
CLINDAMYCIN,CLINDAMYCIN,CHEMBL1753,BRD:BRD-BRD-K23586533-001-03-6;BRD:BRD-K23586533-001-03-6,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,"RESPIRATORY TRACT INFECTIONS, PNEUMONIA, SKIN INFECTIONS, GYNECOLOGIC INFECTIONS, INTRA-ABDOMINAL INFECTIONS, BACTERIAL SEPTICEMIA, BONE AND JOINT INFECTIONS",,LAUNCHED,,Small molecule,Approved,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)CL)N(C)C1;CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)CL)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
CLINDAMYCIN-PALMITATE,CLINDAMYCIN-PALMITATE,,BRD:BRD-A76672327-003-02-0;BRD:BRD-BRD-A76672327-003-02-0,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,"INTRA-ABDOMINAL INFECTIONS, SKIN INFECTIONS, PNEUMONIA, PERITONITIS, GYNECOLOGIC INFECTIONS",,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)CL
CLINDAMYCIN-PHOSPHATE,CLINDAMYCIN-PHOSPHATE,,BRD:BRD-BRD-K27771035-001-02-5;BRD:BRD-K27771035-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,BACTERIAL VAGINOSIS,,LAUNCHED,,,NA,,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)CL)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O
CLINOFIBRATE,CLINOFIBRATE,CHEMBL1897738,BRD:BRD-A90625545-001-02-0;BRD:BRD-BRD-A90625545-001-02-0,rep_primary;rep_single_dose,LIPASE CLEARING FACTOR INHIBITOR,LPL,HYPERTRIGLYCERIDEMIA,,LAUNCHED,,Small molecule,Unknown,BMOVQUBVGICXQN-UHFFFAOYSA-N,CCC(C)(OC1CCC(C2(C3CCC(OC(C)(CC)C(=O)O)CC3)CCCCC2)CC1)C(=O)O;CCC(C)(OC1CCC(CC1)C1(CCCCC1)C1CCC(OC(C)(CC)C(O)=O)CC1)C(O)=O
CLIOQUINOL,CLIOQUINOL,CHEMBL497,BRD:BRD-BRD-K09255212-001-16-6;BRD:BRD-K09255212-001-16-6,rep_primary;rep_single_dose,CHELATING AGENT,OPRK1,,,WITHDRAWN,,Small molecule,Approved,QCDFBFJGMNKBDO-UHFFFAOYSA-N,OC1C(I)CC(CL)C2CCCNC12
CLOBAZAM,CLOBAZAM,CHEMBL70418,BRD:BRD-BRD-K52408781-001-02-8;BRD:BRD-K52408781-001-02-8,rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,SEIZURES,,LAUNCHED,,Small molecule,Approved,CXOXHMZGEKVPMT-UHFFFAOYSA-N,CN1C(=O)CC(=O)N(C2CCCCC2)C2CC(CL)CCC21;CN1C2CCC(CL)CC2N(C2CCCCC2)C(=O)CC1=O
CLOBENPROPIT,CLOBENPROPIT,CHEMBL14690,BRD:BRD-BRD-K71430621-303-02-3;BRD:BRD-K71430621-303-02-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1;HRH2;HRH3;HRH4,,,PRECLINICAL,,Small molecule,NA,UCAIEVHKDLMIFL-UHFFFAOYSA-N,CLC1CCC(CNC(=N)SCCCC2C[NH]CN2)CC1;N=C(NCC1CCC(CL)CC1)SCCCC1C[NH]CN1
CLOBETASOL-PROPIONATE,CLOBETASOL-PROPIONATE,,BRD:BRD-BRD-K10799896-001-26-2;BRD:BRD-K10799896-001-26-2,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;PLA2G1B,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCL
CLOBETASONE-BUTYRATE,CLOBETASONE-BUTYRATE,,BRD:BRD-BRD-K58810291-001-16-2;BRD:BRD-K58810291-001-16-2,rep_primary;rep_single_dose,CORTICOSTEROID AGONIST,NR3C1,"ECZEMA, PSORIASIS, DERMATITIS",,LAUNCHED,,,NA,,CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCL
CLOBUTINOL,CLOBUTINOL,CHEMBL1474889,BRD:BRD-A43809092-003-02-1;BRD:BRD-BRD-A43809092-003-02-1,rep_multi_dose;rep_primary;rep_single_dose,ANTITUSSIVE,,,,WITHDRAWN,,Small molecule,Approved,KVHHQGIIZCJATJ-UHFFFAOYSA-N,CC(CN(C)C)C(C)(O)CC1CCC(CL)CC1
CLOCORTOLONE-PIVALATE,CLOCORTOLONE-PIVALATE,,BRD:BRD-BRD-K38003476-001-09-1;BRD:BRD-K38003476-001-09-1,rep_multi_dose;rep_primary;rep_single_dose,STEROID,NR3C1;PLA2G1B,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(CL)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C
CLODRONIC-ACID,CLODRONIC-ACID,,BRD:BRD-BRD-K72542090-304-02-4;BRD:BRD-K72542090-304-02-4,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,SLC25A4;SLC25A5;SLC25A6,"OSTEOPOROSIS, HYPERPARATHYROIDISM, HYPERCALCEMIA, MULTIPLE MYELOMA",,LAUNCHED,,,NA,,OP(O)(=O)C(CL)(CL)P(O)(O)=O
CLOFARABINE,CLOFARABINE,CHEMBL1750,BRD:BRD-BRD-K34022604-001-06-6;BRD:BRD-K34022604-001-06-6;CTRP:660288,ctrp;rep_multi_dose;rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,POLA1;POLD1;POLE;RRM1;RRM2;RRM2B,ACUTE LYMPHOBLASTIC LEUKEMIA (ALL),,LAUNCHED,,Small molecule,Approved,WDDPHFBMKLOVOX-AYQXTPAHSA-N,NC1NC(CL)NC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F;NC1NC(CL)NC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
CLOFAZIMINE,CLOFAZIMINE,CHEMBL1292,BRD:BRD-BRD-K56614220-001-19-0;BRD:BRD-K56614220-001-19-0,rep_multi_dose;rep_primary;rep_single_dose,GK0582 INHIBITOR,,LEPROSY,,LAUNCHED,,Small molecule,Approved,WDQPAMHFFCXSNU-BGABXYSRSA-N,CC(C)/N=C1\CC2N(-C3CCC(CL)CC3)C3CCCCC3NC-2CC1NC1CCC(CL)CC1;CC(C)\N=C1/CC2N(-C3CCC(CL)CC3)C3CCCCC3NC2CC1NC1CCC(CL)CC1
CLOFEDANOL,CLOFEDANOL,CHEMBL1201313,BRD:BRD-A15687940-001-05-6;BRD:BRD-BRD-A15687940-001-05-6,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Approved,WRCHFMBCVFFYEQ-UHFFFAOYSA-N,CN(C)CCC(O)(C1CCCCC1)C1CCCCC1CL
CLOFIBRATE,CLOFIBRATE,CHEMBL565,BRD:BRD-BRD-K45252063-001-13-6;BRD:BRD-K45252063-001-13-6,rep_multi_dose;rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,LPL;PPARA,"HYPERLIPIDEMIA, CHOLESTEROL",,LAUNCHED,,Small molecule,Approved,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CCOC(=O)C(C)(C)OC1CCC(CL)CC1
CLOFIBRIC-ACID,CLOFIBRIC-ACID,,BRD:BRD-BRD-K19111024-001-20-9;BRD:BRD-K19111024-001-20-9,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA,,,LAUNCHED,,,NA,,CC(C)(OC1CCC(CL)CC1)C(O)=O
CLOFOCTOL,CLOFOCTOL,CHEMBL1476605,BRD:BRD-BRD-K02900412-001-11-3;BRD:BRD-K02900412-001-11-3,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Unknown,HQVZOORKDNCGCK-UHFFFAOYSA-N,CC(C)(C)CC(C)(C)C1CCC(O)C(CC2CCC(CL)CC2CL)C1
CLOMETHIAZOLE,CLOMETHIAZOLE,CHEMBL315795,BRD:BRD-BRD-K50422030-001-05-3;BRD:BRD-K50422030-001-05-3,rep_primary;rep_single_dose,"GABA RECEPTOR ANTAGONIST, GABA RECEPTOR MODULATOR",GABRA1,"PARKINSON'S DISEASE, SEDATIVE, MUSCLE RELAXANT",,LAUNCHED,,Small molecule,Approved,PCLITLDOTJTVDJ-UHFFFAOYSA-N,CC1NCSC1CCCL
CLOMIFENE,CLOMIFENE,CHEMBL2355051,BRD:BRD-BRD-K29950728-048-17-4;BRD:BRD-K29950728-048-17-4,rep_multi_dose;rep_primary;rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,ESR1,INFERTILITY,,LAUNCHED,,Small molecule,Approved,GKIRPKYJQBWNGO-UHFFFAOYSA-N,CCN(CC)CCOC1CCC(C(=C(CL)C2CCCCC2)C2CCCCC2)CC1;CCN(CC)CCOC1CCC(CC1)C(=C(/CL)C1CCCCC1)\C1CCCCC1
CLOMIPRAMINE,CLOMIPRAMINE,CHEMBL415,BRD:BRD-BRD-K52989797-003-26-4;BRD:BRD-K52989797-003-26-4,rep_primary;rep_single_dose,SEROTONIN TRANSPORTER (SERT) INHIBITOR,GSTP1;HTR2A;HTR2B;HTR2C;SLC6A2;SLC6A3;SLC6A4,OBSESSIVE COMPULSIVE DISORDER (OCD),,LAUNCHED,,Small molecule,Approved,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CN(C)CCCN1C2CCCCC2CCC2CCC(CL)CC12;CN(C)CCCN1C2CCCCC2CCC2CCC(CL)CC21
CLONAZEPAM,CLONAZEPAM,CHEMBL452,BRD:BRD-BRD-K38183498-001-02-0;BRD:BRD-K38183498-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;TSPO,"SEIZURES, PANIC DISORDERS",,LAUNCHED,,Small molecule,Approved,DGBIGWXXNGSACT-UHFFFAOYSA-N,[O-][N+](=O)C1CCC2NC(=O)CN=C(C3CCCCC3CL)C2C1;O=C1CN=C(C2CCCCC2CL)C2CC([N+](=O)[O-])CCC2N1
CLONIDINE,CLONIDINE,CHEMBL134,BRD:BRD-BRD-K98530306-003-18-3;BRD:BRD-K98530306-003-18-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"HYPERTENSION, ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)",,LAUNCHED,,Small molecule,Approved,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLC1CCCC(CL)C1N=C1NCCN1;CLC1CCCC(CL)C1NC1=NCCN1
CLONIXIN,CLONIXIN,CHEMBL1332971,BRD:BRD-K18399440-001-11-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,,,Small molecule,Unknown,CLOMYZFHNHFSIQ-UHFFFAOYSA-N,CC1C(CL)CCCC1NC1NCCCC1C(=O)O
CLONIXIN-LYSINATE,CLONIXIN-LYSINATE,,BRD:BRD-BRD-M63173034-001-03-6;BRD:BRD-M63173034-001-03-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,PAIN RELIEF,,LAUNCHED,,,NA,,NCCCC[C@H](N)C(O)=O.CC1C(CL)CCCC1NC1NCCCC1C(O)=O
CLOPAMIDE,CLOPAMIDE,CHEMBL1361347,BRD:BRD-A85651701-001-19-7;BRD:BRD-BRD-A85651701-001-19-7,rep_multi_dose;rep_primary;rep_single_dose,SODIUM/CHLORIDE COTRANSPORTER INHIBITOR,,HYPERTENSION,,LAUNCHED,,Small molecule,Unknown,LBXHRAWDUMTPSE-UHFFFAOYSA-N,CC1CCCC(C)N1NC(=O)C1CCC(CL)C(C1)S(N)(=O)=O;CC1CCCC(C)N1NC(=O)C1CCC(CL)C(S(N)(=O)=O)C1
CLOPERASTINE,CLOPERASTINE,CHEMBL415087,BRD:BRD-A80908310-003-13-8;BRD:BRD-BRD-A80908310-003-13-8,rep_primary;rep_single_dose,ANTITUSSIVE,,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Unknown,FLNXBVJLPJNOSI-UHFFFAOYSA-N,CLC1CCC(C(OCCN2CCCCC2)C2CCCCC2)CC1;CLC1CCC(CC1)C(OCCN1CCCCC1)C1CCCCC1
CLOPERASTINE-FENDIZOATE,CLOPERASTINE-FENDIZOATE,,BRD:BRD-K00003529-458-01-9,rep_single_dose,POTASSIUM CHANNEL ANTAGONIST,,,,,,,NA,,
CLOPIDOGREL,CLOPIDOGREL,CHEMBL1771,BRD:BRD-BRD-K27721098-065-08-6;BRD:BRD-K27721098-065-08-6,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RY12,"MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERY DISEASE (PAD), ACUTE CORONARY SYNDROME (ACS)",,LAUNCHED,,Small molecule,Approved,GKTWGGQPFAXNFI-HNNXBMFYSA-N,COC(=O)[C@@H](N1CCC2SCCC2C1)C1CCCCC1CL;COC(=O)[C@H](C1CCCCC1CL)N1CCC2SCCC2C1
CLOPIDOL,CLOPIDOL,CHEMBL446918,BRD:BRD-BRD-K80036624-001-04-0;BRD:BRD-K80036624-001-04-0,rep_primary;rep_single_dose,,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,ZDPIZLCVJAAHHR-UHFFFAOYSA-N,CC1NC(C)C(CL)C(O)C1CL
CLOPROSTENOL-(+/-),CLOPROSTENOL-(+/-),,BRD:BRD-BRD-K17850764-236-11-9;BRD:BRD-K17850764-236-11-9,rep_primary;rep_single_dose,PROSTAGLANDIN RECEPTOR AGONIST,PTGDR;PTGER1;PTGER3;PTGFR;TBXA2R,,,LAUNCHED,,,NA,,O[C@@H](COC1CCCC(CL)C1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
CLORANOLOL,CLORANOLOL,CHEMBL156791,BRD:BRD-A04971881-003-01-3;BRD:BRD-BRD-A04971881-003-01-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,,,LAUNCHED,,Small molecule,Unknown,XYCMOTOFHFTUIU-UHFFFAOYSA-N,CC(C)(C)NCC(O)COC1CC(CL)CCC1CL
CLORGILINE,CLORGILINE,CHEMBL8706,BRD:BRD-BRD-K73251053-003-22-2;BRD:BRD-K73251053-003-22-2,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA,,,PHASE 2,,Small molecule,Unknown,BTFHLQRNAMSNLC-UHFFFAOYSA-N,C#CCN(C)CCCOC1CCC(CL)CC1CL;CN(CCCOC1CCC(CL)CC1CL)CC#C
CLOROTEPINE,CLOROTEPINE,CHEMBL64249,BRD:BRD-A19053834-050-09-5;BRD:BRD-BRD-A19053834-050-09-5,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, ADRENERGIC RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;DRD2;HRH1;HTR2C;HTR6,PSYCHOSIS,,LAUNCHED,"Multiple values for MOA: {'ADRENERGIC RECEPTOR ANTAGONIST, DOPAMINE RECEPTOR ANTAGONIST', 'DOPAMINE RECEPTOR ANTAGONIST, ADRENERGIC RECEPTOR ANTAGONIST'}, defaulting to 'DOPAMINE RECEPTOR ANTAGONIST, ADRENERGIC RECEPTOR ANTAGONIST'",Small molecule,Unknown,XRYLGRGAWQSVQW-UHFFFAOYSA-N,CN1CCN(C2CC3CCCCC3SC3CCC(CL)CC32)CC1;CN1CCN(CC1)C1CC2CCCCC2SC2CCC(CL)CC12
CLORPRENALINE,CLORPRENALINE,CHEMBL1902627,BRD:BRD-A29281099-003-03-2;BRD:BRD-BRD-A29281099-003-03-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2,ASTHMA,,LAUNCHED,,Small molecule,Unknown,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CC(C)NCC(O)C1CCCCC1CL
CLORSULON,CLORSULON,CHEMBL1474129,BRD:BRD-BRD-K97521363-001-16-1;BRD:BRD-K97521363-001-16-1,rep_primary;rep_single_dose,GLYCOLYSIS INHIBITOR,,"GASTROINTESTINAL ROUNDWORMS, LUNGWORMS, LIVER FLUKES, LICE, MITES",,LAUNCHED,,Small molecule,Unknown,QOVTVIYTBRHADL-UHFFFAOYSA-N,NC1CC(C(CL)=C(CL)CL)C(CC1S(N)(=O)=O)S(N)(=O)=O;NC1CC(C(CL)=C(CL)CL)C(S(N)(=O)=O)CC1S(N)(=O)=O
CLOSANTEL,CLOSANTEL,CHEMBL12131,BRD:BRD-A19952358-001-11-3;BRD:BRD-BRD-A19952358-001-11-3,rep_primary;rep_single_dose,"CHITINASE INHIBITOR, NFKB PATHWAY INHIBITOR",,LIVER FLUKES,,LAUNCHED,,Small molecule,Unknown,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CC1CC(C(C#N)C2CCC(CL)CC2)C(CL)CC1NC(=O)C1CC(I)CC(I)C1O
CLOTIAPINE,CLOTIAPINE,CHEMBL304902,BRD:BRD-BRD-K10990317-001-04-5;BRD:BRD-K10990317-001-04-5,rep_primary;rep_single_dose,,,PSYCHOSIS,,LAUNCHED,,Small molecule,Approved,KAAZGXDPUNNEFN-UHFFFAOYSA-N,CN1CCN(C2=NC3CCCCC3SC3CCC(CL)CC32)CC1;CN1CCN(CC1)C1=NC2CCCCC2SC2CCC(CL)CC12
CLOTRIMAZOLE,CLOTRIMAZOLE,CHEMBL104,BRD:BRD-BRD-K15916496-001-27-9;BRD:BRD-K15916496-001-27-9,rep_multi_dose;rep_primary;rep_single_dose,"CYTOCHROME P450 INHIBITOR, IMIDAZOLINE RECEPTOR LIGAND",CYP3A4;KCNN4;NR1I2;NR1I3;TRPM2;TRPM4;TRPM8,"VULVOVAGINAL CANDIDIASIS, OROPHARYNGEAL CANDIDIASIS",,LAUNCHED,,Small molecule,Approved,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLC1CCCCC1C(C1CCCCC1)(C1CCCCC1)N1CCNC1
CLOXACILLIN,CLOXACILLIN,CHEMBL891,BRD:BRD-BRD-K01244426-236-12-1;BRD:BRD-K01244426-236-12-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,LQOLIRLGBULYKD-JKIFEVAISA-N,CC1ONC(-C2CCCCC2CL)C1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O;CC1ONC(C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-C1CCCCC1CL
CLOXYQUIN,CLOXYQUIN,CHEMBL225164,BRD:BRD-BRD-K46982791-001-09-4;BRD:BRD-K46982791-001-09-4,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNK18,,,PRECLINICAL,,Small molecule,Unknown,CTQMJYWDVABFRZ-UHFFFAOYSA-N,OC1CCC(CL)C2CCCNC12
CLOZAPINE,CLOZAPINE,CHEMBL42;CHEMBL538973,BRD:BRD-BRD-K37289225-001-36-4;BRD:BRD-K37289225-001-36-4,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CALY;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HRH4;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR3A;HTR5A;HTR6;HTR7,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,ARWPDHKDEREYEE-UHFFFAOYSA-N;QZUDBNBUXVUHMW-UHFFFAOYSA-N,CN1CCN(C2=NC3CC(CL)CCC3NC3CCCCC32)CC1;CN1CCN(C2=NC3CC(CL)CCC3NC3CCCCC32)CC1.CL;CN1CCN(CC1)C1=NC2CC(CL)CCC2NC2CCCCC12
CM-4620,CM-4620,CHEMBL4753998,BRD:BRD-K00003438-001-01-9,rep_single_dose,CALCIUM RELEASE ACTIVATED CHANNEL MODULATOR,,,,,,Small molecule,Phase 1,QQMKTHUGOQDEIL-UHFFFAOYSA-N,CC1CCCC(F)C1C(=O)NC1CNC(-C2CC3C(CC2CL)OC(F)(F)O3)CN1
CMK,CMK,,GDSC1:64,gdsc,,,,,,,,NA,,
CMP 5,CMP 5,,BRD:BRD-K00126471-001-01-9,oncref_2,PUTATIVE INHIBITOR OF PRMT5,PRMT5,,,,,,NA,,
CMPD-1,CMPD-1,,BRD:BRD-BRD-K54095730-001-03-1;BRD:BRD-K54095730-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,GNRHR;MAPK14,,,PRECLINICAL,,,NA,,OC1CCC(NC(=O)CCCC2CCC(CC2)-C2CCCCC2F)CC1
CNQX,CNQX,,BRD:BRD-BRD-K19438463-001-05-5;BRD:BRD-K19438463-001-05-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIA3;GRIA4,,,PHASE 1,,,NA,,[O-][N+](=O)C1CC2[NH]C(=O)C(=O)[NH]C2CC1C#N
CNX-2006,CNX-2006,,BRD:BRD-BRD-K24869513-001-02-1;BRD:BRD-K24869513-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,COC1CC(NC2CN(CCF)C2)CCC1NC1NCC(C(NC2CCCC(NC(=O)C=C)C2)N1)C(F)(F)F
CNX-774,CNX-774,,BRD:BRD-BRD-K48443249-001-01-0;BRD:BRD-K48443249-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK,,,PRECLINICAL,,,NA,,CNC(=O)C1CC(OC2CCC(NC3NCC(F)C(NC4CCCC(NC(=O)C=C)C4)N3)CC2)CCN1
CO-101244,CO-101244,,BRD:BRD-BRD-K55677650-003-02-9;BRD:BRD-K55677650-003-02-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2B,,,PRECLINICAL,,,NA,,CC1CCC(CC2(O)CCN(CCOC3CCC(O)CC3)CC2)CC1
CO-102862,CO-102862,,BRD:BRD-BRD-K70912147-001-01-8;BRD:BRD-K70912147-001-01-8,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN4A;SCN9A,,,PHASE 1,,,NA,,NC(=O)N\N=C\C1CCC(OC2CCC(F)CC2)CC1
COBICISTAT,COBICISTAT,CHEMBL2095208,BRD:BRD-BRD-K51040301-001-02-1;BRD:BRD-K51040301-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP3A4;CYP3A43;CYP3A5;CYP3A7,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,CC(C)C1NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2CCCCC2)NC(=O)OCC2CNCS2)CC2CCCCC2)CS1
XL518,COBIMETINIB;RG7420;XL518,CHEMBL2146883,BRD:BRD-BRD-K03390685-001-01-7;BRD:BRD-K03390685-001-01-7;BRD:BRD-K03390685-001-07-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MAP2K1,MAP2K1,MELANOMA,,LAUNCHED,"Multiple values for MOA: {'MEK INHIBITOR', 'INHIBITOR OF MAP2K1'}, defaulting to 'INHIBITOR OF MAP2K1'",Small molecule,Approved,BSMCAPRUBJMWDF-KRWDZBQOSA-N,O=C(C1CCC(F)C(F)C1NC1CCC(I)CC1F)N1CC(O)([C@@H]2CCCCN2)C1;OC1(CN(C1)C(=O)C1CCC(F)C(F)C1NC1CCC(I)CC1F)[C@@H]1CCCCN1
COH29,COH29,CHEMBL4297421,BRD:BRD-K00003307-001-01-9,rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,,,,,,Small molecule,Phase 1,LGGDLPSXAGQFSG-UHFFFAOYSA-N,O=C(NC1NC(-C2CCC(O)C(O)C2)C(-C2CCCCC2)S1)C1CCC(O)C(O)C1
COL-3,COL-3,CHEMBL2104970,CTRP:665914,ctrp,,,,,,,Small molecule,Phase 2,ZXFCRFYULUUSDW-OWXODZSWSA-N,NC(=O)C1=C(O)C[C@@H]2C[C@@H]3CC4CCCC(O)C4C(=O)C3=C(O)[C@]2(O)C1=O
COLCHICINE,COLCHICINE,CHEMBL107,BRD:BRD-BRD-K00259736-001-16-4;BRD:BRD-K00259736-001-16-4,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE INHIBITOR,GLRA1;GLRA2;TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,"GOUT, FEVER",,LAUNCHED,,Small molecule,Approved,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COC1CC2C(C(OC)C1OC)-C1CCC(OC)C(=O)CC1[C@@H](NC(C)=O)CC2;COC1CC2CC[C@H](NC(C)=O)C3CC(=O)C(OC)CCC3-C2C(OC)C1OC
COLESEVALAM,COLESEVALAM,,BRD:BRD-BRD-U08520523-000-01-0;BRD:BRD-U08520523-000-01-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,
COLFORSIN,COLFORSIN,CHEMBL52606,BRD:BRD-A55416093-001-06-4;BRD:BRD-BRD-A55416093-001-06-4,rep_primary;rep_single_dose,ADENYLYL CYCLASE ACTIVATOR,ADCY2;ADCY5,,,PHASE 2,,Small molecule,Unknown,OHCQJHSOBUTRHG-KGGHGJDLSA-N,C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](OC(C)=O)[C@@]2(C)O1;CC(=O)O[C@H]1[C@@H](O)C2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C
COLFORSIN-DAPROATE,COLFORSIN-DAPROATE,,BRD:BRD-BRD-K19388745-003-01-7;BRD:BRD-K19388745-003-01-7,rep_multi_dose;rep_primary;rep_single_dose,ADENYLYL CYCLASE ACTIVATOR,,,,LAUNCHED,,,NA,,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C
COLFOSCERIL-PALMITATE,COLFOSCERIL-PALMITATE,,BRD:BRD-A95886749-001-03-5;BRD:BRD-BRD-A95886749-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,PULMONARY SURFACTANT,,RESPIRATORY DISTRESS SYNDROME (RDS),,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
COLISTIN-B-SULFATE,COLISTIN-B-SULFATE,,BRD:BRD-A36456202-001-01-3;BRD:BRD-BRD-A36456202-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL PERMEABILITY INDUCER,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,,NA,,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O
COMBRETASTATIN-A-4,COMBRETASTATIN-A-4,,BRD:BRD-BRD-K61195623-001-01-4;BRD:BRD-K61195623-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,PHASE 2,,,NA,,COC1CCC(CC1O)\C=C/C1CC(OC)C(OC)C(OC)C1
COMETRIQ,COMETRIQ,CHEMBL2103868;CHEMBL2105717,GDSC1:249,gdsc,,,,,,,Small molecule,Approved,HFCFMRYTXDINDK-WNQIDUERSA-N;ONIQOQHATWINJY-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC;COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC.O=C(O)C[C@H](O)C(=O)O
COMPOUND 1541A,COMPOUND 1541A,,CTRP:411827,ctrp,,,,,,,,NA,,
COMPOUND 1B,COMPOUND 1B,,CTRP:62111,ctrp,,,,,,,,NA,,
COMPOUND 23 CITRATE,COMPOUND 23 CITRATE,,CTRP:417451,ctrp,,,,,,,,NA,,
COMPOUND 7D-CIS,COMPOUND 7D-CIS,,CTRP:411805,ctrp,,,,,,,,NA,,
RINETERKIB,COMPOUND B;RINETERKIB,,BRD:BRD-K00126779-001-01-9,oncref_2,INHIBITOR OF ERK1 AND ERK2,BRAF;MAPK1;MAPK3;RAF1,,,,,,NA,,
COMPOUND-401,COMPOUND-401,,BRD:BRD-BRD-K19655798-001-01-9;BRD:BRD-K19655798-001-01-9,rep_primary;rep_single_dose,DNA DEPENDENT PROTEIN KINASE INHIBITOR,MTOR;PRKDC,,,PRECLINICAL,,,NA,,O=C1CC(NC2C3CCCCC3CCN12)N1CCOCC1
COMPOUND-58112,COMPOUND-58112,,BRD:BRD-BRD-K76139886-003-01-3;BRD:BRD-K76139886-003-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CCCC(CN2C[SI](C)(C)O[SI](C)(C)C2)C1
COMPOUND-W,COMPOUND-W,,BRD:BRD-BRD-K98143539-001-02-2;BRD:BRD-K98143539-001-02-2,rep_primary;rep_single_dose,BETA-SECRETASE INHIBITOR,BACE1,,,PRECLINICAL,,,NA,,OC(=O)C1CC(OC2CCC(CC2)[N+]([O-])=O)CC(OC2CCC(CC2)[N+]([O-])=O)C1
CONIVAPTAN,CONIVAPTAN,CHEMBL1755,BRD:BRD-BRD-K37385792-003-02-1;BRD:BRD-K37385792-003-02-1,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,AVPR1A;AVPR2,HYPONATREMIA,,LAUNCHED,,Small molecule,Approved,IKENVDNFQMCRTR-UHFFFAOYSA-N,CC1NC2C([NH]1)-C1CCCCC1N(C(=O)C1CCC(NC(=O)C3CCCCC3-C3CCCCC3)CC1)CC2;CC1NC2CCN(C(=O)C3CCC(NC(=O)C4CCCCC4-C4CCCCC4)CC3)C3CCCCC3-C2[NH]1
CONVALLATOXIN,CONVALLATOXIN,CHEMBL399336,BRD:BRD-K00004559-001-01-9,rep_single_dose,CARDIAC GLYCOSIDE,,,,,,Small molecule,NA,HULMNSIAKWANQO-JQKSAQOKSA-N,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
COPANLISIB,COPANLISIB,CHEMBL3218576,BRD:BRD-BRD-K24666289-001-04-9;BRD:BRD-K24666289-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,FOLLICULAR LYMPHOMA,,LAUNCHED,,Small molecule,Approved,PZBCKZWLPGJMAO-UHFFFAOYSA-N,COC1C(OCCCN2CCOCC2)CCC2C1N=C(NC(=O)C1CNC(N)NC1)N1CCN=C21;COC1C(OCCCN2CCOCC2)CCC2C3=NCCN3C(NC(=O)C3CNC(N)NC3)=NC12
COPPER-HISTIDINE,COPPER-HISTIDINE,,BRD:BRD-BRD-K36449075-001-01-0;BRD:BRD-K36449075-001-01-0,rep_primary;rep_single_dose,,HAL;HARS;HDC;SLC15A3;SLC15A4;SLC38A3;SLC38A5,,,PHASE 3,,,NA,,N[C@H](CC1C[NH]CN1)C(O)=O
COR-170,COR-170,,BRD:BRD-BRD-K74965187-001-01-3;BRD:BRD-K74965187-001-01-3,rep_primary;rep_single_dose,CANNABINOID RECEPTOR INVERSE AGONIST,CNR2,,,PRECLINICAL,,,NA,,CCCCCN1CC(C(=O)NC23CC4CC(CC(C4)C2)C3)C(=O)C2CC(CCC12)-C1CCCCC1
CORDYCEPIN,CORDYCEPIN,CHEMBL305686,BRD:BRD-BRD-K65428967-001-08-4;BRD:BRD-K65428967-001-08-4,rep_primary;rep_single_dose,DNA INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,OFEZSBMBBKLLBJ-BAJZRUMYSA-N,NC1NCNC2C1NCN2[C@@H]1O[C@H](CO)C[C@H]1O;NC1NCNC2N(CNC12)[C@@H]1O[C@H](CO)C[C@H]1O
COROSOLIC-ACID,COROSOLIC-ACID,,BRD:BRD-BRD-K27885593-001-06-8;BRD:BRD-K27885593-001-06-8,rep_primary;rep_single_dose,"PKC INHIBITOR, PROTEIN TYROSINE KINASE INHIBITOR",HSD11B1;PTPN1,,,PHASE 2,,,NA,,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O
CORT-108297,CORT-108297,CHEMBL271220,BRD:BRD-K00004700-001-01-9,rep_single_dose,GLUCOCORTICOID RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 1,SLKURXRZHJOZOD-RUZDIDTESA-N,CCOC[C@]12CC3CNN(-C4CCC(F)CC4)C3C=C1CCN(S(=O)(=O)C1CCC(C(F)(F)F)CC1)C2
CORTICOSTERONE,CORTICOSTERONE,CHEMBL110739,BRD:BRD-BRD-K73589401-001-23-6;BRD:BRD-K73589401-001-23-6,rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR AGONIST,HSD11B1;NCOA1;NR3C2,,,PRECLINICAL,,Small molecule,Phase 3,OMFXVFTZEKFJBZ-HJTSIMOOSA-N,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO;C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO
CORTISONE,CORTISONE,CHEMBL1499;CHEMBL1650,BRD:BRD-A62731508-001-05-8;BRD:BRD-BRD-A62731508-001-05-8,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"ULCERATIVE COLITIS, RHEUMATOID ARTHRITIS, PSORIASIS, JOINT INFLAMMATION, ECZEMA",,LAUNCHED,,Small molecule,Approved,ITRJWOMZKQRYTA-RFZYENFJSA-N;MFYSYFVPBJMHGN-ZPOLXVRWSA-N,C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO;C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO;CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
CORTISONE-ACETATE,CORTISONE-ACETATE,,BRD:BRD-BRD-K86161929-001-11-7;BRD:BRD-BRD-K86161929-001-13-3;BRD:BRD-K86161929-001-11-7;BRD:BRD-K86161929-001-13-3,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"ASTHMA, RHEUMATOID ARTHRITIS, URTICARIA, OSTEOARTHRITIS, PSORIASIS, ALLERGIC RHINITIS, CONJUNCTIVITIS, ULCERATIVE COLITIS, MENINGITIS",,LAUNCHED,,,NA,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C
CORTODOXONE,CORTODOXONE,CHEMBL253144,BRD:BRD-BRD-K32891457-001-15-5;BRD:BRD-K32891457-001-15-5,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,,,PHASE 3,,Small molecule,Phase 2,WHBHBVVOGNECLV-OBQKJFGGSA-N,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO;C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO;C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
COSMEGEN,COSMEGEN,CHEMBL1554,GDSC2:1911,gdsc,,,,,,,Protein,Approved,RJURFGZVJUQBHK-IIXSONLDSA-N,CC1C2OC3C(C)CCC(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)C3NC-2C(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)C(N)C1=O
COSTUNOLIDE,COSTUNOLIDE,CHEMBL86416,BRD:BRD-BRD-K26833429-001-02-8;BRD:BRD-K26833429-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,TELOMERASE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,HRYLQFBHBWLLLL-AHNJNIBGSA-N,C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1;C=C1C(=O)O[C@@H]2/C=C(\C)CC/C=C(\C)CC[C@@H]12
COSUDEX,COSUDEX,CHEMBL409,GDSC1:150;GDSC1:1502,gdsc,,,,,,,Small molecule,Approved,LKJPYSCBVHEWIU-UHFFFAOYSA-N,CC(O)(CS(=O)(=O)C1CCC(F)CC1)C(=O)NC1CCC(C#N)C(C(F)(F)F)C1
COT-INHIBITOR-1,COT-INHIBITOR-1,,BRD:BRD-K98710228-001-01-6,rep_single_dose,MAPK-INTERACTING KINASE INHIBITOR,MAP3K8,,,,,,NA,,
COT-INHIBITOR-2,COT-INHIBITOR-2,,BRD:BRD-K49468759-001-04-2,rep_single_dose,MAPK-INTERACTING KINASE INHIBITOR,MAP3K8,,,,,,NA,,
COTI-2,COTI-2,,BRD:BRD-K00003348-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,,NA,,
COTININE,COTININE,CHEMBL578211,BRD:BRD-BRD-K94144010-001-13-9;BRD:BRD-K94144010-001-13-9,rep_primary;rep_single_dose,NICOTINE METABOLITE,,,,PHASE 2,,Small molecule,Phase 2,UIKROCXWUNQSPJ-VIFPVBQESA-N,CN1[C@@H](CCC1=O)C1CCCNC1;CN1C(=O)CC[C@H]1C1CCCNC1
COUMARIN,COUMARIN,CHEMBL6466,BRD:BRD-BRD-K23913458-001-20-7;BRD:BRD-K23913458-001-20-7,rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,CA1;CA12;CA14;CA2;CA4;CA6;CA9;CYP2A6,"ULCERATIVE COLITIS, ASTHMA, CELIAC DISEASE",,LAUNCHED,,Small molecule,Approved,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,O=C1CCC2CCCCC2O1
COUMOPHOS,COUMOPHOS,,BRD:BRD-BRD-K41567533-001-08-3;BRD:BRD-K41567533-001-08-3,rep_primary;rep_single_dose,CHOLINESTERASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCOP(=S)(OCC)OC1CCC2C(C)C(CL)C(=O)OC2C1
CP 466722,CP 466722,,GDSC1:152,gdsc,,,,,,,,NA,,
"CP-105,696","CP-105,696",,BRD:BRD-K00004654-001-01-9,rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,,,,,,,NA,,
CP-316819,CP-316819,,BRD:BRD-BRD-K53913008-001-01-5;BRD:BRD-K53913008-001-01-5,rep_primary;rep_single_dose,GLYCOGEN PHOSPHORYLASE INHIBITOR,PYGL,,,PRECLINICAL,,,NA,,CON(C)C(=O)[C@H](O)[C@H](CC1CCCCC1)NC(=O)C1CC2CC(CL)CCC2[NH]1
CP-339818,CP-339818,CHEMBL281622,BRD:BRD-BRD-K52113681-003-02-1;BRD:BRD-K52113681-003-02-1,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNA3,,,PRECLINICAL,,Small molecule,NA,MMGAVKCAGQCFHS-LSDHQDQOSA-N,CCCCC/N=C1\CCN(CC2CCCCC2)C2CCCCC12;CCCCCN=C1CCN(CC2CCCCC2)C2CCCCC12
CP-358774,CP-358774,CHEMBL553,GDSC1:1;GDSC2:1168,gdsc,,,,,,,Small molecule,Approved,AAKJLRGGTJKAMG-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1
CP-376395,CP-376395,,BRD:BRD-BRD-K31394475-001-01-9;BRD:BRD-K31394475-001-01-9,rep_primary;rep_single_dose,"CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST",CRHR1,,,PHASE 1,"Multiple values for MOA: {'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST', 'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST'}, defaulting to 'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST'",,NA,,CCC(CC)NC1CC(C)NC(OC2C(C)CC(C)CC2C)C1C
CP-466722,CP-466722,,GDSC1:152,gdsc,,,,,,,,NA,,
CP-471474,CP-471474,,BRD:BRD-K33234937-001-02-9,rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,MMP1;MMP13;MMP2;MMP3;MMP9,,,,,,NA,,
CP-532623,CP-532623,,BRD:BRD-BRD-K36611520-001-01-6;BRD:BRD-K36611520-001-01-6,rep_primary;rep_single_dose,CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR,CETP,,,PHASE 1,,,NA,,CC[C@@H]1C[C@H](N(CC2CC(CC(C2)C(F)(F)F)C(F)(F)F)C(C)=O)C2CC(CCC2N1C(=O)OC(C)C)C(F)(F)F
CP-547632,CP-547632,CHEMBL253969,BRD:BRD-K00004719-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 2,HXHAJRMTJXHJJZ-UHFFFAOYSA-N,NC(=O)C1C(OCC2C(F)CC(BR)CC2F)NSC1NC(=O)NCCCCN1CCCC1
CP-640186,CP-640186,,BRD:BRD-K26921335-003-01-2,rep_single_dose,ACETYL-COA CARBOXYLASE INHIBITOR,ACACA;ACACB,,,,,,NA,,
CP-673451,CP-673451,,BRD:BRD-BRD-K43621685-001-02-5;BRD:BRD-K43621685-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,PDGFR TYROSINE KINASE RECEPTOR INHIBITOR,KIT;PDGFRA;PDGFRB,,,PRECLINICAL,,,NA,,COCCOC1CCC2N(CNC2C1)-C1CCC2CCCC(N3CCC(N)CC3)C2N1
CP-724714,CP-724714,CHEMBL483321,BRD:BRD-BRD-K76908866-001-07-6;BRD:BRD-K76908866-001-07-6;GDSC1:255,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, PROTEIN TYROSINE KINASE INHIBITOR",ERBB2,,,PHASE 2,,Small molecule,Phase 2,LLVZBTWPGQVVLW-SNAWJCMRSA-N,COCC(=O)NC/C=C/C1CCC2NCNC(NC3CCC(OC4CCC(C)NC4)C(C)C3)C2C1;COCC(=O)NC\C=C\C1CCC2NCNC(NC3CCC(OC4CCC(C)NC4)C(C)C3)C2C1
CP-775146,CP-775146,,BRD:BRD-BRD-K96843359-001-02-6;BRD:BRD-K96843359-001-02-6,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA,,,PRECLINICAL,,,NA,,CC(C)C1CCC(CC(=O)N2CCC[C@H](C2)C2CCCC(OC(C)(C)C(O)=O)C2)CC1
CP-91149,CP-91149,,BRD:BRD-BRD-K19171642-001-02-3;BRD:BRD-K19171642-001-02-3,rep_primary;rep_single_dose,GLYCOGEN PHOSPHORYLASE INHIBITOR,PYGL,,,PRECLINICAL,,,NA,,CN(C)C(=O)[C@H](O)[C@H](CC1CCCCC1)NC(=O)C1CC2CC(CL)CCC2[NH]1
CP-93129,CP-93129,,BRD:BRD-BRD-K81876028-300-02-0;BRD:BRD-K81876028-300-02-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PRECLINICAL,,,NA,,O=C1CCC2[NH]CC(C3=CCNCC3)C2[NH]1
CP-94253,CP-94253,,BRD:BRD-K33860217-003-04-0,rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1B,,,,,,NA,,
"CP-945,598","CP-945,598",CHEMBL2103817;CHEMBL562668,BRD:BRD-BRD-K09090949-001-01-9;BRD:BRD-K09090949-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1,,,PHASE 3,,Small molecule,Phase 3,KPYUQCJBZGQHPL-UHFFFAOYSA-N;UNAZAADNBYXMIV-UHFFFAOYSA-N,CCNC1(C(N)=O)CCN(C2NCNC3C2NC(-C2CCCCC2CL)N3-C2CCC(CL)CC2)CC1;CCNC1(C(N)=O)CCN(C2NCNC3C2NC(-C2CCCCC2CL)N3-C2CCC(CL)CC2)CC1.CL;CCNC1(CCN(CC1)C1NCNC2N(C(NC12)-C1CCCCC1CL)-C1CCC(CL)CC1)C(N)=O
CP-99994,CP-99994,CHEMBL441225,BRD:BRD-BRD-K09946180-300-01-6;BRD:BRD-K09946180-300-01-6,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,,,PHASE 2,,Small molecule,NA,DTQNEFOKTXXQKV-HKUYNNGSSA-N,COC1CCCCC1CN[C@H]1CCCN[C@H]1C1CCCCC1
OSI-774,CP358774;ERLOTINIB;OSI-774,CHEMBL1079742;CHEMBL553,BRD:BRD-BRD-K70401845-003-09-6;BRD:BRD-K70401845-001-15-7;BRD:BRD-K70401845-001-25-9;BRD:BRD-K70401845-003-09-6;CTRP:52928;GDSC1:1;GDSC2:1168,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF EGFR AND ERBB2,EGFR;ERBB2;NR1I2,"NON-SMALL CELL LUNG CANCER (NSCLC), PANCREATIC CANCER",,LAUNCHED,"Multiple values for MOA: {'EGFR INHIBITOR', 'INHIBITOR OF EGFR AND ERBB2'}, defaulting to 'INHIBITOR OF EGFR AND ERBB2'
Multiple values for repurposing_target: {'EGFR;NR1I2', 'EGFR;ERBB2'}, taking the union",Small molecule,Approved,AAKJLRGGTJKAMG-UHFFFAOYSA-N;GTTBEUCJPZQMDZ-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1;C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1.CL;COCCOC1CC2NCNC(NC3CCCC(C3)C#C)C2CC1OCCOC
CP466722,CP466722,,GDSC1:152,gdsc,,,,,,,,NA,,
CP724714,CP724714,,GDSC1:255,gdsc,,,,,,,,NA,,
CPA-INHIBITOR,CPA-INHIBITOR,,BRD:BRD-A69126730-001-01-3;BRD:BRD-BRD-A69126730-001-01-3,rep_primary;rep_single_dose,CARBOXYPEPTIDASE INHIBITOR,CPA1;CPA2,,,PRECLINICAL,,,NA,,ON(CC(CC1CCCCC1)C(O)=O)C(=O)CC1CCCCC1
CPCCOET,CPCCOET,CHEMBL337583,BRD:BRD-A05729358-001-02-0;BRD:BRD-BRD-A05729358-001-02-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1,,,PRECLINICAL,,Small molecule,NA,FXCTZFMSAHZQTR-ZBUQWEBQSA-N,CCOC(=O)[C@]12CC1/C(=N\O)C1CCCCC1O2;CCOC(=O)C12CC1\C(=N/O)C1CCCCC1O2
CPI-0610,CPI-0610,CHEMBL4303404,BRD:BRD-BRD-K19871656-001-01-3;BRD:BRD-K19871656-001-01-3,rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD4,,,PHASE 1,,Small molecule,Phase 3,GCWIQUVXWZWCLE-INIZCTEOSA-N,CC1NOC2[C@H](CC(N)=O)N=C(C3CCC(CL)CC3)C3CCCCC3-C12;CC1NOC2C1-C1CCCCC1C(C1CCC(CL)CC1)=N[C@H]2CC(N)=O
CPI-1189,CPI-1189,CHEMBL4297369,BRD:BRD-BRD-K11073688-001-01-6;BRD:BRD-K11073688-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,TUMOR NECROSIS FACTOR RELEASE INHIBITOR,TNF,,,PHASE 2,,Small molecule,Phase 2,DJKNRCWSXSZACF-UHFFFAOYSA-N,CC(=O)NC1CCC(C(=O)NC(C)(C)C)CC1;CC(=O)NC1CCC(CC1)C(=O)NC(C)(C)C
CPI-1205,CPI-1205,CHEMBL4297463,BRD:BRD-K00003360-001-01-9,rep_single_dose,EZH2 INHIBITOR,,,,,,Small molecule,Phase 1,HPODOLXTMDHLLC-QGZVFWFLSA-N,COC1CC(C)[NH]C(=O)C1CNC(=O)C1C(C)N([C@H](C)C2CCN(CC(F)(F)F)CC2)C2CCCCC12
CPI-169,CPI-169,,BRD:BRD-K97181972-001-01-9,rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,,,,NA,,
CPI-203,CPI-203,,BRD:BRD-BRD-K15811707-001-02-0;BRD:BRD-K15811707-001-02-0,rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD4,,,PRECLINICAL,,,NA,,CC1SC-2C(C1C)C(=N[C@@H](CC(N)=O)C1NNC(C)N-21)C1CCC(CL)CC1
CPI-360,CPI-360,,BRD:BRD-BRD-K18319422-001-01-7;BRD:BRD-K18319422-001-01-7,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PRECLINICAL,,,NA,,COC1CC(C)[NH]C(=O)C1CNC(=O)C1C(C)N([C@H](C)C2CCOCC2)C2CCCCC12
CPI-444,CPI-444,CHEMBL4297184,BRD:BRD-K00003442-001-01-9,rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,KURQKNMKCGYWRJ-HNNXBMFYSA-N,CC1CCC(-C2NC(N)NC3C2NNN3CC2CCCC(CO[C@H]3CCOC3)N2)O1
CPI-613,CPI-613,CHEMBL3186849,BRD:BRD-A06916187-001-02-9;BRD:BRD-BRD-A06916187-001-02-9;GDSC1:415,gdsc;rep_primary;rep_single_dose,PYRUVATE DEHYDROGENASE INHIBITOR,PDHA1,,,PHASE 2,,Small molecule,Phase 3,ZYRLHJIMTROTBO-UHFFFAOYSA-N,O=C(O)CCCCC(CCSCC1CCCCC1)SCC1CCCCC1;OC(=O)CCCCC(CCSCC1CCCCC1)SCC1CCCCC1
CPP,CPP,,BRD:BRD-BRD-K66094457-001-01-5;BRD:BRD-K66094457-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PHASE 2,,,NA,,OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1;OC(=O)C1CN(CCCP(O)(O)=O)CCN1
CPSI-1306-(+/-),CPSI-1306-(+/-),,BRD:BRD-A81603255-001-01-0;BRD:BRD-BRD-A81603255-001-01-0,rep_primary;rep_single_dose,MACROPHAGE MIGRATION INHIBITING FACTOR INHIBITOR,MIF,,,PRECLINICAL,,,NA,,FC1CCC(C2=NOC(CC(=O)N3CCOCC3)C2)C(F)C1
CQS,CQS,,BRD:BRD-K56839624-001-06-9,rep_single_dose,,,,,,,,NA,,
CR-1-31B,CR-1-31B,,CTRP:418209,ctrp,,,,,,,,NA,,
CR8-(R),CR8-(R),,BRD:BRD-BRD-K40331046-305-01-5;BRD:BRD-K40331046-305-01-5,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CCNA2,,,PRECLINICAL,,,NA,,CC[C@H](CO)NC1NC(NCC2CCC(CC2)-C2CCCCN2)C2NCN(C(C)C)C2N1
CRA-032765,CRA-032765,CHEMBL1873475,GDSC2:1799,gdsc,,,,,,,Small molecule,Approved,XYFPWWZEPKGCCK-GOSISDBHSA-N,C=CC(=O)N1CCC[C@@H](N2NC(-C3CCC(OC4CCCCC4)CC3)C3C(N)NCNC32)C1
CREATINE,CREATINE,CHEMBL283800,BRD:BRD-BRD-K19615002-001-02-3;BRD:BRD-K19615002-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,,CKB;CKM;CKMT1A;CKMT2;GAMT;SLC6A8,,,LAUNCHED,,Small molecule,Phase 3,CVSVTCORWBXHQV-UHFFFAOYSA-N,CN(CC(=O)O)C(=N)N;CN(CC(O)=O)C(N)=N
CREATININE,CREATININE,CHEMBL65567,BRD:BRD-BRD-K13495773-001-11-4;BRD:BRD-K13495773-001-11-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Phase 3,DDRJAANPRJIHGJ-UHFFFAOYSA-N,CN1CC(=O)NC1=N
CREATINOL-PHOSPHATE,CREATINOL-PHOSPHATE,,BRD:BRD-BRD-K42991124-001-03-0;BRD:BRD-K42991124-001-03-0,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CN(CCOP(O)(O)=O)C(N)=N
CRENIGACESTAT,CRENIGACESTAT,CHEMBL2338397,BRD:BRD-K00003129-001-01-9,rep_single_dose,NOTCH SIGNALING INHIBITOR,,,,,,Small molecule,Phase 1,YCBAQKQAINQRFW-UGSOOPFHSA-N,C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(CCO)C2NCCCC2-C2CCCCC21
CRENOLANIB,CRENOLANIB,CHEMBL2105728,BRD:BRD-BRD-K22127577-001-03-7;BRD:BRD-K22127577-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,PDGFR TYROSINE KINASE RECEPTOR INHIBITOR,CSF1R;FLT3;KIT;PDGFRA;PDGFRB,,,PHASE 2,,Small molecule,Phase 3,DYNHJHQFHQTFTP-UHFFFAOYSA-N,CC1(COC2CCC3C(C2)NCN3-C2CCC3CCCC(N4CCC(N)CC4)C3N2)COC1;CC1(COC2CCC3N(CNC3C2)-C2CCC3CCCC(N4CCC(N)CC4)C3N2)COC1
CRESOL,CRESOL,CHEMBL1410808,BRD:BRD-BRD-K56940914-001-04-2;BRD:BRD-K56940914-001-04-2,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,QTWJRLJHJPIABL-UHFFFAOYSA-N,CC1CCC(O)CC1;CC1CCC(O)CC1.CC1CCCC(O)C1.CC1CCCCC1O
CRESOPIRINE,CRESOPIRINE,,BRD:BRD-BRD-K58648841-001-04-7;BRD:BRD-K58648841-001-04-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(=O)OC1C(C)CCCC1C(O)=O
CRIDANIMOD,CRIDANIMOD,CHEMBL1569545,BRD:BRD-BRD-K97939847-001-12-0;BRD:BRD-K97939847-001-12-0,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,,,LAUNCHED,,Small molecule,Phase 2,UOMKBIIXHQIERR-UHFFFAOYSA-N,O=C(O)CN1C2CCCCC2C(=O)C2CCCCC21;OC(=O)CN1C2CCCCC2C(=O)C2CCCCC12
CRISABOROLE,CRISABOROLE,CHEMBL484785,BRD:BRD-BRD-K43230258-001-01-4;BRD:BRD-K43230258-001-01-4,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4C;PDE4D,,,PHASE 3,"Multiple values for repurposing_target: {'PDE4A;PDE4B;PDE4C;PDE4D', 'PDE4B'}, taking the union",Small molecule,Approved,USZAGAREISWJDP-UHFFFAOYSA-N,N#CC1CCC(OC2CCC3C(C2)COB3O)CC1;OB1OCC2CC(OC3CCC(CC3)C#N)CCC12
CRISDESALAZINE,CRISDESALAZINE,,BRD:BRD-K00004545-001-01-9,rep_single_dose,FREE RADICAL SCAVENGER,,,,,,,NA,,
PF-02341066,CRIZOTINIB;PF-02341066,CHEMBL601719,BRD:BRD-BRD-K78431006-001-10-2;BRD:BRD-K78431006-001-01-1;BRD:BRD-K78431006-001-10-2;BRD:BRD-K78431006-001-15-1;CTRP:628603;GDSC1:37;GDSC2:1083,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK;MET,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF ALK AND MET', 'ALK TYROSINE KINASE RECEPTOR INHIBITOR'}, defaulting to 'ALK TYROSINE KINASE RECEPTOR INHIBITOR'",Small molecule,Approved,KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](OC1CC(-C2CNN(C3CCNCC3)C2)CNC1N)C1C(CL)CCC(F)C1CL;C[C@@H](OC1CC(CNC1N)-C1CNN(C1)C1CCNCC1)C1C(CL)CCC(F)C1CL
CRIZOTINIB-(S),CRIZOTINIB-(S),,BRD:BRD-BRD-K40308497-001-01-2;BRD:BRD-BRD-K40308497-001-02-0;BRD:BRD-K40308497-001-01-2;BRD:BRD-K40308497-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,MTH1 INHIBITOR,NUDT1,,,PRECLINICAL,,,NA,,C[C@H](OC1CC(CNC1N)-C1CNN(C1)C1CCNCC1)C1C(CL)CCC(F)C1CL
CRIZOTINIB:PLX-4032 (2:1 MOL/MOL),CRIZOTINIB:PLX-4032 (2:1 MOL/MOL),,CTRP:660857,ctrp,,,,,,,,NA,,
CROLIBULIN,CROLIBULIN,CHEMBL2103852,BRD:BRD-K00003162-001-01-9,rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,,,Small molecule,Phase 1,JXONINOYTKKXQQ-CQSZACIVSA-N,COC1CC([C@H]2C(C#N)=C(N)OC3C2CCC(N)C3N)CC(BR)C1OC
CROMAKALIM,CROMAKALIM,CHEMBL49035,BRD:BRD-BRD-M89827113-001-01-5;BRD:BRD-M89827113-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,,KCNJ8,,,PHASE 2,,Small molecule,Unknown,TVZCRIROJQEVOT-UHFFFAOYSA-N,CC1(C)OC2CCC(C#N)CC2C(N2CCCC2=O)C1O;CC1(C)OC2CCC(CC2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)OC2CCC(CC2[C@@H]([C@H]1O)N1CCCC1=O)C#N
CROMOGLICIC-ACID,CROMOGLICIC-ACID,,BRD:BRD-BRD-K20920669-304-09-1;BRD:BRD-K20920669-304-09-1,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,KCNMA1;S100P,"ASTHMA, CONJUNCTIVITIS, URTICARIA, ULCERATIVE COLITIS",,LAUNCHED,,,NA,,OC(COC1CCCC2OC(CC(=O)C12)C(O)=O)COC1CCCC2OC(CC(=O)C12)C(O)=O
CROTAMITON,CROTAMITON,CHEMBL1200709,BRD:BRD-BRD-K57179821-001-15-4;BRD:BRD-K57179821-001-15-4,rep_primary;rep_single_dose,ANTIPRURITIC,,SCABIES,,LAUNCHED,,Small molecule,Approved,DNTGGZPQPQTDQF-XBXARRHUSA-N,C/C=C/C(=O)N(CC)C1CCCCC1C;CCN(C(=O)\C=C\C)C1CCCCC1C
CRT0044876,CRT0044876,,BRD:BRD-BRD-K02816415-001-01-9;BRD:BRD-K02816415-001-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)C1CC2CCCC([N+]([O-])=O)C2[NH]1
CRYSTAL-VIOLET,CRYSTAL-VIOLET,,BRD:BRD-BRD-K60025295-003-06-6;BRD:BRD-K60025295-003-06-6,rep_multi_dose;rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,,,LAUNCHED,,,NA,,CN(C)C1CCC(CC1)C(C1CCC(CC1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
CS-110266,CS-110266,,BRD:BRD-BRD-K15519488-050-01-3;BRD:BRD-K15519488-050-01-3,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,SLC6A3,,,PRECLINICAL,,,NA,,C1CCN(CC1)C1(CCCCC1)C1CC2CCCCC2S1
CS-1421,CS-1421,,GDSC2:1564,gdsc,,,,,,,,NA,,
CS-917,CS-917,,BRD:BRD-BRD-K35601925-001-01-9;BRD:BRD-K35601925-001-01-9,rep_primary;rep_single_dose,FRUCTOSE BIPHOSPHATE INHIBITOR,FBP1,,,PHASE 2,,,NA,,CC(C)CC1SC(N)NC1-C1CCC(O1)P(O)(O)=O
CT 99021,CT 99021,,GDSC1:1241;GDSC1:154,gdsc,,,,,,,,NA,,
CT-7758,CT-7758,CHEMBL4303708,BRD:BRD-BRD-K40870905-001-01-7;BRD:BRD-K40870905-001-01-7,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGA4,,,PHASE 2,,Small molecule,Unknown,KYHVWHYLKOHLKA-FQEVSTJZSA-N,O=C(O)[C@H](CC1CCC(NC2NCCC3CCNCC23)CC1)NC1=C(BR)C(=O)C12CCCCC2;OC(=O)[C@H](CC1CCC(NC2NCCC3CCNCC23)CC1)NC1=C(BR)C(=O)C11CCCCC1
CT7001,CT7001,CHEMBL4297488,BRD:BRD-K00003453-003-01-9,rep_single_dose,CDK INHIBITOR,,,,,,Small molecule,Phase 1,YCVGLKWJKIKVBI-MJGOQNOKSA-N,CC(C)C1CNN2C(NCC3CCCCC3)CC(NC[C@H]3CCNC[C@@H]3O)NC12
CTEP,CTEP,,BRD:BRD-BRD-K30572193-001-02-0;BRD:BRD-K30572193-001-02-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PRECLINICAL,,,NA,,CC1NC(C#CC2CCNC(CL)C2)C(C)N1-C1CCC(OC(F)(F)F)CC1
CTS-1027,CTS-1027,CHEMBL440498,BRD:BRD-BRD-K53508936-001-01-0;BRD:BRD-K53508936-001-01-0,rep_primary;rep_single_dose,METALLOPROTEINASE INHIBITOR,MMP1;MMP13;MMP2;MMP3;MMP9,,,PHASE 2,,Small molecule,Phase 2,ROSNVSQTEGHUKU-UHFFFAOYSA-N,O=C(NO)C1(CS(=O)(=O)C2CCC(OC3CCC(CL)CC3)CC2)CCOCC1;ONC(=O)C1(CS(=O)(=O)C2CCC(OC3CCC(CL)CC3)CC2)CCOCC1
CTS21166,CTS21166,,BRD:BRD-BRD-K89071957-001-01-1;BRD:BRD-K89071957-001-01-1,rep_primary;rep_single_dose,BETA-SECRETASE INHIBITOR,BACE1,,,PHASE 1,,,NA,,CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1CCCCC1)C(O)=O
PF-9363,CTX-648;PF-9363,,BRD:BRD-K00126781-001-01-9,oncref_2,INHIBITOR OF KAT6A AND KAT6B,KAT6A;KAT6B,,,,,,NA,,
CU-CPT-4A,CU-CPT-4A,,BRD:BRD-K58234744-001-02-9,rep_single_dose,TOLL-LIKE RECEPTOR INHIBITOR,TLR3,,,,,,NA,,
CU-T12-9,CU-T12-9,,BRD:BRD-K89462779-001-02-9,rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,TLR1;TLR2,,,,,,NA,,
CUCURBITACIN I,CUCURBITACIN I,CHEMBL387737,CTRP:595102,ctrp,,,,,,,Small molecule,NA,NISPVUDLMHQFRQ-MKIKIEMVSA-N,CC(C)(O)/C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C=C(O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C
CUDC 101,CUDC 101,CHEMBL598797,GDSC1:273,gdsc,,,,,,,Small molecule,Phase 1,PLIVFNIUGLLCEK-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OC)C(OCCCCCCC(=O)NO)CC23)C1
CUDC-101,CUDC-101,CHEMBL598797,BRD:BRD-BRD-K41278234-001-03-0;BRD:BRD-K41278234-001-03-0;GDSC1:273,gdsc;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2,,,PHASE 1,,Small molecule,Phase 1,PLIVFNIUGLLCEK-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OC)C(OCCCCCCC(=O)NO)CC23)C1;COC1CC2NCNC(NC3CCCC(C3)C#C)C2CC1OCCCCCCC(=O)NO
CUDC-427,CUDC-427,CHEMBL4297282,BRD:BRD-BRD-K69351586-001-01-0;BRD:BRD-K69351586-001-01-0,rep_primary;rep_single_dose,APOPTOSIS INHIBITOR,XIAP,,,PHASE 1,,Small molecule,Phase 1,HSHPBORBOJIXSQ-HARLFGEKSA-N,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)NC1SC(NC1-C1CCCCC1)-C1NCCO1;CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NC1SC(-C2NCCO2)NC1-C1CCCCC1)C1CCCCC1
CUDC-907,CUDC-907,CHEMBL3622533,BRD:BRD-BRD-K77638923-001-02-0;BRD:BRD-K77638923-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,HDAC2;PIK3R1,,,PHASE 2,,Small molecule,Phase 2,JOWXJLIFIIOYMS-UHFFFAOYSA-N,COC1CCC(-C2NC(N3CCOCC3)C3SC(CN(C)C4NCC(C(=O)NO)CN4)CC3N2)CN1;COC1CCC(CN1)-C1NC(N2CCOCC2)C2SC(CN(C)C3NCC(CN3)C(=O)NO)CC2N1
CUR-61414,CUR-61414,,BRD:BRD-BRD-K69624312-001-01-1;BRD:BRD-K69624312-001-01-1,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,DHH;IHH;SMO,,,PHASE 1,,,NA,,COC1CCCC(CN([C@H]2C[C@H](N(CC3CCC4OCOC4C3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)C1
CURCUMIN,CURCUMIN,CHEMBL116438,BRD:BRD-BRD-K07572174-001-39-4;BRD:BRD-K07572174-001-39-4;CTRP:28452,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, HISTONE ACETYLTRANSFERASE INHIBITOR, LIPOXYGENASE INHIBITOR, NFKB PATHWAY INHIBITOR",APP;CA1;CA12;CA14;CA2;CA4;CA6;CA9;CHRM3;CYP3A4;DNMT3B;EP300;MMP13;MMP9;NOS2;PTGS1;PTGS2;XDH,,,LAUNCHED,"Multiple values for repurposing_target: {'APP;CA1;CA12;CA14;CA2;CA4;CA6;CA9;CYP3A4;DNMT3B;EP300;MMP13;MMP9;NOS2;PTGS1;PTGS2;XDH', 'APP;CA1;CA12;CA14;CA2;CA4;CA6;CA9;CHRM3;CYP3A4;DNMT3B;EP300;MMP13;MMP9;NOS2;PTGS1;PTGS2;XDH'}, taking the union",Small molecule,Phase 3,ZIUSSTSXXLLKKK-KOBPDPAPSA-N,COC1CC(/C=C/C(=O)/C=C(O)/C=C/C2CCC(O)C(OC)C2)CCC1O;COC1CC(CCC1O)\C=C\C(=O)CC(=O)\C=C\C1CCC(O)C(OC)C1
CURCUMOL,CURCUMOL,,BRD:BRD-BRD-K41933240-001-02-4;BRD:BRD-K41933240-001-02-4,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3,,,PHASE 1,,,NA,,CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C
CUTAMESINE,CUTAMESINE,,BRD:BRD-BRD-K90777969-300-01-2;BRD:BRD-K90777969-300-01-2,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,SIGMAR1,,,PHASE 2,,,NA,,COC1CCC(CCN2CCN(CCCC3CCCCC3)CC2)CC1OC
CV-1808,CV-1808,,BRD:BRD-BRD-K49197823-001-09-8;BRD:BRD-K49197823-001-09-8,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA2A,,,PRECLINICAL,,,NA,,NC1NC(NC2CCCCC2)NC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
CVT-10216,CVT-10216,,BRD:BRD-BRD-K60659193-001-02-8;BRD:BRD-K60659193-001-02-8,rep_primary;rep_single_dose,ALDEHYDE DEHYDROGENASE INHIBITOR,ALDH2,,,PHASE 1,,,NA,,CS(=O)(=O)NC1CCC(CC1)-C1COC2CC(OCC3CCCC(C3)C(O)=O)CCC2C1=O
CW-008,CW-008,,BRD:BRD-K84068331-001-02-9,rep_single_dose,PKA ACTIVATOR,PRKACA,,,,,,NA,,
CX 5461,CX 5461,,GDSC1:300,gdsc,,,,,,,,NA,,
CX-4945,CX-4945,CHEMBL1230165,BRD:BRD-BRD-K81458380-001-04-9;BRD:BRD-K81458380-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,CASEIN KINASE INHIBITOR,CSNK2A1;CSNK2A2;DAPK3;HIPK3,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,MUOKSQABCJCOPU-UHFFFAOYSA-N,O=C(O)C1CCC2C(C1)NC(NC1CCCC(CL)C1)C1CCNCC12;OC(=O)C1CCC2C(C1)NC(NC1CCCC(CL)C1)C1CCNCC21
CX-516,CX-516,CHEMBL136800,BRD:BRD-BRD-K25140590-001-03-0;BRD:BRD-K25140590-001-03-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,ANDGGVOPIJEHOF-UHFFFAOYSA-N,O=C(C1CCC2NCCNC2C1)N1CCCCC1;O=C(N1CCCCC1)C1CCC2OCOC2C1
CX-5461,CX-5461,CHEMBL4303309,BRD:BRD-BRD-K12787259-001-04-3;BRD:BRD-K12787259-001-04-3;GDSC1:300,gdsc;rep_multi_dose;rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,XGPBJCHFROADCK-UHFFFAOYSA-N,CC1CNC(CNC(=O)C2C(=O)C3CCC(N4CCCN(C)CC4)NC3N3C2SC2CCCCC23)CN1;CN1CCCN(CC1)C1CCC2C(N1)N1C3CCCCC3SC1C(C(=O)NCC1CNC(C)CN1)C2=O
CX5461,CX5461,,GDSC1:300,gdsc,,,,,,,,NA,,
CXD101,CXD101,CHEMBL4297489,BRD:BRD-K00003388-001-01-9,rep_single_dose,HDAC INHIBITOR,,,,,,Small molecule,Phase 1,JHDZMASHNBKTPS-UHFFFAOYSA-N,CC1NN(C)CC1CN1CCC(C2CCC(C(=O)NC3CCCCC3N)CC2)CC1
CYACETACIDE,CYACETACIDE,CHEMBL2106008,BRD:BRD-BRD-K39371216-001-01-3;BRD:BRD-K39371216-001-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,HPHBOJANXDKUQD-UHFFFAOYSA-N,N#CCC(=O)NN;NNC(=O)CC#N
CYAMEMAZINE,CYAMEMAZINE,CHEMBL2104153,BRD:BRD-A42881122-001-01-1;BRD:BRD-BRD-A42881122-001-01-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR2A;HTR2C;HTR7,"SCHIZOPHRENIA, ANXIETY",,LAUNCHED,,Small molecule,Unknown,SLFGIOIONGJGRT-UHFFFAOYSA-N,CC(CN(C)C)CN1C2CCCCC2SC2CCC(C#N)CC21;CC(CN(C)C)CN1C2CCCCC2SC2CCC(CC12)C#N
CYANOCOBALAMIN,CYANOCOBALAMIN,CHEMBL2096655;CHEMBL2104118;CHEMBL2104381;CHEMBL2110563,BRD:BRD-A18627414-001-04-9;BRD:BRD-BRD-A18627414-001-04-9,rep_primary;rep_single_dose,"METHYLMALONYL COA MUTASE STIMULANT, VITAMIN B",MMAA;MMACHC;MTHFR;MTR;MTRR;MUT,"ANEMIA, FISH TAPEWORM INFESTATION, CELIAC DISEASE",,LAUNCHED,,Small molecule,Approved,,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[CO+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1CNC2CC(C)C(C)CC12
CYANOPINDOLOL,CYANOPINDOLOL,CHEMBL378501,BRD:BRD-A47884604-051-01-2;BRD:BRD-BRD-A47884604-051-01-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;HTR1A;HTR1D,,,PHASE 2,,Small molecule,NA,QXIUMMLTJVHILT-UHFFFAOYSA-N,CC(C)(C)NCC(O)COC1CCCC2[NH]C(C#N)CC12;CC(C)(C)NCC(O)COC1CCCC2[NH]C(CC12)C#N
CYANOQUINOLINE 11,CYANOQUINOLINE 11,,CTRP:417415,ctrp,,,,,,,,NA,,
CYC-202,CYC-202,CHEMBL14762,GDSC1:110,gdsc,,,,,,,Small molecule,Phase 2,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,CC[C@H](CO)NC1NC(NCC2CCCCC2)C2NCN(C(C)C)C2N1
CYC065,CYC065,CHEMBL4297930,BRD:BRD-K00003404-001-01-9,rep_single_dose,CDK INHIBITOR,,,,,,Unknown,Phase 1,,
CYC116,CYC116,,BRD:BRD-BRD-K64866502-001-03-9;BRD:BRD-K64866502-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;KDR,,,PHASE 1,,,NA,,CC1NC(N)SC1-C1CCNC(NC2CCC(CC2)N2CCOCC2)N1
CYCLAMIC-ACID,CYCLAMIC-ACID,,BRD:BRD-BRD-K50785021-001-02-1;BRD:BRD-K50785021-001-02-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OS(=O)(=O)NC1CCCCC1
CYCLANDELATE,CYCLANDELATE,CHEMBL1480987,BRD:BRD-A27370296-001-03-0;BRD:BRD-BRD-A27370296-001-03-0,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA2D1;CES1,"CLAUDICATION, ARTERIOSCLEROSIS, RAYNAUD'S DISEASE",,LAUNCHED,,Small molecule,Approved,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CC1CC(CC(C)(C)C1)OC(=O)C(O)C1CCCCC1;CC1CC(OC(=O)C(O)C2CCCCC2)CC(C)(C)C1
CYCLIZINE,CYCLIZINE,CHEMBL648,BRD:BRD-BRD-K79501723-001-04-6;BRD:BRD-K79501723-001-04-6,rep_primary;rep_single_dose,HISTAMINE RECEPTOR MODULATOR,HRH1;SULT1E1,"NAUSEA, VOMITING, VERTIGO, MOTION SICKNESS",,LAUNCHED,,Small molecule,Approved,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CN1CCN(C(C2CCCCC2)C2CCCCC2)CC1;CN1CCN(CC1)C(C1CCCCC1)C1CCCCC1
CYCLOBENZAPRINE,CYCLOBENZAPRINE,CHEMBL669,BRD:BRD-BRD-K42348709-003-13-1;BRD:BRD-K42348709-003-13-1,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, SEROTONIN RECEPTOR AGONIST",HTR2A,SPASMS,,LAUNCHED,,Small molecule,Approved,JURKNVYFZMSNLP-UHFFFAOYSA-N,CN(C)CCC=C1C2CCCCC2C=CC2CCCCC12;CN(C)CCC=C1C2CCCCC2C=CC2CCCCC21
CYCLOCREATINE,CYCLOCREATINE,CHEMBL179900,BRD:BRD-BRD-K14379200-001-04-7;BRD:BRD-K14379200-001-04-7,rep_primary;rep_single_dose,CREATINE KINASE SUBSTRATE,,,,PHASE 1,,Small molecule,NA,AMHZIUVRYRVYBA-UHFFFAOYSA-N,NC1=NCCN1CC(=O)O;OC(=O)CN1CCNC1=N
CYCLOCYTIDINE,CYCLOCYTIDINE,,BRD:BRD-BRD-K67536197-003-11-4;BRD:BRD-K67536197-003-11-4,rep_multi_dose;rep_primary;rep_single_dose,"DNA SYNTHESIS INHIBITOR, RNA SYNTHESIS INHIBITOR",,,,PRECLINICAL,,,NA,,OC[C@H]1O[C@@H]2[C@@H](OC3NC(=N)CCN23)[C@@H]1O
CYCLOHEXIMIDE,CYCLOHEXIMIDE,CHEMBL123292,BRD:BRD-BRD-K36055864-001-19-2;BRD:BRD-K36055864-001-19-2,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,RPL3,,,PRECLINICAL,,Small molecule,Unknown,YPHMISFOHDHNIV-FSZOTQKASA-N,C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1;C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1
CYCLOPAMINE,CYCLOPAMINE,CHEMBL254129,BRD:BRD-K58938839-001-06-9;GDSC1:17,gdsc;rep_single_dose,HEDGEHOG PATHWAY INHIBITOR,,,,,,Small molecule,NA,QASFUMOKHFSJGL-LAFRSMQTSA-N,CC1=C2C[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]2CC[C@]12O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
CYCLOPENTHIAZIDE,CYCLOPENTHIAZIDE,CHEMBL1373254,BRD:BRD-A41250306-001-11-7;BRD:BRD-BRD-A41250306-001-11-7,rep_primary;rep_single_dose,THIAZIDE DIURETIC,,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,BKYKPTRYDKTTJY-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1CL)NC(CC1CCCC1)NS2(=O)=O;NS(=O)(=O)C1CC2C(NC(CC3CCCC3)NS2(=O)=O)CC1CL
CYCLOPENTOLATE,CYCLOPENTOLATE,CHEMBL1201338,BRD:BRD-A77291778-003-22-0;BRD:BRD-BRD-A77291778-003-22-0,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,"MYDRIASIS, CYCLOPLEGIA",,LAUNCHED,,Small molecule,Approved,SKYSRIRYMSLOIN-UHFFFAOYSA-N,CN(C)CCOC(=O)C(C1CCCCC1)C1(O)CCCC1
CYCLOPHOSPHAMID,CYCLOPHOSPHAMID,,GDSC2:1512,gdsc,,,,,,,,NA,,
NSC-26271,CYCLOPHOSPHAMIDE;NSC-26271,CHEMBL1200796;CHEMBL88,BRD:BRD-A09722536-002-18-0;BRD:BRD-BRD-A09722536-002-18-0;CTRP:32620;GDSC2:1512,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,CYP2A6;CYP2B6;CYP2C18;CYP2C19;CYP2C8;CYP2C9;CYP2D6;CYP3A4;CYP3A5;CYP3A7,"HODGKIN'S LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA (SLL), BREAST CANCER, NEUROBLASTOMA, BURKITT'S LYMPHOMA, MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), ACUTE MYELOID LEUKEMIA (AML), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), CHRONIC MYELOID LEUKEMIA (CML), TRUE HISTIOCYTIC LYMPHOMA (THL), RETINOBLASTOMA, OVARIAN CANCER",,LAUNCHED,,Small molecule,Approved,CMSMOCZEIVJLDB-UHFFFAOYSA-N;PWOQRKCAHTVFLB-UHFFFAOYSA-N,CLCCN(CCCL)P1(=O)NCCCO1;O.O=P1(N(CCCL)CCCL)NCCCO1;O=P1(N(CCCL)CCCL)NCCCO1
CYCLOPHOSPHANE,CYCLOPHOSPHANE,,GDSC2:1512,gdsc,,,,,,,,NA,,
CYCLOPIAZONIC-ACID,CYCLOPIAZONIC-ACID,,BRD:BRD-A10420615-001-04-4;BRD:BRD-BRD-A10420615-001-04-4,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP2A1,,,PRECLINICAL,,,NA,,CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](CC4CCCC5[NH]CC3C45)C(C)(C)N2C1=O
CYCLOSPORINE,CYCLOSPORIN-A;CYCLOSPORINE,CHEMBL160,BRD:BRD-A69815203-001-07-6;BRD:BRD-BRD-A69815203-001-07-6;BRD:BRD-BRD-K13533483-001-16-2;BRD:BRD-K13533483-001-16-2,rep_multi_dose;rep_primary;rep_single_dose,CALCINEURIN INHIBITOR,ABCB11;CAMLG;FPR1;PPIA;PPIF;PPP3CA;PPP3R2;SLC10A1;SLCO1B1;SLCO1B3,"ORGAN REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS",,LAUNCHED,"Multiple values for Indication: {'ORGAN REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS', 'RHEUMATOID ARTHRITIS, PSORIASIS'}, defaulting to 'ORGAN REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS'
Multiple values for SMILES: {'CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C', 'CCC1NC(=O)C(C(O)C(C)C\\C=C\\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\\C=C\\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C'}, defaulting to 'CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C'
Multiple values for repurposing_target: {'ABCB11;CAMLG;FPR1;PPIA;PPIF;PPP3CA;PPP3R2;SLC10A1;SLCO1B1;SLCO1B3', 'ABCB11;CAMLG;FPR1;PPIA;PPIF;PPP3R2;SLC10A1;SLCO1B1;SLCO1B3'}, taking the union
Multiple values for repurposing_target: {'ABCB11;CAMLG;FPR1;PPIA;PPIF;PPP3CA;PPP3R2;SLC10A1;SLCO1B1;SLCO1B3', 'PPP3CA', 'ABCB11;CAMLG;FPR1;PPIA;PPIF;PPP3R2;SLC10A1;SLCO1B1;SLCO1B3'}, taking the union
Multiple values for structure_id: {'A69815203', 'K13533483'}, defaulting to None",Protein,Approved,PMATZTZNYRCHOR-CGLBZJNRSA-N,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C;CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
CYCLOVALONE,CYCLOVALONE,CHEMBL17205;CHEMBL2362372,BRD:BRD-BRD-K59866480-001-07-3;BRD:BRD-K59866480-001-07-3,rep_multi_dose;rep_primary;rep_single_dose,BREAST CANCER RESISTANCE PROTEIN INHIBITOR,ABCG2,BILE STIMULATION,,LAUNCHED,,Small molecule,Unknown,DHKKONBXGAAFTB-OTYYAQKOSA-N;DHKKONBXGAAFTB-UHFFFAOYSA-N,COC1CC(/C=C2\CCC/C(=C\C3CCC(O)C(OC)C3)C2=O)CCC1O;COC1CC(C=C2CCCC(=CC3CCC(O)C(OC)C3)C2=O)CCC1O;COC1CC(CCC1O)\C=C1/CCC\C(C1=O)=C/C1CCC(O)C(OC)C1
CYCLOVIROBUXIN-D,CYCLOVIROBUXIN-D,,BRD:BRD-BRD-K27799744-001-02-8;BRD:BRD-K27799744-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL MODULATOR,,,,PRECLINICAL,,,NA,,CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C
CYCLUC1,CYCLUC1,,BRD:BRD-K00005335-001-01-9,rep_single_dose,,,,,,,,NA,,
CYM-50260,CYM-50260,,BRD:BRD-BRD-K69877120-001-01-7;BRD:BRD-K69877120-001-01-7,rep_primary;rep_single_dose,"SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST",S1PR4,,,PRECLINICAL,"Multiple values for MOA: {'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST', 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'}, defaulting to 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'",,NA,,FCC1CCC(OCCOC2CCC(CL)CC2CL)C(CL)N1
CYM-50358,CYM-50358,,BRD:BRD-BRD-K80666802-003-01-0;BRD:BRD-K80666802-003-01-0,rep_primary;rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONIST,S1PR4,,,PRECLINICAL,,,NA,,CC1CC(CN)CC(C)C1NC(=O)C1CCC(O1)-C1CC(CL)CCC1CL
CYM-50769,CYM-50769,,BRD:BRD-BRD-K27732927-001-03-6;BRD:BRD-K27732927-001-03-6,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPBWR1,,,PRECLINICAL,,,NA,,COC1CCC(OC2C(CL)CNN(C3C4CCCCC4-C4CCCCC34)C2=O)CC1
CYM-5442,CYM-5442,,BRD:BRD-A43005764-003-01-5;BRD:BRD-BRD-A43005764-003-01-5,rep_primary;rep_single_dose,"SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST",S1PR1,,,PRECLINICAL,"Multiple values for MOA: {'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST', 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'}, defaulting to 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'",,NA,,CCOC1CCC(CC1OCC)-C1NC(NO1)-C1CCCC2C(CCC12)NCCO
CYM-5520,CYM-5520,,BRD:BRD-BRD-K29151923-001-01-5;BRD:BRD-K29151923-001-01-5,rep_primary;rep_single_dose,"SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST",S1PR2,,,PRECLINICAL,"Multiple values for MOA: {'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST', 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'}, defaulting to 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'",,NA,,CC1CC(C(=O)CN2CC(CCC2=O)C#N)C(C)N1CC1CCCCC1
CYM-5541,CYM-5541,,BRD:BRD-K75940276-001-04-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST,S1PR3,,,,,,NA,,
CYPROHEPTADINE,CYPROHEPTADINE,CHEMBL516,BRD:BRD-BRD-K28143534-001-02-2;BRD:BRD-BRD-K28143534-003-25-9;BRD:BRD-K28143534-001-02-2;BRD:BRD-K28143534-003-25-9,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;CHRM1;CHRM2;CHRM3;HRH1;HTR2A;HTR2C;HTR6;HTR7,"ALLERGIC RHINITIS, VASOMOTOR RHINITIS, CONJUNCTIVITIS, URTICARIA, DERMATOGRAPHISM",,LAUNCHED,,Small molecule,Approved,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CN1CCC(=C2C3CCCCC3C=CC3CCCCC32)CC1;CN1CCC(CC1)=C1C2CCCCC2C=CC2CCCCC12
CYPROTERONE-ACETATE,CYPROTERONE-ACETATE,,BRD:BRD-BRD-K41141507-001-16-2;BRD:BRD-K41141507-001-16-2;BRD:BRD-K41141507-001-18-9,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,ADORA1;AR,PROSTATE CANCER,,LAUNCHED,,,NA,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(CL)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
CYROMAZINE,CYROMAZINE,CHEMBL1231107,BRD:BRD-BRD-K36711084-001-02-0;BRD:BRD-K36711084-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,LVQDKIWDGQRHTE-UHFFFAOYSA-N,NC1NC(N)NC(NC2CC2)N1
CYSTEAMINE,CYSTEAMINE,CHEMBL602,BRD:BRD-K92611362-003-03-9,rep_single_dose,TISSUE TRANSGLUTAMINASE INHIBITOR,NPY2R;SST,,,,,Small molecule,Approved,UFULAYFCSOUIOV-UHFFFAOYSA-N,NCCS
CYT-997,CYT-997,CHEMBL552212,BRD:BRD-BRD-K23363278-001-02-1;BRD:BRD-K23363278-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,,,PHASE 2,,Small molecule,Phase 2,MTJHLONVHHPNSI-IBGZPJMESA-N,CCC[C@H](NC1NC(-C2CCC(NC(=O)NCC)C(OC)C2)NCC1C)C1CCCNC1;CCC[C@H](NC1NC(NCC1C)-C1CCC(NC(=O)NCC)C(OC)C1)C1CCCNC1
MOMELOTINIB,CYT387;LM-1149;MOMELOTINIB,CHEMBL1078178;CHEMBL2219411,BRD:BRD-BRD-K87737963-001-06-0;BRD:BRD-K87737963-001-06-0;BRD:BRD-K87737963-001-12-9;CTRP:660429,ctrp;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF JAK1, JAK2 AND ALK2",ALK2;JAK1;JAK2;JAK3,,,PHASE 3,"Multiple values for MOA: {'INHIBITOR OF JAK1, JAK2 AND ALK2', 'JAK INHIBITOR'}, defaulting to 'INHIBITOR OF JAK1, JAK2 AND ALK2'
Multiple values for repurposing_target: {'ALK2;JAK1;JAK2', 'JAK1;JAK2;JAK3'}, taking the union",Small molecule,Phase 3,IPNATXQRPWRHKD-UHFFFAOYSA-N;ZVHNDZWQTBEVRY-UHFFFAOYSA-N,CL.CL.N#CCNC(=O)C1CCC(-C2CCNC(NC3CCC(N4CCOCC4)CC3)N2)CC1;N#CCNC(=O)C1CCC(-C2CCNC(NC3CCC(N4CCOCC4)CC3)N2)CC1;O=C(NCC#N)C1CCC(CC1)-C1CCNC(NC2CCC(CC2)N2CCOCC2)N1
CYTARABINE HYDROCHLORIDE,CYTARABINE HYDROCHLORIDE,CHEMBL1256472,CTRP:62690,ctrp,,,,,,,Small molecule,Phase 3,KCURWTAZOZXKSJ-JBMRGDGGSA-N,CL.NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)N1
CYTISINE,CYTISINE,CHEMBL497939,BRD:BRD-BRD-K74186897-001-12-4;BRD:BRD-BRD-K74186897-001-13-2;BRD:BRD-K74186897-001-12-4;BRD:BRD-K74186897-001-13-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA2;CHRNA3;CHRNA4;CHRNA6;CHRNA7;CHRNB2;CHRNB4,NICOTINISM,,LAUNCHED,,Small molecule,Phase 3,ANJTVLIZGCUXLD-DTWKUNHWSA-N,O=C1CCCC2[C@H]3CNC[C@H](C3)CN12;O=C1CCCC2N1C[C@@H]1CNC[C@H]2C1
CYTOCHALASIN B,CYTOCHALASIN B,CHEMBL411729,CTRP:50163,ctrp,,,,,,,Small molecule,NA,GBOGMAARMMDZGR-TYHYBEHESA-N,C=C1[C@@H](C)[C@H]2[C@H](CC3CCCCC3)NC(=O)[C@]23OC(=O)/C=C/[C@H](O)CCC[C@@H](C)C/C=C/[C@H]3[C@@H]1O
CYTOCHALASIN-B,CYTOCHALASIN-B,,BRD:BRD-BRD-K47000838-001-01-6;BRD:BRD-K47000838-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE INHIBITOR,ACTB,,,PHASE 2,,,NA,,C[C@H]1[C@H]2[C@H](CC3CCCCC3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C
CYTOCHLOR,CYTOCHLOR,CHEMBL4297275,BRD:BRD-BRD-K48988407-001-01-2;BRD:BRD-K48988407-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Phase 1,NGGRGTWYSXYVDK-RRKCRQDMSA-N,NC1NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CC1CL;NC1NC(=O)N(CC1CL)[C@H]1C[C@@H](O)[C@@H](CO)O1
CYTOXAN,CYTOXAN,CHEMBL1200796;CHEMBL88,GDSC2:1512,gdsc,,,,,,,Small molecule,Approved,CMSMOCZEIVJLDB-UHFFFAOYSA-N;PWOQRKCAHTVFLB-UHFFFAOYSA-N,O.O=P1(N(CCCL)CCCL)NCCCO1;O=P1(N(CCCL)CCCL)NCCCO1
CZC-54252,CZC-54252,,BRD:BRD-BRD-K87021635-003-02-2;BRD:BRD-K87021635-003-02-2,rep_primary;rep_single_dose,LEUCINE RICH REPEAT KINASE INHIBITOR,LRRK2,,,PRECLINICAL,,,NA,,COC1CC(CCC1NC1NCC(CL)C(NC2CCCCC2NS(C)(=O)=O)N1)N1CCOCC1
CZC24832,CZC24832,,BRD:BRD-BRD-K01377300-001-01-1;BRD:BRD-K01377300-001-01-1;GDSC2:1615,gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CG,,,PRECLINICAL,,,NA,,CC(C)(C)NS(=O)(=O)C1CNCC(C1)-C1CC(F)C2NC(N)NN2C1
"MEVALONIC-D,-L-ACID-LACTONE","D,L-MEVALONIC-ACID-LACTONE;MEVALONIC-D,-L-ACID-LACTONE",,BRD:BRD-A05674712-001-06-0;BRD:BRD-BRD-A05674712-001-06-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC1(O)CCOC(=O)C1
D-(+)-MALTOSE,D-(+)-MALTOSE,,BRD:BRD-BRD-K74377520-001-01-7;BRD:BRD-K74377520-001-01-7,rep_primary;rep_single_dose,,AMY2B;MGAM,,,PRECLINICAL,,,NA,,OC[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
GARSORASIB,D-1553;GARSORASIB,CHEMBL5095066,BRD:BRD-U00115419-001-01-9,oncref_1,INHIBITOR OF KRAS-G12C,KRAS,,,,,Small molecule,Unknown,DKFRWZJCNPETGI-SJORKVTESA-N,C=CC(=O)N1C[C@H](C)N(C2NC(=O)N(-C3C(C4CC4)NCNC3C3CC3)C3NC(-C4C(N)CCCC4F)C(F)CC23)C[C@H]1C
D-157495,D-157495,,BRD:BRD-K29066607-001-02-9,rep_single_dose,DECAPPING SCAVENGER ENZYME INHIBITOR,,,,,,,NA,,
D-3263,D-3263,CHEMBL3707315,BRD:BRD-K00003205-003-01-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL AGONIST,,,,,,Small molecule,Phase 1,,
D-4476,D-4476,,BRD:BRD-BRD-K09132007-001-07-5;BRD:BRD-K09132007-001-07-5,rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,CSNK1A1;CSNK1D;TGFB1,,,PRECLINICAL,,,NA,,NC(=O)C1CCC(CC1)-C1NC(C([NH]1)-C1CCCCN1)-C1CCC2OCCOC2C1
D-64131,D-64131,,BRD:BRD-BRD-K26997899-001-02-2;BRD:BRD-K26997899-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE INHIBITOR,TUBB,,,PRECLINICAL,,,NA,,COC1CCC2[NH]C(CC2C1)C(=O)C1CCCCC1
D-7193,D-7193,,BRD:BRD-BRD-K32372024-001-01-0;BRD:BRD-K32372024-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O
D-ALPHA-TOCOPHERYL-SUCCINATE,D-ALPHA-TOCOPHERYL-SUCCINATE,,BRD:BRD-BRD-K64636206-001-02-7;BRD:BRD-K64636206-001-02-7,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2C(C)C(OC(=O)CCC(O)=O)C(C)C(C)C2O1
D-DELTA-TOCOPHEROL,D-DELTA-TOCOPHEROL,,BRD:BRD-BRD-K04657451-001-01-0;BRD:BRD-K04657451-001-01-0,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2CC(O)CC(C)C2O1
D-PHENYLALANINE,D-PHENYLALANINE,CHEMBL379630,BRD:BRD-BRD-K00911807-003-01-2;BRD:BRD-K00911807-003-01-2,rep_primary;rep_single_dose,ENKEPHALINASE INHIBITOR,CCBL1;CRH;HCAR3,,,PRECLINICAL,,Small molecule,NA,COLNVLDHVKWLRT-MRVPVSSYSA-N,N[C@H](CC1CCCCC1)C(=O)O;N[C@H](CC1CCCCC1)C(O)=O
D-SERINE,D-SERINE,CHEMBL285123,BRD:BRD-BRD-K71822263-001-03-2;BRD:BRD-K71822263-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GLRA1;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;SERPINB3,,,LAUNCHED,,Small molecule,Phase 3,MTCFGRXMJLQNBG-UWTATZPHSA-N,N[C@H](CO)C(=O)O;N[C@H](CO)C(O)=O
D609,D609,,BRD:BRD-A77118605-237-09-5,rep_single_dose,PHOSPHOLIPASE INHIBITOR,,,,,,,NA,,
DAA-1106,DAA-1106,,BRD:BRD-BRD-K01080633-001-01-9;BRD:BRD-K01080633-001-01-9,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,TSPO,,,PRECLINICAL,,,NA,,COC1CCC(OC)C(CN(C(C)=O)C2CC(F)CCC2OC2CCCCC2)C1
DABIGATRAN,DABIGATRAN,CHEMBL48361,BRD:BRD-BRD-K38168441-001-03-7;BRD:BRD-K38168441-001-03-7,rep_primary;rep_single_dose,THROMBIN INHIBITOR,F2,"STROKE, SYSTEMIC EMBOLISM, PULMONARY EMBOLISM (PE), DEEP VEIN THROMBOSIS (DVT)",,LAUNCHED,,Small molecule,Phase 3,YBSJFWOBGCMAKL-UHFFFAOYSA-N,CN1C(CNC2CCC(C(=N)N)CC2)NC2CC(C(=O)N(CCC(=O)O)C3CCCCN3)CCC21;CN1C(CNC2CCC(CC2)C(N)=N)NC2CC(CCC12)C(=O)N(CCC(O)=O)C1CCCCN1
DABIGATRAN-ETEXILATE,DABIGATRAN-ETEXILATE,,BRD:BRD-BRD-K57041787-001-02-6;BRD:BRD-K57041787-001-02-6,rep_primary;rep_single_dose,THROMBIN INHIBITOR,F2,"STROKE, SYSTEMIC EMBOLISM, PULMONARY EMBOLISM (PE), DEEP VEIN THROMBOSIS (DVT)",,LAUNCHED,,,NA,,CCCCCCOC(=O)\N=C(\N)C1CCC(NCC2NC3CC(CCC3N2C)C(=O)N(CCC(=O)OCC)C2CCCCN2)CC1
GSK-2118436,DABRAFENIB;GSK-2118436,CHEMBL2028663,BRD:BRD-BRD-K09951645-001-06-8;BRD:BRD-K09951645-001-06-8;BRD:BRD-K09951645-001-11-8;BRD:BRD-K09951645-001-14-9;CTRP:687954;GDSC1:1373;GDSC2:1373,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF BRAF,BRAF;LIMK1;NEK11;RAF1;SIK1,MELANOMA,,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF BRAF', 'RAF INHIBITOR'}, defaulting to 'INHIBITOR OF BRAF'
Multiple values for repurposing_target: {'BRAF;LIMK1;NEK11;RAF1;SIK1', 'BRAF'}, taking the union",Small molecule,Approved,BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)C1NC(-C2CCCC(NS(=O)(=O)C3C(F)CCCC3F)C2F)C(-C2CCNC(N)N2)S1;CC(C)(C)C1NC(C(S1)-C1CCNC(N)N1)-C1CCCC(NS(=O)(=O)C2C(F)CCCC2F)C1F
DABUZALGRON,DABUZALGRON,CHEMBL257978,BRD:BRD-K00073934-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,FOYWMEJSRSBQGB-UHFFFAOYSA-N,CC1C(OCC2=NCCN2)CCC(CL)C1NS(C)(=O)=O
DACARBAZINE,DACARBAZINE,CHEMBL476,BRD:BRD-BRD-K35520305-001-17-7;BRD:BRD-K35520305-001-16-9;BRD:BRD-K35520305-001-17-7;CTRP:32622,ctrp;rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,PGD;POLA2,"MELANOMA, HODGKIN'S LYMPHOMA",,LAUNCHED,,Small molecule,Approved,FDKXTQMXEQVLRF-ZHACJKMWSA-N,CN(C)/N=N/C1[NH]CNC1C(N)=O;CN(C)\N=N\C1[NH]CNC1C(N)=O
DACINOSTAT,DACINOSTAT,CHEMBL356066,BRD:BRD-BRD-K56957086-001-06-3;BRD:BRD-K56957086-001-06-3;GDSC1:200,gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9,,,PHASE 1,,Small molecule,Unknown,BWDQBBCUWLSASG-MDZDMXLPSA-N,O=C(/C=C/C1CCC(CN(CCO)CCC2C[NH]C3CCCCC23)CC1)NO;OCCN(CCC1C[NH]C2CCCCC12)CC1CCC(\C=C\C(=O)NO)CC1
DACLATASVIR,DACLATASVIR,CHEMBL2023898,BRD:BRD-BRD-K82861010-001-02-5;BRD:BRD-K82861010-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,HCV INHIBITOR,,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,FKRSSPOQAMALKA-CUPIEXAXSA-N,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1NCC([NH]1)-C1CCC(CC1)-C1CCC(CC1)-C1CNC([NH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C;COC(=O)N[C@H](C(=O)N1CCC[C@H]1C1NCC(-C2CCC(-C3CCC(-C4CNC([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[NH]4)CC3)CC2)[NH]1)C(C)C
DACOMITINIB,DACOMITINIB,CHEMBL2105719;CHEMBL2110732,BRD:BRD-BRD-K57169635-001-04-5;BRD:BRD-K57169635-001-04-5,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2;ERBB4,,,PHASE 3,,Small molecule,Approved,BSPLGGCPNTZPIH-IPZCTEOASA-N;LVXJQMNHJWSHET-AATRIKPKSA-N,COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1NC(=O)/C=C/CN1CCCCC1;COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1NC(=O)/C=C/CN1CCCCC1.O;COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1NC(=O)\C=C\CN1CCCCC1
DACTINOMYCIN,DACTINOMYCIN,CHEMBL1554,BRD:BRD-BRD-K70578146-001-06-7;BRD:BRD-K70578146-001-06-7;GDSC2:1811;GDSC2:1911,gdsc;rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,POLR2A,"TESTICULAR CARCINOMA, WILM'S TUMOR, RHABDOMYOSARCOMA, EWING'S SARCOMA, GESTATIONAL TROPHOBLASTIC DISEASE (GTD)",,LAUNCHED,,Protein,Approved,RJURFGZVJUQBHK-IIXSONLDSA-N,CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2CCC(C)C3OC4C(C)C(=O)C(N)C(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)C4NC23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O;CC1C2OC3C(C)CCC(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)C3NC-2C(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)C(N)C1=O
DACTOLISIB,DACTOLISIB,CHEMBL1879463,GDSC1:1057;GDSC2:1057,gdsc,,,,,,,Small molecule,Phase 3,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,CN1C(=O)N(-C2CCC(C(C)(C)C#N)CC2)C2C3CC(-C4CNC5CCCCC5C4)CCC3NCC21
DAIDZEIN,DAIDZEIN,CHEMBL8145,BRD:BRD-BRD-K42095107-001-17-1;BRD:BRD-K42095107-001-17-1,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESRRA;ESRRB;ESRRG;TRPC5,,,PHASE 2,,Small molecule,Phase 2,ZQSIJRDFPHDXIC-UHFFFAOYSA-N,O=C1C(-C2CCC(O)CC2)COC2CC(O)CCC12;OC1CCC(CC1)-C1COC2CC(O)CCC2C1=O
DAIDZIN,DAIDZIN,CHEMBL486422,BRD:BRD-K12979078-001-02-9,rep_single_dose,ANTIOXIDANT,ALDH2,,,,,Small molecule,NA,KYQZWONCHDNPDP-QNDFHXLGSA-N,O=C1C(-C2CCC(O)CC2)COC2CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC12
DALARGIN,DALARGIN,,BRD:BRD-A89196962-300-01-7;BRD:BRD-BRD-A89196962-300-01-7,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRM1,,,PHASE 2,,,NA,,CC(C)CC(NC(=O)C(CC1CCCCC1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)CC1CCC(O)CC1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O
DALBAVANCIN,DALBAVANCIN,CHEMBL3301669,BRD:BRD-K30177383-001-02-9,rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,PNLIP,,,,,Unknown,Approved,KGPGQDLTDHGEGT-SZUNQUCBSA-N,CN[C@H]1C(=O)N[C@@H]2CC3CCC(CC3)OC3CC4CC(C3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)OC3CCC(CC3CL)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)C2CC(CC(O)C2CL)OC2CC1CCC2O)C1CCC(O)C(C1)-C1C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)CC(O)CC1[C@@H](C(=O)NCCCN(C)C)NC3=O
DALCETRAPIB,DALCETRAPIB,CHEMBL313006,BRD:BRD-BRD-K18849474-001-04-4;BRD:BRD-K18849474-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR,CETP,,,PHASE 3,,Small molecule,Phase 3,YZQLWPMZQVHJED-UHFFFAOYSA-N,CCC(CC)CC1(C(=O)NC2CCCCC2SC(=O)C(C)C)CCCCC1;CCC(CC)CC1(CCCCC1)C(=O)NC1CCCCC1SC(=O)C(C)C
DALFAMPRIDINE,DALFAMPRIDINE,CHEMBL284348,BRD:BRD-BRD-K22482860-001-21-4;BRD:BRD-K22482860-001-21-4,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNA1;KCNA10;KCNA2;KCNA3;KCNA4;KCNA5;KCNA6;KCNA7;KCNB1;KCNB2;KCNC1;KCNC2;KCNC3;KCNC4;KCND1;KCND2;KCND3;KCNF1;KCNG1;KCNG2;KCNG3;KCNG4;KCNH1;KCNH2;KCNH3;KCNH4;KCNH5;KCNH6;KCNH7;KCNH8;KCNJ13;KCNJ5;KCNQ1;KCNQ2;KCNQ3;KCNQ4;KCNQ5;KCNS1;KCNS2;KCNS3;KCNV1;KCNV2,MULTIPLE SCLEROSIS,,LAUNCHED,,Small molecule,Approved,NUKYPUAOHBNCPY-UHFFFAOYSA-N,NC1CCNCC1
DALFOPRISTIN,DALFOPRISTIN,CHEMBL1200937,BRD:BRD-K00003321-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Approved,SUYRLXYYZQTJHF-VMBLUXKRSA-N,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)C3COC(N3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12
DALTROBAN,DALTROBAN,CHEMBL71685,BRD:BRD-BRD-K26813177-001-03-2;BRD:BRD-K26813177-001-03-2,rep_primary;rep_single_dose,THROMBOXANE RECEPTOR ANTAGONIST,TBXA2R,,,PHASE 3,,Small molecule,Unknown,IULOBWFWYDMECP-UHFFFAOYSA-N,O=C(O)CC1CCC(CCNS(=O)(=O)C2CCC(CL)CC2)CC1;OC(=O)CC1CCC(CCNS(=O)(=O)C2CCC(CL)CC2)CC1
DAMINOZIDE,DAMINOZIDE,,BRD:BRD-K83452553-001-07-9,rep_single_dose,KDM2A INHIBITOR,KDM2A;KDM7A;PHF8,,,,,,NA,,
DANAZOL,DANAZOL,CHEMBL1479,BRD:BRD-A92537424-001-04-7;BRD:BRD-BRD-A92537424-001-04-7,rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR ANTAGONIST, PROGESTERONE RECEPTOR AGONIST",AR;CCL2;ESR1;GNRHR;GNRHR2;PGR,"ENDOMETRIOSIS, ANGIOEDEMA",,LAUNCHED,,Small molecule,Approved,POZRVZJJTULAOH-LHZXLZLDSA-N,C[C@]12CCC3C(CCC4=CC5ONCC5C[C@]34C)C1CC[C@@]2(O)C#C;C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC5ONCC5C[C@]4(C)[C@H]3CC[C@@]21C
DANEGAPTIDE,DANEGAPTIDE,CHEMBL560592,BRD:BRD-BRD-K35589454-003-01-1;BRD:BRD-K35589454-003-01-1,rep_primary;rep_single_dose,GAP JUNCTION MODULATOR,,,,PHASE 2,,Small molecule,Phase 3,BIZKIHUJGMSVFD-MNOVXSKESA-N,NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)C1CCCCC1;NCC(=O)N1C[C@H](NC(=O)C2CCCCC2)C[C@H]1C(=O)O
DANIRIXIN,DANIRIXIN,CHEMBL3039531,BRD:BRD-BRD-K13769342-001-01-5;BRD:BRD-K13769342-001-01-5,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR2,,,PHASE 2,,Small molecule,Phase 2,NGYNBSHYFOFVLS-LBPRGKRZSA-N,CC1C(F)CCCC1NC(=O)NC1CCC(CL)C(C1O)S(=O)(=O)[C@H]1CCCNC1;CC1C(F)CCCC1NC(=O)NC1CCC(CL)C(S(=O)(=O)[C@H]2CCCNC2)C1O
DANOFLOXACIN,DANOFLOXACIN,CHEMBL157548,BRD:BRD-BRD-K45916615-066-02-5;BRD:BRD-K45916615-066-02-5,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,BOVINE RESPIRATORY DISEASE (BRD),,LAUNCHED,,Small molecule,Unknown,QMLVECGLEOSESV-RYUDHWBXSA-N,CN1C[C@@H]2C[C@H]1CN2C1CC2C(CC1F)C(=O)C(C(=O)O)CN2C1CC1;CN1C[C@@H]2C[C@H]1CN2C1CC2N(CC(C(O)=O)C(=O)C2CC1F)C1CC1
DANOPREVIR,DANOPREVIR,CHEMBL258734,BRD:BRD-BRD-K08111240-001-02-8;BRD:BRD-K08111240-001-02-8,rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 2,,Small molecule,Phase 3,ZVTDLPBHTSMEJZ-JSZLBQEHSA-N,CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]2C[C@@H](OC(=O)N3CC4CCCC(F)C4C3)CN2C1=O;CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2CCCC(F)C2C1)C(=O)NS(=O)(=O)C1CC1
DANTROLENE,DANTROLENE,CHEMBL1201288,BRD:BRD-BRD-K81272440-236-13-5;BRD:BRD-K81272440-236-13-5,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,RYR1;RYR3,"SPASMS, MALIGNANT HYPERTHERMIA (MH)",,LAUNCHED,,Small molecule,Approved,OZOMQRBLCMDCEG-VIZOYTHASA-N,[O-][N+](=O)C1CCC(CC1)-C1CCC(\C=N\N2CC(=O)NC2=O)O1;O=C1CN(/N=C/C2CCC(-C3CCC([N+](=O)[O-])CC3)O2)C(=O)N1
DANTRON,DANTRON,CHEMBL53418,BRD:BRD-BRD-K10065684-001-07-4;BRD:BRD-K10065684-001-07-4,rep_primary;rep_single_dose,LAXATIVE,,,,WITHDRAWN,,Small molecule,Approved,QBPFLULOKWLNNW-UHFFFAOYSA-N,O=C1C2CCCC(O)C2C(=O)C2C(O)CCCC21;OC1CCCC2C(=O)C3CCCC(O)C3C(=O)C12
DANUSERTIB,DANUSERTIB,CHEMBL402548,BRD:BRD-BRD-K07881437-001-03-8;BRD:BRD-BRD-K07881437-001-04-6;BRD:BRD-K07881437-001-03-8;BRD:BRD-K07881437-001-04-6,rep_multi_dose;rep_primary;rep_single_dose,"AURORA KINASE INHIBITOR, GROWTH FACTOR RECEPTOR INHIBITOR",AURKA;AURKB;AURKC;FGFR1;NTRK1;RET;SLK,,,PHASE 2,,Small molecule,Phase 2,XKFTZKGMDDZMJI-HSZRJFAPSA-N,CO[C@@H](C(=O)N1CC2[NH]NC(NC(=O)C3CCC(CC3)N3CCN(C)CC3)C2C1)C1CCCCC1;CO[C@@H](C(=O)N1CC2[NH]NC(NC(=O)C3CCC(N4CCN(C)CC4)CC3)C2C1)C1CCCCC1
DAPAGLIFLOZIN,DAPAGLIFLOZIN,CHEMBL2103802;CHEMBL429910,BRD:BRD-BRD-K58160573-001-05-4;BRD:BRD-K58160573-001-05-4,rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A1;SLC5A2,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,GOADIQFWSVMMRJ-UPGAGZFNSA-N;JVHXJTBJCFBINQ-ADAARDCZSA-N,CCOC1CCC(CC2CC([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC2CL)CC1;CCOC1CCC(CC2CC([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CCC2CL)CC1.C[C@H](O)CO.O;CCOC1CCC(CC2CC(CCC2CL)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1
DAPANSUTRILE,DAPANSUTRILE,CHEMBL3989943,BRD:BRD-K00004659-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Phase 2,LQFRYKBDZNPJSW-UHFFFAOYSA-N,CS(=O)(=O)CCC#N
DAPHNETIN,DAPHNETIN,CHEMBL244948,BRD:BRD-BRD-K61269089-001-05-5;BRD:BRD-K61269089-001-05-5,rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,ATEFPOUAMCWAQS-UHFFFAOYSA-N,O=C1CCC2CCC(O)C(O)C2O1;OC1CCC2CCC(=O)OC2C1O
DAPIPRAZOLE,DAPIPRAZOLE,CHEMBL1201216,BRD:BRD-BRD-K33133047-001-01-8;BRD:BRD-K33133047-001-01-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D,MYDRIASIS,,LAUNCHED,,Small molecule,Approved,RFWZESUMWJKKRN-UHFFFAOYSA-N,CC1CCCCC1N1CCN(CCC2NNC3CCCCN23)CC1;CC1CCCCC1N1CCN(CCC2NNC3N2CCCC3)CC1
DAPIVIRINE,DAPIVIRINE,CHEMBL1257032;CHEMBL70663,BRD:BRD-BRD-K12885236-001-02-7;BRD:BRD-K12885236-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,CYP3A4;CYP3A5,,,PHASE 3,,Small molecule,Phase 3,ILAYIAGXTHKHNT-HVRMQOCCSA-N;ILAYIAGXTHKHNT-UHFFFAOYSA-N,CC1CC(C)C(NC2CCNC(NC3CCC([14C]#N)CC3)N2)C(C)C1;CC1CC(C)C(NC2CCNC(NC3CCC(C#N)CC3)N2)C(C)C1;CC1CC(C)C(NC2CCNC(NC3CCC(CC3)C#N)N2)C(C)C1
DAPORINAD,DAPORINAD,CHEMBL290745;CHEMBL566757,CTRP:418166;GDSC1:1248;GDSC2:1248,ctrp;gdsc,,,,,,,Small molecule,Phase 2,JBTVOWMPTOMYFD-UHFFFAOYSA-N;KPBNHDGDUADAGP-VAWYXSNFSA-N,CN1CNCC1C(N)(C1CCC(CL)CC1)C1CC2C3C(C1)C(-C1CCCC(CL)C1)CC(=O)N3CCC2;O=C(/C=C/C1CCCNC1)NCCCCC1CCN(C(=O)C2CCCCC2)CC1
DAPOXETINE,DAPOXETINE,CHEMBL2110900,BRD:BRD-BRD-K51579475-003-02-4;BRD:BRD-K51579475-003-02-4,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),HTR1A;HTR1B;HTR2C;SLC6A4,PREMATURE EJACULATION (PE),,LAUNCHED,,Small molecule,Approved,USRHYDPUVLEVMC-FQEVSTJZSA-N,CN(C)[C@@H](CCOC1CCCC2CCCCC12)C1CCCCC1
DAPRODUSTAT,DAPRODUSTAT,CHEMBL3544988,BRD:BRD-BRD-K06455935-001-01-3;BRD:BRD-K06455935-001-01-3,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,EGLN1,,,PHASE 3,,Small molecule,Phase 3,RUEYEZADQJCKGV-UHFFFAOYSA-N,O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O;OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
DAPSONE,DAPSONE,CHEMBL1043,BRD:BRD-BRD-K62363391-001-24-9;BRD:BRD-K62363391-001-24-9,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,DHFR,"DERMATITIS HERPETIFORMIS (DH), LEPROSY",,LAUNCHED,,Small molecule,Approved,MQJKPEGWNLWLTK-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)C1CCC(N)CC1;NC1CCC(S(=O)(=O)C2CCC(N)CC2)CC1
DAPT,DAPT,,BRD:BRD-BRD-K47177710-001-03-1;BRD:BRD-K47177710-001-03-1,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,PRECLINICAL,,,NA,,C[C@H](NC(=O)CC1CC(F)CC(F)C1)C(=O)N[C@H](C(=O)OC(C)(C)C)C1CCCCC1
DAPTOMYCIN,DAPTOMYCIN,CHEMBL387675,BRD:BRD-BRD-K94358652-001-02-1;BRD:BRD-K94358652-001-02-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"SKIN INFECTIONS, ENDOCARDITIS",,LAUNCHED,,Protein,Approved,DOAKLVKFURWEDJ-RWDRXURGSA-N,CCCCCCCCCC(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)C2CCCCC2N)C(=O)O[C@@H]1C;CCCCCCCCCC(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2CCCCC2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O
DARAPLADIB,DARAPLADIB,CHEMBL204021,BRD:BRD-BRD-K19085898-001-01-8;BRD:BRD-K19085898-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLA2G7,,,PHASE 3,,Small molecule,Phase 3,WDPFJWLDPVQCAJ-UHFFFAOYSA-N,CCN(CC)CCN(CC1CCC(-C2CCC(C(F)(F)F)CC2)CC1)C(=O)CN1C(SCC2CCC(F)CC2)NC(=O)C2C1CCC2;CCN(CC)CCN(CC1CCC(CC1)-C1CCC(CC1)C(F)(F)F)C(=O)CN1C2CCCC2C(=O)NC1SCC1CCC(F)CC1
DARAPRIM,DARAPRIM,CHEMBL36,GDSC1:71,gdsc,,,,,,,Small molecule,Approved,WKSAUQYGYAYLPV-UHFFFAOYSA-N,CCC1NC(N)NC(N)C1-C1CCC(CL)CC1
DARGLITAZONE,DARGLITAZONE,CHEMBL55624,BRD:BRD-BRD-K82908348-001-01-9;BRD:BRD-K82908348-001-01-9,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARG,,,PHASE 2,,Small molecule,Unknown,QQKNSPHAFATFNQ-UHFFFAOYSA-N,CC1OC(-C2CCCCC2)NC1CCC(=O)C1CCC(CC2SC(=O)NC2=O)CC1;CC1OC(NC1CCC(=O)C1CCC(CC2SC(O)NC2O)CC1)-C1CCCCC1
DARIFENACIN,DARIFENACIN,CHEMBL1346,BRD:BRD-BRD-K95773607-004-03-8;BRD:BRD-K95773607-004-03-8,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,URINARY INCONTINENCE,,LAUNCHED,,Small molecule,Approved,HXGBXQDTNZMWGS-RUZDIDTESA-N,NC(=O)C([C@@H]1CCN(CCC2CCC3OCCC3C2)C1)(C1CCCCC1)C1CCCCC1;NC(=O)C(C1CCCCC1)(C1CCCCC1)[C@@H]1CCN(CCC2CCC3C(C2)CCO3)C1
DARINAPARSIN,DARINAPARSIN,CHEMBL3247378,CTRP:609121,ctrp,,,,,,,Small molecule,Phase 2,JGDXFQORBMPJGR-YUMQZZPRSA-N,C[AS](C)SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O
ODM-201,DAROLUTAMIDE;ODM-201,CHEMBL4297185,BRD:BRD-A44971162-001-02-7;BRD:BRD-BRD-A44971162-001-02-7,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,,,PHASE 3,,Small molecule,Approved,BLIJXOOIHRSQRB-PXYINDEMSA-N,C[C@@H](CN1CCC(N1)-C1CCC(C#N)C(CL)C1)NC(=O)C1CC([NH]N1)C(C)O;CC(O)C1CC(C(=O)N[C@@H](C)CN2CCC(-C3CCC(C#N)C(CL)C3)N2)N[NH]1
DARUNAVIR,DARUNAVIR,CHEMBL1323,BRD:BRD-BRD-K84986517-001-01-8;BRD:BRD-K84986517-001-01-8,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,CYP3A4,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,CJBJHOAVZSMMDJ-HEXNFIEUSA-N,CC(C)CN(C[C@@H](O)[C@H](CC1CCCCC1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)C1CCC(N)CC1;CC(C)CN(C[C@@H](O)[C@H](CC1CCCCC1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)C1CCC(N)CC1
DARUSENTAN,DARUSENTAN,CHEMBL23261,BRD:BRD-BRD-K54863166-001-01-9;BRD:BRD-K54863166-001-01-9,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,PHASE 3,,Small molecule,Phase 3,FEJVSJIALLTFRP-LJQANCHMSA-N,COC1CC(OC)NC(O[C@H](C(=O)O)C(OC)(C2CCCCC2)C2CCCCC2)N1;COC1CC(OC)NC(O[C@H](C(O)=O)C(OC)(C2CCCCC2)C2CCCCC2)N1
DASABUVIR,DASABUVIR,CHEMBL3137312,BRD:BRD-BRD-K02943813-001-01-9;BRD:BRD-K02943813-001-01-9,rep_primary;rep_single_dose,HCV INHIBITOR,,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,NBRBXGKOEOGLOI-UHFFFAOYSA-N,COC1C(-C2CCC3CC(NS(C)(=O)=O)CCC3C2)CC(-N2CCC(=O)[NH]C2=O)CC1C(C)(C)C;COC1C(CC(CC1C(C)(C)C)-N1CCC(=O)[NH]C1=O)-C1CCC2CC(NS(C)(=O)=O)CCC2C1
DASATINIB,DASATINIB,CHEMBL1421,BRD:BRD-BRD-K49328571-001-15-0;BRD:BRD-K49328571-001-15-0;BRD:BRD-K49328571-001-16-8;CTRP:52882;GDSC1:51;GDSC2:1079,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"BCR-ABL KINASE INHIBITOR, EPHRIN INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, SRC INHIBITOR, TYROSINE KINASE INHIBITOR",ABL1;ABL2;BLK;EPHA2;EPHA3;EPHA5;EPHA6;EPHA8;EPHB1;EPHB2;EPHB4;FGR;FRK;FYN;HCK;KIT;LCK;LYN;PDGFRA;PDGFRB;SRC;SRMS;STAT5B;YES1,"CHRONIC MYELOID LEUKEMIA (CML), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)",,LAUNCHED,"Multiple values for MOA: {'MULTIKINASE INHIBITOR (INCLUDING ABL1 AND PDGFRA)', 'BCR-ABL KINASE INHIBITOR, EPHRIN INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, SRC INHIBITOR, TYROSINE KINASE INHIBITOR'}, defaulting to 'BCR-ABL KINASE INHIBITOR, EPHRIN INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, SRC INHIBITOR, TYROSINE KINASE INHIBITOR'
Multiple values for repurposing_target: {'ABL1;ABL2;BLK;EPHA3;EPHA5;EPHA6;EPHA8;EPHB1;EPHB2;EPHB4;FRK;HCK;LCK;PDGFRA;SRC;YES1', 'ABL1;ABL2;BLK;EPHA2;FGR;FRK;FYN;HCK;KIT;LCK;LYN;PDGFRB;SRC;SRMS;STAT5B;YES1'}, taking the union",Small molecule,Approved,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,CC1NC(NC2NCC(C(=O)NC3C(C)CCCC3CL)S2)CC(N2CCN(CCO)CC2)N1;CC1NC(NC2NCC(S2)C(=O)NC2C(C)CCCC2CL)CC(N1)N1CCN(CCO)CC1
DASOTRALINE,DASOTRALINE,CHEMBL3301595,BRD:BRD-K00003142-003-01-9,rep_single_dose,DOPAMINE-NOREPINEPHRINE-SEROTONIN REUPTAKE INHIBITOR,,,,,,Small molecule,Phase 3,SRPXSILJHWNFMK-MEDUHNTESA-N,N[C@@H]1CC[C@@H](C2CCC(CL)C(CL)C2)C2CCCCC21
DAU-5884,DAU-5884,,BRD:BRD-BRD-K31633810-003-02-8;BRD:BRD-K31633810-003-02-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM3,,,PRECLINICAL,,,NA,,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1CC2CCCCC2NC1=O
DAUCOSTEROL,DAUCOSTEROL,CHEMBL506678,BRD:BRD-BRD-K14276241-001-01-2;BRD:BRD-K14276241-001-01-2,rep_primary;rep_single_dose,APOPTOSIS STIMULANT,,,,PHASE 2,,Small molecule,Unknown,NPJICTMALKLTFW-OFUAXYCQSA-N,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C;CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C
RUBIDOMYCIN,DAUNORUBICIN;RP 13057;RUBIDOMYCIN,CHEMBL178,BRD:BRD-BRD-K43389675-003-16-7;BRD:BRD-BRD-K43389675-003-20-9;BRD:BRD-K43389675-001-02-1;BRD:BRD-K43389675-003-16-7;BRD:BRD-K43389675-003-20-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,"RNA SYNTHESIS INHIBITOR, TOPOISOMERASE INHIBITOR",TOP2A;TOP2B,"ACUTE MYELOID LEUKEMIA (AML), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)",,LAUNCHED,"Multiple values for MOA: {'RNA SYNTHESIS INHIBITOR, TOPOISOMERASE INHIBITOR', 'DNA INTERCALATOR/INHIBITOR OF TOPOISOMERASE'}, defaulting to 'RNA SYNTHESIS INHIBITOR, TOPOISOMERASE INHIBITOR'",Small molecule,Approved,STQGQHZAVUOBTE-VGBVRHCVSA-N,COC1CCCC2C(=O)C3C(O)C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C4C(O)C3C(=O)C12)C(C)=O;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
DAZMEGREL,DAZMEGREL,CHEMBL283656,BRD:BRD-BRD-K20738689-001-01-2;BRD:BRD-K20738689-001-01-2,rep_primary;rep_single_dose,THROMBOXANE SYNTHASE INHIBITOR,TBXAS1,,,PHASE 2,,Small molecule,Unknown,DEQLGSOHGTZKFB-UHFFFAOYSA-N,CC1C(CN2CCNC2)C2CCCCC2N1CCC(=O)O;CC1C(CN2CCNC2)C2CCCCC2N1CCC(O)=O
DAZOXIBEN,DAZOXIBEN,CHEMBL267473,BRD:BRD-BRD-K82767007-001-01-1;BRD:BRD-K82767007-001-01-1,rep_primary;rep_single_dose,THROMBOXANE SYNTHASE INHIBITOR,TBXAS1,,,PHASE 2,,Small molecule,Unknown,XQGZSYKGWHUSDH-UHFFFAOYSA-N,O=C(O)C1CCC(OCCN2CCNC2)CC1;OC(=O)C1CCC(OCCN2CCNC2)CC1
DBEQ,DBEQ,,BRD:BRD-BRD-K59204667-001-03-1;BRD:BRD-K59204667-001-03-1;CTRP:199337,ctrp;rep_primary;rep_single_dose,ATPASE INHIBITOR,CASP3,,,PRECLINICAL,,,NA,,C(NC1NC(NCC2CCCCC2)C2CCCCC2N1)C1CCCCC1
DBI,DBI,,GDSC1:196,gdsc,,,,,,,,NA,,
DBPR-211,DBPR-211,,BRD:BRD-K00004704-001-01-9,rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,,,,,,,NA,,
DBPR108,DBPR108,CHEMBL1082462,BRD:BRD-BRD-K83020231-001-01-2;BRD:BRD-K83020231-001-01-2,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,,,PHASE 1,,Small molecule,Phase 3,VQKSCYBKUIDZEI-STQMWFEESA-N,CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N
DC-260126,DC-260126,,BRD:BRD-K10596918-001-02-9,rep_single_dose,FREE FATTY ACID RECEPTOR ANTAGONIST,FFAR1,,,,,,NA,,
DCC-2618,DCC-2618,CHEMBL4216467,BRD:BRD-BRD-K49246350-001-01-1;BRD:BRD-K49246350-001-01-1,rep_primary;rep_single_dose,"PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, KIT INHIBITOR",KIT;PDGFRA,,,PHASE 1,"Multiple values for MOA: {'KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR', 'PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, KIT INHIBITOR'}, defaulting to 'PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, KIT INHIBITOR'",Small molecule,Approved,CEFJVGZHQAGLHS-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC(NC(=O)NC3CCCCC3)C(F)CC2BR)CC2CNC(NC)CC21;CN1CC(CN1)-C1CC(OC2CC(F)C(NC(=O)C3(CC3)C(=O)NC3CCCCC3)CC2F)CCN1
DCC-3014,DCC-3014,CHEMBL5095202,BRD:BRD-K00091116-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,TVGAHWWPABTBCX-UHFFFAOYSA-N,CC1NC(-C2CNC(NC(C)C)N(C)C2=O)CCC1OC1CCNC(-C2CNN(C)C2)C1
DCEBIO,DCEBIO,,BRD:BRD-BRD-K89299012-001-06-0;BRD:BRD-K89299012-001-06-0,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNN2;KCNN3;KCNN4,,,PRECLINICAL,,,NA,,CCN1C(O)NC2CC(CL)C(CL)CC12
DCP-LA,DCP-LA,,BRD:BRD-K00005344-001-01-9,rep_single_dose,PROTEIN KINASE ACTIVATOR,,,,,,,NA,,
DCPIB,DCPIB,,BRD:BRD-A39255369-001-03-1;BRD:BRD-BRD-A39255369-001-03-1,rep_primary;rep_single_dose,"CHLORIDE CHANNEL BLOCKER, GAP JUNCTION MODULATOR, GLUTAMATE INHIBITOR",SLC1A2,,,PRECLINICAL,,,NA,,CCCCC1(CC2CC(OCCCC(O)=O)C(CL)C(CL)C2C1=O)C1CCCC1
DDD107498 (SUCCINATE),DDD107498 (SUCCINATE),,BRD:BRD-K17754715-036-03-9,rep_single_dose,,,,,,,,NA,,
DDE-28,DDE-28,,GDSC1:192,gdsc,,,,,,,,NA,,
DDR1-IN-1,DDR1-IN-1,,BRD:BRD-K61845293-300-03-9,rep_single_dose,DISCOIDIN DOMAIN RECEPTOR INHIBITOR,DDR1;DDR2,,,,,,NA,,
DEAZAGUANINE,DEAZAGUANINE,,BRD:BRD-K00004562-001-01-9,rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,,,,NA,,
DEBIO-0932,DEBIO-0932,CHEMBL2419346,BRD:BRD-K00003157-001-01-9,rep_single_dose,HSP INHIBITOR,,,,,,Small molecule,Phase 1,RVJIQAYFTOPTKK-UHFFFAOYSA-N,CN(C)C1CC2C(CC1SC1NC3C(N)NCCC3N1CCNCC(C)(C)C)OCO2
DEBRISOQUIN,DEBRISOQUIN,CHEMBL169901,BRD:BRD-BRD-K80419150-001-02-4;BRD:BRD-K80419150-001-02-4,rep_primary;rep_single_dose,ADRENERGIC NEURON BLOCKER,SLC6A2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,JWPGJSVJDAJRLW-UHFFFAOYSA-N,N=C(N)N1CCC2CCCCC2C1;NC(=N)N1CCC2CCCCC2C1
DECAMETHONIUM,DECAMETHONIUM,CHEMBL1190,BRD:BRD-BRD-K49783248-303-08-4;BRD:BRD-K49783248-303-08-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,ACHE;CHRNA2,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,MTCUAOILFDZKCO-UHFFFAOYSA-N,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
DECERNOTINIB,DECERNOTINIB,CHEMBL3039513,BRD:BRD-A95300432-001-01-3;BRD:BRD-BRD-A95300432-001-01-3,rep_primary;rep_single_dose,JAK INHIBITOR,JAK3,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,ASUGUQWIHMTFJL-QGZVFWFLSA-N,CC[C@@](C)(NC1CCNC(-C2C[NH]C3NCCCC23)N1)C(=O)NCC(F)(F)F;CCC(C)(NC1CCNC(N1)-C1C[NH]C2NCCCC12)C(=O)NCC(F)(F)F
DECITABINE:CARBOPLATIN (1:1 MOL/MOL),DECITABINE:CARBOPLATIN (1:1 MOL/MOL),,CTRP:660250,ctrp,,,,,,,,NA,,
DECITABINE:NAVITOCLAX (2:1 MOL/MOL),DECITABINE:NAVITOCLAX (2:1 MOL/MOL),,CTRP:660180,ctrp,,,,,,,,NA,,
DECLOPRAMIDE,DECLOPRAMIDE,CHEMBL1618378,BRD:BRD-K00004661-001-01-9,rep_single_dose,CELL CYCLE INHIBITOR,,,,,,Small molecule,Unknown,YEYAKZXEBSVURO-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1CCC(N)C(CL)C1
DECLOXIZINE,DECLOXIZINE,CHEMBL2106665,BRD:BRD-K00003318-300-01-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,OXBBIHZWNDPBMQ-UHFFFAOYSA-N,OCCOCCN1CCN(C(C2CCCCC2)C2CCCCC2)CC1
DECOGLURANT,DECOGLURANT,CHEMBL3301593,BRD:BRD-K00079087-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,DMJHZVARRXJSEG-UHFFFAOYSA-N,NC1CCC(C#CC2CNN3C(C(F)(F)F)CC(-C4CCC(C(F)(F)F)CC4)NC23)CN1
DECOQUINATE,DECOQUINATE,CHEMBL416230,BRD:BRD-BRD-K17641316-001-04-8;BRD:BRD-K17641316-001-04-8,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,JHAYEQICABJSTP-UHFFFAOYSA-N,CCCCCCCCCCOC1CC2C(O)C(C(=O)OCC)CNC2CC1OCC;CCCCCCCCCCOC1CC2C(O)C(CNC2CC1OCC)C(=O)OCC
VS-6063,DEFACTINIB;PF-04554878;VS-6063,CHEMBL3137305;CHEMBL3137331,BRD:BRD-BRD-K43578482-001-01-4;BRD:BRD-K43578482-001-01-4;BRD:BRD-K43578482-001-06-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,FOCAL ADHESION KINASE INHIBITOR,FAK;PTK2,,,PHASE 2,"Multiple values for MOA: {'FOCAL ADHESION KINASE INHIBITOR', 'INHIBITOR OF FAK'}, defaulting to 'FOCAL ADHESION KINASE INHIBITOR'
Multiple values for repurposing_target: {'PTK2', 'FAK'}, taking the union",Small molecule,Phase 2,FWLMVFUGMHIOAA-UHFFFAOYSA-N;RCHQNUQAHJNRBY-UHFFFAOYSA-N,CNC(=O)C1CCC(NC2NCC(C(F)(F)F)C(NCC3NCCNC3N(C)S(C)(=O)=O)N2)CC1;CNC(=O)C1CCC(NC2NCC(C(F)(F)F)C(NCC3NCCNC3N(C)S(C)(=O)=O)N2)CC1.CL;CNC(=O)C1CCC(NC2NCC(C(NCC3NCCNC3N(C)S(C)(=O)=O)N2)C(F)(F)F)CC1
DEFERASIROX,DEFERASIROX,CHEMBL550348,BRD:BRD-BRD-K97010173-001-04-1;BRD:BRD-K97010173-001-04-1;BRD:BRD-K97010173-001-06-9,rep_multi_dose;rep_primary;rep_single_dose,CHELATING AGENT,CYP3A4,"TRANSFUSIONAL HEMOSIDEROSIS, THALASSEMIA, IRON OVERLOAD",,LAUNCHED,,Small molecule,Approved,BOFQWVMAQOTZIW-UHFFFAOYSA-N,O=C(O)C1CCC(-N2NC(-C3CCCCC3O)NC2-C2CCCCC2O)CC1;OC(=O)C1CCC(CC1)-N1NC(NC1-C1CCCCC1O)-C1CCCCC1O
DEFERIPRONE,DEFERIPRONE,CHEMBL70927,BRD:BRD-BRD-K06878038-001-18-6;BRD:BRD-K06878038-001-18-6,rep_primary;rep_single_dose,CHELATING AGENT,UGT1A6,"TRANSFUSIONAL HEMOSIDEROSIS, THALASSEMIA, IRON OVERLOAD",,LAUNCHED,,Small molecule,Approved,TZXKOCQBRNJULO-UHFFFAOYSA-N,CC1C(O)C(=O)CCN1C
DEFEROXAMINE-MESYLATE,DEFEROXAMINE-MESYLATE,,BRD:BRD-BRD-K09821361-066-25-8;BRD:BRD-K09821361-066-25-8,rep_primary;rep_single_dose,CHELATING AGENT,,"ACUTE IRON INTOXICATION, IRON OVERLOAD",,LAUNCHED,,,NA,,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
DEFLAZACORT,DEFLAZACORT,CHEMBL1201891,BRD:BRD-BRD-K96006502-001-02-6;BRD:BRD-K96006502-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,JOINT INFLAMMATION,,LAUNCHED,,Small molecule,Approved,FBHSPRKOSMHSIF-GRMWVWQJSA-N,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C;CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C
DEFOROLIMUS,DEFOROLIMUS,CHEMBL2103839,BRD:BRD-BRD-K62304154-001-04-2;BRD:BRD-K62304154-001-04-2,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PHASE 3,,Small molecule,Phase 3,BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
DEGARELIX,DEGARELIX,CHEMBL415606,BRD:BRD-A88562598-001-01-7;BRD:BRD-BRD-A88562598-001-01-7,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,GNRHR,PROSTATE CANCER,,LAUNCHED,,Protein,Approved,MEUCPCLKGZSHTA-XYAYPHGZSA-N,CC(=O)N[C@H](CC1CCC2CCCCC2C1)C(=O)N[C@H](CC1CCC(CL)CC1)C(=O)N[C@H](CC1CCCNC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1CCC(NC(=O)[C@@H]2CC(=O)NC(=O)N2)CC1)C(=O)N[C@H](CC1CCC(NC(N)=O)CC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O;CC(C)CC(NC(=O)C(CC1CCC(NC(N)=O)CC1)NC(=O)C(CC1CCC(NC(=O)C2CC(=O)NC(=O)N2)CC1)NC(=O)C(CO)NC(=O)C(CC1CCCNC1)NC(=O)C(CC1CCC(CL)CC1)NC(=O)C(CC1CCC2CCCCC2C1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O
DEHYDROACETIC-ACID,DEHYDROACETIC-ACID,,BRD:BRD-A17300716-001-01-5;BRD:BRD-BRD-A17300716-001-01-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(=O)C1C(=O)OC(C)=CC1=O
DEHYDROCHOLATE,DEHYDROCHOLATE,,BRD:BRD-A64125466-236-04-6;BRD:BRD-BRD-A64125466-236-04-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C[C@H](CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)CC1CC3=O
DEHYDROCHOLATE-ACID,DEHYDROCHOLATE-ACID,,BRD:BRD-A11551002-001-04-6;BRD:BRD-BRD-A11551002-001-04-6,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O
DEHYDROCORYDALINE,DEHYDROCORYDALINE,CHEMBL1917176,BRD:BRD-BRD-K67186445-001-02-1;BRD:BRD-K67186445-001-02-1,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,PHASE 3,,Small molecule,NA,RFKQJTRWODZPHF-UHFFFAOYSA-N,COC1CC2C(CC1OC)-C1C(C)C3CCC(OC)C(OC)C3C[N+]1CC2;COC1CC2CC[N+]3CC4C(OC)C(OC)CCC4C(C)C3-C2CC1OC
DEHYDROEPIANDROSTERONE,DEHYDROEPIANDROSTERONE,CHEMBL90593,BRD:BRD-BRD-K41256143-001-12-7;BRD:BRD-K41256143-001-12-7,rep_primary;rep_single_dose,PROTEIN SYNTHESIS STIMULANT,ESR1;ESR2;G6PD;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;HSD17B1;NR1I2;NR1I3;PPARA;SIGMAR1;SULT2A1;SULT2B1,,,LAUNCHED,,Small molecule,Approved,FMGSKLZLMKYGDP-USOAJAOKSA-N,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12;C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O
DEHYDROEPIANDROSTERONE-SULFATE,DEHYDROEPIANDROSTERONE-SULFATE,,BRD:BRD-BRD-K15360631-325-01-4;BRD:BRD-K15360631-325-01-4,rep_primary;rep_single_dose,"ANDROGEN RECEPTOR AGONIST, ESTROGEN RECEPTOR AGONIST",AR;ESR1;ESR2,MENOPAUSE,,LAUNCHED,,,NA,,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O
DELAFLOXACIN,DELAFLOXACIN,CHEMBL2105637,BRD:BRD-K90991629-100-02-9,rep_single_dose,ANTIINFECTIVE DRUG,,,,,,Small molecule,Approved,DYDCPNMLZGFQTM-UHFFFAOYSA-N,NC1NC(-N2CC(C(=O)O)C(=O)C3CC(F)C(N4CC(O)C4)C(CL)C32)C(F)CC1F
DELAMANID,DELAMANID,CHEMBL218650,BRD:BRD-BRD-K17480742-001-01-1;BRD:BRD-K17480742-001-01-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,XDAOLTSRNUSPPH-XMMPIXPASA-N,C[C@]1(COC2CCC(CC2)N2CCC(CC2)OC2CCC(OC(F)(F)F)CC2)CN2CC(NC2O1)[N+]([O-])=O;C[C@]1(COC2CCC(N3CCC(OC4CCC(OC(F)(F)F)CC4)CC3)CC2)CN2CC([N+](=O)[O-])NC2O1
DELANZOMIB,DELANZOMIB,CHEMBL270515,BRD:BRD-BRD-K59325863-001-02-8;BRD:BRD-BRD-K59325863-001-03-6;BRD:BRD-K59325863-001-02-8;BRD:BRD-K59325863-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,CMA1;CTSG;CYP3A4;ELANE,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,SJFBTAPEPRWNKH-CCKFTAQKSA-N,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1CCCC(-C2CCCCC2)N1)[C@@H](C)O)B(O)O;CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1CCCC(N1)-C1CCCCC1)[C@@H](C)O)B(O)O
DELAPRIL,DELAPRIL,CHEMBL589583,BRD:BRD-BRD-K00573984-003-01-5;BRD:BRD-K00573984-003-01-5,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,WOUOLAUOZXOLJQ-MBSDFSHPSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N(CC(=O)O)C1CC2CCCCC2C1;CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2CCCCC2C1
DELAVIRDINE,DELAVIRDINE,CHEMBL593,BRD:BRD-BRD-K34068325-066-03-7;BRD:BRD-K34068325-066-03-7,rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,CYP3A4,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,WHBIGIKBNXZKFE-UHFFFAOYSA-N,CC(C)NC1CCCNC1N1CCN(C(=O)C2CC3CC(NS(C)(=O)=O)CCC3[NH]2)CC1;CC(C)NC1CCCNC1N1CCN(CC1)C(=O)C1CC2CC(NS(C)(=O)=O)CCC2[NH]1
DELCASERTIB,DELCASERTIB,CHEMBL2107872,BRD:BRD-K00003468-001-01-9,rep_single_dose,PKC INHIBITOR,,,,,,Protein,Phase 2,,
DELGOCITINIB,DELGOCITINIB,CHEMBL4297507,BRD:BRD-K00003500-001-01-9,rep_single_dose,JAK INHIBITOR,,,,,,Small molecule,Phase 3,LOWWYYZBZNSPDT-ZBEGNZNMSA-N,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(C1NCNC3[NH]CCC13)C2
DELIVERT,DELIVERT,CHEMBL408403,BRD:BRD-BRD-K45503887-001-01-1;BRD:BRD-K45503887-001-01-1,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR AGONIST,AGTR1;AGTR2,,,LAUNCHED,,Protein,Approved,CZGUSIXMZVURDU-JZXHSEFVSA-N,CC[C@H](C)[C@H](NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1CNC[NH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CC1CCCCC1)C(O)=O;CC[C@H](C)[C@H](NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](CC1CNC[NH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1CCCCC1)C(=O)O
DELPAZOLID,DELPAZOLID,CHEMBL1673408,BRD:BRD-K00003363-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Phase 2,QLUWQAFDTNAYPN-LLVKDONJSA-N,CN1CCN(C2CCC(N3C[C@H](CO)OC3=O)CC2F)C=N1
DELTARASIN,DELTARASIN,,BRD:BRD-BRD-K90830492-305-01-4;BRD:BRD-K90830492-305-01-4,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,KRAS,,,PRECLINICAL,,,NA,,C(OC1CCC(CC1)-C1NC2CCCCC2N1CC1CCCCC1)[C@H](C1CCNCC1)N1C(NC2CCCCC12)-C1CCCCC1
DEMECARIUM,DEMECARIUM,CHEMBL1201229,BRD:BRD-BRD-K51471001-303-04-7;BRD:BRD-K51471001-303-04-7,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE,"INTRAOCULAR PRESSURE, GLAUCOMA",,LAUNCHED,,Small molecule,Approved,RWZVPVOZTJJMNU-UHFFFAOYSA-N,CN(CCCCCCCCCCN(C)C(=O)OC1CCCC([N+](C)(C)C)C1)C(=O)OC1CCCC([N+](C)(C)C)C1;CN(CCCCCCCCCCN(C)C(=O)OC1CCCC(C1)[N+](C)(C)C)C(=O)OC1CCCC(C1)[N+](C)(C)C
DEMECLOCYCLINE,DEMECLOCYCLINE,CHEMBL1591,BRD:BRD-K00003347-003-01-9,rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,,,,,Small molecule,Approved,FMTDIUIBLCQGJB-SEYHBJAFSA-N,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)C4C(O)CCC(CL)C4[C@@H](O)[C@H]3C[C@@H]12
DENATONIUM-BENZOATE,DENATONIUM-BENZOATE,,BRD:BRD-BRD-K34122555-057-11-5;BRD:BRD-K34122555-057-11-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC[N+](CC)(CC(=O)NC1C(C)CCCC1C)CC1CCCCC1
DENOPAMINE,DENOPAMINE,CHEMBL493682,BRD:BRD-K00004656-001-01-9,rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,,,,,Small molecule,Unknown,VHSBBVZJABQOSG-INIZCTEOSA-N,COC1CCC(CCNC[C@H](O)C2CCC(O)CC2)CC1OC
DENOTIVIR,DENOTIVIR,CHEMBL2104203,BRD:BRD-BRD-K01773083-001-01-4;BRD:BRD-K01773083-001-01-4,rep_primary;rep_single_dose,ANTIVIRAL,,"VIRUS HERPES SIMPLEX (HSV), SKIN INFECTIONS",,LAUNCHED,,Small molecule,Unknown,ZPBLNADJHWHOEP-UHFFFAOYSA-N,CC1NSC(NC(=O)C2CCCCC2)C1C(=O)NC1CCC(CL)CC1
DEOXYCHOLIC-ACID,DEOXYCHOLIC-ACID,,BRD:BRD-BRD-K41170226-001-13-8;BRD:BRD-K41170226-001-13-8,rep_primary;rep_single_dose,"BILIVERDIN REDUCTASE A ACTIVATOR, G PROTEIN-COUPLED RECEPTOR AGONIST",EFTUD1;FPR1;GPBAR1,SUBMENTAL FAT,,LAUNCHED,,,NA,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
DEOXYCORTICOSTERONE-ACETATE,DEOXYCORTICOSTERONE-ACETATE,,BRD:BRD-BRD-K24556098-001-16-7;BRD:BRD-BRD-K24556098-001-19-1;BRD:BRD-K24556098-001-16-7;BRD:BRD-K24556098-001-19-1,rep_multi_dose;rep_primary;rep_single_dose,PROGESTOGEN HORMONE,NR3C2,,,PRECLINICAL,,,NA,,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
DEOXYEPINEPHRINE,DEOXYEPINEPHRINE,,BRD:BRD-BRD-K33151569-003-09-7;BRD:BRD-K33151569-003-09-7,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, DOPAMINE RECEPTOR AGONIST",ADRA1A;DRD1;DRD2,,,PRECLINICAL,,,NA,,CNCCC1CCC(O)C(O)C1
DEPRODONE PROPIONATE,DEPRODONE PROPIONATE,,BRD:BRD-K00090631-001-01-9,rep_single_dose,,,,,,,,NA,,
DEPTROPINE,DEPTROPINE,CHEMBL1946186,BRD:BRD-A65797496-048-09-3;BRD:BRD-BRD-A65797496-048-09-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,,,PRECLINICAL,,Small molecule,Unknown,ZWPODSUQWXAZNC-PMOLBWCYSA-N,CN1[C@@H]2CC[C@H]1C[C@@H](OC1C3CCCCC3CCC3CCCCC31)C2;CN1[C@H]2CC[C@@H]1CC(C2)OC1C2CCCCC2CCC2CCCCC12
DEQUALINIUM,DEQUALINIUM,CHEMBL333826,BRD:BRD-BRD-K77685957-300-09-1;BRD:BRD-K77685957-300-09-1,rep_multi_dose;rep_primary;rep_single_dose,PKC INHIBITOR,KCNN1;KCNN3,,,LAUNCHED,,Small molecule,Approved,PCSWXVJAIHCTMO-UHFFFAOYSA-P,CC1CC(N)C2CCCCC2[N+]1CCCCCCCCCC[N+]1C(C)CC(N)C2CCCCC12;CC1CC(N)C2CCCCC2[N+]1CCCCCCCCCC[N+]1C(C)CC(N)C2CCCCC21
DERACOXIB,DERACOXIB,CHEMBL28636,BRD:BRD-BRD-K68558722-001-04-0;BRD:BRD-K68558722-001-04-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,OSTEOARTHRITIS,,LAUNCHED,,Small molecule,Unknown,WAZQAZKAZLXFMK-UHFFFAOYSA-N,COC1CCC(-C2CC(C(F)F)NN2-C2CCC(S(N)(=O)=O)CC2)CC1F;COC1CCC(CC1F)-C1CC(NN1-C1CCC(CC1)S(N)(=O)=O)C(F)F
DERAZANTINIB,DERAZANTINIB,CHEMBL4297187,BRD:BRD-K00003310-001-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 2,KPJDVVCDVBFRMU-AREMUKBSSA-N,COCCNCCC1CCCC(NC2NCC3C(N2)-C2CCCCC2[C@H](C2CCCCC2F)C3)C1
DESERPIDINE,DESERPIDINE,CHEMBL1200515;CHEMBL3989541,BRD:BRD-BRD-K29462201-001-01-9;BRD:BRD-K29462201-001-01-9,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE;SLC18A2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,CVBMAZKKCSYWQR-WCGOZPBSSA-N;ULBNWNUHGJLQHO-VKMIBBQISA-N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4C([NH]C5CCCCC45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1CC(OC)C(OC)C(OC)C1;COC(=O)[C@H]1[C@H]2C[C@@H]3C4[NH]C5CCC(OC)CC5C4CCN3C[C@H]2C[C@@H](OC(=O)C2CC(OC)C(OC)C(OC)C2)[C@@H]1OC;COC(=O)[C@H]1[C@H]2C[C@@H]3C4[NH]C5CCCCC5C4CCN3C[C@H]2C[C@@H](OC(=O)C2CC(OC)C(OC)C(OC)C2)[C@@H]1OC
DESIDUSTAT,DESIDUSTAT,CHEMBL4650314,BRD:BRD-K00003452-001-01-9,rep_single_dose,HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR,,,,,,Small molecule,Phase 3,IKRKQQLJYBAPQT-UHFFFAOYSA-N,O=C(O)CNC(=O)C1C(O)C2CCCCC2N(OCC2CC2)C1=O
DESIPRAMINE,DESIPRAMINE,CHEMBL72,BRD:BRD-BRD-K60762818-003-26-0;BRD:BRD-K60762818-003-26-0,rep_primary;rep_single_dose,TRICYCLIC ANTIDEPRESSANT,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD2;HRH1;HTR1A;HTR2A;HTR2C;SLC6A2;SLC6A4;SMPD1,DEPRESSION,,LAUNCHED,,Small molecule,Approved,HCYAFALTSJYZDH-UHFFFAOYSA-N,CNCCCN1C2CCCCC2CCC2CCCCC12;CNCCCN1C2CCCCC2CCC2CCCCC21
DESISOBUTYRYL-CICLESONIDE,DESISOBUTYRYL-CICLESONIDE,,BRD:BRD-K00003103-001-01-9,rep_single_dose,CYTOCHROME P450 INHIBITOR,,,,,,,NA,,
DESLANOSIDE,DESLANOSIDE,CHEMBL1614,BRD:BRD-BRD-K99919177-001-01-3;BRD:BRD-K99919177-001-01-3,rep_primary;rep_single_dose,NA/K-ATPASE INHIBITOR,ATP1A1;ATP1A2;ATP1A3;ATP1A4;ATP1B1;ATP1B2;ATP1B3;FXYD2,"CONGESTIVE HEART FAILURE, CARDIAC ARRYTHMIA",,LAUNCHED,,Small molecule,Approved,OBATZBGFDSVCJD-LALPQLPRSA-N,C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1;C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
DESLORATADINE,DESLORATADINE,CHEMBL1172,BRD:BRD-BRD-K82357231-001-17-5;BRD:BRD-K82357231-001-17-5,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,JAUOIFJMECXRGI-UHFFFAOYSA-N,CLC1CCC2C(C1)CCC1CCCNC1C2=C1CCNCC1;CLC1CCC2C(CCC3CCCNC3C2=C2CCNCC2)C1
DESLORELIN,DESLORELIN,CHEMBL2365665,BRD:BRD-K00003134-001-01-9,rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR AGONIST,,,,,,Protein,Phase 2,GJKXGJCSJWBJEZ-XRSSZCMZSA-N,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1
DESMOPRESSIN-ACETATE,DESMOPRESSIN-ACETATE,,BRD:BRD-A49399758-015-01-8;BRD:BRD-BRD-A49399758-015-01-8,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR AGONIST,AVPR1A;AVPR1B;AVPR2;OXTR,"CENTRAL DIABETES INSIPIDUS, NOCTURNAL ENURESIS",,LAUNCHED,,,NA,,NC(=O)CCC1NC(=O)C(CC2CCCCC2)NC(=O)C(CC2CCC(O)CC2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O
DESOGESTREL,DESOGESTREL,CHEMBL1533,BRD:BRD-BRD-K46061689-001-01-9;BRD:BRD-K46061689-001-01-9,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,ESR1;PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,RPLCPCMSCLEKRS-BPIQYHPVSA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC;CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
DESONIDE,DESONIDE,CHEMBL1201109,BRD:BRD-BRD-K21528677-001-02-8;BRD:BRD-BRD-K21528677-001-03-6;BRD:BRD-K21528677-001-02-8;BRD:BRD-K21528677-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;PLA2G1B,CROHN'S DISEASE,,LAUNCHED,,Small molecule,Approved,WBGKWQHBNHJJPZ-LECWWXJVSA-N,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1;CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
DESOXIMETASONE,DESOXIMETASONE,CHEMBL1766,BRD:BRD-A49447682-001-02-4;BRD:BRD-BRD-A49447682-001-02-4,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;PLA2G1B,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Approved,VWVSBHGCDBMOOT-IIEHVVJPSA-N,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO;C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
DESOXYCORTICOSTERONE-PIVALATE,DESOXYCORTICOSTERONE-PIVALATE,CHEMBL1200592,BRD:BRD-BRD-K26024145-001-01-9;BRD:BRD-K26024145-001-01-9,rep_primary;rep_single_dose,CORTICOSTEROID AGONIST,NR3C2,ADDISON'S DISEASE,,LAUNCHED,,Small molecule,Approved,VVOIQBFMTVCINR-WWMZEODYSA-N,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
DESOXYCORTONE,DESOXYCORTONE,CHEMBL1200542,BRD:BRD-BRD-K98521173-001-19-4;BRD:BRD-K98521173-001-19-4,rep_multi_dose;rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR AGONIST,NR3C1;NR3C2,,,PRECLINICAL,,Small molecule,Approved,VPGRYOFKCNULNK-ACXQXYJUSA-N,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO;CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
DESOXYPEGANINE,DESOXYPEGANINE,,BRD:BRD-BRD-K13819402-003-10-2;BRD:BRD-K13819402-003-10-2,rep_primary;rep_single_dose,"ACETYLCHOLINESTERASE INHIBITOR, MONOAMINE OXIDASE INHIBITOR",ACHE,,,PHASE 1,,,NA,,C1CN2CC3CCCCC3N=C2C1
DESVENLAFAXINE,DESVENLAFAXINE,CHEMBL1118,BRD:BRD-A98845662-036-03-7;BRD:BRD-BRD-A98845662-036-03-7,rep_primary;rep_single_dose,SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI),SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,KYYIDSXMWOZKMP-UHFFFAOYSA-N,CN(C)CC(C1CCC(O)CC1)C1(O)CCCCC1
DETOMIDINE,DETOMIDINE,CHEMBL2110829,BRD:BRD-BRD-K77597856-003-02-5;BRD:BRD-K77597856-003-02-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A,SEDATIVE,,LAUNCHED,,Small molecule,Unknown,RHDJRPPFURBGLQ-UHFFFAOYSA-N,CC1CCCC(CC2C[NH]CN2)C1C
DEVAZEPIDE,DEVAZEPIDE,CHEMBL9506,BRD:BRD-K31238592-001-02-9,rep_single_dose,CCK RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,NFHRQQKPEBFUJK-HSZRJFAPSA-N,CN1C(=O)[C@@H](NC(=O)C2CC3CCCCC3[NH]2)N=C(C2CCCCC2)C2CCCCC21
DEXAMETHASONE,DEXAMETHASONE,CHEMBL1200637;CHEMBL2021430;CHEMBL384467,BRD:BRD-A10188456-001-04-9;BRD:BRD-BRD-A10188456-001-04-9;BRD:BRD-BRD-K38775274-001-22-1;BRD:BRD-K38775274-001-22-1;CTRP:277354,ctrp;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,ANXA1;NOS2;NR0B1;NR3C1;NR3C2,"HYPERCALCEMIA, RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OSTEOARTHRITIS, ALLERGIC RHINITIS, ULCERATIVE COLITIS, ANEMIA, MULTIPLE SCLEROSIS, ENTERITIS, LUPUS, DERMATITIS HERPETIFORMIS (DH), NEPHROTIC SYNDROME, PSORIASIS",,LAUNCHED,"Multiple values for structure_id: {'A10188456', 'K38775274'}, defaulting to None",Small molecule,Approved,MQRFYYBWKRACSJ-WKSAPEMMSA-M;PLCQGRYPOISRTQ-FCJDYXGNSA-L;UREBDLICKHMUKA-CXSFZGCWSA-N,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO;C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[NA+].[NA+];C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[NA+];C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
DEXAMETHASONE PALMITATE,DEXAMETHASONE PALMITATE,CHEMBL384467,BRD:BRD-K00090644-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,UREBDLICKHMUKA-CXSFZGCWSA-N,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
DEXAMETHASONE-ACETATE,DEXAMETHASONE-ACETATE,,BRD:BRD-BRD-K47635719-001-21-1;BRD:BRD-K47635719-001-21-1,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,,"HYPERCALCEMIA, RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OSTEOARTHRITIS, ALLERGIC RHINITIS, ULCERATIVE COLITIS, ANEMIA, MULTIPLE SCLEROSIS, ENTERITIS, LUPUS, DERMATITIS HERPETIFORMIS (DH), NEPHROTIC SYNDROME, PSORIASIS",,LAUNCHED,,,NA,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O
DEXAMETHASONE-SODIUM-PHOSPHATE,DEXAMETHASONE-SODIUM-PHOSPHATE,,BRD:BRD-A83802939-304-04-2;BRD:BRD-BRD-A83802939-304-04-2,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"HYPERCALCEMIA, RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OSTEOARTHRITIS, ALLERGIC RHINITIS, ULCERATIVE COLITIS, ANEMIA, MULTIPLE SCLEROSIS, ENTERITIS, LUPUS, DERMATITIS HERPETIFORMIS (DH), NEPHROTIC SYNDROME, PSORIASIS",,LAUNCHED,,,NA,,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O;C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O
DEXCHLORPHENIRAMINE,DEXCHLORPHENIRAMINE,CHEMBL1201353,BRD:BRD-BRD-K39462424-050-09-8;BRD:BRD-K39462424-050-09-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,"ALLERGIC CONJUNCTIVITIS, ALLERGIC RHINITIS, URTICARIA, ANGIOEDEMA",,LAUNCHED,,Small molecule,Approved,SOYKEARSMXGVTM-HNNXBMFYSA-N,CN(C)CC[C@@H](C1CCC(CL)CC1)C1CCCCN1
DEXFENFLURAMINE,DEXFENFLURAMINE,CHEMBL248702,BRD:BRD-BRD-K58626373-003-07-8;BRD:BRD-K58626373-003-07-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2C;SLC6A4,,,WITHDRAWN,,Small molecule,Approved,DBGIVFWFUFKIQN-VIFPVBQESA-N,CCN[C@@H](C)CC1CCCC(C(F)(F)F)C1;CCN[C@@H](C)CC1CCCC(C1)C(F)(F)F
DEXFOSFOSERINE,DEXFOSFOSERINE,CHEMBL284377,BRD:BRD-BRD-K30019776-003-01-5;BRD:BRD-K30019776-003-01-5,rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,CFTR;GRM4;GRM6;GRM7;GRM8;KCNC4;PDPK1;PIM1;PRKACA;PRKCQ;PYGL;PYGM;REG1A;RHO;SERPINB3;SMAD2;TAOK2,,,PRECLINICAL,,Small molecule,Unknown,BZQFBWGGLXLEPQ-REOHCLBHSA-N,N[C@@H](COP(=O)(O)O)C(=O)O;N[C@@H](COP(O)(O)=O)C(O)=O
DEXLANSOPRAZOLE,DEXLANSOPRAZOLE,CHEMBL1201863,BRD:BRD-BRD-K05900209-001-03-4;BRD:BRD-K05900209-001-03-4,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP4A;ATP4B,"GASTROESOPHAGEAL REFLUX DISEASE (GERD), EROSIVE ESOPHAGITIS (EE)",,LAUNCHED,,Small molecule,Approved,MJIHNNLFOKEZEW-RUZDIDTESA-N,CC1C(OCC(F)(F)F)CCNC1C[S@@](=O)C1NC2CCCCC2[NH]1;CC1C(OCC(F)(F)F)CCNC1C[S@@+]([O-])C1NC2CCCCC2[NH]1
DEXLOXIGLUMIDE,DEXLOXIGLUMIDE,CHEMBL550781,BRD:BRD-BRD-K07609981-001-01-7;BRD:BRD-K07609981-001-01-7,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKAR,,,PHASE 3,,Small molecule,Phase 3,QNQZBKQEIFTHFZ-GOSISDBHSA-N,CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1CCC(CL)C(CL)C1;CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1CCC(CL)C(CL)C1
DEXMEDETOMIDINE,DEXMEDETOMIDINE,CHEMBL778,BRD:BRD-K18423410-003-02-5,rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,,,,,Small molecule,Approved,CUHVIMMYOGQXCV-NSHDSACASA-N,CC1CCCC([C@H](C)C2C[NH]CN2)C1C
DEXNIGULDIPINE,DEXNIGULDIPINE,CHEMBL2051956,BRD:BRD-BRD-K44309363-003-02-1;BRD:BRD-K44309363-003-02-1,rep_primary;rep_single_dose,CALMODULIN ANTAGONIST,ADORA3,,,PHASE 2,,Small molecule,Unknown,SVJMLYUFVDMUHP-MGBGTMOVSA-N,COC(=O)C1=C(C)NC(C)=C([C@@H]1C1CCCC(C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1CCCCC1)C1CCCCC1;COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(C3CCCCC3)(C3CCCCC3)CC2)[C@@H]1C1CCCC([N+](=O)[O-])C1
DEXPANTHENOL,DEXPANTHENOL,CHEMBL1200979,BRD:BRD-A59413292-001-08-2;BRD:BRD-BRD-A59413292-001-08-2,rep_primary;rep_single_dose,,,PARALYTIC ILEUS,,LAUNCHED,,Small molecule,Approved,SNPLKNRPJHDVJA-ZETCQYMHSA-N,CC(C)(CO)[C@@H](O)C(=O)NCCCO;CC(C)(CO)C(O)C(=O)NCCCO
DEXRAZOXANE,DEXRAZOXANE,CHEMBL1738,BRD:BRD-BRD-K07265709-003-05-6;BRD:BRD-K07265709-003-05-6,rep_multi_dose;rep_primary;rep_single_dose,"CHELATING AGENT, TOPOISOMERASE INHIBITOR",TOP2A;TOP2B,CARDIOMYOPATHY,,LAUNCHED,,Small molecule,Approved,BMKDZUISNHGIBY-ZETCQYMHSA-N,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
DEXTRAN,DEXTRAN,CHEMBL1697742;CHEMBL2108026;CHEMBL2108451,BRD:BRD-BRD-K67117832-001-01-9;BRD:BRD-K67117832-001-01-9,rep_primary;rep_single_dose,,,"THROMBOSIS, HYPOVOLEMIA",,LAUNCHED,,Oligosaccharide;Small molecule,Phase 3,;FZWBNHMXJMCXLU-BLAUPYHCSA-N,O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O;OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
DEXTROAMPHETAMINE,DEXTROAMPHETAMINE,CHEMBL612,BRD:BRD-BRD-K21160401-065-01-0;BRD:BRD-K21160401-065-01-0,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,ADRA1A;ADRA1B;SLC18A2;SLC6A2;SLC6A3;TAAR1,"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD), NARCOLEPSY",,LAUNCHED,,Small molecule,Approved,KWTSXDURSIMDCE-QMMMGPOBSA-N,C[C@H](N)CC1CCCCC1
DEXTROMETHORPHAN,DEXTROMETHORPHAN,CHEMBL52440,BRD:BRD-BRD-K33211335-004-01-7;BRD:BRD-K33211335-004-01-7,rep_primary;rep_single_dose,"GLUTAMATE RECEPTOR ANTAGONIST, SIGMA RECEPTOR AGONIST",CHRNA2;CHRNA3;CHRNA4;CHRNA7;CHRNB2;CHRNB4;CYBA;CYBB;GRIN3A;NCF1;NCF2;NCF4;OPRD1;OPRK1;OPRM1;PGRMC1;RAC1;RAC2;SIGMAR1;SLC6A2;SLC6A4,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Approved,MKXZASYAUGDDCJ-NJAFHUGGSA-N,COC1CCC2C(C1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3;COC1CCC2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2C1
DEXTROROTATION-NIMORAZOLE-PHOSPHATE-ESTER,DEXTROROTATION-NIMORAZOLE-PHOSPHATE-ESTER,,BRD:BRD-K00003272-001-01-9,rep_single_dose,ANTIINFECTIVE DRUG,,,,,,,NA,,
DEXTROSE,DEXTROSE,CHEMBL1222250,BRD:BRD-BRD-K51431759-001-02-9;BRD:BRD-K51431759-001-02-9,rep_primary;rep_single_dose,,,HYPOGLYCEMIA,,LAUNCHED,,Small molecule,Approved,WQZGKKKJIJFFOK-GASJEMHNSA-N,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O;OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
DFB,DFB,,BRD:BRD-BRD-K82002057-001-01-2;BRD:BRD-K82002057-001-01-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM5,,,PRECLINICAL,,,NA,,FC1CCCC(C1)\C=N\N=C\C1CCCC(F)C1
DG-172,DG-172,,BRD:BRD-K75748943-300-02-9,rep_single_dose,PPAR RECEPTOR INVERSE AGONIST,PPARD,,,,,,NA,,
DG051,DG051,,BRD:BRD-K00003486-003-01-9,rep_single_dose,LEUKOTRIENE SYNTHESIS INHIBITOR,,,,,,,NA,,
DH-97,DH-97,,BRD:BRD-K06014311-001-04-9,rep_single_dose,MELATONIN RECEPTOR ANTAGONIST,MTNR1B,,,,,,NA,,
DHBP,DHBP,,BRD:BRD-K41262162-303-11-9,rep_single_dose,RYANODINE RECEPTOR BLOCKER,,,,,,,NA,,
DIACEREIN,DIACEREIN,CHEMBL41286,BRD:BRD-BRD-K69122748-001-10-1;BRD:BRD-K69122748-001-10-1,rep_primary;rep_single_dose,INTERLEUKIN INHIBITOR,IL1B,OSTEOARTHRITIS,,LAUNCHED,,Small molecule,Approved,TYNLGDBUJLVSMA-UHFFFAOYSA-N,CC(=O)OC1CCCC2C(=O)C3CC(CC(OC(C)=O)C3C(=O)C12)C(O)=O;CC(=O)OC1CCCC2C1C(=O)C1C(OC(C)=O)CC(C(=O)O)CC1C2=O
DIACETAMATE,DIACETAMATE,CHEMBL2106185,BRD:BRD-BRD-K93611241-001-02-2;BRD:BRD-K93611241-001-02-2,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,UJAOSPFULOFZRR-UHFFFAOYSA-N,CC(=O)NC1CCC(OC(C)=O)CC1
DIADENOSINE-TETRAPHOSPHATE,DIADENOSINE-TETRAPHOSPHATE,,BRD:BRD-A15035311-001-01-8;BRD:BRD-BRD-A15035311-001-01-8,rep_primary;rep_single_dose,ADENOSINE KINASE INHIBITOR,P2RY13;P2RY2,,,PHASE 1,,,NA,,NC1NCNC2N(CNC12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)N2CNC3C(N)NCNC23)C(O)C1O
DIANHYDROGALACTITOL,DIANHYDROGALACTITOL,CHEMBL3137322,BRD:BRD-BRD-K68502831-001-01-2;BRD:BRD-K68502831-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,,,,PHASE 1,,Small molecule,Phase 3,AAFJXZWCNVJTMK-GUCUJZIJSA-N,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1;O[C@H]([C@H](O)[C@@H]1CO1)[C@H]1CO1
DIARYLPROPIONITRILE,DIARYLPROPIONITRILE,CHEMBL334773,BRD:BRD-A27143604-001-02-0;BRD:BRD-BRD-A27143604-001-02-0,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR2,,,PRECLINICAL,,Small molecule,NA,GHZHWDWADLAOIQ-UHFFFAOYSA-N,N#CC(CC1CCC(O)CC1)C1CCC(O)CC1;OC1CCC(CC(C#N)C2CCC(O)CC2)CC1
DIATRIZOIC-ACID,DIATRIZOIC-ACID,,BRD:BRD-BRD-K48247567-001-01-9;BRD:BRD-K48247567-001-01-9,rep_primary;rep_single_dose,,,CONTRAST AGENT,,LAUNCHED,,,NA,,CC(=O)NC1C(I)C(NC(C)=O)C(I)C(C(O)=O)C1I
DIAVERIDINE,DIAVERIDINE,CHEMBL19633,BRD:BRD-BRD-K97464279-001-03-5;BRD:BRD-K97464279-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,LDBTVAXGKYIFHO-UHFFFAOYSA-N,COC1CCC(CC2CNC(N)NC2N)CC1OC
DIAZEPAM,DIAZEPAM,CHEMBL12,BRD:BRD-BRD-K16508793-001-05-9;BRD:BRD-K16508793-001-05-9,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,ADRA1A;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GABRR1;GABRR2;GABRR3;TSPO,"GENERALIZED ANXIETY DISORDER (GAD), ABSTINENCE FROM ALCOHOL, HALLUCINOSIS, TREMORS",,LAUNCHED,,Small molecule,Approved,AAOVKJBEBIDNHE-UHFFFAOYSA-N,CN1C(=O)CN=C(C2CCCCC2)C2CC(CL)CCC21;CN1C2CCC(CL)CC2C(=NCC1=O)C1CCCCC1
DIAZOOXONORLEUCINE,DIAZOOXONORLEUCINE,,BRD:BRD-BRD-K38458514-001-01-8;BRD:BRD-K38458514-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PHASE 2,,,NA,,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O
DIAZOXIDE,DIAZOXIDE,CHEMBL181,BRD:BRD-BRD-K73109821-001-20-1;BRD:BRD-K73109821-001-20-1,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,ATP1A1;CA1;CA2;KCNJ11;KCNJ8;KCNMA1;SLC12A3,HYPOGLYCEMIA,,LAUNCHED,,Small molecule,Approved,GDLBFKVLRPITMI-UHFFFAOYSA-N,CC1=NC2CCC(CL)CC2S(=O)(=O)N1
YO-01027,DIBENZAZEPINE;YO-01027,,BRD:BRD-BRD-K04622161-001-02-3;BRD:BRD-K04622161-001-02-3;BRD:BRD-K04622161-001-05-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHBITOR OF GAMMA-SECRETASE COMPLEX,PSEN1,,,PRECLINICAL,"Multiple values for MOA: {'GAMMA SECRETASE INHIBITOR', 'INHBITOR OF GAMMA-SECRETASE COMPLEX'}, defaulting to 'INHBITOR OF GAMMA-SECRETASE COMPLEX'",,NA,,C[C@H](NC(=O)CC1CC(F)CC(F)C1)C(=O)N[C@H]1C2CCCCC2-C2CCCCC2N(C)C1=O
DIBENZEPINE,DIBENZEPINE,CHEMBL99486,BRD:BRD-BRD-K79145749-003-02-2;BRD:BRD-K79145749-003-02-2,rep_primary;rep_single_dose,NOREPINEPHRINE REPUTAKE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,STBMTRPPGSYEFD-UHFFFAOYSA-N,CN(C)CCN1C(=O)C2CCCCC2NC2CCCCC21;CN(C)CCN1C2CCCCC2N(C)C2CCCCC2C1=O
DIBENZOTHIOPHENE,DIBENZOTHIOPHENE,CHEMBL219828,BRD:BRD-BRD-K46863940-001-06-2;BRD:BRD-K46863940-001-06-2,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,IYYZUPMFVPLQIF-UHFFFAOYSA-N,C1CCC2C(C1)SC1CCCCC12;C1CCC2C(C1)SC1CCCCC21
DIBUTYL-PHTHALATE,DIBUTYL-PHTHALATE,,BRD:BRD-BRD-K73477617-001-08-5;BRD:BRD-K73477617-001-08-5,rep_primary;rep_single_dose,,TRPA1,,,PRECLINICAL,,,NA,,CCCCOC(=O)C1CCCCC1C(=O)OCCCC
DICHLORISONE-ACETATE,DICHLORISONE-ACETATE,,BRD:BRD-BRD-K54187111-001-08-4;BRD:BRD-BRD-K54187111-001-09-2;BRD:BRD-K54187111-001-08-4;BRD:BRD-K54187111-001-09-2,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(CL)[C@@H](CL)C[C@]12C
DICHLOROACETATE,DICHLOROACETATE,CHEMBL13960,BRD:BRD-BRD-M97302542-001-03-6;BRD:BRD-M97302542-001-03-6;BRD:BRD-M97302542-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,PYRUVATE DEHYDROGENASE KINASE INHIBITOR,PDK1,,,PHASE 3,,Small molecule,Phase 3,JXTHNDFMNIQAHM-UHFFFAOYSA-N,[NA].OC(=O)C(CL)CL;O=C(O)C(CL)CL
DICHLOROPHEN,DICHLOROPHEN,CHEMBL33845,BRD:BRD-BRD-K62326629-001-19-0;BRD:BRD-K62326629-001-19-0,rep_primary;rep_single_dose,ANTICESTODAL AGENT,,,,LAUNCHED,,Small molecule,Unknown,MDNWOSOZYLHTCG-UHFFFAOYSA-N,OC1CCC(CL)CC1CC1CC(CL)CCC1O
DICHLORVOS,DICHLORVOS,CHEMBL167911,BRD:BRD-BRD-K23779958-001-05-8;BRD:BRD-K23779958-001-05-8,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,OEBRKCOSUFCWJD-UHFFFAOYSA-N,COP(=O)(OC)OC=C(CL)CL
DICLAZURIL,DICLAZURIL,CHEMBL284733,BRD:BRD-A06426627-001-03-5;BRD:BRD-BRD-A06426627-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,EQUINE PROTOZOAL MYELOENCEPHALITIS (EPM),,LAUNCHED,,Small molecule,Unknown,ZSZFUDFOPOMEET-UHFFFAOYSA-N,CLC1CCC(CC1)C(C#N)C1C(CL)CC(CC1CL)-N1NCC(=O)[NH]C1=O;N#CC(C1CCC(CL)CC1)C1C(CL)CC(-N2NCC(=O)[NH]C2=O)CC1CL
DICLOFENAC,DICLOFENAC,CHEMBL139,BRD:BRD-BRD-K08252256-236-33-8;BRD:BRD-K08252256-236-33-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,AKR1C3;ALOX5;ASIC1;ASIC3;KCNQ2;KCNQ3;PLA2G2A;PPARG;PTGS1;PTGS2;SCN4A,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, MIGRAINE HEADACHE",,LAUNCHED,,Small molecule,Approved,DCOPUUMXTXDBNB-UHFFFAOYSA-N,O=C(O)CC1CCCCC1NC1C(CL)CCCC1CL;OC(=O)CC1CCCCC1NC1C(CL)CCCC1CL
DICLOFENAMIDE,DICLOFENAMIDE,CHEMBL17,BRD:BRD-BRD-K71499074-001-12-9;BRD:BRD-K71499074-001-12-9,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA2;CA4;CA7,"GLAUCOMA, EPILEPSY",,LAUNCHED,,Small molecule,Approved,GJQPMPFPNINLKP-UHFFFAOYSA-N,NS(=O)(=O)C1CC(CL)C(CL)C(C1)S(N)(=O)=O;NS(=O)(=O)C1CC(CL)C(CL)C(S(N)(=O)=O)C1
DICLOFENSINE,DICLOFENSINE,CHEMBL287257,BRD:BRD-A51078674-003-01-0;BRD:BRD-BRD-A51078674-003-01-0,rep_primary;rep_single_dose,DOPAMINE REUPTAKE INHIBITOR,DRD1;MAOA;MAOB,,,PHASE 3,,Small molecule,Unknown,ZJDCGVDEEHWEIG-UHFFFAOYSA-N,COC1CCC2C(C1)CN(C)CC2C1CCC(CL)C(CL)C1;COC1CCC2C(CN(C)CC2C1)C1CCC(CL)C(CL)C1
DICLOXACILLIN,DICLOXACILLIN,CHEMBL893,BRD:BRD-BRD-K05673000-236-12-1;BRD:BRD-K05673000-236-12-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,YFAGHNZHGGCZAX-JKIFEVAISA-N,CC1ONC(-C2C(CL)CCCC2CL)C1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O;CC1ONC(C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-C1C(CL)CCCC1CL
DICOUMAROL,DICOUMAROL,CHEMBL1466,BRD:BRD-BRD-K82236179-213-01-0;BRD:BRD-K82236179-213-01-0,rep_primary;rep_single_dose,NADPH INHIBITOR,CRYZ;NQO1;VKORC1,DEEP VEIN THROMBOSIS (DVT),,LAUNCHED,,Small molecule,Approved,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,O=C1OC2CCCCC2C(O)C1CC1C(O)C2CCCCC2OC1=O;OC1C(CC2C(O)C3CCCCC3OC2=O)C(=O)OC2CCCCC12
DICYCLOHEXYLAMINE,DICYCLOHEXYLAMINE,,BRD:BRD-BRD-K57091285-001-07-7;BRD:BRD-K57091285-001-07-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C1CCC(CC1)NC1CCCCC1
DICYCLOVERINE,DICYCLOVERINE,CHEMBL1123,BRD:BRD-BRD-K68507560-003-24-6;BRD:BRD-K68507560-003-24-6,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Approved,CURUTKGFNZGFSE-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1;CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
DIDANOSINE,DIDANOSINE,CHEMBL1460,BRD:BRD-BRD-K99063460-001-13-1;BRD:BRD-K99063460-001-13-1,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,PNP,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,BXZVVICBKDXVGW-NKWVEPMBSA-N,O=C1[NH]CNC2C1NCN2[C@H]1CC[C@@H](CO)O1;OC[C@@H]1CC[C@@H](O1)N1CNC2C(O)NCNC12
DIDEOXYADENOSINE,DIDEOXYADENOSINE,,BRD:BRD-BRD-K84794093-001-07-5;BRD:BRD-K84794093-001-07-5,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,,,PHASE 1,,,NA,,NC1NCNC2N(CNC12)[C@H]1CC[C@@H](CO)O1
DIDOX,DIDOX,,BRD:BRD-BRD-K94146583-001-01-6;BRD:BRD-K94146583-001-01-6,rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,RRM1,BREAST CANCER,,LAUNCHED,,,NA,,ONC(=O)C1CCC(O)C(O)C1
DIENESTROL,DIENESTROL,CHEMBL1018,BRD:BRD-BRD-K95309561-001-24-7;BRD:BRD-K95309561-001-24-7,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,MENOPAUSE,,LAUNCHED,,Small molecule,Approved,NFDFQCUYFHCNBW-SCGPFSFSSA-N,C/C=C(C(=C/C)/C1CCC(O)CC1)\C1CCC(O)CC1;C\C=C(C1CCC(O)CC1)\C(C1CCC(O)CC1)=C\C
DIENOGEST,DIENOGEST,CHEMBL1201864,BRD:BRD-BRD-K50853363-001-02-3;BRD:BRD-K50853363-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,"CONTRACEPTIVE, ENDOMETRIOSIS",,LAUNCHED,,Small molecule,Approved,AZFLJNIPTRTECV-FUMNGEBKSA-N,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N
DIETHYLCARBAMAZINE,DIETHYLCARBAMAZINE,CHEMBL48977;CHEMBL684,BRD:BRD-BRD-K45542189-048-22-1;BRD:BRD-K45542189-048-22-1,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5;PTGS1,FILARIASIS,,LAUNCHED,,Small molecule,Approved,RCKMWOKWVGPNJF-UHFFFAOYSA-N;ZPCPEPNCVMMAMX-UHFFFAOYSA-N,CC/N=C(/CC)NN/C(CC)=N/CC;CCN(CC)C(=O)N1CCN(C)CC1
DIETHYLSTILBESTROL,DIETHYLSTILBESTROL,CHEMBL411,BRD:BRD-BRD-K45330754-001-21-7;BRD:BRD-K45330754-001-21-7,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1;ESR2;ESRRB;ESRRG,,,WITHDRAWN,,Small molecule,Approved,RGLYKWWBQGJZGM-ISLYRVAYSA-N,CC/C(=C(/CC)C1CCC(O)CC1)C1CCC(O)CC1;CC\C(C1CCC(O)CC1)=C(\CC)C1CCC(O)CC1
DIETHYLTOLUAMIDE,DIETHYLTOLUAMIDE,CHEMBL1453317,BRD:BRD-BRD-K94080537-001-09-7;BRD:BRD-K94080537-001-09-7,rep_primary;rep_single_dose,IONOTROPIC RECEPTOR IR40A ACTIVATOR,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Approved,MMOXZBCLCQITDF-UHFFFAOYSA-N,CCN(CC)C(=O)C1CCCC(C)C1
DIFAMILAST,DIFAMILAST,CHEMBL3989968,BRD:BRD-K00091099-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,VFBILHPIHUPBPZ-UHFFFAOYSA-N,CCOC1CCCCC1C(=O)NCC1COC(-C2CCC(OC(F)F)C(OC(C)C)C2)N1
DIFELIKEFALIN,DIFELIKEFALIN,CHEMBL3989915,BRD:BRD-K00077991-001-02-9,rep_single_dose,,,,,,,Protein,Approved,FWMNVWWHGCHHJJ-SKKKGAJSSA-N,CC(C)C[C@@H](NC(=O)[C@@H](CC1CCCCC1)NC(=O)[C@H](N)CC1CCCCC1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1
DIFENPIRAMIDE,DIFENPIRAMIDE,CHEMBL1489662,BRD:BRD-BRD-K96206066-001-07-9;BRD:BRD-K96206066-001-07-9,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTAGLANDIN INHIBITOR",,,,LAUNCHED,,Small molecule,Unknown,PWHROYKAGRUWDQ-UHFFFAOYSA-N,O=C(CC1CCC(-C2CCCCC2)CC1)NC1CCCCN1;O=C(CC1CCC(CC1)-C1CCCCC1)NC1CCCCN1
DIFLORASONE-DIACETATE,DIFLORASONE-DIACETATE,,BRD:BRD-A66869276-001-02-9;BRD:BRD-BRD-A66869276-001-02-9,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,C[C@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O
DIFLOXACIN,DIFLOXACIN,CHEMBL6259,BRD:BRD-BRD-K73923631-003-02-9;BRD:BRD-K73923631-003-02-9,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,"SKIN INFECTIONS, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Unknown,NOCJXYPHIIZEHN-UHFFFAOYSA-N,CN1CCN(C2CC3C(CC2F)C(=O)C(C(=O)O)CN3-C2CCC(F)CC2)CC1;CN1CCN(CC1)C1CC2N(CC(C(O)=O)C(=O)C2CC1F)-C1CCC(F)CC1
DIFLUNISAL,DIFLUNISAL,CHEMBL898,BRD:BRD-BRD-K22031190-001-23-6;BRD:BRD-K22031190-001-23-6,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,Small molecule,Approved,HUPFGZXOMWLGNK-UHFFFAOYSA-N,O=C(O)C1CC(-C2CCC(F)CC2F)CCC1O;OC(=O)C1CC(CCC1O)-C1CCC(F)CC1F
DIFLUPREDNATE,DIFLUPREDNATE,CHEMBL1201749,BRD:BRD-BRD-K33720171-001-01-0;BRD:BRD-K33720171-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,ENDOGENOUS UVEITIS,,LAUNCHED,,Small molecule,Approved,WYQPLTPSGFELIB-JTQPXKBDSA-N,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C;CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O
DIFTALONE,DIFTALONE,CHEMBL1536675,BRD:BRD-BRD-K80076813-001-08-8;BRD:BRD-K80076813-001-08-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,THYROIDITIS,,LAUNCHED,,Small molecule,Unknown,CXSJGNHRBWJXEA-UHFFFAOYSA-N,O=C1C2CCCCC2CN2C(=O)C3CCCCC3CN12;O=C1N2CC3CCCCC3C(=O)N2CC2CCCCC12
DIGITOXIGENIN,DIGITOXIGENIN,CHEMBL1453,BRD:BRD-BRD-K18518344-001-15-9;BRD:BRD-K18518344-001-15-9,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP1A1,,,PRECLINICAL,,Small molecule,NA,XZTUSOXSLKTKJQ-CESUGQOBSA-N,C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O;C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1
DIGITOXIN,DIGITOXIN,CHEMBL254219,BRD:BRD-A93236127-001-04-5;BRD:BRD-BRD-A93236127-001-04-5,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP1A1,,,LAUNCHED,,Small molecule,Approved,WDJUZGPOPHTGOT-XUDUSOBPSA-N,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O;C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C
DIGOXIGENIN,DIGOXIGENIN,CHEMBL1153;CHEMBL1453,BRD:BRD-BRD-K18619710-001-14-4;BRD:BRD-K18619710-001-14-4,rep_multi_dose;rep_primary;rep_single_dose,STEROID,,,,PRECLINICAL,,Small molecule,NA,SHIBSTMRCDJXLN-KCZCNTNESA-N;XZTUSOXSLKTKJQ-CESUGQOBSA-N,C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2C[C@@H](O)[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O;C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O;C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1
DIGOXIN,DIGOXIN,CHEMBL1697843;CHEMBL1751;CHEMBL2074725,BRD:BRD-A94756469-001-04-7;BRD:BRD-BRD-A94756469-001-04-7;BRD:BRD-K23478508-001-27-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF THE SODIUM-POTASSIUM ATPASE (ATP1A1/ATP1B1, ATP1A2/ATP1B1, ATP1A2/ATP1B3)",ATP1A1;ATP1A2;ATP1B1;ATP1B3,"CONGESTIVE HEART FAILURE, ATRIAL FIBRILLATION (AF)",,LAUNCHED,"Multiple values for MOA: {'ATPASE INHIBITOR', 'INHIBITOR OF THE SODIUM-POTASSIUM ATPASE (ATP1A1/ATP1B1, ATP1A2/ATP1B1, ATP1A2/ATP1B3)'}, defaulting to 'INHIBITOR OF THE SODIUM-POTASSIUM ATPASE (ATP1A1/ATP1B1, ATP1A2/ATP1B1, ATP1A2/ATP1B3)'
Multiple values for repurposing_target: {'ATP1A1', 'ATP1A1;ATP1A2;ATP1B1;ATP1B3'}, taking the union
Multiple values for structure_id: {'A94756469', 'K23478508'}, defaulting to None",Small molecule,Approved,HWKJSYYYURVNQU-DXJNJSHLSA-N;IYJMSDVSVHDVGT-PEQKVOOWSA-N;LTMHDMANZUZIPE-PUGKRICDSA-N,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O;C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C;CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O;CO[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@@H]1C
DIHOMO-GAMMA-LINOLENIC-ACID,DIHOMO-GAMMA-LINOLENIC-ACID,,BRD:BRD-BRD-K20152659-001-04-6;BRD:BRD-K20152659-001-04-6,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,PTGS1;PTGS2,,,PHASE 2,,,NA,,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O
DIHYDREXIDINE,DIHYDREXIDINE,CHEMBL25856,BRD:BRD-K31471398-003-06-9,rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD1;DRD2;DRD3;DRD4;DRD5,,,,,Small molecule,Phase 2,BGOQGUHWXBGXJW-RHSMWYFYSA-N,OC1CC2C(CC1O)[C@H]1C3CCCCC3CN[C@@H]1CC2
DIHYDROARTEMISININ,DIHYDROARTEMISININ,CHEMBL252518,BRD:BRD-BRD-K62213621-001-01-6;BRD:BRD-K62213621-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,ANTIMALARIAL AGENT,,MALARIA,,LAUNCHED,,Small molecule,Approved,BJDCWCLMFKKGEE-CMDXXVQNSA-N,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4;C[C@H]1[C@@H](O)O[C@@H]2O[C@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3
DIHYDROERGOCRISTINE,DIHYDROERGOCRISTINE,CHEMBL601773,BRD:BRD-BRD-K97440753-066-18-1;BRD:BRD-K97440753-066-18-1,rep_multi_dose;rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, PROLACTIN INHIBITOR",ADRA1A;ADRB1;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR2A;HTR3A;HTR4;HTR5A;HTR6;HTR7,,,LAUNCHED,,Small molecule,Unknown,DEQITUUQPICUMR-HJPBWRTMSA-N,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3C4CCCC5[NH]CC(C45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3CCCCC3)N2C1=O;CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](CC4C[NH]C5CCCC3C45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3CCCCC3)N2C1=O
DIHYDROERGOTAMINE,DIHYDROERGOTAMINE,CHEMBL1732,BRD:BRD-BRD-K72166146-066-05-4;BRD:BRD-K72166146-066-05-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,ADRA2A;DRD2;HTR1B;HTR1D;HTR1E;HTR1F;HTR2B;HTR7,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,LUZRJRNZXALNLM-JGRZULCMSA-N,CN1C[C@@H](C[C@H]2[C@H]1CC1C[NH]C3CCCC2C13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](CC3CCCCC3)N2C1=O;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4CCCCC4)N3C2=O)C[C@@H]2C3CCCC4[NH]CC(C34)C[C@H]21
DIHYDROMYRICETIN,DIHYDROMYRICETIN,CHEMBL3348861,BRD:BRD-BRD-K01614093-001-02-6;BRD:BRD-K01614093-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Phase 2,KJXSIXMJHKAJOD-LSDHHAIUSA-N,O[C@@H]1[C@H](OC2CC(O)CC(O)C2C1=O)C1CC(O)C(O)C(O)C1;O=C1C2C(O)CC(O)CC2O[C@H](C2CC(O)C(O)C(O)C2)[C@H]1O
DIHYDROROTENONE,DIHYDROROTENONE,CHEMBL3039021,GDSC2:1827,gdsc,,,,,,,Small molecule,NA,DTFARBHXORYQBF-XHEPWMPHSA-N,COC1CC2C(CC1OC)[C@@H]1C(=O)C3CCC4C(C3O[C@@H]1CO2)CC(C(C)C)O4
DIHYDROSTREPTOMYCIN,DIHYDROSTREPTOMYCIN,CHEMBL1950576,BRD:BRD-A67363467-001-01-3;BRD:BRD-BRD-A67363467-001-01-3,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,,,WITHDRAWN,,Small molecule,Approved,ASXBYYWOLISCLQ-HZYVHMACSA-N,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O;CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO
DIHYDROTESTOSTERONE,DIHYDROTESTOSTERONE,CHEMBL27769,BRD:BRD-BRD-K22525962-001-05-0;BRD:BRD-K22525962-001-05-0,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR;HSD17B1,"TETANY, HYPOPARATHYROIDISM",,LAUNCHED,,Small molecule,Phase 2,NVKAWKQGWWIWPM-ABEVXSGRSA-N,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O;C[C@]12CCC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12
DIHYDROXYACETONE,DIHYDROXYACETONE,CHEMBL1229937,BRD:BRD-K18637542-001-01-7,rep_single_dose,,,,,,,Small molecule,Approved,RXKJFZQQPQGTFL-UHFFFAOYSA-N,O=C(CO)CO
DIHYDROXYPHENYLGLYCINE,DIHYDROXYPHENYLGLYCINE,,BRD:BRD-A20589515-001-03-9,rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM1;GRM5,,,,,,NA,,
DILAZEP,DILAZEP,CHEMBL126075,BRD:BRD-BRD-K48722258-300-10-2;BRD:BRD-K48722258-300-10-2,rep_primary;rep_single_dose,ADENOSINE REUPTAKE INHIBITOR,SLC29A1,,,LAUNCHED,,Small molecule,Unknown,QVZCXCJXTMIDME-UHFFFAOYSA-N,COC1CC(C(=O)OCCCN2CCCN(CCCOC(=O)C3CC(OC)C(OC)C(OC)C3)CC2)CC(OC)C1OC;COC1CC(CC(OC)C1OC)C(=O)OCCCN1CCCN(CCCOC(=O)C2CC(OC)C(OC)C(OC)C2)CC1
DILMAPIMOD,DILMAPIMOD,CHEMBL2103838,BRD:BRD-K00003459-001-01-9,rep_single_dose,P38 MAPK INHIBITOR,,,,,,Small molecule,Phase 2,ORVNHOYNEHYKJG-UHFFFAOYSA-N,CC1CC(F)CCC1-C1NC(NC(CO)CO)NC2C1CCC(=O)N2-C1C(F)CCCC1F
DILOXANIDE,DILOXANIDE,CHEMBL2103768,BRD:BRD-BRD-K10974103-001-21-1;BRD:BRD-K10974103-001-21-1,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,AMEBIASIS,,LAUNCHED,,Small molecule,Unknown,GZZZSOOGQLOEOB-UHFFFAOYSA-N,CN(C(=O)C(CL)CL)C1CCC(O)CC1;CN(C(=O)C(CL)CL)C1CCC(OC(=O)C2CCCO2)CC1
DILTIAZEM,DILTIAZEM,CHEMBL23,BRD:BRD-A69636825-003-04-7;BRD:BRD-BRD-A69636825-003-04-7,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1S;CACNA2D1;CACNG1;HTR3A;KCNA5,"HYPERTENSION, ANGINA PECTORIS",,LAUNCHED,,Small molecule,Approved,HSUGRBWQSSZJOP-RTWAWAEBSA-N,COC1CCC([C@@H]2SC3CCCCC3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)CC1;COC1CCC(CC1)[C@@H]1SC2CCCCC2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O;COC1CCC(CC1)C1SC2CCCCC2N(CCN(C)C)C(=O)C1OC(C)=O
DIM-C-PPHCO2ME,DIM-C-PPHCO2ME,,BRD:BRD-K00005337-001-01-9,rep_single_dose,NUCLEAR RECEPTOR ANTAGONIST,,,,,,,NA,,
DIMAPRIT,DIMAPRIT,CHEMBL12344,BRD:BRD-BRD-K23541596-300-07-2;BRD:BRD-K23541596-300-07-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH2;HRH3;HRH4,,,PRECLINICAL,,Small molecule,NA,OLHQOJYVQUNWPL-UHFFFAOYSA-N,CN(C)CCCSC(=N)N;CN(C)CCCSC(N)=N
DIMEMORFAN,DIMEMORFAN,CHEMBL2106325,BRD:BRD-BRD-K29812331-011-01-7;BRD:BRD-K29812331-011-01-7,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,SIGMAR1,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Unknown,KBEZZLAAKIIPFK-NJAFHUGGSA-N,CC1CCC2C(C1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3;CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC1CCC(C)CC31
DIMERCAPROL,DIMERCAPROL,CHEMBL1597,BRD:BRD-A56152450-001-02-0;BRD:BRD-BRD-A56152450-001-02-0,rep_primary;rep_single_dose,CHELATING AGENT,,METAL TOXICITY,,LAUNCHED,,Small molecule,Approved,WQABCVAJNWAXTE-UHFFFAOYSA-N,OCC(S)CS
DIMERCAPTOSUCCINIC-ACID,DIMERCAPTOSUCCINIC-ACID,,BRD:BRD-BRD-K88701661-001-02-9;BRD:BRD-K88701661-001-02-9,rep_primary;rep_single_dose,CHELATING AGENT,DNMT1,METAL TOXICITY,,LAUNCHED,,,NA,,OC(=O)[C@@H](S)[C@@H](S)C(O)=O
DIMESNA,DIMESNA,CHEMBL2009034;CHEMBL2104318,BRD:BRD-BRD-K30126819-304-02-7;BRD:BRD-K30126819-304-02-7,rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,BYUKOOOZTSTOOH-UHFFFAOYSA-N;KQYGMURBTJPBPQ-UHFFFAOYSA-L,O=S(=O)([O-])CCSSCCS(=O)(=O)[O-].[NA+].[NA+];O=S(=O)(O)CCSSCCS(=O)(=O)O;OS(=O)(=O)CCSSCCS(O)(=O)=O
DIMETHINDENE-(S)-(+),DIMETHINDENE-(S)-(+),,BRD:BRD-BRD-K83192048-050-02-7;BRD:BRD-K83192048-050-02-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,HRH1,,,PRECLINICAL,,,NA,,C[C@@H](C1=C(CCN(C)C)CC2CCCCC12)C1CCCCN1
DIMETHISOQUIN,DIMETHISOQUIN,CHEMBL127643,BRD:BRD-BRD-K73391359-003-10-2;BRD:BRD-K73391359-003-10-2,rep_multi_dose;rep_primary;rep_single_dose,LOCAL ANESTHETIC,,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Unknown,XNMYNYSCEJBRPZ-UHFFFAOYSA-N,CCCCC1CC2CCCCC2C(OCCN(C)C)N1
DIMETHYL-FUMARATE,DIMETHYL-FUMARATE,,BRD:BRD-BRD-K31111078-001-04-2;BRD:BRD-K31111078-001-04-2,rep_primary;rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",KEAP1,MULTIPLE SCLEROSIS,,LAUNCHED,"Multiple values for MOA: {'NUCLEAR FACTOR ERYTHROID DERIVED, LIKE (NRF2) ACTIVATOR', 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'}, defaulting to 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'",,NA,,COC(=O)\C=C\C(=O)OC
DIMETHYLOXALYLGLCINE,DIMETHYLOXALYLGLCINE,,GDSC1:165,gdsc,,,,,,,,NA,,
DIMETRIDAZOLE,DIMETRIDAZOLE,CHEMBL38938,BRD:BRD-BRD-K72728560-001-01-4;BRD:BRD-K72728560-001-01-4,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,IBXPYPUJPLLOIN-UHFFFAOYSA-N,CC1NCC([N+](=O)[O-])N1C;CC1NCC(N1C)[N+]([O-])=O
DIMINAZENE-ACETURATE,DIMINAZENE-ACETURATE,,BRD:BRD-BRD-K92848252-001-01-9;BRD:BRD-K92848252-001-01-9,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME ACTIVATOR,AOC1;PRDX5;PRSS1,,,PHASE 3,,,NA,,NC(=N)C1CCC(N\N=N\C2CCC(CC2)C(N)=N)CC1
DIMPYLATE,DIMPYLATE,CHEMBL388560,BRD:BRD-BRD-K60567437-001-10-2;BRD:BRD-K60567437-001-10-2,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,LAUNCHED,,Small molecule,Unknown,FHIVAFMUCKRCQO-UHFFFAOYSA-N,CCOP(=S)(OCC)OC1CC(C)NC(C(C)C)N1;CCOP(=S)(OCC)OC1CC(C)NC(N1)C(C)C
DINACICLIB,DINACICLIB,CHEMBL2103840,BRD:BRD-BRD-K13662825-001-07-5;BRD:BRD-K13662825-001-07-5;CTRP:687578;GDSC2:1180,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK5;CDK9,,,PHASE 3,,Small molecule,Phase 3,PIMQWRZWLQKKBJ-SFHVURJKSA-N,CCC1CNN2C(NCC3CCC[N+]([O-])C3)CC(N3CCCC[C@H]3CCO)NC12;CCC1CNN2C(NCC3CCC[N+]([O-])C3)CC(NC12)N1CCCC[C@H]1CCO
DINITOLMIDE,DINITOLMIDE,CHEMBL472565,BRD:BRD-BRD-K93240442-001-08-4;BRD:BRD-K93240442-001-08-4,rep_primary;rep_single_dose,,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,ZEFNOZRLAWVAQF-UHFFFAOYSA-N,CC1C(C(N)=O)CC([N+](=O)[O-])CC1[N+](=O)[O-];CC1C(CC(CC1[N+]([O-])=O)[N+]([O-])=O)C(N)=O
DINOPROST,DINOPROST,CHEMBL815,BRD:BRD-BRD-K81672972-001-03-1;BRD:BRD-K81672972-001-03-1,rep_primary;rep_single_dose,PROSTACYCLIN ANALOG,PTGDR;PTGDR2;PTGER1;PTGER2;PTGER3;PTGER4;PTGFR;PTGIR;TBXA2R,LABOR INDUCTION,,LAUNCHED,,Small molecule,Approved,PXGPLTODNUVGFL-YNNPMVKQSA-N,CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O;CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
DINOPROSTONE,DINOPROSTONE,CHEMBL548,BRD:BRD-BRD-K26521938-001-09-8;BRD:BRD-K26521938-001-09-8,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,CATSPER1;CATSPER2;CATSPER3;CATSPER4;PTGDR;PTGDR2;PTGER1;PTGER2;PTGER3;PTGER4;PTGFR;TBXA2R,,,WITHDRAWN,,Small molecule,Approved,XEYBRNLFEZDVAW-ARSRFYASSA-N,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O;CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
DINOTEFURAN,DINOTEFURAN,CHEMBL2228155,BRD:BRD-K00084839-001-01-9,rep_single_dose,,,,,,,Small molecule,NA,YKBZOVFACRVRJN-UHFFFAOYSA-N,CN/C(=N/CC1CCOC1)N[N+](=O)[O-]
DIOSCIN,DIOSCIN,CHEMBL507001,BRD:BRD-BRD-K37723606-001-01-5;BRD:BRD-K37723606-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,APOPTOSIS STIMULANT,CXCR3,,,PRECLINICAL,,Small molecule,NA,VNONINPVFQTJOC-ZGXDEBHDSA-N,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1;C[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O[C@@H]7O[C@@H](C)[C@H](O)[C@@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C
DIOSGENIN,DIOSGENIN,CHEMBL412437,BRD:BRD-BRD-K28690501-001-02-1;BRD:BRD-K28690501-001-02-1,rep_primary;rep_single_dose,STEROID,,,,PRECLINICAL,,Small molecule,NA,WQLVFSAGQJTQCK-VKROHFNGSA-N,C[C@@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C;C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1
DIOSMETIN,DIOSMETIN,CHEMBL90568,BRD:BRD-BRD-K26862302-001-05-2;BRD:BRD-K26862302-001-05-2,rep_primary;rep_single_dose,ARYL HYDROCARBON RECEPTOR AGONIST,CYP1B1,COSMETIC,,LAUNCHED,,Small molecule,NA,MBNGWHIJMBWFHU-UHFFFAOYSA-N,COC1CCC(-C2CC(=O)C3C(O)CC(O)CC3O2)CC1O;COC1CCC(CC1O)-C1CC(=O)C2C(O)CC(O)CC2O1
DIOSMIN,DIOSMIN,CHEMBL231884,BRD:BRD-BRD-K94436377-001-10-2;BRD:BRD-K94436377-001-10-2,rep_primary;rep_single_dose,"ARYL HYDROCARBON RECEPTOR AGONIST, CAPILLARY STABILIZING AGENT",AHR,"CHRONIC VENOUS INSUFFICIENCY (CVI), EDEMA, DEEP VEIN THROMBOSIS (DVT), STATIS DERMATITIS, HEAVY LEG SYNDROME",,LAUNCHED,,Small molecule,Approved,GZSOSUNBTXMUFQ-YFAPSIMESA-N,COC1CCC(-C2CC(=O)C3C(O)CC(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)CC3O2)CC1O;COC1CCC(CC1O)-C1CC(=O)C2C(O)CC(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)CC2O1
DIOXYBENZONE,DIOXYBENZONE,CHEMBL1326877,BRD:BRD-BRD-K22193694-001-13-6;BRD:BRD-K22193694-001-13-6,rep_primary;rep_single_dose,TOPICAL SUNSCREEN AGENT,,,,PRECLINICAL,,Small molecule,Unknown,MEZZCSHVIGVWFI-UHFFFAOYSA-N,COC1CCC(C(=O)C2CCCCC2O)C(O)C1
DIPEPTAMIN,DIPEPTAMIN,CHEMBL3707366,BRD:BRD-BRD-K11595419-001-01-4;BRD:BRD-K11595419-001-01-4,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Phase 3,HJCMDXDYPOUFDY-WHFBIAKZSA-N,C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)O;C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O
DIPERODON,DIPERODON,CHEMBL338667,BRD:BRD-A30693873-003-12-8;BRD:BRD-BRD-A30693873-003-12-8,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,Small molecule,Unknown,YUGZHQHSNYIFLG-UHFFFAOYSA-N,O=C(NC1CCCCC1)OCC(CN1CCCCC1)OC(=O)NC1CCCCC1
DIPHEMANIL,DIPHEMANIL,CHEMBL1201340,BRD:BRD-BRD-K93441486-067-12-8;BRD:BRD-K93441486-067-12-8,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM3,SPASMS,,LAUNCHED,,Small molecule,Approved,LCTZPQRFOZKZNK-UHFFFAOYSA-N,C[N+]1(C)CCC(=C(C2CCCCC2)C2CCCCC2)CC1;C[N+]1(C)CCC(CC1)=C(C1CCCCC1)C1CCCCC1
DIPHENCYPRONE,DIPHENCYPRONE,,BRD:BRD-BRD-K51730347-001-06-4;BRD:BRD-K51730347-001-06-4,rep_primary;rep_single_dose,IMMUNOSTIMULANT,,,,PHASE 2,,,NA,,O=C1C(C1-C1CCCCC1)-C1CCCCC1
DIPHENHYDRAMINE,DIPHENHYDRAMINE,CHEMBL1201089;CHEMBL657,BRD:BRD-BRD-K47278471-003-26-3;BRD:BRD-K47278471-003-26-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,HEADACHE,,LAUNCHED,,Small molecule,Approved,SPCKHVPPRJWQRZ-UHFFFAOYSA-N;ZZVUWRFHKOJYTH-UHFFFAOYSA-N,CN(C)CCOC(C1CCCCC1)C1CCCCC1;CN(C)CCOC(C1CCCCC1)C1CCCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
DIPHENIDOL,DIPHENIDOL,CHEMBL936,BRD:BRD-BRD-K01663662-003-20-2;BRD:BRD-K01663662-003-20-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4,VERTIGO,,LAUNCHED,,Small molecule,Approved,OGAKLTJNUQRZJU-UHFFFAOYSA-N,OC(CCCN1CCCCC1)(C1CCCCC1)C1CCCCC1
DIPHENYLENEIODONIUM,DIPHENYLENEIODONIUM,CHEMBL365739,BRD:BRD-BRD-K65814004-003-02-9;BRD:BRD-K65814004-003-02-9,rep_multi_dose;rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS2;NOS3,,,PRECLINICAL,,Small molecule,NA,QFXKXRXFBRLLPQ-UHFFFAOYSA-N,[I+]1C2CCCCC2-C2CCCCC12;C1CCC2C(C1)[I+]C1CCCCC1-2
DIPHENYLPYRALINE,DIPHENYLPYRALINE,CHEMBL1492,BRD:BRD-BRD-K22936972-003-23-6;BRD:BRD-K22936972-003-23-6,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR",HRH1;SLC6A3,ALLERGIC RHINITIS,,LAUNCHED,"Multiple values for MOA: {'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR', 'DOPAMINE UPTAKE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR'",Small molecule,Approved,OWQUZNMMYNAXSL-UHFFFAOYSA-N,CN1CCC(CC1)OC(C1CCCCC1)C1CCCCC1;CN1CCC(OC(C2CCCCC2)C2CCCCC2)CC1
DIPIVEFRINE,DIPIVEFRINE,CHEMBL1201262,BRD:BRD-A47494775-003-11-3;BRD:BRD-BRD-A47494775-003-11-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ACHE;ADRA1A;ADRA2A;ADRB2;BCHE,"GLAUCOMA, INTRAOCULAR PRESSURE",,LAUNCHED,,Small molecule,Approved,OCUJLLGVOUDECM-UHFFFAOYSA-N,CNCC(O)C1CCC(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)C1
DIPRAGLURANT,DIPRAGLURANT,CHEMBL2346738,BRD:BRD-BRD-K64838454-001-01-0;BRD:BRD-K64838454-001-01-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATOR,GRM5,,,PHASE 2,,Small molecule,Phase 2,LZXMUJCJAWVHPZ-UHFFFAOYSA-N,FC1CCC2NC(CCC#CC3CCCCN3)CN2C1
DIPT,DIPT,,BRD:BRD-BRD-K75385383-001-01-5;BRD:BRD-K75385383-001-01-5,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, SEROTONIN REUPTAKE INHIBITOR",HTR1A;HTR2A;HTR2C,,,LAUNCHED,,,NA,,CC(C)N(CCC1C[NH]C2CCCCC12)C(C)C
DIPYRIDAMOLE,DIPYRIDAMOLE,CHEMBL932,BRD:BRD-BRD-K86301799-001-34-8;BRD:BRD-K86301799-001-34-8,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,ADA;PDE10A;PDE1A;PDE1B;PDE1C;PDE2A;PDE3A;PDE3B;PDE4A;PDE4B;PDE4C;PDE4D;PDE5A;PDE6A;PDE6B;PDE6C;PDE6D;PDE6G;PDE6H;PDE7A;PDE7B;PDE8A;PDE8B;PDE9A;SLC29A1,"CORONARY ARTERY DISEASE (CAD), PERIPHERAL ARTERY DISEASE (PAD), HYPERTENSION",,LAUNCHED,,Small molecule,Approved,IZEKFCXSFNUWAM-UHFFFAOYSA-N,OCCN(CCO)C1NC(N2CCCCC2)C2NC(N(CCO)CCO)NC(N3CCCCC3)C2N1;OCCN(CCO)C1NC(N2CCCCC2)C2NC(NC(N3CCCCC3)C2N1)N(CCO)CCO
DIPYROCETYL,DIPYROCETYL,CHEMBL1451173,BRD:BRD-K47608922-001-05-9,rep_single_dose,CHELATING AGENT,,,,,,Small molecule,Unknown,NYIZXMGNIUSNKL-UHFFFAOYSA-N,CC(=O)OC1CCCC(C(=O)O)C1OC(C)=O
DIQUAFOSOL,DIQUAFOSOL,CHEMBL221326,BRD:BRD-K00003514-342-01-9,rep_single_dose,PURINERGIC RECEPTOR ACTIVATOR,,,,,,Small molecule,Phase 3,NMLMACJWHPHKGR-NCOIDOBVSA-N,O=C1CCN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](N4CCC(=O)[NH]C4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C(=O)[NH]1
DIRITHROMYCIN,DIRITHROMYCIN,CHEMBL1237072;CHEMBL3039471,BRD:BRD-BRD-K52756523-001-24-7;BRD:BRD-K52756523-001-24-7,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,BRONCHITIS,,LAUNCHED,,Small molecule,Approved,WLOHNSSYAXHWNR-DWIOZXRMSA-N;WLOHNSSYAXHWNR-GDLCQVGZSA-N,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
DIROXIMEL-FUMARATE,DIROXIMEL-FUMARATE,,BRD:BRD-BRD-K87386013-001-01-7;BRD:BRD-K87386013-001-01-7,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,PHASE 3,,,NA,,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O
DISOPYRAMIDE,DISOPYRAMIDE,CHEMBL517,BRD:BRD-A29734509-011-13-6;BRD:BRD-BRD-A29734509-011-13-6,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,CHRM1;CHRM2;CHRM3;KCND2;KCND3;KCNH2;SCN5A,"VENTRICULAR TACHYCARDIA (VT), VENTRICULAR ARRHYTHMIAS",,LAUNCHED,,Small molecule,Approved,UVTNFZQICZKOEM-UHFFFAOYSA-N,CC(C)N(CCC(C(N)=O)(C1CCCCC1)C1CCCCN1)C(C)C
TETRAETHYLDISULFANEDICARBOTHIOAMIDE,DISULFIRAM;TETRAETHYLDISULFANEDICARBOTHIOAMIDE,CHEMBL964,BRD:BRD-BRD-K32744045-001-31-2;BRD:BRD-K32744045-001-31-2;BRD:BRD-K32744045-001-38-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"ALDEHYDE DEHYDROGENASE INHIBITOR, DNA METHYLTRANSFERASE INHIBITOR, TRPV AGONIST",ALDH1A1;ALDH2;DBH,ABSTINENCE FROM ALCOHOL,,LAUNCHED,"Multiple values for MOA: {'COPPER IONOPHORE; INHIBITOR OF ALDEHYDE DEHYDROGENASE', 'ALDEHYDE DEHYDROGENASE INHIBITOR, DNA METHYLTRANSFERASE INHIBITOR, TRPV AGONIST'}, defaulting to 'ALDEHYDE DEHYDROGENASE INHIBITOR, DNA METHYLTRANSFERASE INHIBITOR, TRPV AGONIST'
Multiple values for repurposing_target: {'ALDH1A1', 'ALDH2;DBH'}, taking the union",Small molecule,Approved,AUZONCFQVSMFAP-UHFFFAOYSA-N,CCN(CC)C(=S)SSC(=S)N(CC)CC
DITIOCARB-SODIUM-TRIHYDRATE,DITIOCARB-SODIUM-TRIHYDRATE,,BRD:BRD-BRD-K40654626-236-01-5;BRD:BRD-K40654626-236-01-5,rep_primary;rep_single_dose,IMMUNOSTIMULANT,CA1;CA2;CA4,,,PHASE 3,,,NA,,CCN(CC)C(S)=S
DITOLYLGUANIDINE,DITOLYLGUANIDINE,CHEMBL282433,BRD:BRD-BRD-K33459542-001-07-4;BRD:BRD-K33459542-001-07-4,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,GRIN1;GRIN2A;GRIN2B;SIGMAR1,,,PRECLINICAL,,Small molecule,NA,OPNUROKCUBTKLF-UHFFFAOYSA-N,CC1CCCCC1NC(=N)NC1CCCCC1C
GDC-6036,DIVARASIB;GDC-6036,CHEMBL5095236,BRD:BRD-K00126478-001-01-9,oncref_2,INHIBITOR OF KRAS-G12C,KRAS,,,,,Small molecule,Phase 2,ZRBPIAWWRPFDPY-IRXDYDNUSA-N,C=CC(=O)N1CCN(C2NC(OC[C@@H]3CCCN3C)NC3C(F)C(-C4NC(N)CC(C)C4C(F)(F)F)C(CL)CC23)[C@@H](C)C1
DIXANTHOGEN,DIXANTHOGEN,CHEMBL331743,BRD:BRD-BRD-K05919151-001-01-6;BRD:BRD-K05919151-001-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,FVIGODVHAVLZOO-UHFFFAOYSA-N,CCOC(=S)SSC(=S)OCC
DIXYRAZINE,DIXYRAZINE,CHEMBL3275586,BRD:BRD-K00003339-001-01-9,rep_single_dose,ANTIPSYCHOTIC,,,,,,Small molecule,Unknown,MSYUMPGNGDNTIQ-UHFFFAOYSA-N,CC(CN1CCN(CCOCCO)CC1)CN1C2CCCCC2SC2CCCCC21
DIZOCILPINE-(+),DIZOCILPINE-(+),,BRD:BRD-BRD-K58930050-050-15-8;BRD:BRD-K58930050-050-15-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PRECLINICAL,,,NA,,C[C@]12N[C@H](CC3CCCCC13)C1CCCCC21
DIZOCILPINE-(-),DIZOCILPINE-(-),,BRD:BRD-BRD-K23163214-050-15-1;BRD:BRD-K23163214-050-15-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,C[C@@]12N[C@@H](CC3CCCCC13)C1CCCCC21
DM4,DM4,,BRD:BRD-K00090635-001-01-9,rep_single_dose,,,,,,,,NA,,
DMAB-ANABASEINE,DMAB-ANABASEINE,,BRD:BRD-BRD-K26573499-300-02-1;BRD:BRD-K26573499-300-02-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,CHRNA7,,,PRECLINICAL,,,NA,,CN(C)C1CCC(CC1)\C=C1CCCN=C/1C1CCCNC1
DMEOB,DMEOB,,BRD:BRD-BRD-K36775483-001-01-4;BRD:BRD-K36775483-001-01-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,GRM5,,,PRECLINICAL,,,NA,,COC1CCCC(C1)\C=N\N=C\C1CCCC(OC)C1
DMH1,DMH1,,BRD:BRD-BRD-K39381259-001-01-0;BRD:BRD-K39381259-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ACVR1,,,PRECLINICAL,,,NA,,CC(C)OC1CCC(CC1)-C1CNC2C(CNN2C1)-C1CCNC2CCCCC12
DMH4,DMH4,,BRD:BRD-BRD-K40575944-001-01-5;BRD:BRD-K40575944-001-01-5,rep_primary;rep_single_dose,VEGFR INHIBITOR,KDR,,,PRECLINICAL,,,NA,,C(CN1CCOCC1)OC1CCC(CC1)-C1CNC2C(CNN2C1)-C1CCCCC1
DMNB,DMNB,,BRD:BRD-BRD-K03564313-001-03-3;BRD:BRD-K03564313-001-03-3,rep_primary;rep_single_dose,DNA DEPENDENT PROTEIN KINASE INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CC(C=O)C(CC1OC)[N+]([O-])=O
DMOG,DMOG,,GDSC1:165,gdsc,,,,,,,,NA,,
DMP-543,DMP-543,,BRD:BRD-BRD-K89274813-001-02-3;BRD:BRD-K89274813-001-02-3,rep_primary;rep_single_dose,ACETYLCHOLINE RELEASE ENHANCER,,,,PHASE 2,,,NA,,FC1CC(CC2(CC3CCNC(F)C3)C3CCCCC3C(=O)C3CCCCC23)CCN1
DMP-777,DMP-777,,BRD:BRD-BRD-K54936858-001-01-6;BRD:BRD-K54936858-001-01-6,rep_primary;rep_single_dose,ELASTASE INHIBITOR,MPO,,,PHASE 2,,,NA,,CCC[C@@H](NC(=O)N1[C@@H](OC2CCC(CC2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)C1CCC2OCOC2C1
DMPS,DMPS,,BRD:BRD-A22971209-001-01-0,rep_single_dose,CHELATING AGENT,,,,,,,NA,,
DNQX,DNQX,CHEMBL155265,BRD:BRD-BRD-K64400208-001-08-3;BRD:BRD-K64400208-001-08-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIK1;GRIN1;GRIN2A;GRIN2B,,,PRECLINICAL,,Small molecule,NA,RWVIMCIPOAXUDG-UHFFFAOYSA-N,[O-][N+](=O)C1CC2[NH]C(=O)C(=O)[NH]C2CC1[N+]([O-])=O;O=[N+]([O-])C1CC2NC(O)C(O)NC2CC1[N+](=O)[O-]
DOBUTAMINE,DOBUTAMINE,CHEMBL926,BRD:BRD-A78322124-003-14-0;BRD:BRD-BRD-A78322124-003-14-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Approved,JRWZLRBJNMZMFE-UHFFFAOYSA-N,CC(CCC1CCC(O)CC1)NCCC1CCC(O)C(O)C1
DOCETAXEL,DOCETAXEL,CHEMBL3545252;CHEMBL92,BRD:BRD-BRD-K30577245-001-04-3;BRD:BRD-BRD-K30577245-341-01-9;BRD:BRD-K30577245-001-04-3;BRD:BRD-K30577245-001-05-0;BRD:BRD-K30577245-341-01-9;CTRP:660364;GDSC1:1007;GDSC2:1007;GDSC2:1819,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,BCL2;MAP2;MAP4;MAPT;NR1I2;TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,"BREAST CANCER, NON-SMALL CELL LUNG CANCER (NSCLC), PROSTATE CANCER, GASTRIC ADENOCARCINOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)",,LAUNCHED,"Multiple values for repurposing_target: {'BCL2;MAP2;MAP4;MAPT;NR1I2;TUBB;TUBB1', 'BCL2;MAP2;MAP4;MAPT;NR1I2;TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8'}, taking the union",Small molecule,Approved,XCDIRYDKECHIPE-QHEQPUDQSA-N;ZDZOTLJHXYCWBA-VCVYQWHSSA-N,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2CCCCC2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3CCCCC3)C(C)=C([C@@H](O)C1=O)C2(C)C;CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C[C@@](O)([C@@H](OC(=O)C4CCCCC4)[C@H]21)C3(C)C;CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C[C@@](O)([C@@H](OC(=O)C4CCCCC4)[C@H]21)C3(C)C.O.O.O
DOCETAXEL:TANESPIMYCIN (2:1 MOL/MOL),DOCETAXEL:TANESPIMYCIN (2:1 MOL/MOL),,CTRP:660217,ctrp,,,,,,,,NA,,
DOCONEXENT-ETHYL-ESTER,DOCONEXENT-ETHYL-ESTER,,BRD:BRD-BRD-K61937613-001-01-1;BRD:BRD-K61937613-001-01-1,rep_primary;rep_single_dose,OMEGA 3 FATTY ACID STIMULANT,,,,LAUNCHED,,,NA,,CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
DOCOSANOL,DOCOSANOL,CHEMBL1200453,BRD:BRD-BRD-K50050533-001-02-1;BRD:BRD-K50050533-001-02-1,rep_primary;rep_single_dose,LIPASE CLEARING FACTOR INHIBITOR,TLR7,COLD SORE,,LAUNCHED,,Small molecule,Approved,NOPFSRXAKWQILS-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCCCCCCO
DOCUSATE,DOCUSATE,CHEMBL1477036,BRD:BRD-A00092689-236-04-9,rep_single_dose,LAXATIVE,,,,,,Small molecule,Approved,HNSDLXPSAYFUHK-UHFFFAOYSA-N,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O
DOFEQUIDAR,DOFEQUIDAR,CHEMBL65067,BRD:BRD-A14941520-051-01-0;BRD:BRD-BRD-A14941520-051-01-0,rep_primary;rep_single_dose,"MRP INHIBITOR, P GLYCOPROTEIN INHIBITOR",ABCB1,,,PHASE 3,,Small molecule,Phase 1,KLWUUPVJTLHYIM-UHFFFAOYSA-N,O=C(C(C1CCCCC1)C1CCCCC1)N1CCN(CC(O)COC2CCCC3NCCCC23)CC1;OC(COC1CCCC2NCCCC12)CN1CCN(CC1)C(=O)C(C1CCCCC1)C1CCCCC1
DOFETILIDE,DOFETILIDE,CHEMBL473,BRD:BRD-BRD-K86887724-001-10-6;BRD:BRD-K86887724-001-10-6,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNH1;KCNH2;KCNJ12;KCNK2,,,WITHDRAWN,,Small molecule,Approved,IXTMWRCNAAVVAI-UHFFFAOYSA-N,CN(CCOC1CCC(NS(C)(=O)=O)CC1)CCC1CCC(NS(C)(=O)=O)CC1
DOLASETRON,DOLASETRON,CHEMBL2368925,BRD:BRD-BRD-K28029915-001-02-2;BRD:BRD-K28029915-001-02-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,UKTAZPQNNNJVKR-KJGYPYNMSA-N,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)C1C[NH]C2CCCCC12;O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)C1C[NH]C2CCCCC12
DOLASTATIN-10,DOLASTATIN-10,CHEMBL39541,BRD:BRD-BRD-K78567475-001-01-4;BRD:BRD-K78567475-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,,,PHASE 2,,Small molecule,Phase 2,OFDNQWIFNXBECV-VFSYNPLYSA-N,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1CCCCC1)C1NCCS1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
DOLUTEGRAVIR,DOLUTEGRAVIR,CHEMBL1229211,BRD:BRD-BRD-K36386086-001-01-1;BRD:BRD-K36386086-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,CYP3A4;CYP3A5;CYP3A7;POU2F2;UGT1A1,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,RHWKPHLQXYSBKR-BMIGLBTASA-N,C[C@@H]1CCO[C@H]2CN3CC(C(=O)NCC4CCC(F)CC4F)C(=O)C(O)C3C(=O)N12;C[C@H]1CCO[C@H]2CN3CC(C(=O)NCC4CCC(F)CC4F)C(=O)C(O)C3C(=O)N12
DOMIPHEN,DOMIPHEN,CHEMBL1187011,BRD:BRD-BRD-K30431096-004-01-3;BRD:BRD-K30431096-004-01-3,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Approved,YXUPZGKORWTXID-UHFFFAOYSA-N,CCCCCCCCCCCC[N+](C)(C)CCOC1CCCCC1
DOMPERIDONE,DOMPERIDONE,CHEMBL219916,BRD:BRD-BRD-K38305202-001-17-4;BRD:BRD-K38305202-001-17-4,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3,FESCUE TOXICOSIS,,LAUNCHED,,Small molecule,Approved,FGXWKSZFVQUSTL-UHFFFAOYSA-N,CLC1CCC2N(C3CCN(CCCN4C5CCCCC5[NH]C4=O)CC3)C(=O)[NH]C2C1;O=C1[NH]C2CCCCC2N1CCCN1CCC(N2C(=O)[NH]C3CC(CL)CCC32)CC1
DONEPEZIL,DONEPEZIL,CHEMBL502,BRD:BRD-A49160188-003-12-7;BRD:BRD-BRD-A49160188-003-12-7,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;HTR2A,ALZHEIMER'S DISEASE,,LAUNCHED,,Small molecule,Approved,ADEBPBSSDYVVLD-UHFFFAOYSA-N,COC1CC2C(CC1OC)C(=O)C(CC1CCN(CC3CCCCC3)CC1)C2;COC1CC2CC(CC3CCN(CC4CCCCC4)CC3)C(=O)C2CC1OC
DONITRIPTAN,DONITRIPTAN,CHEMBL1742428,BRD:BRD-BRD-K31092604-003-03-5;BRD:BRD-K31092604-003-03-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR5A;HTR6,,,PHASE 2,,Small molecule,Phase 2,SOHCKWZVTCTQBG-UHFFFAOYSA-N,N#CC1CCC(N2CCN(C(=O)COC3CCC4[NH]CC(CCN)C4C3)CC2)CC1;NCCC1C[NH]C2CCC(OCC(=O)N3CCN(CC3)C3CCC(CC3)C#N)CC12
DOPAMINE,DOPAMINE,CHEMBL59,BRD:BRD-BRD-K43887077-003-26-3;BRD:BRD-K43887077-003-26-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DBH;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR7;SLC6A2;SLC6A3;SLC6A4,"VENTRICULAR ARRHYTHMIAS, DEPRESSION, HEADACHE, TREMORS",,LAUNCHED,,Small molecule,Approved,VYFYYTLLBUKUHU-UHFFFAOYSA-N,NCCC1CCC(O)C(O)C1
DORAMAPIMOD,DORAMAPIMOD,CHEMBL103667,BRD:BRD-BRD-K74065929-001-07-2;BRD:BRD-K74065929-001-07-2;GDSC1:1042;GDSC2:1042,gdsc;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK11;MAPK12;MAPK13;MAPK14,,,PHASE 2,,Small molecule,Phase 2,MVCOAUNKQVWQHZ-UHFFFAOYSA-N,CC1CCC(-N2NC(C(C)(C)C)CC2NC(=O)NC2CCC(OCCN3CCOCC3)C3CCCCC23)CC1;CC1CCC(CC1)-N1NC(CC1NC(=O)NC1CCC(OCCN2CCOCC2)C2CCCCC12)C(C)(C)C
DORAMECTIN,DORAMECTIN,CHEMBL2361641,BRD:BRD-A16350940-001-01-9;BRD:BRD-BRD-A16350940-001-01-9,rep_primary;rep_single_dose,,,GASTROINTESTINAL ROUNDWORMS,,LAUNCHED,,Small molecule,Unknown,QLFZZSKTJWDQOS-YDBLARSUSA-N,CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(C=C[C@H](C)[C@@H](C6CCCCC6)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O;CO[C@H]1C[C@H](OC2[C@H](C)OC(C[C@@H]2OC)O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(C5)O[C@H](C5CCCCC5)[C@@H](C)C=C2)[C@]34O)O[C@@H](C)[C@@H]1O
DORAVIRINE,DORAVIRINE,CHEMBL2364608,BRD:BRD-K00003231-001-01-9,rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,,,,,Small molecule,Approved,ZIAOVIPSKUPPQW-UHFFFAOYSA-N,CN1C(CN2CCC(C(F)(F)F)C(OC3CC(CL)CC(C#N)C3)C2=O)N[NH]C1=O
DORSOMORPHIN,DORSOMORPHIN,CHEMBL478629,BRD:BRD-K54233340-001-02-2,rep_single_dose,AMPK INHIBITOR,ACVR1;BMPR1A;BMPR1B;EPHA2;FKBP1A;FLT1;FLT3;KDR;LCK;MKNK1;PRKAA1;RPS6KA1;SRC,,,,,Small molecule,NA,XHBVYDAKJHETMP-UHFFFAOYSA-N,C1CC(-C2CNN3CC(-C4CCC(OCCN5CCCCC5)CC4)CNC23)CCN1
DORZAGLIATIN,DORZAGLIATIN,CHEMBL4297508,BRD:BRD-K00090645-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,HMUMWSORCUWQJO-QAPCUYQASA-N,CC(C)C[C@@H](C(=O)NC1CCN(C[C@@H](O)CO)N1)N1CC(OC2CCCCC2CL)=CC1=O
DORZOLAMIDE,DORZOLAMIDE,CHEMBL218490,BRD:BRD-BRD-K71075609-003-01-0;BRD:BRD-K71075609-003-01-0,rep_multi_dose;rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA14;CA2;CA4;CA7,"INTRAOCULAR PRESSURE, GLAUCOMA",,LAUNCHED,,Small molecule,Approved,IAVUPMFITXYVAF-XPUUQOCRSA-N,CCN[C@@H]1C[C@H](C)S(=O)(=O)C2SC(CC12)S(N)(=O)=O;CCN[C@H]1C[C@H](C)S(=O)(=O)C2SC(S(N)(=O)=O)CC21
DOSULEPIN,DOSULEPIN,CHEMBL1492500,BRD:BRD-BRD-K54759182-003-08-0;BRD:BRD-K54759182-003-08-0,rep_primary;rep_single_dose,"NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONINNOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), TRICYCLIC ANTIDEPRESSANT",CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;HRH1;SLC6A2;SLC6A4,DEPRESSION,,LAUNCHED,"Multiple values for MOA: {'NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONIN\x80\x93NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), TRICYCLIC ANTIDEPRESSANT', 'NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), TRICYCLIC ANTIDEPRESSANT'}, defaulting to 'NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONIN\x80\x93NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), TRICYCLIC ANTIDEPRESSANT'",Small molecule,Approved,PHTUQLWOUWZIMZ-GZTJUZNOSA-N,CN(C)CC/C=C1\C2CCCCC2CSC2CCCCC21;CN(C)CC\C=C1/C2CCCCC2CSC2CCCCC12
DOTMP,DOTMP,,BRD:BRD-K00004678-001-01-9,rep_single_dose,,,,,,,,NA,,
DOVITINIB,DOVITINIB,CHEMBL522892,BRD:BRD-BRD-K85402309-001-06-6;BRD:BRD-BRD-K85402309-389-03-2;BRD:BRD-K85402309-001-06-6;BRD:BRD-K85402309-043-01-9;BRD:BRD-K85402309-389-03-2,rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, FGFR INHIBITOR, FLT3 INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",CSF1R;EGFR;FGFR1;FGFR2;FGFR3;FLT1;FLT3;FLT4;INSR;KDR;KIT;PDGFRA;PDGFRB,,,PHASE 3,,Small molecule,Phase 3,PIQCTGMSNWUMAF-UHFFFAOYSA-N,CN1CCN(C2CCC3NC(-C4C(N)C5C(F)CCCC5[NH]C4=O)[NH]C3C2)CC1;CN1CCN(CC1)C1CCC2NC([NH]C2C1)-C1C(N)C2C(F)CCCC2[NH]C1=O
DOXAPRAM,DOXAPRAM,CHEMBL1754,BRD:BRD-A46179541-311-02-0;BRD:BRD-BRD-A46179541-311-02-0,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNK3;KCNK9,"RESPIRATORY DEPRESSION, CENTRAL NERVOUS SYSTEM DEPRESSION, ACUTE HYPERCAPNIA (AHC)",,LAUNCHED,,Small molecule,Approved,XFDJYSQDBULQSI-UHFFFAOYSA-N,CCN1CC(CCN2CCOCC2)C(C1=O)(C1CCCCC1)C1CCCCC1;CCN1CC(CCN2CCOCC2)C(C2CCCCC2)(C2CCCCC2)C1=O
DOXAZOSIN,DOXAZOSIN,CHEMBL707,BRD:BRD-A13188892-066-21-5;BRD:BRD-BRD-A13188892-066-21-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;KCNH2;KCNH6;KCNH7,"BENIGN PROSTATIC HYPERPLASIA (BPH), HYPERTENSION",,LAUNCHED,,Small molecule,Approved,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,COC1CC2NC(N3CCN(C(=O)C4COC5CCCCC5O4)CC3)NC(N)C2CC1OC;COC1CC2NC(NC(N)C2CC1OC)N1CCN(CC1)C(=O)C1COC2CCCCC2O1
DOXEPIN,DOXEPIN,CHEMBL101740;CHEMBL1628227,BRD:BRD-BRD-K37694030-003-12-7;BRD:BRD-K37694030-003-12-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD2;HRH1;HRH2;HRH4;HTR1A;HTR2A;HTR2B;HTR2C;HTR6;KCNH2;SLC6A2;SLC6A4,"DEPRESSION, ANXIETY",,LAUNCHED,,Small molecule,Approved,ODQWQRRAPPTVAG-BOPFTXTBSA-N;ODQWQRRAPPTVAG-UHFFFAOYSA-N,CN(C)CC/C=C1/C2CCCCC2COC2CCCCC21;CN(C)CC\C=C1\C2CCCCC2COC2CCCCC12;CN(C)CCC=C1C2CCCCC2COC2CCCCC21
DOXERCALCIFEROL,DOXERCALCIFEROL,CHEMBL1200810,BRD:BRD-BRD-K82928892-001-02-5;BRD:BRD-K82928892-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,"CHRONIC KIDNEY DISEASE (CKD), HYPERPARATHYROIDISM",,LAUNCHED,,Small molecule,Approved,HKXBNHCUPKIYDM-CGMHZMFXSA-N,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O;CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C
DOXIFLURIDINE,DOXIFLURIDINE,CHEMBL1130,BRD:BRD-BRD-K58262659-001-09-7;BRD:BRD-K58262659-001-09-7,rep_multi_dose;rep_primary;rep_single_dose,THYMIDYLATE SYNTHASE INHIBITOR,TYMS,COLORECTAL CANCER,,LAUNCHED,,Small molecule,Phase 3,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,C[C@H]1O[C@@H](N2CC(F)C(=O)[NH]C2=O)[C@H](O)[C@@H]1O;C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC(F)C(=O)[NH]C1=O
DOXIL,DOXIL,CHEMBL359744;CHEMBL53463,GDSC1:133,gdsc,,,,,,,Small molecule,Approved,AOJJSUZBOXZQNB-TZSSRYMLSA-N;MWWSFMDVAYGXBV-RUELKSSGSA-N,COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.CL
DOXOFYLLINE,DOXOFYLLINE,CHEMBL1527608,BRD:BRD-BRD-K70507123-001-09-7;BRD:BRD-K70507123-001-09-7,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;PDE4A;PDE4B;PDE4C;PDE4D,ASTHMA,,LAUNCHED,,Small molecule,Phase 3,HWXIGFIVGWUZAO-UHFFFAOYSA-N,CN1C(=O)C2C(NCN2CC2OCCO2)N(C)C1=O;CN1C2NCN(CC3OCCO3)C2C(=O)N(C)C1=O
DOXORUBICIN:NAVITOCLAX (2:1 MOL/MOL),DOXORUBICIN:NAVITOCLAX (2:1 MOL/MOL),,CTRP:660280,ctrp,,,,,,,,NA,,
DOXORUBICINE,DOXORUBICINE,,GDSC1:133,gdsc,,,,,,,,NA,,
DOXYCYCLINE,DOXYCYCLINE,CHEMBL1200699,BRD:BRD-A08545410-003-07-8;BRD:BRD-A08545410-003-08-6;BRD:BRD-A08545410-311-01-8;BRD:BRD-A08545410-311-03-4;BRD:BRD-BRD-A08545410-003-07-8;BRD:BRD-BRD-A08545410-003-08-6;BRD:BRD-BRD-A08545410-311-01-8;BRD:BRD-BRD-A08545410-311-03-4,rep_multi_dose;rep_primary;rep_single_dose,METALLOPROTEINASE INHIBITOR,MMP8,PERIODONTITIS,,LAUNCHED,,Small molecule,Approved,XQTWDDCIUJNLTR-CVHRZJFOSA-N,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)C2C(O)CCCC12;C[C@H]1C2CCCC(O)C2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
DOXYLAMINE,DOXYLAMINE,CHEMBL1004,BRD:BRD-A44008656-036-25-8;BRD:BRD-BRD-A44008656-036-25-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,CHRM1;HRH1,SEDATIVE,,LAUNCHED,,Small molecule,Approved,HCFDWZZGGLSKEP-UHFFFAOYSA-N,CN(C)CCOC(C)(C1CCCCC1)C1CCCCN1
DPC,DPC,,BRD:BRD-K00004636-001-01-9,rep_single_dose,,,,,,,,NA,,
DPC-681,DPC-681,,BRD:BRD-BRD-K37087535-001-01-1;BRD:BRD-K37087535-001-01-1,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,,,PHASE 1,,,NA,,CC(C)CN(C[C@@H](O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)CNCC1CCCC(F)C1)C(C)(C)C)S(=O)(=O)C1CCCC(N)C1
DPCPX,DPCPX,,BRD:BRD-BRD-K01824921-001-18-5;BRD:BRD-K01824921-001-18-5,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 1,,,NA,,CCCN1C2[NH]C(NC2C(=O)N(CCC)C1=O)C1CCCC1
DPI-201106,DPI-201106,,BRD:BRD-A64553394-001-04-4;BRD:BRD-BRD-A64553394-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL ACTIVATOR,ADRB2,,,PHASE 2,,,NA,,OC(COC1CCCC2[NH]C(CC12)C#N)CN1CCN(CC1)C(C1CCCCC1)C1CCCCC1
DPO-1,DPO-1,,BRD:BRD-BRD-K99922388-001-02-0;BRD:BRD-K99922388-001-02-0,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNA5,,,PRECLINICAL,,,NA,,CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(C1CCCCC1)C1CCCCC1
DPPE,DPPE,CHEMBL2107467,BRD:BRD-BRD-K80315159-051-02-0;BRD:BRD-K80315159-051-02-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ABCB1;HRH1,,,PHASE 3,,Small molecule,Unknown,TXLHNFOLHRXMAU-UHFFFAOYSA-N,CCN(CC)CCOC1CCC(CC2CCCCC2)CC1;CCN(CC)CCOC1CCC(CC2CCCCC2)CC1.CL
DQP-1105,DQP-1105,,BRD:BRD-A67976398-001-02-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2C;GRIN2D,,,,,,NA,,
DR-2313,DR-2313,,BRD:BRD-K94920105-001-05-9,rep_single_dose,PARP INHIBITOR,PARP1;PARP3,,,,,,NA,,
DR-4485,DR-4485,,BRD:BRD-A39794701-003-01-6;BRD:BRD-BRD-A39794701-003-01-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR7,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)C1=CCN(CCCCC23CCCC4C2C(NC3=O)CCC4CL)CC1
DRF053-(R),DRF053-(R),,BRD:BRD-BRD-K25486274-300-01-0;BRD:BRD-K25486274-300-01-0,rep_primary;rep_single_dose,CDK INHIBITOR,CSNK1A1,,,PRECLINICAL,,,NA,,CC[C@H](CO)NC1NC(NC2CCCC(C2)-C2CCCCN2)C2NCN(C(C)C)C2N1
DROFENINE,DROFENINE,CHEMBL442444,BRD:BRD-A22267103-003-13-1;BRD:BRD-BRD-A22267103-003-13-1,rep_primary;rep_single_dose,,,SPASMS,,LAUNCHED,,Small molecule,Unknown,AGJBLWCLQCKRJP-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C(C1CCCCC1)C1CCCCC1
DROLOXIFENE,DROLOXIFENE,CHEMBL487,BRD:BRD-BRD-K38477637-001-01-0;BRD:BRD-K38477637-001-01-0,rep_primary;rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),ESR1,,,PHASE 3,,Small molecule,Phase 3,ZQZFYGIXNQKOAV-OCEACIFDSA-N,CC/C(=C(/C1CCC(OCCN(C)C)CC1)C1CCCC(O)C1)C1CCCCC1;CC\C(=C(\C1CCC(OCCN(C)C)CC1)C1CCCC(O)C1)C1CCCCC1
DROMOSTANOLONE-PROPIONATE,DROMOSTANOLONE-PROPIONATE,,BRD:BRD-A38706605-001-01-2;BRD:BRD-BRD-A38706605-001-01-2,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,BREAST CANCER,,LAUNCHED,,,NA,,CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C
DRONEDARONE,DRONEDARONE,CHEMBL184412,BRD:BRD-BRD-K05524748-003-04-4;BRD:BRD-K05524748-003-04-4,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;CACNA1C;CACNA1D;CACNA1F;CACNA1S;CACNB1;CACNB2;CACNB3;CACNB4;KCNA5;KCNH2;KCNK2;SCN1A,ATRIAL FIBRILLATION (AF),,LAUNCHED,,Small molecule,Approved,ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,CCCCC1OC2CCC(NS(C)(=O)=O)CC2C1C(=O)C1CCC(OCCCN(CCCC)CCCC)CC1;CCCCN(CCCC)CCCOC1CCC(CC1)C(=O)C1C(CCCC)OC2CCC(NS(C)(=O)=O)CC12
DROPERIDOL,DROPERIDOL,CHEMBL1108,BRD:BRD-BRD-K97158071-001-18-1;BRD:BRD-K97158071-001-18-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;DRD2;DRD3;DRD4;HTR2A,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,RMEDXOLNCUSCGS-UHFFFAOYSA-N,FC1CCC(CC1)C(=O)CCCN1CCC(=CC1)N1C2CCCCC2[NH]C1=O;O=C(CCCN1CC=C(N2C(=O)[NH]C3CCCCC32)CC1)C1CCC(F)CC1
DROPROPIZINE,DROPROPIZINE,CHEMBL1288810;CHEMBL151445,BRD:BRD-A29349577-001-23-0;BRD:BRD-BRD-A29349577-001-23-0,rep_primary;rep_single_dose,ANTITUSSIVE,,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Phase 3,PTVWPYVOOKLBCG-UHFFFAOYSA-N;PTVWPYVOOKLBCG-ZDUSSCGKSA-N,OC[C@@H](O)CN1CCN(C2CCCCC2)CC1;OCC(O)CN1CCN(C2CCCCC2)CC1;OCC(O)CN1CCN(CC1)C1CCCCC1
DROSPIRENONE,DROSPIRENONE,CHEMBL1509,BRD:BRD-BRD-K04394237-001-03-7;BRD:BRD-BRD-K04394237-001-06-0;BRD:BRD-K04394237-001-03-7;BRD:BRD-K04394237-001-06-0,rep_multi_dose;rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,AR;NR3C2;PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,METQSPRSQINEEU-HXCATZOESA-N,C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1;C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12
DROTAVERINE,DROTAVERINE,CHEMBL551978,BRD:BRD-BRD-K14658796-003-01-6;BRD:BRD-K14658796-003-01-6,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,CACNA1C;PDE4A,LABOR INDUCTION,,LAUNCHED,,Small molecule,Phase 3,OMFNSKIUKYOYRG-MOSHPQCFSA-N,CCOC1CCC(/C=C2\NCCC3CC(OCC)C(OCC)CC32)CC1OCC;CCOC1CCC(\C=C2\NCCC3CC(OCC)C(OCC)CC23)CC1OCC
DROXIDOPA,DROXIDOPA,CHEMBL2103827,BRD:BRD-BRD-K20372197-001-03-1;BRD:BRD-K20372197-001-03-1,rep_primary;rep_single_dose,NOREPINEPHRINE PRECURSOR,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3;PAH,"HYPERTENSION, PARKINSON'S DISEASE",,LAUNCHED,,Small molecule,Approved,QXWYKJLNLSIPIN-JGVFFNPUSA-N,N[C@@H]([C@H](O)C1CCC(O)C(O)C1)C(O)=O;N[C@H](C(=O)O)[C@H](O)C1CCC(O)C(O)C1
DROXINOSTAT,DROXINOSTAT,,BRD:BRD-BRD-K11558771-001-13-9;BRD:BRD-K11558771-001-13-9,rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC6;HDAC8,,,PRECLINICAL,,,NA,,CC1CC(CL)CCC1OCCCC(=O)NO
DS-1971A,DS-1971A,CHEMBL4633566,BRD:BRD-K00091281-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,OJKONCJPCULNOW-DYVFJYSZSA-N,CN1NCCC1[C@H]1CCCC[C@@H]1OC1CC(F)C(S(=O)(=O)NC2CCNCN2)CC1CL
DS2-(806622),DS2-(806622),,BRD:BRD-BRD-K09619578-001-01-3;BRD:BRD-K09619578-001-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)C(=O)NC1C(NC2CCCCN12)-C1CCCS1
DSM265,DSM265,CHEMBL1956285,BRD:BRD-K35498911-001-02-9,rep_single_dose,DIHYDROOROTATE DEHYDROGENASE INHIBITOR,,,,,,Small molecule,Phase 2,OIZSVTOIBNSVOS-UHFFFAOYSA-N,CC1CC(NC2CCC(S(F)(F)(F)(F)F)CC2)N2NC(C(C)(F)F)NC2N1
DSPC,DSPC,,BRD:BRD-K00004570-001-01-9,rep_single_dose,,,,,,,,NA,,
DSR-6434,DSR-6434,,BRD:BRD-K46384285-001-02-9,rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,TLR7,,,,,,NA,,
DU-728,DU-728,,BRD:BRD-BRD-K08859203-001-01-9;BRD:BRD-K08859203-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,STRUCTURAL GLYCOPROTEIN ANTAGONIST,ITGA2B;ITGB3,,,PHASE 1,,,NA,,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O
DULOXETINE,DULOXETINE,CHEMBL1175;CHEMBL336920,BRD:BRD-BRD-K71103788-003-12-0;BRD:BRD-K71103788-003-12-0,rep_primary;rep_single_dose,"NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONINNOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)",HTR2A;HTR2C;HTR6;SLC6A2;SLC6A3;SLC6A4,"DEPRESSION, GENERALIZED ANXIETY DISORDER (GAD), MUSCLE PAIN, PERIPHERAL NEUROPATHY",,LAUNCHED,"Multiple values for MOA: {'NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)', 'NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONIN\x80\x93NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)'}, defaulting to 'NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI), SEROTONIN\x80\x93NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)'",Small molecule,Approved,ZEUITGRIYCTCEM-KRWDZBQOSA-N;ZEUITGRIYCTCEM-QGZVFWFLSA-N,CNCC[C@@H](OC1CCCC2CCCCC12)C1CCCS1;CNCC[C@H](OC1CCCC2CCCCC12)C1CCCS1
DUP-697,DUP-697,CHEMBL42485,BRD:BRD-BRD-K06221026-001-06-8;BRD:BRD-K06221026-001-06-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,,,PHASE 1,,Small molecule,NA,AJFTZWGGHJXZOB-UHFFFAOYSA-N,CS(=O)(=O)C1CCC(-C2CC(BR)SC2-C2CCC(F)CC2)CC1;CS(=O)(=O)C1CCC(CC1)-C1CC(BR)SC1-C1CCC(F)CC1
DUSQUETIDE,DUSQUETIDE,CHEMBL3545314,BRD:BRD-K00073831-019-02-9,rep_single_dose,,,,,,,Protein,Phase 3,ZUJBBVJXXYRPFS-DYKIIFRCSA-N,CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O)C(C)C
DUTASTERIDE,DUTASTERIDE,CHEMBL1200969,BRD:BRD-BRD-K30373883-001-02-8;BRD:BRD-K30373883-001-02-8,rep_primary;rep_single_dose,5 ALPHA REDUCTASE INHIBITOR,SRD5A1;SRD5A2;SRD5A3,BENIGN PROSTATIC HYPERPLASIA (BPH),,LAUNCHED,"Multiple values for repurposing_target: {'SRD5A1;SRD5A2', 'SRD5A1;SRD5A2;SRD5A3'}, taking the union",Small molecule,Approved,JWJOTENAMICLJG-QWBYCMEYSA-N,C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)NC3CC(C(F)(F)F)CCC3C(F)(F)F)CC[C@@H]12;C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1CC(CCC1C(F)(F)F)C(F)(F)F
IPI-145,DUVELISIB;IPI-145,CHEMBL3039502,BRD:BRD-BRD-K93468883-001-02-0;BRD:BRD-K93468883-001-02-0,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 3,,Small molecule,Approved,SJVQHLPISAIATJ-ZDUSSCGKSA-N,C[C@H](NC1NCNC2[NH]CNC12)C1CC2CCCC(CL)C2C(=O)N1-C1CCCCC1;C[C@H](NC1NCNC2NC[NH]C12)C1CC2CCCC(CL)C2C(=O)N1-C1CCCCC1
DVD-111,DVD-111,,BRD:BRD-BRD-K22520627-001-01-7;BRD:BRD-K22520627-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CC1CCCCC1
DWK-1339,DWK-1339,,BRD:BRD-K00003171-001-01-9,rep_single_dose,BETA AMYLOID AGGREGATION INHIBITOR,,,,,,,NA,,
DY131,DY131,,BRD:BRD-BRD-K58343622-001-01-6;BRD:BRD-K58343622-001-01-6,rep_primary;rep_single_dose,ESTROGEN-RELATED RECEPTOR AGONIST,ESRRB;ESRRG,,,PRECLINICAL,,,NA,,CCN(CC)C1CCC(CC1)\C=N\NC(=O)C1CCC(O)CC1
DYCLONINE,DYCLONINE,CHEMBL1201217,BRD:BRD-BRD-K72259270-003-25-6;BRD:BRD-K72259270-003-25-6,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN5A,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,BZEWSEKUUPWQDQ-UHFFFAOYSA-N,CCCCOC1CCC(C(=O)CCN2CCCCC2)CC1;CCCCOC1CCC(CC1)C(=O)CCN1CCCCC1
DYDROGESTERONE,DYDROGESTERONE,CHEMBL1200853,BRD:BRD-BRD-K68620903-001-11-4;BRD:BRD-K68620903-001-11-4,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,INFERTILITY,,LAUNCHED,,Small molecule,Approved,JGMOKGBVKVMRFX-HQZYFCCVSA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C
DYNASORE,DYNASORE,CHEMBL1209885,BRD:BRD-K87718015-001-04-9,rep_single_dose,DYNAMIN INHIBITOR,DNM1;DNM1L;DNM2,,,,,Small molecule,NA,SYNDQCRDGGCQRZ-VXLYETTFSA-N,O=C(N/N=C/C1CCC(O)C(O)C1)C1CC2CCCCC2CC1O
DYNOLE-34-2,DYNOLE-34-2,,BRD:BRD-K23479488-001-02-9,rep_single_dose,DYNAMIN INHIBITOR,DNM1,,,,,,NA,,
DYPHYLLINE,DYPHYLLINE,CHEMBL1752,BRD:BRD-A00827783-001-24-6;BRD:BRD-BRD-A00827783-001-24-6,rep_primary;rep_single_dose,"ADENOSINE RECEPTOR ANTAGONIST, PHOSPHODIESTERASE INHIBITOR",ADORA1;ADORA2A;PDE3A;PDE4A;PDE4B;PDE4C;PDE4D;PDE7A;PDE7B,"ASTHMA, BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,KSCFJBIXMNOVSH-UHFFFAOYSA-N,CN1C(=O)C2C(NCN2CC(O)CO)N(C)C1=O;CN1C2NCN(CC(O)CO)C2C(=O)N(C)C1=O
E-2001,E-2001,,BRD:BRD-K00004561-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
E-2012,E-2012,,BRD:BRD-BRD-K50564936-001-01-6;BRD:BRD-K50564936-001-01-6,rep_primary;rep_single_dose,GAMMA SECRETASE MODULATOR,APH1A;APH1B;PSENEN,,,PHASE 1,,,NA,,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC;COC1CC(CCC1-N1CNC(C)C1)\C=C1/CCCN([C@@H](C)C2CCC(F)CC2)C1=O
E-4031,E-4031,,BRD:BRD-BRD-K41713976-300-02-6;BRD:BRD-K41713976-300-02-6,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNH1;KCNH2,,,PHASE 1,,,NA,,CC1CCCC(CCN2CCC(CC2)C(=O)C2CCC(NS(C)(=O)=O)CC2)N1
E-64,E-64,CHEMBL374508,BRD:BRD-BRD-K06273313-001-07-9;BRD:BRD-K06273313-001-07-9,rep_primary;rep_single_dose,"CALPAIN INHIBITOR, CYSTEINE PROTEASE INHIBITOR",CTSS,,,PRECLINICAL,"Multiple values for MOA: {'CYSTEINE PROTEASE INHIBITOR, CALPAIN INHIBITOR', 'CALPAIN INHIBITOR, CYSTEINE PROTEASE INHIBITOR'}, defaulting to 'CALPAIN INHIBITOR, CYSTEINE PROTEASE INHIBITOR'",Small molecule,NA,LTLYEAJONXGNFG-DCAQKATOSA-N,CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N;CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N
E-7386,E-7386,CHEMBL4297491,BRD:BRD-K00091075-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,ZGNKNLOBYFTGRG-GIWKVKTRSA-N,C=CCN1CC(=O)N2[C@@H](CC3CCC(O)CC3F)C(=O)N(CC3CCCC(N4CC(N5CCN(CC)CC5)C4)N3)C[C@@H]2N1C(=O)NCC1CCCCC1
E1210,E1210,,BRD:BRD-K00079239-001-02-9,rep_single_dose,,,,,,,,NA,,
E3330,E3330,,BRD:BRD-K00004649-001-01-9,rep_single_dose,NFKB PATHWAY INHIBITOR,,,,,,,NA,,
E7046,E7046,,BRD:BRD-K00003449-001-01-9,rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,,,,,,,NA,,
E7449,E7449,CHEMBL3644587,BRD:BRD-BRD-K05444225-001-01-7;BRD:BRD-K05444225-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1;PARP2;TNKS;TNKS2,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,JLFSBHQQXIAQEC-UHFFFAOYSA-N,O=C1[NH][NH]C2NC(CN3CC4CCCCC4C3)NC3CCCC1C23;O=C1[NH]NC2C3C(CCCC13)N=C(CN1CC3CCCCC3C1)N2
E7820,E7820,CHEMBL4297376,BRD:BRD-K00003172-001-01-9,rep_single_dose,ANGIOGENESIS INHIBITOR,,,,,,Small molecule,Phase 2,LWGUASZLXHYWIV-UHFFFAOYSA-N,CC1CCC(NS(=O)(=O)C2CCCC(C#N)C2)C2[NH]CC(C#N)C12
EACT,EACT,,BRD:BRD-BRD-K53030960-001-01-4;BRD:BRD-K53030960-001-01-4,rep_primary;rep_single_dose,CALCIUM-ACTIVATED CHLORIDE CHANNEL INHIBITOR,ANO1,,,PRECLINICAL,,,NA,,COCCN(C(=O)C1CC(OC)C(OC)C(OC)C1)C1NC(CS1)-C1CCCCC1
EB-47,EB-47,,BRD:BRD-BRD-K66998413-300-01-6;BRD:BRD-K66998413-300-01-6,rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PRECLINICAL,,,NA,,NC1NCNC2N(CNC12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)NC2CCCC3C(=O)NCC23)CC1
EBASTINE,EBASTINE,CHEMBL305660,BRD:BRD-BRD-K13314656-001-01-0;BRD:BRD-K13314656-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,CYP3A4;HRH1,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Phase 3,MJJALKDDGIKVBE-UHFFFAOYSA-N,CC(C)(C)C1CCC(C(=O)CCCN2CCC(OC(C3CCCCC3)C3CCCCC3)CC2)CC1;CC(C)(C)C1CCC(CC1)C(=O)CCCN1CCC(CC1)OC(C1CCCCC1)C1CCCCC1
EBPC,EBPC,,BRD:BRD-A96485169-001-14-3;BRD:BRD-BRD-A96485169-001-14-3,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,,,PRECLINICAL,,,NA,,CCOC(=O)C1CN(CC2CCCCC2)C(=O)C1=O
EBROTIDINE,EBROTIDINE,CHEMBL1742471,BRD:BRD-BRD-K22421059-001-02-3;BRD:BRD-K22421059-001-02-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,,,WITHDRAWN,,Small molecule,Approved,ZQHFZHPUZXNPMF-UHFFFAOYSA-N,NC(=N)NC1NC(CSCCN\C=N\S(=O)(=O)C2CCC(BR)CC2)CS1;NC(N)=NC1NC(CSCCN/C=N/S(=O)(=O)C2CCC(BR)CC2)CS1
EBSELEN,EBSELEN,CHEMBL51085,BRD:BRD-BRD-K29359156-001-30-1;BRD:BRD-K29359156-001-30-1,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, GLUTATHIONE PEROXIDASE AGONIST, H+/K+-ATPASE INHIBITOR, NITRIC OXIDE SYNTHASE INHIBITOR",ALB,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,DYEFUKCXAQOFHX-UHFFFAOYSA-N,O=C1C2CCCCC2[SE]N1-C1CCCCC1;O=C1N([SE]C2CCCCC12)-C1CCCCC1
EC-144,EC-144,,BRD:BRD-BRD-K41705163-001-01-1;BRD:BRD-K41705163-001-01-1,rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1;HSP90AB1,,,PRECLINICAL,,,NA,,COC1C(C)CNC(CN2CC(C#CCC(C)(C)O)C3C(CL)NC(N)NC23)C1C
EC-23,EC-23,,BRD:BRD-BRD-K81004638-001-01-7;BRD:BRD-K81004638-001-01-7,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB;RARG,,,PRECLINICAL,,,NA,,CC1(C)CCC(C)(C)C2CC(CCC12)C#CC1CCC(CC1)C(O)=O
EC5026,EC5026,,BRD:BRD-K00091074-001-01-9,rep_single_dose,,,,,,,,NA,,
ECABAPIDE,ECABAPIDE,CHEMBL2104348,BRD:BRD-BRD-K47371940-001-01-6;BRD:BRD-K47371940-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,Unknown,JTAGHJPZEDNHHA-UHFFFAOYSA-N,CNC(=O)C1CCCC(NCC(=O)NCCC2CCC(OC)C(OC)C2)C1
ECABET,ECABET,CHEMBL2104585,BRD:BRD-BRD-K03353589-236-01-4;BRD:BRD-K03353589-236-01-4,rep_primary;rep_single_dose,"GASTRIN INHIBITOR, UREASE INHIBITOR",NOXO1,DRY EYE SYNDROME,,LAUNCHED,,Small molecule,Phase 3,IWCWQNVIUXZOMJ-MISYRCLQSA-N,CC(C)C1CC2C(CC1S(=O)(=O)O)[C@@]1(C)CCC[C@@](C)(C(=O)O)[C@@H]1CC2;CC(C)C1CC2CC[C@H]3[C@@](C)(CCC[C@]3(C)C2CC1S(O)(=O)=O)C(O)=O
ECAMSULE-TRIETHANOLAMINE,ECAMSULE-TRIETHANOLAMINE,,BRD:BRD-A47953250-001-01-7;BRD:BRD-BRD-A47953250-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,,,"SKIN PROTECTANT, SUNSCREEN LOTION",,LAUNCHED,,,NA,,CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/C1CCC(CC1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C
ECHINOMYCIN,ECHINOMYCIN,CHEMBL510650,BRD:BRD-A68969091-001-12-7;BRD:BRD-BRD-A68969091-001-12-7,rep_multi_dose;rep_primary;rep_single_dose,DNA INTERCALATING AGENT,,,,PHASE 2,,Small molecule,NA,AUJXLBOHYWTPFV-VLNMHYLBSA-N,CS[C@H]1SC[C@H]2C(=O)N(C)[C@@H](C(C)C)C(=O)OC[C@@H](NC(=O)C3CNC4CCCCC4N3)C(=O)N[C@@H](C)C(=O)N(C)[C@@H]1C(=O)N(C)[C@@H](C(C)C)C(=O)OC[C@@H](NC(=O)C1CNC3CCCCC3N1)C(=O)N[C@@H](C)C(=O)N2C;CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)C1CNC2CCCCC2N1)NC(=O)C1CNC2CCCCC2N1
ECHOTHIOPHATE IODIDE,ECHOTHIOPHATE IODIDE,CHEMBL1200367,BRD:BRD-K00075140-005-02-9,rep_single_dose,,,,,,,Small molecule,Approved,OVXQHPWHMXOFRD-UHFFFAOYSA-M,CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-]
ECONAZOLE,ECONAZOLE,CHEMBL808,BRD:BRD-A51820102-008-28-9;BRD:BRD-BRD-A51820102-008-28-9,rep_primary;rep_single_dose,"LANOSTEROL DEMETHYLASE INHIBITOR, STEROL DEMETHYLASE INHIBITOR",CYP51A1;NPY1R;NPY2R;TRPM2;TRPV5,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS, TINEA VERSICOLOR, CUTANEOUS CANDIDIASIS",,LAUNCHED,,Small molecule,Approved,LEZWWPYKPKIXLL-UHFFFAOYSA-N,CLC1CCC(COC(CN2CCNC2)C2CCC(CL)CC2CL)CC1
ECTOINE,ECTOINE,,BRD:BRD-K34566599-001-03-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,,NA,,
ECTOINE-ZWITTERION,ECTOINE-ZWITTERION,,BRD:BRD-BRD-K60902958-001-01-9;BRD:BRD-K60902958-001-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)[C@@H]1CCNC(=C)N1
EDAGLITAZONE,EDAGLITAZONE,CHEMBL3990804,BRD:BRD-A25182582-001-01-8;BRD:BRD-BRD-A25182582-001-01-8,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARG,,,PHASE 2,,Small molecule,Unknown,HAAXAFNSRADSMK-UHFFFAOYSA-N,CC1OC(-C2CCCCC2)NC1CCOC1CCC(CC2SC(=O)NC2=O)C2SCCC12;CC1OC(NC1CCOC1CCC(CC2SC(=O)NC2=O)C2SCCC12)-C1CCCCC1
EDASALONEXENT,EDASALONEXENT,CHEMBL3786673,BRD:BRD-K00003258-001-01-9,rep_single_dose,NFKB PATHWAY INHIBITOR,,,,,,Small molecule,Phase 3,JQLBBYLGWHUHRW-KUBAVDMBSA-N,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)C1CCCCC1O
EDELFOSINE,EDELFOSINE,CHEMBL107514;CHEMBL28509,BRD:BRD-A30403214-001-03-3;BRD:BRD-BRD-A30403214-001-03-3,rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,,,,PHASE 2,,Small molecule,Unknown,MHFRGQHAERHWKZ-HHHXNRCGSA-N;MHFRGQHAERHWKZ-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC;CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC;CCCCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC
EDITOL,EDITOL,CHEMBL1573178,BRD:BRD-A78588743-001-03-4;BRD:BRD-BRD-A78588743-001-03-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,NSOXQYCFHDMMGV-UHFFFAOYSA-N,CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O
EDO-S101,EDO-S101,CHEMBL3989941,BRD:BRD-K00003432-001-01-9,rep_single_dose,HDAC INHIBITOR,,,,,,Small molecule,Phase 1,GISXTRIGVCKQBX-UHFFFAOYSA-N,CN1C(CCCCCCC(=O)NO)NC2CC(N(CCCL)CCCL)CCC21
EDONERPIC-MALEATE,EDONERPIC-MALEATE,,BRD:BRD-K00003259-050-01-9,rep_single_dose,BETA AMYLOID INHIBITOR,,,,,,,NA,,
EDOXABAN,EDOXABAN,CHEMBL1269025,BRD:BRD-BRD-K29322660-001-01-9;BRD:BRD-K29322660-001-01-9,rep_primary;rep_single_dose,COAGULATION FACTOR INHIBITOR,F10,"STROKE, PULMONARY EMBOLISM (PE), SYSTEMIC EMBOLISM, DEEP VEIN THROMBOSIS (DVT), ATRIAL FIBRILLATION (AF)",,LAUNCHED,,Small molecule,Approved,HGVDHZBSSITLCT-JLJPHGGASA-N,CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)C(=O)NC2CCC(CL)CN2)[C@H](C1)NC(=O)C1NC2CCN(C)CC2S1;CN1CCC2NC(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)NC3CCC(CL)CN3)SC2C1
EDOXUDINE,EDOXUDINE,CHEMBL318153,BRD:BRD-BRD-K86892782-001-17-0;BRD:BRD-K86892782-001-17-0,rep_primary;rep_single_dose,DNA DIRECTED DNA POLYMERASE INHIBITOR,,VIRUS HERPES SIMPLEX (HSV),,LAUNCHED,,Small molecule,Unknown,XACKNLSZYYIACO-DJLDLDEBSA-N,CCC1CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)[NH]C1=O
EDROPHONIUM,EDROPHONIUM,CHEMBL1104;CHEMBL60745,BRD:BRD-BRD-K81128206-003-24-4;BRD:BRD-K81128206-003-24-4,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE,MYASTHENIA GRAVIS,,LAUNCHED,,Small molecule,Approved,CAEPIUXAUPYIIJ-UHFFFAOYSA-N;VWLHWLSRQJQWRG-UHFFFAOYSA-O,CC[N+](C)(C)C1CCCC(O)C1;CC[N+](C)(C)C1CCCC(O)C1.[BR-]
EED226,EED226,,BRD:BRD-BRD-K19002914-001-01-3;BRD:BRD-K19002914-001-01-3,oncref_1;rep_primary;rep_single_dose,ALLOSTERIC INHIBITOR OF EED,EED,,,PRECLINICAL,"Multiple values for MOA: {'ALLOSTERIC INHIBITOR OF EED', 'POLYCOMB PROTEIN INHIBITOR'}, defaulting to 'ALLOSTERIC INHIBITOR OF EED'",,NA,,CS(=O)(=O)C1CCC(CC1)-C1CNC(NCC2CCCO2)N2CNNC12
"EEF2K INHIBITOR, A-484954","EEF2K INHIBITOR, A-484954",,GDSC1:409,gdsc,,,,,,,,NA,,
EF5,EF5,,BRD:BRD-K00004643-001-01-9,rep_single_dose,CYTOCHROME P450 ACTIVATOR,,,,,,,NA,,
EFAPROXIRAL,EFAPROXIRAL,CHEMBL18901,BRD:BRD-BRD-K37355418-236-01-6;BRD:BRD-K37355418-236-01-6,rep_primary;rep_single_dose,"HAEMOGLOBIN OXYGEN RELEASE STIMULANT, HEMOGLOBIN OXYGEN RELEASE STIMULANT",HBA1;HBB,,,PHASE 3,"Multiple values for MOA: {'HAEMOGLOBIN OXYGEN RELEASE STIMULANT, HEMOGLOBIN OXYGEN RELEASE STIMULANT', 'HAEMOGLOBIN OXYGEN RELEASE STIMULANT'}, defaulting to 'HAEMOGLOBIN OXYGEN RELEASE STIMULANT, HEMOGLOBIN OXYGEN RELEASE STIMULANT'",Small molecule,Phase 3,BNFRJXLZYUTIII-UHFFFAOYSA-N,CC1CC(C)CC(NC(=O)CC2CCC(OC(C)(C)C(=O)O)CC2)C1;CC1CC(C)CC(NC(=O)CC2CCC(OC(C)(C)C(O)=O)CC2)C1
EFAROXAN,EFAROXAN,CHEMBL57895,BRD:BRD-A10739734-003-10-6;BRD:BRD-BRD-A10739734-003-10-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADORA2A,,,PHASE 2,,Small molecule,Unknown,RATZLMXRALDSJW-UHFFFAOYSA-N,CCC1(C2=NCCN2)CC2CCCCC2O1;CCC1(CC2CCCCC2O1)C1=NCCN1
EFATUTAZONE,EFATUTAZONE,CHEMBL3545280,BRD:BRD-A24560335-300-01-2;BRD:BRD-BRD-A24560335-300-01-2,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARG,,,PHASE 2,,Small molecule,Phase 2,JCYNMRJCUYVDBC-UHFFFAOYSA-N,CC1CC(OC2CCC3NC(COC4CCC(CC5SC(=O)NC5=O)CC4)N(C)C3C2)CC(C)C1N
EFAVIRENZ,EFAVIRENZ,CHEMBL223228,BRD:BRD-BRD-K40758068-001-08-2;BRD:BRD-K40758068-001-08-2,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,CYP1A2;CYP2B6;CYP2C19;CYP2C9;CYP2D6;CYP3A4,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,XPOQHMRABVBWPR-ZDUSSCGKSA-N,FC(F)(F)[C@]1(OC(=O)NC2CCC(CL)CC12)C#CC1CC1;O=C1NC2CCC(CL)CC2[C@@](C#CC2CC2)(C(F)(F)F)O1
EFINACONAZOLE,EFINACONAZOLE,CHEMBL2103877,BRD:BRD-A30774155-001-01-2;BRD:BRD-BRD-A30774155-001-01-2,rep_primary;rep_single_dose,LANOSTEROL DEMETHYLASE INHIBITOR,CYP51A1,ONYCHOMYCOSIS,,LAUNCHED,,Small molecule,Approved,NFEZZTICAUWDHU-RDTXWAMCSA-N,C[C@@H](N1CCC(=C)CC1)C(O)(CN1CNCN1)C1CCC(F)CC1F;C=C1CCN([C@H](C)[C@](O)(CN2CNCN2)C2CCC(F)CC2F)CC1
EFLETIRIZINE,EFLETIRIZINE,CHEMBL2104290,BRD:BRD-K00004551-001-01-9,rep_single_dose,ANTIHISTAMINE,,,,,,Small molecule,Unknown,BAWMMJAUVBLLEE-UHFFFAOYSA-N,O=C(O)COCCN1CCN(C(C2CCC(F)CC2)C2CCC(F)CC2)CC1
EFLORNITHINE,EFLORNITHINE,CHEMBL830,BRD:BRD-A96292436-003-16-1;BRD:BRD-BRD-A96292436-003-16-1,rep_primary;rep_single_dose,ORNITHINE DECARBOXYLASE INHIBITOR,ARG2;ODC1,FACIAL HAIR REDUCTION,,LAUNCHED,,Small molecule,Approved,VLCYCQAOQCDTCN-UHFFFAOYSA-N,NCCCC(N)(C(=O)O)C(F)F;NCCCC(N)(C(F)F)C(O)=O
EFLOXATE,EFLOXATE,CHEMBL1349073,BRD:BRD-BRD-K55166090-001-09-0;BRD:BRD-K55166090-001-09-0,rep_primary;rep_single_dose,VASODILATOR,,,,PRECLINICAL,,Small molecule,Unknown,ZVXBAHLOGZCFTP-UHFFFAOYSA-N,CCOC(=O)COC1CCC2C(=O)CC(-C3CCCCC3)OC2C1;CCOC(=O)COC1CCC2C(C1)OC(CC2=O)-C1CCCCC1
EFONIDIPINE,EFONIDIPINE,CHEMBL2074922,BRD:BRD-K00004292-003-02-9,rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,,,Small molecule,Unknown,NSVFSAJIGAJDMR-UHFFFAOYSA-N,CC1=C(C(=O)OCCN(CC2CCCCC2)C2CCCCC2)C(C2CCCC([N+](=O)[O-])C2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1
EFONIDIPINE-MONOETHANOLATE,EFONIDIPINE-MONOETHANOLATE,,BRD:BRD-BRD-M92675308-003-07-1;BRD:BRD-M92675308-003-07-1,rep_multi_dose;rep_primary;rep_single_dose,"L-TYPE CALCIUM CHANNEL BLOCKER, T-TYPE CALCIUM CHANNEL BLOCKER",CACNA1C;CACNA1G,,,LAUNCHED,,,NA,,CCO.CC1=C(C(C2CCCC(C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1CCCCC1)C1CCCCC1
EG00229,EG00229,,BRD:BRD-BRD-K50653584-001-01-2;BRD:BRD-K50653584-001-01-2,rep_primary;rep_single_dose,NEUROPILIN RECEPTOR ANTAGONIST,NRP1,,,PRECLINICAL,,,NA,,NC(=N)NCCC[C@H](NC(=O)C1SCCC1NS(=O)(=O)C1CCCC2NSNC12)C(O)=O
EGF816,EGF816,CHEMBL3787344,BRD:BRD-BRD-K22514639-001-05-7;BRD:BRD-K22514639-001-04-0;BRD:BRD-K22514639-001-05-7,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PHASE 2,,Small molecule,Phase 2,IOMMMLWIABWRKL-WUTDNEBXSA-N,CC1CC(C(=O)NC2NC3CCCC(CL)C3N2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)CCN1;CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)N1C(NC(=O)C2CCNC(C)C2)NC2CCCC(CL)C12
EGLUMETAD,EGLUMETAD,CHEMBL8759,BRD:BRD-BRD-K65359424-001-01-3;BRD:BRD-K65359424-001-01-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM2;GRM3;GRM6;GRM8,,,PHASE 2,,Small molecule,Unknown,VTAARTQTOOYTES-RGDLXGNYSA-N,N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O;N[C@@]1(C(=O)O)CC[C@H]2[C@H](C(=O)O)[C@H]21
EHOP-016,EHOP-016,,BRD:BRD-BRD-K32289541-001-01-0;BRD:BRD-K32289541-001-01-0,rep_primary;rep_single_dose,RAS GTPASE INHIBITOR,RAC1;RAC3,,,PRECLINICAL,,,NA,,CCN1C2CCCCC2C2CC(NC3CCNC(NCCCN4CCOCC4)N3)CCC12
EHT 1864,EHT 1864,,GDSC1:1069,gdsc,,,,,,,,NA,,
EHT-1864,EHT-1864,,GDSC1:1069,gdsc,,,,,,,,NA,,
EI1,EI1,,BRD:BRD-K91535048-001-01-2,rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,,,,NA,,
EIF-2ALPHA INHIBITOR,EIF-2ALPHA INHIBITOR,,GDSC1:111,gdsc,,,,,,,,NA,,
EIPA,EIPA,,BRD:BRD-K88120876-001-10-9,rep_single_dose,"SODIUM/HYDROGEN EXCHANGER INHIBITOR, TRANSIENT RECEPTOR POTENTIAL POLYCYSTIC INHIBITOR",ADRA2A;ASIC1;PKD2L1,,,,,,NA,,
EIT-HYDROBROMIDE,EIT-HYDROBROMIDE,,BRD:BRD-BRD-K81623406-004-08-3;BRD:BRD-K81623406-004-08-3,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS2;NOS3,,,PRECLINICAL,,,NA,,CCSC(N)=N
EKB 569,EKB 569,,GDSC1:282,gdsc,,,,,,,,NA,,
EKB-569,EKB-569,CHEMBL607707,GDSC1:282,gdsc,,,,,,,Small molecule,Phase 2,WVUNYSQLFKLYNI-AATRIKPKSA-N,CCOC1CC2NCC(C#N)C(NC3CCC(F)C(CL)C3)C2CC1NC(=O)/C=C/CN(C)C
ELACESTRANT,ELACESTRANT,CHEMBL4297509,BRD:BRD-K00003295-300-01-9,rep_single_dose,ESTROGEN RECEPTOR DEGRADER,,,,,,Small molecule,Phase 3,SIFNOOUKXBRGGB-AREMUKBSSA-N,CCNCCC1CCC(CN(CC)C2CC(OC)CCC2[C@@H]2CCC3CC(O)CCC3C2)CC1
ELACRIDAR,ELACRIDAR,CHEMBL396298,BRD:BRD-BRD-K88807631-001-01-3;BRD:BRD-K88807631-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,P GLYCOPROTEIN INHIBITOR,ABCB1,,,PHASE 1,,Small molecule,Unknown,OSFCMRGOZNQUSW-UHFFFAOYSA-N,COC1CC2C(CC1OC)CN(CCC1CCC(NC(=O)C3CCCC4C(=O)C5CCCC(OC)C5[NH]C34)CC1)CC2;COC1CC2CCN(CCC3CCC(NC(=O)C4CCCC5C4[NH]C4C(OC)CCCC4C5=O)CC3)CC2CC1OC
ELACYTARABINE,ELACYTARABINE,CHEMBL2105665,BRD:BRD-K00004609-001-01-9,rep_single_dose,ANTINEOPLASTIC AGENT,DCK,,,,,Small molecule,Phase 3,FLFGNMFWNBOBGE-FNNZEKJRSA-N,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](N2CCC(N)NC2=O)[C@@H](O)[C@@H]1O
ELAFIBRANOR,ELAFIBRANOR,CHEMBL3707395,BRD:BRD-BRD-K03165895-001-01-9;BRD:BRD-K03165895-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA;PPARD;PPARG,,,PHASE 3,"Multiple values for repurposing_target: {'PPARA;PPARD', 'PPARA;PPARD;PPARG'}, taking the union",Small molecule,Phase 3,AFLFKFHDSCQHOL-IZZDOVSWSA-N,CSC1CCC(C(=O)/C=C/C2CC(C)C(OC(C)(C)C(=O)O)C(C)C2)CC1;CSC1CCC(CC1)C(=O)\C=C\C1CC(C)C(OC(C)(C)C(O)=O)C(C)C1
ELAGOLIX,ELAGOLIX,CHEMBL1208155,BRD:BRD-BRD-K55808645-001-01-4;BRD:BRD-K55808645-001-01-4,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,GNRHR,,,PHASE 3,,Small molecule,Approved,HEAUOKZIVMZVQL-VWLOTQADSA-N,COC1CCCC(-C2C(C)N(CC3C(F)CCCC3C(F)(F)F)C(=O)N(C[C@H](NCCCC(=O)O)C3CCCCC3)C2=O)C1F;COC1CCCC(C1F)-C1C(C)N(CC2C(F)CCCC2C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2CCCCC2)C1=O
ELAMIPRETIDE (TFA),ELAMIPRETIDE (TFA),,BRD:BRD-K00079505-019-02-9,rep_single_dose,,,,,,,,NA,,
ELBASVIR,ELBASVIR,CHEMBL3039514,BRD:BRD-BRD-K09735259-001-01-3;BRD:BRD-K09735259-001-01-3,rep_primary;rep_single_dose,HCV INHIBITOR,,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,BVAZQCUMNICBAQ-PZHYSIFUSA-N,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1NCC([NH]1)-C1CCC2-C3CC4CC(CCC4N3[C@@H](OC2C1)C1CCCCC1)-C1CNC([NH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C;COC(=O)N[C@H](C(=O)N1CCC[C@H]1C1NC(-C2CCC3C(C2)O[C@@H](C2CCCCC2)N2C-3CC3CC(-C4C[NH]C([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)N4)CCC32)C[NH]1)C(C)C
ELCPK,ELCPK,,CTRP:609056,ctrp,,,,,,,,NA,,
ELDECALCITOL,ELDECALCITOL,CHEMBL4297608,BRD:BRD-K00003316-001-01-9,rep_single_dose,BONE FORMATION STIMULANT,VDR,,,,,Small molecule,Phase 3,FZEXGDDBXLBRTD-AYIMTCTASA-N,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O
ELECLAZINE,ELECLAZINE,CHEMBL3707392,BRD:BRD-K00003225-003-01-9,rep_single_dose,LATE SODIUM CURRENT INHIBITOR,,,,,,Small molecule,Phase 3,YNUAEEJQYHYLMS-UHFFFAOYSA-N,O=C1C2CC(-C3CCC(OC(F)(F)F)CC3)CCC2OCCN1CC1NCCCN1
ELENBECESTAT,ELENBECESTAT,CHEMBL4204869,BRD:BRD-K00091278-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,AACUJFVOHGRMTR-DPXNYUHVSA-N,C[C@H]1OC[C@]2(C3CC(NC(=O)C4CNC(C(F)F)CN4)CCC3F)N=C(N)SC[C@H]12
ELEPHANTIN,ELEPHANTIN,CHEMBL399907,GDSC2:1835,gdsc,,,,,,,Small molecule,NA,HSTUUCOYVIWGLJ-DXUAHVLSSA-N,C=C1C(=O)O[C@H]2[C@H]1[C@@H](OC(=O)C=C(C)C)CC1=C[C@@H](C[C@@]3(C)O[C@H]23)OC1=O
STA-4783,ELESCLOMOL;STA-4783,CHEMBL1972860,BRD:BRD-BRD-K82135108-001-04-3;BRD:BRD-K82135108-001-02-7;BRD:BRD-K82135108-001-04-3;GDSC1:1031,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose, ANTI-MITOCHONDRIAL VIA INHIBITION OF FDX1;COPPER IONOPHORE,FDX1;HSPA1A,,,PHASE 3,"Multiple values for MOA: {'OXIDATIVE STRESS INDUCER', 'COPPER IONOPHORE; ANTI-MITOCHONDRIAL VIA INHIBITION OF FDX1'}, defaulting to 'COPPER IONOPHORE; ANTI-MITOCHONDRIAL VIA INHIBITION OF FDX1'
Multiple values for repurposing_target: {'HSPA1A', 'FDX1'}, taking the union",Small molecule,Phase 3,BKJIXTWSNXCKJH-UHFFFAOYSA-N,CN(NC(=O)CC(=O)NN(C)C(=S)C1CCCCC1)C(=S)C1CCCCC1
ELETRIPTAN,ELETRIPTAN,CHEMBL1510,BRD:BRD-BRD-K30652337-004-02-1;BRD:BRD-K30652337-004-02-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2B;HTR7,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,PWVXXGRKLHYWKM-LJQANCHMSA-N,CN1CCC[C@@H]1CC1C[NH]C2CCC(CCS(=O)(=O)C3CCCCC3)CC12
ELEXACAFTOR,ELEXACAFTOR,CHEMBL4298128,BRD:BRD-K00093437-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,MVRHVFSOIWFBTE-INIZCTEOSA-N,CC1NN(C)CC1S(=O)(=O)NC(=O)C1CCC(-N2CCC(OCC(C)(C)C(F)(F)F)N2)NC1N1C[C@@H](C)CC1(C)C
ELIGLUSTAT,ELIGLUSTAT,CHEMBL2110588,BRD:BRD-BRD-K86410485-046-01-0;BRD:BRD-K86410485-046-01-0,rep_primary;rep_single_dose,GLYCOSYL TRANSFERASE INHIBITOR,UGCG,"GAUCHER DISEASE, GAUCHER DISEASE",,LAUNCHED,,Small molecule,Approved,FJZZPCZKBUKGGU-AUSIDOKSSA-N,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1CCC2C(C1)OCCO2;CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1CCC2OCCOC2C1
ELIPRODIL,ELIPRODIL,CHEMBL28564,BRD:BRD-A61392169-001-02-7;BRD:BRD-BRD-A61392169-001-02-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2B,,,PHASE 3,,Small molecule,Phase 2,GGUSQTSTQSHJAH-UHFFFAOYSA-N,OC(CN1CCC(CC2CCC(F)CC2)CC1)C1CCC(CL)CC1
ELLAGIC-ACID,ELLAGIC-ACID,,BRD:BRD-BRD-K30466858-001-09-6;BRD:BRD-K30466858-001-09-6,rep_primary;rep_single_dose,"GLUTATHIONE TRANSFERASE INHIBITOR, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR",CA1;CA12;CA14;CA2;CA3;CA4;CA5A;CA5B;CA6;CA7;CA9;CSNK2A1;GSK3B;PRKACA;PRKCA;PRKCB;SQLE;SYK,,,PHASE 2,,,NA,,OC1CC2C3C(OC(=O)C4CC(O)C(O)C(OC2=O)C34)C1O
ELLENCE,ELLENCE,CHEMBL1200981;CHEMBL417,GDSC2:1511,gdsc,,,,,,,Small molecule,Approved,AOJJSUZBOXZQNB-VTZDEGQISA-N;MWWSFMDVAYGXBV-FGBSZODSSA-N,COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.CL
ELN-441958,ELN-441958,,BRD:BRD-BRD-K50699835-001-01-2;BRD:BRD-K50699835-001-01-2,rep_primary;rep_single_dose,BRADYKININ RECEPTOR ANTAGONIST,BDKRB1,,,PRECLINICAL,,,NA,,CLC1CCCC2CN(C(=O)C12)C1CCCC(C1)C(=O)N1CCC2(CC1)CCN(CC2)C1CCNCC1
ELOCALCITOL,ELOCALCITOL,CHEMBL3545094,CTRP:660319,ctrp,,,,,,,Small molecule,Phase 2,XDBOQJCMEXOPMU-BAHYQGKPSA-N,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@@H](C)C/C=C/C(O)(CC)CC)=CCC23)C[C@@H](O)C[C@@H]1O
ELOXATIN,ELOXATIN,CHEMBL414804,GDSC2:1089,gdsc,,,,,,,Small molecule,Approved,,
ELTANEXOR,ELTANEXOR,CHEMBL4297623,BRD:BRD-K00003369-001-01-9,rep_single_dose,EXPORTIN INHIBITOR,,,,,,Small molecule,Phase 1,JFBAVWVBLRIWHM-AWNIVKPZSA-N,NC(=O)/C(=C/N1CNC(-C2CC(C(F)(F)F)CC(C(F)(F)F)C2)N1)C1CNCNC1
ELTANOLONE,ELTANOLONE,CHEMBL207538;CHEMBL210952,BRD:BRD-BRD-K18172896-001-02-5;BRD:BRD-K18172896-001-02-5,rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,GABRA1;GABRB2;GABRG2,,,PHASE 3,,Small molecule,Approved,AURFZBICLPNKBZ-SYBPFIFISA-N;AURFZBICLPNKBZ-YZRLXODZSA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C;CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
ELTOPRAZINE,ELTOPRAZINE,CHEMBL282614,BRD:BRD-BRD-K86171477-001-01-3;BRD:BRD-K86171477-001-01-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B,,,PHASE 2,,Small molecule,Phase 2,WVLHGCRWEHCIOT-UHFFFAOYSA-N,C1CC2C(C(N3CCNCC3)C1)OCCO2;C1CN(CCN1)C1CCCC2OCCOC12
ELTROMBOPAG,ELTROMBOPAG,CHEMBL461101,BRD:BRD-BRD-K40496271-396-01-1;BRD:BRD-K40496271-396-01-1,rep_multi_dose;rep_primary;rep_single_dose,THROMBOPOIETIN RECEPTOR AGONIST,MPL,"ANEMIA, HEPATITIS C, THROMBOCYTOPENIA",,LAUNCHED,,Small molecule,Approved,XDXWLKQMMKQXPV-QYQHSDTDSA-N,CC1=NN(C(=O)C\1=N\NC1CCCC(-C2CCCC(C2)C(O)=O)C1O)C1CCC(C)C(C)C1;CC1=NN(C2CCC(C)C(C)C2)C(=O)/C1=N\NC1CCCC(-C2CCCC(C(=O)O)C2)C1O
ELUXADOLINE,ELUXADOLINE,CHEMBL2159122,BRD:BRD-BRD-K39560679-001-01-1;BRD:BRD-K39560679-001-01-1,rep_primary;rep_single_dose,"OPIOID RECEPTOR AGONIST, OPIOID RECEPTOR ANTAGONIST, OPIOID RECEPTOR MODULATOR",OPRD1;OPRK1;OPRM1,IRRITABLE BOWEL SYNDROME,,LAUNCHED,"Multiple values for MOA: {'OPIOID RECEPTOR AGONIST, OPIOID RECEPTOR ANTAGONIST, OPIOID RECEPTOR MODULATOR', 'OPIOID RECEPTOR MODULATOR'}, defaulting to 'OPIOID RECEPTOR AGONIST, OPIOID RECEPTOR ANTAGONIST, OPIOID RECEPTOR MODULATOR'",Small molecule,Approved,QFNHIDANIVGXPE-FNZWTVRRSA-N,COC1CCC(CN([C@@H](C)C2NCC([NH]2)-C2CCCCC2)C(=O)[C@@H](N)CC2C(C)CC(CC2C)C(N)=O)CC1C(O)=O;COC1CCC(CN(C(=O)[C@@H](N)CC2C(C)CC(C(N)=O)CC2C)[C@@H](C)C2NCC(-C3CCCCC3)[NH]2)CC1C(=O)O
ELVITEGRAVIR,ELVITEGRAVIR,CHEMBL204656,BRD:BRD-BRD-K54472332-001-03-4;BRD:BRD-K54472332-001-03-4,rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,JUZYLCPPVHEVSV-LJQANCHMSA-N,COC1CC2C(CC1CC1CCCC(CL)C1F)C(=O)C(C(=O)O)CN2[C@H](CO)C(C)C;COC1CC2N(CC(C(O)=O)C(=O)C2CC1CC1CCCC(CL)C1F)[C@H](CO)C(C)C
EMAMECTIN,EMAMECTIN,CHEMBL3138875,BRD:BRD-K00003516-057-01-9,rep_single_dose,GABA RECEPTOR AGONIST,,,,,,Small molecule,NA,CXEGAUYXQAKHKJ-MYANALBDSA-N,CC[C@H](C)C1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@H](NC)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
EMBELIC ACID,EMBELIC ACID,,GDSC1:172,gdsc,,,,,,,,NA,,
EMBELIN,EMBELIN,CHEMBL221137,BRD:BRD-BRD-K86727142-001-12-4;BRD:BRD-K86727142-001-12-4;GDSC1:172,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"HCV INHIBITOR, XIAP INHIBITOR",XIAP,,,PRECLINICAL,,Small molecule,NA,IRSFLDGTOHBADP-UHFFFAOYSA-N,CCCCCCCCCCCC1=C(O)C(=O)C=C(O)C1=O;CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O
EMBERINE,EMBERINE,,GDSC1:172,gdsc,,,,,,,,NA,,
EMD-1214063,EMD-1214063,CHEMBL3402762,BRD:BRD-BRD-K97963946-001-01-3;BRD:BRD-K97963946-001-01-3,rep_primary;rep_single_dose,HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR,MET,,,PHASE 1,,Small molecule,Approved,AHYMHWXQRWRBKT-UHFFFAOYSA-N,CN1CCC(COC2CNC(-C3CCCC(CN4NC(-C5CCCC(C#N)C5)CCC4=O)C3)NC2)CC1;CN1CCC(COC2CNC(NC2)-C2CCCC(CN3NC(CCC3=O)-C3CCCC(C3)C#N)C2)CC1
EMD-386088,EMD-386088,,BRD:BRD-BRD-K47659338-003-02-8;BRD:BRD-K47659338-003-02-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR6,,,PRECLINICAL,,,NA,,CC1[NH]C2CCC(CL)CC2C1C1=CCNCC1
EMD-53998,EMD-53998,,BRD:BRD-A65248799-001-01-7;BRD:BRD-BRD-A65248799-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,TNNC1,,,PHASE 1,,,NA,,COC1CCC(CC1OC)C(=O)N1CCCC2CC(CCC12)C1=NNC(=O)SC1C
EMD-66684,EMD-66684,,BRD:BRD-BRD-K88759641-003-02-8;BRD:BRD-K88759641-003-02-8,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,,,PRECLINICAL,,,NA,,CCCCC1NC2CCN(CC(=O)N(C)C)C(=O)C2N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
EMD534085,EMD534085,,BRD:BRD-K00003185-001-01-9,rep_single_dose,KINESIN INHIBITOR,,,,,,,NA,,
EMEDASTINE,EMEDASTINE,CHEMBL594,BRD:BRD-BRD-K15010214-364-02-7;BRD:BRD-K15010214-364-02-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,KBUZBQVCBVDWKX-UHFFFAOYSA-N,CCOCCN1C(N2CCCN(C)CC2)NC2CCCCC21;CCOCCN1C(NC2CCCCC12)N1CCCN(C)CC1
EMERAMIDE,EMERAMIDE,CHEMBL4297510,BRD:BRD-K00003226-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,Small molecule,Phase 2,JUTBAVRYDAKVGQ-UHFFFAOYSA-N,O=C(NCCS)C1CCCC(C(=O)NCCS)C1
EMETINE,EMETINE,CHEMBL50588,BRD:BRD-A25687296-300-04-3;BRD:BRD-BRD-A25687296-300-04-3,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,RPS2,,,PHASE 2,,Small molecule,Unknown,AUVVAXYIELKVAI-CKBKHPSWSA-N,CC[C@H]1CN2CCC3CC(OC)C(OC)CC3[C@@H]2C[C@@H]1C[C@H]1NCCC2CC(OC)C(OC)CC12;CC[C@H]1CN2CCC3CC(OC)C(OC)CC3[C@@H]2C[C@@H]1C[C@H]1NCCC2CC(OC)C(OC)CC21;CC[C@H]1CN2CCC3CC(OC)C(OC)CC3C2C[C@@H]1CC1NCCC2CC(OC)C(OC)CC12
EMIGLITATE,EMIGLITATE,CHEMBL2106304,BRD:BRD-K00003206-001-01-9,rep_single_dose,ALPHA GLUCOSIDE INHIBITOR,,,,,,Small molecule,Unknown,NWWORXYTJRPSMC-QKPAOTATSA-N,CCOC(=O)C1CCC(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)CC1
EMIXUSTAT,EMIXUSTAT,CHEMBL2107821,BRD:BRD-K00003290-003-01-9,rep_single_dose,RETINOID ISOMEROHYDROLASE INHIBITOR,,,,,,Small molecule,Phase 3,WJIGGYYSZBWCGC-MRXNPFEDSA-N,NCC[C@@H](O)C1CCCC(OCC2CCCCC2)C1
EMODEPSIDE,EMODEPSIDE,CHEMBL2104404,BRD:BRD-K00003414-001-01-9,rep_single_dose,NEMATOCIDE,,,,,,Small molecule,Phase 2,ZMQMTKVVAMWKNY-YSXLEBCMSA-N,CC(C)C[C@H]1C(=O)O[C@H](CC2CCC(N3CCOCC3)CC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](CC2CCC(N3CCOCC3)CC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N1C
EMODIN,EMODIN,CHEMBL289277,BRD:BRD-BRD-K58685305-001-20-4;BRD:BRD-K58685305-001-20-4,rep_primary;rep_single_dose,11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR,CSNK2A1,,,PRECLINICAL,,Small molecule,NA,RHMXXJGYXNZAPX-UHFFFAOYSA-N,CC1CC(O)C2C(=O)C3C(O)CC(O)CC3C(=O)C2C1;CC1CC(O)C2C(C1)C(=O)C1CC(O)CC(O)C1C2=O
EMORFAZONE,EMORFAZONE,CHEMBL2103954,BRD:BRD-BRD-K90629600-001-01-4;BRD:BRD-K90629600-001-01-4,rep_primary;rep_single_dose,"ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT, CYCLOOXYGENASE INHIBITOR",,MOUTH INFLAMMATION,,LAUNCHED,"Multiple values for MOA: {'ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT, CYCLOOXYGENASE INHIBITOR', 'ANTIINFLAMMATORY AGENT, CYCLOOXYGENASE INHIBITOR'}, defaulting to 'ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT, CYCLOOXYGENASE INHIBITOR'",Small molecule,Unknown,URJQOOISAKEBKW-UHFFFAOYSA-N,CCOC1C(CNN(C)C1=O)N1CCOCC1;CCOC1C(N2CCOCC2)CNN(C)C1=O
EMOXIPIN,EMOXIPIN,,BRD:BRD-BRD-K28982731-001-01-6;BRD:BRD-K28982731-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CCC1NC(C)CCC1O
EMPAGLIFLOZIN,EMPAGLIFLOZIN,CHEMBL2107830,BRD:BRD-BRD-K53765467-001-02-1;BRD:BRD-K53765467-001-02-1,rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A1;SLC5A2,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,OBWASQILIWPZMG-QZMOQZSNSA-N,OC[C@H]1O[C@@H](C2CCC(CL)C(CC3CCC(O[C@H]4CCOC4)CC3)C2)[C@H](O)[C@@H](O)[C@@H]1O;OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1CCC(CL)C(CC2CCC(O[C@H]3CCOC3)CC2)C1
EMRICASAN,EMRICASAN,CHEMBL197672,BRD:BRD-K00023644-001-01-9,rep_single_dose,CASPASE INHIBITOR,CASP1;CASP3;CASP7,,,,,Small molecule,Phase 2,SCVHJVCATBPIHN-SJCJKPOMSA-N,C[C@H](NC(=O)C(=O)NC1CCCCC1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COC1C(F)C(F)CC(F)C1F
EMTRICITABINE,EMTRICITABINE,CHEMBL161381;CHEMBL885,BRD:BRD-BRD-K61452026-001-04-6;BRD:BRD-K61452026-001-04-6,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,XQSPYNMVSIKCOC-NTSWFWBYSA-N;XQSPYNMVSIKCOC-UHFFFAOYSA-N,NC1NC(=O)N([C@@H]2CS[C@H](CO)O2)CC1F;NC1NC(=O)N(C2CSC(CO)O2)CC1F;NC1NC(=O)N(CC1F)[C@@H]1CS[C@H](CO)O1
ENALAPRIL,ENALAPRIL,CHEMBL578,BRD:BRD-BRD-K57545991-050-23-1;BRD:BRD-K57545991-050-23-1,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, CONGESTIVE HEART FAILURE, LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)",,LAUNCHED,,Small molecule,Approved,GBXSMTUPTTWBMN-XIRDDKMYSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O;CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
ENALAPRILAT,ENALAPRILAT,CHEMBL3989406;CHEMBL577,BRD:BRD-BRD-K99447003-335-04-1;BRD:BRD-K99447003-335-04-1,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,LZFZMUMEGBBDTC-QEJZJMRPSA-N;MZYVOFLIPYDBGD-MLZQUWKJSA-N,C[C@H](N[C@@H](CCC1CCCCC1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O;C[C@H](N[C@@H](CCC1CCCCC1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O;C[C@H](N[C@@H](CCC1CCCCC1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
ENARODUSTAT,ENARODUSTAT,CHEMBL4297619,BRD:BRD-K00090634-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,NALAUGMPMIVAOW-UHFFFAOYSA-N,O=C(O)CNC(=O)C1C(O)CC(CCC2CCCCC2)N2NCNC12
ENASIDENIB,ENASIDENIB,CHEMBL3989908,BRD:BRD-BRD-K70601687-001-01-3;BRD:BRD-K70601687-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,IDH1,ACUTE MYELOID LEUKEMIA (AML),,LAUNCHED,,Small molecule,Approved,DYLUUSLLRIQKOE-UHFFFAOYSA-N,CC(C)(O)CNC1NC(NC2CCNC(C(F)(F)F)C2)NC(-C2CCCC(C(F)(F)F)N2)N1;CC(C)(O)CNC1NC(NC2CCNC(C2)C(F)(F)F)NC(N1)-C1CCCC(N1)C(F)(F)F
ENCIPRAZINE,ENCIPRAZINE,CHEMBL101284,BRD:BRD-A62197763-001-01-1;BRD:BRD-BRD-A62197763-001-01-1,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1,,,PHASE 3,,Small molecule,Unknown,KSQCNASWXSCJTD-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CC(O)COC2CC(OC)C(OC)C(OC)C2)CC1
LGX818,ENCORAFENIB;LGX818,CHEMBL3301612,BRD:BRD-A56085258-001-01-8;BRD:BRD-BRD-A56085258-001-01-8;BRD:BRD-K00003576-001-01-9;BRD:BRD-K00003576-001-03-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF BRAF,BRAF,,,PHASE 3,"Multiple values for MOA: {'INHIBITOR OF BRAF', 'RAF INHIBITOR'}, defaulting to 'INHIBITOR OF BRAF'
Multiple values for structure_id: {'K00003576', 'A56085258'}, defaulting to None",Small molecule,Approved,CMJCXYNUCSMDBY-ZDUSSCGKSA-N,COC(=O)N[C@@H](C)CNC1NCCC(-C2CN(C(C)C)NC2-C2CC(CL)CC(NS(C)(=O)=O)C2F)N1;COC(=O)NC(C)CNC1NCCC(N1)-C1CN(NC1-C1CC(CL)CC(NS(C)(=O)=O)C1F)C(C)C
ENDO-IWR-1,ENDO-IWR-1,,BRD:BRD-BRD-K61314889-001-04-4;BRD:BRD-BRD-K61314889-001-05-1;BRD:BRD-K61314889-001-04-4;BRD:BRD-K61314889-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,TNKS;TNKS2,,,PRECLINICAL,,,NA,,O=C(NC1CCCC2CCCNC12)C1CCC(CC1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O
ENFLURANE,ENFLURANE,CHEMBL1257,BRD:BRD-A51831848-001-01-7;BRD:BRD-BRD-A51831848-001-01-7,rep_primary;rep_single_dose,MEMBRANE PERMEABILITY INHIBITOR,ATP2C1;ATP5D;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;GLRB;GRIA1;KCNA1;KCNK10;KCNK18;KCNK2;KCNK3;KCNK9;KCNN4,,,LAUNCHED,,Small molecule,Approved,JPGQOUSTVILISH-UHFFFAOYSA-N,FC(F)OC(F)(F)C(F)CL
ENILCONAZOLE,ENILCONAZOLE,CHEMBL356918,BRD:BRD-A11776908-065-01-5;BRD:BRD-BRD-A11776908-065-01-5,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,CYP19A1;CYP1A2;CYP2B6;CYP2C9;CYP2J2;CYP3A4;CYP3A5;NR1I2;PPARA;PTGER2,SKIN INFECTIONS,,LAUNCHED,,Small molecule,Unknown,PZBPKYOVPCNPJY-UHFFFAOYSA-N,C=CCOC(CN1CCNC1)C1CCC(CL)CC1CL;CLC1CCC(C(CN2CCNC2)OCC=C)C(CL)C1
ENIPORIDE,ENIPORIDE,CHEMBL64360,BRD:BRD-K00004568-001-01-9,rep_single_dose,SODIUM/HYDROGEN ANTIPORT INHIBITOR,,,,,,Small molecule,Unknown,UADMBZFZZOBWBB-UHFFFAOYSA-N,CC1CC(-N2CCCC2)C(S(C)(=O)=O)CC1C(=O)N=C(N)N
ENISAMIUM-IODIDE,ENISAMIUM-IODIDE,,BRD:BRD-BRD-K10029415-005-06-9;BRD:BRD-K10029415-005-06-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,C[N+]1CCC(CC1)C(=O)NCC1CCCCC1
ENMD-2076,ENMD-2076,CHEMBL482968;CHEMBL52885,BRD:BRD-BRD-K68488863-001-04-9;BRD:BRD-K68488863-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,"AURORA KINASE INHIBITOR, FLT3 INHIBITOR, VEGFR INHIBITOR",AURKA;FLT3;KDR;PDGFRA;PTK2;SRC,,,PHASE 2,,Small molecule,Phase 2,BLQYVHBZHAISJM-CMDGGOBGSA-N;OVSKGTONMLKNPZ-UHFFFAOYSA-N,CC1CC(NC2CC(N3CCN(C)CC3)NC(/C=C/C3CCCCC3)N2)N[NH]1;CN1CC(C2=C(C3CN(C)C4CC([N+](=O)[O-])CCC34)C(=O)NC2=O)C2CCCCC21;CN1CCN(CC1)C1CC(NC2CC(C)[NH]N2)NC(\C=C\C2CCCCC2)N1
ENOCITABINE,ENOCITABINE,CHEMBL2106589,BRD:BRD-BRD-K32007074-001-02-9;BRD:BRD-K32007074-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,CMPK1;RRM1;TYMS,,,LAUNCHED,,Small molecule,Unknown,SAMRUMKYXPVKPA-VFKOLLTISA-N,CCCCCCCCCCCCCCCCCCCCCC(=O)NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)N1
ENOXACIN,ENOXACIN,CHEMBL826,BRD:BRD-BRD-K78113049-001-16-2;BRD:BRD-K78113049-001-16-2,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,"URINARY TRACT INFECTIONS, GONORRHEA",,LAUNCHED,,Small molecule,Approved,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,CCN1CC(C(=O)O)C(=O)C2CC(F)C(N3CCNCC3)NC21;CCN1CC(C(O)=O)C(=O)C2CC(F)C(NC12)N1CCNCC1
ENOXIMONE,ENOXIMONE,CHEMBL249856,BRD:BRD-BRD-K21152241-001-07-3;BRD:BRD-K21152241-001-07-3,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Approved,ZJKNESGOIKRXQY-UHFFFAOYSA-N,CSC1CCC(C(=O)C2[NH]C(=O)[NH]C2C)CC1;CSC1CCC(CC1)C(=O)C1[NH]C(O)NC1C
ENOXOLONE,ENOXOLONE,CHEMBL230006,BRD:BRD-BRD-K96137854-001-17-1;BRD:BRD-K96137854-001-17-1,rep_primary;rep_single_dose,GAP JUNCTION MODULATOR,HSD11B1,"PEPTIC ULCER DISEASE (PUD), COMMON COLD",,LAUNCHED,,Small molecule,Phase 2,MPDGHEJMBKOTSU-YKLVYJNSSA-N,C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O;CC1(C)[C@@H](O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12
ENPROFYLLINE,ENPROFYLLINE,CHEMBL279898,BRD:BRD-BRD-K35007173-001-07-5;BRD:BRD-K35007173-001-07-5,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,ADORA1;ADORA2A;ADORA2B;ADORA3;PDE4A;PDE4B,,,PHASE 3,,Small molecule,Unknown,SIQPXVQCUCHWDI-UHFFFAOYSA-N,CCCN1C(=O)[NH]C(=O)C2NC[NH]C21;CCCN1C2NC[NH]C2C(=O)[NH]C1=O
ENROFLOXACIN,ENROFLOXACIN,CHEMBL15511,BRD:BRD-BRD-K76534306-001-22-7;BRD:BRD-K76534306-001-22-7,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,"GRAM-NEGATIVE BACTERIAL INFECTIONS, GRAM-NEGATIVE BACTERIAL INFECTIONS",,LAUNCHED,,Small molecule,Unknown,SPFYMRJSYKOXGV-UHFFFAOYSA-N,CCN1CCN(C2CC3C(CC2F)C(=O)C(C(=O)O)CN3C2CC2)CC1;CCN1CCN(CC1)C1CC2N(CC(C(O)=O)C(=O)C2CC1F)C1CC1
ENSARTINIB HYDROCHLORIDE,ENSARTINIB HYDROCHLORIDE,CHEMBL4297219,BRD:BRD-K00073038-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,IERUINQRGJAECT-ISUJJMBGSA-N,C[C@@H]1CN(C(=O)C2CCC(NC(=O)C3CC(O[C@H](C)C4C(CL)CCC(F)C4CL)C(N)NN3)CC2)C[C@H](C)N1.CL.CL
ENTACAPONE,ENTACAPONE,CHEMBL953,BRD:BRD-BRD-K83636919-001-04-8;BRD:BRD-K83636919-001-04-8,rep_primary;rep_single_dose,CATECHOL O METHYLTRANSFERASE INHIBITOR,COMT,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,JRURYQJSLYLRLN-BJMVGYQFSA-N,CCN(CC)C(=O)/C(C#N)=C/C1CC(O)C(O)C([N+](=O)[O-])C1;CCN(CC)C(=O)C(\C#N)=C\C1CC(O)C(O)C(C1)[N+]([O-])=O
ENTASOBULIN,ENTASOBULIN,,BRD:BRD-K00004610-001-01-9,rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,,,,NA,,
ENTECAVIR,ENTECAVIR,CHEMBL713,BRD:BRD-BRD-K08206212-002-01-0;BRD:BRD-K08206212-002-01-0,rep_primary;rep_single_dose,"DNA REPLICATION INHIBITOR, NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR",,HEPATITIS B,,LAUNCHED,,Small molecule,Approved,QDGZDCVAUDNJFG-FXQIFTODSA-N,C=C1[C@H](CO)[C@@H](O)C[C@@H]1N1CNC2C(=O)[NH]C(N)NC21;NC1NC(=O)C2NCN([C@H]3C[C@H](O)[C@@H](CO)C3=C)C2[NH]1
ENTINOSTAT,ENTINOSTAT,CHEMBL27759,BRD:BRD-BRD-K77908580-001-09-6;BRD:BRD-K77908580-001-09-6;CTRP:60218;GDSC1:88;GDSC2:1593,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC9,,,PHASE 3,,Small molecule,Phase 3,INVTYAOGFAGBOE-UHFFFAOYSA-N,NC1CCCCC1NC(=O)C1CCC(CNC(=O)OCC2CCCNC2)CC1
ENTOSPLETINIB,ENTOSPLETINIB,CHEMBL3265032,GDSC2:1630,gdsc,,,,,,,Small molecule,Phase 3,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,C1CN2CC(-C3CCC4CN[NH]C4C3)NC(NC3CCC(N4CCOCC4)CC3)C2N1
ENTRECTINIB,ENTRECTINIB,CHEMBL1983268,BRD:BRD-BRD-K39009484-001-01-4;BRD:BRD-K39009484-001-01-4,rep_primary;rep_single_dose,"ALK TYROSINE KINASE RECEPTOR INHIBITOR, PROTO-ONCOGENE TYROSINE PROTEIN KINASE INHIBITOR",ALK;NTRK1;NTRK2;NTRK3;ROS1,,,PHASE 2,,Small molecule,Approved,HAYYBYPASCDWEQ-UHFFFAOYSA-N,CN1CCN(C2CCC(C(=O)NC3N[NH]C4CCC(CC5CC(F)CC(F)C5)CC34)C(NC3CCOCC3)C2)CC1;CN1CCN(CC1)C1CCC(C(=O)NC2N[NH]C3CCC(CC4CC(F)CC(F)C4)CC23)C(NC2CCOCC2)C1
MDV3100,ENZALUTAMIDE;MDV3100,CHEMBL1082407,BRD:BRD-BRD-K56851771-001-06-8;BRD:BRD-K56851771-001-06-8;BRD:BRD-K56851771-001-09-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF ANDROGEN RECEPTOR,AR,PROSTATE CANCER,,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF ANDROGEN RECEPTOR', 'ANDROGEN RECEPTOR ANTAGONIST'}, defaulting to 'INHIBITOR OF ANDROGEN RECEPTOR'",Small molecule,Approved,WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)C1CCC(CC1F)N1C(=S)N(C(=O)C1(C)C)C1CCC(C#N)C(C1)C(F)(F)F;CNC(=O)C1CCC(N2C(=S)N(C3CCC(C#N)C(C(F)(F)F)C3)C(=O)C2(C)C)CC1F
ENZASTAURIN,ENZASTAURIN,CHEMBL300138,BRD:BRD-BRD-K79404599-001-09-3;BRD:BRD-K79404599-001-09-3;GDSC1:229,gdsc;rep_primary;rep_single_dose,PKC INHIBITOR,AKT1;GSK3B;PRKCA;PRKCB;PRKCD;PRKCG,,,PHASE 3,,Small molecule,Phase 3,AXRCEOKUDYDWLF-UHFFFAOYSA-N,CN1CC(C2=C(C(=O)NC2=O)C2CN(C3CCN(CC4CCCCN4)CC3)C3CCCCC23)C2CCCCC12;CN1CC(C2=C(C3CN(C4CCN(CC5CCCCN5)CC4)C4CCCCC34)C(=O)NC2=O)C2CCCCC21
EO-1428,EO-1428,,BRD:BRD-BRD-K42452249-001-02-5;BRD:BRD-K42452249-001-02-5,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK11;MAPK14,,,PRECLINICAL,,,NA,,CC1CCCCC1C(=O)C1CCC(NC2CCC(BR)CC2N)CC1CL
INCB-024360,EPACADOSTAT;INCB-024360,CHEMBL3545369,BRD:BRD-BRD-K79450420-001-01-8;BRD:BRD-BRD-K79450420-001-02-6;BRD:BRD-K79450420-001-01-8;BRD:BRD-K79450420-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,"INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",IDO1,,,PHASE 3,"Multiple values for Phase: {'PHASE 2', 'PHASE 3'}, defaulting to 'PHASE 3'
Multiple values for SMILES: {'NS(=O)(=O)NCCNC1NONC1\\C(NC1CCC(F)C(BR)C1)=N\\O', 'NS(=O)(=O)NCCNC1NONC1\\C(NC1CCC(F)C(BR)C1)=N\\O, NS(=O)(=O)NCCNC1NONC1\\C(NC1CCC(F)C(BR)C1)=N\\O'}, defaulting to 'NS(=O)(=O)NCCNC1NONC1\\C(NC1CCC(F)C(BR)C1)=N\\O, NS(=O)(=O)NCCNC1NONC1\\C(NC1CCC(F)C(BR)C1)=N\\O'",Small molecule,Phase 3,FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNC1NONC1/C(=N/O)NC1CCC(F)C(BR)C1;NS(=O)(=O)NCCNC1NONC1\C(NC1CCC(F)C(BR)C1)=N\O
EPALRESTAT,EPALRESTAT,CHEMBL56337,BRD:BRD-BRD-K98054437-001-09-9;BRD:BRD-K98054437-001-09-9,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,DIABETIC NEPHROPATHY,,LAUNCHED,,Small molecule,Phase 3,CHNUOJQWGUIOLD-NFZZJPOKSA-N,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\C1CCCCC1;CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1CCCCC1
EPEREZOLID,EPEREZOLID,CHEMBL47955,BRD:BRD-BRD-K47554101-001-01-2;BRD:BRD-K47554101-001-01-2,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,SIMWTRCFFSTNMG-AWEZNQCLSA-N,CC(=O)NC[C@H]1CN(C(=O)O1)C1CCC(N2CCN(CC2)C(=O)CO)C(F)C1;CC(=O)NC[C@H]1CN(C2CCC(N3CCN(C(=O)CO)CC3)C(F)C2)C(=O)O1
EPERISONE,EPERISONE,CHEMBL1902981,BRD:BRD-A04252265-003-01-4;BRD:BRD-BRD-A04252265-003-01-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CYP2J2,"AMYOTROPHIC LATERAL SCLEROSIS (ALS), SPASMS, HEAD INJURY, SPINAL INJURY",,LAUNCHED,,Small molecule,Phase 3,SQUNAWUMZGQQJD-UHFFFAOYSA-N,CCC1CCC(C(=O)C(C)CN2CCCCC2)CC1;CCC1CCC(CC1)C(=O)C(C)CN1CCCCC1
EPETRABOROLE,EPETRABOROLE,CHEMBL3549142,BRD:BRD-K00003130-003-01-9,rep_single_dose,LEUCYL-TRNA SYNTHETASE INHIBITOR,,,,,,Small molecule,Phase 2,FXQIIDINBDJDKL-SNVBAGLBSA-N,NC[C@H]1OB(O)C2C(OCCCO)CCCC21
EPHEDRINE,EPHEDRINE,CHEMBL211456,BRD:BRD-BRD-K45014108-003-01-8;BRD:BRD-K45014108-003-01-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ACHE;ADRA1A;ADRB2;SLC18A2;SLC6A2,"HYPOTENSION, ASTHMA, NARCOLEPSY, OBESITY",,LAUNCHED,,Small molecule,Approved,KWGRBVOPPLSCSI-WPRPVWTQSA-N,CN[C@@H](C)[C@H](O)C1CCCCC1
EPHEDRINE-(RACEMIC),EPHEDRINE-(RACEMIC),,BRD:BRD-A54236247-003-04-3;BRD:BRD-BRD-A54236247-003-04-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA2A;ADRB1;ADRB2;ATF1;ATF2;ATF3;ATF4;ATF5;ATF6;ATF7;FOS;IL2;JDP2;JUN;NFATC1;SLC6A2;SLC6A3;SLC6A4;TNF,"HYPOTENSION, ASTHMA, NARCOLEPSY, OBESITY",,LAUNCHED,"Multiple values for repurposing_target: {'ADRA1A;ADRA2A;ADRB1;ADRB2;ATF1;ATF2;ATF3;ATF4;ATF5;ATF6;ATF7;FOS;IL2;JDP2;JUN;NFATC1;SLC6A2;SLC6A3;SLC6A4;TNF', 'ADRA1A;ADRA2A'}, taking the union",,NA,,CNC(C)C(O)C1CCCCC1
EPI-001,EPI-001,,BRD:BRD-K00077340-001-02-9,rep_single_dose,,,,,,,,NA,,
EPIANDROSTERONE,EPIANDROSTERONE,CHEMBL272195,BRD:BRD-BRD-K42756753-001-01-9;BRD:BRD-K42756753-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,STEROID,G6PD,,,PRECLINICAL,,Small molecule,NA,QGXBDMJGAMFCBF-LUJOEAJASA-N,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O;C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
EPICATECHIN-GALLATE-(-),EPICATECHIN-GALLATE-(-),,BRD:BRD-BRD-K50660797-001-05-1;BRD:BRD-K50660797-001-05-1,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,BACE1;FASN,,,PHASE 2,,,NA,,OC1CC(O)C2C[C@@H](OC(=O)C3CC(O)C(O)C(O)C3)[C@H](OC2C1)C1CCC(O)C(O)C1
EPIGALLOCATECHIN-(-),EPIGALLOCATECHIN-(-),,BRD:BRD-K27529556-001-04-9,rep_single_dose,,,,,,,,NA,,
EPIGALLOCATECHIN-3-MONOGALLATE,EPIGALLOCATECHIN-3-MONOGALLATE,,CTRP:28801,ctrp,,,,,,,,NA,,
EPIGALLOCATECHIN-GALLATE-(-),EPIGALLOCATECHIN-GALLATE-(-),,BRD:BRD-BRD-K55591206-001-20-7;BRD:BRD-K55591206-001-20-7,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,ELANE;EP300;FASN;KAT2B;MMP14;MMP2,,,PHASE 2/PHASE 3,,,NA,,OC1CC(O)C2C[C@@H](OC(=O)C3CC(O)C(O)C(O)C3)[C@H](OC2C1)C1CC(O)C(O)C(O)C1
EPINASTINE,EPINASTINE,CHEMBL1106,BRD:BRD-A98990573-003-01-3;BRD:BRD-BRD-A98990573-003-01-3,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA2A;HRH1;HRH2;HTR2A;HTR7,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,WHWZLSFABNNENI-UHFFFAOYSA-N,NC1=NCC2C3CCCCC3CC3CCCCC3N12;NC1=NCC2N1C1CCCCC1CC1CCCCC21
EPINEPHRINE,EPINEPHRINE,CHEMBL1740;CHEMBL679,BRD:BRD-BRD-K63126190-003-01-6;BRD:BRD-K63126190-003-01-6,rep_multi_dose;rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, CARBONIC ANHYDRASE ACTIVATOR, NEUROTRANSMITTER",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3;PAH;TNF,"CARDIAC ARREST, ANAPHYLACTIC SHOCK, ASTHMA",,LAUNCHED,"Multiple values for MOA: {'ADRENERGIC RECEPTOR AGONIST, CARBONIC ANHYDRASE ACTIVATOR, NEUROTRANSMITTER', 'ADRENERGIC RECEPTOR AGONIST, NEUROTRANSMITTER'}, defaulting to 'ADRENERGIC RECEPTOR AGONIST, CARBONIC ANHYDRASE ACTIVATOR, NEUROTRANSMITTER'",Small molecule,Approved,UCTWMZQNUQWSLP-UHFFFAOYSA-N;UCTWMZQNUQWSLP-VIFPVBQESA-N,CNC[C@H](O)C1CCC(O)C(O)C1;CNCC(O)C1CCC(O)C(O)C1
EPIRIZOLE,EPIRIZOLE,CHEMBL1411693,BRD:BRD-BRD-K39339537-001-21-0;BRD:BRD-K39339537-001-21-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,RHAXSHUQNIEUEY-UHFFFAOYSA-N,COC1CC(C)NC(-N2NC(C)CC2OC)N1;COC1CC(C)NN1-C1NC(C)CC(OC)N1
EPIRUBICIN,EPIRUBICIN,CHEMBL417,BRD:BRD-BRD-K04548931-003-16-5;BRD:BRD-K04548931-003-16-5;GDSC2:1511,gdsc;rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,CHD1;TOP2A,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,AOJJSUZBOXZQNB-VTZDEGQISA-N,COC1CCCC2C(=O)C3C(O)C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4C(O)C3C(=O)C12)C(=O)CO;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
EPITALON (TFA),EPITALON (TFA),,BRD:BRD-K00078221-019-02-9,rep_single_dose,,,,,,,,NA,,
EPITIOSTANOL,EPITIOSTANOL,CHEMBL2106161,BRD:BRD-BRD-K02314383-001-01-3;BRD:BRD-K02314383-001-01-3,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,,,LAUNCHED,,Small molecule,Unknown,OBMLHUPNRURLOK-XGRAFVIBSA-N,C[C@]12C[C@H]3S[C@H]3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12;C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O
EPLERENONE,EPLERENONE,CHEMBL1095097,BRD:BRD-BRD-K19761926-001-02-8;BRD:BRD-BRD-K19761926-001-03-6;BRD:BRD-K19761926-001-02-8;BRD:BRD-K19761926-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,NR3C2,"CONGESTIVE HEART FAILURE, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,JUKPWJGBANNWMW-VWBFHTRKSA-N,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13;COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13
EPO906,EPO906,,GDSC1:201,gdsc,,,,,,,,NA,,
EPOB,EPOB,,GDSC1:201,gdsc,,,,,,,,NA,,
EPOPROSTENOL,EPOPROSTENOL,CHEMBL1139,BRD:BRD-BRD-K64054020-001-03-5;BRD:BRD-K64054020-001-03-5,rep_primary;rep_single_dose,PROSTACYCLIN ANALOG,P2RY12;PTGER1;PTGER4;PTGIR;PTGIS,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,KAQKFAOMNZTLHT-OZUDYXHBSA-N,CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O;CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O
EPOSIN,EPOSIN,,GDSC1:134,gdsc,,,,,,,,NA,,
EPOTHILONE B,EPOTHILONE B,CHEMBL94657,GDSC1:201,gdsc,,,,,,,Small molecule,Phase 3,QXRSDHAAWVKZLJ-PVYNADRNSA-N,C/C(=C\C1CSC(C)N1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
EPOTHILONE-A,EPOTHILONE-A,,BRD:BRD-BRD-K71823332-001-03-7;BRD:BRD-K71823332-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE STABILIZING AGENT,,,,PRECLINICAL,,,NA,,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1CSC(C)N1
EPOTHILONE-B,EPOTHILONE-B,,BRD:BRD-BRD-K68164687-001-01-6;BRD:BRD-K68164687-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,"MICROTUBULE STABILIZING AGENT, TUBULIN POLYMERIZATION INHIBITOR",TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA4A;TUBA8;TUBB;TUBB1;TUBB3;TUBB4A;TUBB4B,,,PHASE 3,,,NA,,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1CSC(C)N1
EPOTHILONE-D,EPOTHILONE-D,,BRD:BRD-BRD-K52762805-001-01-2;BRD:BRD-K52762805-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,"MICROTUBULE STABILIZING AGENT, TUBULIN POLYMERIZATION INHIBITOR",TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA4A;TUBA8;TUBB;TUBB1;TUBB3;TUBB4A;TUBB4B,,,PHASE 2,,,NA,,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1CSC(C)N1
EPPTB,EPPTB,,BRD:BRD-BRD-K42536037-001-01-3;BRD:BRD-K42536037-001-01-3,rep_primary;rep_single_dose,TRACE AMINE ASSOCIATED RECEPTOR ANTAGONIST,TAAR1,,,PRECLINICAL,,,NA,,CCOC1CCCC(NC(=O)C2CCC(N3CCCC3)C(C2)C(F)(F)F)C1
EPRAZINONE,EPRAZINONE,CHEMBL1885437,BRD:BRD-A72212290-300-01-4;BRD:BRD-BRD-A72212290-300-01-4,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,BRONCHOSPASM,,LAUNCHED,,Small molecule,Unknown,BSHWLCACYCVCJE-UHFFFAOYSA-N,CCOC(CN1CCN(CC(C)C(=O)C2CCCCC2)CC1)C1CCCCC1
EPRINOMECTIN,EPRINOMECTIN,CHEMBL3989594,BRD:BRD-A91366704-001-01-9;BRD:BRD-BRD-A91366704-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,,"GASTROINTESTINAL ROUNDWORMS, LUNGWORMS",,LAUNCHED,,Unknown,Unknown,VBPOFUHCXIRECN-ZWZBFTKFSA-N,CC[C@H](C)C1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@H](NC(C)=O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(C=C[C@H](C)C(C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@H]1NC(C)=O;CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C
EPRISTERIDE,EPRISTERIDE,CHEMBL138225,BRD:BRD-K00003478-001-01-9,rep_single_dose,5 ALPHA REDUCTASE INHIBITOR,,,,,,Small molecule,Unknown,VAPSMQAHNAZRKC-PQWRYPMOSA-N,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C=C(C(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C
EPROBEMIDE,EPROBEMIDE,CHEMBL2104298,BRD:BRD-BRD-K17979676-001-01-2;BRD:BRD-K17979676-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA,DEPRESSION,,LAUNCHED,,Small molecule,Unknown,YYFGRAGNYHYWEZ-UHFFFAOYSA-N,CLC1CCC(CC1)C(=O)NCCCN1CCOCC1;O=C(NCCCN1CCOCC1)C1CCC(CL)CC1
EPRODISATE,EPRODISATE,CHEMBL2111092,BRD:BRD-BRD-K11463116-304-03-5;BRD:BRD-K11463116-304-03-5,rep_primary;rep_single_dose,"AMYLOID PROTEIN INHIBITOR, ANTIAMYLOIDOGENIC AGENT",SAA1,,,PHASE 3,"Multiple values for MOA: {'ANTIAMYLOIDOGENIC AGENT, AMYLOID PROTEIN INHIBITOR', 'AMYLOID PROTEIN INHIBITOR, ANTIAMYLOIDOGENIC AGENT'}, defaulting to 'AMYLOID PROTEIN INHIBITOR, ANTIAMYLOIDOGENIC AGENT'",Small molecule,Phase 3,MGNVWUDMMXZUDI-UHFFFAOYSA-N,O=S(=O)(O)CCCS(=O)(=O)O;OS(=O)(=O)CCCS(O)(=O)=O
EPROSARTAN,EPROSARTAN,CHEMBL813,BRD:BRD-BRD-K67977190-066-02-3;BRD:BRD-K67977190-066-02-3,rep_multi_dose;rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,OROAFUQRIXKEMV-LDADJPATSA-N,CCCCC1NCC(/C=C(\CC2CCCS2)C(=O)O)N1CC1CCC(C(=O)O)CC1;CCCCC1NCC(\C=C(/CC2CCCS2)C(O)=O)N1CC1CCC(CC1)C(O)=O
EPTIFIBATIDE,EPTIFIBATIDE,CHEMBL1174,BRD:BRD-A90547603-001-02-5;BRD:BRD-BRD-A90547603-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,PLATELET AGGREGATION INHIBITOR,ITGA2B;ITGB3,"ACUTE CORONARY SYNDROME (ACS), PERCUTANEOUS CORONARY INTERVENTION (PCI)",,LAUNCHED,,Protein,Approved,CZKPOZZJODAYPZ-LROMGURASA-N,N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O;NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(CC2C[NH]C3CCCCC23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O
EPZ-004777,EPZ-004777,,GDSC2:1237,gdsc,,,,,,,,NA,,
EPZ-5676,EPZ-5676,CHEMBL3414626,BRD:BRD-BRD-K26531771-001-01-4;BRD:BRD-BRD-K26531771-001-02-2;BRD:BRD-K26531771-001-01-4;BRD:BRD-K26531771-001-02-2;GDSC2:1563,gdsc;rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,DOT1L,,,PHASE 1,,Small molecule,Phase 1,LXFOLMYKSYSZQS-LURJZOHASA-N,CC(C)N(C[C@H]1O[C@@H](N2CNC3C(N)NCNC32)[C@H](O)[C@@H]1O)[C@H]1C[C@@H](CCC2NC3CC(C(C)(C)C)CCC3[NH]2)C1;CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(N)NCNC12)[C@@H]1C[C@H](CCC2NC3CC(CCC3[NH]2)C(C)(C)C)C1
TAZEMETOSTAT,EPZ-6438;TAZEMETOSTAT,CHEMBL3414621,BRD:BRD-BRD-K11215326-001-03-7;BRD:BRD-K11215326-001-03-7;BRD:BRD-K11215326-001-06-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF EZH2', 'HISTONE LYSINE METHYLTRANSFERASE INHIBITOR'}, defaulting to 'HISTONE LYSINE METHYLTRANSFERASE INHIBITOR'",Small molecule,Approved,NSQSAUGJQHDYNO-UHFFFAOYSA-N,CCN(C1CC(-C2CCC(CN3CCOCC3)CC2)CC(C(=O)NCC2C(C)CC(C)[NH]C2=O)C1C)C1CCOCC1;CCN(C1CCOCC1)C1CC(CC(C(=O)NCC2C(C)CC(C)[NH]C2=O)C1C)-C1CCC(CN2CCOCC2)CC1
EPZ004777,EPZ004777,,BRD:BRD-BRD-K69070623-003-01-7;BRD:BRD-K69070623-003-01-7;GDSC2:1237,gdsc;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,DOT1L,,,PRECLINICAL,,,NA,,CC(C)N(CCCNC(=O)NC1CCC(CC1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC2C(N)NCNC12
EPZ005687,EPZ005687,,BRD:BRD-BRD-K57754230-001-02-7;BRD:BRD-K57754230-001-02-7,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PRECLINICAL,,,NA,,CC1CC(C)C(CNC(=O)C2CC(CC3N(NCC23)C2CCCC2)-C2CCC(CN3CCOCC3)CC2)C(=O)[NH]1
EPZ011989,EPZ011989,,BRD:BRD-BRD-K87468701-001-01-0;BRD:BRD-K87468701-001-01-0,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PRECLINICAL,,,NA,,CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)C1CC(CC(C(=O)NCC2C(C)CC(C)[NH]C2=O)C1C)C#CCN1CCOCC1
EPZ015666,EPZ015666,,BRD:BRD-BRD-K70446295-001-01-7;BRD:BRD-K70446295-001-01-7,rep_primary;rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT5,,,PRECLINICAL,,,NA,,O[C@@H](CNC(=O)C1CC(NC2COC2)NCN1)CN1CCC2CCCCC2C1
EPZ015866,EPZ015866,,GDSC2:2110,gdsc,,,,,,,,NA,,
EPZ020411,EPZ020411,,BRD:BRD-K33586289-003-02-8,rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT6,,,,,,NA,,
EPZ5676,EPZ5676,,GDSC2:1563,gdsc,,,,,,,,NA,,
EQUILIN,EQUILIN,CHEMBL323533,BRD:BRD-A88080608-001-04-2;BRD:BRD-BRD-A88080608-001-04-2,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,HSD17B1,,,PRECLINICAL,,Small molecule,Unknown,WKRLQDKEXYKHJB-HFTRVMKXSA-N,C[C@]12CC[C@H]3C(=CCC4CC(O)CCC43)[C@@H]1CCC2=O;CC12CCC3C(=CCC4CC(O)CCC34)C1CCC2=O
EQUOL,EQUOL,,BRD:BRD-BRD-K54847683-001-03-2;BRD:BRD-BRD-K54847683-001-04-0;BRD:BRD-K54847683-001-03-2;BRD:BRD-K54847683-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1;ESR2,,,LAUNCHED,,,NA,,OC1CCC(CC1)[C@H]1COC2CC(O)CCC2C1
ER-27319,ER-27319,,BRD:BRD-BRD-K11927976-050-02-9;BRD:BRD-K11927976-050-02-9,rep_multi_dose;rep_primary;rep_single_dose,"MEDIATOR RELEASE INHIBITOR, SYK INHIBITOR",SYK,,,PRECLINICAL,,,NA,,CC1CCC2C(C1C)N(CCCN)C1CCCCC1C2=O
ER-50891,ER-50891,,BRD:BRD-K18347943-001-02-9,rep_single_dose,RETINOID RECEPTOR ANTAGONIST,RARA,,,,,,NA,,
ERASTIN,ERASTIN,CHEMBL401989,BRD:BRD-A25004090-001-08-4;BRD:BRD-BRD-A25004090-001-08-4;CTRP:63578,ctrp;rep_multi_dose;rep_primary;rep_single_dose,ION CHANNEL ANTAGONIST,VDAC2,,,PRECLINICAL,,Small molecule,NA,BKQFRNYHFIQEKN-UHFFFAOYSA-N,CCOC1CCCCC1-N1C(=O)C2CCCCC2NC1C(C)N1CCN(CC1)C(=O)COC1CCC(CL)CC1;CCOC1CCCCC1-N1C(C(C)N2CCN(C(=O)COC3CCC(CL)CC3)CC2)NC2CCCCC2C1=O
ERAVACYCLINE,ERAVACYCLINE,CHEMBL1951095,BRD:BRD-K00003240-300-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Approved,HLFSMUUOKPBTSM-ISIOAQNYSA-N,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)C4C(O)C(NC(=O)CN5CCCC5)CC(F)C4C[C@H]3C[C@@H]12
ERBITUX,ERBITUX,CHEMBL1201577,GDSC1:1114,gdsc,,,,,,,Antibody,Approved,,
ERCALCITRIOL,ERCALCITRIOL,CHEMBL4303615,BRD:BRD-BRD-K84163249-001-01-9;BRD:BRD-K84163249-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,,,PHASE 1,,Small molecule,Unknown,ZGLHBRQAEXKACO-XJRQOBMKSA-N,C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C;C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
JNJ-42756493,ERDAFITINIB;JNJ-42756493,CHEMBL3545376,BRD:BRD-BRD-K84868168-001-01-0;BRD:BRD-K84868168-001-01-0,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4",FGFR1;FGFR2;FGFR3;FGFR4,,,PHASE 2,"Multiple values for MOA: {'FGFR INHIBITOR', 'INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4'}, defaulting to 'INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4'",Small molecule,Approved,OLAHOMJCDNXHFI-UHFFFAOYSA-N,COC1CC(OC)CC(C1)N(CCNC(C)C)C1CCC2NCC(NC2C1)-C1CNN(C)C1;COC1CC(OC)CC(N(CCNC(C)C)C2CCC3NCC(-C4CNN(C)C4)NC3C2)C1
ERDOSTEINE,ERDOSTEINE,CHEMBL1697744,BRD:BRD-A05515753-001-03-2;BRD:BRD-BRD-A05515753-001-03-2,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,"BRONCHITIS, COUGH SUPPRESSANT, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), RESPIRATORY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,QGFORSXNKQLDNO-UHFFFAOYSA-N,O=C(O)CSCC(=O)NC1CCSC1=O;OC(=O)CSCC(=O)NC1CCSC1=O
ERGOCALCIFEROL,ERGOCALCIFEROL,CHEMBL1536,BRD:BRD-BRD-K56155962-001-12-1;BRD:BRD-K56155962-001-12-1,rep_primary;rep_single_dose,VITAMIN ANALOG,VDR,"HYPOPARATHYROIDISM, RICKETS, HYPOPHOSPHATEMIA",,LAUNCHED,,Small molecule,Approved,MECHNRXZTMCUDQ-RKHKHRCZSA-N,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12;CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C
ERGONOVINE,ERGONOVINE,CHEMBL119443,BRD:BRD-A26387268-050-04-4;BRD:BRD-BRD-A26387268-050-04-4,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, SEROTONIN RECEPTOR AGONIST",ADRA1A;HTR1E,POSTPARTUM HEMORRHAGE (PPH),,LAUNCHED,,Small molecule,Approved,WVVSZNPYNCNODU-XTQGRXLLSA-N,C[C@@H](CO)NC(=O)[C@@H]1C=C2C3CCCC4[NH]CC(C34)C[C@H]2N(C)C1;CC(CO)NC(=O)C1CN(C)[C@@H]2CC3C[NH]C4CCCC(C2=C1)C34
ERIBULIN,ERIBULIN,CHEMBL1683590,BRD:BRD-K00003156-066-01-9,rep_single_dose,MICROTUBULE INHIBITOR,,,,,,Small molecule,Approved,UFNVPOGXISZXJD-JBQZKEIOSA-N,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
ERISMODEGIB,ERISMODEGIB,CHEMBL2105737,CTRP:636425,ctrp,,,,,,,Small molecule,Approved,VZZJRYRQSPEMTK-CALCHBBNSA-N,CC1C(C(=O)NC2CCC(N3C[C@@H](C)O[C@@H](C)C3)NC2)CCCC1-C1CCC(OC(F)(F)F)CC1
ERIVEDGE,ERIVEDGE,CHEMBL473417,GDSC1:1033,gdsc,,,,,,,Small molecule,Approved,BPQMGSKTAYIVFO-UHFFFAOYSA-N,CS(=O)(=O)C1CCC(C(=O)NC2CCC(CL)C(-C3CCCCN3)C2)C(CL)C1
ERK INHIBITOR II,ERK INHIBITOR II,,GDSC1:263,gdsc,,,,,,,,NA,,
ERK5-IN-1,ERK5-IN-1,,BRD:BRD-K64857848-001-06-4;GDSC1:106,gdsc;rep_single_dose,MAP KINASE INHIBITOR,MAPK7,,,,,,NA,,
ERLOTINIB:PLX-4032 (2:1 MOL/MOL),ERLOTINIB:PLX-4032 (2:1 MOL/MOL),,CTRP:660768,ctrp,,,,,,,,NA,,
ERTEBEREL,ERTEBEREL,CHEMBL278703,BRD:BRD-BRD-K80608265-001-01-6;BRD:BRD-K80608265-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1;ESR2,,,PHASE 2,,Small molecule,Phase 2,XIESSJVMWNJCGZ-VKJFTORMSA-N,OC1CCC([C@@H]2OC3CCC(O)CC3[C@@H]3CCC[C@@H]32)CC1;OC1CCC(CC1)[C@@H]1OC2CCC(O)CC2[C@@H]2CCC[C@H]12
ERTUGLIFLOZIN,ERTUGLIFLOZIN,CHEMBL1770248,BRD:BRD-BRD-K10071630-001-01-0;BRD:BRD-K10071630-001-01-0,rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A2,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,MCIACXAZCBVDEE-CUUWFGFTSA-N,CCOC1CCC(CC2CC([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)CCC2CL)CC1;CCOC1CCC(CC2CC(CCC2CL)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)CC1
ERYTHRITOL,ERYTHRITOL,,BRD:BRD-BRD-K79315489-001-07-8;BRD:BRD-K79315489-001-07-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,OC[C@H](O)[C@H](O)CO
ERYTHROMYCIN,ERYTHROMYCIN,CHEMBL1200506;CHEMBL1741;CHEMBL2106397;CHEMBL2110577;CHEMBL2220427;CHEMBL532,BRD:BRD-BRD-K63550407-001-12-7;BRD:BRD-BRD-K63550407-001-13-5;BRD:BRD-K63550407-001-12-7;BRD:BRD-K63550407-001-13-5,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,MLNR,"LISTERIA, RESPIRATORY TRACT INFECTIONS, SKIN INFECTIONS, SYPHILIS, AMEBIASIS, PELVIC INFLAMMATORY DISEASE, CHLAMYDIA, DIPHTHERIA, ERYTHRASMA",,LAUNCHED,,Small molecule,Approved,AGOYDEPGAOXOCK-KCBOHYOISA-N;CVBHEIRZLPKMSH-SNWVVRALSA-N;HPZGUSZNXKOMCQ-IXGVTZHESA-N;NNRXCKZMQLFUPL-WBMZRJHASA-N;TYQXKHPOXXXCTP-CSLYCKPJSA-N;ULGZDMOVFRHVEP-RWJQBGPGSA-N,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N/OC)[C@H](C)[C@@H](O)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2OC(C)=O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O;CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
ERYTHROMYCIN-ETHYLSUCCINATE,ERYTHROMYCIN-ETHYLSUCCINATE,,BRD:BRD-BRD-K51677086-001-12-0;BRD:BRD-K51677086-001-12-0,rep_primary;rep_single_dose,"CYTOCHROME P450 INHIBITOR, PROTEIN SYNTHESIS INHIBITOR",ABCB1;ALB;CYP3A4;CYP51A1;KCNH2;MLNR;SLC47A1,"LISTERIA, RESPIRATORY TRACT INFECTIONS, SKIN INFECTIONS, SYPHILIS, AMEBIASIS, PELVIC INFLAMMATORY DISEASE, CHLAMYDIA, DIPHTHERIA, ERYTHRASMA",,LAUNCHED,,,NA,,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
ERYTHROSINE,ERYTHROSINE,CHEMBL1332616,BRD:BRD-BRD-K14920963-304-02-7;BRD:BRD-K14920963-304-02-7,rep_primary;rep_single_dose,COLORING AGENT,,,,PRECLINICAL,,Small molecule,Unknown,OALHHIHQOFIMEF-UHFFFAOYSA-N,O=C1OC2(C3CCCCC31)C1CC(I)C(O)C(I)C1OC1C2CC(I)C(O)C1I;OC(=O)C1CCCCC1-C1C2CC(I)C(O)C(I)C2OC2C(I)C(=O)C(I)CC12
ESAPRAZOLE,ESAPRAZOLE,CHEMBL1983100,BRD:BRD-BRD-K92426617-001-06-3;BRD:BRD-K92426617-001-06-3,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,RTFADALJKSFJDZ-UHFFFAOYSA-N,O=C(CN1CCNCC1)NC1CCCCC1
ESAXERENONE,ESAXERENONE,CHEMBL3545393,BRD:BRD-K00003374-001-01-9,rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,,
ESCITALOPRAM,ESCITALOPRAM,CHEMBL1508,BRD:BRD-BRD-K70301876-034-13-7;BRD:BRD-K70301876-034-13-7,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),ADRA1A;CHRM1;HRH1;SLC6A2;SLC6A3;SLC6A4,"DEPRESSION, GENERALIZED ANXIETY DISORDER (GAD)",,LAUNCHED,,Small molecule,Approved,WSEQXVZVJXJVFP-FQEVSTJZSA-N,CN(C)CCC[C@]1(OCC2CC(CCC12)C#N)C1CCC(F)CC1;CN(C)CCC[C@@]1(C2CCC(F)CC2)OCC2CC(C#N)CCC21
ESCULIN,ESCULIN,CHEMBL482581,BRD:BRD-BRD-K36270037-001-01-7;BRD:BRD-K36270037-001-01-7,rep_primary;rep_single_dose,ANTIOXIDANT,,,,PHASE 1,,Small molecule,NA,XHCADAYNFIFUHF-TVKJYDDYSA-N,O=C1CCC2CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(O)CC2O1;OC[C@H]1O[C@@H](OC2CC3CCC(=O)OC3CC2O)[C@@H](O)[C@@H](O)[C@@H]1O
ESI-09,ESI-09,,BRD:BRD-BRD-K77139516-001-02-2;BRD:BRD-K77139516-001-02-2,rep_primary;rep_single_dose,EPAC INHIBITOR,RAPGEF3;RAPGEF4,,,PRECLINICAL,,,NA,,CC(C)(C)C1CC(NO1)C(=O)C(\C#N)=N\NC1CCCC(CL)C1
ESLICARBAZEPINE-ACETATE,ESLICARBAZEPINE-ACETATE,,BRD:BRD-BRD-K61237927-001-01-7;BRD:BRD-K61237927-001-01-7,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,,NA,,CC(=O)O[C@H]1CC2CCCCC2N(C(N)=O)C2CCCCC12
ESMOLOL,ESMOLOL,CHEMBL768,BRD:BRD-A07395371-003-10-0;BRD:BRD-BRD-A07395371-003-10-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1,"VENTRICULAR TACHYCARDIA (VT), HYPERTENSION",,LAUNCHED,,Small molecule,Approved,AQNDDEOPVVGCPG-UHFFFAOYSA-N,COC(=O)CCC1CCC(OCC(O)CNC(C)C)CC1
ESOMEPRAZOLE,ESOMEPRAZOLE,CHEMBL1201320,BRD:BRD-BRD-K61443506-239-01-6;BRD:BRD-K61443506-239-01-6;BRD:BRD-K61443506-239-03-9,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP4A,"GASTROESOPHAGEAL REFLUX DISEASE (GERD), ZOLLINGER-ELLISON SYNDROME, PEPTIC ULCER DISEASE (PUD)",,LAUNCHED,,Small molecule,Approved,SUBDBMMJDZJVOS-DEOSSOPVSA-N,COC1CCC2[NH]C([S@@+]([O-])CC3NCC(C)C(OC)C3C)NC2C1;COC1CCC2[NH]C(NC2C1)[S@@](=O)CC1NCC(C)C(OC)C1C
ESONARIMOD,ESONARIMOD,CHEMBL2003782,BRD:BRD-K00003282-001-01-9,rep_single_dose,ANTIRHEUMATIC DRUG,,,,,,Small molecule,Unknown,YRSSFEUQNAXQMX-UHFFFAOYSA-N,CC(=O)SCC(CC(=O)C1CCC(C)CC1)C(=O)O
ESTETROL,ESTETROL,CHEMBL1230314,BRD:BRD-BRD-K75445017-001-01-1;BRD:BRD-K75445017-001-01-1,rep_primary;rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),ESR1,,,PHASE 3,,Small molecule,Approved,AJIPIJNNOJSSQC-NYLIRDPKSA-N,C[C@]12CC[C@@H]3C4CCC(O)CC4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O;C[C@]12CC[C@H]3[C@@H](CCC4CC(O)CCC34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O
ESTRADIOL,ESTRADIOL,CHEMBL135;CHEMBL286452,BRD:BRD-BRD-K18910433-001-36-6;BRD:BRD-BRD-K18910433-001-43-2;BRD:BRD-K18910433-001-36-6;BRD:BRD-K18910433-001-43-2,rep_multi_dose;rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1;ESR2;GPER1;KCNMA1;NR1I2,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,VOXZDWNPVJITMN-SFFUCWETSA-N;VOXZDWNPVJITMN-ZBRFXRBCSA-N,C[C@]12CC[C@@H]3C4CCC(O)CC4CC[C@H]3[C@@H]1CC[C@@H]2O;C[C@]12CC[C@@H]3C4CCC(O)CC4CC[C@H]3[C@@H]1CC[C@H]2O;C[C@]12CC[C@H]3[C@@H](CCC4CC(O)CCC34)[C@@H]1CC[C@@H]2O
ESTRADIOL-3-O-SULFAMATE,ESTRADIOL-3-O-SULFAMATE,CHEMBL219321,BRD:BRD-K00004741-001-01-9,rep_single_dose,STERYL SULFATASE INHIBITOR,,,,,,Small molecule,NA,YXYXCSOJKUAPJI-ZBRFXRBCSA-N,C[C@]12CC[C@@H]3C4CCC(OS(N)(=O)=O)CC4CC[C@H]3[C@@H]1CC[C@@H]2O
ESTRADIOL-ACETATE,ESTRADIOL-ACETATE,,BRD:BRD-BRD-K53319039-001-01-8;BRD:BRD-K53319039-001-01-8,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,"MENOPAUSE, VAGINAL ATROPHY",,LAUNCHED,,,NA,,CC(=O)OC1CCC2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCC2C1
ESTRADIOL-BENZOATE,ESTRADIOL-BENZOATE,,BRD:BRD-A74765037-001-01-1;BRD:BRD-BRD-A74765037-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,CONTRACEPTIVE AGENT,ESR1,,,PRECLINICAL,,,NA,,C[C@]12CCC3C(CCC4CC(OC(=O)C5CCCCC5)CCC34)C1CC[C@@H]2O
ESTRADIOL-CYPIONATE,ESTRADIOL-CYPIONATE,,BRD:BRD-A91452556-001-04-0;BRD:BRD-BRD-A91452556-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,"HYPOESTROGENISM, MENOPAUSE",,LAUNCHED,,,NA,,C[C@]12CCC3C(CCC4CC(O)CCC34)C1CC[C@@H]2OC(=O)CCC1CCCC1
ESTRADIOL-VALERATE,ESTRADIOL-VALERATE,,BRD:BRD-BRD-K66766661-001-19-2;BRD:BRD-K66766661-001-19-2,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,"PROSTATE CANCER, HYPOESTROGENISM, MENOPAUSE, VAGINAL ATROPHY",,LAUNCHED,,,NA,,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4CC(O)CCC4[C@H]3CC[C@]12C
ESTRAMUSTINE,ESTRAMUSTINE,CHEMBL1575,BRD:BRD-A70858459-001-01-7;BRD:BRD-BRD-A70858459-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,ESR1;ESR2;MAP1A;MAP2,PROSTATE CANCER,,LAUNCHED,,Small molecule,Phase 3,FRPJXPJMRWBBIH-RBRWEJTLSA-N,C[C@]12CC[C@@H]3C4CCC(OC(=O)N(CCCL)CCCL)CC4CC[C@H]3[C@@H]1CC[C@@H]2O;C[C@]12CCC3C(CCC4CC(OC(=O)N(CCCL)CCCL)CCC34)C1CC[C@@H]2O
ESTRAMUSTINE-PHOSPHATE,ESTRAMUSTINE-PHOSPHATE,,BRD:BRD-BRD-K00077635-304-01-2;BRD:BRD-K00077635-304-01-2,rep_multi_dose;rep_primary;rep_single_dose,"DNA SYNTHESIS INHIBITOR, MICROTUBULE INHIBITOR",ESR1;ESR2;MAP1A;MAP2,PROSTATE CANCER,,LAUNCHED,,,NA,,C[C@]12CC[C@H]3[C@@H](CCC4CC(OC(=O)N(CCCL)CCCL)CCC34)[C@@H]1CC[C@@H]2OP(O)(O)=O
ESTRIOL,ESTRIOL,CHEMBL193482,BRD:BRD-BRD-K17016787-001-16-7;BRD:BRD-K17016787-001-16-7,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1;ESR2,"MENOPAUSE, VAGINAL ATROPHY, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,PROQIPRRNZUXQM-ZXXIGWHRSA-N,C[C@]12CC[C@@H]3C4CCC(O)CC4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O;C[C@]12CC[C@H]3[C@@H](CCC4CC(O)CCC34)[C@@H]1C[C@@H](O)[C@@H]2O;CC12CCC3C(CCC4CC(O)CCC34)C1C[C@H](O)[C@@H]2O
ESTRONE,ESTRONE,CHEMBL1405,BRD:BRD-BRD-K81839095-001-25-1;BRD:BRD-BRD-K81839095-001-30-1;BRD:BRD-K81839095-001-25-1;BRD:BRD-K81839095-001-30-1,rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR AGONIST, ESTROGENIC HORMONE",ESR1;ESR2,,,LAUNCHED,,Small molecule,Approved,DNXHEGUUPJUMQT-CBZIJGRNSA-N,C[C@]12CC[C@@H]3C4CCC(O)CC4CC[C@H]3[C@@H]1CCC2=O;C[C@]12CC[C@H]3[C@@H](CCC4CC(O)CCC34)[C@@H]1CCC2=O
ESTROPIPATE,ESTROPIPATE,CHEMBL1200980,BRD:BRD-A22143024-231-03-8;BRD:BRD-BRD-A22143024-231-03-8,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1;ESR2,"OSTEOPOROSIS, MENOPAUSE, VAGINAL ATROPHY, HYPOESTROGENISM",,LAUNCHED,,Small molecule,Approved,HZEQBCVBILBTEP-ZFINNJDLSA-N,C[C@]12CCC3C(CCC4CC(OS(O)(=O)=O)CCC34)C1CCC2=O;C1CNCCN1.C[C@]12CC[C@@H]3C4CCC(OS(=O)(=O)O)CC4CC[C@H]3[C@@H]1CCC2=O
ESZOPICLONE,ESZOPICLONE,CHEMBL1522,BRD:BRD-BRD-K29220403-001-10-8;BRD:BRD-K29220403-001-10-8,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;TSPO,INSOMNIA,,LAUNCHED,,Small molecule,Approved,GBBSUAFBMRNDJC-INIZCTEOSA-N,CN1CCN(C(=O)O[C@H]2C3NCCNC3C(=O)N2C2CCC(CL)CN2)CC1;CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2NCCNC12)C1CCC(CL)CN1
ETACRYNIC-ACID,ETACRYNIC-ACID,,BRD:BRD-BRD-K63630713-001-25-8;BRD:BRD-K63630713-001-25-8,rep_primary;rep_single_dose,SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR,ATP1A1;SLC12A1,"HYPERTENSION, CONGESTIVE HEART FAILURE, EDEMA, HEPATIC CIRRHOSIS, CHRONIC RENAL FAILURE, NEPHROTIC SYNDROME",,LAUNCHED,,,NA,,CCC(=C)C(=O)C1CCC(OCC(O)=O)C(CL)C1CL
ETAFENONE,ETAFENONE,CHEMBL1736151,BRD:BRD-BRD-K84971356-001-01-4;BRD:BRD-K84971356-001-01-4,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,LAUNCHED,,Small molecule,Unknown,OEGDFSLNGABBKJ-UHFFFAOYSA-N,CCN(CC)CCOC1CCCCC1C(=O)CCC1CCCCC1
ETAMSYLATE,ETAMSYLATE,CHEMBL1514715,BRD:BRD-BRD-K71055333-224-05-8;BRD:BRD-K71055333-224-05-8,rep_primary;rep_single_dose,"HAEMOSTATIC AGENT, HEMOSTATIC AGENT",,HEMORRHAGE,,LAUNCHED,"Multiple values for MOA: {'HAEMOSTATIC AGENT, HEMOSTATIC AGENT', 'HAEMOSTATIC AGENT'}, defaulting to 'HAEMOSTATIC AGENT, HEMOSTATIC AGENT'",Small molecule,Approved,HBGOLJKPSFNJSD-UHFFFAOYSA-N,CCNCC.O=S(=O)(O)C1CC(O)CCC1O;OC1CCC(O)C(C1)S(O)(=O)=O
ETANIDAZOLE,ETANIDAZOLE,CHEMBL47405,BRD:BRD-BRD-K96042922-001-09-8;BRD:BRD-K96042922-001-09-8,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,PHASE 3,,Small molecule,Unknown,WCDWBPCFGJXFJZ-UHFFFAOYSA-N,O=C(CN1CCNC1[N+](=O)[O-])NCCO;OCCNC(=O)CN1CCNC1[N+]([O-])=O
ETAZOLATE,ETAZOLATE,CHEMBL356388,BRD:BRD-BRD-K64755930-003-03-2;BRD:BRD-K64755930-003-03-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,GABRB3;PDE4A,,,PHASE 2,,Small molecule,Phase 2,OPQRBXUBWHDHPQ-UHFFFAOYSA-N,CCOC(=O)C1CNC2C(CNN2CC)C1NN=C(C)C;CCOC(=O)C1CNC2N(CC)NCC2C1NN=C(C)C
ETC-159,ETC-159,CHEMBL3633802,BRD:BRD-BRD-K54264768-001-01-2;BRD:BRD-K54264768-001-01-2,rep_primary;rep_single_dose,"PORCUPINE INHIBITOR, BETA CATENIN INHIBITOR",PORCN,,,PHASE 1,"Multiple values for MOA: {'BETA CATENIN INHIBITOR, PORCUPINE INHIBITOR', 'PORCUPINE INHIBITOR, BETA CATENIN INHIBITOR'}, defaulting to 'PORCUPINE INHIBITOR, BETA CATENIN INHIBITOR'",Small molecule,Phase 1,QTRXIFVSTWXRJJ-UHFFFAOYSA-N,CN1C(=O)C2C(NCN2CC(=O)NC2CCC(-C3CCCCC3)NN2)N(C)C1=O;CN1C2NCN(CC(=O)NC3CCC(NN3)-C3CCCCC3)C2C(=O)N(C)C1=O
ETC-206,ETC-206,CHEMBL4211649,BRD:BRD-K00003115-001-01-9,rep_single_dose,MAPK-INTERACTING KINASE INHIBITOR,,,,,,Small molecule,Phase 2,FWRFPHJSGLYXTD-UHFFFAOYSA-N,N#CC1CCC(-C2CNC3CCC(-C4CCC(C(=O)N5CCOCC5)CC4)CN23)CC1
ETEBENECID,ETEBENECID,CHEMBL1705586,BRD:BRD-BRD-K24443618-001-10-2;BRD:BRD-K24443618-001-10-2,rep_primary;rep_single_dose,URICOSURIC BLOCKER,,,,PRECLINICAL,,Small molecule,Unknown,UACOQEQOBAQRDQ-UHFFFAOYSA-N,CCN(CC)S(=O)(=O)C1CCC(C(=O)O)CC1;CCN(CC)S(=O)(=O)C1CCC(CC1)C(O)=O
ETELCALCETIDE (HYDROCHLORIDE),ETELCALCETIDE (HYDROCHLORIDE),,BRD:BRD-K00078514-003-02-9,rep_single_dose,,,,,,,,NA,,
ETEROBARB,ETEROBARB,CHEMBL327407,BRD:BRD-BRD-K64834129-001-19-6;BRD:BRD-K64834129-001-19-6,rep_primary;rep_single_dose,ANTICONVULSANT,,,,PHASE 2,,Small molecule,Unknown,DACOQFZGGLCXMA-UHFFFAOYSA-N,CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)C1CCCCC1;CCC1(C2CCCCC2)C(=O)N(COC)C(=O)N(COC)C1=O
ETHACIZIN,ETHACIZIN,CHEMBL1997663,BRD:BRD-BRD-K10667240-001-01-7;BRD:BRD-K10667240-001-01-7,rep_primary;rep_single_dose,ANTICONVULSANT,,"VENTRICULAR TACHYCARDIA (VT), WOLFF-PARKINSON-WHITE SYNDROME (WPW)",,LAUNCHED,,Small molecule,Unknown,PQXGNJKJMFUPPM-UHFFFAOYSA-N,CCOC(=O)NC1CCC2C(C1)N(C(=O)CCN(CC)CC)C1CCCCC1S2;CCOC(=O)NC1CCC2SC3CCCCC3N(C(=O)CCN(CC)CC)C2C1
ETHACRIDINE-LACTATE-MONOHYDRATE,ETHACRIDINE-LACTATE-MONOHYDRATE,,BRD:BRD-BRD-K24715592-406-02-1;BRD:BRD-K24715592-406-02-1,rep_multi_dose;rep_primary;rep_single_dose,DNA INTERCALATING AGENT,,,,PRECLINICAL,,,NA,,CCOC1CCC2NC3CC(N)CCC3C(N)C2C1
ETHAMBUTOL,ETHAMBUTOL,CHEMBL44884,BRD:BRD-BRD-K93231391-300-05-6;BRD:BRD-K93231391-300-05-6,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,AEUTYOVWOVBAKS-UWVGGRQHSA-N,CC[C@@H](CO)NCCN[C@@H](CC)CO
ETHAMIVAN,ETHAMIVAN,CHEMBL1229908,BRD:BRD-BRD-K38055836-001-21-1;BRD:BRD-K38055836-001-21-1,rep_primary;rep_single_dose,RESPIRATORY STIMULANT,,,,PRECLINICAL,,Small molecule,Approved,BQJODPIMMWWMFC-UHFFFAOYSA-N,CCN(CC)C(=O)C1CCC(O)C(OC)C1
ETHANOLAMINE-OLEATE,ETHANOLAMINE-OLEATE,,BRD:BRD-M75061779-001-01-2,rep_single_dose,IMMUNOSTIMULANT,F12;FABP4;FFAR1;FFAR4;PLD2,,,,,,NA,,
ETHAVERINE,ETHAVERINE,CHEMBL1555736,BRD:BRD-BRD-K36756879-003-08-7;BRD:BRD-K36756879-003-08-7,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,"MUSCLE RELAXANT, SPASMS",,LAUNCHED,,Small molecule,Unknown,ZOWYFYXTIWQBEP-UHFFFAOYSA-N,CCOC1CCC(CC2NCCC3CC(OCC)C(OCC)CC23)CC1OCC
ETHENZAMIDE,ETHENZAMIDE,CHEMBL1483877,BRD:BRD-BRD-K88308881-001-06-8;BRD:BRD-K88308881-001-06-8,rep_primary;rep_single_dose,ANALGESIC AGENT,,"HEADACHE, FEVER, COMMON COLD",,LAUNCHED,,Small molecule,Unknown,SBNKFTQSBPKMBZ-UHFFFAOYSA-N,CCOC1CCCCC1C(N)=O
ETHIMIZOL,ETHIMIZOL,,BRD:BRD-BRD-K19672466-001-02-3;BRD:BRD-K19672466-001-02-3,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,CCN1CNC(C(=O)NC)C1C(=O)NC
ETHINYL-ESTRADIOL,ETHINYL-ESTRADIOL,,BRD:BRD-BRD-K48195008-001-19-9;BRD:BRD-K48195008-001-19-9,rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR AGONIST, ESTROGENIC HORMONE",ESR1;ESR2;NR1I2,CONTRACEPTIVE,,LAUNCHED,,,NA,,C[C@]12CC[C@H]3[C@@H](CCC4CC(O)CCC34)[C@@H]1CC[C@@]2(O)C#C
ETHIONAMIDE,ETHIONAMIDE,CHEMBL1441,BRD:BRD-BRD-K51207550-001-23-0;BRD:BRD-K51207550-001-23-0,rep_primary;rep_single_dose,MYCOLIC SYNTHESIS INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,AEOCXXJPGCBFJA-UHFFFAOYSA-N,CCC1CC(C(N)=S)CCN1;CCC1CC(CCN1)C(S)=N
ETHISTERONE,ETHISTERONE,CHEMBL241694,BRD:BRD-A29111201-001-04-8;BRD:BRD-BRD-A29111201-001-04-8,rep_primary;rep_single_dose,PROGESTOGEN HORMONE,TYR,,,LAUNCHED,,Small molecule,Phase 3,CHNXZKVNWQUJIB-CEGNMAFCSA-N,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C;C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C;CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C
ETHOPABATE,ETHOPABATE,CHEMBL458769,BRD:BRD-BRD-K02475039-001-01-0;BRD:BRD-K02475039-001-01-0,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,GOVWOKSKFSBNGD-UHFFFAOYSA-N,CCOC1CC(NC(C)=O)CCC1C(=O)OC
ETHOSUXIMIDE,ETHOSUXIMIDE,CHEMBL696,BRD:BRD-A99633051-001-07-0;BRD:BRD-BRD-A99633051-001-07-0,rep_primary;rep_single_dose,SUCCINIMIDE ANTIEPILEPTIC,CACNA1G;CACNA1H;CACNA1I,EPILEPSY,,LAUNCHED,,Small molecule,Approved,HAPOVYFOVVWLRS-UHFFFAOYSA-N,CCC1(C)CC(=O)NC1=O
ETHOTOIN,ETHOTOIN,CHEMBL1095,BRD:BRD-A30205217-001-11-2;BRD:BRD-BRD-A30205217-001-11-2,rep_primary;rep_single_dose,HYDANTOIN ANTIEPILEPTIC,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,SZQIFWWUIBRPBZ-UHFFFAOYSA-N,CCN1C(=O)NC(C1=O)C1CCCCC1;CCN1C(=O)NC(C2CCCCC2)C1=O
ETHOXYQUIN,ETHOXYQUIN,,BRD:BRD-K56792340-001-14-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
ETHOXZOLAMIDE,ETHOXZOLAMIDE,CHEMBL18,BRD:BRD-BRD-K18131774-001-17-6;BRD:BRD-K18131774-001-17-6,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA13;CA14;CA2;CA3;CA4;CA5A;CA5B;CA6;CA7;CA9,"GLAUCOMA, DUODENAL ULCER DISEASE",,LAUNCHED,,Small molecule,Approved,OUZWUKMCLIBBOG-UHFFFAOYSA-N,CCOC1CCC2NC(S(N)(=O)=O)SC2C1;CCOC1CCC2NC(SC2C1)S(N)(=O)=O
ETHYL-PARABEN,ETHYL-PARABEN,,BRD:BRD-BRD-K02464583-001-02-2;BRD:BRD-K02464583-001-02-2,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCOC(=O)C1CCC(O)CC1
ETHYL-VANILLIN,ETHYL-VANILLIN,,BRD:BRD-BRD-K82104468-001-05-0;BRD:BRD-K82104468-001-05-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCOC1CC(C=O)CCC1O
ETHYLENEDIAMINETETRAACETIC-ACID,ETHYLENEDIAMINETETRAACETIC-ACID,,BRD:BRD-BRD-K82603084-408-01-1;BRD:BRD-K82603084-408-01-1,rep_primary;rep_single_dose,PKC INHIBITOR,,METAL TOXICITY,,LAUNCHED,,,NA,,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
ETHYLNOREPINEPHRINE,ETHYLNOREPINEPHRINE,CHEMBL31159,BRD:BRD-A68509429-003-03-9;BRD:BRD-BRD-A68509429-003-03-9,rep_primary;rep_single_dose,BRONCHODILATOR,,,,PRECLINICAL,,Small molecule,Unknown,LENNRXOJHWNHSD-UHFFFAOYSA-N,CCC(N)C(O)C1CCC(O)C(O)C1
ETHYNODIOL-DIACETATE,ETHYNODIOL-DIACETATE,,BRD:BRD-BRD-K46331928-001-05-8;BRD:BRD-BRD-K46331928-001-06-6;BRD:BRD-K46331928-001-05-8;BRD:BRD-K46331928-001-06-6,rep_primary;rep_single_dose,,ESR1;PGR,CONTRACEPTIVE,,LAUNCHED,,,NA,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1
ETHYNYLCYTIDINE,ETHYNYLCYTIDINE,,BRD:BRD-K00003207-001-01-9,rep_single_dose,ANTIMETABOLITE,,,,,,,NA,,
ETICLOPRIDE,ETICLOPRIDE,CHEMBL8946,BRD:BRD-BRD-K50417881-003-17-4;BRD:BRD-K50417881-003-17-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;DRD4,,,PRECLINICAL,,Small molecule,Unknown,AADCDMQTJNYOSS-LBPRGKRZSA-N,CCC1CC(CL)C(OC)C(C(=O)NC[C@@H]2CCCN2CC)C1O;CCN1CCC[C@H]1CNC(=O)C1C(O)C(CC)CC(CL)C1OC
ETIDOCAINE (HYDROCHLORIDE),ETIDOCAINE (HYDROCHLORIDE),,BRD:BRD-K00074616-003-02-9,rep_single_dose,,,,,,,,NA,,
ETIDRONIC-ACID,ETIDRONIC-ACID,,BRD:BRD-BRD-K37949327-001-06-3;BRD:BRD-K37949327-001-06-3,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,ATP6V1A;PTPRS,"PAGET'S DISEASE, HETEROTOPIC OSSIFICATION",,LAUNCHED,,,NA,,CC(O)(P(O)(O)=O)P(O)(O)=O
ETIFENIN,ETIFENIN,CHEMBL1323453,BRD:BRD-K63979671-001-11-9,rep_single_dose,RENAL FUNCTION DIAGNOSTIC AGENT,,,,,,Small molecule,Unknown,WNIDXAKKFOKNEF-UHFFFAOYSA-N,CCC1CCCC(CC)C1NC(=O)CN(CC(=O)O)CC(=O)O
ETIFOXINE,ETIFOXINE,CHEMBL2106227,BRD:BRD-K01826330-001-01-9,rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1;GABRA2;GABRA3;GABRA5,,,,,Small molecule,Phase 3,IBYCYJFUEJQSMK-UHFFFAOYSA-N,CCNC1=NC2CCC(CL)CC2C(C)(C2CCCCC2)O1
ETILEFRINE,ETILEFRINE,CHEMBL86882,BRD:BRD-A09925278-003-05-6;BRD:BRD-BRD-A09925278-003-05-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRB1,"HEADACHE, NASAL CONGESTION, FEVER, COUGH SUPPRESSANT, COMMON COLD",,LAUNCHED,,Small molecule,Approved,SQVIAVUSQAWMKL-UHFFFAOYSA-N,CCNCC(O)C1CCCC(O)C1
ETILEVODOPA,ETILEVODOPA,CHEMBL1823681,BRD:BRD-BRD-K90982969-001-01-2;BRD:BRD-K90982969-001-01-2,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD3,,,PHASE 3,,Small molecule,Phase 2,NULMGOSOSZBEQL-QMMMGPOBSA-N,CCOC(=O)[C@@H](N)CC1CCC(O)C(O)C1
ETIZOLAM,ETIZOLAM,CHEMBL1289779,BRD:BRD-BRD-K68232413-001-01-2;BRD:BRD-K68232413-001-01-2,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1,"INSOMNIA, ANXIETY",,LAUNCHED,,Small molecule,Unknown,VMZUTJCNQWMAGF-UHFFFAOYSA-N,CCC1CC2C(S1)-N1C(C)NNC1CN=C2C1CCCCC1CL
ETODOLAC,ETODOLAC,CHEMBL1716091;CHEMBL622,BRD:BRD-A74667430-001-23-6;BRD:BRD-BRD-A74667430-001-23-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2;RXRA,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,NNYBQONXHNTVIJ-QGZVFWFLSA-N;NNYBQONXHNTVIJ-UHFFFAOYSA-N,CCC1CCCC2C3C([NH]C12)[C@@](CC)(CC(=O)O)OCC3;CCC1CCCC2C3C([NH]C12)C(CC)(CC(=O)O)OCC3;CCC1CCCC2C3CCOC(CC)(CC(O)=O)C3[NH]C12
ETOFENAMATE,ETOFENAMATE,CHEMBL1451633,BRD:BRD-BRD-K73541271-001-03-6;BRD:BRD-K73541271-001-03-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"MUSCLE PAIN, JOINT PAIN",,LAUNCHED,,Small molecule,Unknown,XILVEPYQJIOVNB-UHFFFAOYSA-N,O=C(OCCOCCO)C1CCCCC1NC1CCCC(C(F)(F)F)C1;OCCOCCOC(=O)C1CCCCC1NC1CCCC(C1)C(F)(F)F
ETOFIBRATE,ETOFIBRATE,CHEMBL358150,BRD:BRD-BRD-K49338325-001-03-4;BRD:BRD-K49338325-001-03-4,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA,HYPERTRIGLYCERIDEMIA,,LAUNCHED,,Small molecule,Unknown,XXRVYAFBUDSLJX-UHFFFAOYSA-N,CC(C)(OC1CCC(CL)CC1)C(=O)OCCOC(=O)C1CCCNC1
ETOFYLLINE,ETOFYLLINE,CHEMBL699,BRD:BRD-BRD-K83064458-001-23-0;BRD:BRD-K83064458-001-23-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1,"ASTHMA, BRONCHITIS",,LAUNCHED,,Small molecule,Unknown,NWPRCRWQMGIBOT-UHFFFAOYSA-N,CN1C(=O)C2C(NCN2CCO)N(C)C1=O;CN1C2NCN(CCO)C2C(=O)N(C)C1=O
ETOFYLLINE-CLOFIBRATE,ETOFYLLINE-CLOFIBRATE,,BRD:BRD-BRD-K49840922-001-05-1;BRD:BRD-K49840922-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,PLATELET AGGREGATION INHIBITOR,PPARA,,,LAUNCHED,,,NA,,CN1C2NCN(CCOC(=O)C(C)(C)OC3CCC(CL)CC3)C2C(=O)N(C)C1=O
ETOMIDATE,ETOMIDATE,CHEMBL681,BRD:BRD-BRD-K55055802-001-10-2;BRD:BRD-K55055802-001-10-2,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,ADRA2B;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,GENERAL ANAESTHETIC,,LAUNCHED,,Small molecule,Approved,NPUKDXXFDDZOKR-LLVKDONJSA-N,CCOC(=O)C1CNCN1[C@H](C)C1CCCCC1
ETOMOXIR,ETOMOXIR,CHEMBL2051959,BRD:BRD-BRD-K32405725-001-02-8;BRD:BRD-K32405725-001-02-8;CTRP:660082,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CARNITINE PALMITOYLTRANSFERASE INHIBITOR,CPT1A,,,PHASE 2,,Small molecule,Unknown,DZLOHEOHWICNIL-QGZVFWFLSA-N,CCOC(=O)[C@@]1(CCCCCCOC2CCC(CL)CC2)CO1
ETONOGESTREL,ETONOGESTREL,CHEMBL1531,BRD:BRD-A08302182-001-01-7;BRD:BRD-BRD-A08302182-001-01-7,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,ESR1;PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,GCKFUYQCUCGESZ-BPIQYHPVSA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC;CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C
ETOPOPHOS,ETOPOPHOS,CHEMBL1200645,GDSC1:134,gdsc,,,,,,,Small molecule,Approved,LIQODXNTTZAGID-OCBXBXKTSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1OP(=O)(O)O
VP-16213,ETOPOSIDE;VP-16213,CHEMBL44657,BRD:BRD-BRD-K37798499-001-27-2;BRD:BRD-K37798499-001-18-1;BRD:BRD-K37798499-001-27-2;CTRP:48589;GDSC1:134,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF TOPOISOMERASE,TOP2A;TOP2B,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF TOPOISOMERASE', 'TOPOISOMERASE INHIBITOR'}, defaulting to 'INHIBITOR OF TOPOISOMERASE'",Small molecule,Approved,VJJPUSNTGOMMGY-MRVIYFEKSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1O;COC1CC(CC(OC)C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2CC3OCOC3CC12
ETOPOSIDE-PHOSPHATE,ETOPOSIDE-PHOSPHATE,,BRD:BRD-BRD-K72533376-001-01-2;BRD:BRD-K72533376-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,"TESTICULAR CARCINOMA, SMALL CELL LUNG CANCER",,LAUNCHED,,,NA,,COC1CC(CC(OC)C1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2CC3OCOC3CC12
ETORICOXIB,ETORICOXIB,CHEMBL416146,BRD:BRD-BRD-K54770957-001-04-3;BRD:BRD-K54770957-001-04-3,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,"RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OSTEOARTHRITIS, GOUT, ANKYLOSING SPONDYLITIS",,LAUNCHED,,Small molecule,Approved,MNJVRJDLRVPLFE-UHFFFAOYSA-N,CC1CCC(-C2NCC(CL)CC2-C2CCC(S(C)(=O)=O)CC2)CN1;CC1CCC(CN1)-C1NCC(CL)CC1-C1CCC(CC1)S(C)(=O)=O
ETOSALAMIDE,ETOSALAMIDE,CHEMBL2104260,BRD:BRD-BRD-K60914966-001-01-4;BRD:BRD-K60914966-001-01-4,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,PRECLINICAL,,Small molecule,Unknown,XBNRCMFFZFCWMH-UHFFFAOYSA-N,CCOCCOC1CCCCC1C(N)=O
ETP-45658,ETP-45658,,BRD:BRD-BRD-K15858023-001-01-0;BRD:BRD-K15858023-001-01-0,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PRECLINICAL,,,NA,,CN1NCC2C(NC(NC12)-C1CCCC(O)C1)N1CCOCC1
ETP-45835,ETP-45835,,GDSC1:447,gdsc,,,,,,,,NA,,
ETP-46464,ETP-46464,,BRD:BRD-BRD-K24556407-001-02-3;BRD:BRD-K24556407-001-02-3;BRD:BRD-K24556407-001-03-9;CTRP:666716,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF ATR KINASE AND MTOR,ATR;MTOR,,,PRECLINICAL,"Multiple values for MOA: {'ATR KINASE INHIBITOR', 'INHIBITOR OF ATR KINASE AND MTOR'}, defaulting to 'INHIBITOR OF ATR KINASE AND MTOR'",,NA,,CC(C)(C#N)C1CCC(CC1)N1C(=O)OCC2CNC3CCC(CC3C12)-C1CNC2CCCCC2C1
ETRABAMINE,ETRABAMINE,CHEMBL2106160,BRD:BRD-K00004658-001-01-9,rep_single_dose,DOPAMINE RECEPTOR AGONIST,,,,,,Small molecule,Unknown,YDSVAKPJAOSZJA-UHFFFAOYSA-N,CNC1CCC2NCSC2C1
ETRASIMOD,ETRASIMOD,CHEMBL3358920,BRD:BRD-K00003139-001-01-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,MVGWUTBTXDYMND-QGZVFWFLSA-N,O=C(O)C[C@H]1CCC2C1[NH]C1CCC(OCC3CCC(C4CCCC4)C(C(F)(F)F)C3)CC21
ETRAVIRINE,ETRAVIRINE,CHEMBL308954,BRD:BRD-BRD-K74717603-001-02-2;BRD:BRD-K74717603-001-02-2,rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,CYP2C19;CYP2C9;CYP3A4,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,PYGWGZALEOIKDF-UHFFFAOYSA-N,CC1CC(C#N)CC(C)C1OC1NC(NC2CCC(C#N)CC2)NC(N)C1BR;CC1CC(CC(C)C1OC1NC(NC2CCC(CC2)C#N)NC(N)C1BR)C#N
ETRETINATE,ETRETINATE,CHEMBL464,BRD:BRD-K49076555-001-05-6,rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,RARA;RXRG,,,,,Small molecule,Approved,HQMNCQVAMBCHCO-DJRRULDNSA-N,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/C1C(C)CC(OC)C(C)C1C
ETRIPAMIL,ETRIPAMIL,CHEMBL3707312,BRD:BRD-K00090659-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,VAZNEHLGJGSQEL-MHZLTWQESA-N,COC(=O)C1CCCC(CCN(C)CCC[C@@](C#N)(C2CCC(OC)C(OC)C2)C(C)C)C1
EUGENOL,EUGENOL,CHEMBL42710,BRD:BRD-BRD-K32977963-001-05-0;BRD:BRD-K32977963-001-05-0,rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,TOOTHACHE,,LAUNCHED,,Small molecule,Early Phase,RRAFCDWBNXTKKO-UHFFFAOYSA-N,C=CCC1CCC(O)C(OC)C1;COC1CC(CC=C)CCC1O
EUK-134,EUK-134,,BRD:BRD-K19741031-001-01-4,rep_single_dose,CATALASE STIMULANT,APP;SOD2,,,,,,NA,,
EUPATILIN,EUPATILIN,CHEMBL312750,BRD:BRD-BRD-K47031502-001-01-6;BRD:BRD-K47031502-001-01-6,rep_primary;rep_single_dose,MUCUS PROTECTING AGENT,,,,LAUNCHED,,Small molecule,Unknown,DRRWBCNQOKKKOL-UHFFFAOYSA-N,COC1CCC(-C2CC(=O)C3C(O)C(OC)C(O)CC3O2)CC1OC;COC1CCC(CC1OC)-C1CC(=O)C2C(O)C(OC)C(O)CC2O1
EVACETRAPIB,EVACETRAPIB,CHEMBL2017179,BRD:BRD-BRD-K16551357-001-03-2;BRD:BRD-K16551357-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR,CETP,,,PHASE 3,,Small molecule,Phase 3,IHIUGIVXARLYHP-YBXDKENTSA-N,CC1CC(C)C2C(C1)[C@@H](N(CC1CC(C(F)(F)F)CC(C(F)(F)F)C1)C1NNN(C)N1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1;CC1CC(C)C2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(CC3CC(CC(C3)C(F)(F)F)C(F)(F)F)C3NNN(C)N3)C2C1
EVANS-BLUE,EVANS-BLUE,,BRD:BRD-BRD-K24548560-342-02-1;BRD:BRD-K24548560-342-02-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATOR,GRIA1;PTPN1,,,LAUNCHED,,,NA,,CC1CC(CCC1\N=N\C1CCC2C(CC(C(N)C2C1O)S(O)(=O)=O)S(O)(=O)=O)-C1CCC(C(C)C1)\N=N\C1CCC2C(CC(C(N)C2C1O)S(O)(=O)=O)S(O)(=O)=O
EVATANEPAG,EVATANEPAG,CHEMBL563646,BRD:BRD-BRD-K11452913-001-01-9;BRD:BRD-K11452913-001-01-9,rep_primary;rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGER2;PTGER4,,,PHASE 2,,Small molecule,Phase 2,WOHRHWDYFNWPNG-UHFFFAOYSA-N,CC(C)(C)C1CCC(CN(CC2CCCC(OCC(=O)O)C2)S(=O)(=O)C2CCCNC2)CC1;CC(C)(C)C1CCC(CN(CC2CCCC(OCC(O)=O)C2)S(=O)(=O)C2CCCNC2)CC1
EVENAMIDE,EVENAMIDE,CHEMBL3678076,BRD:BRD-K00004688-001-01-9,rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,,,,,,Small molecule,Phase 2,GRHBODILPPXVKN-UHFFFAOYSA-N,CCCCOC1CCCC(CCNCC(=O)N(C)C)C1
RAD001,EVEROLIMUS;RAD001,CHEMBL1908360,BRD:BRD-BRD-K13514097-001-05-3;BRD:BRD-K13514097-001-04-6;BRD:BRD-K13514097-001-05-3;BRD:BRD-U00115429-001-01-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MTOR VIA FKBP12 (FKBP1A),FKBP1A;MTOR,"BREAST CANCER, NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET), RENAL CELL CARCINOMA (RCC), SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA), TUBEROUS SCLEROSIS COMPLEX (TSC), RENAL ANGIOMYOLIPOMA",,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF MTOR VIA FKBP12 (FKBP1A)', 'MTOR INHIBITOR'}, defaulting to 'INHIBITOR OF MTOR VIA FKBP12 (FKBP1A)'
Multiple values for repurposing_target: {'FKBP1A;MTOR', 'MTOR'}, taking the union
Multiple values for structure_id: {'K13514097', 'U00115429'}, defaulting to None",Small molecule,Approved,HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
EVOBRUTINIB,EVOBRUTINIB,CHEMBL4072833,BRD:BRD-K00003405-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Phase 3,QUIWHXQETADMGN-UHFFFAOYSA-N,C=CC(=O)N1CCC(CNC2NCNC(N)C2-C2CCC(OC3CCCCC3)CC2)CC1
EVOCALCET,EVOCALCET,CHEMBL4297621,BRD:BRD-K00003250-001-01-9,rep_single_dose,CALCIUM SENSITIZER,,,,,,Small molecule,Phase 3,RZNUIYPHQFXBAN-XLIONFOSSA-N,C[C@@H](N[C@H]1CCN(C2CCC(CC(=O)O)CC2)C1)C1CCCC2CCCCC12
EVODIAMINE,EVODIAMINE,CHEMBL486598,BRD:BRD-A68631409-001-05-4;BRD:BRD-BRD-A68631409-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,"ATPASE INHIBITOR, TRPV AGONIST",TRPV1,,,PRECLINICAL,,Small molecule,NA,TXDUTHBFYKGSAH-GOSISDBHSA-N,CN1C2CCCCC2C(=O)N2CCC3C([NH]C4CCCCC34)[C@@H]21;CN1C2N(CCC3C2[NH]C2CCCCC32)C(=O)C2CCCCC12
EVOGLIPTIN (TARTRATE),EVOGLIPTIN (TARTRATE),,BRD:BRD-K00076940-046-02-9,rep_single_dose,,,,,,,,NA,,
EVP-6124,EVP-6124,CHEMBL2151572;CHEMBL3137323,BRD:BRD-BRD-K71603915-003-01-8;BRD:BRD-K71603915-003-01-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA7,,,PHASE 3,,Small molecule,Phase 3,OIJYTJGIDVTCFF-ZOWNYOTGSA-N;SSRDSYXGYPJKRR-ZDUSSCGKSA-N,CL.O=C(N[C@H]1CN2CCC1CC2)C1CC2CCCC(CL)C2S1;CLC1CCCC2CC(SC12)C(=O)N[C@H]1CN2CCC1CC2;O=C(N[C@H]1CN2CCC1CC2)C1CC2CCCC(CL)C2S1
EVP4593,EVP4593,,BRD:BRD-BRD-K68395654-001-03-1;BRD:BRD-K68395654-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,,,,PRECLINICAL,,,NA,,NC1CCC2NCNC(NCCC3CCC(OC4CCCCC4)CC3)C2C1
EW-7197,EW-7197,CHEMBL3260567,BRD:BRD-BRD-K74396648-001-01-4;BRD:BRD-K74396648-001-01-4,rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,ACVR1B;TGFBR1,,,PHASE 1,,Small molecule,Phase 2,FJCDSQATIJKQKA-UHFFFAOYSA-N,CC1CCCC(-C2[NH]C(CNC3CCCCC3F)NC2-C2CCC3NCNN3C2)N1;CC1CCCC(N1)-C1[NH]C(CNC2CCCCC2F)NC1-C1CCC2NCNN2C1
EX 527,EX 527,,GDSC1:341,gdsc,,,,,,,,NA,,
EX-527,EX-527,CHEMBL382277,BRD:BRD-A73908300-001-06-7;BRD:BRD-BRD-A73908300-001-06-7;CTRP:608999;GDSC1:341,ctrp;gdsc;rep_primary;rep_single_dose,SIRT INHIBITOR,SIRT1,,,PHASE 2,,Small molecule,Phase 2,NYORQUCSPQVLTE-UHFFFAOYSA-N,NC(=O)C1CCCC2C1[NH]C1CCC(CL)CC21;NC(=O)C1CCCC2C3CC(CL)CCC3NC12
EX-8678,EX-8678,,GDSC1:283,gdsc,,,,,,,,NA,,
EXALAMIDE,EXALAMIDE,CHEMBL1405973,BRD:BRD-BRD-K12609457-001-03-1;BRD:BRD-K12609457-001-03-1,rep_primary;rep_single_dose,MEMBRANE PERMEABILITY INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,CKSJXOVLXUMMFF-UHFFFAOYSA-N,CCCCCCOC1CCCCC1C(N)=O
EXAMORELIN,EXAMORELIN,CHEMBL108335,BRD:BRD-BRD-K35304636-001-01-0;BRD:BRD-K35304636-001-01-0,rep_primary;rep_single_dose,GROWTH HORMONE RELEASING FACTOR AGONIST,GHRHR;GHSR,,,PHASE 2,,Protein,Unknown,RVWNMGKSNGWLOL-GIIHNPQRSA-N,C[C@H](NC(=O)[C@@H](CC1C(C)[NH]C2CCCCC12)NC(=O)[C@@H](N)CC1CNC[NH]1)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN)C(N)=O;CC1[NH]C2CCCCC2C1C[C@@H](NC(=O)[C@@H](N)CC1C[NH]CN1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN)C(N)=O
EXATECAN-MESYLATE,EXATECAN-MESYLATE,,BRD:BRD-BRD-K92150287-066-01-2;BRD:BRD-K92150287-066-01-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 3,,,NA,,CC[C@@]1(O)C(=O)OCC2C1CC1-C3NC4CC(F)C(C)C5CC[C@H](N)C(C3CN1C2=O)C45
EXEL-2880,EXEL-2880,CHEMBL1230609,GDSC1:308;GDSC2:2040,gdsc,,,,,,,Small molecule,Phase 2,CXQHYVUVSFXTMY-UHFFFAOYSA-N,COC1CC2C(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3F)CCNC2CC1OCCCN1CCOCC1
EXELBINE,EXELBINE,,GDSC1:140;GDSC2:2048,gdsc,,,,,,,,NA,,
EXEMESTANE,EXEMESTANE,CHEMBL1200374,BRD:BRD-BRD-K33425534-001-12-5;BRD:BRD-K33425534-001-12-5,rep_multi_dose;rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP19A1,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,BFYIZQONLCFLEV-DAELLWKTSA-N,C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O;C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12
EXHERIN,EXHERIN,CHEMBL3818130,BRD:BRD-BRD-K81795818-019-01-4;BRD:BRD-K81795818-019-01-4,rep_primary;rep_single_dose,CADHERIN ANTAGONIST,CDH2,,,PHASE 2,,Protein,Phase 1,FQVLRGLGWNWPSS-BXBUPLCLSA-N,CC(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC2C[NH]CN2)NC1=O;CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC2CNC[NH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O
EXIFONE,EXIFONE,CHEMBL329522,BRD:BRD-BRD-K65716359-001-02-1;BRD:BRD-K65716359-001-02-1,rep_primary;rep_single_dose,NOOTROPIC AGENT,TYR,,,WITHDRAWN,,Small molecule,Approved,XEDWWPGWIXPVRQ-UHFFFAOYSA-N,O=C(C1CC(O)C(O)C(O)C1)C1CCC(O)C(O)C1O;OC1CCC(C(=O)C2CC(O)C(O)C(O)C2)C(O)C1O
EXISULIND,EXISULIND,CHEMBL488025,BRD:BRD-BRD-K37708699-001-01-4;BRD:BRD-K37708699-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,,,PHASE 3,,Small molecule,Phase 3,MVGSNCBCUWPVDA-MFOYZWKCSA-N,CC1=C(CC(=O)O)C2CC(F)CCC2/C1=C\C1CCC(S(C)(=O)=O)CC1;CC1=C(CC(O)=O)C2CC(F)CCC2C\1=C/C1CCC(CC1)S(C)(=O)=O
EXO-1,EXO-1,,BRD:BRD-BRD-K78633253-001-10-3;BRD:BRD-K78633253-001-10-3,rep_primary;rep_single_dose,ARF INHIBITOR,,,,PRECLINICAL,,,NA,,COC(=O)C1CCCCC1NC(=O)C1CCC(F)CC1
EXO-IWR-1,EXO-IWR-1,,BRD:BRD-K96155658-001-02-9,rep_single_dose,WNT SIGNALING INHIBITOR NEGATIVE CONTROL,TNKS,,,,,,NA,,
EZATIOSTAT,EZATIOSTAT,CHEMBL2110585,BRD:BRD-BRD-K98963219-001-01-2;BRD:BRD-K98963219-001-01-2,rep_primary;rep_single_dose,GLUTATHIONE TRANSFERASE INHIBITOR,GSTP1,,,PHASE 2,,Small molecule,Phase 2,GWEJFLVSOGNLSS-WPFOTENUSA-N,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1CCCCC1)C(=O)N[C@@H](C(=O)OCC)C1CCCCC1
EZETIMIBE,EZETIMIBE,CHEMBL1138,BRD:BRD-BRD-K42260897-001-07-6;BRD:BRD-BRD-K42260897-001-09-2;BRD:BRD-K42260897-001-07-6;BRD:BRD-K42260897-001-09-2,rep_primary;rep_single_dose,"CHOLESTEROL INHIBITOR, NIEMANN-PICK C1-LIKE 1 PROTEIN ANTAGONIST",ANPEP;NPC1L1;SOAT1,"HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, SITOSTEROLEMIA",,LAUNCHED,,Small molecule,Approved,OLNTVTPDXPETLC-XPWALMASSA-N,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1CCC(F)CC1)C1CCC(O)CC1)C1CCC(F)CC1;O=C1[C@H](CC[C@H](O)C2CCC(F)CC2)[C@@H](C2CCC(O)CC2)N1C1CCC(F)CC1;OC(CC[C@@H]1[C@H](N(C1=O)C1CCC(F)CC1)C1CCC(O)CC1)C1CCC(F)CC1
EZUTROMID,EZUTROMID,CHEMBL1773683,BRD:BRD-BRD-K25570267-001-01-4;BRD:BRD-K25570267-001-01-4,rep_primary;rep_single_dose,UTROPHIN ENHANCER,UTRN,,,PHASE 2,,Small molecule,Phase 2,KSGCNXAZROJSNW-UHFFFAOYSA-N,CCN(CC)C1CCC(CC1)-N1NC2CC(C)C(N)CC2N1;CCS(=O)(=O)C1CCC2OC(-C3CCC4CCCCC4C3)NC2C1
F-11440,F-11440,,BRD:BRD-BRD-K87948281-001-01-9;BRD:BRD-K87948281-001-01-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PHASE 2,,,NA,,CN1C(=O)CNN(CCCCN2CCN(CC2)C2NCCCN2)C1=O
F-16915,F-16915,,BRD:BRD-K00003299-001-01-9,rep_single_dose,,,,,,,,NA,,
F351,F351,,BRD:BRD-BRD-K41267922-001-01-4;BRD:BRD-K41267922-001-01-4,rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFB1,,,PHASE 2,,,NA,,CC1CCC(=O)N(C1)-C1CCC(O)CC1
FADROZOLE,FADROZOLE,CHEMBL287677;CHEMBL9298,BRD:BRD-A25619068-003-03-4;BRD:BRD-BRD-A25619068-003-03-4,rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP11B1;CYP19A1,BREAST CANCER,,LAUNCHED,,Small molecule,Unknown,CLPFFLWZZBQMAO-CQSZACIVSA-N;CLPFFLWZZBQMAO-UHFFFAOYSA-N,N#CC1CCC([C@H]2CCCC3CNCN32)CC1;N#CC1CCC(C2CCCC3CNCN32)CC1;N#CC1CCC(CC1)C1CCCC2CNCN12
FAGOMINE,FAGOMINE,CHEMBL108084,BRD:BRD-BRD-K61536264-001-01-3;BRD:BRD-K61536264-001-01-3,rep_primary;rep_single_dose,GLUCOSIDASE INHIBITOR,GLB1,,,PHASE 2,,Small molecule,NA,YZNNBIPIQWYLDM-HSUXUTPPSA-N,OC[C@H]1NCC[C@@H](O)[C@@H]1O
FALECALCITRIOL,FALECALCITRIOL,CHEMBL2106158,BRD:BRD-BRD-K08251020-001-01-0;BRD:BRD-K08251020-001-01-0,rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,HYPERPARATHYROIDISM,,LAUNCHED,,Small molecule,Unknown,XPYGGHVSFMUHLH-UUSULHAXSA-N,C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C;C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(O)(C(F)(F)F)C(F)(F)F)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
FAMCICLOVIR,FAMCICLOVIR,CHEMBL880,BRD:BRD-BRD-K45033733-001-12-2;BRD:BRD-K45033733-001-12-2,rep_multi_dose;rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,"COLD SORE, GENITIAL HERPES, SHINGLES",,LAUNCHED,,Small molecule,Approved,GGXKWVWZWMLJEH-UHFFFAOYSA-N,CC(=O)OCC(CCN1CNC2CNC(N)NC12)COC(C)=O;CC(=O)OCC(CCN1CNC2CNC(N)NC21)COC(C)=O
FAMOTIDINE,FAMOTIDINE,CHEMBL902,BRD:BRD-BRD-K00673382-001-18-9;BRD:BRD-K00673382-001-18-9,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,HEARTBURN,,LAUNCHED,,Small molecule,Approved,XUFQPHANEAPEMJ-UHFFFAOYSA-N,NC(N)=NC1NC(CSCC/C(N)=N/S(N)(=O)=O)CS1;NC(N)=NC1NC(CSCC\C(N)=N/S(N)(=O)=O)CS1
FAMPROFAZONE,FAMPROFAZONE,CHEMBL1475693,BRD:BRD-A08255417-001-14-7;BRD:BRD-BRD-A08255417-001-14-7,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,PRECLINICAL,,Small molecule,Unknown,GNUXVOXXWGNPIV-UHFFFAOYSA-N,CC(C)C1C(CN(C)C(C)CC2CCCCC2)N(C)N(-C2CCCCC2)C1=O;CC(CC1CCCCC1)N(C)CC1C(C(C)C)C(=O)N(-C2CCCCC2)N1C
FANANSERIN,FANANSERIN,CHEMBL83894,BRD:BRD-BRD-K08998509-001-02-4;BRD:BRD-K08998509-001-02-4,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR2A,,,PHASE 2,,Small molecule,Unknown,VGIGHGMPMUCLIQ-UHFFFAOYSA-N,FC1CCC(CC1)N1CCN(CCCN2C3CCCC4CCCC(C34)S2(=O)=O)CC1;O=S1(=O)C2CCCC3CCCC(C23)N1CCCN1CCN(C2CCC(F)CC2)CC1
FANETIZOLE,FANETIZOLE,CHEMBL1993793,BRD:BRD-BRD-K60798049-001-03-8;BRD:BRD-K60798049-001-03-8,rep_primary;rep_single_dose,NEUTROPHIL SUPEROXIDE PRODUCTION,,,,PHASE 3,,Small molecule,Unknown,WEEYMMXMBFJUAI-UHFFFAOYSA-N,C(CC1CCCCC1)NC1NC(CS1)-C1CCCCC1;C1CCC(CCNC2NC(-C3CCCCC3)CS2)CC1
FANTOFARONE,FANTOFARONE,CHEMBL285855,BRD:BRD-K00003465-001-01-9,rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,,,Small molecule,Unknown,ITAMRBIZWGDOHW-UHFFFAOYSA-N,COC1CCC(CCN(C)CCCOC2CCC(S(=O)(=O)C3C(C(C)C)CN4CCCCC34)CC2)CC1OC
FAPI-4,FAPI-4,,BRD:BRD-K00091294-001-01-9,rep_single_dose,,,,,,,,NA,,
FARAMPATOR,FARAMPATOR,CHEMBL1276138,BRD:BRD-K00003507-001-01-9,rep_single_dose,IONOTROPIC GLUTAMATE RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,XFVRBYKKGGDPAJ-UHFFFAOYSA-N,O=C(C1CCC2NONC2C1)N1CCCCC1
FARMORUBICIN,FARMORUBICIN,CHEMBL1200981;CHEMBL417,GDSC2:1511,gdsc,,,,,,,Small molecule,Approved,AOJJSUZBOXZQNB-VTZDEGQISA-N;MWWSFMDVAYGXBV-FGBSZODSSA-N,COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.CL
FARNESYL-THIOSALICYLIC-ACID-AMIDE,FARNESYL-THIOSALICYLIC-ACID-AMIDE,,BRD:BRD-BRD-K14590126-001-01-6;BRD:BRD-K14590126-001-01-6,rep_primary;rep_single_dose,RAS GTPASE INHIBITOR,HRAS,,,PHASE 1,,,NA,,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1CCCCC1C(N)=O
FAROPENEM,FAROPENEM,CHEMBL556262,BRD:BRD-A49622760-001-01-9;BRD:BRD-BRD-A49622760-001-01-9,rep_primary;rep_single_dose,LACTAMASE INHIBITOR,,"PNEUMONIA, BRONCHITIS, SKIN INFECTIONS, URINARY TRACT INFECTIONS, SINUSITIS",,LAUNCHED,,Small molecule,Phase 3,HGGAKXAHAYOLDJ-FHZUQPTBSA-N,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C([C@H]3CCCO3)S[C@H]12;CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O
FAROPENEM-MEDOXOMIL,FAROPENEM-MEDOXOMIL,,BRD:BRD-BRD-K59045783-001-01-1;BRD:BRD-K59045783-001-01-1,rep_primary;rep_single_dose,LACTAMASE INHIBITOR,,"SINUSITIS, PNEUMONIA, BRONCHITIS, SKIN INFECTIONS, URINARY TRACT INFECTIONS",,LAUNCHED,,,NA,,C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCC1OC(=O)OC1C
FARYDAK,FARYDAK,CHEMBL3545368;CHEMBL483254,GDSC1:438,gdsc,,,,,,,Small molecule,Approved,FPOHNWQLNRZRFC-ZHACJKMWSA-N;XVDWNSFFSMWXJJ-ASTDGNLGSA-N,CC(O)C(=O)O.CC1[NH]C2CCCCC2C1CCNCC1CCC(/C=C/C(=O)NO)CC1;CC1[NH]C2CCCCC2C1CCNCC1CCC(/C=C/C(=O)NO)CC1
FASLODEX,FASLODEX,CHEMBL1358,GDSC2:1200,gdsc,,,,,,,Small molecule,Approved,VWUXBMIQPBEWFH-WCCTWKNTSA-N,C[C@]12CC[C@@H]3C4CCC(O)CC4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O
FASORACETAM,FASORACETAM,CHEMBL2106179,BRD:BRD-K00004571-001-01-9,rep_single_dose,GABA RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,GOWRRBABHQUJMX-MRVPVSSYSA-N,O=C1CC[C@H](C(=O)N2CCCCC2)N1
FASUDIL,FASUDIL,CHEMBL38380;CHEMBL541388,BRD:BRD-BRD-K76617868-003-11-9;BRD:BRD-K76617868-003-11-9,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,PKIA;PRKACA;ROCK1;ROCK2,CEREBRAL VASOSPASM,,LAUNCHED,,Small molecule,Phase 3,LFVPBERIVUNMGV-UHFFFAOYSA-N;NGOGFTYYXHNFQH-UHFFFAOYSA-N,CL.O=S(=O)(C1CCCC2CNCCC12)N1CCCNCC1;O=S(=O)(C1CCCC2CNCCC12)N1CCCNCC1;O=S(=O)(N1CCCNCC1)C1CCCC2CNCCC12
FAVIPIRAVIR,FAVIPIRAVIR,CHEMBL221722,BRD:BRD-BRD-K04264130-001-01-4;BRD:BRD-K04264130-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,ZCGNOVWYSGBHAU-UHFFFAOYSA-N,NC(=O)C1NC(F)CNC1O
FDCYD,FDCYD,,BRD:BRD-BRD-K18157228-001-01-7;BRD:BRD-K18157228-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,DNA METHYLTRANSFERASE INHIBITOR,,,,PHASE 2,,,NA,,NC1NC(=O)N(CC1F)[C@H]1C[C@H](O)[C@@H](CO)O1
NCGC00099374,FDI-6;NCGC00099374,,BRD:BRD-K00126477-001-01-9,oncref_2,INHIBITOR OF FOXM1,FOXM1,,,,,,NA,,
FEBANTEL,FEBANTEL,CHEMBL1080983,BRD:BRD-K00076917-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,HMCCXLBXIJMERM-UHFFFAOYSA-N,COCC(=O)NC1CC(SC2CCCCC2)CCC1N=C(NC(=O)OC)NC(=O)OC
FEBUPROL,FEBUPROL,CHEMBL2104223,BRD:BRD-K00004566-001-01-9,rep_single_dose,CHOLERETIC AGENT,,,,,,Small molecule,Unknown,WBLXZPHICYCDGN-UHFFFAOYSA-N,CCCCOCC(O)COC1CCCCC1
FEBUXOSTAT,FEBUXOSTAT,CHEMBL1164729,BRD:BRD-BRD-K48367671-001-05-9;BRD:BRD-K48367671-001-05-9,rep_primary;rep_single_dose,XANTHINE OXIDASE INHIBITOR,XDH,HYPERURICEMIA,,LAUNCHED,,Small molecule,Approved,BQSJTQLCZDPROO-UHFFFAOYSA-N,CC(C)COC1CCC(CC1C#N)-C1NC(C)C(S1)C(O)=O;CC1NC(-C2CCC(OCC(C)C)C(C#N)C2)SC1C(=O)O
FEDOVAPAGON,FEDOVAPAGON,CHEMBL518043,BRD:BRD-K00075618-001-03-9,rep_single_dose,,,,,,,Small molecule,Phase 2,RUOLFWZIFNQQGH-DEOSSOPVSA-N,CC1CC(C(=O)N2CCCCC3CCCCC32)CCC1CNC(=O)N1CCC[C@H]1C(=O)N(C)C
TG101348,FEDRATINIB;SAR302503;TG-101348;TG101348,CHEMBL1287853,BRD:BRD-BRD-K12502280-001-08-0;BRD:BRD-K12502280-001-08-0;BRD:BRD-K12502280-001-19-9;CTRP:411808;GDSC1:306,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, JAK INHIBITOR",BRD4;FLT3;JAK1;JAK2;JAK3;RET;TYK2,,,PHASE 3,"Multiple values for MOA: {'FLT3 INHIBITOR, JAK INHIBITOR', 'INHIBITOR OF JAK2'}, defaulting to 'FLT3 INHIBITOR, JAK INHIBITOR'
Multiple values for repurposing_target: {'BRD4;JAK1;JAK2;JAK3;TYK2', 'FLT3;JAK1;JAK2;RET'}, taking the union",Small molecule,Approved,JOOXLOJCABQBSG-UHFFFAOYSA-N,CC1CNC(NC2CCC(OCCN3CCCC3)CC2)NC1NC1CCCC(C1)S(=O)(=O)NC(C)(C)C;CC1CNC(NC2CCC(OCCN3CCCC3)CC2)NC1NC1CCCC(S(=O)(=O)NC(C)(C)C)C1
FELBAMATE,FELBAMATE,CHEMBL1094,BRD:BRD-BRD-K99107520-001-24-1;BRD:BRD-K99107520-001-24-1,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,EPILEPSY,,LAUNCHED,,Small molecule,Approved,WKGXYQFOCVYPAC-UHFFFAOYSA-N,NC(=O)OCC(COC(N)=O)C1CCCCC1
FELBINAC,FELBINAC,CHEMBL413965,BRD:BRD-BRD-K91740057-001-19-8;BRD:BRD-K91740057-001-19-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,CTSL,"RHEUMATOID ARTHRITIS, MUSCLE PAIN",,LAUNCHED,,Small molecule,Approved,QRZAKQDHEVVFRX-UHFFFAOYSA-N,O=C(O)CC1CCC(-C2CCCCC2)CC1;OC(=O)CC1CCC(CC1)-C1CCCCC1
FELODIPINE,FELODIPINE,CHEMBL1480;CHEMBL428768,BRD:BRD-A30815329-001-10-5;BRD:BRD-BRD-A30815329-001-10-5,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1F;CACNA1H;CACNA1S;CACNA2D1;CACNA2D2;CACNB2;CALM1;CFTR;NR3C2;PDE1A;PDE1B;TNNC1;TNNC2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,RZTAMFZIAATZDJ-HNNXBMFYSA-N;RZTAMFZIAATZDJ-UHFFFAOYSA-N,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1CCCC(CL)C1CL;CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1CCCC(CL)C1CL;CCOC(=O)C1=C(C)NC(C)=C(C1C1CCCC(CL)C1CL)C(=O)OC
FELYPRESSIN,FELYPRESSIN,CHEMBL1908309;CHEMBL3989781,BRD:BRD-K00003319-001-01-9,rep_single_dose,VASOPRESSIN RECEPTOR AGONIST,,,,,,Protein,Unknown,JEFCJMMLFXHSSX-AVIVMPHOSA-N;SFKQVVDKFKYTNA-OGNLOKFRSA-N,NCCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O;NCCCC[C@H](CC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
FENACLON,FENACLON,CHEMBL2106620,BRD:BRD-BRD-K08791496-001-01-0;BRD:BRD-K08791496-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,BITWVVLBVUMFHU-UHFFFAOYSA-N,CLCCC(=O)NCCC1CCCCC1;O=C(CCCL)NCCC1CCCCC1
FENBENDAZOLE,FENBENDAZOLE,CHEMBL37161,BRD:BRD-BRD-K51318897-001-15-3;BRD:BRD-K51318897-001-15-3,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,"GASTROINTESTINAL PARASITES, GASTROINTESTINAL ROUNDWORMS",,LAUNCHED,,Small molecule,Unknown,HDDSHPAODJUKPD-UHFFFAOYSA-N,COC(=O)NC1NC2CC(SC3CCCCC3)CCC2[NH]1;COC(=O)NC1NC2CCC(SC3CCCCC3)CC2[NH]1
FENBUFEN,FENBUFEN,CHEMBL277522,BRD:BRD-BRD-K12513978-001-24-1;BRD:BRD-K12513978-001-24-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,Small molecule,Approved,ZPAKPRAICRBAOD-UHFFFAOYSA-N,O=C(O)CCC(=O)C1CCC(-C2CCCCC2)CC1;OC(=O)CCC(=O)C1CCC(CC1)-C1CCCCC1
FENCLONINE-(+/-),FENCLONINE-(+/-),,BRD:BRD-A81615860-003-01-7;BRD:BRD-BRD-A81615860-003-01-7,rep_primary;rep_single_dose,TRYPTOPHAN HYDROXYLASE INHIBITOR,PAH;TPH1;TPH2,,,PRECLINICAL,,,NA,,NC(CC1CCC(CL)CC1)C(O)=O
FENDILINE,FENDILINE,CHEMBL254832,BRD:BRD-A71033472-003-23-9;BRD:BRD-BRD-A71033472-003-23-9,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,HTR2B,,,PRECLINICAL,,Small molecule,Unknown,NMKSAYKQLCHXDK-UHFFFAOYSA-N,CC(NCCC(C1CCCCC1)C1CCCCC1)C1CCCCC1
FENEBRUTINIB,FENEBRUTINIB,CHEMBL4065122,BRD:BRD-K25290930-001-03-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Phase 3,WNEODWDFDXWOLU-QHCPKHFHSA-N,C[C@H]1CN(C2COC2)CCN1C1CCC(NC2CC(-C3CCNC(N4CCN5C(CC6C5CC(C)(C)C6)C4=O)C3CO)CN(C)C2=O)NC1
FENIGAM,FENIGAM,,BRD:BRD-A66920069-001-01-3;BRD:BRD-BRD-A66920069-001-01-3,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABBR1;GABBR2,"POSTTRAUMATIC STRESS DISORDER, ANXIETY, DEPRESSION",,LAUNCHED,,,NA,,NCC(CC(O)=O)C1CCCCC1
FENOBAM,FENOBAM,CHEMBL2103779;CHEMBL239800,BRD:BRD-BRD-K41160163-001-06-8;BRD:BRD-K41160163-001-06-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PHASE 2,,Small molecule,Phase 1,DWPQODZAOSWNHB-UHFFFAOYSA-N;UNFQKKSADLVQJE-UHFFFAOYSA-N,CN1CC(=O)N=C1NC(=O)NC1CCCC(CL)C1;CN1CC(=O)N=C1NC(=O)NC1CCCC(CL)C1.O
FENOFIBRATE,FENOFIBRATE,CHEMBL672,BRD:BRD-BRD-K50388907-001-30-4;BRD:BRD-K50388907-001-30-4,rep_multi_dose;rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,MMP25;PPARA,"HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA",,LAUNCHED,,Small molecule,Approved,YMTINGFKWWXKFG-UHFFFAOYSA-N,CC(C)OC(=O)C(C)(C)OC1CCC(C(=O)C2CCC(CL)CC2)CC1;CC(C)OC(=O)C(C)(C)OC1CCC(CC1)C(=O)C1CCC(CL)CC1
FENOFIBRIC-ACID,FENOFIBRIC-ACID,,BRD:BRD-BRD-K30213273-001-01-6;BRD:BRD-K30213273-001-01-6,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CLCN1;PPARA,DYSLIPIDEMIA,,LAUNCHED,,,NA,,CC(C)(OC1CCC(CC1)C(=O)C1CCC(CL)CC1)C(O)=O
FENOLDOPAM,FENOLDOPAM,CHEMBL588,BRD:BRD-A50684349-003-02-9;BRD:BRD-BRD-A50684349-003-02-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;DRD1;DRD4;DRD5,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,TVURRHSHRRELCG-UHFFFAOYSA-N,OC1CCC(C2CNCCC3C2CC(O)C(O)C3CL)CC1;OC1CCC(CC1)C1CNCCC2C(CL)C(O)C(O)CC12
FENOPROFEN,FENOPROFEN,CHEMBL1297,BRD:BRD-A81129465-001-03-8;BRD:BRD-BRD-A81129465-001-03-8,rep_multi_dose;rep_primary;rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGS1;PTGS2;SLC5A8,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,Small molecule,Approved,RDJGLLICXDHJDY-UHFFFAOYSA-N,CC(C(=O)O)C1CCCC(OC2CCCCC2)C1;CC(C(O)=O)C1CCCC(OC2CCCCC2)C1
FENOTEROL,FENOTEROL,CHEMBL32800,BRD:BRD-A97104540-004-15-0;BRD:BRD-BRD-A97104540-004-15-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3,,,WITHDRAWN,,Small molecule,Approved,LSLYOANBFKQKPT-UHFFFAOYSA-N,CC(CC1CCC(O)CC1)NCC(O)C1CC(O)CC(O)C1
FENOVERINE,FENOVERINE,CHEMBL1512949,BRD:BRD-BRD-K77564118-001-03-1;BRD:BRD-K77564118-001-03-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,SPASMS,,LAUNCHED,,Small molecule,Phase 3,UBAJTZKNDCEGKL-UHFFFAOYSA-N,O=C(CN1CCN(CC2CCC3C(C2)OCO3)CC1)N1C2CCCCC2SC2CCCCC21;O=C(CN1CCN(CC2CCC3OCOC3C2)CC1)N1C2CCCCC2SC2CCCCC12
FENRETINIDE,FENRETINIDE,CHEMBL7301,BRD:BRD-BRD-K89085489-001-23-2;BRD:BRD-K89085489-001-23-2,rep_multi_dose;rep_primary;rep_single_dose,"APOPTOSIS STIMULANT, RETINOID RECEPTOR AGONIST",RARA,,,PHASE 3,,Small molecule,Phase 3,AKJHMTWEGVYYSE-FXILSDISSA-N,CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)NC1CCC(O)CC1;CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)NC2CCC(O)CC2)C(C)(C)CCC1
FENSPIRIDE,FENSPIRIDE,CHEMBL576127,BRD:BRD-BRD-K26739552-003-15-4;BRD:BRD-K26739552-003-15-4,rep_primary;rep_single_dose,BRONCHODILATOR,,"ASTHMA, OTITIS, SINUSITIS, RHINOPHARYNGITIS, LARYNGITIS",,LAUNCHED,,Small molecule,Approved,FVNFBBAOMBJTST-UHFFFAOYSA-N,O=C1NCC2(CCN(CCC3CCCCC3)CC2)O1
FENTHION,FENTHION,CHEMBL1604375,BRD:BRD-BRD-K67217586-001-08-0;BRD:BRD-K67217586-001-08-0,rep_primary;rep_single_dose,CHOLINESTERASE INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,PNVJTZOFSHSLTO-UHFFFAOYSA-N,COP(=S)(OC)OC1CCC(SC)C(C)C1
FENTIAZAC,FENTIAZAC,CHEMBL589092,BRD:BRD-BRD-K16077845-001-06-1;BRD:BRD-K16077845-001-06-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"MUSCLE PAIN, JOINT PAIN",,LAUNCHED,,Small molecule,Unknown,JIEKMACRVQTPRC-UHFFFAOYSA-N,O=C(O)CC1SC(-C2CCCCC2)NC1-C1CCC(CL)CC1;OC(=O)CC1SC(NC1-C1CCC(CL)CC1)-C1CCCCC1
FENTICONAZOLE,FENTICONAZOLE,CHEMBL1651990,BRD:BRD-A33697453-008-02-4;BRD:BRD-BRD-A33697453-008-02-4,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,VULVOVAGINAL CANDIDIASIS,,LAUNCHED,,Small molecule,Approved,ZCJYUTQZBAIHBS-UHFFFAOYSA-N,CLC1CCC(C(CN2CCNC2)OCC2CCC(SC3CCCCC3)CC2)C(CL)C1
FERB-033,FERB-033,,BRD:BRD-BRD-K61642990-001-01-0;BRD:BRD-K61642990-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,ERBB2,,,PRECLINICAL,,,NA,,O\N=C\C1CCC(-C2CCC(O)C(F)C2)C(CL)C1O
FERROQUINE,FERROQUINE,,BRD:BRD-K00003281-001-01-9,rep_single_dose,ANTIMALARIAL AGENT,,,,,,,NA,,
FERROSTATIN-1,FERROSTATIN-1,,BRD:BRD-K97375133-001-04-9,rep_single_dose,FERROPTOSIS INHIBITOR,,,,,,,NA,,
FERULIC-ACID,FERULIC-ACID,,BRD:BRD-BRD-K66295376-001-13-1;BRD:BRD-K66295376-001-13-1,rep_primary;rep_single_dose,ANTIOXIDANT,CA1;CA12;CA14;CA2;CA4;CA6;CA9,,,PHASE 2,,,NA,,COC1CC(\C=C\C(O)=O)CCC1O
FESOTERODINE,FESOTERODINE,CHEMBL1201764,BRD:BRD-BRD-K46731503-050-01-8;BRD:BRD-K46731503-050-01-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,URINARY INCONTINENCE,,LAUNCHED,,Small molecule,Approved,DCCSDBARQIPTGU-HSZRJFAPSA-N,CC(C)C(=O)OC1CCC(CO)CC1[C@H](CCN(C(C)C)C(C)C)C1CCCCC1;CC(C)N(CC[C@H](C1CCCCC1)C1CC(CO)CCC1OC(=O)C(C)C)C(C)C
FEVIPIPRANT,FEVIPIPRANT,CHEMBL3137332,BRD:BRD-K00003232-001-01-9,rep_single_dose,PROSTAGLANDIN INHIBITOR,,,,,,Small molecule,Phase 3,GFPPXZDRVCSVNR-UHFFFAOYSA-N,CC1C(CC(=O)O)C2CCCNC2N1CC1CCC(S(C)(=O)=O)CC1C(F)(F)F
FEXARAMINE,FEXARAMINE,CHEMBL192966,BRD:BRD-BRD-K08864679-001-02-2;BRD:BRD-K08864679-001-02-2,rep_primary;rep_single_dose,FXR AGONIST,NR1H4,,,PRECLINICAL,,Small molecule,NA,VLQTUNDJHLEFEQ-KGENOOAVSA-N,COC(=O)/C=C/C1CCCC(N(CC2CCC(-C3CCC(N(C)C)CC3)CC2)C(=O)C2CCCCC2)C1;COC(=O)\C=C\C1CCCC(C1)N(CC1CCC(CC1)-C1CCC(CC1)N(C)C)C(=O)C1CCCCC1
FEXINIDAZOLE,FEXINIDAZOLE,CHEMBL1631694,BRD:BRD-BRD-K37069697-001-01-3;BRD:BRD-K37069697-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2/PHASE 3,,Small molecule,Approved,MIWWSGDADVMLTG-UHFFFAOYSA-N,CSC1CCC(OCC2NCC([N+](=O)[O-])N2C)CC1;CSC1CCC(OCC2NCC(N2C)[N+]([O-])=O)CC1
FEXOFENADINE,FEXOFENADINE,CHEMBL914,BRD:BRD-A73368467-003-17-6;BRD:BRD-BRD-A73368467-003-17-6,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,RWTNPBWLLIMQHL-UHFFFAOYSA-N,CC(C)(C(=O)O)C1CCC(C(O)CCCN2CCC(C(O)(C3CCCCC3)C3CCCCC3)CC2)CC1;CC(C)(C(O)=O)C1CCC(CC1)C(O)CCCN1CCC(CC1)C(O)(C1CCCCC1)C1CCCCC1
FEZOLINETANT,FEZOLINETANT,CHEMBL3608680,BRD:BRD-K00003287-001-01-9,rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,PPSNFPASKFYPMN-SECBINFHSA-N,CC1NSC(-C2NNC3N2CCN(C(=O)C2CCC(F)CC2)[C@@H]3C)N1
FG-2216,FG-2216,,BRD:BRD-BRD-K56807945-001-01-2;BRD:BRD-K56807945-001-01-2,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR,EGLN1;EGLN2;HIF1A,,,PHASE 2,,,NA,,OC(=O)CNC(=O)C1NC(CL)C2CCCCC2C1O
FG-4592,FG-4592,CHEMBL2338329,BRD:BRD-BRD-K14385366-001-04-4;BRD:BRD-K14385366-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR,EGLN1;EGLN2;EGLN3,,,PHASE 3,"Multiple values for repurposing_target: {'EGLN1;EGLN2;EGLN3', 'EGLN2'}, taking the union",Small molecule,Approved,YOZBGTLTNGAVFU-UHFFFAOYSA-N,CC1NC(C(=O)NCC(=O)O)C(O)C2CCC(OC3CCCCC3)CC12;CC1NC(C(=O)NCC(O)=O)C(O)C2CCC(OC3CCCCC3)CC12
FG-7142,FG-7142,,BRD:BRD-BRD-K61951118-001-07-9;BRD:BRD-K61951118-001-07-9,rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR INVERSE AGONIST,,,,PRECLINICAL,,,NA,,CNC(=O)C1CC2C(CN1)[NH]C1CCCCC21
ROBLITINIB,FGF401;ROBLITINIB,CHEMBL3545293,BRD:BRD-K00003424-001-01-9;BRD:BRD-K00003424-001-03-9,oncref_2;rep_single_dose,INHIBITOR OF FGFR4,FGFR4,,,,"Multiple values for MOA: {'INHIBITOR OF FGFR4', 'FGFR INHIBITOR'}, defaulting to 'INHIBITOR OF FGFR4'",Small molecule,Phase 2,,
FGIN-1-27,FGIN-1-27,,BRD:BRD-BRD-K09778810-001-10-6;BRD:BRD-K09778810-001-10-6;CTRP:61775,ctrp;rep_primary;rep_single_dose,INOSITOL MONOPHOSPHATASE INHIBITOR,TSPO,,,PRECLINICAL,,,NA,,CCCCCCN(CCCCCC)C(=O)CC1C([NH]C2CCCCC12)-C1CCC(F)CC1
FGIN-1-43,FGIN-1-43,,BRD:BRD-BRD-K66093087-001-03-1;BRD:BRD-K66093087-001-03-1,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,TSPO,,,PRECLINICAL,,,NA,,CCCCCCN(CCCCCC)C(=O)CC1C([NH]C2CCC(CL)CC12)-C1CCC(CL)CC1
FH-535,FH-535,,BRD:BRD-K48112880-001-04-9,rep_single_dose,"PPAR RECEPTOR ANTAGONIST, WNT SIGNALING INHIBITOR",PPARD;PPARG,,,,,,NA,,
FH1,FH1,,BRD:BRD-BRD-K44777625-001-03-5;BRD:BRD-K44777625-001-03-5,rep_primary;rep_single_dose,HEPATOCYTE FUNCTION ENHANCER,,,,PRECLINICAL,,,NA,,CC(=O)NC1CCC(CC2CCC(NC(C)=O)CC2)CC1
FH535,FH535,,GDSC1:173,gdsc,,,,,,,,NA,,
FIACITABINE,FIACITABINE,CHEMBL272557,BRD:BRD-BRD-K07160047-001-01-3;BRD:BRD-K07160047-001-01-3,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,GIMSJJHKKXRFGV-BYPJNBLXSA-N,NC1NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)CC1I;NC1NC(=O)N(CC1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
FIDARESTAT,FIDARESTAT,CHEMBL84446,BRD:BRD-A63752151-001-01-2;BRD:BRD-BRD-A63752151-001-01-2,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,,,PHASE 3,,Small molecule,Unknown,WAAPEIZFCHNLKK-UFBFGSQYSA-N,NC(=O)[C@@H]1C[C@]2(NC(=O)NC2=O)C2CC(F)CCC2O1;NC(=O)C1CC2(NC(=O)NC2=O)C2CC(F)CCC2O1
FIDAXOMICIN,FIDAXOMICIN,CHEMBL1255800,BRD:BRD-BRD-K57371763-001-01-7;BRD:BRD-K57371763-001-01-7,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,DIARRHEA,,LAUNCHED,,Small molecule,Approved,ZVGNESXIJDCBKN-UUEYKCAUSA-N,CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3C(O)C(CL)C(O)C(CL)C3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O;CCC1C(CL)C(O)C(CL)C(O)C1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@@H]3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)/C(C)=C/C(C)=C/C[C@@H]([C@@H](C)O)OC2=O)O[C@@H]1C
FILANESIB,FILANESIB,CHEMBL2347655,BRD:BRD-BRD-K37379014-001-01-2;BRD:BRD-K37379014-001-01-2;BRD:BRD-K37379014-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,"KINESIN INHIBITOR, KINESIN-LIKE SPINDLE PROTEIN INHIBITOR",KIF11,,,PHASE 3,,Small molecule,Phase 2,LLXISKGBWFTGEI-FQEVSTJZSA-N,CON(C)C(=O)N1N=C(C2CC(F)CCC2F)S[C@@]1(CCCN)C1CCCCC1;CON(C)C(=O)N1N=C(S[C@@]1(CCCN)C1CCCCC1)C1CC(F)CCC1F
FILGOTINIB,FILGOTINIB,CHEMBL3301607,BRD:BRD-BRD-K16803204-001-01-6;BRD:BRD-K16803204-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3;TYK2,,,PHASE 2,,Small molecule,Approved,RIJLVEAXPNLDTC-UHFFFAOYSA-N,O=C(NC1NC2CCCC(-C3CCC(CN4CCS(=O)(=O)CC4)CC3)N2N1)C1CC1
FILIBUVIR,FILIBUVIR,CHEMBL490672,BRD:BRD-K00091264-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,SLVAPEZTBDBAPI-GDLZYMKVSA-N,CCC1CC(CC[C@]2(C3CCCC3)CC(O)=C(CC3NC4NC(C)CC(C)N4N3)C(=O)O2)CC(CC)N1
FIMASARTAN,FIMASARTAN,CHEMBL1951143,BRD:BRD-BRD-K21586122-001-01-9;BRD:BRD-K21586122-001-01-9,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,"HYPERTENSION, CONGESTIVE HEART FAILURE, HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Phase 3,AMEROGPZOLAFBN-UHFFFAOYSA-N,CCCCC1NC(C)C(CC(=S)N(C)C)C(=O)N1CC1CCC(-C2CCCCC2-C2NNN[NH]2)CC1;CCCCC1NC(C)C(CC(=S)N(C)C)C(=O)N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
FINAFLOXACIN,FINAFLOXACIN,CHEMBL1908370,BRD:BRD-BRD-K98384930-003-01-5;BRD:BRD-K98384930-003-01-5,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,"INTRA-ABDOMINAL INFECTIONS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CYSTIC FIBROSIS",,LAUNCHED,,Small molecule,Approved,FYMHQCNFKNMJAV-HOTGVXAUSA-N,N#CC1C(N2C[C@@H]3NCCO[C@H]3C2)C(F)CC2C(=O)C(C(=O)O)CN(C3CC3)C12;OC(=O)C1CN(C2CC2)C2C(C#N)C(N3C[C@@H]4NCCO[C@H]4C3)C(F)CC2C1=O
FINASTERIDE,FINASTERIDE,CHEMBL710,BRD:BRD-BRD-K01095011-001-15-9;BRD:BRD-K01095011-001-15-9,rep_primary;rep_single_dose,5 ALPHA REDUCTASE INHIBITOR,AKR1D1;SRD5A1;SRD5A2,ANDROGENETIC ALOPECIA,,LAUNCHED,,Small molecule,Approved,DBEPLOCGEIEOCV-WSBQPABSSA-N,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
FINERENONE,FINERENONE,CHEMBL2181927,BRD:BRD-K00075103-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,BTBHLEZXCOBLCY-QGZVFWFLSA-N,CCOC1NCC(C)C2C1[C@H](C1CCC(C#N)CC1OC)C(C(N)=O)=C(C)N2
FINGOLIMOD,FINGOLIMOD,CHEMBL314854;CHEMBL544665,BRD:BRD-BRD-K88025533-003-03-3;BRD:BRD-K88025533-003-03-3;CTRP:640157,ctrp;rep_primary;rep_single_dose,"IMMUNOSUPPRESSANT, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE PHOSPHATE RECEPTOR AGONIST",S1PR1;S1PR5,MULTIPLE SCLEROSIS,,LAUNCHED,"Multiple values for MOA: {'IMMUNOSUPPRESSANT, SPHINGOSINE PHOSPHATE RECEPTOR AGONIST', 'IMMUNOSUPPRESSANT, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE PHOSPHATE RECEPTOR AGONIST'}, defaulting to 'IMMUNOSUPPRESSANT, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE PHOSPHATE RECEPTOR AGONIST'",Small molecule,Approved,KKGQTZUTZRNORY-UHFFFAOYSA-N;SWZTYAVBMYWFGS-UHFFFAOYSA-N,CCCCCCCCC1CCC(CCC(N)(CO)CO)CC1;CCCCCCCCC1CCC(CCC(N)(CO)CO)CC1.CL
FINGOLIMOD HYDROCHLORIDE; GILENYA; TDI-132; IMUSERA; GILENIA,FINGOLIMOD HYDROCHLORIDE; GILENYA; TDI-132; IMUSERA; GILENIA,CHEMBL544665,GDSC1:546,gdsc,,,,,,,Small molecule,Approved,SWZTYAVBMYWFGS-UHFFFAOYSA-N,CCCCCCCCC1CCC(CCC(N)(CO)CO)CC1.CL
FIPEXIDE,FIPEXIDE,CHEMBL254857,BRD:BRD-BRD-K37688416-003-13-1;BRD:BRD-K37688416-003-13-1,rep_primary;rep_single_dose,PSYCHOACTIVE DRUG,,,,WITHDRAWN,,Small molecule,Approved,BFUJHVVEMMWLHC-UHFFFAOYSA-N,CLC1CCC(OCC(=O)N2CCN(CC3CCC4OCOC4C3)CC2)CC1;O=C(COC1CCC(CL)CC1)N1CCN(CC2CCC3C(C2)OCO3)CC1
FIPI,FIPI,,BRD:BRD-BRD-K61560897-003-01-4;BRD:BRD-K61560897-003-01-4,rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLD1;PLD2,,,PRECLINICAL,,,NA,,FC1CCC2[NH]C(CC2C1)C(=O)NCCN1CCC(CC1)N1C2CCCCC2[NH]C1=O
FIPRONIL,FIPRONIL,CHEMBL101326,BRD:BRD-A50675702-001-07-1;BRD:BRD-BRD-A50675702-001-07-1,rep_primary;rep_single_dose,"CHLORIDE CHANNEL BLOCKER, GABA GATED CHLORIDE CHANNEL BLOCKER",,,,LAUNCHED,,Small molecule,Unknown,ZOCSXAVNDGMNBV-UHFFFAOYSA-N,N#CC1NN(-C2C(CL)CC(C(F)(F)F)CC2CL)C(N)C1[S+]([O-])C(F)(F)F;NC1C(C(NN1-C1C(CL)CC(CC1CL)C(F)(F)F)C#N)S(=O)C(F)(F)F
FIRATEGRAST,FIRATEGRAST,CHEMBL2104967,BRD:BRD-BRD-K17513304-001-01-9;BRD:BRD-K17513304-001-01-9,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGA4,,,PHASE 2,,Small molecule,Phase 2,YLFZHHDVRSYTKT-NRFANRHFSA-N,CCOCC1CC(OC)C(-C2CCC(C[C@H](NC(=O)C3C(F)CCCC3F)C(=O)O)CC2)C(OC)C1;CCOCC1CC(OC)C(-C2CCC(C[C@H](NC(=O)C3C(F)CCCC3F)C(O)=O)CC2)C(OC)C1
FIROCOXIB,FIROCOXIB,CHEMBL69998,BRD:BRD-BRD-K09090523-001-02-1;BRD:BRD-K09090523-001-02-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,OSTEOARTHRITIS,,LAUNCHED,,Small molecule,Unknown,FULAPETWGIGNMT-UHFFFAOYSA-N,CC1(C)OC(=O)C(OCC2CC2)=C1C1CCC(CC1)S(C)(=O)=O;CC1(C)OC(=O)C(OCC2CC2)=C1C1CCC(S(C)(=O)=O)CC1
FIRSOCOSTAT,FIRSOCOSTAT,CHEMBL3407547,BRD:BRD-K00003236-001-01-9,rep_single_dose,ACETYL-COA CARBOXYLASE INHIBITOR,,,,,,Small molecule,Phase 2,ZZWWXIBKLBMSCS-FQEVSTJZSA-N,COC1CCCCC1[C@H](CN1C(=O)N(C(C)(C)C(=O)O)C(=O)C2C(C)C(-C3NCCO3)SC21)OC1CCOCC1
FISETIN,FISETIN,CHEMBL31574,BRD:BRD-K31836715-001-06-8,rep_single_dose,AURORA KINASE INHIBITOR,CDK6;FASN,,,,,Small molecule,Phase 2,XHEFDIBZLJXQHF-UHFFFAOYSA-N,O=C1C(O)C(-C2CCC(O)C(O)C2)OC2CC(O)CCC12
FISOGATINIB,FISOGATINIB,CHEMBL4514636,BRD:BRD-K00003377-001-01-9,rep_single_dose,FIBROBLAST GROWTH FACTOR INHIBITOR,,,,,,Small molecule,Phase 1,MGZKYOAQVGSSGC-DLBZAZTESA-N,C=CC(=O)N[C@H]1CCOC[C@H]1NC1NCC2CC(-C3C(CL)C(OC)CC(OC)C3CL)CCC2N1
FK-33-824,FK-33-824,,BRD:BRD-A01907367-001-01-7;BRD:BRD-BRD-A01907367-001-01-7,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRM1,,,PHASE 2,,,NA,,C[C@H](NC(=O)[C@@H](N)CC1CCC(O)CC1)C(=O)NCC(=O)N(C)[C@@H](CC1CCCCC1)C(=O)N[C@H](CO)CCS(C)=O
FK-3311,FK-3311,,BRD:BRD-BRD-K38350380-001-01-8;BRD:BRD-K38350380-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,,,PHASE 2,,,NA,,CC(=O)C1CCC(NS(C)(=O)=O)C(OC2CCC(F)CC2F)C1
FK-409,FK-409,,BRD:BRD-K00005243-001-01-9,rep_single_dose,GUANYLYL CYCLASE ACTIVATOR,,,,,,,NA,,
FK-866,FK-866,CHEMBL566757,BRD:BRD-BRD-K58550667-001-08-7;BRD:BRD-K58550667-001-08-7,rep_multi_dose;rep_primary;rep_single_dose,NIACINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR,NAMPT,,,PHASE 2,,Small molecule,Phase 2,KPBNHDGDUADAGP-VAWYXSNFSA-N,O=C(/C=C/C1CCCNC1)NCCCCC1CCN(C(=O)C2CCCCC2)CC1;O=C(NCCCCC1CCN(CC1)C(=O)C1CCCCC1)\C=C\C1CCCNC1
FK-888,FK-888,,BRD:BRD-BRD-K83508485-001-02-7;BRD:BRD-K83508485-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1;TACR2,,,PHASE 2,,,NA,,CN(CC1CCCCC1)C(=O)[C@H](CC1CCC2CCCCC2C1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)C1CN(C)C2CCCCC12
FK-962,FK-962,CHEMBL4802206,BRD:BRD-BRD-K80607346-001-01-1;BRD:BRD-K80607346-001-01-1,rep_primary;rep_single_dose,SOMATOSTATIN RECEPTOR AGONIST,,,,PHASE 2,,Unknown,Phase 2,,CC(=O)N1CCC(CC1)NC(=O)C1CCC(F)CC1
FK866,FK866,,GDSC1:1248;GDSC2:1248,gdsc,,,,,,,,NA,,
FLAVOPIRIDOL,FLAVOPIRIDOL,CHEMBL428690,GDSC1:432,gdsc,,,,,,,Small molecule,Phase 3,BIIVYFLTOXDAOV-YVEFUNNKSA-N,CN1CC[C@H](C2C(O)CC(O)C3C(=O)CC(-C4CCCCC4CL)OC23)[C@H](O)C1
FLAVOXATE,FLAVOXATE,CHEMBL1200875;CHEMBL1493,BRD:BRD-BRD-K47639036-003-06-6;BRD:BRD-K47639036-003-06-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2,"URINARY INCONTINENCE, INTERSTITIAL CYSTITIS (IC), URETHRITIS, PROSTATITIS",,LAUNCHED,,Small molecule,Approved,SPIUTQOUKAMGCX-UHFFFAOYSA-N;XOEVKNFZUQEERE-UHFFFAOYSA-N,CC1C(-C2CCCCC2)OC2C(C(=O)OCCN3CCCCC3)CCCC2C1=O;CC1C(-C2CCCCC2)OC2C(C(=O)OCCN3CCCCC3)CCCC2C1=O.CL;CC1C(OC2C(CCCC2C1=O)C(=O)OCCN1CCCCC1)-C1CCCCC1
FLECAINIDE,FLECAINIDE,CHEMBL652,BRD:BRD-A09472452-015-23-4;BRD:BRD-BRD-A09472452-015-23-4,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,KCNA5;KCNA7;SCN4A;SCN5A,"VENTRICULAR TACHYCARDIA (VT), ATRIAL FIBRILLATION (AF), VENTRICULAR ARRHYTHMIAS",,LAUNCHED,,Small molecule,Approved,DJBNUMBKLMJRSA-UHFFFAOYSA-N,FC(F)(F)COC1CCC(OCC(F)(F)F)C(C1)C(=O)NCC1CCCCN1;O=C(NCC1CCCCN1)C1CC(OCC(F)(F)F)CCC1OCC(F)(F)F
FLEROXACIN,FLEROXACIN,CHEMBL6273,BRD:BRD-BRD-K61717546-001-04-3;BRD:BRD-BRD-K61717546-001-05-0;BRD:BRD-K61717546-001-04-3;BRD:BRD-K61717546-001-05-0,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,"GONORRHEA, ENTERITIS, DIARRHEA, RESPIRATORY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Unknown,XBJBPGROQZJDOJ-UHFFFAOYSA-N,CN1CCN(C2C(F)CC3C(=O)C(C(=O)O)CN(CCF)C3C2F)CC1;CN1CCN(CC1)C1C(F)CC2C(C1F)N(CCF)CC(C(O)=O)C2=O
FLESINOXAN,FLESINOXAN,CHEMBL1742477,BRD:BRD-K00091287-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,NYSDRDDQELAVKP-SFHVURJKSA-N,O=C(NCCN1CCN(C2CCCC3C2OC[C@H](CO)O3)CC1)C1CCC(F)CC1
FLI-06,FLI-06,,BRD:BRD-A44500574-001-01-8;BRD:BRD-BRD-A44500574-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,NOTCH SIGNALING INHIBITOR,,,,PRECLINICAL,,,NA,,CC1=C(C(C2CCC(CC2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1
FLIBANSERIN,FLIBANSERIN,CHEMBL231068,BRD:BRD-BRD-K33637378-001-01-7;BRD:BRD-K33637378-001-01-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,DRD4;HTR1A;HTR2A,HYPOACTIVE SEXUAL DESIRE DISORDER,,LAUNCHED,,Small molecule,Approved,PPRRDFIXUUSXRA-UHFFFAOYSA-N,FC(F)(F)C1CCCC(C1)N1CCN(CCN2C3CCCCC3[NH]C2=O)CC1;O=C1[NH]C2CCCCC2N1CCN1CCN(C2CCCC(C(F)(F)F)C2)CC1
FLINDOKALNER,FLINDOKALNER,CHEMBL266510,BRD:BRD-BRD-K56740996-001-01-3;BRD:BRD-K56740996-001-01-3,rep_primary;rep_single_dose,POTASSIUM CHANNEL AGONIST,KCNMA1;KCNN4;KCNQ2;KCNQ4;KCNQ5,,,PHASE 3,,Small molecule,Phase 3,ULYONBAOIMCNEH-HNNXBMFYSA-N,COC1CCC(CL)CC1[C@]1(F)C(=O)NC2CC(C(F)(F)F)CCC21;COC1CCC(CL)CC1[C@]1(F)C(=O)NC2CC(CCC12)C(F)(F)F
FLOCTAFENINE,FLOCTAFENINE,CHEMBL2105075,BRD:BRD-A23418262-001-01-5;BRD:BRD-BRD-A23418262-001-01-5,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,APQPGQGAWABJLN-UHFFFAOYSA-N,O=C(OCC(O)CO)C1CCCCC1NC1CCNC2C(C(F)(F)F)CCCC12;OCC(O)COC(=O)C1CCCCC1NC1CCNC2C(CCCC12)C(F)(F)F
FLOPROPIONE,FLOPROPIONE,CHEMBL1605835,BRD:BRD-BRD-K43383936-001-05-2;BRD:BRD-K43383936-001-05-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A,SPASMS,,LAUNCHED,,Small molecule,Unknown,PTHLEKANMPKYDB-UHFFFAOYSA-N,CCC(=O)C1C(O)CC(O)CC1O
FLORFENICOL,FLORFENICOL,CHEMBL1241590,BRD:BRD-A30886737-001-02-9;BRD:BRD-BRD-A30886737-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,BOVINE RESPIRATORY DISEASE (BRD),,LAUNCHED,,Small molecule,Unknown,AYIRNRDRBQJXIF-NXEZZACHSA-N,CS(=O)(=O)C1CCC([C@@H](O)[C@@H](CF)NC(=O)C(CL)CL)CC1;CS(=O)(=O)C1CCC(CC1)[C@@H](O)[C@@H](CF)NC(=O)C(CL)CL;CS(=O)(=O)C1CCC(CC1)C(O)[C@H](CF)NC(=O)C(CL)CL
FLORIFENINE,FLORIFENINE,CHEMBL2104893,BRD:BRD-K00004567-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Unknown,DQOYUDHAZMAVLD-UHFFFAOYSA-N,O=C(OCCN1CCCC1)C1CCCCC1NC1CCNC2CC(C(F)(F)F)CCC12
FLOSEQUINAN,FLOSEQUINAN,CHEMBL1908307,BRD:BRD-A79643124-001-01-9;BRD:BRD-BRD-A79643124-001-01-9,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,WITHDRAWN,,Small molecule,Approved,UYGONJYYUKVHDD-UHFFFAOYSA-N,CN1CC([S+](C)[O-])C(=O)C2CCC(F)CC21;CN1CC(S(C)=O)C(=O)C2CCC(F)CC12
FLOXURIDINE,FLOXURIDINE,CHEMBL917,BRD:BRD-A03757454-001-03-4;BRD:BRD-BRD-K47832606-001-30-1;BRD:BRD-K47832606-001-30-1,rep_multi_dose;rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,TYMS,COLORECTAL CANCER,,LAUNCHED,"Multiple values for structure_id: {'K47832606', 'A03757454'}, defaulting to None",Small molecule,Approved,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,O=C1[NH]C(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CC1F;OC[C@H]1O[C@H](C[C@@H]1O)N1CC(F)C(=O)[NH]C1=O;OC[C@H]1OC(C[C@H]1O)N1CC(F)C(=O)[NH]C1=O
FLT3-IN-1,FLT3-IN-1,CHEMBL4650283,BRD:BRD-K00003510-001-01-9,rep_single_dose,FLT3 INHIBITOR,,,,,,Small molecule,Phase 1,HJFSVYUFOXAVAA-YUAYGMJFSA-N,CCCNC1NC(NC2CCC(C#N)CC2)NCC1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLUBENDAZOLE,FLUBENDAZOLE,CHEMBL1454946,BRD:BRD-BRD-K86003836-001-10-5;BRD:BRD-K86003836-001-10-5,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,GASTROINTESTINAL PARASITES,,LAUNCHED,,Small molecule,Unknown,CPEUVMUXAHMANV-UHFFFAOYSA-N,COC(=O)NC1NC2CC(C(=O)C3CCC(F)CC3)CCC2[NH]1;COC(=O)NC1NC2CC(CCC2[NH]1)C(=O)C1CCC(F)CC1
FLUCICLOVINE,FLUCICLOVINE,CHEMBL1908917,BRD:BRD-K00085357-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,NTEDWGYJNHZKQW-IWLYVCSRSA-N,N[C@]1(C(=O)O)C[C@@H](F)C1
FLUCLOXACILLIN,FLUCLOXACILLIN,CHEMBL222645,BRD:BRD-BRD-K27871792-001-01-8;BRD:BRD-K27871792-001-01-8,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"GRAM-POSITIVE BACTERIAL INFECTIONS, TONSILLITIS, SINUSITIS, PNEUMONIA, ECZEMA, ENDOCARDITIS, MENINGITIS, ENTERITIS, BACTERIAL SEPTICEMIA",,LAUNCHED,,Small molecule,Approved,UIOFUWFRIANQPC-JKIFEVAISA-N,CC1ONC(-C2C(F)CCCC2CL)C1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O;CC1ONC(C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-C1C(F)CCCC1CL
FLUCONAZOLE,FLUCONAZOLE,CHEMBL106,BRD:BRD-BRD-K05977355-001-19-0;BRD:BRD-K05977355-001-19-0,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,CYP51A1,"ESOPHAGEAL CANDIDIASIS, MENINGITIS",,LAUNCHED,,Small molecule,Approved,RFHAOTPXVQNOHP-UHFFFAOYSA-N,OC(CN1CNCN1)(CN1CNCN1)C1CCC(F)CC1F
FLUCYTOSINE,FLUCYTOSINE,CHEMBL1463,BRD:BRD-BRD-K82143716-001-19-9;BRD:BRD-K82143716-001-19-9,rep_primary;rep_single_dose,OTHER ANTIFUNGAL,DNMT1,"BACTERIAL SEPTICEMIA, ENDOCARDITIS, URINARY TRACT INFECTIONS, MENINGITIS",,LAUNCHED,,Small molecule,Approved,XRECTZIEBJDKEO-UHFFFAOYSA-N,NC1NC(=O)[NH]CC1F
FLUDARA,FLUDARA,CHEMBL1096882,GDSC2:1813,gdsc,,,,,,,Small molecule,Approved,GIUYCYHIANZCFB-FJFJXFQQSA-N,NC1NC(F)NC2C1NCN2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
FLUDARABINE,FLUDARABINE,CHEMBL1096882;CHEMBL1568,BRD:BRD-BRD-K66788707-001-14-3;BRD:BRD-K66788707-001-14-3;GDSC2:1813,gdsc;rep_multi_dose;rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,ADA;DCK;POLA1;RRM1;RRM2,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),,LAUNCHED,"Multiple values for repurposing_target: {'ADA;RRM1;RRM2', 'ADA;DCK;POLA1;RRM1;RRM2'}, taking the union",Small molecule,Approved,GIUYCYHIANZCFB-FJFJXFQQSA-N;HBUBKKRHXORPQB-FJFJXFQQSA-N,NC1NC(F)NC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O;NC1NC(F)NC2C1NCN2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O;NC1NC(F)NC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
FLUDARABINE-PHOSPHATE,FLUDARABINE-PHOSPHATE,,BRD:BRD-BRD-K71106091-001-06-1;BRD:BRD-K71106091-001-06-1,rep_multi_dose;rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,DCK;POLA1;POLD1;POLE;RRM1;RRM2;RRM2B,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),,LAUNCHED,,,NA,,NC1NC(F)NC2N(CNC12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O
FLUDROCORTISONE-ACETATE,FLUDROCORTISONE-ACETATE,,BRD:BRD-BRD-K06408664-001-03-5;BRD:BRD-K06408664-001-03-5;BRD:BRD-K06408664-001-04-9,rep_primary;rep_single_dose,,AR;NR3C1;NR3C2,"ADDISON'S DISEASE, ADRENOGENITAL SYNDROME",,LAUNCHED,,,NA,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
FLUDROXYCORTIDE,FLUDROXYCORTIDE,CHEMBL1201012,BRD:BRD-A49765801-001-04-1;BRD:BRD-BRD-A49765801-001-04-1,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,"SKIN INFECTIONS, PSORIASIS",,LAUNCHED,,Small molecule,Approved,POPFMWWJOGLOIF-XWCQMRHXSA-N,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1;CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
FLUFENAMIC-ACID,FLUFENAMIC-ACID,,BRD:BRD-BRD-K44067360-001-30-3;BRD:BRD-K44067360-001-30-3,rep_multi_dose;rep_primary;rep_single_dose,CHLORIDE CHANNEL BLOCKER,AKR1C3;ANO1;AR;GJA1;GJA10;GJA3;GJA4;GJA5;GJA8;GJA9;GJB1;GJB2;GJB3;GJB4;GJB5;GJB6;GJB7;GJC1;GJC2;GJC3;GJD2;GJD3;GJD4;GJE1;PANX1;PANX2;PANX3;PKD2L1;PTGS1;PTGS2;TRPC5;TRPM2;TRPM5,,,PRECLINICAL,,,NA,,OC(=O)C1CCCCC1NC1CCCC(C1)C(F)(F)F
FLUMATINIB,FLUMATINIB,CHEMBL3545413,BRD:BRD-BRD-K68870568-066-01-5;BRD:BRD-K68870568-066-01-5,rep_multi_dose;rep_primary;rep_single_dose,BCR-ABL KINASE INHIBITOR,ABL1;PDGFRB,,,PHASE 3,,Small molecule,Phase 3,BJCJYEYYYGBROF-UHFFFAOYSA-N,CC1NCC(NC(=O)C2CCC(CN3CCN(C)CC3)C(C(F)(F)F)C2)CC1NC1NCCC(-C2CCCNC2)N1;CN1CCN(CC2CCC(CC2C(F)(F)F)C(=O)NC2CNC(C)C(NC3NCCC(N3)-C3CCCNC3)C2)CC1
FLUMAZENIL,FLUMAZENIL,CHEMBL407,BRD:BRD-BRD-K98769987-001-23-7;BRD:BRD-K98769987-001-23-7,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR ANTAGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,SEDATIVE,,LAUNCHED,,Small molecule,Approved,OFBIFZUFASYYRE-UHFFFAOYSA-N,CCOC(=O)C1NCN-2C1CN(C)C(=O)C1CC(F)CCC-21;CCOC(=O)C1NCN2C1CN(C)C(=O)C1CC(F)CCC1-2
FLUMECINOL,FLUMECINOL,CHEMBL2107440,BRD:BRD-A44181516-001-01-8;BRD:BRD-BRD-A44181516-001-01-8,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,DVASNQYQOZHAJN-UHFFFAOYSA-N,CCC(O)(C1CCCCC1)C1CCCC(C(F)(F)F)C1;CCC(O)(C1CCCCC1)C1CCCC(C1)C(F)(F)F
FLUMEQUINE,FLUMEQUINE,CHEMBL370252,BRD:BRD-A69777949-001-24-2;BRD:BRD-BRD-A69777949-001-24-2,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Unknown,DPSPPJIUMHPXMA-UHFFFAOYSA-N,CC1CCC2CC(F)CC3C(=O)C(C(=O)O)CN1C23;CC1CCC2CC(F)CC3C2N1CC(C(O)=O)C3=O
FLUMETHASONE,FLUMETHASONE,CHEMBL1201392,BRD:BRD-BRD-K61496577-001-19-4;BRD:BRD-BRD-K61496577-001-20-2;BRD:BRD-K61496577-001-19-4;BRD:BRD-K61496577-001-20-2,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;PLA2G1B,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Unknown,WXURHACBFYSXBI-GQKYHHCASA-N,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
FLUMETHASONE-PIVALATE,FLUMETHASONE-PIVALATE,,BRD:BRD-A50064262-001-04-7;BRD:BRD-BRD-A50064262-001-04-7,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,,,LAUNCHED,,,NA,,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C
FLUNARIZINE,FLUNARIZINE,CHEMBL30008,BRD:BRD-BRD-K29582677-300-10-6;BRD:BRD-K29582677-300-10-6,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1G;CACNA1H;CACNA1I;CALM1;HRH1,"MIGRAINE HEADACHE, VERTIGO, PERIPHERAL ARTERY DISEASE (PAD)",,LAUNCHED,,Small molecule,Approved,SMANXXCATUTDDT-QPJJXVBHSA-N,FC1CCC(C(C2CCC(F)CC2)N2CCN(C/C=C/C3CCCCC3)CC2)CC1;FC1CCC(CC1)C(N1CCN(C\C=C\C2CCCCC2)CC1)C1CCC(F)CC1
FLUNISOLIDE,FLUNISOLIDE,CHEMBL1512,BRD:BRD-A65449987-001-10-4;BRD:BRD-BRD-A65449987-001-10-4,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,NR3C1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,XSFJVAJPIHIPKU-XWCQMRHXSA-N,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1;CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO
FLUNIXIN-MEGLUMIN,FLUNIXIN-MEGLUMIN,,BRD:BRD-BRD-K99984802-100-13-5;BRD:BRD-K99984802-100-13-5,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,,,,LAUNCHED,,,NA,,CC1C(NC2NCCCC2C(O)=O)CCCC1C(F)(F)F
FLUOCINOLONE-ACETONIDE,FLUOCINOLONE-ACETONIDE,,BRD:BRD-A15297126-001-04-3;BRD:BRD-BRD-A15297126-001-04-3;BRD:BRD-BRD-K94353609-001-21-6;BRD:BRD-K94353609-001-21-6,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,SEBORRHEIC DERMATITIS,,LAUNCHED,"Multiple values for structure_id: {'K94353609', 'A15297126'}, defaulting to None",,NA,,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C;CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
FLUOCINONIDE,FLUOCINONIDE,CHEMBL1501,BRD:BRD-BRD-K57886322-001-16-6;BRD:BRD-K57886322-001-16-6,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6;SMO,"SEBORRHEIC DERMATITIS, ECZEMA",,LAUNCHED,,Small molecule,Approved,WJOHZNCJWYWUJD-IUGZLZTKSA-N,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C;CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
FLUORESCEIN,FLUORESCEIN,CHEMBL1628233;CHEMBL177756;CHEMBL4297067,BRD:BRD-BRD-K21913543-001-02-4;BRD:BRD-K21913543-001-02-4,rep_primary;rep_single_dose,,SLC22A6,OPHTHALMOLOGY DIAGNOSTIC,,LAUNCHED,,Small molecule,Approved,NJDNXYGOVLYJHP-UHFFFAOYSA-L;VDBJCDWTNCKRTF-UHFFFAOYSA-N;YKGGGCXBWXHKIZ-UHFFFAOYSA-N,O=C([O-])C1CCCCC1-C1C2CCC(=O)CC-2OC2CC([O-])CCC12.[NA+].[NA+];O=C(O)C1CCCCC1-C1C2CCC(=O)CC-2OC2CC(O)CCC12;O=C1C=CC2C(=C1)OC1CC(O)CCC1C21OC(=O)C2CCCCC21;OC1CCC2C(OC3CC(O)CCC3C22OC(=O)C3CCCCC23)C1
FLUOROMETHOLONE,FLUOROMETHOLONE,CHEMBL1200600,BRD:BRD-A13133631-001-04-0;BRD:BRD-BRD-A13133631-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,EYE INFLAMMATION,,LAUNCHED,,Small molecule,Approved,FAOZLTXFLGPHNG-KNAQIMQKSA-N,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12;CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
FLUOROMETHOLONE-ACETATE,FLUOROMETHOLONE-ACETATE,,BRD:BRD-BRD-K02528732-001-02-4;BRD:BRD-K02528732-001-02-4,rep_primary;rep_single_dose,,NR3C1,EYE INFLAMMATION,,LAUNCHED,,,NA,,C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
FLUOROMETHYLCHOLINE,FLUOROMETHYLCHOLINE,CHEMBL3707346,BRD:BRD-BRD-K51199656-003-01-4;BRD:BRD-K51199656-003-01-4,rep_multi_dose;rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Phase 3,TYUACEBEGBGGMO-UHFFFAOYSA-N,C[N+](C)(C)CCOCF;C[N+](C)(CF)CCO
FLUOXETINE,FLUOXETINE,CHEMBL1201082;CHEMBL41,BRD:BRD-A31159102-003-30-4;BRD:BRD-BRD-A31159102-003-30-4,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),ANO1;HTR2B;SLC6A4,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER (OCD), BULIMIA NERVOSA, PANIC DISORDERS, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,GIYXAJPCNFJEHY-UHFFFAOYSA-N;RTHCYVBBDHJXIQ-UHFFFAOYSA-N,CNCCC(OC1CCC(C(F)(F)F)CC1)C1CCCCC1;CNCCC(OC1CCC(C(F)(F)F)CC1)C1CCCCC1.CL;CNCCC(OC1CCC(CC1)C(F)(F)F)C1CCCCC1
FLUOXYMESTERONE,FLUOXYMESTERONE,CHEMBL1445,BRD:BRD-BRD-K24255045-001-05-3;BRD:BRD-K24255045-001-05-3,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR;ESR1;NR3C1;PRLR,HYPOGONADISM,,LAUNCHED,,Small molecule,Approved,YLRFCQOZQXIBAB-RBZZARIASA-N,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C;C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
FLUPENTIXOL,FLUPENTIXOL,CHEMBL42055;CHEMBL54661,BRD:BRD-BRD-K70487031-001-02-8;BRD:BRD-K70487031-001-02-8,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;CHRM1;DRD1;DRD2;DRD3;DRD5;HTR2A,"SCHIZOPHRENIA, DEPRESSION",,LAUNCHED,,Small molecule,Phase 3,NJMYODHXAKYRHW-BLLMUTORSA-N;NJMYODHXAKYRHW-DVZOWYKESA-N,OCCN1CCN(CC/C=C2/C3CCCCC3SC3CCC(C(F)(F)F)CC32)CC1;OCCN1CCN(CC/C=C2\C3CCCCC3SC3CCC(C(F)(F)F)CC32)CC1;OCCN1CCN(CC\C=C2\C3CCCCC3SC3CCC(CC23)C(F)(F)F)CC1
FLUPHENAZINE,FLUPHENAZINE,CHEMBL1200951;CHEMBL726,BRD:BRD-BRD-K55127134-300-11-2;BRD:BRD-K55127134-300-11-2,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CALM1;DRD1;DRD2;DRD5;HRH1;HTR2A;HTR6;HTR7,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,LRWSFOSWNAQHHW-UHFFFAOYSA-N;PLDUPXSUYLZYBN-UHFFFAOYSA-N,CCCCCCC(=O)OCCN1CCN(CCCN2C3CCCCC3SC3CCC(C(F)(F)F)CC32)CC1;OCCN1CCN(CCCN2C3CCCCC3SC3CCC(C(F)(F)F)CC32)CC1;OCCN1CCN(CCCN2C3CCCCC3SC3CCC(CC23)C(F)(F)F)CC1
FLUPIRTINE,FLUPIRTINE,CHEMBL255044,BRD:BRD-BRD-K50720187-051-03-1;BRD:BRD-K50720187-051-03-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,ADRA2A;KCNQ1;KCNQ2,PAIN RELIEF,,LAUNCHED,,Small molecule,Approved,JUUFBMODXQKSTD-UHFFFAOYSA-N,CCOC(=O)NC1CCC(NCC2CCC(F)CC2)NC1N
FLUPRAZINE,FLUPRAZINE,CHEMBL2106753,BRD:BRD-BRD-K44091134-001-01-9;BRD:BRD-K44091134-001-01-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B,,,PHASE 1,,Small molecule,Unknown,CHQKHXJPWDSTPY-UHFFFAOYSA-N,NC(=O)NCCN1CCN(C2CCCC(C(F)(F)F)C2)CC1;NC(=O)NCCN1CCN(CC1)C1CCCC(C1)C(F)(F)F
FLURALANER,FLURALANER,CHEMBL2364610,BRD:BRD-K00003239-001-01-9,rep_single_dose,GABA RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,MLBZKOGAMRTSKP-UHFFFAOYSA-N,CC1CC(C2=NOC(C3CC(CL)CC(CL)C3)(C(F)(F)F)C2)CCC1C(=O)NCC(=O)NCC(F)(F)F
FLURBIPROFEN-(+/-),FLURBIPROFEN-(+/-),,BRD:BRD-A86044036-001-26-5;BRD:BRD-BRD-A86044036-001-26-5,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,,NA,,CC(C(O)=O)C1CCC(C(F)C1)-C1CCCCC1
FLURBIPROFEN-(S)-(+),FLURBIPROFEN-(S)-(+),,BRD:BRD-BRD-K69907333-001-10-6;BRD:BRD-K69907333-001-10-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,,NA,,C[C@H](C(O)=O)C1CCC(C(F)C1)-C1CCCCC1
FLURBIPROFEN-AXETIL,FLURBIPROFEN-AXETIL,,BRD:BRD-K00004724-001-01-9,rep_single_dose,ANALGESIC AGENT,,,,,,,NA,,
FLURIZAN,FLURIZAN,CHEMBL190083,BRD:BRD-BRD-K75410565-001-02-9;BRD:BRD-K75410565-001-02-9,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,APH1B;BACE1;IKBKG;PSEN1;PSEN2;PTGS1;PTGS2,,,PHASE 3,,Small molecule,Phase 3,SYTBZMRGLBWNTM-SNVBAGLBSA-N,C[C@@H](C(=O)O)C1CCC(-C2CCCCC2)C(F)C1;C[C@@H](C(O)=O)C1CCC(C(F)C1)-C1CCCCC1
FLUROTHYL,FLUROTHYL,CHEMBL477874,BRD:BRD-BRD-K14763542-001-02-3;BRD:BRD-K14763542-001-02-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,KGPPDNUWZNWPSI-UHFFFAOYSA-N,FC(F)(F)COCC(F)(F)F
FLUROXENE,FLUROXENE,CHEMBL141446,BRD:BRD-BRD-K56908511-001-01-2;BRD:BRD-K56908511-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,Small molecule,Unknown,DLEGDLSLRSOURQ-UHFFFAOYSA-N,C=COCC(F)(F)F;FC(F)(F)COC=C
FLUSPIRILENE,FLUSPIRILENE,CHEMBL46516,BRD:BRD-BRD-K77947974-001-16-3;BRD:BRD-K77947974-001-16-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CACNG1;DRD2;HRH1;HTR1A;HTR1D;HTR1E;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,QOYHHIBFXOOADH-UHFFFAOYSA-N,FC1CCC(CC1)C(CCCN1CCC2(CC1)N(CNC2=O)C1CCCCC1)C1CCC(F)CC1;O=C1NCN(C2CCCCC2)C12CCN(CCCC(C1CCC(F)CC1)C1CCC(F)CC1)CC2
FLUTAMIDE,FLUTAMIDE,CHEMBL806,BRD:BRD-BRD-K28307902-001-21-7;BRD:BRD-K28307902-001-21-7,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AHR;AR,PROSTATE CANCER,,LAUNCHED,,Small molecule,Approved,MKXKFYHWDHIYRV-UHFFFAOYSA-N,CC(C)C(=O)NC1CCC([N+](=O)[O-])C(C(F)(F)F)C1;CC(C)C(=O)NC1CCC(C(C1)C(F)(F)F)[N+]([O-])=O
FLUTEMETAMOL,FLUTEMETAMOL,CHEMBL579205,BRD:BRD-K00071586-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,VVECGOCJFKTUAX-UHFFFAOYSA-N,CNC1CCC(-C2NC3CCC(O)CC3S2)CC1F
FLUTICASONE FUROATE,FLUTICASONE FUROATE,CHEMBL1676,BRD:BRD-K00084841-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,XTULMSXFIHGYFS-VLSRWLAYSA-N,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1CCCO1)C(=O)SCF
FLUTICASONE-PROPIONATE,FLUTICASONE-PROPIONATE,,BRD:BRD-BRD-K62310379-001-10-5;BRD:BRD-K62310379-001-10-5,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;NR3C2;PGR;PLA2G4A,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF;CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF
FLUTRIMAZOLE,FLUTRIMAZOLE,CHEMBL2107430,BRD:BRD-A00218260-001-03-4;BRD:BRD-BRD-A00218260-001-03-4,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,MYCOSIS,,LAUNCHED,,Small molecule,Approved,QHMWCHQXCUNUAK-UHFFFAOYSA-N,FC1CCC(C(C2CCCCC2)(C2CCCCC2F)N2CCNC2)CC1;FC1CCC(CC1)C(C1CCCCC1)(C1CCCCC1F)N1CCNC1
FLUVASTATIN,FLUVASTATIN,CHEMBL1078;CHEMBL2220442,BRD:BRD-BRD-K66296774-236-11-3;BRD:BRD-K66296774-236-10-5;BRD:BRD-K66296774-236-11-3;CTRP:660322,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF HMGCR,HMGCR,"HYPERCHOLESTEROLEMIA, CONGENITAL HEART DEFECTS",,LAUNCHED,"Multiple values for MOA: {'HMGCR INHIBITOR', 'INHIBITOR OF HMGCR'}, defaulting to 'INHIBITOR OF HMGCR'",Small molecule,Approved,FJLGEFLZQAZZCD-MCBHFWOFSA-N;FJLGEFLZQAZZCD-VAWYXSNFSA-N,CC(C)N1C(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)C(-C2CCC(F)CC2)C2CCCCC21;CC(C)N1C(/C=C/C(O)CC(O)CC(=O)O)C(-C2CCC(F)CC2)C2CCCCC21;CC(C)N1C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(-C2CCC(F)CC2)C2CCCCC12
FLUVOXAMINE,FLUVOXAMINE,CHEMBL814,BRD:BRD-BRD-K53517854-051-01-4;BRD:BRD-K53517854-051-01-4,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),SLC6A4,OBSESSIVE COMPULSIVE DISORDER (OCD),,LAUNCHED,,Small molecule,Approved,CJOFXWAVKWHTFT-XSFVSMFZSA-N,COCCCC/C(=N\OCCN)C1CCC(C(F)(F)F)CC1;COCCCC\C(C1CCC(CC1)C(F)(F)F)=N/OCCN
FMK,FMK,,GDSC1:231,gdsc,,,,,,,,NA,,
FMOC-L-LEUCINE,FMOC-L-LEUCINE,,BRD:BRD-BRD-K15327298-001-05-5;BRD:BRD-K15327298-001-05-5,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,,,,PHASE 2,,,NA,,CC(C)C[C@H](NC(=O)OCC1C2CCCCC2-C2CCCCC12)C(O)=O
FN-1501,FN-1501,CHEMBL4594474,BRD:BRD-K00003096-001-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,Unknown,Phase 1,,
FOLEX,FOLEX,CHEMBL3244648;CHEMBL34259,GDSC1:1008,gdsc,,,,,,,Small molecule,Approved,DASQOOZCTWOQPA-GXKRWWSZSA-L;FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])CC1.[NA+].[NA+];CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1
FOLIC-ACID,FOLIC-ACID,,BRD:BRD-BRD-K18673820-001-15-5;BRD:BRD-K18673820-001-15-5,rep_primary;rep_single_dose,FOLATE RECEPTOR LIGAND,FOLR2;FOLR3;SLC19A1;SLC46A1,MEGALOBLASTIC ANEMIA,,LAUNCHED,,,NA,,NC1NC(=O)C2NC(CNC3CCC(CC3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2[NH]1
FOMEPIZOLE,FOMEPIZOLE,CHEMBL1308,BRD:BRD-BRD-K56810756-001-03-0;BRD:BRD-K56810756-001-03-0,rep_primary;rep_single_dose,ALCOHOL DEHYDROGENASE INHIBITOR,ADH1A;ADH1B;ADH1C;AKR1A1;CAT,POISON ANTIDOTE,,LAUNCHED,,Small molecule,Approved,RIKMMFOAQPJVMX-UHFFFAOYSA-N,CC1CN[NH]C1
FOMOCAINE,FOMOCAINE,CHEMBL1407844,BRD:BRD-BRD-K44942188-001-09-1;BRD:BRD-K44942188-001-09-1,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL MODULATOR,,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Unknown,CVHGCWVMTZWGAY-UHFFFAOYSA-N,C(CN1CCOCC1)CC1CCC(COC2CCCCC2)CC1;C1CCC(OCC2CCC(CCCN3CCOCC3)CC2)CC1
FONDAPARINUX,FONDAPARINUX,CHEMBL1201202;CHEMBL1276258,BRD:BRD-K00003513-363-01-9,rep_single_dose,COAGULATION FACTOR INHIBITOR,F10;SERPINC1,,,,,Oligosaccharide;Small molecule,Approved,KANJSNBRCNMZMV-ABRZTLGGSA-N;TXIFUDXAZRPJLS-CMHJJOLKSA-D,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](COC[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](COC[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[NA+].[NA+].[NA+].[NA+].[NA+].[NA+].[NA+].[NA+].[NA+].[NA+];CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
FORETINIB,FORETINIB,CHEMBL1230609,BRD:BRD-BRD-K03449891-001-08-6;BRD:BRD-K03449891-001-08-6;CTRP:628607;GDSC1:308;GDSC2:2040,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,FLT1;FLT4;KDR;MET,,,PHASE 2,,Small molecule,Phase 2,CXQHYVUVSFXTMY-UHFFFAOYSA-N,COC1CC2C(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3F)CCNC2CC1OCCCN1CCOCC1;COC1CC2C(OC3CCC(NC(=O)C4(CC4)C(=O)NC4CCC(F)CC4)CC3F)CCNC2CC1OCCCN1CCOCC1
FORMESTANE,FORMESTANE,CHEMBL132530,BRD:BRD-A26503646-001-16-6;BRD:BRD-BRD-A26503646-001-16-6,rep_multi_dose;rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP19A1,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,OSVMTWJCGUFAOD-KZQROQTASA-N,C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O;C[C@]12CCC(=O)C(O)=C1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
FORMONONETIN,FORMONONETIN,CHEMBL242341,BRD:BRD-BRD-K55567017-001-12-3;BRD:BRD-K55567017-001-12-3,rep_primary;rep_single_dose,ALCOHOL DEHYDROGENASE INHIBITOR,ADH1C;SLC5A2,,,PRECLINICAL,,Small molecule,Phase 2,HKQYGTCOTHHOMP-UHFFFAOYSA-N,COC1CCC(-C2COC3CC(O)CCC3C2=O)CC1;COC1CCC(CC1)-C1COC2CC(O)CCC2C1=O
FORMOTEROL,FORMOTEROL,CHEMBL1256786,BRD:BRD-BRD-K54006094-051-01-7;BRD:BRD-K54006094-051-01-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,"ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BRONCHOSPASM",,LAUNCHED,,Small molecule,Approved,BPZSYCZIITTYBL-UHFFFAOYSA-N,COC1CCC(C[C@H](C)NC[C@@H](O)C2CCC(O)C(NC=O)C2)CC1;COC1CCC(CC(C)NCC(O)C2CCC(O)C(NC=O)C2)CC1
FORODESINE,FORODESINE,CHEMBL218291,BRD:BRD-BRD-K16505263-003-02-9;BRD:BRD-K16505263-003-02-9,rep_multi_dose;rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,PNP,,,PHASE 2,,Small molecule,Phase 2,IWKXDMQDITUYRK-KUBHLMPHSA-N,O=C1[NH]CNC2C([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)C[NH]C12;OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1C[NH]C2C1[NH]CNC2=O
FOROPAFANT,FOROPAFANT,CHEMBL1628662,BRD:BRD-BRD-K57774929-001-01-3;BRD:BRD-K57774929-001-01-3,rep_primary;rep_single_dose,PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST,PTAFR,,,PHASE 3,,Small molecule,Unknown,VVBFISAUNSXQGZ-UHFFFAOYSA-N,CC(C)C1CC(C(C)C)C(-C2CSC(N(CCN(C)C)CC3CCCNC3)N2)C(C(C)C)C1;CC(C)C1CC(C(C)C)C(-C2CSC(N2)N(CCN(C)C)CC2CCCNC2)C(C1)C(C)C
FORSKOLIN,FORSKOLIN,CHEMBL52606,BRD:BRD-BRD-K09602097-001-13-6;BRD:BRD-K09602097-001-13-6,rep_multi_dose;rep_primary;rep_single_dose,ADENYLYL CYCLASE ACTIVATOR,ADCY2;ADCY5;GNAS,,,LAUNCHED,,Small molecule,Unknown,OHCQJHSOBUTRHG-KGGHGJDLSA-N,C=C[C@@]1(C)CC(=O)[C@]2(O)[C@@]3(C)[C@@H](O)CCC(C)(C)[C@@H]3[C@H](O)[C@H](OC(C)=O)[C@@]2(C)O1;CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C
FOSAMPRENAVIR,FOSAMPRENAVIR,CHEMBL1664,BRD:BRD-BRD-K59110290-238-01-7;BRD:BRD-K59110290-238-01-7,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,MLBVMOWEQCZNCC-OEMFJLHTSA-N,CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1CCCCC1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1CCC(N)CC1;CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1CCCCC1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1CCC(N)CC1
FOSAPREPITANT-DIMEGLUMINE,FOSAPREPITANT-DIMEGLUMINE,,BRD:BRD-BRD-K23848629-401-03-7;BRD:BRD-K23848629-401-03-7,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,"NAUSEA, VOMITING",,LAUNCHED,,,NA,,C[C@@H](O[C@H]1OCCN(CC2NN(C(=O)[NH]2)P(O)(O)=O)[C@H]1C1CCC(F)CC1)C1CC(CC(C1)C(F)(F)F)C(F)(F)F
FOSBRETABULIN,FOSBRETABULIN,CHEMBL1206232,BRD:BRD-BRD-K06814349-304-01-9;BRD:BRD-K06814349-304-01-9;BRD:BRD-K06814349-304-02-7,rep_multi_dose;rep_primary;rep_single_dose,"TUBULIN POLYMERIZATION INHIBITOR, VE-CADHERIN ANTAGONIST",CDH5,,,PHASE 3,,Small molecule,Phase 3,WDOGQTQEKVLZIJ-WAYWQWQTSA-N,COC1CCC(/C=C\C2CC(OC)C(OC)C(OC)C2)CC1OP(=O)(O)O;COC1CCC(C=CC2CC(OC)C(OC)C(OC)C2)CC1OP(O)(O)=O;COC1CCC(CC1OP(O)(O)=O)\C=C/C1CC(OC)C(OC)C(OC)C1
FOSCARNET,FOSCARNET,CHEMBL666,BRD:BRD-BRD-K85146014-314-05-4;BRD:BRD-K85146014-314-05-4,rep_multi_dose;rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,"CYTOMEGALOVIRUS RETINITIS, ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), VIRUS HERPES SIMPLEX (HSV)",,LAUNCHED,,Small molecule,Approved,ZJAOAACCNHFJAH-UHFFFAOYSA-N,O=C(O)P(=O)(O)O;OC(=O)P(O)(O)=O
FOSDAGROCORAT,FOSDAGROCORAT,CHEMBL3137316,BRD:BRD-K00091282-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,BVXLAHSJXXSWFF-KEKPKEOLSA-N,CC1NCCCC1NC(=O)C1CCC2C(C1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21CC1CCCCC1
FOSFLUCONAZOLE,FOSFLUCONAZOLE,CHEMBL1908301,BRD:BRD-K00003384-001-01-9,rep_single_dose,OTHER ANTIFUNGAL,,,,,,Small molecule,Unknown,GHJWNRRCRIGGIO-UHFFFAOYSA-N,O=P(O)(O)OC(CN1CNCN1)(CN1CNCN1)C1CCC(F)CC1F
FOSFOMYCIN,FOSFOMYCIN,CHEMBL1757,BRD:BRD-A10652366-238-04-1;BRD:BRD-BRD-A10652366-238-04-1;BRD:BRD-BRD-K81101512-234-01-9;BRD:BRD-K81101512-234-01-9,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,"Multiple values for structure_id: {'K81101512', 'A10652366'}, defaulting to None",Small molecule,Approved,YMDXZJFXQJVXBF-STHAYSLISA-N,C[C@@H]1O[C@@H]1P(=O)(O)O;C[C@@H]1O[C@@H]1P(O)(O)=O;CC1OC1P(O)(O)=O
FOSFOSAL,FOSFOSAL,CHEMBL287275,BRD:BRD-BRD-K28687144-001-08-7;BRD:BRD-K28687144-001-08-7,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,Small molecule,Unknown,FFKUDWZICMJVPA-UHFFFAOYSA-N,O=C(O)C1CCCCC1OP(=O)(O)O;OC(=O)C1CCCCC1OP(O)(O)=O
FOSINOPRIL,FOSINOPRIL,CHEMBL3039598,BRD:BRD-A51382177-236-03-0;BRD:BRD-BRD-A51382177-236-03-0,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,BIDNLKIUORFRQP-XYGFDPSESA-N,CCC(=O)O[C@@H](O[P@](=O)(CCCCC1CCCCC1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C;CCC(=O)O[C@@H](OP(=O)(CCCCC1CCCCC1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
FOSPHENYTOIN,FOSPHENYTOIN,CHEMBL1201336,BRD:BRD-BRD-K53809807-304-02-4;BRD:BRD-K53809807-304-02-4,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN5A,"EPILEPSY, SEIZURES",,LAUNCHED,,Small molecule,Approved,XWLUWCNOOVRFPX-UHFFFAOYSA-N,O=C1NC(C2CCCCC2)(C2CCCCC2)C(=O)N1COP(=O)(O)O;OP(O)(=O)OCN1C(=O)NC(C1=O)(C1CCCCC1)C1CCCCC1
FOSTAMATINIB,FOSTAMATINIB,CHEMBL2103830,BRD:BRD-BRD-K85178109-001-02-3;BRD:BRD-K85178109-001-02-3,rep_primary;rep_single_dose,SYK INHIBITOR,SYK,CHRONIC IMMUNE THROMBOCYTOPENIA (ITP),,LAUNCHED,,Small molecule,Approved,GKDRMWXFWHEQQT-UHFFFAOYSA-N,COC1CC(NC2NCC(F)C(NC3CCC4C(N3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)N2)CC(OC)C1OC;COC1CC(NC2NCC(F)C(NC3CCC4OC(C)(C)C(=O)N(COP(O)(O)=O)C4N3)N2)CC(OC)C1OC
FOSTEMSAVIR,FOSTEMSAVIR,CHEMBL3301594,BRD:BRD-K00003191-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Approved,SWMDAPWAQQTBOG-UHFFFAOYSA-N,COC1CNC(-N2CNC(C)N2)C2C1C(C(=O)C(=O)N1CCN(C(=O)C3CCCCC3)CC1)CN2COP(=O)(O)O
FOXY-5,FOXY-5,CHEMBL4297281,BRD:BRD-BRD-K13005598-001-02-3;BRD:BRD-K13005598-001-02-3,rep_primary;rep_single_dose,WNT5A PEPTIDE MIMETIC,WNT5A,,,PHASE 1,,Protein,Phase 2,WFZPJYYCTSHDJI-ATIWLJMLSA-N,CSCC[C@H](NC=O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O;CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O
FPA-124,FPA-124,,BRD:BRD-BRD-M17926088-001-01-3;BRD:BRD-M17926088-001-01-3,rep_primary;rep_single_dose,AKT INHIBITOR,,,,PRECLINICAL,,,NA,,CL[CU]CL.NC(=S)N\N=C\C1COC2CCCCC2C1=O
FPH1-(BRD-6125),FPH1-(BRD-6125),,BRD:BRD-BRD-K61250484-001-02-3;BRD:BRD-K61250484-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,HEPATOCYTE FUNCTION ENHANCER,,,,PRECLINICAL,,,NA,,CC1CCC(CL)CC1N(CC(=O)NC1C(F)CCCC1F)S(C)(=O)=O
FPL-12495,FPL-12495,,BRD:BRD-A09368919-001-01-7;BRD:BRD-BRD-A09368919-001-01-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,CC(N)(CC1CCCCC1)C1CCCCC1
FPL-55712,FPL-55712,CHEMBL267475;CHEMBL267976,BRD:BRD-A96456596-001-02-2;BRD:BRD-BRD-A96456596-001-02-2,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,,,,PHASE 1,,Small molecule,NA,LMQBMWHHGVZWMR-UHFFFAOYSA-N;ZDEVPOBNLIVGFA-UHFFFAOYSA-M,CCCC1C(OCC(O)COC2CCC3C(=O)CC(C(=O)[O-])OC3C2CCC)CCC(C(C)=O)C1O.[NA+];CCCC1C(OCC(O)COC2CCC3C(=O)CC(C(=O)O)OC3C2CCC)CCC(C(C)=O)C1O;CCCC1C(OCC(O)COC2CCC3C(OC(CC3=O)C(O)=O)C2CCC)CCC(C(C)=O)C1O
FPL-62064,FPL-62064,,BRD:BRD-BRD-K59875992-001-01-8;BRD:BRD-K59875992-001-01-8,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, LIPOXYGENASE INHIBITOR",,,,PHASE 2,,,NA,,COC1CCC(NC2CCN(N2)-C2CCCCC2)CC1
FPL-64176,FPL-64176,,BRD:BRD-BRD-K78959463-001-13-2;BRD:BRD-K78959463-001-13-2,rep_primary;rep_single_dose,CALCIUM CHANNEL ACTIVATOR,CACNA1C;CACNA1S,,,PRECLINICAL,,,NA,,COC(=O)C1C(C)[NH]C(C)C1C(=O)C1CCCCC1CC1CCCCC1
FPS-ZM1,FPS-ZM1,,BRD:BRD-BRD-K87691185-001-01-2;BRD:BRD-K87691185-001-01-2,rep_primary;rep_single_dose,RAGE RECEPTOR ANTAGONIST,AGER,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)C(=O)N(CC1CCCCC1)C1CCCCC1
FQI-1,FQI-1,,CTRP:102193,ctrp,,,,,,,,NA,,
FQI-2,FQI-2,,CTRP:609091,ctrp,,,,,,,,NA,,
FR 180204,FR 180204,,GDSC1:263,gdsc,,,,,,,,NA,,
FR-122047,FR-122047,CHEMBL275809,BRD:BRD-BRD-K30990140-003-02-4;BRD:BRD-K30990140-003-02-4,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,UBHKJRYGKOSQDJ-UHFFFAOYSA-N,COC1CCC(-C2NC(C(=O)N3CCN(C)CC3)SC2-C2CCC(OC)CC2)CC1;COC1CCC(CC1)-C1NC(SC1-C1CCC(OC)CC1)C(=O)N1CCN(C)CC1
FR-139317,FR-139317,,BRD:BRD-BRD-K19318328-001-01-3;BRD:BRD-K19318328-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,PHASE 1,,,NA,,CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](CC1CN(C)C2CCCCC12)C(=O)N[C@H](CC1CCCCN1)C(O)=O
FR-180204,FR-180204,,BRD:BRD-BRD-K68756823-001-07-1;BRD:BRD-K68756823-001-07-1;GDSC1:263,gdsc;rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK1;MAPK3,,,PRECLINICAL,,,NA,,NC1[NH]NC2NNC(CC12)-C1C(NN2CCCCC12)-C1CCCCC1
FR180204,FR180204,,GDSC1:263,gdsc,,,,,,,,NA,,
FRAKEFAMIDE (TFA),FRAKEFAMIDE (TFA),,BRD:BRD-K00077076-019-02-9,rep_single_dose,,,,,,,,NA,,
FRAX486,FRAX486,,BRD:BRD-K57243773-001-01-6,rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,PAK1;PAK2;PAK3;PAK4,,,,,,NA,,
FRENTIZOLE,FRENTIZOLE,CHEMBL128988,BRD:BRD-BRD-K07202345-001-19-4;BRD:BRD-K07202345-001-19-4,rep_multi_dose;rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,,,,PHASE 1,,Small molecule,Unknown,JHBWYQRKOUBPCA-UHFFFAOYSA-N,COC1CCC2NC(NC(=O)NC3CCCCC3)SC2C1
FRESELESTAT,FRESELESTAT,CHEMBL25892,BRD:BRD-K00004668-001-01-9,rep_single_dose,ELASTASE INHIBITOR,CELA1;ELANE,,,,,Small molecule,Unknown,YSIHYROEMJSOAS-UHFFFAOYSA-N,CC(C)C(NC(=O)CN1C(-C2CCCCC2)NCC(N)C1=O)C(=O)C1NNC(C(C)(C)C)O1
FROVATRIPTAN,FROVATRIPTAN,CHEMBL1279,BRD:BRD-BRD-K08255599-365-01-1;BRD:BRD-K08255599-365-01-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,XPSQPHWEGNHMSK-SECBINFHSA-N,CN[C@@H]1CCC2[NH]C3CCC(C(N)=O)CC3C2C1;CN[C@@H]1CCC2[NH]C3CCC(CC3C2C1)C(N)=O
FRUQUINTINIB,FRUQUINTINIB,CHEMBL4303214,BRD:BRD-BRD-K70504253-001-01-3;BRD:BRD-K70504253-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,KDR,,,PHASE 3,,Small molecule,Phase 3,BALLNEJQLSTPIO-UHFFFAOYSA-N,CNC(=O)C1C(C)OC2CC(OC3NCNC4CC(OC)C(OC)CC34)CCC12
FSC231,FSC231,,CTRP:660079,ctrp,,,,,,,,NA,,
FT011,FT011,CHEMBL1075834,BRD:BRD-K00003378-001-01-9,rep_single_dose,TGF BETA RECEPTOR INHIBITOR,,,,,,Small molecule,Phase 2,UIWZIDIJCUEOMT-PKNBQFBNSA-N,C#CCOC1CCC(/C=C/C(=O)NC2CCCCC2C(=O)O)CC1OC
FTI-277,FTI-277,,GDSC1:166,gdsc,,,,,,,,NA,,
FTORAFUR,FTORAFUR,CHEMBL20883,BRD:BRD-BRD-K99383816-001-02-7;BRD:BRD-BRD-K99383816-001-03-5;BRD:BRD-K99383816-001-02-7;BRD:BRD-K99383816-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,THYMIDYLATE SYNTHASE INHIBITOR,TYMS,COLORECTAL CANCER,,LAUNCHED,,Small molecule,Approved,WFWLQNSHRPWKFK-UHFFFAOYSA-N,FC1CN([C@H]2CCCO2)C(=O)[NH]C1=O;O=C1[NH]C(=O)N(C2CCCO2)CC1F
FTY-720,FTY-720,CHEMBL314854,GDSC1:546,gdsc,,,,,,,Small molecule,Approved,KKGQTZUTZRNORY-UHFFFAOYSA-N,CCCCCCCCC1CCC(CCC(N)(CO)CO)CC1
FUCOXANTHIN,FUCOXANTHIN,CHEMBL1773903,BRD:BRD-K00003355-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Phase 2,MNUMHDZZMWCBBX-JWAQYZNWSA-N,CC(=O)O[C@H]1CC(C)(C)C(=C=C/C(C)=C/C=C/C(C)=C/C=C(C)/C=C/C=C(\C)C(=O)C[C@@]23O[C@]2(C)C[C@@H](O)CC3(C)C)[C@](C)(O)C1
FUDOSTEINE,FUDOSTEINE,CHEMBL1555183,BRD:BRD-BRD-K54838207-001-02-0;BRD:BRD-BRD-K54838207-001-03-8;BRD:BRD-K54838207-001-02-0;BRD:BRD-K54838207-001-03-8,rep_multi_dose;rep_primary;rep_single_dose,MUCOLYTIC AGENT,,CHEST CONGESTION,,LAUNCHED,,Small molecule,Unknown,KINWYTAUPKOPCQ-YFKPBYRVSA-N,N[C@@H](CSCCCO)C(=O)O;N[C@@H](CSCCCO)C(O)=O
FULACIMSTAT,FULACIMSTAT,CHEMBL4297596,BRD:BRD-K00078209-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,JDARDSVOVYVQST-MRXNPFEDSA-N,CN1C(=O)OC2CC(-N3CC(C(=O)O)C(=O)N([C@@H]4CCC5C4CCCC5C(F)(F)F)C3=O)CCC21
ZD-9238,FULVESTRANT;ICI-182780;ZD-182780;ZD-9238,CHEMBL1358,BRD:BRD-A85667082-001-12-7;BRD:BRD-A85667082-001-13-5;BRD:BRD-BRD-A85667082-001-12-7;CTRP:464880;GDSC2:1200;GDSC2:1816,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF ESTROGEN RECEPTOR 1,ESR1;ESR2;GPER1,BREAST CANCER,,LAUNCHED,"Multiple values for MOA: {'ESTROGEN RECEPTOR ANTAGONIST', 'INHIBITOR OF ESTROGEN RECEPTOR 1'}, defaulting to 'INHIBITOR OF ESTROGEN RECEPTOR 1'
Multiple values for repurposing_target: {'ESR1;ESR2;GPER1', 'ESR1'}, taking the union",Small molecule,Approved,VWUXBMIQPBEWFH-WCCTWKNTSA-N,C[C@]12CC[C@@H]3C4CCC(O)CC4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O;C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC1CC(O)CCC31
FUMAGILLIN,FUMAGILLIN,CHEMBL32838,BRD:BRD-A99367815-001-04-9,rep_single_dose,METHIONINE AMINOPEPTIDASE INHIBITOR,METAP2,,,,,Small molecule,Unknown,NGGMYCMLYOUNGM-CSDLUJIJSA-N,CO[C@@H]1[C@H](OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C
FUMONISIN B1,FUMONISIN B1,CHEMBL1241092,CTRP:616353,ctrp,,,,,,,Small molecule,NA,YXBNQTGKGCNTPV-VCEHAEOKSA-N,CCCC[C@@H](C)[C@@H](OC(=O)C[C@H](CC(=O)O)C(=O)O)[C@@H](OC(=O)C[C@H](CC(=O)O)C(=O)O)[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N
FUMONISIN-B1,FUMONISIN-B1,,BRD:BRD-K61915943-001-02-9,rep_single_dose,,CERS1,,,,,,NA,,
FUNAPIDE,FUNAPIDE,CHEMBL3707218,BRD:BRD-K00004702-001-01-9,rep_single_dose,SODIUM CHANNEL BLOCKER,,,,,,Small molecule,Phase 2,NEBUOXBYNAHKFV-NRFANRHFSA-N,O=C1N(CC2CCC(C(F)(F)F)O2)C2CCCCC2[C@]12COC1CC3C(CC12)OCO3
FURAGIN,FURAGIN,CHEMBL3707254,BRD:BRD-K00003314-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Unknown,DECBQELQORZLLP-UAIOPKHMSA-N,O=C1CN(/N=C/C=C/C2CCC([N+](=O)[O-])O2)C(=O)N1
FURALTADONE,FURALTADONE,CHEMBL1189513;CHEMBL3989463,BRD:BRD-A67514145-003-05-8;BRD:BRD-BRD-A67514145-003-05-8,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,YVQVOQKFMFRVGR-NGPAHMQLSA-N;YVQVOQKFMFRVGR-VGOFMYFVSA-N,[O-][N+](=O)C1CCC(\C=N\N2CC(CN3CCOCC3)OC2=O)O1;O=C1O[C@@H](CN2CCOCC2)CN1/N=C/C1CCC([N+](=O)[O-])O1;O=C1OC(CN2CCOCC2)CN1/N=C/C1CCC([N+](=O)[O-])O1
FURAMIDINE,FURAMIDINE,CHEMBL24057,BRD:BRD-K77758223-300-02-9,rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT1,,,,,Small molecule,Unknown,ZJHZBDRZEZEDGB-UHFFFAOYSA-N,N=C(N)C1CCC(-C2CCC(-C3CCC(C(=N)N)CC3)O2)CC1
FURAZOLIDONE,FURAZOLIDONE,CHEMBL1103,BRD:BRD-BRD-K11756522-001-09-9;BRD:BRD-K11756522-001-09-9,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,"DIARRHEA, ENTERITIS, CHOLERA",,LAUNCHED,,Small molecule,Approved,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,[O-][N+](=O)C1CCC(\C=N\N2CCOC2=O)O1;O=C1OCCN1/N=C/C1CCC([N+](=O)[O-])O1
FUREGRELATE,FUREGRELATE,CHEMBL1204948,BRD:BRD-BRD-K55529781-236-03-8;BRD:BRD-K55529781-236-03-8,rep_primary;rep_single_dose,THROMBOXANE SYNTHASE INHIBITOR,TBXAS1,,,PHASE 1,,Small molecule,Unknown,VHWFITPGPFLBGT-UHFFFAOYSA-N,O=C(O)C1CC2CC(CC3CCCNC3)CCC2O1;OC(=O)C1CC2CC(CC3CCCNC3)CCC2O1
FUROSEMIDE,FUROSEMIDE,CHEMBL1788133;CHEMBL35,BRD:BRD-BRD-K78010432-001-21-5;BRD:BRD-K78010432-001-21-5,rep_primary;rep_single_dose,DIURETIC,CA2;GPR35;SLC12A1;SLC12A2,"EDEMA, HYPERTENSION, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME",,LAUNCHED,,Small molecule,Approved,NXDBFIUCDBZBPP-UHFFFAOYSA-N;ZZUFCTLCJUWOSV-UHFFFAOYSA-N,CL.NS(=O)(=O)C1CC(C(=O)O)C(NCC2CCCO2)CC1CL;NS(=O)(=O)C1CC(C(=O)O)C(NCC2CCCO2)CC1CL;NS(=O)(=O)C1CC(C(O)=O)C(NCC2CCCO2)CC1CL
FURSULTIAMINE,FURSULTIAMINE,CHEMBL1740659,BRD:BRD-A71157293-003-10-0;BRD:BRD-BRD-A71157293-003-10-0,rep_primary;rep_single_dose,VITAMIN B,,,,LAUNCHED,,Small molecule,Approved,JTLXCMOFVBXEKD-FOWTUZBSSA-N,C/C(=C(/CCO)SSCC1CCCO1)N(C=O)CC1CNC(C)NC1N;C\C(N(CC1CNC(C)NC1N)C=O)=C(\CCO)SSCC1CCCO1
FURVINA,FURVINA,,BRD:BRD-K00004693-001-01-9,rep_single_dose,QUORUM SENSING SIGNALING INHIBITOR,,,,,,,NA,,
FUSIDIC-ACID,FUSIDIC-ACID,,BRD:BRD-A06935312-001-04-3;BRD:BRD-BRD-A06935312-001-04-3,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,ACNE VULGARIS (AV),,LAUNCHED,,,NA,,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O
TAS-120,FUTIBATINIB;TAS-120,CHEMBL3701238,BRD:BRD-K00003392-001-01-9;BRD:BRD-U00115431-001-01-9,oncref_1;rep_single_dose,"INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4",FGFR1;FGFR2;FGFR3;FGFR4,,,,"Multiple values for MOA: {'FGFR INHIBITOR', 'INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4'}, defaulting to 'INHIBITOR OF FGFR1, FGFR2, FGFR3, AND FGFR4'
Multiple values for structure_id: {'K00003392', 'U00115431'}, defaulting to None",Small molecule,Approved,KEIPNCCJPRMIAX-HNNXBMFYSA-N,C=CC(=O)N1CC[C@H](N2NC(C#CC3CC(OC)CC(OC)C3)C3C(N)NCNC32)C1
G-1,G-1,,BRD:BRD-BRD-K62696033-001-01-4;BRD:BRD-K62696033-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPER1,,,PRECLINICAL,,,NA,,CC(=O)C1CCC2N[C@H]([C@H]3CC=C[C@H]3C2C1)C1CC2OCOC2CC1BR
G-15,G-15,,BRD:BRD-BRD-M30288325-001-01-4;BRD:BRD-M30288325-001-01-4,rep_primary;rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,GPER1,,,PRECLINICAL,,,NA,,BRC1CC2OCOC2CC1[C@H]1NC2CCCCC2[C@H]2C=CC[C@@H]12.BRC1CC2OCOC2CC1[C@@H]1NC2CCCCC2[C@@H]2C=CC[C@H]12
G-749,G-749,CHEMBL4544478,BRD:BRD-K00003126-001-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Unknown,SXWMIXPJPNCXQQ-UHFFFAOYSA-N,CN1CCC(NC2NC(NC3CCC(OC4CCCCC4)CC3)C3C(=O)[NH]CC(BR)C3N2)CC1
G007-LK,G007-LK,,BRD:BRD-BRD-K12198961-001-01-8;BRD:BRD-K12198961-001-01-8,rep_primary;rep_single_dose,TANKYRASE INHIBITOR,TNKS;TNKS2,,,PRECLINICAL,,,NA,,CS(=O)(=O)C1CCC(NC1)-C1NNC(\C=C\C2NNC(O2)-C2CCC(CC2)C#N)N1-C1CCCCC1CL
GABA-LINOLEAMIDE,GABA-LINOLEAMIDE,,BRD:BRD-BRD-K46254452-001-01-5;BRD:BRD-K46254452-001-01-5,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,,,,PHASE 2,,,NA,,CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O
GABAPENTIN,GABAPENTIN,CHEMBL940,BRD:BRD-BRD-K62737565-003-02-6;BRD:BRD-K62737565-003-02-6,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,ADORA1;CACNA1A;CACNA1B;CACNA1C;CACNA1D;CACNA1E;CACNA1F;CACNA1G;CACNA1H;CACNA1I;CACNA1S;CACNA2D1;CACNA2D2;CACNA2D3;CACNA2D4;CACNB1;CACNB2;CACNB3;CACNB4;CACNG1;CACNG2;CACNG3;CACNG4;CACNG5;CACNG6;CACNG7;CACNG8;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,"VIRUS HERPES SIMPLEX (HSV), SHINGLES, SEIZURES, RESTLESS LEG SYNDROME",,LAUNCHED,,Small molecule,Approved,UGJMXCAKCUNAIE-UHFFFAOYSA-N,NCC1(CC(=O)O)CCCCC1;NCC1(CC(O)=O)CCCCC1
GABAPENTIN-ENACARBIL,GABAPENTIN-ENACARBIL,,BRD:BRD-A86665761-001-01-1;BRD:BRD-BRD-A86665761-001-01-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,CACNA1A;CACNA1B;CACNA1C;CACNA1D;CACNA1E;CACNA1F;CACNA1G;CACNA1H;CACNA1I;CACNA1S;CACNA2D1;CACNA2D2;CACNA2D3;CACNA2D4;CACNB1;CACNB2;CACNB3;CACNB4;CACNG1;CACNG2;CACNG3;CACNG4;CACNG5;CACNG6;CACNG7;CACNG8,"RESTLESS LEG SYNDROME, POSTHERPETIC NEURALGIA",,LAUNCHED,,,NA,,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
GABAZINE,GABAZINE,CHEMBL32503,BRD:BRD-BRD-K79905821-004-03-6;BRD:BRD-K79905821-004-03-6,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRG2,,,PRECLINICAL,,Small molecule,NA,ACVGNKYJVGNLIL-UHFFFAOYSA-N,COC1CCC(-C2CCC(=N)N(CCCC(=O)O)N2)CC1;COC1CCC(CC1)-C1CCC(=N)N(CCCC(O)=O)N1
GABEXATE,GABEXATE,CHEMBL87563,BRD:BRD-BRD-K59256312-066-15-7;BRD:BRD-K59256312-066-15-7,rep_primary;rep_single_dose,SERINE PROTEASE INHIBITOR,PRSS1;TPSAB1,PANCREATITIS,,LAUNCHED,,Small molecule,Phase 3,YKGYIDJEEQRWQH-UHFFFAOYSA-N,CCOC(=O)C1CCC(OC(=O)CCCCCNC(=N)N)CC1;CCOC(=O)C1CCC(OC(=O)CCCCCNC(N)=N)CC1
GABOXADOL,GABOXADOL,CHEMBL312443,BRD:BRD-BRD-K89104321-003-14-8;BRD:BRD-K89104321-003-14-8,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRD;GABRR1;GABRR2;GABRR3,,,PHASE 3,,Small molecule,Phase 3,ZXRVKCBLGJOCEE-UHFFFAOYSA-N,OC1NOC2C1CCNC2;OC1NOC2CNCCC12
GADOBUTROL,GADOBUTROL,CHEMBL2218860,BRD:BRD-A67181951-001-01-2;BRD:BRD-BRD-A67181951-001-01-2,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,MRI CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,,OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[GD](OC(=O)C3)OC(=O)C2
GADODIAMIDE,GADODIAMIDE,CHEMBL1200346,BRD:BRD-BRD-K38140108-002-01-2;BRD:BRD-K38140108-002-01-2,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,MRI CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,,CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[GD](OC(=O)C1)OC(=O)C2
GADOTERATE-MEGLUMINE,GADOTERATE-MEGLUMINE,,BRD:BRD-BRD-K11099631-001-07-6;BRD:BRD-K11099631-001-07-6,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,MRI CONTRAST AGENT,,LAUNCHED,,,NA,,OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1
GADOTERIDOL,GADOTERIDOL,CHEMBL1200593,BRD:BRD-A72401848-001-02-2;BRD:BRD-BRD-A72401848-001-02-2,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,MRI CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,,CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[GD](OC(=O)C2)OC(=O)C3
GAL-021,GAL-021,,BRD:BRD-K00003410-001-01-9,rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,,,,NA,,
GALANTAMINE,GALANTAMINE,CHEMBL659,BRD:BRD-BRD-K49481516-004-18-3;BRD:BRD-K49481516-004-18-3,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE;CHRNA1;CHRNA10;CHRNA2;CHRNA3;CHRNA4;CHRNA5;CHRNA6;CHRNA7;CHRNA9;CHRNB1;CHRNB2;CHRNB3;CHRNB4;CHRND;CHRNE;CHRNG,SENILE DEMENTIA,,LAUNCHED,,Small molecule,Approved,ASUTZQLVASHGKV-JDFRZJQESA-N,COC1CCC2C3C1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2;COC1CCC2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3OC1C24
GALETERONE,GALETERONE,CHEMBL2105738,BRD:BRD-A07986123-001-02-8;BRD:BRD-BRD-A07986123-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR;CYP17A1,,,PHASE 3,,Small molecule,Phase 3,PAFKTGFSEFKSQG-PAASFTFBSA-N,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(N3CNC4CCCCC43)=CC[C@@H]12;C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2N1CNC2CCCCC12
GALIDESIVIR,GALIDESIVIR,CHEMBL1236524,BRD:BRD-K00003270-003-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 1,AMFDITJFBUXZQN-KUBHLMPHSA-N,NC1NCNC2C([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)C[NH]C12
GALLAMINE-TRIETHIODIDE,GALLAMINE-TRIETHIODIDE,,BRD:BRD-BRD-K43106192-320-11-8;BRD:BRD-K43106192-320-11-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,ACHE;CHRM2;CHRNA1;CHRNA2,MUSCLE RELAXANT,,LAUNCHED,,,NA,,CC[N+](CC)(CC)CCOC1CCCC(OCC[N+](CC)(CC)CC)C1OCC[N+](CC)(CC)CC
GALLIBISCOQUINAZOLE,GALLIBISCOQUINAZOLE,,GDSC2:1830,gdsc,,,,,,,,NA,,
GALLIC-ACID,GALLIC-ACID,,BRD:BRD-BRD-K77345217-001-05-0;BRD:BRD-K77345217-001-05-0,rep_primary;rep_single_dose,"BETA AMYLOID PROTEIN NEUROTOXICITY INHIBITOR, PPAR RECEPTOR AGONIST",CA1;CA12;CA14;CA2;CA4;CA6;CA9;SELP,,,PRECLINICAL,,,NA,,OC(=O)C1CC(O)C(O)C(O)C1
GALLIUM-TRIQUINOLIN-8-OLATE,GALLIUM-TRIQUINOLIN-8-OLATE,,BRD:BRD-K46648676-001-01-8,rep_single_dose,,,,,,,,NA,,
GALLOPAMIL,GALLOPAMIL,CHEMBL51149;CHEMBL523367,BRD:BRD-A52922642-001-03-7;BRD:BRD-BRD-A52922642-001-03-7,rep_primary;rep_single_dose,L-TYPE CALCIUM CHANNEL BLOCKER,ATP2A2,"HYPERTENSION, CARDIAC ARRYTHMIA",,LAUNCHED,,Small molecule,Phase 2,IERWCEALNGTKIK-UHFFFAOYSA-N;XQLWNAFCTODIRK-UHFFFAOYSA-N,COC1CC(C(C#N)(CCCN(C)CCC2CCCCC2)C(C)C)CC(OC)C1OC;COC1CCC(CCN(C)CCCC(C#N)(C(C)C)C2CC(OC)C(OC)C(OC)C2)CC1OC;COC1CCC(CCN(C)CCCC(C#N)(C2CC(OC)C(OC)C(OC)C2)C(C)C)CC1OC
GAMBOGIC-ACID,GAMBOGIC-ACID,,BRD:BRD-BRD-K08542803-001-03-1;BRD:BRD-K08542803-001-02-3;BRD:BRD-K08542803-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,CASPASE ACTIVATOR,BCL2,,,PHASE 2,,,NA,,CC(C)=CCC[C@@]1(C)OC2C(CC=C(C)C)C3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)C3C(O)C2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C
GAMITHROMYCIN,GAMITHROMYCIN,CHEMBL2107342,BRD:BRD-K00003489-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Unknown,VWAMTBXLZPEDQO-UZSBJOJWSA-N,CCCN1C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@H]1C
GAMMA-AMINOBUTYRIC-ACID,GAMMA-AMINOBUTYRIC-ACID,,BRD:BRD-BRD-K77245796-003-01-6;BRD:BRD-K77245796-003-01-6,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABBR1;GABBR2;GABRA1;GABRA2;GABRA3;GABRA5;GABRB2;GABRG2;GATM;KCTD12;KCTD16;KCTD8;SLC6A1,,,PRECLINICAL,,,NA,,NCCCC(O)=O
GAMMA-LINOLENIC-ACID,GAMMA-LINOLENIC-ACID,,BRD:BRD-BRD-K18059238-001-10-4;BRD:BRD-K18059238-001-10-4,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTANOID RECEPTOR AGONIST",PTGS1;PTGS2,,,PHASE 2,,,NA,,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
GAMMA-SECRETASE INHIBITOR 1,GAMMA-SECRETASE INHIBITOR 1,,GDSC1:45,gdsc,,,,,,,,NA,,
GANAXOLONE,GANAXOLONE,CHEMBL1568698,BRD:BRD-BRD-K28217197-001-01-4;BRD:BRD-K28217197-001-01-4,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6,,,PHASE 3,,Small molecule,Approved,PGTVWKLGGCQMBR-FLBATMFCSA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C
GANCICLOVIR,GANCICLOVIR,CHEMBL1200850;CHEMBL182,BRD:BRD-BRD-K22662435-001-18-3;BRD:BRD-BRD-K22662435-001-19-1;BRD:BRD-K22662435-001-18-3;BRD:BRD-K22662435-001-19-1,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,CYTOMEGALOVIRUS (CMV),,LAUNCHED,,Small molecule,Approved,IRSCQMHQWWYFCW-UHFFFAOYSA-N;JJICLMJFIKGAAU-UHFFFAOYSA-M,NC1NC([O-])C2NCN(COC(CO)CO)C2N1.[NA+];NC1NC2C(NCN2COC(CO)CO)C(=O)[NH]1;NC1NC2N(COC(CO)CO)CNC2C(=O)[NH]1
GANETESPIB,GANETESPIB,CHEMBL2103879,BRD:BRD-BRD-K38852836-001-02-1;BRD:BRD-K38852836-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PHASE 3,,Small molecule,Phase 3,RVAQIUULWULRNW-UHFFFAOYSA-N,CC(C)C1CC(-C2N[NH]C(=O)N2-C2CCC3C(CCN3C)C2)C(O)CC1O;CC(C)C1CC(-C2N[NH]C(=O)N2-C2CCC3N(C)CCC3C2)C(O)CC1O
GANGLIOSIDE-GM1,GANGLIOSIDE-GM1,,BRD:BRD-A30703952-201-01-2;BRD:BRD-BRD-A30703952-201-01-2,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(CC(O)C(NC(C)=O)C(O3)C(O)C(O)CO)C(O)=O)C2O)C(O)C1O)[C@H](O)\C=C\CCCCCCCCCCCCC
GANODERIC-ACID-A,GANODERIC-ACID-A,,BRD:BRD-K00003733-001-01-9,rep_single_dose,JAK INHIBITOR,,,,,,,NA,,
GANT-58,GANT-58,,BRD:BRD-BRD-K64451768-001-05-4;BRD:BRD-K64451768-001-05-4,rep_primary;rep_single_dose,GLI ANTAGONIST,GLI1,,,PRECLINICAL,,,NA,,C1CC(CCN1)-C1SC(C(C1-C1CCNCC1)-C1CCNCC1)-C1CCNCC1
GANT-61,GANT-61,,BRD:BRD-K09485525-001-03-9;CTRP:609332,ctrp;rep_single_dose,GLI ANTAGONIST,GLI1;GLI2,,,,,,NA,,
GARENOXACIN,GARENOXACIN,CHEMBL215303,BRD:BRD-BRD-K77038618-356-01-3;BRD:BRD-K77038618-356-01-3,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,RESPIRATORY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Unknown,NJDRXTDGYFKORP-LLVKDONJSA-N,C[C@H]1NCC2CC(-C3CCC4C(=O)C(C(=O)O)CN(C5CC5)C4C3OC(F)F)CCC21;C[C@H]1NCC2CC(CCC12)-C1CCC2C(C1OC(F)F)N(CC(C(O)=O)C2=O)C1CC1
GASTRODIN,GASTRODIN,CHEMBL274739,BRD:BRD-BRD-K81613478-001-01-8;BRD:BRD-K81613478-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,NA,PUQSUZTXKPLAPR-UJPOAAIJSA-N,OC[C@@H]1O[C@@H](OC2CCC(CO)CC2)[C@H](O)[C@@H](O)[C@@H]1O;OCC1CCC(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1
GATIFLOXACIN,GATIFLOXACIN,CHEMBL31,BRD:BRD-A74980173-001-11-9;BRD:BRD-BRD-A74980173-001-11-9,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,,,WITHDRAWN,,Small molecule,Approved,XUBOMFCQGDBHNK-UHFFFAOYSA-N,COC1C(N2CCNC(C)C2)C(F)CC2C(=O)C(C(=O)O)CN(C3CC3)C12;COC1C(N2CCNC(C)C2)C(F)CC2C1N(CC(C(O)=O)C2=O)C1CC1
GAVESTINEL,GAVESTINEL,CHEMBL44793,BRD:BRD-BRD-K81981783-236-02-9;BRD:BRD-K81981783-236-02-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GLRB;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,,,PHASE 3,"Multiple values for repurposing_target: {'GLRB;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B', 'GLRB'}, taking the union",Small molecule,Unknown,WZBNEZWCNKUOSM-VOTSOKGWSA-N,O=C(/C=C/C1C(C(=O)O)[NH]C2CC(CL)CC(CL)C12)NC1CCCCC1;OC(=O)C1[NH]C2CC(CL)CC(CL)C2C1\C=C\C(=O)NC1CCCCC1
GBR-12783,GBR-12783,,BRD:BRD-BRD-K92015269-300-01-2;BRD:BRD-K92015269-300-01-2,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR",,,,PRECLINICAL,"Multiple values for MOA: {'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR', 'DOPAMINE UPTAKE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR'",,NA,,C(CN1CCN(C\C=C\C2CCCCC2)CC1)OC(C1CCCCC1)C1CCCCC1
GBR-12935,GBR-12935,,BRD:BRD-BRD-K50135270-300-02-3;BRD:BRD-K50135270-300-02-3,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR",AGTR1;SLC6A3,,,PRECLINICAL,"Multiple values for MOA: {'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR', 'DOPAMINE UPTAKE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR'",,NA,,C(CN1CCN(CCOC(C2CCCCC2)C2CCCCC2)CC1)CC1CCCCC1
GBR-13069,GBR-13069,,BRD:BRD-BRD-K92577649-300-01-2;BRD:BRD-K92577649-300-01-2,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR",SLC6A3,,,PRECLINICAL,"Multiple values for MOA: {'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR', 'DOPAMINE UPTAKE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR'",,NA,,FC1CCC(CC1)C(OCCN1CCN(C\C=C\C2CCCCC2)CC1)C1CCC(F)CC1
GDC 0068,GDC 0068,,GDSC2:1924,gdsc,,,,,,,,NA,,
GDC 0810,GDC 0810,,GDSC2:1925,gdsc,,,,,,,,NA,,
TASELISIB,GDC-0032;RG-7604;TASELISIB,CHEMBL2387080,BRD:BRD-BRD-K44844162-001-01-6;BRD:BRD-K44844162-001-01-6;BRD:BRD-K44844162-001-04-0;GDSC2:1561,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF PI3 KINASE ALPHA, DELTA, AND GAMMA",PIK3CA;PIK3CD;PIK3CG,,,PHASE 3,"Multiple values for MOA: {'PI3K INHIBITOR', 'INHIBITOR OF PI3 KINASE ALPHA, DELTA, AND GAMMA'}, defaulting to 'INHIBITOR OF PI3 KINASE ALPHA, DELTA, AND GAMMA'
Multiple values for repurposing_target: {'PIK3CA;PIK3CD;PIK3CG', 'PIK3CA'}, taking the union",Small molecule,Phase 3,BEUQXVWXFDOSAQ-UHFFFAOYSA-N,CC(C)N1NC(C)NC1-C1CN2CCOC3CC(CCC3-C2N1)-C1CNN(C1)C(C)(C)C(N)=O;CC1NC(-C2CN3C(N2)-C2CCC(-C4CNN(C(C)(C)C(N)=O)C4)CC2OCC3)N(C(C)C)N1
RG7440,GDC-0068;IPATASERTIB;RG7440,CHEMBL2177390,BRD:BRD-BRD-K71480163-001-01-4;BRD:BRD-K43002773-001-05-9;BRD:BRD-K71480163-001-01-4;GDSC2:1924,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"INHIBITOR OF AKT1, AKT2, AND AKT3",AKT1;AKT2;AKT3;PRKG1,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF AKT1, AKT2, AND AKT3', 'AKT INHIBITOR'}, defaulting to 'INHIBITOR OF AKT1, AKT2, AND AKT3'
Multiple values for repurposing_target: {'AKT1;AKT2;AKT3;PRKG1', 'AKT1;AKT2;AKT3'}, taking the union
Multiple values for structure_id: {'K43002773', 'K71480163'}, defaulting to None",Small molecule,Phase 3,GRZXWCHAXNAUHY-NSISKUIASA-N,CC(C)NC[C@@H](C(=O)N1CCN(C2NCNC3C2[C@H](C)C[C@H]3O)CC1)C1CCC(CL)CC1;CC(C)NC[C@@H](C(=O)N1CCN(CC1)C1NCNC2[C@@H](O)C[C@@H](C)C12)C1CCC(CL)CC1
INAVOLISIB,GDC-0077;INAVOLISIB,CHEMBL4650215,BRD:BRD-K00003420-001-01-9;BRD:BRD-K00126777-001-01-9;BRD:BRD-K63191384-001-04-9,oncref_2;rep_single_dose,INHIBITOR OF PIK3CA,PIK3CA,,,,"Multiple values for MOA: {'PI3K INHIBITOR', 'INHIBITOR OF PIK3CA'}, defaulting to 'INHIBITOR OF PIK3CA'",Small molecule,Phase 2,SGEUNORSOZVTOL-CABZTGNLSA-N,C[C@H](NC1CCC2C(C1)OCCN1CC(N3C(=O)OC[C@H]3C(F)F)NC1-2)C(N)=O
GDC-0084,GDC-0084,CHEMBL3813842,BRD:BRD-K00003309-001-01-9,rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",,,,,,Small molecule,Phase 2,LGWACEZVCMBSKW-UHFFFAOYSA-N,CC1(C)OCCN2C1NC1C(N3CCOCC3)NC(-C3CNC(N)NC3)NC12
GDC-0152,GDC-0152,CHEMBL2063869,BRD:BRD-BRD-K68938568-001-01-7;BRD:BRD-K68938568-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,XIAP INHIBITOR,BIRC2;BIRC3;BIRC7;XIAP,,,PHASE 1,,Protein,Phase 1,WZRFLSDVFPIXOV-LRQRDZAKSA-N,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)NC1SNNC1-C1CCCCC1;CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NC1SNNC1-C1CCCCC1)C1CCCCC1
GDC-0199,GDC-0199,CHEMBL3137309,GDSC1:412;GDSC2:1909,gdsc,,,,,,,Small molecule,Approved,LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(CN2CCN(C3CCC(C(=O)NS(=O)(=O)C4CCC(NCC5CCOCC5)C([N+](=O)[O-])C4)C(OC4CNC5[NH]CCC5C4)C3)CC2)=C(C2CCC(CL)CC2)C1
GDC-0339,GDC-0339,,BRD:BRD-K00126479-001-01-9,oncref_2,INHIBITOR OF PIM,PIM1;PIM2;PIM3,,,,,,NA,,
GDC-0349,GDC-0349,CHEMBL2331680,BRD:BRD-BRD-K43187018-001-03-3;BRD:BRD-K43187018-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,PIM KINASE INHIBITOR,PIK3CA,,,PHASE 1,,Small molecule,Phase 1,RGJOJUGRHPQXGF-INIZCTEOSA-N,CCNC(=O)NC1CCC(-C2NC3C(C(N4CCOC[C@@H]4C)N2)CCN(C2COC2)C3)CC1;CCNC(=O)NC1CCC(CC1)-C1NC2CN(CCC2C(N1)N1CCOC[C@@H]1C)C1COC1
VISMODEGIB,GDC-0449;VISMODEGIB,CHEMBL473417,BRD:BRD-BRD-K44827188-001-06-0;BRD:BRD-K44827188-001-06-0;BRD:BRD-K44827188-001-12-9;GDSC1:1033,gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,"HEDGEHOG PATHWAY INHIBITOR, SMOOTHENED RECEPTOR ANTAGONIST",SMO,BASAL CELL CARCINOMA (BCC),,LAUNCHED,"Multiple values for MOA: {'HEDGEHOG PATHWAY INHIBITOR, SMOOTHENED RECEPTOR ANTAGONIST', 'INHIBITOR OF SMO'}, defaulting to 'HEDGEHOG PATHWAY INHIBITOR, SMOOTHENED RECEPTOR ANTAGONIST'",Small molecule,Approved,BPQMGSKTAYIVFO-UHFFFAOYSA-N,CLC1CC(CCC1C(=O)NC1CCC(CL)C(C1)-C1CCCCN1)S(C)(=O)=O;CS(=O)(=O)C1CCC(C(=O)NC2CCC(CL)C(-C3CCCCN3)C2)C(CL)C1
GDC-0575,GDC-0575,CHEMBL3545199,BRD:BRD-K00003112-001-01-9,rep_single_dose,CHK INHIBITOR,,,,,,Small molecule,Phase 1,,
GDC-0623,GDC-0623,CHEMBL2146883,BRD:BRD-BRD-K46908090-001-02-2;BRD:BRD-K46908090-001-02-2,rep_primary;rep_single_dose,MEK INHIBITOR,,,,PHASE 1,,Small molecule,Approved,BSMCAPRUBJMWDF-KRWDZBQOSA-N,O=C(C1CCC(F)C(F)C1NC1CCC(I)CC1F)N1CC(O)([C@@H]2CCCCN2)C1;OCCONC(=O)C1CCC2CNCN2C1NC1CCC(I)CC1F
GDC-0810,GDC-0810,CHEMBL3581693,BRD:BRD-BRD-K61923022-001-02-4;BRD:BRD-K61923022-001-02-4;GDSC2:1925,gdsc;rep_primary;rep_single_dose,SELECTIVE ESTROGEN RECEPTOR DESTABILIZER,ESR1,,,PHASE 2,,Small molecule,Phase 2,BURHGPHDEVGCEZ-KJGLQBJMSA-N,CC/C(=C(/C1CCC(/C=C/C(=O)O)CC1)C1CCC2[NH]NCC2C1)C1CCC(F)CC1CL;CC\C(=C(\C1CCC(\C=C\C(O)=O)CC1)C1CCC2[NH]NCC2C1)C1CCC(F)CC1CL
GDC-0834,GDC-0834,,BRD:BRD-A30984645-001-01-5;BRD:BRD-BRD-A30984645-001-01-5,rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK,,,PHASE 1,,,NA,,CN1CCN(C)C(=O)C1C1CCC(NC2NC(CN(C)C2=O)-C2CCCC(NC(=O)C3CC4CCCCC4S3)C2C)CC1
GDC-0879,GDC-0879,,BRD:BRD-BRD-K67578145-001-09-7;BRD:BRD-BRD-K67578145-001-12-1;BRD:BRD-K67578145-001-09-7;BRD:BRD-K67578145-001-12-1;CTRP:606248,ctrp;rep_multi_dose;rep_primary;rep_single_dose,RAF INHIBITOR,BRAF,,,PRECLINICAL,,,NA,,OCCN1CC(C(N1)-C1CCNCC1)-C1CCC2C(CC\C2=N/O)C1
GDC-0927,GDC-0927,CHEMBL4297758,BRD:BRD-K00003101-001-02-9,rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,,,,,,Unknown,Phase 1,,
PICTILISIB,GDC-0941;PICTILISIB,CHEMBL521851,BRD:BRD-BRD-K52911425-001-09-8;BRD:BRD-K52911425-001-01-5;BRD:BRD-K52911425-001-09-8;CTRP:639759;GDSC1:1058;GDSC1:1527;GDSC2:1058,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF PI3 KINASE ALPHA AND DELTA,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 2,"Multiple values for MOA: {'PI3K INHIBITOR', 'INHIBITOR OF PI3 KINASE ALPHA AND DELTA'}, defaulting to 'INHIBITOR OF PI3 KINASE ALPHA AND DELTA'
Multiple values for repurposing_target: {'PIK3CA;PIK3CB;PIK3CD;PIK3CG', 'PIK3CA;PIK3CD'}, taking the union",Small molecule,Phase 2,LHNIIDJUOCFXAP-UHFFFAOYSA-N,CS(=O)(=O)N1CCN(CC2CC3NC(-C4CCCC5[NH]NCC45)NC(N4CCOCC4)C3S2)CC1;CS(=O)(=O)N1CCN(CC2CC3NC(NC(N4CCOCC4)C3S2)-C2CCCC3[NH]NCC23)CC1
GDC-0980,GDC-0980,CHEMBL1922094,BRD:BRD-BRD-K23228615-001-02-8;BRD:BRD-K23228615-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",FGR;MAP3K9;MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;SYK,,,PHASE 2,,Small molecule,Phase 2,YOVVNQKCSKSHKT-HNNXBMFYSA-N,C[C@H](O)C(=O)N1CCN(CC2SC3C(NC(NC3C2C)-C2CNC(N)NC2)N2CCOCC2)CC1;CC1C(CN2CCN(C(=O)[C@H](C)O)CC2)SC2C(N3CCOCC3)NC(-C3CNC(N)NC3)NC12
GDC-0994,GDC-0994,CHEMBL3544964,BRD:BRD-A20830788-001-01-9;BRD:BRD-BRD-A20830788-001-01-9,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK1;MAPK3,,,PHASE 1,,Small molecule,Phase 1,RZUOCXOYPYGSKL-GOSISDBHSA-N,CN1NCCC1NC1NCCC(-C2CCN([C@H](CO)C3CCC(CL)C(F)C3)C(=O)C2)N1;CN1NCCC1NC1NCCC(N1)-C1CCN(C(CO)C2CCC(CL)C(F)C2)C(=O)C1
MIGOPROTAFIB,GDC-1971;MIGOPROTAFIB,,BRD:BRD-K00126782-001-01-9,oncref_2,INHIBITOR OF SHP2,PTPN11,,,,,,NA,,
GDC0032,GDC0032,,GDSC2:1561,gdsc,,,,,,,,NA,,
GDC0068,GDC0068,,GDSC2:1924,gdsc,,,,,,,,NA,,
GDC0449,GDC0449,,GDSC1:1033,gdsc,,,,,,,,NA,,
GDC0810,GDC0810,,GDSC2:1925,gdsc,,,,,,,,NA,,
GDC0941,GDC0941,,GDSC1:1058;GDSC1:1527;GDSC2:1058,gdsc,,,,,,,,NA,,
GDC0980,GDC0980,,GDSC1:382,gdsc,,,,,,,,NA,,
GEDUNIN,GEDUNIN,CHEMBL465226,BRD:BRD-BRD-K02703275-001-07-5;BRD:BRD-K02703275-001-07-5,rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PRECLINICAL,,Small molecule,NA,YJXDGWUNRYLINJ-BHAPSIHVSA-N,CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)C1CCOC1;CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@H](C4CCOC4)OC(=O)[C@H]4O[C@]43[C@@]21C
GEFAPIXANT,GEFAPIXANT,CHEMBL3716057,BRD:BRD-K00004589-001-01-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,HLWURFKMDLAKOD-UHFFFAOYSA-N,COC1CC(C(C)C)C(OC2CNC(N)NC2N)CC1S(N)(=O)=O
GEFITINIB,GEFITINIB,CHEMBL939,BRD:BRD-BRD-K64052750-001-17-5;BRD:BRD-K64052750-001-17-5;BRD:BRD-K64052750-001-22-5;CTRP:52926;GDSC1:1010;GDSC2:1010,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,,Small molecule,Approved,XGALLCVXEZPNRQ-UHFFFAOYSA-N,COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1OCCCN1CCOCC1
GELDANAMYCIN,GELDANAMYCIN,CHEMBL278315,BRD:BRD-K43570081-001-02-4,rep_single_dose,HSP INHIBITOR,HSP90AA1,,,,,Small molecule,Phase 2,QTQAWLPCGQOSGP-KSRBKZBZSA-N,COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O
GEMCABENE,GEMCABENE,CHEMBL2110686,BRD:BRD-K00077939-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,SDMBRCRVFFHJKR-UHFFFAOYSA-N,CC(C)(CCCCOCCCCC(C)(C)C(=O)O)C(=O)O
GEMCADIOL,GEMCADIOL,CHEMBL2105082,BRD:BRD-BRD-K43890836-001-01-6;BRD:BRD-K43890836-001-01-6,rep_primary;rep_single_dose,ANTILIPEMIC,,,,PHASE 2,,Small molecule,Unknown,DJKWDKJYFYUEBQ-UHFFFAOYSA-N,CC(C)(CO)CCCCCCC(C)(C)CO
GEMCITABINE,GEMCITABINE,CHEMBL888,BRD:BRD-BRD-K15108141-001-06-6;BRD:BRD-K15108141-001-06-6;BRD:BRD-U00115291-001-01-9;CTRP:411863;GDSC1:135;GDSC2:1190,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,CMPK1;RRM1;RRM2;TYMS,"OVARIAN CANCER, BREAST CANCER, NON-SMALL CELL LUNG CANCER (NSCLC), PANCREATIC CANCER",,LAUNCHED,"Multiple values for MOA: {'RIBONUCLEOTIDE REDUCTASE INHIBITOR', 'INHIBITOR OF DNA REPLICATION'}, defaulting to 'RIBONUCLEOTIDE REDUCTASE INHIBITOR'
Multiple values for structure_id: {'K15108141', 'U00115291'}, defaulting to None",Small molecule,Approved,SDUQYLNIPVEERB-QPPQHZFASA-N,NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C(=O)N1
GEMCITABINE-ELAIDATE,GEMCITABINE-ELAIDATE,,BRD:BRD-BRD-K09456915-001-01-2;BRD:BRD-K09456915-001-01-2,rep_primary;rep_single_dose,"APOPTOSIS INHIBITOR, DNA SYNTHESIS INHIBITOR",CMPK1;RRM1;TYMS,,,PHASE 1,"Multiple values for MOA: {'DNA SYNTHESIS INHIBITOR, APOPTOSIS INHIBITOR', 'APOPTOSIS INHIBITOR, DNA SYNTHESIS INHIBITOR'}, defaulting to 'APOPTOSIS INHIBITOR, DNA SYNTHESIS INHIBITOR'",,NA,,CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](N2CCC(N)NC2=O)C(F)(F)[C@@H]1O
GEMFIBROZIL,GEMFIBROZIL,CHEMBL457,BRD:BRD-BRD-K11129031-001-27-5;BRD:BRD-K11129031-001-27-5,rep_primary;rep_single_dose,LIPOPROTEIN LIPASE ACTIVATOR,LPL;PPARA;SLCO1B1;SLCO1B3;SLCO2B1,"HYPERLIPIDEMIA, CORONARY HEART DISEASE",,LAUNCHED,,Small molecule,Approved,HEMJJKBWTPKOJG-UHFFFAOYSA-N,CC1CCC(C)C(OCCCC(C)(C)C(=O)O)C1;CC1CCC(C)C(OCCCC(C)(C)C(O)=O)C1
GEMIFLOXACIN,GEMIFLOXACIN,CHEMBL430,BRD:BRD-A40787240-066-04-6;BRD:BRD-BRD-A40787240-066-04-6,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,"BRONCHITIS, PNEUMONIA",,LAUNCHED,,Small molecule,Approved,ZRCVYEYHRGVLOC-HYARGMPZSA-N,CO/N=C1\CN(C2NC3C(CC2F)C(=O)C(C(=O)O)CN3C2CC2)CC1CN;CO\N=C1/CN(CC1CN)C1NC2N(CC(C(O)=O)C(=O)C2CC1F)C1CC1
GEMIGLIPTIN,GEMIGLIPTIN,CHEMBL3707235,BRD:BRD-K00003182-001-01-9,rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,,,,,,Small molecule,Phase 3,ZWPRRQZNBDYKLH-VIFPVBQESA-N,N[C@@H](CC(=O)N1CCC2C(NC(C(F)(F)F)NC2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O
GEMILUKAST,GEMILUKAST,,BRD:BRD-K00078614-001-02-9,rep_single_dose,,,,,,,,NA,,
GEMZAR,GEMZAR,CHEMBL1637;CHEMBL888,GDSC1:135;GDSC2:1190,gdsc,,,,,,,Small molecule,Approved,OKKDEIYWILRZIA-OSZBKLCCSA-N;SDUQYLNIPVEERB-QPPQHZFASA-N,CL.NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C(=O)N1;NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C(=O)N1
GENENTECH CPD 10,GENENTECH CPD 10,,GDSC1:225,gdsc,,,,,,,,NA,,
GENIPIN,GENIPIN,CHEMBL459016,BRD:BRD-BRD-K28824103-001-02-8;BRD:BRD-BRD-K28824103-001-04-4;BRD:BRD-K28824103-001-02-8;BRD:BRD-K28824103-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,CHOLERETIC AGENT,,,,PRECLINICAL,,Small molecule,NA,AZKVWQKMDGGDSV-BCMRRPTOSA-N,COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12;COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO
GENIPOSIDE,GENIPOSIDE,CHEMBL462894,BRD:BRD-BRD-K57275767-001-02-4;BRD:BRD-BRD-K57275767-001-03-2;BRD:BRD-K57275767-001-02-4;BRD:BRD-K57275767-001-03-2,rep_primary;rep_single_dose,GLP RECEPTOR AGONIST,GLP1R,,,PRECLINICAL,,Small molecule,NA,IBFYXTRXDNAPMM-BVTMAQQCSA-N,COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]2C(CO)=CC[C@H]12;COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO
GENIPOSIDIC-ACID,GENIPOSIDIC-ACID,,BRD:BRD-BRD-K73771095-001-02-5;BRD:BRD-BRD-K73771095-001-03-3;BRD:BRD-K73771095-001-02-5;BRD:BRD-K73771095-001-03-3,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,PRECLINICAL,,,NA,,OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O
GENISTEIN,GENISTEIN,CHEMBL44,BRD:BRD-BRD-K43797669-001-30-4;BRD:BRD-K43797669-001-28-8;BRD:BRD-K43797669-001-30-4,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,CFTR;ESR1;ESR2;ESRRA;ESRRB;ESRRG;NCOA1;NCOA2;PPARG;PTK2B;TOP2A;TRPC5,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,TZBJGXHYKVUXJN-UHFFFAOYSA-N,O=C1C(-C2CCC(O)CC2)COC2CC(O)CC(O)C12;OC1CCC(CC1)-C1COC2CC(O)CC(O)C2C1=O
GENTIOPICRIN,GENTIOPICRIN,,BRD:BRD-BRD-K33131085-001-07-2;BRD:BRD-K33131085-001-07-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR DOWNREGULATOR,GRIN2B,,,PHASE 3,,,NA,,OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O
GENZ-123346,GENZ-123346,,BRD:BRD-K70693421-001-01-1,rep_single_dose,GLUCOSYLCERAMIDASE INHIBITOR,UGCG,,,,,,NA,,
GENZ-644282,GENZ-644282,CHEMBL191958,BRD:BRD-BRD-K99475619-001-01-2;BRD:BRD-K99475619-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 1,,Small molecule,Phase 1,BAORCAMWLWRZQG-UHFFFAOYSA-N,CNCCN1C(=O)C2CC(OC)C(OC)CC2C2CNC3CC4C(CC3C21)OCO4;CNCCN1C2C(CNC3CC4OCOC4CC23)C2CC(OC)C(OC)CC2C1=O
GEPEFRINE,GEPEFRINE,CHEMBL2105064;CHEMBL3989731,BRD:BRD-A04447196-001-01-8;BRD:BRD-BRD-A04447196-001-01-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,HYPOTENSION,,LAUNCHED,,Small molecule,Unknown,WTDGMHYYGNJEKQ-UHFFFAOYSA-N;WTDGMHYYGNJEKQ-ZETCQYMHSA-N,C[C@H](N)CC1CCCC(O)C1;CC(N)CC1CCCC(O)C1
GEPON,GEPON,,BRD:BRD-A56754222-001-01-2;BRD:BRD-BRD-A56754222-001-01-2,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,CC(C)[C@@H](NC(=O)C(NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)C(CCC(O)=O)NC(=O)[C@H](N)C(C)O)C(C)O)C(=O)N[C@H](CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NC(CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O
GEPOTIDACIN,GEPOTIDACIN,CHEMBL3317856,BRD:BRD-K33499285-001-02-9,rep_single_dose,TOPOISOMERASE INHIBITOR,,,,,,Small molecule,Phase 3,PZFAZQUREQIODZ-LJQANCHMSA-N,O=C1CCC2NCC(=O)N3C2N1C[C@H]3CN1CCC(NCC2CC3C(CN2)OCCC3)CC1
GESTODENE,GESTODENE,CHEMBL1213583,BRD:BRD-BRD-K97197005-001-03-2;BRD:BRD-K97197005-001-03-2,rep_primary;rep_single_dose,CONTRACEPTIVE AGENT,,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Phase 3,SIGSPDASOTUPFS-XUDSTZEESA-N,C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC;CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C
GESTRINONE,GESTRINONE,CHEMBL1868702,BRD:BRD-BRD-K97472745-001-01-8;BRD:BRD-K97472745-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR ANTAGONIST,AR;ESR1;PGR,ENDOMETRIOSIS,,LAUNCHED,,Small molecule,Approved,BJJXHLWLUDYTGC-ANULTFPQSA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@@]21CC;CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C
GF109203X,GF109203X,,BRD:BRD-K31342827-001-13-8,rep_single_dose,PKC INHIBITOR,PDPK1;PIM1;PRKCI;PRKCZ,,,,,,NA,,
GGSTOP,GGSTOP,,BRD:BRD-A25625670-001-02-7,rep_single_dose,GAMMA GLUTAMYLTRANSFERASE INHIBITOR,GGT1,,,,,,NA,,
GGTI-298,GGTI-298,,BRD:BRD-BRD-K19669037-001-01-1;BRD:BRD-K19669037-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,GGTASE INHIBITOR,CDKN1A,,,PRECLINICAL,,,NA,,COC(=O)[C@H](CC(C)C)NC(=O)C1CCC(NC[C@@H](N)CS)CC1-C1CCCC2CCCCC12
GIDAZEPAM,GIDAZEPAM,,BRD:BRD-BRD-K22588750-001-07-0;BRD:BRD-K22588750-001-07-0,rep_multi_dose;rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR AGONIST,,,,LAUNCHED,,,NA,,NNC(=O)CN1C2CCC(BR)CC2C(=NCC1=O)C1CCCCC1
GILOTRIF,GILOTRIF,CHEMBL1173655;CHEMBL2105712,GDSC1:1032;GDSC1:1377;GDSC2:1032,gdsc,,,,,,,Small molecule,Approved,ULXXDDBFHOBEHA-CWDCEQMOSA-N;USNRYVNRPYXCSP-JUGPPOIOSA-N,CN(C)C/C=C/C(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1O[C@H]1CCOC1;CN(C)C/C=C/C(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O
GILTERITINIB,GILTERITINIB,CHEMBL3301622,BRD:BRD-BRD-K72280606-001-01-2;BRD:BRD-K72280606-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,FLT3 INHIBITOR,FLT3,,,PHASE 3,,Small molecule,Approved,GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCC1NC(C(N)=O)C(NC2CCC(N3CCC(CC3)N3CCN(C)CC3)C(OC)C2)NC1NC1CCOCC1;CCC1NC(C(N)=O)C(NC2CCC(N3CCC(N4CCN(C)CC4)CC3)C(OC)C2)NC1NC1CCOCC1
GIMERACIL,GIMERACIL,CHEMBL1730601,BRD:BRD-BRD-K35687421-001-02-5;BRD:BRD-K35687421-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,DIHYDROPYRIMIDINE DEHYDROGENASE INHIBITOR,DPYD,GASTRIC ADENOCARCINOMA,,LAUNCHED,,Small molecule,Phase 3,ZPLQIPFOCGIIHV-UHFFFAOYSA-N,OC1CC(=O)[NH]CC1CL;OC1CC(O)C(CL)CN1
GINKGOLIDE-A,GINKGOLIDE-A,,BRD:BRD-A95121829-001-08-9;BRD:BRD-BRD-A95121829-001-08-9,rep_multi_dose;rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GLRA1;GLRB,,,PRECLINICAL,,,NA,,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O
GINKGOLIDE-B,GINKGOLIDE-B,,BRD:BRD-A59001851-001-02-1;BRD:BRD-BRD-A59001851-001-02-1,rep_primary;rep_single_dose,PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST,GLRA1;GLRA2;GLRA3;GLRB;HTR3A;HTR3B,,,PHASE 3,,,NA,,C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O;C[C@@H]1C(=O)OC2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O
GINSENOSIDE-C-K,GINSENOSIDE-C-K,,BRD:BRD-BRD-K01942833-001-01-8;BRD:BRD-K01942833-001-01-8,rep_primary;rep_single_dose,"NFKB PATHWAY INHIBITOR, NITRIC OXIDE SYNTHASE INHIBITOR",PTGS2,,,PRECLINICAL,,,NA,,CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C
GINSENOSIDE-RD,GINSENOSIDE-RD,,BRD:BRD-A84810646-001-01-6;BRD:BRD-BRD-A84810646-001-01-6,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PHASE 3,,,NA,,CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C
GINSENOSIDE-RE,GINSENOSIDE-RE,,BRD:BRD-K00003326-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,,NA,,
GINSENOSIDE-RG3,GINSENOSIDE-RE3;GINSENOSIDE-RG3,,BRD:BRD-A44511856-001-01-4;BRD:BRD-BRD-A44511856-001-01-4,rep_primary;rep_single_dose,"ANGIOGENESIS INHIBITOR, APOPTOSIS STIMULANT",KCNH2,,,LAUNCHED,,,NA,,CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C
GIVINOSTAT,GIVINOSTAT,CHEMBL1213492,BRD:BRD-BRD-K13810148-311-03-2;BRD:BRD-K13810148-311-03-2,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9,,,PHASE 2,,Small molecule,Phase 3,YALNUENQHAQXEA-UHFFFAOYSA-N,CCN(CC)CC1CCC2CC(COC(=O)NC3CCC(C(=O)NO)CC3)CCC2C1;CCN(CC)CC1CCC2CC(COC(=O)NC3CCC(CC3)C(=O)NO)CCC2C1
GK921,GK921,,BRD:BRD-K38272302-001-02-7,rep_single_dose,TRANSGLUTAMINASE INHIBITOR,TGM2,,,,,,NA,,
GKA-50,GKA-50,,BRD:BRD-K03827870-001-02-9,rep_single_dose,GLUCOKINASE ACTIVATOR,GCK,,,,,,NA,,
GKT137831,GKT137831,,BRD:BRD-BRD-K79710622-001-02-9;BRD:BRD-K79710622-001-02-9,rep_primary;rep_single_dose,NADPH OXIDASE INHIBITOR,NOX1;NOX4,,,PHASE 2,,,NA,,CN(C)C1CCCC(C1)-C1N(C)C(=O)CC2[NH]N(-C3CCCCC3CL)C(=O)C12
GLAFENINE,GLAFENINE,CHEMBL146095,BRD:BRD-A38076815-003-10-3;BRD:BRD-BRD-A38076815-003-10-3,rep_primary;rep_single_dose,DELTAF508-CFTR CORRECTORS,CFTR,,,WITHDRAWN,,Small molecule,Approved,GWOFUCIGLDBNKM-UHFFFAOYSA-N,O=C(OCC(O)CO)C1CCCCC1NC1CCNC2CC(CL)CCC12;OCC(O)COC(=O)C1CCCCC1NC1CCNC2CC(CL)CCC12
GLASDEGIB,GLASDEGIB,CHEMBL2043437,BRD:BRD-BRD-K34341643-001-01-4;BRD:BRD-K34341643-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,HEDGEHOG PATHWAY INHIBITOR,SMO,,,PHASE 2,,Small molecule,Approved,SFNSLLSYNZWZQG-VQIMIIECSA-N,CN1CC[C@@H](NC(=O)NC2CCC(C#N)CC2)C[C@@H]1C1NC2CCCCC2[NH]1;CN1CC[C@H](C[C@@H]1C1NC2CCCCC2[NH]1)NC(=O)NC1CCC(CC1)C#N
GLECAPREVIR,GLECAPREVIR,CHEMBL3545363,BRD:BRD-K00003260-001-01-9,rep_single_dose,SERINE PROTEASE INHIBITOR,,,,,,Small molecule,Approved,MLSQGNCUYAMAHD-ITNVBOSISA-N,CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)C2NC3CCCCC3NC2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O
GLEEVEC,GLEEVEC,CHEMBL1642;CHEMBL941,GDSC1:34,gdsc,,,,,,,Small molecule,Approved,KTUFNOKKBVMGRW-UHFFFAOYSA-N;YLMAHDNUQAMNNX-UHFFFAOYSA-N,CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NCCC(-C2CCCNC2)N1;CS(=O)(=O)O.CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NCCC(-C2CCCNC2)N1
GLESATINIB,GLESATINIB,CHEMBL3989914,BRD:BRD-K00003288-003-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 2,YRCHYHRCBXNYNU-UHFFFAOYSA-N,COCCNCC1CCC(-C2CC3NCCC(OC4CCC(NC(=S)NC(=O)CC5CCC(F)CC5)CC4F)C3S2)NC1
GLICLAZIDE,GLICLAZIDE,CHEMBL427216,BRD:BRD-A61154809-001-15-9;BRD:BRD-BRD-A61154809-001-15-9,rep_primary;rep_single_dose,"ATP CHANNEL BLOCKER, INSULIN SECRETAGOGUE",ABCC8;VEGFA,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,BOVGTQGAOIONJV-UHFFFAOYSA-N,CC1CCC(CC1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1;CC1CCC(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)CC1
GLIMEPIRIDE,GLIMEPIRIDE,CHEMBL1481,BRD:BRD-BRD-K34776109-001-16-6;BRD:BRD-K34776109-001-16-6,rep_primary;rep_single_dose,INSULIN SECRETAGOGUE,ABCC8;KCNJ1;KCNJ11,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,WIGIZIANZCJQQY-RUCARUNLSA-N,CCC1=C(C)CN(C(=O)NCCC2CCC(CC2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O;CCC1=C(C)CN(C(=O)NCCC2CCC(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)CC2)C1=O
GLIPIZIDE,GLIPIZIDE,CHEMBL1073,BRD:BRD-BRD-K12219985-001-26-1;BRD:BRD-K12219985-001-26-1,rep_primary;rep_single_dose,SULFONYLUREA,ABCC8;KCNJ10;KCNJ11;PPARG,"DIABETES MELLITUS, HYPERGLYCEMIA",,LAUNCHED,,Small molecule,Approved,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,CC1CNC(C(=O)NCCC2CCC(S(=O)(=O)NC(=O)NC3CCCCC3)CC2)CN1;CC1CNC(CN1)C(=O)NCCC1CCC(CC1)S(=O)(=O)NC(=O)NC1CCCCC1
GLIQUIDONE,GLIQUIDONE,CHEMBL383634,BRD:BRD-BRD-K80396088-001-12-0;BRD:BRD-K80396088-001-12-0,rep_primary;rep_single_dose,SULFONYLUREA,ABCC8;KCNJ10;KCNJ8,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,LLJFMFZYVVLQKT-UHFFFAOYSA-N,COC1CCC2C(C1)C(=O)N(CCC1CCC(CC1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C;COC1CCC2C(C1)C(=O)N(CCC1CCC(S(=O)(=O)NC(=O)NC3CCCCC3)CC1)C(=O)C2(C)C
GLN-1062,GLN-1062,CHEMBL5095056,BRD:BRD-K00004731-001-01-9,rep_single_dose,CHOLINESTERASE INHIBITOR,,,,,,Small molecule,Unknown,JKVNJTYHRABHIY-WXVUKLJWSA-N,COC1CCC2C3C1O[C@H]1C[C@@H](OC(=O)C4CCCCC4)C=C[C@@]31CCN(C)C2
GLPG0187,GLPG0187,CHEMBL3319236,BRD:BRD-K00003380-001-01-9,rep_single_dose,INTEGRIN ANTAGONIST,,,,,,Small molecule,Phase 1,CXHCNOMGODVIKB-VWLOTQADSA-N,COC1CCC(S(=O)(=O)N[C@@H](CNC2NC(C)NC(N3CCC(C4CCC5C(N4)NCCC5)CC3)C2C)C(=O)O)CC1
GLPG0492,GLPG0492,CHEMBL3545417,BRD:BRD-BRD-K15893360-001-01-8;BRD:BRD-K15893360-001-01-8,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 1,,Small molecule,Phase 1,,CN1C(=O)N(C(=O)[C@@]1(CO)C1CCCCC1)C1CCC(C#N)C(C1)C(F)(F)F
GLPG0492-R-ENANTIOMER,GLPG0492-R-ENANTIOMER,,BRD:BRD-BRD-K04643927-001-01-6;BRD:BRD-K04643927-001-01-6,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 1,,,NA,,CN1C(=O)N(C(=O)[C@]1(CO)C1CCCCC1)C1CCC(C#N)C(C1)C(F)(F)F
GLPG0974,GLPG0974,CHEMBL3353541,BRD:BRD-K00078613-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,MPMKMQHJHDHPBE-RUZDIDTESA-N,C[C@]1(C(=O)N(CCCC(=O)O)CC2CCCC(CL)C2)CCN1C(=O)C1CSC2CCCCC12
GLPG1837,GLPG1837,,BRD:BRD-K00003095-001-01-9,rep_single_dose,CFTR CHANNEL POTENTIATOR,,,,,,,NA,,
GLUCOSAMINE,GLUCOSAMINE,CHEMBL493287;CHEMBL606759,BRD:BRD-BRD-K29918010-003-04-1;BRD:BRD-K29918010-003-04-1,rep_primary;rep_single_dose,GLYCOSYLATED PROTEIN PRECURSOR,IFNG;IL1B;MMP9;NFKB2;TNF,"MUSCLE PAIN, RHEUMATOID ARTHRITIS, JOINT PAIN, BACKACHE",,LAUNCHED,,Small molecule,Approved,MSWZFWKMSRAUBD-IVMDWMLBSA-N;MSWZFWKMSRAUBD-UKFBFLRUSA-N,N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O;N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O;N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
L-GLUTAMINE,GLUTAMINE-(L);L-GLUTAMINE,CHEMBL930,BRD:BRD-BRD-K83896451-001-06-7;BRD:BRD-K83896451-001-06-7,rep_primary;rep_single_dose,,CTPS1;GLUL;GPRC6A;PPAT,"DIARRHEA, MUCOSITIS, MUSCLE PAIN, JOINT PAIN, PEPTIC ULCER DISEASE (PUD), ULCERATIVE COLITIS, CROHN'S DISEASE, ANXIETY, INSOMNIA",,LAUNCHED,,Small molecule,Approved,ZDXPYRJPNDTMRX-VKHMYHEASA-N,N[C@@H](CCC(N)=O)C(O)=O;NC(=O)CC[C@H](N)C(=O)O
GLUTATHIONE,GLUTATHIONE,CHEMBL1543,BRD:BRD-BRD-K69346723-001-04-8;BRD:BRD-K69346723-001-04-8,rep_primary;rep_single_dose,ANTIOXIDANT,ESD;GGT1;GLO1;GLRX;GLRX2;GPX1;GPX2;GPX3;GPX4;GPX5;GPX6;GPX7;GPX8;GSR;GSS;GSTA1;GSTA2;GSTA3;GSTA4;GSTA5;GSTK1;GSTM1;GSTM2;GSTM3;GSTM4;GSTM5;GSTO1;GSTO2;GSTP1;GSTT1;GSTZ1;HAGH;HPGDS;LTC4S;MGST1;MGST2;MGST3;TXNDC12,,,PHASE 3,,Small molecule,Phase 3,RWSXRVCMGQZWBV-WDSKDSINSA-N,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O;N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O
GLUTATHIONE-MONOISOPROPYL-ESTER,GLUTATHIONE-MONOISOPROPYL-ESTER,,BRD:BRD-BRD-K58937086-001-01-4;BRD:BRD-K58937086-001-01-4,rep_primary;rep_single_dose,LIPID PEROXIDASE INHIBITOR,,,,PHASE 2,,,NA,,CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O
GLY-GLN,GLY-GLN,,BRD:BRD-BRD-K85066592-001-01-6;BRD:BRD-K85066592-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,NCC(=O)N[C@@H](CCC(N)=O)C(O)=O
GLYBURIDE,GLYBURIDE,CHEMBL472,BRD:BRD-BRD-K36927236-001-32-6;BRD:BRD-K36927236-001-32-6,rep_primary;rep_single_dose,"ATP CHANNEL BLOCKER, INSULIN SECRETAGOGUE, SULFONYLUREA",ABCA1;ABCB11;ABCC8;ABCC9;CFTR;CPT1A;KCNJ1;KCNJ11;KCNJ5;KCNJ8;SLCO2B1,"DIABETES MELLITUS, HYPERGLYCEMIA",,LAUNCHED,,Small molecule,Approved,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,COC1CCC(CL)CC1C(=O)NCCC1CCC(CC1)S(=O)(=O)NC(=O)NC1CCCCC1;COC1CCC(CL)CC1C(=O)NCCC1CCC(S(=O)(=O)NC(=O)NC2CCCCC2)CC1
GLYCEROL-MONOLAURATE,GLYCEROL-MONOLAURATE,CHEMBL510533,BRD:BRD-A10773072-001-03-4;BRD:BRD-BRD-A10773072-001-03-4,rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,,,LAUNCHED,,Small molecule,NA,ARIWANIATODDMH-UHFFFAOYSA-N,CCCCCCCCCCCC(=O)OCC(O)CO
GLYCEROL-PHENYLBUTYRATE,GLYCEROL-PHENYLBUTYRATE,,BRD:BRD-K00003520-001-01-9,rep_single_dose,SIGMA RECEPTOR LIGAND,,,,,,,NA,,
GLYCITEIN,GLYCITEIN,CHEMBL513024,BRD:BRD-BRD-K78303961-001-02-3;BRD:BRD-K78303961-001-02-3,rep_primary;rep_single_dose,TUMOR NECROSIS FACTOR RELEASE INHIBITOR,TNF,,,PHASE 3,,Small molecule,NA,DXYUAIFZCFRPTH-UHFFFAOYSA-N,COC1CC2C(=O)C(-C3CCC(O)CC3)COC2CC1O;COC1CC2C(CC1O)OCC(-C1CCC(O)CC1)C2=O
GLYCOPYRROLATE,GLYCOPYRROLATE,CHEMBL1201027,BRD:BRD-A81233518-004-16-1;BRD:BRD-BRD-A81233518-004-16-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,VPNYRYCIDCJBOM-UHFFFAOYSA-M,C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1CCCCC1;C[N+]1(C)CCC(OC(=O)C(O)(C2CCCCC2)C2CCCC2)C1.[BR-]
GM-1485,GM-1485,,BRD:BRD-K00004613-001-01-9,rep_single_dose,IMMUNOPHILIN LIGAND,FKBP1A,,,,,,NA,,
GMX-1778,GMX-1778,CHEMBL17289,CTRP:411843,ctrp,,,,,,,Small molecule,Phase 1,BOIPLTNGIAPDBY-UHFFFAOYSA-N,N#CN=C(NCCCCCCOC1CCC(CL)CC1)NC1CCNCC1
GMX1778,GMX1778,,BRD:BRD-BRD-K69832040-001-01-9;BRD:BRD-K69832040-001-01-9,rep_primary;rep_single_dose,NAMPT INHIBITOR,NAMPT,,,PHASE 1/PHASE 2,,,NA,,CLC1CCC(OCCCCCCN\C(NC#N)=N\C2CCNCC2)CC1
GNE 317,GNE 317,,GDSC2:1926,gdsc,,,,,,,,NA,,
GNE-049,GNE-049,,BRD:BRD-K00126493-001-01-9,oncref_2,INHIBITOR OF EP300/CREBBP BRD,BRD4;BRET;CREBBP;EP300,,,,,,NA,,
GNE-317,GNE-317,,GDSC2:1926,gdsc,,,,,,,,NA,,
GNE-477,GNE-477,,BRD:BRD-K12609995-001-02-9,rep_single_dose,,,,,,,,NA,,
GNE-7915,GNE-7915,,BRD:BRD-K33963447-001-03-9,rep_single_dose,LEUCINE RICH REPEAT KINASE INHIBITOR,,,,,,,NA,,
GNE317,GNE317,,GDSC2:1926,gdsc,,,,,,,,NA,,
GNF-2,GNF-2,,BRD:BRD-BRD-K97056771-001-13-1;BRD:BRD-K97056771-001-13-1;GDSC1:52,gdsc;rep_primary;rep_single_dose,BCR-ABL KINASE INHIBITOR,ABL1;BCR,,,PRECLINICAL,,,NA,,NC(=O)C1CCCC(C1)-C1CC(NC2CCC(OC(F)(F)F)CC2)NCN1
GNF-5,GNF-5,,BRD:BRD-BRD-K87632963-001-03-0;BRD:BRD-K87632963-001-03-0,rep_primary;rep_single_dose,BCR-ABL KINASE INHIBITOR,ABL1;BCR,,,PRECLINICAL,,,NA,,OCCNC(=O)C1CCCC(C1)-C1NCNC(NC2CCC(CC2)OC(F)(F)F)C1
GNF-7,GNF-7,,BRD:BRD-K69075588-001-02-9,rep_single_dose,"GLUCOKINASE INHIBITOR, PROTEIN KINASE INHIBITOR",GCK;TNK2,,,,,,NA,,
GNF-PF-193,GNF-PF-193,CHEMBL94657,GDSC1:201,gdsc,,,,,,,Small molecule,Phase 3,QXRSDHAAWVKZLJ-PVYNADRNSA-N,C/C(=C\C1CSC(C)N1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
GNTI,GNTI,,BRD:BRD-K64748124-300-06-9,rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRK1;OPRM1,,,,,,NA,,
GO-6983,GO-6983,,BRD:BRD-BRD-K36984403-001-02-7;BRD:BRD-K36984403-001-02-7,rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,PRKCA;PRKCB;PRKCD;PRKCG;PRKCZ,,,PRECLINICAL,,,NA,,COC1CCC2N(CCCN(C)C)CC(C3=C(C(=O)NC3=O)C3C[NH]C4CCCCC34)C2C1
GOLGICIDE-A,GOLGICIDE-A,,BRD:BRD-A57886255-001-01-1;BRD:BRD-BRD-A57886255-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,ARF INHIBITOR,GBF1,,,PRECLINICAL,,,NA,,FC1CC(F)C2NC([C@@H]3CC=C[C@@H]3C2C1)C1CCCNC1
GOLVATINIB,GOLVATINIB,CHEMBL3039525,BRD:BRD-BRD-K69001009-001-02-8;BRD:BRD-K69001009-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,KDR;MET,,,PHASE 2,,Small molecule,Phase 2,UQRCJCNVNUFYDX-UHFFFAOYSA-N,CN1CCN(C2CCN(C(=O)NC3CC(OC4CCC(NC(=O)C5(C(=O)NC6CCC(F)CC6)CC5)C(F)C4)CCN3)CC2)CC1;CN1CCN(CC1)C1CCN(CC1)C(=O)NC1CC(OC2CCC(NC(=O)C3(CC3)C(=O)NC3CCC(F)CC3)C(F)C2)CCN1
GONADORELIN,GONADORELIN,CHEMBL1007,BRD:BRD-BRD-K96874295-015-01-0;BRD:BRD-K96874295-015-01-0,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR AGONIST,GNRHR;GNRHR2,"CYSTIC OVARIES, REPRODUCTIVE SYNCHRONY",,LAUNCHED,,Protein,Approved,XLXSAKCOAKORKW-AQJXLSMYSA-N,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O;CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CNC[NH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
GOSERELIN-ACETATE,GOSERELIN-ACETATE,,BRD:BRD-BRD-K99504665-001-01-2;BRD:BRD-K99504665-001-01-2,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR AGONIST,GNRHR;LHCGR,"PROSTATE CANCER, BREAST CANCER, ENDOMETRIOSIS",,LAUNCHED,,,NA,,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
GOSSYPOL,GOSSYPOL,CHEMBL51483,BRD:BRD-BRD-K19295594-015-14-3;BRD:BRD-K19295594-015-14-3;CTRP:25036,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"BCL INHIBITOR, MCL1 INHIBITOR",BCL2,,,PHASE 2,,Small molecule,Phase 3,QBKSWRVVCFFDOT-UHFFFAOYSA-N,CC(C)C1C(O)C(O)C(C=O)C2C(O)C(C(C)CC12)-C1C(C)CC2C(C(C)C)C(O)C(O)C(C=O)C2C1O;CC1CC2C(C(C)C)C(O)C(O)C(C=O)C2C(O)C1-C1C(C)CC2C(C(C)C)C(O)C(O)C(C=O)C2C1O
GP1A,GP1A,,BRD:BRD-BRD-K65285700-001-02-3;BRD:BRD-K65285700-001-02-3,rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR2,,,PRECLINICAL,,,NA,,CC1CCC-2C(CC3C(NN(C-23)-C2CCC(CL)CC2CL)C(=O)NN2CCCCC2)C1
GP2A,GP2A,,BRD:BRD-BRD-K34608650-001-02-4;BRD:BRD-K34608650-001-02-4,rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR2,,,PRECLINICAL,,,NA,,CC1CCC-2C(CC3C(NN(C-23)-C2CCC(CL)CC2CL)C(=O)NC2CCCCC2)C1
GPBAR-A,GPBAR-A,,BRD:BRD-BRD-K67397687-001-01-3;BRD:BRD-K67397687-001-01-3,rep_primary;rep_single_dose,"G PROTEIN COUPLED RECEPTOR AGONIST, G PROTEIN-COUPLED RECEPTOR AGONIST",GPBAR1,,,PRECLINICAL,"Multiple values for MOA: {'G PROTEIN COUPLED RECEPTOR AGONIST, G PROTEIN-COUPLED RECEPTOR AGONIST', 'G PROTEIN COUPLED RECEPTOR AGONIST'}, defaulting to 'G PROTEIN COUPLED RECEPTOR AGONIST, G PROTEIN-COUPLED RECEPTOR AGONIST'",,NA,,FC1CCCCC1-C1CCNC2OCC(=O)N(CC3CC(CC(C3)C(F)(F)F)C(F)(F)F)CC12
GPI-1046,GPI-1046,CHEMBL6367,BRD:BRD-BRD-K44869961-001-01-6;BRD:BRD-K44869961-001-01-6,rep_primary;rep_single_dose,FKBP INHIBITOR,FKBP1A,,,PRECLINICAL,,Small molecule,NA,OQAHHWOPVDDWHD-INIZCTEOSA-N,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCC1CCCNC1
GPI-688,GPI-688,,BRD:BRD-A90201073-001-02-9,rep_single_dose,GLYCOGEN PHOSPHORYLASE INHIBITOR,,,,,,,NA,,
GPP-78,GPP-78,,BRD:BRD-BRD-K83289131-003-01-0;BRD:BRD-K83289131-003-01-0,rep_primary;rep_single_dose,NAMPT INHIBITOR,NAMPT,,,PRECLINICAL,,,NA,,O=C(CCCCCCCN1CC(NN1)-C1CCCNC1)NC1CCCCC1-C1CCCCC1
GPR120-MODULATOR-1,GPR120-MODULATOR-1,,BRD:BRD-BRD-K19409553-001-01-6;BRD:BRD-K19409553-001-01-6,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR MODULATOR,FFAR4,,,PRECLINICAL,,,NA,,CC1CC(OCC2NC(CS2)-C2CCCCC2CL)CCC1OCC(O)=O
GR-103691,GR-103691,,BRD:BRD-BRD-K50891186-001-04-4;BRD:BRD-K50891186-001-04-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD3,,,PRECLINICAL,,,NA,,COC1CCCCC1N1CCN(CCCCNC(=O)C2CCC(CC2)-C2CCC(CC2)C(C)=O)CC1
GR-113808,GR-113808,,BRD:BRD-BRD-K49945136-001-10-0;BRD:BRD-K49945136-001-10-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR4,,,PRECLINICAL,,,NA,,CN1CC(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)C2CCCCC12
GR-127935,GR-127935,CHEMBL15928,BRD:BRD-BRD-K11911061-003-11-9;BRD:BRD-K11911061-003-11-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR6,,,PRECLINICAL,,Small molecule,NA,YDBCEBYHYKAFRX-UHFFFAOYSA-N,COC1CCC(NC(=O)C2CCC(-C3CCC(-C4NOC(C)N4)CC3C)CC2)CC1N1CCN(C)CC1;COC1CCC(NC(=O)C2CCC(CC2)-C2CCC(CC2C)-C2NOC(C)N2)CC1N1CCN(C)CC1
GR-135531,GR-135531,,BRD:BRD-BRD-K83023055-001-02-7;BRD:BRD-K83023055-001-02-7,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,COC(=O)NC1CCC2[NH]CC(CCNC(C)=O)C2C1
GR-144053,GR-144053,,BRD:BRD-BRD-K12120659-305-02-2;BRD:BRD-K12120659-305-02-2,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGA2B;ITGB3,,,PRECLINICAL,,,NA,,NC(=N)C1CCC(CC1)N1CCN(CC1)C1CCN(CC(O)=O)CC1
GR-159897,GR-159897,,BRD:BRD-BRD-K52394958-001-02-7;BRD:BRD-K52394958-001-02-7,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TAC1;TACR2,,,PRECLINICAL,,,NA,,COC1(C[S@@](=O)C2CCCCC2)CCN(CCC2C[NH]C3CCC(F)CC23)CC1
GR-79236,GR-79236,CHEMBL2163568,BRD:BRD-BRD-K40578143-001-02-6;BRD:BRD-K40578143-001-02-6,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A,,,PHASE 1,,Small molecule,NA,GYWXTRVEUURNEW-TVDBPQCTSA-N,OC[C@H]1O[C@@H](N2CNC3C(N[C@H]4CCC[C@@H]4O)NCNC32)[C@H](O)[C@@H]1O;OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(N[C@H]3CCC[C@@H]3O)NCNC12
GR125487,GR125487,,BRD:BRD-BRD-K62594868-082-08-6;BRD:BRD-K62594868-082-08-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR4,,,PRECLINICAL,,,NA,,COC1[NH]C2CCC(F)CC2C1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1
GR46611,GR46611,,BRD:BRD-BRD-K98155362-001-07-7;BRD:BRD-K98155362-001-07-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1D,,,PRECLINICAL,,,NA,,COC1CCC(CNC(=O)\C=C\C2CCC3[NH]CC(CCN(C)C)C3C2)CC1
GRAMINE,GRAMINE,CHEMBL254348,BRD:BRD-BRD-K26005076-001-12-8;BRD:BRD-K26005076-001-12-8,rep_primary;rep_single_dose,NOREPINEPHRINE REPUTAKE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,OCDGBSUVYYVKQZ-UHFFFAOYSA-N,CN(C)CC1C[NH]C2CCCCC12
GRANISETRON,GRANISETRON,CHEMBL289469,BRD:BRD-A10967948-003-06-3;BRD:BRD-BRD-A10967948-003-06-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,CN1C2CCCC1CC(C2)NC(=O)C1NN(C)C2CCCCC12;CN1C2CCCC1CC(NC(=O)C1NN(C)C3CCCCC13)C2
GRAPIPRANT,GRAPIPRANT,CHEMBL3039498,BRD:BRD-BRD-K62050508-001-01-0;BRD:BRD-K62050508-001-01-0,rep_primary;rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGER4,OSTEOARTHRITIS,,LAUNCHED,,Small molecule,Phase 2,HZVLFTCYCLXTGV-UHFFFAOYSA-N,CCC1NC2C(C)NC(C)CC2N1-C1CCC(CCNC(=O)NS(=O)(=O)C2CCC(C)CC2)CC1
GRAZOPREVIR,GRAZOPREVIR,CHEMBL2063090;CHEMBL3039533,BRD:BRD-BRD-K24943235-001-01-3;BRD:BRD-K24943235-001-01-3,rep_primary;rep_single_dose,HCV INHIBITOR,,,,LAUNCHED,,Small molecule,Approved,OBMNJSNZOWALQB-NCQNOWPTSA-N;RXSARIJMSJWJLZ-CIAYNJNFSA-N,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCC1NC3CCC(OC)CC3NC1O2)C(=O)NS(=O)(=O)C1CC1;C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCC1NC3CCC(OC)CC3NC1O2)C(=O)NS(=O)(=O)C1CC1.O;COC1CCC2NC3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)OC3NC2C1)C(C)(C)C
GRISEOFULVIN,GRISEOFULVIN,CHEMBL562,BRD:BRD-BRD-K08273968-001-19-0;BRD:BRD-K08273968-001-19-0,rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,KRT12,"RINGWORM, TINEA PEDIS",,LAUNCHED,,Small molecule,Approved,DDUHZTYCFQRHIY-RBHXEPJQSA-N,COC1=CC(=O)C[C@@H](C)[C@]12OC1C(CL)C(OC)CC(OC)C1C2=O;COC1CC(OC)C(CL)C2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)C12
GS-39783,GS-39783,CHEMBL392394,BRD:BRD-BRD-K75478907-001-02-3;BRD:BRD-K75478907-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABBR1,,,PRECLINICAL,,Small molecule,NA,GSGVDKOCBKBMGG-UHFFFAOYSA-N,CSC1NC(NC2CCCC2)C([N+](=O)[O-])C(NC2CCCC2)N1;CSC1NC(NC2CCCC2)C(C(NC2CCCC2)N1)[N+]([O-])=O
GS-6201,GS-6201,CHEMBL260933,BRD:BRD-BRD-K68453341-001-01-1;BRD:BRD-K68453341-001-01-1,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 1,,Small molecule,Phase 1,KOYXXLLNCXWUNF-UHFFFAOYSA-N,CCCN1C(=O)C2[NH]C(-C3CNN(CC4CCCC(C(F)(F)F)C4)C3)NC2N(CC)C1=O;CCCN1C(=O)N(CC)C2NC([NH]C2C1=O)-C1CNN(CC2CCCC(C2)C(F)(F)F)C1
GS-9620,GS-9620,CHEMBL2424780,BRD:BRD-BRD-K73585091-001-02-3;BRD:BRD-K73585091-001-02-3,rep_primary;rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,TLR7,,,PHASE 2,,Small molecule,Phase 2,VFOKSTCIRGDTBR-UHFFFAOYSA-N,CCCCOC1NC(N)C2C(N1)N(CC1CCCC(CN3CCCC3)C1)CC(=O)N2;CCCCOC1NC(N)C2NC(=O)CN(CC3CCCC(CN4CCCC4)C3)C2N1
GS-967,GS-967,,BRD:BRD-K26526496-001-03-9,rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,,,,,,,NA,,
GS-9973,GS-9973,CHEMBL3265032,BRD:BRD-BRD-K76719364-001-02-5;BRD:BRD-K76719364-001-02-5;GDSC2:1630,gdsc;rep_multi_dose;rep_primary;rep_single_dose,SYK INHIBITOR,SYK,,,PHASE 2,,Small molecule,Phase 3,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,C1CN(CCO1)C1CCC(NC2NC(CN3CCNC23)-C2CCC3CN[NH]C3C2)CC1;C1CN2CC(-C3CCC4CN[NH]C4C3)NC(NC3CCC(N4CCOCC4)CC3)C2N1
GSK 1904529A,GSK 1904529A,,GDSC1:202;GDSC2:1093,gdsc,,,,,,,,NA,,
GSK 2578215A,GSK 2578215A,,GDSC2:1927,gdsc,,,,,,,,NA,,
GSK 269962A,GSK 269962A,,GDSC1:1192;GDSC1:127;GDSC2:1192,gdsc,,,,,,,,NA,,
GSK 602,GSK 602,,GDSC2:1928,gdsc,,,,,,,,NA,,
GSK 650394,GSK 650394,,GDSC1:177,gdsc,,,,,,,,NA,,
GSK 690693,GSK 690693,CHEMBL494089,GDSC1:326,gdsc,,,,,,,Small molecule,Phase 1,KGPGFQWBCSZGEL-ZDUSSCGKSA-N,CCN1C(-C2NONC2N)NC2C(C#CC(C)(C)O)NCC(OC[C@H]3CCCNC3)C21
GSK0660,GSK-0660;GSK0660,,BRD:BRD-BRD-K98684188-001-02-9;BRD:BRD-K98684188-001-02-9,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARD,,,PRECLINICAL,,,NA,,COC(=O)C1SCCC1S(=O)(=O)NC1CCC(NC2CCCCC2)CC1OC
GSK-1070916,GSK-1070916,CHEMBL1090479,GDSC1:226,gdsc,,,,,,,Small molecule,Phase 1,QTBWCSQGBMPECM-UHFFFAOYSA-N,CCN1CC(-C2CCNC3[NH]C(-C4CCCC(CN(C)C)C4)CC23)C(-C2CCC(NC(=O)N(C)C)CC2)N1
GSK-1904529A,GSK-1904529A,,GDSC1:202;GDSC2:1093,gdsc,,,,,,,,NA,,
GSK-2126458,GSK-2126458,CHEMBL1236962,GDSC1:283,gdsc,,,,,,,Small molecule,Phase 1,CGBJSGAELGCMKE-UHFFFAOYSA-N,COC1NCC(-C2CCC3NCCC(-C4CCNNC4)C3C2)CC1NS(=O)(=O)C1CCC(F)CC1F
GSK-2141795,GSK-2141795,CHEMBL3137336,GDSC2:1553;GDSC2:2106,gdsc,,,,,,,Small molecule,Phase 2,AXTAPYRUEKNRBA-JTQLQIEISA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCC(F)C(F)C2)OC1CL
GSK-2578215A,GSK-2578215A,,GDSC2:1927,gdsc,,,,,,,,NA,,
GSK-3 INHIBITOR IX,GSK-3 INHIBITOR IX,,CTRP:52582,ctrp,,,,,,,,NA,,
GSK-3-INHIBITOR-IX,GSK-3-INHIBITOR-IX,,BRD:BRD-BRD-K04923131-001-15-4;BRD:BRD-K04923131-001-15-4,rep_multi_dose;rep_primary;rep_single_dose,"GLYCOGEN SYNTHASE KINASE INHIBITOR, LIPOXYGENASE INHIBITOR",GSK3A;GSK3B,,,PRECLINICAL,,,NA,,O\N=C1/C(NC2CCCCC12)=C1/C(=O)NC2CC(BR)CCC12
GSK37647,GSK-37647;GSK37647,,BRD:BRD-BRD-K26514105-001-01-7;BRD:BRD-K26514105-001-01-7,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,FFAR4,,,PRECLINICAL,,,NA,,COC1CCC(CC1)S(=O)(=O)NC1C(C)CC(C)CC1C
GSK-602,GSK-602,,GDSC2:1928,gdsc,,,,,,,,NA,,
GSK-626616,GSK-626616,,BRD:BRD-K00090633-001-01-9,rep_single_dose,,,,,,,,NA,,
GSK-650394,GSK-650394,CHEMBL558642,GDSC1:177,gdsc,,,,,,,Small molecule,NA,WVSBGSNVCDAMCF-UHFFFAOYSA-N,O=C(O)C1CCC(-C2C[NH]C3NCC(-C4CCCCC4)CC23)CC1C1CCCC1
GSK-690693,GSK-690693,CHEMBL494089,GDSC1:326,gdsc,,,,,,,Small molecule,Phase 1,KGPGFQWBCSZGEL-ZDUSSCGKSA-N,CCN1C(-C2NONC2N)NC2C(C#CC(C)(C)O)NCC(OC[C@H]3CCCNC3)C21
GSK-J1,GSK-J1,,BRD:BRD-BRD-K32847255-001-01-1;BRD:BRD-K32847255-001-01-1,rep_primary;rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,KDM6B,,,PRECLINICAL,,,NA,,OC(=O)CCNC1CC(NC(N1)-C1CCCCN1)N1CCC2CCCCC2CC1
GSK-J2,GSK-J2,,BRD:BRD-BRD-K82484347-001-01-2;BRD:BRD-K82484347-001-01-2,rep_primary;rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,,,,PRECLINICAL,,,NA,,OC(=O)CCNC1CC(NC(N1)-C1CCCNC1)N1CCC2CCCCC2CC1
GSK-J4,GSK-J4,,BRD:BRD-BRD-K98203492-003-04-1;BRD:BRD-K98203492-003-04-1;CTRP:687735,ctrp;rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM6A;KDM6B,,,PRECLINICAL,,,NA,,CCOC(=O)CCNC1CC(NC(N1)-C1CCCCN1)N1CCC2CCCCC2CC1
GSK-J5,GSK-J5,,BRD:BRD-BRD-K55438324-001-01-8;BRD:BRD-K55438324-001-01-8,rep_primary;rep_single_dose,HISTONE DEMETHYLASE CONTROL,,,,PRECLINICAL,,,NA,,CCOC(=O)CCNC1CC(NC(N1)-C1CCCNC1)N1CCC2CCCCC2CC1
GSK-LSD-1,GSK-LSD-1,,BRD:BRD-K33521504-300-01-6,rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM1A,,,,,,NA,,
GSK089,GSK089,CHEMBL1230609,GDSC1:308;GDSC2:2040,gdsc,,,,,,,Small molecule,Phase 2,CXQHYVUVSFXTMY-UHFFFAOYSA-N,COC1CC2C(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3F)CCNC2CC1OCCCN1CCOCC1
GSK1059615,GSK1059615,CHEMBL3544966,BRD:BRD-BRD-K06750613-001-07-3;BRD:BRD-K06750613-001-07-3;CTRP:606471;GDSC1:374,ctrp;gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CG,,,PHASE 1,,Small molecule,Phase 1,QDITZBLZQQZVEE-YBEGLDIGSA-N,O=C1NC(=O)/C(=C/C2CCC3NCCC(-C4CCNCC4)C3C2)S1;O=C1NC(=O)\C(S1)=C\C1CCC2NCCC(-C3CCNCC3)C2C1
GSK1070916,GSK1070916,CHEMBL1090479,BRD:BRD-BRD-K36740062-001-06-6;BRD:BRD-K36740062-001-06-6;GDSC1:226,gdsc;rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC;CYP2D6;CYP3A4,,,PHASE 1,,Small molecule,Phase 1,QTBWCSQGBMPECM-UHFFFAOYSA-N,CCN1CC(-C2CCNC3[NH]C(-C4CCCC(CN(C)C)C4)CC23)C(-C2CCC(NC(=O)N(C)C)CC2)N1;CCN1CC(C(N1)-C1CCC(NC(=O)N(C)C)CC1)-C1CCNC2[NH]C(CC12)-C1CCCC(CN(C)C)C1
TRAMETINIB,GSK1120212;TRAMETINIB,CHEMBL2103875,BRD:BRD-BRD-K12343256-001-08-9;BRD:BRD-K12343256-001-08-9;BRD:BRD-K12343256-001-11-3;BRD:BRD-K12343256-001-14-7;CTRP:687418;GDSC1:1372;GDSC2:1372,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MEK1 AND MEK2,MAP2K1;MAP2K2,MELANOMA,,LAUNCHED,"Multiple values for MOA: {'MEK INHIBITOR', 'INHIBITOR OF MEK1 AND MEK2'}, defaulting to 'INHIBITOR OF MEK1 AND MEK2'",Small molecule,Approved,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CC(=O)NC1CCCC(-N2C(=O)N(C3CC3)C(=O)C3C(NC4CCC(I)CC4F)N(C)C(=O)C(C)C32)C1;CC(=O)NC1CCCC(C1)-N1C2C(C)C(=O)N(C)C(NC3CCC(I)CC3F)C2C(=O)N(C2CC2)C1=O
GSK2816126A,GSK126;GSK2816126;GSK2816126A,CHEMBL3287735,BRD:BRD-BRD-K21867462-001-02-9;BRD:BRD-K21867462-001-02-9;BRD:BRD-K21867462-001-03-7,oncref_1;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PHASE 1,"Multiple values for MOA: {'INHIBITOR OF EZH2', 'HISTONE LYSINE METHYLTRANSFERASE INHIBITOR'}, defaulting to 'HISTONE LYSINE METHYLTRANSFERASE INHIBITOR'",Small molecule,Phase 1,FKSFKBQGSFSOSM-QFIPXVFZSA-N,CC[C@H](C)N1CC(C)C2C(C(=O)NCC3C(C)CC(C)[NH]C3=O)CC(-C3CCC(N4CCNCC4)NC3)CC21;CC[C@H](C)N1CC(C)C2C(CC(CC12)-C1CCC(NC1)N1CCNCC1)C(=O)NCC1C(C)CC(C)[NH]C1=O
GSK1292263,GSK1292263,CHEMBL3187503,BRD:BRD-BRD-K60341624-001-02-2;BRD:BRD-K60341624-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR AGONIST,GRPR,,,PHASE 2,,Small molecule,Phase 2,AYJRTVVIBJSSKN-UHFFFAOYSA-N,CC(C)C1NOC(N1)N1CCC(COC2CCC(NC2)-C2CCC(CC2)S(C)(=O)=O)CC1;CC(C)C1NOC(N2CCC(COC3CCC(-C4CCC(S(C)(=O)=O)CC4)NC3)CC2)N1
GSK1363089,GSK1363089,CHEMBL1230609,GDSC1:308;GDSC2:2040,gdsc,,,,,,,Small molecule,Phase 2,CXQHYVUVSFXTMY-UHFFFAOYSA-N,COC1CC2C(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3F)CCNC2CC1OCCCN1CCOCC1
GSK1562590,GSK1562590,,BRD:BRD-K36697397-003-02-9,rep_single_dose,UROTENSIN RECEPTOR ANTAGONIST,UTS2R,,,,,,NA,,
GSK163090,GSK163090,CHEMBL1631540,BRD:BRD-BRD-K69669039-001-01-8;BRD:BRD-K69669039-001-01-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR1B;HTR1D,,,PHASE 2,,Small molecule,Phase 2,ANGUXJDGJCHGOG-UHFFFAOYSA-N,CC1CCC2C(CCCC2N1)N1CCN(CCC2CCCC(C2)N2CCNC2=O)CC1;CC1CCC2C(N3CCN(CCC4CCCC(N5CCNC5=O)C4)CC3)CCCC2N1
GSK1838705A,GSK1838705A,,BRD:BRD-BRD-K06749501-001-02-1;BRD:BRD-K06749501-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,INSULIN GROWTH FACTOR RECEPTOR INHIBITOR,ALK;IGF1R;INSR;RPS6KA1,,,PRECLINICAL,,,NA,,CNC(=O)C1C(F)CCCC1NC1NC(NC2CC3N(CCC3CC2OC)C(=O)CN(C)C)NC2[NH]CCC12
GSK189254,GSK189254,CHEMBL517140,BRD:BRD-K00003166-001-01-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,WROHEWWOCPRMIA-UHFFFAOYSA-N,CNC(=O)C1CCC(OC2CCC3C(C2)CCN(C2CCC2)CC3)NC1
GSK1904529A,GSK1904529A,,BRD:BRD-BRD-K04833372-001-06-2;BRD:BRD-K04833372-001-06-2;GDSC1:202;GDSC2:1093,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"IGF-1 INHIBITOR, INSULIN GROWTH FACTOR RECEPTOR INHIBITOR, INSULIN RECEPTOR LIGAND",IGF1R;INSR,,,PRECLINICAL,,,NA,,CCC1CC(NC2NCCC(N2)-C2C(NC3CCCCN23)-C2CCC(OC)C(C2)C(=O)NC2C(F)CCCC2F)C(OC)CC1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O
GSK2110183,GSK2110183,CHEMBL2219422,BRD:BRD-BRD-K25412176-001-01-9;BRD:BRD-K25412176-001-01-9;BRD:BRD-K25412176-001-04-9;GDSC2:1912,gdsc;rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,AKT1;AKT2;AKT3,,,PHASE 2,,Small molecule,Phase 2,AFJRDFWMXUECEW-LBPRGKRZSA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCCC(F)C2)SC1CL;CN1NCC(CL)C1-C1CC(SC1CL)C(=O)N[C@H](CN)CC1CCCC(F)C1
GSK2110183C,GSK2110183C,CHEMBL2219422,GDSC2:1912,gdsc,,,,,,,Small molecule,Phase 2,AFJRDFWMXUECEW-LBPRGKRZSA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCCC(F)C2)SC1CL
GSK2118436,GSK2118436,CHEMBL2028663,GDSC1:1373;GDSC2:1373,gdsc,,,,,,,Small molecule,Approved,BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)C1NC(-C2CCCC(NS(=O)(=O)C3C(F)CCCC3F)C2F)C(-C2CCNC(N)N2)S1
GSK2126458,GSK2126458,CHEMBL1236962,BRD:BRD-BRD-K07972848-001-02-0;BRD:BRD-K07972848-001-02-0;GDSC1:283,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 1,,Small molecule,Phase 1,CGBJSGAELGCMKE-UHFFFAOYSA-N,COC1NCC(-C2CCC3NCCC(-C4CCNNC4)C3C2)CC1NS(=O)(=O)C1CCC(F)CC1F;COC1NCC(CC1NS(=O)(=O)C1CCC(F)CC1F)-C1CCC2NCCC(-C3CCNNC3)C2C1
GSK2141795,GSK2141795,CHEMBL3137336,GDSC2:1553;GDSC2:2106,gdsc,,,,,,,Small molecule,Phase 2,AXTAPYRUEKNRBA-JTQLQIEISA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCC(F)C(F)C2)OC1CL
GSK2141795C,GSK2141795C,CHEMBL3137336,GDSC2:1553;GDSC2:2106,gdsc,,,,,,,Small molecule,Phase 2,AXTAPYRUEKNRBA-JTQLQIEISA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCC(F)C(F)C2)OC1CL
GSK2190915,GSK2190915,CHEMBL1922660,BRD:BRD-BRD-K15691453-236-01-6;BRD:BRD-K15691453-236-01-6,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5AP,,,PHASE 2,,Small molecule,Phase 3,DFQGDHBGRSTTHX-UHFFFAOYSA-N,CCOC1CCC(-C2CCC(CN3C(CC(C)(C)C(=O)O)C(SC(C)(C)C)C4CC(OCC5CCC(C)CN5)CCC43)CC2)CN1;CCOC1CCC(CN1)-C1CCC(CN2C(CC(C)(C)C(O)=O)C(SC(C)(C)C)C3CC(OCC4CCC(C)CN4)CCC23)CC1
GSK2193874,GSK2193874,,BRD:BRD-K90737788-001-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPV4,,,,,,NA,,
GSK2194069,GSK2194069,,BRD:BRD-BRD-K95123482-001-01-6;BRD:BRD-K95123482-001-01-6,rep_primary;rep_single_dose,FATTY ACID SYNTHASE INHIBITOR,FASN,,,PRECLINICAL,,,NA,,O=C(C1CC1)N1CC[C@@H](CC2N[NH]C(=O)N2-C2CCC(CC2)-C2CCC3OCCC3C2)C1
GSK2239633A,GSK2239633A,,BRD:BRD-K00003364-001-01-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,,NA,,
GSK2245035,GSK2245035,CHEMBL4297492,BRD:BRD-K00074079-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,LFMPVTVPXHNXOT-HNNXBMFYSA-N,CCC[C@H](C)OC1NC(N)C2[NH]C(=O)N(CCCCCN3CCCCC3)C2N1
GSK2256098,GSK2256098,CHEMBL4742157,BRD:BRD-K00003379-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 2,BVAHPPKGOOJSPU-UHFFFAOYSA-N,CONC(=O)C1CCCCC1NC1CC(NC2CC(C)NN2C(C)C)NCC1CL
GSK2256294A,GSK2256294A,,BRD:BRD-BRD-K62738477-001-01-7;BRD:BRD-K62738477-001-01-7,rep_primary;rep_single_dose,EPOXIDE HYDOLASE INHIBITOR,EPHX2,,,PHASE 1,,,NA,,CNC1NC(C)NC(N[C@H]2CCC[C@H](C2)C(=O)NCC2CCC(CC2C(F)(F)F)C#N)N1
GSK2330672,GSK2330672,CHEMBL2387408,BRD:BRD-BRD-K05858796-001-01-7;BRD:BRD-K05858796-001-01-7,rep_primary;rep_single_dose,BILE ACID TRANSPORTER INHIBITOR,SLC10A2,,,PHASE 2,,Small molecule,Phase 3,CZGVOBIGEBDYTP-VSGBNLITSA-N,CCCC[C@]1(CC)CS(=O)(=O)C2CC(CNC(CC(=O)O)CC(=O)O)C(OC)CC2[C@@H](C2CCCCC2)N1;CCCC[C@]1(CC)CS(=O)(=O)C2CC(CNC(CC(O)=O)CC(O)=O)C(OC)CC2[C@H](N1)C1CCCCC1
GSK2334470,GSK2334470,,BRD:BRD-K70642949-001-03-7,rep_single_dose,PHOSPHOINOSITIDE DEPENDENT KINASE INHIBITOR,AURKA;AURKB;PDPK1,,,,,,NA,,
GSK239512,GSK239512,CHEMBL3092650,BRD:BRD-K00004689-001-01-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,YFRBKEVUUCQYOW-UHFFFAOYSA-N,O=C1CCCN1C1CCC(OC2CCC3C(C2)CCN(C2CCC2)CC3)NC1
GSK256066,GSK256066,CHEMBL570015,BRD:BRD-BRD-K37590257-001-02-8;BRD:BRD-K37590257-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A,,,PHASE 2,,Small molecule,Phase 2,JFHROPTYMMSOLG-UHFFFAOYSA-N,COC1CCCC(NC2C(C(N)=O)CNC3C(C)CC(S(=O)(=O)C4CCCC(C(=O)N(C)C)C4)CC23)C1;COC1CCCC(NC2C(CNC3C(C)CC(CC23)S(=O)(=O)C2CCCC(C2)C(=O)N(C)C)C(N)=O)C1
GSK2578215A,GSK2578215A,,BRD:BRD-BRD-K30185465-001-03-0;BRD:BRD-K30185465-001-03-0;GDSC2:1927,gdsc;rep_primary;rep_single_dose,LEUCINE RICH REPEAT KINASE INHIBITOR,LRRK2,,,PRECLINICAL,,,NA,,FC1CC(CCN1)-C1CCC(OCC2CCCCC2)C(C1)C(=O)NC1CCCNC1
GSK2606414,GSK2606414,,BRD:BRD-K81689258-001-04-8;GDSC2:1618,gdsc;rep_single_dose,PROTEIN KINASE INHIBITOR,EIF2AK3;MYLK2,,,,,,NA,,
GSK2636771,GSK2636771,CHEMBL3188551,BRD:BRD-BRD-K49215523-001-04-2;BRD:BRD-K49215523-001-04-2;CTRP:668723,ctrp;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CB,,,PHASE 2,,Small molecule,Phase 2,XTKLTGBKIDQGQL-UHFFFAOYSA-N,CC1C(CN2C(C)NC3C(C(=O)O)CC(N4CCOCC4)CC32)CCCC1C(F)(F)F;CC1NC2C(CC(CC2N1CC1CCCC(C1C)C(F)(F)F)N1CCOCC1)C(O)=O
GSK2656157,GSK2656157,,BRD:BRD-BRD-K41104902-001-01-3;BRD:BRD-K41104902-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,PERK INHIBITOR,,,,PRECLINICAL,,,NA,,CC1CCCC(CC(=O)N2CCC3C2CCC(-C2CN(C)C4NCNC(N)C24)C3F)N1
GSK269962,GSK269962,,BRD:BRD-BRD-K89464729-001-03-1;BRD:BRD-K89464729-001-03-1,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1;ROCK2,,,PRECLINICAL,,,NA,,CCN1C(NC2CNC(OC3CCCC(NC(=O)C4CCC(OCCN5CCOCC5)CC4)C3)CC12)-C1NONC1N
GSK269962A,GSK269962A,,GDSC1:1192;GDSC1:127;GDSC2:1192,gdsc,,,,,,,,NA,,
GSK2801,GSK2801,,BRD:BRD-BRD-K48062199-001-01-8;BRD:BRD-K48062199-001-01-8,rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BAZ2A;BAZ2B,,,PRECLINICAL,,,NA,,CCCOC1CCN2C(CC(-C3CCCCC3S(C)(=O)=O)C2C1)C(C)=O
GSK2830371,GSK2830371,,BRD:BRD-K17472821-001-01-2,rep_multi_dose;rep_single_dose,PROTEIN PHOSPHATASE INHIBITOR,PPM1D,,,PRECLINICAL,,,NA,,CC1NCC(CL)CC1NCC1CCC(S1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1
GSK2837808A,GSK2837808A,,BRD:BRD-K50679358-001-02-9,rep_single_dose,LACTATE DEHYDROGENASE INHIBITOR,LDHA,,,,,,NA,,
GSK2838232,GSK2838232,CHEMBL4303141,BRD:BRD-BRD-K08398903-001-01-1;BRD:BRD-K08398903-001-01-1,rep_primary;rep_single_dose,HIV GAG INHIBITOR,,,,PHASE 1,,Small molecule,Phase 2,MEOWKUXNVNJAMY-PZFKGGKESA-N,CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]2([C@@H](O)CN(CCN(C)C)CC2CCC(CL)CC2)CC1=O;CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)CC1CCC(CL)CC1
GSK2879552,GSK2879552,CHEMBL3786182,BRD:BRD-BRD-K09223495-001-01-4;BRD:BRD-K09223495-001-01-4,rep_primary;rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM1A,,,PHASE 1,,Small molecule,Phase 1,LRULVYSBRWUVGR-FCHUYYIVSA-N,O=C(O)C1CCC(CN2CCC(CN[C@@H]3C[C@H]3C3CCCCC3)CC2)CC1;OC(=O)C1CCC(CN2CCC(CN[C@@H]3C[C@H]3C3CCCCC3)CC2)CC1
GSK2881078,GSK2881078,CHEMBL3545174,BRD:BRD-K97656802-001-02-9,rep_single_dose,ANDROGEN RECEPTOR MODULATOR,,,,,,Small molecule,Phase 2,,
GSK2981278,GSK2981278,CHEMBL4225088,BRD:BRD-K00003292-001-01-9,rep_single_dose,ROR MODULATOR,,,,,,Small molecule,Phase 1,LZLBRISQTJVZNP-UHFFFAOYSA-N,CCC1CCC(N(CC(C)C)S(=O)(=O)C2CCC(OCC3CCOCC3)C(CO)C2)CC1
GSK2982772,GSK2982772,CHEMBL4071864,BRD:BRD-K00003429-001-01-9,rep_single_dose,RIPK INHIBITOR,,,,,,Small molecule,Phase 2,LYPAFUINURXJSG-AWEZNQCLSA-N,CN1C(=O)[C@@H](NC(=O)C2N[NH]C(CC3CCCCC3)N2)COC2CCCCC21
GSK2983559 (FREE ACID),GSK2983559 (FREE ACID),,BRD:BRD-K00091265-001-01-9,rep_single_dose,,,,,,,,NA,,
GSK3117391,GSK3117391,CHEMBL4297494,BRD:BRD-K00004614-001-01-9,rep_single_dose,HDAC INHIBITOR,,,,,,Small molecule,Phase 2,AFDPFLDWOXXHQM-NRFANRHFSA-N,O=C(CCC1CCC(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)CN1)NO
GSK3179106,GSK3179106,CHEMBL3355009,BRD:BRD-K00003373-001-01-9,rep_single_dose,RET TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 1,IDXKJSSOUXWLDB-UHFFFAOYSA-N,CCOC1CC(=O)[NH]CC1-C1CCC(CC(=O)NC2CC(C(C)(C)C(F)(F)F)ON2)C(F)C1
GSK319347A,GSK319347A,CHEMBL373751,GDSC1:91,gdsc,,,,,,,Small molecule,NA,LDTAHRLHGHFHKP-UHFFFAOYSA-N,COC1CC2NCN(-C3CC(OCC4CCCCC4S(C)(=O)=O)C(C#N)S3)C2CC1OC
GSK3203591,GSK3203591,,GDSC2:2110,gdsc,,,,,,,,NA,,
PEMRAMETOSTAT,GSK3326595;PEMRAMETOSTAT,CHEMBL4466233,BRD:BRD-K00003421-001-01-9,oncref_1;rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT5,,,,"Multiple values for MOA: {'SAM-COOPERATIVE INHIBITOR OF PRMT5', 'PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR'}, defaulting to 'PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR'",Small molecule,Phase 2,JLCCNYVTIWRPIZ-NRFANRHFSA-N,CC(=O)N1CCC(NC2CC(C(=O)NC[C@H](O)CN3CCC4CCCCC4C3)NCN2)CC1
GSK343,GSK343,,GDSC2:1627,gdsc,,,,,,,,NA,,
GSK3484862,GSK3484862,,BRD:BRD-K00095917-001-04-9,oncref_2,NON-COVALENT INHIBITOR OF DNMT1,DNMT1,,,,,,NA,,
GSK356278,GSK356278,CHEMBL4297384,BRD:BRD-K00004711-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Phase 1,AWDJJMXJUOHGLC-UHFFFAOYSA-N,CCN1NCC2C(NC3CCOCC3)C(-C3NNC(CC4SC(C)NC4C)O3)CNC21
GSK369796,GSK369796,CHEMBL147806,BRD:BRD-K00003121-300-01-9,rep_single_dose,POTASSIUM CHANNEL ANTAGONIST,,,,,,Small molecule,Phase 1,ZVMMVSSEAMUNGI-UHFFFAOYSA-N,CC(C)(C)NCC1CCC(NC2CCNC3CC(CL)CCC23)CC1O
GSK3787,GSK3787,,BRD:BRD-BRD-K03155172-001-02-2;BRD:BRD-K03155172-001-02-2,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARD,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCC(NC1)S(=O)(=O)CCNC(=O)C1CCC(CL)CC1
GSK4112,GSK4112,,CTRP:660081,ctrp,,,,,,,,NA,,
GSK429286A,GSK429286A,,BRD:BRD-A10523515-001-07-9;BRD:BRD-BRD-A10523515-001-07-9;GDSC1:230,gdsc;rep_multi_dose;rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1,,,PRECLINICAL,,,NA,,CC1=C(C(CC(=O)N1)C1CCC(CC1)C(F)(F)F)C(=O)NC1CC2CN[NH]C2CC1F
GSK458,GSK458,,GDSC1:283,gdsc,,,,,,,,NA,,
GSK461364,GSK461364,,BRD:BRD-BRD-K92428232-001-10-6;BRD:BRD-K92428232-001-10-6;CTRP:649862,ctrp;rep_multi_dose;rep_primary;rep_single_dose,PLK INHIBITOR,PLK1,,,PHASE 1,,,NA,,C[C@@H](OC1CC(SC1C(N)=O)-N1CNC2CCC(CN3CCN(C)CC3)CC12)C1CCCCC1C(F)(F)F
GSK503,GSK503,,BRD:BRD-BRD-K72293620-001-01-7;BRD:BRD-K72293620-001-01-7,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PRECLINICAL,,,NA,,CC(C)N1CC(C)C2C(CC(CC12)-C1CCC(NC1)N1CCN(C)CC1)C(=O)NCC1C(C)CC(C)[NH]C1=O
GSK525762A,GSK525762A,CHEMBL1232461,CTRP:660245;GDSC1:275;GDSC2:1624,ctrp;gdsc,,,,,,,Small molecule,Phase 2,AAAQFGUYHFJNHI-SFHVURJKSA-N,CCNC(=O)C[C@@H]1N=C(C2CCC(CL)CC2)C2CC(OC)CCC2-N2C(C)NNC21
GSK591,GSK591,,GDSC2:2110,gdsc,,,,,,,,NA,,
GSK602,GSK602,,GDSC2:1928,gdsc,,,,,,,,NA,,
GSK650394,GSK650394,,BRD:BRD-BRD-K14991967-001-02-6;BRD:BRD-K14991967-001-02-6;GDSC1:177,gdsc;rep_multi_dose;rep_primary;rep_single_dose,SERUM/GLUCOCORTICOID REGULATED KINASE INHIBITOR,SGK1;SGK2,,,PRECLINICAL,,,NA,,OC(=O)C1CCC(CC1C1CCCC1)-C1C[NH]C2NCC(CC12)-C1CCCCC1
GSK656,GSK656,,BRD:BRD-K00003483-003-01-9,rep_single_dose,LEUCYL-TRNA SYNTHETASE INHIBITOR,,,,,,,NA,,
GSK690693,GSK690693,CHEMBL494089,BRD:BRD-BRD-K25325018-001-05-6;BRD:BRD-K25325018-001-05-6;GDSC1:326,gdsc;rep_primary;rep_single_dose,AKT INHIBITOR,AKT1;AKT2;AKT3;PAK4;PAK6;PAK7;PRKCQ;PRKG1;PRKX,,,PHASE 1,,Small molecule,Phase 1,KGPGFQWBCSZGEL-ZDUSSCGKSA-N,CCN1C(-C2NONC2N)NC2C(C#CC(C)(C)O)NCC(OC[C@H]3CCCNC3)C21;CCN1C(NC2C(NCC(OC[C@H]3CCCNC3)C12)C#CC(C)(C)O)-C1NONC1N
GSK9027,GSK9027,,BRD:BRD-BRD-K29328421-001-01-6;BRD:BRD-K29328421-001-01-6,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,,,PRECLINICAL,,,NA,,FC1CCC(CC1)-N1NCC2CC(CCC12)-C1CCC(NS(=O)(=O)CC2CCCCC2)CC1C(F)(F)F
GSK923295,GSK923295,CHEMBL4303470,BRD:BRD-BRD-K89015388-001-01-7;BRD:BRD-K89015388-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,CENTROMERE ASSOCIATED PROTEIN INHIBITOR,CENPE,,,PHASE 1,,Small molecule,Phase 1,WHMXDBPHBVLYRC-OFVILXPXSA-N,CC(C)OC1CCC(C(=O)N[C@H](CNC(=O)CN(C)C)CC2CCC(-C3CN4CCCC([C@H](C)O)C4N3)CC2)CC1CL;CC(C)OC1CCC(CC1CL)C(=O)N[C@H](CNC(=O)CN(C)C)CC1CCC(CC1)-C1CN2CCCC([C@H](C)O)C2N1
GTP-14564,GTP-14564,,BRD:BRD-BRD-K16664969-001-03-3;BRD:BRD-K16664969-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, TYROSINE KINASE INHIBITOR",CSF1R;FLT3;KIT;PDGFRB,,,PRECLINICAL,,,NA,,C1CCC(CC1)-C1N[NH]C2C1OC1CCCCC21
GTPL5238,GTPL5238,,GDSC1:175,gdsc,,,,,,,,NA,,
GTPL6653,GTPL6653,,GDSC2:1615,gdsc,,,,,,,,NA,,
GTPL7710,GTPL7710,,GDSC2:1617,gdsc,,,,,,,,NA,,
GTPL7898,GTPL7898,,GDSC2:1629,gdsc,,,,,,,,NA,,
GTPL8020,GTPL8020,,GDSC2:1855,gdsc,,,,,,,,NA,,
GTPL8240,GTPL8240,,GDSC2:1627,gdsc,,,,,,,,NA,,
GTS21,GTS21,,BRD:BRD-BRD-K14235254-001-01-2;BRD:BRD-K14235254-001-01-2,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR AGONIST,CHRNA7,,,PHASE 1/PHASE 2,,,NA,,COC1CCC(\C=C2CCCN=C/2C2CCCNC2)C(OC)C1
GUACETISAL,GUACETISAL,CHEMBL2105097,BRD:BRD-BRD-K00739965-001-01-9;BRD:BRD-K00739965-001-01-9,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,,,,LAUNCHED,,Small molecule,Unknown,HSJFYRYGGKLQBT-UHFFFAOYSA-N,COC1CCCCC1OC(=O)C1CCCCC1OC(C)=O
GUADECITABINE,GUADECITABINE,CHEMBL3544916,BRD:BRD-K00003187-236-01-9,rep_single_dose,DNA METHYLTRANSFERASE INHIBITOR,,,,,,Small molecule,Phase 3,GUWXKKAWLCENJA-WGWHJZDNSA-N,NC1NCN([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](N4CNC5C(=O)[NH]C(N)NC54)C[C@@H]3O)[C@@H](CO)O2)C(=O)N1
GUAIFENESIN,GUAIFENESIN,CHEMBL980,BRD:BRD-A90515964-001-16-5;BRD:BRD-BRD-A90515964-001-16-5,rep_primary;rep_single_dose,EXPECTORANT,,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Approved,HSRJKNPTNIJEKV-UHFFFAOYSA-N,COC1CCCCC1OCC(O)CO
GUANABEN-ACETATE,GUANABEN-ACETATE,,BRD:BRD-BRD-K62736196-015-11-0;BRD:BRD-BRD-K62736196-015-13-6;BRD:BRD-K62736196-015-11-0;BRD:BRD-K62736196-015-13-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,HYPERTENSION,,LAUNCHED,,,NA,,NC(=N)N\N=C\C1C(CL)CCCC1CL
GUANADREL,GUANADREL,CHEMBL1037,BRD:BRD-A14262390-065-01-8;BRD:BRD-BRD-A14262390-065-01-8,rep_primary;rep_single_dose,ADRENERGIC INHIBITOR,SLC6A2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,HPBNRIOWIXYZFK-UHFFFAOYSA-N,N=C(N)NCC1COC2(CCCCC2)O1;NC(=N)NCC1COC2(CCCCC2)O1
GUANCYDINE,GUANCYDINE,CHEMBL1697839,BRD:BRD-K00005334-001-01-9,rep_single_dose,ANTIHYPERTENSIVE AGENT,,,,,,Small molecule,Unknown,VZVGEDRCVUKSEL-UHFFFAOYSA-N,CCC(C)(C)N/C(N)=N/C#N
GUANETHIDINE,GUANETHIDINE,CHEMBL765,BRD:BRD-BRD-K62676709-065-05-5;BRD:BRD-K62676709-065-05-5,rep_primary;rep_single_dose,ADRENERGIC INHIBITOR,SLC6A2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,ACGDKVXYNVEAGU-UHFFFAOYSA-N,N=C(N)NCCN1CCCCCCC1;NC(=N)NCCN1CCCCCCC1
GUANFACINE,GUANFACINE,CHEMBL862,BRD:BRD-BRD-K32830106-001-02-6;BRD:BRD-BRD-K32830106-003-20-4;BRD:BRD-K32830106-001-02-6;BRD:BRD-K32830106-003-20-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,INJOMKTZOLKMBF-UHFFFAOYSA-N,N=C(N)NC(=O)CC1C(CL)CCCC1CL;NC(=N)NC(=O)CC1C(CL)CCCC1CL
GUANIDINE,GUANIDINE,CHEMBL2110935;CHEMBL821,BRD:BRD-BRD-K76037122-001-02-5;BRD:BRD-K76037122-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,ALDH2;DLG4;GAMT;RNASE1,LAMBERT-EATON MYASTHENIC SYNDROME (LEMS),,LAUNCHED,,Small molecule,Approved,UEIBTMGAIXZRBV-UHFFFAOYSA-N;ZRALSGWEFCBTJO-UHFFFAOYSA-N,N=C(N)N;N=C(N)NCCCOC1CCCCC1;NC(N)=N
GUANIDINOETHYLDISULFIDE-BICARBONATE,GUANIDINOETHYLDISULFIDE-BICARBONATE,,BRD:BRD-K69191882-065-01-6,rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS2,,,,,,NA,,
GUANOSINE,GUANOSINE,CHEMBL375655,BRD:BRD-BRD-K92976206-001-01-5;BRD:BRD-K92976206-001-01-5,rep_primary;rep_single_dose,,PNP,,,PRECLINICAL,,Small molecule,NA,NYHBQMYGNKIUIF-UUOKFMHZSA-N,NC1NC2C(NCN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(=O)[NH]1;NC1NC2N(CNC2C(=O)[NH]1)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H]1O
GUE-1654,GUE-1654,,BRD:BRD-BRD-K18745919-001-01-3;BRD:BRD-K18745919-001-01-3,rep_primary;rep_single_dose,OXOEICOSANOID RECEPTOR MODULATOR,OXER1,,,PRECLINICAL,,,NA,,CSC1NC2CCC3NC(NC(=O)C(C4CCCCC4)C4CCCCC4)SC3C2S1
GUSACITINIB,GUSACITINIB,CHEMBL4594275,BRD:BRD-K00091102-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,NLFLXLJXEIUQDL-UHFFFAOYSA-N,N#CCC1CCN(C2NC(NC3CCC(N4CCC(O)CC4)CC3)C3C(=O)[NH]NCC3N2)CC1
GUVACINE,GUVACINE,CHEMBL76768,BRD:BRD-BRD-K01980392-003-11-6;BRD:BRD-K01980392-003-11-6,rep_primary;rep_single_dose,GABA UPTAKE INHIBITOR,SLC6A1;SLC6A11;SLC6A12;SLC6A13,,,PRECLINICAL,,Small molecule,NA,QTDZOWFRBNTPQR-UHFFFAOYSA-N,O=C(O)C1=CCCNC1;OC(=O)C1=CCCNC1
GW 441756,GW 441756,,GDSC1:1023,gdsc,,,,,,,,NA,,
GW-0742,GW-0742,,BRD:BRD-BRD-K82983861-001-04-3;BRD:BRD-K82983861-001-04-3,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARD,,,PRECLINICAL,,,NA,,CC1NC(SC1CSC1CCC(OCC(O)=O)C(C)C1)-C1CCC(C(F)C1)C(F)(F)F
GW-1100,GW-1100,,BRD:BRD-K23614267-001-01-2,rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,FFAR1,,,,,,NA,,
GW-1929,GW-1929,,BRD:BRD-A15415227-003-02-9;BRD:BRD-BRD-A15415227-003-02-9,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARG,,,PRECLINICAL,,,NA,,CN(CCOC1CCC(CC(NC2CCCCC2C(=O)C2CCCCC2)C(O)=O)CC1)C1CCCCN1
GW-2580,GW-2580,CHEMBL261849,BRD:BRD-BRD-K24242599-001-02-8;BRD:BRD-K24242599-001-02-8;GDSC1:193,gdsc;rep_primary;rep_single_dose,CFMS KINASE INHIBITOR,CSF1R,,,PRECLINICAL,,Small molecule,NA,MYQAUKPBNJWPIE-UHFFFAOYSA-N,COC1CCC(COC2CCC(CC3CNC(N)NC3N)CC2OC)CC1
GW-311616,GW-311616,,BRD:BRD-BRD-K37864785-001-01-0;BRD:BRD-K37864785-001-01-0,rep_primary;rep_single_dose,"LEUKOCYTE ELASTASE INHIBITOR, ELASTASE INHIBITOR",ELANE,,,PHASE 1,"Multiple values for MOA: {'ELASTASE INHIBITOR, LEUKOCYTE ELASTASE INHIBITOR', 'LEUKOCYTE ELASTASE INHIBITOR, ELASTASE INHIBITOR'}, defaulting to 'LEUKOCYTE ELASTASE INHIBITOR, ELASTASE INHIBITOR'",,NA,,CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O
GW-3965,GW-3965,,BRD:BRD-BRD-K33818169-003-04-6;BRD:BRD-K33818169-003-04-6,rep_multi_dose;rep_primary;rep_single_dose,LXR AGONIST,NR1H2;NR1H3,,,PRECLINICAL,,,NA,,OC(=O)CC1CCCC(OCCCN(CC(C2CCCCC2)C2CCCCC2)CC2CCCC(C2CL)C(F)(F)F)C1
GW-405833,GW-405833,,BRD:BRD-BRD-K10705233-001-02-2;BRD:BRD-K10705233-001-02-2;CTRP:375447,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR2,,,PRECLINICAL,,,NA,,COC1CCC2N(C(=O)C3CCCC(CL)C3CL)C(C)C(CCN3CCOCC3)C2C1
GW-4064,GW-4064,,BRD:BRD-BRD-K88186167-001-04-8;BRD:BRD-K88186167-001-04-8,rep_primary;rep_single_dose,FXR AGONIST,NR1H4,,,PRECLINICAL,,,NA,,CC(C)C1ONC(C1COC1CCC(\C=C\C2CCCC(C2)C(O)=O)C(CL)C1)-C1C(CL)CCCC1CL
GW-438014A,GW-438014A,,BRD:BRD-BRD-K13039700-066-01-2;BRD:BRD-K13039700-066-01-2,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY5R,,,PRECLINICAL,,,NA,,O=C(NC1NC2CCCCC2N1CCC1CCCCC1)C1CCCCC1
GW-441756,GW-441756,,BRD:BRD-BRD-K41312087-001-02-7;BRD:BRD-K41312087-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,GROWTH FACTOR RECEPTOR INHIBITOR,NTRK1,,,PRECLINICAL,,,NA,,CN1CC(\C=C2/C(=O)NC3CCCNC23)C2CCCCC12
GW-501516,GW-501516,CHEMBL38943,BRD:BRD-BRD-K14880289-001-02-2;BRD:BRD-K14880289-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA;PPARD,,,PHASE 2,,Small molecule,Phase 2,YDBLKRPLXZNVNB-UHFFFAOYSA-N,CC1CC(SCC2SC(-C3CCC(C(F)(F)F)CC3)NC2C)CCC1OCC(=O)O;CC1NC(SC1CSC1CCC(OCC(O)=O)C(C)C1)-C1CCC(CC1)C(F)(F)F
GW-542573X,GW-542573X,,BRD:BRD-K36485341-001-02-9,rep_single_dose,CALCIUM CHANNEL ACTIVATOR,KCNN1,,,,,,NA,,
GW-583340,GW-583340,,BRD:BRD-BRD-K79930101-300-03-7;BRD:BRD-K79930101-300-03-7,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2,,,PRECLINICAL,,,NA,,CS(=O)(=O)CCNCC1NC(CS1)-C1CCC2NCNC(NC3CCC(OCC4CCCC(F)C4)C(CL)C3)C2C1
GW-627368,GW-627368,,BRD:BRD-BRD-K50005760-001-01-1;BRD:BRD-K50005760-001-01-1,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER4,,,PRECLINICAL,,,NA,,CCOC1C2CN(C(=O)C2C(OCC)C2CCCCC12)C1CCC(CC(=O)NS(=O)(=O)C2CCCCC2)CC1
GW-6471,GW-6471,,BRD:BRD-BRD-K20828910-001-02-0;BRD:BRD-K20828910-001-02-0,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARA,,,PRECLINICAL,,,NA,,CCC(=O)NC[C@H](CC1CCC(OCCC2NC(OC2C)-C2CCCCC2)CC1)N\C(C)=C/C(=O)C1CCC(CC1)C(F)(F)F
GW-7647,GW-7647,CHEMBL21241,BRD:BRD-BRD-K96263742-001-14-8;BRD:BRD-K96263742-001-14-8,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA,,,PRECLINICAL,,Small molecule,NA,PKNYXWMTHFMHKD-UHFFFAOYSA-N,CC(C)(SC1CCC(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)CC1)C(=O)O;CC(C)(SC1CCC(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)CC1)C(O)=O
GW-788388,GW-788388,,BRD:BRD-BRD-K78086729-001-02-7;BRD:BRD-K78086729-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,LCK;MAPK14;TGFBR1,,,PRECLINICAL,,,NA,,O=C(NC1CCOCC1)C1CCC(CC1)-C1CC(CCN1)-C1C[NH]NC1-C1CCCCN1
GW-803430,GW-803430,,BRD:BRD-BRD-K65576800-001-01-6;BRD:BRD-K65576800-001-01-6,rep_primary;rep_single_dose,MELANIN INHIBITOR,KCNH2;MCHR1,,,PHASE 1,,,NA,,COC1CC(CCC1OCCN1CCCC1)-N1CNC2CC(SC2C1=O)-C1CCC(CL)CC1
GW-842166,GW-842166,CHEMBL225411,BRD:BRD-BRD-K26823213-001-02-9;BRD:BRD-K26823213-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR2,,,PHASE 2,,Small molecule,Phase 2,TWQYWUXBZHPIIV-UHFFFAOYSA-N,FC(F)(F)C1NC(NC2CCC(CL)CC2CL)NCC1C(=O)NCC1CCOCC1;O=C(NCC1CCOCC1)C1CNC(NC2CCC(CL)CC2CL)NC1C(F)(F)F
GW-843682X,GW-843682X,,BRD:BRD-BRD-K90382497-001-10-7;BRD:BRD-K90382497-001-10-7;CTRP:348997,ctrp;rep_multi_dose;rep_primary;rep_single_dose,PLK INHIBITOR,PLK1;PLK3,,,PRECLINICAL,,,NA,,COC1CC2NCN(-C3CC(OCC4CCCCC4C(F)(F)F)C(S3)C(N)=O)C2CC1OC
GW-9508,GW-9508,CHEMBL207881,BRD:BRD-BRD-K71534238-001-10-0;BRD:BRD-K71534238-001-10-0,rep_primary;rep_single_dose,"FREE FATTY ACID RECEPTOR AGONIST, G PROTEIN-COUPLED RECEPTOR AGONIST",FFAR1;FFAR4,,,PRECLINICAL,,Small molecule,NA,DGENZVKCTGIDRZ-UHFFFAOYSA-N,O=C(O)CCC1CCC(NCC2CCCC(OC3CCCCC3)C2)CC1;OC(=O)CCC1CCC(NCC2CCCC(OC3CCCCC3)C2)CC1
GW-9662,GW-9662,,BRD:BRD-BRD-K93258693-001-17-3;BRD:BRD-K93258693-001-17-3,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,NCOA2;PPARG;RXRA,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCC(CL)C(C1)C(=O)NC1CCCCC1
GW274150,GW274150,CHEMBL114551,BRD:BRD-K65840970-001-02-9,rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,,,,,,Small molecule,Phase 2,MOLOJNHYNHBPCW-ZETCQYMHSA-N,CC(=N)NCCSCC[C@H](N)C(=O)O
GW441756,GW441756,,GDSC1:1023,gdsc,,,,,,,,NA,,
GW7604,GW7604,,BRD:BRD-K00073895-001-02-9,rep_single_dose,,,,,,,,NA,,
GW843682X,GW843682X,CHEMBL514499,GDSC1:87,gdsc,,,,,,,Small molecule,NA,JSKUWFIZUALZLX-UHFFFAOYSA-N,COC1CC2NCN(-C3CC(OCC4CCCCC4C(F)(F)F)C(C(N)=O)S3)C2CC1OC
GW843682X (AN-13),GW843682X (AN-13),,GDSC1:87,gdsc,,,,,,,,NA,,
GX15-070,GX15-070,CHEMBL408194,GDSC1:182;GDSC2:1068,gdsc,,,,,,,Small molecule,Phase 3,RFTSSZJZXOSICM-GRSHGNNSSA-N,COC1=CC(C2CC3CCCCC3[NH]2)=N/C1=C\C1[NH]C(C)CC1C
GX15-070MS,GX15-070MS,CHEMBL2107358,GDSC1:182;GDSC2:1068,gdsc,,,,,,,Small molecule,Phase 3,ZFKXDVMHNXPEIY-PEZBNFGJSA-N,COC1=CC(C2CC3CCCCC3[NH]2)=N/C1=C\C1[NH]C(C)CC1C.CS(=O)(=O)O
GX2580,GX2580,,GDSC1:193,gdsc,,,,,,,,NA,,
GZD824,GZD824,,BRD:BRD-BRD-K35329391-334-01-7;BRD:BRD-K35329391-334-01-7,rep_multi_dose;rep_primary;rep_single_dose,BCR-ABL KINASE INHIBITOR,ABL1;BCR,,,PRECLINICAL,,,NA,,CN1CCN(CC2CCC(NC(=O)C3CCC(C)C(C3)C#CC3CNC4[NH]NCC4C3)CC2C(F)(F)F)CC1
H-151,H-151,,BRD:BRD-K00005333-001-01-9,rep_single_dose,STING ANTAGONIST,,,,,,,NA,,
H-89,H-89,,BRD:BRD-BRD-K27737647-300-03-0;BRD:BRD-K27737647-300-03-0,rep_primary;rep_single_dose,PKA INHIBITOR,GSG2;PKIA;PRKACA,,,PRECLINICAL,,,NA,,BRC1CCC(\C=C\CNCCNS(=O)(=O)C2CCCC3CNCCC23)CC1
H-VAL-PRO-PRO-OH (TFA),H-VAL-PRO-PRO-OH (TFA),,BRD:BRD-K00073449-019-02-9,rep_single_dose,,,,,,,,NA,,
H2L-5765834,H2L-5765834,,BRD:BRD-BRD-K26439554-001-01-3;BRD:BRD-K26439554-001-01-3,rep_primary;rep_single_dose,LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST,LPAR1;LPAR3,,,PRECLINICAL,,,NA,,OC(=O)C1CCC2C(=O)N(C(=O)C2C1)C1CCCC(OC2CCC(CC2)[N+]([O-])=O)C1
HA-1004,HA-1004,,BRD:BRD-BRD-K05434375-001-06-5;BRD:BRD-K05434375-001-06-5,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PHASE 2,,,NA,,NC(=N)NCCNS(=O)(=O)C1CCCC2CNCCC12
HA-130,HA-130,,BRD:BRD-K64452997-001-02-9,rep_single_dose,AUTOTAXIN INHIBITOR,ENPP2,,,,,,NA,,
HA-966-(R)-(+),HA-966-(R)-(+),,BRD:BRD-BRD-K58046914-001-03-8;BRD:BRD-K58046914-001-03-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIA1,,,PRECLINICAL,,,NA,,N[C@@H]1CCN(O)C1=O
HA-966-(S)-(-),HA-966-(S)-(-),,BRD:BRD-BRD-K41304947-001-03-2;BRD:BRD-K41304947-001-03-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1,,,PRECLINICAL,,,NA,,N[C@H]1CCN(O)C1=O
HA14-1,HA14-1,,BRD:BRD-BRD-K18163608-001-05-6;BRD:BRD-K18163608-001-05-6,rep_multi_dose;rep_primary;rep_single_dose,BCL INHIBITOR,BCL2,,,PRECLINICAL,,,NA,,CCOC(=O)[C@@H](C#N)[C@@H]1C2CC(BR)CCC2OC(N)=C1C(=O)OCC
HALCINONIDE,HALCINONIDE,CHEMBL1200845,BRD:BRD-A88138582-001-04-8;BRD:BRD-BRD-A88138582-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Approved,MUQNGPZZQDCDFT-JNQJZLCISA-N,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCL)O1;CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCL;CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCL
HALOBETASOL-PROPIONATE,HALOBETASOL-PROPIONATE,,BRD:BRD-BRD-K65877271-001-01-8;BRD:BRD-K65877271-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;PLA2G1B,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCL
HALOFANTRINE,HALOFANTRINE,CHEMBL1107,BRD:BRD-A51964809-003-12-6;BRD:BRD-BRD-A51964809-003-12-6,rep_multi_dose;rep_primary;rep_single_dose,ANTIMALARIAL AGENT,KCNH2;KCNN4,MALARIA,,LAUNCHED,,Small molecule,Approved,FOHHNHSLJDZUGQ-UHFFFAOYSA-N,CCCCN(CCCC)CCC(O)C1CC2C(CL)CC(CL)CC2C2CC(C(F)(F)F)CCC12;CCCCN(CCCC)CCC(O)C1CC2C(CL)CC(CL)CC2C2CC(CCC12)C(F)(F)F
HALOFUGINONE,HALOFUGINONE,CHEMBL1197091,BRD:BRD-BRD-K54247840-004-01-3;BRD:BRD-K54247840-004-01-3,rep_multi_dose;rep_primary;rep_single_dose,COLLAGENASE INHIBITOR,COL1A1;MMP2,SCLERODERMA,,LAUNCHED,,Small molecule,Phase 2,LVASCWIMLIKXLA-UHFFFAOYSA-N,O[C@H]1CCCN[C@@H]1CC(=O)CN1CNC2CC(BR)C(CL)CC2C1=O;O=C(CC1NCCCC1O)CN1CNC2CC(BR)C(CL)CC2C1=O
HALOPEMIDE,HALOPEMIDE,CHEMBL245621,BRD:BRD-BRD-K50055394-001-03-6;BRD:BRD-K50055394-001-03-6,rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLD1;PLD2,,,PHASE 2,,Small molecule,Unknown,NBHPRWLFLUBAIE-UHFFFAOYSA-N,O=C(NCCN1CCC(N2C(=O)[NH]C3CC(CL)CCC32)CC1)C1CCC(F)CC1;OC1NC2CC(CL)CCC2N1C1CCN(CCNC(=O)C2CCC(F)CC2)CC1
HALOPERIDOL,HALOPERIDOL,CHEMBL54,BRD:BRD-BRD-K67783091-001-26-1;BRD:BRD-K67783091-001-26-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;DRD3;DRD4;DRD5;GRIN2B;HRH1;HTR1A;HTR1D;HTR2A;HTR2B;HTR7;KCNH1,"SCHIZOPHRENIA, TOURETTE'S DISORDER",,LAUNCHED,,Small molecule,Approved,LNEPOXFFQSENCJ-UHFFFAOYSA-N,O=C(CCCN1CCC(O)(C2CCC(CL)CC2)CC1)C1CCC(F)CC1;OC1(CCN(CCCC(=O)C2CCC(F)CC2)CC1)C1CCC(CL)CC1
HALOPERIDOL-DECANOATE,HALOPERIDOL-DECANOATE,,BRD:BRD-BRD-K80859331-001-01-5;BRD:BRD-K80859331-001-01-5,rep_primary;rep_single_dose,PSYCHOACTIVE DRUG,DRD2;DRD3;DRD4;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,,NA,,CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2CCC(F)CC2)CC1)C1CCC(CL)CC1
HALOPROGIN,HALOPROGIN,CHEMBL1289,BRD:BRD-BRD-K13238168-001-02-0;BRD:BRD-K13238168-001-02-0,rep_primary;rep_single_dose,OTHER ANTIFUNGAL,,TINEA PEDIS,,LAUNCHED,,Small molecule,Approved,CTETYYAZBPJBHE-UHFFFAOYSA-N,CLC1CC(CL)C(OCC#CI)CC1CL
HALOTHANE,HALOTHANE,CHEMBL931,BRD:BRD-A20550616-001-02-9;BRD:BRD-BRD-A20550616-001-02-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,ATP2C1;ATP5D;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;GLRB;GNG2;GRIN2A;GRIN3A;GRIN3B;KCNJ3;KCNJ6;KCNK10;KCNK12;KCNK13;KCNK15;KCNK18;KCNK2;KCNK3;KCNK9;KCNMA1;KCNN4;MT-ND1;NPSR1;RHO,GENERAL ANAESTHETIC,,LAUNCHED,,Small molecule,Approved,BCQZXOMGPXTTIC-UHFFFAOYSA-N,FC(F)(F)C(CL)BR
HARMANE,HARMANE,CHEMBL12014,BRD:BRD-BRD-K12630395-001-14-9;BRD:BRD-K12630395-001-14-9,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,,,PRECLINICAL,,Small molecule,NA,PSFDQSOCUJVVGF-UHFFFAOYSA-N,CC1NCCC2C1[NH]C1CCCCC12;CC1NCCC2C3CCCCC3[NH]C12
HARRINGTONINE,HARRINGTONINE,CHEMBL433257,BRD:BRD-BRD-K96358241-001-01-9;BRD:BRD-K96358241-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,,,PHASE 3,,Small molecule,NA,HAVJATCHLFRDHY-KSZYUSJVSA-N,COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCC2CC4C(CC2[C@H]13)OCO4;COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2C3CC4OCOC4CC3CCN3CCC[C@]23C=C1OC
HBED,HBED,,BRD:BRD-K00004555-001-01-9,rep_single_dose,CHELATING AGENT,,,,,,,NA,,
HBX-41108,HBX-41108,,CTRP:679843,ctrp,,,,,,,,NA,,
HC-030031,HC-030031,,BRD:BRD-BRD-K73815512-001-02-5;BRD:BRD-K73815512-001-02-5,rep_primary;rep_single_dose,TRPA1 CHANNEL BLOCKER,TRPA1,,,PHASE 1,,,NA,,CC(C)C1CCC(NC(=O)CN2CNC3N(C)C(=O)N(C)C(=O)C23)CC1
HC-067047,HC-067047,,BRD:BRD-K03391209-001-02-0;CTRP:660083,ctrp;rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPV4,,,,,,NA,,
HC-070,HC-070,,BRD:BRD-K00004601-001-01-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,,,,,,,NA,,
HDAC INHIBITOR XV,HDAC INHIBITOR XV,,GDSC1:271,gdsc,,,,,,,,NA,,
HDAC-42,HDAC-42,,GDSC1:272,gdsc,,,,,,,,NA,,
HECLIN,HECLIN,,BRD:BRD-K49788188-001-02-9,rep_single_dose,UBIQUITIN LIGASE INHIBITOR,NEDD4;SMURF2;WWP1,,,,,,NA,,
HEMADO,HEMADO,,BRD:BRD-BRD-K34672903-001-01-7;BRD:BRD-K34672903-001-01-7,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,CCCCC#CC1NC(NC)C2NCN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2N1
HEMATOXYLIN,HEMATOXYLIN,CHEMBL477197,BRD:BRD-BRD-K78342372-001-02-4;BRD:BRD-K78342372-001-02-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,WZUVPPKBWHMQCE-XJKSGUPXSA-N,OC1CC2C(CC1O)[C@@H]1C3CCC(O)C(O)C3OC[C@]1(O)C2;OC1CC2C[C@@]3(O)COC4C(CCC(O)C4O)[C@H]3C2CC1O
HEMIN,HEMIN,CHEMBL1200662;CHEMBL3707238,BRD:BRD-K74057164-001-01-6,rep_single_dose,ENZYME INDUCER,,,,,,Small molecule,Approved,,
HEMOGLOBIN-MODULATORS-1,HEMOGLOBIN-MODULATORS-1,,BRD:BRD-BRD-K43639297-001-01-9,rep_primary,HEMOGLOBIN MODULATOR,,,,PHASE 3,,,NA,,CC(C)N1NCCC1-C1NCCCC1COC1CCCC(O)C1C=O
HEMOMEX-S,HEMOMEX-S,,BRD:BRD-BRD-K15231341-001-01-5;BRD:BRD-K15231341-001-01-5,rep_primary;rep_single_dose,,PPARG,,,LAUNCHED,,,NA,,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C
HEPSULFAM,HEPSULFAM,,BRD:BRD-K00004739-001-01-9,rep_single_dose,DNA CROSS-LINKING,,,,,,,NA,,
HEPTAMINOL,HEPTAMINOL,CHEMBL2111076,BRD:BRD-A32988684-003-08-7;BRD:BRD-BRD-A32988684-003-08-7,rep_primary;rep_single_dose,VASOCONSTRICTOR,,HYPOTENSION,,LAUNCHED,,Small molecule,Unknown,LREQLEBVOXIEOM-UHFFFAOYSA-N,CC(N)CCCC(C)(C)O
HER2-INHIBITOR-1,HER2-INHIBITOR-1,,BRD:BRD-K89709433-001-03-9,rep_single_dose,EGFR INHIBITOR,,,,,,,NA,,
HESPERADIN,HESPERADIN,CHEMBL514409,BRD:BRD-BRD-K58122457-001-02-2;BRD:BRD-K58122457-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKB,,,PRECLINICAL,,Small molecule,NA,GLDSKRNGVVYJAB-DQSJHHFOSA-N,CCS(=O)(=O)NC1CCC2C(C1)/C(=C(/NC1CCC(CN3CCCCC3)CC1)C1CCCCC1)C(=O)N2;CCS(=O)(=O)NC1CCC2NC(=O)\C(C2C1)=C(/NC1CCC(CN2CCCCC2)CC1)C1CCCCC1
HESPERETIN,HESPERETIN,CHEMBL399121,BRD:BRD-BRD-K30553453-001-13-2;BRD:BRD-K30553453-001-13-2,rep_primary;rep_single_dose,ACAT INHIBITOR,DGAT1;MTTP;SOAT1;SOAT2,,,LAUNCHED,,Small molecule,NA,AIONOLUJZLIMTK-AWEZNQCLSA-N,COC1CCC([C@@H]2CC(=O)C3C(O)CC(O)CC3O2)CC1O;COC1CCC(CC1O)[C@@H]1CC(=O)C2C(O)CC(O)CC2O1
HESPERIDIN,HESPERIDIN,CHEMBL231884;CHEMBL449317,BRD:BRD-BRD-K38903228-001-13-5;BRD:BRD-K38903228-001-13-5,rep_primary;rep_single_dose,FLAVANONE GLYCOSIDE,AURKB;CACNA1B,,,LAUNCHED,"Multiple values for repurposing_target: {'CACNA1B', 'AURKB;CACNA1B'}, taking the union",Small molecule,Approved,GZSOSUNBTXMUFQ-YFAPSIMESA-N;QUQPHWDTPGMPEX-QJBIFVCTSA-N,COC1CCC(-C2CC(=O)C3C(O)CC(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)CC3O2)CC1O;COC1CCC([C@@H]2CC(=O)C3C(O)CC(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)CC3O2)CC1O;COC1CCC(CC1O)[C@@H]1CC(=O)C2C(O)CC(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)CC2O1
HEXACHLOROPHENE,HEXACHLOROPHENE,CHEMBL496,BRD:BRD-BRD-K99792991-001-34-9;BRD:BRD-K99792991-001-34-9,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,GLUD1;SDHD,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,ACGUYXCXAPNIKK-UHFFFAOYSA-N,OC1C(CL)CC(CL)C(CL)C1CC1C(O)C(CL)CC(CL)C1CL
HEXAMETHONIUM,HEXAMETHONIUM,CHEMBL100622;CHEMBL105608,BRD:BRD-BRD-K10598093-303-06-1;BRD:BRD-K10598093-303-06-1,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRNA2;CHRNA3;CHRNA4;CHRNA6,,,PRECLINICAL,,Small molecule,Unknown,PYIHTIJNCRKDBV-UHFFFAOYSA-L;VZJFGSRCJCXDSG-UHFFFAOYSA-N,C[N+](C)(C)CCCCCC[N+](C)(C)C;C[N+](C)(C)CCCCCC[N+](C)(C)C.[CL-].[CL-]
HEXAMETHYLENEBISACETAMIDE,HEXAMETHYLENEBISACETAMIDE,CHEMBL291481,BRD:BRD-BRD-K04710043-001-17-8;BRD:BRD-K04710043-001-17-8,rep_multi_dose;rep_primary;rep_single_dose,"AKT INHIBITOR, DIFFERENTIATION INDUCER, NFKB PATHWAY INHIBITOR",AKT1,,,PHASE 2,,Small molecule,NA,BNQSTAOJRULKNX-UHFFFAOYSA-N,CC(=O)NCCCCCCNC(C)=O
HEXAMINOLEVULINATE,HEXAMINOLEVULINATE,CHEMBL1201784,BRD:BRD-BRD-K73753850-003-01-6;BRD:BRD-K73753850-003-01-6,rep_multi_dose;rep_primary;rep_single_dose,,,DIAGNOSTIC AGENT,,LAUNCHED,,Small molecule,Approved,RYQOILLJDKPETL-UHFFFAOYSA-N,CCCCCCOC(=O)CCC(=O)CN
HEXESTROL,HEXESTROL,CHEMBL6615;CHEMBL9225,BRD:BRD-BRD-K69253806-001-02-0;BRD:BRD-K69253806-001-02-0,rep_primary;rep_single_dose,SYNTHETIC ESTROGEN,AKR1C1;ESR1;ESR2,,,LAUNCHED,,Small molecule,Unknown,PBBGSZCBWVPOOL-HDICACEKSA-N;PBBGSZCBWVPOOL-UHFFFAOYSA-N,CC[C@@H]([C@@H](CC)C1CCC(O)CC1)C1CCC(O)CC1;CC[C@H](C1CCC(O)CC1)[C@@H](CC)C1CCC(O)CC1;CCC(C(CC)C1CCC(O)CC1)C1CCC(O)CC1;CCC(C1CCC(O)CC1)C(CC)C1CCC(O)CC1
HEXOPRENALINE,HEXOPRENALINE,CHEMBL1589896,BRD:BRD-A33894669-065-01-9;BRD:BRD-BRD-A33894669-065-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,ASTHMA,,LAUNCHED,,Small molecule,Unknown,OXLZNBCNGJWPRV-UHFFFAOYSA-N,OC(CNCCCCCCNCC(O)C1CCC(O)C(O)C1)C1CCC(O)C(O)C1;OC1CCC(C(O)CNCCCCCCNCC(O)C2CCC(O)C(O)C2)CC1O
HEXYLCAINE,HEXYLCAINE,CHEMBL1197,BRD:BRD-A97730597-003-11-5;BRD:BRD-BRD-A97730597-003-11-5,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN5A,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,DKLKMKYDWHYZTD-UHFFFAOYSA-N,CC(CNC1CCCCC1)OC(=O)C1CCCCC1
HEXYLRESORCINOL,HEXYLRESORCINOL,CHEMBL443605,BRD:BRD-BRD-K99946902-001-07-5;BRD:BRD-K99946902-001-07-5,rep_multi_dose;rep_primary;rep_single_dose,LOCAL ANESTHETIC,TYR,"SKIN INFECTIONS, FIRST-AID ANTISEPTIC",,LAUNCHED,,Small molecule,Approved,WFJIVOKAWHGMBH-UHFFFAOYSA-N,CCCCCCC1CCC(O)CC1O
HG-5-113-01,HG-5-113-01,,GDSC1:1142,gdsc,,,,,,,,NA,,
HG-5-88-01,HG-5-88-01,,GDSC1:1143,gdsc,,,,,,,,NA,,
HG6-64-1,HG6-64-1,,GDSC1:159,gdsc,,,,,,,,NA,,
HIGENAMINE,HIGENAMINE,CHEMBL19344,BRD:BRD-A55204514-003-01-2;BRD:BRD-BRD-A55204514-003-01-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,,,PHASE 1,,Small molecule,Phase 1,WZRCQWQRFZITDX-UHFFFAOYSA-N,OC1CCC(CC2NCCC3CC(O)C(O)CC23)CC1;OC1CCC(CC2NCCC3CC(O)C(O)CC32)CC1
HIPPURIC-ACID,HIPPURIC-ACID,,BRD:BRD-BRD-K62914667-001-13-9;BRD:BRD-K62914667-001-13-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)CNC(=O)C1CCCCC1
HISTAMINE,HISTAMINE,CHEMBL90,BRD:BRD-BRD-K01674964-300-06-3;BRD:BRD-K01674964-300-06-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH1;HRH2;HRH3;HRH4,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,NTYJJOPFIAHURM-UHFFFAOYSA-N,NCCC1C[NH]CN1
HJC-0350,HJC-0350,,BRD:BRD-BRD-K34411045-001-01-9;BRD:BRD-K34411045-001-01-9,rep_primary;rep_single_dose,GTPASE INHIBITOR,RAPGEF4,,,PRECLINICAL,,,NA,,CC1CC(C)N(C1)S(=O)(=O)C1C(C)CC(C)CC1C
HKI-357,HKI-357,CHEMBL178654,BRD:BRD-BRD-K58811567-001-01-9;BRD:BRD-K58811567-001-01-9,rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PHASE 1,,Small molecule,Phase 1,NERXPXBELDBEPZ-RMKNXTFCSA-N,CCOC1CC2NCC(C#N)C(NC3CCC(OCC4CCCC(F)C4)C(CL)C3)C2CC1NC(=O)/C=C/CN(C)C;CCOC1CC2NCC(C#N)C(NC3CCC(OCC4CCCC(F)C4)C(CL)C3)C2CC1NC(=O)\C=C\CN(C)C
HLCL-61,HLCL-61,,BRD:BRD-BRD-K73746696-003-01-8;BRD:BRD-K73746696-003-01-8,rep_primary;rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT5,,,PRECLINICAL,,,NA,,CCN1C2CCCCC2C2CC(CNCC3CCCCC3OC)CCC12
HLI 373,HLI 373,,CTRP:481311,ctrp,,,,,,,,NA,,
HM-30181,HM-30181,CHEMBL4594298,BRD:BRD-K74319597-001-02-9,rep_single_dose,P GLYCOPROTEIN INHIBITOR,,,,,,Small molecule,Phase 3,AHJUHHDDCJQACA-UHFFFAOYSA-N,COC1CC2C(CC1OC)CN(CCC1CCC(-N3NNC(-C4CC(OC)C(OC)CC4NC(=O)C4CC(=O)C5CCCCC5O4)N3)CC1)CC2
POZIOTINIB,HM781-36B;NOV120101;POZIOTINIB,CHEMBL3545154,BRD:BRD-BRD-K50010139-001-02-3;BRD:BRD-K50010139-001-01-5;BRD:BRD-K50010139-001-02-3;BRD:BRD-K50010139-001-11-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,PAN-HER RECEPTOR TYROSINE KINASE INHIBITOR,EGFR;ERBB2;ERBB4,,,PHASE 2,"Multiple values for MOA: {'PAN-HER RECEPTOR TYROSINE KINASE INHIBITOR', 'EGFR INHIBITOR'}, defaulting to 'PAN-HER RECEPTOR TYROSINE KINASE INHIBITOR'",Small molecule,Phase 3,LPFWVDIFUFFKJU-UHFFFAOYSA-N,C=CC(=O)N1CCC(OC2CC3C(NC4CCC(CL)C(CL)C4F)NCNC3CC2OC)CC1;COC1CC2NCNC(NC3CCC(CL)C(CL)C3F)C2CC1OC1CCN(CC1)C(=O)C=C
HMN-214,HMN-214,CHEMBL3545431,BRD:BRD-BRD-K70511574-001-06-9;BRD:BRD-K70511574-001-06-9,rep_multi_dose;rep_primary;rep_single_dose,PLK INHIBITOR,PLK1,,,PHASE 1,,Small molecule,Phase 1,,COC1CCC(CC1)S(=O)(=O)N(C(C)=O)C1CCCCC1\C=C\C1CC[N+]([O-])CC1
HOKU-81,HOKU-81,,BRD:BRD-K00003598-001-01-9,rep_single_dose,BRONCHODILATOR,,,,,,,NA,,
HOMATROPINE,HOMATROPINE,CHEMBL1618018,BRD:BRD-A74975734-004-09-9;BRD:BRD-A74975734-004-10-7;BRD:BRD-BRD-A74975734-004-09-9;BRD:BRD-BRD-A74975734-004-10-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CES1;CHRM1,PUPIL DILATION,,LAUNCHED,,Small molecule,Approved,ZTVIKZXZYLEVOL-MCOXGKPRSA-N,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(O)C1CCCCC1)C2;CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)C1CCCCC1
HOMATROPINE-METHYLBROMIDE,HOMATROPINE-METHYLBROMIDE,,BRD:BRD-A43999749-004-04-1;BRD:BRD-BRD-A43999749-004-04-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,UVEAL TRACT INFLAMMATION,,LAUNCHED,,,NA,,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)C1CCCCC1
HOMOCHLORCYCLIZINE,HOMOCHLORCYCLIZINE,CHEMBL1515447,BRD:BRD-A22769835-300-05-7;BRD:BRD-BRD-A22769835-300-05-7,rep_primary;rep_single_dose,ANTIHISTAMINE,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Unknown,WEUCDJCFJHYFRL-UHFFFAOYSA-N,CN1CCCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;CN1CCCN(CC1)C(C1CCCCC1)C1CCC(CL)CC1
HOMOHARRINGTONINE,HOMOHARRINGTONINE,CHEMBL46286,BRD:BRD-BRD-K76674262-001-03-3;BRD:BRD-K76674262-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,RPL3,CHRONIC MYELOID LEUKEMIA (CML),,LAUNCHED,,Small molecule,Approved,HYFHYPWGAURHIV-JFIAXGOJSA-N,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCC2CC4C(CC2[C@H]13)OCO4;COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2C3CC4OCOC4CC3CCN3CCC[C@]23C=C1OC
HOMOQUINOLINIC-ACID,HOMOQUINOLINIC-ACID,,BRD:BRD-BRD-K30519779-001-03-1;BRD:BRD-K30519779-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PRECLINICAL,,,NA,,OC(=O)CC1CCCNC1C(O)=O
HOMOSALATE,HOMOSALATE,CHEMBL1377575,BRD:BRD-A34751532-001-06-9;BRD:BRD-BRD-A34751532-001-06-9,rep_multi_dose;rep_primary;rep_single_dose,HSP INDUCER,,,,PRECLINICAL,,Small molecule,Unknown,WSSJONWNBBTCMG-UHFFFAOYSA-N,CC1CC(CC(C)(C)C1)OC(=O)C1CCCCC1O;CC1CC(OC(=O)C2CCCCC2O)CC(C)(C)C1
HONOKIOL,HONOKIOL,CHEMBL16901,BRD:BRD-BRD-K98493452-001-14-9;BRD:BRD-K98493452-001-14-9,rep_primary;rep_single_dose,AKT INHIBITOR,ALOX5;PTGS1;PTGS2,,,PHASE 3,,Small molecule,NA,FVYXIJYOAGAUQK-UHFFFAOYSA-N,C=CCC1CCC(O)C(-C2CCC(O)C(CC=C)C2)C1;OC1CCC(CC1CC=C)-C1CC(CC=C)CCC1O
HORDENINE,HORDENINE,CHEMBL505789,BRD:BRD-BRD-K93631643-001-02-4;BRD:BRD-K93631643-001-02-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,KUBCEEMXQZUPDQ-UHFFFAOYSA-N,CN(C)CCC1CCC(O)CC1
HP-228,HP-228,,BRD:BRD-K00004723-001-01-9,rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,,,,,,,NA,,
HPGDS-IN-1,HPGDS-IN-1,,BRD:BRD-K00003140-001-01-9,rep_single_dose,PROSTAGLANDIN INHIBITOR,,,,,,,NA,,
HPPH,HPPH,CHEMBL500853,BRD:BRD-K00003730-001-01-9,rep_single_dose,PHOTOSENSITIZING AGENT,,,,,,Small molecule,Phase 2,PVXGCBZIVFCMJK-NMWXTPPCSA-N,CCCCCCOC(C)C1C(C)C2CC3NC(C4C5[NH]C(CC6NC(CC1[NH]2)C(C)=C6CC)C(C)C5C(=O)C4)[C@@H](CCC(=O)O)[C@@H]3C
HQK-1001,HQK-1001,CHEMBL1650317,BRD:BRD-BRD-K44963273-001-06-9;BRD:BRD-K44963273-001-06-9,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Phase 2,OOPXYEYPPHJHSE-UHFFFAOYSA-M,CCC(C)(C)C(=O)[O-].[NA+];CCC(C)(C)C(O)=O
HS-276,HS-276,,BRD:BRD-K00126475-001-01-9,oncref_2,INHIBITOR OF TAK1,CAMKK-1;CLK2;CSNK1G2;GCK;IRAK1;MAP4K5;NUAK;TAK1;ULK2,,,,,,NA,,
HSR6071,HSR6071,,BRD:BRD-K00004745-001-01-9,rep_single_dose,ANTIALLERGIC AGENT,,,,,,,NA,,
HT-2157,HT-2157,CHEMBL4297765,BRD:BRD-K00003386-001-01-9,rep_single_dose,GALANIN RECEPTOR 3 ANTAGONIST,,,,,,Unknown,Phase 1,,
HTH-01-015,HTH-01-015,,BRD:BRD-K58726989-001-02-7,rep_single_dose,PROTEIN KINASE INHIBITOR,NUAK1,,,,,,NA,,
HTHQ,HTHQ,,BRD:BRD-K00003389-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
HTMT,HTMT,,BRD:BRD-A66435872-332-01-8;BRD:BRD-BRD-A66435872-332-01-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH4,,,PRECLINICAL,,,NA,,CC(CCCCC(=O)NC1CCC(CC1)C(F)(F)F)NCCC1C[NH]CN1
HUPERZINE-A,HUPERZINE-A,,BRD:BRD-BRD-K62240499-001-05-9;BRD:BRD-K62240499-001-05-9,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,PHASE 2,,,NA,,C\C=C1/[C@@H]2CC3[NH]C(=O)CCC3[C@@]1(N)CC(C)=C2
HWA-486,HWA-486,CHEMBL960,GDSC2:1578,gdsc,,,,,,,Small molecule,Approved,VHOGYURTWQBHIL-UHFFFAOYSA-N,CC1ONCC1C(=O)NC1CCC(C(F)(F)F)CC1
HYCANTHONE,HYCANTHONE,CHEMBL22077,BRD:BRD-BRD-K50406511-001-26-0;BRD:BRD-K50406511-001-26-0,rep_primary;rep_single_dose,RNA SYNTHESIS INHIBITOR,,SCHISTOSOMIASIS,,LAUNCHED,,Small molecule,Unknown,MFZWMTSUNYWVBU-UHFFFAOYSA-N,CCN(CC)CCNC1CCC(CO)C2SC3CCCCC3C(=O)C12
HYDRALAZINE,HYDRALAZINE,CHEMBL276832,BRD:BRD-BRD-K82103381-003-09-4;BRD:BRD-K82103381-003-09-4,rep_primary;rep_single_dose,VASODILATOR,AOC3;P4HA1,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,RPTUSVTUFVMDQK-UHFFFAOYSA-N,NNC1NNCC2CCCCC12
"HYDRASTINE-(1R,9S)","HYDRASTINE-(1R,-9S);HYDRASTINE-(1R,9S)",,BRD:BRD-BRD-K02715688-001-02-1;BRD:BRD-K02715688-001-02-1,rep_primary;rep_single_dose,TYROSINE HYDROXYLASE INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CCC2[C@H](OC(=O)C2C1OC)[C@@H]1N(C)CCC2CC3OCOC3CC12
HYDRASTININE,HYDRASTININE,CHEMBL1314044;CHEMBL1623232,BRD:BRD-A57900429-003-05-8;BRD:BRD-BRD-A57900429-003-05-8,rep_primary;rep_single_dose,HAEMOSTATIC AGENT,,,,PRECLINICAL,,Small molecule,Unknown,LGDCROILDUSHQX-UHFFFAOYSA-N;YOJQZPVUNUQTDF-UHFFFAOYSA-N,C[N+]1=CC2CC3C(CC2CC1)OCO3;CN1CCC2CC3C(CC2C1O)OCO3;CN1CCC2CC3OCOC3CC2C1O
HYDROCHLOROTHIAZIDE,HYDROCHLOROTHIAZIDE,CHEMBL435,BRD:BRD-BRD-K13078532-001-28-4;BRD:BRD-K13078532-001-28-4,rep_primary;rep_single_dose,THIAZIDE DIURETIC,CA1;CA12;CA2;CA4;CA9;KCNMA1;SLC12A3,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,JZUFKLXOESDKRF-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1CL)NCNS2(=O)=O;NS(=O)(=O)C1CC2C(NCNS2(=O)=O)CC1CL
HYDROCORTISONE,HYDROCORTISONE,CHEMBL389621,BRD:BRD-BRD-K93568044-001-32-0;BRD:BRD-K93568044-001-32-0,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,ANXA1;NOS2;NR3C1;NR3C2,"ECZEMA, PSORIASIS, SEBORRHEIC DERMATITIS, ITCHING",,LAUNCHED,,Small molecule,Approved,JYGXADMDTFJGBT-VWUMJDOOSA-N,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO;C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
HYDROCORTISONE-ACETATE,HYDROCORTISONE-ACETATE,,BRD:BRD-A65767837-001-04-4;BRD:BRD-BRD-A65767837-001-04-4,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;NR3C2,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C
HYDROCORTISONE-BUTYRATE,HYDROCORTISONE-BUTYRATE,,BRD:BRD-BRD-K99199077-001-16-1;BRD:BRD-K99199077-001-16-1,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"CORTICOSTEROID-RESPONSIVE DERMATOSES, ECZEMA",,LAUNCHED,,,NA,,CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO
HYDROCORTISONE-HEMISUCCINATE,HYDROCORTISONE-HEMISUCCINATE,,BRD:BRD-A07000685-001-04-4;BRD:BRD-BRD-A07000685-001-04-4,rep_primary;rep_single_dose,,,,,PHASE 2/PHASE 3,,,NA,,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O
HYDROCORTISONE-PHOSPHATE,HYDROCORTISONE-PHOSPHATE,,BRD:BRD-A46186775-369-02-0;BRD:BRD-BRD-A46186775-369-02-0,rep_primary;rep_single_dose,,ANXA1;NOS2;NR3C1,"ASTHMA, NAUSEA, VOMITING, MULTIPLE MYELOMA, CONTACT DERMATITIS, ENTERITIS, COLITIS",,LAUNCHED,,,NA,,CC12C[C@H](O)C3C(CCC4=CC(=O)CCC34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O
HYDROCORTISONE-VALERATE,HYDROCORTISONE-VALERATE,,BRD:BRD-A25143711-001-02-2;BRD:BRD-BRD-A25143711-001-02-2,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO
HYDROFLUMETHIAZIDE,HYDROFLUMETHIAZIDE,CHEMBL1763,BRD:BRD-BRD-K36862742-001-25-6;BRD:BRD-K36862742-001-25-6,rep_primary;rep_single_dose,SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR,ATP1A1;CA1;CA12;CA2;CA4;CA9;KCNMA1;SLC12A1;SLC12A3,"EDEMA, CONGESTIVE HEART FAILURE, HEPATIC CIRRHOSIS, NEPHROTIC SYNDROME, CHRONIC RENAL FAILURE, ACUTE GLOMERULONEPHRITIS (AGN), HYPERTENSION",,LAUNCHED,,Small molecule,Approved,DMDGGSIALPNSEE-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1C(F)(F)F)NCNS2(=O)=O;NS(=O)(=O)C1CC2C(NCNS2(=O)=O)CC1C(F)(F)F
HYDROQUINIDINE,HYDROQUINIDINE,CHEMBL1906890,BRD:BRD-A06390036-001-04-6;BRD:BRD-BRD-A06390036-001-04-6,rep_primary;rep_single_dose,ANTIARRHYTHMIC,,CARDIAC ARRYTHMIA,,LAUNCHED,,Small molecule,Phase 3,LJOQGZACKSYWCH-NBGVHYBESA-N,CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)C1CCNC2CCC(OC)CC12
HYDROXOCOBALAMIN,HYDROXOCOBALAMIN,CHEMBL2103737,BRD:BRD-K00003525-003-01-9,rep_single_dose,VITAMIN B,,,,,,Small molecule,Approved,,
HYDROXYAMPHETAMINE,HYDROXYAMPHETAMINE,CHEMBL1546,BRD:BRD-A80871782-004-06-9;BRD:BRD-BRD-A80871782-004-06-9,rep_primary;rep_single_dose,TRACE AMINE ASSOCIATED RECEPTOR AGONIST,TAAR1,MYDRIASIS,,LAUNCHED,,Small molecule,Approved,GIKNHHRFLCDOEU-UHFFFAOYSA-N,CC(N)CC1CCC(O)CC1
HYDROXYCHLOROQUINE,HYDROXYCHLOROQUINE,CHEMBL1535,BRD:BRD-A99117172-065-04-0;BRD:BRD-BRD-A99117172-065-04-0,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,TLR7;TLR9,MALARIA,,LAUNCHED,,Small molecule,Approved,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,CCN(CCO)CCCC(C)NC1CCNC2CC(CL)CCC12
HYDROXYFASUDIL,HYDROXYFASUDIL,CHEMBL1233300,BRD:BRD-BRD-K77793136-003-03-0;BRD:BRD-K77793136-003-03-0,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,PKIA;PRKACA;ROCK1,,,PRECLINICAL,,Small molecule,NA,ZAVGJDAFCZAWSZ-UHFFFAOYSA-N,O=S(=O)(C1CCCC2C(O)NCCC12)N1CCCNCC1;OC1NCCC2C(CCCC12)S(=O)(=O)N1CCCNCC1
HYDROXYPROGESTERONE,HYDROXYPROGESTERONE,CHEMBL1062;CHEMBL1200848,BRD:BRD-A39791822-001-05-1;BRD:BRD-BRD-A39791822-001-05-1,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,SPONTANEOUS PRETERM BIRTH,,LAUNCHED,,Small molecule,Approved,DBPWSSGDRRHUNT-CEGNMAFCSA-N;DOMWKUIIPQCAJU-LJHIYBGHSA-N,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C;CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C;CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
HYDROXYPROGESTERONE-ACETATE,HYDROXYPROGESTERONE-ACETATE,,BRD:BRD-BRD-K92902018-001-01-9;BRD:BRD-K92902018-001-01-9,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,,,LAUNCHED,,,NA,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O
HYDROXYPROPYL-BETA-CYCLODEXTRIN,HYDROXYPROPYL-BETA-CYCLODEXTRIN,CHEMBL577294,BRD:BRD-A01412266-001-01-0;BRD:BRD-BRD-A01412266-001-01-0,rep_primary;rep_single_dose,,,,,PHASE 2,,Oligosaccharide,Phase 3,ODLHGICHYURWBS-LKONHMLTSA-N,CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(C)O)O[C@H](O[C@@H]4[C@@H](COCC(C)O)O[C@H](O[C@@H]5[C@@H](COCC(C)O)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](COCC(C)O)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O;CC(O)COC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]8COCC(C)O)O[C@@H]7COCC(C)O)O[C@@H]6COCC(C)O)O[C@@H]5COCC(C)O)O[C@@H]4COCC(C)O)O[C@@H]3COCC(C)O
HYDROXYSAFFLOR-YELLOW-A,HYDROXYSAFFLOR-YELLOW-A,,BRD:BRD-K00003327-001-01-9,rep_single_dose,ANTITUMOR AGENT,,,,,,,NA,,
HYDROXYSTILBAMIDINE,HYDROXYSTILBAMIDINE,CHEMBL1301,BRD:BRD-BRD-K62186992-334-02-8;BRD:BRD-K62186992-334-02-8,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,TUESWZZJYCLFNL-DAFODLJHSA-N,N=C(N)C1CCC(/C=C/C2CCC(C(=N)N)CC2O)CC1;NC(=N)C1CCC(CC1)\C=C\C1CCC(CC1O)C(N)=N
"HYDROXYTACRINE-MALEATE-(R,S)","HYDROXYTACRINE-MALEATE-(R,S)",,BRD:BRD-A98299281-050-09-6;BRD:BRD-BRD-A98299281-050-09-6,rep_multi_dose;rep_primary;rep_single_dose,CHOLINESTERASE INHIBITOR,ACHE,,,PRECLINICAL,,,NA,,NC1C2C(O)CCCC2NC2CCCCC12
HYDROXYTOLUIC-ACID,HYDROXYTOLUIC-ACID,,BRD:BRD-BRD-K75608666-001-08-3;BRD:BRD-K75608666-001-08-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC1CCCC(C(O)=O)C1O
HYDROXYUREA,HYDROXYUREA,CHEMBL467,BRD:BRD-BRD-K51747290-001-12-3;BRD:BRD-BRD-K51747290-001-13-1;BRD:BRD-K51747290-001-12-3;BRD:BRD-K51747290-001-13-1,rep_multi_dose;rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,RRM1;RRM2;RRM2B,"CHRONIC MYELOID LEUKEMIA (CML), HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)",,LAUNCHED,,Small molecule,Approved,VSNHCAURESNICA-UHFFFAOYSA-N,NC(=O)NO
HYDROXYZINE,HYDROXYZINE,CHEMBL1201007;CHEMBL3186993;CHEMBL896,BRD:BRD-A62428732-300-06-3;BRD:BRD-BRD-A62428732-300-06-3,rep_primary;rep_single_dose,ANTIHISTAMINE,HRH1,"ANXIETY, URTICARIA, ITCHING, DERMATOSIS, ANXIETY, URTICARIA, ITCHING, DERMATOSIS",,LAUNCHED,,Small molecule,Approved,ANOMHKZSQFYSBR-UHFFFAOYSA-N;IPSVAUIEEPSJRZ-UHFFFAOYSA-N;ZQDWXGKKHFNSQK-UHFFFAOYSA-N,CL.CL.OCCOCCN1CCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;CL.OCCOCCN1CCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;OCCOCCN1CCN(C(C2CCCCC2)C2CCC(CL)CC2)CC1;OCCOCCN1CCN(CC1)C(C1CCCCC1)C1CCC(CL)CC1
HYGROMYCIN-B,HYGROMYCIN-B,,BRD:BRD-A67101513-001-03-7;BRD:BRD-BRD-A67101513-001-03-7,rep_primary;rep_single_dose,POLYPEPTIDE SYNTHESIS INHIBITOR,,,,PRECLINICAL,,,NA,,CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]3OC4(O[C@@H]3[C@@H]2O)O[C@H](C(N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O
HYMECROMONE,HYMECROMONE,CHEMBL12208,BRD:BRD-BRD-K46424862-001-14-1;BRD:BRD-K46424862-001-14-1,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,,,PHASE 2,,Small molecule,Phase 2,HSHNITRMYYLLCV-UHFFFAOYSA-N,CC1CC(=O)OC2CC(O)CCC12
HYODEOXYCHOLIC-ACID,HYODEOXYCHOLIC-ACID,,BRD:BRD-BRD-K44009692-001-02-3;BRD:BRD-K44009692-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,ATHEROSCLEROSIS FORMATION INHIBITOR,,,,PHASE 1,,,NA,,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
HYOSCYAMINE,HYOSCYAMINE,CHEMBL1331216;CHEMBL2165224,BRD:BRD-BRD-K40530731-001-11-6;BRD:BRD-K40530731-001-11-6,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,"PEPTIC ULCER DISEASE (PUD), ACUTE ABDOMINAL VISCERAL SPASM, ULCERATIVE COLITIS, INTERSTITIAL CYSTITIS (IC), ENTEROCOLITIS, IRRITABLE BOWEL SYNDROME, TREMORS, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Approved,RKUNBYITZUJHSG-FXUDXRNXSA-N;WTQYWNWRJNXDEG-RBZJEDDUSA-N,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)[C@H](CO)C1CCCCC1)C2;CN1[C@H]2C[C@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@@H]1[C@@H](O)C2;CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1CCCCC1
HYPERFORIN,HYPERFORIN,CHEMBL501711,CTRP:660327,ctrp,,,,,,,Small molecule,NA,KGSZHKRKHXOAMG-HQKKAZOISA-N,CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@@]2(CC=C(C)C)C(=O)[C@]1(C(=O)C(C)C)C(=O)C(CC=C(C)C)=C2O
HYPERICIN,HYPERICIN,CHEMBL286494,BRD:BRD-BRD-K29673530-001-05-4;BRD:BRD-K29673530-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,,,,PHASE 2,,Antibody,Phase 3,BTXNYTINYBABQR-UHFFFAOYSA-N,CC1CC(O)C2C(=O)C3C(O)CC(O)C4C5C(O)CC(O)C6C(=O)C7C(O)CC(C)C8C1C2C(C34)C(C78)C65;CC1CC(O)C2C3C1C1C(C)CC(O)C4C1C1C3C3C(C(O)CC(O)C3C2=O)C2C(O)CC(O)C(C12)C4=O
HYPERIN,HYPERIN,,BRD:BRD-A63780829-001-11-4;BRD:BRD-BRD-A63780829-001-11-4,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,ACE;AKR1B1,,,PRECLINICAL,,,NA,,OCC1OC(OC2C(OC3CC(O)CC(O)C3C2=O)-C2CCC(O)C(O)C2)C(O)C(O)C1O
HYPOESTOXIDE,HYPOESTOXIDE,,BRD:BRD-A51571244-001-01-9;BRD:BRD-BRD-A51571244-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,IKK INHIBITOR,IKBKB;IL1B;TNF,,,PHASE 1,,,NA,,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C
HYPOXANTHINE,HYPOXANTHINE,CHEMBL1427,BRD:BRD-BRD-K03739921-001-06-8;BRD:BRD-K03739921-001-06-8,rep_primary;rep_single_dose,PARP INHIBITOR,PNP,,,PRECLINICAL,,Small molecule,NA,FDGQSTZJBFJUBT-UHFFFAOYSA-N,O=C1[NH]CNC2NC[NH]C12
I-BET-762,I-BET-762,,BRD:BRD-BRD-K08109215-001-06-4;BRD:BRD-K08109215-001-06-4;GDSC1:275;GDSC2:1624,gdsc;rep_multi_dose;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD2;BRD3;BRD4,,,PHASE 2,,,NA,,CCNC(=O)C[C@@H]1N=C(C2CCC(CL)CC2)C2CC(OC)CCC2-N2C(C)NNC12
I-BET151,I-BET151,,BRD:BRD-BRD-K36363294-001-04-2;BRD:BRD-K36363294-001-04-2;CTRP:660206,ctrp;rep_multi_dose;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD2;BRD3;BRD4,,,PRECLINICAL,,,NA,,COC1CC2C3N([C@H](C)C4CCCCN4)C(=O)[NH]C3CNC2CC1-C1C(C)NOC1C
I-BRD9,I-BRD9,,BRD:BRD-BRD-K04972057-001-01-1;BRD:BRD-K04972057-001-01-1;GDSC2:1928,gdsc;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD9,,,PRECLINICAL,,,NA,,CCN1CC(-C2CCCC(C2)C(F)(F)F)C2SC(CC2C1=O)C(=N)NC1CCS(=O)(=O)CC1
I-BZA,I-BZA,,BRD:BRD-BRD-K14762862-001-01-9;BRD:BRD-K14762862-001-01-9,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CCN(CC)CCNC(=O)C1CCC(I)CC1
I-BZA2,I-BZA2,,BRD:BRD-BRD-K71698503-003-01-6;BRD:BRD-K71698503-003-01-6,rep_primary;rep_single_dose,,,,,PHASE 3,,,NA,,CCN(CC)CCNC(=O)C1CCCCC1I
I-CBP-112,I-CBP-112,,BRD:BRD-K57090026-001-04-9,rep_single_dose,BROMODOMAIN INHIBITOR,CREBBP;EP300,,,,,,NA,,
IACS-10759,IACS-10759,CHEMBL4650499,BRD:BRD-K00003105-003-01-9,rep_single_dose,MITOCHONDRIAL COMPLEX I INHIBITOR,,,,,,Unknown,Phase 1,,
IB-MECA,IB-MECA,CHEMBL119709;CHEMBL3989873,BRD:BRD-BRD-K31135544-001-07-0;BRD:BRD-K31135544-001-07-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 3,,Small molecule,Phase 3,HUJXGQILHAUCCV-MOROJQBDSA-N;JTZRECOPNKCRTE-MOROJQBDSA-N,CNC(=O)[C@H]1O[C@@H](N2CNC3C(NCC4CCC(I)CC4)NCNC32)[C@H](O)[C@@H]1O;CNC(=O)[C@H]1O[C@@H](N2CNC3C(NCC4CCCC(I)C4)NCNC32)[C@H](O)[C@@H]1O;CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(NCC3CCCC(I)C3)NCNC12
IBANDRONATE,IBANDRONATE,CHEMBL997,BRD:BRD-BRD-K08681769-323-03-7;BRD:BRD-K08681769-323-03-7,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,FDPS,OSTEOPOROSIS,,LAUNCHED,,Small molecule,Approved,MPBVHIBUJCELCL-UHFFFAOYSA-N,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O;CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
IBC-293,IBC-293,,BRD:BRD-BRD-K15196155-001-02-3;BRD:BRD-K15196155-001-02-3,rep_primary;rep_single_dose,HYDROXYCARBOXYLIC ACID RECEPTOR AGONIST,HCAR3,,,PRECLINICAL,,,NA,,CC(C)N1NNC2CC(CCC12)C(O)=O
IBERDOMIDE,IBERDOMIDE,CHEMBL3989927,BRD:BRD-K00003408-001-01-9,rep_single_dose,CEREBLON MODULATOR,,,,,,Small molecule,Phase 3,IXZOHGPZAQLIBH-NRFANRHFSA-N,O=C1CC[C@H](N2CC3C(OCC4CCC(CN5CCOCC5)CC4)CCCC3C2=O)C(=O)N1
IBIGLUSTAT,IBIGLUSTAT,CHEMBL4297611,BRD:BRD-K14063023-001-02-9,rep_single_dose,GLUCOSYLCERAMIDASE INHIBITOR,,,,,,Small molecule,Phase 3,YFHRCLAKZBDRHN-MRXNPFEDSA-N,CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)C1CSC(-C2CCC(F)CC2)N1
IBMX,IBMX,,BRD:BRD-BRD-K94979336-001-20-0;BRD:BRD-K94979336-001-20-0,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,ADORA1;PDE2A;PDE3B;PDE4D;PDE5A;PDE6G;PDE7A;PDE8A;PDE9A,,,PRECLINICAL,,,NA,,CC(C)CN1C2[NH]CNC2C(=O)N(C)C1=O
IBOTENIC-ACID,IBOTENIC-ACID,,BRD:BRD-A02971356-001-09-9,rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIN1,,,,,,NA,,
IBROLIPIM,IBROLIPIM,CHEMBL34234,BRD:BRD-BRD-K62490786-001-01-1;BRD:BRD-K62490786-001-01-1,rep_primary;rep_single_dose,LIPOPROTEIN LIPASE ACTIVATOR,LPL,,,PHASE 2,,Small molecule,Unknown,KPRTURMJVWXURQ-UHFFFAOYSA-N,CCOP(=O)(CC1CCC(C(=O)NC2CCC(BR)CC2C#N)CC1)OCC;CCOP(=O)(CC1CCC(CC1)C(=O)NC1CCC(BR)CC1C#N)OCC
IBRUTINIB,IBRUTINIB,CHEMBL1873475,BRD:BRD-BRD-K70301465-001-02-6;BRD:BRD-K70301465-001-02-6;BRD:BRD-K70301465-001-05-9;CTRP:660994;GDSC2:1799,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BLK;BMX;BTK,"CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), MANTLE CELL LYMPHOMA (MCL), WALDENSTROM'S MACROGLOBULINEMIA (WM)",,LAUNCHED,,Small molecule,Approved,XYFPWWZEPKGCCK-GOSISDBHSA-N,C=CC(=O)N1CCC[C@@H](N2NC(-C3CCC(OC4CCCCC4)CC3)C3C(N)NCNC32)C1;NC1NCNC2N(NC(-C3CCC(OC4CCCCC4)CC3)C12)[C@@H]1CCCN(C1)C(=O)C=C
IBUDILAST,IBUDILAST,CHEMBL19449,BRD:BRD-BRD-K16444452-001-09-1;BRD:BRD-K16444452-001-09-1,rep_primary;rep_single_dose,"LEUKOTRIENE RECEPTOR ANTAGONIST, PHOSPHODIESTERASE INHIBITOR",IL1B;IL6;PDE3A;PDE4A;PDE4B;PDE4C;PDE4D;PDE5A,"ASTHMA, STROKE",,LAUNCHED,,Small molecule,Phase 3,ZJVFLBOZORBYFE-UHFFFAOYSA-N,CC(C)C(=O)C1C(C(C)C)NN2CCCCC12;CC(C)C(=O)C1C(NN2CCCCC12)C(C)C
IBUPROFEN,IBUPROFEN,CHEMBL427526;CHEMBL521,BRD:BRD-A17655518-001-24-4;BRD:BRD-BRD-A17655518-001-24-4,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"HEADACHE, MUSCLE PAIN, RHEUMATOID ARTHRITIS, BACKACHE, COMMON COLD, MENSTRUAL PAIN, FEVER, TOOTHACHE",,LAUNCHED,,Small molecule,Approved,HEFNNWSXXWATRW-SNVBAGLBSA-N;HEFNNWSXXWATRW-UHFFFAOYSA-N,CC(C)CC1CCC([C@@H](C)C(=O)O)CC1;CC(C)CC1CCC(C(C)C(=O)O)CC1;CC(C)CC1CCC(CC1)C(C)C(O)=O
IBUPROFEN-(S),IBUPROFEN-(S),,BRD:BRD-BRD-K14965640-001-12-4;BRD:BRD-K14965640-001-12-4,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,ASIC1;BCL2;CFTR;FABP2;PLAT;PPARG;PTGS1;PTGS2;SLC5A8;THBD,,,PRECLINICAL,,,NA,,CC(C)CC1CCC(CC1)[C@H](C)C(O)=O
IBUPROFEN-PICONOL,IBUPROFEN-PICONOL,,BRD:BRD-A75224450-001-02-4;BRD:BRD-BRD-A75224450-001-02-4,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,,NA,,CC(C)CC1CCC(CC1)C(C)C(=O)OCC1CCCCN1
IBUPROXAM,IBUPROXAM,CHEMBL292707,BRD:BRD-A40940854-001-01-1;BRD:BRD-BRD-A40940854-001-01-1,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTAGLANDIN INHIBITOR",ALOX5,"FEVER, JOINT INFLAMMATION, PAIN RELIEF",,LAUNCHED,,Small molecule,Unknown,BYPIURIATSUHDW-UHFFFAOYSA-N,CC(C)CC1CCC(C(C)C(=O)NO)CC1;CC(C)CC1CCC(CC1)C(C)C(=O)NO
IBUTAMOREN,IBUTAMOREN,CHEMBL13817,BRD:BRD-BRD-K44771174-066-01-0;BRD:BRD-K44771174-066-01-0,rep_primary;rep_single_dose,GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST,GHR;GHSR,,,PHASE 2,,Small molecule,Phase 2,UMUPQWIGCOZEOY-JOCHJYFZSA-N,CC(C)(N)C(=O)N[C@H](COCC1CCCCC1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)C1CCCCC12;CC(C)(N)C(=O)N[C@H](COCC1CCCCC1)C(=O)N1CCC2(CN(C3CCCCC23)S(C)(=O)=O)CC1
IBUTILIDE,IBUTILIDE,CHEMBL533,BRD:BRD-A74391928-051-01-3;BRD:BRD-A74391928-051-02-1;BRD:BRD-BRD-A74391928-051-01-3;BRD:BRD-BRD-A74391928-051-02-1,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,CACNA1C;CACNA2D1;CACNB1;CACNG1;KCNH2;KCNH6;KCNH7;KCNJ11;KCNK1;KCNK6,ATRIAL FIBRILLATION (AF),,LAUNCHED,,Small molecule,Approved,ALOBUEHUHMBRLE-UHFFFAOYSA-N,CCCCCCCN(CC)CCCC(O)C1CCC(NS(C)(=O)=O)CC1
IC-87114,IC-87114,,CTRP:55307;GDSC1:236,ctrp;gdsc,,,,,,,,NA,,
ICA-069673,ICA-069673,,BRD:BRD-K59839632-001-02-9,rep_single_dose,VOLTAGE-GATED POTASSIUM CHANNEL ACTIVATOR,KCNQ2;KCNQ3,,,,,,NA,,
ICA-110381,ICA-110381,,BRD:BRD-K71686520-001-02-9,rep_single_dose,VOLTAGE-GATED POTASSIUM CHANNEL ACTIVATOR,KCNQ2,,,,,,NA,,
ICA-121431,ICA-121431,,BRD:BRD-BRD-K03149601-001-02-6;BRD:BRD-K03149601-001-02-6,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN1A;SCN3A,,,PRECLINICAL,,,NA,,O=C(NC1CCC(CC1)S(=O)(=O)NC1NCCS1)C(C1CCCCC1)C1CCCCC1
ICARIIN,ICARIIN,CHEMBL553204,BRD:BRD-BRD-K65639003-001-09-0;BRD:BRD-K65639003-001-09-0,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,,,PHASE 3,,Small molecule,Phase 3,TZJALUIVHRYQQB-XLRXWWTNSA-N,COC1CCC(-C2OC3C(CC=C(C)C)C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)CC(O)C3C(=O)C2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)CC1;COC1CCC(CC1)-C1OC2C(CC=C(C)C)C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CC(O)C2C(=O)C1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O
ICARITIN,ICARITIN,CHEMBL498485,BRD:BRD-BRD-K24476327-001-01-3;BRD:BRD-K24476327-001-01-3,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PDE5A,,,PHASE 2,,Small molecule,Phase 3,TUUXBSASAQJECY-UHFFFAOYSA-N,COC1CCC(-C2OC3C(CC=C(C)C)C(O)CC(O)C3C(=O)C2O)CC1;COC1CCC(CC1)-C1OC2C(CC=C(C)C)C(O)CC(O)C2C(=O)C1O
ICATIBANT-ACETATE,ICATIBANT-ACETATE,,BRD:BRD-BRD-K63772874-001-02-2;BRD:BRD-K63772874-001-02-2,rep_primary;rep_single_dose,BRADYKININ RECEPTOR ANTAGONIST,ANPEP;BDKRB2,ANGIOEDEMA,,LAUNCHED,,,NA,,N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](CC1CCCS1)C(=O)N[C@@H](CO)C(=O)N1CC2CCCCC2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
ICG-001,ICG-001,,BRD:BRD-BRD-K94455792-001-01-8;BRD:BRD-K94455792-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,BETA-CATENIN INHIBITOR,CTNNB1,,,PRECLINICAL,,,NA,,OC1CCC(C[C@H]2N3[C@H](CN(CC4CCCC5CCCCC45)C2=O)N(CCC3=O)C(=O)NCC2CCCCC2)CC1
ICI 176334,ICI 176334,,GDSC1:150;GDSC1:1502,gdsc,,,,,,,,NA,,
"ICI-118,551","ICI-118,551",,BRD:BRD-BRD-K74603273-003-01-1;BRD:BRD-K74603273-003-01-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB2;ADRB3,,,PHASE 2,,,NA,,CC(C)N[C@@H](C)[C@H](O)COC1CCC(C)C2CCCC12
ICI-162846,ICI-162846,,BRD:BRD-BRD-K11071038-001-01-7;BRD:BRD-K11071038-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,,,PHASE 1,,,NA,,NC(=O)CCCCN1CCC(N1)\N=C(/N)NCC(F)(F)F
ICI-169369,ICI-169369,,BRD:BRD-K00004569-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,,NA,,
ICI-176334,ICI-176334,CHEMBL409;CHEMBL63560,GDSC1:150;GDSC1:1502,gdsc,,,,,,,Small molecule,Approved,LKJPYSCBVHEWIU-KRWDZBQOSA-N;LKJPYSCBVHEWIU-UHFFFAOYSA-N,C[C@](O)(CS(=O)(=O)C1CCC(F)CC1)C(=O)NC1CCC(C#N)C(C(F)(F)F)C1;CC(O)(CS(=O)(=O)C1CCC(F)CC1)C(=O)NC1CCC(C#N)C(C(F)(F)F)C1
"ICI-185,282","ICI-185,282",,BRD:BRD-BRD-K29133151-001-03-2;BRD:BRD-K29133151-001-03-2,rep_primary;rep_single_dose,THROMBOXANE RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1C1CCCCC1O)C(F)(F)F
ICI-192605,ICI-192605,,BRD:BRD-BRD-K59433843-001-01-7;BRD:BRD-K59433843-001-01-7,rep_primary;rep_single_dose,THROMBOXANE RECEPTOR ANTAGONIST,TBXA2R,,,PHASE 2,,,NA,,OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1C1CCCCC1O)C1CCCCC1CL
ICI-199441,ICI-199441,CHEMBL38576,BRD:BRD-BRD-K73290745-003-02-6;BRD:BRD-K73290745-003-02-6,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,CYP2D6;OPRD1;OPRK1;OPRM1;UTS2R,,,PRECLINICAL,,Small molecule,NA,AEJOEPSMZCEYJN-HXUWFJFHSA-N,CN([C@H](CN1CCCC1)C1CCCCC1)C(=O)CC1CCC(CL)C(CL)C1;CN(C(=O)CC1CCC(CL)C(CL)C1)[C@H](CN1CCCC1)C1CCCCC1
"ICI-215,001","ICI-215,001",,BRD:BRD-BRD-K52487250-003-01-2;BRD:BRD-K52487250-003-01-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB3,,,PRECLINICAL,,,NA,,O[C@@H](CNCCOC1CCC(OCC(O)=O)CC1)COC1CCCCC1
ICI-46474,ICI-46474,CHEMBL786;CHEMBL83,GDSC1:1199;GDSC2:1199,gdsc,,,,,,,Small molecule,Approved,FQZYTYWMLGAPFJ-OQKDUQJOSA-N;NKANXQFJJICGDU-QPLCGJKRSA-N,CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1;CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
ICI-63197,ICI-63197,,BRD:BRD-BRD-K52219182-001-02-4;BRD:BRD-K52219182-001-02-4,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCCN1C2NC(N)NN2CC(C)C1=O
ICI-89406,ICI-89406,CHEMBL11268,BRD:BRD-A03359064-001-02-3;BRD:BRD-BRD-A03359064-001-02-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,,,PHASE 1,,Small molecule,NA,HTLWRKRZKFAAAH-UHFFFAOYSA-N,N#CC1CCCCC1OCC(O)CNCCNC(=O)NC1CCCCC1;OC(CNCCNC(=O)NC1CCCCC1)COC1CCCCC1C#N
ICL1100013,ICL1100013,,GDSC1:1266,gdsc,,,,,,,,NA,,
ICLAPRIM,ICLAPRIM,CHEMBL134561,BRD:BRD-K00003415-001-01-9,rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,,,,,,Small molecule,Phase 3,HWJPWWYTGBZDEG-UHFFFAOYSA-N,COC1CC(CC2CNC(N)NC2N)C2C(C1OC)OC(C1CC1)C=C2
ICLUSIG,ICLUSIG,CHEMBL1171837;CHEMBL2105708,GDSC1:155,gdsc,,,,,,,Small molecule,Approved,BWTNNZPNKQIADY-UHFFFAOYSA-N;PHXJVRSECIGDHY-UHFFFAOYSA-N,CC1CCC(C(=O)NC2CCC(CN3CCN(C)CC3)C(C(F)(F)F)C2)CC1C#CC1CNC2CCCNN12;CC1CCC(C(=O)NC2CCC(CN3CCN(C)CC3)C(C(F)(F)F)C2)CC1C#CC1CNC2CCCNN12.CL
ICOMUCRET,ICOMUCRET,CHEMBL594621,BRD:BRD-BRD-K41234004-001-03-1;BRD:BRD-K41234004-001-03-1,rep_primary;rep_single_dose,MUCIN PRODUCTION ENHANCER,LTB4R2,,,PHASE 3,,Small molecule,Unknown,JSFATNQSLKRBCI-VAEKSGALSA-N,CCCCC[C@H](O)/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O;CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O
ICOSAPENT,ICOSAPENT,CHEMBL460026,BRD:BRD-BRD-K47192521-001-05-4;BRD:BRD-K47192521-001-05-4,rep_primary;rep_single_dose,PLATELET AGGREGATION INHIBITOR,ACSL3;ACSL4;FADS1;FFAR1;PPARD;PPARG;PTGS1;PTGS2;SLC8A1;TRPV1,HYPERTRIGLYCERIDEMIA,,LAUNCHED,,Small molecule,Phase 3,JAZBEHYOTPTENJ-JLNKQSITSA-N,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O;CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
ICOTINIB,ICOTINIB,CHEMBL2087361,BRD:BRD-BRD-K31698212-001-02-9;BRD:BRD-K31698212-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,,Small molecule,Phase 3,QQLKULDARVNMAL-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC4C(CC23)OCCOCCOCCO4)C1;C#CC1CCCC(NC2NCNC3CC4OCCOCCOCCOC4CC23)C1
ICRT-14,ICRT-14,,BRD:BRD-K18634484-001-02-9,rep_single_dose,"BETA CATENIN INHIBITOR, WNT SIGNALING INHIBITOR",CTNNB1;TCF4,,,,,,NA,,
ID-1101,ID-1101,,BRD:BRD-BRD-K90305467-001-01-3;BRD:BRD-K90305467-001-01-3,rep_primary;rep_single_dose,INSULIN SENSITIZER,INS,,,PHASE 1,,,NA,,C[C@H](O)[C@H](C)[C@H](N)C(O)=O
ID-8,ID-8,,BRD:BRD-BRD-K39166528-001-01-0;BRD:BRD-K39166528-001-01-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-N1C(C)C([N+]([O-])=O)C2CCC(O)CC12
IDALOPIRDINE,IDALOPIRDINE,CHEMBL3286580,BRD:BRD-BRD-K79102359-003-01-6;BRD:BRD-K79102359-003-01-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR6,,,PHASE 3,,Small molecule,Phase 3,YBAWYTYNMZWMMJ-UHFFFAOYSA-N,FC(F)C(F)(F)COC1CCCC(CNCCC2C[NH]C3CC(F)CCC23)C1;FC1CCC2C(CCNCC3CCCC(OCC(F)(F)C(F)F)C3)C[NH]C2C1
IDARUBICIN,IDARUBICIN,CHEMBL1117,BRD:BRD-BRD-K69650333-003-13-2;BRD:BRD-BRD-K69650333-003-14-0;BRD:BRD-K69650333-003-13-2;BRD:BRD-K69650333-003-14-0,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,ACUTE MYELOID LEUKEMIA (AML),,LAUNCHED,,Small molecule,Approved,XDXDZDZNSLXDNA-TZNDIEGXSA-N,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2C(O)C3C(=O)C4CCCCC4C(=O)C3C(O)C12)C(C)=O;CC(=O)[C@]1(O)CC2C(O)C3C(C(O)C2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)C1CCCCC1C3=O
IDASANUTLIN,IDASANUTLIN,CHEMBL2402737,BRD:BRD-BRD-K62627508-001-01-5;BRD:BRD-K62627508-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,MDM INHIBITOR,MDM2;TP53,,,PHASE 3,,Small molecule,Phase 3,TVTXCJFHQKSQQM-LJQIRTBHSA-N,COC1CC(C(=O)O)CCC1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(C2CCC(CL)CC2F)[C@H]1C1CCCC(CL)C1F;COC1CC(CCC1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1C1CCCC(CL)C1F)C1CCC(CL)CC1F)C(O)=O
IDAZOXAN,IDAZOXAN,CHEMBL10316,BRD:BRD-A18696154-003-22-6;BRD:BRD-BRD-A18696154-003-22-6,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;PTGS2,,,PHASE 3,"Multiple values for repurposing_target: {'ADRA2A;PTGS2', 'ADRA2A'}, taking the union",Small molecule,Phase 3,HPMRFMKYPGXPEP-UHFFFAOYSA-N,C1CCC2C(C1)OCC(C1=NCCN1)O2;C1CN=C(N1)C1COC2CCCCC2O1
IDAZOXANE,IDAZOXANE,,BRD:BRD-BRD-K70759443-001-01-4;BRD:BRD-K70759443-001-01-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRA2B;ADRA2C,,,PRECLINICAL,,,NA,,C1CNC(N1)=C1COC2CCCCC2O1
IDEBENONE,IDEBENONE,CHEMBL252556,BRD:BRD-BRD-K37516142-001-10-5;BRD:BRD-K37516142-001-10-5,rep_primary;rep_single_dose,CALCIUM CHANNEL MODULATOR,,"ALZHEIMER'S DISEASE, FRIEDREICH'S ATAXIA, LEBER HEREDITARY OPTIC NEUROPATHY (LHON)",,LAUNCHED,,Small molecule,Approved,JGPMMRGNQUBGND-UHFFFAOYSA-N,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
IDELALISIB,IDELALISIB,CHEMBL2216870,BRD:BRD-BRD-K60866521-001-07-1;BRD:BRD-K60866521-001-07-1;GDSC1:238,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),,LAUNCHED,,Small molecule,Approved,IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](NC1NCNC2[NH]CNC12)C1NC2CCCC(F)C2C(=O)N1-C1CCCCC1
IDF-11774,IDF-11774,,BRD:BRD-K00003098-001-01-9,rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,,,,,,,NA,,
IDH-305,IDH-305,,BRD:BRD-K00003457-001-01-9,rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,,,,,,,NA,,
IDH-C35,IDH-C35,,GDSC2:1913,gdsc,,,,,,,,NA,,
IDO1-IN-5,IDO1-IN-5,,BRD:BRD-K00091266-001-01-9,rep_single_dose,,,,,,,,NA,,
IDO5L,IDO5L,,BRD:BRD-BRD-K22356203-001-01-8;BRD:BRD-K22356203-001-01-8,rep_primary;rep_single_dose,"INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",IDO1,,,PRECLINICAL,,,NA,,NC1NONC1\C(NO)=N/C1CCC(F)C(CL)C1
IDOXURIDINE,IDOXURIDINE,CHEMBL788,BRD:BRD-BRD-K76634210-001-12-1;BRD:BRD-BRD-K76634210-001-14-7;BRD:BRD-K76634210-001-12-1;BRD:BRD-K76634210-001-14-7,rep_multi_dose;rep_primary;rep_single_dose,"DNA DIRECTED DNA POLYMERASE INHIBITOR, DNA SYNTHESIS INHIBITOR",,VIRUS HERPES SIMPLEX (HSV),,LAUNCHED,"Multiple values for MOA: {'DNA DIRECTED DNA POLYMERASE INHIBITOR, DNA SYNTHESIS INHIBITOR', 'DNA DIRECTED DNA POLYMERASE INHIBITOR'}, defaulting to 'DNA DIRECTED DNA POLYMERASE INHIBITOR, DNA SYNTHESIS INHIBITOR'",Small molecule,Approved,XQFRJNBWHJMXHO-RRKCRQDMSA-N,O=C1[NH]C(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CC1I;OC[C@H]1O[C@H](C[C@@H]1O)N1CC(I)C(=O)[NH]C1=O
IDRA-21,IDRA-21,,BRD:BRD-A14344385-001-03-2;BRD:BRD-BRD-A14344385-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRIA1;GRIA2;GRIA3;GRIA4,,,PRECLINICAL,,,NA,,CC1NC2CCC(CL)CC2S(=O)(=O)N1
IDRONOXIL,IDRONOXIL,CHEMBL1957038,BRD:BRD-BRD-K74671368-001-01-8;BRD:BRD-K74671368-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,XIAP INHIBITOR,ENOX2;SPHK1,,,PHASE 3,,Small molecule,Phase 1,ZZUBHVMHNVYXRR-UHFFFAOYSA-N,OC1CCC(C2=CC3CCC(O)CC3OC2)CC1;OC1CCC(CC1)C1=CC2CCC(O)CC2OC1
IEM1460,IEM1460,,BRD:BRD-BRD-K13829090-303-02-9;BRD:BRD-K13829090-303-02-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA2,,,PRECLINICAL,,,NA,,C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2
IEM1754,IEM1754,,BRD:BRD-BRD-K80060353-303-03-9;BRD:BRD-K80060353-303-03-9,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1,,,PRECLINICAL,,,NA,,NCCCCCNCC12CC3CC(CC(C3)C1)C2
IFENPRODIL,IFENPRODIL,CHEMBL305187,BRD:BRD-A24191444-046-02-1;BRD:BRD-A24191444-046-03-9;BRD:BRD-BRD-A24191444-046-02-1;BRD:BRD-BRD-A24191444-046-03-9,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, GLUTAMATE RECEPTOR ANTAGONIST",GRIN1;GRIN2B,,,LAUNCHED,,Small molecule,Approved,UYNVMODNBIQBMV-UHFFFAOYSA-N,CC(C(O)C1CCC(O)CC1)N1CCC(CC2CCCCC2)CC1
IFOSFAMIDE,IFOSFAMIDE,CHEMBL1024,BRD:BRD-A67097164-001-18-7;BRD:BRD-BRD-A67097164-001-18-7;CTRP:35319,ctrp;rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,CYP2A6;CYP2B6;CYP2C18;CYP2C19;CYP2C8;CYP2C9;CYP3A4;CYP3A5;CYP3A7;PTGS1,"TESTICULAR CARCINOMA, HEMORRHAGIC CYSTITIS",,LAUNCHED,,Small molecule,Approved,HOMGKSMUEGBAAB-UHFFFAOYSA-N,CLCCNP1(=O)OCCCN1CCCL;O=P1(NCCCL)OCCCN1CCCL
IGMESINE,IGMESINE,CHEMBL2110660,BRD:BRD-A48376327-003-01-5;BRD:BRD-BRD-A48376327-003-01-5,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,SIGMAR1,,,PHASE 2,,Small molecule,Unknown,VCZSWYIFCKGTJI-JLHYYAGUSA-N,CCC(C/C=C/C1CCCCC1)(C1CCCCC1)N(C)CC1CC1;CCC(C\C=C\C1CCCCC1)(N(C)CC1CC1)C1CCCCC1
IGURATIMOD,IGURATIMOD,CHEMBL2107455,BRD:BRD-BRD-K15426076-001-01-2;BRD:BRD-K15426076-001-01-2,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, NFKB PATHWAY INHIBITOR",PTGS2,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Phase 3,ANMATWQYLIFGOK-UHFFFAOYSA-N,CS(=O)(=O)NC1CC2OCC(NC=O)C(=O)C2CC1OC1CCCCC1
IKK INHIBITOR 3,IKK INHIBITOR 3,,GDSC1:203,gdsc,,,,,,,,NA,,
IKK-16,IKK-16,,BRD:BRD-BRD-K14618467-001-04-6;BRD:BRD-K14618467-001-04-6,rep_multi_dose;rep_primary;rep_single_dose,IKK INHIBITOR,IKBKB,,,PRECLINICAL,,,NA,,O=C(N1CCC(CC1)N1CCCC1)C1CCC(NC2NCCC(N2)-C2CC3CCCCC3S2)CC1
IKK-2-INHIBITOR,IKK-2-INHIBITOR,,BRD:BRD-BRD-K26373640-001-05-1;BRD:BRD-K26373640-001-05-1,rep_primary;rep_single_dose,"IKK INHIBITOR, SYK INHIBITOR",IKBKB,,,PRECLINICAL,,,NA,,NC(=O)C1SC(CC1N)-C1CCSC1
IKK-2-INHIBITOR-V,IKK-2-INHIBITOR-V,,BRD:BRD-BRD-K74305673-001-06-2;BRD:BRD-K74305673-001-06-2,rep_multi_dose;rep_primary;rep_single_dose,"IKK INHIBITOR, NFKB PATHWAY INHIBITOR",IKBKB,,,PHASE 1,,,NA,,OC1CCC(CL)CC1C(=O)NC1CC(CC(C1)C(F)(F)F)C(F)(F)F
IKK-3 INHIBITOR,IKK-3 INHIBITOR,,GDSC1:91,gdsc,,,,,,,,NA,,
ILAPRAZOLE,ILAPRAZOLE,CHEMBL2106370,BRD:BRD-K00003427-001-01-9,rep_single_dose,PROTON PUMP INHIBITOR,,,,,,Small molecule,Phase 3,HRRXCXABAPSOCP-UHFFFAOYSA-N,COC1CCNC(C[S+]([O-])C2NC3CC(-N4CCCC4)CCC3[NH]2)C1C
ILEPCIMIDE,ILEPCIMIDE,CHEMBL118478,BRD:BRD-BRD-K43873574-001-01-8;BRD:BRD-K43873574-001-01-8,rep_primary;rep_single_dose,ANTICONVULSANT,,,,PHASE 3,,Small molecule,Unknown,BLPUOQGPBJPXRL-FNORWQNLSA-N,O=C(/C=C/C1CCC2C(C1)OCO2)N1CCCCC1;O=C(C=CC1CCC2OCOC2C1)N1CCCCC1
ILOMASTAT,ILOMASTAT,CHEMBL19611,BRD:BRD-BRD-K51662849-001-05-4;BRD:BRD-BRD-K51662849-001-08-8;BRD:BRD-K51662849-001-05-4;BRD:BRD-K51662849-001-08-8,rep_multi_dose;rep_primary;rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,ACAN;ADAM28;MMP1;MMP12;MMP13;MMP14;MMP2;MMP3;MMP8;MMP9,,,PHASE 3,,Small molecule,Unknown,NITYDPDXAAFEIT-DYVFJYSZSA-N,CNC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@@H](CC(=O)NO)CC(C)C;CNC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC(C)C)CC(=O)NO
ILOPERIDONE,ILOPERIDONE,CHEMBL14376,BRD:BRD-BRD-K48722833-001-07-6;BRD:BRD-K48722833-001-07-6,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA2C;DRD1;DRD2;DRD3;DRD4;HRH1;HTR1A;HTR2A;HTR6;HTR7,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,XMXHEBAFVSFQEX-UHFFFAOYSA-N,COC1CC(C(C)=O)CCC1OCCCN1CCC(C2NOC3CC(F)CCC23)CC1;COC1CC(CCC1OCCCN1CCC(CC1)C1NOC2CC(F)CCC12)C(C)=O
ILORASERTIB,ILORASERTIB,CHEMBL1980297,BRD:BRD-K00077460-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,WPHKIQPVPYJNAX-UHFFFAOYSA-N,NC1NCC(-C2CNN(CCO)C2)C2SCC(-C3CCC(NC(=O)NC4CCCC(F)C4)CC3)C12
IM156,IM156,CHEMBL4650309,BRD:BRD-K00091083-015-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,AGFDCTOLSXWRDZ-UHFFFAOYSA-N,CC(=O)O.N=C(NC(=N)N1CCCC1)NC1CCC(OC(F)(F)F)CC1
STI-571,IMATINIB;STI-571,CHEMBL1642;CHEMBL941,BRD:BRD-BRD-K92723993-001-06-7;BRD:BRD-K92723993-001-06-7;BRD:BRD-K92723993-001-17-4;CTRP:345041;GDSC1:34,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"BCR-ABL KINASE INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR",ABL1;CSF1R;DDR1;KIT;NTRK1;PDGFRA;PDGFRB;RET,"CHRONIC MYELOID LEUKEMIA (CML), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), MYELODYSPLASTIC DISEASES (MDS), AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), HYPEREOSINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL), DERMATOFIBROSARCOMA PROTUBERANS (DFSP), GASTROINTESTINAL STROMAL TUMORS (GIST)",,LAUNCHED,"Multiple values for MOA: {'BCR-ABL KINASE INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR', 'INHIBITOR OF BCR-ABL1, PDGFRA, AND KIT'}, defaulting to 'BCR-ABL KINASE INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR'
Multiple values for repurposing_target: {'ABL1;KIT;PDGFRA', 'ABL1;CSF1R;DDR1;KIT;NTRK1;PDGFRA;PDGFRB;RET'}, taking the union",Small molecule,Approved,KTUFNOKKBVMGRW-UHFFFAOYSA-N;YLMAHDNUQAMNNX-UHFFFAOYSA-N,CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NCCC(-C2CCCNC2)N1;CN1CCN(CC2CCC(CC2)C(=O)NC2CCC(C)C(NC3NCCC(N3)-C3CCCNC3)C2)CC1;CS(=O)(=O)O.CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NCCC(-C2CCCNC2)N1
IMAZODAN,IMAZODAN,CHEMBL12831,BRD:BRD-K96298462-001-08-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Unknown,VXMYWVMXSWJFCV-UHFFFAOYSA-N,O=C1CCC(C2CCC(-N3CCNC3)CC2)=NN1
IMC-225,IMC-225,CHEMBL1201577,GDSC1:1114,gdsc,,,,,,,Antibody,Approved,,
IMC-C225,IMC-C225,CHEMBL1201577,GDSC1:1114,gdsc,,,,,,,Antibody,Approved,,
IMD-0354,IMD-0354,CHEMBL3545089,GDSC1:442,gdsc,,,,,,,Small molecule,Phase 1,,
IMEGLIMIN,IMEGLIMIN,CHEMBL4297514,BRD:BRD-BRD-K55822903-003-01-8;BRD:BRD-K55822903-003-01-8,rep_primary;rep_single_dose,GLUCONEOGENESIS INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,GFICWFZTBXUVIG-SCSAIBSYSA-N,C[C@@H]1N=C(N)NC(=N1)N(C)C;C[C@H]1N=C(N(C)C)N=C(N)N1
IMETIT,IMETIT,CHEMBL19439,BRD:BRD-BRD-K33183200-303-02-4;BRD:BRD-K33183200-303-02-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH3;HRH4,,,PRECLINICAL,,Small molecule,NA,PEHSVUKQDJULKE-UHFFFAOYSA-N,N=C(N)SCCC1C[NH]CN1;NC(=N)SCCC1C[NH]CN1
IMEXON,IMEXON,CHEMBL146428,BRD:BRD-A78195072-001-06-2;BRD:BRD-BRD-A78195072-001-06-2,rep_primary;rep_single_dose,"APOPTOSIS STIMULANT, RIBONUCLEOTIDE REDUCTASE INHIBITOR",RRM1;RRM2,,,PHASE 2,,Small molecule,Phase 2,BIXBBIPTYBJTRY-UHFFFAOYSA-N,N=C1NC(=O)N2CC12
IMI-28,IMI-28,CHEMBL1200981,GDSC2:1511,gdsc,,,,,,,Small molecule,Approved,MWWSFMDVAYGXBV-FGBSZODSSA-N,COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1.CL
IMIDACLOPRID,IMIDACLOPRID,CHEMBL406819,BRD:BRD-BRD-K76609936-001-08-4;BRD:BRD-K76609936-001-08-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRFAM7A,,,LAUNCHED,,Small molecule,NA,YWTYJOPNNQFBPC-UHFFFAOYSA-N,[O-][N+](=O)NC1=NCCN1CC1CCC(CL)NC1;O=[N+]([O-])/N=C1\NCCN1CC1CCC(CL)NC1
IMIDAFENACIN,IMIDAFENACIN,CHEMBL53366,BRD:BRD-BRD-K29626940-001-01-5;BRD:BRD-K29626940-001-01-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM3,"SPASMS, SPASMS",,LAUNCHED,,Small molecule,Phase 3,SQKXYSGRELMAAU-UHFFFAOYSA-N,CC1NCCN1CCC(C(N)=O)(C1CCCCC1)C1CCCCC1
IMIDAPRIL,IMIDAPRIL,CHEMBL317094,BRD:BRD-BRD-K34332569-001-01-3;BRD:BRD-K34332569-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,KLZWOWYOHUKJIG-BPUTZDHNSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O;CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O
IMIDAZOACRIDINONE,IMIDAZOACRIDINONE,,BRD:BRD-K00004617-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,,NA,,
IMIDUREA,IMIDUREA,CHEMBL65433,BRD:BRD-K00003682-001-01-9,rep_single_dose,OTHER ANTIBIOTIC,,,,,,Small molecule,Unknown,ZCTXEAQXZGPWFG-UHFFFAOYSA-N,O=C(NCNC(=O)NC1C(=O)NC(=O)N1CO)NC1C(=O)NC(=O)N1CO
IMILOXAN,IMILOXAN,CHEMBL347695,BRD:BRD-A10903566-003-07-7;BRD:BRD-BRD-A10903566-003-07-7,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRA2B,,,PHASE 1,,Small molecule,Unknown,UXABARREKCJULM-UHFFFAOYSA-N,CCN1CCNC1CC1COC2CCCCC2O1
IMIPRAMINE,IMIPRAMINE,CHEMBL11;CHEMBL72,BRD:BRD-BRD-K38436528-003-26-1;BRD:BRD-K38436528-003-26-1,rep_primary;rep_single_dose,"NOREPINEPHRINE REPUTAKE INHIBITOR, SEROTONIN REUPTAKE INHIBITOR",ADRA1A;ADRA1B;ADRA1D;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD5;HRH1;HTR1A;HTR2A;HTR2C;HTR6;HTR7;KCND2;KCND3;KCNH1;KCNH2;SLC6A2;SLC6A3;SLC6A4,"DEPRESSION, NOCTURNAL ENURESIS",,LAUNCHED,,Small molecule,Approved,BCGWQEUPMDMJNV-UHFFFAOYSA-N;HCYAFALTSJYZDH-UHFFFAOYSA-N,CN(C)CCCN1C2CCCCC2CCC2CCCCC12;CN(C)CCCN1C2CCCCC2CCC2CCCCC21;CNCCCN1C2CCCCC2CCC2CCCCC21
IMIQUIMOD,IMIQUIMOD,CHEMBL1282,BRD:BRD-BRD-K26657438-001-15-2;BRD:BRD-K26657438-001-15-2,rep_multi_dose;rep_primary;rep_single_dose,"INTERFERON INDUCER, TOLL-LIKE RECEPTOR AGONIST",TLR7;TLR8,"ACTINIC KERATOSIS (AK), GENITAL WARTS, BASAL CELL CARCINOMA (BCC)",,LAUNCHED,,Small molecule,Approved,DOUYETYNHWVLEO-UHFFFAOYSA-N,CC(C)CN1CNC2C(N)NC3CCCCC3C12;CC(C)CN1CNC2C(N)NC3CCCCC3C21
IMIRESTAT,IMIRESTAT,CHEMBL269455,BRD:BRD-K00003208-001-01-9,rep_single_dose,ALDOSE REDUCTASE INHIBITOR,,,,,,Small molecule,Unknown,QCCHBHSAIQIQGO-UHFFFAOYSA-N,O=C1NC(=O)C2(N1)C1CC(F)CCC1-C1CCC(F)CC12
IMISOPASEM-MANGANESE,IMISOPASEM-MANGANESE,,BRD:BRD-K00003154-001-01-9,rep_single_dose,SUPEROXIDE DISMUTASE MIMETIC,,,,,,,NA,,
IMMEPIP,IMMEPIP,CHEMBL18661,BRD:BRD-BRD-K25906698-303-02-7;BRD:BRD-K25906698-303-02-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH3;HRH4,,,PRECLINICAL,,Small molecule,NA,MCNGUYXRBCIGOV-UHFFFAOYSA-N,C(C1CCNCC1)C1C[NH]CN1;C1NC(CC2CCNCC2)C[NH]1
IMMETHRIDINE,IMMETHRIDINE,CHEMBL82298,BRD:BRD-BRD-K49519092-303-03-0;BRD:BRD-K49519092-303-03-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH3,,,PHASE 1,,Small molecule,NA,DFVSGZHJSIEEQQ-UHFFFAOYSA-N,C(C1CNC[NH]1)C1CCNCC1;C1CC(CC2CNC[NH]2)CCN1
IMPENTAMINE,IMPENTAMINE,CHEMBL417096,BRD:BRD-K20049318-303-03-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH3,,,,,Small molecule,NA,MZCJWLAXZRFUPI-UHFFFAOYSA-N,NCCCCCC1C[NH]CN1
IMPORTAZOLE,IMPORTAZOLE,,CTRP:46792,ctrp,,,,,,,,NA,,
IMRECOXIB,IMRECOXIB,CHEMBL504535,BRD:BRD-K00074641-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,AXMZZGKKZDJGAZ-UHFFFAOYSA-N,CCCN1CC(C2CCC(S(C)(=O)=O)CC2)=C(C2CCC(C)CC2)C1=O
IMREG-1,IMREG-1,,BRD:BRD-BRD-K00926464-001-01-8;BRD:BRD-K00926464-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 3,,,NA,,N[C@@H](CC1CCC(O)CC1)C(=O)NCC(=O)NCC(O)=O
INARIGIVIR,INARIGIVIR,CHEMBL1084430,BRD:BRD-K00003532-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 2,LYMICVBGNUEHGE-FUQPUAIBSA-N,CO[C@@H]1[C@H](OP(=O)(S)OC[C@H]2O[C@@H](N3CNC4C(N)NCNC43)C[C@@H]2O)[C@@H](CO)O[C@H]1N1CCC(=O)[NH]C1=O
INARIGIVIR-SOPROXIL,INARIGIVIR-SOPROXIL,,BRD:BRD-K00004751-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,,NA,,
RUXOLITINIB,INC424;INCB018424;RUXOLITINIB,CHEMBL1789941,BRD:BRD-BRD-K53972329-001-07-0;BRD:BRD-K53972329-001-07-0;BRD:BRD-K53972329-001-09-6;CTRP:639450;GDSC1:206;GDSC2:1507,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF JAK1 AND JAK2,JAK1;JAK2;JAK3;TYK2,"MYELOFIBROSIS, POLYCYTHEMIA VERA",,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF JAK1 AND JAK2', 'JAK INHIBITOR'}, defaulting to 'INHIBITOR OF JAK1 AND JAK2'
Multiple values for repurposing_target: {'JAK1;JAK2;JAK3;TYK2', 'JAK1;JAK2'}, taking the union",Small molecule,Approved,HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)N1CC(-C2NCNC3[NH]CCC23)CN1;N#CC[C@H](C1CCCC1)N1CC(CN1)-C1NCNC2[NH]CCC12
INCB-003284,INCB-003284,,BRD:BRD-BRD-K28059174-334-01-2;BRD:BRD-K28059174-334-01-2,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,PHASE 2,,,NA,,COC1CCC(CN1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)C1CCCC(C1)C(F)(F)F
INCB-057643,INCB-057643,CHEMBL4594412,BRD:BRD-K00003102-001-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,Small molecule,Phase 1,VZSAMEOETVNDQH-UHFFFAOYSA-N,CN1C(=O)C(C)(C)OC2C(-C3CN(C)C(=O)C4[NH]CCC34)CC(S(C)(=O)=O)CC21
INCB-18424,INCB-18424,CHEMBL1789941,GDSC1:206;GDSC2:1507,gdsc,,,,,,,Small molecule,Approved,HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)N1CC(-C2NCNC3[NH]CCC23)CN1
INCB-3284,INCB-3284,,BRD:BRD-BRD-K67628093-001-01-9;BRD:BRD-K67628093-001-01-9,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR2,,,PHASE 2,,,NA,,COC1CCC(CN1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)C1CCCC(C1)C(F)(F)F
PEMIGATINIB,INCB054828;PEMIGATINIB,CHEMBL4297522,BRD:BRD-K00104124-001-01-9;BRD:BRD-U00115287-001-01-9,oncref_1;rep_single_dose,"INHIBITOR OF FGFR1, FGFR2, AND FGFR3",FGFR1;FGFR2;FGFR3,,,,"Multiple values for structure_id: {'K00104124', 'U00115287'}, defaulting to None",Small molecule,Approved,HCDMJFOHIXMBOV-UHFFFAOYSA-N,CCN1C(=O)N(C2C(F)C(OC)CC(OC)C2F)CC2CNC3[NH]C(CN4CCOCC4)CC3C21
INCYCLINIDE,INCYCLINIDE,CHEMBL2104970,BRD:BRD-K00003344-001-01-9,rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,,,,,,Small molecule,Phase 2,ZXFCRFYULUUSDW-OWXODZSWSA-N,NC(=O)C1=C(O)C[C@@H]2C[C@@H]3CC4CCCC(O)C4C(=O)C3=C(O)[C@]2(O)C1=O
INDACATEROL,INDACATEROL,CHEMBL1095777,BRD:BRD-BRD-K89208535-051-01-5;BRD:BRD-K89208535-051-01-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2,CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),,LAUNCHED,,Small molecule,Approved,QZZUEBNBZAPZLX-QFIPXVFZSA-N,CCC1CC2C(CC1CC)CC(NC[C@H](O)C1CCC(O)C3[NH]C(=O)CCC13)C2;CCC1CC2CC(CC2CC1CC)NC[C@H](O)C1CCC(O)C2[NH]C(=O)CCC12
INDALPINE,INDALPINE,CHEMBL276520,BRD:BRD-BRD-K64973364-001-01-4;BRD:BRD-K64973364-001-01-4,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),SLC6A4,,,WITHDRAWN,,Small molecule,Approved,SADQVAVFGNTEOD-UHFFFAOYSA-N,C(CC1C[NH]C2CCCCC12)C1CCNCC1;C1CCC2C(CCC3CCNCC3)C[NH]C2C1
INDAPAMIDE,INDAPAMIDE,CHEMBL406,BRD:BRD-A95869247-001-26-9;BRD:BRD-BRD-A95869247-001-26-9,rep_primary;rep_single_dose,THIAZIDE DIURETIC,CA2;HTR3A;KCNE1;KCNQ1;SLC12A3,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,"Multiple values for repurposing_target: {'KCNE1;KCNQ1;SLC12A3', 'CA2;HTR3A;KCNE1;KCNQ1;SLC12A3'}, taking the union",Small molecule,Approved,NDDAHWYSQHTHNT-UHFFFAOYSA-N,CC1CC2CCCCC2N1NC(=O)C1CCC(CL)C(C1)S(N)(=O)=O;CC1CC2CCCCC2N1NC(=O)C1CCC(CL)C(S(N)(=O)=O)C1
INDATRALINE,INDATRALINE,CHEMBL296602;CHEMBL341898,BRD:BRD-BRD-K01649396-003-07-1;BRD:BRD-K01649396-003-07-1,rep_primary;rep_single_dose,NOREPINEPHRINE TRANSPORTER INHIBITOR,MAOA;MAOB,,,PRECLINICAL,,Small molecule,Unknown,SVFXPTLYMIXFRX-UHFFFAOYSA-N;SVFXPTLYMIXFRX-XJKSGUPXSA-N,CN[C@@H]1C[C@@H](C2CCC(CL)C(CL)C2)C2CCCCC21;CN[C@@H]1C[C@H](C2CCCCC12)C1CCC(CL)C(CL)C1;CNC1CC(C2CCC(CL)C(CL)C2)C2CCCCC21
INDEGLITAZAR,INDEGLITAZAR,CHEMBL1232583,BRD:BRD-K00003177-001-01-9,rep_single_dose,PPAR RECEPTOR AGONIST,NCOA1;PPARA;PPARD;PPARG,,,,,Small molecule,Phase 2,YMPALHOKRBVHOJ-UHFFFAOYSA-N,COC1CCC(S(=O)(=O)N2CC(CCC(=O)O)C3CC(OC)CCC32)CC1
INDELOXAZINE,INDELOXAZINE,CHEMBL2105022,BRD:BRD-A59747053-003-01-3;BRD:BRD-BRD-A59747053-003-01-3,rep_primary;rep_single_dose,"NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN REUPTAKE INHIBITOR",,,,WITHDRAWN,,Small molecule,Unknown,MADRVGBADLFHMO-UHFFFAOYSA-N,C(OC1CCCC2C=CCC12)C1CNCCO1;C1=CC2CCCC(OCC3CNCCO3)C2C1
INDIBULIN,INDIBULIN,CHEMBL49642,BRD:BRD-BRD-K74057757-001-01-9;BRD:BRD-K74057757-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,SOLIIYNRSAWTSQ-UHFFFAOYSA-N,CLC1CCC(CN2CC(C(=O)C(=O)NC3CCNCC3)C3CCCCC23)CC1;O=C(NC1CCNCC1)C(=O)C1CN(CC2CCC(CL)CC2)C2CCCCC12
INDINAVIR,INDINAVIR,CHEMBL115,BRD:BRD-BRD-K33226500-001-01-0;BRD:BRD-K33226500-001-01-0,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,CYP3A4;CYP3A5;CYP3A7,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,CBVCZFGXHXORBI-PXQQMZJSSA-N,CC(C)(C)NC(=O)[C@@H]1CN(CC2CCCNC2)CCN1C[C@@H](O)C[C@@H](CC1CCCCC1)C(=O)N[C@@H]1[C@H](O)CC2CCCCC12;CC(C)(C)NC(=O)[C@@H]1CN(CC2CCCNC2)CCN1C[C@@H](O)C[C@@H](CC1CCCCC1)C(=O)N[C@H]1C2CCCCC2C[C@H]1O
INDIPLON,INDIPLON,CHEMBL262075,BRD:BRD-BRD-K90948141-001-01-4;BRD:BRD-K90948141-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1,,,PHASE 3,,Small molecule,Phase 3,CBIAWPMZSFFRGN-UHFFFAOYSA-N,CC(=O)N(C)C1CCCC(-C2CCNC3C(C(=O)C4CCCS4)CNN23)C1;CN(C(C)=O)C1CCCC(C1)-C1CCNC2C(CNN12)C(=O)C1CCCS1
INDIRUBIN,INDIRUBIN,CHEMBL1276127,BRD:BRD-BRD-K17894950-001-14-3;BRD:BRD-K17894950-001-14-3,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, GLYCOGEN SYNTHASE KINASE INHIBITOR",CDK1;CDK5;GSK3A,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,CRDNMYFJWFXOCH-YPKPFQOOSA-N,O=C1NC2CCCCC2/C1=C1/NC2CCCCC2C1=O;O=C1NC2CCCCC2\C1=C1\NC2CCCCC2C1=O
INDIRUBIN-3-MONOXIME,INDIRUBIN-3-MONOXIME,CHEMBL126077,BRD:BRD-BRD-K19136521-001-08-9;BRD:BRD-K19136521-001-08-9,rep_primary;rep_single_dose,"CDK INHIBITOR, GLYCOGEN SYNTHASE KINASE INHIBITOR",CDK1;CDK2;CDK5;CDK5R1;GSK3B,,,PRECLINICAL,,Small molecule,NA,FQCPPVRJPILDIK-UHFFFAOYSA-N,O\N=C1C2CCCCC2NC/1=C1\C(=O)NC2CCCCC12;O=NC1C(-C2C(O)[NH]C3CCCCC23)[NH]C2CCCCC12
INDISULAM,INDISULAM,CHEMBL77517,BRD:BRD-BRD-K17610631-001-03-3;BRD:BRD-K17610631-001-03-3;CTRP:411874,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CA1;CA12;CA14;CA2;CA6;CA7;CA9,,,PHASE 2,,Small molecule,Phase 2,SETFNECMODOHTO-UHFFFAOYSA-N,NS(=O)(=O)C1CCC(CC1)S(=O)(=O)NC1CCCC2C(CL)C[NH]C12;NS(=O)(=O)C1CCC(S(=O)(=O)NC2CCCC3C(CL)C[NH]C23)CC1
INDIUM(III)-ISOPROPOXIDE,INDIUM(III)-ISOPROPOXIDE,,BRD:BRD-BRD-M08274809-001-01-7;BRD:BRD-M08274809-001-01-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,[IN].CC(C)O.CC(C)O.CC(C)O
INDOBUFEN,INDOBUFEN,CHEMBL1765292,BRD:BRD-A16296925-001-01-3;BRD:BRD-BRD-A16296925-001-01-3,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PLATELET AGGREGATION INHIBITOR",PTGS1;PTGS2,THROMBOSIS,,LAUNCHED,,Small molecule,Phase 3,AYDXAULLCROVIT-UHFFFAOYSA-N,CCC(C(=O)O)C1CCC(N2CC3CCCCC3C2=O)CC1;CCC(C(O)=O)C1CCC(CC1)N1CC2CCCCC2C1=O
INDOCYANINE-GREEN,INDOCYANINE-GREEN,,BRD:BRD-BRD-K80762071-236-02-5;BRD:BRD-K80762071-236-02-5,rep_primary;rep_single_dose,CONTRAST AGENT,SLCO1B1,,,LAUNCHED,,,NA,,CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)C3CCC4CCCCC4C3C2(C)C)N(CCCCS(O)(=O)=O)C2CCC3CCCCC3C12
INDOLE-3-CARBINOL,INDOLE-3-CARBINOL,CHEMBL155625,BRD:BRD-BRD-K01815685-001-15-5;BRD:BRD-K01815685-001-15-5,rep_primary;rep_single_dose,"ARYL HYDROCARBON RECEPTOR AGONIST, INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",AHR,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,IVYPNXXAYMYVSP-UHFFFAOYSA-N,OCC1C[NH]C2CCCCC12
INDOMETHACIN,INDOMETHACIN,CHEMBL6,BRD:BRD-BRD-K57222227-001-30-1;BRD:BRD-K57222227-001-30-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,GLO1;PLA2G2A;PPARA;PPARG;PTGDR2;PTGR2;PTGS1;PTGS2;SLC46A1,"RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, OSTEOARTHRITIS, BURSITIS, TENDINITIS",,LAUNCHED,,Small molecule,Approved,CGIGDMFJXJATDK-UHFFFAOYSA-N,COC1CCC2C(C1)C(CC(=O)O)C(C)N2C(=O)C1CCC(CL)CC1;COC1CCC2N(C(=O)C3CCC(CL)CC3)C(C)C(CC(O)=O)C2C1
INDOPROFEN,INDOPROFEN,CHEMBL15870;CHEMBL264931,BRD:BRD-A44090213-001-25-6;BRD:BRD-BRD-A44090213-001-25-6,rep_multi_dose;rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTANOID RECEPTOR ANTAGONIST",CXCR1;CXCR2;PTGS1;PTGS2,,,WITHDRAWN,,Small molecule,Approved,RJMIEHBSYVWVIN-LLVKDONJSA-N;RJMIEHBSYVWVIN-UHFFFAOYSA-N,C[C@@H](C(=O)O)C1CCC(N2CC3CCCCC3C2=O)CC1;CC(C(=O)O)C1CCC(N2CC3CCCCC3C2=O)CC1;CC(C(O)=O)C1CCC(CC1)N1CC2CCCCC2C1=O
INDORAMIN,INDORAMIN,CHEMBL279516,BRD:BRD-BRD-K76953762-001-08-5;BRD:BRD-K76953762-001-08-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2B;ADRA2C,"BENIGN PROSTATIC HYPERPLASIA (BPH), HYPERTENSION",,LAUNCHED,,Small molecule,Approved,JXZZEXZZKAWDSP-UHFFFAOYSA-N,O=C(NC1CCN(CCC2C[NH]C3CCCCC23)CC1)C1CCCCC1
INDOXACARB,INDOXACARB,CHEMBL197676,BRD:BRD-K00089583-001-01-9,rep_single_dose,,,,,,,Small molecule,NA,VBCVPMMZEGZULK-NRFANRHFSA-N,COC(=O)N(C(=O)N1CO[C@@]2(C(=O)OC)CC3CC(CL)CCC3C2=N1)C1CCC(OC(F)(F)F)CC1
INDOXIMOD,INDOXIMOD,CHEMBL571209,BRD:BRD-BRD-K93255255-001-02-1;BRD:BRD-K93255255-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,"INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",IDO1,,,PHASE 2,,Small molecule,Phase 2,ZADWXFSZEAPBJS-SNVBAGLBSA-N,CN1CC(C[C@@H](N)C(=O)O)C2CCCCC21;CN1CC(C[C@@H](N)C(O)=O)C2CCCCC12
INGENOL,INGENOL,CHEMBL2165402,BRD:BRD-K00003329-001-01-9,rep_single_dose,PKC ACTIVATOR,PRKCD;PRKCE,,,,,Small molecule,Phase 3,VEBVPUXQAPLADL-POYOOMFHSA-N,CC1=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]2(O)[C@H]1O)[C@H]1[C@@H](C[C@H]3C)C1(C)C
INGENOL-MEBUTATE,INGENOL-MEBUTATE,,BRD:BRD-BRD-K93779381-001-01-9;BRD:BRD-K93779381-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,PKC ACTIVATOR,PRKCA;PRKCB;PRKCD;PRKCE;PRKCG,ACTINIC KERATOSIS (AK),,LAUNCHED,,,NA,,C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C
INH1,INH1,,BRD:BRD-BRD-K70177501-003-01-4;BRD:BRD-K70177501-003-01-4,rep_multi_dose;rep_primary;rep_single_dose,HEC1 INHIBITOR,NDC80,,,PRECLINICAL,,,NA,,CC1CCC(C(C)C1)-C1CSC(NC(=O)C2CCCCC2)N1
INIMUR,INIMUR,CHEMBL514315,BRD:BRD-A71407503-001-01-8;BRD:BRD-BRD-A71407503-001-01-8,rep_primary;rep_single_dose,OTHER ANTIFUNGAL,,,,LAUNCHED,,Small molecule,Unknown,SRQKTCXJCCHINN-NYYWCZLTSA-N,CSCC1CN(/N=C/C2CCC([N+](=O)[O-])O2)C(=O)O1;CSCC1CN(\N=C\C2CCC(O2)[N+]([O-])=O)C(=O)O1
INIPARIB,INIPARIB,CHEMBL1170047,BRD:BRD-BRD-K11153516-001-05-5;BRD:BRD-K11153516-001-05-5,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PHASE 3,,Small molecule,Phase 3,MDOJTZQKHMAPBK-UHFFFAOYSA-N,NC(=O)C1CCC(I)C([N+](=O)[O-])C1;NC(=O)C1CCC(I)C(C1)[N+]([O-])=O
INLYTA,INLYTA,CHEMBL1289926,GDSC1:1021;GDSC2:1021,gdsc,,,,,,,Small molecule,Approved,RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)C1CCCCC1SC1CCC2C(/C=C/C3CCCCN3)N[NH]C2C1
INOSINE,INOSINE,CHEMBL1556,BRD:BRD-BRD-K79612754-001-19-1;BRD:BRD-BRD-K79612754-001-21-7;BRD:BRD-K79612754-001-19-1;BRD:BRD-K79612754-001-21-7,rep_multi_dose;rep_primary;rep_single_dose,NEUROTROPHIC AGENT,PARP1;PNP,,,LAUNCHED,,Small molecule,Phase 3,UGQMRVRMYYASKQ-KQYNXXCUSA-N,O=C1[NH]CNC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O;OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(O)NCNC12
INOSITOL,INOSITOL,CHEMBL1222251;CHEMBL468154;CHEMBL493737,BRD:BRD-BRD-K52618540-001-09-9;BRD:BRD-K52618540-001-09-9,rep_primary;rep_single_dose,INSULIN SENSITIZER,CDIPT;GBA,,,LAUNCHED,,Small molecule,Phase 3,CDAISMWEOUEBRE-CDRYSYESSA-N;CDAISMWEOUEBRE-GPIVLXJGSA-N;DSCFFEYYQKSRSV-KLJZZCKASA-N,CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O;O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O;O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O;O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O
INOSITOL-HEXANICOTINATE,INOSITOL-HEXANICOTINATE,,BRD:BRD-BRD-K82800842-001-01-9;BRD:BRD-K82800842-001-01-9,rep_primary;rep_single_dose,,,"STATIS DERMATITIS, CLAUDICATION, RAYNAUD'S DISEASE, HYPERTENSION, INSOMNIA, ATHEROSCLEROSIS, RESTLESS LEG SYNDROME, SCHIZOPHRENIA, PSORIASIS, ACNE VULGARIS (AV)",,LAUNCHED,,,NA,,O=C(O[C@H]1[C@H](OC(=O)C2CCCNC2)[C@@H](OC(=O)C2CCCNC2)[C@H](OC(=O)C2CCCNC2)[C@H](OC(=O)C2CCCNC2)[C@@H]1OC(=O)C1CCCNC1)C1CCCNC1
INT-747,INT-747,CHEMBL566315,BRD:BRD-BRD-K30968378-001-01-9;BRD:BRD-K30968378-001-01-9,rep_primary;rep_single_dose,FXR AGONIST,,,,PHASE 3,,Small molecule,Approved,ZXERDUOLZKYMJM-ZWECCWDJSA-N,CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12;CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
INT-767,INT-767,,BRD:BRD-BRD-K33067152-236-01-1;BRD:BRD-K33067152-236-01-1,rep_primary;rep_single_dose,FXR AGONIST,GPBAR1,,,PHASE 1,,,NA,,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
INTEGRIN-ANTAGONIST-1,INTEGRIN-ANTAGONIST-1,,BRD:BRD-BRD-K88165431-003-01-4;BRD:BRD-K88165431-003-01-4,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGAV;ITGB6,,,PHASE 1,,,NA,,CC1CC(C)N(N1)-C1CCCC(C1)[C@@H](CN1CC[C@@H](CCC2=CC=C3CCCN=C3N2)C1)CC(O)=O
INX-08189,INX-08189,CHEMBL1209734,BRD:BRD-K00004752-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 2,YFXGICNMLCGLHJ-RSKRLRQZSA-N,COC1NC(N)NC2C1NCN2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC2CCCC3CCCCC23)[C@@H](O)[C@@]1(C)O
IOBENGUANE,IOBENGUANE,CHEMBL1615779;CHEMBL3989523;CHEMBL818,BRD:BRD-BRD-K43860855-065-11-9;BRD:BRD-K43860855-065-11-9,rep_multi_dose;rep_primary;rep_single_dose,ANTINEOPLASTIC AGENT,,"NEUROBLASTOMA, CONGESTIVE HEART FAILURE, PHEOCHROMOCYTOMA",,LAUNCHED,,Small molecule,Approved,PDWUPXJEEYOOTR-JRGAVVOBSA-N;PDWUPXJEEYOOTR-UHFFFAOYSA-N;XNACDNPGABUBFR-FKNPGSCZSA-N,N=C(N)NCC1CCCC([123I])C1.N=C(N)NCC1CCCC([123I])C1.O=S(=O)(O)O;N=C(N)NCC1CCCC([131I])C1;N=C(N)NCC1CCCC(I)C1;NC(=N)NCC1CCCC(I)C1
IOCETAMIC-ACID,IOCETAMIC-ACID,,BRD:BRD-A37492983-001-10-3;BRD:BRD-BRD-A37492983-001-10-3,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,,NA,,CC(CN(C(C)=O)C1C(I)CC(I)C(N)C1I)C(O)=O
IODIPAMIDE,IODIPAMIDE,CHEMBL1165268,BRD:BRD-BRD-K67261995-001-11-7;BRD:BRD-K67261995-001-11-7,rep_multi_dose;rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,ALB,CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,FFINMCNLQNTKLU-UHFFFAOYSA-N,O=C(CCCCC(=O)NC1C(I)CC(I)C(C(=O)O)C1I)NC1C(I)CC(I)C(C(=O)O)C1I;OC(=O)C1C(I)CC(I)C(NC(=O)CCCCC(=O)NC2C(I)CC(I)C(C(O)=O)C2I)C1I
IODIXANOL,IODIXANOL,CHEMBL1200507,BRD:BRD-A08660406-001-05-9;BRD:BRD-BRD-A08660406-001-05-9,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,Unknown,Approved,NBQNWMBBSKPBAY-UHFFFAOYSA-N,CC(=O)N(CC(O)CN(C(C)=O)C1C(I)C(C(=O)NCC(O)CO)C(I)C(C(=O)NCC(O)CO)C1I)C1C(I)C(C(=O)NCC(O)CO)C(I)C(C(=O)NCC(O)CO)C1I
IODOANTIPYRINE,IODOANTIPYRINE,CHEMBL2104814;CHEMBL24132,BRD:BRD-BRD-K69216798-001-01-9;BRD:BRD-K69216798-001-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,ZZOBLCHCPLOXCE-HJSJVHDISA-N;ZZOBLCHCPLOXCE-UHFFFAOYSA-N,CC1C([131I])C(=O)N(-C2CCCCC2)N1C;CC1C(I)C(=O)N(-C2CCCCC2)N1C
IODODEXETIMIDE,IODODEXETIMIDE,,BRD:BRD-A46813902-001-01-6;BRD:BRD-BRD-A46813902-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,,,PHASE 2,,,NA,,IC1CCC(CN2CCC(CC2)C2(CCC(=O)NC2=O)C2CCCCC2)CC1
IODOPHENPROPIT,IODOPHENPROPIT,CHEMBL498770,BRD:BRD-BRD-K51918615-303-02-9;BRD:BRD-K51918615-303-02-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH3;HRH4,,,PRECLINICAL,,Small molecule,NA,UBHYDQAARZKHEZ-UHFFFAOYSA-N,IC1CCC(CCNC(=N)SCCCC2C[NH]CN2)CC1;N/C(=N/CCC1CCC(I)CC1)SCCCC1CNC[NH]1
IODOQUINOL,IODOQUINOL,CHEMBL86754,BRD:BRD-BRD-K75855670-001-14-2;BRD:BRD-K75855670-001-14-2,rep_primary;rep_single_dose,ANTISEPTIC,,AMEBIASIS,,LAUNCHED,,Small molecule,Unknown,UXZFQZANDVDGMM-UHFFFAOYSA-N,OC1C(I)CC(I)C2CCCNC12
IOHEXOL,IOHEXOL,CHEMBL1200455,BRD:BRD-A60217728-001-11-2;BRD:BRD-BRD-A60217728-001-11-2,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,NTHXOOBQLCIOLC-UHFFFAOYSA-N,CC(=O)N(CC(O)CO)C1C(I)C(C(=O)NCC(O)CO)C(I)C(C(=O)NCC(O)CO)C1I
IOMAZENIL,IOMAZENIL,CHEMBL2105020;CHEMBL2110679,BRD:BRD-K00075696-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,FRIZVHMAECRUBR-KIWWSDKQSA-N;FRIZVHMAECRUBR-UHFFFAOYSA-N,CCOC(=O)C1NCN2C1CN(C)C(=O)C1C([123I])CCCC1-2;CCOC(=O)C1NCN2C1CN(C)C(=O)C1C(I)CCCC1-2
IOPAMIDOL,IOPAMIDOL,CHEMBL1200932,BRD:BRD-BRD-K75868704-001-05-3;BRD:BRD-K75868704-001-05-3,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,XQZXYNRDCRIARQ-LURJTMIESA-N,C[C@H](O)C(=O)NC1C(I)C(C(=O)NC(CO)CO)C(I)C(C(=O)NC(CO)CO)C1I
IOPANIC-ACID,IOPANIC-ACID,,BRD:BRD-A42628519-001-12-4;BRD:BRD-BRD-A42628519-001-12-4,rep_primary;rep_single_dose,THYROID HORMONE INHIBITOR,,,,PRECLINICAL,,,NA,,CCC(CC1C(I)CC(I)C(N)C1I)C(O)=O
IOPODIC-ACID,IOPODIC-ACID,,BRD:BRD-BRD-K51956333-001-03-8;BRD:BRD-K51956333-001-03-8,rep_primary;rep_single_dose,,,CONTRAST AGENT,,LAUNCHED,,,NA,,CN(C)\C=N\C1C(I)CC(I)C(CCC(O)=O)C1I
IOVERSOL,IOVERSOL,CHEMBL1200614,BRD:BRD-A65818372-001-05-3;BRD:BRD-BRD-A65818372-001-05-3,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,AMDBBAQNWSUWGN-UHFFFAOYSA-N,O=C(NCC(O)CO)C1C(I)C(C(=O)NCC(O)CO)C(I)C(N(CCO)C(=O)CO)C1I;OCCN(C(=O)CO)C1C(I)C(C(=O)NCC(O)CO)C(I)C(C(=O)NCC(O)CO)C1I
IOWH032,IOWH032,CHEMBL4297392,BRD:BRD-BRD-K84892605-001-01-1;BRD:BRD-K84892605-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,CFTR CHANNEL ANTAGONIST,CFTR,,,PHASE 2,,Small molecule,Phase 2,DSFNLJXHXBIKDS-UHFFFAOYSA-N,O=C(NCC1CCC(OC2CCCCC2)CC1)C1NC(-C2CC(BR)C(O)C(BR)C2)NO1;OC1C(BR)CC(CC1BR)-C1NOC(N1)C(=O)NCC1CCC(OC2CCCCC2)CC1
IOX 2,IOX 2,,GDSC1:1230,gdsc,,,,,,,,NA,,
IOX-2,IOX-2,,GDSC1:1230,gdsc,,,,,,,,NA,,
IOX1,IOX1,,BRD:BRD-K70751730-001-10-4,rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,EGLN1;KDM3A;KDM4C;KDM6B,,,,,,NA,,
IOX2,IOX2,,BRD:BRD-BRD-K98251413-001-04-0;BRD:BRD-K98251413-001-04-0;GDSC1:1230,gdsc;rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,EGLN1;KDM2A;KDM5C,,,PRECLINICAL,,,NA,,OC(=O)CNC(=O)C1C(O)C2CCCCC2N(CC2CCCCC2)C1=O
IOXAGLIC-ACID,IOXAGLIC-ACID,,BRD:BRD-BRD-K79124250-001-08-9;BRD:BRD-K79124250-001-08-9,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,,NA,,CNC(=O)C1C(I)C(N(C)C(C)=O)C(I)C(C(=O)NCC(=O)NC2C(I)C(C(O)=O)C(I)C(C(=O)NCCO)C2I)C1I
IOXILAN,IOXILAN,CHEMBL1201075,BRD:BRD-A09370961-001-01-0;BRD:BRD-BRD-A09370961-001-01-0,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,ANGIOGRAPHY,,LAUNCHED,,Small molecule,Approved,UUMLTINZBQPNGF-UHFFFAOYSA-N,CC(=O)N(CC(O)CO)C1C(I)C(C(=O)NCCO)C(I)C(C(=O)NCC(O)CO)C1I
IPA 3,IPA 3,,GDSC1:176,gdsc,,,,,,,,NA,,
IPA-3,IPA-3,,GDSC1:176,gdsc,,,,,,,,NA,,
IPAG,IPAG,,BRD:BRD-BRD-K82421491-001-02-6;BRD:BRD-K82421491-001-02-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,IC1CCC(NC(=N)NC2C3CC4CC(C3)CC2C4)CC1
IPI549,IPI549,,BRD:BRD-K00003385-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,,NA,,
IPIDACRINE,IPIDACRINE,CHEMBL130880,BRD:BRD-BRD-K66896231-001-08-1;BRD:BRD-K66896231-001-08-1,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,PHASE 3,,Small molecule,Unknown,YLUSMKAJIQOXPV-UHFFFAOYSA-N,NC1C2C(NC3C1CCC3)CCCC2;NC1C2CCCC2NC2CCCCC12
IPR-456,IPR-456,,CTRP:660084,ctrp,,,,,,,,NA,,
IPRAGLIFLOZIN-L-PROLINE,IPRAGLIFLOZIN-L-PROLINE,,BRD:BRD-BRD-K51247865-001-01-2;BRD:BRD-K51247865-001-01-2,rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A2,DIABETES MELLITUS,,LAUNCHED,,,NA,,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1CCC(F)C(CC2CC3CCCCC3S2)C1
IPRATROPIUM,IPRATROPIUM,CHEMBL1621597,BRD:BRD-A47449001-004-13-7;BRD:BRD-BRD-A47449001-004-13-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,"BRONCHOSPASM, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,OEXHQOGQTVQTAT-BHIXFJMTSA-N,CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)C1CCCCC1)C2;CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1CCCCC1
IPRIFLAVONE,IPRIFLAVONE,CHEMBL165790,BRD:BRD-BRD-K93618743-001-21-0;BRD:BRD-K93618743-001-21-0,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,,OSTEOPOROSIS,,LAUNCHED,,Small molecule,Unknown,SFBODOKJTYAUCM-UHFFFAOYSA-N,CC(C)OC1CCC2C(=O)C(-C3CCCCC3)COC2C1;CC(C)OC1CCC2C(C1)OCC(-C1CCCCC1)C2=O
IPRONIAZID,IPRONIAZID,CHEMBL92401,BRD:BRD-BRD-K88568253-011-19-9;BRD:BRD-K88568253-011-19-9,rep_multi_dose;rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,,,WITHDRAWN,,Small molecule,Approved,NYMGNSNKLVNMIA-UHFFFAOYSA-N,CC(C)NNC(=O)C1CCNCC1
IPSAPIRONE,IPSAPIRONE,CHEMBL8412,BRD:BRD-BRD-K90574421-001-03-5;BRD:BRD-K90574421-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PHASE 3,,Small molecule,Unknown,TZJUVVIWVWFLCD-UHFFFAOYSA-N,O=C1C2CCCCC2S(=O)(=O)N1CCCCN1CCN(C2NCCCN2)CC1;O=C1N(CCCCN2CCN(CC2)C2NCCCN2)S(=O)(=O)C2CCCCC12
IRBESARTAN,IRBESARTAN,CHEMBL1513,BRD:BRD-BRD-K60038276-001-09-0;BRD:BRD-K60038276-001-09-0,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1;JUN;SLC10A1,"HYPERTENSION, DIABETIC NEPHROPATHY",,LAUNCHED,,Small molecule,Approved,YOSHYTLCDANDAN-UHFFFAOYSA-N,CCCCC1=NC2(CCCC2)C(=O)N1CC1CCC(-C2CCCCC2-C2NNN[NH]2)CC1;CCCCC1=NC2(CCCC2)C(=O)N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
IRESSA,IRESSA,CHEMBL939,GDSC1:1010;GDSC2:1010,gdsc,,,,,,,Small molecule,Approved,XGALLCVXEZPNRQ-UHFFFAOYSA-N,COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1OCCCN1CCOCC1
IRGANOX-1010,IRGANOX-1010,,BRD:BRD-K00004549-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
IRGD-PEPTIDE,IRGD-PEPTIDE,,BRD:BRD-K00003335-001-01-9,rep_single_dose,INTEGRIN SIGNALING ACTIVATOR,,,,,,,NA,,
IRINOTECAN,IRINOTECAN,CHEMBL481,BRD:BRD-BRD-K08547377-394-03-5;BRD:BRD-K08547377-001-04-4;BRD:BRD-K08547377-001-05-1;BRD:BRD-K08547377-394-03-5;GDSC2:1088,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF TOPOISOMERASE 1,TOP1;TOP1A;TOP1MT,COLORECTAL CANCER,,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF TOPOISOMERASE 1', 'TOPOISOMERASE INHIBITOR'}, defaulting to 'INHIBITOR OF TOPOISOMERASE 1'
Multiple values for repurposing_target: {'TOP1;TOP1MT', 'TOP1A'}, taking the union",Small molecule,Approved,UWKQSNNFCGGAFS-XIFFEERXSA-N,CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC;CCC1C2CN3C(CC4C(COC(=O)[C@]4(O)CC)C3=O)-C2NC2CCC(OC(=O)N3CCC(CC3)N3CCCCC3)CC12
IRINOTECAN HYDROCHLORIDE,IRINOTECAN HYDROCHLORIDE,CHEMBL1200512;CHEMBL3989514;CHEMBL541887,GDSC2:1088,gdsc,,,,,,,Small molecule,Approved,GURKHSYORGJETM-WAQYZQTGSA-N;KLEAIHJJLUAXIQ-JDRGBKBRSA-N;OHNBIIZWIUBGTK-NYPSMHOZSA-N,CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC.CL;CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC.CL.O;CCC1C2C(NC3CCC(OC(=O)N4CCC(N5CCCCC5)CC4)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC.CL.O.O.O
IRINOTECANUM,IRINOTECANUM,,GDSC2:1088,gdsc,,,,,,,,NA,,
IRL-2500,IRL-2500,,BRD:BRD-BRD-K98357249-001-02-9;BRD:BRD-K98357249-001-02-9,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRB,,,PRECLINICAL,,,NA,,CN([C@H](CC1CCC(CC1)-C1CCCCC1)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(O)=O)C(=O)C1CC(C)CC(C)C1
IROSUSTAT,IROSUSTAT,CHEMBL286738,BRD:BRD-BRD-K87777313-001-02-2;BRD:BRD-K87777313-001-02-2,rep_primary;rep_single_dose,STEROID SULFATASE INHIBITOR,CA2;STS,,,PHASE 2,,Small molecule,Phase 2,DSLPMJSGSBLWRE-UHFFFAOYSA-N,NS(=O)(=O)OC1CCC2C3C(C(=O)OC2C1)CCCCC3;NS(=O)(=O)OC1CCC2C3CCCCCC3C(=O)OC2C1
IRSOGLADINE,IRSOGLADINE,CHEMBL136497,BRD:BRD-BRD-K74195153-050-12-1;BRD:BRD-K74195153-050-12-1,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Phase 1,ATCGGEJZONJOCL-UHFFFAOYSA-N,NC1NC(N)NC(-C2CC(CL)CCC2CL)N1;NC1NC(N)NC(N1)-C1CC(CL)CCC1CL
ISAMOLTANE,ISAMOLTANE,CHEMBL27077,BRD:BRD-A26845397-051-01-9;BRD:BRD-BRD-A26845397-051-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,HTR1A;HTR1B,,,PHASE 1,,Small molecule,Unknown,XVTVPGKWYHWYAD-UHFFFAOYSA-N,CC(C)NCC(O)COC1CCCCC1-N1CCCC1
ISAVUCONAZOLE,ISAVUCONAZOLE,CHEMBL409153,BRD:BRD-A17009129-001-01-3;BRD:BRD-BRD-A17009129-001-01-3,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP3A4,,,PHASE 3,,Small molecule,Approved,DDFOUSQFMYRUQK-RCDICMHDSA-N,C[C@@H](C1NC(-C2CCC(C#N)CC2)CS1)[C@](O)(CN1CNCN1)C1CC(F)CCC1F;C[C@@H](C1NC(CS1)-C1CCC(CC1)C#N)C(O)(CN1CNCN1)C1CC(F)CCC1F
ISAXONINE,ISAXONINE,CHEMBL1740513,BRD:BRD-BRD-K95957366-001-02-6;BRD:BRD-K95957366-001-02-6,rep_primary;rep_single_dose,NERVE GROWTH FACTOR AGONIST,,,,WITHDRAWN,,Small molecule,Approved,FTCYIGBVOHNHCD-UHFFFAOYSA-N,CC(C)NC1NCCCN1
ISBUFYLLINE,ISBUFYLLINE,CHEMBL1453416,BRD:BRD-BRD-K06762493-001-08-1;BRD:BRD-K06762493-001-08-1,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,PHASE 2,,Small molecule,Unknown,WHUWQSQEVISUMC-UHFFFAOYSA-N,CC(C)CN1CNC2C1C(=O)N(C)C(=O)N2C;CC(C)CN1CNC2N(C)C(=O)N(C)C(=O)C12
ISEPAMICIN,ISEPAMICIN,CHEMBL272080,BRD:BRD-BRD-K74759733-065-01-4;BRD:BRD-K74759733-065-01-4,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,"PNEUMONIA, PERITONITIS",,LAUNCHED,,Small molecule,Unknown,UDIIBEDMEYAVNG-ZKFPOVNWSA-N,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CN)OC[C@]1(C)O;CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O
ISLATRAVIR,ISLATRAVIR,CHEMBL517231,BRD:BRD-K00079205-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,IKKXOSBHLYMWAE-QRPMWFLTSA-N,C#C[C@]1(CO)O[C@@H](N2CNC3C(N)NC(F)NC32)C[C@@H]1O
ISO-1,ISO-1,,BRD:BRD-A94055480-001-02-9,rep_single_dose,MACROPHAGE MIGRATION INHIBITING FACTOR INHIBITOR,MIF,,,,,,NA,,
ISOBUTAMBEN,ISOBUTAMBEN,CHEMBL1985617,BRD:BRD-BRD-K96714749-001-01-0;BRD:BRD-K96714749-001-01-0,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,Small molecule,Unknown,PUYOAVGNCWPANW-UHFFFAOYSA-N,CC(C)COC(=O)C1CCC(N)CC1
ISOBUTYRAMIDE,ISOBUTYRAMIDE,CHEMBL352219,BRD:BRD-BRD-K54057105-001-01-2;BRD:BRD-K54057105-001-01-2,rep_primary;rep_single_dose,GENE EXPRESSION STIMULANT,HBE1;HBG1,,,PHASE 2,,Small molecule,NA,WFKAJVHLWXSISD-UHFFFAOYSA-N,CC(C)C(N)=O
ISOCONAZOLE,ISOCONAZOLE,CHEMBL1571863,BRD:BRD-A93353767-008-02-2;BRD:BRD-BRD-A93353767-008-02-2,rep_primary;rep_single_dose,FUNGAL LANOSTEROL DEMETHYLASE INHIBITOR,CYP17A1,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,MPIPASJGOJYODL-UHFFFAOYSA-N,CLC1CCC(C(CN2CCNC2)OCC2C(CL)CCCC2CL)C(CL)C1
ISODIBUT,ISODIBUT,,BRD:BRD-BRD-K60241851-001-11-9;BRD:BRD-K60241851-001-11-9,rep_primary;rep_single_dose,ALDEHYDE REDUCTASE INHIBITOR,,,,PHASE 2,,,NA,,OC(=O)CCCN1C(=O)C2CCCC3CCCC(C1=O)C23
ISOETHARINE,ISOETHARINE,CHEMBL1201213,BRD:BRD-A24587114-066-22-5;BRD:BRD-BRD-A24587114-066-22-5,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2,"BRONCHOSPASM, ASTHMA",,LAUNCHED,,Small molecule,Approved,HUYWAWARQUIQLE-UHFFFAOYSA-N,CCC(NC(C)C)C(O)C1CCC(O)C(O)C1
ISOEVODIAMINE,ISOEVODIAMINE,,CTRP:594664,ctrp,,,,,,,,NA,,
ISOFLOXYTHEPIN,ISOFLOXYTHEPIN,,BRD:BRD-A07704283-001-01-3;BRD:BRD-BRD-A07704283-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,PHASE 2,,,NA,,CC(C)C1CCC2SC3CC(F)CCC3CC(N3CCN(CCO)CC3)C2C1
ISOFLUPREDONE-ACETATE,ISOFLUPREDONE-ACETATE,,BRD:BRD-BRD-K29173907-001-09-2;BRD:BRD-K29173907-001-09-2,rep_multi_dose;rep_primary;rep_single_dose,,NR3C1,,,PRECLINICAL,,,NA,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
ISOFLURANE,ISOFLURANE,CHEMBL1256,BRD:BRD-A31564021-001-01-8;BRD:BRD-BRD-A31564021-001-01-8,rep_primary;rep_single_dose,INHALED ANAESTHETIC,ATP2C1;ATP5D;CALM1;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;GLRB;GRIA1;KCNA1;KCNK10;KCNK18;KCNK2;KCNK3;KCNK9,GENERAL ANAESTHETIC,,LAUNCHED,,Small molecule,Approved,PIWKPBJCKXDKJR-UHFFFAOYSA-N,FC(F)OC(CL)C(F)(F)F
ISOFLUROPHATE,ISOFLUROPHATE,CHEMBL1025,BRD:BRD-K56575995-001-03-0,rep_single_dose,CHOLINESTERASE INHIBITOR,ACHE;BCHE,,,,,Small molecule,Approved,MUCZHBLJLSDCSD-UHFFFAOYSA-N,CC(C)OP(=O)(F)OC(C)C
ISOGUVACINE,ISOGUVACINE,CHEMBL39071,BRD:BRD-BRD-K66480997-003-10-0;BRD:BRD-K66480997-003-10-0,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRR1;GABRR2;GABRR3,,,PRECLINICAL,,Small molecule,NA,KRVDMABBKYMBHG-UHFFFAOYSA-N,O=C(O)C1=CCNCC1;OC(=O)C1=CCNCC1
ISOLEUCINE,ISOLEUCINE,CHEMBL1233584,BRD:BRD-A02232681-001-01-8;BRD:BRD-BRD-A02232681-001-01-8,rep_primary;rep_single_dose,,ACADSB;BCAT1;BCAT2;IARS;IARS2,,,LAUNCHED,,Small molecule,Phase 2,AGPKZVBTJJNPAG-WHFBIAKZSA-N,CC[C@H](C)[C@H](N)C(=O)O;CCC(C)C(N)C(O)=O
ISOLIQUIRITIGENIN,ISOLIQUIRITIGENIN,CHEMBL129795,BRD:BRD-BRD-K33583600-001-16-1;BRD:BRD-K33583600-001-16-1;CTRP:25393,ctrp;rep_primary;rep_single_dose,GUANYLATE CYCLASE ACTIVATOR,GABBR1,,,PRECLINICAL,,Small molecule,NA,DXDRHHKMWQZJHT-FPYGCLRLSA-N,O=C(/C=C/C1CCC(O)CC1)C1CCC(O)CC1O;OC1CCC(CC1)\C=C\C(=O)C1CCC(O)CC1O
ISOMETHEPTENE-MUCATE,ISOMETHEPTENE-MUCATE,CHEMBL1697841,BRD:BRD-A64743628-001-01-5;BRD:BRD-BRD-A64743628-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,,ADRA1A;SLC18A2,HEADACHE,,LAUNCHED,,Small molecule,Approved,XVQUOJBERHHONY-UHFFFAOYSA-N,CNC(C)CCC=C(C)C
ISONIAZID,ISONIAZID,CHEMBL64,BRD:BRD-BRD-K87202646-001-32-6,rep_primary,FABI INHIBITOR,CYP1A2;CYP2C19;CYP2C8;CYP2E1;CYP3A4,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,QRXWMOHMRWLFEY-UHFFFAOYSA-N,NNC(=O)C1CCNCC1
ISONICOTINOHYDROXAMIC ACID,ISONICOTINOHYDROXAMIC ACID,,CTRP:478694,ctrp,,,,,,,,NA,,
ISOPENTYL-4-METHOXYCINNAMATE,ISOPENTYL-4-METHOXYCINNAMATE,,BRD:BRD-K37851352-001-02-9,rep_single_dose,,,,,,,,NA,,
ISOPRENALINE,ISOPRENALINE,CHEMBL1160723;CHEMBL1711;CHEMBL434,BRD:BRD-A04322457-003-17-9;BRD:BRD-BRD-A04322457-003-17-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3;MAPK1;PIK3R1;PIK3R2;PIK3R3,"BRADYCARDIA, HEART BLOCK, ASTHMA",,LAUNCHED,,Small molecule,Approved,IROWCYIEJAOFOW-UHFFFAOYSA-N;JWZZKOKVBUJMES-NSHDSACASA-N;JWZZKOKVBUJMES-UHFFFAOYSA-N,CC(C)NC[C@H](O)C1CCC(O)C(O)C1;CC(C)NCC(O)C1CCC(O)C(O)C1;CC(C)NCC(O)C1CCC(O)C(O)C1.CL
ISOPROPAMIDE-IODIDE,ISOPROPAMIDE-IODIDE,,BRD:BRD-BRD-K14127446-005-22-7;BRD:BRD-K14127446-005-22-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM3;CHRM4,"PEPTIC ULCER DISEASE (PUD), GASTROINTESTINAL ACIDOSIS",,LAUNCHED,,,NA,,CC(C)[N+](C)(CCC(C(N)=O)(C1CCCCC1)C1CCCCC1)C(C)C
ISOPROPYL-MYRISTATE,ISOPROPYL-MYRISTATE,,BRD:BRD-BRD-K13409143-001-01-9;BRD:BRD-K13409143-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,,,COSMETIC,,LAUNCHED,,,NA,,CCCCCCCCCCCCCC(=O)OC(C)C
ISOPROPYL-PALMITATE,ISOPROPYL-PALMITATE,,BRD:BRD-BRD-K30758549-001-01-8;BRD:BRD-K30758549-001-01-8,rep_primary;rep_single_dose,COSMETIC MOISTURIZER,,COSMETIC,,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCC(=O)OC(C)C
ISOQUERCITRIN,ISOQUERCITRIN,CHEMBL250450,BRD:BRD-K73991644-001-07-9,rep_single_dose,ANTIOXIDANT,,,,,,Small molecule,Phase 2,OVSQVDMCBVZWGM-QSOFNFLRSA-N,O=C1C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(-C2CCC(O)C(O)C2)OC2CC(O)CC(O)C12
"ISOQUINOLINE,-6,7-DIMETHOXY-1-METHYL-1,2,3,4-TETRAHYDRO,","ISOQUINOLINE,-6,7-DIMETHOXY-1-METHYL-1,2,3,4-TETRAHYDRO,",,BRD:BRD-A75140635-003-10-9;BRD:BRD-BRD-A75140635-003-10-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CC2CCNC(C)C2CC1OC
ISOSORBIDE-MONONITRATE,ISOSORBIDE-MONONITRATE,,BRD:BRD-BRD-K82225283-001-03-1;BRD:BRD-K82225283-001-03-1,rep_primary;rep_single_dose,NITRIC OXIDE STIMULANT,GUCY1A2;GUCY1A3;GUCY1B2;GUCY1B3,"ANGINA PECTORIS, CORONARY ARTERY DISEASE (CAD)",,LAUNCHED,,,NA,,O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O
ISOSTEVIOL,ISOSTEVIOL,CHEMBL462653,BRD:BRD-A96529864-001-01-3;BRD:BRD-BRD-A96529864-001-01-3,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,NA,KFVUFODCZDRVSS-XGBBNYNSSA-N,C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)C3CC2;C[C@@]12CC[C@@H]3[C@@](CC[C@H]4[C@@]3(C)CCC[C@@]4(C)C(=O)O)(CC1=O)C2
ISOTIQUIMIDE,ISOTIQUIMIDE,CHEMBL2107405,BRD:BRD-A02933148-001-01-8;BRD:BRD-BRD-A02933148-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Unknown,PWPWEYFVLITGNU-UHFFFAOYSA-N,CC1CCNC2C(CCCC12)C(N)=S;CC1CCNC2C1CCCC2C(N)=S
ISOVALERAMIDE,ISOVALERAMIDE,CHEMBL171066,BRD:BRD-BRD-K90069354-001-03-7;BRD:BRD-K90069354-001-03-7,rep_primary;rep_single_dose,ALCOHOL DEHYDROGENASE INHIBITOR,,,,PHASE 2,,Small molecule,Unknown,SANOUVWGPVYVAV-UHFFFAOYSA-N,CC(C)CC(N)=O
ISOX,ISOX,,CTRP:632907,ctrp,,,,,,,,NA,,
ISOX:BORTEZOMIB (250:1 MOL/MOL),ISOX:BORTEZOMIB (250:1 MOL/MOL),,CTRP:660173,ctrp,,,,,,,,NA,,
ISOXEPAC,ISOXEPAC,CHEMBL33211,BRD:BRD-BRD-K92116564-001-01-4;BRD:BRD-K92116564-001-01-4,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,PHASE 2,,Small molecule,Unknown,QFGMXJOBTNZHEL-UHFFFAOYSA-N,O=C(O)CC1CCC2C(C1)C(=O)C1CCCCC1CO2;OC(=O)CC1CCC2OCC3CCCCC3C(=O)C2C1
ISOXICAM,ISOXICAM,CHEMBL53292,BRD:BRD-A75552914-001-15-0;BRD:BRD-BRD-A75552914-001-15-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,WITHDRAWN,,Small molecule,Approved,YYUAYBYLJSNDCX-UHFFFAOYSA-N,CC1CC(NC(=O)C2=C(O)C3CCCCC3S(=O)(=O)N2C)NO1;CN1C(C(=O)NC2CC(C)ON2)C(=O)C2CCCCC2S1(=O)=O
ISOXSUPRINE,ISOXSUPRINE,CHEMBL1197051,BRD:BRD-A16700644-003-04-4;BRD:BRD-BRD-A16700644-003-04-4,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,"RAYNAUD'S DISEASE, ARTERIOSCLEROSIS, BUERGER'S DISEASE",,LAUNCHED,,Small molecule,Approved,BMUKKTUHUDJSNZ-UHFFFAOYSA-N,CC(COC1CCCCC1)NC(C)[C@H](O)C1CCC(O)CC1;CC(COC1CCCCC1)NC(C)C(O)C1CCC(O)CC1
ISPINESIB MESYLATE,ISPINESIB MESYLATE,CHEMBL2347651,GDSC1:208,gdsc,,,,,,,Small molecule,Unknown,MRKSDPIHUJSKRA-HZPIKELBSA-N,CS(=O)(=O)O.CC1CCC(C(=O)N(CCCN)[C@@H](C2NC3CC(CL)CCC3C(=O)N2CC2CCCCC2)C(C)C)CC1
ISRADIPINE,ISRADIPINE,CHEMBL1648,BRD:BRD-A90799790-001-19-9;BRD:BRD-BRD-A90799790-001-19-9,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1F;CACNA1H;CACNA1S;CACNA2D1;CACNA2D2;CACNB2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,HMJIYCCIJYRONP-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1CCCC2NONC12;COC(=O)C1=C(C)NC(C)=C(C1C1CCCC2NONC12)C(=O)OC(C)C
ISRIB,ISRIB,,BRD:BRD-K12826175-001-02-4,rep_single_dose,"EUKARYOTIC TRANSLATION INITIATION FACTOR INHIBITOR, PERK INHIBITOR",EIF2A;EIF2AK3,,,,,,NA,,
ISTAROXIME,ISTAROXIME,CHEMBL2093999;CHEMBL3989692,BRD:BRD-BRD-K95412502-003-01-5;BRD:BRD-K95412502-003-01-5,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP1A1,,,PHASE 2,,Small molecule,Phase 2,CSHMJIGWNVRUHR-QNXQDRBBSA-N;MPYLDWFDPHRTEG-IFVNMTGRSA-N,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O;C[C@]12CCC(=NOCCN)C[C@@H]1C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12;CCCON=C1CC[C@@]2(C)[C@H](C1)C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12
ISTRADEFYLLINE,ISTRADEFYLLINE,CHEMBL431770,BRD:BRD-BRD-K87774949-001-03-9;BRD:BRD-K87774949-001-03-9;CTRP:687694,ctrp;rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,"PARKINSON'S DISEASE, DYSKINESIA",,LAUNCHED,,Small molecule,Approved,IQVRBWUUXZMOPW-PKNBQFBNSA-N,CCN1C(=O)C2C(NC(/C=C/C3CCC(OC)C(OC)C3)N2C)N(CC)C1=O;CCN1C2NC(\C=C\C3CCC(OC)C(OC)C3)N(C)C2C(=O)N(CC)C1=O
ISX-9,ISX-9,,BRD:BRD-K53903639-001-01-3,rep_single_dose,NEURAL STEM CELL INDUCER,NEUROD1,,,,,,NA,,
IT1T,IT1T,,BRD:BRD-K73499906-300-02-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR4,,,,,,NA,,
ITACITINIB,ITACITINIB,CHEMBL3622820,BRD:BRD-BRD-K67482377-001-01-8;BRD:BRD-K67482377-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK1,,,PHASE 2,,Small molecule,Phase 3,KTBSXLIQKWEBRB-UHFFFAOYSA-N,FC1C(CCNC1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1CC(CN1)-C1NCNC2[NH]CCC12;N#CCC1(N2CC(-C3NCNC4[NH]CCC34)CN2)CN(C2CCN(C(=O)C3CCNC(C(F)(F)F)C3F)CC2)C1
ITD-1,ITD-1,,BRD:BRD-A56690687-001-02-9,rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFBR2,,,,,,NA,,
ITE,ITE,,BRD:BRD-BRD-K60298136-001-03-3;BRD:BRD-K60298136-001-03-3,rep_primary;rep_single_dose,ARYL HYDROCARBON RECEPTOR AGONIST,AHR,,,PRECLINICAL,,,NA,,COC(=O)C1CSC(N1)C(=O)C1C[NH]C2CCCCC12
ITI214,ITI214,,BRD:BRD-BRD-K77987496-011-01-9;BRD:BRD-K77987496-011-01-9,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE1A,,,PHASE 1,,,NA,,CN1C2=N[C@@H]3CCC[C@@H]3N2C2NN(CC3CCC(CC3)-C3CCCC(F)N3)C(NC3CCCCC3)C2C1=O
ITK INHIBITOR,ITK INHIBITOR,,GDSC1:63,gdsc,,,,,,,,NA,,
ITOPRIDE,ITOPRIDE,CHEMBL2107457,BRD:BRD-BRD-K96740444-001-02-1;BRD:BRD-K96740444-001-02-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CHRM3;DRD2,"DYSPEPSIA, GASTROPARESIS, HEARTBURN, NAUSEA, VOMITING, ANOREXIA",,LAUNCHED,,Small molecule,Phase 3,QQQIECGTIMUVDS-UHFFFAOYSA-N,COC1CCC(C(=O)NCC2CCC(OCCN(C)C)CC2)CC1OC;COC1CCC(CC1OC)C(=O)NCC1CCC(OCCN(C)C)CC1
ITRACONAZOLE,ITRACONAZOLE,CHEMBL64391,BRD:BRD-A23067620-300-01-3;BRD:BRD-BRD-A23067620-300-01-3;CTRP:63349,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP51A1,"ONYCHOMYCOSIS, HISTOPLASMOSIS, BLASTOMYCOSIS, ASPERGILLOSIS",,LAUNCHED,,Small molecule,Approved,VHVPQPYKVGDNFY-UHFFFAOYSA-N,CCC(C)N1NCN(-C2CCC(CC2)N2CCN(CC2)C2CCC(OC[C@H]3CO[C@@](CN4CNCN4)(O3)C3CCC(CL)CC3CL)CC2)C1=O;CCC(C)N1NCN(-C2CCC(N3CCN(C4CCC(OCC5COC(CN6CNCN6)(C6CCC(CL)CC6CL)O5)CC4)CC3)CC2)C1=O
ITX3,ITX3,,BRD:BRD-K36515744-001-03-5,rep_single_dose,GEF INHIBITOR,TRIO,,,,,,NA,,
ITX5061,ITX5061,,BRD:BRD-K76911699-003-03-9,rep_single_dose,SR-BI INHIBITOR,,,,,,,NA,,
IU1,IU1,,BRD:BRD-BRD-K45841694-001-11-7;BRD:BRD-K45841694-001-11-7;CTRP:272805,ctrp;rep_primary;rep_single_dose,UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR,USP14,,,PRECLINICAL,,,NA,,CC1CC(C(=O)CN2CCCC2)C(C)N1-C1CCC(F)CC1
IVABRADINE,IVABRADINE,CHEMBL2145077;CHEMBL471737,BRD:BRD-BRD-K31385749-003-01-3;BRD:BRD-K31385749-003-01-3,rep_primary;rep_single_dose,"HCN CHANNEL ANTAGONIST, POTASSIUM CHANNEL BLOCKER, SODIUM CHANNEL BLOCKER",HCN1;HCN3;HCN4,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Approved,ACRHBAYQBXXRTO-OAQYLSRUSA-N;HLUKNZUABFFNQS-ZMBIFBSDSA-N,COC1CC2C(CC1OC)CC(=O)N(CCCN(C)C[C@H]1CC3CC(OC)C(OC)CC31)CC2;COC1CC2C(CC1OC)CC(=O)N(CCCN(C)C[C@H]1CC3CC(OC)C(OC)CC31)CC2.CL;COC1CC2C[C@@H](CN(C)CCCN3CCC4CC(OC)C(OC)CC4CC3=O)C2CC1OC
IVACAFTOR,IVACAFTOR,CHEMBL2010601,BRD:BRD-BRD-K52818472-001-02-2;BRD:BRD-K52818472-001-02-2,rep_primary;rep_single_dose,CFTR CHANNEL POTENTIATOR,CFTR,CYSTIC FIBROSIS,,LAUNCHED,,Small molecule,Approved,PURKAOJPTOLRMP-UHFFFAOYSA-N,CC(C)(C)C1CC(C(C)(C)C)C(NC(=O)C2C[NH]C3CCCCC3C2=O)CC1O;CC(C)(C)C1CC(C(NC(=O)C2C[NH]C3CCCCC3C2=O)CC1O)C(C)(C)C
IVERMECTIN,IVERMECTIN,CHEMBL1200633,BRD:BRD-BRD-K85554912-001-06-3;BRD:BRD-BRD-K85554912-001-08-9;BRD:BRD-K85554912-001-06-3;BRD:BRD-K85554912-001-08-9,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,CHRNA7;GABRB3;GLRA3;P2RX7,"GASTROINTESTINAL ROUNDWORMS, LUNGWORMS, CATTLE GRUBS, MITES, LICE, HORN FLIES",,LAUNCHED,,Unknown,Approved,SPBDXSGPUHCETR-JFUDTMANSA-N,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@]54O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O;CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
IVOSIDENIB,IVOSIDENIB,CHEMBL3989958,BRD:BRD-BRD-K93073858-001-01-1;BRD:BRD-K93073858-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,IDH1,ACUTE MYELOID LEUKEMIA (AML),,LAUNCHED,,Small molecule,Approved,WIJZXSAJMHAVGX-DHLKQENFSA-N,FC1CNCC(C1)N([C@H](C(=O)NC1CC(F)(F)C1)C1CCCCC1CL)C(=O)[C@@H]1CCC(=O)N1C1CC(CCN1)C#N;N#CC1CCNC(N2C(=O)CC[C@H]2C(=O)N(C2CNCC(F)C2)[C@H](C(=O)NC2CC(F)(F)C2)C2CCCCC2CL)C1
IWP-2,IWP-2,,GDSC2:1576,gdsc,,,,,,,,NA,,
IWP-L6,IWP-L6,,BRD:BRD-BRD-K53234107-001-01-6;BRD:BRD-K53234107-001-01-6,rep_primary;rep_single_dose,PORCUPINE INHIBITOR,PORCN,,,PRECLINICAL,,,NA,,O=C(CSC1NC2CCSC2C(=O)N1-C1CCCCC1)NC1CCC(CN1)-C1CCCCC1
IXABEPILONE,IXABEPILONE,CHEMBL1201752,BRD:BRD-BRD-K03601870-001-01-2;BRD:BRD-K03601870-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE STABILIZING AGENT,TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,FABUFPQFXZVHFB-PVYNADRNSA-N,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C1CSC(C)N1;C/C(=C\C1CSC(C)N1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1
IXAZOMIB,IXAZOMIB,CHEMBL2141296,BRD:BRD-BRD-K78659596-001-03-9;BRD:BRD-K78659596-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,,MULTIPLE MYELOMA,,LAUNCHED,,Small molecule,Approved,MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)C1CC(CL)CCC1CL)B(O)O
IXAZOMIB-CITRATE,IXAZOMIB-CITRATE,,BRD:BRD-A66419424-001-02-4;BRD:BRD-BRD-A66419424-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,,MULTIPLE MYELOMA,,LAUNCHED,,,NA,,CC(C)C[C@H](NC(=O)CNC(=O)C1CC(CL)CCC1CL)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O
J147,J147,CHEMBL2387144,BRD:BRD-K00004699-001-01-9,rep_single_dose,BDNF INDUCER,,,,,,Small molecule,Phase 1,HYMZAYGFKNNHDN-SSDVNMTOSA-N,COC1CCCC(/C=N/N(C(=O)C(F)(F)F)C2CCC(C)CC2C)C1
JAKAFI,JAKAFI,CHEMBL1795071,GDSC1:206;GDSC2:1507,gdsc,,,,,,,Small molecule,Approved,JFMWPOCYMYGEDM-XFULWGLBSA-N,N#CC[C@H](C1CCCC1)N1CC(-C2NCNC3[NH]CCC23)CN1.O=P(O)(O)O
JD-5037,JD-5037,,BRD:BRD-K00003271-001-01-9,rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,,,,,,,NA,,
OPNURASIB,JDQ-443;NVP-JDQ443;OPNURASIB,CHEMBL5077861,BRD:BRD-K00126788-001-01-9,oncref_2,INHIBITOR OF KRAS-G12C,KRAS,,,,,Small molecule,Phase 3,AZUYLZMQTIKGSC-UHFFFAOYSA-N,C=CC(=O)N1CC2(CC(N3NC(-C4CCC5C(CNN5C)C4)C(-C4C(CL)C(C)CC5[NH]NCC45)C3C)C2)C1
JDTIC,JDTIC,CHEMBL415247,BRD:BRD-BRD-K95837862-300-01-7;BRD:BRD-K95837862-300-01-7,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRK1,,,PHASE 1,,Small molecule,Phase 1,ZLVXBBHTMQJRSX-VMGNSXQWSA-N,CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)C1CCCC(O)C1)NC(=O)[C@H]1CC2CCC(O)CC2CN1;CC(C)[C@@H](CN1CC[C@@](C)(C2CCCC(O)C2)[C@@H](C)C1)NC(=O)[C@H]1CC2CCC(O)CC2CN1
JHW-007,JHW-007,,BRD:BRD-K32892871-003-02-9,rep_single_dose,DOPAMINE REUPTAKE INHIBITOR,SLC6A3,,,,,,NA,,
JI-101,JI-101,CHEMBL3545155,BRD:BRD-K00003209-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 2,ZXBFYBLSJMEBEP-UHFFFAOYSA-N,COC1CCC(BR)CC1NC(=O)NC1CCCC2C1CCN2CC1CCNC(N)C1
JIB04,JIB04,,BRD:BRD-BRD-K76180386-001-01-6;BRD:BRD-K76180386-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM4E,,,PRECLINICAL,,,NA,,CLC1CCC(N\N=C(/C2CCCCC2)C2CCCCN2)NC1
JK-184,JK-184,,BRD:BRD-BRD-K38860038-001-01-2;BRD:BRD-K38860038-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,HEDGEHOG PATHWAY INHIBITOR,,,,PRECLINICAL,,,NA,,CCOC1CCC(NC2NC(CS2)-C2C(C)NC3CCCCN23)CC1
JNJ-10191584,JNJ-10191584,,BRD:BRD-BRD-K15086322-050-01-3;BRD:BRD-K15086322-050-01-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH4,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C(=O)C1NC2CCC(CL)CC2[NH]1
JNJ-10397049,JNJ-10397049,,BRD:BRD-K61721596-001-01-0,rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,,,,NA,,
JNJ-16259685,JNJ-16259685,,BRD:BRD-BRD-K25596805-001-01-8;BRD:BRD-K25596805-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1,,,PRECLINICAL,,,NA,,CO[C@H]1CC[C@H](CC1)C(=O)C1CCC2NC3OCCCC3CC2C1
JNJ-1661010,JNJ-1661010,,BRD:BRD-BRD-K47376733-001-08-1;BRD:BRD-K47376733-001-08-1,rep_primary;rep_single_dose,FAAH INHIBITOR,FAAH,,,PRECLINICAL,,,NA,,O=C(NC1CCCCC1)N1CCN(CC1)C1NC(NS1)-C1CCCCC1
JNJ-17203212,JNJ-17203212,,BRD:BRD-BRD-K51770398-001-01-9;BRD:BRD-K51770398-001-01-9,rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCC(NC(=O)N2CCN(CC2)C2NCCCC2C(F)(F)F)NC1
JNJ-26481585,JNJ-26481585,CHEMBL2105763;CHEMBL3039527,BRD:BRD-BRD-K83837640-001-04-8;BRD:BRD-K83837640-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC10;HDAC11;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9;MDM2,,,PHASE 2,,Small molecule,Phase 2,PAWIYAYFNXQGAP-UHFFFAOYSA-N;TWNOICNTTFKOHQ-UHFFFAOYSA-N,CL.CN1CC(CNCC2CCN(C3NCC(C(=O)NO)CN3)CC2)C2CCCCC21;CN1CC(CNCC2CCN(C3NCC(C(=O)NO)CN3)CC2)C2CCCCC21;CN1CC(CNCC2CCN(CC2)C2NCC(CN2)C(=O)NO)C2CCCCC12
JNJ-26854165,JNJ-26854165,CHEMBL2137530,GDSC1:1133,gdsc,,,,,,,Small molecule,Phase 1,CEGSUKYESLWKJP-UHFFFAOYSA-N,C1CCC2C(CCNC3CCC(NC4CCNCC4)CC3)C[NH]C2C1
JNJ-26990990,JNJ-26990990,,BRD:BRD-BRD-K24864897-001-01-0;BRD:BRD-K24864897-001-01-0,rep_primary;rep_single_dose,ANTICONVULSANT,,,,PHASE 2,,,NA,,NS(=O)(=O)NCC1CSC2CCCCC12
JNJ-27141491,JNJ-27141491,,BRD:BRD-K41895652-001-02-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR2,,,,,,NA,,
JNJ-37822681,JNJ-37822681,CHEMBL3234237,BRD:BRD-BRD-K31802667-001-01-9;BRD:BRD-K31802667-001-01-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2,,,PHASE 2,,Small molecule,Phase 2,UVUYWJWYRLJHEN-UHFFFAOYSA-N,FC1CCC(CN2CCC(CC2)NC2CCC(NN2)C(F)(F)F)CC1F;FC1CCC(CN2CCC(NC3CCC(C(F)(F)F)NN3)CC2)CC1F
JNJ-38877605,JNJ-38877605,CHEMBL2133806,BRD:BRD-BRD-K02123250-001-06-7;BRD:BRD-K02123250-001-06-7,rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,MET,,,PHASE 1,,Small molecule,Phase 1,JRWCBEOAFGHNNU-UHFFFAOYSA-N,CN1CC(-C2CCC3NNC(C(F)(F)C4CCC5NCCCC5C4)N3N2)CN1;CN1CC(CN1)-C1CCC2NNC(N2N1)C(F)(F)C1CCC2NCCCC2C1
JNJ-38877618,JNJ-38877618,CHEMBL5095255,BRD:BRD-K00003094-001-01-9,rep_single_dose,C-MET INHIBITOR,,,,,,Small molecule,Phase 1,KOAWAWHSMVKCON-UHFFFAOYSA-N,FC(F)(C1CCC2NCCCC2C1)C1NNC2CCC(-C3CCNCC3)NN12
JNJ-39758979,JNJ-39758979,CHEMBL3236549,BRD:BRD-K00003403-001-01-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,COOGVHJHSCBOQT-MRVPVSSYSA-N,CC(C)C1CC(N2CC[C@@H](N)C2)NC(N)N1
JNJ-40411813,JNJ-40411813,CHEMBL3337527,BRD:BRD-BRD-K55029398-001-01-6;BRD:BRD-K55029398-001-01-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM2,,,PHASE 2,,Small molecule,Phase 2,HYOGJHCDLQSAHX-UHFFFAOYSA-N,CCCCN1CCC(N2CCC(C3CCCCC3)CC2)C(CL)C1=O;CCCCN1CCC(N2CCC(CC2)C2CCCCC2)C(CL)C1=O
JNJ-42041935,JNJ-42041935,,BRD:BRD-BRD-K01036220-001-01-0;BRD:BRD-K01036220-001-01-0,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR,PDK2,,,PRECLINICAL,,,NA,,OC(=O)C1CNN(C1)-C1NC2CC(CL)C(OC(F)(F)F)CC2[NH]1
JNJ-42165279,JNJ-42165279,CHEMBL4297294,BRD:BRD-BRD-K70330032-001-01-1;BRD:BRD-K70330032-001-01-1,rep_primary;rep_single_dose,FAAH INHIBITOR,FAAH,,,PHASE 2,,Small molecule,Phase 2,YWGYNGCRVZLMCS-UHFFFAOYSA-N,FC1(F)OC2CCC(CN3CCN(CC3)C(=O)NC3CNCCC3CL)CC2O1;O=C(NC1CNCCC1CL)N1CCN(CC2CCC3C(C2)OC(F)(F)O3)CC1
JNJ-47965567,JNJ-47965567,,BRD:BRD-K83547600-001-02-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX7,,,,,,NA,,
JNJ-5207852,JNJ-5207852,CHEMBL129542,BRD:BRD-K27889527-001-10-9,rep_single_dose,,,,,,,Small molecule,NA,PTKHFRNHJULJKT-UHFFFAOYSA-N,C1CC(OCCCN2CCCCC2)CCC1CN1CCCCC1
JNJ-54175446,JNJ-54175446,CHEMBL4079239,BRD:BRD-K00004575-001-01-9,rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,CWFVVQFVGMFTBD-SECBINFHSA-N,C[C@@H]1C2NNN(-C3NCC(F)CN3)C2CCN1C(=O)C1CCCC(C(F)(F)F)C1CL
JNJ-63533054,JNJ-63533054,,BRD:BRD-BRD-K19482962-001-01-8;BRD:BRD-K19482962-001-01-8,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPR139,,,PRECLINICAL,,,NA,,C[C@H](NC(=O)CNC(=O)C1CCCC(CL)C1)C1CCCCC1
JNJ-64619178,JNJ-64619178,CHEMBL4249337,BRD:BRD-K30421675-001-04-9,rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,,,,,,Small molecule,Phase 1,DBSMLQTUDJVICQ-CJODITQLSA-N,NC1NC2CC(CC[C@H]3C[C@@H](N4CCC5C(N)NCNC54)[C@H](O)[C@@H]3O)CCC2CC1BR
JNJ-678,JNJ-678,,BRD:BRD-K00004600-001-01-9,rep_single_dose,RSV FUSION INHIBITOR,,,,,,,NA,,
JNJ-7706621,JNJ-7706621,CHEMBL191003,BRD:BRD-BRD-K11636097-001-03-1;BRD:BRD-K11636097-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,AURKA;AURKB;CDK1;CDK2,,,PRECLINICAL,,Small molecule,NA,KDKUVYLMPJIGKA-UHFFFAOYSA-N,NC1NC(NC2CCC(CC2)S(N)(=O)=O)NN1C(=O)C1C(F)CCCC1F;NC1NC(NC2CCC(S(N)(=O)=O)CC2)NN1C(=O)C1C(F)CCCC1F
JNJ-7777120,JNJ-7777120,CHEMBL129198,BRD:BRD-BRD-K17774839-001-02-9;BRD:BRD-K17774839-001-02-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH4,,,PRECLINICAL,,Small molecule,NA,HUQJRYMLJBBEDO-UHFFFAOYSA-N,CN1CCN(C(=O)C2CC3CC(CL)CCC3[NH]2)CC1;CN1CCN(CC1)C(=O)C1CC2CC(CL)CCC2[NH]1
JNJ38877605,JNJ38877605,,GDSC1:284,gdsc,,,,,,,,NA,,
JNK INHIBITOR 9L,JNK INHIBITOR 9L,,GDSC1:157,gdsc,,,,,,,,NA,,
JNK INHIBITOR VIII,JNK INHIBITOR VIII,,GDSC1:1043,gdsc,,,,,,,,NA,,
JNK-9L,JNK-9L,,GDSC1:157,gdsc,,,,,,,,NA,,
JOSAMYCIN,JOSAMYCIN,CHEMBL224436,BRD:BRD-BRD-K25837718-001-03-8;BRD:BRD-K25837718-001-03-8,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,BRONCHITIS,,LAUNCHED,,Small molecule,Phase 3,XJSFLOJWULLJQS-NGVXBBESSA-N,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1OC(C)=O;CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O
JPH203,JPH203,,BRD:BRD-K00003340-300-01-9,rep_single_dose,SOLUTE CARRIER FAMILY MEMBER INHIBITOR,,,,,,,NA,,
JQ-1,JQ-1,,CTRP:616354;GDSC1:1218;GDSC1:163;GDSC2:2172,ctrp;gdsc,,,,,,,,NA,,
JQ-1:CARBOPLATIN (1:1 MOL/MOL),JQ-1:CARBOPLATIN (1:1 MOL/MOL),,CTRP:660247,ctrp,,,,,,,,NA,,
JQ-1:MK-0752 (1:1 MOL/MOL),JQ-1:MK-0752 (1:1 MOL/MOL),,CTRP:660253,ctrp,,,,,,,,NA,,
JQ-1:NAVITOCLAX (2:1 MOL/MOL),JQ-1:NAVITOCLAX (2:1 MOL/MOL),,CTRP:660252,ctrp,,,,,,,,NA,,
JQ-1:UNC0638 (2:1 MOL/MOL),JQ-1:UNC0638 (2:1 MOL/MOL),,CTRP:660129,ctrp,,,,,,,,NA,,
JQ-1:VORINOSTAT (2:1 MOL/MOL),JQ-1:VORINOSTAT (2:1 MOL/MOL),,CTRP:660823,ctrp,,,,,,,,NA,,
JQ1,JQ1,,GDSC1:1218;GDSC1:163;GDSC2:2172,gdsc,,,,,,,,NA,,
JQ1-(+),JQ1-(+),,BRD:BRD-BRD-K54606188-001-13-1;BRD:BRD-K54606188-001-13-1,rep_multi_dose;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD4;BRDT,,,PRECLINICAL,,,NA,,CC1SC-2C(C1C)C(=N[C@@H](CC(=O)OC(C)(C)C)C1NNC(C)N-21)C1CCC(CL)CC1
JQ12,JQ12,,GDSC1:164,gdsc,,,,,,,,NA,,
JTC-801,JTC-801,,BRD:BRD-BRD-K17705806-003-04-4;BRD:BRD-K17705806-003-04-4,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRL1,,,PHASE 2,,,NA,,CCC1CCC(OCC2CCCCC2C(=O)NC2CCC3NC(C)CC(N)C3C2)CC1
JTE-013,JTE-013,,BRD:BRD-K43330982-001-04-9,rep_single_dose,LYSOPHOSPHOLIPID RECEPTOR ANTAGONIST,P2RY10;S1PR2,,,,,,NA,,
JTE-607,JTE-607,,BRD:BRD-BRD-K81405859-300-01-4;BRD:BRD-K81405859-300-01-4,rep_multi_dose;rep_primary;rep_single_dose,CYTOKINE PRODUCTION INHIBITOR,IL10;IL1B;IL6;TNF,,,PHASE 2,,,NA,,CCOC(=O)[C@H](CC1CCCCC1)NC(=O)C1CC(CL)C(OCCN2CCN(C)CC2)C(CL)C1O
JTE-907,JTE-907,,BRD:BRD-BRD-K63150726-001-02-1;BRD:BRD-K63150726-001-02-1,rep_primary;rep_single_dose,CANNABINOID RECEPTOR INVERSE AGONIST,CNR2,,,PHASE 1,,,NA,,CCCCCOC1C(OC)CCC2CC(C(=O)NCC3CCC4OCOC4C3)C(=O)[NH]C12
JW-480,JW-480,,CTRP:660227,ctrp,,,,,,,,NA,,
JW-55,JW-55,,BRD:BRD-BRD-K53328210-001-04-4;BRD:BRD-K53328210-001-04-4;CTRP:682993,ctrp;rep_primary;rep_single_dose,TANKYRASE INHIBITOR,TNKS;TNKS2,,,PRECLINICAL,,,NA,,COC1CCC(CC1)C1(CNC(=O)C2CCC(NC(=O)C3CCCO3)CC2)CCOCC1
JW-642,JW-642,,BRD:BRD-K48424871-001-04-9,rep_single_dose,MONOACYLGLYCEROL LIPASE INHIBITOR,MGLL,,,,,,NA,,
JW-67,JW-67,,BRD:BRD-BRD-K24554037-001-08-3;BRD:BRD-K24554037-001-08-3,rep_primary;rep_single_dose,WNT PATHWAY INHIBITOR,APC;AXIN1;GSK3B,,,PRECLINICAL,,,NA,,O=C1NC2CCCCC2C11OCC2(CO1)COC1(OC2)C(=O)NC2CCCCC12
JW-7-24-1,JW-7-24-1,,GDSC1:256,gdsc,,,,,,,,NA,,
JW-7-52-1,JW-7-52-1,,GDSC1:83,gdsc,,,,,,,,NA,,
JW-74,JW-74,,BRD:BRD-BRD-K75664313-001-02-6;BRD:BRD-K75664313-001-02-6;CTRP:676728,ctrp;rep_primary;rep_single_dose,"TANKYRASE INHIBITOR, WNT SIGNALING INHIBITOR",TNKS;TNKS2,,,PRECLINICAL,"Multiple values for MOA: {'WNT SIGNALING INHIBITOR, TANKYRASE INHIBITOR', 'TANKYRASE INHIBITOR, WNT SIGNALING INHIBITOR'}, defaulting to 'TANKYRASE INHIBITOR, WNT SIGNALING INHIBITOR'",,NA,,COC1CCC(CC1)-N1C(SCC2NC(NO2)-C2CCC(C)CC2)NNC1-C1CCNCC1
JWZ-5-13,JWZ-5-13,,BRD:BRD-U00115420-001-01-9,oncref_1,VHL-BASED DEGRADER OF CDK7,CDK7,,,,,,NA,,
JX-401,JX-401,,BRD:BRD-BRD-K05464208-001-05-7;BRD:BRD-K05464208-001-05-7,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PRECLINICAL,,,NA,,COC1CC(SC)CCC1C(=O)N1CCC(CC2CCCCC2)CC1
JZL-184,JZL-184,,BRD:BRD-BRD-K45446451-001-05-0;BRD:BRD-K45446451-001-05-0,rep_multi_dose;rep_primary;rep_single_dose,MONOACYLGLUCEROL LIPASE INHIBITOR,MGLL,,,PRECLINICAL,,,NA,,OC(C1CCN(CC1)C(=O)OC1CCC(CC1)[N+]([O-])=O)(C1CCC2OCOC2C1)C1CCC2OCOC2C1
JZL-195,JZL-195,,BRD:BRD-BRD-K38875233-001-03-9;BRD:BRD-K38875233-001-03-9,rep_primary;rep_single_dose,"FAAH INHIBITOR, MONOACYLGLYCEROL LIPASE INHIBITOR",FAAH;MGLL,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCC(OC(=O)N2CCN(CC3CCCC(OC4CCCCC4)C3)CC2)CC1
K-858,K-858,,BRD:BRD-A67748489-001-10-0;BRD:BRD-BRD-A67748489-001-10-0,rep_multi_dose;rep_primary;rep_single_dose,KINESIN-LIKE SPINDLE PROTEIN INHIBITOR,KIF11,,,PRECLINICAL,,,NA,,CC(=O)NC1=NN(C(C)=O)C(C)(S1)C1CCCCC1
K-MAP,K-MAP,,BRD:BRD-A45906415-001-01-9;BRD:BRD-BRD-A45906415-001-01-9,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,OCC1OC(NC2CCC(CC2)C(O)=O)C(O)C(O)C1O
K-RAS(G12C)-INHIBITOR-12,K-RAS(G12C)-INHIBITOR-12,,BRD:BRD-K90756851-001-01-1,rep_single_dose,K-RAS INHIBITOR,KRAS,,,,,,NA,,
K-RAS(G12C)-INHIBITOR-6,K-RAS(G12C)-INHIBITOR-6,,BRD:BRD-BRD-K26305185-001-02-1;BRD:BRD-K26305185-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,K-RAS INHIBITOR,,,,PRECLINICAL,,,NA,,SCCCC(=O)NC1CCN(CC1)C(=O)COC1CCC(CL)CC1CL
K-STROPHANTHIDIN,K-STROPHANTHIDIN,,BRD:BRD-A55312468-001-04-7;BRD:BRD-BRD-A55312468-001-04-7,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP1A1,,,PHASE 2,,,NA,,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1
K02288,K02288,,BRD:BRD-BRD-K58568447-001-01-1;BRD:BRD-K58568447-001-01-1,rep_primary;rep_single_dose,BONE MORPHOGENIC PROTEIN INHIBITOR,BMP1,,,PRECLINICAL,,,NA,,COC1CC(CC(OC)C1OC)-C1CC(CNC1N)-C1CCCC(O)C1
K145,K145,,BRD:BRD-K12106308-003-01-9,rep_single_dose,SPHINGOSINE KINASE INHIBITOR,SPHK2,,,,,,NA,,
KAEMPFEROL,KAEMPFEROL,CHEMBL150,BRD:BRD-BRD-K12807006-001-18-5;BRD:BRD-K12807006-001-18-5,rep_primary;rep_single_dose,"BONE RESORPTION INHIBITOR, ESTROGEN-RELATED RECEPTOR INVERSE AGONIST",AKR1B1;ALOX15B;ALOX5;AR;CYP1B1;GLO1;HSD17B1;UGT3A1,,,PRECLINICAL,,Small molecule,NA,IYRMWMYZSQPJKC-UHFFFAOYSA-N,O=C1C(O)C(-C2CCC(O)CC2)OC2CC(O)CC(O)C12;OC1CCC(CC1)-C1OC2CC(O)CC(O)C2C(=O)C1O
KAF-156,KAF-156,CHEMBL2058833,BRD:BRD-K00004578-001-01-9,rep_single_dose,ANTIMALARIAL AGENT,,,,,,Small molecule,Phase 2,BUPRVECGWBHCQV-UHFFFAOYSA-N,CC1(C)C2NC(-C3CCC(F)CC3)C(NC3CCC(F)CC3)N2CCN1C(=O)CN
KAINIC-ACID,KAINIC-ACID,,BRD:BRD-BRD-K52459018-001-09-1;BRD:BRD-K52459018-001-09-1,rep_primary;rep_single_dose,KAINATE RECEPTOR AGONIST,GRIA1;GRIK1;GRIK2;GRIK3;GRIK4;GRIK5,,,PRECLINICAL,,,NA,,CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
KAKONEIN,KAKONEIN,CHEMBL486386,BRD:BRD-A07815743-001-01-1;BRD:BRD-BRD-A07815743-001-01-1,rep_primary;rep_single_dose,"GABA RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",,,,PHASE 2,,Small molecule,Phase 2,HKEAFJYKMMKDOR-VPRICQMDSA-N,O=C1C(-C2CCC(O)CC2)COC2C([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(O)CCC12;OCC1OC(C(O)C(O)C1O)C1C(O)CCC2C1OCC(-C1CCC(O)CC1)C2=O
KARENITECIN,KARENITECIN,CHEMBL1743260;CHEMBL1997373,BRD:BRD-K00003176-001-01-9,rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,,,Small molecule,Phase 3,POADTFBBIXOWFJ-VWLOTQADSA-N;SYXGVIWFCCQOEK-VWLOTQADSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2C-1NC1CCCCC1C2CC[SI](C)(C)C;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3C(CC[SI](C)(C)C)CCCC3NC2-1
KARTOGENIN,KARTOGENIN,,BRD:BRD-K27584835-001-02-9,rep_single_dose,CHONDROCYTE DIFFERENTIATION STIMULATOR,FLNA,,,,,,NA,,
KASUGAMYCIN,KASUGAMYCIN,CHEMBL1631109,BRD:BRD-K91644281-311-02-9,rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,,,,,Small molecule,NA,PVTHJAPFENJVNC-MHRBZPPQSA-N,C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(=O)O
KB NB 142-70,KB NB 142-70,,GDSC1:407,gdsc,,,,,,,,NA,,
KB-0742 (DIHYDROCHLORIDE),KB-0742 (DIHYDROCHLORIDE),,BRD:BRD-K00010521-300-02-9,rep_single_dose,,,,,,,,NA,,
KB-R7943,KB-R7943,,BRD:BRD-BRD-K17743697-066-03-6;BRD:BRD-K17743697-066-03-6,rep_primary;rep_single_dose,SODIUM/CALCIUM EXCHANGE INHIBITOR,SLC8A1;TRPC3;TRPC5;TRPC6,,,PRECLINICAL,,,NA,,NC(=N)SCCC1CCC(OCC2CCC(CC2)[N+]([O-])=O)CC1
KB-SRC-4,KB-SRC-4,,BRD:BRD-BRD-K88154110-001-01-0;BRD:BRD-K88154110-001-01-0,rep_primary;rep_single_dose,SRC INHIBITOR,SRC,,,PRECLINICAL,,,NA,,NC1NCNC2N(NC(-C3CCC(CL)CC3)C12)-C1CCCC(C1)-C1CNNN1CC1CCCC(C1)-C1CCCCC1
KBG,KBG,,BRD:BRD-A00376169-001-01-6;BRD:BRD-BRD-A00376169-001-01-6,rep_primary;rep_single_dose,NEPRILYSIN INHIBITOR,MME,,,PHASE 2,,,NA,,OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)C1CCCCC1
KD-023,KD-023,,BRD:BRD-BRD-K71164191-001-01-0;BRD:BRD-K71164191-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,ACAT INHIBITOR,ACACA;ACACB,,,PHASE 2,,,NA,,CCCCCCCCCCCCCCOC1CCC(O1)C(O)=O
KD025,KD025,CHEMBL2005186,BRD:BRD-BRD-K88506063-001-01-8;BRD:BRD-K88506063-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK2,,,PHASE 2,,Small molecule,Approved,GKHIVNAUVKXIIY-UHFFFAOYSA-N,CC(C)NC(=O)COC1CCCC(-C2NC(NC3CCC4[NH]NCC4C3)C3CCCCC3N2)C1;CC(C)NC(=O)COC1CCCC(C1)-C1NC(NC2CCC3[NH]NCC3C2)C2CCCCC2N1
KENPAULLONE,KENPAULLONE,CHEMBL296586,BRD:BRD-BRD-K37312348-001-15-0;BRD:BRD-K37312348-001-15-0,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, GLYCOGEN SYNTHASE KINASE INHIBITOR",CCNB1;CDK1;CDK5;GSK3B,,,PRECLINICAL,,Small molecule,NA,QQUXFYAWXPMDOE-UHFFFAOYSA-N,BRC1CCC2[NH]C-3C(CC(=O)NC4CCCCC-34)C2C1;O=C1CC2C([NH]C3CCC(BR)CC23)-C2CCCCC2N1
KESSAR,KESSAR,CHEMBL786,GDSC1:1199;GDSC2:1199,gdsc,,,,,,,Small molecule,Approved,FQZYTYWMLGAPFJ-OQKDUQJOSA-N,CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
KETANSERIN,KETANSERIN,CHEMBL51,BRD:BRD-BRD-K49671696-045-08-5;BRD:BRD-K49671696-045-08-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;DRD1;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR5A;HTR7;SLC18A1;SLC18A2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,FPCCSQOGAWCVBH-UHFFFAOYSA-N,FC1CCC(CC1)C(=O)C1CCN(CCN2C(=O)[NH]C3CCCCC3C2=O)CC1;O=C(C1CCC(F)CC1)C1CCN(CCN2C(=O)[NH]C3CCCCC3C2=O)CC1
KETOCONAZOLE,KETOCONAZOLE,CHEMBL157101;CHEMBL295698,BRD:BRD-A38350138-001-04-9;BRD:BRD-BRD-A38350138-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,AR;CYP19A1;CYP21A2;KCNA10,SEBORRHEIC DERMATITIS,,LAUNCHED,,Small molecule,Approved,XMAYWYJOQHXEEK-UHFFFAOYSA-N;XMAYWYJOQHXEEK-ZEQKJWHPSA-N,CC(=O)N1CCN(C2CCC(OC[C@@H]3CO[C@@](CN4CCNC4)(C4CCC(CL)CC4CL)O3)CC2)CC1;CC(=O)N1CCN(C2CCC(OCC3COC(CN4CCNC4)(C4CCC(CL)CC4CL)O3)CC2)CC1;CC(=O)N1CCN(CC1)C1CCC(OC[C@H]2CO[C@@](CN3CCNC3)(O2)C2CCC(CL)CC2CL)CC1;CC(=O)N1CCN(CC1)C1CCC(OCC2CO[C@@](CN3CCNC3)(O2)C2CCC(CL)CC2CL)CC1
KETOHEXOKINASE-INHIBITOR-1,KETOHEXOKINASE-INHIBITOR-1,,BRD:BRD-K00003341-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,,NA,,
KETOPROFEN,KETOPROFEN,CHEMBL571;CHEMBL75435,BRD:BRD-A97739905-001-26-5;BRD:BRD-BRD-A97739905-001-26-5,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,CXCR1;PTGS1;PTGS2;SLC5A8,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,Small molecule,Approved,DKYWVDODHFEZIM-NSHDSACASA-N;DKYWVDODHFEZIM-UHFFFAOYSA-N,C[C@H](C(=O)O)C1CCCC(C(=O)C2CCCCC2)C1;CC(C(=O)O)C1CCCC(C(=O)C2CCCCC2)C1;CC(C(O)=O)C1CCCC(C1)C(=O)C1CCCCC1
KETOROLAC,KETOROLAC,CHEMBL469,BRD:BRD-A40639672-234-18-0;BRD:BRD-BRD-A40639672-234-18-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,Small molecule,Approved,OZWKMVRBQXNZKK-UHFFFAOYSA-N,O=C(C1CCCCC1)C1CCC2N1CCC2C(=O)O;OC(=O)C1CCN2C1CCC2C(=O)C1CCCCC1
KETOTIFEN,KETOTIFEN,CHEMBL534,BRD:BRD-BRD-K28936863-051-33-0,rep_primary,"HISTAMINE RECEPTOR AGONIST, LEUKOTRIENE RECEPTOR ANTAGONIST, PHOSPHODIESTERASE INHIBITOR",HRH1;PDE4A;PDE4B;PDE4C;PDE4D;PDE7A;PDE7B;PDE8A;PDE8B;PGD,ITCHING,,LAUNCHED,,Small molecule,Approved,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,CN1CCC(=C2C3CCCCC3CC(=O)C3SCCC32)CC1;CN1CCC(CC1)=C1C2CCSC2C(=O)CC2CCCCC12
KEVETRIN,KEVETRIN,CHEMBL4297540,BRD:BRD-BRD-K61339991-003-01-8;BRD:BRD-K61339991-003-01-8,rep_primary;rep_single_dose,P53 ACTIVATOR,,,,PHASE 1,,Small molecule,Phase 2,PRDJGNVQBVXXEO-UHFFFAOYSA-N,N#CCCCSC(=N)N;NC(=N)SCCCC#N
KF-38789,KF-38789,,BRD:BRD-A54927599-001-16-9;BRD:BRD-BRD-A54927599-001-16-9,rep_multi_dose;rep_primary;rep_single_dose,P SELECTIN INHIBITOR,SELP,,,PRECLINICAL,,,NA,,COC1CCC(C2CC(=NCCS2)C2C(O)CC(C)OC2=O)C(OC)C1
KG-5,KG-5,,BRD:BRD-BRD-K90747162-001-01-4;BRD:BRD-K90747162-001-01-4,rep_primary;rep_single_dose,RAF INHIBITOR,BRAF;FLT3;KIT;PDGFRB,,,PRECLINICAL,,,NA,,CSC1NC(N)CC(OC2CCC(CC2)-C2NNC(NC3CCCC(C3)C(F)(F)F)[NH]2)N1
KH-CB19,KH-CB19,,CTRP:660085,ctrp,,,,,,,,NA,,
KHELLIN,KHELLIN,CHEMBL44746,BRD:BRD-BRD-K80353807-001-25-3;BRD:BRD-K80353807-001-25-3,rep_primary;rep_single_dose,VASODILATOR,,,,PHASE 2,,Small molecule,Unknown,HSMPDPBYAYSOBC-UHFFFAOYSA-N,COC1C2CCOC2C(OC)C2OC(C)CC(=O)C12;COC1C2OCCC2C(OC)C2C(=O)CC(C)OC12
KHK-IN-1,KHK-IN-1,,BRD:BRD-K84605263-003-01-6,rep_single_dose,HEXOKINASE INHIBITOR,KHK,,,,,,NA,,
KHS-101,KHS-101,,BRD:BRD-BRD-K78978711-003-01-3;BRD:BRD-K78978711-003-01-3,rep_primary;rep_single_dose,NEURAL STEM CELL INDUCER,TACC3,,,PRECLINICAL,,,NA,,CC(C)CNC1CCNC(NCC2CSC(N2)-C2CCCCC2)N1
KHS101,KHS101,,CTRP:660819,ctrp,,,,,,,,NA,,
KI-16425,KI-16425,,BRD:BRD-A25569250-001-03-3;BRD:BRD-BRD-A25569250-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST,LPAR1;LPAR3,,,PRECLINICAL,,,NA,,CC(OC(=O)NC1C(C)NOC1-C1CCC(CSCCC(O)=O)CC1)C1CCCCC1CL
KI-20227,KI-20227,,BRD:BRD-A88787317-001-01-0;BRD:BRD-BRD-A88787317-001-01-0,rep_primary;rep_single_dose,C-FMS INHIBITOR,CSF1R;KDR;KIT;PDGFRB,,,PRECLINICAL,,,NA,,COC1CC(OC2CCNC3CC(OC)C(OC)CC23)CCC1NC(=O)NC(C)C1NCCS1
KI-8751,KI-8751,,BRD:BRD-BRD-K47150025-001-05-3;BRD:BRD-K47150025-001-05-3,rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",KDR,,,PRECLINICAL,,,NA,,COC1CC2NCCC(OC3CCC(NC(=O)NC4CCC(F)CC4F)C(F)C3)C2CC1OC
KI16198,KI16198,,BRD:BRD-A94323479-001-02-8;BRD:BRD-BRD-A94323479-001-02-8,rep_primary;rep_single_dose,LIPOPROTEIN ANTAGONIST,LPA,,,PRECLINICAL,,,NA,,COC(=O)CCSCC1CCC(CC1)-C1ONC(C)C1NC(=O)OC(C)C1CCCCC1CL
KI8751,KI8751,,CTRP:375560,ctrp,,,,,,,,NA,,
KIFUNENSINE,KIFUNENSINE,CHEMBL1233851,BRD:BRD-BRD-K02898090-001-02-7;BRD:BRD-K02898090-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,MANNOSIDASE INHIBITOR,MAN1B1;MAN2A1,,,PHASE 1,,Small molecule,NA,OIURYJWYVIAOCW-PQMKYFCFSA-N,O=C1N[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)N2C1=O;OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12
KIL8951,KIL8951,CHEMBL1289494,GDSC1:312,gdsc,,,,,,,Small molecule,Approved,SPMVMDHWKHCIDT-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)NC4CC(C)ON4)C(CL)C3)C2CC1OC
KIN001-013,KIN001-013,,GDSC1:52,gdsc,,,,,,,,NA,,
KIN001-019,KIN001-019,,GDSC1:53,gdsc,,,,,,,,NA,,
KIN001-021,KIN001-021,,GDSC1:54,gdsc,,,,,,,,NA,,
KIN001-042,KIN001-042,,GDSC1:289,gdsc,,,,,,,,NA,,
KIN001-055,KIN001-055,,GDSC1:288,gdsc,,,,,,,,NA,,
KIN001-102,KIN001-102,,GDSC1:171;GDSC1:228,gdsc,,,,,,,,NA,,
KIN001-111,KIN001-111,,GDSC1:55,gdsc,,,,,,,,NA,,
KIN001-112,KIN001-112,,GDSC1:56,gdsc,,,,,,,,NA,,
KIN001-123,KIN001-123,,GDSC1:59,gdsc,,,,,,,,NA,,
KIN001-127,KIN001-127,,GDSC1:63,gdsc,,,,,,,,NA,,
KIN001-128,KIN001-128,,GDSC1:64,gdsc,,,,,,,,NA,,
KIN001-135,KIN001-135,,GDSC1:91,gdsc,,,,,,,,NA,,
KIN001-139,KIN001-139,,GDSC1:86,gdsc,,,,,,,,NA,,
KIN001-167,KIN001-167,,GDSC1:223,gdsc,,,,,,,,NA,,
KIN001-173,KIN001-173,,GDSC1:224,gdsc,,,,,,,,NA,,
KIN001-192,KIN001-192,,GDSC1:155,gdsc,,,,,,,,NA,,
KIN001-201,KIN001-201,,GDSC1:221,gdsc,,,,,,,,NA,,
KIN001-204,KIN001-204,,GDSC1:157,gdsc,,,,,,,,NA,,
KIN001-206,KIN001-206,,GDSC1:159,gdsc,,,,,,,,NA,,
KIN001-236,KIN001-236,,GDSC1:286,gdsc,,,,,,,,NA,,
KIN001-242,KIN001-242,,GDSC1:231,gdsc,,,,,,,,NA,,
KIN001-244,KIN001-244,,GDSC1:287,gdsc,,,,,,,,NA,,
KIN001-260,KIN001-260,,GDSC1:290,gdsc,,,,,,,,NA,,
KIN001-266,KIN001-266,,GDSC1:291,gdsc,,,,,,,,NA,,
KIN001-270,KIN001-270,,GDSC1:345,gdsc,,,,,,,,NA,,
KINETIN,KINETIN,CHEMBL1201636;CHEMBL228792,BRD:BRD-BRD-K65667145-001-14-0;BRD:BRD-K65667145-001-14-0,rep_primary;rep_single_dose,CELL DIVISION INDUCER,,SUNBURN,,LAUNCHED,,Enzyme;Small molecule,Approved,;QANMHLXAZMSUEX-UHFFFAOYSA-N,C(NC1NCNC2[NH]CNC12)C1CCCO1;C1COC(CNC2NCNC3[NH]CNC23)C1
KL-001,KL-001,,BRD:BRD-A94580299-001-10-4;BRD:BRD-BRD-A94580299-001-10-4,rep_primary;rep_single_dose,PROTEASOME INHIBITOR,CRY1;CRY2,,,PRECLINICAL,,,NA,,CS(=O)(=O)N(CC(O)CN1C2CCCCC2C2CCCCC12)CC1CCCO1
KM-0118,KM-0118,CHEMBL221186,BRD:BRD-K00005245-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Phase 1,CQVAQQNDZCZBSU-UHFFFAOYSA-N,CN(C)CCNC(=O)COC1C2CCCC1CC1CCCC(C1OCC(=O)NCCN(C)C)CC1CCCC(C1OCC(=O)NCCN(C)C)CC1CCCC(C1OCC(=O)NCCN(C)C)C2
KME-4,KME-4,,BRD:BRD-K00004747-001-01-9,rep_single_dose,PROSTAGLANDIN INHIBITOR,,,,,,,NA,,
KML29,KML29,,BRD:BRD-BRD-K46734292-001-03-6;BRD:BRD-K46734292-001-03-6,rep_primary;rep_single_dose,MONOACYLGLUCEROL LIPASE INHIBITOR,MGLL,,,PRECLINICAL,,,NA,,OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(C1CCC2OCOC2C1)C1CCC2OCOC2C1
KN-62,KN-62,,BRD:BRD-A81177136-001-12-7;BRD:BRD-BRD-A81177136-001-12-7,rep_primary;rep_single_dose,"CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE INHIBITOR, PURINERGIC RECEPTOR ANTAGONIST",AKT1;CAMK2A;CHEK1;LCK;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;P2RX7;PRKCA;ROCK1;RPS6KB1;SGK1,,,PRECLINICAL,,,NA,,CN(C(CC1CCC(OS(=O)(=O)C2CCCC3CNCCC23)CC1)C(=O)N1CCN(CC1)C1CCCCC1)S(=O)(=O)C1CCCC2CNCCC12
KN-93,KN-93,,BRD:BRD-BRD-K93480852-003-01-0;BRD:BRD-K93480852-003-01-0,rep_primary;rep_single_dose,CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE INHIBITOR,CAMK2A,,,PRECLINICAL,,,NA,,COC1CCC(CC1)S(=O)(=O)N(CCO)C1CCCCC1CN(C)C\C=C\C1CCC(CL)CC1
KO-143,KO-143,,CTRP:418172,ctrp,,,,,,,,NA,,
KO143,KO143,,BRD:BRD-BRD-K64642496-001-04-0;BRD:BRD-K64642496-001-04-0,rep_primary;rep_single_dose,BCRP INHIBITOR,ABCB1;ABCC1,,,PRECLINICAL,,,NA,,COC1CCC2C3C[C@@H]4N([C@@H](CC(C)C)C3[NH]C2C1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O
KOBE2602,KOBE2602,,GDSC1:563,gdsc,,,,,,,,NA,,
KOJIC ACID,KOJIC ACID,CHEMBL287556,BRD:BRD-K20878815-001-06-9,rep_single_dose,,,,,,,Small molecule,NA,BEJNERDRQOWKJM-UHFFFAOYSA-N,O=C1CC(CO)OCC1O
KP-1212,KP-1212,CHEMBL3086524,BRD:BRD-BRD-K46690591-001-01-2;BRD:BRD-K46690591-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,LAOLDMMWVYDDID-KVQBGUIXSA-N,NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CN1;NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1
KPT-185,KPT-185,,BRD:BRD-BRD-K71467466-001-02-3;BRD:BRD-K71467466-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,EXPORTIN ANTAGONIST,XPO1,,,PRECLINICAL,,,NA,,COC1CC(CC(C1)C(F)(F)F)-C1NCN(\C=C/C(=O)OC(C)C)N1
KPT-276,KPT-276,,BRD:BRD-BRD-K75352575-001-01-3;BRD:BRD-K75352575-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,EXPORTIN ANTAGONIST,XPO1,,,PRECLINICAL,,,NA,,FC(F)(F)C1CC(CC(C1)C(F)(F)F)-C1NCN(N1)\C=C/C(=O)N1CC(F)(F)C1
KPT-9274,KPT-9274,CHEMBL4297467,BRD:BRD-K00004701-001-01-9,rep_single_dose,NAMPT INHIBITOR,,,,,,Small molecule,Phase 1,MRFOPLWJZULAQD-SWGQDTFXSA-N,NC1CCC(/C=C/C(=O)NCC2CC3CC(-C4CCC(C(=O)N5CCC(F)(F)CC5)CC4)CC(-C4CCC(F)CC4)C3O2)CN1
KPT185,KPT185,,CTRP:660935,ctrp,,,,,,,,NA,,
KR-33494,KR-33494,,BRD:BRD-K00004587-001-01-9,rep_single_dose,CELL DEATH INHIBITOR,,,,,,,NA,,
KRAS (G12C) INHIBITOR-12,KRAS (G12C) INHIBITOR-12,,GDSC2:1855,gdsc,,,,,,,,NA,,
KRCA-0008,KRCA-0008,,BRD:BRD-K40604024-001-02-9,rep_single_dose,ALK INIHIBITOR,ALK,,,,,,NA,,
KRN-633,KRN-633,CHEMBL406381,BRD:BRD-BRD-K90993449-001-02-7;BRD:BRD-K90993449-001-02-7,rep_primary;rep_single_dose,VEGFR INHIBITOR,FLT1;FLT4;KDR,,,PRECLINICAL,,Small molecule,Phase 1,VPBYZLCHOKSGRX-UHFFFAOYSA-N,CCCNC(=O)NC1CCC(OC2NCNC3CC(OC)C(OC)CC23)CC1CL
KRN-951,KRN-951,CHEMBL1289494,GDSC1:312,gdsc,,,,,,,Small molecule,Approved,SPMVMDHWKHCIDT-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)NC4CC(C)ON4)C(CL)C3)C2CC1OC
KS-176,KS-176,,BRD:BRD-BRD-K81053848-001-01-0;BRD:BRD-K81053848-001-01-0,rep_primary;rep_single_dose,BCRP INHIBITOR,ABCG2,,,PRECLINICAL,,,NA,,OCCC1CCC(NC(=O)C2CCCCC2NC(=O)C2CCC(CC2)[N+]([O-])=O)CC1
KT-433,KT-433,,BRD:BRD-BRD-K66437909-001-01-0;BRD:BRD-K66437909-001-01-0,rep_primary;rep_single_dose,URICOSURIC AGENT,,,,PHASE 2,,,NA,,CCC1OC2CCCCC2C1C(=O)C1CCC(OCC(O)=O)CC1
KT-555,KT-555,CHEMBL603469,GDSC1:1024,gdsc,,,,,,,Small molecule,Phase 3,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)CNC4=O
KU 0060648,KU 0060648,,CTRP:632119,ctrp,,,,,,,,NA,,
KU-0063794,KU-0063794,,BRD:BRD-BRD-K67566344-001-07-5;BRD:BRD-K67566344-001-07-5;CTRP:606363,ctrp;rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,COC1CCC(CC1CO)-C1CCC2C(NC(NC2N1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1
KU-57788,KU-57788,,GDSC1:1038;GDSC2:1038,gdsc,,,,,,,,NA,,
KU-60019,KU-60019,,BRD:BRD-BRD-K36016295-001-04-5;BRD:BRD-K36016295-001-04-5;CTRP:660411,ctrp;rep_primary;rep_single_dose,ATM KINASE INHIBITOR,ATM,,,PRECLINICAL,,,NA,,C[C@H]1CN(CC(=O)NC2CCC3SC4C(CC3C2)CCCC4-C2CC(=O)CC(O2)N2CCOCC2)C[C@@H](C)O1
KU14R,KU14R,,BRD:BRD-A38747044-001-02-3;BRD:BRD-BRD-A38747044-001-02-3,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CCC1(CC2CCCCC2O1)C1NCC[NH]1
KU55933,KU55933,,GDSC1:1030;GDSC2:1030,gdsc,,,,,,,,NA,,
KUROMANIN,KUROMANIN,CHEMBL257839,BRD:BRD-BRD-K51337109-003-01-3;BRD:BRD-K51337109-003-01-3,rep_primary;rep_single_dose,RIBOSYL CYCLASE INHIBITOR,CD38,,,PRECLINICAL,,Small molecule,NA,RKWHWFONKJEUEF-GQUPQBGVSA-O,OC[C@H]1O[C@@H](OC2CC3C(O)CC(O)CC3[O+]C2-C2CCC(O)C(O)C2)[C@H](O)[C@@H](O)[C@@H]1O
KW-2449,KW-2449,CHEMBL1908397,BRD:BRD-BRD-K21718444-001-06-8;BRD:BRD-K21718444-001-06-8;CTRP:660413,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"ABL KINASE INHIBITOR, AURORA KINASE INHIBITOR, FLT3 INHIBITOR",ABL1;AURKA;AURKB;FLT3,,,PHASE 1,,Small molecule,Phase 1,YYLKKYCXAOBSRM-JXMROGBWSA-N,O=C(C1CCC(/C=C/C2N[NH]C3CCCCC23)CC1)N1CCNCC1;O=C(N1CCNCC1)C1CCC(CC1)\C=C\C1N[NH]C2CCCCC12
KW-2478,KW-2478,CHEMBL4297298;CHEMBL4300557,BRD:BRD-BRD-K41213548-001-02-0;BRD:BRD-K41213548-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,CKMGYWHSTADSIG-UHFFFAOYSA-N;VFUXSYAXEKYYMB-UHFFFAOYSA-N,CCC1C(O)CC(O)C(C(=O)C2CCC(OCCN3CCOCC3)C(OC)C2)C1CC(=O)N(CCOC)CCOC;CCC1C(O)CC(O)C(C(=O)C2CCC(OCCN3CCOCC3)C(OC)C2)C1CC(=O)N(CCOC)CCOC.CL
KW-3902,KW-3902,CHEMBL52333,BRD:BRD-A95683721-001-03-8;BRD:BRD-BRD-A95683721-001-03-8,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 3,,Small molecule,Phase 3,PJBFVWGQFLYWCB-UHFFFAOYSA-N,CCCN1C(=O)C2NC(C34CC5CC(CC3C5)C4)[NH]C2N(CCC)C1=O;CCCN1C2NC([NH]C2C(=O)N(CCC)C1=O)C12CC3CC1CC(C2)C3
KX2-391,KX2-391,CHEMBL571546,BRD:BRD-BRD-K29968218-001-03-2;BRD:BRD-K29968218-001-03-2;CTRP:660779,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"SRC INHIBITOR, TUBULIN POLYMERIZATION INHIBITOR",SRC,,,PHASE 2,,Small molecule,Approved,HUNGUWOZPQBXGX-UHFFFAOYSA-N,O=C(CC1CCC(-C2CCC(OCCN3CCOCC3)CC2)CN1)NCC1CCCCC1;O=C(CC1CCC(CN1)-C1CCC(OCCN2CCOCC2)CC1)NCC1CCCCC1
KY02111,KY02111,,BRD:BRD-BRD-K13302470-001-02-7;BRD:BRD-K13302470-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,WNT PATHWAY INHIBITOR,DKK1,,,PRECLINICAL,,,NA,,COC1CCC(CCC(=O)NC2NC3CCC(CL)CC3S2)CC1OC
KYNURENIC-ACID,KYNURENIC-ACID,,BRD:BRD-BRD-K85872723-001-15-9;BRD:BRD-K85872723-001-15-9,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GPR35;GRIN1;GRIN2A;GRIN2B,,,PRECLINICAL,,,NA,,OC(=O)C1CC(O)C2CCCCC2N1
L-(+)-RHAMNOSE-MONOHYDRATE,L-(+)-RHAMNOSE-MONOHYDRATE,,BRD:BRD-A86354194-002-01-7;BRD:BRD-BRD-A86354194-002-01-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O
L-152804,L-152804,,BRD:BRD-A42553870-001-14-3;BRD:BRD-BRD-A42553870-001-14-3,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY5R,,,PRECLINICAL,,,NA,,CC1(C)CC(=O)C(C2C3CCCCC3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1
L-161982,L-161982,,BRD:BRD-BRD-K39733634-001-02-6;BRD:BRD-K39733634-001-02-6,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER4,,,PRECLINICAL,,,NA,,CCCCC1NN(-C2CCCCC2C(F)(F)F)C(=O)N1CC1CCC(CC1)-C1CCCCC1S(=O)(=O)NC(=O)C1SCCC1C
L-165041,L-165041,,BRD:BRD-BRD-K98372770-001-08-2;BRD:BRD-K98372770-001-08-2,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARD,,,PRECLINICAL,,,NA,,CCCC1C(OCCCOC2CCC(OCC(O)=O)CC2)CCC(C(C)=O)C1O
L-168049,L-168049,,BRD:BRD-BRD-K18036262-001-02-8;BRD:BRD-K18036262-001-02-8,rep_primary;rep_single_dose,GLUCAGON RECEPTOR ANTAGONIST,GCGR,,,PRECLINICAL,,,NA,,CCCOC1CCC(BR)CC1-C1CC([NH]C1-C1CCNCC1)-C1CCC(CL)CC1
L-365260,L-365260,CHEMBL9387,BRD:BRD-BRD-K34277641-001-01-2;BRD:BRD-K34277641-001-01-2,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKAR;CCKBR;KCNQ1,,,PHASE 2,,Small molecule,NA,KDFQABSFVYLGPM-QFIPXVFZSA-N,CC1CCCC(NC(=O)N[C@@H]2N=C(C3CCCCC3)C3CCCCC3N(C)C2=O)C1;CN1C2CCCCC2C(=N[C@@H](NC(=O)NC2CCCC(C)C2)C1=O)C1CCCCC1
L-368899,L-368899,,BRD:BRD-A43930669-003-02-8;BRD:BRD-BRD-A43930669-003-02-8,rep_primary;rep_single_dose,OXYTOCIN RECEPTOR ANTAGONIST,AVPR1A;AVPR2;OXTR,,,PHASE 1,,,NA,,CC1CCCCC1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C
"L-655,708","L-655,708",,BRD:BRD-BRD-K13474508-001-01-2;BRD:BRD-K13474508-001-01-2,rep_primary;rep_single_dose,GABA RECEPTOR INVERSE AGONIST,GABRA1;GABRA2;GABRA3;GABRA5;GABRG2,,,PRECLINICAL,,,NA,,CCOC(=O)C1NCN-2C1[C@@H]1CCCN1C(=O)C1CC(OC)CCC-21
L-655240,L-655240,,BRD:BRD-BRD-K89402695-001-02-3;BRD:BRD-K89402695-001-02-3,rep_primary;rep_single_dose,THROMBOXANE RECEPTOR ANTAGONIST,PTGES,,,PHASE 1,,,NA,,CC1C(CC(C)(C)C(O)=O)N(CC2CCC(CL)CC2)C2CCC(F)CC12
L-670596,L-670596,,BRD:BRD-A85472596-001-02-2;BRD:BRD-BRD-A85472596-001-02-2,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CS(=O)(=O)C1CCC(CN2C3C(CC(O)=O)CCCC3C3CC(F)CC(F)C23)CC1
L-685458,L-685458,,CTRP:411717,ctrp,,,,,,,,NA,,
L-689560,L-689560,,BRD:BRD-K74284736-001-04-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,,,,NA,,
L-693403,L-693403,,BRD:BRD-BRD-K83322645-050-01-9;BRD:BRD-K83322645-050-01-9,rep_primary;rep_single_dose,"SIGMA RECEPTOR AGONIST, SIGMA RECEPTOR ANTAGONIST",DRD2;SIGMAR1,,,PRECLINICAL,,,NA,,C(N1CCC2(CCC3CCCCC23)CC1)C1CCCCC1
L-694247,L-694247,CHEMBL39317,BRD:BRD-K18816859-001-06-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D,,,,,Small molecule,NA,HKXMQLISPYELRD-UHFFFAOYSA-N,CS(=O)(=O)NC1CCC(CC2NOC(-C3CCC4[NH]CC(CCN)C4C3)N2)CC1
L-701252,L-701252,,BRD:BRD-BRD-K10176267-001-03-3;BRD:BRD-K10176267-001-03-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,,,PRECLINICAL,,,NA,,OC1C(C(=O)C2CC2)C(=O)[NH]C2CC(CL)CCC12
L-701324,L-701324,,BRD:BRD-BRD-K08109516-001-07-8;BRD:BRD-K08109516-001-07-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PRECLINICAL,,,NA,,OC1C(-C2CCCC(OC3CCCCC3)C2)C(=O)[NH]C2CC(CL)CCC12
"L-732,138","L-732,138",,BRD:BRD-BRD-K37952347-001-01-4;BRD:BRD-K37952347-001-01-4,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1;TACR2,,,PRECLINICAL,,,NA,,CC(=O)N[C@H](CC1C[NH]C2CCCCC12)C(=O)OCC1CC(CC(C1)C(F)(F)F)C(F)(F)F
L-733060,L-733060,,BRD:BRD-BRD-K15791587-003-02-5;BRD:BRD-K15791587-003-02-5,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,,,PRECLINICAL,,,NA,,FC(F)(F)C1CC(CO[C@H]2CCCN[C@H]2C2CCCCC2)CC(C1)C(F)(F)F
L-741742,L-741742,,BRD:BRD-BRD-K13211965-003-02-8;BRD:BRD-K13211965-003-02-8,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD3;DRD4;SCN1A;SCN3A,,,PRECLINICAL,,,NA,,CC1C(NOC1-C1CCC(CL)CC1)C1CCN(CCC2CCCCC2)CC1
L-745870,L-745870,CHEMBL267014,BRD:BRD-BRD-K05528470-305-02-2;BRD:BRD-K05528470-305-02-2,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;DRD3;DRD4;HTR1A;HTR2A;HTR6;HTR7,,,PRECLINICAL,,Small molecule,NA,OGJGQVFWEPNYSB-UHFFFAOYSA-N,CLC1CCC(CC1)N1CCN(CC2C[NH]C3NCCCC23)CC1;CLC1CCC(N2CCN(CC3C[NH]C4NCCCC34)CC2)CC1
L-755507,L-755507,CHEMBL12998,BRD:BRD-K39359968-001-03-9,rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3,,,,,Small molecule,NA,NYYJKMXNVNFOFQ-MHZLTWQESA-N,CCCCCCNC(=O)NC1CCC(S(=O)(=O)NC2CCC(CCNC[C@H](O)COC3CCC(O)CC3)CC2)CC1
L-760735,L-760735,,BRD:BRD-K30425481-003-02-9,rep_single_dose,TACHYKININ ANTAGONIST,TACR1,,,,,,NA,,
L-778123,L-778123,CHEMBL279433;CHEMBL4297396,BRD:BRD-BRD-K10958118-003-01-5;BRD:BRD-K10958118-003-01-5,rep_primary;rep_single_dose,FARNESYLTRANSFERASE INHIBITOR,FNTA;FNTB;PGGT1B,,,PHASE 1,,Small molecule,Phase 1,JNUGFGAVPBYSHF-UHFFFAOYSA-N;YNBSQYGTJLIPJS-UHFFFAOYSA-N,CL.N#CC1CCC(CN2CNCC2CN2CCN(C3CCCC(CL)C3)C(=O)C2)CC1;CLC1CCCC(C1)N1CCN(CC2CNCN2CC2CCC(CC2)C#N)CC1=O;N#CC1CCC(CN2CNCC2CN2CCN(C3CCCC(CL)C3)C(=O)C2)CC1
L-798106,"L-798,106;L-798106",,BRD:BRD-BRD-K43905307-001-01-2;BRD:BRD-K43905307-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER3,,,PRECLINICAL,,,NA,,COC1CCC(BR)CC1S(=O)(=O)NC(=O)\C=C\C1CCCCC1CC1CCC2CCCCC2C1
L-838417,L-838417,,BRD:BRD-BRD-K46647427-001-02-0;BRD:BRD-K46647427-001-02-0,rep_primary;rep_single_dose,GABA RECEPTOR PARTIAL AGONIST,GABRA1;GABRA2;GABRA3;GABRA5,,,PRECLINICAL,,,NA,,CN1NCNC1COC1NN2C(NNC2CC1C(C)(C)C)-C1CC(F)CCC1F
L-ARGININE,L-ARGININE,CHEMBL1485;CHEMBL4297982;CHEMBL44752,BRD:BRD-BRD-K76811153-003-01-3;BRD:BRD-K76811153-003-01-3,rep_primary;rep_single_dose,NITRIC OXIDE PRECURSOR,ARG2;ASL;ASS1;AZIN2;GPRC6A;NOS2;NOS3;SLC7A1;SLC7A3;SLC7A4,"CONGESTIVE HEART FAILURE, HYPERTENSION, CORONARY ARTERY DISEASE (CAD), CLAUDICATION, SENILE DEMENTIA, ERECTILE DYSFUNCTION, INFERTILITY, COMMON COLD",,LAUNCHED,,Small molecule;Unknown,Approved,;FKMJXALNHKIDOD-LBPRGKRZSA-N;ODKSFYDXXFIFQN-BYPYZUCNSA-N,COC(=O)[C@H](CCCNC(=N)N)NS(=O)(=O)C1CCC(C)CC1;N[C@H](CCCNC(N)=N)C(O)=O;N=C(N)NCCC[C@H](N)C(=O)O
L-ASPARAGINE-N-HYDROXY,L-ASPARAGINE-N-HYDROXY,,BRD:BRD-BRD-K82178523-001-01-6;BRD:BRD-K82178523-001-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,N[C@@H](CC(=O)NO)C(O)=O
L-ASPARTIC-ACID,L-ASPARTIC-ACID,,BRD:BRD-BRD-K97163964-001-03-3;BRD:BRD-K97163964-001-03-3,rep_primary;rep_single_dose,METALLIC RADICAL FORMATION STIMULANT,ACY1;ACY3;ADSS;ADSSL1;ASNS;ASPA;ASPH;ASRGL1;ASS1;CAD;DARS;DARS2;GOT1;GOT2;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;LYZ;PAICS;RNASE1;SLC1A1;SLC25A12;SLC25A13,,,LAUNCHED,,,NA,,N[C@@H](CC(O)=O)C(O)=O
L-CITRULLINE,L-CITRULLINE,CHEMBL444814,BRD:BRD-A12237696-001-04-2;BRD:BRD-BRD-A12237696-001-04-2,rep_primary;rep_single_dose,NITRIC OXIDE STIMULANT,ASS1;DDAH1;DDAH2;GPRC6A;NOS1;NOS2;NOS3;OTC;PADI1;PADI2;PADI3;PADI4;PADI6,"HYPERTENSION, ERECTILE DYSFUNCTION",,LAUNCHED,,Small molecule,Phase 3,RHGKLRLOHDJJDR-BYPYZUCNSA-N,NC(=O)NCCC[C@H](N)C(=O)O;NC(CCCNC(N)=O)C(O)=O
L-CYSTEINESULFINIC-ACID,L-CYSTEINESULFINIC-ACID,,BRD:BRD-A25800195-001-02-2;BRD:BRD-BRD-A25800195-001-02-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM1;GRM5;GSR;HMGCS2;PAPOLA;PRDX2,,,PRECLINICAL,,,NA,,N[C@@H](CS(O)=O)C(O)=O
L-CYSTINE,L-CYSTINE,,BRD:BRD-A15397381-001-02-5;BRD:BRD-BRD-A15397381-001-02-5,rep_primary;rep_single_dose,,CTNS;SLC3A1;SLC7A11;SLC7A9,,,LAUNCHED,,,NA,,N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O;NC(CSSCC(N)C(O)=O)C(O)=O
L-ERGOTHIONEINE,L-ERGOTHIONEINE,,BRD:BRD-BRD-K26341917-001-01-3;BRD:BRD-K26341917-001-01-3,rep_primary;rep_single_dose,FREE RADICAL SCAVENGER,,,,PHASE 2,,,NA,,C[N+](C)(C)[C@@H](CC1C[NH]C(=S)[NH]1)C(O)=O
L-GLUTAMIC-ACID,L-GLUTAMIC-ACID,,BRD:BRD-BRD-K62309135-001-05-2;BRD:BRD-K62309135-001-05-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,AADAT;AASS;ABAT;ALDH18A1;ASNS;BCAT1;BCAT2;CCBL2;DNPEP;EARS2;ENPEP;EPRS;FOLH1;FPGS;FTCD;GAD1;GAD2;GATB;GCLC;GCLM;GGCX;GLS;GLS2;GLUD1;GLUD2;GLUL;GMPS;GOT1;GOT2;GPT;GPT2;GRIA1;GRIA2;GRIA3;GRIA4;GRID1;GRID2;GRIK1;GRIK2;GRIK3;GRIK4;GRIK5;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;GRM1;GRM2;GRM3;GRM4;GRM6;GRM7;GRM8;LGSN;NADSYN1;NAGS;OPLAH;PFAS;PGCP;PSAT1;SLC1A1;SLC1A2;SLC1A3;SLC1A6;SLC1A7;SLC25A18;SLC25A22;SLC7A11;TAT,,,LAUNCHED,,,NA,,N[C@@H](CCC(O)=O)C(O)=O
L-HYDROXYPROLINE,L-HYDROXYPROLINE,,BRD:BRD-A12454076-001-01-9;BRD:BRD-BRD-A12454076-001-01-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,OC1CNC(C1)C(O)=O
L-KYNURENINE,L-KYNURENINE,CHEMBL498416,BRD:BRD-K20497775-001-06-9,rep_single_dose,ARYL HYDROCARBON RECEPTOR AGONIST,,,,,,Small molecule,Phase 1,YGPSJZOEDVAXAB-QMMMGPOBSA-N,NC1CCCCC1C(=O)C[C@H](N)C(=O)O
L-METHIONINE,L-METHIONINE,CHEMBL42336,BRD:BRD-BRD-K06502269-001-02-6;BRD:BRD-K06502269-001-02-6,rep_primary;rep_single_dose,VOLTAGE-GATED CALCIUM CHANNEL LIGAND,BHMT;BHMT2;METAP2;MTR;MTRR,,,LAUNCHED,,Small molecule,Approved,FFEARJCKVFRZRR-BYPYZUCNSA-N,CSCC[C@H](N)C(=O)O;CSCC[C@H](N)C(O)=O
L-NAME,L-NAME,CHEMBL7890,BRD:BRD-BRD-K33141550-003-05-7;BRD:BRD-K33141550-003-05-7,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS3,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,KCWZGJVSDFYRIX-YFKPBYRVSA-N,COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O;COC(=O)[C@@H](N)CCCNC(=N)N[N+](=O)[O-]
L-NIL,L-NIL,CHEMBL7889,BRD:BRD-BRD-K60036103-003-01-6;BRD:BRD-K60036103-003-01-6,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1;NOS2;NOS3,,,PRECLINICAL,,Small molecule,NA,ONYFNWIHJBLQKE-ZETCQYMHSA-N,CC(=N)NCCCC[C@H](N)C(=O)O;CC(=N)NCCCC[C@H](N)C(O)=O
L-PHENYLISOPROPYLADENOSINE,L-PHENYLISOPROPYLADENOSINE,,BRD:BRD-K25521961-001-06-9,rep_single_dose,,,,,,,,NA,,
L-PROLINE,L-PROLINE,CHEMBL54922,BRD:BRD-BRD-K01666412-001-02-0;BRD:BRD-K01666412-001-02-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,EPRS;L3HYPDH;P3H1;P3H2;P3H3;P4HA1;P4HA2;PARS2;PPIA;PPIB;PPIC;PPIF;PPIG;PPIH;PRODH;PROSC;PYCR1;PYCR2;PYCRL;SLC6A14;SLC6A7,,,LAUNCHED,,Small molecule,Unknown,ONIBWKKTOPOVIA-BYPYZUCNSA-N,O=C(O)[C@@H]1CCCN1;OC(=O)[C@@H]1CCCN1
L-QUISQUALIC-ACID,L-QUISQUALIC-ACID,,BRD:BRD-BRD-K92404805-001-07-0;BRD:BRD-K92404805-001-07-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,FOLH1;GRIA2;GRIK1;GRIK2;GRM1;GRM2;GRM3;GRM5;GRM7;GRM8,,,PRECLINICAL,,,NA,,N[C@@H](CN1OC(=O)[NH]C1=O)C(O)=O
L-THEANINE,L-THEANINE,CHEMBL3039113,BRD:BRD-A08715367-001-01-7;BRD:BRD-BRD-A08715367-001-01-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,LAUNCHED,,Small molecule,Phase 3,DATAGRPVKZEWHA-YFKPBYRVSA-N,CCNC(=O)CC[C@H](N)C(=O)O;CCNC(=O)CCC(N)C(O)=O
L01XC06,L01XC06,,GDSC1:1114,gdsc,,,,,,,,NA,,
LABETALOL,LABETALOL,CHEMBL429,BRD:BRD-A07440155-003-25-4;BRD:BRD-BRD-A07440155-003-25-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRB1;ADRB2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,SGUAFYQXFOLMHL-UHFFFAOYSA-N,CC(CCC1CCCCC1)NCC(O)C1CCC(O)C(C(N)=O)C1;CC(CCC1CCCCC1)NCC(O)C1CCC(O)C(C1)C(N)=O
LACIDIPINE,LACIDIPINE,CHEMBL460291,BRD:BRD-BRD-K43586850-001-02-9;BRD:BRD-K43586850-001-02-9,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,GKQPCPXONLDCMU-CCEZHUSRSA-N,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1CCCCC1/C=C/C(=O)OC(C)(C)C;CCOC(=O)C1=C(C)NC(C)=C(C1C1CCCCC1\C=C\C(=O)OC(C)(C)C)C(=O)OCC
LACITOL,LACITOL,,BRD:BRD-BRD-K40787673-001-02-1;BRD:BRD-K40787673-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,"LAXATIVE, OSMOSIS STIMULANT",,CONSTIPATION,,LAUNCHED,"Multiple values for MOA: {'OSMOSIS STIMULANT', 'LAXATIVE, OSMOSIS STIMULANT'}, defaulting to 'LAXATIVE, OSMOSIS STIMULANT'",,NA,,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
LACOSAMIDE,LACOSAMIDE,CHEMBL58323,BRD:BRD-BRD-K68232650-001-02-2;BRD:BRD-K68232650-001-02-2,rep_primary;rep_single_dose,"COLLAPSIN RESPONSE MEDIATOR PROTEIN INHIBITOR, COLLAPSIN RESPONSE MEDIATOR PROTEIN STIMULANT, SODIUM CHANNEL BLOCKER",SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,VPPJLAIAVCUEMN-GFCCVEGCSA-N,COC[C@@H](NC(C)=O)C(=O)NCC1CCCCC1
LACTULOSE,LACTULOSE,CHEMBL1237068;CHEMBL296306,BRD:BRD-BRD-K77258318-001-04-6;BRD:BRD-K77258318-001-04-6,rep_primary;rep_single_dose,LAXATIVE,,PORTAL-SYSTEMIC ENCEPHALOPATHY (PSE),,LAUNCHED,,Small molecule,Approved,JCQLYHFGKNRPGE-FCVZTGTOSA-N;XVCHNXZRPZGVJA-MILSHCHSSA-N,O.OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O;OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O;OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
LAFLUNIMUS,LAFLUNIMUS,CHEMBL142218,BRD:BRD-K00076962-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,GDHFOVCRYCPOTK-QBFSEMIESA-N,CC1CC(NC(=O)/C(C#N)=C(\O)C2CC2)CCC1C(F)(F)F
LAFUTIDINE,LAFUTIDINE,CHEMBL1742461,BRD:BRD-A67516570-001-02-8;BRD:BRD-BRD-A67516570-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,"DUODENAL ULCER DISEASE, PEPTIC ULCER DISEASE (PUD)",,LAUNCHED,,Small molecule,Phase 3,KMZQAVXSMUKBPD-DJWKRKHSSA-N,O=C(C[S+]([O-])CC1CCCO1)NC/C=C\COC1CC(CN2CCCCC2)CCN1;O=C(CS(=O)CC1CCCO1)NC\C=C/COC1CC(CN2CCCCC2)CCN1
LAMIVUDINE,LAMIVUDINE,CHEMBL141,BRD:BRD-BRD-K02992638-001-11-8;BRD:BRD-K02992638-001-11-8,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,"HUMAN IMMUNODEFICIENCY VIRUS (HIV-1), ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), HEPATITIS B",,LAUNCHED,,Small molecule,Approved,JTEGQNOMFQHVDC-NKWVEPMBSA-N,NC1CCN([C@@H]2CS[C@H](CO)O2)C(=O)N1;NC1CCN(C2CSC(CO)O2)C(=O)N1
LAMOTRIGINE,LAMOTRIGINE,CHEMBL741,BRD:BRD-BRD-K93460210-001-23-7;BRD:BRD-K93460210-001-23-7,rep_primary;rep_single_dose,"SEROTONIN RECEPTOR ANTAGONIST, SODIUM CHANNEL BLOCKER",SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,"EPILEPSY, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,PYZRQGJRPPTADH-UHFFFAOYSA-N,NC1NNC(-C2CCCC(CL)C2CL)C(N)N1;NC1NNC(C(N)N1)-C1CCCC(CL)C1CL
LANABECESTAT,LANABECESTAT,CHEMBL3989948,BRD:BRD-K00003387-001-01-9,rep_single_dose,BETA SECRETASE INHIBITOR,,,,,,Small molecule,Phase 3,WKDNQONLGXOZRG-HRNNMHKYSA-N,CC#CC1CNCC(-C2CCC3C(C2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)C1
LANATOSIDE-C,LANATOSIDE-C,,BRD:BRD-A64242993-001-05-6;BRD:BRD-BRD-A64242993-001-05-6,rep_multi_dose;rep_primary;rep_single_dose,CARDIAC GLYCOSIDE,,,,PRECLINICAL,,,NA,,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
LANDIOLOL,LANDIOLOL,CHEMBL1742466,BRD:BRD-BRD-K86436199-003-01-3;BRD:BRD-K86436199-003-01-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1,CARDIAC ARRYTHMIA,,LAUNCHED,,Small molecule,Phase 3,WMDSZGFJQKSLLH-RBBKRZOGSA-N,CC1(C)OC[C@@H](COC(=O)CCC2CCC(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)CC2)O1
LANIFIBRANOR,LANIFIBRANOR,CHEMBL4091374,BRD:BRD-K00003462-001-01-9,rep_single_dose,PPAR RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,OQDQIFQRNZIEEJ-UHFFFAOYSA-N,O=C(O)CCCC1CC2CC(CL)CCC2N1S(=O)(=O)C1CCC2NCSC2C1
LANOCONAZOLE,LANOCONAZOLE,CHEMBL1555126,BRD:BRD-A54275602-001-01-0;BRD:BRD-BRD-A54275602-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,FUNGAL INFECTION,,LAUNCHED,,Small molecule,Unknown,ZRTQSJFIDWNVJW-WYMLVPIESA-N,CLC1CCCCC1C1CS\C(S1)=C(\C#N)N1CCNC1;N#C/C(=C1/SCC(C2CCCCC2CL)S1)N1CCNC1
LANSOPRAZOLE,LANSOPRAZOLE,CHEMBL1201863;CHEMBL480,BRD:BRD-A49172652-001-27-1;BRD:BRD-BRD-A49172652-001-27-1,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP4A;ATP4B,HEARTBURN,,LAUNCHED,,Small molecule,Approved,MJIHNNLFOKEZEW-RUZDIDTESA-N;MJIHNNLFOKEZEW-UHFFFAOYSA-N,CC1C(OCC(F)(F)F)CCNC1C[S@@+]([O-])C1NC2CCCCC2[NH]1;CC1C(OCC(F)(F)F)CCNC1C[S+]([O-])C1NC2CCCCC2[NH]1;CC1C(OCC(F)(F)F)CCNC1CS(=O)C1NC2CCCCC2[NH]1
LAPATINIB,LAPATINIB,CHEMBL1201179;CHEMBL554,BRD:BRD-BRD-K19687926-379-07-4;BRD:BRD-K19687926-001-04-1;BRD:BRD-K19687926-001-05-8;BRD:BRD-K19687926-001-08-2;BRD:BRD-K19687926-379-07-4;CTRP:634309;GDSC1:119;GDSC2:1558,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF EGFR AND ERBB2,EGFR;ERBB2,BREAST CANCER,,LAUNCHED,"Multiple values for MOA: {'EGFR INHIBITOR', 'INHIBITOR OF EGFR AND ERBB2'}, defaulting to 'INHIBITOR OF EGFR AND ERBB2'",Small molecule,Approved,BCFGMOOMADDAQU-UHFFFAOYSA-N;XNRVGTHNYCNCFF-UHFFFAOYSA-N,CS(=O)(=O)CCNCC1CCC(-C2CCC3NCNC(NC4CCC(OCC5CCCC(F)C5)C(CL)C4)C3C2)O1;CS(=O)(=O)CCNCC1CCC(-C2CCC3NCNC(NC4CCC(OCC5CCCC(F)C5)C(CL)C4)C3C2)O1.CC1CCC(S(=O)(=O)O)CC1.CC1CCC(S(=O)(=O)O)CC1.O;CS(=O)(=O)CCNCC1CCC(O1)-C1CCC2NCNC(NC3CCC(OCC4CCCC(F)C4)C(CL)C3)C2C1
LAPPACONITE,LAPPACONITE,,BRD:BRD-A05906449-004-01-1;BRD:BRD-BRD-A05906449-004-01-1,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,,,,PHASE 2,,,NA,,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)C1CCCCC1NC(C)=O
LAQ824,LAQ824,CHEMBL356066,GDSC1:200,gdsc,,,,,,,Small molecule,Unknown,BWDQBBCUWLSASG-MDZDMXLPSA-N,O=C(/C=C/C1CCC(CN(CCO)CCC2C[NH]C3CCCCC23)CC1)NO
LAQUINIMOD,LAQUINIMOD,CHEMBL66092,BRD:BRD-BRD-K60918217-001-03-8;BRD:BRD-K60918217-001-03-8,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,CXCL2,,,PHASE 3,,Small molecule,Phase 3,GKWPCEFFIHSJOE-UHFFFAOYSA-N,CCN(C(=O)C1C(O)C2C(CL)CCCC2N(C)C1=O)C1CCCCC1
LARAZOTIDE-ACETATE,LARAZOTIDE-ACETATE,,BRD:BRD-K00003469-015-01-9,rep_single_dose,TIGHT JUNCTION REGULATOR,,,,,,,NA,,
LAROPIPRANT,LAROPIPRANT,CHEMBL426559,BRD:BRD-BRD-K48894757-001-01-8;BRD:BRD-K48894757-001-01-8,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGDR;PTGDR2;PTGER1;PTGER2;PTGER3;PTGFR;PTGIR;TBXA2R,CHOLESTEROL,,LAUNCHED,,Small molecule,Approved,NXFFJDQHYLNEJK-CYBMUJFWSA-N,CS(=O)(=O)C1CC(F)CC2C3C(N(CC4CCC(CL)CC4)C12)[C@@H](CC(=O)O)CC3;CS(=O)(=O)C1CC(F)CC2C3CC[C@H](CC(O)=O)C3N(CC3CCC(CL)CC3)C12
LOXO-101,LAROTRECTINIB;LOXO-101,CHEMBL3889654,BRD:BRD-BRD-K36574127-001-01-3;BRD:BRD-K36574127-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,TROPOMYOSIN RECEPTOR KINASE INHIBITOR,NTRK1;NTRK2;NTRK3,,,PHASE 2,,Small molecule,Approved,NYNZQNWKBKUAII-KBXCAEBGSA-N,O[C@H]1CCN(C1)C(=O)NC1CNN2CCC(NC12)N1CCC[C@@H]1C1CC(F)CCC1F;O=C(NC1CNN2CCC(N3CCC[C@@H]3C3CC(F)CCC3F)NC12)N1CC[C@H](O)C1
LAS101057,LAS101057,CHEMBL1672627,BRD:BRD-K00079404-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,XUYURJQIMYCWBB-UHFFFAOYSA-N,O=C(NC1CNC(-C2CCNCC2F)C(-C2CCCNC2)N1)C1CC1
LASALOCID,LASALOCID,CHEMBL145347,BRD:BRD-A72711497-236-03-8;BRD:BRD-BRD-A72711497-236-03-8,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL PERMEABILITY INDUCER,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,BBMULGJBVDDDNI-OWKLGTHSSA-N,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC1CCC(C)C(O)C1C(=O)O)[C@H]1O[C@](CC)([C@H]2CC[C@](O)(CC)[C@H](C)O2)C[C@@H]1C;CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCC1CCC(C)C(O)C1C(O)=O
LASMIDITAN,LASMIDITAN,CHEMBL3039520,BRD:BRD-K00003178-003-01-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,,,,,,Small molecule,Approved,XEDHVZKDSYZQBF-UHFFFAOYSA-N,CN1CCC(C(=O)C2CCCC(NC(=O)C3C(F)CC(F)CC3F)N2)CC1
LASOFOXIFENE,LASOFOXIFENE,CHEMBL328190,BRD:BRD-M93148412-001-02-6,rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),ESR1;ESR2,,,,,Small molecule,Approved,GXESHMAMLJKROZ-IAPPQJPRSA-N,OC1CCC2C(C1)CC[C@H](C1CCCCC1)[C@@H]2C1CCC(OCCN2CCCC2)CC1
LATANOPROST,LATANOPROST,CHEMBL1051,BRD:BRD-BRD-K10961822-001-05-1;BRD:BRD-K10961822-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,PTGFR,"OCULAR HYPERTENSION, GLAUCOMA",,LAUNCHED,,Small molecule,Approved,GGXICVAJURFBLW-CEYXHVGTSA-N,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O;CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1CCCCC1
LATANOPROSTENE BUNOD,LATANOPROSTENE BUNOD,CHEMBL2364612,BRD:BRD-K00029604-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,LOVMMUBRQUFEAH-UIEAZXIASA-N,O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCC2CCCCC2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
LATREPIRDINE,LATREPIRDINE,CHEMBL589390,BRD:BRD-BRD-K55703048-001-07-7;BRD:BRD-K55703048-001-07-7,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,HRH1;HTR6,,,PHASE 3,,Small molecule,Phase 3,JNODQFNWMXFMEV-UHFFFAOYSA-N,CC1CCC2C(C1)C1C(N2CCC2CCC(C)NC2)CCN(C)C1;CN1CCC2C(C1)C1CC(C)CCC1N2CCC1CCC(C)NC1
LAURIC-DIETHANOLAMIDE,LAURIC-DIETHANOLAMIDE,,BRD:BRD-BRD-K11548689-001-01-6;BRD:BRD-K11548689-001-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCCCCCCC(=O)N(CCO)CCO
LAUROCAPRAM,LAUROCAPRAM,CHEMBL76591,BRD:BRD-BRD-K35698076-001-01-2;BRD:BRD-K35698076-001-01-2,rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,Unknown,AXTGDCSMTYGJND-UHFFFAOYSA-N,CCCCCCCCCCCCN1CCCCCC1=O
LAZABEMIDE,LAZABEMIDE,CHEMBL279390,BRD:BRD-BRD-K51486818-003-02-8;BRD:BRD-K51486818-003-02-8,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOB,,,PHASE 3,,Small molecule,Unknown,JZXRLKWWVNUZRB-UHFFFAOYSA-N,NCCNC(=O)C1CCC(CL)CN1
LAZERTINIB,LAZERTINIB,CHEMBL4558324,BRD:BRD-K00003501-001-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 3,RRMJMHOQSALEJJ-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCCC(-N3CC(CN(C)C)C(-C4CCCCC4)N3)N2)C(OC)CC1N1CCOCC1
LB-100,LB-100,CHEMBL4297300,BRD:BRD-A73709786-001-01-3;BRD:BRD-BRD-A73709786-001-01-3,rep_primary;rep_single_dose,PROTEIN PHOSPHATASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 2,JUQMLSGOTNKJKI-IZUQBHJASA-N,CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1;CN1CCN(CC1)C(=O)C1[C@H]2CC[C@H](O2)C1C(O)=O;CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O
LB42708,LB42708,,BRD:BRD-BRD-K18834913-001-01-1;BRD:BRD-K18834913-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,FARNESYLTRANSFERASE INHIBITOR,,,,PRECLINICAL,,,NA,,BRC1CCC(CN2CNCC2CN2CC(C(=O)N3CCOCC3)C(C2)-C2CCCC3CCCCC23)CC1
LBH-589,LBH-589,CHEMBL483254,CTRP:54210,ctrp,,,,,,,Small molecule,Approved,FPOHNWQLNRZRFC-ZHACJKMWSA-N,CC1[NH]C2CCCCC2C1CCNCC1CCC(/C=C/C(=O)NO)CC1
LBH589,LBH589,CHEMBL483254,GDSC1:438,gdsc,,,,,,,Small molecule,Approved,FPOHNWQLNRZRFC-ZHACJKMWSA-N,CC1[NH]C2CCCCC2C1CCNCC1CCC(/C=C/C(=O)NO)CC1
LCL-161,LCL-161,CHEMBL2431768,BRD:BRD-BRD-K08248804-001-01-8;BRD:BRD-K08248804-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,XIAP INHIBITOR,BIRC2;XIAP,,,PHASE 2,,Small molecule,Phase 2,UFPFGVNKHCLJJO-SSKFGXFMSA-N,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C1NC(CS1)C(=O)C1CCC(F)CC1;CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C1NC(C(=O)C2CCC(F)CC2)CS1)C1CCCCC1
LCL161,LCL161,CHEMBL2431768,GDSC1:439;GDSC2:1557,gdsc,,,,,,,Small molecule,Phase 2,UFPFGVNKHCLJJO-SSKFGXFMSA-N,CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C1NC(C(=O)C2CCC(F)CC2)CS1)C1CCCCC1
LCQ908,LCQ908,,BRD:BRD-BRD-K20008181-001-01-3;BRD:BRD-K20008181-001-01-3,rep_primary;rep_single_dose,DIACYLGLYCEROL O ACYLTRANSFERASE INHIBITOR,DGAT1,,,PHASE 3,,,NA,,OC(=O)C[C@H]1CC[C@@H](CC1)C1CCC(CC1)-C1CCC(NC2CCC(NC2)C(F)(F)F)CN1
LDC1267,LDC1267,,BRD:BRD-BRD-K44715996-001-01-0;BRD:BRD-K44715996-001-01-0,rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,AXL;MERTK;TYRO3,,,PRECLINICAL,,,NA,,CCOC1CN(NC1C(=O)NC1CCC(OC2CCNC3CC(OC)C(OC)CC23)C(F)C1)-C1CCC(F)CC1C
LDN-193189,LDN-193189,,GDSC1:478,gdsc,,,,,,,,NA,,
LDN-212854,LDN-212854,,BRD:BRD-BRD-K59831625-001-01-6;BRD:BRD-K59831625-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,BONE MORPHOGENIC PROTEIN INHIBITOR,ABL1;ACVR1;RIPK2,,,PRECLINICAL,,,NA,,C1CN(CCN1)C1CCC(CC1)-C1CNC2C(CNN2C1)-C1CCCC2NCCCC12
LDN-27219,LDN-27219,,BRD:BRD-K51485109-001-02-9,rep_single_dose,TISSUE TRANSGLUTAMINASE INHIBITOR,TGM2,,,,,,NA,,
LDN-57444,LDN-57444,,BRD:BRD-BRD-K94485812-001-02-9;BRD:BRD-K94485812-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR,,,,PRECLINICAL,,,NA,,CC(=O)O\N=C1\C(=O)N(CC2CC(CL)CCC2CL)C2CCC(CL)CC12
LDN193189,LDN193189,,BRD:BRD-K04853698-376-01-4,rep_single_dose,BONE MORPHOGENIC PROTEIN INHIBITOR,ACVR1;BMPR1A,,,,,,NA,,
LDP-341,LDP-341,CHEMBL325041,GDSC1:104;GDSC2:1191,gdsc,,,,,,,Small molecule,Approved,GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1CNCCN1)B(O)O
LE-135,LE-135,,BRD:BRD-BRD-K06593056-001-04-8;BRD:BRD-K06593056-001-04-8;CTRP:375354,ctrp;rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARB,,,PRECLINICAL,,,NA,,CN1C2CC3C(CC2N=C(C2CCC(CC2)C(O)=O)C2CCCCC12)C(C)(C)CCC3(C)C
LEDIPASVIR,LEDIPASVIR,CHEMBL2374220,BRD:BRD-BRD-K05446112-001-01-8;BRD:BRD-K05446112-001-01-8,rep_primary;rep_single_dose,HCV INHIBITOR,,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,VRTWBAAJJOHBQU-KMWAZVGDSA-N,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1NCC([NH]1)-C1CCC2-C3CCC(CC3C(F)(F)C2C1)-C1CCC2NC([NH]C2C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C;COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1C1NC(-C2CCC3C(C2)C(F)(F)C2CC(-C4CCC5[NH]C([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)NC5C4)CCC2-3)C[NH]1)C(C)C
RIBOCICLIB,LEE 011;RIBOCICLIB,CHEMBL3545110,BRD:BRD-BRD-K36788280-001-01-2;BRD:BRD-K36788280-001-01-2;BRD:BRD-K36788280-001-06-9;GDSC2:1632,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF CDK4 AND CDK6,CDK4;CDK6,BREAST CANCER,,LAUNCHED,"Multiple values for MOA: {'CDK INHIBITOR', 'INHIBITOR OF CDK4 AND CDK6'}, defaulting to 'INHIBITOR OF CDK4 AND CDK6'",Small molecule,Approved,RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)C1CC2CNC(NC3CCC(CN3)N3CCNCC3)NC2N1C1CCCC1;CN(C)C(=O)C1CC2CNC(NC3CCC(N4CCNCC4)CN3)NC2N1C1CCCC1
LEE011,LEE011,CHEMBL3545110,GDSC2:1632,gdsc,,,,,,,Small molecule,Approved,RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)C1CC2CNC(NC3CCC(N4CCNCC4)CN3)NC2N1C1CCCC1
LEE011-BBA,LEE011-BBA,CHEMBL3707266,GDSC2:1632,gdsc,,,,,,,Small molecule,Approved,NHANOMFABJQAAH-UHFFFAOYSA-N,CN(C)C(=O)C1CC2CNC(NC3CCC(N4CCNCC4)CN3)NC2N1C1CCCC1.O=C(O)CCC(=O)O
LEFAMULIN,LEFAMULIN,CHEMBL3291398,BRD:BRD-K00071589-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,KPVIXBKIJXZQJX-FCEONZPQSA-N,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
LEFLUNOMIDE,LEFLUNOMIDE,CHEMBL960,BRD:BRD-BRD-K78692225-001-24-5;BRD:BRD-K78692225-001-24-5;GDSC2:1578,gdsc;rep_primary;rep_single_dose,"DIHYDROOROTATE DEHYDROGENASE INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR",AHR;DHODH;PTK2B,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Approved,VHOGYURTWQBHIL-UHFFFAOYSA-N,CC1ONCC1C(=O)NC1CCC(C(F)(F)F)CC1;CC1ONCC1C(=O)NC1CCC(CC1)C(F)(F)F
LEMBOREXANT,LEMBOREXANT,CHEMBL3545367,BRD:BRD-BRD-K78666663-001-01-6;BRD:BRD-K78666663-001-01-6,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,PHASE 3,,Small molecule,Approved,MUGXRYIUWFITCP-PGRDOPGGSA-N,CC1NCC(OC[C@]2(C[C@H]2C(=O)NC2CCC(F)CN2)C2CCCC(F)C2)C(C)N1;CC1NCC(OC[C@@]2(C3CCCC(F)C3)C[C@H]2C(=O)NC2CCC(F)CN2)C(C)N1
LENALIDOMIDE,LENALIDOMIDE,CHEMBL848,BRD:BRD-A17883755-001-06-1;BRD:BRD-A17883755-001-13-9;BRD:BRD-BRD-A17883755-001-06-1;GDSC1:1020,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,MOLECULAR GLUE AND BINDER OF CRBN,CDH5;CRBN;CUL4A;PTGS2;TNF;TNFSF11,"MULTIPLE MYELOMA, MANTLE CELL LYMPHOMA (MCL), MYELODYSPLASTIC DISEASES (MDS)",,LAUNCHED,"Multiple values for MOA: {'MOLECULAR GLUE AND BINDER OF CRBN', 'ANTICANCER AGENT'}, defaulting to 'MOLECULAR GLUE AND BINDER OF CRBN'
Multiple values for repurposing_target: {'CRBN;CUL4A', 'CDH5;CRBN;PTGS2;TNF;TNFSF11'}, taking the union",Small molecule,Approved,GOTYRUGSSMKFNF-UHFFFAOYSA-N,NC1CCCC2C(=O)N(CC12)C1CCC(=O)NC1=O;NC1CCCC2C1CN(C1CCC(=O)NC1=O)C2=O
LENIOLISIB,LENIOLISIB,CHEMBL3643413,BRD:BRD-K00003261-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,Small molecule,Phase 3,MWKYMZXCGYXLPL-ZDUSSCGKSA-N,CCC(=O)N1CC[C@H](NC2NCNC3C2CN(C2CNC(OC)C(C(F)(F)F)C2)CC3)C1
LENVATINIB,LENVATINIB,CHEMBL1289601,BRD:BRD-BRD-K39974922-001-04-3;BRD:BRD-K39974922-001-04-3;CTRP:628639,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",FLT4;KDR,THYROID CANCER,,LAUNCHED,,Small molecule,Approved,WOSKHXYHFSIKNG-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)NC4CC4)C(CL)C3)C2CC1C(N)=O
LEONURINE,LEONURINE,CHEMBL1290284,BRD:BRD-K00004696-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,NA,WNGSUWLDMZFYNZ-UHFFFAOYSA-N,COC1CC(C(=O)OCCCCNC(=N)N)CC(OC)C1O
LEPTOMYCIN B,LEPTOMYCIN B,CHEMBL486133,CTRP:660086,ctrp,,,,,,,Small molecule,NA,YACHGFWEQXFSBS-XYERBDPFSA-N,CCC(=C/[C@H](C)C/C=C/C(C)=C/[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C/C(C)=C/C(=O)O)/C=C/[C@@H]1OC(=O)C=C[C@@H]1C
LEQ506,LEQ506,CHEMBL3133037,BRD:BRD-K00003269-001-01-9,rep_single_dose,G PROTEIN SIGNALING INHIBITOR,,,,,,Small molecule,Phase 1,POERAARDVFVDLO-QGZVFWFLSA-N,CC1C(CC2CCCCC2)NNC(N2CCN(C3CNC(C(C)(C)O)CN3)[C@H](C)C2)C1C
LERCANIDIPINE,LERCANIDIPINE,CHEMBL250270,BRD:BRD-A18992208-003-02-7;BRD:BRD-BRD-A18992208-003-02-7,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA2D1;CACNG1,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,ZDXUKAKRHYTAKV-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C2CCCCC2)C2CCCCC2)C1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1CCCCC1)C1CCCCC1
LERISETRON,LERISETRON,CHEMBL56900,BRD:BRD-BRD-K62398570-300-01-2;BRD:BRD-K62398570-300-01-2,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A,,,PHASE 3,,Small molecule,Phase 3,PWWDCRQZITYKDV-UHFFFAOYSA-N,C(C1CCCCC1)N1C(NC2CCCCC12)N1CCNCC1;C1CCC(CN2C(N3CCNCC3)NC3CCCCC32)CC1
LERSIVIRINE,LERSIVIRINE,CHEMBL571987,BRD:BRD-BRD-K03289534-001-01-4;BRD:BRD-K03289534-001-01-4,rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,MCPUZZJBAHRIPO-UHFFFAOYSA-N,CCC1NN(CCO)C(CC)C1OC1CC(C#N)CC(C#N)C1;CCC1NN(CCO)C(CC)C1OC1CC(CC(C1)C#N)C#N
LESINURAD,LESINURAD,CHEMBL2105720,BRD:BRD-BRD-K75024268-001-01-0;BRD:BRD-K75024268-001-01-0,rep_primary;rep_single_dose,URIC ACID DIURETIC,SLC22A12,GOUT,,LAUNCHED,,Small molecule,Approved,FGQFOYHRJSUHMR-UHFFFAOYSA-N,O=C(O)CSC1NNC(BR)N1-C1CCC(C2CC2)C2CCCCC12;OC(=O)CSC1NNC(BR)N1-C1CCC(C2CC2)C2CCCCC12
LESTAURTINIB,LESTAURTINIB,CHEMBL603469,BRD:BRD-A27376179-001-01-3;BRD:BRD-BRD-A27376179-001-01-3;GDSC1:1024,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, GROWTH FACTOR RECEPTOR INHIBITOR, JAK INHIBITOR",FLT3;NTRK1,,,PHASE 3,,Small molecule,Phase 3,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)CNC4=O;C[C@]12OC(C[C@]1(O)CO)N1C3CCCCC3C3C4C(=O)NCC4C4C5CCCCC5N2C4C13
LETEPRINIM,LETEPRINIM,CHEMBL2104345,BRD:BRD-BRD-K21612934-001-01-1;BRD:BRD-K21612934-001-01-1,rep_primary;rep_single_dose,NERVE GROWTH FACTOR AGONIST,,,,PHASE 2,,Small molecule,Phase 2,JMPOIZCOJJMTHI-UHFFFAOYSA-N,O=C(CCN1CNC2C(=O)[NH]CNC21)NC1CCC(C(=O)O)CC1;OC(=O)C1CCC(NC(=O)CCN2CNC3C(O)NCNC23)CC1
LETERMOVIR,LETERMOVIR,CHEMBL1241951,BRD:BRD-BRD-K94288301-001-01-7;BRD:BRD-K94288301-001-01-7,rep_primary;rep_single_dose,CMV TERMINASE INHIBITOR,,,,PHASE 3,,Small molecule,Approved,FWYSMLBETOMXAG-QHCPKHFHSA-N,COC1CCCC(C1)N1CCN(CC1)C1=NC2C(F)CCCC2[C@H](CC(O)=O)N1C1CC(CCC1OC)C(F)(F)F;COC1CCCC(N2CCN(C3=NC4C(F)CCCC4[C@H](CC(=O)O)N3C3CC(C(F)(F)F)CCC3OC)CC2)C1
LETOSTEINE,LETOSTEINE,CHEMBL2105044,BRD:BRD-A32597168-001-03-6;BRD:BRD-BRD-A32597168-001-03-6,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,"BRONCHITIS, PNEUMONIA",,LAUNCHED,,Small molecule,Unknown,IKOCLISPVJZJEA-UHFFFAOYSA-N,CCOC(=O)CSCCC1NC(C(=O)O)CS1;CCOC(=O)CSCCC1NC(CS1)C(O)=O
LETRAZURIL,LETRAZURIL,CHEMBL2104819,BRD:BRD-K00003474-001-01-9,rep_single_dose,ANTIINFECTIVE DRUG,,,,,,Small molecule,Phase 1,XQKYUBTUOHHNDV-UHFFFAOYSA-N,N#CC(C1CCC(F)CC1)C1C(CL)CC(-N2NCC(=O)[NH]C2=O)CC1CL
LETROZOLE,LETROZOLE,CHEMBL1444,BRD:BRD-BRD-K88789588-001-14-9;BRD:BRD-K88789588-001-14-9,rep_multi_dose;rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP19A1,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,HPJKCIUCZWXJDR-UHFFFAOYSA-N,N#CC1CCC(C(C2CCC(C#N)CC2)N2CNCN2)CC1;N#CC1CCC(CC1)C(C1CCC(CC1)C#N)N1CNCN1
LEUCOVORIN,LEUCOVORIN,CHEMBL1679,BRD:BRD-A75919782-399-02-6;BRD:BRD-BRD-A75919782-399-02-6,rep_multi_dose;rep_primary;rep_single_dose,FOLATE RECEPTOR LIGAND,TYMS,OSTEOSARCOMA,,LAUNCHED,,Small molecule,Approved,VVIAGPKUTFNRDU-ABLWVSNPSA-N,NC1NC(=O)C2C([NH]1)NCC(CNC1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1)N2C=O;NC1NC(=O)C2N(C=O)C(CNC3CCC(CC3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2[NH]1
LEUCYLLEUCINE-METHYL-ESTER,LEUCYLLEUCINE-METHYL-ESTER,,BRD:BRD-BRD-K81136890-003-01-6;BRD:BRD-K81136890-003-01-6,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C
LEUPROLIDE,LEUPROLIDE,CHEMBL1201199,BRD:BRD-BRD-K26323068-001-01-8;BRD:BRD-K26323068-001-01-8,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR AGONIST,GNRHR,PROSTATE CANCER,,LAUNCHED,,Protein,Approved,GFIJNRVAKGFPGQ-LIJARHBVSA-N,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1;CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1
VINCRISTINE,LEUROCRISTINE;NSC-67574;VINCRISTINE,CHEMBL501867;CHEMBL90555,BRD:BRD-BRD-K12251893-065-04-7;BRD:BRD-K12251893-065-01-3;BRD:BRD-K12251893-065-04-7;CTRP:62602;GDSC2:1818,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBA;TUBA4A;TUBB,ACUTE LYMPHOBLASTIC LEUKEMIA (ALL),,LAUNCHED,"Multiple values for MOA: {'TUBULIN POLYMERIZATION INHIBITOR', 'INHIBITOR OF TUBULIN'}, defaulting to 'TUBULIN POLYMERIZATION INHIBITOR'
Multiple values for repurposing_target: {'TUBA;TUBB', 'TUBA4A;TUBB'}, taking the union",Small molecule,Approved,AQTQHPDCURKLKT-JKDPCDLQSA-N;OGWKCGZFUXNPDA-XQKSVPLYSA-N,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1C([NH]C3CCCCC13)[C@@](C2)(C(=O)OC)C1CC2C(CC1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC;CC[C@]1(O)C[C@H]2CN(CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1;CC[C@]1(O)C[C@H]2CN(CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
LEVALBUTEROL,LEVALBUTEROL,CHEMBL1002,BRD:BRD-BRD-K34469523-003-03-0;BRD:BRD-K34469523-003-03-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,BRONCHOSPASM,,LAUNCHED,,Small molecule,Approved,NDAUXUAQIAJITI-LBPRGKRZSA-N,CC(C)(C)NC[C@H](O)C1CCC(O)C(CO)C1
LEVALLORPHAN,LEVALLORPHAN,CHEMBL1254682,BRD:BRD-BRD-K30634073-046-01-0;BRD:BRD-K30634073-046-01-0,rep_primary;rep_single_dose,"OPIOID ANTAGONIST, OPIOID RECEPTOR ANTAGONIST",CHRNA2;OPRM1,RESPIRATORY DEPRESSION,,LAUNCHED,"Multiple values for MOA: {'OPIOID ANTAGONIST, OPIOID RECEPTOR ANTAGONIST', 'OPIOID ANTAGONIST'}, defaulting to 'OPIOID ANTAGONIST, OPIOID RECEPTOR ANTAGONIST'",Small molecule,Approved,OZYUPQUCAUTOBP-QXAKKESOSA-N,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC1CCC(O)CC13;OC1CCC2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)C2C1
LEVAMISOLE,LEVAMISOLE,CHEMBL1454,BRD:BRD-BRD-K73107279-003-12-5;BRD:BRD-K73107279-003-12-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,ALPL;ALPPL2;CHRNA3,,,WITHDRAWN,,Small molecule,Approved,HLFSDGLLUJUHTE-SNVBAGLBSA-N,C1CCC([C@H]2CN3CCSC3=N2)CC1;C1CN2C[C@@H](N=C2S1)C1CCCCC1
LEVAMLODIPINE,LEVAMLODIPINE,CHEMBL2111097,BRD:BRD-K00005329-074-01-9,rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,,,Small molecule,Approved,HTIQEAQVCYTUBX-KRWDZBQOSA-N,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1CCCCC1CL
LEVCROMAKALIM,LEVCROMAKALIM,CHEMBL100,BRD:BRD-K24526313-001-17-7,rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNJ5,,,,,Small molecule,Unknown,TVZCRIROJQEVOT-CABCVRRESA-N,CC1(C)OC2CCC(C#N)CC2[C@@H](N2CCCC2=O)[C@@H]1O
LEVETIRACETAM,LEVETIRACETAM,CHEMBL1286,BRD:BRD-BRD-K49404994-001-10-9;BRD:BRD-K49404994-001-10-9,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1B;SCN1A;SV2A,SEIZURES,,LAUNCHED,,Small molecule,Approved,HPHUVLMMVZITSG-LURJTMIESA-N,CC[C@@H](C(N)=O)N1CCCC1=O;CC[C@H](N1CCCC1=O)C(N)=O
LEVO-PHENCYNONATE,LEVO-PHENCYNONATE,,BRD:BRD-A64698388-003-01-7;BRD:BRD-BRD-A64698388-003-01-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,,,LAUNCHED,,,NA,,CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)C1CCCCC1
LEVOBETAXOLOL,LEVOBETAXOLOL,CHEMBL1201274,BRD:BRD-K43883465-003-02-9,rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,,,,,Small molecule,Approved,NWIUTZDMDHAVTP-KRWDZBQOSA-N,CC(C)NC[C@H](O)COC1CCC(CCOCC2CC2)CC1
LEVOBUNOLOL,LEVOBUNOLOL,CHEMBL1201237,BRD:BRD-BRD-K31812033-003-11-0;BRD:BRD-K31812033-003-11-0,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,"GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,,Small molecule,Approved,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,CC(C)(C)NC[C@H](O)COC1CCCC2C(=O)CCCC12;CC(C)(C)NC[C@H](O)COC1CCCC2C1CCCC2=O
LEVOBUNOLOL-(+),LEVOBUNOLOL-(+),,BRD:BRD-BRD-K73323637-003-10-9;BRD:BRD-K73323637-003-10-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CC(C)(C)NC[C@@H](O)COC1CCCC2C(=O)CCCC12
LEVOBUNOLOL-(+/-),LEVOBUNOLOL-(+/-),,BRD:BRD-A46876182-003-02-8;BRD:BRD-BRD-A46876182-003-02-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CC(C)(C)NCC(O)COC1CCCC2C(=O)CCCC12
LEVOCABASTINE,LEVOCABASTINE,CHEMBL1615438,BRD:BRD-BRD-K33453211-003-11-5;BRD:BRD-K33453211-003-11-5,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1;NTSR2,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,ZCGOMHNNNFPNMX-KYTRFIICSA-N,C[C@@H]1CN([C@H]2CC[C@](C#N)(C3CCC(F)CC3)CC2)CC[C@]1(C(=O)O)C1CCCCC1;C[C@@H]1CN(CC[C@]1(C(O)=O)C1CCCCC1)[C@H]1CC[C@](CC1)(C#N)C1CCC(F)CC1
LEVOCARNITINE,LEVOCARNITINE,CHEMBL1149,BRD:BRD-BRD-K59647213-001-10-5;BRD:BRD-K59647213-001-10-5,rep_multi_dose;rep_primary;rep_single_dose,,CRAT;CROT,CARNITINE DEFICIENCY,,LAUNCHED,,Small molecule,Approved,PHIQHXFUZVPYII-ZCFIWIBFSA-N,C[N+](C)(C)C[C@H](O)CC(=O)[O-];C[N+](C)(C)C[C@H](O)CC(O)=O
LEVOCETIRIZINE,LEVOCETIRIZINE,CHEMBL1201191,BRD:BRD-BRD-K27184429-300-01-3;BRD:BRD-K27184429-300-01-3,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,ZKLPARSLTMPFCP-OAQYLSRUSA-N,O=C(O)COCCN1CCN([C@H](C2CCCCC2)C2CCC(CL)CC2)CC1;OC(=O)COCCN1CCN(CC1)[C@H](C1CCCCC1)C1CCC(CL)CC1
LEVODOPA,LEVODOPA,CHEMBL1009,BRD:BRD-BRD-K34730807-001-17-6;BRD:BRD-K34730807-001-17-6,rep_primary;rep_single_dose,DOPAMINE PRECURSOR,DRD1;DRD2;DRD3;DRD4;DRD5;GPR143,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,WTDRDQBEARUVNC-LURJTMIESA-N,N[C@@H](CC1CCC(O)C(O)C1)C(=O)O;N[C@@H](CC1CCC(O)C(O)C1)C(O)=O
LEVODROPROPIZINE,LEVODROPROPIZINE,CHEMBL1288810,BRD:BRD-BRD-K83551379-001-01-8;BRD:BRD-BRD-K83551379-001-02-6;BRD:BRD-K83551379-001-01-8;BRD:BRD-K83551379-001-02-6,rep_primary;rep_single_dose,ANTITUSSIVE,,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Phase 3,PTVWPYVOOKLBCG-ZDUSSCGKSA-N,OC[C@@H](O)CN1CCN(C2CCCCC2)CC1;OC[C@@H](O)CN1CCN(CC1)C1CCCCC1
LEVOFLOXACIN,LEVOFLOXACIN,CHEMBL33,BRD:BRD-BRD-K09471561-001-18-2;BRD:BRD-K09471561-001-18-2,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,"PNEUMONIA, SINUSITIS, BRONCHITIS, SKIN INFECTIONS, PROSTATITIS, URINARY TRACT INFECTIONS, PYELONEPHRITIS, ANTHRAX, PLAGUE",,LAUNCHED,,Small molecule,Approved,GSDSWSVVBLHKDQ-JTQLQIEISA-N,C[C@H]1COC2C(N3CCN(C)CC3)C(F)CC3C(=O)C(C(=O)O)CN1C23;C[C@H]1COC2C(N3CCN(C)CC3)C(F)CC3C2N1CC(C(O)=O)C3=O
LEVOMEPROMAZINE,LEVOMEPROMAZINE,CHEMBL1764,BRD:BRD-BRD-K35559145-050-08-5;BRD:BRD-K35559145-050-08-5,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HTR2A;HTR2C,"PSYCHOSIS, SCHIZOPHRENIA, BIPOLAR DISORDER, NAUSEA, INSOMNIA",,LAUNCHED,,Small molecule,Approved,VRQVVMDWGGWHTJ-CQSZACIVSA-N,COC1CCC2C(C1)N(C[C@H](C)CN(C)C)C1CCCCC1S2;COC1CCC2SC3CCCCC3N(C[C@H](C)CN(C)C)C2C1
LEVOMEQUITAZINE,LEVOMEQUITAZINE,,BRD:BRD-A67616246-001-07-9;BRD:BRD-BRD-A67616246-001-07-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,,,PHASE 2,,,NA,,C(C1CN2CCC1CC2)N1C2CCCCC2SC2CCCCC12
LEVONORGESTREL,LEVONORGESTREL,CHEMBL1389,BRD:BRD-BRD-K35189033-001-26-1;BRD:BRD-K35189033-001-26-1,rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR AGONIST, GLUCOCORTICOID RECEPTOR ANTAGONIST, PROGESTERONE RECEPTOR AGONIST, PROGESTERONE RECEPTOR ANTAGONIST",AR;ESR1;PGR;SRD5A1,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,WWYNJERNGUHSAO-XUDSTZEESA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC;CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
LEVOSIMENDAN,LEVOSIMENDAN,CHEMBL2051955,BRD:BRD-BRD-K03095347-001-06-1;BRD:BRD-K03095347-001-06-1,rep_primary;rep_single_dose,CALCIUM SENSITIZER,KCNJ11;KCNJ8;PDE3A;TNNC1,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Phase 3,WHXMKTBCFHIYNQ-SECBINFHSA-N,C[C@@H]1CC(=O)NN=C1C1CCC(NN=C(C#N)C#N)CC1
LEVOSULPIRIDE,LEVOSULPIRIDE,CHEMBL267044,BRD:BRD-BRD-K51671335-001-10-6;BRD:BRD-K51671335-001-10-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CA1;CA12;CA7;DRD2;DRD3,"SCHIZOPHRENIA, PSYCHOSIS, ANXIETY, VERTIGO, DYSPEPSIA, IRRITABLE BOWEL SYNDROME, PREMATURE EJACULATION (PE)",,LAUNCHED,,Small molecule,Phase 2,BGRJTUBHPOOWDU-NSHDSACASA-N,CCN1CCC[C@H]1CNC(=O)C1CC(CCC1OC)S(N)(=O)=O;CCN1CCC[C@H]1CNC(=O)C1CC(S(N)(=O)=O)CCC1OC
LEVOTHYROXINE,LEVOTHYROXINE,CHEMBL1624,BRD:BRD-BRD-K30685142-001-15-4;BRD:BRD-K30685142-001-15-4,rep_primary;rep_single_dose,THYROID HORMONE STIMULANT,THRA;THRB,MYXEDEMA COMA,,LAUNCHED,,Small molecule,Approved,XUIIKFGFIJCVMT-LBPRGKRZSA-N,N[C@@H](CC1CC(I)C(OC2CC(I)C(O)C(I)C2)C(I)C1)C(=O)O;N[C@@H](CC1CC(I)C(OC2CC(I)C(O)C(I)C2)C(I)C1)C(O)=O
LFM-A13,LFM-A13,,BRD:BRD-A30655177-001-14-0;BRD:BRD-BRD-A30655177-001-14-0;GDSC1:192,gdsc;rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK,,,PRECLINICAL,,,NA,,CC(=O)C(C#N)C(=O)NC1CC(BR)CCC1BR
LG-100069,LG-100069,CHEMBL1023,GDSC1:186,gdsc,,,,,,,Small molecule,Approved,NAVMQTYZDKMPEU-UHFFFAOYSA-N,C=C(C1CCC(C(=O)O)CC1)C1CC2C(CC1C)C(C)(C)CCC2(C)C
LGD-6972,LGD-6972,CHEMBL4297469,BRD:BRD-K00003132-001-01-9,rep_single_dose,GLUCAGON RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,HKJMCBYPVCGZFB-LDLOPFEMSA-N,CC1CC(C)C(-C2CCC(NC(=O)[C@H](CC3CCC(C(=O)NCCS(=O)(=O)O)CC3)C3CCC(-C4CCC(C(C)(C)C)CC4)CC3)CC2)C(C)C1
LGK-974,LGK-974,CHEMBL3188386,BRD:BRD-BRD-K16810791-001-01-0;BRD:BRD-K16810791-001-01-0;GDSC2:1598,gdsc;rep_primary;rep_single_dose,PORCUPINE INHIBITOR,PORCN,,,PHASE 2,,Small molecule,Phase 2,XXYGTCZJJLTAGH-UHFFFAOYSA-N,CC1CC(-C2NCC(CC(=O)NC3CCC(-C4CNCCN4)CN3)CC2C)CCN1;CC1CC(CCN1)-C1NCC(CC(=O)NC2CCC(CN2)-C2CNCCN2)CC1C
LGK974,LGK974,CHEMBL3188386,GDSC1:573;GDSC2:1598,gdsc,,,,,,,Small molecule,Phase 2,XXYGTCZJJLTAGH-UHFFFAOYSA-N,CC1CC(-C2NCC(CC(=O)NC3CCC(-C4CNCCN4)CN3)CC2C)CCN1
LH846,LH846,,BRD:BRD-BRD-K47409078-001-02-6;BRD:BRD-K47409078-001-02-6,rep_primary;rep_single_dose,CASEIN KINASE INHIBITOR,CSNK1D,,,PRECLINICAL,,,NA,,CC1CC2SC(NC(=O)CC3CCCCC3)NC2CC1CL
LHF-535,LHF-535,CHEMBL4537239,BRD:BRD-K00090654-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,DBNZTRPIBJSUIX-WAYWQWQTSA-N,CC(C)OC1CCC(-N2CNC3CC(/C=C\C4CCC(C(C)(C)O)CC4)CCC32)CC1
LIAROZOLE,LIAROZOLE,CHEMBL389433,BRD:BRD-A57133765-300-01-7;BRD:BRD-BRD-A57133765-300-01-7,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP19A1;CYP26A1,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,UGFHIPBXIWJXNA-UHFFFAOYSA-N,CLC1CCCC(C(C2CCC3[NH]CNC3C2)N2CCNC2)C1;CLC1CCCC(C1)C(C1CCC2NC[NH]C2C1)N1CCNC1
LICARBAZEPINE,LICARBAZEPINE,CHEMBL1067;CHEMBL315985,BRD:BRD-A22642447-001-01-9;BRD:BRD-BRD-A22642447-001-01-9,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,SCN5A,,,PHASE 3,,Small molecule,Approved,BMPDWHIDQYTSHX-AWEZNQCLSA-N;BMPDWHIDQYTSHX-UHFFFAOYSA-N,NC(=O)N1C2CCCCC2C[C@H](O)C2CCCCC21;NC(=O)N1C2CCCCC2CC(O)C2CCCCC12;NC(=O)N1C2CCCCC2CC(O)C2CCCCC21
LICOCHALCONE-A,LICOCHALCONE-A,,BRD:BRD-BRD-K26011976-001-01-0;BRD:BRD-K26011976-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,PTPN1,,,PHASE 3,,,NA,,COC1CC(O)C(CC1C=CC(=O)C1CCC(O)CC1)C(C)(C)C=C
LICOGLIFLOZIN,LICOGLIFLOZIN,CHEMBL4297625,BRD:BRD-K00003504-001-01-9,rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,,,,,,Small molecule,Phase 2,XFJAMQQAAMJFGB-ZQGJOIPISA-N,CCC1CCC([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1CC1CCC2C(C1)OCCO2
LICOSTINEL,LICOSTINEL,CHEMBL289832,BRD:BRD-K81881550-001-03-9,rep_single_dose,NMDA RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,CHFSOFHQIZKQCR-UHFFFAOYSA-N,O=C1[NH]C2CC(CL)C(CL)C([N+](=O)[O-])C2[NH]C1=O
LIDAMIDINE,LIDAMIDINE,CHEMBL448416,BRD:BRD-BRD-K68693535-001-03-4;BRD:BRD-K68693535-001-03-4,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,DIARRHEA,,LAUNCHED,,Small molecule,Unknown,RRHJHSBDJDZUGL-UHFFFAOYSA-N,CN=C(N)NC(=O)NC1C(C)CCCC1C;CNC(=N)NC(=O)NC1C(C)CCCC1C
LIDOCAINE,LIDOCAINE,CHEMBL79,BRD:BRD-BRD-K52662033-003-21-2;BRD:BRD-K52662033-003-21-2,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,EGFR;SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,"ITCHING, ECZEMA, HEMORRHAGE",,LAUNCHED,,Small molecule,Approved,NNJVILVZKWQKPM-UHFFFAOYSA-N,CCN(CC)CC(=O)NC1C(C)CCCC1C
LIDOFLAZINE,LIDOFLAZINE,CHEMBL92870,BRD:BRD-BRD-K62996583-001-10-3;BRD:BRD-K62996583-001-10-3,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,SCN1A;SCN3A;SLC29A1,,,LAUNCHED,,Small molecule,Approved,ZBIAKUMOEKILTF-UHFFFAOYSA-N,CC1CCCC(C)C1NC(=O)CN1CCN(CCCC(C2CCC(F)CC2)C2CCC(F)CC2)CC1
LIFIRAFENIB,LIFIRAFENIB,CHEMBL4209157,BRD:BRD-K00003275-001-01-9,rep_single_dose,RAF INHIBITOR,,,,,,Small molecule,Phase 1,NGFFVZQXSRKHBM-FKBYEOEOSA-N,O=C1CCC2C(OC3CCC4C(C3)[C@@H]3[C@H](O4)[C@H]3C3NC4CC(C(F)(F)F)CCC4[NH]3)CCNC2N1
LIFITEGRAST,LIFITEGRAST,CHEMBL2048028,BRD:BRD-K60265345-001-02-9,rep_single_dose,LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN NEGATIVE MODULATOR,,,,,,Small molecule,Approved,JFOZKMSJYSPYLN-QHCPKHFHSA-N,CS(=O)(=O)C1CCCC(C[C@H](NC(=O)C2C(CL)CC3C(C2CL)CCN(C(=O)C2CCC4CCOC4C2)C3)C(=O)O)C1
LIGANDROL,LIGANDROL,CHEMBL3545356,BRD:BRD-K00091109-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,,
LIGUSTILIDE,LIGUSTILIDE,CHEMBL481246,BRD:BRD-K48875051-001-01-0,rep_single_dose,TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR,TNF,,,,,Small molecule,NA,IQVQXVFMNOFTMU-FLIBITNWSA-N,CCC/C=C1\OC(=O)C2=C1CCC=C2
LIMAPROST-ALFADEX,LIMAPROST-ALFADEX,,BRD:BRD-BRD-K25015158-001-01-2;BRD:BRD-K25015158-001-01-2,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,PTGER1,CLAUDICATION,,LAUNCHED,,,NA,,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O
LIMK1 INHIBITOR BMS4,LIMK1 INHIBITOR BMS4,,GDSC1:406,gdsc,,,,,,,,NA,,
LIMKI-3,LIMKI-3,,BRD:BRD-BRD-K75373031-001-01-7;BRD:BRD-K75373031-001-01-7,rep_primary;rep_single_dose,LIM KINASE INHIBITOR,LIMK1,,,PRECLINICAL,,,NA,,CC(C)C(=O)NC1NCC(S1)-C1CC(NN1-C1C(CL)CCCC1CL)C(F)F
LIMONIN,LIMONIN,CHEMBL517449,BRD:BRD-BRD-K05906022-001-05-1;BRD:BRD-K05906022-001-05-1,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,KBDSLGBFQAGHBE-MSGMIQHVSA-N,CC1(C)O[C@H]2CC(=O)OC[C@]23[C@H]2CC[C@@]4(C)[C@H](C5CCOC5)OC(=O)[C@H]5O[C@]54[C@]2(C)C(=O)C[C@@H]13;CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)C1CCOC1
LINAGLIPTIN,LINAGLIPTIN,CHEMBL237500,BRD:BRD-BRD-K96550715-001-02-6;BRD:BRD-K96550715-001-02-6,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,LTXREWYXXSTFRX-QGZVFWFLSA-N,CC#CCN1C(N2CCC[C@@H](N)C2)NC2C1C(=O)N(CC1NC(C)C3CCCCC3N1)C(=O)N2C;CC#CCN1C(NC2N(C)C(=O)N(CC3NC(C)C4CCCCC4N3)C(=O)C12)N1CCC[C@@H](N)C1
LINALOOL,LINALOOL,CHEMBL25306,BRD:BRD-A43082461-001-06-3;BRD:BRD-BRD-A43082461-001-06-3,rep_multi_dose;rep_primary;rep_single_dose,ANTICONVULSANT,,,,PHASE 1,,Small molecule,NA,CDOSHBSSFJOMGT-UHFFFAOYSA-N,C=CC(C)(O)CCC=C(C)C;CC(C)=CCCC(C)(O)C=C
LINAPRAZAN,LINAPRAZAN,CHEMBL497011,BRD:BRD-K00003366-001-01-9,rep_single_dose,ATP-SENSITIVE POTASSIUM CHANNEL INHIBITOR,,,,,,Small molecule,Unknown,GHVIMBCFLRTFHI-UHFFFAOYSA-N,CC1CCCC(C)C1CNC1CC(C(=O)NCCO)CN2C(C)C(C)NC12
LINCOMYCIN,LINCOMYCIN,CHEMBL1447,BRD:BRD-BRD-K08033334-003-04-3;BRD:BRD-BRD-K81447180-003-21-4;BRD:BRD-K08033334-003-04-3;BRD:BRD-K81447180-003-21-4,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,ENTERITIS,,LAUNCHED,"Multiple values for structure_id: {'K08033334', 'K81447180'}, defaulting to None",Small molecule,Approved,OJMMVQQUTAEWLP-KIDUDLJLSA-N,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1;CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O;CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O
LINEZOLID,LINEZOLID,CHEMBL126,BRD:BRD-BRD-K66876909-001-12-6;BRD:BRD-K66876909-001-12-6,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,MAOA;MAOB,"PNEUMONIA, SKIN INFECTIONS",,LAUNCHED,,Small molecule,Approved,TYZROVQLWOKYKF-ZDUSSCGKSA-N,CC(=O)NC[C@H]1CN(C(=O)O1)C1CCC(N2CCOCC2)C(F)C1;CC(=O)NC[C@H]1CN(C2CCC(N3CCOCC3)C(F)C2)C(=O)O1
LINIFANIB,LINIFANIB,CHEMBL223360,BRD:BRD-BRD-K99749624-001-07-0;BRD:BRD-K99749624-001-07-0;CTRP:606033;GDSC1:277,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",CSF1;CSF1R;FLT1;FLT3;FLT4;KDR;KIT;PDGFRB;RET;TEK,,,PHASE 3,,Small molecule,Phase 3,MPVGZUGXCQEXTM-UHFFFAOYSA-N,CC1CCC(F)C(NC(=O)NC2CCC(-C3CCCC4[NH]NC(N)C34)CC2)C1;CC1CCC(F)C(NC(=O)NC2CCC(CC2)-C2CCCC3[NH]NC(N)C23)C1
LINOPIRDINE,LINOPIRDINE,CHEMBL319111,BRD:BRD-BRD-K59332007-300-02-7;BRD:BRD-K59332007-300-02-7,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNQ2;KCNQ3;KCNQ4;KCNQ5,,,PHASE 3,,Small molecule,Unknown,YEJCDKJIEMIWRQ-UHFFFAOYSA-N,O=C1N(C2CCCCC2)C2CCCCC2C1(CC1CCNCC1)CC1CCNCC1;O=C1N(C2CCCCC2C1(CC1CCNCC1)CC1CCNCC1)C1CCCCC1
LINSIDOMINE,LINSIDOMINE,CHEMBL1189150,BRD:BRD-BRD-K86344238-003-04-6;BRD:BRD-K86344238-003-04-6,rep_primary;rep_single_dose,NITRIC OXIDE DONOR,,ERECTILE DYSFUNCTION,,LAUNCHED,,Small molecule,Unknown,FKDHHVKWGRFRTG-UHFFFAOYSA-N,[NH-]C1C[N+](N2CCOCC2)NO1;NC1C[N+](NO1)N1CCOCC1
LINSITINIB,LINSITINIB,CHEMBL1091644,BRD:BRD-BRD-K86118762-001-01-8;BRD:BRD-K86118762-001-01-8;CTRP:705300;GDSC1:185;GDSC2:1510,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,IGF-1 INHIBITOR,IGF1R;INSR;INSRR,,,PHASE 3,,Small molecule,Phase 3,PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@]1(O)C[C@@H](C2NC(-C3CCC4CCC(-C5CCCCC5)NC4C3)C3C(N)NCCN32)C1;C[C@@]1(O)C[C@@H](C1)C1NC(-C2CCC3CCC(NC3C2)-C2CCCCC2)C2C(N)NCCN12
LINTOPRIDE,LINTOPRIDE,CHEMBL2106767,BRD:BRD-K00004744-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,MJCKISCWHDATBN-UHFFFAOYSA-N,CCN1CCN=C1CNC(=O)C1CC(CL)C(N)CC1OC
LIOTHYRONINE,LIOTHYRONINE,CHEMBL1544;CHEMBL789,BRD:BRD-BRD-K89152108-236-07-6;BRD:BRD-K89152108-236-07-6,rep_primary;rep_single_dose,THYROID HORMONE STIMULANT,THRA;THRB,"HYPOTHYROIDISM, MYXEDEMA COMA",,LAUNCHED,,Small molecule,Approved,AUYYCJSJGJYCDS-LBPRGKRZSA-N;AUYYCJSJGJYCDS-UHFFFAOYSA-N,N[C@@H](CC1CC(I)C(OC2CCC(O)C(I)C2)C(I)C1)C(=O)O;N[C@@H](CC1CC(I)C(OC2CCC(O)C(I)C2)C(I)C1)C(O)=O;NC(CC1CC(I)C(OC2CCC(O)C(I)C2)C(I)C1)C(=O)O
LIOTHYRONINE-(ISOMER),LIOTHYRONINE-(ISOMER),,BRD:BRD-BRD-K46428823-001-02-5;BRD:BRD-K46428823-001-02-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,N[C@H](CC1CC(I)C(OC2CCC(O)C(I)C2)C(I)C1)C(O)=O
LIQUIRITIN,LIQUIRITIN,CHEMBL511995,BRD:BRD-K39084158-001-08-9,rep_single_dose,ANTIOXIDANT,,,,,,Small molecule,NA,DEMKZLAVQYISIA-ZRWXNEIDSA-N,O=C1C[C@@H](C2CCC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CC2)OC2CC(O)CCC21
RLY-4008,LIRAFUGRATINIB;RLY-4008,,BRD:BRD-K00126780-001-01-9,oncref_2,INHIBITOR OF FGFR2,FGFR2,,,,,,NA,,
LIRAGLUTIDE,LIRAGLUTIDE,CHEMBL4084119;CHEMBL4524066,BRD:BRD-A48274390-001-01-8;BRD:BRD-BRD-A48274390-001-01-8,rep_primary;rep_single_dose,GLP RECEPTOR AGONIST,GLP1R,"WEIGHT-LOSS AID, DIABETES MELLITUS",,LAUNCHED,,Protein,Approved,VXEVKSKAINMPFG-QWUNSSNDSA-N;YSDQQAXHVYUZIW-QCIJIYAXSA-N,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1CNC[NH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O;CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1C[NH]CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O;CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC1CCC(O)CC1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC1CCCCC1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(N)CC1CNC[NH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC1CCCCC1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC1C[NH]C2CCCCC12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
LIRANAFTATE,LIRANAFTATE,CHEMBL1591365,BRD:BRD-BRD-K35775715-001-03-1;BRD:BRD-K35775715-001-03-1,rep_primary;rep_single_dose,FUNGAL SQUALENE EPOXIDASE INHIBITOR,,FUNGAL INFECTION,,LAUNCHED,,Small molecule,Unknown,VPHPQNGOVQYUMG-UHFFFAOYSA-N,COC1CCCC(N(C)C(=S)OC2CCC3C(C2)CCCC3)N1;COC1CCCC(N1)N(C)C(=S)OC1CCC2CCCCC2C1
LIRIMILAST,LIRIMILAST,CHEMBL1922282,BRD:BRD-BRD-K31339321-001-03-6;BRD:BRD-K31339321-001-03-6,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,PHASE 2,,Small molecule,Unknown,YPFLFUJKZDAXRA-UHFFFAOYSA-N,CS(=O)(=O)OC1CCC2C(NC(N)=O)C(C(=O)C3CCC(CL)CC3CL)OC2C1;CS(=O)(=O)OC1CCC2C(NC(N)=O)C(OC2C1)C(=O)C1CCC(CL)CC1CL
LISADIMATE,LISADIMATE,CHEMBL2106668,BRD:BRD-A76533773-001-01-9;BRD:BRD-BRD-A76533773-001-01-9,rep_primary;rep_single_dose,TOPICAL SUNSCREEN AGENT,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Unknown,WHQOKFZWSDOTQP-UHFFFAOYSA-N,NC1CCC(C(=O)OCC(O)CO)CC1;NC1CCC(CC1)C(=O)OCC(O)CO
LISINOPRIL,LISINOPRIL,CHEMBL1237;CHEMBL1729579;CHEMBL419213,BRD:BRD-BRD-K67966701-001-11-6;BRD:BRD-BRD-K67966701-001-12-4;BRD:BRD-K67966701-001-11-6;BRD:BRD-K67966701-001-12-4,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE;ACE2,"HYPERTENSION, CONGESTIVE HEART FAILURE, DIABETES MELLITUS",,LAUNCHED,,Small molecule,Approved,BAVDEDVBIHTHJQ-UVJOBNTFSA-N;CZRQXSDBMCMPNJ-ZUIPZQNBSA-N;RLAWWYSOJDYHDC-BZSNNMDCSA-N,NCCCC[C@H](N[C@@H](CCC1CCCCC1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O;NCCCC[C@H](N[C@@H](CCC1CCCCC1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O;NCCCC[C@H](N[C@@H](CCC1CCCCC1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O;NCCCC[C@H](N[C@@H](CCC1CCCCC1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
LISOFYLLINE,LISOFYLLINE,CHEMBL1411,BRD:BRD-A05334458-001-02-8;BRD:BRD-BRD-A05334458-001-02-8,rep_primary;rep_single_dose,"INTERLEUKIN RECEPTOR ANTAGONIST, STAT INHIBITOR",,,,PHASE 2,,Small molecule,Phase 2,NSMXQKNUPPXBRG-SECBINFHSA-N,C[C@@H](O)CCCCN1C(=O)C2C(NCN2C)N(C)C1=O;CC(O)CCCCN1C(=O)N(C)C2NCN(C)C2C1=O
LISURIDE,LISURIDE,CHEMBL157138,BRD:BRD-BRD-K67943528-050-01-4;BRD:BRD-K67943528-050-01-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR6,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,BKRGVLQUQGGVSM-KBXCAEBGSA-N,CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2CC3C[NH]C4CCCC(C2=C1)C34;CCN(CC)C(=O)N[C@H]1C=C2C3CCCC4[NH]CC(C34)C[C@H]2N(C)C1
LITHIUM-ACETOACETATE,LITHIUM-ACETOACETATE,,BRD:BRD-BRD-K73234506-235-02-1;BRD:BRD-K73234506-235-02-1,rep_primary;rep_single_dose,,FAH,,,PRECLINICAL,,,NA,,CC(=O)CC(O)=O
LITHIUM-CITRATE,LITHIUM-CITRATE,,BRD:BRD-BRD-M41245765-001-04-2;BRD:BRD-M41245765-001-04-2,rep_primary;rep_single_dose,,,"BIPOLAR DISORDER, DEPRESSION",,LAUNCHED,,,NA,,[LI].[LI].[LI].OC(=O)CC(O)(CC(O)=O)C(O)=O
LITHOCHOLIC-ACID,LITHOCHOLIC-ACID,,BRD:BRD-BRD-K04497194-001-02-1;BRD:BRD-K04497194-001-02-1,rep_primary;rep_single_dose,"FXR ANTAGONIST, VITAMIN D RECEPTOR AGONIST",GPBAR1;NR1H4;NR1I2;VDR,,,PRECLINICAL,,,NA,,C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
LITRONESIB,LITRONESIB,CHEMBL2105661,BRD:BRD-BRD-K83029223-001-01-3;BRD:BRD-K83029223-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,KINESIN-LIKE SPINDLE PROTEIN INHIBITOR,KIF11,,,PHASE 2,,Small molecule,Phase 2,YVAFBXLHPINSIK-QHCPKHFHSA-N,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)C1CCCCC1;CCNCCS(=O)(=O)NC[C@@]1(C2CCCCC2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C
LIXIVAPTAN,LIXIVAPTAN,CHEMBL49429,BRD:BRD-BRD-K59391348-001-01-7;BRD:BRD-K59391348-001-01-7,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,AVPR2,,,PHASE 3,,Small molecule,Phase 3,PPHTXRNHTVLQED-UHFFFAOYSA-N,CC1CCC(F)CC1C(=O)NC1CCC(C(=O)N2CC3CCCN3CC3CCCCC23)C(CL)C1;CC1CCC(F)CC1C(=O)NC1CCC(C(=O)N2CC3CCCN3CC3CCCCC32)C(CL)C1
LJI308,LJI308,,GDSC2:2107,gdsc,,,,,,,,NA,,
LL-Z1640-2,LL-Z1640-2,,GDSC1:1242,gdsc,,,,,,,,NA,,
LLL CPD,LLL CPD,,GDSC1:9,gdsc,,,,,,,,NA,,
LM-22A4,LM-22A4,,BRD:BRD-BRD-K70404782-001-01-6;BRD:BRD-K70404782-001-01-6,rep_primary;rep_single_dose,TROPOMYOSIN RECEPTOR KINASE INHIBITOR,NTRK2,,,PRECLINICAL,,,NA,,OCCNC(=O)C1CC(CC(C1)C(=O)NCCO)C(=O)NCCO
LM11A-31,LM11A-31,,BRD:BRD-A04649065-001-01-7;BRD:BRD-BRD-A04649065-001-01-7,rep_primary;rep_single_dose,NEUROTROPHIC AGENT,NGFR,,,PHASE 1,,,NA,,CCC(C)C(N)C(=O)NCCN1CCOCC1
LMI070,LMI070,CHEMBL4290141,BRD:BRD-BRD-K08532119-001-01-5;BRD:BRD-K08532119-001-01-5,rep_primary;rep_single_dose,SURVIVAL MOTOR NEURON PROTEIN MODULATOR,SMN1,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,STWTUEAWRAIWJG-UHFFFAOYSA-N,CC1(C)CC(CC(C)(C)N1)OC1CCC(NN1)-C1CCC(CC1O)-C1CN[NH]C1;CC1(C)CC(OC2CCC(-C3CCC(-C4CN[NH]C4)CC3O)NN2)CC(C)(C)N1
LMK-235,LMK-235,,BRD:BRD-K49921286-001-02-6,rep_single_dose,HDAC INHIBITOR,HDAC4;HDAC5,,,,,,NA,,
LOBENDAZOLE,LOBENDAZOLE,CHEMBL2105088,BRD:BRD-BRD-K15834839-001-02-3;BRD:BRD-K15834839-001-02-3,rep_primary;rep_single_dose,ANTHELMINTIC AGENT,,,,PRECLINICAL,,Small molecule,Unknown,OKOVSTKGUBOSTB-UHFFFAOYSA-N,CCOC(=O)NC1NC2CCCCC2[NH]1
LOBENZARIT,LOBENZARIT,CHEMBL1986706,BRD:BRD-BRD-K55847762-304-01-7;BRD:BRD-K55847762-304-01-7,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Unknown,UGDPYGKWIHHBMB-UHFFFAOYSA-N,O=C(O)C1CCCCC1NC1CC(CL)CCC1C(=O)O;OC(=O)C1CCCCC1NC1CC(CL)CCC1C(O)=O
LODENOSINE,LODENOSINE,CHEMBL501916,BRD:BRD-K00004554-001-01-9,rep_single_dose,ANTIRETROVIRAL,,,,,,Small molecule,Unknown,KBEMFSMODRNJHE-JFWOZONXSA-N,NC1NCNC2C1NCN2[C@@H]1O[C@H](CO)C[C@@H]1F
LODOXAMIDE,LODOXAMIDE,CHEMBL1201266;CHEMBL2107161,BRD:BRD-BRD-K66937583-001-01-2;BRD:BRD-K66937583-001-01-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,VERNAL KERATOCONJUNCTIVITIS (VKC),,LAUNCHED,,Small molecule,Approved,BNTAPIYHWPPFBW-UHFFFAOYSA-N;RVGLGHVJXCETIO-UHFFFAOYSA-N,CCOC(=O)C(=O)NC1CC(C#N)CC(NC(=O)C(=O)OCC)C1CL;N#CC1CC(NC(=O)C(=O)O)C(CL)C(NC(=O)C(=O)O)C1;OC(=O)C(=O)NC1CC(CC(NC(=O)C(O)=O)C1CL)C#N
LOFEMIZOLE,LOFEMIZOLE,CHEMBL2111114,BRD:BRD-BRD-K06388517-001-01-2;BRD:BRD-K06388517-001-01-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,PHASE 3,,Small molecule,Unknown,MBKWNJVQSFBLQI-UHFFFAOYSA-N,CC1[NH]CNC1-C1CCC(CL)CC1;CC1NC[NH]C1-C1CCC(CL)CC1
LOFEXIDINE,LOFEXIDINE,CHEMBL17860;CHEMBL1788132;CHEMBL2106205;CHEMBL2107417,BRD:BRD-A02990301-003-06-6;BRD:BRD-BRD-A02990301-003-06-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A,OPIOID WITHDRAWAL,,LAUNCHED,,Small molecule,Approved,DWWHMKBNNNZGHF-UHFFFAOYSA-N;KSMAGQUYOIHWFS-SSDOTTSWSA-N;KSMAGQUYOIHWFS-UHFFFAOYSA-N;KSMAGQUYOIHWFS-ZETCQYMHSA-N,C[C@@H](OC1C(CL)CCCC1CL)C1=NCCN1;C[C@H](OC1C(CL)CCCC1CL)C1=NCCN1;CC(OC1C(CL)CCCC1CL)C1=NCCN1;CC(OC1C(CL)CCCC1CL)C1=NCCN1.CL
LOMEFLOXACIN,LOMEFLOXACIN,CHEMBL561,BRD:BRD-A75850590-213-01-0;BRD:BRD-BRD-A75850590-213-01-0,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,"RESPIRATORY TRACT INFECTIONS, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,CCN1CC(C(=O)O)C(=O)C2CC(F)C(N3CCNC(C)C3)C(F)C21;CCN1CC(C(O)=O)C(=O)C2CC(F)C(N3CCNC(C)C3)C(F)C12
LOMEGUATRIB,LOMEGUATRIB,CHEMBL339133,BRD:BRD-BRD-K27955832-001-02-9;BRD:BRD-K27955832-001-02-9;CTRP:660207,ctrp;rep_multi_dose;rep_primary;rep_single_dose,O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INHIBITOR,MGMT,,,PHASE 2,,Small molecule,Unknown,JUJPKFNFCWJBCX-UHFFFAOYSA-N,NC1NC(OCC2CC(BR)CS2)C2[NH]CNC2N1
LOMERIZINE,LOMERIZINE,CHEMBL29188,BRD:BRD-BRD-K62858456-001-01-8;BRD:BRD-K62858456-001-01-8,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1B;SCN5A,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Unknown,JQSAYKKFZOSZGJ-UHFFFAOYSA-N,COC1CCC(CN2CCN(C(C3CCC(F)CC3)C3CCC(F)CC3)CC2)C(OC)C1OC;COC1CCC(CN2CCN(CC2)C(C2CCC(F)CC2)C2CCC(F)CC2)C(OC)C1OC
LOMITAPIDE,LOMITAPIDE,CHEMBL354541,BRD:BRD-BRD-K92213669-001-01-3;BRD:BRD-K92213669-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,MICROSOMAL TRIGYLCERIDE TRANSFER PROTEIN INHIBITOR,MTTP,HYPERCHOLESTEROLEMIA,,LAUNCHED,,Small molecule,Approved,MBBCVAKAJPKAKM-UHFFFAOYSA-N,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2CCCCC2-C2CCC(CC2)C(F)(F)F)C2CCCCC2-C2CCCCC12;O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)C3CCCCC3-C3CCCCC32)CC1)C1CCCCC1-C1CCC(C(F)(F)F)CC1
SCH 66336,LONAFARNIB;SCH 66336,CHEMBL298734,BRD:BRD-BRD-K41599323-001-02-3;BRD:BRD-K41599323-001-02-3;BRD:BRD-U00115421-001-01-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF FARNESYLTRANSFERASE A AND B,FNTA;FNTB;HRAS;KRAS;NRAS,,,PHASE 3,"Multiple values for MOA: {'FARNESYLTRANSFERASE INHIBITOR', 'INHIBITOR OF FARNESYLTRANSFERASE A AND B'}, defaulting to 'INHIBITOR OF FARNESYLTRANSFERASE A AND B'
Multiple values for repurposing_target: {'FNTA;FNTB', 'FNTA;HRAS;KRAS;NRAS'}, taking the union
Multiple values for structure_id: {'U00115421', 'K41599323'}, defaulting to None",Small molecule,Approved,DHMTURDWPRKSOA-RUZDIDTESA-N,NC(=O)N1CCC(CC(=O)N2CCC([C@H]3C4NCC(BR)CC4CCC4CC(CL)CC(BR)C43)CC2)CC1;NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3NCC(BR)CC3CCC3CC(CL)CC(BR)C23)CC1
LONAPALENE,LONAPALENE,CHEMBL36648,BRD:BRD-K00076155-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,IFWMVQUGSGWCRP-UHFFFAOYSA-N,COC1C(OC)C(OC(C)=O)C2CC(CL)CCC2C1OC(C)=O
LONIDAMINE,LONIDAMINE,CHEMBL1257030,BRD:BRD-BRD-K78513633-001-15-7;BRD:BRD-K78513633-001-15-7,rep_primary;rep_single_dose,GLUCOKINASE INHIBITOR,GCK,,,LAUNCHED,,Small molecule,Phase 3,WDRYRZXSPDWGEB-UHFFFAOYSA-N,O=C(O)C1NN(CC2CCC(CL)CC2CL)C2CCCCC12;OC(=O)C1NN(CC2CCC(CL)CC2CL)C2CCCCC12
LOPERAMIDE,LOPERAMIDE,CHEMBL841,BRD:BRD-BRD-K61250553-003-32-2;BRD:BRD-K61250553-003-32-2,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,CACNA1A;CALM1;OPRD1;OPRK1;OPRM1;POMC,DIARRHEA,,LAUNCHED,,Small molecule,Approved,RDOIQAHITMMDAJ-UHFFFAOYSA-N,CN(C)C(=O)C(CCN1CCC(O)(C2CCC(CL)CC2)CC1)(C1CCCCC1)C1CCCCC1;CN(C)C(=O)C(CCN1CCC(O)(CC1)C1CCC(CL)CC1)(C1CCCCC1)C1CCCCC1
LOPINAVIR,LOPINAVIR,CHEMBL729,BRD:BRD-BRD-K99451608-001-07-3;BRD:BRD-K99451608-001-07-3,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,KJHKTHWMRKYKJE-SUGCFTRWSA-N,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1CCCCC1)NC(=O)COC1C(C)CCCC1C)CC1CCCCC1;CC1CCCC(C)C1OCC(=O)N[C@@H](CC1CCCCC1)[C@@H](O)C[C@H](CC1CCCCC1)NC(=O)[C@H](C(C)C)N1CCCNC1=O
LORACARBEF,LORACARBEF,CHEMBL1013;CHEMBL1200610,BRD:BRD-K28935038-002-03-9,rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,,,Small molecule,Approved,GPYKKBAAPVOCIW-HSASPSRMSA-N;JAPHQRWPEGVNBT-UTUOFQBUSA-N,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CL)CC[C@H]12)C1CCCCC1;N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CL)CC[C@H]12)C1CCCCC1.O
LORATADINE,LORATADINE,CHEMBL998,BRD:BRD-BRD-K82795137-001-26-2;BRD:BRD-K82795137-001-26-2,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, ITCHING",,LAUNCHED,,Small molecule,Approved,JCCNYMKQOSZNPW-UHFFFAOYSA-N,CCOC(=O)N1CCC(=C2C3CCC(CL)CC3CCC3CCCNC32)CC1;CCOC(=O)N1CCC(CC1)=C1C2CCC(CL)CC2CCC2CCCNC12
LORAZEPAM,LORAZEPAM,CHEMBL580,BRD:BRD-A11990600-001-03-4;BRD:BRD-BRD-A11990600-001-03-4,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;TSPO,STATUS EPILEPTICUS,,LAUNCHED,,Small molecule,Approved,DIWRORZWFLOCLC-UHFFFAOYSA-N,O=C1NC2CCC(CL)CC2C(C2CCCCC2CL)=NC1O;OC1N=C(C2CCCCC2CL)C2CC(CL)CCC2NC1=O
LORCASERIN,LORCASERIN,CHEMBL360328,BRD:BRD-BRD-K55013654-003-02-3;BRD:BRD-K55013654-003-02-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A;HTR2B;HTR2C,OBESITY,,LAUNCHED,,Small molecule,Approved,XTTZERNUQAFMOF-QMMMGPOBSA-N,C[C@H]1CNCCC2CCC(CL)CC12;C[C@H]1CNCCC2CCC(CL)CC21
LORECLEZOLE,LORECLEZOLE,CHEMBL1397886,BRD:BRD-BRD-K09659835-003-01-4;BRD:BRD-K09659835-003-01-4,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRB2;GABRB3,,,PHASE 2,,Small molecule,Unknown,XGLHZTBDUXXHOM-WMZJFQQLSA-N,CL/C(=C\N1CNCN1)C1CCC(CL)CC1CL;CL\C(=C/N1CNCN1)C1CCC(CL)CC1CL
LOREDIPLON,LOREDIPLON,CHEMBL3707317,BRD:BRD-BRD-K42066335-001-01-0;BRD:BRD-K42066335-001-01-0,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1,,,PHASE 2,,Small molecule,Unknown,,CN(C(C)=O)C1CC(CCC1F)-C1CCNC2C(CNN12)C(=O)C1CCCS1
LORGLUMIDE,LORGLUMIDE,CHEMBL24938,BRD:BRD-A29854054-236-12-6;BRD:BRD-BRD-A29854054-236-12-6,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKAR;CCKBR,,,PHASE 1,,Small molecule,Unknown,IEKOTSCYBBDIJC-UHFFFAOYSA-N,CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1CCC(CL)C(CL)C1;CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)C1CCC(CL)C(CL)C1
LORLATINIB,LORLATINIB,CHEMBL3286830,BRD:BRD-BRD-K99879819-001-02-1;BRD:BRD-K99879819-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK,,,PHASE 2,,Small molecule,Approved,IIXWYSCJSQVBQM-LLVKDONJSA-N,C[C@H]1OC2CC(CNC2N)-C2C(CN(C)C(=O)C3CCC(F)CC13)NN(C)C2C#N;C[C@H]1OC2CC(CNC2N)-C2C(NN(C)C2C#N)CN(C)C(=O)C2CCC(F)CC21
LORNOXICAM,LORNOXICAM,CHEMBL1569487,BRD:BRD-A90551241-001-10-8;BRD:BRD-BRD-A90551241-001-10-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"OSTEOARTHRITIS, SCIATA",,LAUNCHED,,Small molecule,Approved,WLHQHAUOOXYABV-UHFFFAOYSA-N,CN1C(C(=O)NC2CCCCN2)=C(O)C2SC(CL)CC2S1(=O)=O;CN1C(C(=O)NC2CCCCN2)C(=O)C2SC(CL)CC2S1(=O)=O
LOSARTAN,LOSARTAN,CHEMBL191,BRD:BRD-BRD-K76205745-237-16-5;BRD:BRD-K76205745-237-16-5;BRD:BRD-K76205745-237-22-9,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,"HYPERTENSION, DIABETIC NEPHROPATHY",,LAUNCHED,,Small molecule,Approved,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,CCCCC1NC(CL)C(CO)N1CC1CCC(-C2CCCCC2-C2NNN[NH]2)CC1;CCCCC1NC(CL)C(CO)N1CC1CCC(CC1)-C1CCCCC1-C1NNN[NH]1
LOSMAPIMOD,LOSMAPIMOD,CHEMBL1088752,BRD:BRD-BRD-K56195681-001-01-0;BRD:BRD-K56195681-001-01-0,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PHASE 3,,Small molecule,Phase 3,KKYABQBFGDZVNQ-UHFFFAOYSA-N,CC1C(F)CC(C(=O)NC2CC2)CC1-C1CCC(C(=O)NCC(C)(C)C)CN1;CC1C(F)CC(CC1-C1CCC(CN1)C(=O)NCC(C)(C)C)C(=O)NC1CC1
LOTAMILAST,LOTAMILAST,CHEMBL3989967,BRD:BRD-K00003137-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Phase 2,BBTFKAOFCSOZMB-UHFFFAOYSA-N,CNC1NC(-C2CCCC(NC(=O)C3CCC(C(=O)OC)CC3)C2)C2CC(OC)C(OC)CC2N1
LOTEPREDNOL,LOTEPREDNOL,CHEMBL1200865;CHEMBL1201389,BRD:BRD-BRD-K39983086-001-06-1;BRD:BRD-K39983086-001-06-1,rep_primary;rep_single_dose,"GLUCOCORTICOID RECEPTOR AGONIST, PHOSPHOLIPASE INHIBITOR",NR3C1,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,DMKSVUSAATWOCU-HROMYWEYSA-N;MCKJPJYRCPANCC-XLXYOEISSA-N,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)O;CCOC(=O)O[C@]1(C(=O)OCCL)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C;CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCL
LOTILANER,LOTILANER,CHEMBL3707310,BRD:BRD-K00084842-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,HDKWFBCPLKNOCK-SFHVURJKSA-N,CC1CC(C2=NO[C@@](C3CC(CL)C(CL)C(CL)C3)(C(F)(F)F)C2)SC1C(=O)NCC(=O)NCC(F)(F)F
LOVASTATIN,LOVASTATIN,CHEMBL503,BRD:BRD-BRD-K09416995-001-39-9;BRD:BRD-K09416995-001-39-9;CTRP:30620,ctrp;rep_multi_dose;rep_primary;rep_single_dose,HMGCR INHIBITOR,HDAC2;HMGCR;ITGAL;NR1I2,"CORONARY HEART DISEASE, MYOCARDIAL INFARCTION, HYPERCHOLESTEROLEMIA",,LAUNCHED,,Small molecule,Approved,PCZOHLXUXFIOCF-BXMDZJJMSA-N,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12;CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
LOXAPINE,LOXAPINE,CHEMBL1201155;CHEMBL831,BRD:BRD-BRD-K39915878-036-24-4;BRD:BRD-K39915878-036-24-4,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA2A;ADRA2B;ADRA2C;ADRB1;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HRH2;HRH4;HTR1A;HTR1B;HTR1D;HTR1E;HTR2A;HTR2C;HTR3A;HTR5A;HTR6;HTR7;SLC6A2;SLC6A3;SLC6A4,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,XJGVXQDUIWGIRW-UHFFFAOYSA-N;YQZBAXDVDZTKEQ-UHFFFAOYSA-N,CN1CCN(C2=NC3CCCCC3OC3CCC(CL)CC32)CC1;CN1CCN(C2=NC3CCCCC3OC3CCC(CL)CC32)CC1.O=C(O)CCC(=O)O;CN1CCN(CC1)C1=NC2CCCCC2OC2CCC(CL)CC12
LOXISTATIN-ACID,LOXISTATIN-ACID,,BRD:BRD-BRD-K21937671-001-09-2;BRD:BRD-BRD-K21937671-001-10-0;BRD:BRD-K21937671-001-09-2;BRD:BRD-K21937671-001-10-0,rep_multi_dose;rep_primary;rep_single_dose,CYSTEINE PEPTIDASE INHIBITOR,CTSB,,,PRECLINICAL,,,NA,,CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O
LOXOPROFEN,LOXOPROFEN,CHEMBL19299,BRD:BRD-A43082555-001-01-1;BRD:BRD-A43082555-001-02-9;BRD:BRD-BRD-A43082555-001-01-1;BRD:BRD-BRD-A43082555-001-02-9,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTANOID RECEPTOR ANTAGONIST",PTGS2,PAIN RELIEF,,LAUNCHED,,Small molecule,Phase 3,YMBXTVYHTMGZDW-UHFFFAOYSA-N,CC(C(=O)O)C1CCC(CC2CCCC2=O)CC1;CC(C(O)=O)C1CCC(CC2CCCC2=O)CC1
LP-533401,LP-533401,,BRD:BRD-K00004673-001-01-9,rep_single_dose,TRYPTOPHAN HYDROXYLASE INHIBITOR,,,,,,,NA,,
LPA2-ANTAGONIST-1,LPA2-ANTAGONIST-1,,BRD:BRD-BRD-K32322923-001-01-7;BRD:BRD-K32322923-001-01-7,rep_primary;rep_single_dose,LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST,LPAR2,,,PRECLINICAL,,,NA,,C[C@@H](CN1CCN(CC1)S(=O)(=O)C1CCC(CL)C(CL)C1)NC1NCNC2C(C)CSC12
LRRK2-IN-1,LRRK2-IN-1,,BRD:BRD-BRD-K01436366-001-22-2;BRD:BRD-K01436366-001-22-2;CTRP:607696,ctrp;rep_primary;rep_single_dose,LEUCINE RICH REPEAT KINASE INHIBITOR,LRRK2,,,PRECLINICAL,,,NA,,COC1CC(CCC1NC1NCC2N(C)C(=O)C3CCCCC3N(C)C2N1)C(=O)N1CCC(CC1)N1CCN(C)CC1
LSN-2463359,LSN-2463359,,BRD:BRD-BRD-K79337272-001-01-6;BRD:BRD-K79337272-001-01-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM5,,,PRECLINICAL,,,NA,,CC(C)NC(=O)C1CCC(CN1)C#CC1CCNCC1
LSZ-102,LSZ-102,CHEMBL4298014,BRD:BRD-K00004675-001-01-9,rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),,,,,,Unknown,Phase 1,,
LTA,LTA,,BRD:BRD-BRD-K52914072-001-01-5;BRD:BRD-K52914072-001-01-5,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,N=C(NC1CCCCC1)C1CCCS1
LTA4H-IN-1,LTA4H-IN-1,,BRD:BRD-K00091132-001-01-9,rep_single_dose,,,,,,,,NA,,
LTB4,LTB4,,BRD:BRD-BRD-K53124401-001-03-8;BRD:BRD-K53124401-001-03-8,rep_primary;rep_single_dose,LEUKOCYTE ACTIVATOR,LTB4R;LTB4R2,,,PHASE 2,,,NA,,CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O
LTX-315,LTX-315,CHEMBL4297628,BRD:BRD-K00003300-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,Protein,Phase 2,GGAKLYWEFZCVIT-TVEKFXMRSA-N,NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(C1CCCCC1)C1CCCCC1)C(N)=O
LU-AA-47070,LU-AA-47070,,BRD:BRD-BRD-K83970940-001-01-0;BRD:BRD-K83970940-001-01-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA2A,,,PHASE 2,,,NA,,CC(C)(C)CC(=O)NC1C(F)CC(CC1F)C(=O)\N=C1/SCCN1COP(O)(O)=O
LUBIPROSTONE,LUBIPROSTONE,CHEMBL1201134,BRD:BRD-BRD-K33814251-001-01-4;BRD:BRD-BRD-K33814251-001-02-2;BRD:BRD-K33814251-001-01-4;BRD:BRD-K33814251-001-02-2,rep_primary;rep_single_dose,CHLORIDE CHANNEL ACTIVATOR,CLCN2,"CONSTIPATION, IRRITABLE BOWEL SYNDROME",,LAUNCHED,,Small molecule,Approved,WGFOBBZOWHGYQH-MXHNKVEKSA-N,CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1;CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
LUCANTHONE,LUCANTHONE,CHEMBL279014,BRD:BRD-K00003521-001-01-9,rep_single_dose,ENDONUCLEASE INHIBITOR,APEX1;TOP1;TOP2A,,,,,Small molecule,Phase 2,FBQPGGIHOFZRGH-UHFFFAOYSA-N,CCN(CC)CCNC1CCC(C)C2SC3CCCCC3C(=O)C12
LUCITANIB,LUCITANIB,CHEMBL2220486,BRD:BRD-BRD-K31309378-001-01-5;BRD:BRD-K31309378-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, VEGFR INHIBITOR",FGFR1;FLT1;KDR;KIT;PDGFRA;PDGFRB;RET,,,PHASE 2,,Small molecule,Phase 2,CUDVHEFYRIWYQD-UHFFFAOYSA-N,CNC(=O)C1CCCC2CC(CCC12)OC1CCNC2CC(OCC3(N)CC3)C(OC)CC12;CNC(=O)C1CCCC2CC(OC3CCNC4CC(OCC5(N)CC5)C(OC)CC34)CCC12
LUF-5834,LUF-5834,,BRD:BRD-BRD-K67079690-001-01-2;BRD:BRD-K67079690-001-01-2,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA2A;ADORA2B,,,PRECLINICAL,,,NA,,NC1NC(SCC2NCC[NH]2)C(C#N)C(-C2CCC(O)CC2)C1C#N
LUFENURON,LUFENURON,CHEMBL1364906,BRD:BRD-A71774530-001-05-9;BRD:BRD-BRD-A71774530-001-05-9,rep_primary;rep_single_dose,CHITIN INHIBITOR,,FLEA CONTROL,,LAUNCHED,,Small molecule,Unknown,PWPJGUXAGUPAHP-UHFFFAOYSA-N,FC(C(F)(F)F)C(F)(F)OC1CC(CL)C(NC(=O)NC(=O)C2C(F)CCCC2F)CC1CL;O=C(NC(=O)C1C(F)CCCC1F)NC1CC(CL)C(OC(F)(F)C(F)C(F)(F)F)CC1CL
LULICONAZOLE,LULICONAZOLE,CHEMBL2105689,BRD:BRD-BRD-K71058253-001-01-9;BRD:BRD-K71058253-001-01-9,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,YTAOBBFIOAEMLL-REQDGWNSSA-N,CLC1CCC([C@@H]2CS\C(S2)=C(\C#N)N2CCNC2)C(CL)C1;N#C/C(=C1/SC[C@@H](C2CCC(CL)CC2CL)S1)N1CCNC1
LUMACAFTOR,LUMACAFTOR,CHEMBL2103870,BRD:BRD-BRD-K69236721-001-02-7;BRD:BRD-K69236721-001-02-7,rep_primary;rep_single_dose,CFTR CHANNEL AGONIST,CFTR,CYSTIC FIBROSIS,,LAUNCHED,,Small molecule,Approved,UFSKUSARDNFIRC-UHFFFAOYSA-N,CC1CCC(NC(=O)C2(C3CCC4C(C3)OC(F)(F)O4)CC2)NC1-C1CCCC(C(=O)O)C1;CC1CCC(NC(=O)C2(CC2)C2CCC3OC(F)(F)OC3C2)NC1-C1CCCC(C1)C(O)=O
LUMATEPERONE,LUMATEPERONE,CHEMBL3306803,BRD:BRD-BRD-K10031916-075-01-3;BRD:BRD-K10031916-075-01-3,rep_primary;rep_single_dose,"SEROTONIN RECEPTOR ANTAGONIST, DOPAMINE RECEPTOR MODULATOR",DRD2;HTR2A,,,PHASE 3,"Multiple values for MOA: {'DOPAMINE RECEPTOR MODULATOR, SEROTONIN RECEPTOR ANTAGONIST', 'SEROTONIN RECEPTOR ANTAGONIST, DOPAMINE RECEPTOR MODULATOR'}, defaulting to 'SEROTONIN RECEPTOR ANTAGONIST, DOPAMINE RECEPTOR MODULATOR'",Small molecule,Approved,HOIIHACBCFLJET-SFTDATJTSA-N,CN1CCN2[C@H]3CCN(CCCC(=O)C4CCC(F)CC4)C[C@H]3C3CCCC1C23;CN1CCN2C3C(CCCC31)[C@@H]1CN(CCCC(=O)C3CCC(F)CC3)CC[C@@H]12
LUMINESPIB,LUMINESPIB,CHEMBL252164,GDSC1:194;GDSC2:1559,gdsc,,,,,,,Small molecule,Phase 2,NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)C1NOC(-C2CC(C(C)C)C(O)CC2O)C1-C1CCC(CN2CCOCC2)CC1
LUMIRACOXIB,LUMIRACOXIB,CHEMBL404108,BRD:BRD-BRD-K26901728-001-06-2;BRD:BRD-K26901728-001-06-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,WITHDRAWN,,Small molecule,Approved,KHPKQFYUPIUARC-UHFFFAOYSA-N,CC1CCC(NC2C(F)CCCC2CL)C(CC(=O)O)C1;CC1CCC(NC2C(F)CCCC2CL)C(CC(O)=O)C1
LUPANINE,LUPANINE,CHEMBL459396,BRD:BRD-A92826379-001-01-5;BRD:BRD-BRD-A92826379-001-01-5,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,INS,,,PHASE 1,,Small molecule,NA,JYIJIIVLEOETIQ-XDQVBPFNSA-N,O=C1CCC[C@@H]2[C@H]3C[C@@H](CN12)[C@@H]1CCCCN1C3;O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3
LURASIDONE,LURASIDONE,CHEMBL1237021,BRD:BRD-BRD-K51143828-003-03-1;BRD:BRD-K51143828-003-03-1,rep_multi_dose;rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA2A;ADRA2C;DRD2;HTR1A;HTR2A;HTR7,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,PQXKDMSYBGKCJA-CVTJIBDQSA-N,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(C2NSC3CCCCC23)CC1;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1NSC2CCCCC12
LURBINECTEDIN,LURBINECTEDIN,CHEMBL4297516,BRD:BRD-K00003211-001-01-9,rep_single_dose,DNA BINDING AGENT,,,,,,Small molecule,Approved,YDDMIZRDDREKEP-HWTBNCOESA-N,COC1CCC2[NH]C3C(C2C1)CCN[C@]31CS[C@@H]2C3C(OC(C)=O)C(C)C4C(C3[C@H](COC1=O)N1[C@@H]2[C@H]2C3C(CC(C)C(OC)C3O)C[C@@H]([C@@H]1O)N2C)OCO4
LUSAPERIDONE,LUSAPERIDONE,CHEMBL162501,BRD:BRD-K00004742-001-01-9,rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,ZYXHQIPQIKTEDI-UHFFFAOYSA-N,CC1NC2CCCCN2C(=O)C1CCN1CCC2OC3CCCCC3C2C1
LUSUTROMBOPAG,LUSUTROMBOPAG,CHEMBL2107831,BRD:BRD-K93228461-001-02-9,rep_single_dose,THROMBOPOIETIN RECEPTOR AGONIST,,,,,,Small molecule,Approved,NOZIJMHMKORZBA-KJCUYJGMSA-N,CCCCCCO[C@@H](C)C1CCCC(-C2CSC(NC(=O)C3CC(CL)C(/C=C(\C)C(=O)O)C(CL)C3)N2)C1OC
LUTEOLIN,LUTEOLIN,CHEMBL151,BRD:BRD-BRD-K05236810-001-19-0;BRD:BRD-K05236810-001-19-0,rep_primary;rep_single_dose,GLUCOSIDASE INHIBITOR,TOP1,,,PHASE 2,,Small molecule,Phase 2,IQPNAANSBPBGFQ-UHFFFAOYSA-N,O=C1CC(-C2CCC(O)C(O)C2)OC2CC(O)CC(O)C12;OC1CC(O)C2C(C1)OC(CC2=O)-C1CCC(O)C(O)C1
LUZINDOLE,LUZINDOLE,CHEMBL286615,BRD:BRD-K67013324-001-04-9,rep_single_dose,MELATONIN RECEPTOR ANTAGONIST,MTNR1A;MTNR1B,,,,,Small molecule,NA,WVVXBPKOIZGVNS-UHFFFAOYSA-N,CC(=O)NCCC1C(CC2CCCCC2)[NH]C2CCCCC12
LX1031,LX1031,,BRD:BRD-BRD-K32101625-001-01-6;BRD:BRD-K32101625-001-01-6,rep_primary;rep_single_dose,TRYPTOPHAN HYDROXYLASE INHIBITOR,TPH1,,,PHASE 2,,,NA,,COC1CCCC(C1)-C1CCC(CC1)[C@@H](OC1CC(NC(N)N1)-C1CCC(C[C@H](N)C(O)=O)CC1)C(F)(F)F
LX7101,LX7101,CHEMBL3356433,BRD:BRD-BRD-K21038058-001-01-9;BRD:BRD-K21038058-001-01-9,rep_primary;rep_single_dose,"LIM KINASE INHIBITOR, RHO ASSOCIATED KINASE INHIBITOR",LIMK2;ROCK1;ROCK2,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,PWPNYABQEOGNNC-UHFFFAOYSA-N,CC1C[NH]C2NCNC(N3CCC(CN)(C(=O)NC4CCCC(OC(=O)N(C)C)C4)CC3)C12;CN(C)C(=O)OC1CCCC(NC(=O)C2(CN)CCN(CC2)C2NCNC3[NH]CC(C)C23)C1
NAPORAFENIB,LXH254;NAPORAFENIB,CHEMBL4583691,BRD:BRD-K00003107-001-01-9;BRD:BRD-U00115422-001-01-9,oncref_1;rep_single_dose,"INHIBITOR OF BRAF, BRAF-V600E, AND CRAF",BRAF;CRAF,,,,"Multiple values for MOA: {'RAF INHIBITOR', 'INHIBITOR OF BRAF, BRAF-V600E, AND CRAF'}, defaulting to 'INHIBITOR OF BRAF, BRAF-V600E, AND CRAF'
Multiple values for structure_id: {'U00115422', 'K00003107'}, defaulting to None",Small molecule,Phase 2,UEPXBTCUIIGYCY-UHFFFAOYSA-N,CC1CCC(NC(=O)C2CCNC(C(F)(F)F)C2)CC1-C1CC(OCCO)NC(N2CCOCC2)C1
LXR-623,LXR-623,CHEMBL456237,BRD:BRD-BRD-K54520417-001-01-2;BRD:BRD-K54520417-001-01-2,rep_primary;rep_single_dose,LXR AGONIST,AR;NR1H2;NR1H3;NR1I2;NR3C1,,,PHASE 1,,Small molecule,Phase 1,KYWWJENKIMRJBI-UHFFFAOYSA-N,FC1CCC(-C2C3CCCC(C(F)(F)F)C3NN2CC2CCC(F)CC2CL)CC1;FC1CCC(CC1)-C1N(CC2CCC(F)CC2CL)NC2C(CCCC12)C(F)(F)F
LXS196,LXS196,CHEMBL3982723,BRD:BRD-K00003425-001-01-9,rep_single_dose,PKC INHIBITOR,,,,,,Small molecule,Phase 2,XXJXHXJWQSCNPX-UHFFFAOYSA-N,CC1(N)CCN(C2CCCNC2NC(=O)C2NC(-C3NCCCC3C(F)(F)F)CNC2N)CC1
LY-188011,LY-188011,CHEMBL1637;CHEMBL888,GDSC1:135;GDSC2:1190,gdsc,,,,,,,Small molecule,Approved,OKKDEIYWILRZIA-OSZBKLCCSA-N;SDUQYLNIPVEERB-QPPQHZFASA-N,CL.NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C(=O)N1;NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C(=O)N1
LY-2157299,LY-2157299,CHEMBL2364611,CTRP:660431,ctrp,,,,,,,Small molecule,Phase 2,IVRXNBXKWIJUQB-UHFFFAOYSA-N,CC1CCCC(-C2NN3C(C2-C2CCNC4CCC(C(N)=O)CC24)CCC3)N1
LY-2183240,LY-2183240,,CTRP:375496,ctrp,,,,,,,,NA,,
LY2090314,LY2090314,CHEMBL362558,BRD:BRD-BRD-K78055238-001-01-8;BRD:BRD-K78055238-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3B,,,PHASE 2,,Small molecule,Phase 2,HRJWTAWVFDCTGO-UHFFFAOYSA-N,FC1CC2CN(CCN3CC(C4=C(C(=O)NC4=O)C4CNC5CCCCN45)C(C1)C23)C(=O)N1CCCCC1;O=C1NC(=O)C(C2CNC3CCCCN23)=C1C1CN2C3C(CC(F)CC13)CN(C(=O)N1CCCCC1)CC2
LY2109761,LY2109761,,BRD:BRD-BRD-K47557313-001-02-7;BRD:BRD-K47557313-001-02-7;GDSC2:1852,gdsc;rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFBR1;TGFBR2,,,PRECLINICAL,,,NA,,C(CN1CCOCC1)OC1CCC2C(CCNC2C1)-C1C(NN2CCCC12)-C1CCCCN1
LY2140023,LY2140023,CHEMBL2110730,BRD:BRD-BRD-K49519144-001-04-6;BRD:BRD-K49519144-001-04-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM3,,,PHASE 3,,Small molecule,Phase 3,VOYCNOJFAJAILW-CAMHOICYSA-N,CSCC[C@H](N)C(=O)N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21;N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O
LY215490,LY215490,,BRD:BRD-BRD-K34313798-001-01-6;BRD:BRD-K34313798-001-01-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIA3;GRIA4;GRIK1,,,PHASE 1,,,NA,,OC(=O)[C@@H]1C[C@H]2C[C@@H](CCC3NN[NH]N3)CC[C@H]2CN1
LY2157299,LY2157299,CHEMBL2364611,BRD:BRD-BRD-K78118466-001-03-3;BRD:BRD-K78118466-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFBR1,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,IVRXNBXKWIJUQB-UHFFFAOYSA-N,CC1CCCC(-C2NN3C(C2-C2CCNC4CCC(C(N)=O)CC24)CCC3)N1;CC1CCCC(N1)-C1NN2CCCC2C1-C1CCNC2CCC(CC12)C(N)=O
LY2183240,LY2183240,,BRD:BRD-BRD-K37865504-001-04-1;BRD:BRD-K37865504-001-04-1,rep_multi_dose;rep_primary;rep_single_dose,"FAAH INHIBITOR, FAAH REUPTAKE INHIBITOR",FAAH,,,PRECLINICAL,,,NA,,CN(C)C(=O)N1NNNC1CC1CCC(CC1)-C1CCCCC1
LY2228820,LY2228820,CHEMBL2364626,BRD:BRD-BRD-K59227464-334-02-4;BRD:BRD-K59227464-334-02-4,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PHASE 2,,Small molecule,Phase 2,XPPBBJCBDOEXDN-UHFFFAOYSA-N,CC(C)(C)CN1C(N)NC2CCC(-C3[NH]C(C(C)(C)C)NC3-C3CCC(F)CC3)NC21;CC(C)(C)CN1C(N)NC2CCC(NC12)-C1[NH]C(NC1-C1CCC(F)CC1)C(C)(C)C
LY223982,LY223982,,BRD:BRD-BRD-K35367061-001-01-1;BRD:BRD-K35367061-001-01-1,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,LTB4R,,,PHASE 2,,,NA,,COC1CCC(\C=C\CCCCOC2CCC(CC2CCC(O)=O)C(=O)C2CCCC(C2)C(O)=O)CC1
LY225910,LY225910,,BRD:BRD-BRD-K33864865-001-02-5;BRD:BRD-K33864865-001-02-5,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKBR,,,PRECLINICAL,,,NA,,CC(C)OC1CCCC(C1)-N1C(CCC2C[NH]C3CCC(BR)CC23)NC2CCCCC2C1=O
LY231617,LY231617,,BRD:BRD-K85804405-003-01-3,rep_single_dose,LIPID PEROXIDASE INHIBITOR,,,,,,,NA,,
LY2334737,LY2334737,CHEMBL577711,BRD:BRD-BRD-K04993719-001-01-7;BRD:BRD-K04993719-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,"ANTITUMOR AGENT, RIBONUCLEOTIDE REDUCTASE INHIBITOR",,,,PHASE 1,,Small molecule,Phase 1,MEOYFIHNRBNEPI-UXIGCNINSA-N,CCCC(CCC)C(=O)NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C(=O)N1
LY2365109,LY2365109,,BRD:BRD-BRD-K13888115-003-02-2;BRD:BRD-K13888115-003-02-2,rep_primary;rep_single_dose,"GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR",SLC6A9,,,PRECLINICAL,"Multiple values for MOA: {'GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR', 'GLYCINE TRANSPORTER 1 INHIBITOR'}, defaulting to 'GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR'",,NA,,CN(CCOC1CCC(CC1C(C)(C)C)-C1CCC2OCOC2C1)CC(O)=O
LY2452473,LY2452473,CHEMBL3542265,BRD:BRD-BRD-K90171280-001-01-4;BRD:BRD-K90171280-001-01-4,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 2,,Small molecule,Phase 2,IHIWYQYVBNODSV-KRWDZBQOSA-N,CC(C)OC(=O)N[C@@H]1CC2C(C1)C1CC(CCC1N2CC1CCCCN1)C#N;CC(C)OC(=O)N[C@H]1CC2C(N(CC3CCCCN3)C3CCC(C#N)CC23)C1
LY2510924,LY2510924,,BRD:BRD-K00003131-001-01-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,,NA,,
LY255283,LY255283,,BRD:BRD-BRD-K92492521-001-02-9;BRD:BRD-K92492521-001-02-9,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,LTB4R;LTB4R2,,,PRECLINICAL,,,NA,,CCC1CC(C(C)=O)C(O)CC1OCCCCCC(C)(C)C1NNN[NH]1
LY2562175,LY2562175,CHEMBL3746388,BRD:BRD-K00075537-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,RPVDFHPBGBMWID-UHFFFAOYSA-N,CN1CC(C(=O)O)C2CCC(N3CCC(OCC4C(-C5C(CL)CCCC5CL)NOC4C4CC4)CC3)CC21
LY2584702,LY2584702,CHEMBL3545076,BRD:BRD-BRD-K21833260-075-01-1;BRD:BRD-K21833260-075-01-1,rep_primary;rep_single_dose,RIBOSOMAL PROTEIN INHIBITOR,RPS6KB1,,,PHASE 1,,Small molecule,Phase 1,FYXRSVDHGLUMHB-UHFFFAOYSA-N,CN1CC(-C2CCC(F)C(C(F)(F)F)C2)NC1C1CCN(C2NCNC3[NH]NCC23)CC1;CN1CC(NC1C1CCN(CC1)C1NCNC2[NH]NCC12)-C1CCC(F)C(C1)C(F)(F)F
LY2603618,LY2603618,CHEMBL3039517,BRD:BRD-BRD-K14109347-001-03-4;BRD:BRD-K14109347-001-03-4,rep_multi_dose;rep_primary;rep_single_dose,CHK INHIBITOR,CHEK1,,,PHASE 2,,Small molecule,Phase 2,SYYBDNPGDKKJDU-ZDUSSCGKSA-N,CC1CNC(NC(=O)NC2CC(BR)C(C)CC2OC[C@@H]2CNCCO2)CN1
LY2606368,LY2606368,CHEMBL3544911,BRD:BRD-BRD-K20463415-300-01-4;BRD:BRD-K20463415-300-01-4,rep_multi_dose;rep_primary;rep_single_dose,CHK INHIBITOR,CHEK1,,,PHASE 2,,Small molecule,Phase 2,DOTGPNHGTYJDEP-UHFFFAOYSA-N,COC1CCCC(OCCCN)C1-C1CC(NC2CNC(C#N)CN2)N[NH]1;COC1CCCC(OCCCN)C1-C1CC(NC2CNC(CN2)C#N)N[NH]1
LY2608204,LY2608204,CHEMBL4297399,BRD:BRD-BRD-K12068470-001-02-5;BRD:BRD-BRD-K12068470-001-04-1;BRD:BRD-K12068470-001-02-5;BRD:BRD-K12068470-001-04-1,rep_multi_dose;rep_primary;rep_single_dose,GLUCOKINASE ACTIVATOR,GCK,,,PHASE 2,,Small molecule,Phase 2,QIIVJLHCZUTGSD-CUBQBAPOSA-N,O=C(NC1NCC(SCCN2CCCC2)S1)[C@]1(C2CCC(S(=O)(=O)C3CC3)CC2)C[C@H]1C1CCCCC1;O=C(NC1NCC(SCCN2CCCC2)S1)[C@@]1(C[C@H]1C1CCCCC1)C1CCC(CC1)S(=O)(=O)C1CC1
LY266097,LY266097,,BRD:BRD-A64004759-003-01-9;BRD:BRD-BRD-A64004759-003-01-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2B,,,PRECLINICAL,,,NA,,COC1CCC(CC2NCCC3C2[NH]C2CCC(C)CC32)C(CL)C1OC
LY2784544,LY2784544,CHEMBL2107823,BRD:BRD-BRD-K25630527-001-03-8;BRD:BRD-K25630527-001-03-8,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK2;JAK3,,,PHASE 2,,Small molecule,Phase 2,SQSZANZGUXWJEA-UHFFFAOYSA-N,CC1CC(NC2CC(CN3CCOCC3)C3NC(C)C(CC4CCC(CL)CC4F)N3N2)[NH]N1;CC1CC(NC2CC(CN3CCOCC3)C3NC(C)C(CC4CCC(CL)CC4F)N3N2)N[NH]1
LY2795050,LY2795050,,BRD:BRD-K00003195-001-01-9,rep_single_dose,OPIOID RECEPTOR ANTAGONIST,,,,,,,NA,,
LY2801653,LY2801653,CHEMBL3545307,BRD:BRD-BRD-K18961567-001-01-1;BRD:BRD-K18961567-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,MET INHIBITOR,MET,,,PHASE 2,,Small molecule,Phase 2,QHADVLVFMKEIIP-UHFFFAOYSA-N,CC1CCC(C(=O)NC2CCC(OC3CC4CNN(C)C4CC3-C3CN[NH]C3)C(F)C2)C(=O)N1-C1CCC(F)CC1
LY2811376,LY2811376,CHEMBL2333941,BRD:BRD-BRD-K94534639-001-02-5;BRD:BRD-K94534639-001-02-5,rep_primary;rep_single_dose,BETA-SECRETASE INHIBITOR,BACE1,,,PHASE 1,,Small molecule,Phase 1,MJQMRGWYPNIERM-HNNXBMFYSA-N,C[C@]1(CCSC(N)=N1)C1CC(C(F)CC1F)-C1CNCNC1;C[C@@]1(C2CC(-C3CNCNC3)C(F)CC2F)CCSC(N)=N1
LY2828360,LY2828360,CHEMBL3139186,BRD:BRD-K00005249-001-01-9,rep_single_dose,CANNABINOID RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,UCMNDPDJRSEZPL-UHFFFAOYSA-N,CC1NC(N2CCN(C)CC2)C2NC(-C3CCCCC3CL)N(C3CCOCC3)C2N1
LY2857785,LY2857785,,BRD:BRD-K15382985-001-01-7,rep_single_dose,CDK INHIBITOR,CDK9,,,,,,NA,,
LY2874455,LY2874455,CHEMBL3545264,BRD:BRD-BRD-K17203476-001-01-9;BRD:BRD-K17203476-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,FGFR ANTAGONIST,FGFR1;FGFR2;FGFR3;FGFR4;KDR,,,PHASE 1,,Small molecule,Phase 1,GKJCVYLDJWTWQU-DUXPYHPUSA-N,C[C@@H](OC1CCC2[NH]NC(\C=C\C3CNN(CCO)C3)C2C1)C1C(CL)CNCC1CL;CC(OC1CCC2[NH]NC(/C=C/C3CNN(CCO)C3)C2C1)C1C(CL)CNCC1CL
LY288513,LY288513,,BRD:BRD-K24675965-001-06-9,rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKBR,,,,,,NA,,
LY2886721,LY2886721,CHEMBL2396989,BRD:BRD-BRD-K17953908-001-01-7;BRD:BRD-K17953908-001-01-7,rep_primary;rep_single_dose,BETA-SECRETASE INHIBITOR,BACE1,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,NIDRNVHMMDAAIK-YPMLDQLKSA-N,NC1=N[C@]2(COC[C@@H]2CS1)C1CC(NC(=O)C2CCC(F)CN2)CCC1F;NC1=N[C@@]2(C3CC(NC(=O)C4CCC(F)CN4)CCC3F)COC[C@H]2CS1
LY2922470,LY2922470,,BRD:BRD-K00091082-001-01-9,rep_single_dose,,,,,,,,NA,,
LY294002,LY294002,,BRD:BRD-BRD-K27305650-001-16-6;BRD:BRD-K27305650-001-16-6,rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR, DNA DEPENDENT PROTEIN KINASE INHIBITOR, PHOSPHODIESTERASE INHIBITOR, PLK INHIBITOR",AKT1;CHEK1;GSK3B;LCK;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PIM1;PLK1;PRKCA;PRKDC;ROCK1;RPS6KB1;SGK1,,,PRECLINICAL,"Multiple values for MOA: {'DNA DEPENDENT PROTEIN KINASE INHIBITOR, MTOR INHIBITOR, PHOSPHODIESTERASE INHIBITOR, PI3K INHIBITOR, PLK INHIBITOR', 'MTOR INHIBITOR, PI3K INHIBITOR, DNA DEPENDENT PROTEIN KINASE INHIBITOR, PHOSPHODIESTERASE INHIBITOR, PLK INHIBITOR'}, defaulting to 'MTOR INHIBITOR, PI3K INHIBITOR, DNA DEPENDENT PROTEIN KINASE INHIBITOR, PHOSPHODIESTERASE INHIBITOR, PLK INHIBITOR'
Multiple values for repurposing_target: {'AKT1;CHEK1;GSK3B;LCK;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PLK1;PRKCA;PRKDC;ROCK1;RPS6KB1;SGK1', 'AKT1;CHEK1;GSK3B;LCK;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PIM1;PLK1;PRKCA;PRKDC;ROCK1;RPS6KB1;SGK1'}, taking the union",,NA,,O=C1CC(OC2C(CCCC12)-C1CCCCC1)N1CCOCC1
LY2940094,LY2940094,CHEMBL3545406,BRD:BRD-K00077386-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,,
LY2979165,LY2979165,CHEMBL3544939;CHEMBL4303379,BRD:BRD-BRD-K68220839-413-02-8;BRD:BRD-K68220839-413-02-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM2,,,PHASE 1,,Small molecule,Phase 1,;BBGHHIUQOKQCBW-LDZWZCGGSA-N,C[C@H](N)C(=O)N[C@]1(C[C@@H](SC2NNC[NH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O;C[C@H](N)C(=O)N[C@@]1(C(=O)O)C[C@@H](SC2NNC[NH]2)[C@H]2[C@H](C(=O)O)[C@H]21
LY3000328,LY3000328,,BRD:BRD-BRD-K21070437-001-01-4;BRD:BRD-K21070437-001-01-4,rep_primary;rep_single_dose,CATHEPSIN INHIBITOR,CTSS,,,PHASE 1,,,NA,,CNC(=O)O[C@H]1COC2CCC(CC2[C@@H]1NC(=O)C1CCC(F)CC1)N1CCN(CC1)C1COC1
LY3009120,LY3009120,CHEMBL3545195,BRD:BRD-BRD-K38385169-001-04-5;BRD:BRD-K38385169-001-04-5,rep_primary;rep_single_dose,RAF INHIBITOR,BRAF;RAF1,,,PHASE 1,,Small molecule,Phase 1,,CNC1NCC2CC(C(C)NC2N1)-C1CC(NC(=O)NCCC(C)(C)C)C(F)CC1C
LY3023414,LY3023414,CHEMBL4297181,BRD:BRD-BRD-K82967180-001-01-6;BRD:BRD-K82967180-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,"PI3K INHIBITOR, MTOR INHIBITOR",MTOR,,,PHASE 2,"Multiple values for MOA: {'MTOR INHIBITOR, PI3K INHIBITOR', 'PI3K INHIBITOR, MTOR INHIBITOR'}, defaulting to 'PI3K INHIBITOR, MTOR INHIBITOR'",Small molecule,Phase 2,ACCFLVVUVBJNGT-AWEZNQCLSA-N,CO[C@@H](C)CN1C(=O)N(C)C2CNC3CCC(-C4CNCC(C(C)(C)O)C4)CC3C21;CO[C@@H](C)CN1C2C(CNC3CCC(CC23)-C2CNCC(C2)C(C)(C)O)N(C)C1=O
LY303511,LY303511,,BRD:BRD-BRD-K22385716-001-02-5;BRD:BRD-K22385716-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,"CASEIN KINASE INHIBITOR, MTOR INHIBITOR, PI3K INHIBITOR",BRD2;BRD3;BRD4,,,PRECLINICAL,,,NA,,O=C1CC(OC2C(CCCC12)-C1CCCCC1)N1CCNCC1
LY310762,LY310762,,BRD:BRD-BRD-K41194171-003-09-7;BRD:BRD-K41194171-003-09-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1D,,,PRECLINICAL,,,NA,,CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)C2CCC(F)CC2)C2CCCCC12
LY311727,LY311727,,BRD:BRD-K00004565-001-01-9,rep_single_dose,PHOSPHOLIPASE INHIBITOR,,,,,,,NA,,
LY317615,LY317615,CHEMBL300138,GDSC1:229,gdsc,,,,,,,Small molecule,Phase 3,AXRCEOKUDYDWLF-UHFFFAOYSA-N,CN1CC(C2=C(C3CN(C4CCN(CC5CCCCN5)CC4)C4CCCCC34)C(=O)NC2=O)C2CCCCC21
LY3200882,LY3200882,CHEMBL4594432,BRD:BRD-K00003446-001-01-9,rep_single_dose,TGF BETA RECEPTOR INHIBITOR,,,,,,Small molecule,Phase 1,PNPFMWIDAKQFPY-UHFFFAOYSA-N,CC(C)(O)C1CC(NC2CC(OC3CN(C4CC4)NC3C3CCOCC3)CCN2)CCN1
LY320135,LY320135,,BRD:BRD-BRD-K78637815-001-02-2;BRD:BRD-K78637815-001-02-2,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-C1OC2CC(OC)CCC2C1C(=O)C1CCC(CC1)C#N
TEMUTERKIB,LY3214996;TEMUTERKIB,CHEMBL4650285,BRD:BRD-K00003416-001-01-9,oncref_1;rep_single_dose,INHIBITOR OF ERK1 AND ERK2,MAPK1;MAPK2,,,,"Multiple values for MOA: {'INHIBITOR OF ERK1 AND ERK2', 'ERK INHIBITOR'}, defaulting to 'INHIBITOR OF ERK1 AND ERK2'",Small molecule,Phase 2,JNPRPMBJODOFEC-UHFFFAOYSA-N,CN1NCCC1NC1NCCC(-C2CC3C(S2)C(C)(C)N(CCN2CCOCC2)C3=O)N1
LY3295668,LY3295668,CHEMBL4594367,BRD:BRD-K00004722-001-01-9,rep_single_dose,AURORA KINASE INHIBITOR,,,,,,Unknown,Phase 1,,
LY334370,LY334370,,BRD:BRD-K00003451-001-01-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,,,,,,,NA,,
LY344864,LY344864,,BRD:BRD-BRD-K95899059-003-02-8;BRD:BRD-K95899059-003-02-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR7,,,PRECLINICAL,,,NA,,CN(C)[C@@H]1CCC2[NH]C3CCC(NC(=O)C4CCC(F)CC4)CC3C2C1
LY364947,LY364947,,BRD:BRD-BRD-K06234293-001-04-2;BRD:BRD-K06234293-001-04-2,rep_multi_dose;rep_primary;rep_single_dose,"P38 MAPK INHIBITOR, TGF BETA RECEPTOR INHIBITOR",TGFBR1,,,PRECLINICAL,"Multiple values for MOA: {'TGF BETA RECEPTOR INHIBITOR, P38 MAPK INHIBITOR', 'P38 MAPK INHIBITOR, TGF BETA RECEPTOR INHIBITOR'}, defaulting to 'P38 MAPK INHIBITOR, TGF BETA RECEPTOR INHIBITOR'",,NA,,C1[NH]NC(C1-C1CCNC2CCCCC12)-C1CCCCN1
LY404187,LY404187,,BRD:BRD-A50062753-001-02-9,rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRIA1;GRIA2;GRIA3;GRIA4,,,,,,NA,,
LY411575,LY411575,,BRD:BRD-BRD-K20013301-001-02-6;BRD:BRD-K20013301-001-02-6,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,PRECLINICAL,,,NA,,C[C@H](NC(=O)[C@@H](O)C1CC(F)CC(F)C1)C(=O)N[C@H]1C2CCCCC2-C2CCCCC2N(C)C1=O
LY450108,LY450108,,BRD:BRD-BRD-K54538117-001-01-7;BRD:BRD-K54538117-001-01-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,,,,PHASE 1,,,NA,,C[C@@H](CNS(=O)(=O)C(C)C)C1CCC(NC(=O)C2CC(F)CC(F)C2)CC1
LY456236,LY456236,,BRD:BRD-BRD-K87696786-003-04-4;BRD:BRD-K87696786-003-04-4,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1,,,PRECLINICAL,,,NA,,COC1CCC(NC2NCNC3CCC(OC)CC23)CC1
LYCOPENE,LYCOPENE,CHEMBL501174,BRD:BRD-BRD-K37083340-001-02-3;BRD:BRD-K37083340-001-02-3,rep_primary;rep_single_dose,FREE RADICAL SCAVENGER,,,,PHASE 3,,Small molecule,Phase 3,OAIJSZIZWZSQBC-GYZMGTAESA-N,CC(C)=CCC/C(C)=C/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(\C)CCC=C(C)C;CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C
LYLAMINE,LYLAMINE,,BRD:BRD-K62289640-003-05-9,rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR1,,,,,,NA,,
LYNPARZA,LYNPARZA,CHEMBL521686,GDSC1:1017;GDSC1:1495;GDSC2:1017,gdsc,,,,,,,Small molecule,Approved,FDLYAMZZIXQODN-UHFFFAOYSA-N,O=C(C1CC(CC2N[NH]C(=O)C3CCCCC23)CCC1F)N1CCN(C(=O)C2CC2)CC1
LYOVAC,LYOVAC,,GDSC2:1911,gdsc,,,,,,,,NA,,
LYPRESSIN,LYPRESSIN,CHEMBL1200690,BRD:BRD-BRD-K93331255-001-02-0;BRD:BRD-K93331255-001-02-0,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR AGONIST,AVPR1A;AVPR1B;AVPR2,,,LAUNCHED,,Protein,Approved,BJFIDCADFRDPIO-DZCXQCEKSA-N,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2CCC(O)CC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
M-14157,M-14157,,BRD:BRD-A96977263-001-03-7;BRD:BRD-BRD-A96977263-001-03-7,rep_primary;rep_single_dose,ATP-SENSITIVE POTASSIUM CHANNEL ANTAGONIST,KCNQ1,,,PHASE 2,,,NA,,CCCCCC(O)CCCC(O)=O
M-25,M-25,,BRD:BRD-BRD-K51265828-001-01-0;BRD:BRD-K51265828-001-01-0,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,DHH;IHH;SMO,,,PRECLINICAL,,,NA,,CCCC(CCC)C(=O)NCC1CCC2N(NCC2C1)-C1CCCCC1OC
M-344,M-344,,BRD:BRD-BRD-K45528773-001-06-4;BRD:BRD-BRD-K45528773-001-07-2;BRD:BRD-K45528773-001-06-4;BRD:BRD-K45528773-001-07-2,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC8,,,PRECLINICAL,,,NA,,CN(C)C1CCC(CC1)C(=O)NCCCCCCC(=O)NO
M-39831,M-39831,CHEMBL810,GDSC1:1375;GDSC2:1375,gdsc,,,,,,,Small molecule,Approved,BPEGJWRSRHCHSN-UHFFFAOYSA-N,CN1NNC2C(C(N)=O)NCN2C1=O
M-3M3FBS,M-3M3FBS,,BRD:BRD-BRD-K09635314-001-03-4;BRD:BRD-K09635314-001-03-4,rep_primary;rep_single_dose,PHOSPHOLIPASE ACTIVATOR,PLCB2;PLCB3;PLCD1;PLCG1;PLCG2,,,PRECLINICAL,,,NA,,CC1CC(C)C(C(C)C1)S(=O)(=O)NC1CCCC(C1)C(F)(F)F
M-CHLOROPHENYLBIGUANIDE,M-CHLOROPHENYLBIGUANIDE,,BRD:BRD-BRD-K36965586-003-08-8;BRD:BRD-K36965586-003-08-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR3A;HTR3B,,,PRECLINICAL,,,NA,,NC(=N)NC(=N)NC1CCCC(CL)C1
M-THP,M-THP,,BRD:BRD-BRD-K91147684-001-01-5;BRD:BRD-K91147684-001-01-5,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,OC1CCCC(C1)-C1C2CCC(N2)C(-C2CCCC(O)C2)C2CCC([NH]2)C(-C2CCCC(O)C2)C2CCC(N2)C(-C2CCCC(O)C2)C2CCC1[NH]2
M8-B,M8-B,,BRD:BRD-K90410034-003-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPM8,,,,,,NA,,
MABUPROFEN,MABUPROFEN,CHEMBL2105154,BRD:BRD-A93683007-001-01-9;BRD:BRD-BRD-A93683007-001-01-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,JVGUNCHERKJFCM-UHFFFAOYSA-N,CC(C)CC1CCC(C(C)C(=O)NCCO)CC1;CC(C)CC1CCC(CC1)C(C)C(=O)NCCO
MABUTEROL,MABUTEROL,CHEMBL86749,BRD:BRD-A13116749-003-01-6;BRD:BRD-BRD-A13116749-003-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,,,LAUNCHED,,Small molecule,Unknown,JSJCTEKTBOKRST-UHFFFAOYSA-N,CC(C)(C)NCC(O)C1CC(CL)C(N)C(C(F)(F)F)C1;CC(C)(C)NCC(O)C1CC(CL)C(N)C(C1)C(F)(F)F
MACELIGNAN,MACELIGNAN,,BRD:BRD-BRD-K94948151-001-07-4;BRD:BRD-K94948151-001-07-4,rep_primary;rep_single_dose,"ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT, ANTIOXIDANT",,,,PRECLINICAL,"Multiple values for MOA: {'ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT, ANTIOXIDANT', 'ANTIOXIDANT, ANTIINFLAMMATORY AGENT'}, defaulting to 'ANTI-INFLAMMATORY AGENT, ANTIINFLAMMATORY AGENT, ANTIOXIDANT'",,NA,,COC1CC(C[C@H](C)[C@H](C)CC2CCC3OCOC3C2)CCC1O
MACIMORELIN,MACIMORELIN,CHEMBL278623,BRD:BRD-K00071596-019-01-9,rep_single_dose,,,,,,,Small molecule,Approved,UJVDJAPJQWZRFR-DHIUTWEWSA-N,CC(C)(N)C(=O)N[C@H](CC1C[NH]C2CCCCC12)C(=O)N[C@H](CC1C[NH]C2CCCCC12)NC=O
MACITENTAN,MACITENTAN,CHEMBL2103873,BRD:BRD-BRD-K48812570-001-02-3;BRD:BRD-K48812570-001-02-3,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA;EDNRB,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,JGCMEBMXRHSZKX-UHFFFAOYSA-N,CCCNS(=O)(=O)NC1NCNC(OCCOC2NCC(BR)CN2)C1-C1CCC(BR)CC1
MACITENTAN-N-BUTYL-ANALOGUE,MACITENTAN-N-BUTYL-ANALOGUE,,BRD:BRD-K00003167-001-01-9,rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,,,,,,,NA,,
MACOZINONE,MACOZINONE,CHEMBL3330226,BRD:BRD-K16343284-001-02-9,rep_single_dose,DPRE1 INHIBITOR,,,,,,Small molecule,Phase 2,BJDZBXGJNBMCAV-UHFFFAOYSA-N,O=C1NC(N2CCN(CC3CCCCC3)CC2)SC2C([N+](=O)[O-])CC(C(F)(F)F)CC12
MADECASSOSIDE,MADECASSOSIDE,,BRD:BRD-K00003328-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,,NA,,
MADRASIN,MADRASIN,,BRD:BRD-K48905682-001-11-1,rep_single_dose,CELL SPLICING INHIBITOR,,,,,,,NA,,
MAFENIDE,MAFENIDE,CHEMBL419,BRD:BRD-BRD-K30649484-003-13-7;BRD:BRD-K30649484-003-13-7,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA12;CA14;CA2;CA4;CA6;CA9,"FIRST-AID ANTIBIOTIC, SKIN INFECTIONS",,LAUNCHED,,Small molecule,Approved,TYMRLRRVMHJFTF-UHFFFAOYSA-N,NCC1CCC(CC1)S(N)(=O)=O;NCC1CCC(S(N)(=O)=O)CC1
MAGNOLOL,MAGNOLOL,CHEMBL180920,BRD:BRD-BRD-K26168087-001-09-7;BRD:BRD-K26168087-001-09-7,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,GABRA1;PPARG,,,PRECLINICAL,,Small molecule,NA,VVOAZFWZEDHOOU-UHFFFAOYSA-N,C=CCC1CCC(O)C(-C2CC(CC=C)CCC2O)C1;OC1CCC(CC=C)CC1-C1CC(CC=C)CCC1O
MALIC-ACID,MALIC-ACID,,BRD:BRD-A18396475-001-15-3;BRD:BRD-BRD-A18396475-001-15-3,rep_primary;rep_single_dose,,CS;ME2;PKD2L1,,,LAUNCHED,,,NA,,OC(CC(O)=O)C(O)=O
MALOTILATE,MALOTILATE,CHEMBL1697754,BRD:BRD-BRD-K97884852-001-05-4;BRD:BRD-K97884852-001-05-4,rep_primary;rep_single_dose,PROTEIN SYNTHESIS STIMULANT,,HEPATIC CIRRHOSIS,,LAUNCHED,,Small molecule,Unknown,YPIQVCUJEKAZCP-UHFFFAOYSA-N,CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1
MALTOBIONIC-ACID,MALTOBIONIC-ACID,,BRD:BRD-BRD-K01624185-001-05-7;BRD:BRD-K01624185-001-05-7,rep_primary;rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,,COSMETIC,,LAUNCHED,,,NA,,OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O
MANDELIC-ACID,MANDELIC-ACID,,BRD:BRD-A91448670-001-08-9,rep_single_dose,,,,,,,,NA,,
MANGAFODIPIR,MANGAFODIPIR,CHEMBL1201301,BRD:BRD-K57365211-314-03-9,rep_single_dose,CONTRAST AGENT,,,,,,Small molecule,Approved,,
MANIDIPINE,MANIDIPINE,CHEMBL1085699,BRD:BRD-A90695733-001-07-4;BRD:BRD-BRD-A90695733-001-07-4,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,ANEBWFXPVPTEET-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(C3CCCCC3)C3CCCCC3)CC2)C1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(C1CCCCC1)C1CCCCC1
MANITIMUS,MANITIMUS,CHEMBL2107757,BRD:BRD-K00004729-001-01-9,rep_single_dose,DEHYDROGENASE INHIBITOR,,,,,,Small molecule,Phase 2,OQUXVPJVBSENGK-QXMHVHEDSA-N,N#CCC/C(O)=C(\C#N)C(=O)NC1CCC(C(F)(F)F)CC1
MANNITOL-D,MANNITOL-D,,BRD:BRD-BRD-K30374899-001-09-3;BRD:BRD-K30374899-001-09-3,rep_primary;rep_single_dose,DIURETIC,,"INTRACRANIAL PRESSURE, INTRAOCULAR PRESSURE, CONSTIPATION",,LAUNCHED,,,NA,,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO;OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
MANUMYCIN A,MANUMYCIN A,CHEMBL285848,CTRP:50727,ctrp,,,,,,,Small molecule,NA,TWWQHCKLTXDWBD-MVTGTTCWSA-N,CCCC[C@@H](C)/C=C(C)/C=C(\C)C(=O)NC1=C[C@@](O)(/C=C/C=C/C=C/C(=O)NC2=C(O)CCC2=O)[C@@H]2O[C@@H]2C1=O
MAPRACORAT,MAPRACORAT,CHEMBL2103876,BRD:BRD-K00077013-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,VJGFOYBQOIPQFY-XMMPIXPASA-N,CC1CCC2C(NC[C@](O)(CC(C)(C)C3CC(F)CC4C3OCC4)C(F)(F)F)CCCC2N1
MAPROTILINE,MAPROTILINE,CHEMBL21731,BRD:BRD-BRD-K25433859-003-25-4;BRD:BRD-K25433859-003-25-4,rep_multi_dose;rep_primary;rep_single_dose,"NOREPINEPHRINE REPUTAKE INHIBITOR, TRICYCLIC ANTIDEPRESSANT",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD2;HRH1;HTR2A;HTR2C;HTR7;SLC6A2,"DEPRESSION, DYSTHYMIC DISORDER",,LAUNCHED,,Small molecule,Approved,QSLMDECMDJKHMQ-UHFFFAOYSA-N,CNCCCC12CCC(C3CCCCC13)C1CCCCC21;CNCCCC12CCC(C3CCCCC31)C1CCCCC12
MARAVIROC,MARAVIROC,CHEMBL1201187,BRD:BRD-A04352665-001-05-3;BRD:BRD-BRD-A04352665-001-05-3,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR5,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,GSNHKUDZZFZSJB-QYOOZWMWSA-N,CC(C)C1NNC(C)N1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1CCCCC1;CC1NNC(C(C)C)N1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1CCCCC1
MARBOFLOXACIN,MARBOFLOXACIN,CHEMBL478120,BRD:BRD-BRD-K71926323-001-13-8;BRD:BRD-BRD-K71926323-001-14-6;BRD:BRD-K71926323-001-13-8;BRD:BRD-K71926323-001-14-6,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Unknown,BPFYOAJNDMUVBL-UHFFFAOYSA-N,CN1CCN(C2C(F)CC3C(=O)C(C(=O)O)CN4C3C2OCN4C)CC1;CN1CCN(CC1)C1C(F)CC2C3C1OCN(C)N3CC(C(O)=O)C2=O
MARIBAVIR,MARIBAVIR,CHEMBL515408,BRD:BRD-BRD-K59524082-001-01-3;BRD:BRD-K59524082-001-01-3,rep_primary;rep_single_dose,"CYTOMEGALOVIRUS INHIBITOR, PROTEIN KINASE INHIBITOR",PYGM,,,PHASE 3,,Small molecule,Approved,KJFBVJALEQWJBS-XUXIUFHCSA-N,CC(C)NC1NC2CC(CL)C(CL)CC2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O
MARIMASTAT,MARIMASTAT,CHEMBL279785,BRD:BRD-BRD-K21396683-001-04-8;BRD:BRD-K21396683-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,MMP1;MMP10;MMP11;MMP12;MMP13;MMP14;MMP15;MMP16;MMP17;MMP19;MMP2;MMP20;MMP21;MMP23A;MMP24;MMP25;MMP26;MMP27;MMP28;MMP3;MMP7;MMP8;MMP9,,,PHASE 3,,Small molecule,Phase 3,OCSMOTCMPXTDND-OUAUKWLOSA-N,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C
MARINOPYRROLE A,MARINOPYRROLE A,,CTRP:666910,ctrp,,,,,,,,NA,,
MAROPITANT,MAROPITANT,CHEMBL2111099,BRD:BRD-BRD-K76594255-001-01-6;BRD:BRD-K76594255-001-01-6,rep_primary;rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,TACR1,VOMITING,,LAUNCHED,,Small molecule,Unknown,OMPCVMLFFSQFIX-CONSDPRKSA-N,COC1CCC(C(C)(C)C)CC1CN[C@H]1C2CCN(CC2)[C@H]1C(C1CCCCC1)C1CCCCC1;COC1CCC(CC1CN[C@H]1C2CCN(CC2)[C@H]1C(C1CCCCC1)C1CCCCC1)C(C)(C)C
MASITINIB,MASITINIB,CHEMBL1908391,BRD:BRD-BRD-K71035033-001-07-1;BRD:BRD-K71035033-001-07-1;CTRP:606143;GDSC1:292,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, SRC INHIBITOR",FGFR3;KIT;PDGFRA;PDGFRB,MASTOCYTOMA,,LAUNCHED,,Small molecule,Approved,WJEOLQLKVOPQFV-UHFFFAOYSA-N,CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NC(-C2CCCNC2)CS1;CN1CCN(CC2CCC(CC2)C(=O)NC2CCC(C)C(NC3NC(CS3)-C3CCCNC3)C2)CC1
MASIVET,MASIVET,CHEMBL1908391,GDSC1:292,gdsc,,,,,,,Small molecule,Approved,WJEOLQLKVOPQFV-UHFFFAOYSA-N,CC1CCC(NC(=O)C2CCC(CN3CCN(C)CC3)CC2)CC1NC1NC(-C2CCCNC2)CS1
MASOPROCOL,MASOPROCOL,CHEMBL313972,BRD:BRD-A87130939-001-07-9;BRD:BRD-BRD-A87130939-001-07-9,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,ALOX5,ACTINIC KERATOSIS (AK),,LAUNCHED,,Small molecule,Approved,HCZKYJDFEPMADG-TXEJJXNPSA-N,C[C@H](CC1CCC(O)C(O)C1)[C@@H](C)CC1CCC(O)C(O)C1;CC(CC1CCC(O)C(O)C1)C(C)CC1CCC(O)C(O)C1
MATRINE,MATRINE,CHEMBL204860,BRD:BRD-BRD-K25312248-001-01-5;BRD:BRD-K25312248-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1,,,PHASE 2,,Small molecule,NA,ZSBXGIUJOOQZMP-JLNYLFASSA-N,O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34;O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34
MAVACAMTEN,MAVACAMTEN,CHEMBL4297517,BRD:BRD-K00003497-001-01-9,rep_single_dose,MYOSIN INHIBITOR,,,,,,Small molecule,Approved,RLCLASQCAPXVLM-NSHDSACASA-N,CC(C)N1C(=O)CC(N[C@@H](C)C2CCCCC2)[NH]C1=O
MAVATREP,MAVATREP,CHEMBL2364618,BRD:BRD-K00003237-001-01-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,,,,,,Small molecule,Phase 1,ORDHXXHTBUZRCN-NTEUORMPSA-N,CC(C)(O)C1CCCCC1-C1CCC2[NH]C(/C=C/C3CCC(C(F)(F)F)CC3)NC2C1
MAVOGLURANT,MAVOGLURANT,CHEMBL3087515,BRD:BRD-BRD-K07790550-001-01-6;BRD:BRD-K07790550-001-01-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PHASE 2,,Small molecule,Phase 2,ZFPZEYHRWGMJCV-ZHALLVOQSA-N,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#CC1CCCC(C)C1
MAXACALCITOL,MAXACALCITOL,CHEMBL333950,BRD:BRD-BRD-K81332461-001-01-4;BRD:BRD-K81332461-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,HYPERPARATHYROIDISM,,LAUNCHED,,Small molecule,Phase 3,DTXXSJZBSTYZKE-ZDQKKZTESA-N,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H];C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)OCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
MAYTANSINOL-ISOBUTYRATE,MAYTANSINOL-ISOBUTYRATE,,BRD:BRD-BRD-K15898725-001-01-7;BRD:BRD-K15898725-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CO[C@@H]1\C=C\C=C(C)\CC2CC(OC)C(CL)C(C2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2
MAZINDOL,MAZINDOL,CHEMBL781,BRD:BRD-A68464583-001-02-5;BRD:BRD-BRD-A68464583-001-02-5,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI)",SLC6A2;SLC6A3;SLC6A4,DUCHENNE MUSCULAR DYSTROPHY (DMD),,LAUNCHED,,Small molecule,Approved,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,OC1(C2CCC(CL)CC2)C2CCCCC2C2=NCCN21;OC1(N2CCN=C2C2CCCCC12)C1CCC(CL)CC1
MBX-2982,MBX-2982,CHEMBL3260505,BRD:BRD-BRD-K32218650-001-01-6;BRD:BRD-K32218650-001-01-6,rep_primary;rep_single_dose,GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR AGONIST,GPR119,,,PHASE 2,,Small molecule,Phase 2,NFTMKHWBOINJGM-UHFFFAOYSA-N,CCC1CNC(N2CCC(C3NC(COC4CCC(-N5CNNN5)CC4)CS3)CC2)NC1;CCC1CNC(NC1)N1CCC(CC1)C1NC(COC2CCC(CC2)-N2CNNN2)CS1
MC1568,MC1568,,BRD:BRD-K24031866-001-02-1,rep_single_dose,HDAC INHIBITOR,HDAC2,,,,,,NA,,
MCN-5652-(+/-),MCN-5652-(+/-),,BRD:BRD-K31168993-001-03-9,rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),,,,,,,NA,,
MCOPPB,MCOPPB,,BRD:BRD-BRD-K73276278-305-01-1;BRD:BRD-K73276278-305-01-1,rep_primary;rep_single_dose,"NOCICEPTIN/ORPHANIN FQ (NOP) RECEPTOR AGONIST, NOCICEPTIN/ORPHANIN FQ RECEPTOR AGONIST",OPRL1,,,PRECLINICAL,"Multiple values for MOA: {'NOCICEPTIN/ORPHANIN FQ (NOP) RECEPTOR AGONIST', 'NOCICEPTIN/ORPHANIN FQ (NOP) RECEPTOR AGONIST, NOCICEPTIN/ORPHANIN FQ RECEPTOR AGONIST'}, defaulting to 'NOCICEPTIN/ORPHANIN FQ (NOP) RECEPTOR AGONIST, NOCICEPTIN/ORPHANIN FQ RECEPTOR AGONIST'",,NA,,CC1(CCCCCCC1)N1CCC(CC1)N1C(NC2CCCCC12)[C@@H]1CCCNC1
MCPP,MCPP,CHEMBL478,BRD:BRD-BRD-K75844781-003-08-0;BRD:BRD-K75844781-003-08-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1D;HTR1E;HTR2A;HTR2B;HTR2C;HTR6,,,PHASE 2,,Small molecule,Phase 2,VHFVKMTVMIZMIK-UHFFFAOYSA-N,CLC1CCCC(C1)N1CCNCC1;CLC1CCCC(N2CCNCC2)C1
MD-920,MD-920,,BRD:BRD-BRD-K92758126-001-18-8;BRD:BRD-K92758126-001-18-8,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,AADACL2,,,PHASE 1,,,NA,,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O
MDIVI-1,MDIVI-1,,BRD:BRD-BRD-K61128465-001-09-9;BRD:BRD-K61128465-001-09-9;CTRP:215497,ctrp;rep_primary;rep_single_dose,DYNAMIN INHIBITOR,DNM1,,,PRECLINICAL,,,NA,,COC1CC(C(CL)CC1CL)-N1C(=S)[NH]C2CCCCC2C1=O
MDL-11939,MDL-11939,CHEMBL18972,BRD:BRD-A62057054-001-03-1;BRD:BRD-BRD-A62057054-001-03-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,PHASE 2,,Small molecule,Unknown,AXNGJCOYCMDPQG-UHFFFAOYSA-N,OC(C1CCCCC1)C1CCN(CCC2CCCCC2)CC1;OC(C1CCN(CCC2CCCCC2)CC1)C1CCCCC1
MDL-27531,MDL-27531,,BRD:BRD-K50888640-001-01-6,rep_single_dose,GLYCINE RECEPTOR AGONIST,,,,,,,NA,,
MDL-29951,MDL-29951,,BRD:BRD-BRD-K59753853-001-02-3;BRD:BRD-K59753853-001-02-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,FBP1,,,PRECLINICAL,,,NA,,OC(=O)CCC1C([NH]C2CC(CL)CC(CL)C12)C(O)=O
MDL-72832,MDL-72832,,BRD:BRD-A17453586-003-02-3;BRD:BRD-BRD-A17453586-003-02-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PRECLINICAL,,,NA,,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COC2CCCCC2O1
MDL-73005EF,MDL-73005EF,CHEMBL2218891,BRD:BRD-A50764878-003-02-8;BRD:BRD-BRD-A50764878-003-02-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A,,,PHASE 1,,Small molecule,Unknown,JXBLEDCYKVWLJI-UHFFFAOYSA-N,CS(=O)(=O)O.O=C1CC2(CCCC2)CC(=O)N1CCNCC1COC2CCCCC2O1;O=C1CC2(CCCC2)CC(=O)N1CCNCC1COC2CCCCC2O1
MDR-652,MDR-652,,BRD:BRD-K00091267-001-01-9,rep_single_dose,,,,,,,,NA,,
ME0328,ME-0328;ME0328,,BRD:BRD-A63444178-001-01-5;BRD:BRD-BRD-A63444178-001-01-5;BRD:BRD-BRD-K24283677-001-01-9;BRD:BRD-K24283677-001-01-9,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PARP3,,,PRECLINICAL,"Multiple values for MOA: {'PPAR RECEPTOR ANTAGONIST', 'PARP INHIBITOR'}, defaulting to 'PPAR RECEPTOR ANTAGONIST'
Multiple values for SMILES: {'C[C@H](NC(=O)CCC1NC2CCCCC2C(=O)[NH]1)C1CCCCC1', 'CC(NC(=O)CCC1NC(=O)C2CCCCC2[NH]1)C1CCCCC1'}, defaulting to 'C[C@H](NC(=O)CCC1NC2CCCCC2C(=O)[NH]1)C1CCCCC1'
Multiple values for structure_id: {'K24283677', 'A63444178'}, defaulting to None",,NA,,C[C@H](NC(=O)CCC1NC2CCCCC2C(=O)[NH]1)C1CCCCC1
MEBENDAZOLE,MEBENDAZOLE,CHEMBL685,BRD:BRD-BRD-K77987382-001-13-2;BRD:BRD-K77987382-001-13-2,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBA1A;TUBB;TUBB4B,"PINWORM, WHIPWORM, HOOKWORM, ASCARIASIS",,LAUNCHED,,Small molecule,Approved,OPXLLQIJSORQAM-UHFFFAOYSA-N,COC(=O)NC1NC2CC(C(=O)C3CCCCC3)CCC2[NH]1;COC(=O)NC1NC2CCC(CC2[NH]1)C(=O)C1CCCCC1
MEBEVERINE,MEBEVERINE,CHEMBL282121,BRD:BRD-A09467419-003-22-4;BRD:BRD-BRD-A09467419-003-22-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Approved,VYVKHNNGDFVQGA-UHFFFAOYSA-N,CCN(CCCCOC(=O)C1CCC(OC)C(OC)C1)C(C)CC1CCC(OC)CC1
MEBHYDROLIN,MEBHYDROLIN,CHEMBL1625607,BRD:BRD-BRD-K29713308-001-01-7,rep_primary,ANTIHISTAMINE,,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,FQQIIPAOSKSOJM-UHFFFAOYSA-N,CN1CCC2C(C1)C1CCCCC1N2CC1CCCCC1;CN1CCC2C(C3CCCCC3N2CC2CCCCC2)C1
"MEBHYDROLINE-1,5-NAPHTALENEDISULFONATE","MEBHYDROLINE-1,5-NAPHTALENEDISULFONATE",,BRD:BRD-BRD-K29713308-077-04-1,rep_primary,,,,,PRECLINICAL,,,NA,,CN1CCC2C(C1)C1CCCCC1N2CC1CCCCC1
MEBICAR,MEBICAR,CHEMBL3707390,BRD:BRD-BRD-K76606751-001-01-7;BRD:BRD-K76606751-001-01-7,rep_primary;rep_single_dose,ANXIOLYTIC,,ANXIETY,,LAUNCHED,,Small molecule,Unknown,XIUUSFJTJXFNGH-UHFFFAOYSA-N,CN1C(=O)N(C)C2C1N(C)C(=O)N2C;CN1C2C(N(C)C1=O)N(C)C(=O)N2C
MEBROFENIN,MEBROFENIN,CHEMBL1605443,BRD:BRD-BRD-K96691275-001-01-2;BRD:BRD-K96691275-001-01-2,rep_primary;rep_single_dose,,,DIAGNOSTIC AGENT,,LAUNCHED,,Small molecule,Unknown,MHPZZZZLAQGTHT-UHFFFAOYSA-N,CC1CC(C)C(NC(=O)CN(CC(=O)O)CC(=O)O)C(C)C1BR;CC1CC(C)C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)C1BR
MECAMYLAMINE,MECAMYLAMINE,CHEMBL1398031;CHEMBL267936,BRD:BRD-A20119038-003-07-8;BRD:BRD-BRD-A20119038-003-07-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA1;CHRNA2;CHRNA3;CHRNA4;CHRNA6;CHRNA7;CHRNB4,HYPERTENSION,,LAUNCHED,"Multiple values for repurposing_target: {'CHRNA1;CHRNA2;CHRNA3;CHRNA4;CHRNA6;CHRNA7;CHRNB4', 'CHRNA1;CHRNA2;CHRNA3;CHRNA4;CHRNA6;CHRNA7'}, taking the union",Small molecule,Approved,IMYZQPCYWPFTAG-IQJOONFLSA-N;IMYZQPCYWPFTAG-UHFFFAOYSA-N,CN[C@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C;CNC1(C)C2CCC(C2)C1(C)C
MECARBINATE,MECARBINATE,CHEMBL1881106,BRD:BRD-BRD-K28405228-001-06-7;BRD:BRD-K28405228-001-06-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,YTBNTDMBGXAOCG-UHFFFAOYSA-N,CCOC(=O)C1C(C)N(C)C2CCC(O)CC12
MECHLORETHAMINE,MECHLORETHAMINE,CHEMBL427,BRD:BRD-BRD-K12829205-003-02-8;BRD:BRD-K12829205-003-02-8,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,"HODGKIN'S LYMPHOMA, CHRONIC MYELOID LEUKEMIA (CML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), POLYCYTHEMIA VERA, MYCOSIS, BRONCHOGENIC CARCINOMA",,LAUNCHED,,Small molecule,Approved,HAWPXGHAZFHHAD-UHFFFAOYSA-N,CN(CCCL)CCCL
MECLINERTANT,MECLINERTANT,CHEMBL506981,BRD:BRD-BRD-K25075681-001-02-0;BRD:BRD-K25075681-001-02-0,rep_primary;rep_single_dose,NEUROTENSIN RECEPTOR ANTAGONIST,NTSR1;NTSR2,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,DYLJVOXRWLXDIG-UHFFFAOYSA-N,COC1CCCC(OC)C1-C1CC(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)NN1-C1CCNC2CC(CL)CCC12;COC1CCCC(OC)C1-C1CC(NN1-C1CCNC2CC(CL)CCC12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O
MECLIZINE,MECLIZINE,CHEMBL1623,BRD:BRD-A50311610-300-10-4;BRD:BRD-BRD-A50311610-300-10-4,rep_multi_dose;rep_primary;rep_single_dose,CONSTITUTIVE ANDROSTANE RECEPTOR (CAR) AGONIST,HRH1;NR1I3,"NAUSEA, VOMITING, MOTION SICKNESS",,LAUNCHED,,Small molecule,Approved,OCJYIGYOJCODJL-UHFFFAOYSA-N,CC1CCCC(CN2CCN(C(C3CCCCC3)C3CCC(CL)CC3)CC2)C1;CC1CCCC(CN2CCN(CC2)C(C2CCCCC2)C2CCC(CL)CC2)C1
MECLOCYCLINE-SULFOSALICYLATE,MECLOCYCLINE-SULFOSALICYLATE,,BRD:BRD-A07600638-060-05-2;BRD:BRD-BRD-A07600638-060-05-2,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,"ACNE VULGARIS (AV), SKIN INFECTIONS",,LAUNCHED,,,NA,,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)C4C(O)CCC(CL)C4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O
MECLOFENAMIC-ACID,MECLOFENAMIC-ACID,,BRD:BRD-BRD-K50398167-236-22-7;BRD:BRD-K50398167-236-22-7,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTANOID RECEPTOR ANTAGONIST",ALOX5;CNR1;KCNQ2;KCNQ3;PTGS1;PTGS2,"JOINT PAIN, MUSCLE PAIN, RHEUMATOID ARTHRITIS, PRIMARY DYSMENORRHEA (PD)",,LAUNCHED,,,NA,,CC1CCC(CL)C(NC2CCCCC2C(O)=O)C1CL
MECLOFENOXATE,MECLOFENOXATE,CHEMBL64545,BRD:BRD-BRD-K10314788-003-12-7;BRD:BRD-K10314788-003-12-7,rep_primary;rep_single_dose,NOOTROPIC AGENT,,"SENILE DEMENTIA, ALZHEIMER'S DISEASE",,LAUNCHED,,Small molecule,Unknown,XZTYGFHCIAKPGJ-UHFFFAOYSA-N,CN(C)CCOC(=O)COC1CCC(CL)CC1
MECYSTEINE,MECYSTEINE,CHEMBL1622757,BRD:BRD-K81993098-003-15-0,rep_single_dose,ANALGESIC AGENT,,,,,,Small molecule,Unknown,MCYHPZGUONZRGO-UHFFFAOYSA-N,COC(=O)C(N)CS
MEDETOMIDINE,MEDETOMIDINE,CHEMBL778;CHEMBL77921,BRD:BRD-A21607826-003-05-1;BRD:BRD-BRD-A21607826-003-05-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,SEDATIVE,,LAUNCHED,,Small molecule,Approved,CUHVIMMYOGQXCV-NSHDSACASA-N;CUHVIMMYOGQXCV-UHFFFAOYSA-N,CC(C1C[NH]CN1)C1CCCC(C)C1C;CC1CCCC([C@H](C)C2C[NH]CN2)C1C;CC1CCCC(C(C)C2C[NH]CN2)C1C
MEDICA-16,MEDICA-16,,BRD:BRD-BRD-K92908289-001-01-8;BRD:BRD-K92908289-001-01-8,rep_primary;rep_single_dose,ATP CITRASE LYASE INHIBITOR,FFAR1,,,PHASE 2,,,NA,,CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O
MEDORINONE,MEDORINONE,CHEMBL144399,BRD:BRD-BRD-K40715924-001-01-1;BRD:BRD-K40715924-001-01-1,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Unknown,OCCZJXAHSUCJSA-UHFFFAOYSA-N,CC1NCCC2[NH]C(=O)CCC12
MEDRONIC-ACID,MEDRONIC-ACID,,BRD:BRD-BRD-K94072573-001-09-9;BRD:BRD-K94072573-001-09-9,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,,SKELETAL IMAGING AGENT,,LAUNCHED,,,NA,,OP(O)(=O)CP(O)(O)=O
MEDROXYPROGESTERONE,MEDROXYPROGESTERONE,CHEMBL717,BRD:BRD-BRD-K99615199-001-18-5;BRD:BRD-K99615199-001-18-5,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,ESR1;PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,PSGAAPLEWMOORI-PEINSRQWSA-N,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12;CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
MEDROXYPROGESTERONE-ACETATE,MEDROXYPROGESTERONE-ACETATE,,BRD:BRD-A61221616-001-04-3;BRD:BRD-BRD-A61221616-001-04-3,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,,CONTRACEPTIVE,,LAUNCHED,,,NA,,C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12
MEDRYSONE,MEDRYSONE,CHEMBL1201173,BRD:BRD-BRD-K56515112-001-21-6;BRD:BRD-K56515112-001-21-6,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"CONJUNCTIVITIS, EPISCLERITIS",,LAUNCHED,,Small molecule,Approved,GZENKSODFLBBHQ-ILSZZQPISA-N,C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12;C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12;CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
MEFENAMIC-ACID,MEFENAMIC-ACID,,BRD:BRD-BRD-K92778217-001-32-7;BRD:BRD-K92778217-001-32-7,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,KCNQ1;PTGS1;PTGS2;TRPM3,PRIMARY DYSMENORRHEA (PD),,LAUNCHED,,,NA,,CC1CCCC(NC2CCCCC2C(O)=O)C1C
MEFEXAMIDE,MEFEXAMIDE,CHEMBL1368380,BRD:BRD-BRD-K20655524-003-12-0;BRD:BRD-K20655524-003-12-0,rep_multi_dose;rep_primary;rep_single_dose,PSYCHOACTIVE DRUG,,,,PRECLINICAL,,Small molecule,Unknown,HUNIPYLVUPMFCZ-UHFFFAOYSA-N,CCN(CC)CCNC(=O)COC1CCC(OC)CC1
MEFLOQUINE,MEFLOQUINE,CHEMBL416956,BRD:BRD-A89585551-003-16-6;BRD:BRD-BRD-A89585551-003-16-6,rep_primary;rep_single_dose,"ADENOSINE RECEPTOR ANTAGONIST, HEMOGLOBIN ANTAGONIST",ADORA2A;HBA1,MALARIA,,LAUNCHED,,Small molecule,Approved,XEEQGYMUWCZPDN-UHFFFAOYSA-N,OC(C1CC(C(F)(F)F)NC2C(C(F)(F)F)CCCC12)C1CCCCN1;OC(C1CCCCN1)C1CC(NC2C(CCCC12)C(F)(F)F)C(F)(F)F
MEGESTROL,MEGESTROL,CHEMBL1201139,BRD:BRD-K00004691-001-01-9,rep_single_dose,PROGESTERONE RECEPTOR AGONIST,,,,,,Small molecule,Approved,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
MEGESTROL-ACETATE,MEGESTROL-ACETATE,,BRD:BRD-A35989968-001-04-2;BRD:BRD-BRD-A35989968-001-04-2;BRD:BRD-BRD-K19507340-001-22-1;BRD:BRD-K19507340-001-22-1,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,NR3C1;PGR,"ANOREXIA, CACHEXIA",,LAUNCHED,"Multiple values for structure_id: {'A35989968', 'K19507340'}, defaulting to None",,NA,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O;CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O
MEGLITINIDE,MEGLITINIDE,CHEMBL149930,BRD:BRD-BRD-K51324732-001-01-0;BRD:BRD-K51324732-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,CCR2,,,PHASE 2,,Small molecule,Unknown,SWLAMJPTOQZTAE-UHFFFAOYSA-N,COC1CCC(CL)CC1C(=O)NCCC1CCC(C(=O)O)CC1;COC1CCC(CL)CC1C(=O)NCCC1CCC(CC1)C(O)=O
MEGLUMINE,MEGLUMINE,CHEMBL1200570,BRD:BRD-BRD-K28595280-001-04-5;BRD:BRD-K28595280-001-04-5,rep_primary;rep_single_dose,EXCIPIENT,,,,LAUNCHED,,Small molecule,Approved,MBBZMMPHUWSWHV-BDVNFPICSA-N,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
MEGLUTOL,MEGLUTOL,CHEMBL50444,BRD:BRD-K00495673-001-05-2,rep_single_dose,HMGCR INHIBITOR,HMGCR,,,,,Small molecule,Unknown,NPOAOTPXWNWTSH-UHFFFAOYSA-N,CC(O)(CC(=O)O)CC(=O)O
MEISOINDIGO,MEISOINDIGO,CHEMBL607535,BRD:BRD-BRD-K14529030-001-01-9;BRD:BRD-K14529030-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,STAT INHIBITOR,STAT3,,,PHASE 3,,Small molecule,NA,QNOCRUSVMMAKSC-CCEZHUSRSA-N,CN1C(=O)/C(=C2/C(=O)NC3CCCCC32)C2CCCCC21;CN1C(=O)\C(C2CCCCC12)=C1\C(=O)NC2CCCCC12
MEK1-2-INHIBITOR,MEK1-2-INHIBITOR,,BRD:BRD-BRD-K12244279-001-05-8;BRD:BRD-K12244279-001-05-8,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K2,,,PRECLINICAL,,,NA,,N\C(SC1CCC(N)CC1)=C(\C#N)C1CCCCC1C(F)(F)F
MEKINIST,MEKINIST,CHEMBL2103875;CHEMBL2105741,GDSC1:1372;GDSC2:1372,gdsc,,,,,,,Small molecule,Approved,LIRYPHYGHXZJBZ-UHFFFAOYSA-N;OQUFJVRYDFIQBW-UHFFFAOYSA-N,CC(=O)NC1CCCC(-N2C(=O)N(C3CC3)C(=O)C3C(NC4CCC(I)CC4F)N(C)C(=O)C(C)C32)C1;CC(=O)NC1CCCC(-N2C(=O)N(C3CC3)C(=O)C3C(NC4CCC(I)CC4F)N(C)C(=O)C(C)C32)C1.C[S+](C)[O-]
MELANOTAN-II,MELANOTAN-II,,BRD:BRD-K75989555-001-02-9,rep_single_dose,MELANOCORTIN RECEPTOR AGONIST,,,,,,,NA,,
MELATONIN,MELATONIN,CHEMBL45,BRD:BRD-BRD-K97530723-001-20-9;BRD:BRD-K97530723-001-20-9,rep_primary;rep_single_dose,"MELATONIN RECEPTOR AGONIST, NITRIC OXIDE SYNTHASE INHIBITOR",ASMT;CALM1;CALR;EPX;ESR1;HTR2B;MPO;MTNR1A;MTNR1B;NQO2;RORB,SLEEP CYCLE SUPPORT,,LAUNCHED,,Small molecule,Approved,DRLFMBDRBRZALE-UHFFFAOYSA-N,COC1CCC2[NH]CC(CCNC(C)=O)C2C1
MELENGESTROL-ACETATE,MELENGESTROL-ACETATE,,BRD:BRD-A42746051-001-02-9;BRD:BRD-BRD-A42746051-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C
MELEVODOPA,MELEVODOPA,CHEMBL1328898,BRD:BRD-BRD-K18749874-003-08-9;BRD:BRD-K18749874-003-08-9,rep_primary;rep_single_dose,"DOPAMINE PRECURSOR, DOPAMINE RECEPTOR AGONIST",DDC,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Phase 1,XBBDACCLCFWBSI-ZETCQYMHSA-N,COC(=O)[C@@H](N)CC1CCC(O)C(O)C1;COC(=O)C(N)CC1CCC(O)C(O)C1
MELFLUFEN (HYDROCHLORIDE),MELFLUFEN (HYDROCHLORIDE),,BRD:BRD-K00075584-003-02-9,rep_single_dose,,,,,,,,NA,,
MELOXICAM,MELOXICAM,CHEMBL599,BRD:BRD-A84174393-236-07-1;BRD:BRD-BRD-A84174393-236-07-1,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,CC1CNC(NC(=O)C2=C(O)C3CCCCC3S(=O)(=O)N2C)S1;CN1C(C(=O)NC2NCC(C)S2)C(=O)C2CCCCC2S1(=O)=O
MELPERONE,MELPERONE,CHEMBL1531134,BRD:BRD-BRD-K92984783-003-05-7;BRD:BRD-K92984783-003-05-7,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",DRD2;HTR2A,PSYCHOSIS,,LAUNCHED,,Small molecule,Phase 3,DKMFBWQBDIGMHM-UHFFFAOYSA-N,CC1CCN(CCCC(=O)C2CCC(F)CC2)CC1
MELPHALAN,MELPHALAN,CHEMBL250892;CHEMBL852,BRD:BRD-BRD-K87827419-001-16-8;BRD:BRD-K87827419-001-16-8,rep_multi_dose;rep_primary;rep_single_dose,"DNA ALKYLATING AGENT, DNA INHIBITOR",,MULTIPLE MYELOMA,,LAUNCHED,,Small molecule,Approved,SGDBTWWWUNNDEQ-GFCCVEGCSA-N;SGDBTWWWUNNDEQ-LBPRGKRZSA-N,N[C@@H](CC1CCC(CC1)N(CCCL)CCCL)C(O)=O;N[C@@H](CC1CCC(N(CCCL)CCCL)CC1)C(=O)O;N[C@H](CC1CCC(N(CCCL)CCCL)CC1)C(=O)O
MELUADRINE,MELUADRINE,CHEMBL2104709,BRD:BRD-A07164067-001-01-2;BRD:BRD-BRD-A07164067-001-01-2,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,LIXBJWRFCNRAPA-NSHDSACASA-N,CC(C)(C)NC[C@H](O)C1CCC(O)CC1CL;CC(C)(C)NCC(O)C1CCC(O)CC1CL
MEMANTINE,MEMANTINE,CHEMBL1699;CHEMBL807,BRD:BRD-A79803969-003-16-1;BRD:BRD-BRD-A79803969-003-16-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,CHRFAM7A;DRD2;GRIN1;GRIN2A;GRIN2B;GRIN3A;HTR3A,"ALZHEIMER'S DISEASE, SENILE DEMENTIA",,LAUNCHED,,Small molecule,Approved,BUGYDGFZZOZRHP-UHFFFAOYSA-N;LDDHMLJTFXJGPI-UHFFFAOYSA-N,CC12CC3CC(C)(C1)CC(N)(C3)C2;CC12CC3CC(C)(C1)CC(N)(C3)C2.CL
MENADIONE,MENADIONE,CHEMBL590,BRD:BRD-BRD-K78126613-001-28-5;BRD:BRD-K78126613-001-28-5,rep_multi_dose;rep_primary;rep_single_dose,"MITOCHONDRIAL DNA POLYMERASE INHIBITOR, PHOSPHATASE INHIBITOR",AOX1;BGLAP;F10;F2;F7;F9;GGCX;NQO1;NQO2;PROC;PROS1;PROZ;VKORC1;VKORC1L1,"ULCERATIVE COLITIS, DIARRHEA, HEADACHE, VARICOSE VEINS, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,MJVAVZPDRWSRRC-UHFFFAOYSA-N,CC1=CC(=O)C2CCCCC2C1=O
MENADIONE-BISULFITE,MENADIONE-BISULFITE,,BRD:BRD-A19777893-236-01-9;BRD:BRD-BRD-A19777893-236-01-9,rep_primary;rep_single_dose,VITAMIN K,GGCX;VKORC1;VKORC1L1,,,PHASE 2,,,NA,,CC1(CC(=O)C2CCCCC2C1=O)S(O)(=O)=O
MENBUTONE,MENBUTONE,CHEMBL1972268,BRD:BRD-BRD-K53852914-001-01-8;BRD:BRD-K53852914-001-01-8,rep_primary;rep_single_dose,,,BILE STIMULATION,,LAUNCHED,,Small molecule,Unknown,FHGJSJFIQNQBCK-UHFFFAOYSA-N,COC1CCC(C(=O)CCC(=O)O)C2CCCCC12;COC1CCC(C(=O)CCC(O)=O)C2CCCCC12
MEPACRINE,MEPACRINE,CHEMBL7568,BRD:BRD-A45889380-300-07-1;BRD:BRD-BRD-A45889380-300-07-1,rep_primary;rep_single_dose,"CYTOKINE PRODUCTION INHIBITOR, NFKB PATHWAY INHIBITOR, TP53 ACTIVATOR",PLA2G1B;PLA2G4A;PLA2G6;PLCL1,GIARDIASIS,,LAUNCHED,,Small molecule,Phase 2,GPKJTRJOBQGKQK-UHFFFAOYSA-N,CCN(CC)CCCC(C)NC1C2CCC(CL)CC2NC2CCC(OC)CC12
MEPARFYLON,MEPARFYLON,,BRD:BRD-A11662333-001-03-3;BRD:BRD-BRD-A11662333-001-03-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCC(C)(O)C#C
MEPAZINE,MEPAZINE,CHEMBL395110,BRD:BRD-A82772293-001-03-2;BRD:BRD-BRD-A82772293-001-03-2,rep_primary;rep_single_dose,MALT1 INHIBITOR (JH),MALT1,,,PHASE 2,,Small molecule,Approved,CBHCDHNUZWWAPP-UHFFFAOYSA-N,CN1CCCC(CN2C3CCCCC3SC3CCCCC23)C1;CN1CCCC(CN2C3CCCCC3SC3CCCCC32)C1
MEPENZOLATE,MEPENZOLATE,CHEMBL1724;CHEMBL524004,BRD:BRD-A62421304-004-18-9;BRD:BRD-BRD-A62421304-004-18-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM3,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,GKNPSSNBBWDAGH-UHFFFAOYSA-N;JRRNZNSGDSFFIR-UHFFFAOYSA-M,C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1CCCCC1)C1CCCCC1;C[N+]1(C)CCCC(OC(=O)C(O)(C2CCCCC2)C2CCCCC2)C1;C[N+]1(C)CCCC(OC(=O)C(O)(C2CCCCC2)C2CCCCC2)C1.[BR-]
MEPHENESIN,MEPHENESIN,CHEMBL229128,BRD:BRD-A55469827-001-07-4;BRD:BRD-BRD-A55469827-001-07-4,rep_primary;rep_single_dose,MUSCLE RELAXANT,,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,JWDYCNIAQWPBHD-UHFFFAOYSA-N,CC1CCCCC1OCC(O)CO
MEPHENTERMINE,MEPHENTERMINE,CHEMBL1201234,BRD:BRD-BRD-K18194590-065-08-0;BRD:BRD-K18194590-065-08-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3,HYPOTENSION,,LAUNCHED,,Small molecule,Approved,RXQCGGRTAILOIN-UHFFFAOYSA-N,CNC(C)(C)CC1CCCCC1
MEPHENYTOIN,MEPHENYTOIN,CHEMBL861,BRD:BRD-A83937277-001-10-5;BRD:BRD-BRD-A83937277-001-10-5,rep_multi_dose;rep_primary;rep_single_dose,HYDANTOIN ANTIEPILEPTIC,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,GMHKMTDVRCWUDX-UHFFFAOYSA-N,CCC1(C2CCCCC2)NC(=O)N(C)C1=O;CCC1(NC(=O)N(C)C1=O)C1CCCCC1
MEPIROXOL,MEPIROXOL,CHEMBL1985503,BRD:BRD-BRD-K78299798-001-02-2;BRD:BRD-K78299798-001-02-2,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,LQYJAVWWKTWWKN-UHFFFAOYSA-N,[O-][N+]1CCCC(CO)C1;OCC1CCC[N+]([O-])C1
MEPIVACAINE,MEPIVACAINE,CHEMBL1087;CHEMBL2104634,BRD:BRD-A03216249-003-24-3;BRD:BRD-BRD-A03216249-003-24-3,rep_multi_dose;rep_primary;rep_single_dose,"POTASSIUM CHANNEL BLOCKER, SODIUM CHANNEL BLOCKER",SCN10A,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,INWLQCZOYSRPNW-UHFFFAOYSA-N;INWLQCZOYSRPNW-ZDUSSCGKSA-N,CC1CCCC(C)C1NC(=O)[C@@H]1CCCCN1C;CC1CCCC(C)C1NC(=O)C1CCCCN1C;CN1CCCCC1C(=O)NC1C(C)CCCC1C
MEPROBAMATE,MEPROBAMATE,CHEMBL979,BRD:BRD-BRD-K19180152-001-02-6;BRD:BRD-K19180152-001-02-6,rep_primary;rep_single_dose,,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ,ANXIETY,,LAUNCHED,,Small molecule,Approved,NPPQSCRMBWNHMW-UHFFFAOYSA-N,CCCC(C)(COC(N)=O)COC(N)=O
MEPRYLCAINE,MEPRYLCAINE,CHEMBL127810,BRD:BRD-BRD-K65417056-003-10-1;BRD:BRD-K65417056-003-10-1,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,Small molecule,Unknown,VXJABHHJLXLNMP-UHFFFAOYSA-N,CCCNC(C)(C)COC(=O)C1CCCCC1
MEPTAZINOL,MEPTAZINOL,CHEMBL314437,BRD:BRD-A02710418-003-11-8;BRD:BRD-BRD-A02710418-003-11-8,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,BCHE,PAIN RELIEF,,LAUNCHED,,Small molecule,Approved,JLICHNCFTLFZJN-UHFFFAOYSA-N,CCC1(C2CCCC(O)C2)CCCCN(C)C1;CCC1(CCCCN(C)C1)C1CCCC(O)C1
MEPYRAMINE,MEPYRAMINE,CHEMBL511,BRD:BRD-BRD-K97564742-050-32-7;BRD:BRD-K97564742-050-32-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"COMMON COLD, MENSTRUAL PAIN",,LAUNCHED,,Small molecule,Approved,YECBIJXISLIIDS-UHFFFAOYSA-N,COC1CCC(CC1)CN(CCN(C)C)C1CCCCN1;COC1CCC(CN(CCN(C)C)C2CCCCN2)CC1
MEQUINOL,MEQUINOL,CHEMBL544,BRD:BRD-BRD-K45216060-001-10-0;BRD:BRD-BRD-K45216060-001-11-8;BRD:BRD-K45216060-001-10-0;BRD:BRD-K45216060-001-11-8,rep_primary;rep_single_dose,,TYR,SKIN DEPIGMENTATION,,LAUNCHED,,Small molecule,Approved,NWVVVBRKAWDGAB-UHFFFAOYSA-N,COC1CCC(O)CC1
MERACTINOMYCIN,MERACTINOMYCIN,CHEMBL1554,GDSC2:1911,gdsc,,,,,,,Protein,Approved,RJURFGZVJUQBHK-IIXSONLDSA-N,CC1C2OC3C(C)CCC(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)C3NC-2C(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)C(N)C1=O
MERBARONE,MERBARONE,CHEMBL1765797,BRD:BRD-BRD-K45152786-001-08-4;BRD:BRD-K45152786-001-08-4;BRD:BRD-K45152786-001-09-9,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,,,PHASE 2,,Small molecule,NA,JARCFMKMOFFIGZ-UHFFFAOYSA-N,O=C(NC1CCCCC1)C1C(=O)NC(=S)NC1=O;O=C1NC(=S)NC(=O)C1C(=O)NC1CCCCC1
MERBROMIN,MERBROMIN,CHEMBL2097077;CHEMBL3833381,BRD:BRD-BRD-K21771665-304-04-2;BRD:BRD-K21771665-304-04-2,rep_primary;rep_single_dose,ANTISEPTIC,,FIRST-AID ANTISEPTIC,,LAUNCHED,,Small molecule,Approved,,O[HG]C1C(O)C(BR)CC2C(-C3CCCCC3C(O)=O)C3CC(BR)C(=O)CC3OC12
MERCAPTOPURINE,MERCAPTOPURINE,CHEMBL1200751;CHEMBL1425,BRD:BRD-BRD-K91601245-001-12-0;BRD:BRD-K91601245-001-12-0,rep_multi_dose;rep_primary;rep_single_dose,"IMMUNOSUPPRESSANT, PROTEIN SYNTHESIS INHIBITOR, PURINE ANTAGONIST",HPRT1;IMPDH1;IMPDH2;PPAT,ACUTE LYMPHOBLASTIC LEUKEMIA (ALL),,LAUNCHED,,Small molecule,Approved,GLVAUDGFNGKCSF-UHFFFAOYSA-N;WFFQYWAAEWLHJC-UHFFFAOYSA-N,O.S=C1[NH]CNC2NC[NH]C12;S=C1[NH]CNC2NC[NH]C12;SC1NCNC2NC[NH]C12
MERCAPTOSUCCINIC-ACID,MERCAPTOSUCCINIC-ACID,,BRD:BRD-A43435802-001-02-0;BRD:BRD-BRD-A43435802-001-02-0,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,OC(=O)CC(S)C(O)=O
MERCK60,MERCK60,,BRD:BRD-K04466929-001-12-9;CTRP:61674,ctrp;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2,,,,,,NA,,
MERELETINIB,MERELETINIB,CHEMBL3353410,GDSC2:1919,gdsc,,,,,,,Small molecule,Approved,DUYJMQONPNNFPI-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCCC(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C
MERICITABINE,MERICITABINE,CHEMBL562967,BRD:BRD-BRD-K69726595-001-01-2;BRD:BRD-K69726595-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,MLESJYFEMSJZLZ-MAAOGQSESA-N,CC(C)C(=O)OC[C@H]1O[C@@H](N2CCC(N)NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C
MERIMEPODIB,MERIMEPODIB,CHEMBL304087,BRD:BRD-BRD-K09372874-001-01-0;BRD:BRD-K09372874-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR,IMPDH1,,,PHASE 2,,Small molecule,Phase 2,JBPUGFODGPKTDW-SFHVURJKSA-N,COC1CC(NC(=O)NC2CCCC(CNC(=O)O[C@H]3CCOC3)C2)CCC1-C1CNCO1
MERTANSINE,MERTANSINE,CHEMBL4802230,BRD:BRD-K00003293-001-01-9,rep_single_dose,MICROTUBULE INHIBITOR,,,,,,Small molecule,Unknown,ANZJBCHSOXCCRQ-FKUXLPTCSA-N,COC1CC2CC(C1CL)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@H](C)[C@@H]1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2
MESALAZINE,MESALAZINE,CHEMBL704,BRD:BRD-BRD-K28849549-001-13-4;BRD:BRD-K28849549-001-13-4,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, LIPOXYGENASE INHIBITOR, PROSTANOID RECEPTOR ANTAGONIST",ALOX5;CHUK;IKBKB;MPO;PPARG;PTGS1;PTGS2,"ULCERATIVE COLITIS, INFLAMMATORY BOWEL DISEASE",,LAUNCHED,,Small molecule,Approved,KBOPZPXVLCULAV-UHFFFAOYSA-N,NC1CCC(O)C(C(=O)O)C1;NC1CCC(O)C(C1)C(O)=O
MESNA,MESNA,CHEMBL1098319;CHEMBL975,BRD:BRD-BRD-K49954789-001-02-9;BRD:BRD-K49954789-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,ANTIOXIDANT,,HEMORRHAGIC CYSTITIS,,LAUNCHED,,Small molecule,Approved,XOGTZOOQQBDUSI-UHFFFAOYSA-M;ZNEWHQLOPFWXOF-UHFFFAOYSA-N,O=S(=O)([O-])CCS.[NA+];O=S(=O)(O)CCS;OS(=O)(=O)CCS
MESORIDAZINE,MESORIDAZINE,CHEMBL1088,BRD:BRD-A14395271-074-17-8;BRD:BRD-BRD-A14395271-074-17-8,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,SLVMESMUVMCQIY-UHFFFAOYSA-N,CN1CCCCC1CCN1C2CCCCC2SC2CCC([S+](C)[O-])CC21;CN1CCCCC1CCN1C2CCCCC2SC2CCC(CC12)S(C)=O
MESTINON,MESTINON,CHEMBL1115;CHEMBL812,BRD:BRD-BRD-K69688083-004-23-1;BRD:BRD-K69688083-004-23-1,rep_primary;rep_single_dose,CHOLINESTERASE INHIBITOR,ACHE;BCHE,MYASTHENIA GRAVIS,,LAUNCHED,,Small molecule,Approved,RVOLLAQWKVFTGE-UHFFFAOYSA-N;VNYBTNPBYXSMOO-UHFFFAOYSA-M,CN(C)C(=O)OC1CCC[N+](C)C1;CN(C)C(=O)OC1CCC[N+](C)C1.[BR-]
MESTRANOL,MESTRANOL,CHEMBL1201151,BRD:BRD-BRD-K31920458-001-23-6;BRD:BRD-K31920458-001-23-6,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,IMSSROKUHAOUJS-MJCUULBUSA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4CC(OC)CCC4[C@H]3CC[C@@]21C;COC1CCC2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCC2C1
MESULERGINE,MESULERGINE,CHEMBL12314,BRD:BRD-BRD-K91336023-003-01-0;BRD:BRD-K91336023-003-01-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,HTR2A;HTR2B;HTR2C;HTR3A;HTR3B;HTR6;HTR7,,,PHASE 2,,Small molecule,Unknown,JLVHTNZNKOSCNB-YSVLISHTSA-N,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](CC3CN(C)C4CCCC2C34)N(C)C1;CN1C[C@@H](NS(=O)(=O)N(C)C)C[C@@H]2C3CCCC4C3C(CN4C)C[C@H]21
METACETAMOL,METACETAMOL,CHEMBL9419,BRD:BRD-BRD-K16474819-001-09-6;BRD:BRD-K16474819-001-09-6,rep_primary;rep_single_dose,ANALGESIC AGENT,,,,PRECLINICAL,,Small molecule,Unknown,QLNWXBAGRTUKKI-UHFFFAOYSA-N,CC(=O)NC1CCCC(O)C1
METACRESOL,METACRESOL,CHEMBL298312,BRD:BRD-BRD-K22518984-001-01-8;BRD:BRD-K22518984-001-01-8,rep_primary;rep_single_dose,,INS,,,LAUNCHED,,Small molecule,Unknown,RLSSMJSEOOYNOY-UHFFFAOYSA-N,CC1CCCC(O)C1
METAMIZOLE,METAMIZOLE,,BRD:BRD-BRD-K76812510-236-14-8;BRD:BRD-K76812510-236-14-8,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, OPIOID RECEPTOR AGONIST",PTGS1,,,WITHDRAWN,,,NA,,CN(CS(O)(=O)=O)C1C(C)N(C)N(-C2CCCCC2)C1=O
"METAP2 INHIBITOR, A832234","METAP2 INHIBITOR, A832234",,GDSC1:410,gdsc,,,,,,,,NA,,
METAPROTERENOL,METAPROTERENOL,CHEMBL776,BRD:BRD-A07780951-001-08-9;BRD:BRD-A07780951-065-10-0;BRD:BRD-BRD-A07780951-001-08-9;BRD:BRD-BRD-A07780951-065-10-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,"BRONCHOSPASM, ASTHMA, BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,LMOINURANNBYCM-UHFFFAOYSA-N,CC(C)NCC(O)C1CC(O)CC(O)C1
METARAMINOL,METARAMINOL,CHEMBL1201319,BRD:BRD-BRD-K96253961-046-03-1;BRD:BRD-K96253961-046-03-1,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A,HYPOTENSION,,LAUNCHED,,Small molecule,Approved,WXFIGDLSSYIKKV-RCOVLWMOSA-N,C[C@H](N)[C@H](O)C1CCCC(O)C1
METARRESTIN,METARRESTIN,CHEMBL4594433,BRD:BRD-K31606909-001-03-9,rep_single_dose,,,,,,,Small molecule,Phase 1,WSMXAUJFLWRPNT-DIVCQZSQSA-N,N=C1C2C(-C3CCCCC3)C(-C3CCCCC3)N(CC3CCCCC3)C2NCN1[C@H]1CC[C@H](O)CC1
METATINIB,METATINIB,,BRD:BRD-BRD-K27182532-001-02-3;BRD:BRD-K27182532-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,BCR-ABL KINASE INHIBITOR,ABL1;BCR,,,PHASE 1,,,NA,,NC1NCCC(OC2CCC(NC(=O)C3C[NH]CC(-C4CCC(F)CC4)C3=O)CC2F)C1CL
METAXALONE,METAXALONE,CHEMBL1079604,BRD:BRD-A94709349-001-08-3;BRD:BRD-BRD-A94709349-001-08-3,rep_primary;rep_single_dose,MUSCLE RELAXANT,,MUSCLE PAIN,,LAUNCHED,,Small molecule,Approved,IMWZZHHPURKASS-UHFFFAOYSA-N,CC1CC(C)CC(OCC2CNC(=O)O2)C1
METAZOSIN,METAZOSIN,,BRD:BRD-A78277353-001-01-9;BRD:BRD-BRD-A78277353-001-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A,,,PHASE 2,,,NA,,COC(C)C(=O)N1CCN(CC1)C1NC(N)C2CC(OC)C(OC)CC2N1
METENKEPHALIN,METENKEPHALIN,,BRD:BRD-A38218502-001-01-2;BRD:BRD-BRD-A38218502-001-01-2,rep_primary;rep_single_dose,IMMUNOSTIMULANT,OPRD1,,,PHASE 2,,,NA,,CSCCC(NC(=O)C(CC1CCCCC1)NC(=O)CNC(=O)CNC(=O)C(N)CC1CCC(O)CC1)C(O)=O
METERGOLINE,METERGOLINE,CHEMBL1276418;CHEMBL19215,BRD:BRD-A72309220-001-04-1;BRD:BRD-BRD-A72309220-001-04-1,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR5A;HTR6;HTR7,,,LAUNCHED,,Small molecule,Approved,WZHJKEUHNJHDLS-HCNGEWSSSA-N;WZHJKEUHNJHDLS-QTGUNEKASA-N,CN1C[C@H](CN[11C](=O)OCC2CCCCC2)C[C@@H]2C3CCCC4C3C(CN4C)C[C@H]21;CN1C[C@H](CNC(=O)OCC2CCCCC2)C[C@@H]2C3CCCC4C3C(CN4C)C[C@H]21;CN1C[C@H](CNC(=O)OCC2CCCCC2)C[C@H]2[C@H]1CC1CN(C)C3CCCC2C13;CN1CC(CNC(=O)OCC2CCCCC2)C[C@@H]2C1CC1CN(C)C3CCCC2C13
METFORMIN,METFORMIN,CHEMBL1431,BRD:BRD-BRD-K79602928-003-19-9;BRD:BRD-K79602928-003-19-9,rep_primary;rep_single_dose,INSULIN SENSITIZER,ACACB;PRKAB1,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N;CN(C)C(=N)NC(N)=N
METHACHOLINE,METHACHOLINE,CHEMBL978,BRD:BRD-A18056626-003-22-3;BRD:BRD-BRD-A18056626-003-22-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM2;CHRM3;CHRM4,BRONCHIAL HYPERRESPONSIVENESS DIAGNOSTIC,,LAUNCHED,,Small molecule,Approved,NZWOPGCLSHLLPA-UHFFFAOYSA-N,CC(=O)OC(C)C[N+](C)(C)C;CC(C[N+](C)(C)C)OC(C)=O
METHACYCLINE,METHACYCLINE,CHEMBL249837,BRD:BRD-A49035384-003-28-9;BRD:BRD-A49035384-003-30-5;BRD:BRD-BRD-A49035384-003-28-9;BRD:BRD-BRD-A49035384-003-30-5;BRD:BRD-K00003351-003-01-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,BRONCHITIS,,LAUNCHED,"Multiple values for structure_id: {'A49035384', 'K00003351'}, defaulting to None",Small molecule,Approved,MHIGBKBJSQVXNH-IWVLMIASSA-N,C=C1C2CCCC(O)C2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12;CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)C4C(O)CCCC4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O
METHANESULFONYL-FLUORIDE,METHANESULFONYL-FLUORIDE,,BRD:BRD-K53896891-001-01-2,rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,,,,,,NA,,
METHANTHELINE,METHANTHELINE,CHEMBL1201264,BRD:BRD-K09859624-004-11-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;HRH2,,,,,Small molecule,Approved,GZHFODJQISUKAY-UHFFFAOYSA-N,CC[N+](C)(CC)CCOC(=O)C1C2CCCCC2OC2CCCCC21
METHAPYRILENE,METHAPYRILENE,CHEMBL1411979,BRD:BRD-BRD-K47323024-003-24-4;BRD:BRD-K47323024-003-24-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,,,WITHDRAWN,,Small molecule,Approved,HNJJXZKZRAWDPF-UHFFFAOYSA-N,CN(C)CCN(CC1CCCS1)C1CCCCN1
METHARBITAL,METHARBITAL,CHEMBL450,BRD:BRD-BRD-K88143662-001-01-5;BRD:BRD-K88143662-001-01-5,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,CHRNA4;CHRNA7;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIA2;GRIK2,EPILEPSY,,LAUNCHED,,Small molecule,Approved,FWJKNZONDWOGMI-UHFFFAOYSA-N,CCC1(CC)C(=O)NC(=O)N(C)C1=O
METHAZOLAMIDE,METHAZOLAMIDE,CHEMBL19,BRD:BRD-BRD-K13356952-001-25-1;BRD:BRD-K13356952-001-25-1,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA14;CA2;CA4;CA7,"GLAUCOMA, INTRAOCULAR PRESSURE",,LAUNCHED,,Small molecule,Approved,FLOSMHQXBMRNHR-QPJJXVBHSA-N,CC(=O)/N=C1/SC(S(N)(=O)=O)NN1C;CC(=O)N=C1SC(NN1C)S(N)(=O)=O
METHENAMINE,METHENAMINE,CHEMBL1201270,BRD:BRD-BRD-K30114692-001-15-9;BRD:BRD-K30114692-001-15-9,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,VKYKSIONXSXAKP-UHFFFAOYSA-N,C1N2CN3CN1CN(C2)C3
METHIAZOLE,METHIAZOLE,,BRD:BRD-BRD-K02764365-001-13-6;BRD:BRD-K02764365-001-13-6,rep_multi_dose;rep_primary;rep_single_dose,ANTHELMINTIC AGENT,,,,PRECLINICAL,,,NA,,COC(=O)NC1NC2CC(SC(C)C)CCC2[NH]1
METHICILLIN,METHICILLIN,CHEMBL575,BRD:BRD-BRD-K34388247-236-08-2;BRD:BRD-K34388247-236-08-2,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,,,LAUNCHED,,Small molecule,Approved,RJQXTJLFIWVMTO-TYNCELHUSA-N,COC1CCCC(OC)C1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O;COC1CCCC(OC)C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
METHIMAZOLE,METHIMAZOLE,CHEMBL1515,BRD:BRD-BRD-K54416256-001-19-9;BRD:BRD-K54416256-001-19-9,rep_primary;rep_single_dose,ANTITHYROID AGENT,TPO,HYPERTHYROIDISM,,LAUNCHED,,Small molecule,Approved,PMRYVIKBURPHAH-UHFFFAOYSA-N,CN1CC[NH]C1=S;CN1CCNC1S
METHIOPRIL,METHIOPRIL,,BRD:BRD-A32172948-001-07-6;BRD:BRD-BRD-A32172948-001-07-6,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,,,PHASE 2,,,NA,,CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O
METHOCARBAMOL,METHOCARBAMOL,CHEMBL1201117,BRD:BRD-A31521121-001-26-4;BRD:BRD-BRD-A31521121-001-26-4,rep_multi_dose;rep_primary;rep_single_dose,MUSCLE RELAXANT,CA1,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,GNXFOGHNGIVQEH-UHFFFAOYSA-N,COC1CCCCC1OCC(O)COC(N)=O
METHOPRENE-(S),METHOPRENE-(S),,BRD:BRD-BRD-K34591242-001-04-3;BRD:BRD-K34591242-001-04-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC(C)(C)CCC[C@H](C)C\C=C\C(C)=C\C(=O)OC(C)C
METHOTREXATE,METHOTREXATE,CHEMBL3244648;CHEMBL34259,BRD:BRD-A55424491-001-19-9;BRD:BRD-BRD-A55424491-001-19-9;BRD:BRD-BRD-K59456551-001-22-6;BRD:BRD-K59456551-001-22-6;CTRP:30371;GDSC1:1008,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR,"GESTATIONAL CHORIOCARCINOMA, HYDATIDIFORM MOLE, ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), PSORIASIS, RHEUMATOID ARTHRITIS",,LAUNCHED,"Multiple values for structure_id: {'K59456551', 'A55424491'}, defaulting to None",Small molecule,Approved,DASQOOZCTWOQPA-GXKRWWSZSA-L;FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])CC1.[NA+].[NA+];CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1;CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(CC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O;CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(CC1)C(=O)NC(CCC(O)=O)C(O)=O
METHOXAMINE,METHOXAMINE,CHEMBL524,BRD:BRD-A39189014-003-22-7;BRD:BRD-BRD-A39189014-003-22-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D,HYPOTENSION,,LAUNCHED,,Small molecule,Approved,WJAJPNHVVFWKKL-UHFFFAOYSA-N,COC1CCC(OC)C(C(O)C(C)N)C1;COC1CCC(OC)C(C1)C(O)C(C)N
METHOXSALEN,METHOXSALEN,CHEMBL416,BRD:BRD-BRD-K63430059-001-17-2;BRD:BRD-K63430059-001-17-2,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,CYP1A1;CYP1A2;CYP2A13;CYP2A6;CYP3A4,PSORIASIS,,LAUNCHED,,Small molecule,Approved,QXKHYNVANLEOEG-UHFFFAOYSA-N,COC1C2OCCC2CC2CCC(=O)OC12
METHOXYAMINE,METHOXYAMINE,CHEMBL1213633,BRD:BRD-BRD-K79277568-003-04-7;BRD:BRD-K79277568-003-04-7,rep_primary;rep_single_dose,DNA REPAIR ENZYME INHIBITOR,APEX1,,,PHASE 2,,Small molecule,Phase 2,GMPKIPWJBDOURN-UHFFFAOYSA-N,CON
METHOXYFLURANE,METHOXYFLURANE,CHEMBL1341,BRD:BRD-BRD-K06152156-001-01-8;BRD:BRD-K06152156-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,MEMBRANE PERMEABILITY INHIBITOR,ATP2C1;ATP5D;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;GLRB;GRIA1;KCNA1;MT-ND1,GENERAL ANAESTHETIC,,LAUNCHED,,Small molecule,Approved,RFKMCNOHBTXSMU-UHFFFAOYSA-N,COC(F)(F)C(CL)CL
METHOXYPHENAMINE,METHOXYPHENAMINE,CHEMBL2010507,BRD:BRD-A21474126-001-01-6;BRD:BRD-BRD-A21474126-001-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,ASTHMA,,LAUNCHED,,Small molecule,Approved,OEHAYUOVELTAPG-UHFFFAOYSA-N,CNC(C)CC1CCCCC1OC
METHSCOPOLAMINE,METHSCOPOLAMINE,CHEMBL1201268;CHEMBL376897,BRD:BRD-A03932035-004-04-3;BRD:BRD-BRD-A03932035-004-04-3;BRD:BRD-BRD-K48619321-004-16-8;BRD:BRD-K48619321-004-16-8,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,"Multiple values for structure_id: {'K48619321', 'A03932035'}, defaulting to None",Small molecule,Approved,LZCOQTDXKCNBEE-BPXZUEPWSA-N;LZCOQTDXKCNBEE-IKIFYQGPSA-N,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@H]1[C@@H]1O[C@@H]12;C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1CCCCC1;C[N+]1(C)[C@H]2C[C@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@H]1[C@H]1O[C@H]12;C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)C1CCCCC1
METHSUXIMIDE,METHSUXIMIDE,CHEMBL697,BRD:BRD-A57592049-001-01-6;BRD:BRD-BRD-A57592049-001-01-6,rep_primary;rep_single_dose,"T-TYPE CALCIUM CHANNEL BINDER, T-TYPE CALCIUM CHANNEL BLOCKER",CACNA1G;CACNA1H;CACNA1I,SEIZURES,,LAUNCHED,"Multiple values for MOA: {'T-TYPE CALCIUM CHANNEL BINDER, T-TYPE CALCIUM CHANNEL BLOCKER', 'T-TYPE CALCIUM CHANNEL BINDER'}, defaulting to 'T-TYPE CALCIUM CHANNEL BINDER, T-TYPE CALCIUM CHANNEL BLOCKER'",Small molecule,Approved,AJXPJJZHWIXJCJ-UHFFFAOYSA-N,CN1C(=O)CC(C)(C1=O)C1CCCCC1;CN1C(=O)CC(C)(C2CCCCC2)C1=O
METHYCLOTHIAZIDE,METHYCLOTHIAZIDE,CHEMBL1577,BRD:BRD-A95340155-001-09-7;BRD:BRD-BRD-A95340155-001-09-7,rep_primary;rep_single_dose,CHLORIDE REABSORPTION INHIBITOR,CA1;CA2;CA4;SLC12A1;SLC12A3,"HYPERTENSION, EDEMA",,LAUNCHED,,Small molecule,Approved,CESYKOGBSMNBPD-UHFFFAOYSA-N,CN1C(CCL)NC2CC(CL)C(CC2S1(=O)=O)S(N)(=O)=O;CN1C(CCL)NC2CC(CL)C(S(N)(=O)=O)CC2S1(=O)=O
METHYL-AMINOLEVULINATE,METHYL-AMINOLEVULINATE,,BRD:BRD-K01292611-003-13-7,rep_single_dose,OXIDIZING AGENT,FCGR1A;FECH,,,,,,NA,,
METHYLATROPINE-NITRATE,METHYLATROPINE-NITRATE,,BRD:BRD-A52460047-001-01-3;BRD:BRD-BRD-A52460047-001-01-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,,,PRECLINICAL,,,NA,,C[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)C1CCCCC1
METHYLBENACTYZIUM-BROMIDE,METHYLBENACTYZIUM-BROMIDE,,BRD:BRD-K00003518-004-01-9,rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,,,,,,,NA,,
METHYLBENZETHONIUM-CHLORIDE,METHYLBENZETHONIUM-CHLORIDE,,BRD:BRD-K46531780-003-19-7,rep_single_dose,OTHER ANTIBIOTIC,,,,,,,NA,,
METHYLCOBALAMIN,METHYLCOBALAMIN,CHEMBL2448537;CHEMBL4297672,BRD:BRD-K00003534-001-01-9,rep_single_dose,VITAMIN B,,,,,,Small molecule;Unknown,Phase 2,,
METHYLDOPA,METHYLDOPA,CHEMBL459,BRD:BRD-BRD-K48578705-001-16-8;BRD:BRD-BRD-K48578705-001-17-6;BRD:BRD-K48578705-001-16-8;BRD:BRD-K48578705-001-17-6,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C;DDC,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,CJCSPKMFHVPWAR-JTQLQIEISA-N,C[C@](N)(CC1CCC(O)C(O)C1)C(=O)O;C[C@](N)(CC1CCC(O)C(O)C1)C(O)=O
METHYLERGOMETRINE,METHYLERGOMETRINE,CHEMBL1201356,BRD:BRD-BRD-K34685430-050-12-5;BRD:BRD-K34685430-050-12-5,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",DRD1;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C,"POSTPARTUM HEMORRHAGE (PPH), MIGRAINE HEADACHE",,LAUNCHED,,Small molecule,Approved,UNBRKDKAWYKMIV-QWQRMKEZSA-N,CC[C@@H](CO)NC(=O)[C@@H]1C=C2C3CCCC4[NH]CC(C34)C[C@H]2N(C)C1;CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2CC3C[NH]C4CCCC(C2=C1)C34
METHYLLYCACONITINE,METHYLLYCACONITINE,CHEMBL510275,BRD:BRD-BRD-K43192255-048-03-6;BRD:BRD-K43192255-048-03-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA7,,,PRECLINICAL,,Small molecule,NA,XLTANAWLDBYGFU-BVFBBISOSA-N,CCN1C[C@]2(COC(=O)C3CCCCC3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@](O)([C@@H](OC)[C@H]23)[C@@H]14;CCN1C[C@]2(COC(=O)C3CCCCC3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14
METHYLNALTREXONE,METHYLNALTREXONE,CHEMBL1186579,BRD:BRD-BRD-K33732501-004-01-0;BRD:BRD-K33732501-004-01-0,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,CONSTIPATION,,LAUNCHED,,Small molecule,Approved,JVLBPIPGETUEET-GAAHOAFPSA-O,C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4OC5C2C(C[C@@H]1[C@@]3(O)CCC4=O)CCC5O;C[N+]1(CC2CC2)CC[C@]23C4C5CCC(O)C4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
METHYLPARABEN,METHYLPARABEN,CHEMBL325372,BRD:BRD-K78321730-001-13-9,rep_single_dose,OTHER ANTIFUNGAL,,,,,,Small molecule,Unknown,LXCFILQKKLGQFO-UHFFFAOYSA-N,COC(=O)C1CCC(O)CC1
METHYLPHENIDATE,METHYLPHENIDATE,CHEMBL796,BRD:BRD-A19585813-003-03-3;BRD:BRD-BRD-A19585813-003-03-3,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE-NOREPINEPHRINE REUPTAKE INHIBITOR,SLC6A2;SLC6A3;SLC6A4,"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD), NARCOLEPSY",,LAUNCHED,,Small molecule,Approved,DUGOZIWVEXMGBE-UHFFFAOYSA-N,COC(=O)C(C1CCCCC1)C1CCCCN1;COC(=O)C(C1CCCCN1)C1CCCCC1
METHYLPREDNISOLONE,METHYLPREDNISOLONE,CHEMBL1201081;CHEMBL650,BRD:BRD-BRD-K35240538-001-26-2;BRD:BRD-K35240538-001-26-2,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"HYPERCALCEMIA, THYROIDITIS, ANKYLOSING SPONDYLITIS, BURSITIS, OSTEOARTHRITIS, PSORIATIC ARTHRITIS, SEBORRHEIC DERMATITIS, MYCOSIS, ALLERGIC RHINITIS, PSORIASIS, ANEMIA, MULTIPLE SCLEROSIS, ULCERATIVE COLITIS, ENTERITIS",,LAUNCHED,,Small molecule,Approved,FQISKWAFAHGMGT-SGJOWKDISA-M;VHRSUDSXCMQTMA-PJHHCJLFSA-N,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12;C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[NA+];C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
METHYLPREDNISOLONE-ACEPONATE,METHYLPREDNISOLONE-ACEPONATE,,BRD:BRD-BRD-K24452555-001-01-7;BRD:BRD-K24452555-001-01-7,rep_primary;rep_single_dose,"ANTI-INFLAMMATORY AGENT, GLUCOCORTICOID RECEPTOR AGONIST",NR3C1,"CONGENITAL ADRENAL HYPERPLASIA, THYROIDITIS, HYPERCALCEMIA, RHEUMATOID ARTHRITIS, BURSITIS, EPICONDYLITIS, ALLERGIC RHINITIS, ASTHMA, ULCERATIVE COLITIS, ENTERITIS, OSTEOARTHRITIS, PSORIASIS, MULTIPLE SCLEROSIS, ANEMIA",,LAUNCHED,,,NA,,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O
METHYLPREDNISOLONE-SODIUM-SUCCINATE,METHYLPREDNISOLONE-SODIUM-SUCCINATE,,BRD:BRD-A45044890-236-02-3;BRD:BRD-BRD-A45044890-236-02-3,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,,"HYPERCALCEMIA, THYROIDITIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEBORRHEIC DERMATITIS, ASTHMA, ALLERGIC RHINITIS, SHINGLES, CONJUNCTIVITIS, ULCERATIVE COLITIS, ENTERITIS, ANEMIA, MULTIPLE SCLEROSIS, MYCOSIS",,LAUNCHED,,,NA,,C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12
METHYLSTAT,METHYLSTAT,,CTRP:667933,ctrp,,,,,,,,NA,,
METHYLTHIOURACIL,METHYLTHIOURACIL,CHEMBL1330588,BRD:BRD-BRD-K11900042-001-14-4;BRD:BRD-K11900042-001-14-4,rep_primary;rep_single_dose,,,HYPERTHYROIDISM,,LAUNCHED,,Small molecule,Unknown,HWGBHCRJGXAGEU-UHFFFAOYSA-N,CC1CC(=O)[NH]C(=S)[NH]1
METHYSERGIDE,METHYSERGIDE,CHEMBL1065;CHEMBL485253,BRD:BRD-K35941380-050-28-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR5A;HTR6;HTR7,,,,,Small molecule,Approved,KPJZHOPZRAFDTN-NQUBZZJWSA-N;KPJZHOPZRAFDTN-ZRGWGRIASA-N,CC[C@@H](CO)NC(=O)[C@@H]1C=C2C3CCCC4C3C(CN4C)C[C@H]2N(C)C1;CCC(CO)NC(=O)[C@@H]1C=C2C3CCCC4C3C(CN4C)C[C@H]2N(C)C1
METICRANE,METICRANE,CHEMBL1318341,BRD:BRD-BRD-K58265391-001-12-7;BRD:BRD-K58265391-001-12-7,rep_primary;rep_single_dose,DIURETIC,,EDEMA,,LAUNCHED,,Small molecule,Unknown,FNQQBFNIYODEMB-UHFFFAOYSA-N,CC1CC2C(CC1S(N)(=O)=O)S(=O)(=O)CCC2;CC1CC2CCCS(=O)(=O)C2CC1S(N)(=O)=O
METIPRANOLOL,METIPRANOLOL,CHEMBL1200947;CHEMBL1291,BRD:BRD-A99388803-001-01-5;BRD:BRD-BRD-A99388803-001-01-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,,,WITHDRAWN,,Small molecule,Approved,BLWNYSZZZWQCKO-UHFFFAOYSA-N;BQIPXWYNLPYNHW-UHFFFAOYSA-N,CC(=O)OC1C(C)CC(OCC(O)CNC(C)C)C(C)C1C;CC(=O)OC1C(C)CC(OCC(O)CNC(C)C)C(C)C1C.CL;CC(C)NCC(O)COC1CC(C)C(OC(C)=O)C(C)C1C
METIROSINE,METIROSINE,CHEMBL1200862,BRD:BRD-BRD-K83766205-001-03-8;BRD:BRD-K83766205-001-03-8,rep_primary;rep_single_dose,TYROSINE HYDROXYLASE INHIBITOR,TH,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,NHTGHBARYWONDQ-JTQLQIEISA-N,C[C@](N)(CC1CCC(O)CC1)C(=O)O;C[C@](N)(CC1CCC(O)CC1)C(O)=O
METITEPINE,METITEPINE,CHEMBL93240,BRD:BRD-A07932845-050-15-8;BRD:BRD-BRD-A07932845-050-15-8,rep_primary;rep_single_dose,ANTI-HCVE2,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR5A;HTR6;HTR7,,,PRECLINICAL,,Small molecule,Unknown,RLJFTICUTYVZDG-UHFFFAOYSA-N,CSC1CCC2C(C1)C(N1CCN(C)CC1)CC1CCCCC1S2;CSC1CCC2SC3CCCCC3CC(N3CCN(C)CC3)C2C1
METIXENE,METIXENE,CHEMBL1201342,BRD:BRD-A33711280-003-03-1;BRD:BRD-BRD-A33711280-003-03-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,MJFJKKXQDNNUJF-UHFFFAOYSA-N,CN1CCCC(CC2C3CCCCC3SC3CCCCC23)C1;CN1CCCC(CC2C3CCCCC3SC3CCCCC32)C1
METOCLOPRAMIDE,METOCLOPRAMIDE,CHEMBL86,BRD:BRD-BRD-K75641298-003-25-0;BRD:BRD-K75641298-003-25-0,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",CHRM1;DRD2;HTR3A;HTR3B;HTR4,"GASTROPARESIS, NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,TTWJBBZEZQICBI-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1CC(CL)C(N)CC1OC
METOCURINE,METOCURINE,CHEMBL1259,BRD:BRD-BRD-K16484091-001-01-1;BRD:BRD-K16484091-001-01-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM2;CHRNA2,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,JFXBEKISTKFVAB-AJQTZOPKSA-N,COC1CCC2C[C@@H]3C4C(CC[N+]3(C)C)CC(OC)C(OC)C4OC3CCC(C[C@H]4C5CC(OC1C2)C(OC)CC5CC[N+]4(C)C)CC3;COC1CCC2CC1OC1CC3C(CC1OC)CC[N+](C)(C)[C@H]3CC1CCC(CC1)OC1C(OC)C(OC)CC3C1[C@@H](C2)[N+](C)(C)CC3
METOLAZONE,METOLAZONE,CHEMBL878,BRD:BRD-A61793559-001-15-6;BRD:BRD-BRD-A61793559-001-15-6,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,SLC12A3,"EDEMA, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,AQCHWTWZEMGIFD-UHFFFAOYSA-N,CC1CCCCC1N1C(=O)C2CC(S(N)(=O)=O)C(CL)CC2NC1C;CC1NC2CC(CL)C(CC2C(=O)N1C1CCCCC1C)S(N)(=O)=O
METOPRINE,METOPRINE,CHEMBL264373,BRD:BRD-K77185060-001-08-9,rep_single_dose,,,,,,,Small molecule,Unknown,VQJHOPSWBGJHQS-UHFFFAOYSA-N,CC1NC(N)NC(N)C1-C1CCC(CL)C(CL)C1
METOPROLOL,METOPROLOL,CHEMBL13,BRD:BRD-A03623303-045-09-5;BRD:BRD-BRD-A03623303-045-09-5,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,"HYPERTENSION, ANGINA PECTORIS, MYOCARDIAL INFARCTION",,LAUNCHED,,Small molecule,Approved,IUBSYMUCCVWXPE-UHFFFAOYSA-N,COCCC1CCC(OCC(O)CNC(C)C)CC1
METOXIBUTROPATE,METOXIBUTROPATE,,BRD:BRD-A71725768-001-01-3;BRD:BRD-BRD-A71725768-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,,NA,,COC1CCCCC1OC(=O)C(C)C1CCC(CC(C)C)CC1
METRIZAMIDE,METRIZAMIDE,CHEMBL1200889;CHEMBL462394,BRD:BRD-A45543382-001-10-0;BRD:BRD-BRD-A45543382-001-10-0,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,BAQCROVBDNBEEB-KSDLJXBFSA-N;BAQCROVBDNBEEB-UBYUBLNFSA-N,CC(=O)NC1C(I)C(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]2O)C(I)C(N(C)C(C)=O)C1I;CC(=O)NC1C(I)C(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)C(I)C(N(C)C(C)=O)C1I;CN(C(C)=O)C1C(I)C(NC(C)=O)C(I)C(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)C1I
METRIZOIC-ACID,METRIZOIC-ACID,,BRD:BRD-BRD-K99241550-001-03-5;BRD:BRD-K99241550-001-03-5,rep_primary;rep_single_dose,RADIOPAQUE MEDIUM,,CONTRAST AGENT,,LAUNCHED,,,NA,,CN(C(C)=O)C1C(I)C(NC(C)=O)C(I)C(C(O)=O)C1I
METRONIDAZOLE,METRONIDAZOLE,CHEMBL137,BRD:BRD-BRD-K52020312-001-26-8;BRD:BRD-K52020312-001-26-8,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,CYP2C9;CYP3A4,ROSACEA,,LAUNCHED,,Small molecule,Approved,VAOCPAMSLUNLGC-UHFFFAOYSA-N,CC1NCC([N+](=O)[O-])N1CCO;CC1NCC(N1CCO)[N+]([O-])=O
METYRAPONE,METYRAPONE,CHEMBL934,BRD:BRD-BRD-K46862739-001-14-3;BRD:BRD-K46862739-001-14-3,rep_multi_dose;rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP11B1,ADRENAL DIAGNOSTIC AGENT,,LAUNCHED,,Small molecule,Approved,FJLBFSROUSIWMA-UHFFFAOYSA-N,CC(C)(C(=O)C1CCCNC1)C1CCCNC1
MEVASTATIN,MEVASTATIN,CHEMBL54440,BRD:BRD-BRD-K94441233-001-13-0;BRD:BRD-BRD-K94441233-001-17-1;BRD:BRD-K94441233-001-13-0;BRD:BRD-K94441233-001-17-1,rep_multi_dose;rep_primary;rep_single_dose,HMGCR INHIBITOR,HMGCR,,,PRECLINICAL,,Small molecule,Unknown,AJLFOPYRIVGYMJ-INTXDZFKSA-N,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12;CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
MEXENEONE,MEXENEONE,,BRD:BRD-BRD-K18613660-001-05-5;BRD:BRD-K18613660-001-05-5,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CCC(C(=O)C2CCC(C)CC2)C(O)C1
MEXILETINE,MEXILETINE,CHEMBL146855;CHEMBL147507;CHEMBL558,BRD:BRD-A64092382-003-18-3;BRD:BRD-BRD-A64092382-003-18-3,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,AHR;PLAU;SCN4A;SCN5A,"VENTRICULAR ARRHYTHMIAS, VENTRICULAR TACHYCARDIA (VT)",,LAUNCHED,"Multiple values for repurposing_target: {'AHR;PLAU;SCN4A;SCN5A', 'AHR;SCN4A;SCN5A'}, taking the union",Small molecule,Approved,VLPIATFUUWWMKC-JTQLQIEISA-N;VLPIATFUUWWMKC-SNVBAGLBSA-N;VLPIATFUUWWMKC-UHFFFAOYSA-N,CC(N)COC1C(C)CCCC1C;CC1CCCC(C)C1OC[C@@H](C)N;CC1CCCC(C)C1OC[C@H](C)N;CC1CCCC(C)C1OCC(C)N
MEZLOCILLIN,MEZLOCILLIN,CHEMBL1731,BRD:BRD-BRD-K45114938-236-01-8;BRD:BRD-K45114938-236-01-8,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"GRAM-NEGATIVE BACTERIAL INFECTIONS, GRAM-POSITIVE BACTERIAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,YPBATNHYBCGSSN-VWPFQQQWSA-N,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCN(S(C)(=O)=O)C3=O)C3CCCCC3)C(=O)N2[C@H]1C(=O)O;CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C3CCCCC3)C(=O)N2[C@@H]1C(O)=O
MF-094,MF-094,,BRD:BRD-K00126474-001-01-9,oncref_2,INHIBITOR OF USP30,USP30,,,,,,NA,,
MF-101,MF-101,,BRD:BRD-BRD-K34328244-001-01-4;BRD:BRD-K34328244-001-01-4,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,CYP19A1;XDH,,,PHASE 3,,,NA,,OC1CCC(CC1)[C@@H]1CC(=O)C2CCC(O)CC2O1
MG 132,MG 132,,GDSC1:9,gdsc,,,,,,,,NA,,
MG-132,MG-132,CHEMBL64925,BRD:BRD-BRD-K60230970-001-14-2;BRD:BRD-BRD-K60230970-001-17-5;BRD:BRD-K60230970-001-17-5;CTRP:58948;GDSC1:9,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,PSMB1,,,PRECLINICAL,,Protein,NA,TZYWCYJVHRLUCT-VABKMULXSA-N,CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1CCCCC1;CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1CCCCC1)C=O
MG-624,MG-624,CHEMBL1257065,BRD:BRD-K03128577-005-08-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA7,,,,,Small molecule,Unknown,RDTKUZXIHMTSJO-UEIGIMKUSA-M,CC[N+](CC)(CC)CCOC1CCC(/C=C/C2CCCCC2)CC1.[I-]
MG132,MG132,,GDSC1:9,gdsc,,,,,,,,NA,,
MGCD-265,MGCD-265,CHEMBL3989914,BRD:BRD-BRD-K56277358-001-07-5;BRD:BRD-K56277358-001-07-5;CTRP:628622,ctrp;rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,AXL;MET,,,PRECLINICAL,,Small molecule,Phase 2,YRCHYHRCBXNYNU-UHFFFAOYSA-N,CN1CNC(C1)-C1CC2NCCC(OC3CCC(NC(=S)NC(=O)CC4CCCCC4)CC3F)C2S1;COCCNCC1CCC(-C2CC3NCCC(OC4CCC(NC(=S)NC(=O)CC5CCC(F)CC5)CC4F)C3S2)NC1
MHP,MHP,,BRD:BRD-K00074484-001-02-9,rep_single_dose,,,,,,,,NA,,
MHY1485,MHY1485,,BRD:BRD-K26797311-001-07-9,oncref_2,"MTOR ACTIVATOR, AUTOPHAGY INHIBITOR",MTOR,,,,,,NA,,
MI-1,MI-1,,CTRP:185987,ctrp,,,,,,,,NA,,
MI-14,MI-14,,BRD:BRD-K26726854-001-02-9,rep_single_dose,PI4K INHIBITOR,PI4KB,,,,,,NA,,
MI-2,MI-2,,CTRP:687714,ctrp,,,,,,,,NA,,
MIANSERIN,MIANSERIN,CHEMBL6437,BRD:BRD-A19661776-003-27-6;BRD:BRD-BRD-A19661776-003-27-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD5;HRH1;HRH2;HRH4;HTR1A;HTR1F;HTR2A;HTR2B;HTR2C;HTR6;HTR7;OPRK1;SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,UEQUQVLFIPOEMF-UHFFFAOYSA-N,CN1CCN2C(C1)C1CCCCC1CC1CCCCC21;CN1CCN2C3CCCCC3CC3CCCCC3C2C1
MIBAMPATOR,MIBAMPATOR,CHEMBL1277001,BRD:BRD-BRD-K42981054-001-01-9;BRD:BRD-K42981054-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,GRIA1,,,PHASE 2,,Small molecule,Phase 2,ULRDYYKSPCRXAJ-KRWDZBQOSA-N,CC(C)S(=O)(=O)NC[C@H](C)C1CCC(-C2CCC(CCNS(C)(=O)=O)CC2)CC1;CC(C)S(=O)(=O)NC[C@H](C)C1CCC(CC1)-C1CCC(CCNS(C)(=O)=O)CC1
MIBEFRADIL,MIBEFRADIL,CHEMBL45816,BRD:BRD-BRD-K09549677-300-03-4;BRD:BRD-K09549677-300-03-4,rep_multi_dose;rep_primary;rep_single_dose,T-TYPE CALCIUM CHANNEL BLOCKER,ANO1;CACNA1C;CACNA1D;CACNA1F;CACNA1G;CACNA1H;CACNA1I;CACNA1S;CACNB1;CACNB2;CACNB3;CACNB4;CATSPER1;CATSPER2;CATSPER3;CATSPER4,,,WITHDRAWN,,Small molecule,Approved,HBNPJJILLOYFJU-VMPREFPWSA-N,COCC(=O)O[C@]1(CCN(C)CCCC2NC3CCCCC3[NH]2)CCC2CC(F)CCC2[C@@H]1C(C)C
MICAFUNGIN,MICAFUNGIN,CHEMBL457547,BRD:BRD-K40407248-001-04-9,rep_single_dose,"FUNGAL 1,3-BETA-D-GLUCAN SYNTHASE INHIBITOR",,,,,,Small molecule,Approved,PIEUQSKUWLMALL-YABMTYFHSA-N,CCCCCOC1CCC(-C2CC(-C3CCC(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)C5CCC(O)C(OS(=O)(=O)O)C5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)CC3)NO2)CC1
MICONAZOLE,MICONAZOLE,CHEMBL91,BRD:BRD-A82396632-008-29-0;BRD:BRD-BRD-A82396632-008-29-0,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,KCNH2;KCNH6;KCNH7;KCNMA1;KCNMB1;KCNMB2;KCNMB3;KCNMB4;KCNN1;KCNN2;KCNN3;KCNN4;NOS2;NOS3;TRPM2;TRPV5,"YEAST INFECTION, ITCHING",,LAUNCHED,,Small molecule,Approved,BYBLEWFAAKGYCD-UHFFFAOYSA-N,CLC1CCC(COC(CN2CCNC2)C2CCC(CL)CC2CL)C(CL)C1
MIDAFOTEL,MIDAFOTEL,CHEMBL90564,BRD:BRD-BRD-K45163704-001-01-5;BRD:BRD-K45163704-001-01-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PHASE 3,,Small molecule,Unknown,VZXMZMJSGLFKQI-ABVWVHJUSA-N,O=C(O)[C@H]1CN(C/C=C/P(=O)(O)O)CCN1;OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1
MIDODRINE,MIDODRINE,CHEMBL1201212;CHEMBL255027,BRD:BRD-A79981887-003-16-4;BRD:BRD-BRD-A79981887-003-16-4,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D,HYPOTENSION,,LAUNCHED,,Small molecule,Approved,PTKSEFOSCHHMPD-SNVBAGLBSA-N;PTKSEFOSCHHMPD-UHFFFAOYSA-N,COC1CCC(OC)C([C@H](O)CNC(=O)CN)C1;COC1CCC(OC)C(C(O)CNC(=O)CN)C1;COC1CCC(OC)C(C1)C(O)CNC(=O)CN
MIDOSTAURIN,MIDOSTAURIN,CHEMBL608533,BRD:BRD-BRD-K13646352-001-03-8;BRD:BRD-K13646352-001-03-8;GDSC1:153,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, KIT INHIBITOR, PKC INHIBITOR",FLT3;PRKCG,ACUTE MYELOID LEUKEMIA (AML),,LAUNCHED,,Small molecule,Approved,BMGQWWVMWDBQGC-IIFHNQTCSA-N,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3CCCCC3C3C4CNC(=O)C4C4C5CCCCC5N2C4C13)N(C)C(=O)C1CCCCC1;CO[C@@H]1[C@H](N(C)C(=O)C2CCCCC2)C[C@H]2O[C@]1(C)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)C(=O)NC4
MIFEPRISTONE,MIFEPRISTONE,CHEMBL1276308,BRD:BRD-BRD-K37270826-001-27-6;BRD:BRD-BRD-K37270826-001-31-8;BRD:BRD-K37270826-001-27-6;BRD:BRD-K37270826-001-31-8,rep_multi_dose;rep_primary;rep_single_dose,"GLUCOCORTICOID RECEPTOR ANTAGONIST, PROGESTERONE RECEPTOR ANTAGONIST",AR;NR1I2;NR3C1;PGR,"HYPERGLYCEMIA, DIABETES MELLITUS",,LAUNCHED,,Small molecule,Approved,VKHAHZOOUSRJNA-GCNJZUOMSA-N,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](C3CCC(N(C)C)CC3)C[C@@]21C;CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C1CCC(CC1)N(C)C
MIFOBATE,MIFOBATE,CHEMBL284768,BRD:BRD-A72066420-001-04-5;BRD:BRD-BRD-A72066420-001-04-5,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARG,,,PHASE 2,,Small molecule,Unknown,VQHUQHAPWMNBLP-UHFFFAOYSA-N,COP(=O)(OC)OC(C1CCC(CL)CC1)P(=O)(OC)OC
MIGLITOL,MIGLITOL,CHEMBL1561,BRD:BRD-A63310107-001-04-8;BRD:BRD-BRD-A63310107-001-04-8,rep_primary;rep_single_dose,GLUCOSIDASE INHIBITOR,GAA;GANAB;GANC;MGAM,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,IBAQFPQHRJAVAV-ULAWRXDQSA-N,OCCN1C[C@@H](O)[C@@H](O)C(O)C1CO;OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
MIGLUSTAT,MIGLUSTAT,CHEMBL1029,BRD:BRD-BRD-K33251802-001-01-3;BRD:BRD-K33251802-001-01-3,rep_primary;rep_single_dose,GLYCOSYL TRANSFERASE INHIBITOR,UGCG,GAUCHER DISEASE,,LAUNCHED,,Small molecule,Approved,UQRORFVVSGFNRO-UTINFBMNSA-N,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
MIK665,MIK665,CHEMBL4298096,BRD:BRD-K00005263-001-02-9,rep_single_dose,,,,,,,Unknown,Phase 1,,
MILACEMIDE,MILACEMIDE,CHEMBL75838,BRD:BRD-BRD-K64338723-001-01-6;BRD:BRD-K64338723-001-01-6,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOB,,,PHASE 3,,Small molecule,Unknown,GJNNXIYZWIZFRH-UHFFFAOYSA-N,CCCCCNCC(N)=O
MILADEMETAN,MILADEMETAN,CHEMBL4292264,BRD:BRD-K00003406-001-01-9,rep_single_dose,MDM INHIBITOR,,,,,,Small molecule,Phase 1,RYAYYVTWKAOAJF-QISPRATLSA-N,CC1(C)CCC2(CC1)N[C@@H](C(=O)N[C@@H]1CC[C@@H](C(N)=O)OC1)[C@H](C1CCNC(CL)C1F)[C@]21C(=O)NC2CC(CL)CCC21
MILNACIPRAN,MILNACIPRAN,CHEMBL259209;CHEMBL99946,BRD:BRD-A15202882-003-02-7;BRD:BRD-BRD-A15202882-003-02-7,rep_primary;rep_single_dose,SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI),GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B;SLC6A2;SLC6A4,FIBROMYALGIA,,LAUNCHED,,Small molecule,Approved,GJJFMKBJSRMPLA-DZGCQCFKSA-N;GJJFMKBJSRMPLA-UHFFFAOYSA-N,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1CCCCC1;CCN(CC)C(=O)[C@@]1(C2CCCCC2)C[C@H]1CN;CCN(CC)C(=O)C1(C2CCCCC2)CC1CN;CCN(CC)C(=O)C1(CC1CN)C1CCCCC1
MILRINONE,MILRINONE,CHEMBL189,BRD:BRD-BRD-K67080878-001-15-4;BRD:BRD-K67080878-001-15-4,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE2A;PDE3A;PDE3B;PDE5A,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Approved,PZRHRDRVRGEVNW-UHFFFAOYSA-N,CC1[NH]C(=O)C(C#N)CC1-C1CCNCC1;CC1[NH]C(=O)C(CC1-C1CCNCC1)C#N
MILTEFOSINE,MILTEFOSINE,CHEMBL125,BRD:BRD-A31811760-001-06-7;BRD:BRD-BRD-A31811760-001-06-7,rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,PLA2G1B,LEISHMANIASIS,,LAUNCHED,,Small molecule,Approved,PQLXHQMOHUQAKB-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C;CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C
MIM 1,MIM 1,,GDSC2:1996,gdsc,,,,,,,,NA,,
MIM-1,MIM-1,,GDSC2:1996,gdsc,,,,,,,,NA,,
MIM1,MIM1,,GDSC1:446;GDSC2:1996,gdsc,,,,,,,,NA,,
MINAPRINE,MINAPRINE,CHEMBL278819,BRD:BRD-BRD-K02867583-300-08-9;BRD:BRD-K02867583-300-08-9,rep_primary;rep_single_dose,SEROTONIN REUPTAKE INHIBITOR,ACHE;CHRM1;DRD1;DRD2;HTR2A;HTR2B;HTR2C;MAOA;SLC6A4,,,WITHDRAWN,,Small molecule,Approved,LDMWSLGGVTVJPG-UHFFFAOYSA-N,CC1CC(-C2CCCCC2)NNC1NCCN1CCOCC1;CC1CC(NNC1NCCN1CCOCC1)-C1CCCCC1
MINERVAL,MINERVAL,CHEMBL4594452,BRD:BRD-A74347210-001-01-7;BRD:BRD-BRD-A74347210-001-01-7,rep_primary;rep_single_dose,FAAH INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,JBSOOFITVPOOSY-UHFFFAOYSA-N,CCCCCCCC\C=C/CCCCCCC(O)C(O)=O;CCCCCCCCC=CCCCCCCC(O)C(=O)O
MINOCYCLINE,MINOCYCLINE,CHEMBL1434,BRD:BRD-A69651145-003-07-2;BRD:BRD-BRD-A69651145-003-07-2;BRD:BRD-K00003346-003-01-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,ALOX5;CASP1;CASP3;CYCS;IL1B;MMP9;VEGFA,"FEVER, RESPIRATORY TRACT INFECTIONS, PSITTACOSIS, TRACHOMA, CONJUNCTIVITIS, URETHRITIS, CHANCROID, TULAREMIA, CHOLERA, BRUCELLOSIS",,LAUNCHED,"Multiple values for structure_id: {'K00003346', 'A69651145'}, defaulting to None",Small molecule,Approved,DYKFCLLONBREIL-KVUCHLLUSA-N,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4C(CCC(O)C4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C;CN(C)C1CCC(O)C2C1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
MINOXIDIL,MINOXIDIL,CHEMBL802,BRD:BRD-BRD-K06902185-003-01-7;BRD:BRD-K06902185-003-01-7,rep_primary;rep_single_dose,"KATP ACTIVATOR, KIR6 CHANNEL (KATP) ACTIVATOR, VASODILATOR",ABCC9;KCNJ1;KCNJ10;KCNJ11;KCNJ8;PTGS1,ANDROGENETIC ALOPECIA,,LAUNCHED,,Small molecule,Approved,ZFMITUMMTDLWHR-UHFFFAOYSA-N,NC1CC(N2CCCCC2)NC(N)[N+]1[O-];NC1CC(NC(N)[N+]1[O-])N1CCCCC1
MIOCAMYCIN,MIOCAMYCIN,CHEMBL1091024,BRD:BRD-BRD-K30764557-001-01-5;BRD:BRD-K30764557-001-01-5,rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,"URINARY TRACT INFECTIONS, CHLAMYDIA",,LAUNCHED,,Small molecule,Unknown,GQNZGCARKRHPOH-RQIKCTSVSA-N,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(OC(C)=O)[C@@H](OC(=O)CC)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC;CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C
MIRA 1,MIRA 1,,GDSC2:1931,gdsc,,,,,,,,NA,,
MIRA-1,MIRA-1,,GDSC2:1931,gdsc,,,,,,,,NA,,
MIRA1,MIRA1,,GDSC2:1931,gdsc,,,,,,,,NA,,
MIRABEGRON,MIRABEGRON,CHEMBL2095212,BRD:BRD-BRD-K47949423-001-03-1;BRD:BRD-K47949423-001-03-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1;ADRB2;ADRB3,URINARY INCONTINENCE,,LAUNCHED,,Small molecule,Approved,PBAPPPCECJKMCM-IBGZPJMESA-N,NC1NC(CC(=O)NC2CCC(CCNC[C@H](O)C3CCCCC3)CC2)CS1
MIRIDESAP,MIRIDESAP,CHEMBL25263,BRD:BRD-K00003434-001-01-9,rep_single_dose,AMYLOID PROTEIN INHIBITOR,,,,,,Small molecule,Phase 2,HZLAWYIBLZNRFZ-VXGBXAGGSA-N,O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O
MIRIN,MIRIN,CHEMBL570841,BRD:BRD-K55420858-001-01-0;GDSC1:1048;GDSC2:1048,gdsc;rep_single_dose,MRE11A EXONUCLEASE INHIBITOR,MRE11A,,,,,Small molecule,NA,YBHQCJILTOVLHD-YVMONPNESA-N,N=C1NC(=O)/C(=C/C2CCC(O)CC2)S1
MIRODENAFIL,MIRODENAFIL,CHEMBL4297518,BRD:BRD-BRD-K82967685-300-01-2;BRD:BRD-K82967685-300-01-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,ERECTILE DYSFUNCTION,,LAUNCHED,,Small molecule,Phase 1,MIJFNYMSCFYZNY-UHFFFAOYSA-N,CCCOC1CCC(CC1-C1NC2C(CCC)CN(CC)C2C(=O)[NH]1)S(=O)(=O)N1CCN(CCO)CC1;CCCOC1CCC(S(=O)(=O)N2CCN(CCO)CC2)CC1-C1NC2C(CCC)CN(CC)C2C(=O)[NH]1
MIROGABALIN-BESYLATE,MIROGABALIN-BESYLATE,,BRD:BRD-K00003484-074-01-9,rep_single_dose,CALCIUM CHANNEL ANTAGONIST,,,,,,,NA,,
MIRTAZAPINE,MIRTAZAPINE,CHEMBL1366933;CHEMBL654,BRD:BRD-A64977602-001-15-9;BRD:BRD-BRD-A64977602-001-15-9,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;DRD1;DRD2;DRD3;DRD5;HRH1;HRH3;HTR2A;HTR2B;HTR2C;HTR3A;HTR7;OPRK1;SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,RONZAEMNMFQXRA-MRXNPFEDSA-N;RONZAEMNMFQXRA-UHFFFAOYSA-N,CN1CCN2C(C1)C1CCCCC1CC1CCCNC21;CN1CCN2C3NCCCC3CC3CCCCC3[C@H]2C1;CN1CCN2C3NCCCC3CC3CCCCC3C2C1
MISONIDAZOLE,MISONIDAZOLE,CHEMBL42161,BRD:BRD-A16263897-001-06-6;BRD:BRD-BRD-A16263897-001-06-6,rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,Phase 2,OBBCSXFCDPPXOL-UHFFFAOYSA-N,COCC(O)CN1CCNC1[N+]([O-])=O;COCC(O)CN1CCNC1[N+](=O)[O-]
MISOPROSTOL,MISOPROSTOL,CHEMBL606,BRD:BRD-A72351335-001-04-5;BRD:BRD-BRD-A72351335-001-04-5,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,PTGER2;PTGER3;PTGER4;PTGIR,DUODENAL ULCER DISEASE,,LAUNCHED,,Small molecule,Approved,OJLOPKGSLYJEMD-URPKTTJQSA-N,CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC;CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
MITAPIVAT,MITAPIVAT,CHEMBL4299940,BRD:BRD-K00003136-001-01-9,rep_single_dose,PYRUVATE KINASE ISOZYME ACTIVATOR,,,,,,Small molecule,Approved,XAYGBKHKBBXDAK-UHFFFAOYSA-N,O=C(C1CCC(NS(=O)(=O)C2CCCC3CCCNC23)CC1)N1CCN(CC2CC2)CC1
MITIGLINIDE,MITIGLINIDE,CHEMBL471498,BRD:BRD-BRD-K52959329-238-01-9;BRD:BRD-K52959329-238-01-9,rep_primary;rep_single_dose,INSULIN SECRETAGOGUE,ABCC8;KCNJ10;PPARG,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Phase 3,WPGGHFDDFPHPOB-BBWFWOEESA-N,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)CC1CCCCC1;OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)CC1CCCCC1
MITOFLAXONE,MITOFLAXONE,CHEMBL443793,BRD:BRD-BRD-K35882976-001-04-7;BRD:BRD-K35882976-001-04-7,rep_primary;rep_single_dose,ANTITUMOR AGENT,VWF,,,PHASE 2,,Small molecule,Unknown,TZZNWMJZDWYJAZ-UHFFFAOYSA-N,O=C(O)CC1CCCC2C(=O)CC(-C3CCCCC3)OC12;OC(=O)CC1CCCC2C1OC(CC2=O)-C1CCCCC1
MITOMYCIN,MITOMYCIN,CHEMBL105,CTRP:50732,ctrp,,,,,,,Small molecule,Approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
MITOMYCIN-C,MITOMYCIN-C,CHEMBL105,BRD:BRD-A48237631-001-04-8;BRD:BRD-BRD-A48237631-001-04-8;GDSC1:136,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"DNA ALKYLATING AGENT, DNA SYNTHESIS INHIBITOR",,"PANCREATIC CANCER, GASTRIC ADENOCARCINOMA",,LAUNCHED,,Small molecule,Approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O;CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
MITOQUINONE,MITOQUINONE,CHEMBL1229093,BRD:BRD-K00003362-066-01-9,rep_single_dose,ANTIOXIDANT,,,,,,Small molecule,Phase 2,OIIMUKXVVLRCAF-UHFFFAOYSA-N,COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](C2CCCCC2)(C2CCCCC2)C2CCCCC2)=C(C)C1=O
MITOSOL,MITOSOL,CHEMBL105,GDSC1:136,gdsc,,,,,,,Small molecule,Approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
MITOTANE,MITOTANE,CHEMBL1670,BRD:BRD-A31204924-001-14-2,rep_single_dose,ANTINEOPLASTIC AGENT,CYP11A1;CYP11B1;ESR1,,,,,Small molecule,Approved,JWBOIMRXGHLCPP-UHFFFAOYSA-N,CLC1CCC(C(C2CCCCC2CL)C(CL)CL)CC1
NSC-301739,MITOXANTRONE;NSC-301739,CHEMBL1417019;CHEMBL58,BRD:BRD-BRD-K21680192-300-14-4;BRD:BRD-K21680192-300-14-4;GDSC2:1810,gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF TOPOISOMERASE,TOP2A;TOP2B,"MULTIPLE SCLEROSIS, PROSTATE CANCER, ACUTE MYELOID LEUKEMIA (AML)",,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF TOPOISOMERASE', 'TOPOISOMERASE INHIBITOR'}, defaulting to 'INHIBITOR OF TOPOISOMERASE'
Multiple values for repurposing_target: {'TOP2A', 'TOP2A;TOP2B'}, taking the union",Small molecule,Approved,KKZJGLLVHKMTCM-UHFFFAOYSA-N;ZAHQPTJLOCWVPG-UHFFFAOYSA-N,CL.CL.O=C1C2C(O)CCC(O)C2C(=O)C2C(NCCNCCO)CCC(NCCNCCO)C21;O=C1C2C(O)CCC(O)C2C(=O)C2C(NCCNCCO)CCC(NCCNCCO)C21;OCCNCCNC1CCC(NCCNCCO)C2C(=O)C3C(O)CCC(O)C3C(=O)C12
MITOZYTREX,MITOZYTREX,CHEMBL105,GDSC1:136,gdsc,,,,,,,Small molecule,Approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
MIVEBRESIB,MIVEBRESIB,CHEMBL3987016,BRD:BRD-K00003356-001-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,Small molecule,Phase 1,RDONXGFGWSSFMY-UHFFFAOYSA-N,CCS(=O)(=O)NC1CCC(OC2CCC(F)CC2F)C(-C2CN(C)C(=O)C3[NH]CCC23)C1
MIVOBULIN,MIVOBULIN,CHEMBL1233800,BRD:BRD-K39576764-071-01-6,rep_single_dose,MICROTUBULE INHIBITOR,,,,,,Small molecule,Unknown,XXBDOTXPQDVHIP-JTQLQIEISA-N,CCOC(=O)NC1CC2C(C(N)N1)N=C(C1CCCCC1)[C@H](C)N2
MIW-815,MIW-815,,BRD:BRD-K00003146-318-01-9,rep_single_dose,INTERFERON INDUCER,,,,,,,NA,,
MIZOLASTINE,MIZOLASTINE,CHEMBL94454,BRD:BRD-BRD-K21884483-001-03-7;BRD:BRD-K21884483-001-03-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"URTICARIA, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Approved,PVLJETXTTWAYEW-UHFFFAOYSA-N,CN(C1CCN(CC1)C1NC2CCCCC2N1CC1CCC(F)CC1)C1NCCC(=O)[NH]1;CN(C1NCCC(=O)[NH]1)C1CCN(C2NC3CCCCC3N2CC2CCC(F)CC2)CC1
MIZORIBINE,MIZORIBINE,CHEMBL245019,BRD:BRD-BRD-K88061624-001-21-4;BRD:BRD-K88061624-001-21-4,rep_primary;rep_single_dose,"IMMUNOSUPPRESSANT, INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR",IMPDH1,,,LAUNCHED,,Small molecule,Phase 3,HZQDCMWJEBCWBR-UUOKFMHZSA-N,NC(=O)C1NCN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1O
MJ-15,MJ-15,,BRD:BRD-K71315565-001-02-9,rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1,,,,,,NA,,
MK 0457,MK 0457,,GDSC1:32;GDSC2:1096,gdsc,,,,,,,,NA,,
MK 2206,MK 2206,,GDSC1:1053;GDSC2:1053,gdsc,,,,,,,,NA,,
MK-0354,MK-0354,,BRD:BRD-BRD-K91405252-001-01-9;BRD:BRD-K91405252-001-01-9,rep_primary;rep_single_dose,NIACIN RECEPTOR AGONIST,HCAR2;HCAR3,,,PHASE 2,,,NA,,C1CC2[NH]NC(-C3NNN[NH]3)C2C1
MK-0429,MK-0429,,BRD:BRD-K00076647-001-02-9,rep_single_dose,,,,,,,,NA,,
MK-045,MK-045,CHEMBL572878,GDSC1:32;GDSC2:1096,gdsc,,,,,,,Small molecule,Phase 2,GCIKSSRWRFVXBI-UHFFFAOYSA-N,CC1CC(NC2CC(N3CCN(C)CC3)NC(SC3CCC(NC(=O)C4CC4)CC3)N2)N[NH]1
MK-0457,MK-0457,CHEMBL2105657;CHEMBL572878,GDSC1:32;GDSC2:1096,gdsc,,,,,,,Small molecule,Phase 2,GCIKSSRWRFVXBI-UHFFFAOYSA-N;MHFUWOIXNMZFIW-WNQIDUERSA-N,C[C@H](O)C(=O)O.CC1CC(NC2CC(N3CCN(C)CC3)NC(SC3CCC(NC(=O)C4CC4)CC3)N2)N[NH]1;CC1CC(NC2CC(N3CCN(C)CC3)NC(SC3CCC(NC(=O)C4CC4)CC3)N2)N[NH]1
MK-0557,MK-0557,CHEMBL595573,BRD:BRD-K00003190-001-01-9,rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,RMYZIRFUCOMQRH-CAJLXGCNSA-N,O=C1O[C@]2(CC[C@H](C(=O)NC3CCN(-C4CCCCC4F)N3)CC2)C2CNCCC21
MK-0608,MK-0608,,BRD:BRD-K00004557-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,,NA,,
MK-0683,MK-0683,CHEMBL98,GDSC1:1012;GDSC2:1012,gdsc,,,,,,,Small molecule,Approved,WAEXFXRVDQXREF-UHFFFAOYSA-N,O=C(CCCCCCC(=O)NC1CCCCC1)NO
MK-0752,MK-0752,CHEMBL4205422,BRD:BRD-BRD-K18850819-001-04-6;BRD:BRD-K18850819-001-04-6;CTRP:660332,ctrp;rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,XCGJIFAKUZNNOR-QCKZDCLWSA-N,O=C(O)CC[C@H]1CC[C@@](C2CC(F)CCC2F)(S(=O)(=O)C2CCC(CL)CC2)CC1;OC(=O)CC[C@H]1CC[C@@](CC1)(C1CC(F)CCC1F)S(=O)(=O)C1CCC(CL)CC1
MK-0773,MK-0773,CHEMBL3545333,BRD:BRD-BRD-K38868394-001-01-3;BRD:BRD-K38868394-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 2,,Small molecule,Phase 2,GBEUKTWTUSPHEE-PAWGCEJPSA-N,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCC5NC6CCCNC6[NH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O;CN1C(=O)C(F)=C[C@]2(C)C3CC[C@@]4(C)C(CC[C@@H]4C(=O)NCC4NC5NCCCC5[NH]4)C3CCC12
MK-0812,MK-0812,CHEMBL4297538,BRD:BRD-BRD-K14175878-001-01-6;BRD:BRD-K14175878-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR2,,,PHASE 2,,Small molecule,Phase 2,UNVWTBOGMHPKJM-CWKRKGSWSA-N,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCC2NCC(CC2C1)C(F)(F)F;CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](CN2CCC3NCC(C(F)(F)F)CC3C2)(C(C)C)C1
MK-0893,MK-0893,CHEMBL1933349,BRD:BRD-BRD-K16732600-001-01-7;BRD:BRD-K16732600-001-01-7,rep_primary;rep_single_dose,GLUCAGON RECEPTOR ANTAGONIST,GCGR,,,PHASE 2,,Small molecule,Phase 2,DNTVJEMGHBIUMW-IBGZPJMESA-N,COC1CCC2CC(-C3CC(-C4CC(CL)CC(CL)C4)NN3[C@@H](C)C3CCC(C(=O)NCCC(=O)O)CC3)CCC2C1;COC1CCC2CC(CCC2C1)-C1CC(NN1[C@@H](C)C1CCC(CC1)C(=O)NCCC(O)=O)-C1CC(CL)CC(CL)C1
MK-0941,MK-0941,CHEMBL3580737;CHEMBL4297302,BRD:BRD-K00079347-066-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,KJSGTWFWVTYPFZ-AWEZNQCLSA-N;PIDNRTWDGDJKSQ-UQKRIMTDSA-N,CCS(=O)(=O)C1CCC(OC2CC(O[C@@H](C)CO)CC(C(=O)NC3CCN(C)N3)C2)CN1;CCS(=O)(=O)C1CCC(OC2CC(O[C@@H](C)CO)CC(C(=O)NC3CCN(C)N3)C2)CN1.CS(=O)(=O)O
MK-1064,MK-1064,CHEMBL3338866,BRD:BRD-K00003304-001-01-9,rep_single_dose,OREXIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 1,CKTWQGHVNRYNCM-UHFFFAOYSA-N,COC1CCC(CNC(=O)C2CC(-C3CNCC(CL)C3)CNC2-C2CCCCN2)NC1OC
MK-1903,MK-1903,,BRD:BRD-K00004660-001-01-9,rep_single_dose,NIACIN RECEPTOR AGONIST,,,,,,,NA,,
MK-2206,MK-2206,CHEMBL1079175,BRD:BRD-BRD-K68065987-300-09-1;BRD:BRD-K68065987-300-09-1;CTRP:377381;GDSC1:1053;GDSC2:1053,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,AKT1;AKT2;AKT3,,,PHASE 2,,Small molecule,Phase 2,ULDXWLCXEDXJGE-UHFFFAOYSA-N,NC1(C2CCC(-C3NC4CCN5C(=O)[NH]NC5C4CC3-C3CCCCC3)CC2)CCC1;NC1(CCC1)C1CCC(CC1)-C1NC2CCN3C(N[NH]C3=O)C2CC1-C1CCCCC1
MK-2295,MK-2295,CHEMBL3545227,BRD:BRD-BRD-K43316319-001-01-8;BRD:BRD-K43316319-001-01-8,rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PHASE 2,,Small molecule,Phase 2,,FC(F)(F)C1CCC(NC2NCNC3CC(CCC23)-C2NCCCC2C(F)(F)F)CC1
MK-2461,MK-2461,CHEMBL1822792,BRD:BRD-BRD-K56405753-001-02-4;BRD:BRD-K56405753-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, VEGFR INHIBITOR",FGFR1;FGFR2;FGFR3;FLT1;FLT3;FLT4;KDR;MERTK;MET;MST1R;NTRK1;NTRK2;PDGFRB,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,JGEBLDKNWBUGRZ-HXUWFJFHSA-N,CN(C[C@@H]1COCCO1)S(=O)(=O)NC1CCC2CCC3NCC(-C4CNN(C)C4)CC3C(=O)C2C1;CN(C[C@@H]1COCCO1)S(=O)(=O)NC1CCC2CCC3NCC(CC3C(=O)C2C1)-C1CNN(C)C1
MK-2894,MK-2894,,BRD:BRD-K27983781-001-01-4,rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGER4,,,,,,NA,,
MK-3207,MK-3207,CHEMBL1910936,BRD:BRD-BRD-K66911501-003-01-2;BRD:BRD-K66911501-003-01-2,rep_multi_dose;rep_primary;rep_single_dose,CALCITONIN ANTAGONIST,CALCA,,,PHASE 2,,Small molecule,Phase 2,AZAANWYREOQRFB-SETSBSEESA-N,FC1CC(F)CC(C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1CCC2C[C@]3(CC2C1)C(=O)NC1NCCCC31;O=C(CN1C(=O)C2(CCCC2)NC[C@H]1C1CC(F)CC(F)C1)NC1CCC2C(C1)C[C@@]1(C2)C(=O)NC2NCCCC21
MK-3697,MK-3697,,BRD:BRD-BRD-K95828359-001-01-0;BRD:BRD-K95828359-001-01-0,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR2,,,PHASE 2,,,NA,,COC1CCC(CNC(=O)C2CC(NCC2-C2NCCS2)-C2CNCC(C)C2)NC1OC
MK-4074,MK-4074,,BRD:BRD-K00003482-001-01-9,rep_single_dose,ACETYL-COA CARBOXYLASE INHIBITOR,,,,,,,NA,,
NIRAPARIB,MK-4827;NIRAPARIB,CHEMBL1094636,BRD:BRD-BRD-K54955827-001-02-2;BRD:BRD-K54955827-001-02-2;GDSC2:1177,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF PARP1 AND PARP2,PARP1;PARP2,PRIMARY PERITONEAL CANCER (PPC),,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF PARP1 AND PARP2', 'PARP INHIBITOR'}, defaulting to 'INHIBITOR OF PARP1 AND PARP2'
Multiple values for repurposing_target: {'PARP1', 'PARP1;PARP2'}, taking the union",Small molecule,Approved,PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)C1CCCC2CN(-C3CCC([C@@H]4CCCNC4)CC3)NC12;NC(=O)C1CCCC2CN(NC12)-C1CCC(CC1)[C@@H]1CCCNC1
MK-5046,MK-5046,,BRD:BRD-K03886848-001-01-8,rep_single_dose,BOMBESIN RECEPTOR AGONIST,BRS3;GRPR;NMBR,,,,,,NA,,
MK-5108,MK-5108,CHEMBL3182444,BRD:BRD-BRD-K53665955-001-03-0;BRD:BRD-K53665955-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC,,,PHASE 1,,Small molecule,Phase 1,LCVIRAZGMYMNNT-UHFFFAOYSA-N,O=C(O)C1(CC2CCCC(NC3NCCS3)N2)CCC(OC2CCCC(CL)C2F)CC1;OC(=O)[C@@]1(CC2CCCC(NC3NCCS3)N2)CC[C@@H](CC1)OC1CCCC(CL)C1F
MK-571,MK-571,CHEMBL15177,BRD:BRD-A73679382-236-01-8;BRD:BRD-BRD-A73679382-236-01-8,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,ABCC2;CYSLTR1,,,PHASE 2,,Small molecule,NA,AXUZQJFHDNNPFG-UXBLZVDNSA-N,CN(C)C(=O)CCSC(SCCC(=O)O)C1CCCC(/C=C/C2CCC3CCC(CL)CC3N2)C1;CN(C)C(=O)CCSC(SCCC(O)=O)C1CCCC(\C=C\C2CCC3CCC(CL)CC3N2)C1
MK-6096,MK-6096,CHEMBL2107822,BRD:BRD-BRD-K03894385-001-01-1;BRD:BRD-K03894385-001-01-1,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,PHASE 2,,Small molecule,Phase 2,NPFDWHQSDBWQLH-QZTJIDSGSA-N,C[C@@H]1CC[C@@H](COC2CCC(F)CN2)CN1C(=O)C1CC(C)CCC1-C1NCCCN1;CC1CCC(-C2NCCCN2)C(C(=O)N2C[C@H](COC3CCC(F)CN3)CC[C@H]2C)C1
MK-7246,MK-7246,CHEMBL561132,BRD:BRD-K00003199-001-01-9,rep_single_dose,CRTH RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 1,JTCAGRAKUAAYDY-OAHLLOKOSA-N,CN([C@@H]1CCC2C(CC(=O)O)C3CCCCC3N2C1)S(=O)(=O)C1CCC(F)CC1
MK-7622,MK-7622,CHEMBL4078588,BRD:BRD-K00003194-001-01-9,rep_single_dose,CHOLINERGIC RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,JUVQLZBJFOGEEO-GOTSBHOMSA-N,CC1CCC(CC2CC3C(=O)N([C@H]4CCCC[C@@H]4O)CNC3C3CCCCC23)CN1
MK-7965,MK-7965,CHEMBL2103840,GDSC2:1180,gdsc,,,,,,,Small molecule,Phase 3,PIMQWRZWLQKKBJ-SFHVURJKSA-N,CCC1CNN2C(NCC3CCC[N+]([O-])C3)CC(N3CCCC[C@H]3CCO)NC12
MK-8033,MK-8033,CHEMBL2323775,BRD:BRD-BRD-K55512740-001-01-6;BRD:BRD-K55512740-001-01-6,rep_primary;rep_single_dose,C-MET INHIBITOR,MET,,,PHASE 1,,Small molecule,Phase 1,VMJFTOSOFDEKTM-UHFFFAOYSA-N,CN1CC(-C2CNC3CCC4CCC(CS(=O)(=O)NCC5CCCCN5)CC4C(=O)C3C2)CN1;CN1CC(CN1)-C1CNC2CCC3CCC(CS(=O)(=O)NCC4CCCCN4)CC3C(=O)C2C1
MK-8245,MK-8245,CHEMBL1938870,BRD:BRD-BRD-K29656036-001-02-5;BRD:BRD-K29656036-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,STEAROYL-COA DESATURASE INHIBITOR,SCD,,,PHASE 2,,Small molecule,Phase 1,UJEAABFSXKCSGI-UHFFFAOYSA-N,O=C(O)CN1NNC(-C2CC(N3CCC(OC4CC(F)CCC4BR)CC3)NO2)N1;OC(=O)CN1NNC(N1)-C1CC(NO1)N1CCC(CC1)OC1CC(F)CCC1BR
MK-8617,MK-8617,,BRD:BRD-K00003397-001-01-9,rep_single_dose,HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR,,,,,,,NA,,
MK-8628,MK-8628,CHEMBL3581647,GDSC2:1626,gdsc,,,,,,,Small molecule,Phase 2,GNMUEVRJHCWKTO-FQEVSTJZSA-N,CC1SC2C(C1C)C(C1CCC(CL)CC1)=N[C@@H](CC(=O)NC1CCC(O)CC1)C1NNC(C)N1-2
MK-8745,MK-8745,,BRD:BRD-BRD-K25279140-001-01-5;BRD:BRD-K25279140-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA,,,PRECLINICAL,,,NA,,FC1C(CL)CCCC1C(=O)N1CCN(CC2CCCC(NC3NCCS3)N2)CC1
MK-8776,MK-8776,CHEMBL2386889,GDSC2:2046,gdsc,,,,,,,Small molecule,Phase 2,GMIZZEXBPRLVIV-SECBINFHSA-N,CN1CC(-C2CNN3C(N)C(BR)C([C@@H]4CCCNC4)NC23)CN1
MK-886,MK-886,,BRD:BRD-K20168484-001-07-9,rep_single_dose,LIPOXYGENASE INHIBITOR,,,,,,,NA,,
MK-8998,MK-8998,CHEMBL1684950,BRD:BRD-K86677390-001-02-9,rep_single_dose,T-TYPE CALCIUM CHANNEL BLOCKER,,,,,,Small molecule,Phase 2,IQIKXZMPPBEWAD-CQSZACIVSA-N,CC(C)C1CCC(CC(=O)N[C@H](C)C2CCC(OCC(F)(F)F)CN2)CC1
MK2-IN-1,MK2-IN-1,,BRD:BRD-K90316462-003-01-1,rep_single_dose,MAP KINASE INHIBITOR,MAPKAPK2,,,,,,NA,,
MK2206,MK2206,CHEMBL1079175,GDSC1:1053;GDSC2:1053,gdsc,,,,,,,Small molecule,Phase 2,ULDXWLCXEDXJGE-UHFFFAOYSA-N,NC1(C2CCC(-C3NC4CCN5C(=O)[NH]NC5C4CC3-C3CCCCC3)CC2)CCC1
MK4827,MK4827,CHEMBL1094636,GDSC2:1177,gdsc,,,,,,,Small molecule,Approved,PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)C1CCCC2CN(-C3CCC([C@@H]4CCCNC4)CC3)NC12
ML179,ML-179;ML179,,BRD:BRD-BRD-K77547509-001-03-3;BRD:BRD-K77547509-001-03-3,rep_primary;rep_single_dose,LIVER RECEPTOR HOMOLOG INVERSE AGONIST,NR5A2,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCCC(C1)N1CCN(CC1)C1CC(=O)N(C2CCCCC2)C(=O)[NH]1
ML193,ML-193;ML193,,BRD:BRD-BRD-K27539181-001-08-5;BRD:BRD-K27539181-001-08-5,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR ANTAGONIST,GPR55,,,PRECLINICAL,,,NA,,CC1NOC(NS(=O)(=O)C2CCC(NC(=O)C3CC(NC4C(C)CC(C)CC34)-C3CCCCN3)CC2)C1C
ML213,ML-213;ML213,,BRD:BRD-A12633378-001-07-0;BRD:BRD-BRD-A12633378-001-07-0;BRD:BRD-K00004301-001-01-9,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNQ4,,,PRECLINICAL,"Multiple values for structure_id: {'K00004301', 'A12633378'}, defaulting to None",,NA,,CC1CC(C)C(NC(=O)C2CC3CCC2C3)C(C)C1
ML228,ML-228;ML228,,BRD:BRD-BRD-K44432556-001-05-5;BRD:BRD-K44432556-001-05-5,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR ACTIVATOR,HIF1A,,,PRECLINICAL,,,NA,,C(NC1NC(NNC1-C1CCCCC1)-C1CCCCN1)C1CCC(CC1)-C1CCCCC1
ML277,ML-277;ML277,,BRD:BRD-BRD-K60020910-001-02-5;BRD:BRD-K60020910-001-02-5,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNQ1,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-C1CSC(NC(=O)[C@H]2CCCCN2S(=O)(=O)C2CCC(C)CC2)N1
ML281,ML-281;ML281,,BRD:BRD-BRD-K48188942-001-03-7;BRD:BRD-K48188942-001-03-7,rep_primary;rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,STK33,,,PRECLINICAL,,,NA,,CC(C)C1CCC(NC(=O)C2CCCS2)C(C1)-C1NC2CCCCC2[NH]C1=O
ML323,ML-323;ML323,,BRD:BRD-BRD-K93942811-001-01-3;BRD:BRD-K93942811-001-01-3;GDSC2:1629,gdsc;rep_primary;rep_single_dose,UBIQUITIN SPECIFIC PROTEASE INHIBITOR,USP1,,,PRECLINICAL,,,NA,,CC(C)C1CCCCC1-C1NCC(C)C(NCC2CCC(CC2)-N2CCNN2)N1
ML3403,ML-3403;ML3403,,BRD:BRD-A29014990-001-02-3;BRD:BRD-BRD-A29014990-001-02-3,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,CYP3A4;MAPK11;MAPK12;MAPK14,,,PRECLINICAL,,,NA,,CSC1NC(C([NH]1)-C1CCNC(NC(C)C2CCCCC2)C1)-C1CCC(F)CC1
ML348,ML-348;ML348,,BRD:BRD-BRD-K81044214-001-06-4;BRD:BRD-K81044214-001-06-4,rep_primary;rep_single_dose,LYSOPHOSPHOLIPASE INHIBITOR,LYPLA1,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCC(CL)C(NC(=O)CN2CCN(CC2)C(=O)C2CCCO2)C1
ML365,ML-365;ML365,,BRD:BRD-BRD-K02160913-001-02-7;BRD:BRD-K02160913-001-02-7,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNK3;KCNK9,,,PRECLINICAL,,,NA,,COC1CCCCC1C(=O)NC1CCCC(NC(=O)C2CCCC(C)C2)C1
ML9,ML-9;ML9,,BRD:BRD-BRD-K68402494-003-03-5;BRD:BRD-K68402494-003-03-5,rep_primary;rep_single_dose,MYOSIN LIGHT CHAIN KINASE INHIBITOR,TRPC6,,,PRECLINICAL,,,NA,,CLC1CCCC2C(CCCC12)S(=O)(=O)N1CCCNCC1
ML006,ML006,,CTRP:17712,ctrp,,,,,,,,NA,,
ML029,ML029,,CTRP:350548,ctrp,,,,,,,,NA,,
ML031,ML031,,CTRP:96171,ctrp,,,,,,,,NA,,
ML050,ML050,,CTRP:153820,ctrp,,,,,,,,NA,,
ML083,ML083,,CTRP:255961,ctrp,,,,,,,,NA,,
ML10302,ML10302,,BRD:BRD-K69343602-003-02-9,rep_single_dose,SEROTONIN RECEPTOR PARTIAL AGONIST,HTR3A;HTR3B;HTR4,,,,,,NA,,
ML130,ML130,,BRD:BRD-BRD-K89306950-001-12-5;BRD:BRD-K89306950-001-12-5,rep_primary;rep_single_dose,NOD1 INHIBITOR,,,,PRECLINICAL,,,NA,,CC1CCC(CC1)S(=O)(=O)N1C(N)NC2CCCCC12
ML133,ML133,,BRD:BRD-BRD-K33743361-003-02-6;BRD:BRD-K33743361-003-02-6,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,COC1CCC(CNCC2CCCC3CCCCC23)CC1
ML141,ML141,,BRD:BRD-A28422330-001-11-9,rep_single_dose,GTPASE INHIBITOR,CDC42,,,,,,NA,,
ML161,ML161,,BRD:BRD-BRD-K59036917-001-16-7;BRD:BRD-K59036917-001-16-7,rep_primary;rep_single_dose,PROTEASE-ACTIVATED RECEPTOR INHIBITOR,,,,PRECLINICAL,,,NA,,CCCC(=O)NC1CCCC(NC(=O)C2CCCCC2BR)C1
ML162,ML162,,CTRP:154846,ctrp,,,,,,,,NA,,
ML167,ML167,,BRD:BRD-BRD-K64835161-001-02-8;BRD:BRD-K64835161-001-02-8,rep_primary;rep_single_dose,"CLK INHIBITOR, DYRK INHIBITOR",CLK4;DYRK1B,,,PRECLINICAL,,,NA,,CC1CCC(CNC2NCNC3CCC(CC23)-C2CCC(CO)O2)O1
ML203,ML203,,CTRP:411816,ctrp,,,,,,,,NA,,
ML204,ML204,,BRD:BRD-BRD-K80021413-001-08-8;BRD:BRD-K80021413-001-08-8,rep_primary;rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPC4;TRPC5,,,PRECLINICAL,,,NA,,CC1CC(NC2CCCCC12)N1CCCCC1
ML210,ML210,,BRD:BRD-K01877528-001-20-9;CTRP:609110,ctrp;oncref_1,INHIBITOR OF GPX4,GPX4,,,,,,NA,,
ML218,ML218,,BRD:BRD-K92995792-003-03-9,rep_single_dose,T-TYPE CALCIUM CHANNEL BLOCKER,CACNA1G;CACNA1H;CACNA1I,,,,,,NA,,
ML239,ML239,,CTRP:609781,ctrp,,,,,,,,NA,,
ML258,ML258,,CTRP:660314,ctrp,,,,,,,,NA,,
ML298,ML298,,BRD:BRD-K24600306-003-02-9,rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLD2,,,,,,NA,,
ML311,ML311,,CTRP:290356,ctrp,,,,,,,,NA,,
ML312,ML312,,CTRP:434195,ctrp,,,,,,,,NA,,
ML314,ML314,,BRD:BRD-BRD-K92606079-001-02-0;BRD:BRD-K92606079-001-02-0,rep_primary;rep_single_dose,NEUROTENSIN AGONIST,NTSR1,,,PRECLINICAL,,,NA,,COC1CCCCC1N1CCN(CC1)C1NC(NC2CC(OC)C(OC)CC12)C1CC1
ML320,ML320,,CTRP:659682,ctrp,,,,,,,,NA,,
ML324,ML324,,BRD:BRD-K25611237-001-02-1,rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM4A,,,,,,NA,,
ML334 DIASTEREOMER,ML334 DIASTEREOMER,,CTRP:654278,ctrp,,,,,,,,NA,,
ML347,ML347,,BRD:BRD-BRD-K33892651-001-02-4;BRD:BRD-K33892651-001-02-4,rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ACVR1;ACVRL1;BMPR1A,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-C1CNC2C(CNN2C1)-C1CCCC2NCCCC12
ML355,ML355,CHEMBL3113165,BRD:BRD-K15324227-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,OWHBVKBNNRYMIN-UHFFFAOYSA-N,COC1CCCC(CNC2CCC(S(=O)(=O)NC3NC4CCCCC4S3)CC2)C1O
ML786,ML786,,BRD:BRD-K52644305-300-02-9,rep_single_dose,RAF INHIBITOR,BRAF;RAF1,,,,,,NA,,
MLN 4924,MLN 4924,CHEMBL1231160,GDSC1:1529;GDSC2:1529,gdsc,,,,,,,Small molecule,Phase 3,MPUQHZXIXSTTDU-QXGSTGNESA-N,NS(=O)(=O)OC[C@@H]1C[C@@H](N2CCC3C(N[C@H]4CCC5CCCCC54)NCNC32)C[C@@H]1O
MLN-4924,MLN-4924,CHEMBL1231160,GDSC1:1529;GDSC2:1529,gdsc,,,,,,,Small molecule,Phase 3,MPUQHZXIXSTTDU-QXGSTGNESA-N,NS(=O)(=O)OC[C@@H]1C[C@@H](N2CCC3C(N[C@H]4CCC5CCCCC54)NCNC32)C[C@@H]1O
MLN8054,MLN-8054;MLN8054,CHEMBL259084,BRD:BRD-BRD-K83963101-001-06-9;BRD:BRD-K83963101-001-06-9,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA,,,PHASE 1,,Small molecule,Phase 1,HHFBDROWDBDFBR-UHFFFAOYSA-N,O=C(O)C1CCC(NC2NCC3C(N2)-C2CCC(CL)CC2C(C2C(F)CCCC2F)=NC3)CC1;OC(=O)C1CCC(NC2NCC3CN=C(C4CC(CL)CCC4-C3N2)C2C(F)CCCC2F)CC1
MLN0128,MLN0128,CHEMBL3545097,BRD:BRD-BRD-K59317601-001-05-5;BRD:BRD-K59317601-001-05-5,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR;PIK3CA;PIK3CD;PIK3CG,,,PHASE 2,,Small molecule,Phase 2,GYLDXIAOMVERTK-UHFFFAOYSA-N,CC(C)N1NC(-C2CCC3OC(N)NC3C2)C2C(N)NCNC12;CC(C)N1NC(-C2CCC3OC(N)NC3C2)C2C(N)NCNC21
MLN1117,MLN1117,CHEMBL3935857,BRD:BRD-BRD-K73877023-001-01-9;BRD:BRD-K73877023-001-01-9,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,BLGWHBSBBJNKJO-UHFFFAOYSA-N,NC1NC2CC(-C3CCC4NCC(C(=O)N5CCOCC5)N4C3)CCC2O1;NC1NC2CC(CCC2O1)-C1CCC2NCC(C(=O)N3CCOCC3)N2C1
MLN2238,MLN2238,CHEMBL2141296,CTRP:632873,ctrp,,,,,,,Small molecule,Approved,MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)C1CC(CL)CCC1CL)B(O)O
MLN2480,MLN2480,,BRD:BRD-BRD-K43410529-001-02-3;BRD:BRD-K43410529-001-02-3;CTRP:687579,ctrp;rep_primary;rep_single_dose,RAF INHIBITOR,,,,PHASE 1,,,NA,,C[C@@H](NC(=O)C1NCNC(N)C1CL)C1NCC(S1)C(=O)NC1CC(C(CL)CN1)C(F)(F)F
PEVONEDISTAT,MLN4924;PEVONEDISTAT,CHEMBL1231160,BRD:BRD-BRD-K67844266-003-01-9;BRD:BRD-K00003376-001-03-9;BRD:BRD-K67844266-003-01-9;CTRP:411809;GDSC1:1529;GDSC2:1529,ctrp;gdsc;oncref_2;rep_multi_dose;rep_primary;rep_single_dose,NEDD ACTIVATING ENZYME INHIBITOR,NAE1;UBA3,,,PHASE 2,"Multiple values for MOA: {'NEDD ACTIVATING ENZYME INHIBITOR', 'INHIBITOR OF NAE1'}, defaulting to 'NEDD ACTIVATING ENZYME INHIBITOR'
Multiple values for repurposing_target: {'NAE1;UBA3', 'NAE1'}, taking the union
Multiple values for structure_id: {'K00003376', 'K67844266'}, defaulting to None",Small molecule,Phase 3,MPUQHZXIXSTTDU-QXGSTGNESA-N,NS(=O)(=O)OC[C@@H]1C[C@@H](N2CCC3C(N[C@H]4CCC5CCCCC54)NCNC32)C[C@@H]1O;NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)N1CCC2C(N[C@H]3CCC4CCCCC34)NCNC12
TAK-243,MLN7243;TAK-243,CHEMBL4297405,BRD:BRD-K67844266-001-07-9;BRD:BRD-U00127223-001-01-9,oncref_2,INHIBITOR OF UAE,UBA1,,,,,Small molecule,Phase 1,KJDAGXLMHXUAGV-DGWLBADLSA-N,NS(=O)(=O)OC[C@H]1C[C@@H](NC2CCNC3CC(-C4CCCC(SC(F)(F)F)C4)NN23)[C@H](O)[C@@H]1O
MLN8237,MLN8237,CHEMBL483158,GDSC1:431;GDSC2:1051,gdsc,,,,,,,Small molecule,Phase 3,ZLHFILGSQDJULK-UHFFFAOYSA-N,COC1CC(NC2NCC3C(N2)-C2CCC(CL)CC2C(C2C(F)CCCC2OC)=NC3)CCC1C(=O)O
MM-102,MM-102,,BRD:BRD-BRD-K68474068-001-01-8;BRD:BRD-K68474068-001-01-8,rep_primary;rep_single_dose,WDR5/MLL INTERACTION INHIBITOR,,,,PRECLINICAL,,,NA,,CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(C1CCC(F)CC1)C1CCC(F)CC1
MM-11253,MM-11253,,BRD:BRD-BRD-K98353094-001-01-6;BRD:BRD-K98353094-001-01-6,rep_primary;rep_single_dose,RETINOID RECEPTOR ANTAGONIST,RARG,,,PRECLINICAL,,,NA,,CC1(C)CCC(C)(C)C2CC(CCC12)C1(SCCS1)C1CCC2CC(CCC2C1)C(O)=O
MM-206,MM-206,,BRD:BRD-K00004622-001-01-9,rep_single_dose,STAT INHIBITOR,,,,,,,NA,,
MM77,MM77,,BRD:BRD-BRD-K50293352-300-02-1;BRD:BRD-K50293352-300-02-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A,,,PRECLINICAL,,,NA,,COC1CCCCC1N1CCN(CCCCN2C(=O)CCC2=O)CC1
MMC,MMC,,GDSC1:136,gdsc,,,,,,,,NA,,
MMPX,MMPX,,BRD:BRD-BRD-K56077740-001-09-2;BRD:BRD-K56077740-001-09-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,PRECLINICAL,,,NA,,COCC1NC2N(CC(C)C)C(=O)N(C)C(=O)C2[NH]1
MMV-390048,MMV-390048,CHEMBL2041980,BRD:BRD-K78973789-001-02-9,rep_single_dose,PI4K INHIBITOR,,,,,,Small molecule,Phase 1,RTJQABCNNLMCJF-UHFFFAOYSA-N,CS(=O)(=O)C1CCC(-C2CNC(N)C(-C3CCC(C(F)(F)F)NC3)C2)CC1
MN-64,MN-64,,BRD:BRD-BRD-K16183658-001-01-4;BRD:BRD-K16183658-001-01-4;GDSC2:1854,gdsc;rep_primary;rep_single_dose,TANKYRASE INHIBITOR,TNKS,,,PRECLINICAL,,,NA,,CC(C)C1CCC(CC1)-C1CC(=O)C2CCCCC2O1
MNITMT,MNITMT,,BRD:BRD-BRD-K63151507-001-02-4;BRD:BRD-K63151507-001-02-4,rep_primary;rep_single_dose,LYMPHOCYTE INHIBITOR,,,,PRECLINICAL,,,NA,,CN1CNNC1SC1C(NCN1C)[N+]([O-])=O
"MNS-(3,4-METHYLENEDIOXY-NITROSTYRENE)","MNS-(3,4-METHYLENEDIOXY-NITROSTYRENE)",,BRD:BRD-BRD-K42205652-001-02-7,rep_primary,"SRC INHIBITOR, SYK INHIBITOR",SRC;SYK,,,PRECLINICAL,,,NA,,[O-][N+](=O)\C=C\C1CCC2OCOC2C1
MOBOCERTINIB,MOBOCERTINIB,CHEMBL4650319,BRD:BRD-K00069020-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,AZSRSNUQCUDCGG-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCC(C(=O)OC(C)C)C(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C
MOCETINOSTAT,MOCETINOSTAT,CHEMBL272980,BRD:BRD-BRD-K16485616-001-08-9;BRD:BRD-K16485616-001-08-9,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC11;HDAC2;HDAC3,,,PHASE 2,,Small molecule,Phase 2,HRNLUBSXIHFDHP-UHFFFAOYSA-N,NC1CCCCC1NC(=O)C1CCC(CNC2NCCC(-C3CCCNC3)N2)CC1;NC1CCCCC1NC(=O)C1CCC(CNC2NCCC(N2)-C2CCCNC2)CC1
MOCLOBEMIDE,MOCLOBEMIDE,CHEMBL86304,BRD:BRD-BRD-K07237224-001-19-6;BRD:BRD-K07237224-001-19-6,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,"DEPRESSION, ANXIETY",,LAUNCHED,,Small molecule,Approved,YHXISWVBGDMDLQ-UHFFFAOYSA-N,CLC1CCC(CC1)C(=O)NCCN1CCOCC1;O=C(NCCN1CCOCC1)C1CCC(CL)CC1
MODALINE,MODALINE,CHEMBL2111121,BRD:BRD-BRD-K25317177-065-01-4;BRD:BRD-K25317177-065-01-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,BJHCGMHPEKLROM-UHFFFAOYSA-N,CC1NCCNC1N1CCCCC1
MOEXIPRIL,MOEXIPRIL,CHEMBL1165,BRD:BRD-BRD-K34441861-003-07-0;BRD:BRD-K34441861-003-07-0,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE;ACE2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,UWWDHYUMIORJTA-HSQYWUDLSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CC2CC(OC)C(OC)CC2C[C@H]1C(=O)O;CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CC2CC(OC)C(OC)CC2C[C@H]1C(O)=O
MOFEGILINE,MOFEGILINE,CHEMBL489079,BRD:BRD-BRD-K52598503-003-01-1;BRD:BRD-K52598503-003-01-1,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,,,PHASE 1,,Small molecule,Unknown,VXLBSYHAEKDUSU-JXMROGBWSA-N,NC/C(=C/F)CCC1CCC(F)CC1;NC\C(CCC1CCC(F)CC1)=C\F
MOFEZOLAC,MOFEZOLAC,CHEMBL259972,BRD:BRD-BRD-K49372556-001-04-1;BRD:BRD-K49372556-001-04-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1,"RHEUMATOID ARTHRITIS, OSTEOPOROSIS",,LAUNCHED,,Small molecule,Unknown,DJEIHHYCDCTAAH-UHFFFAOYSA-N,COC1CCC(-C2NOC(CC(=O)O)C2-C2CCC(OC)CC2)CC1;COC1CCC(CC1)-C1NOC(CC(O)=O)C1-C1CCC(OC)CC1
MOGUISTEINE,MOGUISTEINE,CHEMBL146980,BRD:BRD-A87673115-001-04-1;BRD:BRD-BRD-A87673115-001-04-1,rep_primary;rep_single_dose,ATP-SENSITIVE POTASSIUM CHANNEL INHIBITOR,,,,PHASE 2,,Small molecule,Unknown,WSYVIAQNTFPTBI-UHFFFAOYSA-N,CCOC(=O)CC(=O)N1CCSC1COC1CCCCC1OC
MOLIDUSTAT,MOLIDUSTAT,CHEMBL3646118,BRD:BRD-BRD-K01291782-001-01-1;BRD:BRD-K01291782-001-01-1,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,EGLN2,,,PHASE 2,,Small molecule,Phase 2,IJMBOKOTALXLKS-UHFFFAOYSA-N,O=C1C(-N2CCNN2)C[NH]N1-C1CC(N2CCOCC2)NCN1;O=C1C(C[NH]N1-C1CC(NCN1)N1CCOCC1)-N1CCNN1
MOLINDONE,MOLINDONE,CHEMBL460,BRD:BRD-A65280694-003-13-7;BRD:BRD-BRD-A65280694-003-13-7,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CHRM1;DRD2;HRH1;HTR1A;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,KLPWJLBORRMFGK-UHFFFAOYSA-N,CCC1C(C)[NH]C2C1C(=O)C(CN1CCOCC1)CC2;CCC1C(C)[NH]C2CCC(CN3CCOCC3)C(=O)C12
MOLNUPIRAVIR,MOLNUPIRAVIR,CHEMBL4650320,BRD:BRD-K00090621-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,HTNPEHXGEKVIHG-QCNRFFRDSA-N,CC(C)C(=O)OC[C@H]1O[C@@H](N2CC/C(=N\O)[NH]C2=O)[C@H](O)[C@@H]1O
MOLSIDOMINE,MOLSIDOMINE,CHEMBL1256353;CHEMBL1329455,BRD:BRD-BRD-K63861289-001-19-6;BRD:BRD-K63861289-001-19-6,rep_primary;rep_single_dose,GUANYLATE CYCLASE STIMULANT,GUCY1A3,CORONARY ARTERY DISEASE (CAD),,LAUNCHED,,Small molecule,Approved,XLFWDASMENKTKL-NTMALXAHSA-N;XLFWDASMENKTKL-UHFFFAOYSA-N,CCOC(=O)[N-]C1C[N+](N2CCOCC2)NO1;CCOC(=O)/N=C1/C[N+](N2CCOCC2)[N-]O1;CCOC(=O)NC1C[N+](NO1)N1CCOCC1
MOMETASONE-FUROATE,MOMETASONE-FUROATE,,BRD:BRD-BRD-K60640630-001-11-0;BRD:BRD-K60640630-001-11-0,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(CL)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C1CCCO1)C(=O)CCL
MONASTROL,MONASTROL,CHEMBL236789,BRD:BRD-A78377521-001-05-5;BRD:BRD-BRD-A78377521-001-05-5,rep_primary;rep_single_dose,KINESIN INHIBITOR,KIF11,,,PRECLINICAL,,Small molecule,NA,LOBCDGHHHHGHFA-UHFFFAOYSA-N,CCOC(=O)C1=C(C)NC(=S)NC1C1CCCC(O)C1
MONENSIN,MONENSIN,CHEMBL256105,BRD:BRD-A06627858-236-03-0;BRD:BRD-BRD-A06627858-236-03-0,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL PERMEABILITY INDUCER,,,,LAUNCHED,,Small molecule,Unknown,GAOZTHIDHYLHMS-KEOBGNEYSA-N,CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C;CC[C@@]1([C@@H]2O[C@@H]([C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)C[C@@H]2C)CC[C@H]([C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(=O)O)O3)O2)O1
MONEPANTEL,MONEPANTEL,CHEMBL256563,BRD:BRD-K00004607-001-01-9,rep_single_dose,MTOR INHIBITOR,,,,,,Small molecule,Phase 1,WTERNLDOAPYGJD-SFHVURJKSA-N,C[C@](C#N)(COC1CC(C#N)CCC1C(F)(F)F)NC(=O)C1CCC(SC(F)(F)F)CC1
MONOBENZONE,MONOBENZONE,CHEMBL1388,BRD:BRD-BRD-K54262262-001-09-0;BRD:BRD-K54262262-001-09-0,rep_multi_dose;rep_primary;rep_single_dose,MELANIN INHIBITOR,TYR,SKIN DEPIGMENTATION,,LAUNCHED,,Small molecule,Approved,VYQNWZOUAUKGHI-UHFFFAOYSA-N,OC1CCC(OCC2CCCCC2)CC1
MONOCROTALINE,MONOCROTALINE,CHEMBL521035,BRD:BRD-K65508953-001-13-9,rep_single_dose,ANTITUMOR AGENT,,,,,,Small molecule,NA,QVCMHGGNRFRMAD-XFGHUUIASA-N,C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23
MONOCTANOIN,MONOCTANOIN,CHEMBL3301678;CHEMBL3304484,BRD:BRD-A48938994-001-14-1;BRD:BRD-BRD-A48938994-001-14-1,rep_primary;rep_single_dose,,,GALLSTONES,,LAUNCHED,,Small molecule,Approved,JFUMHQVCWWFATH-UHFFFAOYSA-N;YTORMSBGFMQNEO-UHFFFAOYSA-N,CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO;CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO.OCC(O)CO;CCCCCCCC(=O)OCC(O)CO
MONOMETHYL-FUMARATE,MONOMETHYL-FUMARATE,,BRD:BRD-K00004695-001-01-9,rep_single_dose,,,,,,,,NA,,
MONOSODIUM-ALPHA-LUMINOL,MONOSODIUM-ALPHA-LUMINOL,,BRD:BRD-BRD-K52559566-001-02-9;BRD:BRD-K52559566-001-02-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,NC1CCCC2C1C(=O)[NH][NH]C2=O
MONOSTEARIN,MONOSTEARIN,CHEMBL255696,BRD:BRD-A31454688-001-01-6;BRD:BRD-BRD-A31454688-001-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,VBICKXHEKHSIBG-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO
MONTELUKAST,MONTELUKAST,CHEMBL787,BRD:BRD-BRD-K69470111-236-08-9;BRD:BRD-K69470111-236-08-9,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,ALOX5;CYSLTR1,"ASTHMA, ALLERGIC RHINITIS, EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB)",,LAUNCHED,,Small molecule,Approved,UCHDWCPVSPXUMX-TZIWLTJVSA-N,CC(C)(O)C1CCCCC1CC[C@@H](SCC1(CC(=O)O)CC1)C1CCCC(/C=C/C2CCC3CCC(CL)CC3N2)C1;CC(C)(O)C1CCCCC1CC[C@@H](SCC1(CC(O)=O)CC1)C1CCCC(\C=C\C2CCC3CCC(CL)CC3N2)C1
MOPROLOL,MOPROLOL,CHEMBL156901;CHEMBL2106030,BRD:BRD-A51747092-003-03-0;BRD:BRD-BRD-A51747092-003-03-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,"HYPERTENSION, GLAUCOMA, ANXIETY",,LAUNCHED,,Small molecule,Unknown,LFTFGCDECFPSQD-NSHDSACASA-N;LFTFGCDECFPSQD-UHFFFAOYSA-N,COC1CCCCC1OC[C@@H](O)CNC(C)C;COC1CCCCC1OCC(O)CNC(C)C
MORACIZINE,MORACIZINE,CHEMBL1075,BRD:BRD-BRD-K21548250-003-19-1;BRD:BRD-K21548250-003-19-1,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN5A,VENTRICULAR ARRHYTHMIAS,,LAUNCHED,,Small molecule,Approved,FUBVWMNBEHXPSU-UHFFFAOYSA-N,CCOC(=O)NC1CCC2C(C1)N(C(=O)CCN1CCOCC1)C1CCCCC1S2;CCOC(=O)NC1CCC2SC3CCCCC3N(C(=O)CCN3CCOCC3)C2C1
MORANTEL,MORANTEL,CHEMBL1240978,BRD:BRD-K71454870-046-01-8,rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,,,Small molecule,Unknown,NVEPPWDVLBMNMB-SNAWJCMRSA-N,CC1CCSC1/C=C/C1=NCCCN1C
MORIN,MORIN,CHEMBL28626,BRD:BRD-BRD-K11590034-002-03-4;BRD:BRD-K11590034-002-03-4,rep_multi_dose;rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,ADORA2A;ESR2;FASN;MCL1;SLC22A12,,,PRECLINICAL,,Small molecule,NA,YXOLAZRVSSWPPT-UHFFFAOYSA-N,O=C1C(O)C(-C2CCC(O)CC2O)OC2CC(O)CC(O)C12;OC1CCC(C(O)C1)-C1OC2CC(O)CC(O)C2C(=O)C1O
MORINIDAZOLE,MORINIDAZOLE,CHEMBL3884248,BRD:BRD-A40546373-001-01-8;BRD:BRD-BRD-A40546373-001-01-8,rep_primary;rep_single_dose,OTHER ANTIBIOTIC,CYP51A1,,,LAUNCHED,,Small molecule,Unknown,GAZGHCHCYRSPIV-UHFFFAOYSA-N,CC1NCC([N+](=O)[O-])N1CC(O)CN1CCOCC1;CC1NCC(N1CC(O)CN1CCOCC1)[N+]([O-])=O
MORNIFLUMATE,MORNIFLUMATE,CHEMBL2105059,BRD:BRD-BRD-K38938675-001-01-4;BRD:BRD-K38938675-001-01-4,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,LDXSPUSKBDTEKA-UHFFFAOYSA-N,FC(F)(F)C1CCCC(NC2NCCCC2C(=O)OCCN2CCOCC2)C1;O=C(OCCN1CCOCC1)C1CCCNC1NC1CCCC(C(F)(F)F)C1
MOROXYDINE,MOROXYDINE,CHEMBL1490434,BRD:BRD-BRD-K57291914-003-09-4;BRD:BRD-K57291914-003-09-4,rep_primary;rep_single_dose,ANTIVIRAL,,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,Small molecule,Unknown,KJHOZAZQWVKILO-UHFFFAOYSA-N,N=C(N)NC(=N)N1CCOCC1;NC(=N)NC(=N)N1CCOCC1
MORPHOTHIADIN,MORPHOTHIADIN,,BRD:BRD-K00003491-001-01-9,rep_single_dose,ANTIINFECTIVE DRUG,,,,,,,NA,,
MOSAPRIDE,MOSAPRIDE,CHEMBL60889,BRD:BRD-A39052811-048-11-0;BRD:BRD-BRD-A39052811-048-11-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR4,"HYPERTROPHIC GASTRITIS (GHG), GASTROESOPHAGEAL REFLUX DISEASE (GERD), DYSPEPSIA, IRRITABLE BOWEL SYNDROME",,LAUNCHED,,Small molecule,Phase 3,YPELFRMCRYSPKZ-UHFFFAOYSA-N,CCOC1CC(N)C(CL)CC1C(=O)NCC1CN(CC2CCC(F)CC2)CCO1
MOTAPIZONE,MOTAPIZONE,CHEMBL2104670,BRD:BRD-K00004657-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Unknown,NPFVRBCDMFKOPY-UHFFFAOYSA-N,CC1CC(=O)NN=C1C1CC(-N2CCNC2)CS1
MOTESANIB,MOTESANIB,CHEMBL572881,BRD:BRD-BRD-K99616396-001-05-1;BRD:BRD-K99616396-001-05-1;GDSC1:1029,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",FLT1;FLT4;KDR;KIT,,,PHASE 3,,Small molecule,Phase 3,RAHBGWKEPAQNFF-UHFFFAOYSA-N,CC1(C)CNC2CC(NC(=O)C3CCCNC3NCC3CCNCC3)CCC12;CC1(C)CNC2CC(NC(=O)C3CCCNC3NCC3CCNCC3)CCC21
MOTOLIMOD,MOTOLIMOD,CHEMBL3301618,BRD:BRD-BRD-K11785681-001-01-2;BRD:BRD-K11785681-001-01-2,rep_primary;rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,TLR8,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,QSPOQCXMGPDIHI-UHFFFAOYSA-N,CCCN(CCC)C(=O)C1=CC2CCC(-C3CCC(C(=O)N4CCCC4)CC3)CC2N=C(N)C1;CCCN(CCC)C(=O)C1=CC2CCC(CC2N=C(N)C1)-C1CCC(CC1)C(=O)N1CCCC1
MOXAVERINE,MOXAVERINE,CHEMBL2105060,BRD:BRD-BRD-K12742203-003-01-7;BRD:BRD-K12742203-003-01-7,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,SPASMS,,LAUNCHED,,Small molecule,Phase 2,MYCMTMIGRXJNSO-UHFFFAOYSA-N,CCC1CC2CC(OC)C(OC)CC2C(CC2CCCCC2)N1
MOXIDECTIN,MOXIDECTIN,CHEMBL2104415,BRD:BRD-BRD-K61988078-001-01-2;BRD:BRD-K61988078-001-01-2,rep_primary;rep_single_dose,CHLORIDE CHANNEL ANTAGONIST,,GASTROINTESTINAL PARASITES,,LAUNCHED,,Small molecule,Approved,YZBLFMPOMVTDJY-LSGXYNIPSA-N,CO/N=C1\C[C@]2(C[C@@H]3C[C@@H](C/C=C(\C)C[C@@H](C)/C=C/C=C4\CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@H](/C(C)=C/C(C)C)[C@H]1C;CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C
MOXIFLOXACIN,MOXIFLOXACIN,CHEMBL32,BRD:BRD-BRD-K66615216-003-14-8;BRD:BRD-K66615216-003-14-8,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,"SINUSITIS, BRONCHITIS, PNEUMONIA, SKIN INFECTIONS, INTRA-ABDOMINAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,FABPRXSRWADJSP-MEDUHNTESA-N,COC1C(N2C[C@@H]3CCCN[C@@H]3C2)C(F)CC2C(=O)C(C(=O)O)CN(C3CC3)C12;COC1C(N2C[C@@H]3CCCN[C@@H]3C2)C(F)CC2C1N(CC(C(O)=O)C2=O)C1CC1
MOXISYLYTE,MOXISYLYTE,CHEMBL159226,BRD:BRD-BRD-K81144366-003-19-7;BRD:BRD-K81144366-003-19-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,WITHDRAWN,,Small molecule,Approved,VRYMTAVOXVTQEF-UHFFFAOYSA-N,CC(=O)OC1CC(C(C)C)C(OCCN(C)C)CC1C;CC(C)C1CC(OC(C)=O)C(C)CC1OCCN(C)C
MOXONIDINE,MOXONIDINE,CHEMBL19236,BRD:BRD-BRD-K77771411-003-10-7;BRD:BRD-K77771411-003-10-7,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,WPNJAUFVNXKLIM-UHFFFAOYSA-N,COC1NC(C)NC(CL)C1NC1=NCCN1
MOZAVAPTAN,MOZAVAPTAN,CHEMBL420762,BRD:BRD-A31095847-001-02-3;BRD:BRD-BRD-A31095847-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,AVPR1A;AVPR1B;AVPR2,HYPONATREMIA,,LAUNCHED,,Small molecule,Unknown,WRNXUQJJCIZICJ-UHFFFAOYSA-N,CC1CCCCC1C(=O)NC1CCC(C(=O)N2CCCC(N(C)C)C3CCCCC32)CC1;CN(C)C1CCCN(C(=O)C2CCC(NC(=O)C3CCCCC3C)CC2)C2CCCCC12
MP 470,MP 470,CHEMBL2103851,GDSC1:293,gdsc,,,,,,,Small molecule,Phase 2,FOFDIMHVKGYHRU-UHFFFAOYSA-N,S=C(NCC1CCC2C(C1)OCO2)N1CCN(C2NCNC3C2OC2CCCCC23)CC1
MP-470,MP-470,CHEMBL2103851,GDSC1:293,gdsc,,,,,,,Small molecule,Phase 2,FOFDIMHVKGYHRU-UHFFFAOYSA-N,S=C(NCC1CCC2C(C1)OCO2)N1CCN(C2NCNC3C2OC2CCCCC23)CC1
MP470,MP470,CHEMBL2103851,GDSC1:293,gdsc,,,,,,,Small molecule,Phase 2,FOFDIMHVKGYHRU-UHFFFAOYSA-N,S=C(NCC1CCC2C(C1)OCO2)N1CCN(C2NCNC3C2OC2CCCCC23)CC1
MPEP,MPEP,,BRD:BRD-BRD-K60690191-001-03-3;BRD:BRD-K60690191-001-03-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1;GRM4;GRM5,,,PRECLINICAL,,,NA,,CC1CCCC(N1)C#CC1CCCCC1
MPI-0479605,MPI-0479605,,BRD:BRD-BRD-K45551181-001-02-1;BRD:BRD-K45551181-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,MITOTIC KINASE INHIBITOR,TTK,,,PRECLINICAL,,,NA,,CC1CC(CCC1NC1NC(NC2CCCCC2)C2[NH]CNC2N1)N1CCOCC1
MPS-1-IN-1,MPS-1-IN-1,,GDSC1:294,gdsc,,,,,,,,NA,,
MPS-BAY-2A,MPS-BAY-2A,,BRD:BRD-K18530250-001-02-9,rep_single_dose,MONOPOLAR SPINDLE 1 KINASE INHIBITOR,TTK,,,,,,NA,,
MPS1-IN-1,MPS1-IN-1,,BRD:BRD-K94853001-300-04-9,rep_single_dose,MONOPOLAR SPINDLE 1 KINASE INHIBITOR,TTK,,,,,,NA,,
MPS1-IN-5,MPS1-IN-5,CHEMBL4303241,BRD:BRD-K43812936-001-01-9,rep_single_dose,PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Phase 1,NRJKIOCCERLIDG-GOSISDBHSA-N,COC1CC(S(C)(=O)=O)CCC1NC1NC2CCC(-C3CCC(NC(=O)[C@H](C)C4CCC(F)CC4)CC3)CN2N1
MR-16728,MR-16728,,BRD:BRD-A30590053-003-02-9;BRD:BRD-BRD-A30590053-003-02-9,rep_primary;rep_single_dose,ACETYLCHOLINE RELEASE ENHANCER,,,,PRECLINICAL,,,NA,,O=C(NCCCN1CCCCCC1)C(C1CCCCC1)C1CCCCC1
MR-948,MR-948,,BRD:BRD-BRD-K84883208-001-01-1;BRD:BRD-K84883208-001-01-1,rep_primary;rep_single_dose,THROMBOXANE SYNTHASE INHIBITOR,TBXAS1,,,PHASE 1,,,NA,,OCCC1CCC(OCCN2CCNC2)CC1
MRK-016,MRK-016,,BRD:BRD-BRD-K44022883-001-01-7;BRD:BRD-K44022883-001-01-7,rep_primary;rep_single_dose,GABA RECEPTOR INVERSE AGONIST,GABRA1;GABRA2;GABRA3;GABRA5,,,PHASE 1,,,NA,,CC1CC(NO1)-C1NNCC2C(C(OCC3NCNN3C)NN12)C(C)(C)C
MRK-409,MRK-409,,BRD:BRD-BRD-K57416838-001-01-1;BRD:BRD-K57416838-001-01-1,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,,,,PHASE 1,,,NA,,CN1NCNC1COC1NN2C(NNC2CC1C1CCC1)-C1C(F)CCCC1F
MRK-560,MRK-560,CHEMBL1091513,BRD:BRD-K68795758-001-02-9,rep_single_dose,GAMMA SECRETASE INHIBITOR,APP,,,,,Small molecule,NA,WDZVWDXOIGQJIO-UHFFFAOYSA-N,O=S(=O)(NC1CCC(C2CC(F)CCC2F)(S(=O)(=O)C2CCC(CL)CC2)CC1)C(F)(F)F
MRS-1220,MRS-1220,,BRD:BRD-BRD-K37618799-001-03-0;BRD:BRD-K37618799-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,CLC1CCC2NC(NC(=O)CC3CCCCC3)N3NC(NC3C2C1)-C1CCCO1
MRS-1334,MRS-1334,,BRD:BRD-A06784547-001-03-9,rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA3,,,,,,NA,,
MRS1845,MRS-1845;MRS1845,,BRD:BRD-A78093359-001-06-3;BRD:BRD-BRD-A78093359-001-06-3,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC
MRS3777,MRS-3777;MRS3777,,BRD:BRD-BRD-K10575656-034-01-0;BRD:BRD-BRD-M86143595-034-03-4;BRD:BRD-K10575656-034-01-0;BRD:BRD-M86143595-034-03-4,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,"Multiple values for SMILES: {'C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12', 'C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12.C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12'}, defaulting to 'C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12.C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12'
Multiple values for repurposing_target: {'ADORA2A', 'ADORA1;ADORA2A;ADORA2B;ADORA3'}, taking the union
Multiple values for structure_id: {'K10575656', 'M86143595'}, defaulting to None",,NA,,C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12.C1CCC(CC1)NC1NC(OC2CCCCC2)NC2[NH]CNC12
MRT68921,MRT68921,,BRD:BRD-K00002753-001-02-9,oncref_2,INHIBITOR OF ULK1 AND ULK2,ULK1;ULK2,,,,,,NA,,
MRTX-1133,MRTX-1133,,BRD:BRD-U00115284-001-01-9,oncref_1,INHIBITOR OF KRAS-G12D,KRAS,,,,,,NA,,
MRTX-1257,MRTX-1257,,BRD:BRD-K00006887-001-02-9,oncref_1,INHIBITOR OF KRAS-G12C,KRAS,,,,,,NA,,
MRTX-1719,MRTX-1719,,BRD:BRD-U00115283-001-01-9,oncref_1,MTA-COOPERATIVE INHIBITOR OF PRMT5,PRMT5,,,,,,NA,,
MRTX-9768,MRTX-9768,,BRD:BRD-U00115282-001-01-9,oncref_1,MTA-COOPERATIVE INHIBITOR OF PRMT5,PRMT5,,,,,,NA,,
MRTX0902,MRTX0902,,BRD:BRD-K00126473-001-01-9,oncref_2,INHIBITOR OF SOS1,SOS1,,,,,,NA,,
MRTX1133,MRTX1133,,BRD:BRD-K00104122-001-01-9,rep_single_dose,,,,,,,,NA,,
MRX-2843,MRX-2843,CHEMBL4650408,BRD:BRD-K00003417-001-01-9,rep_single_dose,MER TYROSINE KINASE INHIBITOR,,,,,,Unknown,Phase 1,,
MS-275,MS-275,CHEMBL27759,GDSC1:88;GDSC2:1593,gdsc,,,,,,,Small molecule,Phase 3,INVTYAOGFAGBOE-UHFFFAOYSA-N,NC1CCCCC1NC(=O)C1CCC(CNC(=O)OCC2CCCNC2)CC1
MS-424,MS-424,,BRD:BRD-K00004683-001-01-9,rep_single_dose,GLUTAMATE TRANSPORTER MODULATOR,,,,,,,NA,,
MS4078,MS4078,,BRD:BRD-U00114871-001-01-9,oncref_1,CERITINIB-BASED DEGRADER OF ALK,ALK,,,,,,NA,,
MSC2360844,MSC2360844,CHEMBL3683575,BRD:BRD-K00091079-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,NFHSJYKXENYICE-UHFFFAOYSA-N,O=C(C1NN(-C2CCC(CN3CCOCC3)CC2)C2C1CS(=O)(=O)C1C(F)CCCC1-2)N1CCOCC1
MSDC-0160,MSDC-0160,CHEMBL146624,BRD:BRD-K00003381-001-01-9,rep_single_dose,INSULIN SENSITIZER,,,,,,Small molecule,Phase 2,IRNJSRAGRIZIHD-UHFFFAOYSA-N,CCC1CCC(C(=O)COC2CCC(CC3SC(=O)NC3=O)CC2)NC1
MSDC-0602K,MSDC-0602K,,BRD:BRD-K00004703-001-01-9,rep_single_dose,MITOCHONDRIAL PYRUVATE CARRIER MODULATOR,,,,,,,NA,,
MST 312,MST 312,,GDSC2:1930,gdsc,,,,,,,,NA,,
MST-312,MST-312,,CTRP:411865;GDSC2:1930,ctrp;gdsc,,,,,,,,NA,,
MST312,MST312,,GDSC2:1930,gdsc,,,,,,,,NA,,
MSX-122,MSX-122,CHEMBL3545330,BRD:BRD-BRD-K25143390-001-01-0;BRD:BRD-K25143390-001-01-0,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR4,,,PHASE 1,,Small molecule,Phase 1,PXZXYRKDDXKDTK-UHFFFAOYSA-N,C(NC1NCCCN1)C1CCC(CNC2NCCCN2)CC1;C1CNC(NCC2CCC(CNC3NCCCN3)CC2)NC1
MTPG,MTPG,,BRD:BRD-A28329383-001-02-1;BRD:BRD-BRD-A28329383-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM2;GRM3,,,PRECLINICAL,,,NA,,CC(N)(C(O)=O)C1CCC(CC1)-C1NNN[NH]1
MUBRITINIB,MUBRITINIB,CHEMBL1614707,BRD:BRD-BRD-K19061412-001-02-4;BRD:BRD-K19061412-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,EGFR;ERBB2,,,PHASE 1,,Small molecule,Phase 1,ZTFBIUXIQYRUNT-MDWZMJQESA-N,FC(F)(F)C1CCC(/C=C/C2NC(COC3CCC(CCCCN4CCNN4)CC3)CO2)CC1;FC(F)(F)C1CCC(\C=C\C2NC(COC3CCC(CCCCN4CCNN4)CC3)CO2)CC1
MUPIROCIN,MUPIROCIN,CHEMBL2068726;CHEMBL3989715;CHEMBL719,BRD:BRD-BRD-K15262564-001-15-0;BRD:BRD-K15262564-001-15-0,rep_primary;rep_single_dose,ISOLEUCYL-TRNA SYNTHETASE INHIBITOR,,IMPETIGO,,LAUNCHED,,Small molecule,Approved,DDHVILIIHBIMQU-YJGQQKNPSA-L;HAXVBVDETFUQGV-LNQHITRNSA-L;MINDHVHHQZYEEK-HBBNESRFSA-N,C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O;C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.[CA+2];C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.O.O.[CA+2];C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O
MUSCIMOL,MUSCIMOL,CHEMBL273481,BRD:BRD-BRD-K60441002-001-04-8;BRD:BRD-K60441002-001-04-8,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRR1;GABRR2;GABRR3,,,PHASE 1,,Small molecule,Phase 1,ZJQHPWUVQPJPQT-UHFFFAOYSA-N,NCC1CC(O)NO1
MUT056399,MUT056399,,BRD:BRD-BRD-K72078047-001-01-7;BRD:BRD-K72078047-001-01-7,rep_primary;rep_single_dose,FABI INHIBITOR,,,,PHASE 1,,,NA,,CCC1CC(O)C(OC2CCC(CC2F)C(N)=O)CC1F
MW-150,MW-150,CHEMBL4129018,BRD:BRD-K00091273-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,CIIVUDIZZJLXCN-UHFFFAOYSA-N,CN1CCN(C2CC(-C3CCNCC3)C(-C3CCC4CCCCC4C3)NN2)CC1
MY-5445,MY-5445,,BRD:BRD-BRD-K90524085-001-07-8;BRD:BRD-K90524085-001-07-8,rep_primary;rep_single_dose,"PHOSPHODIESTERASE INHIBITOR, PLATELET AGGREGATION INHIBITOR",PDE5A,,,PRECLINICAL,,,NA,,CLC1CCCC(NC2NNC(-C3CCCCC3)C3CCCCC23)C1
MYCOPHENOLATE-MOFETIL,MYCOPHENOLATE-MOFETIL,,BRD:BRD-BRD-K92428153-001-04-4;BRD:BRD-K92428153-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,"DEHYDROGENASE INHIBITOR, INOSITOL MONOPHOSPHATASE INHIBITOR",IMPDH1;IMPDH2,ORGAN REJECTION,,LAUNCHED,,,NA,,COC1C(C)C2COC(=O)C2C(O)C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
MYCOPHENOLIC-ACID,MYCOPHENOLIC-ACID,,BRD:BRD-BRD-K63750851-001-20-7;BRD:BRD-K63750851-001-20-7,rep_multi_dose;rep_primary;rep_single_dose,"DEHYDROGENASE INHIBITOR, INOSITOL MONOPHOSPHATASE INHIBITOR",IMPDH1;IMPDH2,ORGAN REJECTION,,LAUNCHED,,,NA,,COC1C(C)C2COC(=O)C2C(O)C1C\C=C(/C)CCC(O)=O
MYRICETIN,MYRICETIN,CHEMBL164,BRD:BRD-BRD-K43149758-001-22-7;BRD:BRD-K43149758-001-22-7;CTRP:29985,ctrp;rep_primary;rep_single_dose,"ANDROGEN RECEPTOR AGONIST, CYTOCHROME P450 INHIBITOR",PIK3CG,,,PRECLINICAL,,Small molecule,NA,IKMDFBPHZNJCSN-UHFFFAOYSA-N,O=C1C(O)C(-C2CC(O)C(O)C(O)C2)OC2CC(O)CC(O)C12;OC1CC(O)C2C(C1)OC(-C1CC(O)C(O)C(O)C1)C(O)C2=O
MYRICITRIN,MYRICITRIN,CHEMBL454576,BRD:BRD-BRD-K29834313-001-01-4;BRD:BRD-K29834313-001-01-4,rep_primary;rep_single_dose,PKC INHIBITOR,NOS1;PRKCA,,,PRECLINICAL,,Small molecule,NA,DCYOADKBABEMIQ-FHAIKQJESA-N,C[C@@H]1O[C@@H](OC2C(OC3CC(O)CC(O)C3C2=O)-C2CC(O)C(O)C(O)C2)[C@@H](O)[C@H](O)[C@H]1O;C[C@H]1O[C@@H](OC2C(-C3CC(O)C(O)C(O)C3)OC3CC(O)CC(O)C3C2=O)[C@@H](O)[C@@H](O)[C@@H]1O
MYRIOCIN,MYRIOCIN,CHEMBL55076,CTRP:417977,ctrp,,,,,,,Small molecule,NA,ZZIKIHCNFWXKDY-GNTQXERDSA-N,CCCCCCC(=O)CCCCCC/C=C/C[C@@H](O)[C@H](O)[C@@](N)(CO)C(=O)O
MYTOZYTREX,MYTOZYTREX,CHEMBL105,GDSC1:136,gdsc,,,,,,,Small molecule,Approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
"N-(2-BROMO-6-FLUOROPHENYL)-4,5-DIHYDRO-1H-IMIDAZOL","N-(2-BROMO-6-FLUOROPHENYL)-4,5-DIHYDRO-1H-IMIDAZOL",,BRD:BRD-K00077192-001-02-9,rep_single_dose,,,,,,,,NA,,
N-(P-AMYLCINNAMOYL)-ANTHRANILIC-ACID,N-(P-AMYLCINNAMOYL)-ANTHRANILIC-ACID,,BRD:BRD-K77817104-001-02-9,rep_single_dose,PHOSPHOLIPASE INHIBITOR,,,,,,,NA,,
N-ACETYL-D-GLUCOSAMINE,N-ACETYL-D-GLUCOSAMINE,,BRD:BRD-BRD-K80653534-001-01-7;BRD:BRD-K80653534-001-01-7,rep_primary;rep_single_dose,,B4GALT1;B4GALT2;B4GALT3;B4GALT4;NAGK;NAGLU;NAGPA;RENBP,,,PHASE 2/PHASE 3,,,NA,,CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO
N-ACETYL-TYROSINE,N-ACETYL-TYROSINE,,BRD:BRD-A24857382-001-03-4;BRD:BRD-BRD-A24857382-001-03-4,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CC(=O)NC(CC1CCC(O)CC1)C(O)=O
N-ACETYLCARNOSINE,N-ACETYLCARNOSINE,,BRD:BRD-BRD-K52523550-001-01-5;BRD:BRD-K52523550-001-01-5,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CC(=O)NCCC(=O)N[C@@H](CC1C[NH]CN1)C(O)=O
N-ACETYLCYSTEINE AMIDE,N-ACETYLCYSTEINE AMIDE,,BRD:BRD-K00091105-001-01-9,rep_single_dose,,,,,,,,NA,,
N-ACETYLGLYCYL-D-GLUTAMIC-ACID,N-ACETYLGLYCYL-D-GLUTAMIC-ACID,,BRD:BRD-BRD-K28121004-001-01-1;BRD:BRD-K28121004-001-01-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O
N-ACETYLMANNOSAMINE,N-ACETYLMANNOSAMINE,CHEMBL1231391,BRD:BRD-A92872453-001-01-8;BRD:BRD-BRD-A92872453-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,,CHIT1,,,PHASE 1,,Small molecule,Phase 2,OVRNDRQMDRJTHS-UOLFYFMNSA-N,CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O;CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O
N-ACETYLTRYPTAMINE,N-ACETYLTRYPTAMINE,CHEMBL33171,BRD:BRD-BRD-K73700643-001-11-2;BRD:BRD-K73700643-001-11-2,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,,,,PRECLINICAL,,Small molecule,NA,NVUGEQAEQJTCIX-UHFFFAOYSA-N,CC(=O)NCCC1C[NH]C2CCCCC12
N-ALPHA-METHYLHISTAMINE-DIHYDROCHLORIDE,N-ALPHA-METHYLHISTAMINE-DIHYDROCHLORIDE,,BRD:BRD-BRD-K64422603-300-02-7;BRD:BRD-K64422603-300-02-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH4,,,PHASE 3,,,NA,,CNCCC1CNC[NH]1
N-BENZYLNALTRINDOLE,N-BENZYLNALTRINDOLE,,BRD:BRD-A33514596-003-01-2;BRD:BRD-BRD-A33514596-003-01-2,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,OC1CCC2CC3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C1C(C[C@@]35O)C2CCCCC2N1CC1CCCCC1
N-HYDROXYNICOTINAMIDE,N-HYDROXYNICOTINAMIDE,,BRD:BRD-BRD-K28030264-001-02-7;BRD:BRD-K28030264-001-02-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,ONC(=O)C1CCCNC1
"N-METHYL-(-)EPHEDRINE-[1R,2S]","N-METHYL-(-)EPHEDRINE-[1R,2S]",,BRD:BRD-BRD-K82236108-001-04-9;BRD:BRD-K82236108-001-04-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,C[C@@H]([C@H](O)C1CCCCC1)N(C)C
N-METHYLFORMAMIDE,N-METHYLFORMAMIDE,,BRD:BRD-K33445938-001-01-8,rep_single_dose,,,,,,,,NA,,
N-METHYLLIDOCAINE-IODIDE,N-METHYLLIDOCAINE-IODIDE,,BRD:BRD-BRD-K60060639-005-02-2;BRD:BRD-K60060639-005-02-2,rep_primary;rep_single_dose,ANTIARRHYTHMIC MEDICATION,,,,PRECLINICAL,,,NA,,CC[N+](C)(CC)CC(=O)NC1C(C)CCCC1C
N-METHYLQUIPAZINE,N-METHYLQUIPAZINE,,BRD:BRD-BRD-K62056274-332-01-8;BRD:BRD-K62056274-332-01-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1D;HTR2A;HTR2B;HTR2C;HTR3A;HTR3B;HTR6;SLC6A4,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CCC2CCCCC2N1
N-MPPP,N-MPPP,,BRD:BRD-BRD-K93806173-003-01-8;BRD:BRD-K93806173-003-01-8,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CN([C@H](CN1CCCC1)C1CCCCC1)C(=O)CC1CCCCC1
N-SALICOYLAMINOPHENOL,N-SALICOYLAMINOPHENOL,,BRD:BRD-BRD-K39693230-001-01-2;BRD:BRD-K39693230-001-01-2,rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,,,,PRECLINICAL,,,NA,,OC1CCC(NC(=O)C2CCCCC2O)CC1
N-[2-(PIPERIDINYLAMINO)ETHYL]-4-IODOBENZAMIDE,N-[2-(PIPERIDINYLAMINO)ETHYL]-4-IODOBENZAMIDE,,BRD:BRD-BRD-K78844995-001-02-6;BRD:BRD-K78844995-001-02-6,rep_primary;rep_single_dose,SIGMA RECEPTOR LIGAND,,,,PRECLINICAL,,,NA,,IC1CCC(CC1)C(=O)NCCN1CCCCC1
N1-(B-D-RIBOFURANOSYL)-5-AMINOIMIDAZOLE-4-CARBOXAMIDE,N1-(B-D-RIBOFURANOSYL)-5-AMINOIMIDAZOLE-4-CARBOXAMIDE,,GDSC1:1001,gdsc,,,,,,,,NA,,
N20C,N20C,,BRD:BRD-BRD-K41143549-003-02-4;BRD:BRD-K41143549-003-02-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,NC(=O)CNCCC(C1CCCCC1)C1CCCCC1
N6-CYCLOPENTYLADENOSINE,N6-CYCLOPENTYLADENOSINE,CHEMBL68738,BRD:BRD-BRD-K60150510-001-15-6;BRD:BRD-K60150510-001-15-6,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3;SLC29A1,,,PRECLINICAL,,Small molecule,NA,SQMWSBKSHWARHU-SDBHATRESA-N,OC[C@H]1O[C@@H](N2CNC3C(NC4CCCC4)NCNC32)[C@H](O)[C@@H]1O;OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(NC3CCCC3)NCNC12
N6-METHYLADENOSINE,N6-METHYLADENOSINE,,BRD:BRD-BRD-K81807412-001-10-6;BRD:BRD-K81807412-001-10-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CNC1NCNC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
N6022,N6022,CHEMBL1738699,BRD:BRD-BRD-K82522873-001-01-1;BRD:BRD-K82522873-001-01-1,rep_primary;rep_single_dose,ALCOHOL DEHYDROGENASE INHIBITOR,ADH5,,,PHASE 1/PHASE 2,,Small molecule,Phase 3,YVPGZQLRPAGKLA-UHFFFAOYSA-N,CC1CC(C(N)=O)CCC1-N1C(CCC(=O)O)CCC1-C1CCC(-N2CCNC2)CC1;CC1CC(CCC1-N1C(CCC(O)=O)CCC1-C1CCC(CC1)-N1CCNC1)C(N)=O
N9-ISOPROPYLOLOMOUCINE,N9-ISOPROPYLOLOMOUCINE,,CTRP:45093,ctrp,,,,,,,,NA,,
NAB-2,NAB-2,,BRD:BRD-BRD-K36804890-001-01-9;BRD:BRD-K36804890-001-01-9,rep_primary;rep_single_dose,UBIQUITIN LIGASE TRANSPORT PROMOTER,NEDD4,,,PRECLINICAL,,,NA,,CC1CCC(C)C(C1)-N1CNC2CC(CCC12)C(=O)NCC1CCCCC1CL
NABUMETONE,NABUMETONE,CHEMBL1070,BRD:BRD-BRD-K65146499-001-27-9;BRD:BRD-K65146499-001-27-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,Small molecule,Approved,BLXXJMDCKKHMKV-UHFFFAOYSA-N,COC1CCC2CC(CCC(C)=O)CCC2C1
NADIDE,NADIDE,CHEMBL1234613,BRD:BRD-A11132253-001-08-2;BRD:BRD-BRD-A11132253-001-08-2,rep_multi_dose;rep_primary;rep_single_dose,ELECTRON ACCEPTOR,AHCY;AKR1A1;ALDH2;BLVRA;DHPS;DLD;GALE;HMGCR;HSD17B1;HSD17B4;IMPDH2;MGAM;P2RY11;SORD;TRPM2,,,LAUNCHED,,Small molecule,Unknown,BAWFJGJZGIEFAR-NNYOXOHSSA-N,NC(=O)C1CCC[N+]([C@@H]2O[C@H](COP(=O)([O-])OP(=O)(O)OC[C@H]3O[C@@H](N4CNC5C(N)NCNC54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C1;NC(=O)C1CCC[N+](C1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2CNC3C(N)NCNC23)[C@@H](O)[C@H]1O
NADIFLOXACIN,NADIFLOXACIN,CHEMBL363449,BRD:BRD-A24397426-001-10-4;BRD:BRD-BRD-A24397426-001-10-4,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,"ACNE VULGARIS (AV), SKIN INFECTIONS",,LAUNCHED,,Small molecule,Phase 3,JYJTVFIEFKZWCJ-UHFFFAOYSA-N,CC1CCC2C(N3CCC(O)CC3)C(F)CC3C(=O)C(C(=O)O)CN1C23;CC1CCC2C(N3CCC(O)CC3)C(F)CC3C2N1CC(C(O)=O)C3=O
NAFADOTRIDE,NAFADOTRIDE,CHEMBL286252,BRD:BRD-A71262238-001-08-4;BRD:BRD-BRD-A71262238-001-08-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;HTR1A,,,PRECLINICAL,,Small molecule,NA,IDZASIQMRGPBCQ-UHFFFAOYSA-N,CCCCN1CCCC1CNC(=O)C1CC(C#N)C2CCCCC2C1OC
NAFAMOSTAT,NAFAMOSTAT,CHEMBL273264,BRD:BRD-BRD-K06674495-334-03-2;BRD:BRD-K06674495-334-03-2,rep_primary;rep_single_dose,SERINE PROTEASE INHIBITOR,ASIC1;ASIC2;ASIC3;C1R;PRSS1;TPSAB1;TRPM7,,,LAUNCHED,,Small molecule,Phase 3,MQQNFDZXWVTQEH-UHFFFAOYSA-N,N=C(N)NC1CCC(C(=O)OC2CCC3CC(C(=N)N)CCC3C2)CC1;NC(=N)NC1CCC(CC1)C(=O)OC1CCC2CC(CCC2C1)C(N)=N
NAFCILLIN,NAFCILLIN,CHEMBL1443,BRD:BRD-BRD-K18574842-236-17-7;BRD:BRD-BRD-K18574842-323-10-8;BRD:BRD-K18574842-236-17-7;BRD:BRD-K18574842-323-10-8,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,CYP1A2;CYP3A4;SLC22A6,GRAM-POSITIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,GPXLMGHLHQJAGZ-JTDSTZFVSA-N,CCOC1CCC2CCCCC2C1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O;CCOC1CCC2CCCCC2C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
NAFTIDROFURYL,NAFTIDROFURYL,CHEMBL1439099;CHEMBL1443491;CHEMBL1620794,BRD:BRD-A67862938-034-14-9;BRD:BRD-BRD-A67862938-034-14-9,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,CLAUDICATION,,LAUNCHED,,Small molecule,Unknown,KBAFPSLPKGSANY-UHFFFAOYSA-N;KBAFPSLPKGSANY-VXKWHMMOSA-N;SSAJNPNVUYMUCI-UHFFFAOYSA-N,CCN(CC)CCOC(=O)[C@@H](CC1CCCC2CCCCC12)C[C@@H]1CCCO1;CCN(CC)CCOC(=O)C(CC1CCCC2CCCCC12)CC1CCCO1;CCN(CC)CCOC(=O)C(CC1CCCC2CCCCC12)CC1CCCO1.O=C(O)C(=O)O;CCN(CC)CCOC(=O)C(CC1CCCO1)CC1CCCC2CCCCC12
NAFTIFINE,NAFTIFINE,CHEMBL626,BRD:BRD-BRD-K74141488-003-11-2;BRD:BRD-K74141488-003-11-2,rep_multi_dose;rep_primary;rep_single_dose,FUNGAL SQUALENE EPOXIDASE INHIBITOR,SQLE,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,OZGNYLLQHRPOBR-DHZHZOJOSA-N,CN(C/C=C/C1CCCCC1)CC1CCCC2CCCCC12;CN(C\C=C\C1CCCCC1)CC1CCCC2CCCCC12
NAFTOPIDIL,NAFTOPIDIL,CHEMBL142635,BRD:BRD-A01787639-003-16-9;BRD:BRD-BRD-A01787639-003-16-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A,BENIGN PROSTATIC HYPERPLASIA (BPH),,LAUNCHED,,Small molecule,Phase 3,HRRBJVNMSRJFHQ-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CC(O)COC2CCCC3CCCCC23)CC1
NAKITERPIOSIN,NAKITERPIOSIN,,CTRP:417452,ctrp,,,,,,,,NA,,
NALBUPHINE,NALBUPHINE,CHEMBL1201132;CHEMBL895,BRD:BRD-BRD-K66404838-310-01-1;BRD:BRD-K66404838-310-01-1,rep_primary;rep_single_dose,"OPIOID RECEPTOR AGONIST, OPIOID RECEPTOR ANTAGONIST",OPRD1;OPRK1;OPRM1,PAIN RELIEF,,LAUNCHED,,Small molecule,Approved,NETZHAKZCGBWSS-CEDHKZHLSA-N;YZLZPSJXMWGIFH-BCXQGASESA-N,CL.OC1CCC2C3C1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314;O[C@H]1CC[C@@]2(O)[C@H]3CC4CCC(O)C5O[C@@H]1[C@]2(CCN3CC1CCC1)C45;OC1CCC2C3C1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
NALFURAFINE,NALFURAFINE,CHEMBL267495,BRD:BRD-BRD-K89272869-003-01-8;BRD:BRD-K89272869-003-01-8,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1;OPRM1,UREMIC PRURITUS,,LAUNCHED,,Small molecule,Phase 3,XGZZHZMWIXFATA-UEZBDDGYSA-N,CN([C@@H]1CC[C@@]2(O)[C@H]3CC4CCC(O)C5O[C@@H]1[C@]2(CCN3CC1CC1)C45)C(=O)\C=C\C1CCOC1;CN(C(=O)/C=C/C1CCOC1)[C@@H]1CC[C@@]2(O)[C@H]3CC4CCC(O)C5C4[C@@]2(CCN3CC2CC2)[C@H]1O5
NALIDIXIC-ACID,NALIDIXIC-ACID,,BRD:BRD-BRD-K47886988-001-21-4;BRD:BRD-K47886988-001-21-4,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,,,NA,,CCN1CC(C(O)=O)C(=O)C2CCC(C)NC12
NALMEFENE,NALMEFENE,CHEMBL982,BRD:BRD-A72767275-003-01-6;BRD:BRD-BRD-A72767275-003-01-6,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,RESPIRATORY DEPRESSION,,LAUNCHED,,Small molecule,Approved,WJBLNOPPDWQMCH-MBPVOVBZSA-N,C=C1CC[C@@]2(O)[C@H]3CC4CCC(O)C5C4[C@@]2(CCN3CC2CC2)[C@H]1O5;OC1CCC2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C(=C)CC[C@@]35O;OC1CCC2CC3N(CC4CC4)CCC45C(OC1C24)C(=C)CCC35O
NALOXEGOL,NALOXEGOL,CHEMBL2219418,BRD:BRD-BRD-K41458421-034-01-6;BRD:BRD-K41458421-034-01-6,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRM1,CONSTIPATION,,LAUNCHED,,Small molecule,Approved,XNKCCCKFOQNXKV-ZRSCBOBOSA-N,C=CCN1CC[C@]23C4C5CCC(O)C4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5;COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4CCC(O)C5O[C@@H]1[C@]2(CCN3CC=C)C45
NALOXONE,NALOXONE,CHEMBL1718;CHEMBL80,BRD:BRD-BRD-K67511046-001-02-3;BRD:BRD-K67511046-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,CREB1;ESR1;OPRD1;OPRK1;OPRM1;TLR4,RESPIRATORY DEPRESSION,,LAUNCHED,,Small molecule,Approved,RGPDIGOSVORSAK-STHHAXOLSA-N;UZHSEJADLWPNLE-GRGSLBFTSA-N,C=CCN1CC[C@]23C4C5CCC(O)C4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5;C=CCN1CC[C@]23C4C5CCC(O)C4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.CL;OC1CCC2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1C24)C(=O)CC[C@@]35O
NALOXONE-BENZOYLHYDRAZONE,NALOXONE-BENZOYLHYDRAZONE,,BRD:BRD-BRD-K70898774-001-03-5;BRD:BRD-K70898774-001-03-5,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRK1;OPRM1,,,PRECLINICAL,,,NA,,OC1CCC2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1C24)\C(CC[C@@]35O)=N\NC(=O)C1CCCCC1
NALTREXONE,NALTREXONE,CHEMBL19019,BRD:BRD-BRD-K88172511-003-20-3;BRD:BRD-BRD-K88172511-003-21-1;BRD:BRD-K88172511-003-20-3;BRD:BRD-K88172511-003-21-1,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1;SIGMAR1,ABSTINENCE FROM ALCOHOL,,LAUNCHED,,Small molecule,Approved,DQCKKXVULJGBQN-XFWGSAIBSA-N,O=C1CC[C@@]2(O)[C@H]3CC4CCC(O)C5C4[C@@]2(CCN3CC2CC2)[C@H]1O5;OC1CCC2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C(=O)CC[C@@]35O
NALTRIBEN,NALTRIBEN,CHEMBL100940,BRD:BRD-A19102171-066-01-4;BRD:BRD-BRD-A19102171-066-01-4,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,,,PRECLINICAL,,Small molecule,NA,ZHVWWEYETMPAMX-IFKAHUTRSA-N,OC1CCC2C3C1O[C@H]1C4OC5CCCCC5C4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314;OC1CCC2CC3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C1OC2CCCCC2C1C[C@@]35O
NALTRINDOLE,NALTRINDOLE,CHEMBL567175,BRD:BRD-A47342814-003-01-8;BRD:BRD-BRD-A47342814-003-01-8,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,,,PRECLINICAL,,Small molecule,NA,WIYUZYBFCWCCQJ-IFKAHUTRSA-N,OC1CCC2C3C1O[C@H]1C4[NH]C5CCCCC5C4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314;OC1CCC2CC3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C1[NH]C2CCCCC2C1C[C@@]35O
NAMPT-IN-1,NAMPT-IN-1,,BRD:BRD-BRD-K18280217-001-01-0;BRD:BRD-K18280217-001-01-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(C)(O)CS(=O)(=O)NC1CCC2CN(CCC2C1)C(=O)COC1CCCNC1
NAN-190,NAN-190,CHEMBL8618,BRD:BRD-BRD-K69195780-004-08-4;BRD:BRD-K69195780-004-08-4,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;HTR1A;HTR1F,,,PRECLINICAL,,Small molecule,NA,SJDOMIRMMUGQQK-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CCCCN2C(=O)C3CCCCC3C2=O)CC1
NANCHANGMYCIN,NANCHANGMYCIN,,BRD:BRD-A73871920-236-03-6;BRD:BRD-BRD-A73871920-236-03-6,rep_multi_dose;rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,,,PRECLINICAL,,,NA,,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C
NANDROLONE,NANDROLONE,CHEMBL2104906;CHEMBL757,BRD:BRD-BRD-K52080565-001-09-2;BRD:BRD-K52080565-001-09-2,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR AGONIST,AR;CYP19A1;MAOA;MAOB,ANEMIA,,LAUNCHED,,Small molecule,Phase 3,NPAGDVCDWIYMMC-IZPLOLCNSA-N;REACBNMPQDINOF-YBBIQVIJSA-N,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2O;C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O;CC12C=CC(C(=O)O[C@H]3CC[C@H]4[C@@H]5CCC6=CC(=O)CC[C@@H]6[C@H]5CC[C@]34C)(CC1)CC2
NANDROLONE-DECANOATE,NANDROLONE-DECANOATE,,BRD:BRD-BRD-K78352627-001-01-8;BRD:BRD-K78352627-001-01-8,rep_primary;rep_single_dose,ANDROGENIC STEROID,AR,,,PHASE 1,,,NA,,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
NAPABUCASIN,NAPABUCASIN,CHEMBL64130,BRD:BRD-BRD-K22064724-001-01-8;BRD:BRD-K22064724-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,STAT INHIBITOR,STAT3,,,PHASE 3,,Small molecule,Phase 3,DPHUWDIXHNQOSY-UHFFFAOYSA-N,CC(=O)C1CC2C(O1)C(=O)C1CCCCC1C2=O
NAPAMEZOLE,NAPAMEZOLE,CHEMBL167493,BRD:BRD-K00004563-001-01-9,rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, MONOAMINE REUPTAKE INHIBITOR",,,,,,Small molecule,Unknown,WETRBJOSGIDJHQ-UHFFFAOYSA-N,C1=C(CC2=NCCN2)CCC2CCCCC21
NAPHAZOLINE,NAPHAZOLINE,CHEMBL761,BRD:BRD-BRD-K77641333-003-27-1;BRD:BRD-K77641333-003-27-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA2A,EYE IRRITATION,,LAUNCHED,,Small molecule,Approved,CNIIGCLFLJGOGP-UHFFFAOYSA-N,C(C1=NCCN1)C1CCCC2CCCCC12;C1CCC2C(CC3=NCCN3)CCCC2C1
NAPHTHOQUINE-PHOSPHATE,NAPHTHOQUINE-PHOSPHATE,,BRD:BRD-BRD-K13664493-316-02-5;BRD:BRD-K13664493-316-02-5,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,,,,LAUNCHED,,,NA,,CC(C)(C)NCC1CC(NC2CCNC3CC(CL)CCC23)C2CCCCC2C1O
NAPIRIMUS,NAPIRIMUS,CHEMBL2105168,BRD:BRD-BRD-K91234829-001-01-7;BRD:BRD-K91234829-001-01-7,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,,,,PHASE 1,,Small molecule,Unknown,CNUPQURTHORUGH-UHFFFAOYSA-N,CN1CC(C(=O)C2CCCC3CCCCC23)CC1C(=O)O;CN1CC(CC1C(O)=O)C(=O)C1CCCC2CCCCC12
NAPROXEN,NAPROXEN,CHEMBL154,BRD:BRD-BRD-K59197931-001-04-5;BRD:BRD-K59197931-001-04-5,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"PAIN RELIEF, RHEUMATOID ARTHRITIS, HEADACHE, TOOTHACHE, BACKACHE, MUSCLE PAIN, COMMON COLD, FEVER",,LAUNCHED,,Small molecule,Approved,CMWTZPSULFXXJA-VIFPVBQESA-N,COC1CCC2CC([C@H](C)C(=O)O)CCC2C1;COC1CCC2CC(CCC2C1)[C@H](C)C(O)=O
NAQUOTINIB,NAQUOTINIB,CHEMBL3663929,BRD:BRD-K64114733-066-03-9,rep_single_dose,EGFR INHIBITOR,,,,,,Small molecule,Phase 3,QKDCLUARMDUUKN-XMMPIXPASA-N,C=CC(=O)N1CC[C@@H](OC2NC(NC3CCC(N4CCC(N5CCN(C)CC5)CC4)CC3)C(C(N)=O)NC2CC)C1
NARASIN,NARASIN,CHEMBL2104423,BRD:BRD-A25608658-001-01-1;BRD:BRD-BRD-A25608658-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,VHKXXVVRRDYCIK-CWCPJSEDSA-N,CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C;CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O
NARATRIPTAN,NARATRIPTAN,CHEMBL1200601;CHEMBL1278,BRD:BRD-BRD-K61337602-003-02-1;BRD:BRD-K61337602-003-02-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,AMKVXSZCKVJAGH-UHFFFAOYSA-N;AWEZYKMQFAUBTD-UHFFFAOYSA-N,CNS(=O)(=O)CCC1CCC2[NH]CC(C3CCN(C)CC3)C2C1;CNS(=O)(=O)CCC1CCC2[NH]CC(C3CCN(C)CC3)C2C1.CL
NARCICLASINE,NARCICLASINE,CHEMBL98745,CTRP:632243,ctrp,,,,,,,Small molecule,NA,LZAZURSABQIKGB-AEKGRLRDSA-N,O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)C2CC3C(C(O)C21)OCO3
NARINGENIN,NARINGENIN,CHEMBL9352,BRD:BRD-BRD-K08832567-001-11-5;BRD:BRD-K08832567-001-11-5,rep_primary;rep_single_dose,"AROMATASE INHIBITOR, TRPV ANTAGONIST",CYP19A1;CYP1B1;ESR2;GLO1;HSD17B1,,,PHASE 1,,Small molecule,NA,FTVWIRXFELQLPI-ZDUSSCGKSA-N,O=C1C[C@@H](C2CCC(O)CC2)OC2CC(O)CC(O)C21;OC1CCC(CC1)[C@@H]1CC(=O)C2C(O)CC(O)CC2O1
NARINGENINIC-ACID,NARINGENINIC-ACID,,BRD:BRD-BRD-K87122641-001-10-7;BRD:BRD-K87122641-001-10-7,rep_primary;rep_single_dose,,HCAR2;PTGR1,,,PHASE 1,,,NA,,OC(=O)\C=C\C1CCC(O)CC1
NARINGIN,NARINGIN,CHEMBL451532,BRD:BRD-BRD-K02953697-001-09-2;BRD:BRD-K02953697-001-09-2,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,SLCO1A2,,,PRECLINICAL,,Small molecule,NA,DFPMSGMNTNDNHN-ZPHOTFPESA-N,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2CC(O)C3C(=O)C[C@H](OC3C2)C2CCC(O)CC2)[C@H](O)[C@H](O)[C@H]1O;C[C@@H]1O[C@@H](O[C@H]2[C@H](OC3CC(O)C4C(C3)O[C@H](C3CCC(O)CC3)CC4=O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
NARINGIN-DIHYDROCHALCONE,NARINGIN-DIHYDROCHALCONE,,BRD:BRD-BRD-K13511380-001-01-4;BRD:BRD-K13511380-001-01-4,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,,,,PRECLINICAL,,,NA,,C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2CC(O)C(C(=O)CCC3CCC(O)CC3)C(O)C2)[C@H](O)[C@H](O)[C@H]1O
NARLAPREVIR,NARLAPREVIR,CHEMBL1255891,BRD:BRD-BRD-K38287497-001-01-2;BRD:BRD-K38287497-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,RICZEKWVNZFTNZ-LFGITCQGSA-N,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1
NAS-181,NAS-181,,BRD:BRD-K00004235-334-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1B,,,,,,NA,,
NASTORAZEPIDE,NASTORAZEPIDE,,BRD:BRD-BRD-K17295893-001-01-0;BRD:BRD-K17295893-001-01-0;BRD:BRD-K17295893-238-03-9,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKBR,,,PHASE 2,,,NA,,CC(C)(C)C(=O)CN1C2CCCCC2N(C[C@@H](NC(=O)NC2CCCC(C2)C(O)=O)C1=O)C1CCCCC1
NATAMYCIN,NATAMYCIN,CHEMBL1200656,BRD:BRD-BRD-K90563805-001-02-6;BRD:BRD-K90563805-001-02-6,rep_primary;rep_single_dose,FUNGAL ERGOSTEROL INHIBITOR,,"CONJUNCTIVITIS, FUNGAL KERATOSIS, BLEPHARITIS",,LAUNCHED,,Small molecule,Approved,NCXMLFZGDNKEPB-FFPOYIOWSA-N,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O;C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O
NATEGLINIDE,NATEGLINIDE,CHEMBL249263;CHEMBL783,BRD:BRD-BRD-K44353683-001-08-3;BRD:BRD-K44353683-001-08-3,rep_primary;rep_single_dose,INSULIN SECRETAGOGUE,ABCC8;KCNJ10;KCNJ11;PPARG,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,OELFLUMRDSZNSF-BRWVUGGUSA-N;OELFLUMRDSZNSF-ULQDDVLXSA-N,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](CC1CCCCC1)C(O)=O;CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1CCCCC1)C(O)=O;CC(C)[C@H]1CC[C@H](C(=O)N[C@@H](CC2CCCCC2)C(=O)O)CC1;CC(C)[C@H]1CC[C@H](C(=O)N[C@H](CC2CCCCC2)C(=O)O)CC1
NAV-26,NAV-26,,BRD:BRD-A84202322-001-01-7;BRD:BRD-BRD-A84202322-001-01-7,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,SCN9A,,,PRECLINICAL,,,NA,,FC(F)(F)OC1CCC(CNC(=O)C2N(C3CCOCC3)C(=O)C3CCCCC23)CC1
NAVARIXIN,NAVARIXIN,CHEMBL2103864;CHEMBL216981,BRD:BRD-BRD-K82850175-001-01-1;BRD:BRD-K82850175-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR1;CXCR2,,,PHASE 2,,Small molecule,Phase 2,AFTCWZSEWTXWTL-BTQNPOSSSA-N;RXIUEIPPLAFSDF-CYBMUJFWSA-N,CC[C@@H](NC1C(NC2CCCC(C(=O)N(C)C)C2O)C(=O)C1=O)C1CCC(C)O1;CC[C@@H](NC1C(NC2CCCC(C(=O)N(C)C)C2O)C(=O)C1=O)C1CCC(C)O1.O
NAVELBINE,NAVELBINE,CHEMBL538943,GDSC1:140;GDSC2:2048,gdsc,,,,,,,Small molecule,Approved,CILBMBUYJCWATM-UDRBCWGGSA-N,CCC1=C[C@@H]2CN(C1)CC1C([NH]C3CCCCC13)[C@@](C(=O)OC)(C1CC3C(CC1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
NAVITOCLAX:BIRINAPANT (1:1 MOL/MOL),NAVITOCLAX:BIRINAPANT (1:1 MOL/MOL),,CTRP:660172,ctrp,,,,,,,,NA,,
NAVITOCLAX:GEMCITABINE (1:1 MOL/MOL),NAVITOCLAX:GEMCITABINE (1:1 MOL/MOL),,CTRP:660225,ctrp,,,,,,,,NA,,
NAVITOCLAX:MST-312 (1:1 MOL/MOL),NAVITOCLAX:MST-312 (1:1 MOL/MOL),,CTRP:660222,ctrp,,,,,,,,NA,,
NAVITOCLAX:PIPERLONGUMINE (1:1 MOL/MOL),NAVITOCLAX:PIPERLONGUMINE (1:1 MOL/MOL),,CTRP:660284,ctrp,,,,,,,,NA,,
NAVITOCLAX:PLURIPOTIN (1:1 MOL/MOL),NAVITOCLAX:PLURIPOTIN (1:1 MOL/MOL),,CTRP:660246,ctrp,,,,,,,,NA,,
NAVITOCLAX:PLX-4032 (1:1 MOL/MOL),NAVITOCLAX:PLX-4032 (1:1 MOL/MOL),,CTRP:660219,ctrp,,,,,,,,NA,,
NAVITOCLAX:SORAFENIB (1:1 MOL/MOL),NAVITOCLAX:SORAFENIB (1:1 MOL/MOL),,CTRP:660283,ctrp,,,,,,,,NA,,
NAVOXIMOD,NAVOXIMOD,CHEMBL3989951,BRD:BRD-K00078423-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,YGACXVRLDHEXKY-WXRXAMBDSA-N,O[C@H](C[C@H]1C2C(F)CCCC2-C2CNCN21)[C@H]1CC[C@H](O)CC1
NAXAGOLIDE,NAXAGOLIDE,CHEMBL69271,BRD:BRD-K00004670-001-01-9,rep_single_dose,DOPAMINE RECEPTOR AGONIST,,,,,,Small molecule,Unknown,JCSREICEMHWFAY-HUUCEWRRSA-N,CCCN1CCO[C@@H]2C3CC(O)CCC3CC[C@H]21
NB-001,NB-001,CHEMBL4297305,BRD:BRD-K00004647-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 3,CVPTTZZCRDVGSU-UHFFFAOYSA-N,NC1NCNC2C1NCN2CCNCCCCCO
NBI-27914,NBI-27914,,BRD:BRD-BRD-K61177364-003-02-9;BRD:BRD-K61177364-003-02-9,rep_primary;rep_single_dose,"CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST",CRHR1,,,PRECLINICAL,"Multiple values for MOA: {'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST', 'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST'}, defaulting to 'CORTICOSTEROID RELEASING FACTOR RECEPTOR ANTAGONIST, CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST'",,NA,,CCCN(CC1CC1)C1NC(C)NC(NC2C(CL)CC(CL)CC2CL)C1CL
NBI-74330-(+/-),NBI-74330-(+/-),,BRD:BRD-A86523169-001-01-0;BRD:BRD-BRD-A86523169-001-01-0,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR3,,,PRECLINICAL,,,NA,,CCOC1CCC(CC1)-N1C(NC2NCCCC2C1=O)C(C)N(CC1CCCNC1)C(=O)CC1CCC(F)C(C1)C(F)(F)F
NBI-98782,NBI-98782,,BRD:BRD-K15241725-001-02-9,rep_single_dose,VESICULAR MONOAMINE TRANSPORTER INHIBITOR,,,,,,,NA,,
NBQX,NBQX,CHEMBL222519,BRD:BRD-BRD-K11796549-001-04-5;BRD:BRD-K11796549-001-04-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIA3;GRIA4;GRIK1;GRIN1;GRIN2A;GRIN2B,,,PRECLINICAL,,Small molecule,NA,UQNAFPHGVPVTAL-UHFFFAOYSA-N,NS(=O)(=O)C1CCCC2C1C([N+](=O)[O-])CC1NC(O)C(O)NC12;NS(=O)(=O)C1CCCC2C1C(CC1[NH]C(=O)C(=O)[NH]C21)[N+]([O-])=O
NCS-382,NCS-382,,BRD:BRD-A85025557-001-02-5;BRD:BRD-BRD-A85025557-001-02-5,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1;GABBR2;SLC52A2,,,PRECLINICAL,,,NA,,OC1C2CCCCC2CCC\C1=C/C(O)=O
NCX-1015,NCX-1015,,BRD:BRD-K00004749-001-01-9,rep_single_dose,INTERLEUKIN SYTHESIS STIMULATOR,,,,,,,NA,,
NDD-094,NDD-094,,BRD:BRD-K00004664-001-01-9,rep_single_dose,,,,,,,,NA,,
NDT-9513727,NDT-9513727,,BRD:BRD-K17539220-001-02-9,rep_single_dose,COMPLEMENT ANTAGONIST,C5AR1,,,,,,NA,,
NE-100,NE-100,,BRD:BRD-BRD-K11443721-003-01-6;BRD:BRD-K11443721-003-01-6,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,SIGMAR1,,,PHASE 2,,,NA,,CCCN(CCC)CCC1CCC(OC)C(OCCC2CCCCC2)C1
NEBIVOLOL,NEBIVOLOL,CHEMBL434394,BRD:BRD-BRD-K04956647-003-02-5;BRD:BRD-K04956647-003-02-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,KOHIRBRYDXPAMZ-UHFFFAOYSA-N,O[C@H](CNC[C@@H](O)[C@@H]1CCC2CC(F)CCC2O1)[C@H]1CCC2CC(F)CCC2O1;OC(CNCC(O)C1CCC2CC(F)CCC2O1)C1CCC2CC(F)CCC2O1
NEBRACETAM,NEBRACETAM,CHEMBL2104682,BRD:BRD-A51355958-003-01-9;BRD:BRD-BRD-A51355958-003-01-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1,,,PHASE 3,,Small molecule,Unknown,LCAFGJGYCUMTGS-UHFFFAOYSA-N,NCC1CC(=O)N(CC2CCCCC2)C1;NCC1CN(CC2CCCCC2)C(=O)C1
NECA,NECA,CHEMBL464859,BRD:BRD-BRD-K14395568-001-16-3;BRD:BRD-K14395568-001-16-3,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3;HSP90B1,,,LAUNCHED,,Small molecule,NA,JADDQZYHOWSFJD-FLNNQWSLSA-N,CCNC(=O)[C@H]1O[C@@H](N2CNC3C(N)NCNC32)[C@H](O)[C@@H]1O;CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CNC2C(N)NCNC12
NECROSTATIN-1,NECROSTATIN-1,CHEMBL195008,BRD:BRD-A36318220-001-08-8;BRD:BRD-BRD-A36318220-001-08-8;CTRP:375435,ctrp;rep_primary;rep_single_dose,RIPK INHIBITOR,RIPK1,,,PRECLINICAL,,Small molecule,NA,TXUWMXQFNYDOEZ-UHFFFAOYSA-N,CN1C(=O)C(CC2C[NH]C3CCCCC23)NC1=S;CN1C(=S)NC(CC2C[NH]C3CCCCC23)C1=O
NECROSTATIN-2,NECROSTATIN-2,,BRD:BRD-BRD-K68851986-001-01-6;BRD:BRD-K68851986-001-01-6,rep_primary;rep_single_dose,"NECROPTOSIS INHIBITOR, RIPK INHIBITOR",RIPK2,,,PRECLINICAL,,,NA,,CN1C(=O)N[C@H](CC2C[NH]C3C(CL)CCCC23)C1=O
NECROSTATIN-7,NECROSTATIN-7,,CTRP:660201,ctrp,,,,,,,,NA,,
NECROSULFONAMIDE,NECROSULFONAMIDE,,CTRP:677522,ctrp,,,,,,,,NA,,
NEDAPLATIN,NEDAPLATIN,CHEMBL3137685,BRD:BRD-BRD-K73469236-001-01-8;BRD:BRD-K73469236-001-01-8,rep_primary;rep_single_dose,DNA INHIBITOR,,,,LAUNCHED,,Small molecule,Phase 3,,N[PT]1(N)OCC(=O)O1;N[PT++]1(N)OCC(=O)O1
NEDOCROMIL,NEDOCROMIL,CHEMBL746,BRD:BRD-BRD-K64716392-001-01-3;BRD:BRD-K64716392-001-01-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,CYSLTR1;CYSLTR2;FPR1;HSP90AA1;PTGDR,"ITCHING, CONJUNCTIVITIS",,LAUNCHED,,Small molecule,Approved,RQTOOFIXOKYGAN-UHFFFAOYSA-N,CCCC1C2OC(C(=O)O)CC(=O)C2CC2C(=O)CC(C(=O)O)N(CC)C12;CCCC1C2OC(CC(=O)C2CC2C1N(CC)C(CC2=O)C(O)=O)C(O)=O
NEFAZODONE,NEFAZODONE,CHEMBL623,BRD:BRD-BRD-K90789829-001-07-8;BRD:BRD-K90789829-001-07-8,rep_primary;rep_single_dose,"ADRENERGIC INHIBITOR, NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN RECEPTOR ANTAGONIST, SEROTONIN REUPTAKE INHIBITOR",ADRA1A;ADRA1B;ADRA2A;CYP3A4;HTR1A;HTR2A;HTR2C;SLC6A2;SLC6A3;SLC6A4,,,WITHDRAWN,,Small molecule,Approved,VRBKIVRKKCLPHA-UHFFFAOYSA-N,CCC1NN(CCCN2CCN(C3CCCC(CL)C3)CC2)C(=O)N1CCOC1CCCCC1;CCC1NN(CCCN2CCN(CC2)C2CCCC(CL)C2)C(=O)N1CCOC1CCCCC1
NEFIRACETAM,NEFIRACETAM,CHEMBL260829,BRD:BRD-BRD-K65678996-001-05-5;BRD:BRD-K65678996-001-05-5,rep_multi_dose;rep_primary;rep_single_dose,"ACETYLCHOLINE RECEPTOR AGONIST, BENZODIAZEPINE RECEPTOR AGONIST",CHRM1,,,PHASE 3,,Small molecule,Phase 2,NGHTXZCKLWZPGK-UHFFFAOYSA-N,CC1CCCC(C)C1NC(=O)CN1CCCC1=O
NEFOPAM,NEFOPAM,CHEMBL465026,BRD:BRD-A78877355-001-03-0;BRD:BRD-BRD-A78877355-001-03-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,PAIN RELIEF,,LAUNCHED,,Small molecule,Approved,RGPDEAGGEXEMMM-UHFFFAOYSA-N,CN1CCOC(C2CCCCC2)C2CCCCC2C1
NELARABINE,NELARABINE,CHEMBL1201112,BRD:BRD-BRD-K84466663-001-05-4;BRD:BRD-K84466663-001-05-4;CTRP:660391;GDSC2:1814,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"DNA SYNTHESIS INHIBITOR, T CELL INHIBITOR",POLA1,"ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)",,LAUNCHED,,Small molecule,Approved,IXOXBSCIXZEQEQ-UHTZMRCNSA-N,COC1NC(N)NC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O;COC1NC(N)NC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
NELFINAVIR,NELFINAVIR,CHEMBL584,BRD:BRD-BRD-K74117820-066-10-8;BRD:BRD-K74117820-066-10-8,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,CYP1A2;CYP2B6;CYP2C19;CYP2C9;CYP2D6;CYP3A4;CYP3A7,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,QAGYKUNXZHXKMR-HKWSIXNMSA-N,CC1C(O)CCCC1C(=O)N[C@@H](CSC1CCCCC1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
NELOCIGUAT,NELOCIGUAT,,BRD:BRD-K00003315-001-01-9,rep_single_dose,GUANYLATE CYCLASE STIMULANT,,,,,,,NA,,
NELOTANSERIN,NELOTANSERIN,CHEMBL598172,BRD:BRD-K00003466-001-01-9,rep_single_dose,SEROTONIN RECEPTOR INVERSE AGONIST,,,,,,Small molecule,Phase 2,COSPVUFTLGQDQL-UHFFFAOYSA-N,COC1CCC(NC(=O)NC2CCC(F)CC2F)CC1-C1C(BR)CNN1C
NEMAZOLINE,NEMAZOLINE,CHEMBL2110957,BRD:BRD-K00004662-001-01-9,rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, ADRENERGIC RECEPTOR ANTAGONIST",,,,,,Small molecule,Unknown,FXNNRWAIGIEAST-UHFFFAOYSA-N,NC1C(CL)CC(CC2=NCCN2)CC1CL
NEMIRALISIB,NEMIRALISIB,CHEMBL2216859,BRD:BRD-K00003285-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,MCIDWGZGWVSZMK-UHFFFAOYSA-N,CC(C)N1CCN(CC2CNC(-C3CC(-C4CCCC5[NH]CCC45)CC4[NH]NCC34)O2)CC1
NEMONAPRIDE,NEMONAPRIDE,CHEMBL20734,BRD:BRD-BRD-M80207679-001-01-5;BRD:BRD-M80207679-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;DRD4,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Unknown,KRVOJOCLBAAKSJ-UHFFFAOYSA-N,CNC1CC(OC)C(C(=O)NC2CCN(CC3CCCCC3)C2C)CC1CL;CNC1CC(OC)C(CC1CL)C(=O)N[C@@H]1CCN(CC2CCCCC2)[C@@H]1C.CNC1CC(OC)C(CC1CL)C(=O)N[C@H]1CCN(CC2CCCCC2)[C@H]1C
NEMOREXANT,NEMOREXANT,CHEMBL4297590,BRD:BRD-K00003505-001-01-9,rep_single_dose,OREXIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,NBGABHGMJVIVBW-QHCPKHFHSA-N,COC1CCC(-N2NCCN2)C(C(=O)N2CCC[C@@]2(C)C2NC3C(C)C(CL)CCC3[NH]2)C1
NEMORUBICIN,NEMORUBICIN,CHEMBL1232279,BRD:BRD-BRD-K51911221-001-01-2;BRD:BRD-K51911221-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1;TOP2A,,,PHASE 2,,Small molecule,Unknown,CTMCWCONSULRHO-UHQPFXKFSA-N,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(CC3C(O)C4C(=O)C5CCCC(OC)C5C(=O)C4C(O)C23)C(=O)CO)O[C@@H](C)[C@H]1O;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N2CCO[C@H](OC)C2)[C@H](O)[C@H](C)O1
NEO-GILURYTMAL,NEO-GILURYTMAL,CHEMBL3833388,BRD:BRD-A53539450-004-01-7;BRD:BRD-BRD-A53539450-004-01-7,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,VZAUGYDMVQSQAO-BAYLNNJJSA-M,CCC[N+]12[C@H](O)[C@@H](CC)[C@@H]3C[C@H]1[C@@H]1N(C)C4CCCCC4[C@]14C[C@H]2[C@@H]3[C@H]4O.O=C([O-])C(O)C(O)C(=O)O;CCC[N+]12[C@H]3C[C@]45C(O)C3[C@@H](CC1[C@@H]4N(C)C1CCCCC51)[C@H](CC)[C@H]2O
NEOHESPERIDIN,NEOHESPERIDIN,CHEMBL506398,BRD:BRD-BRD-K96299080-001-02-7;BRD:BRD-K96299080-001-02-7,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,ARGKVCXINMKCAZ-UZRWAPQLSA-N,COC1CC(O)CC(C1)[C@@H]1CC(=O)C2C(O)CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)CC2O1;COC1CCC([C@@H]2CC(=O)C3C(O)CC(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)CC3O2)CC1O
NEOHESPERIDIN-DIHYDROCHALCONE,NEOHESPERIDIN-DIHYDROCHALCONE,,BRD:BRD-BRD-K61032563-001-02-9;BRD:BRD-K61032563-001-02-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CCC(CCC(=O)C2C(O)CC(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)CC2O)CC1O
NEOPELTOLIDE,NEOPELTOLIDE,CHEMBL223238,CTRP:411774,ctrp,,,,,,,Small molecule,NA,YRSJLYCTJWNTMF-NRBUTUAXSA-N,CCC[C@@H]1C[C@H](OC)C[C@H](C)C[C@@H]2C[C@@H](OC(=O)/C=C\CCC3COC(/C=C\CNC(=O)OC)N3)C[C@H](CC(=O)O1)O2
NEOSAR,NEOSAR,CHEMBL1200796;CHEMBL88,GDSC2:1512,gdsc,,,,,,,Small molecule,Approved,CMSMOCZEIVJLDB-UHFFFAOYSA-N;PWOQRKCAHTVFLB-UHFFFAOYSA-N,O.O=P1(N(CCCL)CCCL)NCCCO1;O=P1(N(CCCL)CCCL)NCCCO1
NEOSTIGMINE,NEOSTIGMINE,CHEMBL278020;CHEMBL54126,BRD:BRD-BRD-K18922609-004-23-1;BRD:BRD-K18922609-004-23-1,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE,MYASTHENIA GRAVIS,,LAUNCHED,,Small molecule,Approved,ALWKGYPQUAPLQC-UHFFFAOYSA-N;LULNWZDBKTWDGK-UHFFFAOYSA-M,CN(C)C(=O)OC1CCCC([N+](C)(C)C)C1;CN(C)C(=O)OC1CCCC([N+](C)(C)C)C1.[BR-];CN(C)C(=O)OC1CCCC(C1)[N+](C)(C)C
NEPAFENAC,NEPAFENAC,CHEMBL1021,BRD:BRD-BRD-K04112579-001-07-0;BRD:BRD-K04112579-001-07-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,EYE INFLAMMATION,,LAUNCHED,,Small molecule,Approved,QEFAQIPZVLVERP-UHFFFAOYSA-N,NC(=O)CC1CCCC(C(=O)C2CCCCC2)C1N
NEPICASTAT,NEPICASTAT,CHEMBL1188395,BRD:BRD-BRD-K09126848-003-01-9;BRD:BRD-K09126848-003-01-9,rep_primary;rep_single_dose,DOPAMINE BETA HYDROXYLASE INHIBITOR,DBH,,,PHASE 2,,Small molecule,Phase 2,YZZVIKDAOTXDEB-JTQLQIEISA-N,NCC1C[NH]C(=S)N1[C@H]1CCC2C(F)CC(F)CC2C1
NEPINALONE (HYDROCHLORIDE),NEPINALONE (HYDROCHLORIDE),,BRD:BRD-K00079018-003-02-9,rep_single_dose,,,,,,,,NA,,
NERATINIB,NERATINIB,CHEMBL180022,BRD:BRD-BRD-K85606544-001-09-1;BRD:BRD-K85606544-001-09-1;CTRP:418038,ctrp;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2;KDR,,,PHASE 3,,Small molecule,Approved,JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOC1CC2NCC(C#N)C(NC3CCC(OCC4CCCCN4)C(CL)C3)C2CC1NC(=O)/C=C/CN(C)C;CCOC1CC2NCC(C#N)C(NC3CCC(OCC4CCCCN4)C(CL)C3)C2CC1NC(=O)\C=C\CN(C)C
NERBACADOL,NERBACADOL,CHEMBL2104808,BRD:BRD-BRD-K43647122-001-01-3;BRD:BRD-K43647122-001-01-3,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,PHASE 3,,Small molecule,Unknown,ZWNGSOLJLMBZFZ-UHFFFAOYSA-N,CC1ONCC1C(=O)N1CCCCC1
NERIDRONIC-ACID,NERIDRONIC-ACID,,BRD:BRD-BRD-K60212747-236-01-1;BRD:BRD-K60212747-236-01-1,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,FDPS,"BRITTLE BONE DISEASE, PAGET'S DISEASE",,LAUNCHED,,,NA,,NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
NESBUVIR,NESBUVIR,CHEMBL1092581,BRD:BRD-BRD-K79989959-001-01-4;BRD:BRD-K79989959-001-01-4,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,WTDWVLJJJOTABN-UHFFFAOYSA-N,CNC(=O)C1C(-C2CCC(F)CC2)OC2CC(N(CCO)S(C)(=O)=O)C(C3CC3)CC12;CNC(=O)C1C(OC2CC(N(CCO)S(C)(=O)=O)C(CC12)C1CC1)-C1CCC(F)CC1
NETARSUDIL MESYLATE,NETARSUDIL MESYLATE,CHEMBL4594251,BRD:BRD-K00029607-334-02-9,rep_single_dose,,,,,,,Small molecule,Approved,QQDRLKRHJOAQDC-FBHGDYMESA-N,CS(=O)(=O)O.CS(=O)(=O)O.CC1CCC(C(=O)OCC2CCC([C@@H](CN)C(=O)NC3CCC4CNCCC4C3)CC2)C(C)C1
NETICONAZOLE,NETICONAZOLE,CHEMBL2107447,BRD:BRD-K00074531-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,VWOIKFDZQQLJBJ-DTQAZKPQSA-N,CCCCCOC1CCCCC1/C(=C\SC)N1CCNC1
NETILMICIN,NETILMICIN,CHEMBL1572,BRD:BRD-A59825838-326-01-4;BRD:BRD-BRD-A59825838-326-01-4,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,CIDUJQMULVCIBT-MQDUPKMGSA-N,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O;CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O
NETUPITANT,NETUPITANT,CHEMBL206253,BRD:BRD-BRD-K97428065-001-01-2;BRD:BRD-K97428065-001-01-2,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,WAXQNWCZJDTGBU-UHFFFAOYSA-N,CC1CCCCC1-C1CC(N2CCN(C)CC2)NCC1N(C)C(=O)C(C)(C)C1CC(C(F)(F)F)CC(C(F)(F)F)C1;CN(C(=O)C(C)(C)C1CC(CC(C1)C(F)(F)F)C(F)(F)F)C1CNC(CC1-C1CCCCC1C)N1CCN(C)CC1
NEU2000,NEU2000,,BRD:BRD-K00003470-001-01-9,rep_single_dose,IONOTROPIC GLUTAMATE RECEPTOR ANTAGONIST,,,,,,,NA,,
NEURODAZINE,NEURODAZINE,,BRD:BRD-K22631935-001-02-7,rep_single_dose,NEUROGENESIS OF NON-PLURIPOTENT C2C12 MYOBLAST INDUCER,,,,,,,NA,,
NEURONAL DIFFERENTIATION INDUCER III,NEURONAL DIFFERENTIATION INDUCER III,,CTRP:411733,ctrp,,,,,,,,NA,,
NEUROPATHIAZOL,NEUROPATHIAZOL,,BRD:BRD-K28567778-001-02-7,rep_single_dose,NEURAL STEM CELL INDUCER,BMP2;LIF,,,,,,NA,,
NEVANIMIBE HYDROCHLORIDE,NEVANIMIBE HYDROCHLORIDE,CHEMBL542103,BRD:BRD-K00091091-003-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,SDOOGTHIDFZUNM-UHFFFAOYSA-N,CC(C)C1CCCC(C(C)C)C1NC(=O)NCC1(C2CCC(N(C)C)CC2)CCCC1.CL
NEVIRAPINE,NEVIRAPINE,CHEMBL57,BRD:BRD-BRD-K15502390-001-20-9;BRD:BRD-K15502390-001-20-9,rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,CYP1A2;CYP2A6;CYP2B6;CYP2C9;CYP2D6;CYP3A4;CYP3A5,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,NQDJXKOVJZTUJA-UHFFFAOYSA-N,CC1CCNC2C1NC(=O)C1CCCNC1N2C1CC1
NEXAVAR,NEXAVAR,CHEMBL1200485;CHEMBL1336,GDSC1:30;GDSC2:1085,gdsc,,,,,,,Small molecule,Approved,IVDHYUQIDRJSTI-UHFFFAOYSA-N;MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C(F)(F)F)C3)CC2)CCN1;CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C(F)(F)F)C3)CC2)CCN1.CC1CCC(S(=O)(=O)O)CC1
NEXTURASTAT-A,NEXTURASTAT-A,,BRD:BRD-BRD-K70402238-001-02-8;BRD:BRD-K70402238-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC6,,,PRECLINICAL,,,NA,,CCCCN(CC1CCC(CC1)C(=O)NO)C(=O)NC1CCCCC1
NFKB-ACTIVATION-INHIBITOR-II,NFKB-ACTIVATION-INHIBITOR-II,,BRD:BRD-K83354763-001-07-9,rep_single_dose,NFKB PATHWAY INHIBITOR,RELA,,,,,,NA,,
NG-25,NG-25,,GDSC1:260,gdsc,,,,,,,,NA,,
NG-NITRO-ARGININE,NG-NITRO-ARGININE,,BRD:BRD-BRD-K89223384-001-05-2;BRD:BRD-K89223384-001-05-2,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1;NOS2;NOS3,,,PHASE 1,,,NA,,N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O
NG25,NG25,,GDSC1:260,gdsc,,,,,,,,NA,,
NGB-2904,NGB-2904,,BRD:BRD-BRD-K05181084-003-03-7;BRD:BRD-K05181084-003-03-7,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD3,,,PRECLINICAL,,,NA,,CLC1CCCC(N2CCN(CCCCNC(=O)C3CCC-4C(CC5CCCCC-45)C3)CC2)C1CL
NGD-94-1,NGD-94-1,,BRD:BRD-BRD-K28639661-001-01-6;BRD:BRD-K28639661-001-01-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD4,,,PHASE 1,,,NA,,C(N1CCN(CC1)C1NCCCN1)C1CNC([NH]1)-C1CCCCC1
NGD-98-2,NGD-98-2,,BRD:BRD-K81779590-003-02-9,rep_single_dose,CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST,CRHR1,,,,,,NA,,
NGP555,NGP555,,BRD:BRD-K00003490-001-01-9,rep_single_dose,GAMMA SECRETASE MODULATOR,,,,,,,NA,,
NH125,NH125,,BRD:BRD-BRD-K31086665-005-04-6;BRD:BRD-K31086665-005-04-6,rep_multi_dose;rep_primary;rep_single_dose,EUKARYOTIC TRANSLATION ELONGATION FACTOR 2 INHIBITOR,,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCCCCC[N+]1CCN(CC2CCCCC2)C1C
NHI-2,NHI-2,,BRD:BRD-K05653025-001-02-9,rep_single_dose,LACTATE DEHYDROGENASE INHIBITOR,LDHA,,,,,,NA,,
NI-57,NI-57,,BRD:BRD-BRD-K03042257-001-01-2;BRD:BRD-K03042257-001-01-2,rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD1;BRPF1;BRPF3,,,PRECLINICAL,,,NA,,COC1CC(CCC1S(=O)(=O)NC1CCC2N(C)C(=O)C(C)CC2C1)C#N
NIACIN,NIACIN,CHEMBL573,BRD:BRD-BRD-K60237333-001-27-1;BRD:BRD-K60237333-001-27-1,rep_multi_dose;rep_primary;rep_single_dose,"NAD PRECURSOR, VITAMIN B",DGAT2;HCAR1;HCAR2;HCAR3;NNMT;QPRT,HYPERTRIGLYCERIDEMIA,,LAUNCHED,,Small molecule,Approved,PVNIIMVLHYAWGP-UHFFFAOYSA-N,O=C(O)C1CCCNC1;OC(=O)C1CCCNC1
NIALAMIDE,NIALAMIDE,CHEMBL1256841,BRD:BRD-BRD-K12102668-001-25-5;BRD:BRD-K12102668-001-25-5,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,COMT;MAOA;MAOB,,,WITHDRAWN,,Small molecule,Approved,NOIIUHRQUVNIDD-UHFFFAOYSA-N,O=C(CCNNC(=O)C1CCNCC1)NCC1CCCCC1
NIBENTAN,NIBENTAN,,BRD:BRD-A85876464-001-01-5;BRD:BRD-BRD-A85876464-001-01-5,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,,,,PHASE 2,,,NA,,CCN(CC)CCCCC(NC(=O)C1CCC(CC1)[N+]([O-])=O)C1CCCCC1
NICAINOPROL,NICAINOPROL,CHEMBL2106788,BRD:BRD-K00003382-001-01-9,rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,,,,,,Small molecule,Unknown,AUIHHZBJBKRDIE-UHFFFAOYSA-N,CC(C)NCC(O)COC1CCCC2C1N(C(=O)C1CCCNC1)CCC2
NICARAVEN,NICARAVEN,CHEMBL1705525,BRD:BRD-A86871940-001-01-9;BRD:BRD-BRD-A86871940-001-01-9,rep_primary;rep_single_dose,FREE RADICAL SCAVENGER,,,,PHASE 3,,Small molecule,Unknown,KTXBOOWDLPUROC-UHFFFAOYSA-N,CC(CNC(=O)C1CCCNC1)NC(=O)C1CCCNC1
NICARDIPINE,NICARDIPINE,CHEMBL1484,BRD:BRD-A26711594-003-10-6;BRD:BRD-BRD-A26711594-003-10-6,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,ADORA3;ADRA1A;ADRA1B;ADRA1D;CACNA1C;CACNA1D;CACNA2D1;CACNB2;CALM1;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;PDE1A;PDE1B,"CHRONIC STABLE ANGINA, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC2CCCCC2)C1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OCCN(C)CC1CCCCC1
NICERGOLINE,NICERGOLINE,CHEMBL1372950,BRD:BRD-BRD-K76810206-001-07-3;BRD:BRD-BRD-K76810206-001-08-1;BRD:BRD-K76810206-001-07-3;BRD:BRD-K76810206-001-08-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A,"RAYNAUD'S DISEASE, MIGRAINE HEADACHE, ATHEROSCLEROSIS, THROMBOSIS, RAYNAUD'S DISEASE, MIGRAINE HEADACHE, ATHEROSCLEROSIS, THROMBOSIS",,LAUNCHED,,Small molecule,Approved,YSEXMKHXIOCEJA-FVFQAYNVSA-N,CO[C@]12C[C@@H](COC(=O)C3CNCC(BR)C3)CN(C)[C@@H]1CC1CN(C)C3CCCC2C13
NICERITROL,NICERITROL,CHEMBL1697762,BRD:BRD-BRD-K11256763-001-01-5;BRD:BRD-K11256763-001-01-5,rep_primary;rep_single_dose,NAD PRECURSOR,,HYPERLIPIDEMIA,,LAUNCHED,,Small molecule,Unknown,KUEUWHJGRZKESU-UHFFFAOYSA-N,O=C(OCC(COC(=O)C1CCCNC1)(COC(=O)C1CCCNC1)COC(=O)C1CCCNC1)C1CCCNC1
NICLOSAMIDE,NICLOSAMIDE,CHEMBL1448,BRD:BRD-BRD-K35960502-001-20-0;BRD:BRD-K35960502-001-20-0;CTRP:32653,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"DNA REPLICATION INHIBITOR, STAT INHIBITOR",STAT3,TAPEWORM,,LAUNCHED,,Small molecule,Approved,RJMUSRYZPJIFPJ-UHFFFAOYSA-N,O=C(NC1CCC([N+](=O)[O-])CC1CL)C1CC(CL)CCC1O;OC1CCC(CL)CC1C(=O)NC1CCC(CC1CL)[N+]([O-])=O
NICODICOSAPENT,NICODICOSAPENT,,BRD:BRD-K00003262-001-01-9,rep_single_dose,STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) INHIBITOR,,,,,,,NA,,
NICORANDIL,NICORANDIL,CHEMBL284906,BRD:BRD-BRD-K97752965-001-16-4;BRD:BRD-K97752965-001-16-4,rep_multi_dose;rep_primary;rep_single_dose,"NITRIC OXIDE DONOR, POTASSIUM CHANNEL ACTIVATOR",KCNJ11,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Approved,LBHIOVVIQHSOQN-UHFFFAOYSA-N,[O-][N+](=O)OCCNC(=O)C1CCCNC1;O=C(NCCO[N+](=O)[O-])C1CCCNC1
NICOTINAMIDE,NICOTINAMIDE,CHEMBL1140,BRD:BRD-BRD-K28912512-001-23-2;BRD:BRD-K28912512-001-23-2,rep_primary;rep_single_dose,PROTEIN SYNTHESIS STIMULANT,BST1;LDHA;PARP1;SIRT5,ACNE VULGARIS (AV),,LAUNCHED,,Small molecule,Approved,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NC(=O)C1CCCNC1
NICOTINE,NICOTINE,CHEMBL3,BRD:BRD-A93695607-322-02-5;BRD:BRD-BRD-A93695607-322-02-5;BRD:BRD-BRD-K05395900-322-05-4;BRD:BRD-K05395900-322-05-4,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHAT;CHRNA10;CHRNA2;CHRNA3;CHRNA4;CHRNA5;CHRNA6;CHRNA7;CHRNA9;CHRNB2;CHRNB3;CHRNB4;CYP19A1;TBXAS1;TRPA1,SMOKING CESSATION,,LAUNCHED,"Multiple values for structure_id: {'A93695607', 'K05395900'}, defaulting to None",Small molecule,Approved,SNICXCGAKADSCV-JTQLQIEISA-N,CN1CCC[C@H]1C1CCCNC1;CN1CCCC1C1CCCNC1
NICOTINYL-ALCOHOL-TARTRATE,NICOTINYL-ALCOHOL-TARTRATE,,BRD:BRD-BRD-K76600340-045-04-9;BRD:BRD-K76600340-045-04-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,OCC1CCCNC1
NIDA-41020,NIDA-41020,,BRD:BRD-BRD-K17617556-001-01-3;BRD:BRD-K17617556-001-01-3,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-C1C(C)C(NN1-C1CCC(CL)CC1CL)C(=O)NN1CCCCC1
NIDUFEXOR,NIDUFEXOR,CHEMBL4297626,BRD:BRD-K00091135-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,JYTIXGYXBIBOMN-UHFFFAOYSA-N,CN1NC(C(=O)N(CC2CCCCC2)CC2CCC(C(=O)O)CC2)C2C1-C1CC(CL)CCC1OC2
NIFEDIPINE,NIFEDIPINE,CHEMBL193,BRD:BRD-K96354014-001-29-4,rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1F;CACNA1H;CACNA1S;CACNA2D1;CACNB2;CALM1;GLRA1;GLRA3;GLRB;KCNA1;KCNA5;NR1I2;TRPM3,,,,,Small molecule,Approved,HYIMSNHJOBLJNT-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1CCCCC1[N+](=O)[O-]
NIFEKALANT,NIFEKALANT,CHEMBL360861,BRD:BRD-BRD-K32311154-001-01-0;BRD:BRD-K32311154-001-01-0,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,,"VENTRICULAR ARRHYTHMIAS, VENTRICULAR TACHYCARDIA (VT)",,LAUNCHED,,Small molecule,Phase 3,OEBPANQZQGQPHF-UHFFFAOYSA-N,CN1C(NCCN(CCO)CCCC2CCC([N+](=O)[O-])CC2)CC(=O)N(C)C1=O;CN1C(NCCN(CCO)CCCC2CCC(CC2)[N+]([O-])=O)CC(=O)N(C)C1=O
NIFENALOL,NIFENALOL,CHEMBL127349,BRD:BRD-A21280314-001-06-8;BRD:BRD-BRD-A21280314-001-06-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,,,LAUNCHED,,Small molecule,Unknown,UAORFCGRZIGNCI-UHFFFAOYSA-N,CC(C)NCC(O)C1CCC([N+](=O)[O-])CC1;CC(C)NCC(O)C1CCC(CC1)[N+]([O-])=O
NIFENAZONE,NIFENAZONE,CHEMBL1413176,BRD:BRD-BRD-K47407372-001-17-1;BRD:BRD-K47407372-001-17-1,rep_primary;rep_single_dose,ANALGESIC AGENT,,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,BRZANEXCSZCZCI-UHFFFAOYSA-N,CC1C(NC(=O)C2CCCNC2)C(=O)N(-C2CCCCC2)N1C
NIFLUMIC-ACID,NIFLUMIC-ACID,,BRD:BRD-BRD-K98763141-001-30-8;BRD:BRD-K98763141-001-30-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,ANO1;CLCN1;CLCNKA;CLCNKB;KCNQ1;PLA2G1B;PLA2G4A;PTGS1;PTGS2;UGT1A9,"JOINT PAIN, MUSCLE PAIN",,LAUNCHED,,,NA,,OC(=O)C1CCCNC1NC1CCCC(C1)C(F)(F)F
NIFUROXAZIDE,NIFUROXAZIDE,CHEMBL244888,BRD:BRD-BRD-K68188368-001-09-4;BRD:BRD-K68188368-001-09-4,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,"COLITIS, DIARRHEA",,LAUNCHED,,Small molecule,Approved,YCWSUKQGVSGXJO-NTUHNPAUSA-N,O=C(N/N=C/C1CCC([N+](=O)[O-])O1)C1CCC(O)CC1;OC1CCC(CC1)C(=O)N\N=C\C1CCC(O1)[N+]([O-])=O
NIFURSOL,NIFURSOL,CHEMBL485549,BRD:BRD-BRD-K85757157-001-01-7;BRD:BRD-K85757157-001-01-7,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,XXUXXCZCUGIGPP-WLRTZDKTSA-N,O=C(N/N=C/C1CCC([N+](=O)[O-])O1)C1CC([N+](=O)[O-])CC([N+](=O)[O-])C1O;OC1C(CC(CC1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\C1CCC(O1)[N+]([O-])=O
NIFURTIMOX,NIFURTIMOX,CHEMBL290960,BRD:BRD-A00100033-001-08-9;BRD:BRD-BRD-A00100033-001-08-9,rep_primary;rep_single_dose,DNA INHIBITOR,,"CHAGAS DISEASE, AFRICAN TRYPANOSOMIASIS",,LAUNCHED,,Small molecule,Approved,ARFHIAQFJWUCFH-IZZDOVSWSA-N,CC1CS(=O)(=O)CCN1/N=C/C1CCC([N+](=O)[O-])O1;CC1CS(=O)(=O)CCN1N=CC1CCC(O1)[N+]([O-])=O
NIGULDIPINE-(S)-(+),NIGULDIPINE-(S)-(+),,BRD:BRD-BRD-K59333713-003-02-0;BRD:BRD-K59333713-003-02-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A,,,PRECLINICAL,,,NA,,COC(=O)C1=C(C)NC(C)=C([C@H]1C1CCCC(C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1CCCCC1)C1CCCCC1
NIKETHAMIDE,NIKETHAMIDE,CHEMBL2104607,BRD:BRD-BRD-K91544578-001-03-8;BRD:BRD-K91544578-001-03-8,rep_primary;rep_single_dose,IMMUNOSTIMULANT,,,,WITHDRAWN,,Small molecule,Approved,NCYVXEGFNDZQCU-UHFFFAOYSA-N,CCN(CC)C(=O)C1CCCNC1
NILOTINIB,NILOTINIB,CHEMBL255863,BRD:BRD-BRD-K81528515-001-13-8;BRD:BRD-K81528515-001-02-1;BRD:BRD-K81528515-001-13-8;CTRP:374749;GDSC1:1013;GDSC2:1013,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,"ABL KINASE INHIBITOR, BCR-ABL KINASE INHIBITOR",ABL1;KIT;PDGFRA,CHRONIC MYELOID LEUKEMIA (CML),,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF BCR-ABL1, PDGFRA, AND KIT', 'ABL KINASE INHIBITOR, BCR-ABL KINASE INHIBITOR'}, defaulting to 'ABL KINASE INHIBITOR, BCR-ABL KINASE INHIBITOR'
Multiple values for repurposing_target: {'ABL1;KIT;PDGFRA', 'ABL1;KIT'}, taking the union",Small molecule,Approved,HHZIURLSWUIHRB-UHFFFAOYSA-N,CC1CN(-C2CC(NC(=O)C3CCC(C)C(NC4NCCC(-C5CCCNC5)N4)C3)CC(C(F)(F)F)C2)CN1;CC1CN(CN1)-C1CC(NC(=O)C2CCC(C)C(NC3NCCC(N3)-C3CCCNC3)C2)CC(C1)C(F)(F)F
NILUTAMIDE,NILUTAMIDE,CHEMBL1274,BRD:BRD-BRD-K23566484-001-15-1;BRD:BRD-K23566484-001-15-1,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,PROSTATE CANCER,,LAUNCHED,,Small molecule,Approved,XWXYUMMDTVBTOU-UHFFFAOYSA-N,CC1(C)NC(=O)N(C1=O)C1CCC(C(C1)C(F)(F)F)[N+]([O-])=O;CC1(C)NC(=O)N(C2CCC([N+](=O)[O-])C(C(F)(F)F)C2)C1=O
NILVADIPINE,NILVADIPINE,CHEMBL517427,BRD:BRD-A84687895-001-03-2;BRD:BRD-BRD-A84687895-001-03-2,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1S;CACNA2D1;CACNA2D3;CACNB2,"HYPERTENSION, CEREBRAL ARTERY OCCLUSION",,LAUNCHED,,Small molecule,Phase 3,FAIIFDPAEUKBEP-UHFFFAOYSA-N,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC(C)C)C#N
NIM811,NIM811,CHEMBL1688529,BRD:BRD-K00003331-001-01-9,oncref_1;rep_single_dose,CYCLOPHILIN AND MITOCHONDRIAL PERMEABILITY TRANSITION INHIBITOR,PPID,,,,"Multiple values for MOA: {'CYCLOPHILIN AND MITOCHONDRIAL PERMEABILITY TRANSITION INHIBITOR', 'MITOCHONDRIAL PERMEABILITY TRANSITION INHIBITOR'}, defaulting to 'CYCLOPHILIN AND MITOCHONDRIAL PERMEABILITY TRANSITION INHIBITOR'",Protein,Phase 2,RPJPZDVUUKWPGT-FOIHOXPVSA-N,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
NIMESULIDE,NIMESULIDE,CHEMBL56367,BRD:BRD-BRD-K76775527-001-30-2;BRD:BRD-K76775527-001-30-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,LTF;PLA2G2E;PTGS1;PTGS2,"OSTEOARTHRITIS, MENSTRUAL PAIN",,LAUNCHED,,Small molecule,Approved,HYWYRSMBCFDLJT-UHFFFAOYSA-N,CS(=O)(=O)NC1CCC([N+](=O)[O-])CC1OC1CCCCC1;CS(=O)(=O)NC1CCC(CC1OC1CCCCC1)[N+]([O-])=O
NIMODIPINE,NIMODIPINE,CHEMBL1428;CHEMBL255033,BRD:BRD-A58048407-001-18-8;BRD:BRD-BRD-A58048407-001-18-8,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,AHR;CACNA1C;CACNA1D;CACNA1F;CACNA1S;CACNB1;CACNB2;CACNB3;CACNB4;CFTR;NR3C2,HEMORRHAGE,,LAUNCHED,,Small molecule,Approved,UIAGMCDKSXEBJQ-IBGZPJMESA-N;UIAGMCDKSXEBJQ-UHFFFAOYSA-N,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1CCCC([N+](=O)[O-])C1;COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1CCCC([N+](=O)[O-])C1;COCCOC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC(C)C
NIMORAZOLE,NIMORAZOLE,CHEMBL435966,BRD:BRD-BRD-K79145628-001-05-5;BRD:BRD-K79145628-001-05-5,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC),,LAUNCHED,,Small molecule,Approved,MDJFHRLTPRPZLY-UHFFFAOYSA-N,[O-][N+](=O)C1CNCN1CCN1CCOCC1;O=[N+]([O-])C1CNCN1CCN1CCOCC1
NINGETINIB-TOSYLATE,NINGETINIB-TOSYLATE,,BRD:BRD-K00003476-075-01-9,rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,,,,,,,NA,,
NINTEDANIB,NINTEDANIB,CHEMBL502835,BRD:BRD-BRD-K49075727-001-08-5;BRD:BRD-K49075727-001-08-5;CTRP:628601,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",FGFR1;FGFR2;FGFR3;FGFR4;FLT1;FLT4;KDR;PDGFRA;PDGFRB,IDIOPATHIC PULMONARY FIBROSIS (IPF),,LAUNCHED,,Small molecule,Approved,XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)C1CCC2C(C1)NC(=O)/C2=C(\NC1CCC(N(C)C(=O)CN2CCN(C)CC2)CC1)C1CCCCC1;COC(=O)C1CCC2C(NC(=O)\C2=C(/NC2CCC(CC2)N(C)C(=O)CN2CCN(C)CC2)C2CCCCC2)C1
NIRIDAZOLE,NIRIDAZOLE,CHEMBL152632,BRD:BRD-BRD-K53123955-001-10-5;BRD:BRD-K53123955-001-10-5,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHOFRUCTOKINASE INHIBITOR,,SCHISTOSOMIASIS,,LAUNCHED,,Small molecule,Unknown,RDXLYGJSWZYTFJ-UHFFFAOYSA-N,[O-][N+](=O)C1CNC(S1)N1CCNC1=O;O=C1NCCN1C1NCC([N+](=O)[O-])S1
NISOLDIPINE,NISOLDIPINE,CHEMBL1726,BRD:BRD-A84465106-001-09-5,rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1F;CACNA1S,,,,,Small molecule,Approved,VKQFCGNPDRICFG-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1CCCCC1[N+](=O)[O-]
NISOXETINE,NISOXETINE,CHEMBL295467,BRD:BRD-A95696066-003-13-8;BRD:BRD-BRD-A95696066-003-13-8,rep_multi_dose;rep_primary;rep_single_dose,NOREPINEPHRINE REUPTAKE INHIBITOR,SLC6A2;SLC6A3;SLC6A4,,,PHASE 1,,Small molecule,Unknown,ITJNARMNRKSWTA-UHFFFAOYSA-N,CNCCC(OC1CCCCC1OC)C1CCCCC1
NITARSONE,NITARSONE,,BRD:BRD-BRD-K56707426-001-02-0;BRD:BRD-K56707426-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,,,BLACKHEAD DISEASE,,LAUNCHED,,,NA,,O[AS](O)(=O)C1CCC(CC1)[N+]([O-])=O
NITAZOXANIDE,NITAZOXANIDE,CHEMBL1401,BRD:BRD-BRD-K96471533-001-09-0;BRD:BRD-K96471533-001-09-0,rep_primary;rep_single_dose,PYRUVATE FERREDOXIN OXIDOREDUCTASE INHIBITOR,,DIARRHEA,,LAUNCHED,,Small molecule,Approved,YQNQNVDNTFHQSW-UHFFFAOYSA-N,CC(=O)OC1CCCCC1C(=O)NC1NCC([N+](=O)[O-])S1;CC(=O)OC1CCCCC1C(=O)NC1NCC(S1)[N+]([O-])=O
NITENPYRAM,NITENPYRAM,CHEMBL259728,BRD:BRD-BRD-K47887731-001-01-4;BRD:BRD-K47887731-001-01-4,rep_primary;rep_single_dose,,,FLEA CONTROL,,LAUNCHED,,Small molecule,NA,CFRPSFYHXJZSBI-DHZHZOJOSA-N,CCN(CC1CCC(CL)NC1)/C(=C/[N+](=O)[O-])NC;CCN(CC1CCC(CL)NC1)C(\NC)=C\[N+]([O-])=O
NITHIAMIDE,NITHIAMIDE,CHEMBL1872946,BRD:BRD-BRD-K39467894-001-05-9;BRD:BRD-BRD-K39467894-001-06-7;BRD:BRD-K39467894-001-05-9;BRD:BRD-K39467894-001-06-7,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,,,PRECLINICAL,,Small molecule,Unknown,UJRRDDHEMZLWFI-UHFFFAOYSA-N,CC(=O)NC1NCC([N+](=O)[O-])S1;CC(=O)NC1NCC(S1)[N+]([O-])=O
NITISINONE,NITISINONE,CHEMBL1337,BRD:BRD-BRD-K01109406-001-03-7;BRD:BRD-K01109406-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITOR,HPD,TYROSINEMIA,,LAUNCHED,,Small molecule,Approved,OUBCNLGXQFSTLU-UHFFFAOYSA-N,[O-][N+](=O)C1CC(CCC1C(=O)C1C(=O)CCCC1=O)C(F)(F)F;O=C1CCCC(=O)C1C(=O)C1CCC(C(F)(F)F)CC1[N+](=O)[O-]
NITRENDIPINE,NITRENDIPINE,CHEMBL475534,BRD:BRD-A02006392-001-16-4;BRD:BRD-BRD-A02006392-001-16-4,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C;CACNA1D;CACNA1H;CACNA1S;CACNA2D1;CACNA2D2;CACNB2;CACNG1;KCNN4,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,PVHUJELLJLJGLN-UHFFFAOYSA-N,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1CCCC([N+](=O)[O-])C1;CCOC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC
NITROCARAMIPHEN,NITROCARAMIPHEN,,BRD:BRD-BRD-K28453807-003-11-2;BRD:BRD-K28453807-003-11-2,rep_multi_dose;rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1,,,PRECLINICAL,,,NA,,CCN(CC)CCOC(=O)C1(CCCC1)C1CCC(CC1)[N+]([O-])=O
NITROFLURBIPROFEN,NITROFLURBIPROFEN,,BRD:BRD-K00004737-001-01-9,rep_single_dose,CYCLOOXYGENASE INHIBITOR,,,,,,,NA,,
NITROFURANTOIN,NITROFURANTOIN,CHEMBL572,BRD:BRD-BRD-K76927775-001-11-8;BRD:BRD-K76927775-001-11-8,rep_primary;rep_single_dose,DNA INHIBITOR,,"URINARY TRACT INFECTIONS, PYELONEPHRITIS",,LAUNCHED,,Small molecule,Approved,NXFQHRVNIOXGAQ-YCRREMRBSA-N,[O-][N+](=O)C1CCC(\C=N\N2CC(=O)NC2=O)O1;O=C1CN(/N=C/C2CCC([N+](=O)[O-])O2)C(=O)N1
NITROFURAZONE,NITROFURAZONE,CHEMBL869,BRD:BRD-BRD-K79092138-001-11-0;BRD:BRD-K79092138-001-11-0,rep_primary;rep_single_dose,BACTERIAL DNA INHIBITOR,,FIRST-AID ANTIBIOTIC,,LAUNCHED,,Small molecule,Approved,IAIWVQXQOWNYOU-FPYGCLRLSA-N,NC(=O)N/N=C/C1CCC([N+](=O)[O-])O1;NC(=O)N\N=C\C1CCC(O1)[N+]([O-])=O
NITROMIDE,NITROMIDE,CHEMBL1437065,BRD:BRD-BRD-K76381435-001-08-6;BRD:BRD-K76381435-001-08-6,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,UUKWKUSGGZNXGA-UHFFFAOYSA-N,NC(=O)C1CC([N+](=O)[O-])CC([N+](=O)[O-])C1;NC(=O)C1CC(CC(C1)[N+]([O-])=O)[N+]([O-])=O
NIZATIDINE,NIZATIDINE,CHEMBL3183075,BRD:BRD-BRD-K73589491-001-11-2;BRD:BRD-K73589491-001-11-2,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,"DUODENAL ULCER DISEASE, EROSIVE ESOPHAGITIS (EE), ULCERATIVE ESOPHAGITIS (UE), GASTROESOPHAGEAL REFLUX DISEASE (GERD)",,LAUNCHED,,Small molecule,Approved,SGXXNSQHWDMGGP-UHFFFAOYSA-N,CN\C(NCCSCC1CSC(CN(C)C)N1)=C/[N+]([O-])=O;CNC(=C[N+](=O)[O-])NCCSCC1CSC(CN(C)C)N1
NIZOFENONE,NIZOFENONE,CHEMBL2106822,BRD:BRD-BRD-K84011460-051-01-7;BRD:BRD-K84011460-051-01-7,rep_multi_dose;rep_primary;rep_single_dose,ION CHANNEL ANTAGONIST,,STROKE,,LAUNCHED,,Small molecule,Unknown,WZGBZLHGOVJDET-UHFFFAOYSA-N,CCN(CC)CC1NCCN1-C1CCC([N+](=O)[O-])CC1C(=O)C1CCCCC1CL;CCN(CC)CC1NCCN1-C1CCC(CC1C(=O)C1CCCCC1CL)[N+]([O-])=O
NK-252,NK-252,,BRD:BRD-K47441935-001-02-9,rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",NFE2L2,,,,,,NA,,
NKP-1339,NKP-1339,CHEMBL4297410,BRD:BRD-BRD-K81645297-236-01-1;BRD:BRD-K81645297-236-01-1,rep_primary;rep_single_dose,HSP INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,,CL[RU](CL)(CL)(CL)([N+]1CC2CCCCC2[NH]1)[N+]1CC2CCCCC2[NH]1;CL[RU+3](CL)(CL)(CL)([N+]1CC2CCCCC2[NH]1)[N+]1CC2CCCCC2[NH]1
NKY-80,NKY-80,,BRD:BRD-A75015151-001-08-9,rep_single_dose,ADENYLYL CYCLASE INHIBITOR,ADCY5,,,,,,NA,,
NLG919,NLG919,CHEMBL3989951,BRD:BRD-A62133859-001-03-7;BRD:BRD-BRD-A62133859-001-03-7,rep_primary;rep_single_dose,"INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",IDO1,,,PHASE 1,,Small molecule,Phase 1,YGACXVRLDHEXKY-WXRXAMBDSA-N,O[C@H](C[C@H]1C2C(F)CCCC2-C2CNCN21)[C@H]1CC[C@H](O)CC1;OC(CC1C2CCCCC2-C2CNCN12)C1CCCCC1
NM107,NM107,,BRD:BRD-A66966115-001-01-0;BRD:BRD-BRD-A66966115-001-01-0,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 2,,,NA,,CC1(O)C(O)C(CO)OC1N1CCC(N)NC1=O
NMDA,NMDA,CHEMBL291278,BRD:BRD-BRD-K62414032-001-12-0;BRD:BRD-K62414032-001-12-0,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,PRECLINICAL,,Small molecule,Phase 2,HOKKHZGPKSLGJE-GSVOUGTGSA-N,CN[C@H](CC(=O)O)C(=O)O;CN[C@H](CC(O)=O)C(O)=O
NMDI14,NMDI14,,BRD:BRD-A76106214-001-09-9,oncref_2,INHIBITOR OF SMG7-UPF1 INTERACTION,SMG7,,,,,,NA,,
NMS-1286937,NMS-1286937,CHEMBL1094408;CHEMBL1738758,BRD:BRD-BRD-K83699324-001-01-1;BRD:BRD-K83699324-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,PLK INHIBITOR,FLT3;PLK1;PLK2;PLK3,,,PHASE 1,,Small molecule,Phase 2,QHLVBNKYJGBCQJ-UHFFFAOYSA-N;SWTRIZHCIUWGAU-UHFFFAOYSA-N,CN1CCN(C2CCC(OC(F)(F)F)C(NC3NCC4C(N3)-C3C(C(C(N)=O)NN3CCO)CC4)C2)CC1;CN1CCN(CC1)C1CCC(OC(F)(F)F)C(NC2NCC3CCC4C(NN(CCO)C4-C3N2)C(N)=O)C1;COC1CCC(N2CCN(C)CC2)CC1NC1NCC2C(N1)-C1C(C(C(N)=O)NN1C)CC2
NMS-873,NMS-873,,BRD:BRD-BRD-K26253904-001-01-5;BRD:BRD-K26253904-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,VCP,,,PRECLINICAL,,,NA,,CC1CC(OCC2NNC(SC3CCCC3)N2-C2CCCNC2)CCC1-C1CCC(CC1)S(C)(=O)=O
NMS-E973,NMS-E973,,BRD:BRD-BRD-K58770988-001-01-8;BRD:BRD-K58770988-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,,,,PRECLINICAL,,,NA,,CN1CCC(CC1)NC(=O)C1CC(ON1)-C1C(O)CC(O)CC1OC1CCC(CC1)[N+]([O-])=O
NMS-P715,NMS-P715,,BRD:BRD-BRD-K54170555-001-01-8;BRD:BRD-K54170555-001-01-8,rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCC1CCCC(CC)C1NC(=O)C1NN(C)C-2C1CCC1CNC(NC3CCC(CC3OC(F)(F)F)C(=O)NC3CCN(C)CC3)NC-21
NN-DNJ,NN-DNJ,,BRD:BRD-K00004640-001-01-9,rep_single_dose,GLUCOSIDASE INHIBITOR,GBA,,,,,,NA,,
NNC-05-2090,NNC-05-2090,,BRD:BRD-BRD-K85015012-003-02-9;BRD:BRD-K85015012-003-02-9,rep_primary;rep_single_dose,"GABA UPTAKE INHIBITOR, GAT INHIBITOR",SLC6A12,,,PRECLINICAL,,,NA,,COC1CCCCC1C1(O)CCN(CCCN2C3CCCCC3C3CCCCC23)CC1
NNC-55-0396,NNC-55-0396,,BRD:BRD-BRD-K78122587-300-02-7;BRD:BRD-K78122587-300-02-7,rep_primary;rep_single_dose,T-TYPE CALCIUM CHANNEL BLOCKER,CATSPER1;CATSPER2;CATSPER3;CATSPER4,,,PRECLINICAL,,,NA,,CC(C)[C@H]1C2CCC(F)CC2CC[C@@]1(CCN(C)CCCC1NC2CCCCC2[NH]1)OC(=O)C1CC1
NNC-63-0532,NNC-63-0532,,BRD:BRD-BRD-K72904818-001-01-1;BRD:BRD-K72904818-001-01-1,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRL1,,,PRECLINICAL,,,NA,,COC(=O)CN1CN(C2CCCCC2)C2(CCN(CC3CCCC4CCCCC34)CC2)C1=O
NNC-711,NNC-711,,BRD:BRD-BRD-K42221274-003-07-7;BRD:BRD-K42221274-003-07-7,rep_primary;rep_single_dose,GABA UPTAKE INHIBITOR,SIGMAR1;SLC6A1,,,PRECLINICAL,,,NA,,OC(=O)C1=CCCN(CCON=C(C2CCCCC2)C2CCCCC2)C1
NOBILETIN,NOBILETIN,CHEMBL76447,BRD:BRD-BRD-K06753942-001-14-5;BRD:BRD-K06753942-001-14-5,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1,,,PRECLINICAL,,Small molecule,NA,MRIAQLRQZPPODS-UHFFFAOYSA-N,COC1CCC(-C2CC(=O)C3C(OC)C(OC)C(OC)C(OC)C3O2)CC1OC;COC1CCC(CC1OC)-C1CC(=O)C2C(OC)C(OC)C(OC)C(OC)C2O1
NOCODAZOLE,NOCODAZOLE,CHEMBL9514,BRD:BRD-BRD-K12539581-001-23-7;BRD:BRD-K12539581-001-23-7,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,HPGDS,,,PRECLINICAL,,Small molecule,Unknown,KYRVNWMVYQXFEU-UHFFFAOYSA-N,COC(=O)NC1NC2CC(C(=O)C3CCCS3)CCC2[NH]1;COC(=O)NC1NC2CC(CCC2[NH]1)C(=O)C1CCCS1
NOLATREXED,NOLATREXED,CHEMBL320775,BRD:BRD-BRD-K36636143-001-01-0;BRD:BRD-K36636143-001-01-0,rep_primary;rep_single_dose,THYMIDYLATE SYNTHASE INHIBITOR,TYMS,,,PHASE 3,,Small molecule,Phase 3,XHWRWCSCBDLOLM-UHFFFAOYSA-N,CC1CCC2NC(N)[NH]C(=O)C2C1SC1CCNCC1;CC1CCC2NC(N)NC(O)C2C1SC1CCNCC1
NOLVADEX,NOLVADEX,CHEMBL786;CHEMBL83,GDSC1:1199;GDSC2:1199,gdsc,,,,,,,Small molecule,Approved,FQZYTYWMLGAPFJ-OQKDUQJOSA-N;NKANXQFJJICGDU-QPLCGJKRSA-N,CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1;CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
NOMEGESTROL-ACETATE,NOMEGESTROL-ACETATE,,BRD:BRD-BRD-K27351809-001-09-5;BRD:BRD-K27351809-001-09-5,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,CONTRACEPTIVE,,LAUNCHED,,,NA,,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O
NOMIFENSINE,NOMIFENSINE,CHEMBL273575,BRD:BRD-A29644307-050-17-0;BRD:BRD-BRD-A29644307-050-17-0,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR, NORADRENALINE UPTAKE INHIBITOR",DRD2;MAOA;MAOB;MPO;SLC6A2;SLC6A3,,,WITHDRAWN,"Multiple values for MOA: {'DOPAMINE UPTAKE INHIBITOR, NORADRENALINE UPTAKE INHIBITOR', 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR, NORADRENALINE UPTAKE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR, NORADRENALINE UPTAKE INHIBITOR'",Small molecule,Approved,XXPANQJNYNUNES-UHFFFAOYSA-N,CN1CC(C2CCCCC2)C2CCCC(N)C2C1;CN1CC2C(N)CCCC2C(C2CCCCC2)C1
NONIVAMIDE,NONIVAMIDE,CHEMBL75124,BRD:BRD-BRD-K05907307-001-07-1;BRD:BRD-K05907307-001-07-1,rep_primary;rep_single_dose,TRPV AGONIST,TRPV1,"RHEUMATOID ARTHRITIS, MUSCLE PAIN",,LAUNCHED,,Small molecule,Phase 3,RGOVYLWUIBMPGK-UHFFFAOYSA-N,CCCCCCCCC(=O)NCC1CCC(O)C(OC)C1
NONOXYNOL-9,NONOXYNOL-9,CHEMBL1410,BRD:BRD-BRD-K88625236-001-04-2;BRD:BRD-K88625236-001-04-2,rep_multi_dose;rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,FBWNMEQMRUMQSO-UHFFFAOYSA-N,CCCCCCCCCC1CCC(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)CC1
NOR-BINALTORPHIMINE-DIHYDROCHLORIDE,NOR-BINALTORPHIMINE-DIHYDROCHLORIDE,,BRD:BRD-BRD-K36381762-300-02-7,rep_primary,OPIOID RECEPTOR ANTAGONIST,OPRD1;OPRK1;OPRM1,,,PRECLINICAL,,,NA,,OC1CCC2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1C24)C1[NH]C2[C@@H]4OC6C7C(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)CC2C1C[C@@]35O)CCC6O
NORCYCLOBENZAPRINE,NORCYCLOBENZAPRINE,,BRD:BRD-BRD-K63165456-001-10-8;BRD:BRD-K63165456-001-10-8,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",,,,PRECLINICAL,,,NA,,CNCCC=C1C2CCCCC2C=CC2CCCCC12
NORELGESTROMIN,NORELGESTROMIN,CHEMBL1200807,BRD:BRD-BRD-K42504537-001-01-6;BRD:BRD-K42504537-001-01-6,rep_primary;rep_single_dose,,PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,ISHXLNHNDMZNMC-VTKCIJPMSA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC;CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C
NOREPINEPHRINE,NOREPINEPHRINE,CHEMBL1434513;CHEMBL1437,BRD:BRD-BRD-K87349682-347-03-8;BRD:BRD-K87349682-347-03-8,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3;PAH;SLC18A1;SLC18A2,"HYPERTENSION, URTICARIA, HEADACHE, SEASONAL AFFECTIVE DISORDER",,LAUNCHED,,Small molecule,Approved,LNBCGLZYLJMGKP-JZGIKJSDSA-N;SFLSHLFXELFNJZ-QMMMGPOBSA-N,NC[C@H](O)C1CCC(O)C(O)C1;NC[C@H](O)C1CCC(O)C(O)C1.O.O=C(O)C(O)C(O)C(=O)O
NORETHINDRONE,NORETHINDRONE,CHEMBL1162,BRD:BRD-BRD-K92073408-001-15-7;BRD:BRD-BRD-K92073408-001-16-5;BRD:BRD-K92073408-001-15-7;BRD:BRD-K92073408-001-16-5,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,ENDOMETRIOSIS,,LAUNCHED,,Small molecule,Approved,VIKNJXKGJWUCNN-XGXHKTLJSA-N,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C;C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
NORETHINDRONE-ACETATE,NORETHINDRONE-ACETATE,,BRD:BRD-A09349126-001-10-7;BRD:BRD-BRD-A09349126-001-10-7,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,,"MENOPAUSE, OSTEOPOROSIS, VAGINAL ATROPHY",,LAUNCHED,,,NA,,CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C
NORETHISTERONE-ENANTHATE,NORETHISTERONE-ENANTHATE,,BRD:BRD-BRD-K07625016-001-01-2;BRD:BRD-K07625016-001-01-2,rep_primary;rep_single_dose,CONTRACEPTIVE AGENT,,CONTRACEPTIVE,,LAUNCHED,,,NA,,CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C
NORETYNODREL,NORETYNODREL,CHEMBL1387,BRD:BRD-A00758722-001-04-9;BRD:BRD-BRD-A00758722-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,PROGESTOGEN HORMONE,PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,ICTXHFFSOAJUMG-SLHNCBLASA-N,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C;C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
NORFLOXACIN,NORFLOXACIN,CHEMBL9,BRD:BRD-BRD-K11196887-001-21-2;BRD:BRD-BRD-K11196887-001-22-0;BRD:BRD-K11196887-001-21-2;BRD:BRD-K11196887-001-22-0,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,"URINARY TRACT INFECTIONS, GONORRHEA, PROSTATITIS",,LAUNCHED,,Small molecule,Approved,OGJPXUAPXNRGGI-UHFFFAOYSA-N,CCN1CC(C(=O)O)C(=O)C2CC(F)C(N3CCNCC3)CC21;CCN1CC(C(O)=O)C(=O)C2CC(F)C(CC12)N1CCNCC1
NORFLUOXETINE,NORFLUOXETINE,CHEMBL1494;CHEMBL465123,BRD:BRD-A79769222-001-01-3;BRD:BRD-BRD-A79769222-001-01-3,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),HTR2B,,,PHASE 1,,Small molecule,Unknown,WIQRCHMSJFFONW-HNNXBMFYSA-N;WIQRCHMSJFFONW-UHFFFAOYSA-N,NCC[C@H](OC1CCC(C(F)(F)F)CC1)C1CCCCC1;NCCC(OC1CCC(C(F)(F)F)CC1)C1CCCCC1;NCCC(OC1CCC(CC1)C(F)(F)F)C1CCCCC1
NORGESTREL,NORGESTREL,CHEMBL1389;CHEMBL2107797,BRD:BRD-A14886633-001-01-6;BRD:BRD-BRD-A14886633-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,AR;ESR1;PGR;SRD5A1,CONTRACEPTIVE,,LAUNCHED,"Multiple values for repurposing_target: {'AR;ESR1;PGR;SRD5A1', 'PGR'}, taking the union",Small molecule,Approved,WWYNJERNGUHSAO-CULCCENASA-N;WWYNJERNGUHSAO-XUDSTZEESA-N,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC;C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC;CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
NORNICOTINE,NORNICOTINE,CHEMBL1132,BRD:BRD-A24543851-001-05-7;BRD:BRD-BRD-A24543851-001-05-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,Small molecule,Phase 1,MYKUKUCHPMASKF-UHFFFAOYSA-N,C1CNC(C1)C1CCCNC1;C1CNCC(C2CCCN2)C1
NORTRIPTYLINE,NORTRIPTYLINE,CHEMBL445,BRD:BRD-BRD-K91263825-003-21-4;BRD:BRD-K91263825-003-21-4,rep_primary;rep_single_dose,TRICYCLIC ANTIDEPRESSANT,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD2;HRH1;HTR1A;HTR2A;HTR2C;HTR6;KCNJ10;PGRMC1;SIGMAR1;SLC6A2;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,CNCCC=C1C2CCCCC2CCC2CCCCC12;CNCCC=C1C2CCCCC2CCC2CCCCC21
NOSCAPINE,NOSCAPINE,CHEMBL364713,BRD:BRD-BRD-K91301684-003-05-5;BRD:BRD-K91301684-003-05-5,rep_primary;rep_single_dose,"BRADYKININ RECEPTOR ANTAGONIST, TUBULIN POLYMERIZATION INHIBITOR",SIGMAR1,COUGH SUPPRESSANT,,LAUNCHED,,Small molecule,Approved,AKNNEGZIBPJZJG-MSOLQXFVSA-N,COC1CCC2[C@@H](OC(=O)C2C1OC)[C@@H]1N(C)CCC2CC3OCOC3C(OC)C12;COC1CCC2[C@H](OC(=O)C2C1OC)[C@@H]1N(C)CCC2CC3OCOC3C(OC)C12;COC1CCC2C(C1OC)C(=O)O[C@@H]2[C@H]1C2C(CC3C(C2OC)OCO3)CCN1C
NOV-002,NOV-002,,BRD:BRD-BRD-K11411329-001-01-3;BRD:BRD-K11411329-001-01-3,rep_primary;rep_single_dose,,GSR;GSTM2,,,PHASE 3,,,NA,,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O
NOVOBIOCIN,NOVOBIOCIN,CHEMBL3183453;CHEMBL3544972;CHEMBL36506,BRD:BRD-BRD-K85307935-236-09-5;BRD:BRD-BRD-K85307935-236-10-3;BRD:BRD-K85307935-236-09-5;BRD:BRD-K85307935-236-10-3,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,MASTITIS,,LAUNCHED,,Small molecule,Approved,HEJBMFPJLCJWER-CWPVBXIBSA-L;WWPRGAYLRGSOSU-RNROJPEYSA-M;YJQPYGGHQPGBLI-KGSXXDOSSA-N,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2CCC3C([O-])C(NC(=O)C4CCC(O)C(CC=C(C)C)C4)C(=O)OC3C2C)OC1(C)C.[NA+];CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2CCC3C([O-])C(NC(=O)C4CCC(O)C(CC=C(C)C)C4)C(=O)OC3C2C)OC1(C)C.CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2CCC3C([O-])C(NC(=O)C4CCC(O)C(CC=C(C)C)C4)C(=O)OC3C2C)OC1(C)C.[CA+2];CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2CCC3C(O)C(NC(=O)C4CCC(O)C(CC=C(C)C)C4)C(=O)OC3C2C)OC1(C)C
NP-G2-044,NP-G2-044,CHEMBL4297473,BRD:BRD-K00090625-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,XLLRLAABUFOJPC-UHFFFAOYSA-N,CC1OCCC1C(=O)NC1NN(CC2CCC(C(F)(F)F)CC2)C2CCCCC12
NPC-01,NPC-01,,BRD:BRD-BRD-K58277159-001-01-7;BRD:BRD-K58277159-001-01-7,rep_primary;rep_single_dose,STEROID,,,,PHASE 3,,,NA,,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O
NPC-15199,NPC-15199,,BRD:BRD-BRD-K65275554-001-04-7;BRD:BRD-K65275554-001-04-7,rep_primary;rep_single_dose,ICAM1 ANTAGONIST,PPARG,,,PHASE 2,,,NA,,CC(C)C[C@@H](NC(=O)OCC1C2CCCCC2-C2CCCCC12)C(O)=O
NPC-26,NPC-26,,CTRP:609058,ctrp,,,,,,,,NA,,
NPK76-II-72-1,NPK76-II-72-1,,GDSC1:257,gdsc,,,,,,,,NA,,
NPPB,NPPB,,BRD:BRD-BRD-K89272762-001-12-7;BRD:BRD-K89272762-001-12-7,rep_primary;rep_single_dose,CHLORIDE CHANNEL BLOCKER,ANO1;CLCN2;CLCN7;TRPA1,,,PRECLINICAL,,,NA,,OC(=O)C1CC(CCC1NCCCC1CCCCC1)[N+]([O-])=O
NPS-2143,NPS-2143,,BRD:BRD-BRD-K75506300-001-01-6;BRD:BRD-K75506300-001-01-6,rep_primary;rep_single_dose,CALCIUM RECEPTOR ANTAGONIST,CASR,,,PRECLINICAL,,,NA,,CC(C)(CC1CCC2CCCCC2C1)NC[C@@H](O)COC1CCCC(CL)C1C#N
NPS-2407,NPS-2407,,BRD:BRD-K00004686-001-01-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,,,,NA,,
NPY-5RA972,NPY-5RA972,,BRD:BRD-BRD-K95600043-001-01-5;BRD:BRD-K95600043-001-01-5,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY5R,,,PRECLINICAL,,,NA,,CC(C)N1C2CCCCC2C2C(C)C(NC(=O)N3CCOCC3)CCC12
NQDI-1,NQDI-1,,BRD:BRD-BRD-K61918008-001-07-1;BRD:BRD-K61918008-001-07-1,rep_primary;rep_single_dose,CASPASE INHIBITOR,CASP3,,,PRECLINICAL,,,NA,,CCOC(=O)C1C(O)NC2CCCC3C(=O)C4CCCCC4-C1C23
NRC-2694,NRC-2694,,BRD:BRD-K00076493-001-02-9,rep_single_dose,,,,,,,,NA,,
NS-018,NS-018,CHEMBL3545217,BRD:BRD-BRD-K21865955-003-01-5;BRD:BRD-K21865955-003-01-5,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3;TYK2,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,,C[C@H](NC1CC(CC(NC2CNCCN2)N1)-C1CNN(C)C1)C1CCC(F)CC1
NS-11394,NS-11394,,BRD:BRD-K00004548-001-01-9,rep_single_dose,GABA RECEPTOR AGONIST,,,,,,,NA,,
NS-1643,NS-1643,,BRD:BRD-K73738482-001-01-7,rep_single_dose,VOLTAGE-GATED POTASSIUM CHANNEL ACTIVATOR,KCNH2;KCNH6;KCNMA1,,,,,,NA,,
NS-19504,NS-19504,,BRD:BRD-K03808106-001-02-9,rep_single_dose,CALCIUM-ACTIVATED POTASSIUM CHANNEL ACTIVATOR,KCNMA1,,,,,,NA,,
NS-309,NS-309,,BRD:BRD-K00004295-001-01-9,rep_single_dose,CALCIUM-ACTIVATED POTASSIUM CHANNEL ACTIVATOR,KCNN1;KCNN2;KCNN3;KCNN4,,,,,,NA,,
NS-3623,NS-3623,,BRD:BRD-K24434292-001-01-3,rep_single_dose,VOLTAGE-GATED POTASSIUM CHANNEL ACTIVATOR,KCNH2,,,,,,NA,,
NS-5806,NS-5806,,BRD:BRD-K93314017-001-02-9,rep_single_dose,VOLTAGE-GATED POTASSIUM CHANNEL ACTIVATOR,KCND3,,,,,,NA,,
NS-8593,NS-8593,,BRD:BRD-BRD-K34624869-003-01-6;BRD:BRD-K34624869-003-01-6,rep_primary;rep_single_dose,CALCIUM-ACTIVATED POTASSIUM CHANNEL MODULATOR,KCNN1;KCNN2;KCNN3,,,PRECLINICAL,,,NA,,C1C[C@@H](NC2NC3CCCCC3[NH]2)C2CCCCC2C1
NS-9283,NS-9283,,BRD:BRD-BRD-K40176866-001-01-6;BRD:BRD-K40176866-001-01-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATOR,CHRNA4,,,PRECLINICAL,,,NA,,N#CC1CCCC(C1)-C1NC(NO1)-C1CCCNC1
NSC 19630,NSC 19630,,GDSC2:1931,gdsc,,,,,,,,NA,,
RITA,NSC 652287;RITA,,BRD:BRD-BRD-K00317371-001-06-1;BRD:BRD-K00317371-001-06-1;BRD:BRD-K00317371-001-09-9;CTRP:375492,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,CROSSLINKING PRODRUG VIA SULT1A1,MDM2;SULT1A1,,,PRECLINICAL,"Multiple values for MOA: {'CROSSLINKING PRODRUG VIA SULT1A1', 'MDM INHIBITOR'}, defaulting to 'CROSSLINKING PRODRUG VIA SULT1A1'
Multiple values for repurposing_target: {'MDM2', 'SULT1A1'}, taking the union",,NA,,OCC1CCC(S1)-C1CCC(O1)-C1CCC(CO)S1
NSC 74859,NSC 74859,,CTRP:411734,ctrp,,,,,,,,NA,,
NSC 83265,NSC 83265,,GDSC1:41,gdsc,,,,,,,,NA,,
NSC 87877,NSC 87877,,GDSC1:147,gdsc,,,,,,,,NA,,
NSC-19630,NSC-19630,,GDSC2:1931,gdsc,,,,,,,,NA,,
NSC-207895,NSC-207895,,GDSC1:269,gdsc,,,,,,,,NA,,
NSC-23766,NSC-23766,,BRD:BRD-A80213327-305-08-3;BRD:BRD-BRD-A80213327-305-08-3,rep_multi_dose;rep_primary;rep_single_dose,RAS GTPASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCN(CC)CCCC(C)NC1NC(C)CC(NC2CCC3NC(C)CC(N)C3C2)N1
NSC-26980,NSC-26980,CHEMBL105,GDSC1:136,gdsc,,,,,,,Small molecule,Approved,NWIBSHFKIJFRCO-WUDYKRTCSA-N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
NSC-319726,NSC-319726,,BRD:BRD-BRD-K99170882-001-04-3;BRD:BRD-K99170882-001-04-3,rep_multi_dose;rep_primary;rep_single_dose,P53 ACTIVATOR,,,,PRECLINICAL,,,NA,,C\C(C1CCCCN1)=N/NC(=S)N1CCC1
NSC-3852,NSC-3852,,BRD:BRD-BRD-K13169950-001-14-4;BRD:BRD-K13169950-001-14-4,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1,,,PRECLINICAL,,,NA,,OC1CCC([N+][O-])C2CCCNC12
NSC-405020,NSC-405020,,BRD:BRD-A67975844-001-01-8;BRD:BRD-BRD-A67975844-001-01-8,rep_primary;rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,MMP1,,,PRECLINICAL,,,NA,,CCCC(C)NC(=O)C1CCC(CL)C(CL)C1
NSC-4644,NSC-4644,,BRD:BRD-BRD-K64874225-001-04-7;BRD:BRD-K64874225-001-04-7,rep_primary;rep_single_dose,"ACAT INHIBITOR, STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) INHIBITOR",PYGM,,,PHASE 2,,,NA,,CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12
NSC5844,NSC-5844;NSC5844,,BRD:BRD-BRD-K73799155-001-01-5;BRD:BRD-K73799155-001-01-5,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR AGONIST,CCR1,,,PRECLINICAL,,,NA,,C(CNC1CCNC2CC(CL)CCC12)NC1CCNC2CC(CL)CCC12
NSC-632839,NSC-632839,,BRD:BRD-BRD-K81197548-003-01-4;BRD:BRD-K81197548-003-01-4,rep_multi_dose;rep_primary;rep_single_dose,UBIQUITIN SPECIFIC PROTEASE INHIBITOR,SENP2;USP1;USP2;USP7,,,PRECLINICAL,,,NA,,CC1CCC(CC1)\C=C1/CNC\C(C1=O)=C/C1CCC(C)CC1
NSC-636819,NSC-636819,,BRD:BRD-K61120504-001-01-6,rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,KDM4A;KDM4B,,,,,,NA,,
NSC-663284,NSC-663284,,BRD:BRD-BRD-K03109492-001-02-2;BRD:BRD-K03109492-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,CDC INHIBITOR,CDC25A;CDC25B;CDC25C,,,PRECLINICAL,,,NA,,CLC1=C(NCCN2CCOCC2)C(=O)C2NCCCC2C1=O
NSC-697923,NSC-697923,,BRD:BRD-BRD-K20605374-001-05-4;BRD:BRD-K20605374-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,UBIQUITIN-CONJUGATING ENZYME INHIBITOR,UBE2N,,,PRECLINICAL,,,NA,,CC1CCC(CC1)S(=O)(=O)C1CCC(O1)[N+]([O-])=O
NSC-87877,NSC-87877,,GDSC1:147,gdsc,,,,,,,,NA,,
NSC-9965,NSC-9965,,BRD:BRD-BRD-K49811169-004-06-6;BRD:BRD-K49811169-004-06-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA4;CHRNB2,,,PRECLINICAL,,,NA,,CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1
NSC19630,NSC19630,,CTRP:580922;GDSC2:1931,ctrp;gdsc,,,,,,,,NA,,
NSC207895,NSC207895,,GDSC1:269,gdsc,,,,,,,,NA,,
NSC23766,NSC23766,,CTRP:44503,ctrp,,,,,,,,NA,,
NSC30930,NSC30930,,CTRP:182395,ctrp,,,,,,,,NA,,
NSC319726,NSC319726,,GDSC1:461,gdsc,,,,,,,,NA,,
NSC48300,NSC48300,,CTRP:594399,ctrp,,,,,,,,NA,,
NSC632839,NSC632839,,CTRP:375594,ctrp,,,,,,,,NA,,
NSC95397,NSC95397,,CTRP:50715,ctrp,,,,,,,,NA,,
NSI-189,NSI-189,CHEMBL4302505,BRD:BRD-BRD-K74371986-001-01-7;BRD:BRD-K74371986-001-01-7,rep_primary;rep_single_dose,NEUROTROPHIC AGENT,,,,PHASE 2,,Small molecule,Phase 2,DYTOQURYRYYNOR-UHFFFAOYSA-N,CC(C)CCNC1NCCCC1C(=O)N1CCN(CC2CCCCC2)CC1
NSP-805,NSP-805,,BRD:BRD-K00004733-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,,NA,,
NTNCB,NTNCB,,BRD:BRD-A40413915-003-01-2;BRD:BRD-BRD-A40413915-003-01-2,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY5R,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCCCC1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCC3CCCCC3C2)CC1
NTRC-824,NTRC-824,,BRD:BRD-K07788774-001-02-9,rep_single_dose,NEUROTENSIN RECEPTOR ANTAGONIST,NTSR2,,,,,,NA,,
NTZDPA,NTZDPA,,BRD:BRD-BRD-K54708045-001-02-1;BRD:BRD-K54708045-001-02-1,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARG,,,PRECLINICAL,,,NA,,OC(=O)C1N(CC2CCC(CL)CC2)C2CCC(CL)CC2C1SC1CCCCC1
NU-1025,NU-1025,,BRD:BRD-BRD-K48692744-001-02-0;BRD:BRD-K48692744-001-02-0,rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PRECLINICAL,,,NA,,CC1NC2C(O)CCCC2C(=O)[NH]1
NU-2058,NU-2058,,BRD:BRD-K20976221-001-12-0,rep_single_dose,CYCLIN D INHIBITOR,CCNA2;CDK2,,,,,,NA,,
NU6027,NU-6027;NU6027,,BRD:BRD-BRD-K03294269-001-08-0;BRD:BRD-K03294269-001-08-0,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CCNA2;CDK2,,,PRECLINICAL,,,NA,,NC1NC(N)C([N+][O-])C(OCC2CCCCC2)N1
NU-7026,NU-7026,,BRD:BRD-BRD-K09537769-001-04-0;BRD:BRD-K09537769-001-04-0,rep_primary;rep_single_dose,"DNA DEPENDENT PROTEIN KINASE INHIBITOR, MTOR INHIBITOR, PI3K INHIBITOR",PRKDC,,,PRECLINICAL,,,NA,,O=C1CC(OC2C3CCCCC3CCC12)N1CCOCC1
NU-7432,NU-7432,,GDSC1:1038;GDSC2:1038,gdsc,,,,,,,,NA,,
NU-7441,NU-7441,,BRD:BRD-BRD-K00337317-001-06-6;BRD:BRD-K00337317-001-06-6,rep_primary;rep_single_dose,DNA DEPENDENT PROTEIN KINASE INHIBITOR,PRKDC,,,PRECLINICAL,,,NA,,O=C1CC(OC2C(CCCC12)-C1CCCC2C3CCCCC3SC12)N1CCOCC1
NU-7741,NU-7741,,GDSC1:1038;GDSC2:1038,gdsc,,,,,,,,NA,,
NU7441,NU7441,,GDSC1:1038;GDSC2:1038,gdsc,,,,,,,,NA,,
NUCLOMEDONE,NUCLOMEDONE,CHEMBL2106465,BRD:BRD-A96466199-001-01-4;BRD:BRD-BRD-A96466199-001-01-4,rep_primary;rep_single_dose,IMMUNOSUPPRESSANT,,,,PHASE 3,,Small molecule,Unknown,QSKVYHYMQQQAFS-UHFFFAOYSA-N,CLC1CCC(CC2C(=O)N=C3SCCN3C2=O)CC1;O=C1N=C2SCCN2C(=O)C1CC1CCC(CL)CC1
REBEMADLIN,NUTLIN-3;NUTLIN-3A;REBEMADLIN,CHEMBL191334,BRD:BRD-A12230535-001-06-7;BRD:BRD-A12230535-001-10-9;BRD:BRD-BRD-A12230535-001-06-7;CTRP:411722,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF TP53/MDM2/4 INTERACTION,MDM2;MDM4;TP53,,,PRECLINICAL,"Multiple values for MOA: {'MDM INHIBITOR', 'INHIBITOR OF TP53/MDM2/4 INTERACTION'}, defaulting to 'INHIBITOR OF TP53/MDM2/4 INTERACTION'
Multiple values for repurposing_target: {'MDM2;TP53', 'MDM2;MDM4;TP53'}, taking the union",Small molecule,NA,BDUHCSBCVGXTJM-WUFINQPMSA-N,COC1CCC(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)C2CCC(CL)CC2)C2CCC(CL)CC2)C(OC(C)C)C1;COC1CCC(C2=N[C@@H](C3CCC(CL)CC3)[C@@H](C3CCC(CL)CC3)N2C(=O)N2CCNC(=O)C2)C(OC(C)C)C1;COC1CCC(C2=NC(C(N2C(=O)N2CCNC(=O)C2)C2CCC(CL)CC2)C2CCC(CL)CC2)C(OC(C)C)C1
NUTLIN-3A (-),NUTLIN-3A (-),,GDSC1:1047;GDSC2:1047,gdsc,,,,,,,,NA,,
NUVENZEPINE,NUVENZEPINE,CHEMBL2107170,BRD:BRD-K00004743-001-01-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,HPKYRXAEGNUARA-UHFFFAOYSA-N,CN1CCC(C(=O)N2C3CCCCC3NC(=O)C3CCCNC32)CC1
NVP ADW742,NVP ADW742,,GDSC2:1932,gdsc,,,,,,,,NA,,
NVP-231,NVP-231,,BRD:BRD-BRD-K01573278-001-02-1;BRD:BRD-K01573278-001-02-1;CTRP:660331,ctrp;rep_primary;rep_single_dose,CERAMIDASE INHIBITOR,CERK,,,PRECLINICAL,,,NA,,O=C(NC1NC2CCC(NC(=O)C34CC5CC(CC(C5)C3)C4)CC2S1)C1CCCCC1
NVP-ADW742,NVP-ADW742,,BRD:BRD-BRD-K15179513-001-03-4;BRD:BRD-K15179513-001-03-4;CTRP:660287;GDSC2:1932,ctrp;gdsc;rep_primary;rep_single_dose,INSULIN GROWTH FACTOR RECEPTOR INHIBITOR,IGF1R,,,PRECLINICAL,,,NA,,NC1NCNC2N(CC(-C3CCCC(OCC4CCCCC4)C3)C12)[C@H]1C[C@H](CN2CCCC2)C1
NVP-AEW541,NVP-AEW541,CHEMBL551064,BRD:BRD-BRD-K24696047-001-02-3;BRD:BRD-K24696047-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,IGF-1 INHIBITOR,IGF1R;INSR,,,PRECLINICAL,,Small molecule,Phase 1,USVCWSAJUAARAL-MEMLXQNLSA-N,NC1NCNC2C1C(-C1CCCC(OCC3CCCCC3)C1)CN2[C@H]1C[C@H](N2CCC2)C1;NC1NCNC2N(CC(-C3CCCC(OCC4CCCCC4)C3)C12)[C@@H]1C[C@H](CN2CCC2)C1
NVP-AUY922,NVP-AUY922,CHEMBL252164,BRD:BRD-BRD-K41859756-001-06-8;BRD:BRD-K41859756-001-06-8;GDSC1:194;GDSC2:1559,gdsc;rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1;HSP90AB1,,,PHASE 2,,Small molecule,Phase 2,NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)C1NOC(-C2CC(C(C)C)C(O)CC2O)C1-C1CCC(CN2CCOCC2)CC1;CCNC(=O)C1NOC(C1-C1CCC(CN2CCOCC2)CC1)-C1CC(C(C)C)C(O)CC1O
NVP-BEZ235,NVP-BEZ235,CHEMBL1879463,BRD:BRD-BRD-K12184916-001-15-4;BRD:BRD-K12184916-001-15-4;BRD:BRD-K12184916-001-19-6;CTRP:348992;GDSC1:1057;GDSC2:1057,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",ATR;MTOR;PIK3CA;PIK3CD;PIK3CG,,,PHASE 2,,Small molecule,Phase 3,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,CN1C(=O)N(-C2CCC(C(C)(C)C#N)CC2)C2C3CC(-C4CNC5CCCCC5C4)CCC3NCC21;CN1C2CNC3CCC(CC3C2N(-C2CCC(CC2)C(C)(C)C#N)C1=O)-C1CNC2CCCCC2C1
NVP-BHG712,NVP-BHG712,,BRD:BRD-BRD-K79259477-001-04-9;BRD:BRD-K79259477-001-04-9;GDSC1:295,gdsc;rep_multi_dose;rep_primary;rep_single_dose,EPHRIN INHIBITOR,EPHB4,,,PRECLINICAL,,,NA,,CC1CCC(CC1NC1NC(NC2N(C)NCC12)-C1CCCNC1)C(=O)NC1CCCC(C1)C(F)(F)F
NVP-BKM120,NVP-BKM120,CHEMBL2017974,GDSC2:1873,gdsc,,,,,,,Small molecule,Phase 3,CWHUFRVAEUJCEF-UHFFFAOYSA-N,NC1CC(C(F)(F)F)C(-C2CC(N3CCOCC3)NC(N3CCOCC3)N2)CN1
NVP-BSK805,NVP-BSK805,,BRD:BRD-BRD-K02017404-300-06-2;BRD:BRD-K02017404-300-06-2;CTRP:660434,ctrp;rep_primary;rep_single_dose,JAK INHIBITOR,JAK2,,,PRECLINICAL,,,NA,,FC1CC(CC(F)C1CN1CCOCC1)-C1CCCC2NCC(NC12)-C1CNN(C1)C1CCNCC1
NVP-BVU972,NVP-BVU972,,BRD:BRD-BRD-K77943374-001-02-8;BRD:BRD-K77943374-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,MET INHIBITOR,MET,,,PRECLINICAL,,,NA,,CN1CC(CN1)-C1CCC2NCC(CC3CCC4NCCCC4C3)N2N1
NVP-BYL719,NVP-BYL719,CHEMBL2396661,GDSC2:1560,gdsc,,,,,,,Small molecule,Approved,STUWGJZDJHPWGZ-LBPRGKRZSA-N,CC1NC(NC(=O)N2CCC[C@H]2C(N)=O)SC1-C1CCNC(C(C)(C)C(F)(F)F)C1
NVP-DPP728,NVP-DPP728,,BRD:BRD-BRD-K77396579-300-01-0;BRD:BRD-K77396579-300-01-0,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,,,PHASE 2,,,NA,,O=C(CNCCNC1CCC(CN1)C#N)N1CCC[C@H]1C#N
NVP-HSP990,NVP-HSP990,,BRD:BRD-BRD-K67915505-001-01-2;BRD:BRD-K67915505-001-01-2,rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1;HSP90AB1,,,PHASE 1,,,NA,,COC1CCCC(N1)-C1CC(F)CCC1[C@H]1CC2NC(N)NC(C)C2C(=O)N1
NVP-LAQ824,NVP-LAQ824,CHEMBL356066,GDSC1:200,gdsc,,,,,,,Small molecule,Unknown,BWDQBBCUWLSASG-MDZDMXLPSA-N,O=C(/C=C/C1CCC(CN(CCO)CCC2C[NH]C3CCCCC23)CC1)NO
NVP-LEE011,NVP-LEE011,CHEMBL3545110,GDSC2:1632,gdsc,,,,,,,Small molecule,Approved,RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)C1CC2CNC(NC3CCC(N4CCNCC4)CN3)NC2N1C1CCCC1
NVP-TAE 684,NVP-TAE 684,,GDSC1:35,gdsc,,,,,,,,NA,,
NVP-TAE226,NVP-TAE226,,BRD:BRD-BRD-K21025364-001-04-9;BRD:BRD-BRD-K21025364-001-05-6;BRD:BRD-K21025364-001-04-9;BRD:BRD-K21025364-001-05-6,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,PTK2,,,PRECLINICAL,,,NA,,CNC(=O)C1CCCCC1NC1NC(NC2CCC(CC2OC)N2CCOCC2)NCC1CL
NVP-TAE684,NVP-TAE684,CHEMBL509032,BRD:BRD-BRD-K50140147-001-10-1;BRD:BRD-K50140147-001-10-1;CTRP:606249;GDSC1:35,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK;INSR,,,PRECLINICAL,,Small molecule,NA,QQWUGDVOUVUTOY-UHFFFAOYSA-N,COC1CC(CCC1NC1NCC(CL)C(NC2CCCCC2S(=O)(=O)C(C)C)N1)N1CCC(CC1)N1CCN(C)CC1;COC1CC(N2CCC(N3CCN(C)CC3)CC2)CCC1NC1NCC(CL)C(NC2CCCCC2S(=O)(=O)C(C)C)N1
NVP-TNKS656,NVP-TNKS656,,BRD:BRD-K87454346-001-01-1,rep_single_dose,TANKYRASE INHIBITOR,TNKS2,,,,,,NA,,
NVP-XAV939,NVP-XAV939,,GDSC1:1268;GDSC2:1268,gdsc,,,,,,,,NA,,
NVPADW742,NVPADW742,,GDSC2:1932,gdsc,,,,,,,,NA,,
NVS-PAK1-1,NVS-PAK1-1,,BRD:BRD-BRD-K28132190-001-02-0;BRD:BRD-K28132190-001-02-0,rep_primary;rep_single_dose,P21 ACTIVATED KINASE INHIBITOR,PAK1,,,PRECLINICAL,,,NA,,CC(C)NC(=O)N1CC[C@@H](C1)NC1=NC2CC(F)CCC2N(CC(F)F)C2CCC(CL)CC12
NXY-059,NXY-059,CHEMBL2107334,BRD:BRD-BRD-K46133855-304-03-8;BRD:BRD-K46133855-304-03-8,rep_primary;rep_single_dose,FREE RADICAL SCAVENGER,,,,PHASE 3,,Small molecule,Phase 3,XLZOVRYBVCMCGL-UHFFFAOYSA-L,CC(C)(C)[N+]([O-])=CC1CCC(S(=O)(=O)[O-])CC1S(=O)(=O)[O-].[NA+].[NA+];CC(C)(C)[N+](\[O-])=C\C1CCC(CC1S(O)(=O)=O)S(O)(=O)=O
O-1918,O-1918,,BRD:BRD-BRD-K18316707-001-02-7;BRD:BRD-K18316707-001-02-7,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,COC1CC(C)CC(OC)C1[C@@H]1C=C(C)CC[C@H]1C(C)=C
O-304,O-304,,BRD:BRD-K00003113-001-01-9,rep_single_dose,AMPK ACTIVATOR,,,,,,,NA,,
O-3M3FBS,O-3M3FBS,,BRD:BRD-BRD-K46384212-001-02-9;BRD:BRD-K46384212-001-02-9,rep_primary;rep_single_dose,PHOSPHOLIPASE ACTIVATOR,,,,PRECLINICAL,,,NA,,CC1CC(C)C(C(C)C1)S(=O)(=O)NC1CCCCC1C(F)(F)F
O-6-BENZYLGUANINE,O-6-BENZYLGUANINE,,CTRP:345712,ctrp,,,,,,,,NA,,
O-ACETYL-L-SERINE,O-ACETYL-L-SERINE,,BRD:BRD-BRD-K63247785-001-01-5;BRD:BRD-K63247785-001-01-5,rep_primary;rep_single_dose,,PTGS1,,,PRECLINICAL,,,NA,,CC(=O)OC[C@H](N)C(O)=O
O-MERCAPTO-BENZOIC-ACID,O-MERCAPTO-BENZOIC-ACID,,BRD:BRD-BRD-K36998189-001-03-5;BRD:BRD-K36998189-001-03-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)C1CCCCC1S
O6-BENZYLGUANINE,O6-BENZYLGUANINE,CHEMBL407874,BRD:BRD-BRD-K92041145-001-09-5;BRD:BRD-K92041145-001-09-5,rep_multi_dose;rep_primary;rep_single_dose,O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INHIBITOR,MGMT,,,PHASE 3,,Small molecule,Phase 3,KRWMERLEINMZFT-UHFFFAOYSA-N,NC1NC(OCC2CCCCC2)C2[NH]CNC2N1;NC1NC(OCC2CCCCC2)C2NC[NH]C2N1
OAC1,OAC1,,BRD:BRD-BRD-K10878147-001-02-2;BRD:BRD-K10878147-001-02-2,rep_primary;rep_single_dose,OCT ACTIVATOR,,,,PRECLINICAL,,,NA,,O=C(NC1CC2CC[NH]C2CN1)C1CCCCC1
OAC2,OAC2,,BRD:BRD-BRD-K18305454-001-07-4;BRD:BRD-K18305454-001-07-4,rep_primary;rep_single_dose,OCT ACTIVATOR,POU5F1,,,PRECLINICAL,,,NA,,O=C(NC1CCC2[NH]CCC2C1)C1CCCCC1
OBATOCLAX,OBATOCLAX,CHEMBL2107358;CHEMBL408194,BRD:BRD-BRD-K15600710-066-04-1;BRD:BRD-K15600710-066-04-1;BRD:BRD-K15600710-066-05-8;CTRP:606142;GDSC1:182;GDSC2:1068,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,BCL INHIBITOR,BCL2,,,PHASE 3,,Small molecule,Phase 3,RFTSSZJZXOSICM-GRSHGNNSSA-N;ZFKXDVMHNXPEIY-PEZBNFGJSA-N,COC1=CC(=N\C\1=C/C1[NH]C(C)CC1C)C1CC2CCCCC2[NH]1;COC1=CC(C2CC3CCCCC3[NH]2)=N/C1=C\C1[NH]C(C)CC1C;COC1=CC(C2CC3CCCCC3[NH]2)=N/C1=C\C1[NH]C(C)CC1C.CS(=O)(=O)O
OBATOCLAX MESYLATE,OBATOCLAX MESYLATE,CHEMBL2107358,GDSC1:182;GDSC2:1068,gdsc,,,,,,,Small molecule,Phase 3,ZFKXDVMHNXPEIY-PEZBNFGJSA-N,COC1=CC(C2CC3CCCCC3[NH]2)=N/C1=C\C1[NH]C(C)CC1C.CS(=O)(=O)O
OBIDOXIME,OBIDOXIME,CHEMBL291233;CHEMBL451635,BRD:BRD-BRD-K33588785-001-01-9;BRD:BRD-K33588785-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,CHOLINESTERASE REACTIVATOR,ACHE,"POISON ANTIDOTE, NERVE GAS POISONING",,LAUNCHED,,Small molecule,Unknown,HIGRLDNHDGYWQJ-UHFFFAOYSA-P;ZIFJVJZWVSPZLE-UHFFFAOYSA-N,O/N=C/C1CC[N+](COC[N+]2CCC(/C=N/O)CC2)CC1;O/N=C/C1CC[N+](COC[N+]2CCC(/C=N/O)CC2)CC1.[CL-].[CL-];O\N=C\C1CC[N+](COC[N+]2CCC(CC2)\C=N\O)CC1
OC000459,OC000459,CHEMBL560993,BRD:BRD-BRD-K36463073-001-03-9;BRD:BRD-K36463073-001-03-9,rep_primary;rep_single_dose,CRTH RECEPTOR ANTAGONIST,PTGDR2,,,PHASE 2,,Small molecule,Phase 2,FATGTHLOZSXOBC-UHFFFAOYSA-N,CC1C(CC2CCC3CCCCC3N2)C2CC(F)CCC2N1CC(=O)O;CC1C(CC2CCC3CCCCC3N2)C2CC(F)CCC2N1CC(O)=O
OCAPERIDONE,OCAPERIDONE,CHEMBL2104619,BRD:BRD-K00003399-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,ZZQNEJILGNNOEP-UHFFFAOYSA-N,CC1NC2C(C)CCCN2C(=O)C1CCN1CCC(C2NOC3CC(F)CCC23)CC1
OCINAPLON,OCINAPLON,CHEMBL2105199,BRD:BRD-BRD-K92581468-001-01-6;BRD:BRD-K92581468-001-01-6,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1;GABRA2;GABRA3;GABRA5,,,PHASE 3,,Small molecule,Unknown,OQJFBUOFGHPMSR-UHFFFAOYSA-N,O=C(C1CCCCN1)C1CNN2C(-C3CCNCC3)CCNC12;O=C(C1CNN2C(CCNC12)-C1CCNCC1)C1CCCCN1
OCLACITINIB,OCLACITINIB,CHEMBL2103874,BRD:BRD-K00084846-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,HJWLJNBZVZDLAQ-HAQNSBGRSA-N,CNS(=O)(=O)C[C@H]1CC[C@H](N(C)C2[NH]CNC3NCCC2-3)CC1
OCO-1112,OCO-1112,,BRD:BRD-BRD-K22097830-001-01-9;BRD:BRD-K22097830-001-01-9,rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,,,,PHASE 2,,,NA,,CC(C)C1CCC(CC1)C(=O)NCCOC1CCC(CC1)C(O)=O
OCTANOIC ACID,OCTANOIC ACID,CHEMBL324846;CHEMBL557076,GDSC1:180,gdsc,,,,,,,Small molecule,Phase 2,BYKRNSHANADUFY-UHFFFAOYSA-M;WWZKQHOCKIZLMA-UHFFFAOYSA-N,CCCCCCCC(=O)[O-].[NA+];CCCCCCCC(=O)O
OCTENIDINE,OCTENIDINE,CHEMBL1199480;CHEMBL36342,BRD:BRD-BRD-K04568635-300-01-4;BRD:BRD-K04568635-300-01-4,rep_multi_dose;rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,,,,LAUNCHED,,Small molecule,Phase 2,SMGTYJPMKXNQFY-UHFFFAOYSA-N;ZVXNYZWXUADSRV-UHFFFAOYSA-N,CCCCCCCCN=C1CCN(CCCCCCCCCCN2CCC(=NCCCCCCCC)CC2)CC1;CCCCCCCCN=C1CCN(CCCCCCCCCCN2CCC(=NCCCCCCCC)CC2)CC1.CL.CL;CCCCCCCCN=C1CCN(CCCCCCCCCCN2CCC(CC2)=NCCCCCCCC)CC1
OCTINOXATE,OCTINOXATE,CHEMBL1200608;CHEMBL3183184,BRD:BRD-BRD-K19972289-001-01-4;BRD:BRD-K19972289-001-01-4,rep_primary;rep_single_dose,,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Approved,YBGZDTIWKVFICR-JLHYYAGUSA-N;YBGZDTIWKVFICR-UHFFFAOYSA-N,CCCC[C@@H](CC)COC(=O)\C=C\C1CCC(OC)CC1;CCCCC(CC)COC(=O)/C=C/C1CCC(OC)CC1;CCCCC(CC)COC(=O)C=CC1CCC(OC)CC1
OCTISALATE,OCTISALATE,CHEMBL1329203,BRD:BRD-BRD-K95161686-001-02-8;BRD:BRD-K95161686-001-02-8,rep_primary;rep_single_dose,,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Unknown,FMRHJJZUHUTGKE-UHFFFAOYSA-N,CCCC[C@@H](CC)COC(=O)C1CCCCC1O;CCCCC(CC)COC(=O)C1CCCCC1O
OCTOCRYLENE,OCTOCRYLENE,CHEMBL1201147,BRD:BRD-BRD-K39023557-001-01-7;BRD:BRD-K39023557-001-01-7,rep_primary;rep_single_dose,,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Approved,FMJSMJQBSVNSBF-UHFFFAOYSA-N,CCCC[C@@H](CC)COC(=O)C(C#N)=C(C1CCCCC1)C1CCCCC1;CCCCC(CC)COC(=O)C(C#N)=C(C1CCCCC1)C1CCCCC1
OCTODRINE,OCTODRINE,CHEMBL2105833,BRD:BRD-A37873789-003-02-9,rep_single_dose,ANTITUMOR AGENT,,,,,,Small molecule,Unknown,QNIVIMYXGGFTAK-UHFFFAOYSA-N,CC(C)CCCC(C)N
OCTOPAMINE,OCTOPAMINE,CHEMBL53929,BRD:BRD-A14240607-003-26-1;BRD:BRD-BRD-A14240607-003-26-1,rep_multi_dose;rep_primary;rep_single_dose,TRACE AMINE ASSOCIATED RECEPTOR AGONIST,F10;TAAR1,,,PRECLINICAL,,Small molecule,Unknown,QHGUCRYDKWKLMG-UHFFFAOYSA-N,NCC(O)C1CCC(O)CC1
OCTREOTIDE,OCTREOTIDE,CHEMBL1680,BRD:BRD-A64173453-015-02-3;BRD:BRD-BRD-A64173453-015-02-3,rep_primary;rep_single_dose,SOMATOSTATIN RECEPTOR AGONIST,SSTR1;SSTR2;SSTR3;SSTR5,"DIARRHEA, ACROMEGALY, CARCINOID TUMORS",,LAUNCHED,,Protein,Approved,DEQANNDTNATYII-OULOTJBUSA-N,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@@H](NC(=O)[C@H](N)CC2CCCCC2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O;CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)CC2CCCCC2)C(=O)NC(CC2CCCCC2)C(=O)NC(CC2C[NH]C3CCCCC23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1
ODANACATIB,ODANACATIB,CHEMBL481611,BRD:BRD-BRD-K22822991-001-02-3;BRD:BRD-K22822991-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,CATHEPSIN INHIBITOR,CTSK,,,PHASE 3,,Small molecule,Phase 3,FWIVDMJALNEADT-SFTDATJTSA-N,CC(C)(F)C[C@H](N[C@@H](C1CCC(-C2CCC(S(C)(=O)=O)CC2)CC1)C(F)(F)F)C(=O)NC1(C#N)CC1;CC(C)(F)C[C@H](N[C@@H](C1CCC(CC1)-C1CCC(CC1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N
ODM-203,ODM-203,,BRD:BRD-K00091101-001-01-9,rep_single_dose,,,,,,,,NA,,
OF-1,OF-1,,BRD:BRD-K92658264-001-02-9;GDSC2:1853,gdsc;rep_single_dose,BROMODOMAIN INHIBITOR,BRD1,,,,,,NA,,
OFLOXACIN,OFLOXACIN,CHEMBL33;CHEMBL4,BRD:BRD-A24228527-213-01-9;BRD:BRD-BRD-A24228527-213-01-9,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,"RESPIRATORY TRACT INFECTIONS, SINUSITIS, SKIN INFECTIONS, BONE AND JOINT INFECTIONS, INTRA-ABDOMINAL INFECTIONS, DIARRHEA, FEVER, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,GSDSWSVVBLHKDQ-JTQLQIEISA-N;GSDSWSVVBLHKDQ-UHFFFAOYSA-N,C[C@H]1COC2C(N3CCN(C)CC3)C(F)CC3C(=O)C(C(=O)O)CN1C23;CC1COC2C(N3CCN(C)CC3)C(F)CC3C(=O)C(C(=O)O)CN1C23;CC1COC2C(N3CCN(C)CC3)C(F)CC3C2N1CC(C(O)=O)C3=O
OG-L002,OG-L002,,BRD:BRD-BRD-K26349472-001-01-3;BRD:BRD-K26349472-001-01-3,rep_primary;rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM1A,,,PRECLINICAL,,,NA,,N[C@H]1C[C@@H]1C1CCC(CC1)-C1CCCC(O)C1
OGERIN,OGERIN,CHEMBL4548689,BRD:BRD-K00005341-001-01-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR MODULATOR,,,,,,Unknown,NA,MDGIEDNDSFMSLP-UHFFFAOYSA-N,NC1NC(NCC2CCCCC2)NC(-C2CCCCC2CO)N1
OGLEMILAST,OGLEMILAST,CHEMBL4297520,BRD:BRD-BRD-K92303087-001-01-6;BRD:BRD-K92303087-001-01-6,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,OKFDRAHPFKMAJH-UHFFFAOYSA-N,CS(=O)(=O)NC1CCC2OC3C(OC(F)F)CCC(C(=O)NC4C(CL)CNCC4CL)C3C2C1
OGLUFANIDE,OGLUFANIDE,CHEMBL2111029,BRD:BRD-K00003164-001-01-9,rep_single_dose,VEGF ANTAGONIST,,,,,,Small molecule,Phase 3,LLEUXCDZPQOJMY-AAEUAGOBSA-N,N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)O
OICR-9429,OICR-9429,,BRD:BRD-K94083718-001-03-9,rep_single_dose,WDR5/MLL INTERACTION INHIBITOR,WDR5,,,,,,NA,,
OLANEXIDINE,OLANEXIDINE,CHEMBL1190262,BRD:BRD-K00074735-014-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,ZZQMUJGZCZTLQD-UHFFFAOYSA-N,CCCCCCCCNC(=N)NC(=N)NCC1CCC(CL)C(CL)C1
OLANZAPINE,OLANZAPINE,CHEMBL715,BRD:BRD-BRD-K18895904-001-16-1;BRD:BRD-K18895904-001-16-1,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA2A;ADRA2B;ADRA2C;ADRB1;ADRB2;ADRB3;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;HRH1;HRH2;HRH4;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR3A;HTR5A;HTR6;HTR7,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,KVWDHTXUZHCGIO-UHFFFAOYSA-N,CC1CC2C(S1)NC1CCCCC1N=C2N1CCN(C)CC1;CN1CCN(CC1)C1=NC2CCCCC2NC2SC(C)CC12
OLDA,OLDA,,BRD:BRD-BRD-K95523387-001-09-6;BRD:BRD-K95523387-001-09-6,rep_multi_dose;rep_primary;rep_single_dose,TRPV AGONIST,GPR119,,,PRECLINICAL,,,NA,,CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1CCC(O)C(O)C1
OLEAMIDE,OLEAMIDE,CHEMBL15927,BRD:BRD-BRD-K06644925-001-03-0;BRD:BRD-K06644925-001-03-0,rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,HTR7;PLA2G2A,,,PRECLINICAL,,Small molecule,NA,FATBGEAMYMYZAF-KTKRTIGZSA-N,CCCCCCCC/C=C\CCCCCCCC(N)=O;CCCCCCCC\C=C/CCCCCCCC(N)=O
OLEANDRIN,OLEANDRIN,CHEMBL1075789;CHEMBL4285883,BRD:BRD-BRD-K98006098-001-01-6;BRD:BRD-K98006098-001-01-6,rep_primary;rep_single_dose,NA/K-ATPASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,JLPDBLFIVFSOCC-XYXFTTADSA-N;QWTDCDSWAVIWER-VSBFTHSSSA-N,CC(=O)O[C@H]1C[C@]2(O)[C@@H]3CC[C@@H]4C[C@@H](O[C@H]5C[C@H](O)[C@@H](O)[C@H](C)O5)CC[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1C1=CC(=O)OC1;CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@@H](C5=CC(=O)OC5)[C@@H](OC(C)=O)C[C@]43O)C2)O[C@@H](C)[C@@H]1O;CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O
OLEANOLIC-ACID,OLEANOLIC-ACID,,BRD:BRD-BRD-K90647725-001-06-5;BRD:BRD-BRD-K90647725-001-07-3;BRD:BRD-K90647725-001-06-5;BRD:BRD-K90647725-001-07-3,rep_multi_dose;rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPBAR1,,,PRECLINICAL,,,NA,,CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O
OLEOYLETHANOLAMIDE,OLEOYLETHANOLAMIDE,CHEMBL280065,BRD:BRD-BRD-K66956375-001-11-3;BRD:BRD-K66956375-001-11-3,rep_multi_dose;rep_primary;rep_single_dose,"CANNABINOID RECEPTOR AGONIST, GLUCOSE DEPENDENT INSULINOTROPIC RECEPTOR AGONIST, POTASSIUM CHANNEL BLOCKER, PPAR RECEPTOR AGONIST",CNR1;GPR119;GPR55;PPARA,,,PRECLINICAL,,Small molecule,NA,BOWVQLFMWHZBEF-KTKRTIGZSA-N,CCCCCCCC/C=C\CCCCCCCC(=O)NCCO;CCCCCCCC\C=C/CCCCCCCC(=O)NCCO
OLEUROPEIN,OLEUROPEIN,CHEMBL1911053,BRD:BRD-A00842753-001-01-9;BRD:BRD-BRD-A00842753-001-01-9,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,GPER1,,,PHASE 2,,Small molecule,NA,RFWGABANNQMHMZ-ZCHJGGQASA-N,C/C=C1/[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)OC=C(C(=O)OC)[C@H]1CC(=O)OCCC1CCC(O)C(O)C1;COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCC1CCC(O)C(O)C1
OLIGOMYCIN A,OLIGOMYCIN A,CHEMBL1256136;CHEMBL3989875,CTRP:411869,ctrp,,,,,,,Small molecule,Unknown,LVWVMRBMGDJZLM-BONFEJLISA-N;MNULEGDCPYONBU-BOXGPLBDSA-N,CC[C@@H]1/C=C/C=C/C[C@H](C)[C@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]2[C@@H](C)[C@@H](CC1)O[C@@]1(CC[C@@H](C)[C@@H](C[C@H](C)O)O1)[C@@H]2C;CC[C@H]1/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@H]2C[C@@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)O[C@@H](CC1)[C@H]2C
OLIGOMYCIN-A,OLIGOMYCIN-A,,BRD:BRD-A81541225-001-06-8;BRD:BRD-BRD-A81541225-001-06-8,rep_multi_dose;rep_primary;rep_single_dose,"ATP SYNTHASE INHIBITOR, ATPASE INHIBITOR",ATP5A1,,,PRECLINICAL,,,NA,,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C
OLINCIGUAT,OLINCIGUAT,CHEMBL4297616,BRD:BRD-K00091274-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,YWQFJNWMWZMXRW-HXUWFJFHSA-N,NC(=O)[C@](O)(CNC1NC(-C2CC(-C3CCON3)N(CC3CCCCC3F)N2)NCC1F)C(F)(F)F
OLMESARTAN,OLMESARTAN,CHEMBL1516,BRD:BRD-BRD-K83144676-001-09-5;BRD:BRD-K83144676-001-09-5,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,VTRAEEWXHOVJFV-UHFFFAOYSA-N,CCCC1NC(C(C(O)=O)N1CC1CCC(CC1)-C1CCCCC1-C1NN[NH]N1)C(C)(C)O;CCCC1NC(C(C)(C)O)C(C(=O)O)N1CC1CCC(-C2CCCCC2-C2NNN[NH]2)CC1
OLMESARTAN-MEDOXOMIL,OLMESARTAN-MEDOXOMIL,,BRD:BRD-BRD-K78485176-001-07-8;BRD:BRD-K78485176-001-07-8,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,HYPERTENSION,,LAUNCHED,,,NA,,CCCC1NC(C(C)(C)O)C(C(=O)OCC2OC(=O)OC2C)N1CC1CCC(CC1)-C1CCCCC1-C1NN[NH]N1
OLMUTINIB,OLMUTINIB,CHEMBL3786343,BRD:BRD-BRD-K60421517-001-01-4;BRD:BRD-K60421517-001-01-4,rep_primary;rep_single_dose,"EGFR INHIBITOR, BRUTON'S TYROSINE KINASE (BTK) INHIBITOR",BTK;EGFR,,,LAUNCHED,"Multiple values for MOA: {""BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, EGFR INHIBITOR"", ""EGFR INHIBITOR, BRUTON'S TYROSINE KINASE (BTK) INHIBITOR""}, defaulting to ""EGFR INHIBITOR, BRUTON'S TYROSINE KINASE (BTK) INHIBITOR""",Small molecule,Phase 2,FDMQDKQUTRLUBU-UHFFFAOYSA-N,C=CC(=O)NC1CCCC(OC2NC(NC3CCC(N4CCN(C)CC4)CC3)NC3CCSC23)C1;CN1CCN(CC1)C1CCC(NC2NC(OC3CCCC(NC(=O)C=C)C3)C3SCCC3N2)CC1
OLODANRIGAN,OLODANRIGAN,CHEMBL34124,BRD:BRD-K00003151-001-01-9,rep_single_dose,ANGIOTENSIN ANTAGONIST,,,,,,Small molecule,Phase 2,GHBCIXGRCZIPNQ-MHZLTWQESA-N,COC1CCC2C(C1OCC1CCCCC1)C[C@@H](C(=O)O)N(C(=O)C(C1CCCCC1)C1CCCCC1)C2
OLOMOUCINE,OLOMOUCINE,CHEMBL280074,BRD:BRD-BRD-K82731415-001-07-0;BRD:BRD-K82731415-001-07-0,rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK5;MAPK1,,,PRECLINICAL,,Small molecule,NA,GTVPOLSIJWJJNY-UHFFFAOYSA-N,CN1CNC2C(NCC3CCCCC3)NC(NCCO)NC12;CN1CNC2C(NCC3CCCCC3)NC(NCCO)NC21
OLOPATADINE,OLOPATADINE,CHEMBL1189432,BRD:BRD-BRD-K67637637-003-12-6;BRD:BRD-K67637637-003-12-6,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1;S100A1;S100A12;S100A13;S100A2;S100B,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,JBIMVDZLSHOPLA-LSCVHKIXSA-N,CN(C)CC/C=C1/C2CCCCC2COC2CCC(CC(=O)O)CC21;CN(C)CC\C=C1\C2CCCCC2COC2CCC(CC(O)=O)CC12
OLPRINONE,OLPRINONE,CHEMBL1474900,BRD:BRD-BRD-K20745393-003-01-0;BRD:BRD-K20745393-003-01-0,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Unknown,JPAWFIIYTJQOKW-UHFFFAOYSA-N,CC1[NH]C(=O)C(C#N)CC1-C1CCC2NCCN2C1;CC1[NH]C(=O)C(CC1-C1CCC2NCCN2C1)C#N
OLSALAZINE,OLSALAZINE,CHEMBL425,BRD:BRD-BRD-K57853941-304-02-5;BRD:BRD-K57853941-304-02-5,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,IFNG;TPMT,ULCERATIVE COLITIS,,LAUNCHED,,Small molecule,Approved,QQBDLJCYGRGAKP-FOCLMDBBSA-N,O=C(O)C1CC(/N=N/C2CCC(O)C(C(=O)O)C2)CCC1O;OC(=O)C1CC(CCC1O)\N=N\C1CCC(O)C(C1)C(O)=O
OLTIPRAZ,OLTIPRAZ,CHEMBL178459,BRD:BRD-BRD-K86972824-001-01-4;BRD:BRD-BRD-K86972824-001-02-2;BRD:BRD-K86972824-001-01-4;BRD:BRD-K86972824-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",ANG,,,PHASE 3,"Multiple values for MOA: {'NUCLEAR FACTOR ERYTHROID DERIVED, LIKE (NRF2) ACTIVATOR', 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'}, defaulting to 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'",Small molecule,Phase 3,CKNAQFVBEHDJQV-UHFFFAOYSA-N,CC1C(-C2CNCCN2)SSC1=S;CC1C(SSC1=S)-C1CNCCN1
OLUMACOSTAT-GLASARETIL,OLUMACOSTAT-GLASARETIL,,BRD:BRD-K00004611-001-01-9,rep_single_dose,ACETYL-COA CARBOXYLASE INHIBITOR,,,,,,,NA,,
OLUTASIDENIB,OLUTASIDENIB,CHEMBL4297610,BRD:BRD-K00091092-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,NEQYWYXGTJDAKR-JTQLQIEISA-N,C[C@H](NC1CCC(C#N)N(C)C1=O)C1CC2CC(CL)CCC2[NH]C1=O
OLVANIL,OLVANIL,CHEMBL76903,BRD:BRD-BRD-K31560319-001-01-5;BRD:BRD-K31560319-001-01-5,rep_primary;rep_single_dose,TRPV AGONIST,CNR1;GPR119;TRPV1,,,PRECLINICAL,,Small molecule,Unknown,OPZKBPQVWDSATI-KHPPLWFESA-N,CCCCCCCC/C=C\CCCCCCCC(=O)NCC1CCC(O)C(OC)C1;CCCCCCCC\C=C/CCCCCCCC(=O)NCC1CCC(O)C(OC)C1
OMACETAXINE MEPESUCCINATE,OMACETAXINE MEPESUCCINATE,CHEMBL46286,CTRP:375219,ctrp,,,,,,,Small molecule,Approved,HYFHYPWGAURHIV-JFIAXGOJSA-N,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCC2CC4C(CC2[C@H]13)OCO4
OMACICLOVIR,OMACICLOVIR,CHEMBL2105375,BRD:BRD-K00091117-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,SCBFBAWJWLXVHS-ZCFIWIBFSA-N,NC1NC2C(NCN2C[C@H](CO)CCO)C(=O)[NH]1
OMADACYCLINE,OMADACYCLINE,CHEMBL1689772,BRD:BRD-K00003569-003-01-9,rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,,,,,Small molecule,Approved,JEECQCWWSTZDCK-IQZGDKDPSA-N,CN(C)C1CC(CNCC(C)(C)C)C(O)C2C1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
OMAPATRILAT,OMAPATRILAT,CHEMBL289556,BRD:BRD-K00003265-001-01-9,rep_single_dose,METALLOPROTEINASE INHIBITOR,ACE;MME,,,,,Small molecule,Unknown,LVRLSYPNFFBYCZ-VGWMRTNUSA-N,O=C(N[C@H]1CCS[C@H]2CCC[C@@H](C(=O)O)N2C1=O)[C@@H](S)CC1CCCCC1
OMARIGLIPTIN,OMARIGLIPTIN,CHEMBL2105762,BRD:BRD-BRD-K14171291-001-01-4;BRD:BRD-K14171291-001-01-4,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,,,LAUNCHED,,Small molecule,Phase 3,MKMPWKUAHLTIBJ-ISTRZQFTSA-N,CS(=O)(=O)N1CC2C(N1)CN([C@H]1CO[C@H](C3CC(F)CCC3F)[C@@H](N)C1)C2;CS(=O)(=O)N1CC2CN(CC2N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1CC(F)CCC1F
OMBITASVIR,OMBITASVIR,CHEMBL3127326,BRD:BRD-K11072003-001-02-4,rep_single_dose,HCV INHIBITOR,,,,,,Small molecule,Approved,PIDFDZJZLOTZTM-KHVQSSSXSA-N,COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NC1CCC([C@@H]2CC[C@@H](C3CCC(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)CC3)N2C2CCC(C(C)(C)C)CC2)CC1)C(C)C
OMBRABULIN,OMBRABULIN,CHEMBL572284,BRD:BRD-K00003267-003-01-9,rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,,,Small molecule,Phase 3,IXWNTLSTOZFSCM-YVACAVLKSA-N,COC1CCC(/C=C\C2CC(OC)C(OC)C(OC)C2)CC1NC(=O)[C@@H](N)CO
OMDM-2,OMDM-2,,BRD:BRD-BRD-K48830578-001-01-9;BRD:BRD-K48830578-001-01-9,rep_primary;rep_single_dose,FAAH INHIBITOR,GPR119,,,PRECLINICAL,,,NA,,CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)CC1CCC(O)CC1
OMECAMTIV-MECARBIL,OMECAMTIV-MECARBIL,,BRD:BRD-BRD-K36680103-001-01-6;BRD:BRD-K36680103-001-01-6,rep_primary;rep_single_dose,CARDIAC MYOSIN ACTIVATOR,MYBPC3,,,PHASE 2,,,NA,,COC(=O)N1CCN(CC2CCCC(NC(=O)NC3CCC(C)NC3)C2F)CC1
OMEGA-3-ACID-ESTERS,OMEGA-3-ACID-ESTERS,,BRD:BRD-BRD-K31139048-001-03-2;BRD:BRD-K31139048-001-03-2,rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,,,,LAUNCHED,,,NA,,CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
OMEPRAZOLE,OMEPRAZOLE,CHEMBL1201320;CHEMBL1503,BRD:BRD-A55962179-001-22-1;BRD:BRD-BRD-A55962179-001-22-1,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP4A;CLCN2,HEARTBURN,,LAUNCHED,,Small molecule,Approved,SUBDBMMJDZJVOS-DEOSSOPVSA-N;SUBDBMMJDZJVOS-UHFFFAOYSA-N,COC1CCC2[NH]C([S@@+]([O-])CC3NCC(C)C(OC)C3C)NC2C1;COC1CCC2[NH]C([S+]([O-])CC3NCC(C)C(OC)C3C)NC2C1;COC1CCC2NC([NH]C2C1)S(=O)CC1NCC(C)C(OC)C1C
OMEPRAZOLE-MAGNESIUM,OMEPRAZOLE-MAGNESIUM,,BRD:BRD-A56892734-001-09-4;BRD:BRD-BRD-A56892734-001-09-4,rep_primary;rep_single_dose,PROTON PUMP INHIBITOR,ATP4A;ATP4B,"GASTROESOPHAGEAL REFLUX DISEASE (GERD), HEARTBURN",,LAUNCHED,,,NA,,COC1CCC2N([MG]N3C(NC4CC(OC)CCC34)S(=O)CC3NCC(C)C(OC)C3C)C(NC2C1)S(=O)CC1NCC(C)C(OC)C1C
OMEPRAZOLE-SULFIDE,OMEPRAZOLE-SULFIDE,,BRD:BRD-BRD-K69035426-001-01-3;BRD:BRD-K69035426-001-01-3,rep_primary;rep_single_dose,ATPASE INHIBITOR,,,,PHASE 1,,,NA,,COC1CCC2NC(SCC3NCC(C)C(OC)C3C)[NH]C2C1
OMIPALISIB,OMIPALISIB,CHEMBL1236962,GDSC1:283,gdsc,,,,,,,Small molecule,Phase 1,CGBJSGAELGCMKE-UHFFFAOYSA-N,COC1NCC(-C2CCC3NCCC(-C4CCNNC4)C3C2)CC1NS(=O)(=O)C1CCC(F)CC1F
OMTRIPTOLIDE,OMTRIPTOLIDE,CHEMBL2110669,BRD:BRD-K00003212-001-01-9,rep_single_dose,ERK1 AND ERK2 PHOSPHORYLATION INHIBITOR,,,,,,Small molecule,Unknown,HROMYAWHLUOUPY-AHCCQAQQSA-N,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]13[C@]1(O[C@H]1C[C@H]1C4=C(CC[C@@]13C)C(=O)OC4)[C@@H]2OC(=O)CCC(=O)O
ON-01500,ON-01500,,BRD:BRD-K55790047-001-02-9,rep_single_dose,APOPTOSIS STIMULANT,,,,,,,NA,,
ON123300,ON123300,CHEMBL3115681,BRD:BRD-K88554883-001-03-2,rep_single_dose,CDK INHIBITOR,CDK4;NUAK1;PDGFRB,,,,,Small molecule,Phase 1,VADOZMZXXRBXNY-UHFFFAOYSA-N,CN1CCN(C2CCC(NC3NCC4CC(C#N)C(=O)N(C5CCCC5)C4N3)CC2)CC1
ONC201,ONC201,CHEMBL4297310,BRD:BRD-BRD-K58529924-001-01-5;BRD:BRD-K58529924-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,"AKT INHIBITOR, MAP KINASE INHIBITOR",TNFSF10,,,PHASE 2,,Small molecule,Phase 3,VLULRUCCHYVXOH-UHFFFAOYSA-N,CC1CCCCC1CN1C(=O)C2=C(CCN(CC3CCCCC3)C2)N2CCN=C12;CC1CCCCC1CN1C2=NCCN2C2=C(CN(CC3CCCCC3)CC2)C1=O
ONCRASIN-1,ONCRASIN-1,,BRD:BRD-BRD-K43449605-001-01-0;BRD:BRD-K43449605-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,APOPTOSIS STIMULANT,,,,PRECLINICAL,,,NA,,CLC1CCC(CN2CC(C=O)C3CCCCC23)CC1
ONDANSETRON,ONDANSETRON,CHEMBL46,BRD:BRD-A19736161-001-06-7;BRD:BRD-BRD-A19736161-001-06-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR1B;HTR3A;HTR3B;HTR4;OPRM1,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,FELGMEQIXOGIFQ-UHFFFAOYSA-N,CC1NCCN1CC1CCC2C(C1=O)C1CCCCC1N2C;CC1NCCN1CC1CCC2C(C3CCCCC3N2C)C1=O
ONO-4059,ONO-4059,CHEMBL4071161,BRD:BRD-A13689093-001-01-8;BRD:BRD-BRD-A13689093-001-01-8;BRD:BRD-K00003197-001-02-9,rep_primary;rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK,,,PHASE 1,"Multiple values for structure_id: {'K00003197', 'A13689093'}, defaulting to None",Small molecule,Phase 2,SEJLPXCPMNSRAM-GOSISDBHSA-N,CC#CC(=O)N1CC[C@@H](N2C(=O)N(-C3CCC(OC4CCCCC4)CC3)C3C(N)NCNC32)C1;NC1NCNC2N(C3CCCN(C3)C(=O)C=C)C(=O)N(-C3CCC(OC4CCCCC4)CC3)C12
ONO-4817,ONO-4817,,BRD:BRD-BRD-K58894520-001-01-1;BRD:BRD-K58894520-001-01-1,rep_primary;rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,MMP8,,,PHASE 1,,,NA,,CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)C1CCC(OC2CCCCC2)CC1
ONO-8130,ONO-8130,,BRD:BRD-K76725781-001-02-9,rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER1,,,,,,NA,,
ONO-AE3-208,ONO-AE3-208,,BRD:BRD-A80567330-001-01-7;BRD:BRD-BRD-A80567330-001-01-7,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER4,,,PRECLINICAL,,,NA,,CC(C(=O)NC1CC(CCC1CCCC(O)=O)C#N)C1CCC(F)C2CCCCC12
ONX-0914,ONX-0914,,BRD:BRD-BRD-K60446698-001-01-2;BRD:BRD-K60446698-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CCC(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)[C@]2(C)CO2)CC1
ONXOL,ONXOL,CHEMBL428647,GDSC1:11;GDSC2:1080,gdsc,,,,,,,Small molecule,Approved,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)C3CCCCC3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4CCCCC4)C4CCCCC4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
OP-0595,OP-0595,,BRD:BRD-K00004708-001-01-9,rep_single_dose,BETA LACTAMASE INHIBITOR,,,,,,,NA,,
OPC-21268,OPC-21268,,BRD:BRD-BRD-K19426040-001-01-1;BRD:BRD-K19426040-001-01-1,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,AVPR1A;AVPR2;OXTR,,,PHASE 1,,,NA,,CC(=O)NCCCOC1CCC(CC1)C(=O)N1CCC(CC1)N1C(=O)CCC2CCCCC12
OPICAPONE,OPICAPONE,CHEMBL1089318,BRD:BRD-BRD-K66192203-001-02-2;BRD:BRD-K66192203-001-02-2,rep_primary;rep_single_dose,CATECHOL O METHYLTRANSFERASE INHIBITOR,COMT,,,PHASE 3,,Small molecule,Approved,ASOADIZOVZTJSR-UHFFFAOYSA-N,CC1C(CL)C(C)[N+]([O-])C(CL)C1-C1NOC(-C2CC(O)C(O)C([N+](=O)[O-])C2)N1;CC1C(CL)C(C)[N+]([O-])C(CL)C1-C1NOC(N1)-C1CC(O)C(O)C(C1)[N+]([O-])=O
OPIPRAMOL,OPIPRAMOL,CHEMBL370753,BRD:BRD-BRD-K43786866-300-02-3;BRD:BRD-K43786866-300-02-3,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,,GENERALIZED ANXIETY DISORDER (GAD),,LAUNCHED,,Small molecule,Phase 3,YNZFUWZUGRBMHL-UHFFFAOYSA-N,OCCN1CCN(CCCN2C3CCCCC3C=CC3CCCCC23)CC1;OCCN1CCN(CCCN2C3CCCCC3C=CC3CCCCC32)CC1
OPROZOMIB,OPROZOMIB,CHEMBL2103884,BRD:BRD-A36331462-001-02-1;BRD:BRD-BRD-A36331462-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,PROTEASOME INHIBITOR,,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,SWZXEVABPLUDIO-WSZYKNRRSA-N,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1CNC(C)S1)C(=O)N[C@@H](CC1CCCCC1)C(=O)C1(C)CO1;COC[C@H](NC(=O)C1CNC(C)S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC1CCCCC1)C(=O)[C@@]1(C)CO1
OR-1896,OR-1896,,BRD:BRD-K86283245-001-03-9,rep_single_dose,,,,,,,,NA,,
OR-486,OR-486,,BRD:BRD-K18602506-001-09-9,rep_single_dose,CATECHOL O METHYLTRANSFERASE INHIBITOR,COMT,,,,,,NA,,
ORANTINIB,ORANTINIB,CHEMBL274654,BRD:BRD-BRD-K55966568-001-05-4;BRD:BRD-K55966568-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",AURKA;AURKB;EGFR;FGFR1;FGFR2;KDR;PDGFRA;PDGFRB,,,PHASE 3,,Small molecule,Phase 3,NHFDRBXTEDBWCZ-ZROIWOOFSA-N,CC1[NH]C(/C=C2\C(=O)NC3CCCCC32)C(C)C1CCC(=O)O;CC1[NH]C(\C=C2/C(=O)NC3CCCCC23)C(C)C1CCC(O)=O
ORBIFLOXACIN,ORBIFLOXACIN,CHEMBL295433,BRD:BRD-BRD-K63001556-001-08-8;BRD:BRD-BRD-K63001556-001-09-6;BRD:BRD-K63001556-001-08-8;BRD:BRD-K63001556-001-09-6,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Unknown,QIPQASLPWJVQMH-DTORHVGOSA-N,C[C@@H]1CN(C2C(F)C(F)C3C(=O)C(C(=O)O)CN(C4CC4)C3C2F)C[C@H](C)N1;C[C@H]1CN(C[C@@H](C)N1)C1C(F)C(F)C2C(C1F)N(CC(C(O)=O)C2=O)C1CC1
ORE1001,ORE1001,CHEMBL429844,BRD:BRD-BRD-K67068943-001-01-0;BRD:BRD-K67068943-001-01-0,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE2,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,NTCCRGGIJNDEAB-IRXDYDNUSA-N,CC(C)C[C@H](N[C@@H](CC1CNCN1CC1CC(CL)CC(CL)C1)C(=O)O)C(=O)O;CC(C)C[C@H](N[C@@H](CC1CNCN1CC1CC(CL)CC(CL)C1)C(O)=O)C(O)=O
ORG-12962,ORG-12962,,BRD:BRD-BRD-K07409305-001-01-1;BRD:BRD-K07409305-001-01-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A;HTR2B;HTR2C,,,PHASE 2,,,NA,,FC(F)(F)C1CCC(NC1CL)N1CCNCC1
ORG-25543,ORG-25543,,BRD:BRD-BRD-K32853922-003-01-8;BRD:BRD-K32853922-003-01-8,rep_primary;rep_single_dose,GLYCINE TRANSPORTER INHIBITOR,GLRB;SLC6A5,,,PRECLINICAL,,,NA,,COC1CC(CC(OC)C1OCC1CCCCC1)C(=O)NCC1(CCCC1)N(C)C
ORG-26576,ORG-26576,CHEMBL3707401,BRD:BRD-BRD-K40002998-001-01-5;BRD:BRD-K40002998-001-01-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,,,,PHASE 2,,Small molecule,Phase 2,,O=C1N2CCC[C@H]2COC2NCCCC12
ORG-27569,ORG-27569,,BRD:BRD-BRD-K57597776-001-01-2;BRD:BRD-K57597776-001-01-2,rep_primary;rep_single_dose,CANNABINOID RECEPTOR MODULATOR,CNR1,,,PRECLINICAL,,,NA,,CCC1C([NH]C2CCC(CL)CC12)C(=O)NCCC1CCC(CC1)N1CCCCC1
ORG-9768,ORG-9768,,BRD:BRD-BRD-K41434598-003-01-9;BRD:BRD-K41434598-003-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A,,,PHASE 1,,,NA,,CC1(CN)CC2CCCCC2C1
ORIDONIN,ORIDONIN,CHEMBL454570;CHEMBL4639672,BRD:BRD-BRD-K23925186-001-01-0;BRD:BRD-BRD-K23925186-001-02-8;BRD:BRD-K23925186-001-01-0;BRD:BRD-K23925186-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,BCL INHIBITOR,BCL2,,,PRECLINICAL,,Small molecule,Unknown,SDHTXBWLVGWJFT-BAFGBBEMSA-N;SDHTXBWLVGWJFT-UMXDBTPVSA-N,C=C1C(=O)[C@]23[C@H](O)[C@H]1CC[C@H]2[C@@]12CO[C@@]3(O)[C@@H](O)[C@@H]1C(C)(C)CC[C@@H]2O;C=C1C(=O)[C@]23C(O)[C@H]1CC[C@H]2[C@@]12CO[C@]3(O)[C@@H](O)[C@@H]1C(C)(C)CC[C@@H]2O;O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C
ORITAVANCIN,ORITAVANCIN,CHEMBL1688530,BRD:BRD-A33352494-316-01-6;BRD:BRD-BRD-A33352494-316-01-6,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,SKIN INFECTIONS,,LAUNCHED,,Unknown,Approved,VHFGEBVPHAGQPI-LXKZPTCJSA-N,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C4CC(O)CC(O)C4-C4CC3CCC4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)C3CCC(C(CL)C3)OC3CC2CC(C3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCC3CCC(-C4CCC(CL)CC4)CC3)[C@@H](O)[C@H](C)O2)OC2CCC(CC2CL)[C@H]1O;CNC(CC(C)C)C(=O)NC1C(O)C2CCC(OC3CC4CC(OC5CCC(CC5CL)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)C1CCC(O)C(C1)-C1C(O)CC(O)CC1C(NC5=O)C(O)=O)C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCC3CCC(CC3)-C3CCC(CL)CC3)C(O)C(C)O1)C(CL)C2
ORLISTAT,ORLISTAT,CHEMBL175247,BRD:BRD-BRD-K63343048-001-12-2;BRD:BRD-K63343048-001-12-2,rep_primary;rep_single_dose,LIPASE INHIBITOR,CNR1;DAGLA;DAGLB;FASN;LIPF;PNLIP,WEIGHT-LOSS AID,,LAUNCHED,,Small molecule,Approved,AHLBNYSZXLDEJQ-FWEHEUNISA-N,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O;CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O
ORMELOXIFENE,ORMELOXIFENE,CHEMBL154126,BRD:BRD-K00004639-001-01-9,rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),,,,,,Small molecule,Unknown,XZEUAXYWNKYKPL-UHFFFAOYSA-N,COC1CCC2C(C1)OC(C)(C)C(C1CCCCC1)C2C1CCC(OCCN2CCCC2)CC1
ORNIDAZOLE,ORNIDAZOLE,CHEMBL1449676,BRD:BRD-A42759514-001-20-5;BRD:BRD-BRD-A42759514-001-20-5,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,PROTOZOAN INFECTION,,LAUNCHED,,Small molecule,Approved,IPWKIXLWTCNBKN-UHFFFAOYSA-N,CC1NCC([N+](=O)[O-])N1CC(O)CCL;CC1NCC(N1CC(O)CCL)[N+]([O-])=O
ORNIPRESSIN,ORNIPRESSIN,CHEMBL1819440,BRD:BRD-K00003333-001-01-9,rep_single_dose,VASOCONSTRICTOR,,,,,,Protein,Unknown,MUNMIGOEDGHVLE-LGYYRGKSSA-N,NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2CCC(O)CC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
ORNITHINE,ORNITHINE,CHEMBL446143,BRD:BRD-A13561534-003-02-0;BRD:BRD-BRD-A13561534-003-02-0,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY MODULATOR,ARG1;ARG2;GATM;GPRC6A;OAT;OAZ1;OAZ2;OAZ3;OTC;SLC25A15;SLC25A2;SLC7A1;SLC7A2;SLC7A3;SLC7A4,,,LAUNCHED,,Small molecule,Phase 3,AHLPHDHHMVZTML-BYPYZUCNSA-N,NCCC[C@H](N)C(=O)O;NCCCC(N)C(O)=O
OROTIC-ACID,OROTIC-ACID,,BRD:BRD-BRD-K32572029-001-04-4;BRD:BRD-K32572029-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,,DHODH,,,PHASE 2,,,NA,,OC(=O)C1CC(=O)[NH]C(=O)[NH]1
ORPHENADRINE,ORPHENADRINE,CHEMBL900,BRD:BRD-A53576514-048-14-3;BRD:BRD-BRD-A53576514-048-14-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,GRIN1;GRIN2D;GRIN3A;GRIN3B;HRH1;SCN10A;SLC6A2,MUSCLE PAIN,,LAUNCHED,,Small molecule,Approved,QVYRGXJJSLMXQH-UHFFFAOYSA-N,CC1CCCCC1C(OCCN(C)C)C1CCCCC1;CN(C)CCOC(C1CCCCC1)C1CCCCC1C
ORTERONEL,ORTERONEL,CHEMBL1921976,BRD:BRD-BRD-K00674894-001-01-4;BRD:BRD-K00674894-001-01-4,rep_primary;rep_single_dose,"ANDROGEN BIOSYNTHESIS INHIBITOR, ANDROGEN RECEPTOR ANTAGONIST, CYTOCHROME P450 INHIBITOR",CYP17A1,,,PHASE 3,,Small molecule,Phase 3,OZPFIJIOIVJZMN-SFHVURJKSA-N,CNC(=O)C1CCC2CC([C@@]3(O)CCN4CNCC43)CCC2C1;CNC(=O)C1CCC2CC(CCC2C1)[C@]1(O)CCN2CNCC12
ORY-1001,ORY-1001,,BRD:BRD-BRD-K59711701-300-02-1;BRD:BRD-K59711701-300-02-1,rep_primary;rep_single_dose,HISTONE LYSINE DEMETHYLASE INHIBITOR,KDM1A,,,PHASE 1/PHASE 2,,,NA,,NC1CCC(CC1)N[C@@H]1C[C@H]1C1CCCCC1
OSELTAMIVIR-CARBOXYLATE,OSELTAMIVIR-CARBOXYLATE,,BRD:BRD-BRD-K93767137-001-01-1;BRD:BRD-K93767137-001-01-1,rep_primary;rep_single_dose,NEURAMINIDASE INHIBITOR,,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,,NA,,CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O
OSELTAMIVIR-PHOSPHATE,OSELTAMIVIR-PHOSPHATE,,BRD:BRD-BRD-K76011241-001-01-8;BRD:BRD-K76011241-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,NEURAMINIDASE INHIBITOR,CES1;NEU1;NEU2,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,,NA,,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
OSEMOZOTAN,OSEMOZOTAN,CHEMBL1742408,BRD:BRD-BRD-K60371362-001-01-7;BRD:BRD-K60371362-001-01-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,MEEQBDCQPIZMLY-HNNXBMFYSA-N,C(CNC[C@H]1COC2CCCCC2O1)COC1CCC2OCOC2C1;C1CCC2C(C1)OC[C@H](CNCCCOC1CCC3C(C1)OCO3)O2
OSI 930 OSI930,OSI 930 OSI930,,GDSC1:298,gdsc,,,,,,,,NA,,
OSI-027,OSI-027,CHEMBL3120215,BRD:BRD-BRD-K87124298-001-03-4;BRD:BRD-K87124298-001-03-4;CTRP:660433;GDSC1:299;GDSC2:1594,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PHASE 1,,Small molecule,Phase 2,JROFGZPOBKIAEW-HAQNSBGRSA-N,COC1CCCC2CC(-C3NC([C@H]4CC[C@H](C(=O)O)CC4)N4NCNC(N)C34)[NH]C12;COC1CCCC2CC([NH]C12)-C1NC([C@H]2CC[C@@H](CC2)C(O)=O)N2NCNC(N)C12
OSI-420,OSI-420,,BRD:BRD-BRD-K73309154-003-02-8;BRD:BRD-K73309154-003-02-8,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,COCCOC1CC2NCNC(NC3CCCC(C3)C#C)C2CC1OCCO
OSI-906,OSI-906,CHEMBL1091644,GDSC1:185;GDSC2:1510,gdsc,,,,,,,Small molecule,Phase 3,PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@]1(O)C[C@@H](C2NC(-C3CCC4CCC(-C5CCCCC5)NC4C3)C3C(N)NCCN32)C1
OSI-930,OSI-930,CHEMBL1614710,BRD:BRD-BRD-K25340465-001-11-1;BRD:BRD-K25340465-001-11-1;CTRP:628620;GDSC1:298,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, VEGFR INHIBITOR",FLT1;KDR;KIT,,,PHASE 1,"Multiple values for repurposing_target: {'KDR;KIT', 'FLT1;KDR;KIT'}, taking the union",Small molecule,Phase 1,FGTCROZDHDSNIO-UHFFFAOYSA-N,FC(F)(F)OC1CCC(NC(=O)C2SCCC2NCC2CCNC3CCCCC23)CC1;O=C(NC1CCC(OC(F)(F)F)CC1)C1SCCC1NCC1CCNC2CCCCC12
OSILODROSTAT,OSILODROSTAT,CHEMBL3099695,BRD:BRD-K00003210-001-01-9,rep_single_dose,CYTOCHROME P450 INHIBITOR,,,,,,Small molecule,Approved,USUZGMWDZDXMDG-CYBMUJFWSA-N,N#CC1CCC([C@H]2CCC3CNCN32)C(F)C1
OSIMERTINIB,OSIMERTINIB,CHEMBL3353410,BRD:BRD-BRD-K42805893-001-04-9;BRD:BRD-K42805893-001-04-9;GDSC2:1919,gdsc;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,,Small molecule,Approved,DUYJMQONPNNFPI-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCCC(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C;COC1CC(N(C)CCN(C)C)C(NC(=O)C=C)CC1NC1NCCC(N1)-C1CN(C)C2CCCCC12
OSPEMIFENE,OSPEMIFENE,CHEMBL2105395,BRD:BRD-BRD-K44184170-001-01-7;BRD:BRD-K44184170-001-01-7,rep_primary;rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),ESR1;ESR2,"VAGINAL ATROPHY, DYSPAREUNIA, MENOPAUSE",,LAUNCHED,,Small molecule,Approved,LUMKNAVTFCDUIE-VHXPQNKSSA-N,OCCOC1CCC(/C(=C(/CCCL)C2CCCCC2)C2CCCCC2)CC1;OCCOC1CCC(CC1)C(\C1CCCCC1)=C(\CCCL)C1CCCCC1
OSTARINE,OSTARINE,CHEMBL1738889,BRD:BRD-BRD-K29735307-001-02-9;BRD:BRD-K29735307-001-02-9,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 3,,Small molecule,Phase 3,JNGVJMBLXIUVRD-SFHVURJKSA-N,C[C@](O)(COC1CCC(C#N)CC1)C(=O)NC1CCC(C#N)C(C(F)(F)F)C1;C[C@](O)(COC1CCC(CC1)C#N)C(=O)NC1CCC(C#N)C(C1)C(F)(F)F
OSTHOL,OSTHOL,,BRD:BRD-BRD-K78294846-001-12-4;BRD:BRD-K78294846-001-12-4,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,COC1CCC2CCC(=O)OC2C1CC=C(C)C
OSU 03012,OSU 03012,,GDSC1:167,gdsc,,,,,,,,NA,,
OSU-03012,OSU-03012,CHEMBL1650595,GDSC1:167,gdsc,,,,,,,Small molecule,Phase 1,YULUCECVQOCQFQ-UHFFFAOYSA-N,NCC(=O)NC1CCC(-N2NC(C(F)(F)F)CC2-C2CCC3C(CCC4CCCCC43)C2)CC1
OSU03012,OSU03012,,GDSC1:167,gdsc,,,,,,,,NA,,
OT-R-ANTAGONIST-1,OT-R-ANTAGONIST-1,,BRD:BRD-BRD-K42009284-001-01-1;BRD:BRD-K42009284-001-01-1,rep_primary;rep_single_dose,OXYTOCIN RECEPTOR ANTAGONIST,AVPR1A;OXTR,,,PRECLINICAL,,,NA,,CO\N=C1\C[C@H](N(C1)C(=O)C1CCC(CC1)-C1CCCCC1C)C(=O)NC[C@@H](O)C1CCCCC1
OTAMIXABAN,OTAMIXABAN,CHEMBL46618,BRD:BRD-BRD-K80082640-001-01-0;BRD:BRD-K80082640-001-01-0,rep_primary;rep_single_dose,COAGULATION FACTOR INHIBITOR,F10,,,PHASE 3,,Small molecule,Phase 3,PFGVNLZDWRZPJW-OPAMFIHVSA-N,COC(=O)[C@H](CC1CCCC(C(=N)N)C1)[C@@H](C)NC(=O)C1CCC(-C2CC[N+]([O-])CC2)CC1;COC(=O)[C@H](CC1CCCC(C1)C(N)=N)[C@@H](C)NC(=O)C1CCC(CC1)-C1CC[N+]([O-])CC1
OTENZEPAD,OTENZEPAD,CHEMBL17045,BRD:BRD-A00520476-001-07-4;BRD:BRD-BRD-A00520476-001-07-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,,,PHASE 3,,Small molecule,Unknown,UBRKDAVQCKZSPO-UHFFFAOYSA-N,CCN(CC)CC1CCCCN1CC(=O)N1C2CCCCC2C(=O)NC2CCCNC12;CCN(CC)CC1CCCCN1CC(=O)N1C2CCCCC2C(=O)NC2CCCNC21
OTESECONAZOLE,OTESECONAZOLE,CHEMBL3311228,BRD:BRD-K00077023-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,IDUYJRXRDSPPRC-NRFANRHFSA-N,O[C@@](CN1CNNN1)(C1CCC(F)CC1F)C(F)(F)C1CCC(-C2CCC(OCC(F)(F)F)CC2)CN1
OTILONIUM,OTILONIUM,CHEMBL1433361,BRD:BRD-BRD-K85337334-004-02-6;BRD:BRD-K85337334-004-02-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CACNA1C,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Phase 3,NQHNLNLJPDMBFN-UHFFFAOYSA-O,CCCCCCCCOC1CCCCC1C(=O)NC1CCC(C(=O)OCC[N+](C)(CC)CC)CC1;CCCCCCCCOC1CCCCC1C(=O)NC1CCC(CC1)C(=O)OCC[N+](C)(CC)CC
OTS167,OTS167,,BRD:BRD-BRD-K53417444-003-03-1;BRD:BRD-K53417444-003-03-1,rep_multi_dose;rep_primary;rep_single_dose,MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE INHIBITOR,MELK,,,PHASE 1,,,NA,,CN(C)C[C@H]1CC[C@@H](CC1)NC1C(CNC2CCC(NC12)-C1CC(CL)C(O)C(CL)C1)C(C)=O
OTS514,OTS514,,BRD:BRD-K38018935-001-01-1,rep_single_dose,TOPK INHIBITOR,,,,,,,NA,,
OTX-015,OTX-015,CHEMBL3581647,GDSC2:1626,gdsc,,,,,,,Small molecule,Phase 2,GNMUEVRJHCWKTO-FQEVSTJZSA-N,CC1SC2C(C1C)C(C1CCC(CL)CC1)=N[C@@H](CC(=O)NC1CCC(O)CC1)C1NNC(C)N1-2
OTX015,OTX015,CHEMBL3581647,BRD:BRD-BRD-K43471985-001-03-0;BRD:BRD-BRD-K43471985-001-05-5;BRD:BRD-K43471985-001-03-0;BRD:BRD-K43471985-001-05-5;GDSC2:1626,gdsc;rep_multi_dose;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD2;BRD3;BRD4,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,GNMUEVRJHCWKTO-FQEVSTJZSA-N,CC1SC-2C(C1C)C(=N[C@@H](CC(=O)NC1CCC(O)CC1)C1NNC(C)N-21)C1CCC(CL)CC1;CC1SC2C(C1C)C(C1CCC(CL)CC1)=N[C@@H](CC(=O)NC1CCC(O)CC1)C1NNC(C)N1-2
OUABAIN,OUABAIN,CHEMBL1889436;CHEMBL222863,BRD:BRD-BRD-K33277808-331-01-3;BRD:BRD-K33277808-331-01-3;CTRP:37190,ctrp;rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP1A1,"HYPERTENSION, CARDIAC ARRYTHMIA",,LAUNCHED,,Small molecule,Approved,LPMXVESGRSUGHW-HBYQJFLCSA-N;TYBARJRCFHUHSN-DMJRSANLSA-N,C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O;C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O;C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O.O.O.O.O.O.O.O.O
OXA-06,OXA-06,,BRD:BRD-BRD-K98736329-300-01-5;BRD:BRD-K98736329-300-01-5,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1;ROCK2,,,PRECLINICAL,,,NA,,FC1CCCCC1CNCC1CCC(CC1)-C1CCNC2[NH]CCC12
OXACEPROL,OXACEPROL,CHEMBL1407356;CHEMBL2105621,BRD:BRD-K65230684-001-06-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Unknown,BAPRUDZDYCKSOQ-GDVGLLTNSA-N;BAPRUDZDYCKSOQ-RITPCOANSA-N,CC(=O)N1C[C@H](O)C[C@H]1C(=O)O;CC(=O)N1CC(O)C[C@H]1C(=O)O
OXACILLIN,OXACILLIN,CHEMBL819,BRD:BRD-BRD-K96786677-236-02-4;BRD:BRD-BRD-K96786677-323-02-0;BRD:BRD-K96786677-236-02-4;BRD:BRD-K96786677-323-02-0,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,STAPHYLOCOCCAL INFECTIONS,,LAUNCHED,,Small molecule,Approved,UWYHMGVUTGAWSP-JKIFEVAISA-N,CC1ONC(-C2CCCCC2)C1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O;CC1ONC(C1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-C1CCCCC1
OXALIPLATIN,OXALIPLATIN,CHEMBL414804,BRD:BRD-BRD-K78960041-001-03-2;BRD:BRD-BRD-K78960041-001-05-7;BRD:BRD-K78960041-001-03-2;BRD:BRD-K78960041-001-05-7;CTRP:375582;GDSC2:1089;GDSC2:1806,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,COLORECTAL CANCER,,LAUNCHED,,Small molecule,Approved,,O=C1O[PT]2(N[C@@H]3CCCC[C@H]3N2)OC1=O
OXALOACETATE,OXALOACETATE,CHEMBL1794791,BRD:BRD-BRD-K61279411-001-02-0;BRD:BRD-K61279411-001-02-0,rep_primary;rep_single_dose,GLUTAMATE RELEASE INHIBITOR,CS;SPR,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,KHPXUQMNIQBQEV-UHFFFAOYSA-N,O=C(O)CC(=O)C(=O)O;OC(=O)CC(=O)C(O)=O
OXAMNIQUINE,OXAMNIQUINE,CHEMBL847,BRD:BRD-A04843135-001-09-9,rep_single_dose,,,,,,,Small molecule,Approved,XCGYUJZMCCFSRP-UHFFFAOYSA-N,CC(C)NCC1CCC2CC(CO)C([N+](=O)[O-])CC2N1
OXANDROLONE,OXANDROLONE,CHEMBL1200436,BRD:BRD-BRD-K92467929-001-01-1;BRD:BRD-K92467929-001-01-1,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,WEIGHT-GAIN AID,,LAUNCHED,,Small molecule,Approved,QSLJIVKCVHQPLV-PEMPUTJUSA-N,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C;C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
OXAPROZIN,OXAPROZIN,CHEMBL1071,BRD:BRD-BRD-K25394294-001-14-9;BRD:BRD-K25394294-001-14-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,OFPXSFXSNFPTHF-UHFFFAOYSA-N,O=C(O)CCC1NC(-C2CCCCC2)C(-C2CCCCC2)O1;OC(=O)CCC1NC(C(O1)-C1CCCCC1)-C1CCCCC1
OXATOMIDE,OXATOMIDE,CHEMBL13828,BRD:BRD-BRD-K02079473-001-01-3;BRD:BRD-K02079473-001-01-3,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,BAINIUMDFURPJM-UHFFFAOYSA-N,O=C1[NH]C2CCCCC2N1CCCN1CCN(C(C2CCCCC2)C2CCCCC2)CC1;O=C1[NH]C2CCCCC2N1CCCN1CCN(CC1)C(C1CCCCC1)C1CCCCC1
OXAZEPAM,OXAZEPAM,CHEMBL568,BRD:BRD-A50049929-001-01-9;BRD:BRD-BRD-A50049929-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GABRR1;GABRR2;GABRR3,ANXIETY,,LAUNCHED,,Small molecule,Approved,ADIMAYPTOBDMTL-UHFFFAOYSA-N,O=C1NC2CCC(CL)CC2C(C2CCCCC2)=NC1O;OC1N=C(C2CCCCC2)C2CC(CL)CCC2NC1=O
OXCARBAZEPINE,OXCARBAZEPINE,CHEMBL1068,BRD:BRD-BRD-K04196797-001-24-4;BRD:BRD-K04196797-001-24-4,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,CTRLABGOLIVAIY-UHFFFAOYSA-N,NC(=O)N1C2CCCCC2CC(=O)C2CCCCC12;NC(=O)N1C2CCCCC2CC(=O)C2CCCCC21
OXELAIDIN,OXELAIDIN,,BRD:BRD-BRD-K17977438-048-02-4;BRD:BRD-K17977438-048-02-4,rep_primary;rep_single_dose,ANTITUSSIVE,,COUGH SUPPRESSANT,,LAUNCHED,,,NA,,CCN(CC)CCOCCOC(=O)C(CC)(CC)C1CCCCC1
OXETHAZAINE,OXETHAZAINE,CHEMBL127592,BRD:BRD-BRD-K56940463-001-13-8;BRD:BRD-K56940463-001-13-8,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Phase 3,FTLDJPRFCGDUFH-UHFFFAOYSA-N,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1CCCCC1)C(C)(C)CC1CCCCC1
OXF-BD-02,OXF-BD-02,,BRD:BRD-A73891132-001-02-9,rep_single_dose,BROMODOMAIN INHIBITOR,BRD4,,,,,,NA,,
OXFENDAZOLE,OXFENDAZOLE,CHEMBL42442,BRD:BRD-A33447119-001-10-8;BRD:BRD-BRD-A33447119-001-10-8,rep_primary;rep_single_dose,ANTHELMINTIC AGENT,,"LUNGWORMS, TAPEWORM, GASTROINTESTINAL ROUNDWORMS",,LAUNCHED,,Small molecule,Phase 2,BEZZFPOZAYTVHN-UHFFFAOYSA-N,COC(=O)NC1NC2CC([S+]([O-])C3CCCCC3)CCC2[NH]1;COC(=O)NC1NC2CCC(CC2[NH]1)S(=O)C1CCCCC1
OXFENICINE,OXFENICINE,CHEMBL1232077,BRD:BRD-A86525947-001-01-4;BRD:BRD-BRD-A86525947-001-01-4,rep_primary;rep_single_dose,CARNITINE PALMITOYLTRANSFERASE INHIBITOR,CPT1A;CPT1B,,,PHASE 1,,Small molecule,Unknown,LJCWONGJFPCTTL-ZETCQYMHSA-N,N[C@@H](C(O)=O)C1CCC(O)CC1;N[C@H](C(=O)O)C1CCC(O)CC1;NC(C(O)=O)C1CCC(O)CC1
OXIBENDAZOLE,OXIBENDAZOLE,CHEMBL1087630,BRD:BRD-BRD-K52075715-001-06-7;BRD:BRD-K52075715-001-06-7,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB;TUBB4B,STRONGYLES,,LAUNCHED,,Small molecule,Unknown,RAOCRURYZCVHMG-UHFFFAOYSA-N,CCCOC1CCC2[NH]C(NC(=O)OC)NC2C1;CCCOC1CCC2NC(NC(=O)OC)[NH]C2C1
OXICONAZOLE,OXICONAZOLE,CHEMBL1262,BRD:BRD-BRD-K56104152-008-04-1;BRD:BRD-K56104152-008-04-1,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,QRJJEGAJXVEBNE-HKOYGPOVSA-N,CLC1CCC(CO/N=C(\CN2CCNC2)C2CCC(CL)CC2CL)C(CL)C1;CLC1CCC(CO\N=C(/CN2CCNC2)C2CCC(CL)CC2CL)C(CL)C1
OXINIACIC-ACID,OXINIACIC-ACID,,BRD:BRD-BRD-K20417253-001-01-9;BRD:BRD-K20417253-001-01-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)C1CCC[N+]([O-])C1
OXIPEROMIDE,OXIPEROMIDE,CHEMBL2059304,BRD:BRD-BRD-K78096648-001-05-7;BRD:BRD-K78096648-001-05-7,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,PHASE 2,,Small molecule,Unknown,NVDBBGBUTKLRSN-UHFFFAOYSA-N,O=C1[NH]C2CCCCC2N1C1CCN(CCOC2CCCCC2)CC1;OC1NC2CCCCC2N1C1CCN(CCOC2CCCCC2)CC1
OXIRACETAM,OXIRACETAM,CHEMBL36633,BRD:BRD-BRD-K50677762-001-01-5;BRD:BRD-K50677762-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,LAUNCHED,,Small molecule,Phase 2,IHLAQQPQKRMGSS-UHFFFAOYSA-N,NC(=O)CN1C[C@H](O)CC1=O;NC(=O)CN1CC(O)CC1=O
OXOLINIC-ACID,OXOLINIC-ACID,,BRD:BRD-BRD-K73394555-237-01-1;BRD:BRD-K73394555-237-01-1,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCN1CC(C(O)=O)C(=O)C2CC3OCOC3CC12
OXONIC-ACID,OXONIC-ACID,,BRD:BRD-BRD-K31468676-237-01-8;BRD:BRD-K31468676-237-01-8,rep_multi_dose;rep_primary;rep_single_dose,URICASE INHIBITOR,,,,PRECLINICAL,,,NA,,OC(=O)C1NC(=O)[NH]C(=O)[NH]1
OXOTREMORINE-M,OXOTREMORINE-M,,BRD:BRD-BRD-K01942991-005-08-2;BRD:BRD-K01942991-005-08-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4,,,PRECLINICAL,,,NA,,C[N+](C)(C)CC#CCN1CCCC1=O
OXPRENOLOL,OXPRENOLOL,CHEMBL546,BRD:BRD-A43671941-003-11-9;BRD:BRD-BRD-A43671941-003-11-9,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,"ANGINA PECTORIS, HYPERTENSION, CARDIAC ARRYTHMIA",,LAUNCHED,,Small molecule,Approved,CEMAWMOMDPGJMB-UHFFFAOYSA-N,C=CCOC1CCCCC1OCC(O)CNC(C)C;CC(C)NCC(O)COC1CCCCC1OCC=C
OXYBENZONE,OXYBENZONE,CHEMBL1625,BRD:BRD-BRD-K59037100-001-14-7;BRD:BRD-K59037100-001-14-7,rep_primary;rep_single_dose,LIPASE INHIBITOR,LIPE,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Approved,DXGLGDHPHMLXJC-UHFFFAOYSA-N,COC1CCC(C(=O)C2CCCCC2)C(O)C1
OXYBUPROCAINE,OXYBUPROCAINE,CHEMBL1200,BRD:BRD-BRD-K04185004-003-11-9;BRD:BRD-K04185004-003-11-9,rep_primary;rep_single_dose,LOCAL ANESTHETIC,SCN10A,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Approved,CMHHMUWAYWTMGS-UHFFFAOYSA-N,CCCCOC1CC(C(=O)OCCN(CC)CC)CCC1N;CCCCOC1CC(CCC1N)C(=O)OCCN(CC)CC
OXYBUTYNIN,OXYBUTYNIN,CHEMBL1231;CHEMBL1394756;CHEMBL185434,BRD:BRD-A65013509-003-24-4;BRD:BRD-BRD-A65013509-003-24-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,URINARY INCONTINENCE,,LAUNCHED,,Small molecule,Approved,XIQVNETUBQGFHX-JOCHJYFZSA-N;XIQVNETUBQGFHX-QFIPXVFZSA-N;XIQVNETUBQGFHX-UHFFFAOYSA-N,CCN(CC)CC#CCOC(=O)[C@](O)(C1CCCCC1)C1CCCCC1;CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)C1CCCCC1;CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1CCCCC1
OXYCLOZANIDE,OXYCLOZANIDE,CHEMBL2105450,BRD:BRD-BRD-K07283971-001-01-3;BRD:BRD-K07283971-001-01-3,rep_primary;rep_single_dose,,,FASCIOLIASIS,,LAUNCHED,,Small molecule,Unknown,JYWIYHUXVMAGLG-UHFFFAOYSA-N,O=C(NC1CC(CL)CC(CL)C1O)C1C(O)C(CL)CC(CL)C1CL;OC1C(CL)CC(CL)CC1NC(=O)C1C(O)C(CL)CC(CL)C1CL
OXYFEDRINE,OXYFEDRINE,CHEMBL1651913,BRD:BRD-BRD-K73027814-003-01-0;BRD:BRD-K73027814-003-01-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Unknown,GDYUVHBMFVMBAF-LIRRHRJNSA-N,COC1CCCC(C(=O)CCN[C@@H](C)[C@H](O)C2CCCCC2)C1;COC1CCCC(C1)C(=O)CCN[C@@H](C)[C@H](O)C1CCCCC1
OXYMATRINE,OXYMATRINE,CHEMBL458337,BRD:BRD-A57833392-001-01-7;BRD:BRD-BRD-A57833392-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,XVPBINOPNYFXID-LHDUFFHYSA-N,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23;O=C1CCC[C@@H]2[C@H]3CCC[N+]4([O-])CCC[C@@H](CN12)[C@@H]34
OXYMETAZOLINE,OXYMETAZOLINE,CHEMBL762,BRD:BRD-BRD-K16195444-003-26-0;BRD:BRD-K16195444-003-26-0,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;HTR1B;HTR1D;HTR2C,NASAL CONGESTION,,LAUNCHED,,Small molecule,Approved,WYWIFABBXFUGLM-UHFFFAOYSA-N,CC1CC(C(C)(C)C)C(O)C(C)C1CC1=NCCN1;CC1CC(C(O)C(C)C1CC1=NCCN1)C(C)(C)C
OXYPHENCYCLIMINE,OXYPHENCYCLIMINE,CHEMBL1495,BRD:BRD-A58193911-003-18-7;BRD:BRD-BRD-A58193911-003-18-7,rep_multi_dose;rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,DUDKAZCAISNGQN-UHFFFAOYSA-N,CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1CCCCC1
OXYPHENISATIN ACETATE,OXYPHENISATIN ACETATE,CHEMBL1402684,GDSC2:1804,gdsc,,,,,,,Small molecule,Approved,PHPUXYRXPHEJDF-UHFFFAOYSA-N,CC(=O)OC1CCC(C2(C3CCC(OC(C)=O)CC3)C(=O)NC3CCCCC32)CC1
OXYPHENONIUM,OXYPHENONIUM,CHEMBL1201286,BRD:BRD-A14208071-004-19-8;BRD:BRD-BRD-A14208071-004-19-8,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM3,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,"Multiple values for repurposing_target: {'CHRM1;CHRM3', 'CHRM1'}, taking the union",Small molecule,Approved,GFRUPHOKLBPHTQ-UHFFFAOYSA-N,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1CCCCC1
OXYPURINOL,OXYPURINOL,CHEMBL859,BRD:BRD-BRD-K31841515-001-07-8;BRD:BRD-K31841515-001-07-8,rep_primary;rep_single_dose,XANTHINE OXIDASE INHIBITOR,XDH,,,PHASE 2/PHASE 3,,Small molecule,Approved,HXNFUBHNUDHIGC-UHFFFAOYSA-N,O=C1[NH]C2N[NH]CC2C(=O)[NH]1;OC1NC(O)C2CN[NH]C2N1
OXYQUINOLINE,OXYQUINOLINE,CHEMBL310555,BRD:BRD-BRD-K66808046-065-03-7;BRD:BRD-K66808046-065-03-7,rep_multi_dose;rep_primary;rep_single_dose,CHELATING AGENT,METAP2,COSMETIC,,LAUNCHED,,Small molecule,Unknown,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OC1CCCC2CCCNC12
OXYTOCIN,OXYTOCIN,CHEMBL2104384;CHEMBL395429;CHEMBL435716,BRD:BRD-BRD-K25243230-001-01-2;BRD:BRD-K25243230-001-01-2,rep_primary;rep_single_dose,OXYTOCIN RECEPTOR AGONIST,AVPR1A;AVPR1B;AVPR2;OXTR,LABOR INDUCTION,,LAUNCHED,,Protein,Approved,GTYWGUNQAMYZPF-FAJKJHJLSA-N;VIFAMMRBZBWEID-VQWBKVQXSA-N;XNOPRXBHLZRZKH-DSZYJQQASA-N,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCC(O)CC2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC1=O;CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCC(O)CC2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O;CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCC(O)CC2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O;CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCC(O)CC2)NC(=O)CCSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
OZAGREL,OZAGREL,CHEMBL11662,BRD:BRD-BRD-K53061490-003-13-9;BRD:BRD-K53061490-003-13-9,rep_primary;rep_single_dose,THROMBOXANE SYNTHASE INHIBITOR,TBXAS1,STROKE,,LAUNCHED,,Small molecule,Phase 3,SHZKQBHERIJWAO-AATRIKPKSA-N,O=C(O)/C=C/C1CCC(CN2CCNC2)CC1;OC(=O)\C=C\C1CCC(CN2CCNC2)CC1
OZANIMOD,OZANIMOD,CHEMBL3707247,BRD:BRD-BRD-K46625559-001-01-8;BRD:BRD-K46625559-001-01-8,rep_primary;rep_single_dose,"SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST",S1PR1,,,PHASE 3,"Multiple values for MOA: {'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST', 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'}, defaulting to 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'",Small molecule,Approved,XRVDGNKRPOAQTN-FQEVSTJZSA-N,CC(C)OC1CCC(-C2NC(-C3CCCC4C3CC[C@@H]4NCCO)NO2)CC1C#N;CC(C)OC1CCC(CC1C#N)-C1NC(NO1)-C1CCCC2[C@H](CCC12)NCCO
OZENOXACIN,OZENOXACIN,CHEMBL3990047,BRD:BRD-K00003184-001-01-9,rep_single_dose,ANTIINFECTIVE DRUG,,,,,,Small molecule,Approved,XPIJWUTXQAGSLK-UHFFFAOYSA-N,CNC1NCC(-C2CCC3C(=O)C(C(=O)O)CN(C4CC4)C3C2C)CC1C
OZOLINONE,OZOLINONE,CHEMBL3989840,BRD:BRD-A72297358-001-01-8;BRD:BRD-BRD-A72297358-001-01-8,rep_primary;rep_single_dose,DIURETIC,,,,PHASE 3,,Small molecule,Unknown,NQFBZYYUAFJYNS-FPLPWBNLSA-N,CN1C(=O)C(N2CCCCC2)S/C1=C\C(=O)O;CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1
P 22077,P 22077,,GDSC2:1933,gdsc,,,,,,,,NA,,
P-22077,P-22077,,GDSC2:1933,gdsc,,,,,,,,NA,,
P22077,P22077,,BRD:BRD-BRD-K97714174-001-01-3;BRD:BRD-K97714174-001-01-3;GDSC2:1933,gdsc;rep_multi_dose;rep_primary;rep_single_dose,UBIQUITIN SPECIFIC PROTEASE INHIBITOR,USP7,,,PRECLINICAL,,,NA,,CC(=O)C1CC(C(SC2CCC(F)CC2F)S1)[N+]([O-])=O
P276-00,P276-00,CHEMBL3545283,BRD:BRD-BRD-K51791723-003-01-7;BRD:BRD-K51791723-003-01-7,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK4;CDK9,,,PHASE 2,,Small molecule,Phase 2,QLUYMIVVAYRECT-UHFFFAOYSA-N,CN1CC[C@H]([C@@H]1CO)C1C(O)CC(O)C2C1OC(CC2=O)-C1CCCCC1CL;CN1CCC(C2C(O)CC(O)C3C(=O)CC(-C4CCCCC4CL)OC23)C1CO
P505-15,P505-15,CHEMBL3545138,GDSC2:1631,gdsc,,,,,,,Small molecule,Phase 1,,
P5091,P5091,,BRD:BRD-BRD-K13606314-001-01-3;BRD:BRD-K13606314-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,UBIQUITIN SPECIFIC PROTEASE INHIBITOR,USP7,,,PRECLINICAL,,,NA,,CC(=O)C1CC(C(SC2CCCC(CL)C2CL)S1)[N+]([O-])=O
P7C3,P7C3,,BRD:BRD-A09487507-001-03-9,rep_single_dose,NAMPT INHIBITOR,NAMPT,,,,,,NA,,
PA-452,PA-452,,BRD:BRD-BRD-K11428250-001-01-0;BRD:BRD-K11428250-001-01-0,rep_primary;rep_single_dose,RETINOID RECEPTOR ANTAGONIST,RXRA,,,PRECLINICAL,,,NA,,CCCCCCOC1CC2C(CC1N(C)C1NCC(CN1)C(O)=O)C(C)(C)CCC2(C)C
PRETOMANID,PA-824;PRETOMANID,CHEMBL227875,BRD:BRD-BRD-K96671969-001-03-1;BRD:BRD-K96671969-001-03-1,rep_primary;rep_single_dose,NITRIC OXIDE DONOR,FASN,,,PHASE 3,,Small molecule,Approved,ZLHZLMOSPGACSZ-NSHDSACASA-N,[O-][N+](=O)C1CN2C[C@@H](COC2N1)OCC1CCC(OC(F)(F)F)CC1;O=[N+]([O-])C1CN2C(N1)OC[C@@H](OCC1CCC(OC(F)(F)F)CC1)C2
PAC-1,PAC-1,CHEMBL591429,BRD:BRD-BRD-K92991072-001-04-9;BRD:BRD-K92991072-001-04-9;CTRP:411832;GDSC1:175,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,CASPASE ACTIVATOR,CASP3,,,PHASE 1,,Small molecule,Phase 1,YQNRVGJCPCNMKT-LFVJCYFKSA-N,C=CCC1CCCC(/C=N/NC(=O)CN2CCN(CC3CCCCC3)CC2)C1O;OC1C(CC=C)CCCC1\C=N\NC(=O)CN1CCN(CC2CCCCC2)CC1
PACLITAXEL,PACLITAXEL,CHEMBL428647,BRD:BRD-BRD-K62008436-001-22-1;BRD:BRD-K62008436-001-22-1;BRD:BRD-K62008436-001-23-9;BRD:BRD-U00115290-001-01-9;CTRP:26956;GDSC1:11;GDSC2:1080,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF MICROTUBULE ASSEMBLY,BCL2;MAP2;MAP4;MAPT;NR1I2;TLR4;TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,"OVARIAN CANCER, BREAST CANCER, NON-SMALL CELL LUNG CANCER (NSCLC)",,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF MICROTUBULE ASSEMBLY', 'TUBULIN POLYMERIZATION INHIBITOR'}, defaulting to 'INHIBITOR OF MICROTUBULE ASSEMBLY'
Multiple values for repurposing_target: {'BCL2;MAP2;MAP4;MAPT;NR1I2;TLR4;TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8', 'TUBB'}, taking the union
Multiple values for repurposing_target: {'BCL2;MAP2;MAP4;MAPT;NR1I2;TLR4;TUBB;TUBB1', 'BCL2;MAP2;MAP4;MAPT;NR1I2;TLR4;TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8'}, taking the union
Multiple values for structure_id: {'U00115290', 'K62008436'}, defaulting to None",Small molecule,Approved,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3CCCCC3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1CCCCC1)C1CCCCC1;CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)C3CCCCC3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4CCCCC4)C4CCCCC4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
PACOCF3,PACOCF3,,BRD:BRD-BRD-K05677083-001-05-4;BRD:BRD-K05677083-001-05-4,rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLA2G4A,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCCCCC(=O)C(F)(F)F
SB1518,PACRITINIB;SB1518,CHEMBL2035187,BRD:BRD-BRD-K19034817-001-01-4;BRD:BRD-K19034817-001-01-4;BRD:BRD-K19034817-001-08-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, JAK INHIBITOR",FLT3;JAK1;JAK2;JAK3,,,PHASE 3,"Multiple values for MOA: {'FLT3 INHIBITOR, JAK INHIBITOR', 'INHIBITOR OF JAK2 AND FLT3'}, defaulting to 'FLT3 INHIBITOR, JAK INHIBITOR'
Multiple values for repurposing_target: {'FLT3;JAK1;JAK2;JAK3', 'FLT3;JAK2'}, taking the union",Small molecule,Approved,HWXVIOGONBBTBY-ONEGZZNKSA-N,C(CN1CCCC1)OC1CCC2NC3NCCC(N3)-C3CCCC(COC\C=C\COCC1C2)C3;C1=N/C2=N/C3CCC(OCCN4CCCC4)C(C3)COC/C=C/COCC3CCCC(C3)C(=C1)N2
PADSEVONIL,PADSEVONIL,CHEMBL4297521,BRD:BRD-K00003493-001-01-9,rep_single_dose,ANTIEPILEPTIC,,,,,,Small molecule,Phase 3,DCXFIOLWWRXEQH-SSDOTTSWSA-N,COCC1NN2C(CN3C[C@@H](CC(F)(F)CL)CC3=O)C(C(F)(F)F)NC2S1
PAEONIFLORIN,PAEONIFLORIN,CHEMBL1078549,BRD:BRD-K83631119-001-04-9,rep_single_dose,ANTICONVULSANT,,,,,,Small molecule,Phase 3,YKRGDOXKVOZESV-QYDSDWLYSA-N,C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)C4CCCCC4)[C@@H]3C[C@]12O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
PAEONOL,PAEONOL,CHEMBL1079227,BRD:BRD-BRD-K94239562-001-05-5;BRD:BRD-K94239562-001-05-5,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,PRECLINICAL,,Small molecule,NA,UILPJVPSNHJFIK-UHFFFAOYSA-N,COC1CCC(C(C)=O)C(O)C1
PAFURAMIDINE,PAFURAMIDINE,CHEMBL319669,BRD:BRD-BRD-K68805147-001-01-8;BRD:BRD-K68805147-001-01-8,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,UKOQVLAXCBRRGH-UHFFFAOYSA-N,CONC(=N)C1CCC(-C2CCC(-C3CCC(C(=N)NOC)CC3)O2)CC1;CONC(=N)C1CCC(CC1)-C1CCC(O1)-C1CCC(CC1)C(=N)NOC
PAGOCLONE,PAGOCLONE,CHEMBL2104745,BRD:BRD-K00003428-001-01-9,rep_single_dose,GABA RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,HIUPRQPBWVEQJJ-UHFFFAOYSA-N,CC(C)CCC(=O)CC1C2CCCCC2C(=O)N1C1CCC2CCC(CL)NC2N1
PD-0332991,PALBOCICLIB;PD-0332991,CHEMBL189963,BRD:BRD-BRD-K51313569-003-03-3;BRD:BRD-K51313569-001-06-0;BRD:BRD-K51313569-001-07-8;BRD:BRD-K51313569-003-03-3;GDSC1:1054;GDSC2:1054,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF CDK4 AND CDK6,CDK4;CDK6,BREAST CANCER,,LAUNCHED,"Multiple values for MOA: {'CDK INHIBITOR', 'INHIBITOR OF CDK4 AND CDK6'}, defaulting to 'INHIBITOR OF CDK4 AND CDK6'",Small molecule,Approved,AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1C(C)C2CNC(NC3CCC(CN3)N3CCNCC3)NC2N(C2CCCC2)C1=O;CC(=O)C1C(C)C2CNC(NC3CCC(N4CCNCC4)CN3)NC2N(C2CCCC2)C1=O
PALIFOSFAMIDE,PALIFOSFAMIDE,CHEMBL889,BRD:BRD-BRD-K12047401-001-01-5;BRD:BRD-K12047401-001-01-5,rep_primary;rep_single_dose,DNA ALKYLATING AGENT,,,,PHASE 3,,Small molecule,Phase 3,BKCJZNIZRWYHBN-UHFFFAOYSA-N,O=P(O)(NCCCL)NCCCL;OP(=O)(NCCCL)NCCCL
PALIPERIDONE,PALIPERIDONE,CHEMBL1621,BRD:BRD-A99888680-001-03-8;BRD:BRD-A99888680-001-04-6;BRD:BRD-BRD-A99888680-001-03-8;BRD:BRD-BRD-A99888680-001-04-6,rep_multi_dose;rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA2A;ADRA2B;ADRA2C;CYP2D6;CYP3A4;CYP3A5;DRD1;DRD2;DRD3;DRD4;HRH1;HTR1A;HTR1D;HTR2A;HTR2C,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,PMXMIIMHBWHSKN-UHFFFAOYSA-N,CC1NC2C(O)CCCN2C(=O)C1CCN1CCC(CC1)C1NOC2CC(F)CCC12;CC1NC2N(C(=O)C1CCN1CCC(C3NOC4CC(F)CCC34)CC1)CCCC2O
PALMATINE-CHLORIDE,PALMATINE-CHLORIDE,,BRD:BRD-BRD-K58466253-003-14-0;BRD:BRD-K58466253-003-14-0,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE SYNTHESIS INHIBITOR,CYP3A4,,,PRECLINICAL,,,NA,,COC1CC2CC[N+]3CC4C(OC)C(OC)CCC4CC3-C2CC1OC
PALMITOLEIC-ACID,PALMITOLEIC-ACID,,BRD:BRD-BRD-K91356052-001-04-0;BRD:BRD-K91356052-001-04-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCC\C=C/CCCCCCCC(O)=O
PALMITOYLCARNITINE,PALMITOYLCARNITINE,,BRD:BRD-A77577770-003-08-9;BRD:BRD-BRD-A77577770-003-08-9,rep_primary;rep_single_dose,PROTEIN KINASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C
PALMITOYLETHANOLAMIDE,PALMITOYLETHANOLAMIDE,CHEMBL417675,BRD:BRD-BRD-K68095457-001-10-1;BRD:BRD-K68095457-001-10-1,rep_multi_dose;rep_primary;rep_single_dose,CANNABINOID RECEPTOR AGONIST,CNR2;GPR119;GPR55,,,LAUNCHED,,Small molecule,Phase 3,HXYVTAGFYLMHSO-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC(=O)NCCO
PALMOSTATIN B,PALMOSTATIN B,CHEMBL1673415,CTRP:679844,ctrp,,,,,,,Small molecule,NA,ASVWFAVGLYUDFD-PMACEKPBSA-N,CCCCCCCCCC[C@@H]1C(=O)O[C@H]1CCC1CCC(OC)C(OC)C1
PALOMID-529,PALOMID-529,CHEMBL2141712,BRD:BRD-A50998626-001-02-1;BRD:BRD-BRD-A50998626-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,"AKT INHIBITOR, MTOR INHIBITOR",MTOR,,,PHASE 1,,Small molecule,Phase 1,YEAHTLOYHVWAKW-UHFFFAOYSA-N,COC1CCC(COC2CC3OC(=O)C4CC(C(C)O)CCC4C3CC2OC)CC1;COC1CCC(COC2CC3OC(=O)C4CC(CCC4C3CC2OC)C(C)O)CC1
PALONOSETRON,PALONOSETRON,CHEMBL1189679,BRD:BRD-BRD-K08924299-003-06-1;BRD:BRD-K08924299-003-06-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,CPZBLNMUGSZIPR-NVXWUHKLSA-N,O=C1C2CCCC3C2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2;O=C1N(C[C@H]2CCCC3CCCC1C23)[C@@H]1CN2CCC1CC2
PALOSURAN,PALOSURAN,CHEMBL567303,BRD:BRD-BRD-K07682953-001-01-8;BRD:BRD-K07682953-001-01-8,rep_primary;rep_single_dose,UROTENSIN RECEPTOR ANTAGONIST,UTS2R,,,PHASE 2,,Small molecule,Phase 2,WYJCYXOCHXWTHG-UHFFFAOYSA-N,CC1CC(NC(=O)NCCN2CCC(O)(CC3CCCCC3)CC2)C2CCCCC2N1
PALOVAROTENE,PALOVAROTENE,CHEMBL2105648,BRD:BRD-BRD-K83794243-001-01-8;BRD:BRD-K83794243-001-01-8,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARG,,,PHASE 2,,Small molecule,Phase 3,YTFHCXIPDIHOIA-DHZHZOJOSA-N,CC1(C)CCC(C)(C)C2CC(\C=C\C3CCC(CC3)C(O)=O)C(CN3CCCN3)CC12;CC1(C)CCC(C)(C)C2CC(CN3CCCN3)C(/C=C/C3CCC(C(=O)O)CC3)CC21
PAMABROM,PAMABROM,CHEMBL2104825;CHEMBL316160,BRD:BRD-M67659203-001-02-7,rep_single_dose,DIURETIC,,,,,,Small molecule,Unknown,ATOTUUBRFJHZQG-UHFFFAOYSA-N;SKTFQHRVFFOHTQ-UHFFFAOYSA-N,CC(C)(N)CO.CN1C(=O)C2[NH]C(BR)NC2N(C)C1=O;CN1C(=O)C2[NH]C(BR)NC2N(C)C1=O
PAMICOGREL,PAMICOGREL,CHEMBL2104947,BRD:BRD-K00075290-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,ISCHOARKJADAKJ-UHFFFAOYSA-N,CCOC(=O)CN1CCCC1-C1NC(-C2CCC(OC)CC2)C(-C2CCC(OC)CC2)S1
PAMIDRONATE,PAMIDRONATE,CHEMBL834,BRD:BRD-BRD-K58513245-304-02-7;BRD:BRD-K58513245-304-02-7,rep_primary;rep_single_dose,BONE RESORPTION INHIBITOR,FDPS,"HYPERCALCEMIA, PAGET'S DISEASE, BREAST CANCER, MULTIPLE MYELOMA",,LAUNCHED,,Small molecule,Approved,WRUUGTRCQOWXEG-UHFFFAOYSA-N,NCCC(O)(P(=O)(O)O)P(=O)(O)O;NCCC(O)(P(O)(O)=O)P(O)(O)=O
PAMIPARIB,PAMIPARIB,CHEMBL4112930,BRD:BRD-K00003461-001-01-9,rep_single_dose,PARP INHIBITOR,,,,,,Small molecule,Phase 3,DENYZIUJOTUUNY-MRXNPFEDSA-N,C[C@]12CCCN1CC1=NNC(=O)C3CC(F)CC4[NH]C2C1C34
PANCURONIUM,PANCURONIUM,CHEMBL185073,BRD:BRD-BRD-K50817623-303-05-7;BRD:BRD-K50817623-303-05-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM2;CHRM3;CHRNA1;CHRNA2,"ENDOTRACHEAL INTUBATION, MUSCLE RELAXANT",,LAUNCHED,,Small molecule,Approved,GVEAYVLWDAFXET-XGHATYIMSA-N,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1;CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1
PANDACOSTAT,PANDACOSTAT,,CTRP:417098,ctrp,,,,,,,,NA,,
PANIPENEM,PANIPENEM,CHEMBL339323,BRD:BRD-K00004671-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Unknown,TYMABNNERDVXID-DLYFRVTGSA-N,CC(=N)N1CC[C@H](SC2=C(C(=O)O)N3C(=O)[C@H]([C@@H](C)O)[C@H]3C2)C1
PANOBINOSTAT,PANOBINOSTAT,CHEMBL483254,BRD:BRD-BRD-K02130563-001-11-4;BRD:BRD-K02130563-001-11-4;GDSC1:438,gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC4;HDAC6;HDAC7;HDAC8;HDAC9,MULTIPLE MYELOMA,,LAUNCHED,,Small molecule,Approved,FPOHNWQLNRZRFC-ZHACJKMWSA-N,CC1[NH]C2CCCCC2C1CCNCC1CCC(/C=C/C(=O)NO)CC1;CC1[NH]C2CCCCC2C1CCNCC1CCC(\C=C\C(=O)NO)CC1
PANTETHINE,PANTETHINE,CHEMBL2104786,BRD:BRD-BRD-K68764924-001-03-2;BRD:BRD-K68764924-001-03-2,rep_primary;rep_single_dose,COENZYME A PRECURSOR,,,,LAUNCHED,,Small molecule,Phase 3,DJWYOLJPSHDSAL-ROUUACIJSA-N,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO;CC(C)(CO)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO
PANTOPRAZOLE,PANTOPRAZOLE,CHEMBL1502,BRD:BRD-A22380646-236-05-8;BRD:BRD-BRD-A22380646-236-05-8;BRD:BRD-K00003243-236-01-9,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP4A,"GASTROESOPHAGEAL REFLUX DISEASE (GERD), EROSIVE ESOPHAGITIS (EE), ZOLLINGER-ELLISON SYNDROME",,LAUNCHED,"Multiple values for structure_id: {'K00003243', 'A22380646'}, defaulting to None",Small molecule,Approved,IQPSEEYGBUAQFF-UHFFFAOYSA-N,COC1CCNC(C[S+]([O-])C2NC3CC(OC(F)F)CCC3[NH]2)C1OC;COC1CCNC(CS(=O)C2NC3CC(OC(F)F)CCC3[NH]2)C1OC
PANTOTHENIC-ACID,PANTOTHENIC-ACID,,BRD:BRD-BRD-K29392254-001-02-2;BRD:BRD-K29392254-001-02-2,rep_primary;rep_single_dose,COENZYME A PRECURSOR,,,,LAUNCHED,,,NA,,CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O
PAOPA,PAOPA,,BRD:BRD-K18573821-001-03-9,rep_single_dose,DOPAMINE RECEPTOR MODULATOR,DRD2,,,,,,NA,,
PAPAVERINE,PAPAVERINE,CHEMBL19224,BRD:BRD-BRD-K15567136-003-27-2;BRD:BRD-K15567136-003-27-2,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE10A;PDE4B;PDE5A,"MYOCARDIAL INFARCTION, ANGINA PECTORIS, PULMONARY EMBOLISM (PE), COLITIS, VASCULAR SPASM",,LAUNCHED,,Small molecule,Approved,XQYZDYMELSJDRZ-UHFFFAOYSA-N,COC1CCC(CC2NCCC3CC(OC)C(OC)CC23)CC1OC
PAQUINIMOD,PAQUINIMOD,CHEMBL67776,BRD:BRD-K00003371-001-01-9,rep_single_dose,S100A9 INHIBITOR,,,,,,Small molecule,Phase 2,DIKSYHCCYVYKRO-UHFFFAOYSA-N,CCC1CCCC2C1C(O)C(C(=O)N(CC)C1CCCCC1)C(=O)N2C
PARA-TOLUENESULFONAMIDE,PARA-TOLUENESULFONAMIDE,CHEMBL574,BRD:BRD-BRD-K62412084-001-07-1;BRD:BRD-K62412084-001-07-1,rep_primary;rep_single_dose,,CA12;CA2;CA6;CA9,,,PHASE 3,,Small molecule,Phase 3,LMYRWZFENFIFIT-UHFFFAOYSA-N,CC1CCC(CC1)S(N)(=O)=O;CC1CCC(S(N)(=O)=O)CC1
PARACETAMOL,PARACETAMOL,CHEMBL112,BRD:BRD-BRD-K41524689-001-23-5;BRD:BRD-K41524689-001-23-5,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,FAAH;PTGS1;PTGS2;TRPV1,"PAIN RELIEF, FEVER",,LAUNCHED,,Small molecule,Approved,RZVAJINKPMORJF-UHFFFAOYSA-N,CC(=O)NC1CCC(O)CC1
PARACHLOROPHENOL,PARACHLOROPHENOL,CHEMBL57053,BRD:BRD-BRD-K40992116-001-09-7;BRD:BRD-K40992116-001-09-7,rep_multi_dose;rep_primary;rep_single_dose,ANTIINFECTIVE DRUG,,,,LAUNCHED,,Small molecule,Unknown,WXNZTHHGJRFXKQ-UHFFFAOYSA-N,OC1CCC(CL)CC1
PARAXANTHINE,PARAXANTHINE,CHEMBL1158,BRD:BRD-BRD-K24084088-001-11-3;BRD:BRD-K24084088-001-11-3,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,PHASE 1,,Small molecule,Early Phase,QUNWUDVFRNGTCO-UHFFFAOYSA-N,CN1C(=O)[NH]C2NCN(C)C2C1=O;CN1CNC2[NH]C(=O)N(C)C(=O)C12
PARBENDAZOLE,PARBENDAZOLE,CHEMBL528271,BRD:BRD-BRD-K02407574-001-09-7;BRD:BRD-K02407574-001-09-7;CTRP:28172,ctrp;rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,,,PRECLINICAL,,Small molecule,Unknown,YRWLZFXJFBZBEY-UHFFFAOYSA-N,CCCCC1CCC2[NH]C(NC(=O)OC)NC2C1
PARCETASAL,PARCETASAL,CHEMBL2105451,BRD:BRD-K00004740-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Unknown,ZAPRLADYRFPQSH-UHFFFAOYSA-N,CC(=O)NC1CCC(OC2(C)OC(=O)C3CCCCC3O2)CC1
PARDOPRUNOX,PARDOPRUNOX,CHEMBL2103832,BRD:BRD-BRD-K11851476-003-01-7;BRD:BRD-K11851476-003-01-7,rep_multi_dose;rep_primary;rep_single_dose,"SEROTONIN RECEPTOR AGONIST, DOPAMINE RECEPTOR AGONIST",DRD2;DRD3;DRD4;HTR1A;HTR7,,,PHASE 3,"Multiple values for MOA: {'DOPAMINE RECEPTOR AGONIST, SEROTONIN RECEPTOR AGONIST', 'SEROTONIN RECEPTOR AGONIST, DOPAMINE RECEPTOR AGONIST'}, defaulting to 'SEROTONIN RECEPTOR AGONIST, DOPAMINE RECEPTOR AGONIST'",Small molecule,Phase 3,YVPUUUDAZYFFQT-UHFFFAOYSA-N,CN1CCN(C2CCCC3[NH]C(=O)OC23)CC1;CN1CCN(CC1)C1CCCC2[NH]C(=O)OC12
PARECOXIB,PARECOXIB,CHEMBL1206690,BRD:BRD-BRD-K13800121-001-01-5;BRD:BRD-K13800121-001-01-5,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,LTF,PAIN RELIEF,,LAUNCHED,,Small molecule,Approved,TZRHLKRLEZJVIJ-UHFFFAOYSA-N,CCC(=O)NS(=O)(=O)C1CCC(-C2C(-C3CCCCC3)NOC2C)CC1;CCC(=O)NS(=O)(=O)C1CCC(CC1)-C1C(C)ONC1-C1CCCCC1
PARETHOXYCAINE,PARETHOXYCAINE,CHEMBL421669,BRD:BRD-K54799382-003-08-4,rep_single_dose,LOCAL ANESTHETIC,,,,,,Small molecule,Unknown,OWWVHQUOYSPNNE-UHFFFAOYSA-N,CCOC1CCC(C(=O)OCCN(CC)CC)CC1
PARGYLINE,PARGYLINE,CHEMBL673,BRD:BRD-BRD-K83597974-003-22-2;BRD:BRD-K83597974-003-22-2,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,DPWPWRLQFGFJFI-UHFFFAOYSA-N,C#CCN(C)CC1CCCCC1;CN(CC#C)CC1CCCCC1
PARICALCITOL,PARICALCITOL,CHEMBL1200622,BRD:BRD-BRD-K60585088-001-01-5;BRD:BRD-K60585088-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,"CHRONIC KIDNEY DISEASE (CKD), HYPERTHYROIDISM",,LAUNCHED,,Small molecule,Approved,BPKAHTKRCLCHEA-UBFJEZKGSA-N,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C;C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1
PARITAPREVIR,PARITAPREVIR,CHEMBL3391662,BRD:BRD-BRD-K89920762-001-01-4;BRD:BRD-K89920762-001-01-4,rep_primary;rep_single_dose,HCV INHIBITOR,,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,UAUIUKWPKRJZJV-QPLHLKROSA-N,CC1CNC(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](OC4NC5CCCCC5C5CCCCC45)CN3C2=O)CN1;CC1CNC(CN1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC1NC2CCCCC2C2CCCCC12)C(=O)NS(=O)(=O)C1CC1
PAROMOMYCIN,PAROMOMYCIN,CHEMBL370143,BRD:BRD-BRD-K36524108-065-04-0;BRD:BRD-K36524108-065-04-0,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,AMEBIASIS,,LAUNCHED,,Small molecule,Approved,UOZODPSAJZTQNH-LSWIJEOBSA-N,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O;NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O
PAROXETINE,PAROXETINE,CHEMBL490,BRD:BRD-BRD-K37991163-003-13-4;BRD:BRD-K37991163-003-13-4,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;HTR2A;SLC6A2;SLC6A4,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER (OCD), GENERALIZED ANXIETY DISORDER (GAD), PANIC DISORDERS, POSTTRAUMATIC STRESS DISORDER, SOCIAL ANXIETY DISORDER",,LAUNCHED,,Small molecule,Approved,AHOUBRCZNHFOSL-YOEHRIQHSA-N,FC1CCC([C@@H]2CCNC[C@H]2COC2CCC3C(C2)OCO3)CC1;FC1CCC(CC1)[C@@H]1CCNC[C@H]1COC1CCC2OCOC2C1
PAROXYPROPIONE,PAROXYPROPIONE,CHEMBL312311,BRD:BRD-BRD-K07441213-001-18-9;BRD:BRD-K07441213-001-18-9,rep_primary;rep_single_dose,GONADOTROPIN INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,RARSHUDCJQSEFJ-UHFFFAOYSA-N,CCC(=O)C1CCC(O)CC1
PARSACLISIB,PARSACLISIB,CHEMBL4297615,BRD:BRD-K00004594-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,Small molecule,Phase 3,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,CCOC1C([C@H](C)N2NC(C)C3C(N)NCNC32)CC(CL)C(F)C1[C@@H]1CNC(=O)C1
PARTHENOLIDE,PARTHENOLIDE,CHEMBL540445,BRD:BRD-BRD-K98548675-001-05-9;BRD:BRD-K98548675-001-05-9;CTRP:411792;GDSC1:89,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,,,,PHASE 1,,Small molecule,Phase 2,KTEXNACQROZXEV-SLXBATTESA-N,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1;C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21
PARTHENOLIDE-(-),PARTHENOLIDE-(-),,BRD:BRD-BRD-K34851558-001-02-3;BRD:BRD-K34851558-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,HDAC1,,,PRECLINICAL,,,NA,,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1
PARTHENOLIDE-(ALTERNATE-STEREO),PARTHENOLIDE-(ALTERNATE-STEREO),,BRD:BRD-BRD-K28120222-001-08-4;BRD:BRD-K28120222-001-08-4,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,IKBKB;RELA,,,PRECLINICAL,,,NA,,C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1
PASINIAZID,PASINIAZID,,BRD:BRD-BRD-K87202646-061-04-9,rep_primary,CYCLOOXYGENASE INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,,NA,,NNC(=O)C1CCNCC1
PASIREOTIDE,PASIREOTIDE,CHEMBL3039583,BRD:BRD-BRD-K59715032-362-01-4;BRD:BRD-K59715032-362-01-4,rep_primary;rep_single_dose,SOMATOSTATIN RECEPTOR AGONIST,SSTR1;SSTR2;SSTR3;SSTR5,"CUSHING'S SYNDROME, ACROMEGALY",,LAUNCHED,,Protein,Approved,VMZMNAABQBOLAK-IXZCVAHUSA-N,NCCCC[C@@H]1NC(=O)[C@@H](CC2C[NH]C3CCCCC23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC2CCC(OCC3CCCCC3)CC2)NC1=O)OC(=O)NCCN)C1CCCCC1;NCCCC[C@@H]1NC(=O)[C@@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](C2CCCCC2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC2CCC(OCC3CCCCC3)CC2)NC1=O
PAT-1251,PAT-1251,CHEMBL4116649,BRD:BRD-K00003481-001-01-9,rep_single_dose,LYSYL OXIDASE INHIBITOR,,,,,,Small molecule,Phase 2,ODGXXYXJORZPHE-ZIAGYGMSSA-N,NCC1CC(OC2CCCC(C(=O)N3C[C@@H](O)[C@H](F)C3)C2)NC(C(F)(F)F)C1
PATUPILONE,PATUPILONE,CHEMBL94657,GDSC1:201,gdsc,,,,,,,Small molecule,Phase 3,QXRSDHAAWVKZLJ-PVYNADRNSA-N,C/C(=C\C1CSC(C)N1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
PAVINETANT,PAVINETANT,CHEMBL3545233,BRD:BRD-K00003170-001-01-9,rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,QYTBBBAHNIWFOD-NRFANRHFSA-N,CC[C@H](NC(=O)C1C(NS(C)(=O)=O)C(-C2CCCCC2)NC2CCCCC12)C1CCCCC1
PAXENE,PAXENE,CHEMBL428647,GDSC1:11;GDSC2:1080,gdsc,,,,,,,Small molecule,Approved,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)C3CCCCC3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4CCCCC4)C4CCCCC4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
PAZOPANIB,PAZOPANIB,CHEMBL477772,BRD:BRD-BRD-K74514084-001-03-9;BRD:BRD-K74514084-001-03-9;BRD:BRD-K74514084-003-09-2;CTRP:640265;GDSC1:199,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",CSF1R;FGF1;FGFR1;FGFR3;FLT1;FLT4;ITK;KDR;KIT;PDGFRA;PDGFRB;SH2B3,"RENAL CELL CARCINOMA (RCC), SOFT TISSUE SARCOMA (STS)",,LAUNCHED,,Small molecule,Approved,CUIHSIWYWATEQL-UHFFFAOYSA-N,CC1CCC(NC2NCCC(N(C)C3CCC4C(C)N(C)NC4C3)N2)CC1S(N)(=O)=O;CN(C1CCC2C(C)N(C)NC2C1)C1CCNC(NC2CCC(C)C(C2)S(N)(=O)=O)N1
PAZUFLOXACIN,PAZUFLOXACIN,CHEMBL240163,BRD:BRD-BRD-K66412701-066-01-6;BRD:BRD-K66412701-066-01-6,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,,"PNEUMONIA, PERITONITIS, BACTERIAL SEPTICEMIA",,LAUNCHED,,Small molecule,Phase 3,XAGMUUZPGZWTRP-ZETCQYMHSA-N,C[C@H]1COC2C(C(F)CC3C2N1CC(C(O)=O)C3=O)C1(N)CC1;C[C@H]1COC2C(C3(N)CC3)C(F)CC3C(=O)C(C(=O)O)CN1C23
PBI-4050,PBI-4050,CHEMBL4297635,BRD:BRD-K00003391-236-01-9,rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,PEGQOIGYZLJMIB-UHFFFAOYSA-N,CCCCCC1CCCC(CC(=O)O)C1
PBT-1033,PBT-1033,,BRD:BRD-K00004615-001-01-9,rep_single_dose,CHELATING AGENT,,,,,,,NA,,
PCA-4248,PCA-4248,,BRD:BRD-A29289453-001-04-7;BRD:BRD-BRD-A29289453-001-04-7,rep_primary;rep_single_dose,PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST,PTAFR,,,PHASE 1,,,NA,,COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSC1CCCCC1
PCI-24781,PCI-24781,CHEMBL2103863,BRD:BRD-BRD-K12867552-001-04-7;BRD:BRD-K12867552-001-04-7,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC6,,,PHASE 1/PHASE 2,,Small molecule,Phase 3,MAUCONCHVWBMHK-UHFFFAOYSA-N,CN(C)CC1C(C(=O)NCCOC2CCC(C(=O)NO)CC2)OC2CCCCC12;CN(C)CC1C(OC2CCCCC12)C(=O)NCCOC1CCC(CC1)C(=O)NO
PCI-27483,PCI-27483,CHEMBL4297315,BRD:BRD-K00003213-001-01-9,rep_single_dose,ERK1 AND ERK2 PHOSPHORYLATION INHIBITOR,,,,,,Small molecule,Phase 2,WDJHHCAKBRKCLW-IBGZPJMESA-N,N=C(N)C1CCC2NC(-C3CC(CC(=O)N[C@@H](CC(=O)O)C(=O)O)CC(-C4CC(S(N)(=O)=O)CCC4O)C3O)[NH]C2C1
PCI-29732,PCI-29732,,BRD:BRD-K71223042-001-03-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,BTK,,,,,,NA,,
PCI-32765,PCI-32765,CHEMBL1873475,GDSC2:1799,gdsc,,,,,,,Small molecule,Approved,XYFPWWZEPKGCCK-GOSISDBHSA-N,C=CC(=O)N1CCC[C@@H](N2NC(-C3CCC(OC4CCCCC4)CC3)C3C(N)NCNC32)C1
PCI-32765-00,PCI-32765-00,CHEMBL1873475,GDSC2:1799,gdsc,,,,,,,Small molecule,Approved,XYFPWWZEPKGCCK-GOSISDBHSA-N,C=CC(=O)N1CCC[C@@H](N2NC(-C3CCC(OC4CCCCC4)CC3)C3C(N)NCNC32)C1
PCI-34051,PCI-34051,,BRD:BRD-BRD-K88742110-001-07-9;BRD:BRD-K88742110-001-07-9;GDSC2:1621,gdsc;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC10;HDAC6;HDAC8,,,PRECLINICAL,,,NA,,COC1CCC(CN2CCC3CCC(CC23)C(=O)NO)CC1
PCO-400,PCO-400,,BRD:BRD-K52721684-001-04-8,rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNJ8,,,,,,NA,,
PCO371,PCO371,CHEMBL3976807,BRD:BRD-K00079290-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,LDZJFVOUPUFOHX-UHFFFAOYSA-N,CC1CC(N2C(=O)NC(=O)C2(C)C)CC(C)C1CCS(=O)(=O)N1CCC2(CC1)N=C(C1CCC(OC(F)(F)F)CC1)NC2=O
PD 0325901,PD 0325901,CHEMBL507361,GDSC1:1060;GDSC2:1060,gdsc,,,,,,,Small molecule,Phase 2,SUDAHWBOROXANE-SECBINFHSA-N,O=C(NOC[C@H](O)CO)C1CCC(F)C(F)C1NC1CCC(I)CC1F
PD 153035,PD 153035,,CTRP:52133,ctrp,,,,,,,,NA,,
PD 173074,PD 173074,,GDSC1:1049;GDSC2:1049,gdsc,,,,,,,,NA,,
PD-0325901,PD-0325901,CHEMBL507361,BRD:BRD-BRD-K49865102-001-08-4;BRD:BRD-K49865102-001-08-4;GDSC1:1060;GDSC2:1060,gdsc;rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1,,,PHASE 2,,Small molecule,Phase 2,SUDAHWBOROXANE-SECBINFHSA-N,O=C(NOC[C@H](O)CO)C1CCC(F)C(F)C1NC1CCC(I)CC1F;OC[C@@H](O)CONC(=O)C1CCC(F)C(F)C1NC1CCC(I)CC1F
PD-102807,PD-102807,,BRD:BRD-A89337244-001-02-9;BRD:BRD-BRD-A89337244-001-02-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM4,,,PRECLINICAL,,,NA,,CCOC(=O)C1C(C)[NH]C2CCC3OC4N(CCC5CC(OC)CCC45)CC3C12
PD-118057,PD-118057,,BRD:BRD-K34657753-001-01-9,rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNH2,,,,,,NA,,
PD-123319,PD-123319,,BRD:BRD-BRD-K34713073-001-01-3;BRD:BRD-K34713073-001-01-3,rep_primary;rep_single_dose,ANGIOTENSIN ANTAGONIST,AGTR2,,,PHASE 1,,,NA,,CN(C)C1CCC(CN2CNC3CN([C@@H](CC23)C(O)=O)C(=O)C(C2CCCCC2)C2CCCCC2)CC1C
PD-128907,PD-128907,,BRD:BRD-BRD-K38797369-003-01-1;BRD:BRD-BRD-K62456038-003-07-1;BRD:BRD-K38797369-003-01-1;BRD:BRD-K62456038-003-07-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2;DRD3,,,PRECLINICAL,"Multiple values for structure_id: {'K62456038', 'K38797369'}, defaulting to None",,NA,,CCCN1CCO[C@@H]2[C@@H]1COC1CCC(O)CC21;CCCN1CCO[C@H]2[C@@H]1COC1CCC(O)CC21;CCCN1CCO[C@H]2[C@H]1COC1CCC(O)CC21
PD-153035,PD-153035,,BRD:BRD-BRD-K26603252-003-04-9;BRD:BRD-K26603252-003-04-9,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;KDR,,,PHASE 1,,,NA,,COC1CC2NCNC(NC3CCCC(BR)C3)C2CC1OC
PD-160170,PD-160170,,BRD:BRD-BRD-K12079898-001-02-6;BRD:BRD-K12079898-001-02-6,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY1R,,,PRECLINICAL,,,NA,,CC(C)C1CCCCC1S(=O)(=O)C1CC(N)C2NCCCC2C1[N+]([O-])=O
PD-161570,PD-161570,,BRD:BRD-K97152684-001-03-9,rep_single_dose,FGFR INHIBITOR,FGFR1,,,,,,NA,,
PD-166285,PD-166285,,BRD:BRD-K93217218-300-03-9,rep_single_dose,SRC INHIBITOR,EGFR;FGFR1;PDGFRB;PKMYT1;SRC;WEE1,,,,,,NA,,
PD-166793,PD-166793,,BRD:BRD-BRD-K60984070-001-01-0;BRD:BRD-K60984070-001-01-0,rep_primary;rep_single_dose,"COLLAGENASE INHIBITOR, METALLOPROTEINASE INHIBITOR",MMP13;MMP2;MMP3,,,PRECLINICAL,,,NA,,CC(C)[C@H](NS(=O)(=O)C1CCC(CC1)-C1CCC(BR)CC1)C(O)=O
PD-168393,PD-168393,,BRD:BRD-BRD-K17702546-001-03-2;BRD:BRD-K17702546-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2;SRC,,,PRECLINICAL,,,NA,,BRC1CCCC(NC2NCNC3CCC(NC(=O)C=C)CC23)C1
PD-168568,PD-168568,,BRD:BRD-A82013137-300-01-1;BRD:BRD-BRD-A82013137-300-01-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD4,,,PRECLINICAL,,,NA,,CC1CCC(CC1C)N1CCN(CCC2NC(=O)C3CCCCC23)CC1
PD-173074,PD-173074,CHEMBL189584,BRD:BRD-BRD-K97764662-001-17-3;BRD:BRD-K97764662-001-17-3;GDSC1:1049;GDSC2:1049,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, VEGFR INHIBITOR",FGFR1;FGFR2;FGFR3;FGFR4;FLT1;FLT4;KDR;PDGFRA;PDGFRB,,,PRECLINICAL,,Small molecule,NA,DXCUKNQANPLTEJ-UHFFFAOYSA-N,CCN(CC)CCCCNC1NCC2CC(-C3CC(OC)CC(OC)C3)C(NC(=O)NC(C)(C)C)NC2N1
PD-173212,PD-173212,,BRD:BRD-K04426574-001-03-9,rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1B,,,,,,NA,,
PD-18435,PD-18435,CHEMBL105442,GDSC1:1015,gdsc,,,,,,,Small molecule,Phase 2,GFMMXOIFOQCCGU-UHFFFAOYSA-N,O=C(NOCC1CC1)C1CCC(F)C(F)C1NC1CCC(I)CC1CL
PD-184352,PD-184352,CHEMBL105442,BRD:BRD-BRD-K05104363-001-10-0;BRD:BRD-K05104363-001-10-0;GDSC1:1015,gdsc;rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1;MAP3K1;MAP3K2,,,PHASE 2,,Small molecule,Phase 2,GFMMXOIFOQCCGU-UHFFFAOYSA-N,FC1CCC(C(=O)NOCC2CC2)C(NC2CCC(I)CC2CL)C1F;O=C(NOCC1CC1)C1CCC(F)C(F)C1NC1CCC(I)CC1CL
PD-198306,PD-198306,,BRD:BRD-BRD-K88677950-001-03-9;BRD:BRD-K88677950-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,"MAP KINASE INHIBITOR, MEK INHIBITOR",MAP2K1;MAP2K2,,,PRECLINICAL,,,NA,,CC1CC(I)CCC1NC1C(F)C(F)C(F)CC1C(=O)NOCC1CC1
PD-318088,PD-318088,,BRD:BRD-A57798112-001-03-7;BRD:BRD-BRD-A57798112-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1,,,PRECLINICAL,,,NA,,OCC(O)CONC(=O)C1CC(BR)C(F)C(F)C1NC1CCC(I)CC1F
PD-407824,PD-407824,,BRD:BRD-BRD-K82823804-001-04-1;BRD:BRD-K82823804-001-04-1,rep_multi_dose;rep_primary;rep_single_dose,PKC INHIBITOR,WEE1,,,PRECLINICAL,,,NA,,OC1CCC2[NH]C3CC(C4C(=O)NC(=O)C4C3C2C1)-C1CCCCC1
PD-81723,PD-81723,,BRD:BRD-K77951111-001-05-9,rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,,,,,,NA,,
PD-98059,PD-98059,,BRD:BRD-BRD-K62810658-001-12-2;BRD:BRD-K62810658-001-12-2,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,AKT1;CHEK1;GSK3B;LCK;MAP2K1;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;PRKCA;RAF1;ROCK1;RPS6KB1;SGK1,,,PRECLINICAL,,,NA,,COC1CCCC(-C2CC(=O)C3CCCCC3O2)C1N
PD0325901,PD0325901,,GDSC1:1060;GDSC2:1060,gdsc,,,,,,,,NA,,
PD0332991,PD0332991,,GDSC1:1054;GDSC2:1054,gdsc,,,,,,,,NA,,
PD1-PDL-INHIBITOR-1,PD1-PDL-INHIBITOR-1,,BRD:BRD-BRD-K04032780-001-01-8;BRD:BRD-K04032780-001-01-8,rep_primary;rep_single_dose,PROGRAMMED DEATH LIGAND INHIBITOR,CD274,,,PRECLINICAL,,,NA,,COC1CC(OCC2CCCC(-C3CCCCC3)C2C)CC(OC)C1CN1CCCC[C@H]1C(O)=O
PD173074,PD173074,,GDSC1:1049;GDSC2:1049,gdsc,,,,,,,,NA,,
PD318088,PD318088,,CTRP:660410,ctrp,,,,,,,,NA,,
PDD-00017273,PDD-00017273,,BRD:BRD-K00021095-001-01-9,rep_single_dose,PARG INHIBITOR,,,,,,,NA,,
PDE10-IN-1,PDE10-IN-1,,BRD:BRD-BRD-K38145871-001-01-8;BRD:BRD-K38145871-001-01-8,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE10A,,,PRECLINICAL,,,NA,,CC1C(NC2C3CCCNC3CCN12)[C@@H]1C[C@H]1C1NC2C(C)NCC(C)N2N1
PDK1 INHIBITOR 7,PDK1 INHIBITOR 7,,GDSC1:287,gdsc,,,,,,,,NA,,
PDK1 INHIBITOR AR-12,PDK1 INHIBITOR AR-12,CHEMBL1650595,GDSC1:167,gdsc,,,,,,,Small molecule,Phase 1,YULUCECVQOCQFQ-UHFFFAOYSA-N,NCC(=O)NC1CCC(-N2NC(C(F)(F)F)CC2-C2CCC3C(CCC4CCCCC43)C2)CC1
PDMP,PDMP,,CTRP:58472,ctrp,,,,,,,,NA,,
PDP-EA,PDP-EA,,BRD:BRD-BRD-K26358347-001-01-7;BRD:BRD-K26358347-001-01-7,rep_primary;rep_single_dose,FAAH ACTIVATOR,FAAH,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCCCCC1CCCC(OCC(=O)NCCO)C1
PEFICITINIB,PEFICITINIB,CHEMBL3137308,BRD:BRD-A14577621-001-01-5;BRD:BRD-BRD-A14577621-001-01-5,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3,,,PHASE 3,,Small molecule,Phase 3,DREIJXJRTLTGJC-ZLBJMMTISA-N,NC(=O)C1CNC2[NH]CCC2C1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2;NC(=O)C1CNC2[NH]CCC2C1N[C@@H]1C2C[C@@H]3C[C@H]1C[C@@](O)(C3)C2;NC(=O)C1CNC2[NH]CCC2C1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2
PEFLOXACIN,PEFLOXACIN,CHEMBL267648,BRD:BRD-BRD-K55034111-066-17-1;BRD:BRD-K55034111-066-17-1,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,"GASTROINTESTINAL INFECTIONS, URETHRITIS, GONORRHEA, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,FHFYDNQZQSQIAI-UHFFFAOYSA-N,CCN1CC(C(=O)O)C(=O)C2CC(F)C(N3CCN(C)CC3)CC21;CCN1CC(C(O)=O)C(=O)C2CC(F)C(CC12)N1CCN(C)CC1
PELANSERIN,PELANSERIN,CHEMBL2110706,BRD:BRD-BRD-K96436774-001-01-8;BRD:BRD-K96436774-001-01-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A,,,PHASE 2,,Small molecule,Unknown,WPKPLSFHHBBLRY-UHFFFAOYSA-N,O=C1[NH]C2CCCCC2C(=O)N1CCCN1CCN(C2CCCCC2)CC1;O=C1[NH]C2CCCCC2C(=O)N1CCCN1CCN(CC1)C1CCCCC1
PELITINIB,PELITINIB,CHEMBL607707,BRD:BRD-BRD-K08799216-001-05-3;BRD:BRD-K08799216-001-05-3;GDSC1:282,gdsc;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PHASE 2,,Small molecule,Phase 2,WVUNYSQLFKLYNI-AATRIKPKSA-N,CCOC1CC2NCC(C#N)C(NC3CCC(F)C(CL)C3)C2CC1NC(=O)/C=C/CN(C)C;CCOC1CC2NCC(C#N)C(NC3CCC(F)C(CL)C3)C2CC1NC(=O)\C=C\CN(C)C
PELRINONE,PELRINONE,CHEMBL17125,BRD:BRD-K00004687-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Unknown,NZXHFDXOCVIYLO-UHFFFAOYSA-N,CC1NC(=O)C(C#N)C(NCC2CCCNC2)[NH]1
PEMAFIBRATE,PEMAFIBRATE,CHEMBL247951,BRD:BRD-K00003251-001-01-9,rep_single_dose,PPAR RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,ZHKNLJLMDFQVHJ-RUZDIDTESA-N,CC[C@@H](OC1CCCC(CN(CCCOC2CCC(OC)CC2)C2NC3CCCCC3O2)C1)C(=O)O
PEMETREXED,PEMETREXED,CHEMBL225072,BRD:BRD-BRD-K32842773-434-01-8;BRD:BRD-K32842773-380-01-3;BRD:BRD-K32842773-434-01-8;GDSC1:428,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"DIHYDROFOLATE REDUCTASE INHIBITOR, THYMIDYLATE SYNTHASE INHIBITOR",ATIC;DHFR;GART;TYMS,"NON-SMALL CELL LUNG CANCER (NSCLC), MESOTHELIOMA",,LAUNCHED,,Small molecule,Approved,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,NC1NC(=O)C2C(CCC3CCC(CC3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C[NH]C2[NH]1;NC1NC2[NH]CC(CCC3CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC3)C2C(=O)[NH]1
PEMIROLAST,PEMIROLAST,CHEMBL1201198,BRD:BRD-BRD-K31731454-237-02-5;BRD:BRD-K31731454-237-02-5;BRD:BRD-K31731454-237-04-9,rep_primary;rep_single_dose,MEDIATOR RELEASE INHIBITOR,HRH1,ASTHMA,,LAUNCHED,,Small molecule,Approved,HIANJWSAHKJQTH-UHFFFAOYSA-N,CC1CCCN2C(=O)C(-C3NNN[NH]3)CNC12;CC1CCCN2C1NCC(-C1NNN[NH]1)C2=O
PENBUTOLOL,PENBUTOLOL,CHEMBL1290,BRD:BRD-BRD-K55705469-065-01-0;BRD:BRD-K55705469-065-01-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;HTR1A;HTR1B,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,KQXKVJAGOJTNJS-HNNXBMFYSA-N,CC(C)(C)NC[C@H](O)COC1CCCCC1C1CCCC1
PENCICLOVIR,PENCICLOVIR,CHEMBL1540,BRD:BRD-BRD-K47780086-001-07-9;BRD:BRD-K47780086-001-07-9,rep_primary;rep_single_dose,DNA DIRECTED DNA POLYMERASE INHIBITOR,,COLD SORE,,LAUNCHED,,Small molecule,Approved,JNTOCHDNEULJHD-UHFFFAOYSA-N,NC1NC(O)C2NCN(CCC(CO)CO)C2N1
PENFLURIDOL,PENFLURIDOL,CHEMBL47050,BRD:BRD-BRD-K15409150-001-05-8;BRD:BRD-K15409150-001-05-8,rep_multi_dose;rep_primary;rep_single_dose,T-TYPE CALCIUM CHANNEL BLOCKER,CACNA1G,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Unknown,MDLAAYDRRZXJIF-UHFFFAOYSA-N,OC1(C2CCC(CL)C(C(F)(F)F)C2)CCN(CCCC(C2CCC(F)CC2)C2CCC(F)CC2)CC1;OC1(CCN(CCCC(C2CCC(F)CC2)C2CCC(F)CC2)CC1)C1CCC(CL)C(C1)C(F)(F)F
PENICILLAMINE-(D),PENICILLAMINE-(D),,BRD:BRD-BRD-K17518951-001-03-0;BRD:BRD-K17518951-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,CHELATING AGENT,,"WILSON'S DISEASE, RHEUMATOID ARTHRITIS, CYSTINURIA",,LAUNCHED,,,NA,,CC(C)(S)[C@@H](N)C(O)=O
PENICILLIN-V-POTASSIUM,PENICILLIN-V-POTASSIUM,,BRD:BRD-BRD-K43966364-237-04-8;BRD:BRD-K43966364-237-04-8,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"PNEUMONIA, EAR INFECTIONS, SKIN INFECTIONS, THROAT INFECTIONS, CHOLERA, SCARLET FEVER",,LAUNCHED,,,NA,,CC1(C)S[C@@H]2[C@H](NC(=O)COC3CCCCC3)C(=O)N2[C@H]1C(O)=O
PENTACOSANOIC-ACID,PENTACOSANOIC-ACID,,BRD:BRD-BRD-K48996094-001-01-3;BRD:BRD-K48996094-001-01-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O
PENTAGASTRIN,PENTAGASTRIN,CHEMBL1328,BRD:BRD-BRD-K78789465-001-01-6;BRD:BRD-BRD-K78789465-001-02-4;BRD:BRD-K78789465-001-01-6;BRD:BRD-K78789465-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,CCK RECEPTOR AGONIST,CCKBR,"ANACIDITY DIAGNOSTIC, GASTRIC HYPERSECRETION DIAGNOSTIC, ANACIDITY DIAGNOSTIC, GASTRIC HYPERSECRETION DIAGNOSTIC",,LAUNCHED,,Small molecule,Approved,NEYNJQRKHLUJRU-DZUOILHNSA-N,CSCC[C@H](NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(N)=O;CSCC[C@H](NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
PENTAMIDINE,PENTAMIDINE,CHEMBL55,BRD:BRD-BRD-K13183738-317-10-2;BRD:BRD-K13183738-317-10-2,rep_multi_dose;rep_primary;rep_single_dose,ANTI-PNEUMOCYSTIS AGENT,TRDMT1,PNEUMONIA,,LAUNCHED,,Small molecule,Approved,XDRYMKDFEDOLFX-UHFFFAOYSA-N,N=C(N)C1CCC(OCCCCCOC2CCC(C(=N)N)CC2)CC1;NC(=N)C1CCC(OCCCCCOC2CCC(CC2)C(N)=N)CC1
PENTETIC-ACID,PENTETIC-ACID,,BRD:BRD-BRD-K40621224-001-06-7;BRD:BRD-K40621224-001-06-7,rep_primary;rep_single_dose,CHELATING AGENT,PGD,,,PHASE 2,,,NA,,OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O
PENTOBARBITAL,PENTOBARBITAL,CHEMBL448,BRD:BRD-A44448661-001-04-8;BRD:BRD-BRD-A44448661-001-04-8,rep_primary;rep_single_dose,"BARBITURATE ANTIEPILEPTIC, GABA RECEPTOR MODULATOR",CHRNA4;CHRNA7;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIA2;GRIK2;GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D;GRIN3A;GRIN3B,,,WITHDRAWN,,Small molecule,Approved,WEXRUCMBJFQVBZ-UHFFFAOYSA-N,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
PENTOLINIUM,PENTOLINIUM,CHEMBL1271,BRD:BRD-BRD-K44942604-346-05-4;BRD:BRD-K44942604-346-05-4,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRNA10;CHRNA3;CHRNA4;CHRNB4,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,XSBSKEQEUFOSDD-UHFFFAOYSA-N,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
PENTOSTATIN,PENTOSTATIN,CHEMBL1580,BRD:BRD-BRD-K91543828-001-02-0;BRD:BRD-K91543828-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,"ADENOSINE DEAMINASE INHIBITOR, RIBONUCLEOTIDE REDUCTASE INHIBITOR",ADA,HAIRY CELL LEUKEMIA,,LAUNCHED,,Small molecule,Approved,FPVKHBSQESCIEP-JQCXWYLXSA-N,OC[C@H]1O[C@@H](N2CNC3C2N=CNC[C@H]3O)C[C@@H]1O;OC[C@H]1O[C@H](C[C@@H]1O)N1CNC2[C@H](O)CNC=NC12;OC[C@H]1O[C@H](CC1O)N1CNC2[C@H](O)CNC=NC12
PENTOXIFYLLINE,PENTOXIFYLLINE,CHEMBL628,BRD:BRD-BRD-K57569181-001-27-5;BRD:BRD-K57569181-001-27-5,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,ADORA1;ADORA2A;ADORA2B;ADRA2B;NT5E;PDE10A;PDE1A;PDE1B;PDE1C;PDE2A;PDE3A;PDE3B;PDE4A;PDE4B;PDE4C;PDE4D;PDE5A;PDE6A;PDE6B;PDE6C;PDE6D;PDE6G;PDE6H;PDE7A;PDE7B;PDE8A;PDE8B;PDE9A;TNF,CLAUDICATION,,LAUNCHED,,Small molecule,Approved,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,CC(=O)CCCCN1C(=O)C2C(NCN2C)N(C)C1=O;CC(=O)CCCCN1C(=O)N(C)C2NCN(C)C2C1=O
PENTYLENETETRAZOL,PENTYLENETETRAZOL,CHEMBL116943,BRD:BRD-BRD-K57718010-001-11-9;BRD:BRD-K57718010-001-11-9,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,,,,WITHDRAWN,,Small molecule,Phase 2,CWRVKFFCRWGWCS-UHFFFAOYSA-N,C1CCC2NNNN2CC1
PEPOSERTIB,PEPOSERTIB,CHEMBL4297629,BRD:BRD-K00003426-001-01-9,rep_single_dose,DNA DEPENDENT PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Phase 1,MOWXJLUYGFNTAL-DEOSSOPVSA-N,COC1CCC([C@@H](O)C2CC(-C3NCNC4CC(N5CCOCC5)CCC34)C(F)CC2CL)NN1
PEPSTATIN,PEPSTATIN,CHEMBL296588,BRD:BRD-BRD-K13571841-001-14-4;BRD:BRD-K13571841-001-14-4,rep_multi_dose;rep_primary;rep_single_dose,ASPARTIC PROTEASE INHIBITOR,CTSB;CTSD;CTSL;REN,,,PRECLINICAL,,Small molecule,Unknown,FAXGPCHRFPCXOO-LXTPJMTPSA-N,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O;CC(C)CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)O)C(C)C)C(C)C
PERAMIVIR,PERAMIVIR,CHEMBL139367;CHEMBL3989402,BRD:BRD-BRD-K00519864-341-03-3;BRD:BRD-K00519864-341-03-3,rep_primary;rep_single_dose,NEURAMINIDASE INHIBITOR,,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,Small molecule,Approved,RFUCJKFZFXNIGB-ZBBHRWOZSA-N;XRQDFNLINLXZLB-CKIKVBCHSA-N,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N;CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N.O.O.O;CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
PERAMPANEL,PERAMPANEL,CHEMBL1214124,BRD:BRD-BRD-K41438959-001-01-7;BRD:BRD-K41438959-001-01-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIA3;GRIA4,SEIZURES,,LAUNCHED,,Small molecule,Approved,PRMWGUBFXWROHD-UHFFFAOYSA-N,N#CC1CCCCC1-C1CC(-C2CCCCN2)CN(-C2CCCCC2)C1=O;O=C1C(CC(CN1-C1CCCCC1)-C1CCCCN1)-C1CCCCC1C#N
PERCHLOZONE,PERCHLOZONE,,BRD:BRD-BRD-K86435560-001-01-0;BRD:BRD-K86435560-001-01-0,rep_primary;rep_single_dose,,,TUBERCULOSIS,,LAUNCHED,,,NA,,NC(=S)NN=CC1CCNCC1
PERETINOIN,PERETINOIN,CHEMBL4303228,BRD:BRD-BRD-K99431849-001-01-7;BRD:BRD-K99431849-001-01-7,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RXRA,,,PHASE 3,,Small molecule,Phase 3,UUBHZHZSIKRVIV-KCXSXWJSSA-N,CC(C)=CCC/C(C)=C/CC/C(C)=C/C=C/C(C)=C/C(=O)O;CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O
PERFLUAMINE,PERFLUAMINE,CHEMBL2104877,BRD:BRD-BRD-K16758059-001-01-8;BRD:BRD-K16758059-001-01-8,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,JAJLKEVKNDUJBG-UHFFFAOYSA-N,FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F
PERFLUBRON,PERFLUBRON,CHEMBL1200866,BRD:BRD-BRD-K92988025-001-01-9;BRD:BRD-K92988025-001-01-9,rep_primary;rep_single_dose,CONTRAST AGENT,,CONTRAST AGENT,,LAUNCHED,,Small molecule,Approved,WTWWXOGTJWMJHI-UHFFFAOYSA-N,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)BR
PERFLUOROHEXYLOCTANE,PERFLUOROHEXYLOCTANE,,BRD:BRD-K00004546-001-01-9,rep_single_dose,,,,,,,,NA,,
PERGOLIDE,PERGOLIDE,CHEMBL531,BRD:BRD-BRD-K60770992-066-25-0;BRD:BRD-K60770992-066-25-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C,,,WITHDRAWN,,Small molecule,Approved,YEHCICAEULNIGD-MZMPZRCHSA-N,CCCN1C[C@H](CSC)C[C@@H]2C3CCCC4[NH]CC(C34)C[C@H]21;CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC1C[NH]C3CCCC2C13
PERHEXILINE,PERHEXILINE,CHEMBL75880,BRD:BRD-A19633847-050-32-1;BRD:BRD-BRD-A19633847-050-32-1,rep_primary;rep_single_dose,CARNITINE PALMITOYLTRANSFERASE INHIBITOR,CPT1A;CPT2,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Approved,CYXKNKQEMFBLER-UHFFFAOYSA-N,C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1;C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
PERICYAZINE,PERICYAZINE,CHEMBL251940,BRD:BRD-K89669299-001-04-9,rep_single_dose,,,,,,,Small molecule,Approved,LUALIOATIOESLM-UHFFFAOYSA-N,N#CC1CCC2C(C1)N(CCCN1CCC(O)CC1)C1CCCCC1S2
PERIFOSINE,PERIFOSINE,CHEMBL372764,BRD:BRD-A89082344-001-08-7;BRD:BRD-BRD-A89082344-001-08-7,rep_primary;rep_single_dose,AKT INHIBITOR,AKT1,,,PHASE 3,,Small molecule,Phase 3,SZFPYBIJACMNJV-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1;CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1
PERILLYL-ALCOHOL,PERILLYL-ALCOHOL,,BRD:BRD-A13323580-001-04-8;BRD:BRD-BRD-A13323580-001-04-8,rep_primary;rep_single_dose,"APOPTOSIS STIMULANT, FARNESYLTRANSFERASE INHIBITOR",FNTA,,,PHASE 2,,,NA,,CC(=C)C1CCC(CO)=CC1
PERINDOPRIL,PERINDOPRIL,CHEMBL1581,BRD:BRD-BRD-K92731339-227-04-9;BRD:BRD-K92731339-227-04-9,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, MYOCARDIAL INFARCTION, CORONARY ARTERY DISEASE (CAD)",,LAUNCHED,,Small molecule,Approved,IPVQLZZIHOAWMC-QXKUPLGCSA-N,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC;CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC
PEROSPIRONE,PEROSPIRONE,CHEMBL1472975,BRD:BRD-BRD-K85503079-001-02-8;BRD:BRD-K85503079-001-02-8,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",DRD2;DRD3;DRD4,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Unknown,FBVFZWUMDDXLLG-HDICACEKSA-N,O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(C2NSC3CCCCC23)CC1;O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)C1NSC2CCCCC12
PERPHENAZINE,PERPHENAZINE,CHEMBL567,BRD:BRD-BRD-K10995081-001-27-9;BRD:BRD-K10995081-001-27-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CALM1;DRD1;DRD2;HRH1;HTR2A;HTR2C;HTR6;HTR7,"SCHIZOPHRENIA, NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,RGCVKNLCSQQDEP-UHFFFAOYSA-N,OCCN1CCN(CCCN2C3CCCCC3SC3CCC(CL)CC23)CC1;OCCN1CCN(CCCN2C3CCCCC3SC3CCC(CL)CC32)CC1
PERUVOSIDE,PERUVOSIDE,CHEMBL1075790,BRD:BRD-A72716251-001-01-5;BRD:BRD-BRD-A72716251-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,CARDIAC GLYCOSIDE,,,,PHASE 1,,Small molecule,Unknown,PMTSPAGBAFCORP-HBUONDEYSA-N,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O;CO[C@H]1[C@H](O)[C@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)O[C@@H](C)[C@@H]1O
PERZINFOTEL,PERZINFOTEL,CHEMBL452461,BRD:BRD-BRD-K04643877-001-03-2;BRD:BRD-K04643877-001-03-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1;GRIN2A;GRIN2B,,,PHASE 2,,Small molecule,Phase 2,BDABGOLMYNHHTR-UHFFFAOYSA-N,O=C1C2C(C1=O)N(CCP(=O)(O)O)CCCN2;OP(O)(=O)CCN1CCCNC2C1C(=O)C2=O
PETCM,PETCM,,BRD:BRD-A93477898-001-04-2;BRD:BRD-BRD-A93477898-001-04-2,rep_multi_dose;rep_primary;rep_single_dose,CASPASE ACTIVATOR,CASP3,,,PRECLINICAL,,,NA,,OC(CC1CCNCC1)C(CL)(CL)CL
PETESICATIB,PETESICATIB,CHEMBL4297638,BRD:BRD-K00091277-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,KXAAIORSMACJSI-AEFFLSMTSA-N,CN1CC(-C2CCC(S(=O)(=O)[C@@H]3C[C@@H](C(=O)NC4(C#N)CC4)N(C(=O)C4(C(F)(F)F)CC4)C3)C(C(F)(F)F)C2)CN1
PEXACERFONT,PEXACERFONT,CHEMBL482950,BRD:BRD-K00073864-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,LBWQSAZEYIZZCE-SNVBAGLBSA-N,CC[C@@H](C)NC1NC(C)NC2C(-C3CCC(OC)NC3C)C(C)NN12
PEXIDARTINIB,PEXIDARTINIB,CHEMBL3813873,BRD:BRD-BRD-K54519451-001-02-9;BRD:BRD-K54519451-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,CSF1R;FLT3;KIT,,,PHASE 3,,Small molecule,Approved,JGWRKYUXBBNENE-UHFFFAOYSA-N,FC(F)(F)C1CCC(CNC2CCC(CC3C[NH]C4NCC(CL)CC34)CN2)CN1
PEXMETINIB,PEXMETINIB,CHEMBL3991932,BRD:BRD-BRD-K53405000-001-02-8;BRD:BRD-K53405000-001-02-8,rep_primary;rep_single_dose,"MAP KINASE INHIBITOR, TIE TYROSINE KINASE INHIBITOR",MAPK14;TEK,,,PHASE 1,"Multiple values for MOA: {'TIE TYROSINE KINASE INHIBITOR, MAP KINASE INHIBITOR', 'MAP KINASE INHIBITOR, TIE TYROSINE KINASE INHIBITOR'}, defaulting to 'MAP KINASE INHIBITOR, TIE TYROSINE KINASE INHIBITOR'",Small molecule,Phase 1,LNMRSSIMGCDUTP-UHFFFAOYSA-N,CC1CCC(-N2NC(C(C)(C)C)CC2NC(=O)NCC2CC(F)CCC2OC2CCC3C(CNN3CCO)C2)CC1;CC1CCC(CC1)-N1NC(CC1NC(=O)NCC1CC(F)CCC1OC1CCC2N(CCO)NCC2C1)C(C)(C)C
PF 03716556,PF 03716556,,BRD:BRD-K00091129-001-01-9,rep_single_dose,,,,,,,,NA,,
PF 04531083,PF 04531083,,BRD:BRD-K00076501-001-02-9,rep_single_dose,,,,,,,,NA,,
PF 2341066,PF 2341066,,GDSC1:37;GDSC2:1083,gdsc,,,,,,,,NA,,
PF 4708671,PF 4708671,,GDSC1:1129;GDSC2:1129,gdsc,,,,,,,,NA,,
PF-00080665-73,PF-00080665-73,CHEMBL2364621,GDSC1:1054;GDSC2:1054,gdsc,,,,,,,Small molecule,Phase 2,LYYVFHRFIJKPOV-UHFFFAOYSA-N,CC(=O)C1C(C)C2CNC(NC3CCC(N4CCNCC4)CN3)NC2N(C2CCCC2)C1=O.O=S(=O)(O)CCO
PF-00299804,PF-00299804,CHEMBL2105719;CHEMBL2110732,GDSC1:363,gdsc,,,,,,,Small molecule,Approved,BSPLGGCPNTZPIH-IPZCTEOASA-N;LVXJQMNHJWSHET-AATRIKPKSA-N,COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1NC(=O)/C=C/CN1CCCCC1;COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1NC(=O)/C=C/CN1CCCCC1.O
PF-00562271,PF-00562271,CHEMBL1084546,GDSC1:158,gdsc,,,,,,,Small molecule,Phase 1,MZDKLVOWGIOKTN-UHFFFAOYSA-N,CN(C1NCCCC1CNC1NC(NC2CCC3C(C2)CC(=O)N3)NCC1C(F)(F)F)S(C)(=O)=O
PF-01367338,PF-01367338,CHEMBL2105733,GDSC1:1175,gdsc,,,,,,,Small molecule,Phase 1,FCCGJTKEKXUBFZ-UHFFFAOYSA-N,CNCC1CCC(-C2[NH]C3CC(F)CC4C3C2CCNC4=O)CC1.O=P(O)(O)O
PF-02413873,PF-02413873,,BRD:BRD-K00004632-001-01-9,rep_single_dose,PROGESTERONE RECEPTOR ANTAGONIST,,,,,,,NA,,
PF-02545920,PF-02545920,CHEMBL562318,BRD:BRD-BRD-K31519811-001-02-2;BRD:BRD-K31519811-001-02-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE10A,,,PHASE 2,,Small molecule,Phase 2,AZEXWHKOMMASPA-UHFFFAOYSA-N,CN1CC(-C2CCNCC2)C(-C2CCC(OCC3CCC4CCCCC4N3)CC2)N1;CN1CC(C(N1)-C1CCC(OCC2CCC3CCCCC3N2)CC1)-C1CCNCC1
PF-03049423,PF-03049423,CHEMBL591501,BRD:BRD-BRD-K07070922-001-01-4;BRD:BRD-K07070922-001-01-4,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,,,PHASE 2,,Small molecule,Phase 2,MNLNAGRCHNMKKJ-UHFFFAOYSA-N,CCCOCCN1C(=O)C(N2CCN(CCO)CC2)NC2CNC(-C3CCC(OC)NC3)CC21;CCCOCCN1C2CC(NCC2NC(N2CCN(CCO)CC2)C1=O)-C1CCC(OC)NC1
PF-03084014,PF-03084014,CHEMBL1770916,BRD:BRD-BRD-K61691541-001-01-1;BRD:BRD-K61691541-001-01-1,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 3,VFCRKLWBYMDAED-REWPJTCUSA-N,CCC[C@H](N[C@H]1CCC2CC(F)CC(F)C2C1)C(=O)NC1CN(C(C)(C)CNCC(C)(C)C)CN1;CCC[C@H](N[C@H]1CCC2CC(F)CC(F)C2C1)C(=O)NC1CN(CN1)C(C)(C)CNCC(C)(C)C
PF-03463275,PF-03463275,CHEMBL563251,BRD:BRD-K00075673-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,KYLOBHXXQOZRKK-FICVDOATSA-N,CN1C[C@@H]2[C@H](C1)[C@H]2CN(CC1CCC(F)C(CL)C1)C(=O)C1CN(C)CN1
PF-03758309,PF-03758309,CHEMBL3128043,BRD:BRD-BRD-K37764012-001-04-1;BRD:BRD-K37764012-001-04-1,rep_multi_dose;rep_primary;rep_single_dose,P21 ACTIVATED KINASE INHIBITOR,PAK4,,,PHASE 1,,Small molecule,Phase 1,AYCPARAPKDAOEN-LJQANCHMSA-N,CC1NC(NC2N[NH]C3C2CN(C(=O)N[C@H](CN(C)C)C2CCCCC2)C3(C)C)C2SCCC2N1;CN(C)C[C@@H](NC(=O)N1CC2C(NC3NC(C)NC4CCSC34)N[NH]C2C1(C)C)C1CCCCC1
PF-03814735,PF-03814735,CHEMBL3545078,BRD:BRD-BRD-K68747584-001-02-0;BRD:BRD-K68747584-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB,,,PHASE 1,,Small molecule,Phase 1,,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C1CC(NC3NCC(C(NC4CCC4)N3)C(F)(F)F)CCC21
PF-03882845,PF-03882845,CHEMBL3545175,BRD:BRD-BRD-K51041191-001-01-4;BRD:BRD-K51041191-001-01-4;BRD:BRD-K51041191-001-02-9,rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,,,,PHASE 1,,Small molecule,Phase 1,,OC(=O)C1CCC2C3=C(CCC2C1)[C@H](C1CCCC1)N(N3)C1CCC(C#N)C(CL)C1
PF-04136309,PF-04136309,CHEMBL4650501,BRD:BRD-BRD-K94420399-001-01-9;BRD:BRD-K94420399-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,PHASE 2,,Unknown,Phase 2,,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)C1CCCC(C1)C(F)(F)F)C1CCC(CN1)-C1NCCCN1
PF-04217903,PF-04217903,CHEMBL2001019,BRD:BRD-BRD-K73319509-001-08-0;BRD:BRD-K73319509-001-08-0,rep_multi_dose;rep_primary;rep_single_dose,C-MET INHIBITOR,MET,,,PHASE 1,,Small molecule,Phase 1,PDMUGYOXRHVNMO-UHFFFAOYSA-N,OCCN1CC(-C2CNC3NNN(CC4CCC5NCCCC5C4)C3N2)CN1;OCCN1CC(CN1)-C1CNC2NNN(CC3CCC4NCCCC4C3)C2N1
PF-04418948,PF-04418948,CHEMBL3286797,BRD:BRD-BRD-K54871792-001-02-2;BRD:BRD-K54871792-001-02-2,rep_primary;rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGER2,,,PHASE 1,,Small molecule,Phase 1,LWJGMYMNSNVCEM-UHFFFAOYSA-N,COC1CCC2CC(OCC3(C(=O)O)CN(C(=O)C4CCC(F)CC4)C3)CCC2C1;COC1CCC2CC(OCC3(CN(C3)C(=O)C3CCC(F)CC3)C(O)=O)CCC2C1
PF-04447943,PF-04447943,CHEMBL2179105,BRD:BRD-BRD-K50031829-001-01-6;BRD:BRD-K50031829-001-01-6,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE9A,,,PHASE 2,,Small molecule,Phase 2,IWXUVYOOUMLUTQ-CZUORRHYSA-N,C[C@@H]1CN(CC2NCCCN2)C[C@H]1C1NC2C(CNN2C2CCOCC2)C(=O)[NH]1;C[C@@H]1CN(CC2NCCCN2)C[C@H]1C1NC2N(NCC2C(=O)[NH]1)C1CCOCC1
PF-04457845,PF-04457845,CHEMBL1651534,BRD:BRD-BRD-K86816506-001-01-8;BRD:BRD-K86816506-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,FAAH INHIBITOR,FAAH,,,PHASE 2,,Small molecule,Phase 2,BATCTBJIJJEPHM-UHFFFAOYSA-N,FC(F)(F)C1CCC(OC2CCCC(C=C3CCN(CC3)C(=O)NC3CCCNN3)C2)NC1;O=C(NC1CCCNN1)N1CCC(=CC2CCCC(OC3CCC(C(F)(F)F)CN3)C2)CC1
PF-04620110,PF-04620110,CHEMBL1835919,BRD:BRD-BRD-K30550578-001-01-3;BRD:BRD-K30550578-001-01-3,rep_primary;rep_single_dose,DIACYLGLYCEROL O ACYLTRANSFERASE INHIBITOR,DGAT1,,,PHASE 1,,Small molecule,Phase 1,GEVVQZHMFVFGLN-HDJSIYSDSA-N,NC1NCNC2C1C(=O)N(C1CCC([C@H]3CC[C@H](CC(=O)O)CC3)CC1)CCO2;NC1NCNC2OCCN(C3CCC(CC3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)C12
PF-04691502,PF-04691502,CHEMBL1234354,BRD:BRD-BRD-K07310275-001-02-5;BRD:BRD-K07310275-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR;PIK3CA,,,PHASE 2,,Small molecule,Phase 2,XDLYKKIQACFMJG-WKILWMFISA-N,COC1CCC(-C2CC3C(C)NC(N)NC3N([C@H]3CC[C@H](OCCO)CC3)C2=O)CN1;COC1CCC(CN1)-C1CC2C(C)NC(N)NC2N([C@H]2CC[C@@H](CC2)OCCO)C1=O
PF-04885614,PF-04885614,,BRD:BRD-K92435527-001-03-9,rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,SCN10A,,,,,,NA,,
PF-04937319,PF-04937319,CHEMBL2165615,BRD:BRD-BRD-K27755542-001-01-6;BRD:BRD-K27755542-001-01-6,rep_primary;rep_single_dose,GLUCOKINASE ACTIVATOR,GCK,,,PHASE 2,,Small molecule,Phase 2,MASKQITXHVYVFL-UHFFFAOYSA-N,CC1CNC(NC(=O)C2CC(OC3CNC(C(=O)N(C)C)NC3)C3CC(C)OC3C2)CN1;CN(C)C(=O)C1NCC(OC2CC(CC3OC(C)CC23)C(=O)NC2CNC(C)CN2)CN1
PF-04995274,PF-04995274,CHEMBL2152922,BRD:BRD-K00004635-001-01-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,,,,,,Small molecule,Phase 1,WLLOFQROROXOMO-GOSISDBHSA-N,OC1(CN2CCC(COC3NOC4CCCC(O[C@@H]5CCOC5)C34)CC2)CCOCC1
PF-05089771,PF-05089771,CHEMBL3545171,BRD:BRD-K00003145-001-01-9,rep_single_dose,SODIUM CHANNEL BLOCKER,,,,,,Small molecule,Phase 2,,
PF-05175157,PF-05175157,CHEMBL3359265,BRD:BRD-K00002423-001-02-9,rep_single_dose,ACETYL-COA CARBOXYLASE INHIBITOR,,,,,,Small molecule,Phase 2,BDXXSFOJPYSYOC-UHFFFAOYSA-N,CC1NC2CCC(C(=O)N3CCC4(CC3)CC(=O)C3C(CNN3C(C)C)C4)CC2[NH]1
PF-05180999,PF-05180999,CHEMBL3092562,BRD:BRD-K00003097-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Phase 1,CLGCHUKGBICQTE-UHFFFAOYSA-N,CC1NC(-C2CNN(C)C2-C2CCC(C(F)(F)F)CN2)C2C(N3CCC3)NCNN12
PF-05190457,PF-05190457,CHEMBL3287218,BRD:BRD-BRD-K02554563-001-01-6;BRD:BRD-K02554563-001-01-6,rep_primary;rep_single_dose,GROWTH HORMONE SECRETAGOGUE RECEPTOR INVERSE AGONIST,GHSR,,,PHASE 2,,Small molecule,Phase 2,ZIUDADZJCKGWKR-AREMUKBSSA-N,CC1CC(-C2CCC3C(C2)CC[C@H]3N2CC3(CCN(C(=O)CC4CN5CC(C)SC5N4)CC3)C2)NCN1;CC1CN2CC(CC(=O)N3CCC4(CN(C4)[C@@H]4CCC5CC(CCC45)-C4CC(C)NCN4)CC3)NC2S1
PF-05212384,PF-05212384,CHEMBL592445,BRD:BRD-BRD-K07955840-001-02-3;BRD:BRD-K07955840-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR;PIK3CA,,,PHASE 2,,Small molecule,Phase 3,DWZAEMINVBZMHQ-UHFFFAOYSA-N,CN(C)C1CCN(C(=O)C2CCC(NC(=O)NC3CCC(-C4NC(N5CCOCC5)NC(N5CCOCC5)N4)CC3)CC2)CC1;CN(C)C1CCN(CC1)C(=O)C1CCC(NC(=O)NC2CCC(CC2)-C2NC(NC(N2)N2CCOCC2)N2CCOCC2)CC1
PF-06260414,PF-06260414,CHEMBL4297476,BRD:BRD-K00004644-001-01-9,rep_single_dose,ANDROGEN RECEPTOR MODULATOR,,,,,,Small molecule,Phase 1,ZKAVFOXYJCREBQ-SNVBAGLBSA-N,C[C@@H]1CNS(=O)(=O)N(C2CCC3C(C#N)NCCC3C2)C1
PF-06273340,PF-06273340,CHEMBL4212531,BRD:BRD-K00004638-001-01-9,rep_single_dose,TYROSINE KINASE RECEPTOR INHIBITOR,,,,,,Small molecule,Phase 1,BPIWZDNVMQQBQX-UHFFFAOYSA-N,CC(C)(CO)N1CC(C(=O)C2CNCC(NC(=O)CC3CCC(CL)CN3)C2)C2CNC(N)NC21
PF-06282999,PF-06282999,CHEMBL3633460,BRD:BRD-K00003279-001-01-9,rep_single_dose,MYELOPEROXIDASE INHIBITOR,,,,,,Small molecule,Phase 1,ICYNYWFGIDGBRD-UHFFFAOYSA-N,COC1CCC(CL)CC1-C1CC(=O)[NH]C(=S)N1CC(N)=O
PF-06305591,PF-06305591,CHEMBL4297317,BRD:BRD-K00004712-001-01-9,rep_single_dose,SODIUM CHANNEL BLOCKER,,,,,,Small molecule,Phase 1,APWZIFIAVVFPNT-PELKAZGASA-N,C[C@@H](C(N)=O)[C@H](N)C1NC2CCC(C(C)(C)C)CC2[NH]1
PF-06409577,PF-06409577,,BRD:BRD-K00003731-001-01-9,rep_single_dose,PROTEIN KINASE ACTIVATOR,,,,,,,NA,,
PF-06412562,PF-06412562,,BRD:BRD-K00004652-001-01-9,rep_single_dose,DOPAMINE RECEPTOR PARTIAL AGONIST,,,,,,,NA,,
PF-06447475,PF-06447475,,BRD:BRD-BRD-K83114366-001-02-8;BRD:BRD-K83114366-001-02-8,rep_primary;rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,LRRK2,,,PRECLINICAL,,,NA,,N#CC1CCCC(C1)-C1C[NH]C2NCNC(N3CCOCC3)C12
PF-06459988,PF-06459988,CHEMBL3786098,BRD:BRD-K00003311-001-01-9,rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Phase 2,ODMXWZROLKITMS-RISCZKNCSA-N,C=CC(=O)N1C[C@H](COC2NC(NC3CNN(C)C3)NC3[NH]CC(CL)C23)[C@@H](OC)C1
PF-06463922,PF-06463922,CHEMBL3286830,BRD:BRD-A23124853-001-01-4;BRD:BRD-BRD-A23124853-001-01-4,rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,ALK;FES;ROS1,,,PHASE 2,,Small molecule,Approved,IIXWYSCJSQVBQM-LLVKDONJSA-N,C[C@H]1OC2CC(CNC2N)-C2C(NN(C)C2C#N)CN(C)C(=O)C2CCC(F)CC21;CC1OC2CC(CNC2N)-C2C(CN(C)C(=O)C3CCC(F)CC13)NN(C)C2C#N
PF-06650833,PF-06650833,CHEMBL4081711,BRD:BRD-K00003296-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 2,JKDGKIBAOAFRPJ-ZBINZKHDSA-N,CC[C@@H]1[C@H](F)C(=O)N[C@@H]1COC1NCCC2CC(C(N)=O)C(OC)CC12
PF-06651600,PF-06651600,CHEMBL4085457,BRD:BRD-K47084954-001-02-9,rep_single_dose,JAK INHIBITOR,,,,,,Small molecule,Phase 3,CBRJPFGIXUFMTM-WDEREUQCSA-N,C=CC(=O)N1C[C@H](NC2NCNC3[NH]CCC23)CC[C@@H]1C
PF-06747775,PF-06747775,CHEMBL3989970,BRD:BRD-K00004648-001-01-9,rep_single_dose,EGFR INHIBITOR,,,,,,Small molecule,Phase 2,JYIUNVOCEFIUIU-GHMZBOCLSA-N,C=CC(=O)N[C@@H]1CN(C2NC(NC3CN(C)NC3OC)C3NCN(C)C3N2)C[C@H]1F
PF-06751979,PF-06751979,CHEMBL4297807,BRD:BRD-K00004598-001-01-9,rep_single_dose,BETA SECRETASE INHIBITOR,,,,,,Unknown,Phase 1,,
PF-06840003,PF-06840003,CHEMBL4086143,BRD:BRD-K00003400-001-01-9,rep_single_dose,"INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR",,,,,,Small molecule,Phase 1,MXKLDYKORJEOPR-UHFFFAOYSA-N,O=C1CC(C2C[NH]C3CCC(F)CC23)C(=O)N1
PF-06873600,PF-06873600,CHEMBL4446357,BRD:BRD-K00004750-001-01-9;BRD:BRD-K00004750-001-03-9,oncref_2;rep_single_dose,"INHIBITOR OF CDK2, CDK4, AND CDK6",CDK2;CDK4;CDK6,,,,"Multiple values for MOA: {'CDK INHIBITOR', 'INHIBITOR OF CDK2, CDK4, AND CDK6'}, defaulting to 'INHIBITOR OF CDK2, CDK4, AND CDK6'",Small molecule,Phase 2,QIEKHLDZKRQLLN-FOIQADDNSA-N,C[C@@]1(O)CCC[C@H]1N1C(=O)C(C(F)F)CC2CNC(NC3CCN(S(C)(=O)=O)CC3)NC21
PF-06928215,PF-06928215,,BRD:BRD-K00005326-001-01-9,rep_single_dose,CYCLIC GMP-AMP SYNTHASE INHIBITOR,,,,,,,NA,,
PF-06952229,PF-06952229,CHEMBL5095192,BRD:BRD-K00091071-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,IPBLCOKXDQHSQW-UHFFFAOYSA-N,CC(C)C1CNC(-C2CC(CL)CCC2F)CC1NC1CCNCC1C(=O)NC(CO)CO
PF-07104091,PF-07104091,,BRD:BRD-K00126469-001-01-9,oncref_2,INHIBITOR OF CDK2,CDK2,,,,,,NA,,
PF-184,PF-184,,CTRP:660208,ctrp,,,,,,,,NA,,
PF-2341066,PF-2341066,CHEMBL601719,GDSC1:37;GDSC2:1083,gdsc,,,,,,,Small molecule,Approved,KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](OC1CC(-C2CNN(C3CCNCC3)C2)CNC1N)C1C(CL)CCC(F)C1CL
PF-3274167,PF-3274167,,BRD:BRD-BRD-K31417912-001-01-9;BRD:BRD-K31417912-001-01-9,rep_primary;rep_single_dose,OXYTOCIN RECEPTOR ANTAGONIST,AVPR1A;OXTR,,,PHASE 2,,,NA,,COCC1NNC(N2CC(C2)OC2CCC(F)CC2CL)N1-C1CCC(OC)NC1
PF-3758309,PF-3758309,CHEMBL3128043,CTRP:687953,ctrp,,,,,,,Small molecule,Phase 1,AYCPARAPKDAOEN-LJQANCHMSA-N,CC1NC(NC2N[NH]C3C2CN(C(=O)N[C@H](CN(C)C)C2CCCCC2)C3(C)C)C2SCCC2N1
PF-3845,PF-3845,,BRD:BRD-BRD-K68997413-001-05-1;BRD:BRD-K68997413-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,FAAH INHIBITOR,FAAH,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCC(OC2CCCC(CC3CCN(CC3)C(=O)NC3CCCNC3)C2)NC1
PF-4191834,PF-4191834,CHEMBL4297416,BRD:BRD-K00004633-001-01-9,rep_single_dose,LIPOXYGENASE INHIBITOR,,,,,,Small molecule,Phase 2,DVNQWYLVSNPCJZ-UHFFFAOYSA-N,CN1NCCC1-C1CCC(SC2CCCC(C3(C(N)=O)CCOCC3)C2)CC1
PF-429242,PF-429242,,BRD:BRD-K11821338-300-02-9,rep_single_dose,SREBP INHIBITOR,MBTPS1,,,,,,NA,,
PF-431396,PF-431396,,BRD:BRD-BRD-K93788137-001-04-1;BRD:BRD-K93788137-001-04-1,rep_primary;rep_single_dose,FOCAL ADHESION KINASE INHIBITOR,PTK2;PTK2B,,,PRECLINICAL,,,NA,,CN(C1CCCCC1CNC1NC(NC2CCC3NC(=O)CC3C2)NCC1C(F)(F)F)S(C)(=O)=O
PF-4708671,PF-4708671,,BRD:BRD-BRD-K14711741-001-02-1;BRD:BRD-K14711741-001-02-1;GDSC1:1129;GDSC2:1129,gdsc;rep_primary;rep_single_dose,RIBOSOMAL PROTEIN INHIBITOR,RPS6KB1,,,PRECLINICAL,,,NA,,CCC1CNCNC1N1CCN(CC1)CC1NC2CC(CCC2[NH]1)C(F)(F)F
PF-736,PF-477736;PF-736,CHEMBL3545137,BRD:BRD-BRD-K03063480-001-05-8;BRD:BRD-BRD-K03063480-001-06-6;BRD:BRD-K03063480-001-05-8;BRD:BRD-K03063480-001-06-6;BRD:BRD-K03063480-001-08-9,oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF CHEK1,CHEK1;CHEK2,,,PHASE 1,"Multiple values for MOA: {'INHIBITOR OF CHEK1', 'CHK INHIBITOR'}, defaulting to 'INHIBITOR OF CHEK1'
Multiple values for repurposing_target: {'CHEK1;CHEK2', 'CHEK1'}, taking the union",Small molecule,Phase 1,YFNWWNRZJGMDBR-UHFFFAOYSA-N,CN1CC(C2=NC3CC(NC(=O)C(N)C4CCCCC4)CC4C3C2=CNNC4=O)CN1;CN1CC(CN1)-C1[NH]C2CC(NC(=O)[C@H](N)C3CCCCC3)CC3C2C1CN[NH]C3=O
PF-4800567,PF-4800567,,BRD:BRD-BRD-K43428468-003-04-0;BRD:BRD-K43428468-003-04-0,rep_primary;rep_single_dose,CASEIN KINASE INHIBITOR,CSNK1D;CSNK1E,,,PRECLINICAL,,,NA,,NC1NCNC2N(NC(COC3CCCC(CL)C3)C12)C1CCOCC1
PF-4800567 HYDROCHLORIDE,PF-4800567 HYDROCHLORIDE,,CTRP:688962,ctrp,,,,,,,,NA,,
PF-4981517,PF-4981517,,BRD:BRD-BRD-K78318619-001-02-7;BRD:BRD-K78318619-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP3A4,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1C(CNN1C)-C1NN(C)C2NCNC(N3CC[C@@H](C3)N3CCCCC3)C12
PF-514273,PF-514273,,BRD:BRD-K00004642-001-01-9,rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,,,,,,,NA,,
PF-5274857,PF-5274857,,BRD:BRD-BRD-K40302533-001-02-9;BRD:BRD-K40302533-001-02-9,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,SMO,,,PRECLINICAL,,,NA,,CC1CNC(C(C)C1)-C1CC(NCC1CL)N1CCN(CC1)C(=O)CCS(C)(=O)=O
PF-543,PF-543,,CTRP:660073;GDSC1:408,ctrp;gdsc,,,,,,,,NA,,
PF-562271,PF-562271,CHEMBL1084546,BRD:BRD-BRD-K99545815-001-06-3;BRD:BRD-K99545815-001-06-3;GDSC1:158,gdsc;rep_multi_dose;rep_primary;rep_single_dose,FOCAL ADHESION KINASE INHIBITOR,PTK2;PTK2B,,,PHASE 1,,Small molecule,Phase 1,MZDKLVOWGIOKTN-UHFFFAOYSA-N,CN(C1NCCCC1CNC1NC(NC2CCC3C(C2)CC(=O)N3)NCC1C(F)(F)F)S(C)(=O)=O;CN(C1NCCCC1CNC1NC(NC2CCC3NC(=O)CC3C2)NCC1C(F)(F)F)S(C)(=O)=O
PF-573228,PF-573228,,BRD:BRD-BRD-K79239947-001-06-8;BRD:BRD-K79239947-001-06-8;BRD:BRD-U00115423-001-01-9;CTRP:660075,ctrp;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,FOCAL ADHESION KINASE INHIBITOR,CDK1;CDK2;CDK7;FAK;GSK3B;IKBKB,,,PRECLINICAL,"Multiple values for MOA: {'FOCAL ADHESION KINASE INHIBITOR', 'INHIBITOR OF FAK'}, defaulting to 'FOCAL ADHESION KINASE INHIBITOR'
Multiple values for repurposing_target: {'FAK', 'CDK1;CDK2;CDK7;GSK3B;IKBKB'}, taking the union
Multiple values for structure_id: {'U00115423', 'K79239947'}, defaulting to None",,NA,,CS(=O)(=O)C1CCCC(CNC2NC(NC3CCC4NC(=O)CCC4C3)NCC2C(F)(F)F)C1
PF-670462,PF-670462,,BRD:BRD-BRD-K96295391-300-01-7;BRD:BRD-K96295391-300-01-7,rep_primary;rep_single_dose,CASEIN KINASE INHIBITOR,CSNK1D;CSNK1E,,,PRECLINICAL,,,NA,,NC1NCCC(N1)-C1C(NCN1C1CCCCC1)-C1CCC(F)CC1
PF-750,PF-750,,BRD:BRD-K83213911-001-08-9;CTRP:411719,ctrp;rep_single_dose,FAAH INHIBITOR,FAAH,,,,,,NA,,
PF-8380,PF-8380,,BRD:BRD-K50865540-001-02-3,rep_single_dose,AUTOTAXIN INHIBITOR,ENPP2,,,,,,NA,,
PF-915275,PF-915275,,BRD:BRD-BRD-K18289362-001-02-2;BRD:BRD-K18289362-001-02-2,rep_primary;rep_single_dose,11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR,HSD11B1,,,PHASE 1,,,NA,,NC1CCCC(NS(=O)(=O)C2CCC(CC2)-C2CCC(CC2)C#N)N1
PF2341066,PF2341066,,GDSC1:37;GDSC2:1083,gdsc,,,,,,,,NA,,
PF4708671,PF4708671,,GDSC1:1129;GDSC2:1129,gdsc,,,,,,,,NA,,
PFI-1,PFI-1,,BRD:BRD-BRD-K13094524-001-07-5;BRD:BRD-K13094524-001-07-5;GDSC1:1219,gdsc;rep_multi_dose;rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,BRD4,,,PRECLINICAL,,,NA,,COC1CCCCC1S(=O)(=O)NC1CCC2NC(=O)N(C)CC2C1
PFI-3,PFI-3,,BRD:BRD-K61524559-001-04-7;GDSC1:1530;GDSC2:1620,gdsc;rep_single_dose,BROMODOMAIN INHIBITOR,PBRM1;SMARCA4,,,,,,NA,,
PFI-4,PFI-4,,BRD:BRD-K13106865-001-02-9,rep_single_dose,BROMODOMAIN INHIBITOR,BRPF1,,,,,,NA,,
PFI-6,PFI-6,,BRD:BRD-K00126494-001-01-9,oncref_2,INHIBITOR OF MLLT1 AND MLLT3,MLLT1;MLLT3,,,,,,NA,,
PFK-015,PFK-015,,BRD:BRD-BRD-K95573441-001-01-2;BRD:BRD-K95573441-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHOFRUCTOKINASE INHIBITOR,PFKFB3,,,PHASE 1,,,NA,,O=C(\C=C\C1CCC2CCCCC2N1)C1CCNCC1
PFK-158,PFK-158,CHEMBL4303611,BRD:BRD-BRD-K28010364-001-01-0;BRD:BRD-K28010364-001-01-0,rep_primary;rep_single_dose,PHOSPHOFRUCTOKINASE INHIBITOR,PFKFB3,,,PHASE 1,,Small molecule,Phase 1,IAJOMYABKVAZCN-AATRIKPKSA-N,FC(F)(F)C1CCC2CCC(\C=C\C(=O)C3CCNCC3)NC2C1;O=C(/C=C/C1CCC2CCC(C(F)(F)F)CC2N1)C1CCNCC1
PG-9,PG-9,,BRD:BRD-A70268693-050-01-2;BRD:BRD-BRD-A70268693-050-01-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CC(C(=O)OC1CC2CCC(C1)N2C)C1CCC(BR)CC1
PGL5001,PGL5001,CHEMBL3545213,BRD:BRD-A53813595-001-01-8;BRD:BRD-BRD-A53813595-001-01-8,rep_primary;rep_single_dose,JNK INHIBITOR,MAPK10;MAPK8;MAPK9,,,PHASE 2,,Small molecule,Phase 2,XCPPIJCBCWUBNT-UHFFFAOYSA-N,N#CC(C1CCNC(OCC2CCC(CN3CCOCC3)CC2)N1)C1NC2CCCCC2S1;N#CC(C1NC2CCCCC2S1)C1CCNC(OCC2CCC(CN3CCOCC3)CC2)N1
PH-797804,PH-797804,CHEMBL1088751,BRD:BRD-BRD-K95880107-001-02-4;BRD:BRD-K95880107-001-02-4,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK11;MAPK14,,,PHASE 2,,Small molecule,Phase 2,KCAJXIDMCNPGHZ-UHFFFAOYSA-N,CNC(=O)C1CCC(C)C(-N2C(C)CC(OCC3CCC(F)CC3F)C(BR)C2=O)C1;CNC(=O)C1CCC(C)C(C1)-N1C(C)CC(OCC2CCC(F)CC2F)C(BR)C1=O
PHA 665752,PHA 665752,,GDSC1:6,gdsc,,,,,,,,NA,,
PHA 793887,PHA 793887,,GDSC1:301,gdsc,,,,,,,,NA,,
PHA-543613,PHA-543613,CHEMBL214268,BRD:BRD-K00004641-001-01-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,,,,,,Small molecule,Phase 1,IPKZCLGGYKRDES-ZDUSSCGKSA-N,O=C(N[C@H]1CN2CCC1CC2)C1CC2CCOC2CN1
PHA-568487,PHA-568487,,BRD:BRD-K48053228-051-02-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,CHRNA7,,,,,,NA,,
PHA-665752,PHA-665752,CHEMBL450786,BRD:BRD-BRD-K95435023-001-08-5;BRD:BRD-BRD-K95435023-001-10-1;BRD:BRD-K95435023-001-08-5;BRD:BRD-K95435023-001-10-1;GDSC1:6,gdsc;rep_multi_dose;rep_primary;rep_single_dose,C-MET INHIBITOR,MET,,,PRECLINICAL,,Small molecule,NA,OYONTEXKYJZFHA-SSHUPFPWSA-N,CC1[NH]C(/C=C2\C(=O)NC3CCC(S(=O)(=O)CC4C(CL)CCCC4CL)CC32)C(C)C1C(=O)N1CCC[C@@H]1CN1CCCC1;CC1[NH]C(\C=C2/C(=O)NC3CCC(CC23)S(=O)(=O)CC2C(CL)CCCC2CL)C(C)C1C(=O)N1CCC[C@@H]1CN1CCCC1
PHA-680632,PHA-680632,CHEMBL363160,BRD:BRD-BRD-K09443272-001-03-3;BRD:BRD-K09443272-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC,,,PRECLINICAL,,Small molecule,NA,OBWNXGOQPLDDPS-UHFFFAOYSA-N,CCC1CCCC(CC)C1NC(=O)N1CC2[NH]NC(NC(=O)C3CCC(CC3)N3CCN(C)CC3)C2C1;CCC1CCCC(CC)C1NC(=O)N1CC2[NH]NC(NC(=O)C3CCC(N4CCN(C)CC4)CC3)C2C1
PHA-767491,PHA-767491,,BRD:BRD-BRD-K50000283-001-04-4;BRD:BRD-K50000283-001-04-4,rep_multi_dose;rep_primary;rep_single_dose,CDC INHIBITOR,CDK1;RPS6KB1,,,PRECLINICAL,,,NA,,O=C1NCCC2[NH]C(CC12)-C1CCNCC1
PHA-793887,PHA-793887,CHEMBL1230607,BRD:BRD-BRD-K64800655-001-07-4;BRD:BRD-K64800655-001-07-4;CTRP:640007;GDSC1:301,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK4;CDK5;CDK7;CDK9,,,PHASE 1,,Small molecule,Phase 1,HUXYBQXJVXOMKX-UHFFFAOYSA-N,CC(C)CC(=O)NC1N[NH]C2C1CN(C(=O)C1CCN(C)CC1)C2(C)C
PHA-848125,PHA-848125,CHEMBL564829,BRD:BRD-BRD-K60997853-001-02-3;BRD:BRD-K60997853-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, GROWTH FACTOR RECEPTOR INHIBITOR",CDK2;CDK4;CDK7;NTRK1,,,PHASE 2,,Small molecule,Phase 2,RXZMYLDMFYNEIM-UHFFFAOYSA-N,CNC(=O)C1NN(C)C-2C1C(C)(C)CC1CNC(NC3CCC(CC3)N3CCN(C)CC3)NC-21;CNC(=O)C1NN(C)C2C1C(C)(C)CC1CNC(NC3CCC(N4CCN(C)CC4)CC3)NC1-2
PHA665752,PHA665752,,GDSC1:6,gdsc,,,,,,,,NA,,
PHA793887,PHA793887,,GDSC1:301,gdsc,,,,,,,,NA,,
PHCCC,PHCCC,,BRD:BRD-A59709458-001-01-8;BRD:BRD-BRD-A59709458-001-01-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRM1;GRM4,,,PRECLINICAL,,,NA,,O\N=C1/C2CC2(OC2CCCCC12)C(=O)NC1CCCCC1
PHENACAINE,PHENACAINE,CHEMBL127123,BRD:BRD-BRD-K81092066-311-01-6;BRD:BRD-K81092066-311-01-6,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,LOCAL ANESTHETIC,,LAUNCHED,,Small molecule,Unknown,QXDAEKSDNVPFJG-UHFFFAOYSA-N,CCOC1CCC(/N=C(\C)NC2CCC(OCC)CC2)CC1;CCOC1CCC(NC(C)=NC2CCC(OCC)CC2)CC1
PHENACEMIDE,PHENACEMIDE,CHEMBL918,BRD:BRD-BRD-K40905133-001-04-9;BRD:BRD-K40905133-001-04-9,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,"EPILEPSY, SEIZURES",,LAUNCHED,,Small molecule,Approved,XPFRXWCVYUEORT-UHFFFAOYSA-N,NC(=O)NC(=O)CC1CCCCC1
PHENACETIN,PHENACETIN,CHEMBL16073,BRD:BRD-BRD-K38323065-001-19-9;BRD:BRD-K38323065-001-19-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1,,,WITHDRAWN,,Small molecule,Approved,CPJSUEIXXCENMM-UHFFFAOYSA-N,CCOC1CCC(NC(C)=O)CC1
PHENAZONE,PHENAZONE,CHEMBL277474,BRD:BRD-BRD-K46937689-001-15-0;BRD:BRD-K46937689-001-15-0,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,PAIN RELIEF,,LAUNCHED,,Small molecule,Approved,VEQOALNAAJBPNY-UHFFFAOYSA-N,CC1CC(=O)N(-C2CCCCC2)N1C
PHENAZOPYRIDINE,PHENAZOPYRIDINE,CHEMBL1242,BRD:BRD-BRD-K76304753-003-20-3;BRD:BRD-BRD-K76304753-003-21-1;BRD:BRD-K76304753-003-20-3;BRD:BRD-K76304753-003-21-1,rep_primary;rep_single_dose,LOCAL ANESTHETIC,SCN1A,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,QPFYXYFORQJZEC-FOCLMDBBSA-N,NC1CCC(/N=N/C2CCCCC2)C(N)N1;NC1CCC(\N=N\C2CCCCC2)C(N)N1
PHENELZINE,PHENELZINE,CHEMBL1089,BRD:BRD-BRD-K87024524-065-17-7;BRD:BRD-K87024524-065-17-7,rep_multi_dose;rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,ABAT;AOC3;GAD2;GPT;GPT2;MAOA;MAOB;SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,RMUCZJUITONUFY-UHFFFAOYSA-N,NNCCC1CCCCC1
PHENFORMIN,PHENFORMIN,CHEMBL170988,BRD:BRD-BRD-K11399644-003-11-3;BRD:BRD-K11399644-003-11-3;GDSC1:196,gdsc;rep_primary;rep_single_dose,AMPK ACTIVATOR,KCNJ8;PRKAA1,,,WITHDRAWN,,Small molecule,Approved,ICFJFFQQTFMIBG-UHFFFAOYSA-N,N=C(N)NC(=N)NCCC1CCCCC1;NC(=N)NC(=N)NCCC1CCCCC1
PHENINDIONE,PHENINDIONE,CHEMBL711,BRD:BRD-BRD-K70592963-001-31-6;BRD:BRD-K70592963-001-31-6,rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,VKORC1,DEEP VEIN THROMBOSIS (DVT),,LAUNCHED,,Small molecule,Approved,NFBAXHOPROOJAW-UHFFFAOYSA-N,O=C1C(C(=O)C2CCCCC12)C1CCCCC1;O=C1C2CCCCC2C(=O)C1C1CCCCC1
PHENIRAMINE,PHENIRAMINE,CHEMBL1193,BRD:BRD-A23072235-050-18-5;BRD:BRD-BRD-A23072235-050-18-5,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,IJHNSHDBIRRJRN-UHFFFAOYSA-N,CN(C)CCC(C1CCCCC1)C1CCCCN1
PHENOLPHTHALEIN,PHENOLPHTHALEIN,CHEMBL2109222;CHEMBL63857,BRD:BRD-BRD-K19227686-001-18-6;BRD:BRD-K19227686-001-18-6,rep_primary;rep_single_dose,INDICATOR DYE,UGT1A9,,,WITHDRAWN,,Small molecule;Unknown,Approved,;KJFMBFZCATUALV-UHFFFAOYSA-N,O=C1OC(C2CCC(O)CC2)(C2CCC(O)CC2)C2CCCCC21;OC1CCC(CC1)C1(OC(=O)C2CCCCC12)C1CCC(O)CC1
PHENOLSULFONPHTHALEIN,PHENOLSULFONPHTHALEIN,CHEMBL258921,BRD:BRD-BRD-K79892937-001-02-5;BRD:BRD-K79892937-001-02-5,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,BELBBZDIHDAJOR-UHFFFAOYSA-N,O=S1(=O)OC(C2CCC(O)CC2)(C2CCC(O)CC2)C2CCCCC21;OC1CCC(CC1)C1(OS(=O)(=O)C2CCCCC12)C1CCC(O)CC1
PHENOTHIAZINE,PHENOTHIAZINE,CHEMBL828,BRD:BRD-BRD-K59597909-001-17-6;BRD:BRD-K59597909-001-17-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,Small molecule,Unknown,WJFKNYWRSNBZNX-UHFFFAOYSA-N,C1CCC2C(C1)NC1CCCCC1S2;N1C2CCCCC2SC2CCCCC12
PHENOTHRIN,PHENOTHRIN,CHEMBL1322884,BRD:BRD-A22106989-001-05-0;BRD:BRD-BRD-A22106989-001-05-0,rep_primary;rep_single_dose,,,LICE,,LAUNCHED,,Small molecule,Approved,SBNFWQZLDJGRLK-UHFFFAOYSA-N,CC(C)=CC1C(C(=O)OCC2CCCC(OC3CCCCC3)C2)C1(C)C
PHENPROBAMATE,PHENPROBAMATE,CHEMBL1079576,BRD:BRD-BRD-K22009844-001-12-5;BRD:BRD-K22009844-001-12-5,rep_primary;rep_single_dose,MUSCLE RELAXANT,,"ANXIETY, MUSCLE RELAXANT",,LAUNCHED,,Small molecule,Unknown,CAMYKONBWHRPDD-UHFFFAOYSA-N,NC(=O)OCCCC1CCCCC1
PHENPROCOUMON,PHENPROCOUMON,CHEMBL1465;CHEMBL16694,BRD:BRD-A49838158-001-01-1;BRD:BRD-BRD-A49838158-001-01-1,rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,VKORC1,"THROMBOSIS, PULMONARY EMBOLISM (PE)",,LAUNCHED,,Small molecule,Approved,DQDAYGNAKTZFIW-UHFFFAOYSA-N;QNDUUBVQYBBRBW-UHFFFAOYSA-N,CCC(C1CCCCC1)C1C(O)C2CCCCC2OC1=O;CCC(C1CCCCC1)C1C(O)OC2CCCCC2C1=O
PHENSERINE,PHENSERINE,CHEMBL4297417;CHEMBL74926,BRD:BRD-BRD-K46580984-001-03-6;BRD:BRD-K46580984-001-03-6,rep_primary;rep_single_dose,"ACETYLCHOLINESTERASE INHIBITOR, BETA AMYLOID SYNTHESIS INHIBITOR",ACHE;BCHE,,,PHASE 3,,Small molecule,Phase 3,PBHFNBQPZCRWQP-AZUAARDMSA-N;PBHFNBQPZCRWQP-QUCCMNQESA-N,CN1CC[C@]2(C)[C@H]1N(C)C1CCC(OC(=O)NC3CCCCC3)CC21;CN1CC[C@]2(C)C3CC(OC(=O)NC4CCCCC4)CCC3N(C)[C@H]12;CN1CC[C@@]2(C)C3CC(OC(=O)NC4CCCCC4)CCC3N(C)[C@@H]12
PHENSUXIMIDE,PHENSUXIMIDE,CHEMBL797,BRD:BRD-A18043272-001-09-9;BRD:BRD-BRD-A18043272-001-09-9,rep_primary;rep_single_dose,SUCCINIMIDE ANTIEPILEPTIC,CACNA1G;CACNA1H;CACNA1I,SEIZURES,,LAUNCHED,,Small molecule,Approved,WLWFNJKHKGIJNW-UHFFFAOYSA-N,CN1C(=O)CC(C1=O)C1CCCCC1;CN1C(=O)CC(C2CCCCC2)C1=O
PHENTERMINE,PHENTERMINE,CHEMBL1574,BRD:BRD-BRD-K96319534-003-03-9;BRD:BRD-K96319534-003-03-9,rep_primary;rep_single_dose,"DOPAMINE UPTAKE INHIBITOR, SEROTONIN REUPTAKE INHIBITOR",MAOA;MAOB;SLC6A2;SLC6A3;SLC6A4,WEIGHT-LOSS AID,,LAUNCHED,,Small molecule,Approved,DHHVAGZRUROJKS-UHFFFAOYSA-N,CC(C)(N)CC1CCCCC1
PHENTOLAMINE,PHENTOLAMINE,CHEMBL597,BRD:BRD-BRD-K90333595-003-21-4;BRD:BRD-K90333595-003-21-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"PHEOCHROMOCYTOMA, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,MRBDMNSDAVCSSF-UHFFFAOYSA-N,CC1CCC(CC1)N(CC1=NCCN1)C1CCCC(O)C1;CC1CCC(N(CC2=NCCN2)C2CCCC(O)C2)CC1
PHENYL-AMINOSALICYLATE,PHENYL-AMINOSALICYLATE,,BRD:BRD-BRD-K73157543-001-04-1;BRD:BRD-K73157543-001-04-1,rep_primary;rep_single_dose,,,TUBERCULOSIS,,LAUNCHED,,,NA,,NC1CCC(C(=O)OC2CCCCC2)C(O)C1
PHENYL-SALICYLATE,PHENYL-SALICYLATE,,BRD:BRD-K44091963-001-04-9,rep_single_dose,ANTISEPTIC,,,,,,,NA,,
PHENYLACETYLGLUTAMINE,PHENYLACETYLGLUTAMINE,,BRD:BRD-BRD-K70592483-001-01-0;BRD:BRD-K70592483-001-01-0,rep_primary;rep_single_dose,"DNA METHYLASE INHIBITOR, PROTEIN SYNTHESIS INHIBITOR",,,,PHASE 2,,,NA,,NC(=O)CC[C@H](NC(=O)CC1CCCCC1)C(O)=O
PHENYLBENZIMIDAZOLE-SULFONIC-ACID,PHENYLBENZIMIDAZOLE-SULFONIC-ACID,,BRD:BRD-BRD-K02729857-001-01-9;BRD:BRD-K02729857-001-01-9,rep_primary;rep_single_dose,,,SUNSCREEN LOTION,,LAUNCHED,,,NA,,OS(=O)(=O)C1CCC2[NH]C(NC2C1)-C1CCCCC1
PHENYLBUTAZONE,PHENYLBUTAZONE,CHEMBL101,BRD:BRD-BRD-K10843433-001-22-7;BRD:BRD-BRD-K10843433-001-23-5;BRD:BRD-K10843433-001-22-7;BRD:BRD-K10843433-001-23-5,rep_multi_dose;rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTANOID RECEPTOR ANTAGONIST",PTGIS;PTGS1;PTGS2,,,WITHDRAWN,,Small molecule,Approved,VYMDGNCVAMGZFE-UHFFFAOYSA-N,CCCCC1C(=O)N(C2CCCCC2)N(C2CCCCC2)C1=O;CCCCC1C(=O)N(N(C1=O)C1CCCCC1)C1CCCCC1
PHENYLBUTYRATE,PHENYLBUTYRATE,CHEMBL1469,BRD:BRD-BRD-K67102207-236-07-7;BRD:BRD-K67102207-236-07-7,rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1,UREA CYCLE DISORDERS,,LAUNCHED,,Small molecule,Approved,OBKXEAXTFZPCHS-UHFFFAOYSA-N,O=C(O)CCCC1CCCCC1;OC(=O)CCCC1CCCCC1
PHENYLEPHRINE,PHENYLEPHRINE,CHEMBL1215,BRD:BRD-BRD-K73381542-003-23-4;BRD:BRD-K73381542-003-23-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D,"NASAL CONGESTION, HEMORRHOIDS, HYPOTENSION",,LAUNCHED,,Small molecule,Approved,SONNWYBIRXJNDC-VIFPVBQESA-N,CNC[C@H](O)C1CCCC(O)C1
PHENYLMERCURIC-ACETATE,PHENYLMERCURIC-ACETATE,,BRD:BRD-BRD-K74193284-001-04-8;BRD:BRD-K74193284-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,OTHER ANTIFUNGAL,,,,PRECLINICAL,,,NA,,CC(=O)O[HG]C1CCCCC1
PHENYLMETHYLSULFONYL-FLUORIDE,PHENYLMETHYLSULFONYL-FLUORIDE,,BRD:BRD-K33422401-001-06-4,rep_single_dose,SERINE PROTEASE INHIBITOR,,,,,,,NA,,
PHENYLPIRACETAM,PHENYLPIRACETAM,,BRD:BRD-A65683612-001-07-7;BRD:BRD-BRD-A65683612-001-07-7,rep_primary;rep_single_dose,NORADRENALINE UPTAKE INHIBITOR,,"ANXIETY, FATIGUE, DEPRESSION",,LAUNCHED,,,NA,,NC(=O)CN1CC(CC1=O)C1CCCCC1
PHENYTOIN,PHENYTOIN,CHEMBL16,BRD:BRD-BRD-K55930204-236-24-3;BRD:BRD-K55930204-236-24-3,rep_primary;rep_single_dose,HYDANTOIN ANTIEPILEPTIC,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,CXOFVDLJLONNDW-UHFFFAOYSA-N,O=C1NC(=O)C(C2CCCCC2)(C2CCCCC2)N1;O=C1NC(=O)C(N1)(C1CCCCC1)C1CCCCC1
PHIKAN-083,PHIKAN-083,,BRD:BRD-K44400149-003-02-9,rep_single_dose,P53 STABILIZING AGENT,TP53,,,,,,NA,,
PHLORETIN,PHLORETIN,CHEMBL45068,BRD:BRD-BRD-K15563106-001-18-0;BRD:BRD-K15563106-001-18-0;CTRP:24173,ctrp;rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,AQP9;CLCN3;SLC23A1,,,LAUNCHED,,Small molecule,NA,VGEREEWJJVICBM-UHFFFAOYSA-N,O=C(CCC1CCC(O)CC1)C1C(O)CC(O)CC1O;OC1CCC(CCC(=O)C2C(O)CC(O)CC2O)CC1
PHLORIZIN,PHLORIZIN,CHEMBL245067,BRD:BRD-BRD-K24601397-001-01-1;BRD:BRD-K24601397-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A1;SLC5A11;SLC5A2;SLC5A3,,,PRECLINICAL,,Small molecule,NA,IOUVKUPGCMBWBT-QNDFHXLGSA-N,O=C(CCC1CCC(O)CC1)C1C(O)CC(O)CC1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O;OC[C@H]1O[C@@H](OC2CC(O)CC(O)C2C(=O)CCC2CCC(O)CC2)[C@@H](O)[C@@H](O)[C@@H]1O
PHLOROGLUCIN,PHLOROGLUCIN,CHEMBL473159,BRD:BRD-BRD-K00405906-001-01-9;BRD:BRD-K00405906-001-01-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,QCDYQQDYXPDABM-UHFFFAOYSA-N,OC1CC(O)CC(O)C1
PHORTRESS,PHORTRESS,,BRD:BRD-BRD-K74558903-300-01-5;BRD:BRD-K74558903-300-01-5,rep_primary;rep_single_dose,ARYL HYDROCARBON RECEPTOR LIGAND,AHR,,,PHASE 1,,,NA,,CC1CC(CCC1NC(=O)[C@@H](N)CCCCN)-C1NC2CC(F)CCC2S1
PHOSPHATIDYLCHOLINE,PHOSPHATIDYLCHOLINE,CHEMBL503481,BRD:BRD-BRD-U51753822-000-01-1;BRD:BRD-U51753822-000-01-1,rep_primary;rep_single_dose,,PCTP,"HEPATITIS B, HEPATITIS C, ECZEMA, GALLBLADDER DISEASE, CHOLESTEROL, PREMENSTRUAL SYNDROME",,LAUNCHED,,Small molecule,Phase 3,ZZWQHNRGJQENEP-KXQOOQHDSA-N,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC;CCCCCCCCCCCCCCSCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CSCCCCCCCCCCCCCC
PHP-501,PHP-501,,BRD:BRD-K07460388-019-02-9,rep_single_dose,GABA RECEPTOR ANTAGONIST,GABRA1;GABRB2;GABRG2,,,,,,NA,,
PHT-427,PHT-427,,BRD:BRD-BRD-K59745944-001-02-0;BRD:BRD-K59745944-001-02-0,rep_primary;rep_single_dose,"AKT INHIBITOR, PYRUVATE DEHYDROGENASE INHIBITOR",AKT2;PDPK1,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCC1CCC(CC1)S(=O)(=O)NC1NNCS1
PHTHALYLSULFACETAMIDE,PHTHALYLSULFACETAMIDE,CHEMBL2106951,BRD:BRD-BRD-K77115421-001-02-6;BRD:BRD-K77115421-001-02-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,SNWQKAWITMVCQW-UHFFFAOYSA-N,CC(=O)NS(=O)(=O)C1CCC(NC(=O)C2CCCCC2C(=O)O)CC1;CC(=O)NS(=O)(=O)C1CCC(NC(=O)C2CCCCC2C(O)=O)CC1
PHTHALYLSULFATHIAZOLE,PHTHALYLSULFATHIAZOLE,CHEMBL1524273,BRD:BRD-BRD-K64659768-001-12-8;BRD:BRD-K64659768-001-12-8,rep_primary;rep_single_dose,DIHYDROPTEROATE SYNTHETASE INHIBITOR,,"DYSENTRY, COLITIS",,LAUNCHED,,Small molecule,Approved,PBMSWVPMRUJMPE-UHFFFAOYSA-N,O=C(O)C1CCCCC1C(=O)NC1CCC(S(=O)(=O)NC2NCCS2)CC1;OC(=O)C1CCCCC1C(=O)NC1CCC(CC1)S(=O)(=O)NC1NCCS1
PHTPP,PHTPP,,BRD:BRD-BRD-K76568384-001-02-2;BRD:BRD-K76568384-001-02-2,rep_primary;rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,ESR2,,,PRECLINICAL,,,NA,,OC1CCC(CC1)-C1C(NN2C(CC(NC12)C(F)(F)F)C(F)(F)F)-C1CCCCC1
PHYSOSTIGMINE,PHYSOSTIGMINE,CHEMBL94,BRD:BRD-BRD-K25650355-065-02-0;BRD:BRD-K25650355-065-02-0,rep_primary;rep_single_dose,"ACETYLCHOLINESTERASE INHIBITOR, CHOLINESTERASE INHIBITOR",ACHE;BCHE,"HYPOTENSION, ALZHEIMER'S DISEASE, GLAUCOMA, GASTROPARESIS",,LAUNCHED,"Multiple values for MOA: {'CHOLINESTERASE INHIBITOR', 'ACETYLCHOLINESTERASE INHIBITOR, CHOLINESTERASE INHIBITOR'}, defaulting to 'ACETYLCHOLINESTERASE INHIBITOR, CHOLINESTERASE INHIBITOR'",Small molecule,Approved,PIJVFDBKTWXHHD-HIFRSBDPSA-N,CNC(=O)OC1CCC2C(C1)[C@]1(C)CCN(C)[C@@H]1N2C;CNC(=O)OC1CCC2N(C)[C@H]3N(C)CC[C@@]3(C)C2C1
PHYTOSPHINGOSINE,PHYTOSPHINGOSINE,CHEMBL236036,BRD:BRD-BRD-K05048137-001-03-9;BRD:BRD-K05048137-001-03-9,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,NA,AERBNCYCJBRYDG-KSZLIROESA-N,CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO
PI 103,PI 103,,GDSC1:302,gdsc,,,,,,,,NA,,
PI-103,PI-103,CHEMBL573339,BRD:BRD-BRD-K67868012-001-07-6;BRD:BRD-K67868012-001-07-6;CTRP:411742;GDSC1:302,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC,,,PRECLINICAL,,Small molecule,NA,TUVCWJQQGGETHL-UHFFFAOYSA-N,OC1CCCC(-C2NC(N3CCOCC3)C3OC4NCCCC4C3N2)C1;OC1CCCC(C1)-C1NC(N2CCOCC2)C2OC3NCCCC3C2N1
PI-828,PI-828,,BRD:BRD-BRD-K97365803-001-02-1;BRD:BRD-K97365803-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,,,,PRECLINICAL,,,NA,,NC1CCC(CC1)-C1CCCC2C1OC(CC2=O)N1CCOCC1
PI103,PI103,,GDSC1:302,gdsc,,,,,,,,NA,,
PI3K-IN-2,PI3K-IN-2,CHEMBL4084907,BRD:BRD-BRD-K62374002-001-01-5;BRD:BRD-K62374002-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,ADGGYDAFIHSYFI-UHFFFAOYSA-N,NC1CC(C(CN1)-C1NC(NC(N1)N1CCOCC1)N1CCOCC1)C(F)(F)F;NC1CC(C(F)(F)F)C(-C2NC(N3CCOCC3)NC(N3CCOCC3)N2)CN1
PI3KD-IN-2,PI3KD-IN-2,,BRD:BRD-K00004592-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,,NA,,
PI4KIII-BETA-INHIBITOR-1,PI4KIII-BETA-INHIBITOR-1,,BRD:BRD-BRD-K75528696-001-01-2;BRD:BRD-K75528696-001-01-2,rep_primary;rep_single_dose,PI4K INHIBITOR,PI4K2B,,,PRECLINICAL,,,NA,,COC1CCC(CC1S(=O)(=O)NC1CCC(O)CC1)-C1SC(NC(=O)C(C)(C)C)NC1C
PIBENZIMOL,PIBENZIMOL,,BRD:BRD-BRD-K17026858-001-01-2;BRD:BRD-BRD-K79132813-001-09-0;BRD:BRD-K17026858-001-01-2;BRD:BRD-K79132813-001-09-0,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,,,PHASE 2,"Multiple values for structure_id: {'K17026858', 'K79132813'}, defaulting to None",,NA,,C1CCC2[NH]C(NC2C1)-C1NC2CCCCC2[NH]1;CN1CCN(CC1)C1CCC2NC([NH]C2C1)-C1CCC2NC([NH]C2C1)-C1CCC(O)CC1
PIBOSEROD,PIBOSEROD,CHEMBL356359,BRD:BRD-BRD-K02750403-001-01-4;BRD:BRD-K02750403-001-01-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2B;HTR4,,,PHASE 2,,Small molecule,Phase 2,KVCSJPATKXABRQ-UHFFFAOYSA-N,CCCCN1CCC(CNC(=O)C2C3N(C4CCCCC24)CCCO3)CC1;CCCCN1CCC(CNC(=O)C2C3OCCCN3C3CCCCC23)CC1
PIBRENTASVIR,PIBRENTASVIR,CHEMBL3545123,BRD:BRD-K00071592-001-01-9;BRD:BRD-K00076315-001-02-9,rep_single_dose,,,,,,"Multiple values for structure_id: {'K00076315', 'K00071592'}, defaulting to None",Small molecule,Approved,VJYSBPDEJWLKKJ-NLIMODCCSA-N,COC(=O)N[C@H](C(=O)N1CCC[C@H]1C1NC2CC([C@H]3CC[C@H](C4CC5NC([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)[NH]C5CC4F)N3C3CC(F)C(N4CCC(C5CCC(F)CC5)CC4)C(F)C3)C(F)CC2[NH]1)[C@@H](C)OC
PICARTAMIDE,PICARTAMIDE,CHEMBL100424,BRD:BRD-A71765060-001-01-4;BRD:BRD-BRD-A71765060-001-01-4,rep_primary;rep_single_dose,H+/K+-ATPASE INHIBITOR,ATP4A,,,PHASE 2,,Small molecule,Unknown,ITNLONMDUMHEOK-UHFFFAOYSA-N,CNC(=S)C1(C2CCCCN2)CCCS1;CNC(=S)C1(CCCS1)C1CCCCN1
PICEATANNOL,PICEATANNOL,CHEMBL23327;CHEMBL69863,BRD:BRD-BRD-K91509126-001-23-6;BRD:BRD-K91509126-001-23-6,rep_primary;rep_single_dose,SYK INHIBITOR,ATP5A1;ATP5B;ATP5C1;IRF3,,,PRECLINICAL,,Small molecule,NA,CDRPUGZCRXZLFL-OWOJBTEDSA-N;PMXCMJLOPOFPBT-HNNXBMFYSA-N,CC(C)[C@H](CO)NC1NC(NC2CCCC(CL)C2)C2NCN(C(C)C)C2N1;OC1CC(O)CC(/C=C/C2CCC(O)C(O)C2)C1;OC1CC(O)CC(C1)\C=C\C1CCC(O)C(O)C1
PICLAMILAST,PICLAMILAST,CHEMBL42126,BRD:BRD-BRD-K47642186-001-01-3;BRD:BRD-K47642186-001-01-3,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4C;PDE4D,,,PHASE 2,,Small molecule,Unknown,RRRUXBQSQLKHEL-UHFFFAOYSA-N,COC1CCC(C(=O)NC2C(CL)CNCC2CL)CC1OC1CCCC1;COC1CCC(CC1OC1CCCC1)C(=O)NC1C(CL)CNCC1CL
PICOLAMINE,PICOLAMINE,CHEMBL1988272,BRD:BRD-BRD-K68653965-001-01-1;BRD:BRD-K68653965-001-01-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,HDOUGSFASVGDCS-UHFFFAOYSA-N,NCC1CCCNC1
PICOLINATE,PICOLINATE,,GDSC2:1635,gdsc,,,,,,,,NA,,
PICOLINICI-ACID,PICOLINICI-ACID,,GDSC2:1635,gdsc,,,,,,,,NA,,
PICONOL,PICONOL,CHEMBL2103981,BRD:BRD-BRD-K28492574-001-01-6;BRD:BRD-K28492574-001-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,SHNUBALDGXWUJI-UHFFFAOYSA-N,OCC1CCCCN1
PICOTAMIDE,PICOTAMIDE,CHEMBL1257015,BRD:BRD-BRD-K67277431-002-10-5;BRD:BRD-K67277431-002-10-5,rep_primary;rep_single_dose,"THROMBOXANE RECEPTOR ANTAGONIST, THROMBOXANE SYNTHASE INHIBITOR",TBXA2R,THROMBOSIS,,LAUNCHED,,Small molecule,Approved,KYWCWBXGRWWINE-UHFFFAOYSA-N,COC1CCC(C(=O)NCC2CCCNC2)CC1C(=O)NCC1CCCNC1;COC1CCC(CC1C(=O)NCC1CCCNC1)C(=O)NCC1CCCNC1
PICROTIN,PICROTIN,CHEMBL478523,BRD:BRD-A91822151-001-05-0;BRD:BRD-BRD-A91822151-001-05-0,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABRA1;GABRR1;GLRA1;GLRA2;GLRA3;GLRB,,,PHASE 2,,Small molecule,NA,RYEFFICCPKWYML-QCGISDTRSA-N,CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]34C(=O)O[C@H]2[C@]14C;CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C
PICROTOXININ,PICROTOXININ,CHEMBL47244,BRD:BRD-BRD-K36461289-001-05-8;BRD:BRD-K36461289-001-05-8,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GLRA1;GLRA2;GLRA3;GLRB;HTR3A;HTR3B,,,PRECLINICAL,,Small molecule,NA,PIMZUZSSNYHVCU-YKWPQBAZSA-N,C=C(C)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]34C(=O)O[C@H]2[C@]14C;CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C
PIDOLIC-ACID,PIDOLIC-ACID,,BRD:BRD-BRD-K57313110-001-06-8;BRD:BRD-K57313110-001-06-8,rep_primary;rep_single_dose,,ADAM28;AMY1A;AMY2A;AMY2B;ANG;CCL8;HCRT;IGLC1;KRTAP5-2;TFF2;VEGFA,XEROSIS CUTIS,,LAUNCHED,,,NA,,OC(=O)[C@@H]1CCC(=O)N1
PIDOTIMOD,PIDOTIMOD,CHEMBL1488165,BRD:BRD-BRD-K44442813-001-12-9;BRD:BRD-K44442813-001-12-9,rep_primary;rep_single_dose,"INTERFERON RECEPTOR AGONIST, INTERLEUKIN RECEPTOR AGONIST",,IMMUNE ADJUVANT,,LAUNCHED,,Small molecule,Unknown,UUTKICFRNVKFRG-WDSKDSINSA-N,O=C1CC[C@@H](C(=O)N2CSC[C@H]2C(=O)O)N1;OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1
PIFITHRIN-ALPHA,PIFITHRIN-ALPHA,,CTRP:50747,ctrp,,,,,,,,NA,,
PIFITHRIN-CYCLIC,PIFITHRIN-CYCLIC,,BRD:BRD-BRD-K31792052-004-02-7;BRD:BRD-K31792052-004-02-7,rep_primary;rep_single_dose,TP53 INHIBITOR,TP53,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1CN2C3CCCCC3SC2N1
PIFITHRIN-MU,PIFITHRIN-MU,,BRD:BRD-BRD-K96799727-001-06-6;BRD:BRD-K96799727-001-06-6;CTRP:375596,ctrp;rep_primary;rep_single_dose,HSP INHIBITOR,HSPA1A;TP53,,,PRECLINICAL,,,NA,,NS(=O)(=O)C#CC1CCCCC1
PIK 93,PIK 93,,GDSC1:303,gdsc,,,,,,,,NA,,
PIK-293,PIK-293,,BRD:BRD-BRD-K30977212-001-02-8;BRD:BRD-K30977212-001-02-8,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PRECLINICAL,,,NA,,CC1CCCCC1-N1C(CN2NCC3C(N)NCNC23)NC2CCCC(C)C2C1=O
PIK-294,PIK-294,,BRD:BRD-BRD-K50631926-001-02-3;BRD:BRD-K50631926-001-02-3,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CB;PIK3CD;PIK3CG,,,PRECLINICAL,,,NA,,CC1CCCCC1-N1C(CN2NC(-C3CCCC(O)C3)C3C(N)NCNC23)NC2CCCC(C)C2C1=O
PIK-75,PIK-75,,BRD:BRD-BRD-K49371609-003-03-8;BRD:BRD-K49371609-003-03-8,rep_multi_dose;rep_primary;rep_single_dose,"DNA PROTEIN KINASE INHIBITOR, PI3K INHIBITOR",PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC,,,PRECLINICAL,,,NA,,CN(\N=C\C1CNC2CCC(BR)CN12)S(=O)(=O)C1CC(CCC1C)[N+]([O-])=O
PIK-93,PIK-93,,BRD:BRD-BRD-K29395450-001-06-8;BRD:BRD-K29395450-001-06-8;CTRP:660774;GDSC1:303,ctrp;gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PI4KB;PIK3C3;PIK3CG,,,PRECLINICAL,,,NA,,CC(=O)NC1NC(C)C(S1)-C1CCC(CL)C(C1)S(=O)(=O)NCCO
PIK93,PIK93,,GDSC1:303,gdsc,,,,,,,,NA,,
PIKAMILONE,PIKAMILONE,,BRD:BRD-BRD-K56691760-001-01-2;BRD:BRD-K56691760-001-01-2,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,OC(=O)CCCNC(=O)C1CCCNC1
PIKETOPROFEN,PIKETOPROFEN,CHEMBL2106966,BRD:BRD-A85548292-001-01-8;BRD:BRD-BRD-A85548292-001-01-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,ASFKKFRSMGBFRO-UHFFFAOYSA-N,CC(C(=O)NC1CC(C)CCN1)C1CCCC(C1)C(=O)C1CCCCC1;CC1CCNC(NC(=O)C(C)C2CCCC(C(=O)C3CCCCC3)C2)C1
PILARALISIB,PILARALISIB,CHEMBL3218575;CHEMBL3360203,BRD:BRD-BRD-K49456274-001-01-9;BRD:BRD-K49456274-001-01-9;GDSC1:372,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,MQMKRQLTIWPEDM-UHFFFAOYSA-N;QINPEPAQOBZPOF-UHFFFAOYSA-N,CC1CCC(S(=O)(=O)NC2NC3CCCCC3NC2NC2CCC3NSNC3C2)CC1;COC1CCC(CL)C(NC2NC3CCCCC3NC2NS(=O)(=O)C2CCCC(NC(=O)C(C)(C)N)C2)C1
PILOCARPINE,PILOCARPINE,CHEMBL550;CHEMBL611494,BRD:BRD-BRD-K85090592-008-22-7;BRD:BRD-K85090592-008-22-7,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,"GLAUCOMA, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,QCHFTSOMWOSFHM-PSASIEDQSA-N;QCHFTSOMWOSFHM-WPRPVWTQSA-N,CC[C@@H]1C(=O)OC[C@@H]1CC1CNCN1C;CC[C@H]1[C@@H](CC2CNCN2C)COC1=O;CC[C@H]1C(=O)OC[C@H]1CC1CNCN1C
PILSICAINIDE,PILSICAINIDE,CHEMBL163238,BRD:BRD-BRD-K83245588-001-01-4;BRD:BRD-K83245588-001-01-4,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN5A,CARDIAC ARRYTHMIA,,LAUNCHED,,Small molecule,Unknown,BCQTVJKBTWGHCX-UHFFFAOYSA-N,CC1CCCC(C)C1NC(=O)CC12CCCN1CCC2
PIM-1-INHIBITOR-2,PIM-1-INHIBITOR-2,,BRD:BRD-K48832421-001-03-9,rep_single_dose,PIM KINASE INHIBITOR,PIM1,,,,,,NA,,
PIM-447,PIM-447,CHEMBL3545194,BRD:BRD-K00003280-300-01-9,rep_single_dose,PIM KINASE INHIBITOR,,,,,,Small molecule,Phase 1,,
PIMAVANSERIN,PIMAVANSERIN,CHEMBL2111101,BRD:BRD-BRD-K83405785-001-01-5;BRD:BRD-K83405785-001-01-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR INVERSE AGONIST,DRD2;HTR2A,,,LAUNCHED,,Small molecule,Approved,RKEWSXXUOLRFBX-UHFFFAOYSA-N,CC(C)COC1CCC(CNC(=O)N(CC2CCC(F)CC2)C2CCN(C)CC2)CC1
PIMECROLIMUS,PIMECROLIMUS,CHEMBL1200686,BRD:BRD-BRD-K92107055-001-01-9;BRD:BRD-K92107055-001-01-9,rep_primary;rep_single_dose,CALCINEURIN INHIBITOR,FKBP1A;MTOR,ECZEMA,,LAUNCHED,,Small molecule,Approved,KASDHRXLYQOAKZ-XDSKOBMDSA-N,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](CL)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC;CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](CL)[C@@H](C1)OC
PIMETHIXENE,PIMETHIXENE,CHEMBL152408,BRD:BRD-BRD-K88090157-050-10-8;BRD:BRD-K88090157-050-10-8,rep_primary;rep_single_dose,ANTIHISTAMINE,,"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD), ANXIETY, SLEEP CYCLE SUPPORT, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Unknown,NZLVRVYNQYGMAB-UHFFFAOYSA-N,CN1CCC(=C2C3CCCCC3SC3CCCCC32)CC1;CN1CCC(CC1)=C1C2CCCCC2SC2CCCCC12
PIMOBENDAN,PIMOBENDAN,CHEMBL24646,BRD:BRD-A84575140-001-02-4;BRD:BRD-BRD-A84575140-001-02-4,rep_primary;rep_single_dose,"CALCIUM SENSITIZER, PHOSPHODIESTERASE INHIBITOR",PDE3A,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Unknown,GLBJJMFZWDBELO-UHFFFAOYSA-N,COC1CCC(-C2NC3CC(C4=NNC(=O)CC4C)CCC3[NH]2)CC1;COC1CCC(CC1)-C1NC2CC(CCC2[NH]1)C1=NNC(=O)CC1C
PIMODIVIR,PIMODIVIR,CHEMBL3318007,BRD:BRD-K00003127-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 3,JGPXDNKSIXAZEQ-SBBZOCNPSA-N,O=C(O)[C@H]1C2CCC(CC2)[C@@H]1NC1NC(-C2C[NH]C3NCC(F)CC23)NCC1F
PIMONIDAZOLE,PIMONIDAZOLE,CHEMBL58752,BRD:BRD-A67521319-001-01-6;BRD:BRD-BRD-A67521319-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,Phase 2,WVWOOAYQYLJEFD-UHFFFAOYSA-N,O=[N+]([O-])C1NCCN1CC(O)CN1CCCCC1;OC(CN1CCCCC1)CN1CCNC1[N+]([O-])=O
PIMOZIDE,PIMOZIDE,CHEMBL1423,BRD:BRD-BRD-K01292756-001-25-0;BRD:BRD-K01292756-001-25-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CACNA1I;CALM1;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HTR1A;HTR2A;KCNA10;KCNH2,TOURETTE'S DISORDER,,LAUNCHED,,Small molecule,Approved,YVUQSNJEYSNKRX-UHFFFAOYSA-N,FC1CCC(CC1)C(CCCN1CCC(CC1)N1C2CCCCC2[NH]C1=O)C1CCC(F)CC1;O=C1[NH]C2CCCCC2N1C1CCN(CCCC(C2CCC(F)CC2)C2CCC(F)CC2)CC1
SULFOPIN,PIN1-3;SULFOPIN,,BRD:BRD-U00115292-001-01-9,oncref_1,INHIBITOR OF PIN1,PIN1,,,,,,NA,,
PINACIDIL,PINACIDIL,CHEMBL1159;CHEMBL1200338,BRD:BRD-A43882281-001-15-5;BRD:BRD-BRD-A43882281-001-15-5,rep_primary;rep_single_dose,"ATP CHANNEL ACTIVATOR, POTASSIUM CHANNEL ACTIVATOR",ABCC8;ABCC9,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,AFJCNBBHEVLGCZ-UHFFFAOYSA-N;IVVNZDGDKPTYHK-UHFFFAOYSA-N,CC(N/C(=N\C#N)NC1CCNCC1)C(C)(C)C;CC(N/C(=N\C#N)NC1CCNCC1)C(C)(C)C.O;CC(N\C(NC1CCNCC1)=N\C#N)C(C)(C)C
PINAVERIUM,PINAVERIUM,CHEMBL1909324,BRD:BRD-A70998768-004-01-1;BRD:BRD-BRD-A70998768-004-01-1,rep_primary;rep_single_dose,T-TYPE CALCIUM CHANNEL BLOCKER,CACNA1C,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Approved,DDHUTBKXLWCZCO-UHFFFAOYSA-N,COC1CC(BR)C(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)CC1OC;COC1CC(BR)C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)CC1OC
PINCAINIDE,PINCAINIDE,CHEMBL1867802,BRD:BRD-BRD-K90727284-001-05-0;BRD:BRD-K90727284-001-05-0,rep_primary;rep_single_dose,ANTIARRHYTHMIC,,,,PHASE 1,,Small molecule,Unknown,RJOUHGWLHPOQSA-UHFFFAOYSA-N,CC1CCCC(C)C1NC(=O)CN1CCCCCC1
PINDOLOL,PINDOLOL,CHEMBL500,BRD:BRD-A97701745-001-16-0;BRD:BRD-BRD-A97701745-001-16-0,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;HTR1A;HTR1B;HTR2A;HTR2B,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,JZQKKSLKJUAGIC-UHFFFAOYSA-N,CC(C)NCC(O)COC1CCCC2[NH]CCC12
PINDOLOL-(-),PINDOLOL-(-),,BRD:BRD-K95598440-001-10-9,rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR1A,,,,,,NA,,
PINITOL,PINITOL,CHEMBL493737,BRD:BRD-A69275535-001-01-5;BRD:BRD-BRD-A69275535-001-01-5,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,DSCFFEYYQKSRSV-KLJZZCKASA-N,CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O;COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O
PINOCEMBRIN,PINOCEMBRIN,CHEMBL399910,BRD:BRD-BRD-K94689771-001-09-0;BRD:BRD-K94689771-001-09-0,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP1B1,,,PHASE 2,,Small molecule,Phase 2,URFCJEUYXNAHFI-ZDUSSCGKSA-N,O=C1C[C@@H](C2CCCCC2)OC2CC(O)CC(O)C21;OC1CC(O)C2C(=O)C[C@H](OC2C1)C1CCCCC1
PINOMETOSTAT,PINOMETOSTAT,CHEMBL3414626,GDSC2:1563,gdsc,,,,,,,Small molecule,Phase 1,LXFOLMYKSYSZQS-LURJZOHASA-N,CC(C)N(C[C@H]1O[C@@H](N2CNC3C(N)NCNC32)[C@H](O)[C@@H]1O)[C@H]1C[C@@H](CCC2NC3CC(C(C)(C)C)CCC3[NH]2)C1
PIOGLITAZONE,PIOGLITAZONE,CHEMBL595,BRD:BRD-A48430263-003-17-2;BRD:BRD-BRD-A48430263-003-17-2,rep_primary;rep_single_dose,"INSULIN SENSITIZER, PPAR RECEPTOR AGONIST",PPARG;TRPM3,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,HYAFETHFCAUJAY-UHFFFAOYSA-N,CCC1CCC(CCOC2CCC(CC3SC(=O)NC3=O)CC2)NC1
PIPAMPERONE,PIPAMPERONE,CHEMBL440294,BRD:BRD-BRD-K26801045-001-02-9;BRD:BRD-K26801045-001-02-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;HRH1;HTR1A;HTR1B;HTR1D;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Phase 3,AXKPFOAXAHJUAG-UHFFFAOYSA-N,NC(=O)C1(CCN(CCCC(=O)C2CCC(F)CC2)CC1)N1CCCCC1;NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)C2CCC(F)CC2)CC1
PIPECURONIUM,PIPECURONIUM,CHEMBL1201206,BRD:BRD-A21544762-303-01-5;BRD:BRD-BRD-A21544762-303-01-5,rep_primary;rep_single_dose,NEUROMUSCULAR BLOCKER,CHRM2;CHRM3;CHRNA2,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,OWWLUIWOFHMHOQ-XGHATYIMSA-N,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1;CC(=O)OC1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
PIPEMIDIC-ACID,PIPEMIDIC-ACID,,BRD:BRD-BRD-K08999871-213-01-5;BRD:BRD-K08999871-213-01-5,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,,NA,,CCN1CC(C(O)=O)C(=O)C2CNC(NC12)N1CCNCC1
PIPENZOLATE,PIPENZOLATE,CHEMBL1393947;CHEMBL1619528,BRD:BRD-A53561827-004-23-1;BRD:BRD-BRD-A53561827-004-23-1,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1,SPASMS,,LAUNCHED,,Small molecule,Approved,WPUKUEMZZRVAKZ-NFBKMPQASA-N;WPUKUEMZZRVAKZ-UHFFFAOYSA-N,CC[N@+]1(C)CCC[C@@H](OC(=O)C(O)(C2CCCCC2)C2CCCCC2)C1;CC[N+]1(C)CCCC(C1)OC(=O)C(O)(C1CCCCC1)C1CCCCC1;CC[N+]1(C)CCCC(OC(=O)C(O)(C2CCCCC2)C2CCCCC2)C1
PIPERACETAZINE,PIPERACETAZINE,CHEMBL1584,BRD:BRD-BRD-K16277217-001-10-9;BRD:BRD-K16277217-001-10-9,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,BTFMCMVEUCGQDX-UHFFFAOYSA-N,CC(=O)C1CCC2C(C1)N(CCCN1CCC(CCO)CC1)C1CCCCC1S2;CC(=O)C1CCC2SC3CCCCC3N(CCCN3CCC(CCO)CC3)C2C1
PIPERACILLIN,PIPERACILLIN,CHEMBL1200820;CHEMBL702,BRD:BRD-BRD-K86873305-236-14-7;BRD:BRD-K86873305-236-14-7,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"INTRA-ABDOMINAL INFECTIONS, SKIN INFECTIONS, PELVIC INFLAMMATORY DISEASE, PNEUMONIA",,LAUNCHED,,Small molecule,Approved,IVBHGBMCVLDMKU-GXNBUGAJSA-N;WCMIIGXFCMNQDS-IDYPWDAWSA-M,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H]2SC(C)(C)[C@@H]3C(=O)[O-])C2CCCCC2)C(=O)C1=O.[NA+];CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H]2SC(C)(C)[C@@H]3C(=O)O)C2CCCCC2)C(=O)C1=O;CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C2CCCCC2)C(=O)C1=O;CCN1CCN(C(=O)NC(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)C2CCCCC2)C(=O)C1=O
PIPERAQUINE-PHOSPHATE,PIPERAQUINE-PHOSPHATE,,BRD:BRD-BRD-K27382019-418-01-9;BRD:BRD-K27382019-418-01-9,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,,MALARIA,,LAUNCHED,,,NA,,CLC1CCC2C(CCNC2C1)N1CCN(CCCN2CCN(CC2)C2CCNC3CC(CL)CCC23)CC1
PIPERAZINE,PIPERAZINE,CHEMBL1412,BRD:BRD-BRD-K13249881-001-02-3;BRD:BRD-K13249881-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRB3,GASTROINTESTINAL ROUNDWORMS,,LAUNCHED,,Small molecule,Approved,GLUUGHFHXGJENI-UHFFFAOYSA-N,C1CNCCN1
PIPERAZINEDIONE,PIPERAZINEDIONE,CHEMBL125229,BRD:BRD-BRD-K95941975-001-01-5;BRD:BRD-K95941975-001-01-5,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,PHASE 2,,Small molecule,NA,BXRNXXXXHLBUKK-UHFFFAOYSA-N,O=C1CNC(=O)CN1
PIPERIDOLATE,PIPERIDOLATE,CHEMBL1474977;CHEMBL1623992,BRD:BRD-A97479839-003-13-3;BRD:BRD-BRD-A97479839-003-13-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,SPASMS,,LAUNCHED,,Small molecule,Approved,KTHVBAZBLKXIHZ-LJQANCHMSA-N;KTHVBAZBLKXIHZ-UHFFFAOYSA-N,CCN1CCC[C@@H](OC(=O)C(C2CCCCC2)C2CCCCC2)C1;CCN1CCCC(C1)OC(=O)C(C1CCCCC1)C1CCCCC1;CCN1CCCC(OC(=O)C(C2CCCCC2)C2CCCCC2)C1
PIPERINE,PIPERINE,CHEMBL43185,BRD:BRD-BRD-K59522102-001-14-6;BRD:BRD-BRD-K59522102-001-15-3;BRD:BRD-K59522102-001-14-6;BRD:BRD-K59522102-001-15-3,rep_multi_dose;rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB;TRPV1,,,PHASE 1,,Small molecule,Phase 2,MXXWOMGUGJBKIW-YPCIICBESA-N,O=C(/C=C/C=C/C1CCC2C(C1)OCO2)N1CCCCC1;O=C(\C=C\C=C\C1CCC2OCOC2C1)N1CCCCC1
PIPERLONGUMINE,PIPERLONGUMINE,,CTRP:39782;GDSC1:1243,ctrp;gdsc,,,,,,,,NA,,
PIPERLONGUMINE:MST-312 (1:1 MOL/MOL),PIPERLONGUMINE:MST-312 (1:1 MOL/MOL),,CTRP:660224,ctrp,,,,,,,,NA,,
PIPERONYL-BUTOXIDE,PIPERONYL-BUTOXIDE,,BRD:BRD-BRD-K76452401-001-03-6;BRD:BRD-K76452401-001-03-6,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,,LICE,,LAUNCHED,,,NA,,CCCCOCCOCCOCC1CC2OCOC2CC1CCC
PIPLARTINE,PIPLARTINE,CHEMBL465843,GDSC1:1243,gdsc,,,,,,,Small molecule,NA,VABYUUZNAVQNPG-BQYQJAHWSA-N,COC1CC(/C=C/C(=O)N2CCC=CC2=O)CC(OC)C1OC
PIPOBROMAN,PIPOBROMAN,CHEMBL1585,BRD:BRD-K15656090-001-07-3,rep_single_dose,DNA ALKYLATING AGENT,,,,,,Small molecule,Approved,NJBFOOCLYDNZJN-UHFFFAOYSA-N,O=C(CCBR)N1CCN(C(=O)CCBR)CC1
PIPOFEZINE,PIPOFEZINE,CHEMBL1886755,BRD:BRD-K00003317-312-01-9,rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),,,,,,Small molecule,Unknown,SDYYIRPAZHJOLM-UHFFFAOYSA-N,CN1CCN(C2CC3C(NN2)OC2CCCCC2N3C)CC1
PIPOTIAZINE,PIPOTIAZINE,CHEMBL2106439;CHEMBL398880,BRD:BRD-K00004560-001-01-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;HTR1A;HTR2A,,,,,Small molecule,Approved,JOMHSQGEWSNUKU-UHFFFAOYSA-N;KTOYYUONFQWSMW-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3CCCCC3SC3CCC(S(=O)(=O)N(C)C)CC32)CC1;CN(C)S(=O)(=O)C1CCC2C(C1)N(CCCN1CCC(CCO)CC1)C1CCCCC1S2
PIPOTIAZINE-PALMITATE,PIPOTIAZINE-PALMITATE,,BRD:BRD-BRD-K48429278-001-01-3;BRD:BRD-K48429278-001-01-3,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",DRD1;DRD2;HTR1A;HTR2A,,,LAUNCHED,,,NA,,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3CCCCC3SC3CCC(CC23)S(=O)(=O)N(C)C)CC1
PIRACETAM,PIRACETAM,CHEMBL36715,BRD:BRD-BRD-K19456237-001-27-6;BRD:BRD-K19456237-001-27-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,GRIA1;GRIA2;GRIA3;GRIA4,SENILE DEMENTIA,,LAUNCHED,,Small molecule,Approved,GMZVRMREEHBGGF-UHFFFAOYSA-N,NC(=O)CN1CCCC1=O
PIRENOXINE,PIRENOXINE,CHEMBL1372341,BRD:BRD-BRD-K65992024-001-01-5;BRD:BRD-K65992024-001-01-5,rep_primary;rep_single_dose,AGE INHIBITOR,,CATARACTS,,LAUNCHED,,Small molecule,Unknown,OKPNYGAWTYOBFZ-UHFFFAOYSA-N,O=C(O)C1CC(O)C2C3NC4CCCCC4OC-3CC(=O)C2N1;OC(=O)C1CC(O)C2C3NC4CCCCC4OC3CC(=O)C2N1
PIRENPERONE,PIRENPERONE,CHEMBL18331,BRD:BRD-BRD-K25224017-001-25-0;BRD:BRD-K25224017-001-25-0,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR7,,,PRECLINICAL,,Small molecule,Unknown,HXCNRYXBZNHDNE-UHFFFAOYSA-N,CC1NC2CCCCN2C(=O)C1CCN1CCC(C(=O)C2CCC(F)CC2)CC1;CC1NC2CCCCN2C(=O)C1CCN1CCC(CC1)C(=O)C1CCC(F)CC1
PIRENZEPINE,PIRENZEPINE,CHEMBL9967,BRD:BRD-BRD-K89375097-300-08-8;BRD:BRD-K89375097-300-08-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,RMHMFHUVIITRHF-UHFFFAOYSA-N,CN1CCN(CC(=O)N2C3CCCCC3C(=O)NC3CCCNC23)CC1;CN1CCN(CC(=O)N2C3CCCCC3C(=O)NC3CCCNC32)CC1
PIRETANIDE,PIRETANIDE,CHEMBL349803,BRD:BRD-BRD-K87990216-001-10-2;BRD:BRD-K87990216-001-10-2,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,SLC12A1;SLC12A2,"HYPERTENSION, EDEMA",,LAUNCHED,,Small molecule,Approved,UJEWTUDSLQGTOA-UHFFFAOYSA-N,NS(=O)(=O)C1CC(C(=O)O)CC(N2CCCC2)C1OC1CCCCC1;NS(=O)(=O)C1CC(CC(N2CCCC2)C1OC1CCCCC1)C(O)=O
PIRFENIDONE,PIRFENIDONE,CHEMBL1256391,BRD:BRD-BRD-K96862998-001-15-5;BRD:BRD-K96862998-001-15-5,rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,FURIN;TNF,IDIOPATHIC PULMONARY FIBROSIS (IPF),,LAUNCHED,,Small molecule,Approved,ISWRGOKTTBVCFA-UHFFFAOYSA-N,CC1CCC(=O)N(-C2CCCCC2)C1;CC1CCC(=O)N(C1)-C1CCCCC1
PIRIBEDIL,PIRIBEDIL,CHEMBL1371770,BRD:BRD-BRD-K47936004-003-11-4;BRD:BRD-K47936004-003-11-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA1A;ADRA2A;ADRA2C;DRD2;DRD3;DRD4;HTR1A;HTR2B,"PARKINSON'S DISEASE, DIZZINESS",,LAUNCHED,,Small molecule,Approved,OQDPVLVUJFGPGQ-UHFFFAOYSA-N,C(N1CCN(CC1)C1NCCCN1)C1CCC2OCOC2C1;C1CNC(N2CCN(CC3CCC4C(C3)OCO4)CC2)NC1
PIRICAPIRON,PIRICAPIRON,,BRD:BRD-A04203391-001-08-3;BRD:BRD-BRD-A04203391-001-08-3,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR2A,,,PHASE 2,,,NA,,CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)C1CCCCN1)C2=O
PIRINIXIC-ACID,PIRINIXIC-ACID,,BRD:BRD-BRD-K01902415-001-11-7;BRD:BRD-K01902415-001-11-7,rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARA,,,PRECLINICAL,,,NA,,CC1CCCC(NC2CC(CL)NC(SCC(O)=O)N2)C1C
PIRLINDOLE,PIRLINDOLE,CHEMBL32350,BRD:BRD-A54490543-066-11-9;BRD:BRD-BRD-A54490543-066-11-9,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA,DEPRESSION,,LAUNCHED,,Small molecule,Unknown,IWVRVEIKCBFZNF-UHFFFAOYSA-N,CC1CCC2C(C1)C1C3N2CCNC3CCC1;CC1CCC2N3CCNC4CCCC(C34)C2C1
PIRMENOL,PIRMENOL,CHEMBL432103,BRD:BRD-K00003530-003-01-9,rep_single_dose,ACETYLCHOLINE RECEPTOR INHIBITOR,,,,,,Small molecule,Unknown,APUDBKTWDCXQJA-UHFFFAOYSA-N,CC1CCCC(C)N1CCCC(O)(C1CCCCC1)C1CCCCN1
PIRODAVIR,PIRODAVIR,CHEMBL298019,BRD:BRD-BRD-K22261391-001-01-2;BRD:BRD-K22261391-001-01-2,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,KCHIOGFOPPOUJC-UHFFFAOYSA-N,CCOC(=O)C1CCC(OCCC2CCN(C3CCC(C)NN3)CC2)CC1;CCOC(=O)C1CCC(OCCC2CCN(CC2)C2CCC(C)NN2)CC1
PIROMIDIC-ACID,PIROMIDIC-ACID,,BRD:BRD-BRD-K37682401-001-09-3;BRD:BRD-BRD-K37682401-213-01-1;BRD:BRD-K37682401-001-09-3;BRD:BRD-K37682401-213-01-1,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,,,PHASE 2,,,NA,,CCN1CC(C(O)=O)C(=O)C2CNC(NC12)N1CCCC1
PIROXICAM,PIROXICAM,CHEMBL527,BRD:BRD-A57382968-001-29-0;BRD:BRD-BRD-A57382968-001-29-0,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,QYSPLQLAKJAUJT-UHFFFAOYSA-N,CN1C(C(=O)NC2CCCCN2)=C(O)C2CCCCC2S1(=O)=O;CN1C(C(=O)NC2CCCCN2)C(=O)C2CCCCC2S1(=O)=O
PIROXIMONE,PIROXIMONE,CHEMBL58355,BRD:BRD-BRD-K71977764-001-01-2;BRD:BRD-K71977764-001-01-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A,,,PHASE 2,,Small molecule,Unknown,OQGWJZOWLHWFME-UHFFFAOYSA-N,CCC1[NH]C(=O)[NH]C1C(=O)C1CCNCC1;CCC1[NH]C(O)NC1C(=O)C1CCNCC1
PIROZADIL,PIROZADIL,CHEMBL2106888,BRD:BRD-K00004581-001-01-9,rep_single_dose,HYPOLIPIDEMIC,,,,,,Small molecule,Unknown,DIIBXMIIOQXTHW-UHFFFAOYSA-N,COC1CC(C(=O)OCC2CCCC(COC(=O)C3CC(OC)C(OC)C(OC)C3)N2)CC(OC)C1OC
PIRQUINOZOL,PIRQUINOZOL,CHEMBL2106923,BRD:BRD-BRD-K63651590-001-01-3;BRD:BRD-K63651590-001-01-3,rep_primary;rep_single_dose,HISTAMINE RELEASE INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,XLUKOGNIEDDIMV-UHFFFAOYSA-N,O=C1[NH]C2CCCCC2C2CC(CO)NN12;OCC1CC2C3CCCCC3[NH]C(=O)N2N1
PITAVASTATIN,PITAVASTATIN,CHEMBL1201753,BRD:BRD-BRD-K75958547-238-01-0;BRD:BRD-K75958547-238-01-0;BRD:BRD-K75958547-238-04-9,rep_multi_dose;rep_primary;rep_single_dose,HMGCR INHIBITOR,HMGCR,HYPERLIPIDEMIA,,LAUNCHED,,Small molecule,Approved,VGYFMXBACGZSIL-MCBHFWOFSA-N,O[C@H](C[C@H](O)\C=C\C1C(NC2CCCCC2C1-C1CCC(F)CC1)C1CC1)CC(O)=O;O=C(O)C[C@H](O)C[C@H](O)/C=C/C1C(C2CC2)NC2CCCCC2C1-C1CCC(F)CC1
PITSTOP2,PITSTOP2,,CTRP:660985,ctrp,,,,,,,,NA,,
PIVMECILLINAM,PIVMECILLINAM,CHEMBL1650818,BRD:BRD-BRD-K67100011-003-06-3;BRD:BRD-K67100011-003-06-3,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,"URINARY TRACT INFECTIONS, GRAM-NEGATIVE BACTERIAL INFECTIONS",,LAUNCHED,,Small molecule,Approved,NPGNOVNWUSPMDP-UTEPHESZSA-N,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O;CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](/N=C/N3CCCCCC3)[C@H]2SC1(C)C
PIZOTIFEN,PIZOTIFEN,CHEMBL294951,BRD:BRD-BRD-K75958195-037-09-4;BRD:BRD-K75958195-037-09-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR2A;HTR2C,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Unknown,FIADGNVRKBPQEU-UHFFFAOYSA-N,CN1CCC(=C2C3CCCCC3CCC3SCCC32)CC1;CN1CCC(CC1)=C1C2CCSC2CCC2CCCCC12
PJ-34,PJ-34,,BRD:BRD-BRD-K11853856-001-01-7;BRD:BRD-K11853856-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,EEF2;PARP1;PARP15;PARP3,,,PRECLINICAL,,,NA,,CN(C)CC(=O)NC1CCC2[NH]C(=O)C3CCCCC3C2C1
PK-11195,PK-11195,CHEMBL481537,BRD:BRD-A41451487-001-11-2;BRD:BRD-BRD-A41451487-001-11-2,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR ANTAGONIST,TSPO,,,PHASE 1,,Small molecule,NA,RAVIZVQZGXBOQO-UHFFFAOYSA-N,CCC(C)N(C)C(=O)C1CC2CCCCC2C(-C2CCCCC2CL)N1;CCC(C)N(C)C(=O)C1CC2CCCCC2C(N1)-C1CCCCC1CL
PK-44,PK-44,,BRD:BRD-K04035716-011-02-9,rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,,,,,,NA,,
PK-THPP,PK-THPP,,BRD:BRD-BRD-K44043890-001-01-4;BRD:BRD-K44043890-001-01-4,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNK9,,,PRECLINICAL,,,NA,,CCCC(=O)C1CCN(CC1)C1NCNC2CCN(CC12)C(=O)C1CCC(CC1)-C1CCCCC1
PKC412,PKC412,,GDSC1:153,gdsc,,,,,,,,NA,,
PKI-166,PKI-166,CHEMBL1963502,BRD:BRD-BRD-K10115470-001-01-8;BRD:BRD-K10115470-001-01-8,rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PHASE 1,,Small molecule,Phase 1,XRYJULCDUUATMC-CYBMUJFWSA-N,C[C@@H](NC1NCNC2[NH]C(-C3CCC(O)CC3)CC12)C1CCCCC1;C[C@@H](NC1NCNC2[NH]C(CC12)-C1CCC(O)CC1)C1CCCCC1
PKI-179,PKI-179,CHEMBL1258517,BRD:BRD-A28467416-002-01-0;BRD:BRD-BRD-A28467416-002-01-0,rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR,,,PHASE 1,,Small molecule,Phase 1,WXUUCRLKXQMWRY-UHFFFAOYSA-N,O=C(NC1CCNCC1)NC1CCC(-C2NC(N3CCOCC3)NC(N3C4CCC3COC4)N2)CC1;O=C(NC1CCNCC1)NC1CCC(CC1)-C1NC(NC(N1)N1CCOCC1)N1C2CCC1COC2
PL-DI,PL-DI,,CTRP:609440,ctrp,,,,,,,,NA,,
PLATIN,PLATIN,,CTRP:375395,ctrp,,,,,,,,NA,,
PLATINOL,PLATINOL,CHEMBL11359;CHEMBL1386,GDSC1:1005;GDSC2:1005,gdsc,,,,,,,Small molecule,Approved,,
PLECONARIL,PLECONARIL,CHEMBL29609,BRD:BRD-BRD-K27625831-001-02-9;BRD:BRD-K27625831-001-02-9,rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,Phase 2,KQOXLKOJHVFTRN-UHFFFAOYSA-N,CC1CC(CCCOC2C(C)CC(-C3NOC(C(F)(F)F)N3)CC2C)ON1;CC1CC(CCCOC2C(C)CC(CC2C)-C2NOC(N2)C(F)(F)F)ON1
PLERIXAFOR,PLERIXAFOR,CHEMBL18442,BRD:BRD-BRD-K33240821-001-06-2;BRD:BRD-K33240821-001-06-2;BRD:BRD-K33240821-400-02-5,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,ACKR3;CCR4;CXCR4,"NON-HODGKIN LYMPHOMA (NHL), MULTIPLE MYELOMA",,LAUNCHED,,Small molecule,Approved,YIQPUIGJQJDJOS-UHFFFAOYSA-N,C(N1CCCNCCNCCCNCC1)C1CCC(CN2CCCNCCNCCCNCC2)CC1;C1CC(CN2CCCNCCNCCCNCC2)CCC1CN1CCCNCCNCCCNCC1
PLINABULIN,PLINABULIN,CHEMBL1096380,BRD:BRD-BRD-K99498722-001-02-6;BRD:BRD-K99498722-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,UNRCMCRRFYFGFX-TYPNBTCFSA-N,CC(C)(C)C1[NH]CNC1/C=C1\[NH]C(=O)/C(=C/C2CCCCC2)[NH]C1=O;CC(C)(C)C1[NH]CNC1\C=C1/[NH]C(=O)\C(=C\C2CCCCC2)[NH]C1=O
PLOVAMER-ACETATE,PLOVAMER-ACETATE,,BRD:BRD-A20781140-001-01-7;BRD:BRD-BRD-A20781140-001-01-7,rep_primary;rep_single_dose,,TAT;TH;YARS;YARS2,,,PHASE 2,,,NA,,NC(CC1CCC(O)CC1)C(O)=O
PLUMBAGIN,PLUMBAGIN,CHEMBL295316,BRD:BRD-K36137799-001-06-9,rep_single_dose,ANTICANCER AGENT,,,,,,Small molecule,Phase 1,VCMMXZQDRFWYSE-UHFFFAOYSA-N,CC1=CC(=O)C2C(O)CCCC2C1=O
PLURIPOTIN,PLURIPOTIN,,CTRP:411833,ctrp,,,,,,,,NA,,
PLURISIN-1,PLURISIN-#1;PLURISIN-1,,BRD:BRD-BRD-K99149715-001-01-6;BRD:BRD-K99149715-001-01-6,rep_primary;rep_single_dose,STEAROYL-COA DESATURASE INHIBITOR,SCD,,,PRECLINICAL,,,NA,,O=C(NNC1CCCCC1)C1CCNCC1
PLX 4720,PLX 4720,,GDSC1:1036;GDSC1:1371;GDSC2:1036,gdsc,,,,,,,,NA,,
PLX-4032,PLX-4032,CHEMBL1229517,CTRP:649420,ctrp,,,,,,,Small molecule,Approved,GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)NC1CCC(F)C(C(=O)C2C[NH]C3NCC(-C4CCC(CL)CC4)CC23)C1F
PLX4720,PLX-4720;PLX4720,CHEMBL1230020,BRD:BRD-BRD-K16478699-001-09-2;BRD:BRD-K16478699-001-09-2;CTRP:606256;GDSC1:1036;GDSC1:1371;GDSC2:1036,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,RAF INHIBITOR,BRAF;KDR,,,PRECLINICAL,,Small molecule,NA,YZDJQTHVDDOVHR-UHFFFAOYSA-N,CCCS(=O)(=O)NC1CCC(F)C(C(=O)C2C[NH]C3NCC(CL)CC23)C1F
VEMURAFENIB,PLX4032;VEMURAFENIB,CHEMBL1229517,BRD:BRD-BRD-K56343971-001-10-6;BRD:BRD-K56343971-001-10-6;BRD:BRD-K56343971-001-14-8;BRD:BRD-K56343971-001-19-9,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF BRAF-V600E,BRAF;RAF1,MELANOMA,,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF BRAF-V600E', 'RAF INHIBITOR'}, defaulting to 'INHIBITOR OF BRAF-V600E'
Multiple values for repurposing_target: {'BRAF', 'BRAF;RAF1'}, taking the union",Small molecule,Approved,GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)NC1CCC(F)C(C(=O)C2C[NH]C3NCC(-C4CCC(CL)CC4)CC23)C1F;CCCS(=O)(=O)NC1CCC(F)C(C(=O)C2C[NH]C3NCC(CC23)-C2CCC(CL)CC2)C1F
PLX51107,PLX51107,,BRD:BRD-K00003099-001-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,,NA,,
PLX647,PLX647,,BRD:BRD-K79294107-300-02-9,rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,CSF1R;KIT,,,,,,NA,,
PLX8394,PLX8394,CHEMBL4303729,BRD:BRD-BRD-K53723268-001-01-3;BRD:BRD-K53723268-001-01-3;BRD:BRD-U00115428-001-01-9,oncref_1;rep_primary;rep_single_dose,"INHIBITOR OF BRAF, BRAF-V600E, AND CRAF",BRAF;CRAF,,,PHASE 1/PHASE 2,"Multiple values for MOA: {'SERINE/THREONINE KINASE INHIBITOR', 'INHIBITOR OF BRAF, BRAF-V600E, AND CRAF'}, defaulting to 'INHIBITOR OF BRAF, BRAF-V600E, AND CRAF'
Multiple values for repurposing_target: {'BRAF;CRAF', 'BRAF'}, taking the union
Multiple values for structure_id: {'K53723268', 'U00115428'}, defaulting to None",Small molecule,Phase 1,YYACLQUDUDXAPA-MRXNPFEDSA-N,F[C@@H]1CCN(C1)S(=O)(=O)NC1CCC(F)C(C(=O)C2C[NH]C3NCC(CC23)-C2CNC(NC2)C2CC2)C1F;O=C(C1C(F)CCC(NS(=O)(=O)N2CC[C@@H](F)C2)C1F)C1C[NH]C2NCC(-C3CNC(C4CC4)NC3)CC12
PMPA,PMPA,CHEMBL1486;CHEMBL3989702,BRD:BRD-A74387232-001-02-5;BRD:BRD-BRD-A74387232-001-02-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,FOLH1,,,PRECLINICAL,,Small molecule,Approved,PINIEAOMWQJGBW-FYZOBXCZSA-N;VCMJCVGFSROFHV-WZGZYPNHSA-N,C[C@H](CN1CNC2C(N)NCNC21)OCP(=O)(O)O.O;CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1CNC2C(N)NCNC21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O;OC(=O)CCC(CP(O)(O)=O)C(O)=O
PNU-120596,PNU-120596,,BRD:BRD-BRD-K71731651-001-04-3;BRD:BRD-K71731651-001-04-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA7,,,PRECLINICAL,,,NA,,COC1CC(OC)C(NC(=O)NC2CC(C)ON2)CC1CL
PNU-142633,PNU-142633,,BRD:BRD-BRD-K81616657-001-01-4;BRD:BRD-K81616657-001-01-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1D,,,PHASE 2,,,NA,,CNC(=O)C1CCC2[C@H](CCN3CCN(CC3)C3CCC(CC3)C(N)=O)OCCC2C1
PNU-177864,PNU-177864,,BRD:BRD-K04635846-003-02-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD3,,,,,,NA,,
PNU-22394,PNU-22394,CHEMBL6557,BRD:BRD-BRD-K16551401-003-03-4;BRD:BRD-K16551401-003-03-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A;HTR2B;HTR2C;MAOA;MAOB,,,PHASE 2,,Small molecule,NA,ZBXDOQWPGBISAR-UHFFFAOYSA-N,CN1C2C(C3CCCCC31)CCNCC2;CN1C2CCNCCC2C2CCCCC12
PNU-282987,PNU-282987,CHEMBL177611,BRD:BRD-BRD-K28863208-001-02-0;BRD:BRD-K28863208-001-02-0,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR AGONIST,CHRNA7,,,PRECLINICAL,,Small molecule,NA,WECKJONDRAUFDD-ZDUSSCGKSA-N,CLC1CCC(CC1)C(=O)N[C@H]1CN2CCC1CC2;O=C(N[C@H]1CN2CCC1CC2)C1CCC(CL)CC1
PNU-37883,PNU-37883,,BRD:BRD-BRD-K12769093-003-01-3;BRD:BRD-K12769093-003-01-3,rep_primary;rep_single_dose,ATP-SENSITIVE POTASSIUM CHANNEL ANTAGONIST,,,,PRECLINICAL,,,NA,,C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2
PNU-74654,PNU-74654,,BRD:BRD-BRD-K30707190-001-04-1;BRD:BRD-K30707190-001-04-1,rep_primary;rep_single_dose,BETA-CATENIN INHIBITOR,CTNNB1;TCF4,,,PRECLINICAL,,,NA,,CC1CCC(\C=N\NC(=O)C2CCCCC2OC2CCCCC2)O1
POCAPAVIR,POCAPAVIR,,BRD:BRD-K00003464-001-01-9,rep_single_dose,ENTEROVIRUS CAPSID INHIBITOR,,,,,,,NA,,
PODOPHYLLOTOXIN,PODOPHYLLOTOXIN,CHEMBL61,BRD:BRD-BRD-K47869605-001-32-0;BRD:BRD-K47869605-001-32-0,rep_multi_dose;rep_primary;rep_single_dose,"MICROTUBULE INHIBITOR, TUBULIN POLYMERIZATION INHIBITOR",IGF1R;TOP2A;TUBA4A;TUBB,GENITAL WARTS,,LAUNCHED,,Small molecule,Approved,YJGVMLPVUAXIQN-XVVDYKMHSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1OC;COC1CC(CC(OC)C1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)C2CC3OCOC3CC12
PODOPHYLLOTOXIN BROMIDE,PODOPHYLLOTOXIN BROMIDE,,GDSC2:1825,gdsc,,,,,,,,NA,,
POLAPREZINC,POLAPREZINC,CHEMBL242948,BRD:BRD-K00003535-001-01-9,rep_single_dose,CHELATING AGENT,,,,,,Small molecule,Phase 2,CQOVPNPJLQNMDC-ZETCQYMHSA-N,NCCC(=O)N[C@@H](CC1C[NH]CN1)C(=O)O
POLIDOCANOL,POLIDOCANOL,CHEMBL1231723,BRD:BRD-BRD-K35798650-001-01-4;BRD:BRD-K35798650-001-01-4,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,VARICOSE VEINS,,LAUNCHED,,Small molecule,Approved,ONJQDTZCDSESIW-UHFFFAOYSA-N,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
POLYDATIN,POLYDATIN,CHEMBL142652,BRD:BRD-BRD-K43236057-001-07-1;BRD:BRD-K43236057-001-07-1,rep_multi_dose;rep_primary;rep_single_dose,ICAM1 EXPRESSION INHIBITOR,ICAM1,,,PHASE 2,,Small molecule,Phase 2,HSTZMXCBWJGKHG-CUYWLFDKSA-N,OC[C@H]1O[C@@H](OC2CC(O)CC(/C=C/C3CCC(O)CC3)C2)[C@H](O)[C@@H](O)[C@@H]1O;OC[C@H]1O[C@@H](OC2CC(O)CC(\C=C\C3CCC(O)CC3)C2)[C@H](O)[C@@H](O)[C@@H]1O
POLYINOSINE,POLYINOSINE,,BRD:BRD-A67531813-001-01-6;BRD:BRD-BRD-A67531813-001-01-6,rep_primary;rep_single_dose,IMMUNOSTIMULANT,ADSSL1;HPRT1;IMPDH2;PYGM,,,PRECLINICAL,,,NA,,OC1C(COP(O)(O)=O)OC(C1O)N1CNC2C(O)NCNC12
POLYMYXIN B NONAPEPTIDE (TFA),POLYMYXIN B NONAPEPTIDE (TFA),,BRD:BRD-K00091270-459-01-9,rep_single_dose,,,,,,,,NA,,
POLYMYXIN-B-SULFATE,POLYMYXIN-B-SULFATE,,BRD:BRD-A08641215-065-05-5,rep_single_dose,BACTERIAL PERMEABILITY INDUCER,,,,,,,NA,,
POLYTHIAZIDE,POLYTHIAZIDE,CHEMBL1587,BRD:BRD-A15739803-001-01-0;BRD:BRD-BRD-A15739803-001-01-0,rep_primary;rep_single_dose,SODIUM/CHLORIDE COTRANSPORTER INHIBITOR,SLC12A3,"EDEMA, CONGESTIVE HEART FAILURE, HEPATIC CIRRHOSIS, NEPHROTIC SYNDROME, ACUTE GLOMERULONEPHRITIS (AGN), CHRONIC RENAL FAILURE, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,CYLWJCABXYDINA-UHFFFAOYSA-N,CN1C(CSCC(F)(F)F)NC2CC(CL)C(CC2S1(=O)=O)S(N)(=O)=O;CN1C(CSCC(F)(F)F)NC2CC(CL)C(S(N)(=O)=O)CC2S1(=O)=O
POMALIDOMIDE,POMALIDOMIDE,CHEMBL43452,BRD:BRD-A12994259-001-02-1;BRD:BRD-BRD-A12994259-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,"ANGIOGENESIS INHIBITOR, TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR",CRBN;PTGS2;TNF,MULTIPLE MYELOMA,,LAUNCHED,,Small molecule,Approved,UVSMNLNDYGZFPF-UHFFFAOYSA-N,NC1CCCC2C(=O)N(C3CCC(=O)NC3=O)C(=O)C12;NC1CCCC2C1C(=O)N(C1CCC(=O)NC1=O)C2=O
PONATINIB,PONATINIB,CHEMBL1171837,BRD:BRD-BRD-K44227013-001-06-4;BRD:BRD-K44227013-001-06-4;GDSC1:155,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"BCR-ABL KINASE INHIBITOR, FLT3 INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR",ABL1;BCR;FGFR1;FGFR2;FGFR3;FGFR4;FLT3;KDR;KIT;LCK;LYN;PDGFRA;RET;SRC;TEK,"CHRONIC MYELOID LEUKEMIA (CML), ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)",,LAUNCHED,,Small molecule,Approved,PHXJVRSECIGDHY-UHFFFAOYSA-N,CC1CCC(C(=O)NC2CCC(CN3CCN(C)CC3)C(C(F)(F)F)C2)CC1C#CC1CNC2CCCNN12;CN1CCN(CC2CCC(NC(=O)C3CCC(C)C(C3)C#CC3CNC4CCCNN34)CC2C(F)(F)F)CC1
PONESIMOD,PONESIMOD,CHEMBL1096146,BRD:BRD-BRD-K44030614-001-01-6;BRD:BRD-K44030614-001-01-6,rep_primary;rep_single_dose,"SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST",S1PR1,,,PHASE 3,"Multiple values for MOA: {'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST', 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'}, defaulting to 'SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST, SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST'",Small molecule,Approved,LPAUOXUZGSBGDU-STDDISTJSA-N,CCC/N=C1\S/C(=C\C2CCC(OC[C@H](O)CO)C(CL)C2)C(=O)N1C1CCCCC1C;CCC\N=C1/S\C(=C/C2CCC(OC[C@H](O)CO)C(CL)C2)C(=O)N1C1CCCCC1C
POSACONAZOLE,POSACONAZOLE,CHEMBL1397,BRD:BRD-BRD-K06222852-001-03-2;BRD:BRD-K06222852-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,CYP3A4,OROPHARYNGEAL CANDIDIASIS,,LAUNCHED,,Small molecule,Approved,RAGOYPUPXAKGKH-XAKZXMRKSA-N,CC[C@@H]([C@H](C)O)N1NCN(-C2CCC(CC2)N2CCN(CC2)C2CCC(OC[C@@H]3CO[C@](CN4CNCN4)(C3)C3CCC(F)CC3F)CC2)C1=O;CC[C@@H]([C@H](C)O)N1NCN(-C2CCC(N3CCN(C4CCC(OC[C@@H]5CO[C@@](CN6CNCN6)(C6CCC(F)CC6F)C5)CC4)CC3)CC2)C1=O
POTASSIUM-CANRENOATE,POTASSIUM-CANRENOATE,,BRD:BRD-BRD-K46556543-001-01-4;BRD:BRD-BRD-K46556543-237-10-5;BRD:BRD-K46556543-001-01-4;BRD:BRD-K46556543-237-10-5,rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,NR3C2,EDEMA,,LAUNCHED,,,NA,,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O
POTASSIUM-IODIDE,POTASSIUM-IODIDE,,BRD:BRD-M55321172-001-03-3,rep_single_dose,,,,,,,,NA,,
POTASSIUM-P-AMINOBENZOATE,POTASSIUM-P-AMINOBENZOATE,,BRD:BRD-BRD-K58497451-237-10-7;BRD:BRD-K58497451-237-10-7,rep_primary;rep_single_dose,,,"SCLERODERMA, DERMATOMYOSITIS, PEYRONIE'S DISEASE",,LAUNCHED,,,NA,,NC1CCC(CC1)C(O)=O
POZANICLINE,POZANICLINE,CHEMBL127071,BRD:BRD-BRD-K79803033-300-01-3;BRD:BRD-K79803033-300-01-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA4;CHRNB2,,,PHASE 2,,Small molecule,Phase 2,YRVIKLBSVVNSHF-JTQLQIEISA-N,CC1NCCCC1OC[C@@H]1CCCN1
PP-1,PP-1,,BRD:BRD-BRD-K47598052-001-15-8;BRD:BRD-K47598052-001-15-8,rep_multi_dose;rep_primary;rep_single_dose,SRC INHIBITOR,HCK;RET,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1NN(C2NCNC(N)C12)C(C)(C)C
PP-121,PP-121,,BRD:BRD-BRD-K81801188-001-02-8;BRD:BRD-K81801188-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,ABL1;EGFR;HCK;KDR;MTOR;PDGFRA;PIK3CA;PIK3CB;PIK3CD;PIK3CG;PRKDC;SRC,,,PRECLINICAL,,,NA,,C1CCC(C1)N1NC(-C2CNC3[NH]CCC3C2)C2C(N)NCNC12
PP-2,PP-2,,BRD:BRD-BRD-K95785537-001-23-1;BRD:BRD-K95785537-001-23-1,rep_multi_dose;rep_primary;rep_single_dose,SRC INHIBITOR,ABL1;LCK;LYN;RIPK2;SRC,,,PRECLINICAL,,,NA,,CC(C)(C)N1NC(-C2CCC(CL)CC2)C2C(N)NCNC12
PP242,PP242,,BRD:BRD-BRD-K87112191-001-04-5;BRD:BRD-K87112191-001-04-5,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR;PASK,,,PRECLINICAL,,,NA,,CC(C)N1NC(-C2CC3CC(O)CCC3[NH]2)C2C(N)NCNC12
PPT,PPT,,BRD:BRD-BRD-K00312224-001-09-5;BRD:BRD-K00312224-001-09-5,rep_multi_dose;rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,,,PRECLINICAL,,,NA,,CCCC1C(NN(C1-C1CCC(O)CC1)-C1CCC(O)CC1)-C1CCC(O)CC1
PPY-A,PPY-A,,BRD:BRD-BRD-K72514671-001-01-4;BRD:BRD-K72514671-001-01-4,rep_primary;rep_single_dose,ABL KINASE INHIBITOR,ABL1;BCR,,,PRECLINICAL,,,NA,,COC1CCCCC1-C1C[NH]C2NCC(CC12)-C1CNCC(C1)C(=O)N(C)C
PQ-401,PQ-401,,BRD:BRD-BRD-K67537649-001-04-5;BRD:BRD-K67537649-001-04-5,rep_multi_dose;rep_primary;rep_single_dose,IGF-1 INHIBITOR,IGF1R,,,PRECLINICAL,,,NA,,COC1CCC(CL)CC1NC(=O)NC1CC(C)NC2CCCCC12
PR-619,PR-619,,BRD:BRD-BRD-K54395039-001-01-7;BRD:BRD-K54395039-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,DUB INHIBITOR,,,,PRECLINICAL,,,NA,,NC1NC(N)C(SC#N)CC1SC#N
PRACTOLOL,PRACTOLOL,CHEMBL6995,BRD:BRD-A41304429-001-14-8;BRD:BRD-BRD-A41304429-001-14-8,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1,,,WITHDRAWN,,Small molecule,Approved,DURULFYMVIFBIR-UHFFFAOYSA-N,CC(=O)NC1CCC(OCC(O)CNC(C)C)CC1;CC(C)NCC(O)COC1CCC(NC(C)=O)CC1
PRADEFOVIR,PRADEFOVIR,CHEMBL2096895,BRD:BRD-K00003119-066-01-9,rep_single_dose,CYTOCHROME P450 ACTIVATOR,,,,,,Small molecule,Phase 3,GWNHAOBXDGOXRR-HJFSHJIFSA-N,NC1NCNC2C1NCN2CCOC[P@@]1(=O)OCC[C@@H](C2CCCC(CL)C2)O1
PRALATREXATE,PRALATREXATE,CHEMBL1201746,BRD:BRD-A74914197-001-02-9;BRD:BRD-BRD-A74914197-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR;TYMS,PERIPHERAL T-CELL LYMPHOMA (PTCL),,LAUNCHED,,Small molecule,Approved,OGSBUKJUDHAQEA-WMCAAGNKSA-N,C#CCC(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1;NC1NC(N)C2NC(CC(CC#C)C3CCC(CC3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2N1
PRALIDOXIME,PRALIDOXIME,CHEMBL1420,BRD:BRD-BRD-K84281997-003-08-4;BRD:BRD-K84281997-003-08-4,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE,ORGANOPHOSPHATE POISONING,,LAUNCHED,,Small molecule,Approved,JBKPUQTUERUYQE-UHFFFAOYSA-O,C[N+]1CCCCC1\C=N\O;C[N+]1CCCCC1C=NO
PRALIDOXIME-CHLORIDE,PRALIDOXIME-CHLORIDE,,BRD:BRD-BRD-K24221957-003-01-6;BRD:BRD-K24221957-003-01-6,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE,RESPIRATORY DEPRESSION,,LAUNCHED,,,NA,,C[N+]1CCCCC1C[N+][O-]
PRALMORELIN,PRALMORELIN,CHEMBL106593,BRD:BRD-K00004629-001-01-9,rep_single_dose,GROWTH HORMONE RELEASING PEPTIDE LIGAND AGONIST,,,,,,Protein,Unknown,HRNLPPBUBKMZMT-RDRUQFPZSA-N,C[C@H](NC(=O)[C@@H](CC1CCC2CCCCC2C1)NC(=O)[C@@H](C)N)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN)C(N)=O
PRAMIPEXOLE,PRAMIPEXOLE,CHEMBL301265,BRD:BRD-BRD-K06388322-312-02-6;BRD:BRD-K06388322-312-02-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,FASDKYOPVNHBLU-ZETCQYMHSA-N,CCCN[C@H]1CCC2NC(N)SC2C1
PRAMIRACETAM,PRAMIRACETAM,CHEMBL159776,BRD:BRD-BRD-K21123171-001-02-9;BRD:BRD-K21123171-001-02-9,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,LAUNCHED,,Small molecule,Unknown,ZULJGOSFKWFVRX-UHFFFAOYSA-N,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C
PRAMOXINE,PRAMOXINE,CHEMBL1198,BRD:BRD-BRD-K46523383-003-22-9;BRD:BRD-K46523383-003-22-9,rep_primary;rep_single_dose,TOPICAL ANESTHETIC,,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Approved,DQKXQSGTHWVTAD-UHFFFAOYSA-N,CCCCOC1CCC(OCCCN2CCOCC2)CC1
PRANIDIPINE,PRANIDIPINE,CHEMBL1096842,BRD:BRD-A68083442-001-01-6;BRD:BRD-BRD-A68083442-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1C,,,PHASE 2,,Small molecule,Unknown,XTFPDGZNWTZCMF-DHZHZOJOSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/C2CCCCC2)C1C1CCCC([N+](=O)[O-])C1;COC(=O)C1=C(C)NC(C)=C(C1C1CCCC(C1)[N+]([O-])=O)C(=O)OC\C=C\C1CCCCC1
PRANLUKAST,PRANLUKAST,CHEMBL21333,BRD:BRD-BRD-K97045029-001-02-7;BRD:BRD-BRD-K97045029-001-04-3;BRD:BRD-K97045029-001-02-7;BRD:BRD-K97045029-001-04-3,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,CYSLTR1;CYSLTR2;IL5;MUC2;NFKB1;RNASE3;TNF,"BRONCHOSPASM, ASTHMA, BRONCHOSPASM, ASTHMA",,LAUNCHED,,Small molecule,Phase 3,NBQKINXMPLXUET-UHFFFAOYSA-N,O=C(NC1CCCC2C(=O)CC(-C3NNN[NH]3)OC12)C1CCC(OCCCCC2CCCCC2)CC1;O=C(NC1CCCC2C1OC(CC2=O)-C1NNN[NH]1)C1CCC(OCCCCC2CCCCC2)CC1
PRANOPROFEN,PRANOPROFEN,CHEMBL367463,BRD:BRD-A64610707-001-04-4;BRD:BRD-BRD-A64610707-001-04-4,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,TVQZAMVBTVNYLA-UHFFFAOYSA-N,CC(C(=O)O)C1CCC2C(C1)CC1CCCNC1O2;CC(C(O)=O)C1CCC2OC3NCCCC3CC2C1
PRASTERONE-ACETATE,PRASTERONE-ACETATE,,BRD:BRD-A20758144-001-04-5;BRD:BRD-BRD-A20758144-001-04-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(=O)O[C@H]1CC[C@]2(C)C3CC[C@@]4(C)C(CCC4=O)C3CC=C2C1
PRASUGREL,PRASUGREL,CHEMBL1201772,BRD:BRD-A83029242-001-05-3;BRD:BRD-BRD-A83029242-001-05-3,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RY12,"MYOCARDIAL INFARCTION, ACUTE CORONARY SYNDROME (ACS)",,LAUNCHED,,Small molecule,Approved,DTGLZDAWLRGWQN-UHFFFAOYSA-N,CC(=O)OC1CC2C(S1)CCN(C(C(=O)C1CC1)C1CCCCC1F)C2;CC(=O)OC1CC2CN(CCC2S1)C(C(=O)C1CC1)C1CCCCC1F
PRAVADOLINE,PRAVADOLINE,CHEMBL13178,BRD:BRD-BRD-K46209126-001-06-4;BRD:BRD-K46209126-001-06-4,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,CNR1;CNR2,,,PRECLINICAL,,Small molecule,Unknown,MEUQWHZOUDZXHH-UHFFFAOYSA-N,COC1CCC(C(=O)C2C(C)N(CCN3CCOCC3)C3CCCCC23)CC1;COC1CCC(CC1)C(=O)C1C(C)N(CCN2CCOCC2)C2CCCCC12
PRAVASTATIN,PRAVASTATIN,CHEMBL1144,BRD:BRD-BRD-K60511616-236-08-9;BRD:BRD-K60511616-236-08-9,rep_primary;rep_single_dose,HMGCR INHIBITOR,HMGCR;SLCO1B1,"HYPERCHOLESTEROLEMIA, MYOCARDIAL INFARCTION, HYPERLIPIDEMIA",,LAUNCHED,,Small molecule,Approved,TUZYXOIXSAXUGO-PZAWKZKUSA-N,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21;CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12;CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)C12
PRAXEL,PRAXEL,,GDSC1:11;GDSC2:1080,gdsc,,,,,,,,NA,,
PRAZIQUANTEL,PRAZIQUANTEL,CHEMBL1235551;CHEMBL976,BRD:BRD-A21858158-001-23-5;BRD:BRD-BRD-A21858158-001-23-5,rep_primary;rep_single_dose,ANTHELMINTIC AGENT,,"GASTROINTESTINAL PARASITES, CYSTIC HYDATID DISEASE, SCHISTOSOMIASIS",,LAUNCHED,,Small molecule,Approved,FSVJFNAIGNNGKK-KRWDZBQOSA-N;FSVJFNAIGNNGKK-UHFFFAOYSA-N,O=C(C1CCCCC1)N1CC(=O)N2CCC3CCCCC3[C@@H]2C1;O=C(C1CCCCC1)N1CC(=O)N2CCC3CCCCC3C2C1;O=C(C1CCCCC1)N1CC2N(CCC3CCCCC23)C(=O)C1
PRAZOSIN,PRAZOSIN,CHEMBL2,BRD:BRD-BRD-K49111258-003-29-7;BRD:BRD-K49111258-003-29-7,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;KCNH2;KCNH6;KCNH7,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,IENZQIKPVFGBNW-UHFFFAOYSA-N,COC1CC2NC(N3CCN(C(=O)C4CCCO4)CC3)NC(N)C2CC1OC;COC1CC2NC(NC(N)C2CC1OC)N1CCN(CC1)C(=O)C1CCCO1
PRE-084,PRE-084,,BRD:BRD-BRD-K57304726-003-06-9;BRD:BRD-K57304726-003-06-9,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,SIGMAR1,,,PRECLINICAL,,,NA,,O=C(OCCN1CCOCC1)C1(CCCCC1)C1CCCCC1
PRECLAMOL,PRECLAMOL,CHEMBL7549,BRD:BRD-BRD-K02908048-003-06-4;BRD:BRD-K02908048-003-06-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2,,,PHASE 2,,Small molecule,Unknown,HTSNFXAICLXZMA-CYBMUJFWSA-N,CCCN1CCC[C@@H](C1)C1CCCC(O)C1;CCCN1CCC[C@@H](C2CCCC(O)C2)C1
PREDNISOLONE,PREDNISOLONE,CHEMBL131,BRD:BRD-A27887842-001-04-0;BRD:BRD-BRD-A27887842-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;NR3C2;SERPINA6,"CONJUNCTIVITIS, ROSACEA, PUNCTATE KERATITIS, SHINGLES, IRITIS, CYCLITIS",,LAUNCHED,,Small molecule,Approved,OIGNJSKKLXVSLS-VWUMJDOOSA-N,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO;C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
PREDNISOLONE-ACETATE,PREDNISOLONE-ACETATE,,BRD:BRD-A01643550-001-04-9;BRD:BRD-BRD-A01643550-001-04-9;BRD:BRD-BRD-K45664306-001-19-6;BRD:BRD-K45664306-001-19-6,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"CONJUNCTIVITIS, ROSACEA, PUNCTATE KERATITIS, SHINGLES, IRITIS, CYCLITIS",,LAUNCHED,"Multiple values for structure_id: {'A01643550', 'K45664306'}, defaulting to None",,NA,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C;CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C
PREDNISOLONE-HEMISUCCINATE,PREDNISOLONE-HEMISUCCINATE,,BRD:BRD-A78391468-001-02-8;BRD:BRD-BRD-A78391468-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,,,PRECLINICAL,,,NA,,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O
PREDNISOLONE-SODIUM-PHOSPHATE,PREDNISOLONE-SODIUM-PHOSPHATE,,BRD:BRD-A94523291-304-02-7;BRD:BRD-BRD-A94523291-304-02-7,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1,"ALLERGIC RHINITIS, ASTHMA, CONTACT DERMATITIS, MYCOSIS, LUPUS, HYPERCALCEMIA, THYROIDITIS, CONGENITAL ADRENAL HYPERPLASIA, MULTIPLE SCLEROSIS, ULCERATIVE COLITIS, ENTERITIS, THROMBOCYTHEMIA, PNEUMONIA, ASTHMA, MENINGITIS, PSORIATIC ARTHRITIS, RHEUMATOID ARTHRITIS",,LAUNCHED,,,NA,,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O
PREDNISOLONE-TEBUTATE,PREDNISOLONE-TEBUTATE,,BRD:BRD-A53151380-001-01-2;BRD:BRD-BRD-A53151380-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,LAUNCHED,,,NA,,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C
PREDNISONE,PREDNISONE,CHEMBL635,BRD:BRD-BRD-K85883481-001-25-7;BRD:BRD-K85883481-001-25-7,rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,HSD11B1;NR3C1,"CONGENITAL ADRENAL HYPERPLASIA, HYPERCALCEMIA, RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, BURSITIS, OSTEOARTHRITIS, EPICONDYLITIS, DERMATOMYOSITIS, PSORIASIS, MYCOSIS, CONJUNCTIVITIS, ANEMIA, ULCERATIVE COLITIS, ENTERITIS, MULTIPLE SCLEROSIS, MENINGITIS",,LAUNCHED,,Small molecule,Approved,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO;C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
PREGABALIN,PREGABALIN,CHEMBL1059,BRD:BRD-BRD-K66786476-001-01-3;BRD:BRD-K66786476-001-01-3,rep_primary;rep_single_dose,VOLTAGE-GATED CALCIUM CHANNEL LIGAND,CACNA1A;CACNA1B;CACNA1C;CACNA1D;CACNA1E;CACNA1F;CACNA1G;CACNA1H;CACNA1I;CACNA1S;CACNA2D1;CACNA2D2;CACNA2D3;CACNA2D4;CACNB1;CACNB2;CACNB3;CACNB4;CACNG1;CACNG2;CACNG3;CACNG4;CACNG5;CACNG6;CACNG7;CACNG8,"PERIPHERAL NEUROPATHY, SEIZURES, FIBROMYALGIA, POSTHERPETIC NEURALGIA",,LAUNCHED,,Small molecule,Approved,AYXYPKUFHZROOJ-ZETCQYMHSA-N,CC(C)C[C@H](CN)CC(=O)O;CC(C)C[C@H](CN)CC(O)=O
PREGNANOLONE,PREGNANOLONE,CHEMBL210952,BRD:BRD-A03204438-001-01-2;BRD:BRD-BRD-A03204438-001-01-2,rep_primary;rep_single_dose,GABA RECEPTOR POSITIVE ALLOSTERIC MODULATOR,,,,PHASE 2,,Small molecule,Unknown,AURFZBICLPNKBZ-YZRLXODZSA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C;CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
PREGNENOLONE,PREGNENOLONE,CHEMBL2105373;CHEMBL253363,BRD:BRD-BRD-K43880410-001-14-4;BRD:BRD-K43880410-001-14-4,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,CYP17A1;SULT2B1,,,LAUNCHED,,Small molecule,Phase 3,ORNBQBCIOKFOEO-QGVNFLHTSA-N;OZZAYJQNMKMUSD-DMISRAGPSA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C;CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OC(=O)CCC(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C
PREGNENOLONE-SUCCINATE,PREGNENOLONE-SUCCINATE,,BRD:BRD-A35912562-001-02-8;BRD:BRD-BRD-A35912562-001-02-8,rep_primary;rep_single_dose,GABA RECEPTOR NEGATIVE ALLOSTERIC MODULATOR,CYP17A1,,,PRECLINICAL,,,NA,,CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O
PRELADENANT,PRELADENANT,CHEMBL240624,BRD:BRD-BRD-K46290096-001-01-1;BRD:BRD-K46290096-001-01-1,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 3,,Small molecule,Phase 3,DTYWJKSSUANMHD-UHFFFAOYSA-N,COCCOC1CCC(CC1)N1CCN(CCN2NCC3C2NC(N)N2NC(NC32)-C2CCCO2)CC1;COCCOC1CCC(N2CCN(CCN3NCC4C3NC(N)N3NC(-C5CCCO5)NC43)CC2)CC1
PRENYLAMINE,PRENYLAMINE,CHEMBL24072,BRD:BRD-A10662413-043-11-2;BRD:BRD-BRD-A10662413-043-11-2,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CALM1;MYLK2,,,WITHDRAWN,,Small molecule,Approved,IFFPICMESYHZPQ-UHFFFAOYSA-N,CC(CC1CCCCC1)NCCC(C1CCCCC1)C1CCCCC1
PRESATOVIR,PRESATOVIR,CHEMBL3410450,BRD:BRD-BRD-K45906612-001-01-8;BRD:BRD-K45906612-001-01-8,rep_primary;rep_single_dose,RSV FUSION INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,GOFXWTVKPWJNGD-UWJYYQICSA-N,CC1CN2NC([C@@H]3CCCCN3C(=O)C3CC(CL)CCC3NS(C)(=O)=O)CC2NC1N1CC[C@H](N)C1;CC1CN2NC(CC2NC1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)C1CC(CL)CCC1NS(C)(=O)=O
PRI-724,PRI-724,CHEMBL4297813,BRD:BRD-K00091108-001-01-9,rep_single_dose,,,,,,,Unknown,Phase 2,,
PRIDINOL,PRIDINOL,CHEMBL404215,BRD:BRD-BRD-K17565903-066-23-1;BRD:BRD-K17565903-066-23-1,rep_primary;rep_single_dose,MUSCLE RELAXANT,,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Unknown,RQXCLMGKHJWMOA-UHFFFAOYSA-N,OC(CCN1CCCCC1)(C1CCCCC1)C1CCCCC1
PRIDOPIDINE,PRIDOPIDINE,CHEMBL596802,BRD:BRD-K00003473-001-01-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,YGKUEOZJFIXDGI-UHFFFAOYSA-N,CCCN1CCC(C2CCCC(S(C)(=O)=O)C2)CC1
PRILOCAINE,PRILOCAINE,CHEMBL1194,BRD:BRD-A53952395-003-25-1;BRD:BRD-BRD-A53952395-003-25-1,rep_primary;rep_single_dose,LOCAL ANESTHETIC,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,MVFGUOIZUNYYSO-UHFFFAOYSA-N,CCCNC(C)C(=O)NC1CCCCC1C
PRIMA 1MET,PRIMA 1MET,,GDSC2:1131,gdsc,,,,,,,,NA,,
PRIMA-1,PRIMA-1,,CTRP:50131,ctrp,,,,,,,,NA,,
PRIMA-1-MET,PRIMA-1-MET,,CTRP:594663,ctrp,,,,,,,,NA,,
PRIMA-1MET,PRIMA-1MET,CHEMBL3186011,GDSC2:1131,gdsc,,,,,,,Small molecule,Phase 3,BGBNULCRKBVAKL-UHFFFAOYSA-N,COCC1(CO)C(=O)C2CCN1CC2
PRIMA1,PRIMA1,,BRD:BRD-BRD-K15318909-001-10-5;BRD:BRD-K15318909-001-10-5,rep_primary;rep_single_dose,TP53 INHIBITOR,ACHE,,,PRECLINICAL,,,NA,,OCC1(CO)N2CCC(CC2)C1=O
PRIMAQUINE,PRIMAQUINE,CHEMBL43128;CHEMBL506,BRD:BRD-A55913614-316-09-6;BRD:BRD-BRD-A55913614-316-09-6,rep_multi_dose;rep_primary;rep_single_dose,"ANTIMALARIAL AGENT, DNA INHIBITOR",KRT7;NQO2,MALARIA,,LAUNCHED,,Small molecule,Approved,GJOHLWZHWQUKAU-UHFFFAOYSA-N;INDBQLZJXZLFIT-UHFFFAOYSA-N,COC1CC(NC(C)CCCN)C2NCCCC2C1;COC1CC(NC(C)CCCN)C2NCCCC2C1.O=P(O)(O)O.O=P(O)(O)O
PRIMIDONE,PRIMIDONE,CHEMBL856,BRD:BRD-BRD-K32247306-001-29-4;BRD:BRD-K32247306-001-29-4,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,CHRNA4;CHRNA7;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIA2;GRIK2;SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,DQMZLTXERSFNPB-UHFFFAOYSA-N,CCC1(C(=O)NCNC1=O)C1CCCCC1;CCC1(C2CCCCC2)C(=O)NCNC1=O
PRINABEREL,PRINABEREL,CHEMBL450940,BRD:BRD-BRD-K87316765-001-01-4;BRD:BRD-K87316765-001-01-4,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR2;NCOA1,,,PHASE 2,,Small molecule,Phase 2,MQIMZDXIAHJKQP-UHFFFAOYSA-N,C=CC1CC(O)CC2NC(-C3CCC(O)C(F)C3)OC12;OC1CC(C=C)C2OC(NC2C1)-C1CCC(O)C(F)C1
PRINOMASTAT,PRINOMASTAT,CHEMBL75094,BRD:BRD-K00003122-001-01-9,rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,,,,,,Small molecule,Phase 3,YKPYIPVDTNNYCN-INIZCTEOSA-N,CC1(C)SCCN(S(=O)(=O)C2CCC(OC3CCNCC3)CC2)[C@H]1C(=O)NO
PRIRALFINAMIDE,PRIRALFINAMIDE,CHEMBL2107771,BRD:BRD-BRD-K01662324-001-01-8;BRD:BRD-K01662324-001-01-8,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,CACNA1B,,,PHASE 3,,Small molecule,Phase 3,BHJIBOFHEFDSAU-LBPRGKRZSA-N,C[C@H](NCC1CCC(OCC2CCCCC2F)CC1)C(N)=O
PRISOTINOL,PRISOTINOL,CHEMBL2106875,BRD:BRD-K00004547-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,WQRPBKUCJBWQRT-UHFFFAOYSA-N,CC(C)NC(C)CC1CCC(O)CN1
PRITELIVIR,PRITELIVIR,CHEMBL4069597,BRD:BRD-BRD-K25204779-001-01-1;BRD:BRD-K25204779-001-01-1,rep_primary;rep_single_dose,HELICASE PRIMASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 3,IVZKZONQVYTCKC-UHFFFAOYSA-N,CC1NC(N(C)C(=O)CC2CCC(-C3CCCCN3)CC2)SC1S(N)(=O)=O;CN(C(=O)CC1CCC(CC1)-C1CCCCN1)C1NC(C)C(S1)S(N)(=O)=O
PRL-3 INHIBITOR I,PRL-3 INHIBITOR I,,CTRP:411727,ctrp,,,,,,,,NA,,
PRLX-93936,PRLX-93936,,BRD:BRD-K00004604-001-01-9,rep_single_dose,VOLTAGE-DEPENDENT ANION SELECTIVE CHANNEL PROTEIN INHIBITOR,,,,,,,NA,,
PRN1008,PRN1008,CHEMBL3702854,BRD:BRD-K00004599-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Phase 3,LCFFREMLXLZNHE-GBOLQPHISA-N,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](N2NC(-C3CCC(OC4CCCCC4)CC3F)C3C(N)NCNC32)C1)N1CCN(C2COC2)CC1
PRN1371,PRN1371,CHEMBL4068509,BRD:BRD-K00003430-001-01-9,rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 1,PUIXMSRTTHLNKI-UHFFFAOYSA-N,C=CC(=O)N1CCN(CCCN2C(=O)C(-C3C(CL)C(OC)CC(OC)C3CL)CC3CNC(NC)NC32)CC1
PROACIPIMOX,PROACIPIMOX,,BRD:BRD-BRD-K53605365-001-01-4;BRD:BRD-K53605365-001-01-4,rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,,,,PHASE 1,,,NA,,COCC1C[N+]([O-])C(C)CN1
PROADIFEN,PROADIFEN,CHEMBL282567,BRD:BRD-BRD-K46317332-003-17-8;BRD:BRD-K46317332-003-17-8,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS1,,,PRECLINICAL,,Small molecule,Unknown,SNTQPLDRUZOSDP-UHFFFAOYSA-N,CCCC(C(=O)OCCN(CC)CC)(C1CCCCC1)C1CCCCC1
PROBENECID,PROBENECID,CHEMBL897,BRD:BRD-BRD-K95237249-001-26-5;BRD:BRD-K95237249-001-26-5,rep_primary;rep_single_dose,URICOSURIC BLOCKER,PANX1;SLC22A11;SLC22A6;SLC22A8;SLCO1C1,"HYPERURICEMIA, GOUT",,LAUNCHED,,Small molecule,Approved,DBABZHXKTCFAPX-UHFFFAOYSA-N,CCCN(CCC)S(=O)(=O)C1CCC(C(=O)O)CC1;CCCN(CCC)S(=O)(=O)C1CCC(CC1)C(O)=O
PROBUCOL,PROBUCOL,CHEMBL608,BRD:BRD-BRD-K72029282-001-22-0;BRD:BRD-K72029282-001-22-0,rep_primary;rep_single_dose,ATHEROGENESIS INHIBITOR,ABCA1;ABCB11;CES1,CORONARY ARTERY DISEASE (CAD),,LAUNCHED,,Small molecule,Approved,FYPMFJGVHOHGLL-UHFFFAOYSA-N,CC(C)(SC1CC(C(C)(C)C)C(O)C(C(C)(C)C)C1)SC1CC(C(C)(C)C)C(O)C(C(C)(C)C)C1;CC(C)(SC1CC(C(O)C(C1)C(C)(C)C)C(C)(C)C)SC1CC(C(O)C(C1)C(C)(C)C)C(C)(C)C
PROCAINAMIDE,PROCAINAMIDE,CHEMBL640,BRD:BRD-BRD-K75089421-003-24-5;BRD:BRD-K75089421-003-24-5,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,DNMT1;SCN5A,"VENTRICULAR ARRHYTHMIAS, VENTRICULAR TACHYCARDIA (VT)",,LAUNCHED,,Small molecule,Approved,REQCZEXYDRLIBE-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1CCC(N)CC1
PROCAINE,PROCAINE,CHEMBL569,BRD:BRD-BRD-K24616672-003-20-1;BRD:BRD-K24616672-003-20-1,rep_primary;rep_single_dose,HMGCR INHIBITOR,CHRNA2;GRIN3A;HTR3A;KCNMA1;KCNMB1;KCNMB2;KCNMB3;KCNMB4;KCNN1;KCNN2;KCNN3;KCNN4;MAOA;MAOB;RYR1;RYR2;SCN10A;SLC6A3,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,MFDFERRIHVXMIY-UHFFFAOYSA-N,CCN(CC)CCOC(=O)C1CCC(N)CC1
PROCARBAZINE,PROCARBAZINE,CHEMBL1321,CTRP:28183,ctrp,,,,,,,Small molecule,Approved,CPTBDICYNRMXFX-UHFFFAOYSA-N,CNNCC1CCC(C(=O)NC(C)C)CC1
PROCATEROL,PROCATEROL,CHEMBL160519,BRD:BRD-BRD-K78666826-003-01-6;BRD:BRD-K78666826-003-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,ASTHMA,,LAUNCHED,,Small molecule,Phase 3,FKNXQNWAXFXVNW-UHFFFAOYSA-N,CC[C@H](NC(C)C)[C@H](O)C1CCC(O)C2[NH]C(=O)CCC12;CCC(NC(C)C)C(O)C1CCC(O)C2[NH]C(=O)CCC12
PROCHLORPERAZINE,PROCHLORPERAZINE,CHEMBL728,BRD:BRD-BRD-K19352500-070-12-4;BRD:BRD-K19352500-070-12-4;CTRP:33166,ctrp;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;DRD3;DRD4,"NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,WIKYUJGCLQQFNW-UHFFFAOYSA-N,CN1CCN(CCCN2C3CCCCC3SC3CCC(CL)CC23)CC1;CN1CCN(CCCN2C3CCCCC3SC3CCC(CL)CC32)CC1
PROCODAZOLE,PROCODAZOLE,CHEMBL596009,BRD:BRD-BRD-K54824716-001-04-0;BRD:BRD-K54824716-001-04-0,rep_primary;rep_single_dose,IMMUNOSTIMULANT,,,,PRECLINICAL,,Small molecule,Unknown,XYWJNTOURDMTPI-UHFFFAOYSA-N,O=C(O)CCC1NC2CCCCC2[NH]1;OC(=O)CCC1NC2CCCCC2[NH]1
PROCYANIDIN-B-2,PROCYANIDIN-B-2,,BRD:BRD-BRD-K72093555-001-01-0;BRD:BRD-K72093555-001-01-0,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,O[C@H]1CC2C(O)CC(O)C([C@@H]3[C@@H](O)[C@H](OC4CC(O)CC(O)C34)C3CCC(O)C(O)C3)C2O[C@@H]1C1CCC(O)C(O)C1
PROCYCLIDINE,PROCYCLIDINE,CHEMBL86715,BRD:BRD-A31800922-003-25-1;BRD:BRD-BRD-A31800922-003-25-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,"PARKINSONISM, PARKINSON'S DISEASE, AKATHISIA, DYSTONIA",,LAUNCHED,,Small molecule,Approved,WYDUSKDSKCASEF-UHFFFAOYSA-N,OC(CCN1CCCC1)(C1CCCCC1)C1CCCCC1
PROCYSTEINE,PROCYSTEINE,CHEMBL442218,BRD:BRD-BRD-K92413528-001-06-9;BRD:BRD-K92413528-001-06-9,rep_primary;rep_single_dose,GLUTATHIONE SYNTHASE STIMULANT,,,,PHASE 3,,Small molecule,Phase 2,BMLMGCPTLHPWPY-REOHCLBHSA-N,O=C1N[C@H](C(=O)O)CS1;OC(=O)[C@@H]1CSC(=O)N1
PROCYTOX,PROCYTOX,CHEMBL1200796,GDSC2:1512,gdsc,,,,,,,Small molecule,Approved,PWOQRKCAHTVFLB-UHFFFAOYSA-N,O.O=P1(N(CCCL)CCCL)NCCCO1
PROFLAVINE-HEMISULFATE,PROFLAVINE-HEMISULFATE,,BRD:BRD-BRD-K68408467-065-01-8;BRD:BRD-K68408467-065-01-8,rep_multi_dose;rep_primary;rep_single_dose,TOPICAL ANESTHETIC,F2,,,PHASE 2,,,NA,,NC1CCC2CC3CCC(N)CC3NC2C1
PROGESTERONE,PROGESTERONE,CHEMBL103,BRD:BRD-BRD-K64994968-001-32-5;BRD:BRD-K64994968-001-32-5,rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,CATSPER1;CATSPER2;CATSPER3;CATSPER4;CYP17A1;ESR1;NR3C2;OPRK1;PGR;TRPC5,"INFERTILITY, AMENORRHEA",,LAUNCHED,,Small molecule,Approved,RJKFOVLPORLFTN-LEKSSAKUSA-N,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
PROGLUMIDE,PROGLUMIDE,CHEMBL316561,BRD:BRD-A44863528-001-13-2;BRD:BRD-BRD-A44863528-001-13-2,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKAR;CCKBR,,,WITHDRAWN,,Small molecule,Approved,DGMKFQYCZXERLX-UHFFFAOYSA-N,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1CCCCC1;CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1CCCCC1
PROGUANIL,PROGUANIL,CHEMBL1201059;CHEMBL1377,BRD:BRD-BRD-K28183345-003-11-4;BRD:BRD-K28183345-003-11-4,rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR,MALARIA,,LAUNCHED,,Small molecule,Approved,SARMGXPVOFNNNG-UHFFFAOYSA-N;SSOLNOMRVKKSON-UHFFFAOYSA-N,CC(C)NC(=N)NC(=N)NC1CCC(CL)CC1;CC(C)NC(=N)NC(=N)NC1CCC(CL)CC1.CL
PROLYLLEUCYLGLYCINAMIDE,PROLYLLEUCYLGLYCINAMIDE,,BRD:BRD-A09911125-001-01-4;BRD:BRD-BRD-A09911125-001-01-4,rep_primary;rep_single_dose,MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITOR,,,,PHASE 2,,,NA,,CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O
PROMAZINE,PROMAZINE,CHEMBL564,BRD:BRD-BRD-K06980535-003-25-9;BRD:BRD-K06980535-003-25-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;HRH1;HTR2A;HTR2C,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,CN(C)CCCN1C2CCCCC2SC2CCCCC12;CN(C)CCCN1C2CCCCC2SC2CCCCC21
PROMETHAZINE,PROMETHAZINE,CHEMBL1200750;CHEMBL251904;CHEMBL643,BRD:BRD-A46335897-003-27-8;BRD:BRD-BRD-A46335897-003-27-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,ADRA1A;CALM1;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD2;HRH1;HTR2A,"SEDATIVE, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Approved,PWWVAXIEGOYWEE-UHFFFAOYSA-N;PWWVAXIEGOYWEE-ZDUSSCGKSA-N;XXPDBLUZJRXNNZ-UHFFFAOYSA-N,C[C@@H](CN1C2CCCCC2SC2CCCCC21)N(C)C;CC(CN1C2CCCCC2SC2CCCCC12)N(C)C;CC(CN1C2CCCCC2SC2CCCCC21)N(C)C;CC(CN1C2CCCCC2SC2CCCCC21)N(C)C.CL
PRONETHALOL,PRONETHALOL,CHEMBL16476,BRD:BRD-A87715314-003-14-4;BRD:BRD-BRD-A87715314-003-14-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,WITHDRAWN,,Small molecule,Approved,HRSANNODOVBCST-UHFFFAOYSA-N,CC(C)NCC(O)C1CCC2CCCCC2C1
PROPACETAMOL,PROPACETAMOL,CHEMBL1851805,BRD:BRD-BRD-K54496168-003-01-2;BRD:BRD-K54496168-003-01-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,"FEVER, PAIN RELIEF",,LAUNCHED,,Small molecule,Unknown,QTGAJCQTLIRCFL-UHFFFAOYSA-N,CCN(CC)CC(=O)OC1CCC(NC(C)=O)CC1
PROPAFENONE,PROPAFENONE,CHEMBL631,BRD:BRD-A26334849-001-06-2;BRD:BRD-BRD-A26334849-001-06-2,rep_primary;rep_single_dose,ANTIARRHYTHMIC,ADRB1;ADRB2;KCNA5;KCNH2;SCN5A,"ATRIAL FIBRILLATION (AF), VENTRICULAR TACHYCARDIA (VT), VENTRICULAR ARRHYTHMIAS",,LAUNCHED,,Small molecule,Approved,JWHAUXFOSRPERK-UHFFFAOYSA-N,CCCNCC(O)COC1CCCCC1C(=O)CCC1CCCCC1
PROPAGERMANIUM,PROPAGERMANIUM,CHEMBL2109214,BRD:BRD-K53382462-001-02-0,rep_single_dose,"CCR AGONIST, INTERFERON RECEPTOR AGONIST",CCR2,,,,,Small molecule,Phase 2,,
PROPANTHELINE,PROPANTHELINE,CHEMBL1180725,BRD:BRD-BRD-K90885812-004-24-2;BRD:BRD-K90885812-004-24-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,VVWYOYDLCMFIEM-UHFFFAOYSA-N,CC(C)[N+](C)(CCOC(=O)C1C2CCCCC2OC2CCCCC12)C(C)C;CC(C)[N+](C)(CCOC(=O)C1C2CCCCC2OC2CCCCC21)C(C)C
PROPENTOFYLLINE,PROPENTOFYLLINE,CHEMBL1079905,BRD:BRD-BRD-K59273480-001-10-6;BRD:BRD-K59273480-001-10-6,rep_primary;rep_single_dose,"ADENOSINE REUPTAKE INHIBITOR, PHOSPHODIESTERASE INHIBITOR",PDE1A,STROKE,,LAUNCHED,,Small molecule,Unknown,RBQOQRRFDPXAGN-UHFFFAOYSA-N,CCCN1CNC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C;CCCN1CNC2N(C)C(=O)N(CCCCC(C)=O)C(=O)C12
PROPIVERINE,PROPIVERINE,CHEMBL1078261,BRD:BRD-BRD-K91244729-003-01-3;BRD:BRD-K91244729-003-01-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,URINARY INCONTINENCE,,LAUNCHED,,Small molecule,Approved,QPCVHQBVMYCJOM-UHFFFAOYSA-N,CCCOC(C(=O)OC1CCN(C)CC1)(C1CCCCC1)C1CCCCC1
PROPOFOL,PROPOFOL,CHEMBL526,BRD:BRD-BRD-K82255054-001-15-9;BRD:BRD-K82255054-001-15-9,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,FAAH;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;SCN2A;SCN4A,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,OLBCVFGFOZPWHH-UHFFFAOYSA-N,CC(C)C1CCCC(C(C)C)C1O
PROPOXUR,PROPOXUR,CHEMBL446060,BRD:BRD-BRD-K08231299-001-08-1;BRD:BRD-K08231299-001-08-1,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,ISRUGXGCCGIOQO-UHFFFAOYSA-N,CNC(=O)OC1CCCCC1OC(C)C
PROPOXYCAINE,PROPOXYCAINE,CHEMBL1195,BRD:BRD-BRD-K18250272-003-11-0;BRD:BRD-K18250272-003-11-0,rep_multi_dose;rep_primary;rep_single_dose,LOCAL ANESTHETIC,,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,CAJIGINSTLKQMM-UHFFFAOYSA-N,CCCOC1CC(N)CCC1C(=O)OCCN(CC)CC
PROPRANOLOL,PROPRANOLOL,CHEMBL27;CHEMBL275742,BRD:BRD-A10070317-003-28-3;BRD:BRD-BRD-A10070317-003-28-3,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,"HYPERTENSION, ANGINA PECTORIS, MIGRAINE HEADACHE",,LAUNCHED,,Small molecule,Approved,AQHHHDLHHXJYJD-CQSZACIVSA-N;AQHHHDLHHXJYJD-UHFFFAOYSA-N,CC(C)NC[C@@H](O)COC1CCCC2CCCCC12;CC(C)NCC(O)COC1CCCC2CCCCC12
PROPRANOLOL-(R),PROPRANOLOL-(R),,BRD:BRD-BRD-K92830582-003-10-5;BRD:BRD-K92830582-003-10-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB2;ADRB3,,,PRECLINICAL,,,NA,,CC(C)NC[C@@H](O)COC1CCCC2CCCCC12
PROPRANOLOL-(S),PROPRANOLOL-(S),,BRD:BRD-BRD-K13994703-003-15-8;BRD:BRD-K13994703-003-15-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3;HTR1A;HTR1B;HTR5A;SLC10A1,,,PRECLINICAL,,,NA,,CC(C)NC[C@H](O)COC1CCCC2CCCCC12
PROPYLENE-GLYCOL,PROPYLENE-GLYCOL,,BRD:BRD-A19232309-001-08-6,rep_single_dose,,,,,,,,NA,,
PROPYLHEXEDRINE,PROPYLHEXEDRINE,CHEMBL2105014;CHEMBL2105275,BRD:BRD-A35667010-001-01-8;BRD:BRD-BRD-A35667010-001-01-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,SLC18A2;TAAR1,"NASAL CONGESTION, FEVER, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Unknown,JCRIVQIOJSSCQD-UHFFFAOYSA-N;JCRIVQIOJSSCQD-VIFPVBQESA-N,CN[C@@H](C)CC1CCCCC1;CNC(C)CC1CCCCC1
PROPYLPARABEN,PROPYLPARABEN,CHEMBL194014,BRD:BRD-K60783397-001-12-9,rep_single_dose,,,,,,,Small molecule,Unknown,QELSKZZBTMNZEB-UHFFFAOYSA-N,CCCOC(=O)C1CCC(O)CC1
PROPYLTHIOURACIL,PROPYLTHIOURACIL,CHEMBL1518,BRD:BRD-BRD-K48168960-001-19-2;BRD:BRD-K48168960-001-19-2,rep_primary;rep_single_dose,THYROID PEROXIDASE INHIBITOR,DIO1;TPO,"HYPERTHYROIDISM, GRAVE'S DISEASE, GOITER",,LAUNCHED,,Small molecule,Approved,KNAHARQHSZJURB-UHFFFAOYSA-N,CCCC1CC(=O)[NH]C(=S)[NH]1
PROPYPHENAZONE,PROPYPHENAZONE,CHEMBL28318,BRD:BRD-K06520168-001-03-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Unknown,PXWLVJLKJGVOKE-UHFFFAOYSA-N,CC1C(C(C)C)C(=O)N(-C2CCCCC2)N1C
PROQUAZONE,PROQUAZONE,CHEMBL268501,BRD:BRD-BRD-K54339150-001-01-8;BRD:BRD-K54339150-001-01-8,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,Small molecule,Unknown,JTIGKVIOEQASGT-UHFFFAOYSA-N,CC(C)N1C2CC(C)CCC2C(NC1=O)-C1CCCCC1;CC1CCC2C(-C3CCCCC3)NC(=O)N(C(C)C)C2C1
PROSCILLARIDIN-A,PROSCILLARIDIN-A,,BRD:BRD-A11815689-001-01-1;BRD:BRD-BRD-A11815689-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,,,"CONGESTIVE HEART FAILURE, CARDIAC ARRYTHMIA",,LAUNCHED,,,NA,,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)C2CCC(=O)OC2)C(O)C(O)[C@H]1O
PROTIONAMIDE,PROTIONAMIDE,CHEMBL1378024,BRD:BRD-BRD-K75360161-001-18-0;BRD:BRD-K75360161-001-18-0,rep_primary;rep_single_dose,,,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,VRDIULHPQTYCLN-UHFFFAOYSA-N,CCCC1CC(C(N)=S)CCN1;CCCC1CC(CCN1)C(S)=N
PROTIRELIN,PROTIRELIN,CHEMBL1472,BRD:BRD-A16997652-001-02-3;BRD:BRD-BRD-A16997652-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,THYROTROPIN RELEASING HORMONE RECEPTOR AGONIST,TRHR,THYROID FUNCTION DIAGNOSTIC,,LAUNCHED,,Protein,Approved,XNSAINXGIQZQOO-SRVKXCTJSA-N,NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1;NC(=O)C1CCCN1C(=O)C(CC1C[NH]CN1)NC(=O)C1CCC(=O)N1
PROTRIPTYLINE,PROTRIPTYLINE,CHEMBL668,BRD:BRD-BRD-K42098891-003-20-5;BRD:BRD-K42098891-003-20-5,rep_primary;rep_single_dose,TRICYCLIC ANTIDEPRESSANT,SLC6A2;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,BWPIARFWQZKAIA-UHFFFAOYSA-N,CNCCCC1C2CCCCC2C=CC2CCCCC12;CNCCCC1C2CCCCC2C=CC2CCCCC21
PROXODOLOL,PROXODOLOL,,BRD:BRD-A29944538-003-08-3;BRD:BRD-BRD-A29944538-003-08-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,LAUNCHED,,,NA,,CC1NOC(COC2CCCCC2OCC(O)CNC(C)(C)C)N1
PROXYFAN,PROXYFAN,CHEMBL19173,BRD:BRD-BRD-K77171813-034-01-8;BRD:BRD-K77171813-034-01-8,rep_primary;rep_single_dose,HISTAMINE RECEPTOR MODULATOR,HRH3,,,PRECLINICAL,,Small molecule,NA,WNWALBVQAAIULR-UHFFFAOYSA-N,C(COCC1CCCCC1)CC1CNC[NH]1;C1CCC(COCCCC2C[NH]CN2)CC1
PROXYMETACAINE,PROXYMETACAINE,CHEMBL1196;CHEMBL1200464,BRD:BRD-BRD-K79116891-003-15-1;BRD:BRD-K79116891-003-15-1,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN5A,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,BFUUJUGQJUTPAF-UHFFFAOYSA-N;KCLANYCVBBTKTO-UHFFFAOYSA-N,CCCOC1CCC(C(=O)OCCN(CC)CC)CC1N;CCCOC1CCC(C(=O)OCCN(CC)CC)CC1N.CL;CCCOC1CCC(CC1N)C(=O)OCCN(CC)CC
PROXYPHYLLINE,PROXYPHYLLINE,CHEMBL37390,BRD:BRD-A28887267-001-19-3;BRD:BRD-BRD-A28887267-001-19-3,rep_primary;rep_single_dose,,,ASTHMA,,LAUNCHED,,Small molecule,Approved,KYHQZNGJUGFTGR-UHFFFAOYSA-N,CC(O)CN1CNC2C1C(=O)N(C)C(=O)N2C;CC(O)CN1CNC2N(C)C(=O)N(C)C(=O)C12
PRT-2607,PRT-2607,CHEMBL3545138,GDSC2:1631,gdsc,,,,,,,Small molecule,Phase 1,,
PRT062070,PRT062070,,BRD:BRD-BRD-K25835157-001-01-4;BRD:BRD-K25835157-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,"JAK INHIBITOR, SYK INHIBITOR",SYK,,,PHASE 1,,,NA,,CCS(=O)(=O)N1CCN(CC1)C1CCC(NC2NCC(C(N)=O)C(NC3CC3)N2)CC1
PRT062607,PRT062607,,BRD:BRD-BRD-K53734668-003-02-0;BRD:BRD-BRD-K53734668-003-04-6;BRD:BRD-K53734668-003-02-0;BRD:BRD-K53734668-003-04-6;GDSC2:1631,gdsc;rep_multi_dose;rep_primary;rep_single_dose,SYK INHIBITOR,FGR;MAP3K9;SYK,,,PHASE 2,,,NA,,N[C@H]1CCCC[C@H]1NC1NCC(C(N)=O)C(NC2CCCC(C2)-N2NCCN2)N1
PRUCALOPRIDE,PRUCALOPRIDE,CHEMBL117287,BRD:BRD-BRD-K33681278-036-01-2;BRD:BRD-K33681278-036-01-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR4,CONSTIPATION,,LAUNCHED,,Small molecule,Approved,ZPMNHBXQOOVQJL-UHFFFAOYSA-N,COCCCN1CCC(CC1)NC(=O)C1CC(CL)C(N)C2CCOC12;COCCCN1CCC(NC(=O)C2CC(CL)C(N)C3C2OCC3)CC1
PRULIFLOXACIN,PRULIFLOXACIN,CHEMBL422648,BRD:BRD-A92341659-001-04-0;BRD:BRD-BRD-A92341659-001-04-0,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,"URINARY TRACT INFECTIONS, BRONCHITIS, DIARRHEA",,LAUNCHED,,Small molecule,Phase 3,PWNMXPDKBYZCOO-UHFFFAOYSA-N,CC1OC(=O)OC1CN1CCN(C2CC3C(CC2F)C(=O)C(C(=O)O)C2N3C(C)S2)CC1;CC1SC2C(C(O)=O)C(=O)C3CC(F)C(CC3N12)N1CCN(CC2OC(=O)OC2C)CC1
PRUVANSERIN,PRUVANSERIN,CHEMBL1215661,BRD:BRD-BRD-K43837174-003-01-3;BRD:BRD-K43837174-003-01-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2C,,,PHASE 2,,Small molecule,Phase 2,AQRLDDAFYYAIJP-UHFFFAOYSA-N,FC1CCC(CCN2CCN(CC2)C(=O)C2CCCC3C(C[NH]C23)C#N)CC1;N#CC1C[NH]C2C(C(=O)N3CCN(CCC4CCC(F)CC4)CC3)CCCC12
PRX-07034,PRX-07034,,BRD:BRD-K00004616-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,,NA,,
PRX-08066,PRX-08066,CHEMBL4297322;CHEMBL513994,BRD:BRD-BRD-K16757695-050-02-5;BRD:BRD-K16757695-050-02-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2B,,,PHASE 2,,Small molecule,Phase 2,IENZFHBNCRQMNP-UHFFFAOYSA-N;RPYIKXHIQXRXEM-WLHGVMLRSA-N,FC1CCC(CN2CCC(CC2)NC2NCNC3SC(CL)CC23)CC1C#N;N#CC1CC(CN2CCC(NC3NCNC4SC(CL)CC34)CC2)CCC1F;N#CC1CC(CN2CCC(NC3NCNC4SC(CL)CC34)CC2)CCC1F.O=C(O)/C=C/C(=O)O
PS-341,PS-341,CHEMBL325041,GDSC1:104;GDSC2:1191,gdsc,,,,,,,Small molecule,Approved,GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1CNCCN1)B(O)O
PS178990,PS178990,,BRD:BRD-BRD-K99092662-001-01-1;BRD:BRD-K99092662-001-01-1,rep_primary;rep_single_dose,ANDROGEN RECEPTOR MODULATOR,AR,,,PHASE 1,,,NA,,CC1C(CCC(C#N)C1CL)N1C(=O)[C@@H]2[C@H](O)CCN2C1=O
PSB-06126,PSB-06126,,BRD:BRD-BRD-K71266197-236-02-7;BRD:BRD-K71266197-236-02-7,rep_primary;rep_single_dose,NTPDASE INHIBITOR,ENTPD3,,,PRECLINICAL,,,NA,,NC1C2C(=O)C3CCCCC3C(=O)C2C(NC2CCCC3CCCCC23)CC1S(O)(=O)=O
PSB-11,PSB-11,,BRD:BRD-BRD-K10177585-003-02-4;BRD:BRD-K10177585-003-02-4,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA3,,,PRECLINICAL,,,NA,,CC[C@@H]1CN2C(=N1)C1[NH]C(NC1N(C)C2=O)-C1CCCCC1
PSB-1115,PSB-1115,,BRD:BRD-BRD-K49027941-001-01-1;BRD:BRD-K49027941-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,CCCN1C(=O)[NH]C2NC([NH]C2C1=O)-C1CCC(CC1)S(O)(=O)=O
PSB-36,PSB-36,,BRD:BRD-A70407468-001-02-0;BRD:BRD-BRD-A70407468-001-02-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,CCCCN1C(=O)N(CCCO)C2NC([NH]C2C1=O)C12CC3CC1CC(C2)C3
PSB-603,PSB-603,,BRD:BRD-BRD-K05419687-001-01-0;BRD:BRD-K05419687-001-01-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,,NA,,CCCN1C(=O)[NH]C2NC([NH]C2C1=O)-C1CCC(CC1)S(=O)(=O)N1CCN(CC1)C1CCC(CL)CC1
PSI-6130,PSI-6130,,BRD:BRD-BRD-K07798980-001-01-9;BRD:BRD-K07798980-001-01-9,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 1,,,NA,,C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1CCC(N)NC1=O
PSI-697,PSI-697,CHEMBL219046,BRD:BRD-K00003192-001-01-9,rep_single_dose,P SELECTIN INHIBITOR,,,,,,Small molecule,Phase 1,DIEPFYNZGUUVHD-UHFFFAOYSA-N,O=C(O)C1C(O)C(CC2CCC(CL)CC2)NC2C3C(CCC12)CCCC3
SOFOSBUVIR,PSI-7976;SOFOSBUVIR,CHEMBL1259059,BRD:BRD-BRD-K05674516-001-01-7;BRD:BRD-BRD-K05674516-001-02-5;BRD:BRD-K05674516-001-01-7;BRD:BRD-K05674516-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,"HCV INHIBITOR, RNA POLYMERASE INHIBITOR",,HEPATITIS C,,PRECLINICAL,"Multiple values for MOA: {'HCV INHIBITOR', 'HCV INHIBITOR, RNA POLYMERASE INHIBITOR'}, defaulting to 'HCV INHIBITOR, RNA POLYMERASE INHIBITOR'
Multiple values for MOA: {'HCV INHIBITOR', 'RNA POLYMERASE INHIBITOR', 'HCV INHIBITOR, RNA POLYMERASE INHIBITOR'}, defaulting to 'HCV INHIBITOR, RNA POLYMERASE INHIBITOR'
Multiple values for Phase: {'PRECLINICAL', 'LAUNCHED'}, defaulting to 'PRECLINICAL'",Small molecule,Approved,TTZHDVOVKQGIBA-IQWMDFIBSA-N,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2CCC(=O)[NH]C2=O)[C@](C)(F)[C@@H]1O)OC1CCCCC1;CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](N2CCC(=O)[NH]C2=O)[C@](C)(F)[C@@H]1O)OC1CCCCC1
PSNCBAM-1,PSNCBAM-1,,BRD:BRD-K33502629-001-02-9,rep_single_dose,CANNABINOID RECEPTOR MODULATOR,CNR1,,,,,,NA,,
PSORALEN,PSORALEN,CHEMBL164660,BRD:BRD-BRD-K47264279-001-08-9;BRD:BRD-K47264279-001-08-9,rep_primary;rep_single_dose,,MAOA;MAOB,"PSORIASIS, ECZEMA, VITILIGO",,LAUNCHED,,Small molecule,Phase 1,ZCCUUQDIBDJBTK-UHFFFAOYSA-N,O=C1CCC2CC3CCOC3CC2O1
PT2385,PT-2385;PT2385,,BRD:BRD-BRD-K20850787-001-01-6;BRD:BRD-K20850787-001-01-6,oncref_2;rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,EPAS1;HIF2A,,,PHASE 1,"Multiple values for MOA: {'HYPOXIA INDUCIBLE FACTOR INHIBITOR', 'ANTAGONIST OF HIF2A'}, defaulting to 'HYPOXIA INDUCIBLE FACTOR INHIBITOR'
Multiple values for repurposing_target: {'HIF2A', 'EPAS1'}, taking the union",,NA,,CS(=O)(=O)C1CCC(OC2CC(F)CC(C2)C#N)C2CC(F)(F)[C@@H](O)C12
PT2399,PT2399,,BRD:BRD-K00090636-001-01-9;BRD:BRD-K00090636-001-02-9,oncref_2;rep_single_dose,INHIBITOR OF HIF2A AND ARNT INTERACTION,HIF2A,,,,,,NA,,
PTC-028,PTC-028,,BRD:BRD-K00010388-001-01-9,rep_single_dose,BMI-1 INHIBITOR,,,,,,,NA,,
PTC-209,PTC-209,,BRD:BRD-BRD-K83834509-001-01-1;BRD:BRD-K83834509-001-01-1;BRD:BRD-K83834509-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,BMI-1 INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CC(BR)C(NC2NC(CS2)-C2C(C)NC3NCCCN23)C(BR)C1
PTC596,PTC596,CHEMBL4594353,BRD:BRD-K00090626-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,TWLWOOPCEXYVBE-UHFFFAOYSA-N,CC1NC2CCC(F)CC2N1-C1NC(N)C(F)C(NC2CCC(C(F)(F)F)CC2)N1
PTEROSTILBENE,PTEROSTILBENE,CHEMBL83527,BRD:BRD-BRD-K53097745-001-01-5;BRD:BRD-K53097745-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PPAR RECEPTOR AGONIST",PTGS2,,,PHASE 2/PHASE 3,,Small molecule,Phase 2,VLEUZFDZJKSGMX-ONEGZZNKSA-N,COC1CC(/C=C/C2CCC(O)CC2)CC(OC)C1;COC1CC(OC)CC(C=CC2CCC(O)CC2)C1
PTI-428,PTI-428,CHEMBL4297479,BRD:BRD-K00091089-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,XPEHHUISIBFLHX-RAIGVLPGSA-N,C[C@@H](O)C1NNC([C@H]2C[C@H](NC(=O)C3CC(-C4CCCCC4)NO3)C2)O1
PU-H71,PU-H71,CHEMBL200102,BRD:BRD-BRD-K36529613-001-02-6;BRD:BRD-K36529613-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PHASE 1,,Small molecule,Phase 1,SUPVGFZUWFMATN-UHFFFAOYSA-N,CC(C)NCCCN1C(SC2CC3C(CC2I)OCO3)NC2C(N)NCNC21;CC(C)NCCCN1C(SC2CC3OCOC3CC2I)NC2C(N)NCNC12
PUERARIN,PUERARIN,CHEMBL486386,BRD:BRD-BRD-K89048337-001-06-9;BRD:BRD-K89048337-001-06-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,PHASE 2,,Small molecule,Phase 2,HKEAFJYKMMKDOR-VPRICQMDSA-N,O=C1C(-C2CCC(O)CC2)COC2C([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(O)CCC12;OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1C(O)CCC2C1OCC(-C1CCC(O)CC1)C2=O
PUMOSETRAG,PUMOSETRAG,CHEMBL1643880,BRD:BRD-BRD-K44164034-003-01-1;BRD:BRD-K44164034-003-01-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR3A;HTR4,,,PHASE 2,,Small molecule,Phase 2,AFUWQWYPPZFWCO-LBPRGKRZSA-N,O=C(N[C@H]1CN2CCC1CC2)C1C[NH]C2CCSC2C1=O;OC1C(CNC2CCSC12)C(=O)N[C@H]1CN2CCC1CC2
PURMORPHAMINE,PURMORPHAMINE,CHEMBL1221984,BRD:BRD-BRD-K73397362-001-06-6;BRD:BRD-K73397362-001-06-6;CTRP:52576,ctrp;rep_primary;rep_single_dose,SMOOTHENED RECEPTOR AGONIST,SMO,,,PRECLINICAL,,Small molecule,NA,FYBHCRQFSFYWPY-UHFFFAOYSA-N,C1CCC(CC1)N1CNC2C(NC3CCC(CC3)N3CCOCC3)NC(OC3CCCC4CCCCC34)NC12;C1CCC2C(OC3NC(NC4CCC(N5CCOCC5)CC4)C4NCN(C5CCCCC5)C4N3)CCCC2C1
PUROMYCIN,PUROMYCIN,CHEMBL469912,BRD:BRD-A28970875-300-04-9;BRD:BRD-BRD-A28970875-300-04-9,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,NHP2L1;RPL10L;RPL11;RPL13A;RPL15;RPL19;RPL23;RPL23A;RPL26L1;RPL3;RPL37;RPL8;RSL24D1,,,PRECLINICAL,,Small molecule,Unknown,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,COC1CCC(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)N2CNC3C(NCNC23)N(C)C)CC1;COC1CCC(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@H](N3CNC4C(N(C)C)NCNC43)O[C@@H]2CO)CC1
PURVALANOL-A,PURVALANOL-A,,BRD:BRD-BRD-K50836978-001-02-5;BRD:BRD-K50836978-001-02-5,rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK4;CDK5;CSNK1G3;RPS6KA1;SRC,,,PRECLINICAL,,,NA,,CC(C)[C@H](CO)NC1NC(NC2CCCC(CL)C2)C2NCN(C(C)C)C2N1
PURVALANOL-B,PURVALANOL-B,,BRD:BRD-BRD-K41564320-001-02-0;BRD:BRD-K41564320-001-02-0,rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,CDK2;CDK4;CDK5;MAPK1;MAPK3;SRPK2,,,PRECLINICAL,,,NA,,CC(C)[C@H](CO)NC1NC(NC2CCC(C(O)=O)C(CL)C2)C2NCN(C(C)C)C2N1
PUTRESCINE,PUTRESCINE,CHEMBL46257,BRD:BRD-K75282878-300-05-3,rep_single_dose,TISSUE TRANSGLUTAMINASE INHIBITOR,AMD1;KCNJ4;ODC1,,,,,Small molecule,Phase 3,KIDHWZJUCRJVML-UHFFFAOYSA-N,NCCCCN
PX-12,PX-12,CHEMBL406050,BRD:BRD-A56592690-001-04-3;BRD:BRD-BRD-A56592690-001-04-3;CTRP:609124,ctrp;rep_primary;rep_single_dose,THIOREDOXIN INHIBITOR,CNR1;TXN;TXNRD1,,,PHASE 2,"Multiple values for repurposing_target: {'CNR1;TXN;TXNRD1', 'TXN;TXNRD1'}, taking the union",Small molecule,Phase 2,BPBPYQWMFCTCNG-UHFFFAOYSA-N,CCC(C)SSC1NCC[NH]1
PX-478,PX-478,CHEMBL4297816,BRD:BRD-A26835809-300-01-3;BRD:BRD-BRD-A26835809-300-01-3,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,,,,PHASE 1,,Unknown,Phase 1,,NC(CC1CCC(CC1)[N+]([O-])(CCCL)CCCL)C(O)=O
PXD-101,PXD-101,CHEMBL408513,GDSC1:274,gdsc,,,,,,,Small molecule,Approved,NCNRHFGMJRPRSK-MDZDMXLPSA-N,O=C(/C=C/C1CCCC(S(=O)(=O)NC2CCCCC2)C1)NO
PXD101,PXD101,CHEMBL408513,GDSC1:274,gdsc,,,,,,,Small molecule,Approved,NCNRHFGMJRPRSK-MDZDMXLPSA-N,O=C(/C=C/C1CCCC(S(=O)(=O)NC2CCCCC2)C1)NO
PYM50028,PYM50028,,BRD:BRD-BRD-K62277907-001-01-6;BRD:BRD-K62277907-001-01-6,rep_primary;rep_single_dose,NEUROTROPHIC AGENT,,,,PHASE 2,,,NA,,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1
PYR-41,PYR-41,,CTRP:660202,ctrp,,,,,,,,NA,,
PYRANTEL,PYRANTEL,CHEMBL1626223,BRD:BRD-BRD-K82118441-001-03-7;BRD:BRD-K82118441-001-03-7,rep_primary;rep_single_dose,"ACETYLCHOLINE RECEPTOR AGONIST, NICOTINIC RECEPTOR AGONIST",,"GASTROINTESTINAL ROUNDWORMS, GASTROINTESTINAL ROUNDWORMS",,LAUNCHED,"Multiple values for MOA: {'ACETYLCHOLINE RECEPTOR AGONIST, NICOTINIC RECEPTOR AGONIST', 'NICOTINIC RECEPTOR AGONIST'}, defaulting to 'ACETYLCHOLINE RECEPTOR AGONIST, NICOTINIC RECEPTOR AGONIST'",Small molecule,Approved,YSAUAVHXTIETRK-AATRIKPKSA-N,CN1CCCN=C1/C=C/C1CCCS1;OC(=O)C1CC2CCCCC2C(CC2C(O)C(CC3CCCCC23)C(O)=O)C1O
PYRANTEL-PAMOATE,PYRANTEL-PAMOATE,,BRD:BRD-K20672254-046-05-4,rep_single_dose,NEUROMUSCULAR BLOCKER,,,,,,,NA,,
PYRAZINAMIDE,PYRAZINAMIDE,CHEMBL614,BRD:BRD-BRD-K28667793-001-28-1;BRD:BRD-K28667793-001-28-1,rep_primary;rep_single_dose,FATTY ACID SYNTHASE INHIBITOR,FASN,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,IPEHBUMCGVEMRF-UHFFFAOYSA-N,NC(=O)C1CNCCN1
PYRAZINOYLGUANIDINE,PYRAZINOYLGUANIDINE,,BRD:BRD-BRD-K61693562-300-01-7;BRD:BRD-K61693562-300-01-7,rep_primary;rep_single_dose,DIURETIC,,,,PHASE 1,,,NA,,NC(=N)NC(=O)C1CNCCN1
PYRAZOLANTHRONE,PYRAZOLANTHRONE,,BRD:BRD-BRD-K01567962-001-23-0;BRD:BRD-K01567962-001-23-0;CTRP:44511,ctrp;rep_primary;rep_single_dose,JNK INHIBITOR,MAPK10;MAPK8;MAPK8IP1;MAPK9;TTK,,,PRECLINICAL,,,NA,,O=C1C2CCCCC2-C2N[NH]C3CCCC1C23
PYRETHRINS,PYRETHRINS,CHEMBL2096637,BRD:BRD-K00010129-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,VXSIXFKKSNGRRO-MXOVTSAMSA-N,C=C/C=C\CC1=C(C)[C@@H](OC(=O)[C@@H]2[C@@H](/C=C(\C)C(=O)OC)C2(C)C)CC1=O.C=C/C=C\CC1=C(C)[C@@H](OC(=O)[C@@H]2[C@@H](C=C(C)C)C2(C)C)CC1=O
PYRIDOSTATIN,PYRIDOSTATIN,CHEMBL2349416,GDSC2:2044,gdsc,,,,,,,Small molecule,NA,VGHSATQVJCTKEF-UHFFFAOYSA-N,NCCOC1CC(C(=O)NC2CC(OCCN)C3CCCCC3N2)NC(C(=O)NC2CC(OCCN)C3CCCCC3N2)C1
PYRIDOXAL,PYRIDOXAL,CHEMBL102970,BRD:BRD-BRD-K76204040-001-03-8;BRD:BRD-K76204040-001-03-8,rep_primary;rep_single_dose,,PDXK,EPILEPSY,,LAUNCHED,,Small molecule,Phase 3,RADKZDMFGJYCBB-UHFFFAOYSA-N,CC1NCC(CO)C(C=O)C1O
PYRIDOXAL-ISONICOTINOYL-HYDRAZONE,PYRIDOXAL-ISONICOTINOYL-HYDRAZONE,,BRD:BRD-BRD-K42019693-001-01-5;BRD:BRD-K42019693-001-01-5,rep_primary;rep_single_dose,APOPTOSIS STIMULANT,,,,PHASE 2,,,NA,,CC1NCC(CO)C(\C=N\NC(=O)C2CCNCC2)C1O
PYRIDOXAMINE,PYRIDOXAMINE,CHEMBL4298078;CHEMBL593019,BRD:BRD-BRD-K96669468-300-01-1;BRD:BRD-K96669468-300-01-1,rep_primary;rep_single_dose,AGE INHIBITOR,,,,PHASE 3,,Small molecule;Unknown,Phase 3,;NHZMQXZHNVQTQA-UHFFFAOYSA-N,CC1NCC(CO)C(CN)C1O
PYRIDOXINE,PYRIDOXINE,CHEMBL1364,BRD:BRD-BRD-K14349461-003-13-1;BRD:BRD-K14349461-003-13-1,rep_primary;rep_single_dose,VITAMIN B,DDC;PDXK,VITAMIN B6 DEFICIENCY,,LAUNCHED,,Small molecule,Approved,LXNHXLLTXMVWPM-UHFFFAOYSA-N,CC1NCC(CO)C(CO)C1O
PYRIMETHAMINE,PYRIMETHAMINE,CHEMBL36,BRD:BRD-BRD-K88429204-001-35-1;BRD:BRD-K88429204-001-35-1;GDSC1:71,gdsc;rep_multi_dose;rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR;SLC47A1,MALARIA,,LAUNCHED,,Small molecule,Approved,WKSAUQYGYAYLPV-UHFFFAOYSA-N,CCC1NC(N)NC(N)C1-C1CCC(CL)CC1
PYRINTEGRIN,PYRINTEGRIN,,BRD:BRD-K94659840-001-02-9,rep_single_dose,INTEGRIN SIGNALING ACTIVATOR,,,,,,,NA,,
PYRIPROXYFEN,PYRIPROXYFEN,CHEMBL1883234,BRD:BRD-K00084847-001-01-9,rep_single_dose,,,,,,,Small molecule,NA,NHDHVHZZCFYRSB-UHFFFAOYSA-N,CC(COC1CCC(OC2CCCCC2)CC1)OC1CCCCN1
PYRITHIONE-ZINC,PYRITHIONE-ZINC,,BRD:BRD-BRD-K16136380-001-01-7;BRD:BRD-K16136380-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,ATP SYNTHASE INHIBITOR,KCNQ1;KCNQ2;KCNQ4;KCNQ5,DANDRUFF,,LAUNCHED,,,NA,,O1[N+]2CCCCC2S[ZN]11O[N+]2CCCCC2S1
PYRITHYLDIONE,PYRITHYLDIONE,CHEMBL1722501,BRD:BRD-BRD-K36116267-001-15-3;BRD:BRD-K36116267-001-15-3,rep_primary;rep_single_dose,PSYCHOACTIVE DRUG,,,,WITHDRAWN,,Small molecule,Unknown,NZASCBIBXNPDMH-UHFFFAOYSA-N,CCC1(CC)C(=O)C=CNC1=O;CCC1(CC)C(=O)NC=CC1=O
PYRITINOL,PYRITINOL,CHEMBL488093,BRD:BRD-BRD-K82181219-001-04-3;BRD:BRD-K82181219-001-04-3,rep_multi_dose;rep_primary;rep_single_dose,,,"RHEUMATOID ARTHRITIS, SENILE DEMENTIA",,LAUNCHED,,Small molecule,Phase 3,SIXLXDIJGIWWFU-UHFFFAOYSA-N,CC1NCC(CSSCC2CNC(C)C(O)C2CO)C(CO)C1O
PYRONARIDINE,PYRONARIDINE,CHEMBL35228,BRD:BRD-BRD-K73132780-001-01-2;BRD:BRD-K73132780-001-01-2,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,,,,PHASE 3,,Small molecule,Phase 3,DJUFPMUQJKWIJB-UHFFFAOYSA-N,COC1CCC2NC3CC(CL)CCC3C(NC3CC(CN4CCCC4)C(O)C(CN4CCCC4)C3)C2N1
SHR-1258,PYROTINIB;SHR-1258,CHEMBL3544956,BRD:BRD-K00003463-001-01-9;BRD:BRD-K00003463-001-03-9,oncref_2;rep_single_dose,PAN-HER RECEPTOR TYROSINE KINASE INHIBITOR,EGFR;ERBB2;ERBB4,,,,"Multiple values for MOA: {'KINASE INHIBITOR', 'PAN-HER RECEPTOR TYROSINE KINASE INHIBITOR'}, defaulting to 'PAN-HER RECEPTOR TYROSINE KINASE INHIBITOR'",Small molecule,Phase 3,,
PYROXAMIDE,PYROXAMIDE,CHEMBL353581,BRD:BRD-BRD-K11663430-001-02-3;BRD:BRD-K11663430-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1,,,PHASE 1,,Small molecule,Phase 1,PTJGLFIIZFVFJV-UHFFFAOYSA-N,O=C(CCCCCCC(=O)NC1CCCNC1)NO;ONC(=O)CCCCCCC(=O)NC1CCCNC1
PZ-2891,PZ-2891,,BRD:BRD-K00005336-001-01-9,rep_single_dose,PANTOTHENATE KINASE ACTIVATOR,,,,,,,NA,,
Q-203,Q-203,CHEMBL3298910,BRD:BRD-BRD-K59853741-001-01-9;BRD:BRD-K59853741-001-01-9,rep_primary;rep_single_dose,ATP SYNTHASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 2,OJICYBSWSZGRFB-UHFFFAOYSA-N,CCC1NC2CCC(CL)CN2C1C(=O)NCC1CCC(CC1)N1CCC(CC1)C1CCC(OC(F)(F)F)CC1;CCC1NC2CCC(CL)CN2C1C(=O)NCC1CCC(N2CCC(C3CCC(OC(F)(F)F)CC3)CC2)CC1
QL-VIII-58,QL-VIII-58,,GDSC1:1166,gdsc,,,,,,,,NA,,
QL-X-138,QL-X-138,,GDSC1:331,gdsc,,,,,,,,NA,,
QL-XI-92,QL-XI-92,,GDSC1:329,gdsc,,,,,,,,NA,,
QL-XII-47,QL-XII-47,,GDSC1:235,gdsc,,,,,,,,NA,,
QL-XII-61,QL-XII-61,,GDSC1:1203,gdsc,,,,,,,,NA,,
QS-11,QS-11,,CTRP:609681,ctrp,,,,,,,,NA,,
QS11,QS11,,GDSC1:151,gdsc,,,,,,,,NA,,
QUAZINONE,QUAZINONE,CHEMBL320341,BRD:BRD-BRD-K63631219-001-01-6;BRD:BRD-K63631219-001-01-6,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A;PDE3B,,,PHASE 2,,Small molecule,Unknown,BHZFZYLBVSWUMT-ZCFIWIBFSA-N,C[C@@H]1C(=O)NC2=NC3CCCC(CL)C3CN21;CC1C(O)NC2NC3CCCC(CL)C3CN12
QUERCETIN,QUERCETIN,CHEMBL50,BRD:BRD-BRD-K97399794-001-15-3;BRD:BRD-K97399794-001-15-3,rep_primary;rep_single_dose,POLAR AUXIN TRANSPORT INHIBITOR,ATP5A1;ATP5B;ATP5C1;HCK;HIBCH;PIK3CG;PIM1;STK17B;UGT3A1,"FATIGUE, ALLERGIC RHINITIS, DROWSINESS",,LAUNCHED,,Small molecule,Phase 3,REFJWTPEDVJJIY-UHFFFAOYSA-N,O=C1C(O)C(-C2CCC(O)C(O)C2)OC2CC(O)CC(O)C12;OC1CC(O)C2C(C1)OC(-C1CCC(O)C(O)C1)C(O)C2=O
QUETIAPINE,QUETIAPINE,CHEMBL716,BRD:BRD-BRD-K68867920-051-11-5;BRD:BRD-K68867920-051-11-5,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2C;HTR3A;HTR6;HTR7;SLC6A2,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,URKOMYMAXPYINW-UHFFFAOYSA-N,OCCOCCN1CCN(C2=NC3CCCCC3SC3CCCCC32)CC1;OCCOCCN1CCN(CC1)C1=NC2CCCCC2SC2CCCCC12
QUIFLAPON,QUIFLAPON,CHEMBL16596,BRD:BRD-BRD-K39503511-001-03-9;BRD:BRD-K39503511-001-03-9,rep_primary;rep_single_dose,LEUKOTRIENE SYNTHESIS INHIBITOR,ALOX5;ALOX5AP,,,PHASE 2,,Small molecule,Unknown,NZOONKHCNQFYCI-UHFFFAOYSA-N,CC(C)(C)SC1C(CC(C)(C)C(=O)O)N(CC2CCC(CL)CC2)C2CCC(OCC3CCC4CCCCC4N3)CC12;CC(C)(C)SC1C(CC(C)(C)C(O)=O)N(CC2CCC(CL)CC2)C2CCC(OCC3CCC4CCCCC4N3)CC12
QUINAGOLIDE,QUINAGOLIDE,CHEMBL2218861;CHEMBL290962,BRD:BRD-BRD-K02995728-003-01-9;BRD:BRD-K02995728-003-01-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2,HYPERPROLACTINEMIA,,LAUNCHED,,Small molecule,Phase 2,GDFGTRDCCWFXTG-UHFFFAOYSA-N;GDFGTRDCCWFXTG-ZIFCJYIRSA-N,CCCN1C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]2CC3C(O)CCCC3C[C@H]21;CCCN1C[C@H](C[C@@H]2CC3C(O)CCCC3C[C@@H]12)NS(=O)(=O)N(CC)CC;CCCN1CC(NS(=O)(=O)N(CC)CC)CC2CC3C(O)CCCC3CC21
QUINAPRIL,QUINAPRIL,CHEMBL1592,BRD:BRD-BRD-K72222507-003-16-8;BRD:BRD-K72222507-003-16-8,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, CONGESTIVE HEART FAILURE, ANGIOEDEMA",,LAUNCHED,,Small molecule,Approved,JSDRRTOADPPCHY-HSQYWUDLSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CC2CCCCC2C[C@H]1C(=O)O;CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CC2CCCCC2C[C@H]1C(O)=O
QUINELORANE,QUINELORANE,CHEMBL155731,BRD:BRD-BRD-K13261168-300-01-0;BRD:BRD-K13261168-300-01-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2;DRD3,,,PHASE 3,,Small molecule,Unknown,TUFADSGTJUOBEH-ZWNOBZJWSA-N,CCCN1CCC[C@@H]2CC3NC(N)NCC3C[C@@H]12;CCCN1CCC[C@@H]2CC3NC(N)NCC3C[C@H]21
QUINESTROL,QUINESTROL,CHEMBL1201165,BRD:BRD-A16439188-001-01-1;BRD:BRD-BRD-A16439188-001-01-1,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ESR1,MENOPAUSE,,LAUNCHED,,Small molecule,Approved,PWZUUYSISTUNDW-VAFBSOEGSA-N,C[C@]12CCC3C(CCC4CC(OC5CCCC5)CCC34)C1CC[C@@]2(O)C#C;C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4CC(OC5CCCC5)CCC4[C@H]3CC[C@@]21C
QUINETHAZONE,QUINETHAZONE,CHEMBL1532,BRD:BRD-A59303141-001-10-4;BRD:BRD-BRD-A59303141-001-10-4,rep_multi_dose;rep_primary;rep_single_dose,THIAZIDE DIURETIC,CA1;CA2;SLC12A1;SLC12A2;SLC12A3,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,AGMMTXLNIQSRCG-UHFFFAOYSA-N,CCC1NC(=O)C2CC(C(CL)CC2N1)S(N)(=O)=O;CCC1NC(=O)C2CC(S(N)(=O)=O)C(CL)CC2N1
QUINIDINE,QUINIDINE,CHEMBL1294;CHEMBL21578;CHEMBL3707183,BRD:BRD-BRD-K59632282-052-03-1;BRD:BRD-K59632282-052-03-1,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,KCNA5;KCNA7;KCNH1;KCNH2;KCNH5;KCNK1;KCNK6;SCN5A;SLC29A4,"MALARIA, ATRIAL FIBRILLATION (AF), VENTRICULAR ARRHYTHMIAS",,LAUNCHED,,Small molecule,Approved,LOUPRKONTZGTKE-LHHVKLHASA-N;LOUPRKONTZGTKE-NBGVHYBESA-N;ZHNFLHYOFXQIOW-AHSOWCEXSA-N,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C1CCNC2CCC(OC)CC12;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C1CCNC2CCC(OC)CC12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)C1CCNC2CCC(OC)CC12.O.O.O=S(=O)(O)O;C=C[C@H]1CN2CCC1C[C@@H]2[C@@H](O)C1CCNC2CCC(OC)CC12;COC1CCC2NCCC([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2C1
QUININE,QUININE,CHEMBL170;CHEMBL2146083;CHEMBL2146084;CHEMBL2146105;CHEMBL2359966;CHEMBL3707329,BRD:BRD-BRD-K07940445-310-02-9;BRD:BRD-K07940445-310-02-9,rep_primary;rep_single_dose,HEMOZOIN BIOCRYSTALLIZATION INHIBITOR,GP9;KCNB2;KCNN4;SLC29A4,MALARIA,,LAUNCHED,,Small molecule,Approved,AMEXZRFCGITZNZ-HZQSTTLBSA-N;HDZGBIRSORQVNB-DSXUQNDKSA-N;JGWCVXDJEMKYEA-INGJVHGESA-N;LOUPRKONTZGTKE-WZBLMQSHSA-N;MAYUSTFJKJSJNC-DSXUQNDKSA-N;ZHNFLHYOFXQIOW-LPYZJUEESA-N,BR.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12;C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12;C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.O=P(O)(O)O.O=P(O)(O)O;C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.O.O.O=S(=O)(O)O;C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.O=C(O)C1CCCCC1O;C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)C1CCNC2CCC(OC)CC12.O=S(=O)(O)O.O=S(=O)(O)O;COC1CCC2NCCC([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)C2C1;COC1CCC2NCCC([C@@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2C1
QUININE-ETHYL-CARBONATE,QUININE-ETHYL-CARBONATE,,BRD:BRD-BRD-K97028990-001-04-4;BRD:BRD-K97028990-001-04-4,rep_primary;rep_single_dose,,,MALARIA,,LAUNCHED,,,NA,,CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)C1CCNC2CCC(OC)CC12
QUINOLINIC-ACID,QUINOLINIC-ACID,,BRD:BRD-BRD-K51885093-001-11-2;BRD:BRD-K51885093-001-11-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,OC(=O)C1CCCNC1C(O)=O
QUINPIROL-(-),QUINPIROL-(-),,BRD:BRD-BRD-K26548821-003-10-5;BRD:BRD-K26548821-003-10-5,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD1;DRD2;DRD3;DRD4;HTR1A;HTR2A;HTR2B;HTR2C,,,PHASE 2,,,NA,,CCCN1CCC[C@@H]2CC3N[NH]CC3C[C@@H]12
QUIPAZINE,QUIPAZINE,CHEMBL18772,BRD:BRD-BRD-K77925998-050-14-3;BRD:BRD-K77925998-050-14-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1D;HTR2A;HTR2B;HTR2C;HTR3A;HTR3B;HTR6;SLC6A4,,,PRECLINICAL,,Small molecule,Unknown,XRXDAJYKGWNHTQ-UHFFFAOYSA-N,C1CCC2NC(N3CCNCC3)CCC2C1;C1CN(CCN1)C1CCC2CCCCC2N1
QUIZARTINIB,QUIZARTINIB,CHEMBL576982,BRD:BRD-BRD-K93918653-001-08-9;BRD:BRD-K93918653-001-08-9;CTRP:640011;GDSC1:254,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,FLT3 INHIBITOR,CSF1R;FLT3;KIT;PDGFRA;PDGFRB;RET,,,PHASE 3,,Small molecule,Phase 3,CVWXJKQAOSCOAB-UHFFFAOYSA-N,CC(C)(C)C1CC(NC(=O)NC2CCC(-C3CN4C(N3)SC3CC(OCCN5CCOCC5)CCC34)CC2)NO1;CC(C)(C)C1CC(NC(=O)NC2CCC(CC2)-C2CN3C(N2)SC2CC(OCCN4CCOCC4)CCC32)NO1
QW-BI-011,QW-BI-011,,CTRP:362063,ctrp,,,,,,,,NA,,
QX-222,QX-222,,BRD:BRD-BRD-K40782193-003-02-9;BRD:BRD-K40782193-003-02-9,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,CC1CCCC(C)C1NC(=O)C[N+](C)(C)C
QX-314,QX-314,,BRD:BRD-BRD-K56596464-004-10-7;BRD:BRD-K56596464-004-10-7,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,MAPK14;TGFBR1,,,PRECLINICAL,,,NA,,CC[N+](CC)(CC)CC(=O)NC1C(C)CCCC1C
R-121919,R-121919,,BRD:BRD-K00004717-001-01-9,rep_single_dose,CRF RECEPTOR ANTAGONIST,,,,,,,NA,,
R-1415,R-1415,CHEMBL553,GDSC1:1;GDSC2:1168,gdsc,,,,,,,Small molecule,Approved,AAKJLRGGTJKAMG-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1
R-1479,R-1479,CHEMBL393857,BRD:BRD-BRD-K28442028-001-01-3;BRD:BRD-K28442028-001-01-3,rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,ODLGMSQBFONGNG-JVZYCSMKSA-N,[N-]=[N+]=N[C@]1(CO)O[C@@H](N2CCC(N)NC2=O)[C@H](O)[C@@H]1O;NC1CCN([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)C(=O)N1
R-1485,R-1485,,BRD:BRD-BRD-K96418224-300-01-8;BRD:BRD-K96418224-300-01-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR6,,,PHASE 1,,,NA,,FC1CCCCC1S(=O)(=O)N1CCOC2C(CCCC12)N1CCNCC1
R-1487,R-1487,CHEMBL1230122;CHEMBL1766582,BRD:BRD-K00004710-001-01-9,rep_single_dose,P38 MAPK INHIBITOR,,,,,,Small molecule,Phase 1,KKKRKRMVJRHDMG-UHFFFAOYSA-N;RQHSAIGGUWVOBG-UHFFFAOYSA-N,CL.CN1C(=O)C(OC2CCC(F)CC2F)CC2CNC(NC3CCOCC3)NC21;CN1C(=O)C(OC2CCC(F)CC2F)CC2CNC(NC3CCOCC3)NC21
R-268712,R-268712,,BRD:BRD-K83904070-001-02-9,rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,TGFBR1,,,,,,NA,,
R-428,R-428,CHEMBL3809489,BRD:BRD-BRD-K14870255-001-02-3;BRD:BRD-K14870255-001-02-3,rep_primary;rep_single_dose,AXL KINASE INHIBITOR,AXL,,,PHASE 1,,Small molecule,Phase 2,KXMZDGSRSGHMMK-VWLOTQADSA-N,NC1NC(NC2CCC3C(C2)CC[C@@H](N2CCCC2)CC3)NN1-C1CC2C(NN1)-C1CCCCC1CCC2;NC1NC(NC2CCC3CC[C@@H](CCC3C2)N2CCCC2)NN1-C1CC2CCCC3CCCCC3-C2NN1
R-59022,R-59022,,BRD:BRD-BRD-K54665485-001-07-9;BRD:BRD-K54665485-001-07-9,rep_primary;rep_single_dose,"DIACYLGLYCEROL KINASE INHIBITOR, PROTEIN KINASE INHIBITOR",DGKA,,,PRECLINICAL,,,NA,,CC1NC2SCCN2C(=O)C1CCN1CCC(CC1)=C(C1CCCCC1)C1CCC(F)CC1
R-96544,R-96544,,BRD:BRD-BRD-K15588452-003-02-7;BRD:BRD-K15588452-003-02-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A,,,PRECLINICAL,,,NA,,COC1CCCC(CCC2CCCCC2OCC[C@@H]2C[C@@H](O)CN2C)C1
R112,R112,,BRD:BRD-K23902832-001-01-7,rep_single_dose,SYK INHIBITOR,SYK,,,,,,NA,,
TIPIFARNIB,R115777;TIPIFARNIB,CHEMBL289228,BRD:BRD-BRD-K62965247-001-04-9;BRD:BRD-K62965247-001-04-9;BRD:BRD-U00115426-001-01-9;GDSC1:204,gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF FARNESYLTRANSFERASE A AND B,FNTA;FNTB,,,PHASE 3,"Multiple values for MOA: {'FARNESYLTRANSFERASE INHIBITOR', 'INHIBITOR OF FARNESYLTRANSFERASE A AND B'}, defaulting to 'INHIBITOR OF FARNESYLTRANSFERASE A AND B'
Multiple values for structure_id: {'U00115426', 'K62965247'}, defaulting to None",Small molecule,Phase 3,PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1CNCC1[C@@](N)(C1CCC(CL)CC1)C1CCC2C(C1)C(-C1CCCC(CL)C1)CC(=O)N2C;CN1CNCC1[C@@](N)(C1CCC(CL)CC1)C1CCC2N(C)C(=O)CC(-C3CCCC(CL)C3)C2C1
R306465,R306465,CHEMBL609583,BRD:BRD-BRD-K86687746-001-01-3;BRD:BRD-K86687746-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,MUTBJZVSRNUIHA-UHFFFAOYSA-N,O=C(NO)C1CNC(N2CCN(S(=O)(=O)C3CCC4CCCCC4C3)CC2)NC1;ONC(=O)C1CNC(NC1)N1CCN(CC1)S(=O)(=O)C1CCC2CCCCC2C1
R406,R406,,BRD:BRD-BRD-K20285085-001-07-1;BRD:BRD-BRD-K20285085-074-04-5;BRD:BRD-K20285085-001-07-1;BRD:BRD-K20285085-074-04-5,rep_multi_dose;rep_primary;rep_single_dose,SYK INHIBITOR,RET;SYK,,,PHASE 1,,,NA,,COC1CC(NC2NCC(F)C(NC3CCC4OC(C)(C)C(=O)NC4N3)N2)CC(OC)C1OC
R428,R428,CHEMBL2023349;CHEMBL3809489,CTRP:660993,ctrp,,,,,,,Small molecule,Phase 2,KXMZDGSRSGHMMK-UHFFFAOYSA-N;KXMZDGSRSGHMMK-VWLOTQADSA-N,NC1NC(NC2CCC3C(C2)CC[C@@H](N2CCCC2)CC3)NN1-C1CC2C(NN1)-C1CCCCC1CCC2;NC1NC(NC2CCC3C(C2)CCC(N2CCCC2)CC3)NN1-C1CC2C(NN1)-C1CCCCC1CCC2
R547,R547,,BRD:BRD-BRD-K52233191-001-02-4;BRD:BRD-K52233191-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK4;CDK7,,,PHASE 1,,,NA,,COC1CCC(F)C(F)C1C(=O)C1CNC(NC2CCN(CC2)S(C)(=O)=O)NC1N
RABEPRAZOLE,RABEPRAZOLE,CHEMBL1219;CHEMBL1615209,BRD:BRD-A39390670-236-10-7;BRD:BRD-BRD-A39390670-236-10-7,rep_multi_dose;rep_primary;rep_single_dose,"ATPASE INHIBITOR, GASTRIN INHIBITOR",ATP4A,"GASTROESOPHAGEAL REFLUX DISEASE (GERD), DUODENAL ULCER DISEASE, ZOLLINGER-ELLISON SYNDROME",,LAUNCHED,,Small molecule,Approved,YREYEVIYCVEVJK-RUZDIDTESA-N;YREYEVIYCVEVJK-UHFFFAOYSA-N,COCCCOC1CCNC(C[S@@+]([O-])C2NC3CCCCC3[NH]2)C1C;COCCCOC1CCNC(C[S+]([O-])C2NC3CCCCC3[NH]2)C1C;COCCCOC1CCNC(CS(=O)C2NC3CCCCC3[NH]2)C1C
RACECADOTRIL,RACECADOTRIL,CHEMBL2103772,BRD:BRD-A08187463-001-12-9;BRD:BRD-BRD-A08187463-001-12-9,rep_multi_dose;rep_primary;rep_single_dose,ENKEPHALINASE INHIBITOR,MME,DIARRHEA,,LAUNCHED,,Small molecule,Approved,ODUOJXZPIYUATO-UHFFFAOYSA-N,CC(=O)SCC(CC1CCCCC1)C(=O)NCC(=O)OCC1CCCCC1
RACLOPRIDE,RACLOPRIDE,CHEMBL8809,BRD:BRD-BRD-K04111260-001-10-0;BRD:BRD-K04111260-001-10-0,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;HTR1A,,,LAUNCHED,,Small molecule,Phase 1,WAOQONBSWFLFPE-VIFPVBQESA-N,CCN1CCC[C@H]1CNC(=O)C1C(O)C(CL)CC(CL)C1OC
RACTOPAMINE,RACTOPAMINE,CHEMBL509336,BRD:BRD-A86414188-003-01-5;BRD:BRD-BRD-A86414188-003-01-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,,,LAUNCHED,,Small molecule,Unknown,YJQZYXCXBBCEAQ-UHFFFAOYSA-N,CC(CCC1CCC(O)CC1)NCC(O)C1CCC(O)CC1
RAD140,RAD140,CHEMBL1672635,BRD:BRD-K00003169-001-01-9,rep_single_dose,ANDROGEN RECEPTOR MODULATOR,,,,,,Small molecule,Phase 1,XMBUPPIEVAFYHO-KPZWWZAWSA-N,CC1C(N[C@@H](C2NNC(-C3CCC(C#N)CC3)O2)[C@H](C)O)CCC(C#N)C1CL
RADAFAXINE,RADAFAXINE,CHEMBL1172928,BRD:BRD-BRD-K13394247-003-01-4;BRD:BRD-K13394247-003-01-4,rep_primary;rep_single_dose,DOPAMINE-NOREPINEPHRINE REUPTAKE INHIBITOR,SLC6A3,,,PHASE 2,,Small molecule,Phase 2,RCOBKSKAZMVBHT-TVQRCGJNSA-N,C[C@@H]1NC(C)(C)CO[C@@]1(O)C1CCCC(CL)C1
RADEZOLID,RADEZOLID,CHEMBL455461,BRD:BRD-BRD-K84683831-001-01-0;BRD:BRD-K84683831-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,"BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR, BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR",,,,PHASE 2,,Small molecule,Phase 2,BTTNOGHPGJANSW-IBGZPJMESA-N,CC(=O)NC[C@H]1CN(C(=O)O1)C1CCC(C(F)C1)-C1CCC(CNCC2CNN[NH]2)CC1;CC(=O)NC[C@H]1CN(C2CCC(-C3CCC(CNCC4CNN[NH]4)CC3)C(F)C2)C(=O)O1
RADIPRODIL,RADIPRODIL,CHEMBL182066,BRD:BRD-K00005328-001-01-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,GKGRZLGAQZPEHO-UHFFFAOYSA-N,O=C(NC1CCC2NC(O)OC2C1)C(=O)N1CCC(CC2CCC(F)CC2)CC1
RADOTINIB,RADOTINIB,CHEMBL4297524,BRD:BRD-K00004716-001-01-9,rep_single_dose,BCR-ABL KINASE INHIBITOR,,,,,,Small molecule,Phase 3,DUPWHXBITIZIKZ-UHFFFAOYSA-N,CC1CN(-C2CC(NC(=O)C3CCC(C)C(NC4NCCC(-C5CNCCN5)N4)C3)CC(C(F)(F)F)C2)CN1
RAF265,RAF265,CHEMBL558752,BRD:BRD-BRD-K93123848-001-04-1;BRD:BRD-K93123848-001-04-1;CTRP:660414,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"RAF INHIBITOR, VEGFR INHIBITOR",BRAF,,,PHASE 2,,Small molecule,Phase 2,YABJJWZLRMPFSI-UHFFFAOYSA-N,CN1C(NC2CCC(C(F)(F)F)CC2)NC2CC(OC3CCNC(-C4NCC(C(F)(F)F)[NH]4)C3)CCC21;CN1C(NC2CCC(CC2)C(F)(F)F)NC2CC(OC3CCNC(C3)-C3NCC([NH]3)C(F)(F)F)CCC12
RAF709,RAF709,,BRD:BRD-K00010389-001-01-9,rep_single_dose,RAF INHIBITOR,,,,,,,NA,,
RALINEPAG,RALINEPAG,CHEMBL3301604,BRD:BRD-K00003227-001-01-9,rep_single_dose,IP1 PROSTACYCLIN RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,NPDKXVKJRHPDQT-IYARVYRRSA-N,O=C(O)COC[C@H]1CC[C@H](COC(=O)N(C2CCCCC2)C2CCC(CL)CC2)CC1
RALOXIFENE,RALOXIFENE,CHEMBL81,BRD:BRD-BRD-K63828191-003-32-1;BRD:BRD-K63828191-003-32-1,rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR ANTAGONIST, SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)",ESR1;ESR2,"OSTEOPOROSIS, BREAST CANCER",,LAUNCHED,,Small molecule,Approved,GZUITABIAKMVPG-UHFFFAOYSA-N,O=C(C1CCC(OCCN2CCCCC2)CC1)C1C(-C2CCC(O)CC2)SC2CC(O)CCC12;OC1CCC(CC1)-C1SC2CC(O)CCC2C1C(=O)C1CCC(OCCN2CCCCC2)CC1
RALTEGRAVIR,RALTEGRAVIR,CHEMBL254316,BRD:BRD-BRD-K05658747-001-02-9;BRD:BRD-K05658747-001-02-9,rep_primary;rep_single_dose,HIV INTEGRASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,CZFFBEXEKNGXKS-UHFFFAOYSA-N,CC1NNC(C(=O)NC(C)(C)C2NC(C(=O)NCC3CCC(F)CC3)C(O)C(=O)N2C)O1;CC1NNC(O1)C(=O)NC(C)(C)C1NC(C(=O)NCC2CCC(F)CC2)C(O)C(=O)N1C
RALTITREXED,RALTITREXED,CHEMBL225071,BRD:BRD-BRD-K89839824-001-05-3;BRD:BRD-K89839824-001-05-3,rep_multi_dose;rep_primary;rep_single_dose,THYMIDYLATE SYNTHASE INHIBITOR,FPGS;TYMS,MESOTHELIOMA,,LAUNCHED,,Small molecule,Approved,IVTVGDXNLFLDRM-HNNXBMFYSA-N,CC1NC(=O)C2CC(CN(C)C3CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)S3)CCC2[NH]1;CN(CC1CCC2[NH]C(C)NC(=O)C2C1)C1CCC(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
RAMATROBAN,RAMATROBAN,CHEMBL361812,BRD:BRD-BRD-K08586861-001-01-1;BRD:BRD-K08586861-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGDR2;TBXA2R,"CORONARY ARTERY DISEASE (CAD), ASTHMA",,LAUNCHED,,Small molecule,Phase 2,LDXDSHIEDAPSSA-OAHLLOKOSA-N,O=C(O)CCN1C2C(C3CCCCC31)C[C@H](NS(=O)(=O)C1CCC(F)CC1)CC2;OC(=O)CCN1C2CC[C@H](CC2C2CCCCC12)NS(=O)(=O)C1CCC(F)CC1
RAMELTEON,RAMELTEON,CHEMBL1218,BRD:BRD-BRD-K28761891-001-10-1;BRD:BRD-K28761891-001-10-1,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,MTNR1A;MTNR1B,INSOMNIA,,LAUNCHED,,Small molecule,Approved,YLXDSYKOBKBWJQ-LBPRGKRZSA-N,CCC(=O)NCC[C@@H]1CCC2CCC3C(C21)CCO3;CCC(=O)NCC[C@@H]1CCC2CCC3OCCC3C12
RAMIFENAZONE,RAMIFENAZONE,CHEMBL157337,BRD:BRD-BRD-K85333151-003-13-4;BRD:BRD-K85333151-003-13-4,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,"PAIN RELIEF, FEVER",,LAUNCHED,,Small molecule,Unknown,XOZLRRYPUKAKMU-UHFFFAOYSA-N,CC(C)NC1C(C)N(C)N(-C2CCCCC2)C1=O;CC1C(NC(C)C)C(=O)N(-C2CCCCC2)N1C
RAMIPRIL,RAMIPRIL,CHEMBL1168,BRD:BRD-BRD-K89348303-001-14-7;BRD:BRD-K89348303-001-14-7,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,HDACQVRGBOVJII-JBDAPHQKSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21;CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O
RAMOSETRON,RAMOSETRON,CHEMBL1643895,BRD:BRD-BRD-K85046107-003-01-2;BRD:BRD-K85046107-003-01-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A,"NAUSEA, VOMITING, IRRITABLE BOWEL SYNDROME",,LAUNCHED,,Small molecule,Phase 3,NTHPAPBPFQJABD-LLVKDONJSA-N,CN1CC(C(=O)[C@@H]2CCC3[NH]CNC3C2)C2CCCCC21;CN1CC(C(=O)[C@@H]2CCC3NC[NH]C3C2)C2CCCCC12
RANIRESTAT,RANIRESTAT,CHEMBL132846;CHEMBL334830,BRD:BRD-BRD-K50489389-001-01-8;BRD:BRD-K50489389-001-01-8,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,,,PHASE 3,,Small molecule,Phase 3,QCVNMNYRNIMDKV-QGZVFWFLSA-N;QCVNMNYRNIMDKV-UHFFFAOYSA-N,FC1CC(BR)CCC1CN1C(=O)C2CCCN2[C@@]2(CC(=O)NC2=O)C1=O;O=C1C[C@@]2(C(=O)N1)C(=O)N(CC1CCC(BR)CC1F)C(=O)C1CCCN12;O=C1CC2(C(=O)N1)C(=O)N(CC1CCC(BR)CC1F)C(=O)C1CCCN12
RANITIDINE,RANITIDINE,CHEMBL1790041,BRD:BRD-BRD-K70505054-003-12-4;BRD:BRD-K70505054-003-12-4,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,HEARTBURN,,LAUNCHED,,Small molecule,Approved,VMXUWOKSQNHOCA-UHFFFAOYSA-N,CN\C(NCCSCC1CCC(CN(C)C)O1)=C/[N+]([O-])=O;CNC(=C[N+](=O)[O-])NCCSCC1CCC(CN(C)C)O1
RANITIDINE (HYDROCHLORIDE),RANITIDINE (HYDROCHLORIDE),,BRD:BRD-K76687997-003-07-9,rep_single_dose,,,,,,,,NA,,
RANOLAZINE,RANOLAZINE,CHEMBL1404,BRD:BRD-A97674275-001-11-8;BRD:BRD-BRD-A97674275-001-11-8,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A;SCN4A;SCN5A;SCN9A,CHRONIC STABLE ANGINA,,LAUNCHED,,Small molecule,Approved,XKLMZUWKNUAPSZ-UHFFFAOYSA-N,COC1CCCCC1OCC(O)CN1CCN(CC(=O)NC2C(C)CCCC2C)CC1
RAS INHIBITOR ABD-7,RAS INHIBITOR ABD-7,,BRD:BRD-K00126787-001-01-9,oncref_2,RAS-EFFECTOR PPI INHIBITOR,HRAS;KRAS;NRAS,,,,,,NA,,
RASAGILINE,RASAGILINE,CHEMBL887,BRD:BRD-BRD-K58114536-001-01-6;BRD:BRD-K58114536-001-01-6,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,BCL2;MAOB,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,RUOKEQAAGRXIBM-GFCCVEGCSA-N,C#CCN[C@@H]1CCC2CCCCC12;C#CCN[C@@H]1CCC2CCCCC21
RAUWOLSCINE,RAUWOLSCINE,CHEMBL10347,BRD:BRD-K77474816-003-15-9,rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRA2B;ADRA2C;HTR1B;HTR1D;HTR1E;HTR2B,,,,,Small molecule,NA,BLGXFZZNTVWLAY-DIRVCLHFSA-N,COC(=O)[C@H]1[C@H]2C[C@H]3C4[NH]C5CCCCC5C4CCN3C[C@H]2CC[C@@H]1O
RAVOXERTINIB,RAVOXERTINIB,CHEMBL3544964,BRD:BRD-BRD-K86309810-001-01-5;BRD:BRD-K86309810-001-01-5,rep_primary;rep_single_dose,ERK1 AND ERK2 PHOSPHORYLATION INHIBITOR,MAPK1;MAPK3,,,PHASE 1,,Small molecule,Phase 1,RZUOCXOYPYGSKL-GOSISDBHSA-N,CN1NCCC1NC1NCCC(-C2CCN([C@H](CO)C3CCC(CL)C(F)C3)C(=O)C2)N1;CN1NCCC1NC1NCCC(N1)-C1CCN([C@H](CO)C2CCC(CL)C(F)C2)C(=O)C1
RAVUCONAZOLE,RAVUCONAZOLE,CHEMBL294029,BRD:BRD-BRD-K03503561-001-01-4;BRD:BRD-K03503561-001-01-4,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 1,OPAHEYNNJWPQPX-RCDICMHDSA-N,C[C@@H](C1NC(-C2CCC(C#N)CC2)CS1)[C@](O)(CN1CNCN1)C1CCC(F)CC1F;C[C@@H](C1NC(CS1)-C1CCC(CC1)C#N)[C@](O)(CN1CNCN1)C1CCC(F)CC1F
RBC8,RBC8,,BRD:BRD-A67036568-001-03-9,rep_single_dose,RAL GTPASE INHIBITOR,RALA;RALB,,,,,,NA,,
RDEA119,RDEA119,CHEMBL1236682,GDSC1:1014;GDSC1:1526,gdsc,,,,,,,Small molecule,Phase 2,RDSACQWTXKSHJT-NSHDSACASA-N,COC1CC(F)C(F)C(NC2CCC(I)CC2F)C1NS(=O)(=O)C1(C[C@H](O)CO)CC1
REBAMIPIDE,REBAMIPIDE,CHEMBL1697771,BRD:BRD-A15909516-001-06-6;BRD:BRD-BRD-A15909516-001-06-6,rep_primary;rep_single_dose,FREE RADICAL SCAVENGER,FPR1,"PEPTIC ULCER DISEASE (PUD), GASTRITIS",,LAUNCHED,,Small molecule,Phase 3,ALLWOAVDORUJLA-UHFFFAOYSA-N,O=C(NC(CC1CC(=O)[NH]C2CCCCC12)C(=O)O)C1CCC(CL)CC1;OC(=O)C(CC1CC(=O)[NH]C2CCCCC12)NC(=O)C1CCC(CL)CC1
REBASTINIB,REBASTINIB,CHEMBL1738757,BRD:BRD-BRD-K76694128-001-05-0;BRD:BRD-K76694128-001-05-0,rep_primary;rep_single_dose,"BCR-ABL KINASE INHIBITOR, TIE TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR",ABL1;BCR;FGR;FLT3;HCK;LYN;SRC,,,PHASE 1,,Small molecule,Phase 2,WVXNSAVVKYZVOE-UHFFFAOYSA-N,CNC(=O)C1CC(OC2CCC(NC(=O)NC3CC(C(C)(C)C)NN3-C3CCC4NCCCC4C3)C(F)C2)CCN1;CNC(=O)C1CC(OC2CCC(NC(=O)NC3CC(NN3-C3CCC4NCCCC4C3)C(C)(C)C)C(F)C2)CCN1
REBOXETINE,REBOXETINE,CHEMBL14370;CHEMBL180101,BRD:BRD-BRD-M39350793-334-01-1;BRD:BRD-M39350793-334-01-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,SLC6A2,DEPRESSION,,LAUNCHED,,Small molecule,Approved,CBQGYUDMJHNJBX-OALUTQOASA-N;CBQGYUDMJHNJBX-UHFFFAOYSA-N,CCOC1CCCCC1O[C@@H]([C@H]1CNCCO1)C1CCCCC1;CCOC1CCCCC1O[C@@H]([C@H]1CNCCO1)C1CCCCC1.CCOC1CCCCC1O[C@H]([C@@H]1CNCCO1)C1CCCCC1;CCOC1CCCCC1O[C@@H](C1CCCCC1)[C@@H]1CNCCO1;CCOC1CCCCC1OC(C1CCCCC1)C1CNCCO1;CCOC1CCCCC1OC(C1CNCCO1)C1CCCCC1
RECENTIN,RECENTIN,CHEMBL2103798;CHEMBL491473,GDSC2:1922,gdsc,,,,,,,Small molecule,Phase 3,JRMGHBVACUJCRP-BTJKTKAUSA-N;XXJWYDDUDKYVKI-UHFFFAOYSA-N,COC1CC2C(OC3CCC4[NH]C(C)CC4C3F)NCNC2CC1OCCCN1CCCC1;COC1CC2C(OC3CCC4[NH]C(C)CC4C3F)NCNC2CC1OCCCN1CCCC1.O=C(O)/C=C\C(=O)O
RECILISIB,RECILISIB,CHEMBL2219421,BRD:BRD-K00075424-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,KBEKQQJUNVQLDZ-MDZDMXLPSA-N,O=C(O)C1CCC(/C=C/S(=O)(=O)CC2CCC(CL)CC2)CC1
RECLAST,RECLAST,CHEMBL924,GDSC2:1802,gdsc,,,,,,,Small molecule,Approved,XRASPMIURGNCCH-UHFFFAOYSA-N,O=P(O)(O)C(O)(CN1CCNC1)P(=O)(O)O
REFAMETINIB,REFAMETINIB,CHEMBL1236682,BRD:BRD-BRD-K85751432-001-03-3;BRD:BRD-K85751432-001-03-3;GDSC1:1014;GDSC1:1526,gdsc;rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1;MAP2K2,,,PHASE 2,,Small molecule,Phase 2,RDSACQWTXKSHJT-NSHDSACASA-N,COC1CC(F)C(F)C(NC2CCC(I)CC2F)C1NS(=O)(=O)C1(C[C@H](O)CO)CC1
REGADENOSON,REGADENOSON,CHEMBL317052;CHEMBL3989695,BRD:BRD-A78341343-001-01-6;BRD:BRD-BRD-A78341343-001-01-6,rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,MYOCARDIAL PERFUSION IMAGING (MPI),,LAUNCHED,,Small molecule,Approved,CDQVVPUXSPZONN-WPPLYIOHSA-N;LZPZPHGJDAGEJZ-AKAIJSEGSA-N,CNC(=O)C1CNN(-C2NC(N)C3NCN([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C3N2)C1;CNC(=O)C1CNN(-C2NC(N)C3NCN([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C3N2)C1.O;CNC(=O)C1CNN(C1)-C1NC(N)C2NCN([C@@H]3O[C@H](CO)C(O)C3O)C2N1
REGORAFENIB,REGORAFENIB,CHEMBL1946170,BRD:BRD-BRD-K16730910-001-07-3;BRD:BRD-K16730910-001-07-3;CTRP:628613,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"FGFR INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, RAF INHIBITOR, RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR",ABL1;BRAF;DDR2;EPHA2;FGFR1;FGFR2;FLT1;FLT4;FRK;KDR;KIT;MAPK11;NTRK1;PDGFRA;PDGFRB;RAF1;RET;TEK,"COLORECTAL CANCER, GASTROINTESTINAL STROMAL TUMORS (GIST)",,LAUNCHED,,Small molecule,Approved,FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C(F)(F)F)C3)C(F)C2)CCN1;CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C3)C(F)(F)F)C(F)C2)CCN1
RELCOVAPTAN,RELCOVAPTAN,CHEMBL419667,BRD:BRD-BRD-K96720755-001-02-6;BRD:BRD-K96720755-001-02-6,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,AVPR1A;AVPR1B;AVPR2;OXTR,,,PHASE 2,,Small molecule,Phase 2,CEBYCSRFKCEUSW-NAYZPBBASA-N,COC1CCC(CC1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(C2CC(CL)CCC12)C1CCCCC1CL;COC1CCC(S(=O)(=O)N2C3CCC(CL)CC3[C@](O)(C3CCCCC3CL)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)CC1OC
RELEBACTAM,RELEBACTAM,CHEMBL3112741;CHEMBL3301605,BRD:BRD-BRD-K63018010-001-01-7;BRD:BRD-K63018010-001-01-7,rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,,,PHASE 3,,Small molecule,Approved,SMOBCLHAZXOKDQ-ZJUUUORDSA-N;TWFRCSHLWKJBQH-UXQCFNEQSA-N,O.O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O;O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O;OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
RELUGOLIX,RELUGOLIX,CHEMBL1800159,BRD:BRD-K00003216-001-01-9,rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,AOMXMOCNKJTRQP-UHFFFAOYSA-N,CONC(=O)NC1CCC(-C2SC3C(C2CN(C)C)C(=O)N(-C2CCC(OC)NN2)C(=O)N3CC2C(F)CCCC2F)CC1
REMACEMIDE,REMACEMIDE,CHEMBL25843,BRD:BRD-A36074203-003-07-6;BRD:BRD-BRD-A36074203-003-07-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,,,PHASE 3,,Small molecule,Unknown,YSGASDXSLKIKOD-UHFFFAOYSA-N,CC(CC1CCCCC1)(NC(=O)CN)C1CCCCC1
REMDESIVIR,REMDESIVIR,CHEMBL4065616,BRD:BRD-K00071599-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,RWWYLEGWBNMMLJ-YSOARWBDSA-N,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(C2CCC3C(N)NCNN23)[C@H](O)[C@@H]1O)OC1CCCCC1
REMETINOSTAT,REMETINOSTAT,CHEMBL3707219,BRD:BRD-K00004584-001-01-9,rep_single_dose,HDAC INHIBITOR,,,,,,Small molecule,Phase 2,XDZAHHULFQIBFE-UHFFFAOYSA-N,COC(=O)C1CCC(OC(=O)CCCCCCC(=O)NO)CC1
REMIMAZOLAM,REMIMAZOLAM,CHEMBL4297526,BRD:BRD-BRD-K89413285-074-01-5;BRD:BRD-K89413285-074-01-5,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABBR1,,,PHASE 3,,Small molecule,Approved,CYHWMBVXXDIZNZ-KRWDZBQOSA-N,COC(=O)CC[C@@H]1N=C(C2CCCCN2)C2CC(BR)CCC2-N2C(C)CNC12;COC(=O)CC[C@@H]1N=C(C2CCCCN2)C2CC(BR)CCC2-N2C(C)CNC21
REMODELIN,REMODELIN,,BRD:BRD-K75349868-001-03-9,rep_single_dose,TRANSFERASE INHIBITOR,NAT10,,,,,,NA,,
REMOGLIFLOZIN ETABONATE,REMOGLIFLOZIN ETABONATE,CHEMBL2028665,BRD:BRD-K00090650-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,UAOCLDQAQNNEAX-ABMICEGHSA-N,CCOC(=O)OC[C@H]1O[C@@H](OC2NN(C(C)C)C(C)C2CC2CCC(OC(C)C)CC2)[C@H](O)[C@@H](O)[C@@H]1O
REMOXIPRIDE,REMOXIPRIDE,CHEMBL22242,BRD:BRD-BRD-K54094468-003-11-1;BRD:BRD-K54094468-003-11-1,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;DRD4;HTR2A;SIGMAR1,,,WITHDRAWN,,Small molecule,Approved,GUJRSXAPGDDABA-NSHDSACASA-N,CCN1CCC[C@H]1CNC(=O)C1C(OC)CCC(BR)C1OC
RENOVA,RENOVA,CHEMBL38,GDSC1:1009,gdsc,,,,,,,Small molecule,Approved,SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
REPAGLINIDE,REPAGLINIDE,CHEMBL1272,BRD:BRD-BRD-K82846253-001-15-4;BRD:BRD-K82846253-001-15-4,rep_multi_dose;rep_primary;rep_single_dose,INSULIN SECRETAGOGUE,ABCC8;KCNJ11;PPARG,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,FAEKWTJYAYMJKF-QHCPKHFHSA-N,CCOC1CC(CC(=O)N[C@@H](CC(C)C)C2CCCCC2N2CCCCC2)CCC1C(=O)O;CCOC1CC(CC(=O)N[C@@H](CC(C)C)C2CCCCC2N2CCCCC2)CCC1C(O)=O
REPARIXIN,REPARIXIN,CHEMBL191413,BRD:BRD-BRD-K58486055-001-02-7;BRD:BRD-K58486055-001-02-7,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR1;CXCR2,,,PHASE 3,,Small molecule,Phase 3,KQDRVXQXKZXMHP-LLVKDONJSA-N,CC(C)CC1CCC([C@@H](C)C(=O)NS(C)(=O)=O)CC1;CC(C)CC1CCC(CC1)[C@@H](C)C(=O)NS(C)(=O)=O
REPLIGEN 136,REPLIGEN 136,,CTRP:628408,ctrp,,,,,,,,NA,,
REPOTRECTINIB,REPOTRECTINIB,CHEMBL4298138,BRD:BRD-K00003447-001-01-9,rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Phase 1,FIKPXCOQUIZNHB-WDEREUQCSA-N,C[C@H]1CNC(=O)C2CNN3CCC(NC23)N[C@H](C)C2CC(F)CCC2O1
REPSOX,REPSOX,,BRD:BRD-BRD-K80480517-001-02-4;BRD:BRD-K80480517-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFBR1,,,PRECLINICAL,,,NA,,CC1CCCC(N1)-C1N[NH]CC1-C1CCC2NCCCC2N1
RESATORVID,RESATORVID,CHEMBL225157,BRD:BRD-BRD-K61567297-001-01-9;BRD:BRD-K61567297-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,"TOLL-LIKE RECEPTOR ANTAGONIST, TOLL-LIKE RECEPTOR INHIBITOR",TLR4,,,PHASE 3,"Multiple values for MOA: {'TOLL-LIKE RECEPTOR ANTAGONIST, TOLL-LIKE RECEPTOR INHIBITOR', 'TOLL-LIKE RECEPTOR ANTAGONIST'}, defaulting to 'TOLL-LIKE RECEPTOR ANTAGONIST, TOLL-LIKE RECEPTOR INHIBITOR'",Small molecule,Phase 3,LEEIJTHMHDMWLJ-CQSZACIVSA-N,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC1CCC(F)CC1CL
RESERPINE,RESERPINE,CHEMBL772,BRD:BRD-BRD-K95921201-001-14-6;BRD:BRD-K95921201-001-14-6,rep_primary;rep_single_dose,VESICULAR MONOAMINE TRANSPORTER INHIBITOR,SLC18A1;SLC18A2,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,QEVHRUUCFGRFIF-MDEJGZGSSA-N,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4C([NH]C5CC(OC)CCC45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C1CC(OC)C(OC)C(OC)C1;COC(=O)[C@H]1[C@H]2C[C@@H]3C4[NH]C5CC(OC)CCC5C4CCN3C[C@H]2C[C@@H](OC(=O)C2CC(OC)C(OC)C(OC)C2)[C@@H]1OC
RESIBUFOGENIN,RESIBUFOGENIN,CHEMBL250172,BRD:BRD-BRD-K25970317-001-01-6;BRD:BRD-K25970317-001-01-6,rep_primary;rep_single_dose,NA/K-ATPASE INHIBITOR,,,,PHASE 2,,Small molecule,Unknown,ATLJNLYIJOCWJE-CWMZOUAVSA-N,C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3CCC(=O)OC3)C[C@H]3O[C@]132;C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2C1CCC(=O)OC1
RESIQUIMOD,RESIQUIMOD,CHEMBL383322,BRD:BRD-BRD-K76210423-001-01-6;BRD:BRD-K76210423-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,TLR7;TLR8,,,PHASE 3,,Small molecule,Phase 2,BXNMTOQRYBFHNZ-UHFFFAOYSA-N,CCOCC1NC2C(N)NC3CCCCC3C2N1CC(C)(C)O
RESMETIROM,RESMETIROM,CHEMBL3261331,BRD:BRD-K00003123-001-01-9,rep_single_dose,THYROID HORMONE RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,FDBYIYFVSAHJLY-UHFFFAOYSA-N,CC(C)C1CC(OC2C(CL)CC(-N3NC(C#N)C(=O)[NH]C3=O)CC2CL)N[NH]C1=O
RESMINOSTAT,RESMINOSTAT,CHEMBL4296717,BRD:BRD-BRD-K28822270-001-01-1;BRD:BRD-K28822270-001-01-1;BRD:BRD-K28822270-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC3;HDAC6;HDAC8,,,PHASE 2,,Small molecule,Phase 2,FECGNJPYVFEKOD-VMPITWQZSA-N,CN(C)CC1CCC(CC1)S(=O)(=O)N1CCC(C1)\C=C\C(=O)NO;CN(C)CC1CCC(S(=O)(=O)N2CCC(/C=C/C(=O)NO)C2)CC1
RESORCINOL,RESORCINOL,CHEMBL24147,BRD:BRD-BRD-K74190368-001-04-3;BRD:BRD-K74190368-001-04-3,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,CA12;CA14;CA2;PTGS1,"ACNE VULGARIS (AV), ECZEMA, PSORIASIS, SEBORRHEIC DERMATITIS",,LAUNCHED,,Small molecule,Approved,GHMLBKRAJCXXBS-UHFFFAOYSA-N,OC1CCCC(O)C1
RESVERATROL,RESVERATROL,CHEMBL165,BRD:BRD-BRD-K80738081-001-46-8;BRD:BRD-K80738081-001-46-8,rep_primary;rep_single_dose,"CYTOCHROME P450 INHIBITOR, SIRT ACTIVATOR",CSNK2A1;NQO2;PTGS1;PTGS2,,,LAUNCHED,,Small molecule,Phase 3,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,OC1CCC(/C=C/C2CC(O)CC(O)C2)CC1;OC1CCC(CC1)\C=C\C1CC(O)CC(O)C1
RETAGLIPTIN,RETAGLIPTIN,CHEMBL4297435,BRD:BRD-K00003118-011-01-9,rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,,,,,,Small molecule,Phase 3,WIIAMRXFUJLYEF-SNVBAGLBSA-N,COC(=O)C1NC(C(F)(F)F)N2C1CN(C(=O)C[C@H](N)CC1CC(F)C(F)CC1F)CC2
RETAPAMULIN,RETAPAMULIN,CHEMBL1658,BRD:BRD-BRD-K33082088-001-03-3;BRD:BRD-K33082088-001-03-3,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,IMPETIGO,,LAUNCHED,,Small molecule,Approved,STZYTFJPGGDRJD-NHUWBDDWSA-N,C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C;C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2C[C@H]3CC[C@@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O
RETIGABINE,RETIGABINE,CHEMBL41355,BRD:BRD-BRD-K89917372-001-01-2;BRD:BRD-K89917372-001-01-2,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNQ1;KCNQ2;KCNQ3;KCNQ4;KCNQ5,EPILEPSY,,LAUNCHED,,Small molecule,Approved,PCOBBVZJEWWZFR-UHFFFAOYSA-N,CCOC(=O)NC1CCC(NCC2CCC(F)CC2)CC1N
RETINALDEHYDE,RETINALDEHYDE,,BRD:BRD-BRD-K79884267-001-01-4;BRD:BRD-K79884267-001-01-4,rep_primary;rep_single_dose,,,COSMETIC,,LAUNCHED,,,NA,,CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O
REV-5901,REV-5901,CHEMBL8747,BRD:BRD-A68281735-001-18-6;BRD:BRD-BRD-A68281735-001-18-6,rep_primary;rep_single_dose,"LEUKOTRIENE RECEPTOR ANTAGONIST, LIPOXYGENASE INHIBITOR",ALOX5,,,PHASE 2,,Small molecule,NA,JRLOEMCOOZSCQP-UHFFFAOYSA-N,CCCCCC(O)C1CCCC(OCC2CCC3CCCCC3N2)C1
REVEFENACIN,REVEFENACIN,CHEMBL3833319,BRD:BRD-K00003198-001-01-9,rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,FYDWDCIFZSGNBU-UHFFFAOYSA-N,CN(CCN1CCC(OC(=O)NC2CCCCC2-C2CCCCC2)CC1)C(=O)C1CCC(CN2CCC(C(N)=O)CC2)CC1
REVERSAN,REVERSAN,,BRD:BRD-BRD-K79700588-001-09-7;BRD:BRD-K79700588-001-09-7,rep_primary;rep_single_dose,MRP INHIBITOR,ABCC1,,,PRECLINICAL,,,NA,,O=C(NCCCN1CCOCC1)C1CNN2C(CC(NC12)-C1CCCCC1)-C1CCCCC1
REVERSINE,REVERSINE,CHEMBL188343,BRD:BRD-K77286328-001-03-7,rep_single_dose,AURORA KINASE INHIBITOR,AURKB;INCENP;MAP2K1,,,,,Small molecule,NA,ZFLJHSQHILSNCM-UHFFFAOYSA-N,C1NC2C(NC3CCCCC3)NC(NC3CCC(N4CCOCC4)CC3)NC2[NH]1
REVLIMID,REVLIMID,CHEMBL848,GDSC1:1020,gdsc,,,,,,,Small molecule,Approved,GOTYRUGSSMKFNF-UHFFFAOYSA-N,NC1CCCC2C1CN(C1CCC(=O)NC1=O)C2=O
REYNOUTRIN,REYNOUTRIN,CHEMBL488198,BRD:BRD-K00005343-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,Small molecule,NA,PZZRDJXEMZMZFD-BWYUNELBSA-N,O=C1C(O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)C(-C2CCC(O)C(O)C2)OC2CC(O)CC(O)C12
RG-108,RG-108,,CTRP:411831,ctrp,,,,,,,,NA,,
RG-1415,RG-1415,CHEMBL553,GDSC1:1;GDSC2:1168,gdsc,,,,,,,Small molecule,Approved,AAKJLRGGTJKAMG-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1
RG-7621,RG-7621,,GDSC1:1058;GDSC1:1527;GDSC2:1058,gdsc,,,,,,,,NA,,
RG108,RG108,,BRD:BRD-BRD-K89391146-001-08-0;BRD:BRD-K89391146-001-08-0,rep_multi_dose;rep_primary;rep_single_dose,DNA METHYLTRANSFERASE INHIBITOR,DNMT1;DNMT3B,,,PRECLINICAL,,,NA,,OC(=O)[C@H](CC1C[NH]C2CCCCC12)N1C(=O)C2CCCCC2C1=O
RG2833,RG2833,,BRD:BRD-BRD-K02389548-001-02-5;BRD:BRD-K02389548-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC3,,,PHASE 1,,,NA,,CC1CCC(CC1)C(=O)NCCCCCC(=O)NC1CCCCC1N
RG4733,RG4733,,BRD:BRD-BRD-K22024824-001-03-7;BRD:BRD-K22024824-001-03-7,rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,PSEN1,,,PHASE 2,,,NA,,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2CCCCC2-C2CCCCC2NC1=O
RG7112,RG7112,CHEMBL2386346,BRD:BRD-A78210457-001-01-5;BRD:BRD-BRD-A78210457-001-01-5,rep_primary;rep_single_dose,MDM INHIBITOR,MDM2,,,PHASE 1,,Small molecule,Phase 1,QBGKPEROWUKSBK-QPPIDDCLSA-N,CCOC1CC(C(C)(C)C)CCC1C1=N[C@@](C)(C2CCC(CL)CC2)[C@@](C)(C2CCC(CL)CC2)N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1;CCOC1CC(CCC1C1=NC(C)(C2CCC(CL)CC2)C(C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)C1CCC(CL)CC1)C(C)(C)C
RG7604,RG7604,,GDSC2:1561,gdsc,,,,,,,,NA,,
RG7800,RG7800,,BRD:BRD-K00004590-001-01-9,rep_single_dose,RNA SPLICING MODIFIER,,,,,,,NA,,
RG7834,RG7834,,BRD:BRD-K00004573-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,,NA,,
RGB-286638,RGB-286638,CHEMBL3545083,BRD:BRD-BRD-K20986415-001-01-8;BRD:BRD-K20986415-001-01-8,rep_primary;rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK3;CDK4;CDK5;CDK6;CDK7;CDK9;FLT3;GSK3B;JAK2;MAP3K7;MAPK9,,,PHASE 1,,Small molecule,Phase 1,XLSYZSRXVVCHLS-UHFFFAOYSA-N,COCCN1CCN(CC2CCC(-C3N[NH]C4C3C(=O)C3C(NC(=O)NN5CCOCC5)CCCC3-4)CC2)CC1;COCCN1CCN(CC2CCC(CC2)-C2N[NH]C3-C4CCCC(NC(=O)NN5CCOCC5)C4C(=O)C23)CC1
RGFP966,RGFP966,,BRD:BRD-BRD-K61688984-001-02-9;BRD:BRD-K61688984-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC3,,,PRECLINICAL,,,NA,,NC1CC(F)CCC1NC(=O)\C=C\C1CNN(C\C=C\C2CCCCC2)C1
RGX-104,RGX-104,CHEMBL573677,BRD:BRD-K00004597-001-01-9,rep_single_dose,LXR AGONIST,,,,,,Small molecule,Phase 1,ZLJZDYOBXVOTSA-XMMPIXPASA-N,C[C@H](CCOC1CCCC(CC(=O)O)C1)N(CC1CCCC(C(F)(F)F)C1CL)CC(C1CCCCC1)C1CCCCC1
RHC-80267,RHC-80267,,BRD:BRD-BRD-K56047318-001-06-3;BRD:BRD-K56047318-001-06-3,rep_primary;rep_single_dose,TRIACYLGLYCEROL LIPASE INHIBITOR,DAGLA;DAGLB,,,PRECLINICAL,,,NA,,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1
RHEIN,RHEIN,CHEMBL418068,BRD:BRD-BRD-K27335680-001-10-0;BRD:BRD-K27335680-001-10-0,rep_primary;rep_single_dose,,HSP90AA1,,,PHASE 1,,Small molecule,NA,FCDLCPWAQCPTKC-UHFFFAOYSA-N,O=C(O)C1CC(O)C2C(C1)C(=O)C1CCCC(O)C1C2=O;OC(=O)C1CC(O)C2C(=O)C3C(O)CCCC3C(=O)C2C1
RHEOCHRYSIDIN,RHEOCHRYSIDIN,,BRD:BRD-BRD-K67772619-001-05-1;BRD:BRD-K67772619-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,PTPN1,,,PRECLINICAL,,,NA,,COC1CC(O)C2C(=O)C3C(O)CC(C)CC3C(=O)C2C1
RHEUMATREX,RHEUMATREX,CHEMBL34259,GDSC1:1008,gdsc,,,,,,,Small molecule,Approved,FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1
RHODAMINE-123,RHODAMINE-123,,BRD:BRD-BRD-K47169076-003-01-6;BRD:BRD-K47169076-003-01-6,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,COC(=O)C1CCCCC1-C1C2CCC(N)CC2[O+]C2CC(N)CCC12
RI-1,RI-1,,BRD:BRD-BRD-K79555887-001-01-0;BRD:BRD-K79555887-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,,RAD51,,,PRECLINICAL,,,NA,,CLC1=C(N2CCOCC2)C(=O)N(C1=O)C1CCC(CL)C(CL)C1
RIBAVIRIN,RIBAVIRIN,CHEMBL1643,BRD:BRD-BRD-K60369935-001-18-3;BRD:BRD-K60369935-001-18-3,rep_multi_dose;rep_primary;rep_single_dose,ANTIVIRAL,ADK;ENPP1;IMPDH1;IMPDH2;NT5C2,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,IWUCXVSUMQZMFG-AFCXAGJDSA-N,NC(=O)C1NCN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)N1;NC(=O)C1NCN(N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
RIBITOL,RIBITOL,,BRD:BRD-BRD-K49313711-001-05-4;BRD:BRD-K49313711-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC[C@H](O)[C@H](O)[C@H](O)CO
RIBOFLAVIN,RIBOFLAVIN,CHEMBL1534,BRD:BRD-BRD-K70246307-001-04-1;BRD:BRD-BRD-K92760278-001-07-3;BRD:BRD-K70246307-001-04-1;BRD:BRD-K92760278-001-07-3,rep_multi_dose;rep_primary;rep_single_dose,"VITAMIN B, VITAMIN B2",BLVRB;RFK,JAUNDICE,,LAUNCHED,"Multiple values for MOA: {'VITAMIN B2', 'VITAMIN B, VITAMIN B2'}, defaulting to 'VITAMIN B, VITAMIN B2'
Multiple values for structure_id: {'K70246307', 'K92760278'}, defaulting to None",Small molecule,Approved,AUNGANRZJHBGPY-SCRDCRAPSA-N,CC1CC2NC3C(=O)[NH]C(=O)NC-3N(C[C@H](O)[C@H](O)[C@H](O)CO)C2CC1C;CC1CC2NC3C(NC(=O)[NH]C3=O)N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)C2CC1C;CC1CC2NC3C(NC(=O)[NH]C3=O)N(C[C@H](O)[C@H](O)[C@H](O)CO)C2CC1C
RIBOFLAVIN-TETRABUTYRATE,RIBOFLAVIN-TETRABUTYRATE,,BRD:BRD-K74227494-001-03-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
RIBOSTAMYCIN,RIBOSTAMYCIN,CHEMBL221572,BRD:BRD-BRD-K55188888-065-01-2;BRD:BRD-K55188888-065-01-2,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,P4HB,"HUMAN IMMUNODEFICIENCY VIRUS (HIV-1), HUMAN IMMUNODEFICIENCY VIRUS (HIV-1)",,LAUNCHED,,Small molecule,Unknown,NSKGQURZWSPSBC-VVPCINPTSA-N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O;NC[C@H]1O[C@H](O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](N)C[C@@H]2N)[C@H](N)[C@@H](O)[C@@H]1O;NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O
RIDINILAZOLE,RIDINILAZOLE,CHEMBL3753858,BRD:BRD-K77897005-001-02-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Phase 3,UHQFBTAJFNVZIV-UHFFFAOYSA-N,C1CC(-C2NC3CC(-C4CCC5[NH]C(-C6CCNCC6)NC5C4)CCC3[NH]2)CCN1
RIFABUTIN,RIFABUTIN,CHEMBL444633,BRD:BRD-BRD-K30563334-001-02-9;BRD:BRD-K30563334-001-02-9,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,HSP90AA1;HSP90B1,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,ATEBXHFBFRCZMA-VXTBVIBXSA-N,CO[C@H]1/C=C/O[C@@]2(C)OC3C(C)C(O)C4C(C3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O;CO[C@H]1\C=C\O[C@@]2(C)OC3C(C2=O)C2C(C(O)C3C)C(O)C(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=NC3(CCN(CC(C)C)CC3)N=C21
RIFAMPIN,RIFAMPIN,CHEMBL374478,BRD:BRD-A23603052-001-03-2;BRD:BRD-BRD-A23603052-001-03-2;BRD:BRD-BRD-K01507359-001-22-9;BRD:BRD-K01507359-001-22-9,rep_multi_dose;rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,NR1I2;SLCO1A2;SLCO1B1;SLCO1B3,"TUBERCULOSIS, MENINGITIS",,LAUNCHED,"Multiple values for structure_id: {'K01507359', 'A23603052'}, defaulting to None",Small molecule,Approved,JQXXHWHPUNPDRT-WLSIYKJHSA-N,CO[C@H]1/C=C/O[C@@]2(C)OC3C(C)C(O)C4C(O)C(C(/C=N/N5CCN(C)CC5)C(O)C4C3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C;CO[C@H]1\C=C\O[C@@]2(C)OC3C(C2=O)C2C(O)C(\C=N\N4CCN(C)CC4)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)C2C(O)C3C;CO[C@H]1\C=C\O[C@@]2(C)OC3C(C2=O)C2C(O)C(C=NN4CCN(C)CC4)C(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)C(O)C2C(O)C3C
RIFAMYCIN-SV,RIFAMYCIN-SV,,BRD:BRD-BRD-K13277760-001-01-2;BRD:BRD-K13277760-001-01-2,rep_primary;rep_single_dose,RNA SYNTHESIS INHIBITOR,,,,PHASE 3,,,NA,,CO[C@H]1C=CO[C@@]2(C)OC3C(C2=O)C2C(O)CC(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)C(O)C2C(O)C3C
RIFAPENTINE,RIFAPENTINE,CHEMBL1660,BRD:BRD-BRD-K28346421-001-06-8;BRD:BRD-K28346421-001-06-8,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,CYP2C8;CYP2C9;CYP3A4,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,WDZCUPBHRAEYDL-GZAUEHORSA-N,CO[C@H]1/C=C/O[C@@]2(C)OC3C(C)C(O)C4C(O)C(C(/C=N/N5CCN(C6CCCC6)CC5)C(O)C4C3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C;CO[C@H]1\C=C\O[C@@]2(C)OC3C(C2=O)C2C(O)C(\C=N\N4CCN(CC4)C4CCCC4)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)C2C(O)C3C
RIFAXIMIN,RIFAXIMIN,CHEMBL1617,BRD:BRD-BRD-K92838188-001-01-9;BRD:BRD-K92838188-001-01-9,rep_primary;rep_single_dose,RNA SYNTHESIS INHIBITOR,NR1I2,"DIARRHEA, IRRITABLE BOWEL SYNDROME, HEPATIC ENCEPHALOPATHY (HE)",,LAUNCHED,,Small molecule,Approved,NZCRJKRKKOLAOJ-XRCRFVBUSA-N,CO[C@H]1/C=C/O[C@@]2(C)OC3C(C)C(O)C4C(O)C(C5C(NC6CC(C)CCN65)C4C3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C;CO[C@H]1C=CO[C@@]2(C)OC3C(C2=O)C2C4NC5CC(C)CCN5C4C(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)C2C(O)C3C
RIGOSERTIB,RIGOSERTIB,CHEMBL1241855,BRD:BRD-BRD-K55187425-236-05-2;BRD:BRD-K55187425-236-05-2;CTRP:660397,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"CELL CYCLE INHIBITOR, PLK INHIBITOR",PLK1,,,PHASE 3,,Small molecule,Phase 3,OWBFCJROIKNMGD-BQYQJAHWSA-N,COC1CC(OC)C(/C=C/S(=O)(=O)CC2CCC(OC)C(NCC(=O)O)C2)C(OC)C1;COC1CC(OC)C(\C=C\S(=O)(=O)CC2CCC(OC)C(NCC(O)=O)C2)C(OC)C1
RILAPLADIB,RILAPLADIB,CHEMBL2104981,BRD:BRD-K00004676-001-01-9,rep_single_dose,PHOSPHOLIPASE INHIBITOR,,,,,,Small molecule,Phase 2,NNBGCSGCRSCFEA-UHFFFAOYSA-N,COCCN1CCC(N(CC2CCC(-C3CCC(C(F)(F)F)CC3)CC2)C(=O)CN2C(SCC3CCCC(F)C3F)CC(=O)C3CCCCC32)CC1
RILMENIDINE,RILMENIDINE,CHEMBL289480,BRD:BRD-BRD-K01638814-011-01-4;BRD:BRD-K01638814-011-01-4,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, IMIDAZOLINE RECEPTOR AGONIST",ADRA2A,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,CQXADFVORZEARL-UHFFFAOYSA-N,C1CC1C(NC1=NCCO1)C1CC1;C1COC(NC(C2CC2)C2CC2)=N1
RILPIVIRINE,RILPIVIRINE,CHEMBL175691,BRD:BRD-BRD-K06240250-001-01-6;BRD:BRD-K06240250-001-01-6,rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,NR1I2;SCN10A,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,YIBOMRUWOWDFLG-ONEGZZNKSA-N,CC1CC(/C=C/C#N)CC(C)C1NC1CCNC(NC2CCC(C#N)CC2)N1;CC1CC(\C=C\C#N)CC(C)C1NC1CCNC(NC2CCC(CC2)C#N)N1
RILUZOLE,RILUZOLE,CHEMBL744,BRD:BRD-BRD-K21283037-001-21-5;BRD:BRD-K21283037-001-21-5,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE INHIBITOR,KCNK10;KCNK2;KCNK4;KCNN4;SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A;SLC7A11,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,LAUNCHED,,Small molecule,Approved,FTALBRSUTCGOEG-UHFFFAOYSA-N,NC1NC2CCC(OC(F)(F)F)CC2S1
RIMACALIB,RIMACALIB,CHEMBL2107772,BRD:BRD-K00076949-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,MYTIJGWONQOOLC-HNNXBMFYSA-N,C[C@@H](C1CCC(-C2CCCCC2)C(F)C1)C1CC(NC(=N)N2CCOCC2)ON1
RIMANTADINE,RIMANTADINE,CHEMBL959,BRD:BRD-A75479906-001-02-4;BRD:BRD-BRD-A75479906-001-02-4,rep_primary;rep_single_dose,"ANTIVIRAL, RNA SYNTHESIS INHIBITOR",,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,Small molecule,Approved,UBCHPRBFMUDMNC-UHFFFAOYSA-N,CC(N)C12CC3CC(CC(C3)C1)C2
RIMCAZOLE,RIMCAZOLE,CHEMBL275707,BRD:BRD-BRD-K70490179-300-01-2;BRD:BRD-K70490179-300-01-2,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,SIGMAR1,,,PHASE 1,,Small molecule,Unknown,GUDVQJXODNJRIJ-CALCHBBNSA-N,C[C@@H]1CN(CCCN2C3CCCCC3C3CCCCC32)C[C@H](C)N1;C[C@H]1CN(CCCN2C3CCCCC3C3CCCCC23)C[C@@H](C)N1
RIMEPORIDE,RIMEPORIDE,CHEMBL2107802,BRD:BRD-K00004645-001-01-9,rep_single_dose,SODIUM/HYDROGEN EXCHANGER INHIBITOR,,,,,,Small molecule,Phase 1,GROMEQPXDKRRIE-UHFFFAOYSA-N,CC1CC(S(C)(=O)=O)C(S(C)(=O)=O)CC1C(=O)NC(=N)N
RIMEXOLONE,RIMEXOLONE,CHEMBL1200617,BRD:BRD-BRD-K31627533-001-09-5;BRD:BRD-K31627533-001-09-5,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,ANTERIOR UVEITIS,,LAUNCHED,,Small molecule,Approved,QTTRZHGPGKRAFB-OOKHYKNYSA-N,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C;CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C
RIMONABANT,RIMONABANT,CHEMBL111,BRD:BRD-BRD-K13296708-001-05-8;BRD:BRD-K13296708-001-05-8,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1;GPR55,,,WITHDRAWN,,Small molecule,Approved,JZCPYUJPEARBJL-UHFFFAOYSA-N,CC1C(C(=O)NN2CCCCC2)NN(-C2CCC(CL)CC2CL)C1-C1CCC(CL)CC1;CC1C(NN(C1-C1CCC(CL)CC1)-C1CCC(CL)CC1CL)C(=O)NN1CCCCC1
RIOCIGUAT,RIOCIGUAT,CHEMBL2107834,BRD:BRD-BRD-K84783599-001-01-0;BRD:BRD-K84783599-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,GUANYLATE CYCLASE STIMULANT,GUCY1A2;GUCY1A3;GUCY1B2;GUCY1B3,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,WXXSNCNJFUAIDG-UHFFFAOYSA-N,COC(=O)N(C)C1C(N)NC(-C2NN(CC3CCCCC3F)C3NCCCC23)NC1N;COC(=O)N(C)C1C(N)NC(NC1N)-C1NN(CC2CCCCC2F)C2NCCCC12
RIODIPINE,RIODIPINE,CHEMBL1891684,BRD:BRD-BRD-K36379990-001-01-1;BRD:BRD-K36379990-001-01-1,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PHASE 2,,Small molecule,Unknown,AZVFIZVKGSPGPK-UHFFFAOYSA-N,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1CCCCC1OC(F)F;COC(=O)C1=C(C)NC(C)=C(C1C1CCCCC1OC(F)F)C(=O)OC
RIODOXOL,RIODOXOL,,BRD:BRD-K48963429-001-01-9,rep_single_dose,OTHER ANTIBIOTIC,,,,,,,NA,,
RIPASUDIL,RIPASUDIL,CHEMBL3426621,BRD:BRD-BRD-K53814070-310-01-3;BRD:BRD-K53814070-310-01-3,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1;ROCK2,"GLAUCOMA, OCULAR HYPERTENSION",,LAUNCHED,,Small molecule,Phase 3,QSKQVZWVLOIIEV-NSHDSACASA-N,C[C@H]1CNCCCN1S(=O)(=O)C1CCCC2CNCC(F)C12
RIPAZEPAM,RIPAZEPAM,CHEMBL159298,BRD:BRD-BRD-K57427145-001-01-6;BRD:BRD-K57427145-001-01-6,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1,,,PHASE 2,,Small molecule,Unknown,YFHYNLHGFKXAIQ-UHFFFAOYSA-N,CCN1NC(C)C2C1C(C1CCCCC1)=NCC(=O)N2;CCN1NC(C)C2NC(=O)CN=C(C12)C1CCCCC1
RIPRETINIB,RIPRETINIB,CHEMBL4216467,BRD:BRD-K00005241-001-01-9,rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Approved,CEFJVGZHQAGLHS-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC(NC(=O)NC3CCCCC3)C(F)CC2BR)CC2CNC(NC)CC21
RISDIPLAM,RISDIPLAM,CHEMBL4297528,BRD:BRD-K00003506-001-01-9,rep_single_dose,RNA SPLICING INHIBITOR,,,,,,Small molecule,Approved,ASKZRYGFUPSJPN-UHFFFAOYSA-N,CC1CN2NC(-C3CC(=O)N4CC(N5CCNC6(CC6)C5)CCC4N3)CC(C)C2N1
RISEDRONATE,RISEDRONATE,CHEMBL923,BRD:BRD-K05185389-001-02-6,rep_single_dose,OSTEOCLAST INHIBITOR,FDPS,,,,,Small molecule,Approved,IIDJRNMFWXDHID-UHFFFAOYSA-N,O=P(O)(O)C(O)(CC1CCCNC1)P(=O)(O)O
RISLENEMDAZ,RISLENEMDAZ,CHEMBL2068839,BRD:BRD-K00003471-001-01-9,rep_single_dose,IONOTROPIC GLUTAMATE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,RECBFDWSXWAXHY-IAGOWNOFSA-N,CC1CCC(COC(=O)N2CC[C@H](CNC3NCCCN3)[C@H](F)C2)CC1
RISPERIDONE,RISPERIDONE,CHEMBL85,BRD:BRD-BRD-K53857191-001-22-7;BRD:BRD-K53857191-001-22-7,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD4;HRH1;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2C;HTR6;HTR7,"SCHIZOPHRENIA, BIPOLAR DISORDER, IRRITABILITY",,LAUNCHED,,Small molecule,Approved,RAPZEAPATHNIPO-UHFFFAOYSA-N,CC1NC2CCCCN2C(=O)C1CCN1CCC(CC1)C1NOC2CC(F)CCC12;CC1NC2N(C(=O)C1CCN1CCC(C3NOC4CC(F)CCC34)CC1)CCCC2
RITANSERIN,RITANSERIN,CHEMBL267777,BRD:BRD-BRD-K40887525-001-21-9;BRD:BRD-K40887525-001-21-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C;HTR5A;HTR6;HTR7,,,PHASE 3,,Small molecule,Phase 2,JUQLTPCYUFPYKE-UHFFFAOYSA-N,CC1NC2SCCN2C(=O)C1CCN1CCC(=C(C2CCC(F)CC2)C2CCC(F)CC2)CC1;CC1NC2SCCN2C(=O)C1CCN1CCC(CC1)=C(C1CCC(F)CC1)C1CCC(F)CC1
RITODRINE,RITODRINE,CHEMBL785;CHEMBL83063,BRD:BRD-A59174698-003-18-5;BRD:BRD-BRD-A59174698-003-18-5;BRD:BRD-BRD-K14003026-003-09-0;BRD:BRD-K14003026-003-09-0,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,PREMATURE LABOR,,LAUNCHED,"Multiple values for structure_id: {'K14003026', 'A59174698'}, defaulting to None",Small molecule,Approved,IOVGROKTTNBUGK-SJCJKPOMSA-N;IOVGROKTTNBUGK-UHFFFAOYSA-N,C[C@@H](NCCC1CCC(O)CC1)[C@@H](O)C1CCC(O)CC1;C[C@H](NCCC1CCC(O)CC1)[C@H](O)C1CCC(O)CC1;CC(NCCC1CCC(O)CC1)C(O)C1CCC(O)CC1
RITONAVIR,RITONAVIR,CHEMBL163,BRD:BRD-BRD-K51485625-001-08-4;BRD:BRD-K51485625-001-08-4,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,CYP1A2;CYP2B6;CYP2C19;CYP2C8;CYP2C9;CYP2D6;CYP2E1;CYP3A4;CYP3A5;CYP3A7,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,NCDNCNXCDXHOMX-XGKFQTDJSA-N,CC(C)[C@H](NC(=O)N(C)CC1CSC(N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1CCCCC1)NC(=O)OCC1CNCS1)CC1CCCCC1;CC(C)C1NC(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC2CCCCC2)C[C@H](O)[C@H](CC2CCCCC2)NC(=O)OCC2CNCS2)C(C)C)CS1
RIVANICLINE,RIVANICLINE,CHEMBL132966,BRD:BRD-BRD-K79966802-034-01-2;BRD:BRD-K79966802-034-01-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA4;CHRNB2;CXCL8,,,PHASE 2,,Small molecule,Unknown,JUOSGGQXEBBCJB-GORDUTHDSA-N,CNCC/C=C/C1CCCNC1;CNCC\C=C\C1CCCNC1
RIVAROXABAN,RIVAROXABAN,CHEMBL198362,BRD:BRD-BRD-K37130656-001-04-6;BRD:BRD-K37130656-001-04-6,rep_primary;rep_single_dose,COAGULATION FACTOR INHIBITOR,F10,"STROKE, SYSTEMIC EMBOLISM, ATRIAL FIBRILLATION (AF), DEEP VEIN THROMBOSIS (DVT), PULMONARY EMBOLISM (PE)",,LAUNCHED,,Small molecule,Approved,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,CLC1CCC(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1CCC(CC1)N1CCOCC1=O;O=C(NC[C@H]1CN(C2CCC(N3CCOCC3=O)CC2)C(=O)O1)C1CCC(CL)S1
RIVASTIGMINE,RIVASTIGMINE,CHEMBL636,BRD:BRD-BRD-K10706131-046-03-6;BRD:BRD-K10706131-046-03-6,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE,"ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SENILE DEMENTIA",,LAUNCHED,,Small molecule,Approved,XSVMFMHYUFZWBK-NSHDSACASA-N,CCN(C)C(=O)OC1CCCC([C@H](C)N(C)C)C1;CCN(C)C(=O)OC1CCCC(C1)[C@H](C)N(C)C
RIZATRIPTAN,RIZATRIPTAN,CHEMBL905,BRD:BRD-BRD-K75699339-057-08-1;BRD:BRD-K75699339-057-08-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,ULFRLSNUDGIQQP-UHFFFAOYSA-N,CN(C)CCC1C[NH]C2CCC(CN3CNCN3)CC12
RKI-1447,RKI-1447,,BRD:BRD-BRD-K19333160-001-01-3;BRD:BRD-K19333160-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,CDC42BPA;DMPK;LIMK1;MYLK;PAK1;PKN1;ROCK1;ROCK2,,,PRECLINICAL,,,NA,,OC1CCCC(CNC(=O)NC2NC(CS2)-C2CCNCC2)C1
RMC-0331,RM-023;RMC-0331,,BRD:BRD-U00115424-001-01-9,oncref_1,INHIBITOR OF THE KRAS-SOS1 INTERACTION,KRAS;SOS1,,,,,,NA,,
RMC-4550,RMC-4550,,BRD:BRD-K00010386-001-01-9,rep_single_dose,SHIP2 PHOSPHATASE INHIBITOR,,,,,,,NA,,
RMC4550,RMC4550,,BRD:BRD-U00115410-001-01-9,oncref_1,INHIBITOR OF SHP2,PTPN11,,,,,,NA,,
RN-1,RN-1,,BRD:BRD-K41415459-300-02-9,rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,KDM1A,,,,,,NA,,
RN-1734,RN-1734,,BRD:BRD-BRD-K95581532-001-01-5;BRD:BRD-K95581532-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV4,,,PRECLINICAL,,,NA,,CC(C)NCCN(C(C)C)S(=O)(=O)C1CCC(CL)CC1CL
RN-1747,RN-1747,,BRD:BRD-BRD-K45519571-001-01-8;BRD:BRD-K45519571-001-01-8,rep_primary;rep_single_dose,TRPV AGONIST,TRPV4,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CC(CL)CCC1S(=O)(=O)N1CCN(CC2CCCCC2)CC1
RO-04-5595,RO-04-5595,,BRD:BRD-A63546914-003-02-0;BRD:BRD-BRD-A63546914-003-02-0,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2B,,,PRECLINICAL,,,NA,,COC1CC2CCN(C)C(CCC3CCC(CL)CC3)C2CC1O
RO-08-2750,RO-08-2750,,BRD:BRD-BRD-K00486786-001-02-2;BRD:BRD-K00486786-001-02-2,rep_primary;rep_single_dose,NGF BINDING INHIBITOR,NGF;NGFR,,,PRECLINICAL,"Multiple values for repurposing_target: {'NGF;NGFR', 'NGF'}, taking the union",,NA,,CC1CC2NC3C(NC(=O)[NH]C3=O)N(C)C2CC1C=O
RO-10-5824,RO-10-5824,,BRD:BRD-BRD-K79684402-300-02-8;BRD:BRD-K79684402-300-02-8,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD4,,,PRECLINICAL,,,NA,,CC1NCC(CN2CCC(=CC2)C2CCCCC2)C(N)N1
RO-106-9920,RO-106-9920,,BRD:BRD-A53134341-001-03-2;BRD:BRD-BRD-A53134341-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,,,,PRECLINICAL,,,NA,,O=S(C1CCCCC1)C1CCC2NNNN2N1
RO-1138452,RO-1138452,,BRD:BRD-BRD-K77220725-003-01-5;BRD:BRD-K77220725-003-01-5,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGIR,,,PRECLINICAL,,,NA,,CC(C)OC1CCC(CC2CCC(NC3=NCCN3)CC2)CC1
RO-15-4513,RO-15-4513,CHEMBL6597,BRD:BRD-BRD-K82823076-001-02-6;BRD:BRD-K82823076-001-02-6,rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR INVERSE AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB2;GABRG2,,,PRECLINICAL,,Small molecule,NA,CFSOJZTUTOQNIA-UHFFFAOYSA-N,CCOC(=O)C1NCN-2C1CN(C)C(=O)C1CC(CCC-21)N=[N+]=[N-];CCOC(=O)C1NCN2C1CN(C)C(=O)C1CC(N=[N+]=[N-])CCC1-2
RO-19-4605,RO-19-4605,,BRD:BRD-BRD-K80778372-001-02-5;BRD:BRD-K80778372-001-02-5,rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR INVERSE AGONIST,GABRA1;GABRA2;GABRA3;GABRA5,,,PRECLINICAL,,,NA,,CN1CC2C(NCN2-C2CCSC2C1=O)C(=O)OC(C)(C)C
RO-20-1724,RO-20-1724,CHEMBL18701,BRD:BRD-A07207424-001-13-2;BRD:BRD-BRD-A07207424-001-13-2,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A;PDE4A;PDE4B;PDE4C;PDE4D,,,PRECLINICAL,,Small molecule,NA,PDMUULPVBYQBBK-UHFFFAOYSA-N,CCCCOC1CC(CC2CNC(=O)N2)CCC1OC
RO-25-6981,RO-25-6981,,BRD:BRD-BRD-K51541829-050-01-0;BRD:BRD-K51541829-050-01-0,rep_primary;rep_single_dose,"GLUTAMATE RECEPTOR ANTAGONIST, MONAMINE TRANSPORTER MODULATOR",GRIN2B,,,PRECLINICAL,,,NA,,C[C@@H](CN1CCC(CC2CCCCC2)CC1)[C@@H](O)C1CCC(O)CC1
RO-28-1675,RO-28-1675,,BRD:BRD-BRD-K21672174-001-03-0;BRD:BRD-K21672174-001-03-0,rep_primary;rep_single_dose,GLUCOKINASE ACTIVATOR,GCK,,,PRECLINICAL,,,NA,,CS(=O)(=O)C1CCC(CC1)[C@@H](CC1CCCC1)C(=O)NC1NCCS1
RO-3,RO-3,,BRD:BRD-BRD-K00354853-001-01-2;BRD:BRD-K00354853-001-01-2,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RX3,,,PRECLINICAL,,,NA,,COC1CC(CC2CNC(N)NC2N)C(CC1OC)C(C)C
RO-3306,RO-3306,,BRD:BRD-BRD-K78373679-001-03-7;BRD:BRD-K78373679-001-03-7;GDSC1:1052;GDSC2:1052,gdsc;rep_primary;rep_single_dose,CDK INHIBITOR,CDK1,,,PRECLINICAL,,,NA,,O=C1N=C(NCC2CCCS2)S\C1=C/C1CCC2NCCCC2C1
RO-48-6791,RO-48-6791,,BRD:BRD-K00004572-001-01-9,rep_single_dose,GABA RECEPTOR MODULATOR,,,,,,,NA,,
RO-48-8071,RO-48-8071,,BRD:BRD-BRD-K55192287-051-01-1;BRD:BRD-K55192287-051-01-1,rep_primary;rep_single_dose,OXIDOSQUALENE CYCLASE INHIBITOR,LSS,,,PRECLINICAL,,,NA,,CN(CCCCCCOC1CCC(C(=O)C2CCC(BR)CC2)C(F)C1)CC=C
RO-4987655,RO-4987655,CHEMBL1614766,BRD:BRD-BRD-K64538373-001-01-4;BRD:BRD-K64538373-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1,,,PHASE 1,,Small molecule,Phase 1,FIMYFEGKMOCQKT-UHFFFAOYSA-N,O=C(NOCCO)C1CC(CN2OCCCC2=O)C(F)C(F)C1NC1CCC(I)CC1F;OCCONC(=O)C1CC(CN2OCCCC2=O)C(F)C(F)C1NC1CCC(I)CC1F
RO-5028442,RO-5028442,CHEMBL3416885,BRD:BRD-K00003149-001-01-9,rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 1,QZXVLRCMAHJVIP-UHFFFAOYSA-N,CN(C)CCN1CC(C(=O)N2CCC3(CC2)OCC2CCCCC23)C2CCC(CL)CC21
RO-508231,RO-508231,CHEMBL553,GDSC1:1;GDSC2:1168,gdsc,,,,,,,Small molecule,Approved,AAKJLRGGTJKAMG-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1
RO-5126766,RO-5126766,CHEMBL3264002,BRD:BRD-BRD-K82804538-001-01-0;BRD:BRD-K82804538-001-01-0,rep_primary;rep_single_dose,"MEK INHIBITOR, RAF INHIBITOR",BRAF;MAP2K1;MAP2K2;RAF1,,,PHASE 1,"Multiple values for MOA: {'RAF INHIBITOR, MEK INHIBITOR', 'MEK INHIBITOR, RAF INHIBITOR'}, defaulting to 'MEK INHIBITOR, RAF INHIBITOR'",Small molecule,Phase 1,LMMJFBMMJUMSJS-UHFFFAOYSA-N,CNS(=O)(=O)NC1NCCC(CC2C(C)C3CCC(OC4NCCCN4)CC3OC2=O)C1F
RO-5263397,RO-5263397,,BRD:BRD-K00004623-001-01-9,rep_single_dose,TRACE AMINE ASSOCIATED RECEPTOR AGONIST,,,,,,,NA,,
RO-60-0175,RO-60-0175,,BRD:BRD-BRD-K28007504-051-01-2;BRD:BRD-K28007504-051-01-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,,NA,,C[C@H](N)CN1CCC2CC(F)C(CL)CC12
RO-61-8048,RO-61-8048,,BRD:BRD-BRD-K12639498-001-01-3;BRD:BRD-K12639498-001-01-3,rep_primary;rep_single_dose,KYNURENINE 3-MONOOXYGENASE INHIBITOR,KMO,,,PRECLINICAL,,,NA,,COC1CCC(CC1OC)S(=O)(=O)NC1NC(CS1)-C1CCCC(C1)[N+]([O-])=O
RO-67-7476,RO-67-7476,,BRD:BRD-K91333421-001-02-9,rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM1,,,,,,NA,,
RO-90-7501,RO-90-7501,,BRD:BRD-BRD-K58299615-001-03-5;BRD:BRD-K58299615-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,BETA AMYLOID PROTEIN NEUROTOXICITY INHIBITOR,APP,,,PRECLINICAL,,,NA,,NC1CCC(CC1)-C1NC2CCC(CC2[NH]1)-C1NC2CCC(N)CC2[NH]1
RO-9187,RO-9187,,BRD:BRD-BRD-K57284066-001-01-6;BRD:BRD-K57284066-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,HCV INHIBITOR,,,,PRECLINICAL,,,NA,,NC1CCN([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)C(=O)N1
RO4929097,RO4929097,CHEMBL4297422,CTRP:687577,ctrp,,,,,,,Small molecule,Phase 2,OJPLJFIFUQPSJR-INIZCTEOSA-N,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@@H]1C(=O)NC2CCCCC2-C2CCCCC21
ROBALZOTAN,ROBALZOTAN,CHEMBL1628569,BRD:BRD-BRD-K26169680-003-01-9;BRD:BRD-K26169680-003-01-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A,,,PHASE 2,,Small molecule,Phase 2,MQTUXRKNJYPMCG-CYBMUJFWSA-N,NC(=O)C1CCC(F)C2C1C[C@@H](N(C1CCC1)C1CCC1)CO2;NC(=O)C1CCC(F)C2OC[C@@H](CC12)N(C1CCC1)C1CCC1
ROCILETINIB,ROCILETINIB,CHEMBL3545308,BRD:BRD-BRD-K33610132-001-02-9;BRD:BRD-K33610132-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PHASE 3,,Small molecule,Phase 3,HUFOZJXAKZVRNJ-UHFFFAOYSA-N,C=CC(=O)NC1CCCC(NC2NC(NC3CCC(N4CCN(C(C)=O)CC4)CC3OC)NCC2C(F)(F)F)C1;COC1CC(CCC1NC1NCC(C(NC2CCCC(NC(=O)C=C)C2)N1)C(F)(F)F)N1CCN(CC1)C(C)=O
ROCURONIUM,ROCURONIUM,CHEMBL1201244,BRD:BRD-BRD-K43305603-004-02-8;BRD:BRD-K43305603-004-02-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM2;CHRNA2;HTR3A,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,YXRDKMPIGHSVRX-OOJCLDBCSA-N,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1;CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1
ROFECOXIB,ROFECOXIB,CHEMBL122,BRD:BRD-BRD-K21733600-001-14-1;BRD:BRD-K21733600-001-14-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,ELN;PTGS2,,,WITHDRAWN,,Small molecule,Approved,RZJQGNCSTQAWON-UHFFFAOYSA-N,CS(=O)(=O)C1CCC(C2=C(C3CCCCC3)C(=O)OC2)CC1;CS(=O)(=O)C1CCC(CC1)C1=C(C(=O)OC1)C1CCCCC1
ROFLUMILAST,ROFLUMILAST,CHEMBL193240,BRD:BRD-BRD-K03194791-001-04-8;BRD:BRD-K03194791-001-04-8,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A;PDE4B;PDE4C;PDE4D,"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BRONCHITIS",,LAUNCHED,,Small molecule,Approved,MNDBXUUTURYVHR-UHFFFAOYSA-N,FC(F)OC1CCC(CC1OCC1CC1)C(=O)NC1C(CL)CNCC1CL;O=C(NC1C(CL)CNCC1CL)C1CCC(OC(F)F)C(OCC2CC2)C1
ROLAPITANT,ROLAPITANT,CHEMBL3707331,BRD:BRD-K00003175-001-01-9,rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,FIVSJYGQAIEMOC-ZGNKEGEESA-N,C[C@@H](OC[C@@]1(C2CCCCC2)CC[C@]2(CCC(=O)N2)CN1)C1CC(C(F)(F)F)CC(C(F)(F)F)C1
ROLIPRAM,ROLIPRAM,CHEMBL63,BRD:BRD-A34255068-001-34-5;BRD:BRD-BRD-A34255068-001-34-5,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,PHASE 3,,Small molecule,Phase 2,HJORMJIFDVBMOB-UHFFFAOYSA-N,COC1CCC(C2CNC(=O)C2)CC1OC1CCCC1;COC1CCC(CC1OC1CCCC1)C1CNC(=O)C1
ROLIPRAM-S(+),ROLIPRAM-S(+),,BRD:BRD-BRD-K65856711-001-04-4,rep_primary,PHOSPHODIESTERASE INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CCC(CC1OC1CCCC1)[C@H]1CNC(=O)C1
ROLUPERIDONE,ROLUPERIDONE,CHEMBL4297605,BRD:BRD-K00003283-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,RNRYULFRLCBRQS-UHFFFAOYSA-N,O=C(CN1CCC(CN2CC3CCCCC3C2=O)CC1)C1CCC(F)CC1
ROLZIRACETAM,ROLZIRACETAM,CHEMBL51396,BRD:BRD-BRD-K38564664-001-01-1;BRD:BRD-K38564664-001-01-1,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,IEZDOKQWPWZVQF-UHFFFAOYSA-N,O=C1CCC2CCC(=O)N12
ROMIDEPSIN,ROMIDEPSIN,CHEMBL343448,BRD:BRD-BRD-K61397605-001-03-4;BRD:BRD-K61397605-001-03-4,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9,CUTANEOUS T-CELL LYMPHOMA (CTCL),,LAUNCHED,,Protein,Approved,OHRURASPPZQGQM-GCCNXGTGSA-N,C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O;C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
RONIDAZOLE,RONIDAZOLE,CHEMBL290299,BRD:BRD-BRD-K94266545-001-24-1;BRD:BRD-K94266545-001-24-1,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,"HISTOMONIASIS, DYSENTRY",,LAUNCHED,,Small molecule,Unknown,PQFRTXSWDXZRRS-UHFFFAOYSA-N,CN1C([N+](=O)[O-])CNC1COC(N)=O;CN1C(COC(N)=O)NCC1[N+]([O-])=O
ROPINIROLE,ROPINIROLE,CHEMBL589,BRD:BRD-BRD-K15933101-003-06-1;BRD:BRD-K15933101-003-06-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C,"PARKINSON'S DISEASE, RESTLESS LEG SYNDROME",,LAUNCHED,,Small molecule,Approved,UHSKFQJFRQCDBE-UHFFFAOYSA-N,CCCN(CCC)CCC1CCCC2C1CC(=O)N2;CCCN(CCC)CCC1CCCC2NC(=O)CC12
ROPIVACAINE,ROPIVACAINE,CHEMBL1077896,BRD:BRD-BRD-K50938786-003-11-8;BRD:BRD-K50938786-003-11-8,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN10A,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,ZKMNUMMKYBVTFN-HNNXBMFYSA-N,CCCN1CCCC[C@H]1C(=O)NC1C(C)CCCC1C
ROQUINIMEX,ROQUINIMEX,CHEMBL11672,BRD:BRD-BRD-K03384561-001-02-7;BRD:BRD-K03384561-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,"ANGIOGENESIS INHIBITOR, TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR",,,,PHASE 3,,Small molecule,Unknown,SGOOQMRIPALTEL-UHFFFAOYSA-N,CN(C(=O)C1C(O)C2CCCCC2N(C)C1=O)C1CCCCC1
ROSAMICIN,ROSAMICIN,CHEMBL8965,BRD:BRD-K00004538-001-01-9,rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,,,,,Small molecule,Unknown,IUPCWCLVECYZRV-JZMZINANSA-N,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@]2(C)O[C@H]2[C@@H]1C
ROSCOVITINE,ROSCOVITINE,CHEMBL14762,BRD:BRD-BRD-K07691486-001-15-5;BRD:BRD-K07691486-001-15-5;BRD:BRD-K07691486-001-19-7;GDSC1:110,gdsc;rep_multi_dose;rep_primary;rep_single_dose,CDK INHIBITOR,CDK2;CDK9,,,PHASE 2,,Small molecule,Phase 2,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,CC[C@H](CO)NC1NC(NCC2CCCCC2)C2NCN(C(C)C)C2N1
ROSE-BENGAL-LACTONE,ROSE-BENGAL-LACTONE,,BRD:BRD-BRD-K36163066-304-02-4;BRD:BRD-K36163066-304-02-4,rep_primary;rep_single_dose,COLORING AGENT,,STAINING AGENT,,LAUNCHED,,,NA,,OC1C(I)CC2C(OC3C(I)C(O)C(I)CC3C22OC(=O)C3C2C(CL)C(CL)C(CL)C3CL)C1I
ROSIGLITAZONE,ROSIGLITAZONE,CHEMBL121,BRD:BRD-A97437073-050-14-5;BRD:BRD-BRD-A97437073-050-14-5,rep_primary;rep_single_dose,"INSULIN SENSITIZER, PPAR RECEPTOR AGONIST",ACSL4;FFAR1;PPARG;TRPC5;TRPM3,,,WITHDRAWN,,Small molecule,Approved,YASAKCUCGLMORW-UHFFFAOYSA-N,CN(CCOC1CCC(CC2SC(=O)NC2=O)CC1)C1CCCCN1
ROSIPTOR,ROSIPTOR,CHEMBL3989954,BRD:BRD-K00003494-001-01-9,rep_single_dose,SHIP1 PHOSPHATASE ACTIVATOR,,,,,,Small molecule,Phase 3,MDEJTPWQNNMAQF-BVMLLJBZSA-N,C=C1CC[C@H]2[C@H](CN)[C@@H]([C@@]3(C)CC[C@H](O)C[C@@H]3CO)CC[C@]12C
ROSMARINIC-ACID,ROSMARINIC-ACID,,BRD:BRD-BRD-K20313525-001-04-6;BRD:BRD-K20313525-001-04-6,rep_primary;rep_single_dose,GABA TRANSAMINASE INHIBITOR,MCL1;TYR,,,LAUNCHED,,,NA,,OC(=O)[C@@H](CC1CCC(O)C(O)C1)OC(=O)\C=C\C1CCC(O)C(O)C1
ROSOXACIN,ROSOXACIN,CHEMBL291157,BRD:BRD-BRD-K49841478-001-01-6;BRD:BRD-K49841478-001-01-6,rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,XBPZXDSZHPDXQU-UHFFFAOYSA-N,CCN1CC(C(=O)O)C(=O)C2CCC(-C3CCNCC3)CC21;CCN1CC(C(O)=O)C(=O)C2CCC(CC12)-C1CCNCC1
ROSTAFUROXINE,ROSTAFUROXINE,,BRD:BRD-BRD-K11672787-001-01-5;BRD:BRD-K11672787-001-01-5,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP1A1,,,PHASE 2,,,NA,,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1CCOC1
ROSUVASTATIN,ROSUVASTATIN,CHEMBL1496,BRD:BRD-BRD-K82941592-238-04-5;BRD:BRD-K82941592-238-04-5;BRD:BRD-K82941592-238-07-9,rep_primary;rep_single_dose,HMGCR INHIBITOR,HMGCR,"HYPERLIPIDEMIA, DYSLIPIDEMIA, HYPERTRIGLYCERIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS",,LAUNCHED,,Small molecule,Approved,BPRHUIZQVSMCRT-VEUZHWNKSA-N,CC(C)C1NC(N(C)S(C)(=O)=O)NC(-C2CCC(F)CC2)C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O;CC(C)C1NC(NC(-C2CCC(F)CC2)C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O
ROTIGOTINE,ROTIGOTINE,CHEMBL1303,BRD:BRD-BRD-K91111634-001-01-2;BRD:BRD-K91111634-001-01-2,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,ADRA2B;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A,"PARKINSON'S DISEASE, RESTLESS LEG SYNDROME",,LAUNCHED,,Small molecule,Approved,KFQYTPMOWPVWEJ-INIZCTEOSA-N,CCCN(CCC1CCCS1)[C@H]1CCC2C(O)CCCC2C1
ROTUNDINE,ROTUNDINE,CHEMBL487182,BRD:BRD-BRD-K35719256-001-02-6;BRD:BRD-K35719256-001-02-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,DRD1;DRD2;DRD3;HTR1A,,,LAUNCHED,,Small molecule,Phase 2,AEQDJSLRWYMAQI-KRWDZBQOSA-N,COC1CC2C(CC1OC)[C@@H]1CC3CCC(OC)C(OC)C3CN1CC2;COC1CC2CCN3CC4C(C[C@H]3C2CC1OC)CCC(OC)C4OC
ROVAZOLAC,ROVAZOLAC,CHEMBL4297218,BRD:BRD-K00003502-001-01-9,rep_single_dose,LXR AGONIST,,,,,,Small molecule,Phase 2,ZUMNJDGBYXHASJ-UHFFFAOYSA-N,CCOC(=O)CN1NC(C(F)(F)F)CC1-C1CCC(-C2CCCC(S(C)(=O)=O)C2)CC1
ROXARSONE,ROXARSONE,CHEMBL1321154,BRD:BRD-BRD-K22685337-001-13-4;BRD:BRD-K22685337-001-13-4,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,WEIGHT-GAIN AID,,LAUNCHED,,Small molecule,NA,XMVJITFPVVRMHC-UHFFFAOYSA-N,O=[N+]([O-])C1CC([AS](=O)(O)O)CCC1O;OC1CCC(CC1[N+]([O-])=O)[AS](O)(O)=O
ROXATIDINE-ACETATE,ROXATIDINE-ACETATE,,BRD:BRD-BRD-K81855038-003-13-9;BRD:BRD-K81855038-003-13-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,"ZOLLINGER-ELLISON SYNDROME, EROSIVE ESOPHAGITIS (EE), GASTROESOPHAGEAL REFLUX DISEASE (GERD), GASTRITIS",,LAUNCHED,,,NA,,CC(=O)OCC(=O)NCCCOC1CCCC(CN2CCCCC2)C1
ROXITHROMYCIN,ROXITHROMYCIN,CHEMBL1214185,BRD:BRD-BRD-K38684403-001-05-4;BRD:BRD-K38684403-001-05-4,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,ABCB1;MLNR,"RESPIRATORY TRACT INFECTIONS, URINARY TRACT INFECTIONS, SKIN INFECTIONS",,LAUNCHED,,Small molecule,Approved,RXZBMPWDPOLZGW-XMRMVWPWSA-N,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O;CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
RP-001,RP-001,,BRD:BRD-A29148886-003-02-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST,S1PR1,,,,,,NA,,
RP-54745,RP-54745,,BRD:BRD-K00073937-001-02-9,rep_single_dose,,,,,,,,NA,,
RP-56976,RP-56976,CHEMBL3545252;CHEMBL92,GDSC1:1007;GDSC2:1007;GDSC2:1819,gdsc,,,,,,,Small molecule,Approved,XCDIRYDKECHIPE-QHEQPUDQSA-N;ZDZOTLJHXYCWBA-VCVYQWHSSA-N,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C[C@@](O)([C@@H](OC(=O)C4CCCCC4)[C@H]21)C3(C)C;CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C[C@@](O)([C@@H](OC(=O)C4CCCCC4)[C@H]21)C3(C)C.O.O.O
RP-6306,RP-6306,CHEMBL5095288,BRD:BRD-K00126480-001-01-9,oncref_2,INHIBITOR OF PKMYT1,PKMYT1,,,,,Unknown,Phase 1,,
RQ-00203078,RQ-00203078,,BRD:BRD-K87973152-001-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPM8,,,,,,NA,,
RS-0481,RS-0481,,BRD:BRD-A00055058-001-01-0;BRD:BRD-BRD-A00055058-001-01-0,rep_primary;rep_single_dose,IMMUNOSTIMULANT,,,,PHASE 2,,,NA,,CC(NC(=O)C1CSCN1C(=O)C1CCCCC1)C1CCCCC1
RS-100329,RS-100329,,BRD:BRD-BRD-K08640512-003-02-3;BRD:BRD-K08640512-003-02-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1D,,,PRECLINICAL,,,NA,,CC1C[NH]C(=O)N(CCCN2CCN(CC2)C2CCCCC2OCC(F)(F)F)C1=O
RS-102221,RS-102221,CHEMBL88402,BRD:BRD-BRD-K87048468-003-02-7;BRD:BRD-K87048468-003-02-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,Small molecule,NA,HZZZZODVDSHQRG-UHFFFAOYSA-N,COC1CC(OC)C(C(=O)CCCCN2CCC3(CC2)NC(=O)NC3=O)CC1NS(=O)(=O)C1CCC(C(F)(F)F)CC1;COC1CC(OC)C(CC1NS(=O)(=O)C1CCC(CC1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O
RS-102895,RS-102895,,BRD:BRD-BRD-K83063356-003-02-5;BRD:BRD-K83063356-003-02-5,rep_primary;rep_single_dose,CCR ANTAGONIST,CCR2,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCC(CCN2CCC3(CC2)OC(=O)NC2CCCCC32)CC1
RS-127445,RS-127445,,BRD:BRD-BRD-K90825648-001-02-0;BRD:BRD-K90825648-001-02-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,PHASE 1,,,NA,,CC(C)C1CC(NC(N)N1)-C1CCC(F)C2CCCCC12
RS-16566,RS-16566,,BRD:BRD-BRD-K80725821-300-02-9;BRD:BRD-K80725821-300-02-9,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,PRECLINICAL,,,NA,,CC(C)N1CNC2C(CC(CL)CC12)C(=O)N[C@H]1CN2CCC1CC2
RS-17053,RS-17053,,BRD:BRD-BRD-K76840893-003-02-5;BRD:BRD-K76840893-003-02-5,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1D,,,PRECLINICAL,,,NA,,CC(C)(CC1C[NH]C2CCC(CL)CC12)NCCOC1CCCCC1OCC1CC1
RS-23597-190,RS-23597-190,,BRD:BRD-BRD-K01868942-003-02-7;BRD:BRD-K01868942-003-02-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR4,,,PRECLINICAL,,,NA,,COC1CC(N)C(CL)CC1C(=O)OCCCN1CCCCC1
RS-39604,RS-39604,,BRD:BRD-BRD-K20742498-003-02-9;BRD:BRD-K20742498-003-02-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR4,,,PRECLINICAL,,,NA,,COC1CC(COC2CC(N)C(CL)CC2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)CC(OC)C1
RS-45041-190,RS-45041-190,,BRD:BRD-BRD-K26160755-003-02-6;BRD:BRD-K26160755-003-02-6,rep_primary;rep_single_dose,IMIDAZOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CLC1CCCC2CN(CC12)C1=NCCN1
RS-504393,RS-504393,,BRD:BRD-BRD-K87510569-001-02-8;BRD:BRD-K87510569-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCL2;CCR2,,,PRECLINICAL,,,NA,,CC1OC(NC1CCN1CCC2(CC1)OC(=O)NC1CCC(C)CC21)-C1CCCCC1
RS-56812,RS-56812,,BRD:BRD-BRD-K20714604-003-02-9;BRD:BRD-K20714604-003-02-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR PARTIAL AGONIST,HTR3A,,,PRECLINICAL,,,NA,,CN1CC(C(=O)C(=O)N[C@H]2CN3CCC2CC3)C2CCCCC12
RS-67333,RS-67333,,BRD:BRD-BRD-K46142322-003-02-4;BRD:BRD-K46142322-003-02-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR PARTIAL AGONIST,HTR4,,,PRECLINICAL,,,NA,,CCCCN1CCC(CCC(=O)C2CC(CL)C(N)CC2OC)CC1
RS-67506,RS-67506,,BRD:BRD-BRD-K50018155-003-02-1;BRD:BRD-K50018155-003-02-1,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR PARTIAL AGONIST,HTR4,,,PRECLINICAL,,,NA,,COC1CC(N)C(CL)CC1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1
RS-79948,RS-79948,,BRD:BRD-BRD-K86600316-003-02-0;BRD:BRD-K86600316-003-02-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A,,,PRECLINICAL,,,NA,,CCS(=O)(=O)N1CCC[C@@H]2CN3CCC4CC(OC)CCC4[C@@H]3C[C@H]12
RSV604,RSV604,CHEMBL223402,BRD:BRD-BRD-K30159788-001-01-9;BRD:BRD-K30159788-001-01-9,rep_primary;rep_single_dose,RSV REPLICATION INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,MTPVBMVUENFFLL-HXUWFJFHSA-N,FC1CCCCC1NC(=O)N[C@H]1N=C(C2CCCCC2)C2CCCCC2NC1=O;O=C(NC1CCCCC1F)N[C@H]1N=C(C2CCCCC2)C2CCCCC2NC1=O
RTA-408,RTA-408,CHEMBL4303525,BRD:BRD-BRD-K56211775-001-03-8;BRD:BRD-K56211775-001-03-8,rep_primary;rep_single_dose,NITRIC OXIDE PRODUCTION INHIBITOR,NFE2L2,,,PHASE 2,,Small molecule,Phase 2,RJCWBNBKOKFWNY-IDPLTSGASA-N,CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2;CC1(C)CC[C@]2(NC(=O)C(C)(F)F)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1
RTRAIL,RTRAIL,,GDSC1:1261,gdsc,,,,,,,,NA,,
RU-28318,RU-28318,,BRD:BRD-BRD-K37687387-237-01-7;BRD:BRD-K37687387-237-01-7,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,NR3C2,,,PHASE 2,,,NA,,CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12
RU-58841,RU-58841,CHEMBL9337,BRD:BRD-BRD-K62762455-001-01-3;BRD:BRD-K62762455-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,AR,,,PHASE 2,,Small molecule,NA,ARBYGDBJECGMGA-UHFFFAOYSA-N,CC1(C)C(=O)N(C2CCC(C#N)C(C(F)(F)F)C2)C(=O)N1CCCCO;CC1(C)N(CCCCO)C(=O)N(C1=O)C1CCC(C#N)C(C1)C(F)(F)F
RU-SKI 43,RU-SKI 43,,GDSC1:576,gdsc,,,,,,,,NA,,
RU-SKI-43,RU-SKI-43,,BRD:BRD-A33603104-003-02-9,rep_single_dose,HEDGEHOG PATHWAY INHIBITOR,HHAT,,,,,,NA,,
RUBEX,RUBEX,CHEMBL359744;CHEMBL53463,GDSC1:133,gdsc,,,,,,,Small molecule,Approved,AOJJSUZBOXZQNB-TZSSRYMLSA-N;MWWSFMDVAYGXBV-RUELKSSGSA-N,COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;COC1CCCC2C1C(=O)C1C(O)C3C(C(O)C1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.CL
RUBITECAN,RUBITECAN,CHEMBL77305,BRD:BRD-BRD-K79821389-001-03-5;BRD:BRD-K79821389-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 3,,Small molecule,Phase 3,VHXNKPBCCMUMSW-FQEVSTJZSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1-C3NC4CCCC([N+]([O-])=O)C4CC3CN1C2=O;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3C([N+](=O)[O-])CCCC3NC2-1
RUBOXISTAURIN,RUBOXISTAURIN,CHEMBL91829,BRD:BRD-K27677357-003-04-9,rep_single_dose,PKC INHIBITOR,,,,,,Small molecule,Phase 3,ZCBUQCWBWNUWSU-SFHVURJKSA-N,CN(C)C[C@@H]1CCN2CC(C3CCCCC32)C2=C(C(=O)NC2=O)C2CN(C3CCCCC23)CCO1
RUCAPARIB,RUCAPARIB,CHEMBL1173055,BRD:BRD-BRD-K88560311-011-06-3;BRD:BRD-K88560311-011-06-3;GDSC1:1175,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1;PARP2,,,PHASE 3,,Small molecule,Approved,HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCC1CCC(-C2[NH]C3CC(F)CC4C3C2CCNC4=O)CC1;CNCC1CCC(CC1)-C1[NH]C2CC(F)CC3C(=O)NCCC1C23
RUCINOL,RUCINOL,CHEMBL450195,BRD:BRD-BRD-K61036791-001-01-6;BRD:BRD-K61036791-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,TYROSINASE INHIBITOR,TYR,,,PHASE 1,,Small molecule,NA,CSHZYWUPJWVTMQ-UHFFFAOYSA-N,CCCCC1CCC(O)CC1O
RUFINAMIDE,RUFINAMIDE,CHEMBL1201754,BRD:BRD-BRD-K20079257-001-09-6;BRD:BRD-K20079257-001-09-6,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,GRM5;SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,,Small molecule,Approved,POGQSBRIGCQNEG-UHFFFAOYSA-N,NC(=O)C1CN(CC2C(F)CCCC2F)NN1
RUFLOXACIN,RUFLOXACIN,CHEMBL295619,BRD:BRD-BRD-K62374253-001-07-8;BRD:BRD-K62374253-001-07-8,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Unknown,NJCJBUHJQLFDSW-UHFFFAOYSA-N,CN1CCN(C2C(F)CC3C(=O)C(C(=O)O)CN4C3C2SCC4)CC1;CN1CCN(CC1)C1C(F)CC2C3C1SCCN3CC(C(O)=O)C2=O
RUPATADINE,RUPATADINE,CHEMBL91397,BRD:BRD-BRD-K98004573-051-02-8;BRD:BRD-K98004573-051-02-8,rep_primary;rep_single_dose,"HISTAMINE RECEPTOR ANTAGONIST, PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST",HRH1;PTAFR,"ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Phase 3,WUZYKBABMWJHDL-UHFFFAOYSA-N,CC1CNCC(CN2CCC(=C3C4CCC(CL)CC4CCC4CCCNC43)CC2)C1;CC1CNCC(CN2CCC(CC2)=C2C3CCC(CL)CC3CCC3CCCNC23)C1
RUPINTRIVIR,RUPINTRIVIR,CHEMBL20210,BRD:BRD-K00075060-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,CAYJBRBGZBCZKO-BHGBQCOSSA-N,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)C1CC(C)ON1)C(C)C)CC1CCC(F)CC1
RUTAECARPINE,RUTAECARPINE,CHEMBL85139,BRD:BRD-BRD-K94723713-001-10-6;BRD:BRD-K94723713-001-10-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,,,PRECLINICAL,,Small molecule,NA,ACVGWSKVRYFWRP-UHFFFAOYSA-N,O=C1C2CCCCC2NC2N1CCC1C-2[NH]C2CCCCC12;O=C1N2CCC3C([NH]C4CCCCC34)-C2NC2CCCCC12
RUTIN,RUTIN,CHEMBL226335,BRD:BRD-BRD-K20482099-001-09-4;BRD:BRD-BRD-K20482099-001-11-0;BRD:BRD-K20482099-001-09-4;BRD:BRD-K20482099-001-11-0,rep_multi_dose;rep_primary;rep_single_dose,"ANTIOXIDANT, CAPILLARY STABILIZING AGENT, NITRIC OXIDE SCAVENGER",AKR1C3,"JOINT PAIN, NASAL CONGESTION, CONSTIPATION, IRRITABILITY, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Phase 2,IKGXIBQEEMLURG-NVPNHPEKSA-N,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3C(-C4CCC(O)C(O)C4)OC4CC(O)CC(O)C4C3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O;C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3C(OC4CC(O)CC(O)C4C3=O)-C3CCC(O)C(O)C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
RUXOLITINIB PHOSPHATE,RUXOLITINIB PHOSPHATE,CHEMBL1795071,GDSC1:206;GDSC2:1507,gdsc,,,,,,,Small molecule,Approved,JFMWPOCYMYGEDM-XFULWGLBSA-N,N#CC[C@H](C1CCCC1)N1CC(-C2NCNC3[NH]CCC23)CN1.O=P(O)(O)O
RUXOLITINIB-(S),RUXOLITINIB-(S),,BRD:BRD-BRD-K19601669-001-03-5;BRD:BRD-K19601669-001-03-5,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2,,,PRECLINICAL,,,NA,,N#CC[C@@H](C1CCCC1)N1CC(CN1)-C1NCNC2[NH]CCC12
RV1729,RV1729,,BRD:BRD-K00004579-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,,NA,,
RVX-208,RVX-208,CHEMBL2393130,GDSC2:1625,gdsc,,,,,,,Small molecule,Phase 3,NETXMUIMUZJUTB-UHFFFAOYSA-N,COC1CC(OC)C2C(=O)[NH]C(-C3CC(C)C(OCCO)C(C)C3)NC2C1
RWJ-21757,RWJ-21757,CHEMBL292008,BRD:BRD-BRD-K00091711-001-01-2;BRD:BRD-K00091711-001-01-2,rep_primary;rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,TLR7,,,PHASE 1,,Small molecule,Unknown,VDCRFBBZFHHYGT-IOSLPCCCSA-N,C=CCN1C(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C2NC(N)[NH]C(=O)C21;NC1NC2N([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C(=O)N(CC=C)C2C(=O)[NH]1
RWJ-50271,RWJ-50271,,BRD:BRD-BRD-K94623186-001-01-5;BRD:BRD-K94623186-001-01-5,rep_primary;rep_single_dose,INTEGRIN INHIBITOR,ICAM1,,,PRECLINICAL,,,NA,,CC1C(CNN1-C1NC(CS1)-C1CCCC(C1)C(F)(F)F)C(=O)NCCCO
RWJ-67657,RWJ-67657,CHEMBL190333,BRD:BRD-BRD-K07074923-001-01-5;BRD:BRD-K07074923-001-01-5,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK14;PTGS2,,,PHASE 1,,Small molecule,Phase 1,QSUSKMBNZQHHPA-UHFFFAOYSA-N,OCCC#CC1NC(-C2CCC(F)CC2)C(-C2CCNCC2)N1CCCC1CCCCC1;OCCC#CC1NC(C(-C2CCNCC2)N1CCCC1CCCCC1)-C1CCC(F)CC1
RX-3117,RX-3117,CHEMBL2064455,BRD:BRD-BRD-K66213167-001-01-2;BRD:BRD-K66213167-001-01-2,rep_primary;rep_single_dose,"DNA SYNTHESIS INHIBITOR, CDK INHIBITOR",CDK2;DNMT1,,,PHASE 1/PHASE 2,"Multiple values for MOA: {'CDK INHIBITOR, DNA SYNTHESIS INHIBITOR', 'DNA SYNTHESIS INHIBITOR, CDK INHIBITOR'}, defaulting to 'DNA SYNTHESIS INHIBITOR, CDK INHIBITOR'",Small molecule,Phase 1,QLLGKCJUPWYJON-HLTSFMKQSA-N,NC1CCN([C@@H]2C(F)=C(CO)[C@@H](O)[C@H]2O)C(=O)N1;NC1CCN([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)C(=O)N1
RX-821002,RX-821002,,BRD:BRD-A65597028-003-07-3;BRD:BRD-BRD-A65597028-003-07-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,,,PRECLINICAL,,,NA,,COC1(COC2CCCCC2O1)C1=NCCN1
RYUVIDINE,RYUVIDINE,,BRD:BRD-BRD-K06426971-001-02-7;BRD:BRD-K06426971-001-02-7,rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,CDK2;CDK4,,,PRECLINICAL,,,NA,,CC1NC2C(S1)C(=O)C=C(NC1CCC(C)CC1)C2=O
S-07662,S-07662,,BRD:BRD-K37635256-001-02-9,rep_single_dose,CAR ANTAGONIST,NR1I3,,,,,,NA,,
S-111,S-111,,BRD:BRD-BRD-K60005752-001-01-9;BRD:BRD-K60005752-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1,,,PHASE 2,,,NA,,CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C
S-14506,S-14506,,BRD:BRD-BRD-K46766488-003-02-0;BRD:BRD-K46766488-003-02-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PRECLINICAL,,,NA,,COC1CCC2CCCC(N3CCN(CCNC(=O)C4CCC(F)CC4)CC3)C2C1
S-17092,S-17092,,BRD:BRD-K00004618-001-01-9,rep_single_dose,PROLYL ENDOPEPTIDASE INHIBITOR,,,,,,,NA,,
S-3304,S-3304,CHEMBL297792,BRD:BRD-K00003475-001-01-9,rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,,,,,,Small molecule,Phase 1,YWCLDDLVLSQGSZ-JOCHJYFZSA-N,CC1CCC(C#CC2CCC(S(=O)(=O)N[C@H](CC3C[NH]C4CCCCC34)C(=O)O)S2)CC1
S-38093,S-38093,,BRD:BRD-K00003455-001-01-9,rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,,,,NA,,
S-ISOPROPYLISOTHIOUREA,S-ISOPROPYLISOTHIOUREA,,BRD:BRD-BRD-K10673031-004-02-0;BRD:BRD-K10673031-004-02-0,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS3,,,PRECLINICAL,,,NA,,CC(C)SC(N)=N
S-METHYLCYSTEINE,S-METHYLCYSTEINE,,BRD:BRD-BRD-K63123526-001-01-2;BRD:BRD-K63123526-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,,CTSD;MGMT,,,PHASE 1,,,NA,,CSC[C@H](N)C(O)=O
S-NITROSOGLUTATHIONE,S-NITROSOGLUTATHIONE,CHEMBL63507,BRD:BRD-BRD-K94780074-001-06-7;BRD:BRD-K94780074-001-06-7,rep_primary;rep_single_dose,NITRIC OXIDE STIMULANT,PTPN1,,,PHASE 1,,Small molecule,NA,HYHSBSXUHZOYLX-WDSKDSINSA-N,N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O;N[C@@H](CCC(=O)N[C@@H](CSN=O)C(=O)NCC(=O)O)C(=O)O
S-SULFO-L-CYSTEINE-SODIUM-SALT,S-SULFO-L-CYSTEINE-SODIUM-SALT,,BRD:BRD-BRD-K59527975-236-01-8,rep_primary,GLUTAMATE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,N[C@@H](CSS(O)(=O)=O)C(O)=O
S-TRITYL-L-CYSTEINE,S-TRITYL-L-CYSTEINE,CHEMBL392695,BRD:BRD-K09774593-001-02-9;GDSC1:41,gdsc;rep_single_dose,MITOTIC KINESIN INHIBITOR,,,,,,Small molecule,NA,DLMYFMLKORXJPO-FQEVSTJZSA-N,N[C@@H](CSC(C1CCCCC1)(C1CCCCC1)C1CCCCC1)C(=O)O
S15535,S15535,,BRD:BRD-K00004653-001-01-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,,,,,,,NA,,
S18986,S18986,,BRD:BRD-BRD-K02501528-001-01-1;BRD:BRD-K02501528-001-01-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,GRIA1;GRIA2;GRIA3;GRIA4,,,PHASE 2,,,NA,,O=S1(=O)N[C@H]2CCCN2C2CCCCC12
S1P1-AGONIST-III,S1P1-AGONIST-III,,BRD:BRD-K12745498-001-03-4,rep_single_dose,SPHINGOSINE KINASE INHIBITOR,S1PR1,,,,,,NA,,
S26948,S26948,,BRD:BRD-BRD-K48826825-001-01-8;BRD:BRD-K48826825-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,PPAR RECEPTOR AGONIST,PPARG,,,PRECLINICAL,,,NA,,COC(=O)C(CC1CCC(OCCN2C3CCC(CC3SC2=O)C(=O)C2CCCCC2)CC1)C(=O)OC
S4,S4,,BRD:BRD-K96798615-001-02-9,rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA12;CA9,,,,,,NA,,
S49076,S49076,,BRD:BRD-K00003147-001-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,,NA,,
S55746,S55746,CHEMBL4650448,BRD:BRD-K00091090-001-01-9,rep_single_dose,,,,,,,Unknown,Phase 1,,
S63845,S63845,,BRD:BRD-K91876515-001-03-9,rep_single_dose,MCL1 INHIBITOR,,,,,,,NA,,
SA-47,SA-47,,BRD:BRD-K99819791-001-02-9,rep_single_dose,FAAH INHIBITOR,FAAH,,,,,,NA,,
SABUTOCLAX,SABUTOCLAX,,GDSC2:1849,gdsc,,,,,,,,NA,,
SACCHARIN,SACCHARIN,CHEMBL310671,BRD:BRD-BRD-K46493214-001-06-7;BRD:BRD-K46493214-001-06-7,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,CA1;CA12;CA2;CA9,,,LAUNCHED,,Small molecule,Phase 3,CVHZOJJKTDOEJC-UHFFFAOYSA-N,O=C1NS(=O)(=O)C2CCCCC12;O=C1NS(=O)(=O)C2CCCCC21
SACLOFEN,SACLOFEN,,BRD:BRD-A24122750-001-03-7;BRD:BRD-BRD-A24122750-001-03-7,rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1;GABBR2;KCTD12;KCTD16;KCTD8,,,PRECLINICAL,,,NA,,NCC(CS(O)(=O)=O)C1CCC(CL)CC1
SACUBITRIL,SACUBITRIL,CHEMBL3137301,BRD:BRD-BRD-K91456750-238-01-7;BRD:BRD-K91456750-238-01-7,rep_primary;rep_single_dose,NEPRILYSIN INHIBITOR,MME,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Approved,PYNXFZCZUAOOQC-UTKZUKDTSA-N,CCOC(=O)[C@H](C)C[C@@H](CC1CCC(-C2CCCCC2)CC1)NC(=O)CCC(=O)O;CCOC(=O)[C@H](C)C[C@@H](CC1CCC(CC1)-C1CCCCC1)NC(=O)CCC(O)=O
SACUBITRILAT,SACUBITRILAT,CHEMBL417007,BRD:BRD-K00003252-001-01-9,rep_single_dose,NEPRILYSIN INHIBITOR,,,,,,Small molecule,Unknown,DOBNVUFHFMVMDB-BEFAXECRSA-N,C[C@H](C[C@@H](CC1CCC(-C2CCCCC2)CC1)NC(=O)CCC(=O)O)C(=O)O
SAFINAMIDE,SAFINAMIDE,CHEMBL396778,BRD:BRD-BRD-K92613113-066-02-7;BRD:BRD-K92613113-066-02-7,rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR, GLUTAMATE INHIBITOR, MONOAMINE OXIDASE INHIBITOR",MAOB,PARKINSON'S DISEASE,,LAUNCHED,"Multiple values for MOA: {'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR, GLUTAMATE INHIBITOR, MONOAMINE OXIDASE INHIBITOR', 'DOPAMINE UPTAKE INHIBITOR, GLUTAMATE INHIBITOR, MONOAMINE OXIDASE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR, GLUTAMATE INHIBITOR, MONOAMINE OXIDASE INHIBITOR'",Small molecule,Approved,NEMGRZFTLSKBAP-LBPRGKRZSA-N,C[C@H](NCC1CCC(OCC2CCCC(F)C2)CC1)C(N)=O
SAFINGOL,SAFINGOL,CHEMBL1442934;CHEMBL448741,BRD:BRD-BRD-K93944989-001-08-0;BRD:BRD-K93944989-001-08-0,rep_primary;rep_single_dose,PKC INHIBITOR,TRPM3,,,PHASE 1,,Small molecule,Phase 1,OTKJDMGTUTTYMP-ROUUACIJSA-N;OTKJDMGTUTTYMP-ZWKOTPCHSA-N,CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO;CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO
SAG,SAG,,BRD:BRD-K99433989-001-02-9,rep_single_dose,SMOOTHENED RECEPTOR AGONIST,SMO;TRPC6,,,,,,NA,,
SAHA,SAHA,,GDSC1:1012;GDSC2:1012,gdsc,,,,,,,,NA,,
SAL003,SAL003,,BRD:BRD-A45869167-001-10-0;BRD:BRD-BRD-A45869167-001-10-0,rep_primary;rep_single_dose,EUKARYOTIC TRANSLATION INITIATION FACTOR INHIBITOR,EIF2A,,,PRECLINICAL,,,NA,,CLC1CCC(CC1)NC(=S)NC(C(CL)(CL)CL)NC(=O)\C=C\C1CCCCC1
SALAZODINE,SALAZODINE,CHEMBL2105427,BRD:BRD-BRD-K15045219-001-01-8;BRD:BRD-K15045219-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,YFUATOCFMCWUEH-FMQUCBEESA-N,COC1CCC(NS(=O)(=O)C2CCC(/N=N/C3CCC(O)C(C(=O)O)C3)CC2)NN1;COC1CCC(NS(=O)(=O)C2CCC(CC2)N=NC2CCC(O)C(C2)C(O)=O)NN1
SALERMIDE,SALERMIDE,CHEMBL597845,CTRP:616352,ctrp,,,,,,,Small molecule,NA,HQSSEGBEYORUBY-WPWMEQJKSA-N,CC(C(=O)NC1CCCC(/N=C/C2C(O)CCC3CCCCC23)C1)C1CCCCC1
SALERMIDE:PLX-4032 (12:1 MOL/MOL),SALERMIDE:PLX-4032 (12:1 MOL/MOL),,CTRP:660269,ctrp,,,,,,,,NA,,
SALICIN,SALICIN,CHEMBL462997,BRD:BRD-BRD-K64614248-001-12-3;BRD:BRD-K64614248-001-12-3,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,PHASE 1,,Small molecule,Unknown,NGFMICBWJRZIBI-UJPOAAIJSA-N,OC[C@H]1O[C@@H](OC2CCCCC2CO)[C@H](O)[C@@H](O)[C@@H]1O;OCC1CCCCC1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
SALICYL-ALCOHOL,SALICYL-ALCOHOL,,BRD:BRD-BRD-K08493205-001-04-9;BRD:BRD-K08493205-001-04-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OCC1CCCCC1O
SALICYLAMIDE,SALICYLAMIDE,CHEMBL27577,BRD:BRD-BRD-K81130846-001-17-4;BRD:BRD-K81130846-001-17-4,rep_primary;rep_single_dose,ANALGESIC AGENT,,"PAIN RELIEF, FEVER",,LAUNCHED,,Small molecule,Unknown,SKZKKFZAGNVIMN-UHFFFAOYSA-N,NC(=O)C1CCCCC1O
SALICYLANILIDE,SALICYLANILIDE,CHEMBL82970,BRD:BRD-BRD-K83036479-001-09-2;BRD:BRD-K83036479-001-09-2,rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,,,PRECLINICAL,,Small molecule,Unknown,WKEDVNSFRWHDNR-UHFFFAOYSA-N,O=C(NC1CCCCC1)C1CCCCC1O;OC1CCCCC1C(=O)NC1CCCCC1
SALICYLIC-ACID,SALICYLIC-ACID,,BRD:BRD-BRD-K93632104-001-17-2,rep_primary,CYCLOOXYGENASE INHIBITOR,AKR1C1;PTGS1;PTGS2,ACNE VULGARIS (AV),,LAUNCHED,,,NA,,OC(=O)C1CCCCC1O
SALIDROSIDE,SALIDROSIDE,CHEMBL465208,BRD:BRD-BRD-K66030860-001-03-6;BRD:BRD-K66030860-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,BETA AMYLOID PROTEIN NEUROTOXICITY INHIBITOR,APP,,,PRECLINICAL,,Small molecule,NA,ILRCGYURZSFMEG-RKQHYHRCSA-N,OC[C@H]1O[C@@H](OCCC2CCC(O)CC2)[C@H](O)[C@@H](O)[C@@H]1O
SALINOMYCIN,SALINOMYCIN,CHEMBL1208572;CHEMBL2104423,BRD:BRD-A28301258-001-03-0;BRD:BRD-A28301258-001-04-8;BRD:BRD-BRD-A28301258-001-03-0;BRD:BRD-BRD-A28301258-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,KQXDHUJYNAXLNZ-XQSDOZFQSA-N;VHKXXVVRRDYCIK-CWCPJSEDSA-N,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C;CC[C@@H](C(=O)O)[C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@](O)(CC)[C@H](C)O5)O4)O3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@@H]1C;CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O
SALIRASIB,SALIRASIB,CHEMBL23293,BRD:BRD-BRD-K98453471-001-01-7;BRD:BRD-K98453471-001-01-7,rep_primary;rep_single_dose,MTOR INHIBITOR,TRPA1,,,PHASE 2,,Small molecule,Phase 2,WUILNKCFCLNXOK-CFBAGHHKSA-N,CC(C)=CCC/C(C)=C/CC/C(C)=C/CSC1CCCCC1C(=O)O;CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1CCCCC1C(O)=O
SALUBRINAL,SALUBRINAL,CHEMBL180127,BRD:BRD-A45107007-001-03-4;BRD:BRD-BRD-A45107007-001-03-4;GDSC1:111,gdsc;rep_primary;rep_single_dose,EUKARYOTIC TRANSLATION INITIATION FACTOR INHIBITOR,EIF2S1,,,PRECLINICAL,,Small molecule,NA,LCOIAYJMPKXARU-VAWYXSNFSA-N,CLC(CL)(CL)C(NC(=O)\C=C\C1CCCCC1)NC(=S)NC1CCCC2CCCNC12;O=C(/C=C/C1CCCCC1)NC(NC(=S)NC1CCCC2CCCNC12)C(CL)(CL)CL
SALVIANOLIC-ACID-A,SALVIANOLIC-ACID-A,,BRD:BRD-K00005247-001-01-9,rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,,,,,,,NA,,
SALVIANOLIC-ACID-B,SALVIANOLIC-ACID-B,,BRD:BRD-BRD-K18898553-001-01-1;BRD:BRD-K18898553-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, METALLOPROTEINASE INHIBITOR",MMP9,,,PHASE 2,"Multiple values for MOA: {'METALLOPROTEINASE INHIBITOR, EGFR INHIBITOR', 'EGFR INHIBITOR, METALLOPROTEINASE INHIBITOR'}, defaulting to 'EGFR INHIBITOR, METALLOPROTEINASE INHIBITOR'",,NA,,OC(=O)[C@@H](CC1CCC(O)C(O)C1)OC(=O)\C=C\C1CCC(O)C2O[C@H]([C@H](C(=O)O[C@H](CC3CCC(O)C(O)C3)C(O)=O)C12)C1CCC(O)C(O)C1
SALVINORIN-A,SALVINORIN-A,,BRD:BRD-BRD-K19284129-001-02-6;BRD:BRD-K19284129-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRD1;OPRK1;OPRM1,,,PHASE 1,,,NA,,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)C1CCOC1
SAM-315,SAM-315,,BRD:BRD-K00004553-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,,NA,,
SAMERIDINE,SAMERIDINE,CHEMBL2104504,BRD:BRD-K00004552-001-01-9,rep_single_dose,OPIOID RECEPTOR MODULATOR,,,,,,Small molecule,Unknown,TYWUGCGYWNSRPS-UHFFFAOYSA-N,CCCCCCN1CCC(C(=O)N(C)CC)(C2CCCCC2)CC1
SANAZOLE,SANAZOLE,,BRD:BRD-BRD-K37747025-001-08-2;BRD:BRD-K37747025-001-08-2,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,COCCNC(=O)CN1CNC(N1)[N+]([O-])=O
SANCYCLINE,SANCYCLINE,CHEMBL2009312,BRD:BRD-K00003242-001-01-9,rep_single_dose,ANTITUMOR AGENT,,,,,,Small molecule,Unknown,XDVCLKFLRAWGIT-ADOAZJKMSA-N,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)C4C(O)CCCC4C[C@H]3C[C@@H]12
SANGIVAMYCIN,SANGIVAMYCIN,CHEMBL101892,BRD:BRD-A64064900-001-02-3;BRD:BRD-BRD-A64064900-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,,,PHASE 1,,Small molecule,NA,OBZJZDHRXBKKTJ-JTFADIMSSA-N,NC(=O)C1CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C2NCNC(N)C12;NC(=O)C1CN(C2OC(CO)[C@H](O)[C@@H]2O)C2NCNC(N)C12
SANGUINARIUM-CHLORIDE,SANGUINARIUM-CHLORIDE,,BRD:BRD-BRD-K66898851-003-03-3;BRD:BRD-K66898851-003-03-3,rep_primary;rep_single_dose,APOPTOSIS STIMULANT,CASP3,,,PHASE 1,,,NA,,C[N+]1CC2C3OCOC3CCC2C2CCC3CC4OCOC4CC3C12
SANT-1,SANT-1,,BRD:BRD-BRD-K99741577-001-01-7;BRD:BRD-K99741577-001-01-7,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,SHH;SMO,,,PRECLINICAL,,,NA,,CC1NN(C(C)C1\C=N\N1CCN(CC2CCCCC2)CC1)-C1CCCCC1
SANT-2,SANT-2,,BRD:BRD-BRD-K35781423-001-01-6;BRD:BRD-K35781423-001-01-6,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,SHH;SMO,,,PRECLINICAL,,,NA,,CCOC1CC(CC(OCC)C1OCC)C(=O)NC1CCC(CL)C(C1)-C1NC2CCCCC2[NH]1
SAPACITABINE,SAPACITABINE,CHEMBL2105681,BRD:BRD-K00003214-001-01-9,rep_single_dose,DNA SYNTHESIS INHIBITOR,,,,,,Small molecule,Phase 3,LBGFKUUHOPIEMA-PEARBKPGSA-N,CCCCCCCCCCCCCCCC(=O)NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)C(=O)N1
SAPITINIB,SAPITINIB,CHEMBL2408045,GDSC2:1549,gdsc,,,,,,,Small molecule,Phase 2,DFJSJLGUIXFDJP-UHFFFAOYSA-N,CNC(=O)CN1CCC(OC2CC3C(NC4CCCC(CL)C4F)NCNC3CC2OC)CC1
SAPROPTERIN,SAPROPTERIN,CHEMBL1201774,BRD:BRD-BRD-K36859431-300-02-3;BRD:BRD-K36859431-300-02-3,rep_primary;rep_single_dose,PHENYLALANINE 4-HYDROXYLASE STIMULANT,NOS3;PAH;TH;TPH1,HYPERPHENYLALANINEMIA (HPA),,LAUNCHED,,Small molecule,Approved,FNKQXYHWGSIFBK-RPDRRWSUSA-N,C[C@H](O)[C@H](O)[C@H]1CNC2NC(N)[NH]C(=O)C2N1;C[C@H](O)[C@H](O)[C@H]1CNC2NC(N)NC(O)C2N1
SAQUINAVIR,SAQUINAVIR,CHEMBL114,BRD:BRD-A26690767-066-01-9;BRD:BRD-BRD-A26690767-066-01-9,rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,CYP3A4,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,QWAXKHKRTORLEM-UGJKXSETSA-N,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC(N)=O)NC(=O)C1CCC2CCCCC2N1;CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@@H](O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC(N)=O)NC(=O)C1CCC2CCCCC2N1
SAR-245409,SAR-245409,CHEMBL3545366,BRD:BRD-BRD-K75308783-001-07-0;BRD:BRD-K75308783-001-07-0,rep_primary;rep_single_dose,PI3K INHIBITOR,MTOR;PIK3CG,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,RGHYDLZMTYDBDT-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC[NH]N2)CC2C(C)NC(N)NC21;COC1CC(NC2NC3CCCCC3NC2NS(=O)(=O)C2CCC(NC(=O)C3CCC(C)C(OC)C3)CC2)CC(OC)C1
SAR-260301,SAR-260301,CHEMBL3545008,BRD:BRD-K00073070-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,,
SAR-302503,SAR-302503,CHEMBL1287853,GDSC1:306,gdsc,,,,,,,Small molecule,Approved,JOOXLOJCABQBSG-UHFFFAOYSA-N,CC1CNC(NC2CCC(OCCN3CCCC3)CC2)NC1NC1CCCC(S(=O)(=O)NC(C)(C)C)C1
SAR125844,SAR125844,CHEMBL3545325,BRD:BRD-K00078317-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,,
SAR131675,SAR131675,,BRD:BRD-BRD-K38904395-001-02-3;BRD:BRD-K38904395-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,FLT4,,,PRECLINICAL,,,NA,,CCN1C(N)C(C(=O)NC)C(=O)C2CCC(NC12)C#C[C@@](C)(O)COC
SAR245409,SAR245409,CHEMBL3545366,GDSC1:375,gdsc,,,,,,,Small molecule,Phase 2,RGHYDLZMTYDBDT-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC[NH]N2)CC2C(C)NC(N)NC21
SAR405,SAR405,,BRD:BRD-BRD-K72868067-001-02-4;BRD:BRD-K72868067-001-02-4,rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3C3,,,PRECLINICAL,,,NA,,C[C@@H]1COCCN1C1CC(=O)N2CC[C@H](N(CC3CNCC(CL)C3)C2N1)C(F)(F)F
SAR405838,SAR405838,CHEMBL2381408,BRD:BRD-A16035238-001-01-7;BRD:BRD-BRD-A16035238-001-01-7,rep_primary;rep_single_dose,MDM INHIBITOR,MDM2,,,PHASE 1,,Small molecule,Phase 1,IDKAKZRYYDCJDU-HBMMIIHUSA-N,CC(C)(C)C[C@@H]1N[C@@H](C(=O)N[C@H]2CC[C@H](O)CC2)[C@H](C2CCCC(CL)C2F)[C@]12C(=O)NC1CC(CL)CCC12;CC(C)(C)C[C@H]1N[C@H]([C@H](C2CCCC(CL)C2F)[C@@]11C(=O)NC2CC(CL)CCC12)C(=O)N[C@H]1CC[C@H](O)CC1;CC(C)(C)CC1NC(C(C2CCCC(CL)C2F)C11C(=O)NC2CC(CL)CCC12)C(=O)NC1CCC(O)CC1
SAR407899,SAR407899,CHEMBL3545341,BRD:BRD-BRD-K56912469-003-02-0;BRD:BRD-K56912469-003-02-0,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1,,,PHASE 2,,Small molecule,Phase 2,KMNVOGVCCZNVNU-UHFFFAOYSA-N,CL.O=C1[NH]CCC2CC(OC3CCNCC3)CCC12;O=C1[NH]CCC2CC(OC3CCNCC3)CCC12
SAR439859,SAR439859,CHEMBL4475463,BRD:BRD-K00091093-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,KISZAGQTIXIVAR-VWLOTQADSA-N,O=C(O)C1CCC2C(C1)CCCC(C1CCC(CL)CC1CL)=C2C1CCC(O[C@H]2CCN(CCCF)C2)CC1
SARACATINIB,SARACATINIB,CHEMBL217092,BRD:BRD-BRD-K19540840-001-09-4;BRD:BRD-K19540840-001-09-4;CTRP:606035;GDSC1:38,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,SRC INHIBITOR,ABL1;LCK;SRC;YES1,,,PHASE 2/PHASE 3,,Small molecule,Phase 3,OUKYUETWWIPKQR-UHFFFAOYSA-N,CN1CCN(CCOC2CC(OC3CCOCC3)C3C(NC4C(CL)CCC5C4OCO5)NCNC3C2)CC1;CN1CCN(CCOC2CC(OC3CCOCC3)C3C(NC4C5OCOC5CCC4CL)NCNC3C2)CC1
SARAFLOXACIN,SARAFLOXACIN,CHEMBL37858,BRD:BRD-BRD-K08525451-003-05-2;BRD:BRD-K08525451-003-05-2,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,,,LAUNCHED,,Small molecule,Unknown,XBHBWNFJWIASRO-UHFFFAOYSA-N,O=C(O)C1CN(-C2CCC(F)CC2)C2CC(N3CCNCC3)C(F)CC2C1=O;OC(=O)C1CN(-C2CCC(F)CC2)C2CC(N3CCNCC3)C(F)CC2C1=O
SARCOSINE,SARCOSINE,CHEMBL304383,BRD:BRD-BRD-K51263939-001-08-6;BRD:BRD-K51263939-001-08-6,rep_primary;rep_single_dose,"GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR",SLC6A9,,,PHASE 2,"Multiple values for MOA: {'GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR', 'GLYCINE TRANSPORTER 1 INHIBITOR'}, defaulting to 'GLYCINE TRANSPORTER 1 INHIBITOR, GLYCINE TRANSPORTER INHIBITOR'",Small molecule,Phase 2,FSYKKLYZXJSNPZ-UHFFFAOYSA-N,CNCC(=O)O;CNCC(O)=O
SARDOMOZIDE,SARDOMOZIDE,CHEMBL65789,BRD:BRD-K00003165-300-01-9,rep_single_dose,S-ADENOSYLMETHIONINE DECARBOXYLASE INHIBITOR,,,,,,Small molecule,Unknown,CYPGNVSXMAUSJY-CXUHLZMHSA-N,N=C(N)C1CCCC2C1CC/C2=N\N=C(N)N
SAREDUTANT,SAREDUTANT,CHEMBL308148,BRD:BRD-K00091297-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,PGKXDIMONUAMFR-AREMUKBSSA-N,CC(=O)NC1(C2CCCCC2)CCN(CC[C@H](CN(C)C(=O)C2CCCCC2)C2CCC(CL)C(CL)C2)CC1
SARI-59-801,SARI-59-801,,BRD:BRD-A92448440-001-01-3;BRD:BRD-BRD-A92448440-001-01-3,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,CCC1NOC(C)C1-C1[NH]C2CCCCC2C1C(O)CN(C)C
SAROGLITAZAR,SAROGLITAZAR,CHEMBL4297530,BRD:BRD-K79878800-239-02-9,rep_single_dose,PPAR RECEPTOR AGONIST,PPARA;PPARG,,,,,Small molecule,Phase 3,MRWFZSLZNUJVQW-DEOSSOPVSA-N,CCO[C@@H](CC1CCC(OCCN2C(C)CCC2-C2CCC(SC)CC2)CC1)C(=O)O
SAROLANER,SAROLANER,CHEMBL3137302,BRD:BRD-K00084848-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,FLEFKKUZMDEUIP-QFIPXVFZSA-N,CS(=O)(=O)CC(=O)N1CC2(C1)OCC1CC(C3=NO[C@@](C4CC(CL)C(F)C(CL)C4)(C(F)(F)F)C3)CCC12
SARPOGRELATE,SARPOGRELATE,CHEMBL52939;CHEMBL541829,BRD:BRD-A34358106-003-01-6;BRD:BRD-BRD-A34358106-003-01-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,"DIABETES MELLITUS, ANGINA PECTORIS, RAYNAUD'S DISEASE, ATHEROSCLEROSIS, BUERGER'S DISEASE",,LAUNCHED,,Small molecule,Phase 3,FFYNAVGJSYHHFO-UHFFFAOYSA-N;POQBIDFFYCYHOB-UHFFFAOYSA-N,COC1CCCC(CCC2CCCCC2OCC(CN(C)C)OC(=O)CCC(=O)O)C1;COC1CCCC(CCC2CCCCC2OCC(CN(C)C)OC(=O)CCC(=O)O)C1.CL;COC1CCCC(CCC2CCCCC2OCC(CN(C)C)OC(=O)CCC(O)=O)C1
SASAPYRINE,SASAPYRINE,CHEMBL154111,BRD:BRD-BRD-K48892307-001-04-1;BRD:BRD-K48892307-001-04-1,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,PTGS1;PTGS2,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS",,LAUNCHED,,Small molecule,Approved,WVYADZUPLLSGPU-UHFFFAOYSA-N,O=C(OC1CCCCC1C(=O)O)C1CCCCC1O;OC(=O)C1CCCCC1OC(=O)C1CCCCC1O
SATRAPLATIN,SATRAPLATIN,CHEMBL3833367,BRD:BRD-BRD-K42497885-001-01-1;BRD:BRD-K42497885-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,,,,PHASE 3,,Small molecule,Phase 3,,CC(=O)O[PT](N)(CL)(CL)(NC1CCCCC1)OC(C)=O;NC1CCCCC1.CC(=O)O[PT+4](C)(C)(CL)(CL)OC(C)=O
VOLITINIB,SAVOLITINIB;VOLITINIB,CHEMBL3334567,BRD:BRD-K98028353-001-02-8;GDSC2:1936,gdsc;oncref_1;rep_multi_dose;rep_single_dose,INHIBITOR OF MET,MET,,,PHASE 2,"Multiple values for MOA: {'INHIBITOR OF MET', 'C-MET INHIBITOR'}, defaulting to 'INHIBITOR OF MET'",Small molecule,Phase 3,XYDNMOZJKOGZLS-NSHDSACASA-N,C[C@@H](C1CCC2NCCN2C1)N1NNC2NCC(-C3CNN(C)C3)NC21;C[C@@H](C1CCC2NCCN2C1)N1NNC2NCC(NC12)-C1CNN(C)C1
SAXAGLIPTIN,SAXAGLIPTIN,CHEMBL2103745;CHEMBL385517,BRD:BRD-A81513827-001-03-6;BRD:BRD-BRD-A81513827-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,AFNTWHMDBNQQPX-NHKADLRUSA-N;QGJUIPDUBHWZPV-SGTAVMJGSA-N,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2;N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2;N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O
SB 216763,SB 216763,,GDSC1:1025;GDSC2:1025,gdsc,,,,,,,,NA,,
SB 505124,SB 505124,,GDSC1:1194;GDSC1:476;GDSC2:1194,gdsc,,,,,,,,NA,,
SB 52334,SB 52334,,GDSC1:304,gdsc,,,,,,,,NA,,
SB-200646,SB-200646,,BRD:BRD-BRD-K77677632-003-02-6;BRD:BRD-K77677632-003-02-6,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2B;HTR2C,,,PRECLINICAL,,,NA,,CN1CCC2CC(NC(=O)NC3CCCNC3)CCC12
SB-202190,SB-202190,CHEMBL278041,BRD:BRD-BRD-K54330070-001-15-4;BRD:BRD-K54330070-001-15-4,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,AKT1;ALOX5;CHEK1;GSK3B;LCK;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;PRKCA;ROCK1;RPS6KB1;SGK1,,,PRECLINICAL,,Small molecule,NA,QHKYPYXTTXKZST-UHFFFAOYSA-N,OC1CCC(-C2NC(-C3CCC(F)CC3)C(-C3CCNCC3)[NH]2)CC1;OC1CCC(CC1)-C1NC(C([NH]1)-C1CCNCC1)-C1CCC(F)CC1
SB-203186,SB-203186,,BRD:BRD-BRD-K27141178-003-07-3;BRD:BRD-K27141178-003-07-3,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR4,,,PRECLINICAL,,,NA,,O=C(OCCN1CCCCC1)C1C[NH]C2CCCCC12
SB-203580,SB-203580,CHEMBL10,BRD:BRD-A37704979-001-10-7;BRD:BRD-BRD-A37704979-001-10-7,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,AKT1;ALOX5;CHEK1;CYP2D6;CYP3A4;GAK;GSK3B;LCK;MAPK1;MAPK10;MAPK11;MAPK12;MAPK14;MAPK8;MAPK9;PRKCA;RAF1;RIPK2;ROCK1;RPS6KB1;SGK1;SRC;TNF,,,PRECLINICAL,,Small molecule,NA,CDMGBJANTYXAIV-UHFFFAOYSA-N,C[S+]([O-])C1CCC(-C2NC(-C3CCC(F)CC3)C(-C3CCNCC3)[NH]2)CC1;CS(=O)C1CCC(CC1)-C1NC(C([NH]1)-C1CCNCC1)-C1CCC(F)CC1
SB-205384,SB-205384,,BRD:BRD-A22707317-001-10-8;BRD:BRD-BRD-A22707317-001-10-8,rep_multi_dose;rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA3;GABRA5;GABRA6,,,PRECLINICAL,,,NA,,CC#CCOC(=O)C1C(C)NC2SC3CC(O)CCC3C2C1N
SB-206553,SB-206553,,BRD:BRD-BRD-K36395411-003-02-2;BRD:BRD-K36395411-003-02-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,,NA,,CN1CCC2CC3N(CCC3CC12)C(=O)NC1CCCNC1
SB-216641,SB-216641,,BRD:BRD-BRD-K30867024-003-03-3;BRD:BRD-K30867024-003-03-3,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,,NA,,COC1CCC(NC(=O)C2CCC(CC2)-C2CCC(CC2C)-C2NOC(C)N2)CC1OCCN(C)C
SB-216763,SB-216763,CHEMBL102714,BRD:BRD-BRD-K59184148-001-21-6;BRD:BRD-K59184148-001-21-6;GDSC1:1025;GDSC2:1025,gdsc;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,CCNA2;CDK2;GSK3A;GSK3B,,,PRECLINICAL,,Small molecule,NA,JCSGFHVFHSKIJH-UHFFFAOYSA-N,CN1CC(C2=C(C(=O)NC2=O)C2CCC(CL)CC2CL)C2CCCCC12;CN1CC(C2=C(C3CCC(CL)CC3CL)C(=O)NC2=O)C2CCCCC21
SB-218078,SB-218078,,BRD:BRD-A06352508-001-03-7;BRD:BRD-BRD-A06352508-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,CHK INHIBITOR,CHEK1,,,PRECLINICAL,,,NA,,O=C1NC(=O)C2C1C1C3CCCCC3N3C4CCC(O4)N4C5CCCCC5C2C4C13
SB-218795,SB-218795,,BRD:BRD-BRD-K61097567-001-08-5;BRD:BRD-K61097567-001-08-5,rep_multi_dose;rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR3,,,PRECLINICAL,,,NA,,COC(=O)[C@H](NC(=O)C1CC(NC2CCCCC12)-C1CCCCC1)C1CCCCC1
SB-221284,SB-221284,,BRD:BRD-BRD-K14807180-001-02-5;BRD:BRD-K14807180-001-02-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,,NA,,CSC1CC2CCN(C(=O)NC3CCCNC3)C2CC1C(F)(F)F
SB-222200,SB-222200,CHEMBL10284,BRD:BRD-BRD-K04414442-001-08-3;BRD:BRD-K04414442-001-08-3,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR3,,,PRECLINICAL,,Small molecule,NA,MQNYRKWJSMQECI-QFIPXVFZSA-N,CC[C@H](NC(=O)C1C(C)C(-C2CCCCC2)NC2CCCCC12)C1CCCCC1;CC[C@H](NC(=O)C1C(C)C(NC2CCCCC12)-C1CCCCC1)C1CCCCC1
SB-225002,SB-225002,,BRD:BRD-BRD-K61323504-001-04-0;BRD:BRD-K61323504-001-04-0;CTRP:52123,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR2,,,PRECLINICAL,,,NA,,OC1CC(CCC1NC(=O)NC1CCCCC1BR)[N+]([O-])=O
SB-228357,SB-228357,,BRD:BRD-BRD-K15424032-001-03-6;BRD:BRD-K15424032-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,PRECLINICAL,,,NA,,COC1CC2CCN(C(=O)NC3CC(F)CC(C3)-C3CCCNC3)C2CC1C(F)(F)F
SB-2343,SB-2343,,BRD:BRD-BRD-K98795921-001-01-7;BRD:BRD-K98795921-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR;PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 1,,,NA,,CC(C)N1C(C)NC2C(NC(NC12)N1CCOCC1)-C1CNC(N)NC1
SB-239063,SB-239063,,BRD:BRD-BRD-K82091397-001-03-0;BRD:BRD-K82091397-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK11;MAPK14;PTGS2,,,PRECLINICAL,,,NA,,COC1NCCC(N1)-C1C(NCN1[C@H]1CC[C@H](O)CC1)-C1CCC(F)CC1
SB-242235,SB-242235,CHEMBL95692,BRD:BRD-BRD-K19412355-001-01-0;BRD:BRD-K19412355-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,HSPB1;MAPK14,,,PHASE 1,,Small molecule,NA,PDTYLGXVBIWRIM-UHFFFAOYSA-N,COC1NCCC(-C2C(-C3CCC(F)CC3)NCN2C2CCNCC2)N1;COC1NCCC(N1)-C1C(NCN1C1CCNCC1)-C1CCC(F)CC1
SB-243213,SB-243213,CHEMBL14460,BRD:BRD-BRD-K99968849-300-01-4;BRD:BRD-K99968849-300-01-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR INVERSE AGONIST,HTR2A;HTR2B;HTR2C;HTR6,,,PHASE 1,,Small molecule,NA,ZETBBVYSBABLHL-UHFFFAOYSA-N,CC1CC2C(CC1C(F)(F)F)N(C(=O)NC1CCC(OC3CCCNC3C)NC1)CC2;CC1CC2CCN(C(=O)NC3CCC(OC4CCCNC4C)NC3)C2CC1C(F)(F)F
SB-258585,SB-258585,,BRD:BRD-BRD-K80639402-003-02-9;BRD:BRD-K80639402-003-02-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR6,,,PRECLINICAL,,,NA,,COC1CCC(NS(=O)(=O)C2CCC(I)CC2)CC1N1CCN(C)CC1
SB-268262,SB-268262,,BRD:BRD-A91031770-001-01-8;BRD:BRD-BRD-A91031770-001-01-8,rep_primary;rep_single_dose,CALCITONIN ANTAGONIST,CALCA,,,PRECLINICAL,,,NA,,CN(C(=O)C1CCC(C(C1)[N+]([O-])=O)S(=O)C1NCCS1)C1CCCCC1C
SB-269970,SB-269970,,BRD:BRD-BRD-K24201553-003-11-5;BRD:BRD-K24201553-003-11-5,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR7,,,PRECLINICAL,,,NA,,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)C2CCCC(O)C2)CC1
SB-271046,SB-271046,,BRD:BRD-BRD-K82467063-001-02-7;BRD:BRD-K82467063-001-02-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR6,,,PHASE 1,,,NA,,COC1CCC(NS(=O)(=O)C2SC3CCC(CL)CC3C2C)CC1N1CCNCC1
SB-297006,SB-297006,,BRD:BRD-K16107558-001-02-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR3,,,,,,NA,,
SB-328437,SB-328437,,BRD:BRD-BRD-K78720403-001-01-6;BRD:BRD-K78720403-001-01-6,rep_primary;rep_single_dose,CCR ANTAGONIST,,,,PRECLINICAL,,,NA,,COC(=O)[C@H](CC1CCC(CC1)[N+]([O-])=O)NC(=O)C1CCCC2CCCCC12
SB-334867,SB-334867,,BRD:BRD-BRD-K41567364-001-04-6;BRD:BRD-K41567364-001-04-6,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,PRECLINICAL,,,NA,,CC1NC2CCC(NC(=O)NC3CCNC4CCCNC34)CC2O1
SB-366791,SB-366791,,BRD:BRD-BRD-K61536336-001-01-7;BRD:BRD-K61536336-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PRECLINICAL,,,NA,,COC1CCCC(NC(=O)\C=C\C2CCC(CL)CC2)C1
SB-399885,SB-399885,CHEMBL1210710,BRD:BRD-BRD-K03988082-001-01-7;BRD:BRD-K03988082-001-01-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR6,,,PRECLINICAL,,Small molecule,NA,ATKZKAYWARYLBW-UHFFFAOYSA-N,COC1CCC(CC1N1CCNCC1)S(=O)(=O)NC1CC(CL)CC(CL)C1OC;COC1CCC(S(=O)(=O)NC2CC(CL)CC(CL)C2OC)CC1N1CCNCC1
SB-408124,SB-408124,,BRD:BRD-BRD-K53913732-001-05-9;BRD:BRD-K53913732-001-05-9,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,,,PRECLINICAL,,,NA,,CN(C)C1CCC(NC(=O)NC2CC(C)NC3C(F)CC(F)CC23)CC1
SB-415286,SB-415286,,BRD:BRD-BRD-K76805682-001-15-9;BRD:BRD-K76805682-001-15-9,rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3A;GSK3B;RPS6KB1,,,PRECLINICAL,,,NA,,OC1CCC(NC2=C(C(=O)NC2=O)C2CCCCC2[N+]([O-])=O)CC1CL
SB-431542,SB-431542,CHEMBL440084,BRD:BRD-BRD-K67298865-001-09-0;BRD:BRD-K67298865-001-09-0;CTRP:50753,ctrp;rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,ACVR1C;TGFBR1,,,PRECLINICAL,,Small molecule,NA,FHYUGAJXYORMHI-UHFFFAOYSA-N,NC(=O)C1CCC(-C2NC(-C3CCCCN3)C(-C3CCC4C(C3)OCO4)[NH]2)CC1;NC(=O)C1CCC(CC1)-C1NC(C([NH]1)-C1CCCCN1)-C1CCC2OCOC2C1
SB-452533,SB-452533,,BRD:BRD-K03665769-001-02-9,rep_single_dose,TRPV ANTAGONIST,TRPV1,,,,,,NA,,
SB-505124,SB-505124,,BRD:BRD-BRD-K40109029-001-02-9;BRD:BRD-K40109029-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,ALK TYROSINE KINASE RECEPTOR INHIBITOR,TGFBR1,,,PRECLINICAL,,,NA,,CC1CCCC(N1)-C1[NH]C(NC1-C1CCC2OCOC2C1)C(C)(C)C
SB-52334,SB-52334,,GDSC1:304,gdsc,,,,,,,,NA,,
SB-525334,SB-525334,,BRD:BRD-BRD-K37720887-001-07-8;BRD:BRD-K37720887-001-07-8;CTRP:639962,ctrp;rep_multi_dose;rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFBR1,,,PRECLINICAL,,,NA,,CC1CCCC(N1)-C1[NH]C(NC1-C1CCC2NCCNC2C1)C(C)(C)C
SB-590885,SB-590885,CHEMBL477989,BRD:BRD-BRD-K78809024-001-05-7;BRD:BRD-K78809024-001-05-7;GDSC1:1061,gdsc;rep_multi_dose;rep_primary;rep_single_dose,RAF INHIBITOR,BRAF,,,PRECLINICAL,,Small molecule,NA,MLSAQOINCGAULQ-QFMPWRQOSA-N,CN(C)CCOC1CCC(-C2NC(-C3CCNCC3)C(-C3CCC4C(C3)CC/C4=N\O)[NH]2)CC1;CN(C)CCOC1CCC(CC1)-C1NC(C([NH]1)-C1CCC2C(CC\C2=N/O)C1)-C1CCNCC1
SB-612111,SB-612111,,BRD:BRD-K08333979-003-02-9,rep_single_dose,NOCICEPTIN/ORPHANIN FQ RECEPTOR ANTAGONIST,OPRL1,,,,,,NA,,
SB-649868,SB-649868,CHEMBL1272307,BRD:BRD-K00003485-001-01-9,rep_single_dose,OREXIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,ZJXIUGNEAIHSBI-IBGZPJMESA-N,CC1NC(C(=O)N2CCCC[C@H]2CNC(=O)C2CCCC3OCCC23)C(-C2CCC(F)CC2)S1
SB-657510,SB-657510,,BRD:BRD-BRD-K95292280-001-01-3;BRD:BRD-K95292280-001-01-3,rep_multi_dose;rep_primary;rep_single_dose,UROTENSIN RECEPTOR ANTAGONIST,UTS2R,,,PRECLINICAL,,,NA,,COC1CC(BR)C(CC1OC)S(=O)(=O)NC1CCC(CL)C(O[C@@H]2CCN(C)C2)C1
SB-683698,SB-683698,,BRD:BRD-BRD-K24968862-001-01-0;BRD:BRD-K24968862-001-01-0,rep_primary;rep_single_dose,INTEGRIN ANTAGONIST,ITGA4;ITGAV;ITGB1;ITGB7,,,PHASE 1,,,NA,,COC1CCCC(OC)C1-C1CCC(C[C@H](NC(=O)C2C(CL)CCCC2CL)C(O)=O)CC1
SB-705498,SB-705498,CHEMBL207433,BRD:BRD-BRD-K65991129-001-02-9;BRD:BRD-K65991129-001-02-9,rep_primary;rep_single_dose,TRPV ANTAGONIST,TRPV1,,,PHASE 2,,Small molecule,Phase 2,JYILLRHXRVTRSH-GFCCVEGCSA-N,FC(F)(F)C1CCC(NC1)N1CC[C@H](C1)NC(=O)NC1CCCCC1BR;O=C(NC1CCCCC1BR)N[C@@H]1CCN(C2CCC(C(F)(F)F)CN2)C1
SB-706375,SB-706375,,BRD:BRD-BRD-K68633027-001-01-9;BRD:BRD-K68633027-001-01-9,rep_primary;rep_single_dose,UROTENSIN RECEPTOR ANTAGONIST,UTS2R,,,PRECLINICAL,,,NA,,COC1CC(BR)C(CC1OC)S(=O)(=O)NC1CCC(C(O[C@@H]2CCN(C)C2)C1)C(F)(F)F
SB-742457,SB-742457,CHEMBL1083390,BRD:BRD-BRD-K78941306-001-02-4;BRD:BRD-K78941306-001-02-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR6,,,PHASE 3,,Small molecule,Phase 3,JJZFWROHYSMCMU-UHFFFAOYSA-N,O=S(=O)(C1CCCCC1)C1CNC2C(CCCC2C1)N1CCNCC1;O=S(=O)(C1CCCCC1)C1CNC2C(N3CCNCC3)CCCC2C1
SB-743921,SB-743921,CHEMBL2325429,BRD:BRD-BRD-K68532323-003-02-8;BRD:BRD-K68532323-003-02-8;CTRP:660238,ctrp;rep_multi_dose;rep_primary;rep_single_dose,KINESIN-LIKE SPINDLE PROTEIN INHIBITOR,KIF11,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,PGXYIBJJCLWJST-MUUNZHRXSA-N,CC(C)[C@@H](N(CCCN)C(=O)C1CCC(C)CC1)C1OC2CC(CL)CCC2C(=O)C1CC1CCCCC1;CC1CCC(C(=O)N(CCCN)[C@@H](C2OC3CC(CL)CCC3C(=O)C2CC2CCCCC2)C(C)C)CC1
SB-747651A,SB-747651A,,BRD:BRD-BRD-K49597925-300-01-9;BRD:BRD-K49597925-300-01-9,rep_primary;rep_single_dose,KINASE INHIBITOR,AKT1;AKT3;ROCK1;RPS6KA5;RPS6KB1,,,PRECLINICAL,,,NA,,CCN1C(NC2CNCC(CNC3CCNCC3)C12)-C1NONC1N
SB-756050,SB-756050,CHEMBL4303545,BRD:BRD-BRD-K45168550-001-01-9;BRD:BRD-K45168550-001-01-9,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPBAR1,,,PHASE 1,,Small molecule,Phase 1,GJUFPAZNBPFNRI-UHFFFAOYSA-N,COC1CCC(CC1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)C1CCC(OC)C(OC)C1;COC1CCC(S(=O)(=O)N2CCCN(S(=O)(=O)C3CCC(OC)C(OC)C3)CC2)CC1OC
SB-772077B,SB-772077B,,BRD:BRD-BRD-K49110935-300-01-9;BRD:BRD-K49110935-300-01-9,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1;ROCK2,,,PRECLINICAL,,,NA,,CCN1C(NC2CNCC(C(=O)N3CC[C@H](N)C3)C12)-C1NONC1N
SB-939,SB-939,CHEMBL1851943,BRD:BRD-BRD-K86797399-001-04-4;BRD:BRD-BRD-K86797399-001-05-1;BRD:BRD-K86797399-001-04-4;BRD:BRD-K86797399-001-05-1,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC10;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC9,,,PHASE 2,"Multiple values for repurposing_target: {'HDAC1;HDAC10;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC9', 'HDAC1;HDAC10;HDAC3;HDAC4;HDAC5;HDAC9'}, taking the union",Small molecule,Phase 3,JHDKZFFAIZKUCU-ZRDIBKRKSA-N,CCCCC1NC2CC(/C=C/C(=O)NO)CCC2N1CCN(CC)CC;CCCCC1NC2CC(CCC2N1CCN(CC)CC)\C=C\C(=O)NO
SB216763,SB216763,,GDSC1:1025;GDSC2:1025,gdsc,,,,,,,,NA,,
SB505124,SB505124,,GDSC1:1194;GDSC1:476;GDSC2:1194,gdsc,,,,,,,,NA,,
SB52334,SB52334,,GDSC1:304,gdsc,,,,,,,,NA,,
SB590885,SB590885,CHEMBL477989,GDSC1:1061,gdsc,,,,,,,Small molecule,NA,MLSAQOINCGAULQ-QFMPWRQOSA-N,CN(C)CCOC1CCC(-C2NC(-C3CCNCC3)C(-C3CCC4C(C3)CC/C4=N\O)[NH]2)CC1
SBE-13,SBE-13,,BRD:BRD-BRD-K71667152-003-09-8;BRD:BRD-K71667152-003-09-8,rep_primary;rep_single_dose,PLK INHIBITOR,PLK1,,,PRECLINICAL,,,NA,,COC1CCC(CCNCC2CCC(OCC3CCC(CL)NC3)C(OC)C2)CC1OC
SBHA,SBHA,,BRD:BRD-K54729176-001-03-9,rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC3,,,,,,NA,,
SBI-115,SBI-115,,BRD:BRD-K00005340-001-01-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR ANTAGONIST,,,,,,,NA,,
SC-10,SC-10,,BRD:BRD-BRD-K05361803-001-03-9;BRD:BRD-K05361803-001-03-9,rep_primary;rep_single_dose,PROTEIN KINASE ACTIVATOR,PRKCA,,,PRECLINICAL,,,NA,,CCCCCCCNS(=O)(=O)C1CCCC2C(CL)CCCC12
SC-12267,SC-12267,CHEMBL197194,BRD:BRD-BRD-K40797222-001-01-8;BRD:BRD-K40797222-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,DIHYDROOROTATE DEHYDROGENASE INHIBITOR,IL17A,,,PHASE 2,,Small molecule,Phase 3,XPRDUGXOWVXZLL-UHFFFAOYSA-N,COC1CCCC(-C2CCC(NC(=O)C3=C(C(=O)O)CCC3)C(F)C2)C1;COC1CCCC(C1)-C1CCC(NC(=O)C2=C(CCC2)C(O)=O)C(F)C1
SC-144,SC-144,,BRD:BRD-BRD-K55305701-001-01-2;BRD:BRD-K55305701-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,P GLYCOPROTEIN INHIBITOR,,,,PRECLINICAL,,,NA,,FC1CCC2C(C1)NC(NNC(=O)C1CNCCN1)C1CCCN21
SC-19220,SC-19220,,BRD:BRD-BRD-K52512893-001-08-9;BRD:BRD-K52512893-001-08-9,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER1,,,PRECLINICAL,,,NA,,CC(=O)NNC(=O)N1CC2CCCCC2OC2CCC(CL)CC12
SC-236,SC-236,,BRD:BRD-BRD-K76365178-001-01-5;BRD:BRD-K76365178-001-01-5,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS2,,,PRECLINICAL,,,NA,,NS(=O)(=O)C1CCC(CC1)-N1NC(CC1-C1CCC(CL)CC1)C(F)(F)F
SC-51089,SC-51089,,BRD:BRD-K62715847-003-02-9,rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,PTGER1,,,,,,NA,,
SC-560,SC-560,CHEMBL26915,BRD:BRD-BRD-K14767410-001-02-3;BRD:BRD-K14767410-001-02-3,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1,,,PRECLINICAL,,Small molecule,NA,PQUGCKBLVKJMNT-UHFFFAOYSA-N,COC1CCC(-N2NC(C(F)(F)F)CC2-C2CCC(CL)CC2)CC1;COC1CCC(CC1)-N1NC(CC1-C1CCC(CL)CC1)C(F)(F)F
SC-9,SC-9,,BRD:BRD-BRD-K25875056-001-02-0;BRD:BRD-K25875056-001-02-0,rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE ACTIVATOR,PRKCA,,,PRECLINICAL,,,NA,,CLC1CCCC2C(CCCC12)S(=O)(=O)NCCCCCCC1CCCCC1
SC79,SC79,,BRD:BRD-K00126778-001-01-9,oncref_2,ACTIVATOR OF AKT,AKT1;AKT2;AKT3,,,,,,NA,,
SCABERTOPIN,SCABERTOPIN,,BRD:BRD-K00005327-001-01-9,rep_single_dose,ANTICANCER AGENT,,,,,,,NA,,
SCH 52365,SCH 52365,CHEMBL810,GDSC1:1375;GDSC2:1375,gdsc,,,,,,,Small molecule,Approved,BPEGJWRSRHCHSN-UHFFFAOYSA-N,CN1NNC2C(C(N)=O)NCN2C1=O
SCH 727965,SCH 727965,CHEMBL2103840,GDSC2:1180,gdsc,,,,,,,Small molecule,Phase 3,PIMQWRZWLQKKBJ-SFHVURJKSA-N,CCC1CNN2C(NCC3CCC[N+]([O-])C3)CC(N3CCCC[C@H]3CCO)NC12
SCH-202676,SCH-202676,,BRD:BRD-K29562203-004-12-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR MODULATOR,CHRM1;CHRM2;DRD1;DRD2,,,,,,NA,,
SCH-221510,SCH-221510,,BRD:BRD-K00004286-001-01-9,rep_single_dose,NOCICEPTIN/ORPHANIN FQ RECEPTOR AGONIST,OPRL1,,,,,,NA,,
SCH-23390,SCH-23390,CHEMBL62,BRD:BRD-BRD-K45435259-003-11-1;BRD:BRD-K45435259-003-11-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD5;HTR2C;KCNJ4;KCNJ6,,,PRECLINICAL,,Small molecule,NA,GOTMKOSCLKVOGG-OAHLLOKOSA-N,CN1CCC2CC(CL)C(O)CC2[C@@H](C2CCCCC2)C1;CN1CCC2CC(CL)C(O)CC2[C@H](C1)C1CCCCC1
SCH-28080,SCH-28080,,BRD:BRD-BRD-K55748775-001-02-2;BRD:BRD-K55748775-001-02-2,rep_primary;rep_single_dose,ATPASE INHIBITOR,ATP4A,,,PHASE 1,,,NA,,CC1NC2C(OCC3CCCCC3)CCCN2C1CC#N
SCH-51344,SCH-51344,,BRD:BRD-K02460719-001-02-9,rep_single_dose,MTH1 INHIBITOR,NUDT1,,,,,,NA,,
SCH-529074,SCH-529074,,CTRP:609062,ctrp,,,,,,,,NA,,
SCH-58261,SCH-58261,CHEMBL17127,BRD:BRD-BRD-K81225797-001-02-3;BRD:BRD-K81225797-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,Small molecule,NA,UTLPKQYUXOEJIL-UHFFFAOYSA-N,NC1NC2C(CNN2CCC2CCCCC2)C2NC(-C3CCCO3)NN12;NC1NC2N(CCC3CCCCC3)NCC2C2NC(NN12)-C1CCCO1
SCH-727-965,SCH-727-965,,GDSC2:1180,gdsc,,,,,,,,NA,,
SCH-79797,SCH-79797,,CTRP:375264,ctrp,,,,,,,,NA,,
SCH-900776,SCH-900776,CHEMBL2386889,BRD:BRD-BRD-K75009076-001-02-1;BRD:BRD-K75009076-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,CHK INHIBITOR,CDK2;CHEK1,,,PHASE 2,,Small molecule,Phase 2,GMIZZEXBPRLVIV-SECBINFHSA-N,CN1CC(-C2CNN3C(N)C(BR)C([C@@H]4CCCNC4)NC23)CN1;CN1CC(CN1)-C1CNN2C(N)C(BR)C(NC12)[C@@H]1CCCNC1
SCH727965,SCH727965,,GDSC2:1180,gdsc,,,,,,,,NA,,
SCH772984,SCH772984,,GDSC2:1564,gdsc,,,,,,,,NA,,
SCH900776,SCH900776,,GDSC2:2046,gdsc,,,,,,,,NA,,
SCHISANDRIN-B,SCHISANDRIN-B,,BRD:BRD-BRD-K86294588-001-01-9;BRD:BRD-K86294588-001-01-9,rep_primary;rep_single_dose,ANTIOXIDANT,ATR,,,PRECLINICAL,,,NA,,COC1CC2C[C@H](C)[C@@H](C)CC3CC4OCOC4C(OC)C3-C2C(OC)C1OC
SCHISANDROL-B,SCHISANDROL-B,,BRD:BRD-BRD-K18878288-001-06-4;BRD:BRD-K18878288-001-06-4,rep_primary;rep_single_dose,LIPID PEROXIDASE INHIBITOR,,,,PHASE 3,,,NA,,COC1CC2C[C@](C)(O)[C@@H](C)CC3CC4OCOC4C(OC)C3-C2C(OC)C1OC
SCLAREOL,SCLAREOL,CHEMBL294740,BRD:BRD-A23127772-001-02-3;BRD:BRD-BRD-A23127772-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,XVULBTBTFGYVRC-HHUCQEJWSA-N,C=C[C@](C)(O)CC[C@@H]1[C@@]2(C)CCCC(C)(C)[C@@H]2CC[C@@]1(C)O;CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C
SCLAREOLIDE,SCLAREOLIDE,,BRD:BRD-BRD-K72925150-001-11-1;BRD:BRD-K72925150-001-11-1,rep_primary;rep_single_dose,OTHER ANTIFUNGAL,,,,LAUNCHED,,,NA,,C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2
SCMC-LYS,SCMC-LYS,,BRD:BRD-BRD-K33809398-001-01-8;BRD:BRD-K33809398-001-01-8,rep_primary;rep_single_dose,MUCOLYTIC AGENT,GSTP1,,,LAUNCHED,,,NA,,N[C@@H](CSCC(O)=O)C(O)=O
SCOPINE,SCOPINE,,BRD:BRD-BRD-K75923785-003-02-1;BRD:BRD-K75923785-003-02-1,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21
SCOPOLAMINE,SCOPOLAMINE,CHEMBL1187846;CHEMBL569713,BRD:BRD-BRD-K64990126-004-01-1;BRD:BRD-K64990126-004-01-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,"MOTION SICKNESS, VOMITING, NAUSEA",,LAUNCHED,,Small molecule,Approved,STECJAGHUSJQJN-FWXGHANASA-N;STECJAGHUSJQJN-ODICJLLRSA-N,CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@H]1[C@@H]1O[C@@H]12;CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)C3CCCCC3)C[C@H]1[C@@H]1O[C@H]12;CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1CCCCC1;CN1[C@H]2C[C@H](C[C@@H]1[C@@H]1O[C@H]21)OC(=O)[C@H](CO)C1CCCCC1
SCOPOLAMINE-N-OXIDE,SCOPOLAMINE-N-OXIDE,,BRD:BRD-A49906757-004-09-8;BRD:BRD-BRD-A49906757-004-09-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;SI,,,PRECLINICAL,,,NA,,C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1CCCCC1
SCP-1,SCP-1,,BRD:BRD-BRD-K20548681-001-01-3;BRD:BRD-K20548681-001-01-3,rep_primary;rep_single_dose,ANALGESIC AGENT,,,,PHASE 1,,,NA,,OC1CCC(NC(=O)CN2C(=O)C3CCCCC3S2(=O)=O)CC1
SCRIPTAID,SCRIPTAID,CHEMBL96051,BRD:BRD-BRD-K22503835-001-11-0;BRD:BRD-K22503835-001-11-0,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9,,,PRECLINICAL,,Small molecule,NA,JTDYUFSDZATMKU-UHFFFAOYSA-N,O=C(CCCCCN1C(=O)C2CCCC3CCCC(C23)C1=O)NO;ONC(=O)CCCCCN1C(=O)C2CCCC3CCCC(C1=O)C23
SCS,SCS,,BRD:BRD-BRD-K78496197-001-03-9;BRD:BRD-K78496197-001-03-9,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC1CCCCC1\C=N\NC(=O)C1CCCCC1O
SD-0006,SD-0006,CHEMBL1090173,BRD:BRD-K00003093-001-01-9,rep_single_dose,P38 MAPK INHIBITOR,,,,,,Small molecule,Phase 1,CATQHDWESBRRQA-UHFFFAOYSA-N,O=C(CO)N1CCC(C2N[NH]C(-C3CCC(CL)CC3)C2-C2CCNCN2)CC1
SD-169,SD-169,,BRD:BRD-BRD-K91904471-001-02-4;BRD:BRD-K91904471-001-02-4,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PRECLINICAL,,,NA,,NC(=O)C1CCC2[NH]CCC2C1
SD-208,SD-208,,BRD:BRD-BRD-K24566386-001-01-9;BRD:BRD-K24566386-001-01-9,rep_primary;rep_single_dose,TGF BETA RECEPTOR INHIBITOR,TGFBR1,,,PRECLINICAL,,,NA,,FC1CCC(CL)CC1-C1NC(NC2CCNCC2)C2NCCNC2N1
SD-2590,SD-2590,,BRD:BRD-K51102532-003-02-9,rep_single_dose,MATRIX METALLOPROTEASE INHIBITOR,MMP1;MMP13;MMP2,,,,,,NA,,
SDM25N,SDM25N,,BRD:BRD-A75769826-003-02-1;BRD:BRD-BRD-A75769826-003-02-1,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,OPRD1,,,PRECLINICAL,,,NA,,CC(=C)CN1CC[C@@]23[C@H]4OC5C2C(CC1[C@]3(O)CC1C4[NH]C2CCCCC12)CCC5O
SDZ-205-557,SDZ-205-557,,BRD:BRD-BRD-K15868788-003-07-7;BRD:BRD-K15868788-003-07-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A;HTR3B,,,PRECLINICAL,,,NA,,CCN(CC)CCOC(=O)C1CC(CL)C(N)CC1OC
SDZ-21009,SDZ-21009,,BRD:BRD-A15530910-001-02-1;BRD:BRD-BRD-A15530910-001-02-1,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR1A;HTR1B,,,PRECLINICAL,,,NA,,CC(C)OC(=O)C1CC2C(OCC(O)CNC(C)(C)C)CCCC2[NH]1
SDZ-220-040,SDZ-220-040,,BRD:BRD-K82266792-001-03-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,,,,,,NA,,
SDZ-220-581,SDZ-220-581,,BRD:BRD-BRD-K27168049-001-02-8;BRD:BRD-K27168049-001-02-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN1,,,PRECLINICAL,,,NA,,N[C@@H](CC1CC(CP(O)(O)=O)CC(C1)-C1CCCCC1CL)C(O)=O
SDZ-MKS 492,SDZ-MKS 492,,BRD:BRD-K00076721-001-02-9,rep_single_dose,,,,,,,,NA,,
SDZ-NKT-343,SDZ-NKT-343,,BRD:BRD-BRD-K65820248-001-01-8;BRD:BRD-K65820248-001-01-8,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR1,,,PHASE 1,,,NA,,CN(CC1CCCCC1)C(=O)[C@H](CC1CCC2CCCCC2C1)NC(=O)[C@@H]1CCCN1C(=O)NC1CCCCC1[N+]([O-])=O
SDZ-SER-082,SDZ-SER-082,,BRD:BRD-K31339597-051-03-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C,,,,,,NA,,
SDZ-WAG-994,SDZ-WAG-994,,BRD:BRD-BRD-K39558284-001-01-2;BRD:BRD-K39558284-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,,,PHASE 2,,,NA,,CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1CNC2C(NC3CCCCC3)NCNC12
SE-METHYLSELENOCYSTEINE,SE-METHYLSELENOCYSTEINE,CHEMBL62382,BRD:BRD-BRD-K74227499-001-01-1;BRD:BRD-K74227499-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Phase 1,XDSSPSLGNGIIHP-VKHMYHEASA-N,C[SE]C[C@H](N)C(=O)O;C[SE]C[C@H](N)C(O)=O
SECALCIFEROL,SECALCIFEROL,CHEMBL1590076,BRD:BRD-BRD-K02965577-001-03-4;BRD:BRD-K02965577-001-03-4,rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,BONE FRACTURE,,LAUNCHED,,Small molecule,Unknown,FCKJYANJHNLEEP-XRWYNYHCSA-N,C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C;C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(C)O)CC[C@@H]12
SECLAZONE,SECLAZONE,CHEMBL2105593,BRD:BRD-A53472930-001-01-7;BRD:BRD-BRD-A53472930-001-01-7,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,PHASE 1,,Small molecule,Unknown,XWXVKXXKKLBDDJ-UHFFFAOYSA-N,CLC1CCC2OC3CCON3C(=O)C2C1;O=C1C2CC(CL)CCC2OC2CCON12
SECLIDEMSTAT,SECLIDEMSTAT,CHEMBL4297641,BRD:BRD-K00003454-001-01-9,rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,,,,,,Small molecule,Phase 1,MVSQDUZRRVBYLA-HYARGMPZSA-N,C/C(=N\NC(=O)C1CCCC(S(=O)(=O)N2CCN(C)CC2)C1)C1CC(CL)CCC1O
SECNIDAZOLE,SECNIDAZOLE,CHEMBL498847,BRD:BRD-A70083328-001-23-5;BRD:BRD-A70083328-001-24-3;BRD:BRD-BRD-A70083328-001-23-5;BRD:BRD-BRD-A70083328-001-24-3,rep_multi_dose;rep_primary;rep_single_dose,"ACETYLCHOLINESTERASE INHIBITOR, MICROTUBULE INHIBITOR",,PROTOZOAN INFECTION,,LAUNCHED,,Small molecule,Approved,KPQZUUQMTUIKBP-UHFFFAOYSA-N,CC(O)CN1C(C)NCC1[N+]([O-])=O;CC1NCC([N+](=O)[O-])N1CC(C)O
SECOISOLARICIRESINOL-(-),SECOISOLARICIRESINOL-(-),,BRD:BRD-BRD-K91733562-001-05-0;BRD:BRD-K91733562-001-05-0,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CC(C[C@@H](CO)[C@H](CO)CC2CCC(O)C(OC)C2)CCC1O
SECOISOLARICIRESINOL-DIGLUCOSIDE,SECOISOLARICIRESINOL-DIGLUCOSIDE,,BRD:BRD-BRD-K77320845-001-01-2;BRD:BRD-K77320845-001-01-2,rep_primary;rep_single_dose,ANTIOXIDANT,,,,PHASE 2,,,NA,,COC1CC(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC2CCC(O)C(OC)C2)CCC1O
SECURININE,SECURININE,CHEMBL303062,BRD:BRD-BRD-K49071277-001-04-7;BRD:BRD-K49071277-001-04-7,rep_multi_dose;rep_primary;rep_single_dose,"GABA RECEPTOR ANTAGONIST, TP53 ACTIVATOR",GABRA1,,,PRECLINICAL,,Small molecule,Unknown,SWZMSZQQJRKFBP-WZRBSPASSA-N,O=C1C=C2C=C[C@@H]3C[C@@]2(O1)[C@H]1CCCCN31;O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31
SEGESTERONE-ACETATE,SEGESTERONE-ACETATE,,BRD:BRD-K00003150-001-01-9,rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,,,,,,NA,,
SEL120-34A (MONOHYDROCHLORIDE),SEL120-34A (MONOHYDROCHLORIDE),,BRD:BRD-K00091121-003-01-9,rep_single_dose,,,,,,,,NA,,
SELADELPAR,SELADELPAR,CHEMBL230158,BRD:BRD-K00003284-236-01-9,rep_single_dose,PPAR RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,JWHYSEDOYMYMNM-QGZVFWFLSA-N,CCO[C@H](COC1CCC(C(F)(F)F)CC1)CSC1CCC(OCC(=O)O)C(C)C1
SELAMECTIN,SELAMECTIN,CHEMBL1908325,BRD:BRD-A58564983-001-04-6;BRD:BRD-BRD-A58564983-001-04-6,rep_multi_dose;rep_primary;rep_single_dose,NEMATOCIDE,,FLEA CONTROL,,LAUNCHED,,Small molecule,Unknown,AFJYYKSVHJGXSN-XHKIUTQPSA-N,CO[C@H]1C[C@H](O[C@@H]2/C(C)=C/C[C@@H]3C[C@@H](C[C@]4(CC[C@H](C)[C@@H](C5CCCCC5)O4)O3)OC(=O)[C@@H]3C=C(C)/C(=N/O)[C@H]4OC/C(=C\C=C\[C@@H]2C)[C@]43O)O[C@@H](C)[C@@H]1O;CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O
SELEGILINE,SELEGILINE,CHEMBL972,BRD:BRD-A28545468-003-16-6;BRD:BRD-BRD-A28545468-003-16-6,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,PARKINSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,MEZLKOACVSPNER-GFCCVEGCSA-N,C#CCN(C)[C@H](C)CC1CCCCC1;CC(CC1CCCCC1)N(C)CC#C
SELENOMETHIONINE,SELENOMETHIONINE,CHEMBL113178;CHEMBL1201054,BRD:BRD-BRD-K74664543-213-01-2;BRD:BRD-K74664543-213-01-2,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,RJFAYQIBOAGBLC-BYPYZUCNSA-N;RJFAYQIBOAGBLC-ZEMBQCNESA-N,C[75SE]CC[C@H](N)C(=O)O;C[SE]CC[C@H](N)C(=O)O;C[SE]CC[C@H](N)C(O)=O;C[SE]CCC(N)C(O)=O
SELETALISIB,SELETALISIB,CHEMBL4297648,BRD:BRD-K00003228-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,Small molecule,Phase 2,LNLJHGXOFYUARS-OAQYLSRUSA-N,[O-][N+]1CCCC(-C2NC3C(CL)CCCC3CC2[C@@H](NC2NCNC3CCCNC23)C(F)(F)F)C1
SELEXIPAG,SELEXIPAG,CHEMBL238804,BRD:BRD-BRD-K21191422-001-01-5;BRD:BRD-K21191422-001-01-5,rep_primary;rep_single_dose,"PLATELET AGGREGATION INHIBITOR, IP1 PROSTACYCLIN RECEPTOR AGONIST",PTGIR,,,PHASE 3,"Multiple values for MOA: {'IP1 PROSTACYCLIN RECEPTOR AGONIST, PLATELET AGGREGATION INHIBITOR', 'PLATELET AGGREGATION INHIBITOR, IP1 PROSTACYCLIN RECEPTOR AGONIST'}, defaulting to 'PLATELET AGGREGATION INHIBITOR, IP1 PROSTACYCLIN RECEPTOR AGONIST'",Small molecule,Approved,QXWZQTURMXZVHJ-UHFFFAOYSA-N,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1CNC(-C2CCCCC2)C(-C2CCCCC2)N1;CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1CNC(-C2CCCCC2)C(N1)-C1CCCCC1
SELICICLIB,SELICICLIB,CHEMBL14762,GDSC1:110,gdsc,,,,,,,Small molecule,Phase 2,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,CC[C@H](CO)NC1NC(NCC2CCCCC2)C2NCN(C(C)C)C2N1
SELINEXOR,SELINEXOR,CHEMBL3545185,BRD:BRD-BRD-K21361524-001-01-1;BRD:BRD-K21361524-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,EXPORTIN ANTAGONIST,XPO1,,,PHASE 2/PHASE 3,,Small molecule,Approved,DEVSOMFAQLZNKR-RJRFIUFISA-N,FC(F)(F)C1CC(CC(C1)C(F)(F)F)-C1NCN(\C=C/C(=O)NNC2CNCCN2)N1;O=C(/C=C\N1CNC(-C2CC(C(F)(F)F)CC(C(F)(F)F)C2)N1)NNC1CNCCN1
SELISISTAT,SELISISTAT,,GDSC1:341,gdsc,,,,,,,,NA,,
SELITRECTINIB,SELITRECTINIB,CHEMBL4297627,BRD:BRD-K00003441-001-01-9,rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 1,OEBIHOVSAMBXIB-SJKOYZFVSA-N,C[C@@H]1CCC2NCC(F)CC2[C@H]2CCCN2C2CCN3NCC(C3N2)C(=O)N1
SELONSERTIB,SELONSERTIB,CHEMBL3916717,BRD:BRD-K00003274-001-01-9,rep_single_dose,MAP KINASE ACTIVATOR,,,,,,Small molecule,Phase 3,YIDDLAAKOYYGJG-UHFFFAOYSA-N,CC1CC(F)C(C(=O)NC2CCCC(-C3NNCN3C(C)C)N2)CC1-N1CNC(C2CC2)C1
SELPERCATINIB,SELPERCATINIB,CHEMBL4559134,BRD:BRD-K00091095-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,XIIOFHFUYBLOLW-UHFFFAOYSA-N,COC1CCC(CN2C3CC2CN(C2CCC(-C4CC(OCC(C)(C)O)CN5NCC(C#N)C45)CN2)C3)CN1
SELTOREXANT,SELTOREXANT,CHEMBL3597971,BRD:BRD-K00073947-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,SQOCEMCKYDVLMM-UHFFFAOYSA-N,CC1CC(C)NC(N2CC3CN(C(=O)C4C(F)CCCC4-N4NCCN4)CC3C2)N1
SELUMETINIB,SELUMETINIB,CHEMBL1614701,BRD:BRD-BRD-K57080016-001-15-9;BRD:BRD-K57080016-001-15-9;CTRP:348991;GDSC1:1062;GDSC1:1498,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1,,,PHASE 3,,Small molecule,Approved,CYOHGALHFOKKQC-UHFFFAOYSA-N,CN1CNC2C(F)C(NC3CCC(BR)CC3CL)C(C(=O)NOCCO)CC21;CN1CNC2C(F)C(NC3CCC(BR)CC3CL)C(CC12)C(=O)NOCCO
SELUMETINIB:BRD-A02303741 (4:1 MOL/MOL),SELUMETINIB:BRD-A02303741 (4:1 MOL/MOL),,CTRP:660178,ctrp,,,,,,,,NA,,
SELUMETINIB:DECITABINE (4:1 MOL/MOL),SELUMETINIB:DECITABINE (4:1 MOL/MOL),,CTRP:660249,ctrp,,,,,,,,NA,,
SELUMETINIB:GDC-0941 (4:1 MOL/MOL),SELUMETINIB:GDC-0941 (4:1 MOL/MOL),,CTRP:660174,ctrp,,,,,,,,NA,,
SELUMETINIB:JQ-1 (4:1 MOL/MOL),SELUMETINIB:JQ-1 (4:1 MOL/MOL),,CTRP:660177,ctrp,,,,,,,,NA,,
SELUMETINIB:MK-2206 (8:1 MOL/MOL),SELUMETINIB:MK-2206 (8:1 MOL/MOL),,CTRP:660218,ctrp,,,,,,,,NA,,
SELUMETINIB:NAVITOCLAX (8:1 MOL/MOL),SELUMETINIB:NAVITOCLAX (8:1 MOL/MOL),,CTRP:660248,ctrp,,,,,,,,NA,,
SELUMETINIB:PIPERLONGUMINE (8:1 MOL/MOL),SELUMETINIB:PIPERLONGUMINE (8:1 MOL/MOL),,CTRP:660220,ctrp,,,,,,,,NA,,
SELUMETINIB:PLX-4032 (8:1 MOL/MOL),SELUMETINIB:PLX-4032 (8:1 MOL/MOL),,CTRP:660133,ctrp,,,,,,,,NA,,
SELUMETINIB:TRETINOIN (2:1 MOL/MOL),SELUMETINIB:TRETINOIN (2:1 MOL/MOL),,CTRP:660175,ctrp,,,,,,,,NA,,
SELUMETINIB:UNC0638 (4:1 MOL/MOL),SELUMETINIB:UNC0638 (4:1 MOL/MOL),,CTRP:660281,ctrp,,,,,,,,NA,,
SELUMETINIB:VORINOSTAT (8:1 MOL/MOL),SELUMETINIB:VORINOSTAT (8:1 MOL/MOL),,CTRP:660176,ctrp,,,,,,,,NA,,
SEMAGACESTAT,SEMAGACESTAT,CHEMBL520733,BRD:BRD-BRD-K81957469-001-01-0;BRD:BRD-K81957469-001-01-0;CTRP:660341,ctrp;rep_primary;rep_single_dose,GAMMA SECRETASE INHIBITOR,PSEN1,,,PHASE 3,,Small molecule,Phase 3,PKXWXXPNHIWQHW-RCBQFDQVSA-N,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCC2CCCCC21;CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C2CCCCC2CCN(C)C1=O
SEMAPIMOD,SEMAPIMOD,CHEMBL2107779,BRD:BRD-BRD-K21237892-376-01-3;BRD:BRD-K21237892-376-01-3,rep_primary;rep_single_dose,"CYTOKINE PRODUCTION INHIBITOR, P38 MAPK INHIBITOR",MAPK14,,,PHASE 2,,Small molecule,Phase 2,PWDYHMBTPGXCSN-VCBMUGGBSA-N,C/C(=N\NC(=N)N)C1CC(NC(=O)CCCCCCCCC(=O)NC2CC(/C(C)=N/NC(=N)N)CC(/C(C)=N/NC(=N)N)C2)CC(/C(C)=N/NC(=N)N)C1;NC(=N)NNC(=C)C1CC(NC(=O)CCCCCCCCC(=O)NC2CC(CC(C2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)CC(C1)C(=C)NNC(N)=N
SEMAXANIB,SEMAXANIB,CHEMBL276711,BRD:BRD-BRD-K63504947-001-15-4;BRD:BRD-K63504947-001-14-7;BRD:BRD-K63504947-001-15-4,rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,FGFR1;FLT1;KDR;KIT;PDGFRA;PDGFRB;RET,,,PHASE 3,,Small molecule,Phase 3,WUWDLXZGHZSWQZ-WQLSENKSSA-N,CC1CC(C)C(/C=C2\C(=O)NC3CCCCC32)[NH]1;CC1CC(C)C(\C=C2/C(=O)NC3CCCCC23)[NH]1
SEN-1269,SEN-1269,,BRD:BRD-BRD-K70614402-001-01-0;BRD:BRD-K70614402-001-01-0,rep_primary;rep_single_dose,BETA AMYLOID INHIBITOR,APP,,,PRECLINICAL,,,NA,,CN(C)C1CCCC(OC2CNC(NC3CCCC(O)C3)NC2)C1
SENAPARIB,SENAPARIB,CHEMBL4802152,BRD:BRD-K00090647-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,VBTUJTGLLREMNW-UHFFFAOYSA-N,O=C(C1CC(CN2C(=O)[NH]C(=O)C3C(F)CCCC32)CCC1F)N1CCN(C2NCCCN2)CC1
SENICAPOC,SENICAPOC,CHEMBL405821,BRD:BRD-BRD-K21295289-001-01-6;BRD:BRD-K21295289-001-01-6,rep_primary;rep_single_dose,INTERMEDIATE CONDUCTANCE POTASSIUM CHANNEL BLOCKER,KCNN4,,,PHASE 3,,Small molecule,Phase 3,SCTZUZTYRMOMKT-UHFFFAOYSA-N,NC(=O)C(C1CCCCC1)(C1CCC(F)CC1)C1CCC(F)CC1
SENNOSIDE-A,SENNOSIDE-A,,BRD:BRD-A30370660-001-04-1;BRD:BRD-BRD-A30370660-001-04-1,rep_primary;rep_single_dose,GLYCOSIDE AGONIST,,CONSTIPATION,,LAUNCHED,,,NA,,OC[C@H]1O[C@H](OC2CCCC3C([C@H]4C5CCCC(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C5C(=O)C5C(O)CC(CC45)C(O)=O)C4CC(CC(O)C4C(=O)C23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O
SEOCALCITOL,SEOCALCITOL,CHEMBL1908376,BRD:BRD-BRD-K28456624-001-01-1;BRD:BRD-K28456624-001-01-1,rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,,,PHASE 3,,Small molecule,Phase 3,LVLLALCJVJNGQQ-SEODYNFXSA-N,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O;CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C
SEP-227900,SEP-227900,,BRD:BRD-BRD-K49504902-001-01-6;BRD:BRD-K49504902-001-01-6,rep_primary;rep_single_dose,D-AMINO ACID OXIDASE INHIBITOR,DAO,,,PHASE 1,,,NA,,OC(=O)C1CC2OCCC2[NH]1
YM-155,SEPANTRONIUM BROMIDE;YM-155,CHEMBL2105734,BRD:BRD-BRD-K76703230-004-03-3;BRD:BRD-BRD-K76703230-004-04-1;BRD:BRD-K76703230-001-02-1;BRD:BRD-K76703230-004-03-3;BRD:BRD-K76703230-004-04-1;CTRP:417979;GDSC1:268;GDSC2:1941,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose, SUBSTRATE FOR SLC35F2 AND EXPORTED BY ABCB1;DNA DAMAGING AGENT,BIRC5;SLC35F2,,,PHASE 2,"Multiple values for MOA: {'SURVIVIN INHIBITOR', 'DNA DAMAGING AGENT; SUBSTRATE FOR SLC35F2 AND EXPORTED BY ABCB1'}, defaulting to 'DNA DAMAGING AGENT; SUBSTRATE FOR SLC35F2 AND EXPORTED BY ABCB1'
Multiple values for repurposing_target: {'BIRC5', 'SLC35F2'}, taking the union",Small molecule,Phase 2,QBIYUDDJPRGKNJ-UHFFFAOYSA-M,COCC[N+]1C2C(N(CC3CNCCN3)C1C)C(=O)C1CCCCC1C2=O.[BR-];COCCN1C2C(C(=O)C3CCCCC3C2=O)[N+](CC2CNCCN2)C1C
SERATRODAST,SERATRODAST,CHEMBL70972,BRD:BRD-A60765580-001-03-4,rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,TBXA2R,,,,,Small molecule,Unknown,ZBVKEHDGYSLCCC-UHFFFAOYSA-N,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)C2CCCCC2)=C(C)C1=O
SERDEMETAN,SERDEMETAN,CHEMBL2137530,BRD:BRD-BRD-K65924316-001-03-1;BRD:BRD-K65924316-001-03-1;CTRP:418164;GDSC1:1133,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,MDM INHIBITOR,MDM2,,,PHASE 1,,Small molecule,Phase 1,CEGSUKYESLWKJP-UHFFFAOYSA-N,C(CC1C[NH]C2CCCCC12)NC1CCC(NC2CCNCC2)CC1;C1CCC2C(CCNC3CCC(NC4CCNCC4)CC3)C[NH]C2C1
SERDEMETAN:SCH-529074 (1:1 MOL/MOL),SERDEMETAN:SCH-529074 (1:1 MOL/MOL),,CTRP:660132,ctrp,,,,,,,,NA,,
SEROTONIN,SEROTONIN,CHEMBL39,BRD:BRD-BRD-K38580127-003-15-4;BRD:BRD-K38580127-003-15-4,rep_primary;rep_single_dose,GROWTH FACTOR RECEPTOR ACTIVATOR,DRD1;DRD5;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR3A;HTR3B;HTR4;HTR5A;HTR6;HTR7;SLC36A1,"ANXIETY, DEPRESSION, SLEEPLESSNESS",,LAUNCHED,,Small molecule,Phase 3,QZAYGJVTTNCVMB-UHFFFAOYSA-N,NCCC1C[NH]C2CCC(O)CC12
SERTACONAZOLE,SERTACONAZOLE,CHEMBL1201196;CHEMBL1410877,BRD:BRD-A95939040-001-01-2;BRD:BRD-BRD-A95939040-001-01-2,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,TINEA PEDIS,,LAUNCHED,,Small molecule,Approved,JLGKQTAYUIMGRK-IBGZPJMESA-N;JLGKQTAYUIMGRK-UHFFFAOYSA-N,CLC1CCC([C@H](CN2CCNC2)OCC2CSC3C(CL)CCCC23)C(CL)C1;CLC1CCC(C(CN2CCNC2)OCC2CSC3C(CL)CCCC23)C(CL)C1
SERTINDOLE,SERTINDOLE,CHEMBL12713,BRD:BRD-BRD-K69116396-001-04-1;BRD:BRD-K69116396-001-04-1,rep_multi_dose;rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA1D;DRD2;DRD3;DRD4;HRH1;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2C;HTR6;KCNH2,,,WITHDRAWN,,Small molecule,Approved,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,FC1CCC(CC1)-N1CC(C2CCN(CCN3CCNC3=O)CC2)C2CC(CL)CCC12;O=C1NCCN1CCN1CCC(C2CN(-C3CCC(F)CC3)C3CCC(CL)CC23)CC1
SERTRALINE,SERTRALINE,CHEMBL809,BRD:BRD-BRD-K82036761-003-20-3;BRD:BRD-K82036761-003-20-3,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),SLC6A3;SLC6A4,"DEPRESSION, OBSESSIVE COMPULSIVE DISORDER (OCD), PANIC DISORDERS, POSTTRAUMATIC STRESS DISORDER, PREMENSTRUAL SYNDROME, SOCIAL ANXIETY DISORDER",,LAUNCHED,,Small molecule,Approved,VGKDLMBJGBXTGI-SJCJKPOMSA-N,CN[C@H]1CC[C@@H](C2CCC(CL)C(CL)C2)C2CCCCC12;CN[C@H]1CC[C@@H](C2CCC(CL)C(CL)C2)C2CCCCC21
SESAMIN,SESAMIN,CHEMBL252915,BRD:BRD-BRD-K11631773-001-10-8;BRD:BRD-K11631773-001-10-8,rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,PEYUIKBAABKQKQ-AFHBHXEDSA-N,C1CC2C(CC1[C@H]1OC[C@H]3[C@@H]1CO[C@@H]3C1CCC3C(C1)OCO3)OCO2;C1OC2CCC(CC2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2C1CCC2OCOC2C1
SETIPIPRANT,SETIPIPRANT,CHEMBL2386081,BRD:BRD-BRD-K24497734-001-01-6;BRD:BRD-K24497734-001-01-6,rep_primary;rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGDR2,,,PHASE 3,,Small molecule,Phase 3,IHAXLPDVOWLUOS-UHFFFAOYSA-N,O=C(O)CN1C2C(C3CC(F)CCC31)CN(C(=O)C1CCCC3CCCCC13)CC2;OC(=O)CN1C2CCN(CC2C2CC(F)CCC12)C(=O)C1CCCC2CCCCC12
SETIPTILINE,SETIPTILINE,CHEMBL2104895,BRD:BRD-BRD-K36732695-001-01-9;BRD:BRD-K36732695-001-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,HRH1;HTR2A;HTR2C,DEPRESSION,,LAUNCHED,,Small molecule,Unknown,GVPIXRLYKVFFMK-UHFFFAOYSA-N,CN1CCC2=C(C1)C1CCCCC1CC1CCCCC12;CN1CCC2=C(C1)C1CCCCC1CC1CCCCC21
SETMELANOTIDE,SETMELANOTIDE,CHEMBL3301624,BRD:BRD-K00003298-001-01-9,rep_single_dose,MELANOCORTIN RECEPTOR AGONIST,,,,,,Protein,Approved,HDHDTKMUACZDAA-PHNIDTBTSA-N,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CC2CCCCC2)NC(=O)[C@H](CC2C[NH]CN2)NC(=O)[C@@H](C)NC1=O
SEVELAMER,SEVELAMER,CHEMBL1201798,BRD:BRD-BRD-U45393375-000-01-6;BRD:BRD-U45393375-000-01-6,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHATE ANTAGONIST,,CHRONIC KIDNEY DISEASE (CKD),,LAUNCHED,,Small molecule,Approved,ZNSIZMQNQCNRBW-UHFFFAOYSA-N,C=CCN.CLCC1CO1;NCC=C.CLCC1CO1
SEVOFLURANE,SEVOFLURANE,CHEMBL1200694,BRD:BRD-BRD-K05638300-001-01-2;BRD:BRD-K05638300-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,ATP2C1;ATP5D;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GLRA1;GLRB;GRIA1;KCNA1;KCNK10;KCNK18;KCNK2;KCNK3;KCNK9;MT-ND1,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,DFEYYRMXOJXZRJ-UHFFFAOYSA-N,FCOC(C(F)(F)F)C(F)(F)F
SEW-2871,SEW-2871,,BRD:BRD-BRD-K15601958-001-03-9;BRD:BRD-K15601958-001-03-9,rep_primary;rep_single_dose,LYSOPHOSPHOLIPID RECEPTOR AGONIST,S1PR1,,,PRECLINICAL,,,NA,,FC(F)(F)C1SC(CC1-C1CCCCC1)-C1NC(NO1)-C1CCCC(C1)C(F)(F)F
SF-11,SF-11,,BRD:BRD-K42629487-001-09-9,rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,MCOLN3;NPY2R,,,,,,NA,,
SGC-0946,SGC-0946,,BRD:BRD-BRD-K69577666-001-01-3;BRD:BRD-K69577666-001-01-3,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,,,,PRECLINICAL,,,NA,,CC(C)N(CCCNC(=O)NC1CCC(CC1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC(BR)C2C(N)NCNC12
SGC-707,SGC-707,,BRD:BRD-K86718786-001-03-9,rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT3,,,,,,NA,,
SGC-CBP30,SGC-CBP30,,BRD:BRD-BRD-K24821794-001-01-4;BRD:BRD-K24821794-001-01-4,rep_primary;rep_single_dose,BROMODOMAIN INHIBITOR,CREBBP;EP300,,,PRECLINICAL,,,NA,,COC1CCC(CCC2NC3CC(CCC3N2C[C@H](C)N2CCOCC2)-C2C(C)NOC2C)CC1CL
SGC0946,SGC0946,,GDSC1:1264,gdsc,,,,,,,,NA,,
SGI-1027,SGI-1027,,BRD:BRD-BRD-K61228301-001-01-2;BRD:BRD-K61228301-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,DNA METHYLTRANSFERASE INHIBITOR,DNMT1;DNMT3A;DNMT3B,,,PRECLINICAL,,,NA,,CC1CC(NC2CCC(NC(=O)C3CCC(NC4CCNC5CCCCC45)CC3)CC2)NC(N)N1
SGI-1776,SGI-1776,CHEMBL1952329,BRD:BRD-BRD-K80700417-001-04-2;BRD:BRD-K80700417-001-04-2,rep_multi_dose;rep_primary;rep_single_dose,PIM KINASE INHIBITOR,FLT3;PIM1;PIM2;PIM3,,,PHASE 1,,Small molecule,Phase 1,MHXGEROHKGDZGO-UHFFFAOYSA-N,CN1CCC(CNC2CCC3NCC(-C4CCCC(OC(F)(F)F)C4)N3N2)CC1
SGS-742,SGS-742,CHEMBL112797,BRD:BRD-K00004650-001-01-9,rep_single_dose,GABA RECEPTOR ANTAGONIST,GABBR1;GABBR2,,,,,Small molecule,Phase 2,ONNMDRQRSGKZCN-UHFFFAOYSA-N,CCCCP(=O)(O)CCCN
SGX523,SGX-523;SGX523,CHEMBL1236107,BRD:BRD-BRD-K19477839-001-07-6;BRD:BRD-K19477839-001-07-6;BRD:BRD-K19477839-001-10-9;CTRP:635882,ctrp;oncref_2;rep_primary;rep_single_dose,HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR,MET,,,PHASE 1,"Multiple values for MOA: {'INHIBITOR OF MET', 'HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR'}, defaulting to 'HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR'",Small molecule,Phase 1,BCZUAADEACICHN-UHFFFAOYSA-N,CN1CC(-C2CCC3NNC(SC4CCC5NCCCC5C4)N3N2)CN1;CN1CC(CN1)-C1CCC2NNC(SC3CCC4NCCCC4C3)N2N1
SHA-68,SHA-68,,BRD:BRD-A63344375-001-01-8;BRD:BRD-BRD-A63344375-001-01-8,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPSR1,,,PRECLINICAL,,,NA,,FC1CCC(CNC(=O)N2CCN3C(C2)C(OC3=O)(C2CCCCC2)C2CCCCC2)CC1
SHIKIMIC-ACID,SHIKIMIC-ACID,,BRD:BRD-A92096630-001-02-8;BRD:BRD-BRD-A92096630-001-02-8,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,O[C@@H]1CC(=CC(O)C1O)C(O)=O
SHIKONIN,SHIKONIN,CHEMBL9470,GDSC1:170,gdsc,,,,,,,Small molecule,NA,NEZONWMXZKDMKF-SNVBAGLBSA-N,CC(C)=CC[C@@H](O)C1=CC(=O)C2C(O)CCC(O)C2C1=O
SHP099,SHP099,,BRD:BRD-BRD-K00818915-003-01-8;BRD:BRD-K00818915-003-01-8,rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,PTPN11,,,PRECLINICAL,,,NA,,CC1(N)CCN(CC1)C1CNC(C(N)N1)-C1CCCC(CL)C1CL
SIB-1553A,SIB-1553A,,BRD:BRD-A79052425-003-01-5;BRD:BRD-BRD-A79052425-003-01-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNB4,,,PHASE 2,,,NA,,CN1CCCC1CCSC1CCC(O)CC1
SIB-1757,SIB-1757,,BRD:BRD-BRD-K98157055-001-10-9;BRD:BRD-K98157055-001-10-9,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM5,,,PRECLINICAL,,,NA,,CC1CCC(O)C(N=NC2CCCCC2)N1
SIB-1893,SIB-1893,,BRD:BRD-K14561059-001-06-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM4;GRM5,,,,,,NA,,
SIBOFIMLOC,SIBOFIMLOC,CHEMBL4594305,BRD:BRD-K00090658-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,SFHMWDMKUYVSQJ-VECBPBMLSA-N,CC(=O)N1CCC2(CC1)C1CC(C#C[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)CCC1-C1CCC(C#C[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)CC12
SIBUTRAMINE,SIBUTRAMINE,CHEMBL1419,BRD:BRD-A23359898-003-10-0;BRD:BRD-BRD-A23359898-003-10-0,rep_primary;rep_single_dose,SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI),SLC6A2;SLC6A3;SLC6A4,,,WITHDRAWN,,Small molecule,Approved,UNAANXDKBXWMLN-UHFFFAOYSA-N,CC(C)CC(N(C)C)C1(C2CCC(CL)CC2)CCC1;CC(C)CC(N(C)C)C1(CCC1)C1CCC(CL)CC1
SID 26681509,SID 26681509,,CTRP:411731,ctrp,,,,,,,,NA,,
SID-7969543,SID-7969543,,BRD:BRD-A43885598-001-08-1;BRD:BRD-BRD-A43885598-001-08-1,rep_multi_dose;rep_primary;rep_single_dose,STEROIDOGENIC FACTOR ANTAGONIST,NR5A1,,,PRECLINICAL,,,NA,,CCOC(=O)C(C)OC1CCCC2C1CCN(CC(=O)NC1CCC3OCCOC3C1)C2=O
SIGUAZODAN,SIGUAZODAN,CHEMBL1256712,BRD:BRD-A62071884-001-04-6;BRD:BRD-BRD-A62071884-001-04-6,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE3A,,,PHASE 1,,Small molecule,Unknown,NUHPODZZKHQQET-UHFFFAOYSA-N,CN/C(=N\C1CCC(C2=NNC(=O)CC2C)CC1)NC#N;CN\C(NC#N)=N/C1CCC(CC1)C1=NNC(=O)CC1C
SILDENAFIL,SILDENAFIL,CHEMBL192,BRD:BRD-BRD-K79759585-048-04-8;BRD:BRD-K79759585-048-04-8;CTRP:27872,ctrp;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A;PDE6G;PDE6H;SLCO1B1;SLCO1B3,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,BNRNXUUZRGQAQC-UHFFFAOYSA-N,CCCC1NN(C)C2C(=O)[NH]C(-C3CC(S(=O)(=O)N4CCN(C)CC4)CCC3OCC)NC12;CCCC1NN(C)C2C1NC([NH]C2=O)-C1CC(CCC1OCC)S(=O)(=O)N1CCN(C)CC1
SILIBININ,SILIBININ,CHEMBL9509,BRD:BRD-BRD-K80353138-001-12-1;BRD:BRD-K80353138-001-12-1,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,ALOX5,HEPATIC CIRRHOSIS,,LAUNCHED,,Small molecule,Phase 3,SEBFKMXJBCUCAI-DBMPWETRSA-N,COC1CC(C2OC3CC([C@H]4OC5CC(O)CC(O)C5C(=O)[C@@H]4O)CCC3OC2CO)CCC1O;COC1CC(CCC1O)[C@H]1OC2CC(CCC2O[C@@H]1CO)[C@H]1OC2CC(O)CC(O)C2C(=O)[C@@H]1O
SILMITASERTIB,SILMITASERTIB,CHEMBL1230165,CTRP:660421,ctrp,,,,,,,Small molecule,Phase 2,MUOKSQABCJCOPU-UHFFFAOYSA-N,O=C(O)C1CCC2C(C1)NC(NC1CCCC(CL)C1)C1CCNCC12
SILODOSIN,SILODOSIN,CHEMBL24778,BRD:BRD-BRD-K10906636-001-02-9;BRD:BRD-K10906636-001-02-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D,BENIGN PROSTATIC HYPERPLASIA (BPH),,LAUNCHED,,Small molecule,Approved,PNCPYILNMDWPEY-QGZVFWFLSA-N,C[C@H](CC1CC2C(C(C(N)=O)C1)N(CCCO)CC2)NCCOC1CCCCC1OCC(F)(F)F;C[C@H](CC1CC2CCN(CCCO)C2C(C1)C(N)=O)NCCOC1CCCCC1OCC(F)(F)F
SILVER-SULFADIAZINE,SILVER-SULFADIAZINE,,BRD:BRD-BRD-K68379918-001-01-1;BRD:BRD-K68379918-001-01-1,rep_primary;rep_single_dose,PABA ANTAGONIST,,SEPSIS,,LAUNCHED,,,NA,,NC1CCC(CC1)S(=O)(=O)N([AG])C1NCCCN1
SIMEPREVIR,SIMEPREVIR,CHEMBL501849,BRD:BRD-A68493689-001-01-9;BRD:BRD-BRD-A68493689-001-01-9,rep_primary;rep_single_dose,HCV INHIBITOR,CYP1A2;CYP3A4,HEPATITIS C,,LAUNCHED,,Small molecule,Approved,JTZZSQYMACOLNN-VDWJNHBNSA-N,COC1CCC2C(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)CC(NC2C1C)-C1NC(CS1)C(C)C;COC1CCC2C(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)CC(-C3NC(C(C)C)CS3)NC2C1C
SIMUROSERTIB,SIMUROSERTIB,CHEMBL4297644,BRD:BRD-K00004727-001-01-9,rep_single_dose,KINASE INHIBITOR,,,,,,Small molecule,Phase 2,XGVXKJKTISMIOW-ZDUSSCGKSA-N,CC1N[NH]CC1-C1CC2NC([C@@H]3CC4CCN3CC4)[NH]C(=O)C2S1
SIMVASTATIN,SIMVASTATIN,CHEMBL1064,BRD:BRD-BRD-K22134346-001-22-3;BRD:BRD-BRD-K22134346-001-24-9;BRD:BRD-K22134346-001-22-3;BRD:BRD-K22134346-001-24-9;CTRP:27894,ctrp;rep_multi_dose;rep_primary;rep_single_dose,HMGCR INHIBITOR,HMGCR;ITGB2,"HYPERCHOLESTEROLEMIA, CORONARY HEART DISEASE, MYOCARDIAL INFARCTION, STROKE, HYPERLIPIDEMIA",,LAUNCHED,,Small molecule,Approved,RYMZZMVNJRMUDD-HGQWONQESA-N,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12;CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
SINCALIDE,SINCALIDE,CHEMBL1121,BRD:BRD-K00003334-001-01-9,rep_single_dose,CHOLECYSTOKININ AGONIST,,,,,,Protein,Approved,IZTQOLKUZKXIRV-YRVFCXMDSA-N,CSCC[C@H](NC(=O)[C@H](CC1CCC(OS(=O)(=O)O)CC1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
SINEFUNGIN,SINEFUNGIN,CHEMBL1214186,BRD:BRD-K91100918-001-03-8,rep_single_dose,"DNA METHYLTRANSFERASE INHIBITOR, RNA SYNTHESIS INHIBITOR",CARM1,,,,,Small molecule,Unknown,LMXOHSDXUQEUSF-YECHIGJVSA-N,NC1NCNC2C1NCN2[C@@H]1O[C@H](C[C@@H](N)CC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O
SINOMENINE,SINOMENINE,CHEMBL248095,BRD:BRD-BRD-K83459933-001-05-4;BRD:BRD-K83459933-001-05-4,rep_primary;rep_single_dose,ANGIOGENESIS INHIBITOR,,,,PRECLINICAL,,Small molecule,NA,INYYVPJSBIVGPH-QHRIQVFBSA-N,COC1=C[C@@H]2[C@@H]3CC4CCC(OC)C(O)C4[C@]2(CCN3C)CC1=O
SINULARIN,SINULARIN,,GDSC2:1838,gdsc,,,,,,,,NA,,
SIPATRIGINE,SIPATRIGINE,CHEMBL28854,BRD:BRD-BRD-K53195974-001-01-9;BRD:BRD-K53195974-001-01-9,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,CACNA1D;SCN10A;SCN1A;SCN3A;SCN4A;SCN5A;SCN9A,,,PHASE 2,,Small molecule,Unknown,PDOCBJADCWMDGL-UHFFFAOYSA-N,CN1CCN(C2NCC(-C3CC(CL)CC(CL)C3CL)C(N)N2)CC1;CN1CCN(CC1)C1NCC(C(N)N1)-C1CC(CL)CC(CL)C1CL
SIPONIMOD,SIPONIMOD,CHEMBL2336071,BRD:BRD-BRD-K62384160-001-02-0;BRD:BRD-K62384160-001-02-0,rep_primary;rep_single_dose,"SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, SPHINGOSINE PHOSPHATE RECEPTOR MODULATOR",S1PR1,,,PHASE 3,"Multiple values for MOA: {'SPHINGOSINE PHOSPHATE RECEPTOR MODULATOR', 'SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, SPHINGOSINE PHOSPHATE RECEPTOR MODULATOR'}, defaulting to 'SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, SPHINGOSINE PHOSPHATE RECEPTOR MODULATOR'",Small molecule,Approved,KIHYPELVXPAIDH-HNSNBQBZSA-N,CCC1CC(/C(C)=N/OCC2CCC(C3CCCCC3)C(C(F)(F)F)C2)CCC1CN1CC(C(=O)O)C1;CCC1CC(CCC1CN1CC(C1)C(O)=O)C(\C)=N\OCC1CCC(C2CCCCC2)C(C1)C(F)(F)F
SIRAMESINE,SIRAMESINE,CHEMBL61479,BRD:BRD-BRD-K51333959-003-01-3;BRD:BRD-K51333959-003-01-3,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D,,,PHASE 2,,Small molecule,Unknown,XWAONOGAGZNUSF-UHFFFAOYSA-N,FC1CCC(-N2CC(CCCCN3CCC4(CC3)OCC3CCCCC34)C3CCCCC32)CC1;FC1CCC(CC1)-N1CC(CCCCN2CCC3(CC2)OCC2CCCCC32)C2CCCCC12
SIREMADLIN,SIREMADLIN,CHEMBL3653256,BRD:BRD-K65480835-001-02-9,rep_single_dose,MDM INHIBITOR,,,,,,Small molecule,Phase 2,AGBSXNCBIWWLHD-FQEVSTJZSA-N,COC1NCC(-C2NC3C(N2C(C)C)[C@H](C2CCC(CL)CC2)N(C2CC(CL)CN(C)C2=O)C3=O)C(OC)N1
SIROLIMUS:BORTEZOMIB (250:1 MOL/MOL),SIROLIMUS:BORTEZOMIB (250:1 MOL/MOL),,CTRP:660134,ctrp,,,,,,,,NA,,
SIRREAL-2,SIRREAL-2,,BRD:BRD-BRD-K16472653-001-01-6;BRD:BRD-K16472653-001-01-6,rep_primary;rep_single_dose,SIRT INHIBITOR,SIRT2,,,PRECLINICAL,,,NA,,CC1CC(C)NC(SCC(=O)NC2NCC(CC3CCCC4CCCCC34)S2)N1
SIS3,SIS3,,BRD:BRD-K38905597-003-02-9,rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,SMAD3;TGFBR1,,,,,,NA,,
SITAFLOXACIN,SITAFLOXACIN,CHEMBL108821;CHEMBL3989504,BRD:BRD-BRD-K10836013-001-01-3;BRD:BRD-K10836013-001-01-3,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,BURULI ULCER,,LAUNCHED,,Small molecule,Phase 3,ANCJYRJLOUSQBW-JJZGMWGRSA-N;PNUZDKCDAWUEGK-CYZMBNFOSA-N,N[C@@H]1CN(C2C(F)CC3C(=O)C(C(=O)O)CN([C@@H]4C[C@@H]4F)C3C2CL)CC12CC2;N[C@@H]1CN(C2C(F)CC3C(=O)C(C(=O)O)CN([C@@H]4C[C@@H]4F)C3C2CL)CC12CC2.O;N[C@@H]1CN(CC11CC1)C1C(F)CC2C(C1CL)N(CC(C(O)=O)C2=O)[C@@H]1C[C@@H]1F
SITAGLIPTIN,SITAGLIPTIN,CHEMBL1422,BRD:BRD-BRD-K19416115-001-05-3;BRD:BRD-K19416115-001-05-3;CTRP:58442,ctrp;rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,MFFMDFFZMYYVKS-SECBINFHSA-N,N[C@@H](CC(=O)N1CCN2C(C1)NNC2C(F)(F)F)CC1CC(F)C(F)CC1F;N[C@@H](CC(=O)N1CCN2C(NNC2C(F)(F)F)C1)CC1CC(F)C(F)CC1F
SITAXENTAN,SITAXENTAN,CHEMBL282724,BRD:BRD-BRD-K63806092-236-02-6;BRD:BRD-K63806092-236-02-6;BRD:BRD-K63806092-236-06-9,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA;EDNRB,,,WITHDRAWN,"Multiple values for repurposing_target: {'EDNRA;EDNRB', 'EDNRA'}, taking the union",Small molecule,Approved,PHWXUGHIIBDVKD-UHFFFAOYSA-N,CC1CC2C(CC1CC(=O)C1SCCC1S(=O)(=O)NC1ONC(C)C1CL)OCO2;CC1NOC(NS(=O)(=O)C2CCSC2C(=O)CC2CC3OCOC3CC2C)C1CL
SITRAVATINIB,SITRAVATINIB,CHEMBL3989926,BRD:BRD-K00003238-001-01-9,rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,,,,,,Small molecule,Phase 3,WLAVZAAODLTUSW-UHFFFAOYSA-N,COCCNCC1CCC(-C2CC3NCCC(OC4CCC(NC(=O)C5(C(=O)NC6CCC(F)CC6)CC5)CC4F)C3S2)NC1
SIVELESTAT,SIVELESTAT,CHEMBL76688,BRD:BRD-BRD-K02152879-414-02-1;BRD:BRD-K02152879-414-02-1,rep_primary;rep_single_dose,ELASTASE INHIBITOR,CELA1;ELANE,ACUTE LUNG INJURY,,LAUNCHED,,Small molecule,Phase 3,BTGNGJJLZOIYID-UHFFFAOYSA-N,CC(C)(C)C(=O)OC1CCC(CC1)S(=O)(=O)NC1CCCCC1C(=O)NCC(O)=O;CC(C)(C)C(=O)OC1CCC(S(=O)(=O)NC2CCCCC2C(=O)NCC(=O)O)CC1
SJ-172550,SJ-172550,,CTRP:416777,ctrp,,,,,,,,NA,,
SJ-733,SJ-733,CHEMBL4207489,BRD:BRD-K34798115-001-02-9,rep_single_dose,ATPASE INHIBITOR,,,,,,Small molecule,Phase 2,VKCPFWKTFZAOTO-LEWJYISDSA-N,N#CC1CC(NC(=O)[C@H]2C3CCCCC3C(=O)N(CC(F)(F)F)[C@@H]2C2CCCNC2)CCC1F
SJG-136,SJG-136,CHEMBL16498,BRD:BRD-K00003173-001-01-9,rep_single_dose,DNA INTERCALATING AGENT,,,,,,Small molecule,Phase 2,RWZVMMQNDHPRQD-SFTDATJTSA-N,C=C1C[C@H]2C=NC3CC(OCCCOC4CC5C(CC4OC)C(=O)N4CC(=C)C[C@H]4C=N5)C(OC)CC3C(=O)N2C1
SK&F-10047-(+),SK&F-10047-(+),,BRD:BRD-A47364545-003-02-6;BRD:BRD-BRD-A47364545-003-02-6,rep_primary;rep_single_dose,SIGMA RECEPTOR AGONIST,SIGMAR1,,,PHASE 1,,,NA,,C[C@H]1C2CC3CCC(O)CC3[C@@]1(C)CCN2CC=C
SKA-31,SKA-31,,BRD:BRD-BRD-K67304264-001-08-5;BRD:BRD-K67304264-001-08-5,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNN4,,,PRECLINICAL,,,NA,,NC1NC2C(CCC3CCCCC23)S1
SKEPINONE-L,SKEPINONE-L,CHEMBL2152944,BRD:BRD-BRD-K83607951-001-02-2;BRD:BRD-K83607951-001-02-2;CTRP:688799,ctrp;rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PRECLINICAL,,Small molecule,NA,HXMGCTFLLWPVFM-GOSISDBHSA-N,O=C1C2CCC(NC3CCC(F)CC3F)CC2CCC2CCC(OC[C@H](O)CO)CC21;OC[C@@H](O)COC1CCC2CCC3CC(NC4CCC(F)CC4F)CCC3C(=O)C2C1
SKF-38393,SKF-38393,CHEMBL286080,BRD:BRD-A88548664-004-02-7;BRD:BRD-BRD-A88548664-004-02-7,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,CALY;DRD1;DRD5,,,PRECLINICAL,,Small molecule,NA,JUDKOGFHZYMDMF-UHFFFAOYSA-N,OC1CC2C(CC1O)C(C1CCCCC1)CNCC2;OC1CC2CCNCC(C3CCCCC3)C2CC1O
SKF-77434,SKF-77434,,BRD:BRD-A64227845-004-09-3;BRD:BRD-BRD-A64227845-004-09-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD1,,,PRECLINICAL,,,NA,,OC1CC2CCN(CC=C)CC(C3CCCCC3)C2CC1O
SKF-81297,SKF-81297,,BRD:BRD-A09828896-004-11-0;BRD:BRD-BRD-A09828896-004-11-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD1;DRD5,,,PRECLINICAL,,,NA,,OC1CC2C(CNCCC2C(CL)C1O)C1CCCCC1
SKF-83566,SKF-83566,,BRD:BRD-A52588987-004-08-2;BRD:BRD-BRD-A52588987-004-08-2,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD5,,,PRECLINICAL,,,NA,,CN1CCC2CC(BR)C(O)CC2C(C1)C1CCCCC1
SKF-86002,SKF-86002,,BRD:BRD-BRD-K96809896-300-02-3;BRD:BRD-K96809896-300-02-3,rep_primary;rep_single_dose,P38 MAPK INHIBITOR,ALOX5;MAPK14,,,PRECLINICAL,,,NA,,FC1CCC(CC1)-C1NC2SCCN2C1-C1CCNCC1
SKF-89976A,SKF-89976A,,BRD:BRD-A49046702-003-08-3;BRD:BRD-BRD-A49046702-003-08-3,rep_primary;rep_single_dose,GABA UPTAKE INHIBITOR,SLC6A1,,,PRECLINICAL,,,NA,,OC(=O)C1CCCN(CCC=C(C2CCCCC2)C2CCCCC2)C1
SKF-96365,SKF-96365,,BRD:BRD-A72703248-003-04-9;BRD:BRD-BRD-A72703248-003-04-9,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CYP3A4;PKD2;TRPC1;TRPC3;TRPC4;TRPC5;TRPV2,,,PRECLINICAL,,,NA,,COC1CCC(CCCOC(CN2CCNC2)C2CCC(OC)CC2)CC1
SKI-606,SKI-606,CHEMBL288441,GDSC1:1019,gdsc,,,,,,,Small molecule,Approved,UBPYILGKFZZVDX-UHFFFAOYSA-N,COC1CC(NC2C(C#N)CNC3CC(OCCCN4CCN(C)CC4)C(OC)CC23)C(CL)CC1CL
SKI-II,SKI-II,,BRD:BRD-BRD-K20755323-001-05-9;BRD:BRD-K20755323-001-05-9;CTRP:375366,ctrp;rep_multi_dose;rep_primary;rep_single_dose,SPHINGOSINE KINASE INHIBITOR,SPHK1,,,PRECLINICAL,,,NA,,OC1CCC(NC2NC(CS2)-C2CCC(CL)CC2)CC1
SKLB-1028,SKLB-1028,,BRD:BRD-K00004690-001-01-9,rep_single_dose,"ABL KINASE INHIBITOR, EGFR INHIBITOR, FLT3 INHIBITOR",,,,,,,NA,,
SKLB1002,SKLB1002,,BRD:BRD-BRD-K29895144-001-01-0;BRD:BRD-K29895144-001-01-0,rep_primary;rep_single_dose,VEGFR INHIBITOR,KDR,,,PRECLINICAL,,,NA,,COC1CC2NCNC(SC3NNC(C)S3)C2CC1OC
SL 0101-1,SL 0101-1,,GDSC1:1039,gdsc,,,,,,,,NA,,
SL-0101,SL-0101,,GDSC1:1039,gdsc,,,,,,,,NA,,
SL0101,SL0101,,GDSC1:1039,gdsc,,,,,,,,NA,,
SLV-319-(+/-),SLV-319-(+/-),,BRD:BRD-A54228901-001-01-7;BRD:BRD-BRD-A54228901-001-01-7,rep_primary;rep_single_dose,CANNABINOID RECEPTOR ANTAGONIST,CNR1;DRD2;HTR1A,,,PHASE 2,,,NA,,C\N=C(\NS(=O)(=O)C1CCC(CL)CC1)N1CC(C(=N1)C1CCC(CL)CC1)C1CCCCC1
SLV-320,SLV-320,CHEMBL592435,BRD:BRD-BRD-K34445261-001-02-2;BRD:BRD-K34445261-001-02-2,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 2,,Small molecule,Phase 2,RBZNJGHIKXAKQE-UHFFFAOYSA-N,O[C@H]1CC[C@@H](CC1)NC1NC(NC2[NH]CCC12)-C1CCCCC1;OC1CCC(NC2NC(-C3CCCCC3)NC3[NH]CCC23)CC1
SM-108,SM-108,,BRD:BRD-BRD-K70053378-001-01-1;BRD:BRD-K70053378-001-01-1,rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,NC(=O)C1[NH]CNC1O
SM-164,SM-164,,BRD:BRD-K06191411-001-02-5,rep_single_dose,XIAP INHIBITOR,BIRC2;BIRC3;XIAP,,,,,,NA,,
SM-21,SM-21,,BRD:BRD-A92933783-050-01-6;BRD:BRD-BRD-A92933783-050-01-6,rep_primary;rep_single_dose,SIGMA RECEPTOR ANTAGONIST,PGRMC1,,,PRECLINICAL,,,NA,,CCC(OC1CCC(CL)CC1)C(=O)OC1CC2CCC(C1)N2C
SMER-28,SMER-28,,BRD:BRD-BRD-K08478539-001-13-8;BRD:BRD-K08478539-001-13-8,rep_primary;rep_single_dose,AUTOPHAGY INDUCER,SNCA,,,PRECLINICAL,,,NA,,BRC1CCC2NCNC(NCC=C)C2C1
SMER-3,SMER-3,,CTRP:660286,ctrp,,,,,,,,NA,,
SMI-4A,SMI-4A,,BRD:BRD-BRD-K70159787-001-01-1;BRD:BRD-K70159787-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,PIM KINASE INHIBITOR,PIM1,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCCC(C1)\C=C1\SC(=O)NC1=O
SN 38,SN 38,CHEMBL837,GDSC1:1494,gdsc,,,,,,,Small molecule,Phase 2,FJHBVJOVLFPMQE-QFIPXVFZSA-N,CCC1C2C(NC3CCC(O)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC
SN-2,SN-2,,BRD:BRD-A64319165-001-07-0;BRD:BRD-BRD-A64319165-001-07-0,rep_primary;rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL AGONIST,MCOLN3,,,PRECLINICAL,,,NA,,CC1CC(C)C(C2=NOC3C4CCC(C4)C23)C(C)C1
SN38,SN-38;SN38,CHEMBL837,BRD:BRD-BRD-K89561498-001-01-7;BRD:BRD-K89561498-001-01-7;BRD:BRD-K89561498-001-02-5;BRD:BRD-U00115289-001-01-9;CTRP:375637;GDSC1:1494,ctrp;gdsc;oncref_1;rep_multi_dose;rep_primary;rep_single_dose,INHIBITOR OF TOPOISOMERASE 1,TOP1;TOP1A,COLORECTAL CANCER,,LAUNCHED,"Multiple values for MOA: {'INHIBITOR OF TOPOISOMERASE 1', 'TOPOISOMERASE INHIBITOR'}, defaulting to 'INHIBITOR OF TOPOISOMERASE 1'
Multiple values for repurposing_target: {'TOP1A', 'TOP1'}, taking the union",Small molecule,Phase 2,FJHBVJOVLFPMQE-QFIPXVFZSA-N,CCC1C2C(NC3CCC(O)CC13)-C1CC3C(C(=O)N1C2)COC(=O)[C@]3(O)CC;CCC1C2CN3C(CC4C(COC(=O)[C@]4(O)CC)C3=O)-C2NC2CCC(O)CC12
SN-6,SN-6,,BRD:BRD-A14316475-001-02-3;BRD:BRD-BRD-A14316475-001-02-3,rep_primary;rep_single_dose,SODIUM/CALCIUM EXCHANGE INHIBITOR,,,,PRECLINICAL,,,NA,,CCOC(=O)C1CSC(N1)CC1CCC(OCC2CCC([N+]([O-])=O)CC2)CC1
SNAP,SNAP,,BRD:BRD-A67006024-001-04-8;BRD:BRD-BRD-A67006024-001-04-8,rep_primary;rep_single_dose,NITRIC OXIDE DONOR,PTPN1,,,PHASE 2,,,NA,,CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-]
SNAP-94847,SNAP-94847,,BRD:BRD-BRD-K49702221-003-01-6;BRD:BRD-K49702221-003-01-6,rep_primary;rep_single_dose,,ADRA1A;DRD2,,,PRECLINICAL,,,NA,,CC(C)C(=O)NC1CCC(C)C(C1)C1CCN(CC2CCC(OC3CCC(F)C(F)C3)CC2)CC1
SNC-80,SNC-80,CHEMBL13470,BRD:BRD-BRD-K29546239-001-02-3;BRD:BRD-K29546239-001-02-3,rep_primary;rep_single_dose,,OPRD1,,,PRECLINICAL,,Small molecule,NA,KQWVAUSXZDRQPZ-UMTXDNHDSA-N,C=CCN1C[C@H](C)N([C@H](C2CCC(C(=O)N(CC)CC)CC2)C2CCCC(OC)C2)C[C@H]1C;CCN(CC)C(=O)C1CCC(CC1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)C1CCCC(OC)C1
SNDX-5613,SNDX-5613,CHEMBL4650278,BRD:BRD-K00090651-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,AXNUWYROYVRYIM-OQIJCFCCSA-N,CCN(C(=O)C1CC(F)CCC1OC1CNCNC1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)C1CC(F)CCC1OC1CNCNC1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
SNG-1153,SNG-1153,,BRD:BRD-K75016267-001-02-9,rep_single_dose,SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM),ESR1,,,,,,NA,,
SNS-032,SNS-032,CHEMBL296468,CTRP:606254,ctrp,,,,,,,Small molecule,Phase 1,OUSFTKFNBAZUKL-UHFFFAOYSA-N,CC(C)(C)C1CNC(CSC2CNC(NC(=O)C3CCNCC3)S2)O1
SNS-314,SNS-314,CHEMBL482767;CHEMBL518051,BRD:BRD-BRD-K71512533-066-02-8;BRD:BRD-K71512533-066-02-8,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB;AURKC,,,PHASE 1,,Small molecule,Phase 1,FAYAUAZLLLJJGH-UHFFFAOYSA-N;FYCODPVDEFFWSR-UHFFFAOYSA-N,CLC1CCCC(NC(=O)NC2NCC(CCNC3NCNC4CCSC34)S2)C1;CS(=O)(=O)O.O=C(NC1CCCC(CL)C1)NC1NCC(CCNC2NCNC3CCSC23)S1;O=C(NC1CCCC(CL)C1)NC1NCC(CCNC2NCNC3CCSC23)S1
SNX 2112,SNX 2112,,GDSC1:328,gdsc,,,,,,,,NA,,
SNX-2112,SNX-2112,CHEMBL560895,BRD:BRD-BRD-K71281111-001-04-3;BRD:BRD-K71281111-001-04-3;CTRP:362338;GDSC1:328,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,ZFVRYNYOPQZKDG-MQMHXKEQSA-N,CC1(C)CC(=O)C2C(C(F)(F)F)NN(-C3CCC(C(N)=O)C(N[C@H]4CC[C@H](O)CC4)C3)C2C1;CC1(C)CC2C(C(NN2-C2CCC(C(N)=O)C(N[C@H]3CC[C@H](O)CC3)C2)C(F)(F)F)C(=O)C1
SNX-2112:BORTEZOMIB (250:1 MOL/MOL),SNX-2112:BORTEZOMIB (250:1 MOL/MOL),,CTRP:660251,ctrp,,,,,,,,NA,,
SNX-5422,SNX-5422,CHEMBL1195136,BRD:BRD-BRD-K73197500-001-02-2;BRD:BRD-K73197500-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1;HSP90AB1,,,PHASE 1/PHASE 2,"Multiple values for repurposing_target: {'HSP90AA1', 'HSP90AA1;HSP90AB1'}, taking the union",Small molecule,Phase 2,AVDSOVJPJZVBTC-CTYIDZIISA-N,CC1(C)CC(=O)C2C(C(F)(F)F)NN(-C3CCC(C(N)=O)C(N[C@H]4CC[C@H](OC(=O)CN)CC4)C3)C2C1;CC1(C)CC2C(C(NN2-C2CCC(C(N)=O)C(N[C@H]3CC[C@@H](CC3)OC(=O)CN)C2)C(F)(F)F)C(=O)C1
SOBETIROME,SOBETIROME,CHEMBL107400,BRD:BRD-BRD-K85406984-001-01-0;BRD:BRD-K85406984-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,THYROID HORMONE RECEPTOR AGONIST,THRA;THRB,,,PHASE 1,,Small molecule,Phase 1,QNAZTOHXCZPOSA-UHFFFAOYSA-N,CC(C)C1CC(CC2C(C)CC(OCC(O)=O)CC2C)CCC1O;CC1CC(OCC(=O)O)CC(C)C1CC1CCC(O)C(C(C)C)C1
SOBLIDOTIN,SOBLIDOTIN,CHEMBL3989512,BRD:BRD-K00003174-001-01-9,rep_single_dose,MICROTUBULE INHIBITOR,,,,,,Small molecule,Phase 2,DZMVCVHATYROOS-ZBFGKEHZSA-N,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1CCCCC1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C
SOBUZOXANE,SOBUZOXANE,CHEMBL1256871,BRD:BRD-K87595680-001-05-9,rep_single_dose,TOPOISOMERASE INHIBITOR,,,,,,Small molecule,Unknown,OCOKWVBYZHBHLU-UHFFFAOYSA-N,CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O
SODIUM-ASCORBATE,SODIUM-ASCORBATE,,BRD:BRD-A67265925-236-02-6,rep_single_dose,,,,,,,,NA,,
SODIUM-BUTYRATE,SODIUM-BUTYRATE,,BRD:BRD-BRD-K05878375-236-05-7;BRD:BRD-K05878375-236-05-7,rep_primary;rep_single_dose,HDAC INHIBITOR,BCHE;FFAR2;FFAR3;HDAC1;HDAC2;HDAC3;HDAC8,,,PHASE 2,,,NA,,CCCC(O)=O
SODIUM-DANSHENSU,SODIUM-DANSHENSU,,BRD:BRD-A93699261-236-03-4;BRD:BRD-BRD-A93699261-236-03-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(CC1CCC(O)C(O)C1)C(O)=O
SODIUM-DODECYL-SULFATE,SODIUM-DODECYL-SULFATE,,BRD:BRD-M58433298-001-02-4,rep_single_dose,,ALB,,,,,,NA,,
SODIUM-GLUCOHEPTONATE,SODIUM-GLUCOHEPTONATE,,BRD:BRD-BRD-K35952844-236-01-6,rep_primary,,,,,LAUNCHED,,,NA,,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O
SODIUM-GLUCONATE,SODIUM-GLUCONATE,,BRD:BRD-BRD-M54096567-001-01-9;BRD:BRD-M54096567-001-01-9,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,[NA].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O;OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O
SODIUM-GUALENATE,SODIUM-GUALENATE,,BRD:BRD-BRD-K80043866-236-01-1;BRD:BRD-K80043866-236-01-1,rep_primary;rep_single_dose,ANTACID,,,,LAUNCHED,,,NA,,CC(C)C1CCC(C)C2C(CC(C)C2C1)S(O)(=O)=O
SODIUM-MONOFLUOROPHOSPHATE,SODIUM-MONOFLUOROPHOSPHATE,,BRD:BRD-BRD-K99308954-304-02-4;BRD:BRD-K99308954-304-02-4,rep_primary;rep_single_dose,,PYGM,CAVITIES,,LAUNCHED,,,NA,,OP(O)(F)=O
SODIUM-NITRITE,SODIUM-NITRITE,,BRD:BRD-K61230716-236-03-5,rep_single_dose,NITRIC OXIDE DONOR,,,,,,,NA,,
SODIUM-NITROPRUSSIDE,SODIUM-NITROPRUSSIDE,,BRD:BRD-K00003606-380-01-9,rep_single_dose,NITRIC OXIDE DONOR,,,,,,,NA,,
SODIUM-ORTHOVANADATE,SODIUM-ORTHOVANADATE,CHEMBL179166,BRD:BRD-K60600693-314-03-2,rep_single_dose,,,,,,,Small molecule,NA,,
SODIUM-OXYBATE,SODIUM-OXYBATE,,BRD:BRD-BRD-K82166906-236-02-8;BRD:BRD-K82166906-236-02-8,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRB1;HCAR1;SLC52A2,NARCOLEPSY,,LAUNCHED,,,NA,,OCCCC(O)=O
SODIUM-PICOSULFATE,SODIUM-PICOSULFATE,,BRD:BRD-BRD-K77251551-304-02-9;BRD:BRD-K77251551-304-02-9,rep_primary;rep_single_dose,,,CONSTIPATION,,LAUNCHED,,,NA,,OS(=O)(=O)OC1CCC(CC1)C(C1CCC(OS(O)(=O)=O)CC1)C1CCCCN1
SODIUM-SALICYLATE,SODIUM-SALICYLATE,,BRD:BRD-BRD-K93632104-001-18-0,rep_primary,PROSTANOID RECEPTOR ANTAGONIST,ASIC3;PTGS1;PTGS2,"FEVER, PAIN RELIEF",,LAUNCHED,,,NA,,OC(=O)C1CCCCC1O
SODIUM-STIBOGLUCONATE,SODIUM-STIBOGLUCONATE,,BRD:BRD-A60786380-412-01-5;BRD:BRD-BRD-A60786380-412-01-5,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE PHOSPHATASE INHIBITOR,PTPN6;TOP1,LEISHMANIASIS,,LAUNCHED,,,NA,,OCC(O)C1O[SB]2(O)(O[SB]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O
SODIUM-TANSHINONE-II-A-SULFONATE,SODIUM-TANSHINONE-II-A-SULFONATE,,BRD:BRD-BRD-K84798689-236-02-9;BRD:BRD-K84798689-236-02-9,rep_multi_dose;rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,,,,PHASE 2,,,NA,,CC1C2C(OC1S(O)(=O)=O)-C1CCC3C(CCCC3(C)C)C1C(=O)C2=O
SODIUM-TETRADECYL-SULFATE,SODIUM-TETRADECYL-SULFATE,,BRD:BRD-A55664972-236-02-6;BRD:BRD-BRD-A55664972-236-02-6;BRD:BRD-BRD-K84544951-236-01-0;BRD:BRD-K84544951-236-01-0,rep_primary;rep_single_dose,,PROC;PROS1,"VARICOSE VEINS, VARICOSE VEINS",,LAUNCHED,"Multiple values for structure_id: {'K84544951', 'A55664972'}, defaulting to None",,NA,,CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O;CCCCCCCCCCCCCCOS(O)(=O)=O
SOFALCONE,SOFALCONE,CHEMBL1441961,BRD:BRD-BRD-K01039503-001-01-2;BRD:BRD-K01039503-001-01-2,rep_primary;rep_single_dose,MUCUS PROTECTING AGENT,CBR1,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Unknown,GFWRVVCDTLRWPK-KPKJPENVSA-N,CC(C)=CCOC1CCC(/C=C/C(=O)C2CCC(OCC=C(C)C)CC2OCC(=O)O)CC1;CC(C)=CCOC1CCC(\C=C\C(=O)C2CCC(OCC=C(C)C)CC2OCC(O)=O)CC1
SOFOSBUVIR-IMPURITY-M,SOFOSBUVIR-IMPURITY-M,,BRD:BRD-K00003527-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,,NA,,
SOGRAZEPIDE,SOGRAZEPIDE,CHEMBL324547,BRD:BRD-K00004608-001-01-9,rep_single_dose,GASTRIN INHIBITOR,,,,,,Protein,Phase 2,YDZYKNJZCVIKPP-VWLOTQADSA-N,CNC1CCCC(NC(=O)N[C@@H]2N=C(C3CCCCN3)C3CCCCC3N(CC(=O)C(C)(C)C)C2=O)C1
SOLAMARGINE,SOLAMARGINE,CHEMBL443114,BRD:BRD-A65562236-001-01-2;BRD:BRD-BRD-A65562236-001-01-2,rep_primary;rep_single_dose,APOPTOSIS INHIBITOR,,,,PHASE 3,,Small molecule,NA,MBWUSSKCCUMJHO-ZGXDEBHDSA-N,C[C@@H]1CC[C@@]2(NC1)O[C@H]1C[C@H]3[C@@H]4CC=C5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O[C@@H]7O[C@@H](C)[C@H](O)[C@@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C;CC1C2C(CC3C4CC=C5CC(CCC5(C)C4CCC23C)OC2OC(CO)C(OC3OC(C)C(O)C(O)C3O)C(O)C2OC2OC(C)C(O)C(O)C2O)OC11CCC(C)CN1
SOLCITINIB,SOLCITINIB,CHEMBL3301606,BRD:BRD-BRD-K69215269-001-01-1;BRD:BRD-K69215269-001-01-1,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1,,,PHASE 1,,Small molecule,Phase 2,MPYACSQFXVMWNO-UHFFFAOYSA-N,CC1(C)CN(C(=O)C2CCC(-C3CCCC4NC(NC(=O)C5CC5)NN34)CC2)C1;CC1(C)CN(C1)C(=O)C1CCC(CC1)-C1CCCC2NC(NC(=O)C3CC3)NN12
SOLIFENACIN-SUCCINATE,SOLIFENACIN-SUCCINATE,,BRD:BRD-BRD-K24723746-036-02-5;BRD:BRD-K24723746-036-02-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,"URINARY INCONTINENCE, URINARY FREQUENCY",,LAUNCHED,,,NA,,O=C(O[C@H]1CN2CCC1CC2)N1CCC2CCCCC2[C@@H]1C1CCCCC1
SOLITHROMYCIN,SOLITHROMYCIN,CHEMBL1232510;CHEMBL1240704,BRD:BRD-BRD-K32256160-001-01-9;BRD:BRD-K32256160-001-01-9,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,IXXFZUPTQVDPPK-ZAWHAJPISA-N;QHOXYVNRQLJLAO-FDCTVVDYSA-N,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3CC(NN3)-C3CCCC(N)C3)C(=O)O[C@]12C)OC;CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3CC(-C4CCCC(N)C4)NN3)C(=O)O[C@]12C;CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)C[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3CC(-C4CCCC(N)C4)NN3)C(=O)O[C@]12C
SOLRIAMFETOL,SOLRIAMFETOL,CHEMBL4297212;CHEMBL4297620,BRD:BRD-K00004707-001-01-9,rep_single_dose,DOPAMINE REUPTAKE INHIBITOR,,,,,,Small molecule,Approved,KAOVAAHCFNYXNJ-SBSPUUFOSA-N;UCTRAOBQFUDCSR-SECBINFHSA-N,CL.NC(=O)OC[C@H](N)CC1CCCCC1;NC(=O)OC[C@H](N)CC1CCCCC1
SOLTAMOX,SOLTAMOX,CHEMBL786;CHEMBL83,GDSC1:1199;GDSC2:1199,gdsc,,,,,,,Small molecule,Approved,FQZYTYWMLGAPFJ-OQKDUQJOSA-N;NKANXQFJJICGDU-QPLCGJKRSA-N,CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1;CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
SOMANTADINE,SOMANTADINE,CHEMBL2111145,BRD:BRD-BRD-K85764479-003-01-0;BRD:BRD-K85764479-003-01-0,rep_primary;rep_single_dose,ANTIVIRAL,,,,PHASE 1,,Small molecule,Unknown,OWKXRDQRMTVCEX-UHFFFAOYSA-N,CC(C)(N)CC12CC3CC(CC(C3)C1)C2
SOMATOSTATIN,SOMATOSTATIN,CHEMBL1823872,BRD:BRD-BRD-K14681867-001-01-6;BRD:BRD-K14681867-001-01-6,rep_primary;rep_single_dose,SOMATOSTATIN RECEPTOR AGONIST,OPRD1;OPRM1;SSTR1;SSTR2;SSTR3;SSTR4;SSTR5,HEMORRHAGE,,LAUNCHED,,Protein,Phase 3,NHXLMOGPVYXJNR-ATOGVRKGSA-N,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2CCCCC2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N;C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2C[NH]C3CCCCC23)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O
SONEPIPRAZOLE,SONEPIPRAZOLE,CHEMBL69759,BRD:BRD-K69857269-001-03-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,WNUQCGWXPNGORO-NRFANRHFSA-N,NS(=O)(=O)C1CCC(N2CCN(CC[C@@H]3OCCC4CCCCC43)CC2)CC1
SONIDEGIB,SONIDEGIB,CHEMBL2105737,BRD:BRD-BRD-K19796430-001-05-6;BRD:BRD-K19796430-001-05-6,rep_multi_dose;rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,SMO,BASAL CELL CARCINOMA (BCC),,LAUNCHED,,Small molecule,Approved,VZZJRYRQSPEMTK-CALCHBBNSA-N,C[C@H]1CN(C[C@@H](C)O1)C1CCC(NC(=O)C2CCCC(-C3CCC(OC(F)(F)F)CC3)C2C)CN1;CC1C(C(=O)NC2CCC(N3C[C@@H](C)O[C@@H](C)C3)NC2)CCCC1-C1CCC(OC(F)(F)F)CC1
SOPHOCARPINE,SOPHOCARPINE,CHEMBL377725,BRD:BRD-BRD-K66845263-001-03-0;BRD:BRD-K66845263-001-03-0,rep_primary;rep_single_dose,,,,,PHASE 3,,Small molecule,NA,AAGFPTSOPGCENQ-JLNYLFASSA-N,O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34
SORAFENIB,SORAFENIB,CHEMBL1336,BRD:BRD-BRD-K23984367-075-15-2;BRD:BRD-K23984367-001-07-5;BRD:BRD-K23984367-075-15-2;CTRP:349006;GDSC1:30;GDSC2:1085,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, RAF INHIBITOR, RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR",BRAF;DDR2;FGFR1;FLT1;FLT3;FLT4;KDR;KIT;PDGFRB;RAF1;RET,"RENAL CELL CARCINOMA (RCC), THYROID CANCER, HEPATOCELLULAR CARCINOMA (HCC)",,LAUNCHED,,Small molecule,Approved,MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C(F)(F)F)C3)CC2)CCN1;CNC(=O)C1CC(OC2CCC(NC(=O)NC3CCC(CL)C(C3)C(F)(F)F)CC2)CCN1
SORAPRAZAN,SORAPRAZAN,CHEMBL2105502,BRD:BRD-K00004585-001-01-9,rep_single_dose,PROTON PUMP INHIBITOR,,,,,,Small molecule,Unknown,PWILYDZRJORZDR-MISYRCLQSA-N,COCCO[C@@H]1C2CCN3C(C)C(C)NC3C2N[C@H](C2CCCCC2)[C@H]1O
SORBIC-ACID,SORBIC-ACID,,BRD:BRD-BRD-K55892330-001-01-8;BRD:BRD-K55892330-001-01-8,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC=CC=CC(O)=O
SORBINIL,SORBINIL,CHEMBL266497,BRD:BRD-A89164055-001-03-3;BRD:BRD-BRD-A89164055-001-03-3,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1B1,,,PHASE 3,,Small molecule,Phase 3,LXANPKRCLVQAOG-NSHDSACASA-N,FC1CCC2OCCC3(NC(=O)NC3=O)C2C1;O=C1NC(=O)[C@@]2(CCOC3CCC(F)CC32)N1
SORBITOL,SORBITOL,CHEMBL1682,BRD:BRD-BRD-K66035042-001-10-1;BRD:BRD-K66035042-001-10-1,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,,,LAUNCHED,,Small molecule,Approved,FBPFZTCFMRRESA-JGWLITMVSA-N,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO;OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO;OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
SOTAGLIFLOZIN,SOTAGLIFLOZIN,CHEMBL3039507,BRD:BRD-BRD-K05850076-001-01-5;BRD:BRD-K05850076-001-01-5,rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,SLC5A1;SLC5A2,,,PHASE 3,,Small molecule,Approved,QKDRXGFQVGOQKS-CRSSMBPESA-N,CCOC1CCC(CC2CC([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)CCC2CL)CC1;CCOC1CCC(CC2CC(CCC2CL)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)CC1
SOTALOL,SOTALOL,CHEMBL252312;CHEMBL471,BRD:BRD-A33168282-003-18-0;BRD:BRD-BRD-A33168282-003-18-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;KCNH2,"ATRIAL FIBRILLATION (AF), VENTRICULAR ARRHYTHMIAS",,LAUNCHED,,Small molecule,Approved,ZBMZVLHSJCTVON-GFCCVEGCSA-N;ZBMZVLHSJCTVON-UHFFFAOYSA-N,CC(C)NC[C@@H](O)C1CCC(NS(C)(=O)=O)CC1;CC(C)NCC(O)C1CCC(NS(C)(=O)=O)CC1
SOTRASTAURIN,SOTRASTAURIN,CHEMBL565612,BRD:BRD-BRD-K16761703-001-03-8;BRD:BRD-K16761703-001-03-8;CTRP:661032,ctrp;rep_primary;rep_single_dose,PKC INHIBITOR,PRKCA;PRKCB;PRKCD;PRKCE;PRKCH;PRKCQ,,,PHASE 2,,Small molecule,Phase 2,OAVGBZOFDPFGPJ-UHFFFAOYSA-N,CN1CCN(C2NC(C3=C(C4C[NH]C5CCCCC45)C(=O)NC3=O)C3CCCCC3N2)CC1;CN1CCN(CC1)C1NC(C2=C(C(=O)NC2=O)C2C[NH]C3CCCCC23)C2CCCCC2N1
SP-100030,SP-100030,,BRD:BRD-K71900389-001-02-9,rep_single_dose,NFKB PATHWAY INHIBITOR,JUN;NFKB1,,,,,,NA,,
SP-141,SP-141,,BRD:BRD-BRD-K28571773-001-01-6;BRD:BRD-K28571773-001-01-6,rep_primary;rep_single_dose,UBIQUITIN LIGASE INHIBITOR,MDM2,,,PRECLINICAL,,,NA,,COC1CCC2[NH]C3C(NCCC3C2C1)-C1CCCC2CCCCC12
SP-420,SP-420,CHEMBL1092665,BRD:BRD-BRD-K23005288-001-01-8;BRD:BRD-K23005288-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Phase 2,YASYAEVZKXPYIZ-MRXNPFEDSA-N,COCCOCCOC1CCC(C2=N[C@](C)(CS2)C(O)=O)C(O)C1;COCCOCCOC1CCC(C2=N[C@@](C)(C(=O)O)CS2)C(O)C1
SP-924,SP-924,CHEMBL603469,GDSC1:1024,gdsc,,,,,,,Small molecule,Phase 3,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)CNC4=O
SPAGLUMIC-ACID,SPAGLUMIC-ACID,,BRD:BRD-BRD-K68405354-001-06-4;BRD:BRD-BRD-K68405354-001-07-2;BRD:BRD-K68405354-001-06-4;BRD:BRD-K68405354-001-07-2,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM3,"ALLERGIC CONJUNCTIVITIS, ALLERGIC RHINITIS",,LAUNCHED,,,NA,,CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O
SPARFLOXACIN,SPARFLOXACIN,CHEMBL850,BRD:BRD-BRD-K07612980-001-05-3;BRD:BRD-BRD-K07612980-001-07-9;BRD:BRD-K07612980-001-05-3;BRD:BRD-K07612980-001-07-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,,,WITHDRAWN,,Small molecule,Approved,DZZWHBIBMUVIIW-DTORHVGOSA-N,C[C@@H]1CN(C2C(F)C(N)C3C(=O)C(C(=O)O)CN(C4CC4)C3C2F)C[C@H](C)N1;C[C@H]1CN(C[C@@H](C)N1)C1C(F)C(N)C2C(C1F)N(CC(C(O)=O)C2=O)C1CC1
SPARSENTAN,SPARSENTAN,CHEMBL539423,BRD:BRD-K00003253-001-01-9,rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,WRFHGDPIDHPWIQ-UHFFFAOYSA-N,CCCCC1=NC2(CCCC2)C(=O)N1CC1CCC(-C2CCCCC2S(=O)(=O)NC2NOC(C)C2C)C(COCC)C1
SPARTEINE-(+),SPARTEINE-(+),,BRD:BRD-K38203080-001-01-2,rep_single_dose,,,,,,,,NA,,
SPARTEINE-(-),SPARTEINE-(-),,BRD:BRD-K86872788-065-01-5,rep_single_dose,,,,,,,,NA,,
SPARTEINE-SULFATE,SPARTEINE-SULFATE,,BRD:BRD-BRD-K32847234-065-04-6;BRD:BRD-K32847234-065-04-6,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1
SPAUTIN-1,SPAUTIN-1,,BRD:BRD-K84964099-001-03-9;CTRP:657183,ctrp;rep_single_dose,DEUBIQUITINASE INHIBITOR,USP10;USP13,,,,,,NA,,
SPERMIDINE,SPERMIDINE,CHEMBL19612,BRD:BRD-BRD-K40438880-305-06-6;BRD:BRD-K40438880-305-06-6,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR MODULATOR,KCNJ4;TXNRD1,,,PRECLINICAL,,Small molecule,Phase 3,ATHGHQPFGPMSJY-UHFFFAOYSA-N,NCCCCNCCCN
SPERMINE,SPERMINE,CHEMBL23194,BRD:BRD-BRD-K18375018-376-02-3;BRD:BRD-K18375018-376-02-3,rep_multi_dose;rep_primary;rep_single_dose,,CA14;CA4;CA6;CA9;CASR;GRIN1;GRIN2A;KCNJ4;ODC1;SMOX;SMS;TRPM4;TRPM5,,,PRECLINICAL,,Small molecule,Early Phase,PFNFFQXMRSDOHW-UHFFFAOYSA-N,NCCCNCCCCNCCCN
SPHINGOSINE KINASE 1 INHIBITOR II,SPHINGOSINE KINASE 1 INHIBITOR II,,GDSC1:408,gdsc,,,,,,,,NA,,
SPHINGOSYLPHOSPHORYLCHOLINE,SPHINGOSYLPHOSPHORYLCHOLINE,,BRD:BRD-A35379661-001-04-6;BRD:BRD-BRD-A35379661-001-04-6,rep_primary;rep_single_dose,GENE EXPRESSION STIMULANT,GPR12,,,PRECLINICAL,,,NA,,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C
SPINOSAD,SPINOSAD,CHEMBL2040681;CHEMBL4297065,BRD:BRD-K00080753-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,JFLRKDZMHNBDQS-SGSTVUCESA-N;JFLRKDZMHNBDQS-UCQUSYKYSA-N,CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C(C)[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1.CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1;CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@@H]3[C@@H](C=C(C)[C@@H]4C[C@@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@@H]34)[C@@H]2CC(=O)O1.CC[C@H]1CCC[C@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)[C@@H](C)C(=O)C2=C[C@H]3[C@@H]4C[C@H](O[C@@H]5O[C@@H](C)[C@H](OC)[C@@H](OC)[C@H]5OC)C[C@H]4C=C[C@H]3C2CC(=O)O1
SPIPERONE,SPIPERONE,CHEMBL267930,BRD:BRD-BRD-K55468218-001-26-1;BRD:BRD-K55468218-001-26-1,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;DRD1;DRD2;DRD3;DRD4;DRD5;HTR1A;HTR1D;HTR2A;HTR2B;HTR2C;HTR6;HTR7,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Unknown,DKGZKTPJOSAWFA-UHFFFAOYSA-N,FC1CCC(CC1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1CCCCC1;O=C(CCCN1CCC2(CC1)C(=O)NCN2C1CCCCC1)C1CCC(F)CC1
SPIRADOLINE,SPIRADOLINE,CHEMBL118865;CHEMBL70586,BRD:BRD-BRD-K28192623-066-08-1;BRD:BRD-K28192623-066-08-1,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1,,,PHASE 2,,Small molecule,Phase 1,NYKCGQQJNVPOLU-ONTIZHBOSA-N;NYKCGQQJNVPOLU-UHFFFAOYSA-N,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)CC1CCC(CL)C(CL)C1;CN(C(=O)CC1CCC(CL)C(CL)C1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1;CN(C(=O)CC1CCC(CL)C(CL)C1)C1CCC2(CCCO2)CC1N1CCCC1
SPIRAMYCIN,SPIRAMYCIN,CHEMBL453514,BRD:BRD-A67305656-001-01-5;BRD:BRD-BRD-A67305656-001-01-5,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,"TOXOPLASMOSIS, SOFT TISSUE INFECTION",,LAUNCHED,,Small molecule,Approved,ACTOXUHEUCPTEW-CEUOBAOPSA-N,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O;CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C
SPIRAPRIL HYDROCHLORIDE,SPIRAPRIL HYDROCHLORIDE,CHEMBL1200831,BRD:BRD-K00074789-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,CLDOLNORSLLQDI-OOAIBONUSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.CL
SPIRONOLACTONE,SPIRONOLACTONE,CHEMBL1393,BRD:BRD-BRD-K90027355-001-13-3;BRD:BRD-BRD-K90027355-001-19-0;BRD:BRD-K90027355-001-13-3;BRD:BRD-K90027355-001-19-0,rep_multi_dose;rep_primary;rep_single_dose,MINERALOCORTICOID RECEPTOR ANTAGONIST,AR;CACNA1A;CACNA1B;CACNA1C;CACNA1D;CACNA1F;CACNA1G;CACNA1H;CACNA1I;CACNA1S;CACNA2D1;CACNA2D2;CACNA2D3;CACNB1;CACNB2;CACNB3;CACNB4;CACNG1;CYP11B2;NR3C1;NR3C2;PGR;SHBG,"HYPERALDOSTERONISM, CONGESTIVE HEART FAILURE, HEPATIC CIRRHOSIS, NEPHROTIC SYNDROME, HYPERTENSION, HYPOKALEMIA",,LAUNCHED,,Small molecule,Approved,LXMSZDCAJNLERA-ZHYRCANASA-N,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12;CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12
SPIROXATRINE,SPIROXATRINE,CHEMBL300555,BRD:BRD-A72483914-001-03-7;BRD:BRD-BRD-A72483914-001-03-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;HTR1A;HTR2B,,,PRECLINICAL,,Small molecule,Unknown,JVGBTTIJPBFLTE-UHFFFAOYSA-N,O=C1NCN(C2CCCCC2)C11CCN(CC2COC3CCCCC3O2)CC1;O=C1NCN(C2CCCCC2)C12CCN(CC1COC3CCCCC3O1)CC2
SPIZOFURONE,SPIZOFURONE,CHEMBL18098,BRD:BRD-BRD-K94934625-001-01-5;BRD:BRD-K94934625-001-01-5,rep_primary;rep_single_dose,,,,,WITHDRAWN,,Small molecule,Unknown,SETMGIIITGNLAS-UHFFFAOYSA-N,CC(=O)C1CCC2C(C1)C(=O)C1(CC1)O2;CC(=O)C1CCC2OC3(CC3)C(=O)C2C1
SPM-924,SPM-924,CHEMBL603469,GDSC1:1024,gdsc,,,,,,,Small molecule,Phase 3,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)CNC4=O
SPP86,SPP-86;SPP86,,BRD:BRD-BRD-K63253858-001-01-5;BRD:BRD-K63253858-001-01-5,rep_primary;rep_single_dose,RECEPTOR TYROSINE PROTEIN KINASE INHIBITOR,RET,,,PRECLINICAL,,,NA,,CC(C)N1NC(C#CC2CCCCC2)C2C(N)NCNC12
SPP301,SPP301,CHEMBL3989834,BRD:BRD-BRD-K19203487-001-01-4;BRD:BRD-K19203487-001-01-4,rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,PHASE 3,,Small molecule,Phase 3,YBWLTKFZAOSWSM-UHFFFAOYSA-N,COC1CCCCC1OC1C(NS(=O)(=O)C2CCC(C)CN2)NC(-C2CCNCC2)NC1OC;COC1CCCCC1OC1C(NS(=O)(=O)C2CCC(C)CN2)NC(NC1OC)-C1CCNCC1
SPRYCEL,SPRYCEL,CHEMBL1421,GDSC1:51;GDSC2:1079,gdsc,,,,,,,Small molecule,Approved,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,CC1NC(NC2NCC(C(=O)NC3C(C)CCCC3CL)S2)CC(N2CCN(CCO)CC2)N1
SQ-109,SQ-109,CHEMBL561057,BRD:BRD-A08772153-001-02-4;BRD:BRD-BRD-A08772153-001-02-4,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,FDFT1,,,PHASE 3,,Small molecule,Phase 2,JFIBVDBTCDTBRH-REZTVBANSA-N,CC(C)=CCC/C(C)=C/CNCCNC1C2CC3CC(C2)CC1C3;CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2
SQ-22536,SQ-22536,,BRD:BRD-A56987319-001-12-9;BRD:BRD-BRD-A56987319-001-12-9,rep_primary;rep_single_dose,ADENYLYL CYCLASE INHIBITOR,ADCY1,,,PRECLINICAL,,,NA,,NC1NCNC2N(CNC12)C1CCCO1
SQUALAMINE,SQUALAMINE,CHEMBL444929,BRD:BRD-K00003215-043-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 3,UIRKNQLZZXALBI-MSVGPLKSSA-N,CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O
SQUARIC-ACID-DIBUTYL-ESTER,SQUARIC-ACID-DIBUTYL-ESTER,,BRD:BRD-K00004684-001-01-9,rep_single_dose,OXIDATIVE STRESS INDUCER,,,,,,,NA,,
SR 146131,SR 146131,,BRD:BRD-K00076260-001-02-9,rep_single_dose,,,,,,,,NA,,
SR-1078,SR-1078,,BRD:BRD-K26501486-001-02-9,rep_single_dose,RETINOID RECEPTOR AGONIST,RORA;RORC,,,,,,NA,,
SR-140333,SR-140333,CHEMBL1178725,BRD:BRD-BRD-K60931454-003-01-3;BRD:BRD-K60931454-003-01-3,rep_primary;rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,TACR1,,,PHASE 2,,Small molecule,Phase 2,RPDFDSQFBCJTDY-GAQXSTBRSA-N,CC(C)OC1CCCC(CC(=O)N2CCC[C@](CC[N+]34CCC(C5CCCCC5)(CC3)CC4)(C3CCC(CL)C(CL)C3)C2)C1;CC(C)OC1CCCC(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)C3CCCCC3)(C2)C2CCC(CL)C(CL)C2)C1
SR-1664,SR-1664,,BRD:BRD-K62814487-001-03-0,rep_single_dose,PPAR RECEPTOR LIGAND,PPARG,,,,,,NA,,
SR-2211,SR-2211,,BRD:BRD-K11641193-001-03-9,rep_single_dose,RETINOID RECEPTOR INVERSE AGONIST,RORC,,,,,,NA,,
SR-2640,SR-2640,CHEMBL18132,BRD:BRD-BRD-K62562723-003-02-7;BRD:BRD-K62562723-003-02-7,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,CYSLTR1,,,PHASE 2,,Small molecule,NA,LMPZHLXYBWGGNT-UHFFFAOYSA-N,O=C(O)C1CCCCC1NC1CCCC(OCC2CCC3CCCCC3N2)C1;OC(=O)C1CCCCC1NC1CCCC(OCC2CCC3CCCCC3N2)C1
SR-27897,SR-27897,CHEMBL249973,BRD:BRD-BRD-K35629949-001-02-0;BRD:BRD-K35629949-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKAR,,,PHASE 2,,Small molecule,Unknown,ILNRQFBVVQUOLP-UHFFFAOYSA-N,O=C(O)CN1C(C(=O)NC2NC(-C3CCCCC3CL)CS2)CC2CCCCC21;OC(=O)CN1C(CC2CCCCC12)C(=O)NC1NC(CS1)-C1CCCCC1CL
SR-31747,SR-31747,,BRD:BRD-K00074858-003-02-9,rep_single_dose,,,,,,,,NA,,
SR-3306,SR-3306,,BRD:BRD-BRD-K60952143-001-01-0;BRD:BRD-K60952143-001-01-0,rep_primary;rep_single_dose,JNK INHIBITOR,MAPK10;MAPK8;MAPK9,,,PRECLINICAL,,,NA,,CC1CCC(CN1)-C1NCN(N1)-C1CCC(NC2NCCC(N2)-C2CCCC(C2)N2CCOCC2)CC1
SR-33805,SR-33805,,BRD:BRD-BRD-K43002771-034-01-6;BRD:BRD-K43002771-034-01-6,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PHASE 1,,,NA,,COC1CCC(CCN(C)CCCOC2CCC(CC2)S(=O)(=O)C2C(C(C)C)C3CCCCC3N2C)CC1OC
SR-3576,SR-3576,,BRD:BRD-BRD-K50378376-001-01-8;BRD:BRD-K50378376-001-01-8,rep_primary;rep_single_dose,JNK INHIBITOR,MAPK10,,,PRECLINICAL,,,NA,,COC1CC(NC(=O)C2CCCC(C2)-N2CC(NC(=O)NC3CCCC(C)C3)CN2)CC(OC)C1OC
SR-3677,SR-3677,CHEMBL521179,BRD:BRD-A86468475-300-02-9,rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK2,,,,,Small molecule,NA,OQWZIAVXCYIZNN-UHFFFAOYSA-N,CN(C)CCOC1CC(-C2CN[NH]C2)CCC1NC(=O)C1COC2CCCCC2O1
SR-57227A,SR-57227A,,BRD:BRD-BRD-K09397065-003-06-1;BRD:BRD-K09397065-003-06-1,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR3A,,,PHASE 2,,,NA,,NC1CCN(CC1)C1CCCC(CL)N1
SR-59230A,SR-59230A,,BRD:BRD-BRD-K35430135-003-02-3;BRD:BRD-K35430135-003-02-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,,,PRECLINICAL,,,NA,,CCC1CCCCC1OC[C@@H](O)CN[C@H]1CCCC2CCCCC12
SR-95639A,SR-95639A,,BRD:BRD-BRD-K19309090-300-05-5;BRD:BRD-K19309090-300-05-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1,,,PRECLINICAL,,,NA,,C(CN1CCOCC1)NC1CC2CCCC3CCCCC3-C2NN1
SR-II-138A,SR-II-138A,,CTRP:411770,ctrp,,,,,,,,NA,,
SR1001,SR1001,,CTRP:660317,ctrp,,,,,,,,NA,,
SR8278,SR8278,,CTRP:668858,ctrp,,,,,,,,NA,,
SRC-KINASE-INHIBITOR-I,SRC-KINASE-INHIBITOR-I,,BRD:BRD-BRD-K50495309-001-02-0;BRD:BRD-K50495309-001-02-0,rep_primary;rep_single_dose,SRC INHIBITOR,CSK;LCK;RIPK2,,,PRECLINICAL,,,NA,,COC1CC2NCNC(NC3CCC(OC4CCCCC4)CC3)C2CC1OC
SRPIN340,SRPIN340,,BRD:BRD-BRD-K62621335-001-01-7;BRD:BRD-K62621335-001-01-7,rep_primary;rep_single_dose,SERINE ARGININE PROTEIN KINASE INHIBITOR,SRPK1;SRPK2,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCC(N2CCCCC2)C(NC(=O)C2CCNCC2)C1
SRT-1720,SRT-1720,,CTRP:411820,ctrp,,,,,,,,NA,,
SRT1720,SRT1720,,BRD:BRD-BRD-K95926480-003-03-6;BRD:BRD-K95926480-003-03-6,rep_multi_dose;rep_primary;rep_single_dose,SIRT ACTIVATOR,SIRT1,,,PRECLINICAL,,,NA,,O=C(NC1CCCCC1-C1CN2C(CN3CCNCC3)CSC2N1)C1CNC2CCCCC2N1
SRT2104,SRT2104,CHEMBL4297436,BRD:BRD-BRD-K48452630-001-01-8;BRD:BRD-K48452630-001-01-8,rep_primary;rep_single_dose,SIRT ACTIVATOR,SIRT1,,,PHASE 2,,Small molecule,Phase 2,LAMQVIQMVKWXOC-UHFFFAOYSA-N,CC1NC(-C2CCCNC2)SC1C(=O)NC1CCCCC1-C1CN2C(CN3CCOCC3)CSC2N1;CC1NC(SC1C(=O)NC1CCCCC1-C1CN2C(CN3CCOCC3)CSC2N1)-C1CCCNC1
SSR180711,SSR-180711;SSR180711,CHEMBL559478,BRD:BRD-BRD-K02782351-003-01-5;BRD:BRD-K00004316-003-01-9;BRD:BRD-K02782351-003-01-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA7,,,PHASE 2,"Multiple values for structure_id: {'K02782351', 'K00004316'}, defaulting to None",Small molecule,Phase 2,RXLOZRCLQMJJLC-UHFFFAOYSA-N,BRC1CCC(OC(=O)N2CCN3CCC2CC3)CC1;O=C(OC1CCC(BR)CC1)N1CCN2CCC1CC2
SSR128129E,SSR128129E,,BRD:BRD-BRD-K65890018-236-01-1;BRD:BRD-K65890018-236-01-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1C(C)C(C(=O)C2CCC(N)C(C2)C(O)=O)N2CCCCC12
SSR240612,SSR240612,,BRD:BRD-K00003186-003-01-9,rep_single_dose,BRADYKININ RECEPTOR ANTAGONIST,,,,,,,NA,,
SSTR5 ANTAGONIST 1,SSTR5 ANTAGONIST 1,,BRD:BRD-K00091080-001-01-9,rep_single_dose,,,,,,,,NA,,
ST-1535,ST-1535,CHEMBL197669,BRD:BRD-K00004706-001-01-9,rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 1,CYYQMAWUIRPCNW-UHFFFAOYSA-N,CCCCC1NC(N)C2NC(-N3NCCN3)N(C)C2N1
ST-1859,ST-1859,,BRD:BRD-BRD-K73524797-001-01-1;BRD:BRD-K73524797-001-01-1,rep_primary;rep_single_dose,ANTIAMYLOIDOGENIC AGENT,,,,PHASE 1,,,NA,,OC1CCC2CCCCC2C1CC1C(O)CCC2CCCCC12
ST-2825,ST-2825,,BRD:BRD-BRD-K68470841-001-01-0;BRD:BRD-K68470841-001-01-0,rep_primary;rep_single_dose,MYELOID DIFFERENTIATION PRIMARY RESPONSE INHIBITOR,MYD88,,,PRECLINICAL,,,NA,,NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)CC3CCC(NC(=O)COC4CCC(CL)CC4CL)CC3)C(=O)N12
ST-91,ST-91,,BRD:BRD-BRD-K18905250-003-02-4;BRD:BRD-K18905250-003-02-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,CCC1CCCC(CC)C1N=C1NCCN1
STA-5326,STA-5326,CHEMBL4297643,BRD:BRD-BRD-K41783120-001-02-8;BRD:BRD-K41783120-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,INTERLEUKIN SYNTHESIS INHIBITOR,IL12A,,,PHASE 2,,Small molecule,Phase 2,HSKAZIJJKRAJAV-KOEQRZSOSA-N,CC1CCCC(/C=N/NC2CC(N3CCOCC3)NC(OCCC3CCCCN3)N2)C1;CC1CCCC(\C=N\NC2CC(NC(OCCC3CCCCN3)N2)N2CCOCC2)C1
STANOZOLOL,STANOZOLOL,CHEMBL2079587,BRD:BRD-BRD-K46791647-001-01-2;BRD:BRD-K46791647-001-01-2,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,ANEMIA,,LAUNCHED,,Small molecule,Approved,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5[NH]NCC5C[C@]4(C)[C@H]3CC[C@]12C;C[C@]12CC3C[NH]NC3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
STAT3-INHIBITOR-VI,STAT3-INHIBITOR-VI,,BRD:BRD-K40853697-001-20-5,rep_single_dose,STAT INHIBITOR,STAT3,,,,,,NA,,
STATIL,STATIL,,BRD:BRD-K68332390-001-04-9,rep_single_dose,ALDOSE REDUCTASE INHIBITOR,,,,,,,NA,,
STATTIC,STATTIC,,BRD:BRD-BRD-K17061841-001-03-5;BRD:BRD-K17061841-001-03-5,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCC2C=CS(=O)(=O)C2C1
STAUROSPORINE,STAUROSPORINE,CHEMBL388978,CTRP:50769,ctrp,,,,,,,Small molecule,NA,HKSZLNNOFSGOKW-FYTWVXJKSA-N,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)N1C3CCCCC3C3C4C(C5C6CCCCC6N2C5C31)C(=O)NC4
STAVUDINE,STAVUDINE,CHEMBL991,BRD:BRD-BRD-K93880783-001-26-6;BRD:BRD-K93880783-001-26-6,rep_primary;rep_single_dose,"DNA DIRECTED DNA POLYMERASE INHIBITOR, NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR",,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,XNKLLVCARDGLGL-JGVFFNPUSA-N,CC1CN([C@@H]2O[C@H](CO)C=C2)C(=O)[NH]C1=O;CC1CN([C@H]2C=C[C@@H](CO)O2)C(=O)[NH]C1=O
STEMREGENIN 1,STEMREGENIN 1,,CTRP:609063,ctrp,,,,,,,,NA,,
STEMREGENIN-1,STEMREGENIN-1,,BRD:BRD-BRD-K36739687-001-03-0;BRD:BRD-K36739687-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,ARYL HYDROCARBON RECEPTOR ANTAGONIST,AHR,,,PRECLINICAL,,,NA,,CC(C)N1CNC2C(NCCC3CCC(O)CC3)NC(NC12)-C1CSC2CCCCC12
STEPRONIN,STEPRONIN,CHEMBL2107531,BRD:BRD-A04506385-001-01-2;BRD:BRD-BRD-A04506385-001-01-2,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,,,LAUNCHED,,Small molecule,Unknown,JNYSEDHQJCOWQU-UHFFFAOYSA-N,CC(SC(=O)C1CCCS1)C(=O)NCC(=O)O;CC(SC(=O)C1CCCS1)C(=O)NCC(O)=O
STETADERM,STETADERM,,BRD:BRD-BRD-K93900986-001-15-0;BRD:BRD-K93900986-001-15-0,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C
STF-118804,STF-118804,,BRD:BRD-BRD-K39171998-001-01-1;BRD:BRD-K39171998-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,NAMPT INHIBITOR,NAMPT,,,PRECLINICAL,,,NA,,CC1OC(NC1CS(=O)(=O)C1CCC(C)CC1)-C1CCC(CC1)C(=O)NCC1CCCNC1
STF-31,STF-31,,BRD:BRD-BRD-K22477529-001-02-7;BRD:BRD-K22477529-001-02-7;CTRP:652975,ctrp;rep_primary;rep_single_dose,NAMPT INHIBITOR,NAMPT;SLC2A1,,,PRECLINICAL,,,NA,,CC(C)(C)C1CCC(CC1)S(=O)(=O)NCC1CCC(CC1)C(=O)NC1CCCNC1
STF-62247,STF-62247,,BRD:BRD-BRD-K85479953-001-11-3;BRD:BRD-K85479953-001-11-3;GDSC1:258,gdsc;rep_primary;rep_single_dose,AUTOPHAGY INDUCER,,,,PRECLINICAL,,,NA,,CC1CCCC(NC2NC(CS2)-C2CCNCC2)C1
STF62247,STF62247,,GDSC1:258,gdsc,,,,,,,,NA,,
STREPTOMYCIN,STREPTOMYCIN,CHEMBL1950576;CHEMBL372795,BRD:BRD-BRD-K07166362-330-02-8;BRD:BRD-K07166362-330-02-8,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,TUBERCULOSIS,,LAUNCHED,,Small molecule,Approved,ASXBYYWOLISCLQ-HZYVHMACSA-N;UCSJYZPVAKXKNQ-HZYVHMACSA-N,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O;CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O;CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O
STREPTOZOTOCIN,STREPTOZOTOCIN,CHEMBL1651906,BRD:BRD-BRD-K34411947-001-12-5;BRD:BRD-K34411947-001-12-5,rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,SLC2A2,PANCREATIC CANCER,,LAUNCHED,,Small molecule,Approved,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O;CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O;CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
STRONTIUM-RANELATE,STRONTIUM-RANELATE,,BRD:BRD-K83146339-001-04-0,rep_single_dose,"BONE FORMATION STIMULANT, BONE RESORPTION INHIBITOR",CASR,,,,,,NA,,
STRYCHNINE,STRYCHNINE,CHEMBL2103753;CHEMBL2146114;CHEMBL227934;CHEMBL612118,BRD:BRD-A09094913-065-01-0;BRD:BRD-BRD-A09094913-065-01-0,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;CHRNA10;CHRNA9;GLRA1;GLRA2;GLRA3;GLRB,,,PRECLINICAL,,Small molecule,Unknown,GOOCRIHPADOQAS-ZNUXJMJHSA-N;PCGVPMHGSJFFTI-ZEYGOCRCSA-N;QMGVPVSNSZLJIA-FVWCLLPLSA-N;VNIVZTFZIJTNDV-ZEYGOCRCSA-N,O=C1C[C@@H]2OCC=C3CN4CC[C@]56C7CCCCC7N1[C@H]5[C@H]2[C@H]3C[C@H]46;O=C1C[C@@H]2OCC=C3CN4CC[C@]56C7CCCCC7N1[C@H]5[C@H]2[C@H]3C[C@H]46.O=[N+]([O-])O;O=C1C[C@@H]2OCC=C3CN4CC[C@]56C7CCCCC7N1[C@H]5[C@H]2[C@H]3C[C@H]46.O=C1C[C@@H]2OCC=C3CN4CC[C@]56C7CCCCC7N1[C@H]5[C@H]2[C@H]3C[C@H]46.O=S(=O)(O)O;O=C1C[C@@H]2OCC=C3CN4CC[C@]56C7CCCCC7N1[C@H]5[C@H]2[C@H]3C[C@H]46.O=P(O)(O)O;O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1C1CCCCC61
SU-101,SU-101,CHEMBL960,GDSC2:1578,gdsc,,,,,,,Small molecule,Approved,VHOGYURTWQBHIL-UHFFFAOYSA-N,CC1ONCC1C(=O)NC1CCC(C(F)(F)F)CC1
SU-11248,SU-11248,CHEMBL535,GDSC1:5,gdsc,,,,,,,Small molecule,Approved,WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)C1C(C)[NH]C(/C=C2\C(=O)NC3CCC(F)CC32)C1C
SU11274,SU-11274;SU11274,,BRD:BRD-BRD-K02965346-001-07-5;BRD:BRD-K02965346-001-07-5;CTRP:606586;GDSC1:285,ctrp;gdsc;rep_primary;rep_single_dose,"HEPATOCYTE GROWTH FACTOR RECEPTOR INHIBITOR, TYROSINE KINASE INHIBITOR",MET,,,PRECLINICAL,,,NA,,CN(C1CCCC(CL)C1)S(=O)(=O)C1CCC2NC(=O)\C(=C/C3[NH]C(C)C(C(=O)N4CCN(C)CC4)C3C)C2C1
SU014813,SU014813,,BRD:BRD-BRD-K75911534-001-01-6;BRD:BRD-K75911534-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,"PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",KDR,,,PHASE 2,,,NA,,CC1[NH]C(\C=C2\C(=O)NC3CCC(F)CC23)C(C)C1C(=O)NC[C@H](O)CN1CCOCC1
SU16F,SU16F,,BRD:BRD-K91106808-001-03-9,rep_single_dose,PDGFR TYROSINE KINASE RECEPTOR INHIBITOR,PDGFRB,,,,,,NA,,
SU3327,SU3327,,BRD:BRD-BRD-K32730239-001-01-0;BRD:BRD-K32730239-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,JNK INHIBITOR,MAPK8,,,PRECLINICAL,,,NA,,NC1NNC(SC2NCC(S2)[N+]([O-])=O)S1
SU9516,SU9516,CHEMBL258805,BRD:BRD-K94883909-001-17-7,rep_single_dose,CDK INHIBITOR,CDK1;CDK2;CDK4;CDK5,,,,,Small molecule,Phase 1,QNUKRWAIZMBVCU-WCIBSUBMSA-N,COC1CCC2C(C1)/C(=C/C1CNC[NH]1)C(=O)N2
SUBERANILOHYDROXAMIC ACID,SUBERANILOHYDROXAMIC ACID,,GDSC1:1012;GDSC2:1012,gdsc,,,,,,,,NA,,
SUBEROYLANILIDE HYDROXAMIC ACID,SUBEROYLANILIDE HYDROXAMIC ACID,CHEMBL98,GDSC1:1012;GDSC2:1012,gdsc,,,,,,,Small molecule,Approved,WAEXFXRVDQXREF-UHFFFAOYSA-N,O=C(CCCCCCC(=O)NC1CCCCC1)NO
SUBSTANCE-P,SUBSTANCE-P,,BRD:BRD-BRD-K23106423-001-01-0;BRD:BRD-K23106423-001-01-0,rep_primary;rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,TACR1;TACR2;TACR3,,,PHASE 1,,,NA,,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O
SUCCINIC-ACID,SUCCINIC-ACID,,BRD:BRD-BRD-K45238818-001-02-6;BRD:BRD-K45238818-001-02-6,rep_primary;rep_single_dose,,ALDH5A1;ASPH;BBOX1;HSD17B6;OXCT1;OXCT2;P3H1;P3H2;P3H3;P4HA1;P4HA2;PLOD1;PLOD3;SDHA;SDHB;SDHC;SDHD;SLC13A1;SLC13A2;SLC13A3;SLC25A10;SUCLA2;SUCLG1;SUCLG2;SUCNR1;TMLHE,,,LAUNCHED,,,NA,,OC(=O)CCC(O)=O
SUCCINOBUCOL,SUCCINOBUCOL,CHEMBL83626,BRD:BRD-K00003183-001-01-9,rep_single_dose,ANTIOXIDANT,VCAM1,,,,,Small molecule,Phase 3,RKSMVPNZHBRNNS-UHFFFAOYSA-N,CC(C)(SC1CC(C(C)(C)C)C(O)C(C(C)(C)C)C1)SC1CC(C(C)(C)C)C(OC(=O)CCC(=O)O)C(C(C)(C)C)C1
SUCCINYLSULFATHIAZOLE,SUCCINYLSULFATHIAZOLE,CHEMBL1484857,BRD:BRD-BRD-K01950558-001-14-7;BRD:BRD-K01950558-001-14-7,rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR,,,PHASE 2,,Small molecule,Unknown,SKVLYVHULOWXTD-UHFFFAOYSA-N,O=C(O)CCC(=O)NC1CCC(S(=O)(=O)NC2NCCS2)CC1;OC(=O)CCC(=O)NC1CCC(CC1)S(=O)(=O)NC1NCCS1
SUCRALOSE,SUCRALOSE,CHEMBL2107529,BRD:BRD-BRD-K58968598-001-03-6;BRD:BRD-K58968598-001-03-6,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Phase 3,BAQAVOSOZGMPRM-KBFHZYTNSA-N,OC[C@@H]1O[C@H](O[C@]2(CCL)O[C@H](CCL)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H](O)[C@H]1CL;OC[C@H]1O[C@H](O[C@]2(CCL)O[C@H](CCL)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1CL
SUCROSE,SUCROSE,CHEMBL253582,BRD:BRD-K74724920-001-02-4,rep_single_dose,,ACTA1;ATOX1;C22ORF28;LYZ,,,,,Small molecule,Approved,CZMRCDWAGMRECN-UGDNZRGBSA-N,OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
SUCROSE-OCTAACETATE,SUCROSE-OCTAACETATE,CHEMBL2105790,BRD:BRD-BRD-K01294196-001-01-5;BRD:BRD-K01294196-001-01-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,ZIJKGAXBCRWEOL-SAXBRCJISA-N,CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O
SUFENTANIL,SUFENTANIL,CHEMBL658,BRD:BRD-BRD-K21547160-001-01-4;BRD:BRD-K21547160-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR MODULATOR,OPRD1;OPRK1;OPRM1,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,GGCSSNBKKAUURC-UHFFFAOYSA-N,CCC(=O)N(C1CCCCC1)C1(COC)CCN(CCC2CCCS2)CC1
SUFUGOLIX,SUFUGOLIX,CHEMBL22055,BRD:BRD-K00004582-001-01-9,rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,UCQSBGOFELXYIN-UHFFFAOYSA-N,CONC(=O)NC1CCC(-C2SC3C(C2CN(C)CC2CCCCC2)C(=O)N(-C2CCCCC2)C(=O)N3CC2C(F)CCCC2F)CC1
SUGAMMADEX,SUGAMMADEX,CHEMBL2111107,BRD:BRD-K00003322-363-01-9,rep_single_dose,NEUROMUSCULAR BLOCKADE REVERSAL AGENT,,,,,,Oligosaccharide,Approved,WHRODDIHRRDWEW-ZWYCLXBASA-N,O=C(O)CCSC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]9[C@H](O)C(O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]9CSCCC(=O)O)O[C@@H]8CSCCC(=O)O)O[C@@H]7CSCCC(=O)O)O[C@@H]6CSCCC(=O)O)O[C@@H]5CSCCC(=O)O)O[C@@H]4CSCCC(=O)O)O[C@@H]3CSCCC(=O)O
SULBACTAM,SULBACTAM,CHEMBL403,BRD:BRD-BRD-K44133266-001-10-0;BRD:BRD-K44133266-001-10-0,rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,"SKIN INFECTIONS, INTRA-ABDOMINAL INFECTIONS, GYNECOLOGIC INFECTIONS",,LAUNCHED,,Small molecule,Approved,FKENQMMABCRJMK-RITPCOANSA-N,CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O;CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O;CC1(C)C(N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
SULBACTAM-PIVOXIL,SULBACTAM-PIVOXIL,,BRD:BRD-A63431791-001-01-9;BRD:BRD-BRD-A63431791-001-01-9,rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,SKIN INFECTIONS,,LAUNCHED,,,NA,,CC(C)(C)C(=O)OCOC(=O)C1N2C(CC2=O)S(=O)(=O)C1(C)C
SULBENTINE,SULBENTINE,CHEMBL151803,BRD:BRD-BRD-K72384124-001-08-0;BRD:BRD-K72384124-001-08-0,rep_primary;rep_single_dose,OTHER ANTIFUNGAL,,,,PRECLINICAL,,Small molecule,Unknown,QFVAWNPSRQWSDU-UHFFFAOYSA-N,S=C1SCN(CC2CCCCC2)CN1CC1CCCCC1
SULBUTIAMINE,SULBUTIAMINE,CHEMBL2105813,BRD:BRD-BRD-K12539416-001-01-4;BRD:BRD-K12539416-001-01-4,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,ASTHENIA,,LAUNCHED,,Small molecule,Unknown,CKHJPWQVLKHBIH-ZDSKVHJSSA-N,C/C(=C(\CCOC(=O)C(C)C)SS/C(CCOC(=O)C(C)C)=C(/C)N(C=O)CC1CNC(C)NC1N)N(C=O)CC1CNC(C)NC1N;CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(CC1CNC(C)NC1N)C=O)=C(\C)N(CC1CNC(C)NC1N)C=O
SULCONAZOLE,SULCONAZOLE,CHEMBL1221,BRD:BRD-A70649075-008-30-8;BRD:BRD-BRD-A70649075-008-30-8,rep_multi_dose;rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,AFNXATANNDIXLG-UHFFFAOYSA-N,CLC1CCC(CSC(CN2CCNC2)C2CCC(CL)CC2CL)CC1
SULFABENZAMIDE,SULFABENZAMIDE,CHEMBL1243,BRD:BRD-BRD-K59983611-001-21-9;BRD:BRD-K59983611-001-21-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,,,LAUNCHED,,Small molecule,Approved,PBCZLFBEBARBBI-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC(=O)C1CCCCC1;NC1CCC(S(=O)(=O)NC(=O)C2CCCCC2)CC1
SULFACARBAMIDE,SULFACARBAMIDE,CHEMBL139877,BRD:BRD-BRD-K13486660-001-01-0;BRD:BRD-K13486660-001-01-0,rep_primary;rep_single_dose,,,,,WITHDRAWN,,Small molecule,Approved,WVAKABMNNSMCDK-UHFFFAOYSA-N,NC(=O)NS(=O)(=O)C1CCC(N)CC1
SULFACETAMIDE,SULFACETAMIDE,CHEMBL455,BRD:BRD-BRD-K21520694-236-02-6;BRD:BRD-K21520694-236-02-6,rep_primary;rep_single_dose,PABA ANTAGONIST,,CONJUNCTIVITIS,,LAUNCHED,,Small molecule,Approved,SKIVFJLNDNKQPD-UHFFFAOYSA-N,CC(=O)NS(=O)(=O)C1CCC(N)CC1
SULFACHLORPYRIDAZINE,SULFACHLORPYRIDAZINE,CHEMBL1443577,BRD:BRD-BRD-K32021043-001-14-3;BRD:BRD-K32021043-001-14-3,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Unknown,XOXHILFPRYWFOD-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC1CCC(CL)NN1;NC1CCC(S(=O)(=O)NC2CCC(CL)NN2)CC1
SULFADIAZINE,SULFADIAZINE,CHEMBL1382627;CHEMBL439,BRD:BRD-BRD-K32273377-001-17-9;BRD:BRD-K32273377-001-17-9,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,"MALARIA, MENINGITIS, URINARY TRACT INFECTIONS, CONJUNCTIVITIS, TRACHOMA, CHANCROID",,LAUNCHED,,Small molecule,Approved,SEEPANYCNGTZFQ-UHFFFAOYSA-N;UEJSSZHHYBHCEL-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC1NCCCN1;NC1CCC(S(=O)(=O)[N-]C2NCCCN2)CC1.[AG+];NC1CCC(S(=O)(=O)NC2NCCCN2)CC1
SULFADOXINE,SULFADOXINE,CHEMBL1539,BRD:BRD-BRD-K55250441-001-13-0;BRD:BRD-K55250441-001-13-0,rep_primary;rep_single_dose,DIHYDROPTEROATE SYNTHASE INHIBITOR,,MALARIA,,LAUNCHED,,Small molecule,Approved,PJSFRIWCGOHTNF-UHFFFAOYSA-N,COC1NCNC(NS(=O)(=O)C2CCC(N)CC2)C1OC
SULFAFURAZOLE,SULFAFURAZOLE,CHEMBL453,BRD:BRD-BRD-K50859149-001-19-5;BRD:BRD-K50859149-001-19-5,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,NHUHCSRWZMLRLA-UHFFFAOYSA-N,CC1NOC(NS(=O)(=O)C2CCC(N)CC2)C1C
SULFAGUANIDINE,SULFAGUANIDINE,CHEMBL338802,BRD:BRD-BRD-K45086103-001-15-5;BRD:BRD-BRD-K45086103-001-16-3;BRD:BRD-K45086103-001-15-5;BRD:BRD-K45086103-001-16-3,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,BRBKOPJOKNSWSG-UHFFFAOYSA-N,N=C(N)NS(=O)(=O)C1CCC(N)CC1;NC(=N)NS(=O)(=O)C1CCC(N)CC1
SULFAMERAZINE,SULFAMERAZINE,CHEMBL438,BRD:BRD-BRD-K93524252-001-24-7;BRD:BRD-K93524252-001-24-7,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,"COCCIDIOSIS, CHOLERA",,LAUNCHED,,Small molecule,Approved,QPPBRPIAZZHUNT-UHFFFAOYSA-N,CC1CCNC(NS(=O)(=O)C2CCC(N)CC2)N1
SULFAMETER,SULFAMETER,CHEMBL1200359,BRD:BRD-BRD-K87492696-001-16-5;BRD:BRD-K87492696-001-16-5,rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,GPTONYMQFTZPKC-UHFFFAOYSA-N,COC1CNC(NS(=O)(=O)C2CCC(N)CC2)NC1
SULFAMETHAZINE,SULFAMETHAZINE,CHEMBL446,BRD:BRD-BRD-K11640013-001-15-8;BRD:BRD-BRD-K11640013-236-10-1;BRD:BRD-K11640013-001-15-8;BRD:BRD-K11640013-236-10-1,rep_multi_dose;rep_primary;rep_single_dose,PABA ANTAGONIST,,"ENTERITIS, ENTERITIS",,LAUNCHED,,Small molecule,Approved,ASWVTGNCAZCNNR-UHFFFAOYSA-N,CC1CC(C)NC(NS(=O)(=O)C2CCC(N)CC2)N1
SULFAMETHIZOLE,SULFAMETHIZOLE,CHEMBL1191,BRD:BRD-BRD-K31682896-001-24-0;BRD:BRD-K31682896-001-24-0,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,VACCAVUAMIDAGB-UHFFFAOYSA-N,CC1NNC(NS(=O)(=O)C2CCC(N)CC2)S1
SULFAMETHOXAZOLE,SULFAMETHOXAZOLE,CHEMBL443,BRD:BRD-BRD-K28494619-001-28-2;BRD:BRD-K28494619-001-28-2,rep_primary;rep_single_dose,PABA ANTAGONIST,,"PNEUMONIA, ENTERITIS, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,JLKIGFTWXXRPMT-UHFFFAOYSA-N,CC1CC(NS(=O)(=O)C2CCC(N)CC2)NO1
SULFAMETHOXYPYRIDAZINE,SULFAMETHOXYPYRIDAZINE,CHEMBL268869,BRD:BRD-BRD-K00938507-001-17-8;BRD:BRD-K00938507-001-17-8,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,,,WITHDRAWN,,Small molecule,Approved,VLYWMPOKSSWJAL-UHFFFAOYSA-N,COC1CCC(NS(=O)(=O)C2CCC(N)CC2)NN1
SULFAMETOPYRAZINE,SULFAMETOPYRAZINE,CHEMBL1525826,BRD:BRD-BRD-K17205817-001-06-1;BRD:BRD-K17205817-001-06-1,rep_primary;rep_single_dose,PABA ANTAGONIST,,"MALARIA, URINARY TRACT INFECTIONS, RESPIRATORY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,KXRZBTAEDBELFD-UHFFFAOYSA-N,COC1NCCNC1NS(=O)(=O)C1CCC(N)CC1
SULFAMONOMETHOXINE,SULFAMONOMETHOXINE,CHEMBL462990,BRD:BRD-BRD-K14116214-001-09-6;BRD:BRD-K14116214-001-09-6,rep_primary;rep_single_dose,BACTERIAL ANTIFOLATE,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Unknown,WMPXPUYPYQKQCX-UHFFFAOYSA-N,COC1CC(NS(=O)(=O)C2CCC(N)CC2)NCN1
SULFAMOXOLE,SULFAMOXOLE,CHEMBL2105399,BRD:BRD-BRD-K19742012-001-02-3;BRD:BRD-K19742012-001-02-3,rep_primary;rep_single_dose,PABA ANTAGONIST,,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Unknown,CYFLXLSBHQBMFT-UHFFFAOYSA-N,CC1NC(NS(=O)(=O)C2CCC(N)CC2)OC1C
SULFANILAMIDE,SULFANILAMIDE,CHEMBL21,BRD:BRD-BRD-K02594908-001-16-4;BRD:BRD-K02594908-001-16-4,rep_multi_dose;rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CYP2C19;CYP2C9;CYP2D6;CYP2E1;CYP3A4,VULVOVAGINAL CANDIDIASIS,,LAUNCHED,,Small molecule,Approved,FDDDEECHVMSUSB-UHFFFAOYSA-N,NC1CCC(CC1)S(N)(=O)=O;NC1CCC(S(N)(=O)=O)CC1
SULFANITRAN,SULFANITRAN,CHEMBL493636,BRD:BRD-BRD-K76845197-001-05-4;BRD:BRD-K76845197-001-05-4,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,GWBPFRGXNGPPMF-UHFFFAOYSA-N,CC(=O)NC1CCC(CC1)S(=O)(=O)NC1CCC(CC1)[N+]([O-])=O;CC(=O)NC1CCC(S(=O)(=O)NC2CCC([N+](=O)[O-])CC2)CC1
SULFAPHENAZOLE,SULFAPHENAZOLE,CHEMBL1109,BRD:BRD-BRD-K10671814-001-14-8;BRD:BRD-K10671814-001-14-8,rep_primary;rep_single_dose,DIHYDROPTEROATE SYNTHETASE INHIBITOR,DHPS,URINARY TRACT INFECTIONS,,LAUNCHED,,Small molecule,Approved,QWCJHSGMANYXCW-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC1CCNN1-C1CCCCC1;NC1CCC(S(=O)(=O)NC2CCNN2-C2CCCCC2)CC1
SULFAPYRIDINE,SULFAPYRIDINE,CHEMBL700,BRD:BRD-BRD-K41406082-001-16-2;BRD:BRD-K41406082-001-16-2,rep_primary;rep_single_dose,PABA ANTAGONIST,,,,LAUNCHED,,Small molecule,Approved,GECHUMIMRBOMGK-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC1CCCCN1;NC1CCC(S(=O)(=O)NC2CCCCN2)CC1
SULFAQUINOXALINE,SULFAQUINOXALINE,CHEMBL1437847,BRD:BRD-BRD-K71133585-236-14-4;BRD:BRD-K71133585-236-14-4,rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,NHZLNPMOSADWGC-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC1CNC2CCCCC2N1;NC1CCC(S(=O)(=O)NC2CNC3CCCCC3N2)CC1
SULFASALAZINE,SULFASALAZINE,CHEMBL421,BRD:BRD-BRD-K10670311-001-15-5;BRD:BRD-K10670311-001-15-5,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,ACAT1;ALOX5;CHUK;IKBKB;PLA2G1B;PPARG;PTGS1;PTGS2;SLC46A1;SLC7A11;TBXAS1,ULCERATIVE COLITIS,,LAUNCHED,,Small molecule,Approved,NCEXYHBECQHGNR-QZQOTICOSA-N,O=C(O)C1CC(/N=N/C2CCC(S(=O)(=O)NC3CCCCN3)CC2)CCC1O;OC(=O)C1CC(CCC1O)\N=N\C1CCC(CC1)S(=O)(=O)NC1CCCCN1
SULFATHIAZOLE,SULFATHIAZOLE,CHEMBL437,BRD:BRD-BRD-K14705039-001-16-4;BRD:BRD-K14705039-001-16-4,rep_primary;rep_single_dose,DIHYDROPTEROATE SYNTHASE INHIBITOR,,,,LAUNCHED,,Small molecule,Approved,JNMRHUJNCSQMMB-UHFFFAOYSA-N,NC1CCC(CC1)S(=O)(=O)NC1NCCS1;NC1CCC(S(=O)(=O)NC2NCCS2)CC1
SULFATINIB,SULFATINIB,CHEMBL4297190,BRD:BRD-K00003125-001-01-9,rep_single_dose,TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 3,TTZSNFLLYPYKIL-UHFFFAOYSA-N,CC1CC2CC(OC3CCNC(NC4CCCC(CS(=O)(=O)NCCN(C)C)C4)N3)CCC2[NH]1
SULFINPYRAZONE,SULFINPYRAZONE,CHEMBL832,BRD:BRD-A36217750-001-16-3;BRD:BRD-BRD-A36217750-001-16-3,rep_primary;rep_single_dose,URICOSURIC BLOCKER,ABCC1;ABCC2;FPR1;SLC22A12,GOUT,,LAUNCHED,,Small molecule,Approved,MBGGBVCUIVRRBF-UHFFFAOYSA-N,O=C1C(CC[S+]([O-])C2CCCCC2)C(=O)N(C2CCCCC2)N1C1CCCCC1;O=C1C(CCS(=O)C2CCCCC2)C(=O)N(N1C1CCCCC1)C1CCCCC1
SULFISOMIDIN,SULFISOMIDIN,,BRD:BRD-K52416806-001-05-9,rep_single_dose,ANTIBACTERIAL,,,,,,,NA,,
SULFORAPHANE,SULFORAPHANE,CHEMBL48802,BRD:BRD-A58955223-001-03-8;BRD:BRD-BRD-A58955223-001-03-8,rep_primary;rep_single_dose,"ANTICANCER AGENT, ARYL HYDROCARBON RECEPTOR ANTAGONIST",NFE2L2,,,PHASE 2,,Small molecule,Phase 3,SUVMJBTUFCVSAD-UHFFFAOYSA-N,C[S+]([O-])CCCCN=C=S;CS(=O)CCCCN=C=S
SULINDAC,SULINDAC,CHEMBL15770,BRD:BRD-A13946108-001-17-1;BRD:BRD-BRD-A13946108-001-17-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,AKR1B1;MAPK3;PPARD;PTGDR2;PTGS1;PTGS2,"OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS",,LAUNCHED,,Small molecule,Approved,MLKXDPUZXIRXEP-MFOYZWKCSA-N,CC1=C(CC(=O)O)C2CC(F)CCC2/C1=C\C1CCC([S+](C)[O-])CC1;CC1=C(CC(O)=O)C2CC(F)CCC2C\1=C/C1CCC(CC1)S(C)=O
SULISOBENZONE,SULISOBENZONE,CHEMBL2059073,BRD:BRD-BRD-K38602774-001-03-2;BRD:BRD-K38602774-001-03-2,rep_primary;rep_single_dose,,,SUNSCREEN LOTION,,LAUNCHED,,Small molecule,Unknown,CXVGEDCSTKKODG-UHFFFAOYSA-N,COC1CC(O)C(C(=O)C2CCCCC2)CC1S(=O)(=O)O;COC1CC(O)C(CC1S(O)(=O)=O)C(=O)C1CCCCC1
SULMAZOLE,SULMAZOLE,CHEMBL286020,BRD:BRD-A22081593-001-11-1;BRD:BRD-BRD-A22081593-001-11-1,rep_multi_dose;rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,PHASE 1,,Small molecule,Unknown,XMFCOYRWYYXZMY-UHFFFAOYSA-N,COC1CC([S+](C)[O-])CCC1-C1NC2CCCNC2[NH]1;COC1CC(CCC1-C1NC2NCCCC2[NH]1)S(C)=O
SULMETOZINE,SULMETOZINE,,BRD:BRD-BRD-K29570907-001-07-3;BRD:BRD-K29570907-001-07-3,rep_primary;rep_single_dose,GASTRIN INHIBITOR,GAST,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,,NA,,COC1CC(CC(OC)C1OC)C(=S)N1CCOCC1
SULOCTIDIL,SULOCTIDIL,CHEMBL404849;CHEMBL588119,BRD:BRD-A34205397-001-04-5;BRD:BRD-BRD-A34205397-001-04-5,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,WITHDRAWN,,Small molecule,Approved,BFCDFTHTSVTWOG-UHFFFAOYSA-N;BFCDFTHTSVTWOG-YLJYHZDGSA-N,CCCCCCCCN[C@H](C)[C@@H](O)C1CCC(SC(C)C)CC1;CCCCCCCCNC(C)C(O)C1CCC(SC(C)C)CC1
SULOL,SULOL,CHEMBL960,GDSC2:1578,gdsc,,,,,,,Small molecule,Approved,VHOGYURTWQBHIL-UHFFFAOYSA-N,CC1ONCC1C(=O)NC1CCC(C(F)(F)F)CC1
SULOPENEM,SULOPENEM,CHEMBL1908305,BRD:BRD-K00004713-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Phase 3,FLSUCZWOEMTFAQ-PRBGKLEPSA-N,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@H]3CC[S@@+]([O-])C3)S[C@H]12
SULPHADIMETHOXINE,SULPHADIMETHOXINE,CHEMBL62193,BRD:BRD-BRD-K71125014-001-27-1;BRD:BRD-K71125014-001-27-1,rep_primary;rep_single_dose,DIHYDROPTEROATE SYNTHETASE INHIBITOR,,,,LAUNCHED,,Small molecule,Approved,ZZORFUFYDOWNEF-UHFFFAOYSA-N,COC1CC(NS(=O)(=O)C2CCC(N)CC2)NC(OC)N1
SULPIRIDE,SULPIRIDE,CHEMBL26;CHEMBL267044,BRD:BRD-A55272860-001-14-6;BRD:BRD-A55272860-001-15-3;BRD:BRD-BRD-A55272860-001-14-6;BRD:BRD-BRD-A55272860-001-15-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,"SCHIZOPHRENIA, SCHIZOPHRENIA",,LAUNCHED,,Small molecule,Approved,BGRJTUBHPOOWDU-NSHDSACASA-N;BGRJTUBHPOOWDU-UHFFFAOYSA-N,CCN1CCC[C@H]1CNC(=O)C1CC(S(N)(=O)=O)CCC1OC;CCN1CCCC1CNC(=O)C1CC(CCC1OC)S(N)(=O)=O;CCN1CCCC1CNC(=O)C1CC(S(N)(=O)=O)CCC1OC
SULTAMICILLIN,SULTAMICILLIN,CHEMBL506110,BRD:BRD-K00004694-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Approved,OPYGFNJSCUDTBT-PMLPCWDUSA-N,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3CCCCC3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C
SULTIAME,SULTIAME,CHEMBL328560,BRD:BRD-K00003488-001-01-9,rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA2,,,,,Small molecule,Approved,HMHVCUVYZFYAJI-UHFFFAOYSA-N,NS(=O)(=O)C1CCC(N2CCCCS2(=O)=O)CC1
SULTOPRIDE,SULTOPRIDE,CHEMBL277945,BRD:BRD-K00003312-003-01-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,UNRHXEPDKXPRTM-UHFFFAOYSA-N,CCN1CCCC1CNC(=O)C1CC(S(=O)(=O)CC)CCC1OC
SUMANIROLE,SUMANIROLE,CHEMBL419792,BRD:BRD-BRD-K30485548-050-01-6;BRD:BRD-K30485548-050-01-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,DRD2,,,PHASE 3,,Small molecule,Phase 3,RKZSNTNMEFVBDT-MRVPVSSYSA-N,CN[C@@H]1CC2CCCC3[NH]C(=O)N(C23)C1;CN[C@@H]1CC2CCCC3NC(O)N(C1)C23
SUMATRIPTAN,SUMATRIPTAN,CHEMBL128,BRD:BRD-BRD-K50938287-036-13-8;BRD:BRD-K50938287-036-13-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR5A;HTR6;HTR7,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,KQKPFRSPSRPDEB-UHFFFAOYSA-N,CNS(=O)(=O)CC1CCC2[NH]CC(CCN(C)C)C2C1
SUN-11602,SUN-11602,,BRD:BRD-K71250460-001-02-9,rep_single_dose,FIBROBLAST GROWTH FACTOR MIMETIC,FGFR1,,,,,,NA,,
SUNITINIB,SUNITINIB,CHEMBL535,BRD:BRD-BRD-K42828737-044-09-0;BRD:BRD-K42828737-001-03-3;BRD:BRD-K42828737-044-09-0;CTRP:374750;GDSC1:5,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR",CSF1R;FGFR1;FLT1;FLT3;FLT4;KDR;KIT;PDGFRA;PDGFRB;RET,"GASTROINTESTINAL STROMAL TUMORS (GIST), RENAL CELL CARCINOMA (RCC), NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET)",,LAUNCHED,,Small molecule,Approved,WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)C1C(C)[NH]C(/C=C2\C(=O)NC3CCC(F)CC32)C1C;CCN(CC)CCNC(=O)C1C(C)[NH]C(\C=C2/C(=O)NC3CCC(F)CC23)C1C
SUNITINIB MALATE,SUNITINIB MALATE,CHEMBL1567,GDSC1:5,gdsc,,,,,,,Small molecule,Approved,LBWFXVZLPYTWQI-IPOVEDGCSA-N,CCN(CC)CCNC(=O)C1C(C)[NH]C(/C=C2\C(=O)NC3CCC(F)CC32)C1C.O=C(O)C[C@H](O)C(=O)O
SUPROFEN,SUPROFEN,CHEMBL956,BRD:BRD-A34006693-001-15-4;BRD:BRD-BRD-A34006693-001-15-4,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,WITHDRAWN,,Small molecule,Approved,MDKGKXOCJGEUJW-UHFFFAOYSA-N,CC(C(=O)O)C1CCC(C(=O)C2CCCS2)CC1;CC(C(O)=O)C1CCC(CC1)C(=O)C1CCCS1
SURAMIN,SURAMIN,CHEMBL265502,BRD:BRD-BRD-K70327167-348-13-4;BRD:BRD-K70327167-348-13-4,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,F2;FSHR;P2RY1;P2RY11;P2RY13;P2RY2;PLA2G2A;RYR1;RYR2;SIRT5,"AFRICAN TRYPANOSOMIASIS, ONCHOCERCIASIS",,LAUNCHED,,Small molecule,Phase 3,FIAFUQMPZJWCLV-UHFFFAOYSA-N,CC1CCC(C(=O)NC2CCC(S(=O)(=O)O)C3CC(S(=O)(=O)O)CC(S(=O)(=O)O)C23)CC1NC(=O)C1CCCC(NC(=O)NC2CCCC(C(=O)NC3CC(C(=O)NC4CCC(S(=O)(=O)O)C5CC(S(=O)(=O)O)CC(S(=O)(=O)O)C45)CCC3C)C2)C1;CC1CCC(CC1NC(=O)C1CCCC(NC(=O)NC2CCCC(C2)C(=O)NC2CC(CCC2C)C(=O)NC2CCC(C3CC(CC(C23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C1)C(=O)NC1CCC(C2CC(CC(C12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O
SURITOZOLE,SURITOZOLE,CHEMBL278764,BRD:BRD-BRD-K98557884-001-01-6;BRD:BRD-K98557884-001-01-6,rep_primary;rep_single_dose,GABA RECEPTOR INVERSE AGONIST,GABBR1,,,PHASE 2,,Small molecule,Unknown,IWDUZEHNLHFBRZ-UHFFFAOYSA-N,CN1NC(-C2CCCC(F)C2)N(C)C1=S
SUTENT,SUTENT,CHEMBL1567;CHEMBL535,GDSC1:5,gdsc,,,,,,,Small molecule,Approved,LBWFXVZLPYTWQI-IPOVEDGCSA-N;WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)C1C(C)[NH]C(/C=C2\C(=O)NC3CCC(F)CC32)C1C;CCN(CC)CCNC(=O)C1C(C)[NH]C(/C=C2\C(=O)NC3CCC(F)CC32)C1C.O=C(O)C[C@H](O)C(=O)O
SUTEZOLID,SUTEZOLID,CHEMBL288149,BRD:BRD-BRD-K86670086-001-02-5;BRD:BRD-K86670086-001-02-5,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,FNDDDNOJWPQCBZ-ZDUSSCGKSA-N,CC(=O)NC[C@H]1CN(C(=O)O1)C1CCC(N2CCSCC2)C(F)C1;CC(=O)NC[C@H]1CN(C2CCC(N3CCSCC3)C(F)C2)C(=O)O1
SUVOREXANT,SUVOREXANT,CHEMBL1083659,BRD:BRD-BRD-K94293891-001-01-3;BRD:BRD-K94293891-001-01-3,rep_primary;rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR1;HCRTR2,INSOMNIA,,LAUNCHED,,Small molecule,Approved,JYTNQNCOQXFQPK-MRXNPFEDSA-N,C[C@@H]1CCN(CCN1C(=O)C1CC(C)CCC1-N1NCCN1)C1NC2CC(CL)CCC2O1;CC1CCC(-N2NCCN2)C(C(=O)N2CCN(C3NC4CC(CL)CCC4O3)CC[C@H]2C)C1
SUXIBUZONE,SUXIBUZONE,CHEMBL1414320,BRD:BRD-BRD-K78815826-001-14-6;BRD:BRD-K78815826-001-14-6,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,"JOINT PAIN, MUSCLE PAIN",,LAUNCHED,,Small molecule,Unknown,ONWXNHPOAGOMTG-UHFFFAOYSA-N,CCCCC1(COC(=O)CCC(=O)O)C(=O)N(C2CCCCC2)N(C2CCCCC2)C1=O;CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)C1CCCCC1)C1CCCCC1
SWAINSONINE,SWAINSONINE,CHEMBL371197,BRD:BRD-BRD-K15170068-001-03-2;BRD:BRD-K15170068-001-03-2,rep_primary;rep_single_dose,ALPHA MANNOSIDASE INHIBITOR,MAN2A1,,,PHASE 2,,Small molecule,Unknown,FXUAIOOAOAVCGD-WCTZXXKLSA-N,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O;O[C@H]1[C@H]2[C@H](O)CCCN2C[C@H]1O
SX-011,SX-011,,BRD:BRD-BRD-K45385835-001-02-4;BRD:BRD-K45385835-001-02-4,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK14,,,PRECLINICAL,,,NA,,CN(C)C(=O)C(=O)C1CN(C)C2CC(CL)C(CC12)C(=O)N1CCC(CC2CCC(F)CC2)CC1
SX-682,SX-682,CHEMBL4297480,BRD:BRD-K00091103-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,SDUDZBCEHIZMFZ-UHFFFAOYSA-N,O=C(NC1CCC(F)CC1)C1CNC(SCC2CC(OC(F)(F)F)CCC2B(O)O)NC1
SY-640,SY-640,,BRD:BRD-K00004665-001-01-9,rep_single_dose,,,,,,,,NA,,
SYK INHIBITOR,SYK INHIBITOR,,GDSC1:178,gdsc,,,,,,,,NA,,
SYM-2081,SYM-2081,CHEMBL288166,BRD:BRD-BRD-K72106461-001-02-1;BRD:BRD-K72106461-001-02-1,rep_primary;rep_single_dose,KAINATE RECEPTOR ANTAGONIST,GRIK1;GRIK2;GRIK3;GRIK4;GRIK5;SLC1A2,,,PRECLINICAL,,Small molecule,NA,KRKRAOXTGDJWNI-DMTCNVIQSA-N,C[C@H](C[C@H](N)C(=O)O)C(=O)O;C[C@H](C[C@H](N)C(O)=O)C(O)=O
SYM-2206,SYM-2206,,BRD:BRD-A77218119-001-03-5;BRD:BRD-BRD-A77218119-001-03-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIA3;GRIA4,,,PRECLINICAL,,,NA,,CCCNC(=O)N1N=C(C2CCC(N)CC2)C2CC3OCOC3CC2C1C
SYNEPHRINE,SYNEPHRINE,CHEMBL33720,BRD:BRD-A04327189-001-15-1;BRD:BRD-A04327189-003-03-3;BRD:BRD-BRD-A04327189-001-15-1;BRD:BRD-BRD-A04327189-003-03-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A,,,LAUNCHED,,Small molecule,Unknown,YRCWQPVGYLYSOX-UHFFFAOYSA-N,CNCC(O)C1CCC(O)CC1
SZ4TA2,SZ4TA2,,CTRP:688138,ctrp,,,,,,,,NA,,
T-0070907,T-0070907,,BRD:BRD-BRD-K31843556-001-04-1;BRD:BRD-K31843556-001-04-1,rep_primary;rep_single_dose,PPAR RECEPTOR ANTAGONIST,PPARG,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCC(CL)C(C1)C(=O)NC1CCNCC1
T-0156,T-0156,,BRD:BRD-BRD-K63516691-003-02-0;BRD:BRD-K63516691-003-02-0,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,,,PRECLINICAL,,,NA,,COC(=O)C1C(-C2CC(OC)C(OC)C(OC)C2)C2CCNC(OCC3NCCCN3)C2C(=O)N1CC1CCNC(C)C1
T-025,T-025,,BRD:BRD-K16605796-001-01-9,rep_single_dose,CLK INHIBITOR,,,,,,,NA,,
T-0901317,T-0901317,,BRD:BRD-BRD-K23383398-001-09-9;BRD:BRD-K23383398-001-09-9,rep_primary;rep_single_dose,LXR AGONIST,NCOA1;NCOA2;NR1H2;NR1H3;NR1I2;RXRB,,,PRECLINICAL,,,NA,,OC(C1CCC(CC1)N(CC(F)(F)F)S(=O)(=O)C1CCCCC1)(C(F)(F)F)C(F)(F)F
T-1095,T-1095,,BRD:BRD-K00004631-001-01-9,rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,,,,,,,NA,,
T-1101 (TOSYLATE),T-1101 (TOSYLATE),,BRD:BRD-K00091066-075-01-9,rep_single_dose,,,,,,,,NA,,
T-5224,T-5224,,BRD:BRD-BRD-K84925803-001-01-9;BRD:BRD-K84925803-001-01-9,rep_primary;rep_single_dose,AP INHIBITOR,JUN,,,PHASE 2,,,NA,,OC(=O)CCC1CC(CCC1OCC1CCC2C(O)NOC2C1)C(=O)C1CCC(OC2CCCC2)CC1O
T-5601640,T-5601640,,BRD:BRD-BRD-K83492904-001-01-9;BRD:BRD-K83492904-001-01-9,rep_primary;rep_single_dose,LIM KINASE INHIBITOR,LIMK2,,,PRECLINICAL,,,NA,,CC1CC(ON1)C(=O)NC1CCCC(C1)C(=O)NC1CCCC(C1)C(F)(F)F
T-807,T-807,CHEMBL3546271,BRD:BRD-K00003402-001-01-9,rep_single_dose,PET RADIOTRACER,,,,,,Small molecule,Approved,GETAAWDSFUCLBS-UHFFFAOYSA-N,FC1CCC(-C2CCC3C(C2)[NH]C2CCNCC23)CN1
T0901317,T0901317,CHEMBL62136,GDSC1:333,gdsc,,,,,,,Small molecule,NA,SGIWFELWJPNFDH-UHFFFAOYSA-N,O=S(=O)(C1CCCCC1)N(CC(F)(F)F)C1CCC(C(O)(C(F)(F)F)C(F)(F)F)CC1
TA-01,TA-01,,BRD:BRD-BRD-K79856806-001-01-0;BRD:BRD-K79856806-001-01-0,rep_primary;rep_single_dose,"CASEIN KINASE INHIBITOR, MAP KINASE INHIBITOR",CSNK1D;CSNK1E;MAPK14,,,PRECLINICAL,,,NA,,FC1CCC(CC1)-C1NC([NH]C1-C1CCNCC1)-C1C(F)CCCC1F
TABIMORELIN,TABIMORELIN,CHEMBL281764,BRD:BRD-BRD-K53600683-051-01-5;BRD:BRD-K53600683-051-01-5,rep_primary;rep_single_dose,GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST,GHSR,,,PHASE 2,,Small molecule,Phase 2,WURGZWOTGMLDJP-ZCYANPAGSA-N,CNC(=O)[C@@H](CC1CCCCC1)N(C)C(=O)[C@@H](CC1CCC2CCCCC2C1)N(C)C(=O)/C=C/CC(C)(C)N;CNC(=O)[C@@H](CC1CCCCC1)N(C)C(=O)[C@@H](CC1CCC2CCCCC2C1)N(C)C(=O)\C=C\CC(C)(C)N
TACALCITOL,TACALCITOL,CHEMBL2105611,BRD:BRD-BRD-K73237276-001-01-0;BRD:BRD-K73237276-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN D RECEPTOR AGONIST,VDR,"PSORIASIS, CHAPPED LIPS",,LAUNCHED,,Small molecule,Approved,BJYLYJCXYAMOFT-RSFVBTMBSA-N,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O;CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C
TACEDINALINE,TACEDINALINE,CHEMBL235191,BRD:BRD-BRD-K52313696-001-12-3;BRD:BRD-K52313696-001-12-3;CTRP:54200,ctrp;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1,,,PHASE 3,,Small molecule,Phase 3,VAZAPHZUAVEOMC-UHFFFAOYSA-N,CC(=O)NC1CCC(C(=O)NC2CCCCC2N)CC1;CC(=O)NC1CCC(CC1)C(=O)NC1CCCCC1N
TACRINE,TACRINE,CHEMBL95,BRD:BRD-BRD-K81473089-003-26-1;BRD:BRD-K81473089-003-26-1,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,ACHE;BCHE,ALZHEIMER'S DISEASE,,LAUNCHED,,Small molecule,Approved,YLJREFDVOIBQDA-UHFFFAOYSA-N,NC1C2C(NC3CCCCC13)CCCC2;NC1C2CCCCC2NC2CCCCC12
TACROLIMUS,TACROLIMUS,CHEMBL269732;CHEMBL3989887,BRD:BRD-BRD-K69608737-001-10-2;BRD:BRD-K69608737-001-10-2;CTRP:50737,ctrp;rep_multi_dose;rep_primary;rep_single_dose,CALCINEURIN INHIBITOR,FKBP1A,ORGAN REJECTION,,LAUNCHED,,Small molecule,Approved,NWJQLQGQZSIBAF-MLAUYUEBSA-N;QJJXYPPXXYFBGM-LFZNUXCKSA-N,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC;C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O;CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
TADALAFIL,TADALAFIL,CHEMBL779,BRD:BRD-BRD-K93645900-001-11-3;BRD:BRD-K93645900-001-11-3,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE11A;PDE5A,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,WOXKDUGGOYFFRN-IIBYNOLFSA-N,CN1CC(=O)N2[C@H](C3CCC4C(C3)OCO4)C3[NH]C4CCCCC4C3C[C@@H]2C1=O;CN1CC(=O)N2[C@H](CC3C([NH]C4CCCCC34)[C@H]2C2CCC3OCOC3C2)C1=O
TAE-684,TAE-684,CHEMBL509032,GDSC1:35,gdsc,,,,,,,Small molecule,NA,QQWUGDVOUVUTOY-UHFFFAOYSA-N,COC1CC(N2CCC(N3CCN(C)CC3)CC2)CCC1NC1NCC(CL)C(NC2CCCCC2S(=O)(=O)C(C)C)N1
TAE684,TAE684,,GDSC1:35,gdsc,,,,,,,,NA,,
TAFAMIDIS-MEGLUMINE,TAFAMIDIS-MEGLUMINE,,BRD:BRD-BRD-K23728141-001-01-2;BRD:BRD-K23728141-001-01-2,rep_primary;rep_single_dose,TRANSTHYRETIN AMYLOID INHIBITOR,TTR,FAMILIAL AMYLOID POLYNEUROPATHY (FAP),,LAUNCHED,,,NA,,OC(=O)C1CCC2NC(OC2C1)-C1CC(CL)CC(CL)C1
TAFENOQUINE,TAFENOQUINE,CHEMBL298470,BRD:BRD-A78965079-036-01-8;BRD:BRD-BRD-A78965079-036-01-8,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,,,,PHASE 3,,Small molecule,Approved,LBHLFPGPEGDCJG-UHFFFAOYSA-N,COC1CC(C)C2C(OC3CCCC(C(F)(F)F)C3)C(OC)CC(NC(C)CCCN)C2N1;COC1CC(C)C2C(OC3CCCC(C3)C(F)(F)F)C(OC)CC(NC(C)CCCN)C2N1
TAFINLAR,TAFINLAR,CHEMBL2028663;CHEMBL2105729,GDSC1:1373;GDSC2:1373,gdsc,,,,,,,Small molecule,Approved,BFSMGDJOXZAERB-UHFFFAOYSA-N;YKGMKSIHIVVYKY-UHFFFAOYSA-N,CC(C)(C)C1NC(-C2CCCC(NS(=O)(=O)C3C(F)CCCC3F)C2F)C(-C2CCNC(N)N2)S1;CC(C)(C)C1NC(-C2CCCC(NS(=O)(=O)C3C(F)CCCC3F)C2F)C(-C2CCNC(N)N2)S1.CS(=O)(=O)O
TAFLUPROST,TAFLUPROST,CHEMBL1963683,BRD:BRD-K65059905-001-02-9,rep_single_dose,PROSTAGLANDIN INHIBITOR,PTGFR,,,,,Small molecule,Approved,WSNODXPBBALQOF-VEJSHDCNSA-N,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COC2CCCCC2)[C@H](O)C[C@@H]1O
TAGATOSE,TAGATOSE,CHEMBL1236183,BRD:BRD-A73556557-001-06-4;BRD:BRD-BRD-A73556557-001-06-4;BRD:BRD-BRD-K89588135-001-01-9;BRD:BRD-K89588135-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHORYLASE INHIBITOR,PYGL,,,PHASE 3,"Multiple values for structure_id: {'K89588135', 'A73556557'}, defaulting to None",Small molecule,Phase 3,BJHIKXHVCXFQLS-PQLUHFTBSA-N,O=C(CO)[C@@H](O)[C@@H](O)[C@H](O)CO;OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O;OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO;OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO;OCC(O)C(O)C(O)C(=O)CO
TAGRISSO,TAGRISSO,CHEMBL3353410;CHEMBL3545063,GDSC2:1919,gdsc,,,,,,,Small molecule,Approved,DUYJMQONPNNFPI-UHFFFAOYSA-N;FUKSNUHSJBTCFJ-UHFFFAOYSA-N,C=CC(=O)NC1CC(NC2NCCC(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C;C=CC(=O)NC1CC(NC2NCCC(-C3CN(C)C4CCCCC34)N2)C(OC)CC1N(C)CCN(C)C.CS(=O)(=O)O
TAK 715,TAK 715,CHEMBL363648,GDSC1:221,gdsc,,,,,,,Small molecule,Phase 2,HEKAIDKUDLCBRU-UHFFFAOYSA-N,CCC1NC(-C2CCCC(C)C2)C(-C2CCNC(NC(=O)C3CCCCC3)C2)S1
TAK-063,TAK-063,CHEMBL3989972,BRD:BRD-BRD-K57155378-001-01-1;BRD:BRD-K57155378-001-01-1,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE10A,,,PHASE 2,,Small molecule,Phase 2,KVHRYLNQDWXAGI-UHFFFAOYSA-N,COC1CN(-C2CCC(-N3CCCN3)CC2F)NC(-C2CCNN2-C2CCCCC2)C1=O;COC1CN(NC(-C2CCNN2-C2CCCCC2)C1=O)-C1CCC(CC1F)-N1CCCN1
TAK-071,TAK-071,CHEMBL4594351,BRD:BRD-K00091106-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,WFSARWQASFQZMG-VXKWHMMOSA-N,CC1C(CC2CCC(-N3CCCN3)CC2)CC2C(C1F)CN([C@H]1COCC[C@@H]1O)C2=O
TAK-220,TAK-220,,BRD:BRD-BRD-K38793468-001-01-4;BRD:BRD-K38793468-001-01-4,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR5,,,PHASE 1,,,NA,,CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(CC2CCC(CC2)C(N)=O)CC1)C1CCC(C)C(CL)C1
TAK-285,TAK-285,CHEMBL1614725,BRD:BRD-BRD-K80343549-001-02-6;BRD:BRD-K80343549-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,ERBB2,,,PHASE 1,,Small molecule,Phase 1,ZYQXEVJIFYIBHZ-UHFFFAOYSA-N,CC(C)(O)CC(=O)NCCN1CCC2NCNC(NC3CCC(OC4CCCC(C(F)(F)F)C4)C(CL)C3)C21;CC(C)(O)CC(=O)NCCN1CCC2NCNC(NC3CCC(OC4CCCC(C4)C(F)(F)F)C(CL)C3)C12
TAK-593,TAK-593,CHEMBL2180604,BRD:BRD-BRD-K67262033-001-01-0;BRD:BRD-K67262033-001-01-0,rep_primary;rep_single_dose,VEGFR INHIBITOR,PDGFRA,,,PHASE 1,,Small molecule,Phase 1,DZFZXPPHBWCXPQ-UHFFFAOYSA-N,CC1CC(C(=O)NC2CC(OC3CCC4NC(NC(=O)C5CC5)CN4N3)CCC2C)N(C)N1
TAK-632,TAK-632,,BRD:BRD-BRD-K31866293-001-01-6;BRD:BRD-K31866293-001-01-6,oncref_2;rep_multi_dose;rep_primary;rep_single_dose,PAN RAF INHIBITOR,BRAF;RAF1,,,PRECLINICAL,"Multiple values for MOA: {'PAN RAF INHIBITOR', 'RAF INHIBITOR'}, defaulting to 'PAN RAF INHIBITOR'
Multiple values for repurposing_target: {'BRAF', 'BRAF;RAF1'}, taking the union",,NA,,FC1CCC(OC2CCC3NC(NC(=O)C4CC4)SC3C2C#N)CC1NC(=O)CC1CCCC(C1)C(F)(F)F
TAK-659,TAK-659,CHEMBL4594253,BRD:BRD-K71500795-003-02-9,rep_single_dose,SPLEEN ASSOCIATED TYROSINE KINASE INHIBITOR,,,,,,Small molecule,Phase 2,ZVPYVZMKBQYKQG-ZVWHLABXSA-N,CN1CC(-C2NC(N[C@@H]3CCCC[C@@H]3N)C(F)C3C2C(=O)NC3)CN1.O=C(O)CC(O)(CC(=O)O)C(=O)O
TAK-715,TAK-715,CHEMBL363648,BRD:BRD-BRD-K52751261-001-06-1;BRD:BRD-K52751261-001-06-1;GDSC1:221,gdsc;rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK14,,,PHASE 2,,Small molecule,Phase 2,HEKAIDKUDLCBRU-UHFFFAOYSA-N,CCC1NC(-C2CCCC(C)C2)C(-C2CCNC(NC(=O)C3CCCCC3)C2)S1;CCC1NC(C(S1)-C1CCNC(NC(=O)C2CCCCC2)C1)-C1CCCC(C)C1
TAK-733,TAK-733,CHEMBL1615025,BRD:BRD-BRD-K26667523-001-02-5;BRD:BRD-K26667523-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,MAP2K1,,,PHASE 1,,Small molecule,Phase 1,RCLQNICOARASSR-SECBINFHSA-N,CN1C(=O)C(F)C(NC2CCC(I)CC2F)C2C(=O)N(C[C@@H](O)CO)CNC21;CN1C2NCN(C[C@@H](O)CO)C(=O)C2C(NC2CCC(I)CC2F)C(F)C1=O
TAK-779,TAK-779,,BRD:BRD-K00003155-003-01-9,rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,,,,NA,,
TAK-875,TAK-875,CHEMBL1829174,BRD:BRD-BRD-K58501140-002-01-0;BRD:BRD-K58501140-002-01-0,rep_primary;rep_single_dose,INSULIN SECRETAGOGUE,FFAR1,,,PHASE 3,,Small molecule,Phase 3,BZCALJIHZVNMGJ-HSZRJFAPSA-N,CC1CC(OCCCS(C)(=O)=O)CC(C)C1-C1CCCC(COC2CCC3[C@H](CC(O)=O)COC3C2)C1;CC1CC(OCCCS(C)(=O)=O)CC(C)C1-C1CCCC(COC2CCC3C(C2)OC[C@H]3CC(=O)O)C1
TAK-901,TAK-901,CHEMBL3544932,BRD:BRD-BRD-K01683783-001-02-6;BRD:BRD-K01683783-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKB,,,PHASE 1,,Small molecule,Phase 1,WKDACQVEJIVHMZ-UHFFFAOYSA-N,CCS(=O)(=O)C1CCCC(-C2CC(C(=O)NC3CCN(C)CC3)C(C)C3[NH]C4NCC(C)CC4C23)C1;CCS(=O)(=O)C1CCCC(C1)-C1CC(C(=O)NC2CCN(C)CC2)C(C)C2[NH]C3NCC(C)CC3C12
TAK-960,TAK-960,CHEMBL2392545,BRD:BRD-BRD-K48059512-003-01-0;BRD:BRD-K48059512-003-01-0,rep_primary;rep_single_dose,PLK INHIBITOR,PLK1,,,PHASE 1,,Small molecule,Phase 1,GWRSATNRNFYMDI-UHFFFAOYSA-N,COC1CC(C(=O)NC2CCN(C)CC2)C(F)CC1NC1NCC2C(N1)N(C1CCCC1)CC(F)(F)C(=O)N2C;COC1CC(C(=O)NC2CCN(C)CC2)C(F)CC1NC1NCC2N(C)C(=O)C(F)(F)CN(C3CCCC3)C2N1
TALADEGIB,TALADEGIB,CHEMBL2142592,BRD:BRD-BRD-K50498985-001-03-3;BRD:BRD-K50498985-001-03-3,rep_primary;rep_single_dose,SMOOTHENED RECEPTOR ANTAGONIST,DHH;IHH;SMO,,,PHASE 2,,Small molecule,Phase 2,SZBGQDXLNMELTB-UHFFFAOYSA-N,CN(C(=O)C1CCC(F)CC1C(F)(F)F)C1CCN(C2NNC(-C3CCNN3C)C3CCCCC23)CC1;CN(C1CCN(CC1)C1NNC(-C2CCNN2C)C2CCCCC12)C(=O)C1CCC(F)CC1C(F)(F)F
TALAMPANEL,TALAMPANEL,CHEMBL61872,BRD:BRD-BRD-K80359953-001-01-3;BRD:BRD-K80359953-001-01-3,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIA1;GRIA2;GRIA3;GRIA4,,,PHASE 2,,Small molecule,Phase 2,JACAAXNEHGBPOQ-LLVKDONJSA-N,C[C@@H]1CC2CC3OCOC3CC2C(=NN1C(C)=O)C1CCC(N)CC1;CC(=O)N1N=C(C2CCC(N)CC2)C2CC3C(CC2C[C@H]1C)OCO3
TALAPORFIN,TALAPORFIN,CHEMBL2111186,BRD:BRD-K00004965-342-01-9,rep_single_dose,PHOTOSENSITIZING AGENT,,,,,,Small molecule,Phase 3,VSEIDZLLWQQJGK-WSUYNKMOSA-N,C=CC1C(C)C2CC3NC(C(CC(=O)N[C@@H](CC(=O)O)C(=O)O)C4[NH]C(CC5NC(CC1[NH]2)C(C)=C5CC)C(C)C4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C
TALAROZOLE,TALAROZOLE,CHEMBL459505,BRD:BRD-A95755460-001-01-3;BRD:BRD-BRD-A95755460-001-01-3,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP26A1,,,PHASE 2,,Small molecule,Phase 2,SNFYYXUGUBUECJ-UHFFFAOYSA-N,CCC(CC)C(C1CCC(NC2NC3CCCCC3S2)CC1)N1CNCN1
TALAZOPARIB,TALAZOPARIB,CHEMBL3137320,BRD:BRD-BRD-K95142244-001-01-5;BRD:BRD-K95142244-001-01-5;GDSC1:1259;GDSC2:1259,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP2,,,PHASE 3,,Small molecule,Approved,HWGQMRYQVZSGDQ-HZPDHXFCSA-N,CN1NCNC1[C@@H]1[C@H](NC2CC(F)CC3C2C1N[NH]C3=O)C1CCC(F)CC1;CN1NCNC1[C@H]1C2N[NH]C(=O)C3CC(F)CC(C23)N[C@@H]1C1CCC(F)CC1
TALC,TALC,CHEMBL3989756;CHEMBL3990276,BRD:BRD-BRD-M92352362-002-02-3;BRD:BRD-M92352362-002-02-3,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,FPAFDBFIGPHWGO-UHFFFAOYSA-N;XBPUDTAATCFDRE-UHFFFAOYSA-N,O.O=[MG].O=[MG].O=[MG].O=[SI]=O.O=[SI]=O.O=[SI]=O.O=[SI]=O;O=[MG].O=[MG].O=[MG].O=[SI]=O.O=[SI]=O.O=[SI]=O.O=[SI]=O
TALINOLOL,TALINOLOL,CHEMBL152067,BRD:BRD-A94276798-001-01-4;BRD:BRD-BRD-A94276798-001-01-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 1,MXFWWQICDIZSOA-UHFFFAOYSA-N,CC(C)(C)NCC(O)COC1CCC(NC(=O)NC2CCCCC2)CC1
TALIPEXOLE,TALIPEXOLE,CHEMBL279085,BRD:BRD-BRD-K75615183-300-03-9;BRD:BRD-K75615183-300-03-9,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR AGONIST, DOPAMINE RECEPTOR AGONIST",ADRA2A;DRD2;HTR3A,GENITIAL HERPES,,LAUNCHED,,Small molecule,Unknown,DHSSDEDRBUKTQY-UHFFFAOYSA-N,C=CCN1CCC2NC(N)SC2CC1;NC1NC2CCN(CC=C)CCC2S1
TALMAPIMOD,TALMAPIMOD,CHEMBL514201,BRD:BRD-BRD-K17555800-003-01-5;BRD:BRD-K17555800-003-01-5;BRD:BRD-K17555800-003-02-3,rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,IL1B;MAPK11;MAPK14;MT-CO2;TNF,,,PHASE 2,"Multiple values for repurposing_target: {'IL1B;MAPK11;MAPK14;MT-CO2;TNF', 'MAPK11;MAPK14'}, taking the union",Small molecule,Phase 2,ZMELOYOKMZBMRB-DLBZAZTESA-N,C[C@@H]1CN(CC2CCC(F)CC2)[C@@H](C)CN1C(=O)C1CC2C(C(=O)C(=O)N(C)C)CN(C)C2CC1CL;C[C@H]1CN([C@H](C)CN1CC1CCC(F)CC1)C(=O)C1CC2C(CN(C)C2CC1CL)C(=O)C(=O)N(C)C
TALNETANT,TALNETANT,CHEMBL10188,BRD:BRD-BRD-K47095176-001-01-6;BRD:BRD-K47095176-001-01-6,rep_primary;rep_single_dose,TACHYKININ ANTAGONIST,TACR2;TACR3,,,PHASE 2,,Small molecule,Phase 2,BIAVGWDGIJKWRM-FQEVSTJZSA-N,CC[C@H](NC(=O)C1C(O)C(-C2CCCCC2)NC2CCCCC12)C1CCCCC1;CC[C@H](NC(=O)C1C(O)C(NC2CCCCC12)-C1CCCCC1)C1CCCCC1
TALNIFLUMATE,TALNIFLUMATE,CHEMBL1081506,BRD:BRD-A98378129-001-02-2;BRD:BRD-BRD-A98378129-001-02-2,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,CLCA1,PAIN RELIEF,,LAUNCHED,,Small molecule,Unknown,ANMLJLFWUCQGKZ-UHFFFAOYSA-N,FC(F)(F)C1CCCC(NC2NCCCC2C(=O)OC2OC(=O)C3CCCCC23)C1;O=C1OC(OC(=O)C2CCCNC2NC2CCCC(C(F)(F)F)C2)C2CCCCC21
TALOPRAM,TALOPRAM,CHEMBL299233,BRD:BRD-A02532772-003-01-7;BRD:BRD-BRD-A02532772-003-01-7,rep_primary;rep_single_dose,ADRENERGIC INHIBITOR,SLC6A2,,,PHASE 2,,Small molecule,Unknown,LJBBMCNHIUJBDU-UHFFFAOYSA-N,CNCCCC1(C2CCCCC2)OC(C)(C)C2CCCCC21;CNCCCC1(OC(C)(C)C2CCCCC12)C1CCCCC1
TALSACLIDINE,TALSACLIDINE,CHEMBL2111051,BRD:BRD-K00004651-001-01-9,rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,,,Small molecule,Phase 2,XVFJONKUSLSKSW-JTQLQIEISA-N,C#CCO[C@H]1CN2CCC1CC2
TALTIRELIN,TALTIRELIN,CHEMBL2107016,BRD:BRD-BRD-K93869735-001-01-1;BRD:BRD-K93869735-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,THYROTROPIN RELEASING HORMONE RECEPTOR AGONIST,TRHR,SPINOCEREBELLAR ATAXIA,,LAUNCHED,,Protein,Unknown,LQZAIAZUDWIVPM-SRVKXCTJSA-N,CN1C(=O)C[C@@H](C(=O)N[C@@H](CC2C[NH]CN2)C(=O)N2CCC[C@H]2C(N)=O)NC1=O;CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC1CNC[NH]1)C(=O)N1CCC[C@H]1C(N)=O
TALTOBULIN,TALTOBULIN,CHEMBL182319,BRD:BRD-BRD-K87512222-019-01-7;BRD:BRD-K87512222-019-01-7,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,CNTMOLDWXSVYKD-PSRNMDMQSA-N,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)C1CCCCC1;CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](/C=C(\C)C(=O)O)C(C)C)C(C)(C)C)C(C)(C)C1CCCCC1
TAMATINIB,TAMATINIB,CHEMBL475251,CTRP:417818,ctrp,,,,,,,Small molecule,Phase 2,NHHQJBCNYHBUSI-UHFFFAOYSA-N,COC1CC(NC2NCC(F)C(NC3CCC4C(N3)NC(=O)C(C)(C)O4)N2)CC(OC)C1OC
TAME,TAME,,BRD:BRD-BRD-K72231366-001-02-3;BRD:BRD-K72231366-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1CCC(C)CC1
TAMIBAROTENE,TAMIBAROTENE,CHEMBL25202,BRD:BRD-BRD-K36627727-001-05-4;BRD:BRD-K36627727-001-05-4,rep_multi_dose;rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB,ACUTE PROMYELOCYTIC LEUKEMIA (APL),,LAUNCHED,,Small molecule,Phase 3,MUTNCGKQJGXKEM-UHFFFAOYSA-N,CC1(C)CCC(C)(C)C2CC(NC(=O)C3CCC(C(=O)O)CC3)CCC21;CC1(C)CCC(C)(C)C2CC(NC(=O)C3CCC(CC3)C(O)=O)CCC12
TAMINADENANT,TAMINADENANT,,BRD:BRD-K00004682-001-01-9,rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,,,,,,,NA,,
TAMOXIFEN,TAMOXIFEN,CHEMBL83,BRD:BRD-BRD-K93754473-048-20-2;BRD:BRD-K93754473-048-20-2;CTRP:26972;GDSC1:1199;GDSC2:1199,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR ANTAGONIST, SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)",EBP;ESR1;ESR2;GPER1;PRKCA;PRKCB;PRKCD;PRKCE;PRKCG;PRKCI;PRKCQ;PRKCZ,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,NKANXQFJJICGDU-QPLCGJKRSA-N,CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1;CC\C(C1CCCCC1)=C(/C1CCCCC1)C1CCC(OCCN(C)C)CC1
TAMSULOSIN,TAMSULOSIN,CHEMBL836,BRD:BRD-BRD-K74339692-001-01-9;BRD:BRD-K74339692-001-01-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D,BENIGN PROSTATIC HYPERPLASIA (BPH),,LAUNCHED,,Small molecule,Approved,DRHKJLXJIQTDTD-OAHLLOKOSA-N,CCOC1CCCCC1OCCN[C@H](C)CC1CCC(OC)C(C1)S(N)(=O)=O;CCOC1CCCCC1OCCN[C@H](C)CC1CCC(OC)C(S(N)(=O)=O)C1
TANAPROGET,TANAPROGET,CHEMBL539163,BRD:BRD-BRD-K99604664-001-01-1;BRD:BRD-K99604664-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR AGONIST,PGR,,,PHASE 2,,Small molecule,Unknown,PYVFWTPEBMRKSR-UHFFFAOYSA-N,CN1C(C#N)CCC1-C1CCC2C(C1)C(C)(C)OC(=S)N2;CN1C(CCC1-C1CCC2NC(=S)OC(C)(C)C2C1)C#N
TANDOSPIRONE,TANDOSPIRONE,CHEMBL274047,BRD:BRD-BRD-K65904673-001-01-4;BRD:BRD-K65904673-001-01-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,"GENERALIZED ANXIETY DISORDER (GAD), DYSTHYMIC DISORDER",,LAUNCHED,,Small molecule,Unknown,CEIJFEGBUDEYSX-FZDBZEDMSA-N,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1CCCCN1CCN(C2NCCCN2)CC1;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)C1NCCCN1
TANDUTINIB,TANDUTINIB,CHEMBL124660,BRD:BRD-BRD-K89162000-001-06-4;BRD:BRD-K89162000-001-06-4;CTRP:464458,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"FLT3 INHIBITOR, KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR",CSF1R;FLT3;KIT;PDGFD;PDGFRB,,,PHASE 2,,Small molecule,Phase 2,UXXQOJXBIDBUAC-UHFFFAOYSA-N,COC1CC2C(N3CCN(C(=O)NC4CCC(OC(C)C)CC4)CC3)NCNC2CC1OCCCN1CCCCC1;COC1CC2C(NCNC2CC1OCCCN1CCCCC1)N1CCN(CC1)C(=O)NC1CCC(OC(C)C)CC1
TANESPIMYCIN,TANESPIMYCIN,CHEMBL109480,BRD:BRD-BRD-K81473043-001-14-6;BRD:BRD-K81473043-001-14-6;BRD:BRD-K81473043-001-19-5;CTRP:50134;GDSC1:1026,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PHASE 3,,Small molecule,Phase 3,AYUNIORJHRXIBJ-TXHRRWQRSA-N,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O;CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O
TANESPIMYCIN:BORTEZOMIB (250:1 MOL/MOL),TANESPIMYCIN:BORTEZOMIB (250:1 MOL/MOL),,CTRP:660221,ctrp,,,,,,,,NA,,
TANESPIMYCIN:GEMCITABINE (1:1 MOL/MOL),TANESPIMYCIN:GEMCITABINE (1:1 MOL/MOL),,CTRP:660216,ctrp,,,,,,,,NA,,
TANGERITIN,TANGERITIN,,BRD:BRD-BRD-K25186396-001-09-6;BRD:BRD-K25186396-001-09-6,rep_primary;rep_single_dose,CELL CYCLE INHIBITOR,,,,PRECLINICAL,,,NA,,COC1CCC(CC1)-C1CC(=O)C2C(OC)C(OC)C(OC)C(OC)C2O1
TANNIC-ACID,TANNIC-ACID,,BRD:BRD-K01584643-001-04-9,rep_single_dose,PARG INHIBITOR,ANO1,,,,,,NA,,
TANSHINONE-I,TANSHINONE-I,,BRD:BRD-BRD-K34073885-001-09-3;BRD:BRD-K34073885-001-09-3,rep_multi_dose;rep_primary;rep_single_dose,AP INHIBITOR,IFNG,,,PHASE 2,,,NA,,CC1COC-2C1C(=O)C(=O)C1C-2CCC2C(C)CCCC12
TANSHINONE-IIA,TANSHINONE-IIA,,BRD:BRD-BRD-K00141480-001-15-4;BRD:BRD-K00141480-001-15-4,rep_primary;rep_single_dose,"ANTI-INFLAMMATORY AGENT, INTERLEUKIN INHIBITOR",IL1B;NR1I2;TNF,,,PHASE 2/PHASE 3,,,NA,,CC1COC-2C1C(=O)C(=O)C1C-2CCC2C1CCCC2(C)C
TAPENTADOL,TAPENTADOL,CHEMBL1201776,BRD:BRD-BRD-K25699529-003-01-1;BRD:BRD-K25699529-003-01-1,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,HTR3A;OPRD1;OPRK1;OPRM1;SLC6A2;SLC6A4,"ACUTE PAIN, MUSCLE PAIN",,LAUNCHED,,Small molecule,Approved,KWTWDQCKEHXFFR-SMDDNHRTSA-N,CC[C@@H]([C@@H](C)CN(C)C)C1CCCC(O)C1;CC[C@@H](C1CCCC(O)C1)[C@@H](C)CN(C)C;CC[C@H]([C@@H](C)CN(C)C)C1CCCC(O)C1
TAPINAROF,TAPINAROF,CHEMBL259571,BRD:BRD-K00003498-001-01-9,rep_single_dose,ARYL HYDROCARBON RECEPTOR AGONIST,,,,,,Small molecule,Approved,ZISJNXNHJRQYJO-CMDGGOBGSA-N,CC(C)C1C(O)CC(/C=C/C2CCCCC2)CC1O
TAPRENEPAG,TAPRENEPAG,CHEMBL2107783,BRD:BRD-BRD-K88854110-001-01-5;BRD:BRD-K88854110-001-01-5,rep_primary;rep_single_dose,PROSTAGLANDIN RECEPTOR AGONIST,PTGER2,,,PHASE 2,,Small molecule,Unknown,MFFBXYNKZHTCEY-UHFFFAOYSA-N,O=C(O)COC1CCCC(CN(CC2CCC(-N3CCCN3)CC2)S(=O)(=O)C2CCCNC2)C1;OC(=O)COC1CCCC(CN(CC2CCC(CC2)-N2CCCN2)S(=O)(=O)C2CCCNC2)C1
TARAFENACIN,TARAFENACIN,CHEMBL1779046,BRD:BRD-BRD-K59390331-045-01-5;BRD:BRD-K59390331-045-01-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM3,,,PHASE 2,,Small molecule,Phase 2,UXZDMXYRRQJIBJ-IBGZPJMESA-N,FC1CCCC(C1)N(CC1CC(F)C(F)C(F)C1)C(=O)O[C@H]1CN2CCC1CC2;O=C(O[C@H]1CN2CCC1CC2)N(CC1CC(F)C(F)C(F)C1)C1CCCC(F)C1
TARANABANT,TARANABANT,CHEMBL220360,BRD:BRD-BRD-K35169477-001-01-9;BRD:BRD-K35169477-001-01-9,rep_primary;rep_single_dose,CANNABINOID RECEPTOR INVERSE AGONIST,CNR1,,,PHASE 3,,Small molecule,Phase 3,QLYKJCMUNUWAGO-GAJHUEQPSA-N,C[C@H](NC(=O)C(C)(C)OC1CCC(C(F)(F)F)CN1)[C@@H](CC1CCC(CL)CC1)C1CCCC(C#N)C1;C[C@H](NC(=O)C(C)(C)OC1CCC(CN1)C(F)(F)F)[C@@H](CC1CCC(CL)CC1)C1CCCC(C1)C#N
TARCEVA,TARCEVA,CHEMBL1079742;CHEMBL553,GDSC1:1;GDSC2:1168,gdsc,,,,,,,Small molecule,Approved,AAKJLRGGTJKAMG-UHFFFAOYSA-N;GTTBEUCJPZQMDZ-UHFFFAOYSA-N,C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1;C#CC1CCCC(NC2NCNC3CC(OCCOC)C(OCCOC)CC23)C1.CL
TARGININE,TARGININE,CHEMBL256147,BRD:BRD-BRD-K59506194-015-04-9;BRD:BRD-K59506194-015-04-9,rep_primary;rep_single_dose,NITRIC OXIDE SYNTHASE INHIBITOR,NOS3,,,PHASE 3,,Small molecule,Phase 3,NTNWOCRCBQPEKQ-YFKPBYRVSA-N,CNC(=N)NCCC[C@H](N)C(=O)O;CNC(=N)NCCC[C@H](N)C(O)=O
TARGRET,TARGRET,,GDSC1:186,gdsc,,,,,,,,NA,,
TARGRETIN,TARGRETIN,CHEMBL1023,GDSC1:186,gdsc,,,,,,,Small molecule,Approved,NAVMQTYZDKMPEU-UHFFFAOYSA-N,C=C(C1CCC(C(=O)O)CC1)C1CC2C(CC1C)C(C)(C)CCC2(C)C
TARGRETYN,TARGRETYN,,GDSC1:186,gdsc,,,,,,,,NA,,
TARGREXIN,TARGREXIN,,GDSC1:186,gdsc,,,,,,,,NA,,
TARIQUIDAR,TARIQUIDAR,CHEMBL348475,BRD:BRD-BRD-K09353376-001-03-9;BRD:BRD-K09353376-001-03-9,rep_primary;rep_single_dose,P GLYCOPROTEIN INHIBITOR,ABCB1,,,PHASE 3,,Small molecule,Phase 3,LGGHDPFKSSRQNS-UHFFFAOYSA-N,COC1CC2C(CC1OC)CN(CCC1CCC(NC(=O)C3CC(OC)C(OC)CC3NC(=O)C3CNC4CCCCC4C3)CC1)CC2;COC1CC2CCN(CCC3CCC(NC(=O)C4CC(OC)C(OC)CC4NC(=O)C4CNC5CCCCC5C4)CC3)CC2CC1OC
TARTARIC-ACID,TARTARIC-ACID,,BRD:BRD-K36474365-001-09-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
TAS-103,TAS-103,,BRD:BRD-BRD-K09426783-300-01-0;BRD:BRD-K09426783-300-01-0,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1,,,PHASE 1,,,NA,,CN(C)CCNC1NC2CC(O)CCC2C2-C3CCCCC3C(=O)C12
TAS-116,TAS-116,CHEMBL3661115,BRD:BRD-K00074122-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,NVVPMZUGELHVMH-UHFFFAOYSA-N,CCC1CC(C(N)=O)CCC1-N1NC(C(C)C)C2C(-N3CNC(-C4CNN(C)C4)C3)CCNC21
TAS4464,TAS4464,,BRD:BRD-K00091290-001-01-9,rep_single_dose,,,,,,,,NA,,
TASIGNA,TASIGNA,CHEMBL1201740;CHEMBL255863,GDSC1:1013;GDSC2:1013,gdsc,,,,,,,Small molecule,Approved,HHZIURLSWUIHRB-UHFFFAOYSA-N;YCBPQSYLYYBPDW-UHFFFAOYSA-N,CC1CN(-C2CC(NC(=O)C3CCC(C)C(NC4NCCC(-C5CCCNC5)N4)C3)CC(C(F)(F)F)C2)CN1;CC1CN(-C2CC(NC(=O)C3CCC(C)C(NC4NCCC(-C5CCCNC5)N4)C3)CC(C(F)(F)F)C2)CN1.CL.O
TASIMELTEON,TASIMELTEON,CHEMBL2103822,BRD:BRD-BRD-K62971431-001-01-9;BRD:BRD-K62971431-001-01-9,rep_primary;rep_single_dose,MELATONIN RECEPTOR AGONIST,MTNR1A;MTNR1B,NON-24-HOUR SLEEP-WAKE DISORDER,,LAUNCHED,,Small molecule,Approved,PTOIAAWZLUQTIO-GXFFZTMASA-N,CCC(=O)NC[C@@H]1C[C@H]1C1CCCC2C1CCO2;CCC(=O)NC[C@@H]1C[C@H]1C1CCCC2OCCC12
TASISULAM,TASISULAM,CHEMBL2110587,BRD:BRD-BRD-K42495768-001-01-7;BRD:BRD-K42495768-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,APOPTOSIS STIMULANT,,,,PHASE 3,,Small molecule,Phase 3,WWONFUQGBVOKOF-UHFFFAOYSA-N,CLC1CCC(C(=O)NS(=O)(=O)C2CCC(BR)S2)C(CL)C1;O=C(NS(=O)(=O)C1CCC(BR)S1)C1CCC(CL)CC1CL
TASQUINIMOD,TASQUINIMOD,CHEMBL2107784,BRD:BRD-BRD-K14653796-001-01-1;BRD:BRD-K14653796-001-01-1,rep_primary;rep_single_dose,"ANGIOGENESIS INHIBITOR, S100A9 INHIBITOR",HDAC4,,,PHASE 3,,Small molecule,Phase 3,ONDYALNGTUAJDX-UHFFFAOYSA-N,COC1CCCC2C1C(O)C(C(=O)N(C)C1CCC(C(F)(F)F)CC1)C(=O)N2C;COC1CCCC2N(C)C(=O)C(C(=O)N(C)C3CCC(CC3)C(F)(F)F)C(O)C12
TASULDINE,TASULDINE,CHEMBL358392,BRD:BRD-BRD-K10415035-001-04-4;BRD:BRD-K10415035-001-04-4,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,,,PHASE 3,,Small molecule,Unknown,HMCTXMOKMWELFJ-UHFFFAOYSA-N,C(SC1NCCCN1)C1CCCNC1;C1CNC(SCC2CCCNC2)NC1
TAURINE,TAURINE,CHEMBL239243,BRD:BRD-BRD-K51474575-001-10-4;BRD:BRD-K51474575-001-10-4,rep_multi_dose;rep_primary;rep_single_dose,ANTIOXIDANT,,"ANXIETY, IRRITABILITY, SLEEPLESSNESS",,LAUNCHED,,Small molecule,Approved,XOAAWQZATWQOTB-UHFFFAOYSA-N,NCCS(=O)(=O)O;NCCS(O)(=O)=O
TAUROCHOLATE,TAUROCHOLATE,,BRD:BRD-BRD-K81062487-001-05-8;BRD:BRD-K81062487-001-05-8,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,CEL;FABP6;SLCO1C1,,,PHASE 1,,,NA,,C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
TAUROGLYCOCHOLATE,TAUROGLYCOCHOLATE,,BRD:BRD-K00003523-236-01-9,rep_single_dose,MEMBRANE PERMEABILITY ENHANCER,,,,,,,NA,,
TAVABOROLE,TAVABOROLE,CHEMBL443052,BRD:BRD-BRD-K76713213-001-02-1;BRD:BRD-K76713213-001-02-1,rep_primary;rep_single_dose,LEUCYL-TRNA SYNTHETASE INHIBITOR,,ONYCHOMYCOSIS,,LAUNCHED,,Small molecule,Approved,LFQDNHWZDQTITF-UHFFFAOYSA-N,OB1OCC2CC(F)CCC12;OB1OCC2CC(F)CCC21
TAVILERMIDE,TAVILERMIDE,CHEMBL3544981,BRD:BRD-K00003254-001-01-9,rep_single_dose,TYROSINE KINASE PARTIAL AGONIST,,,,,,Protein,Phase 3,DVJXNXPFYJIACK-ULQDDVLXSA-N,NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)C2CC([N+](=O)[O-])CCC2OCC[C@@H](C(=O)NCC(=O)O)NC1=O
TAXIFOLIN,TAXIFOLIN,CHEMBL337309,BRD:BRD-BRD-K94649603-001-10-6;BRD:BRD-K94649603-001-10-6,rep_primary;rep_single_dose,OPIOID RECEPTOR ANTAGONIST,ADIPOR2,,,PHASE 2,,Small molecule,NA,CXQWRCVTCMQVQX-UHFFFAOYSA-N,O[C@@H]1[C@H](OC2CC(O)CC(O)C2C1=O)C1CCC(O)C(O)C1;O=C1C2C(O)CC(O)CC2OC(C2CCC(O)C(O)C2)C1O
TAXOL,TAXOL,CHEMBL428647,GDSC1:11;GDSC2:1080,gdsc,,,,,,,Small molecule,Approved,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)C3CCCCC3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4CCCCC4)C4CCCCC4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
TAXOTERE,TAXOTERE,CHEMBL3545252;CHEMBL92,GDSC1:1007;GDSC2:1007;GDSC2:1819,gdsc,,,,,,,Small molecule,Approved,XCDIRYDKECHIPE-QHEQPUDQSA-N;ZDZOTLJHXYCWBA-VCVYQWHSSA-N,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C[C@@](O)([C@@H](OC(=O)C4CCCCC4)[C@H]21)C3(C)C;CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4CCCCC4)C[C@@](O)([C@@H](OC(=O)C4CCCCC4)[C@H]21)C3(C)C.O.O.O
TAZAROTENE,TAZAROTENE,CHEMBL1657,BRD:BRD-BRD-K76841105-001-04-7;BRD:BRD-K76841105-001-04-7,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB;RARG;RXRB,"COSMETIC, SUNSCREEN LOTION",,LAUNCHED,,Small molecule,Approved,OGQICQVSFDPSEI-UHFFFAOYSA-N,CCOC(=O)C1CCC(C#CC2CCC3C(C2)C(C)(C)CCS3)NC1;CCOC(=O)C1CCC(NC1)C#CC1CCC2SCCC(C)(C)C2C1
TAZOBACTAM,TAZOBACTAM,CHEMBL404,BRD:BRD-A18611368-001-01-5;BRD:BRD-BRD-A18611368-001-01-5,rep_primary;rep_single_dose,BETA LACTAMASE INHIBITOR,,PNEUMONIA,,LAUNCHED,,Small molecule,Approved,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,C[C@]1(CN2CCNN2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O;C[C@]1(CN2CCNN2)C(N2C(CC2=O)S1(=O)=O)C(O)=O
TBA-354,TBA-354,CHEMBL1630563,BRD:BRD-BRD-K56405978-001-01-5;BRD:BRD-K56405978-001-01-5,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Phase 1,ZXSGSFMORAILEY-HNNXBMFYSA-N,[O-][N+](=O)C1CN2C[C@@H](COC2N1)OCC1CCC(NC1)-C1CCC(OC(F)(F)F)CC1;O=[N+]([O-])C1CN2C(N1)OC[C@@H](OCC1CCC(-C3CCC(OC(F)(F)F)CC3)NC1)C2
TBOA-(DL),TBOA-(DL),,BRD:BRD-BRD-M77041484-001-01-8;BRD:BRD-M77041484-001-01-8,rep_primary;rep_single_dose,EXCITATORY AMINO ACID TRANSPORTER INHIBITOR,SLC1A1;SLC1A2;SLC1A3;SLC1A6;SLC1A7,,,PRECLINICAL,,,NA,,N[C@@H]([C@H](OCC1CCCCC1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCC1CCCCC1)C(O)=O)C(O)=O
TC-A-2317,TC-A-2317,,BRD:BRD-A12147465-003-02-9,rep_single_dose,AURORA KINASE INHIBITOR,AURKA,,,,,,NA,,
TC-ASK-10,TC-ASK-10,,BRD:BRD-BRD-K29660062-300-01-2;BRD:BRD-K29660062-300-01-2,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAP3K5;MAP3K6,,,PRECLINICAL,,,NA,,CC(C)(C)C1CCC(CC1)C(=O)NC1CN2CC(CCC2N1)-N1CCNC1
TC-E-5002,TC-E-5002,,BRD:BRD-BRD-K15256258-001-01-3;BRD:BRD-K15256258-001-01-3,rep_primary;rep_single_dose,HISTONE DEMETHYLASE INHIBITOR,KDM2A;KDM4A;KDM4C;KDM5A;KDM6A;KDM7A;PHF8,,,PRECLINICAL,,,NA,,ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1
TC-E-5006,TC-E-5006,,BRD:BRD-A66521565-001-01-8;BRD:BRD-BRD-A66521565-001-01-8,rep_primary;rep_single_dose,GAMMA SECRETASE MODULATOR,APP,,,PRECLINICAL,,,NA,,CC(C(O)=O)C1CCC(C(N2CCC(C)CC2)C2CCC(F)CC2)C(C1)-C1CCC(CC1)C(F)(F)F
TC-F-2,TC-F-2,,BRD:BRD-BRD-K26041695-001-02-5;BRD:BRD-K26041695-001-02-5,rep_primary;rep_single_dose,FAAH INHIBITOR,FAAH,,,PRECLINICAL,,,NA,,CCN1C2CCCCC2N([C@H]2CCCN(C2)C2NCCC(N2)-C2CC3CCCCC3O2)C1=O
TC-FPR-43,TC-FPR-43,,BRD:BRD-BRD-K16497916-001-01-6;BRD:BRD-K16497916-001-01-6,rep_primary;rep_single_dose,FORMYL PEPTIDE RECEPTOR AGONIST,FPR2,,,PRECLINICAL,,,NA,,CC(C)C1C(NC(=O)NC2CCC(CL)CC2)C(=O)N(-C2CCCCC2)N1C
TC-G-1000,TC-G-1000,,BRD:BRD-K27010807-050-02-9,rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,,,,,,NA,,
TC-G-1004,TC-G-1004,,BRD:BRD-K76989898-001-02-9,rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA2A,,,,,,NA,,
TC-G-1005,TC-G-1005,,BRD:BRD-K16939217-001-02-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPBAR1,,,,,,NA,,
TC-G-1008,TC-G-1008,,BRD:BRD-BRD-K87199310-001-01-4;BRD:BRD-K87199310-001-01-4,rep_primary;rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPR39,,,PRECLINICAL,,,NA,,CNC1NC(NCC2CCC(NS(C)(=O)=O)CC2CL)CC(N1)-C1CCCCN1
TC-H-106,TC-H-106,,BRD:BRD-K45044657-001-01-4,rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC8,,,,,,NA,,
TC-I-15,TC-I-15,,BRD:BRD-BRD-K17621556-001-01-5;BRD:BRD-K17621556-001-01-5,rep_primary;rep_single_dose,INTEGRIN INHIBITOR,ITGA2;ITGB1,,,PRECLINICAL,,,NA,,CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCC1CCCCC1)C(O)=O)S(=O)(=O)C1CCCCC1
TC-I-2000,TC-I-2000,,BRD:BRD-A83792282-001-01-6;BRD:BRD-BRD-A83792282-001-01-6,rep_primary;rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPM8,,,PRECLINICAL,,,NA,,FC1CCC(NC(=O)N2CCC3CCCCC3C2C2CCC(CC2)C(F)(F)F)CC1
TC-I-2014,TC-I-2014,,BRD:BRD-K05262258-001-02-9,rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPM8,,,,,,NA,,
TC-LPA5-4,TC-LPA5-4,,BRD:BRD-BRD-K32031961-001-01-7;BRD:BRD-K32031961-001-01-7,rep_primary;rep_single_dose,LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST,LPAR5,,,PRECLINICAL,,,NA,,COC1CCCC(C1)-N1NC(CC1-C1CCC(C2CCCCC2)C(CL)C1)C(O)=O
TC-MPS1-12,TC-MPS1-12,,BRD:BRD-BRD-K76792630-001-01-2;BRD:BRD-K76792630-001-01-2,rep_primary;rep_single_dose,MONOPOLAR SPINDLE 1 KINASE INHIBITOR,TTK,,,PRECLINICAL,,,NA,,CC(C)(C)NC1NC(NC2CCC(CC2)C(N)=O)CC(N)C1C#N
TC-N-1752,TC-N-1752,,BRD:BRD-BRD-K78161388-001-01-2;BRD:BRD-K78161388-001-01-2,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN9A,,,PRECLINICAL,,,NA,,CC(=O)NC1CCCC(NC2NCNC(N2)N2CCC(CC2)OCC2CCC(OC(F)(F)F)CC2)C1C
TC-NTR1-17,TC-NTR1-17,,BRD:BRD-BRD-K79608170-001-02-1;BRD:BRD-K79608170-001-02-1,rep_primary;rep_single_dose,NEUROTENSIN AGONIST,NTSR1,,,PRECLINICAL,,,NA,,COC1CCCC(OC)C1-C1CC(NN1-C1CCNC2CC(CL)CCC12)C(=O)N[C@@H](CC(C)C)C(O)=O
TC-O-9311,TC-O-9311,,BRD:BRD-K54297077-001-02-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPR139,,,,,,NA,,
TC-OT-39,TC-OT-39,,BRD:BRD-BRD-K55013981-001-01-3;BRD:BRD-K55013981-001-01-3,rep_primary;rep_single_dose,"OXYTOCIN RECEPTOR AGONIST, VASOPRESSIN RECEPTOR AGONIST",AVPR1A;OXT,,,PRECLINICAL,,,NA,,CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCC1CCC(CC1C)C(=O)N1CC2CNN(C)C2NC2CCCCC12
TC-S-7003,TC-S-7003,,BRD:BRD-K34362291-001-02-9,rep_single_dose,SRC INHIBITOR,LCK,,,,,,NA,,
TC-S-7004,TC-S-7004,,BRD:BRD-BRD-K89517477-001-01-4;BRD:BRD-K89517477-001-01-4,rep_primary;rep_single_dose,DYRK INHIBITOR,DYRK1A;DYRK1B,,,PRECLINICAL,,,NA,,COC1NCC2CC(C(=O)NC3CC(CCC3CL)C(=O)NCC3CCCC(CL)C3)C(=O)[NH]C2N1
TC-S-7005,TC-S-7005,,BRD:BRD-BRD-K89584803-001-01-9;BRD:BRD-K89584803-001-01-9,rep_primary;rep_single_dose,PLK INHIBITOR,PLK2,,,PRECLINICAL,,,NA,,C[C@H](NC1CC2C(NOC2CN1)-C1CCC2OCOC2C1)C1CCCCC1
TC-S-7006,TC-S-7006,,BRD:BRD-K51776215-001-03-9,rep_single_dose,MAP KINASE INHIBITOR,MAP3K8,,,,,,NA,,
TC-S-7009,TC-S-7009,,BRD:BRD-BRD-K21894922-001-01-9;BRD:BRD-K21894922-001-01-9,rep_primary;rep_single_dose,HYPOXIA INDUCIBLE FACTOR INHIBITOR,EPAS1,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1C(NC2CC(F)CC(CL)C2)CCC2NONC12
TC-SP-14,TC-SP-14,,BRD:BRD-K87461578-001-02-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST,S1PR1,,,,,,NA,,
TC1,TC1,,BRD:BRD-A13964793-001-02-6;BRD:BRD-BRD-A13964793-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,BETA-SECRETASE INHIBITOR,BACE1,,,PRECLINICAL,,,NA,,OC12C3C4C5C3C(C3C5CC4C13)N2CCC1CCCC(F)C1
TC2559,TC2559,,BRD:BRD-BRD-K24227647-364-01-5;BRD:BRD-K24227647-364-01-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA4,,,PRECLINICAL,,,NA,,CCOC1CNCC(\C=C\CCNC)C1
TCN201,TCN201,,BRD:BRD-BRD-K09787262-001-01-9;BRD:BRD-K09787262-001-01-9,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2A,,,PRECLINICAL,,,NA,,FC1CCC(CC1CL)S(=O)(=O)NCC1CCC(CC1)C(=O)NNC(=O)C1CCCCC1
TCN238,TCN238,,BRD:BRD-K77915400-001-01-6,rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM4,,,,,,NA,,
TCS2002,TCS-2002;TCS2002,,BRD:BRD-A50028488-001-01-6;BRD:BRD-BRD-A50028488-001-01-6;BRD:BRD-K00004294-001-01-9,rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3B,,,PRECLINICAL,"Multiple values for structure_id: {'A50028488', 'K00004294'}, defaulting to None",,NA,,CC1NNC(O1)-C1CCC2OCC(-C3CCC(CC3)S(C)=O)C2C1
TCS-21311,TCS-21311,,BRD:BRD-K49461364-001-01-0,rep_single_dose,JAK INHIBITOR,JAK3,,,,,,NA,,
TCS-2210,TCS-2210,,BRD:BRD-K19958299-001-02-9,rep_single_dose,NEURAL STEM CELL INDUCER,,,,,,,NA,,
TCS-2314,TCS-2314,,BRD:BRD-BRD-K55216666-001-01-4;BRD:BRD-K55216666-001-01-4,rep_primary;rep_single_dose,INTEGRIN INHIBITOR,ITGA4;ITGB1,,,PRECLINICAL,,,NA,,CC1CCCCC1NC(=O)NC1CCC(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)CC1
TCS-3035,TCS-3035,,BRD:BRD-K81935556-001-02-9,rep_single_dose,G PROTEIN-COUPLED RECEPTOR AGONIST,GPR35,,,,,,NA,,
TCS-359,TCS-359,,BRD:BRD-BRD-K81376179-001-04-8;BRD:BRD-K81376179-001-04-8,rep_primary;rep_single_dose,FLT3 INHIBITOR,FLT3,,,PRECLINICAL,,,NA,,COC1CCC(CC1OC)C(=O)NC1SC2CCCCC2C1C(N)=O
TCS-5861528,TCS-5861528,,BRD:BRD-A16560607-001-02-5;BRD:BRD-BRD-A16560607-001-02-5,rep_primary;rep_single_dose,TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST,TRPA1,,,PRECLINICAL,,,NA,,CCC(C)C1CCC(NC(=O)CN2CNC3N(C)C(=O)N(C)C(=O)C23)CC1
TCS-HDAC6-20B,TCS-HDAC6-20B,,BRD:BRD-BRD-K68358632-001-01-0;BRD:BRD-K68358632-001-01-0,rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC6,,,PRECLINICAL,,,NA,,CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2
TCS-OX2-29,TCS-OX2-29,,BRD:BRD-K29424831-003-01-3,rep_single_dose,OREXIN RECEPTOR ANTAGONIST,HCRTR2,,,,,,NA,,
TCS-PIM-1-1,TCS-PIM-1-1,,BRD:BRD-BRD-K08902330-001-01-3;BRD:BRD-K08902330-001-01-3,rep_primary;rep_single_dose,PIM KINASE INHIBITOR,PIM1,,,PRECLINICAL,,,NA,,OC1CCC(BR)CC1-C1CC(-C2CCCCC2)C(C#N)C(=O)[NH]1
TCV-309,TCV-309,,BRD:BRD-K00003278-003-01-9,rep_single_dose,PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST,,,,,,,NA,,
TD139,TD139,CHEMBL4297442,BRD:BRD-K00003308-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Phase 2,YGIDGBAHDZEYMT-MQFIMZJJSA-N,OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@H](N3CC(-C4CCCC(F)C4)NN3)[C@H]2O)[C@H](O)[C@@H](N2CC(-C3CCCC(F)C3)NN2)[C@H]1O
TEBANICLINE (DIHYDROCHLORIDE),TEBANICLINE (DIHYDROCHLORIDE),,BRD:BRD-K00091289-300-01-9,rep_single_dose,,,,,,,,NA,,
TEBIPENEM,TEBIPENEM,CHEMBL576981,BRD:BRD-BRD-K06900071-001-01-2;BRD:BRD-K06900071-001-01-2,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,CNR1,"PNEUMONIA, OTITIS",,LAUNCHED,,Small molecule,Phase 1,GXXLUDOKHXEFBQ-YJFSRANCSA-N,C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C;C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@H]12
TECADENOSON,TECADENOSON,CHEMBL392149,BRD:BRD-K00003289-001-01-9,rep_single_dose,ADENOSINE RECEPTOR AGONIST,ADORA1,,,,,Small molecule,Phase 2,OESBDSFYJMDRJY-BAYCTPFLSA-N,OC[C@H]1O[C@@H](N2CNC3C(N[C@@H]4CCOC4)NCNC32)[C@H](O)[C@@H]1O
TECALCET,TECALCET,CHEMBL292376,BRD:BRD-BRD-K41662846-003-01-5;BRD:BRD-K41662846-003-01-5,rep_primary;rep_single_dose,CALCIUM-SENSING RECEPTOR AGONIST,CASR,,,PHASE 2,,Small molecule,Phase 2,ZVQUCWXZCKWZBP-CQSZACIVSA-N,COC1CCCC([C@@H](C)NCCCC2CCCCC2CL)C1;COC1CCCC(C1)[C@@H](C)NCCCC1CCCCC1CL
TECARFARIN,TECARFARIN,CHEMBL2105664,BRD:BRD-K00079520-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 3,QFLNTQDOVCLQKW-UHFFFAOYSA-N,CC(OC(=O)C1CCC(CC2C(O)C3CCCCC3OC2=O)CC1)(C(F)(F)F)C(F)(F)F
TECASTEMIZOLE,TECASTEMIZOLE,CHEMBL61301,BRD:BRD-BRD-K48195801-001-01-6;BRD:BRD-K48195801-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,KCNH2,,,PHASE 3,,Small molecule,Unknown,SFOVDSLXFUGAIV-UHFFFAOYSA-N,FC1CCC(CN2C(NC3CCNCC3)NC3CCCCC23)CC1;FC1CCC(CN2C(NC3CCNCC3)NC3CCCCC32)CC1
TECOVIRIMAT,TECOVIRIMAT,CHEMBL1242629;CHEMBL1257073,BRD:BRD-BRD-K24312986-001-01-2;BRD:BRD-K24312986-001-01-2,rep_primary;rep_single_dose,ORTHOPOXVIRUS EGRESS INHIBITOR,,,,PHASE 3,,Small molecule,Approved,CSKDFZIMJXRJGH-KUAIZNHUSA-N;CSKDFZIMJXRJGH-VWLPUNTISA-N,FC(F)(F)C1CCC(CC1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O;O=C(NN1C(=O)[C@@H]2[C@@H]3C=C[C@@H]([C@H]4C[C@@H]34)[C@@H]2C1=O)C1CCC(C(F)(F)F)CC1;O=C(NN1C(=O)[C@@H]2C3C=CC([C@H]4C[C@@H]34)[C@@H]2C1=O)C1CCC(C(F)(F)F)CC1
TEDIZOLID,TEDIZOLID,CHEMBL1257051,BRD:BRD-BRD-K59436580-001-01-7;BRD:BRD-K59436580-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,SKIN INFECTIONS,,LAUNCHED,,Small molecule,Approved,XFALPSLJIHVRKE-GFCCVEGCSA-N,CN1NNC(-C2CCC(-C3CCC(N4C[C@H](CO)OC4=O)CC3F)CN2)N1;CN1NNC(N1)-C1CCC(CN1)-C1CCC(CC1F)N1C[C@H](CO)OC1=O
TEDIZOLID-PHOSPHATE,TEDIZOLID-PHOSPHATE,,BRD:BRD-BRD-K89121095-001-01-7;BRD:BRD-K89121095-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,SKIN INFECTIONS,,LAUNCHED,,,NA,,CN1NNC(N1)-C1CCC(CN1)-C1CCC(CC1F)N1C[C@H](COP(O)(O)=O)OC1=O
TEFINOSTAT,TEFINOSTAT,CHEMBL4297582,BRD:BRD-K00091118-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,GLNWREBYRLDPQP-MHZLTWQESA-N,O=C(CCCCCCC(=O)NC1CCC(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)CC1)NO
TEGASEROD,TEGASEROD,CHEMBL76370,BRD:BRD-BRD-K88743730-050-04-1;BRD:BRD-K88743730-050-04-1,rep_primary;rep_single_dose,SEROTONIN RECEPTOR PARTIAL AGONIST,HTR2A;HTR2B;HTR2C;HTR4,,,WITHDRAWN,,Small molecule,Approved,IKBKZGMPCYNSLU-RGVLZGJSSA-N,CCCCCNC(=N)N/N=C/C1C[NH]C2CCC(OC)CC12;CCCCCNC(=N)N\N=C\C1C[NH]C2CCC(OC)CC12
TEGLICAR,TEGLICAR,CHEMBL1231506,BRD:BRD-K00074712-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,BMZYTDRMCBZVNH-HXUWFJFHSA-N,CCCCCCCCCCCCCCNC(=O)N[C@H](CC(=O)[O-])C[N+](C)(C)C
TEGOBUVIR,TEGOBUVIR,CHEMBL1957287,BRD:BRD-BRD-K26701552-001-01-8;BRD:BRD-K26701552-001-01-8,rep_primary;rep_single_dose,"HCV INHIBITOR, PROTEASE INHIBITOR",,,,PHASE 3,,Small molecule,Phase 2,XBEQSQDCBSKCHJ-UHFFFAOYSA-N,FC1CCCCC1-C1NC2CCN(CC3CCC(-C4CCC(C(F)(F)F)CC4C(F)(F)F)NN3)CC-2N1;FC1CCCCC1-C1NC2CCN(CC3CCC(NN3)-C3CCC(CC3C(F)(F)F)C(F)(F)F)CC2N1
TEIJIN-COMPOUND-1,TEIJIN-COMPOUND-1,,BRD:BRD-BRD-K51528698-003-01-4;BRD:BRD-K51528698-003-01-4,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR2,,,PRECLINICAL,,,NA,,FC(F)(F)C1CCCC(C1)C(=O)NCC(=O)N[C@@H]1CCN(CC2CCC(CL)CC2)C1
TELAPREVIR,TELAPREVIR,CHEMBL231813,BRD:BRD-BRD-K72912098-001-02-3;BRD:BRD-K72912098-001-02-3,rep_primary;rep_single_dose,HCV INHIBITOR,CTSA;PGR,HEPATITIS C,,LAUNCHED,,Protein,Approved,BBAWEDCPNXPBQM-GDEBMMAJSA-N,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CNCCN1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1
TELATINIB,TELATINIB,CHEMBL2079588,BRD:BRD-BRD-K84564571-001-02-4;BRD:BRD-K84564571-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",KDR,,,PHASE 2,,Small molecule,Phase 2,QFCXANHHBCGMAS-UHFFFAOYSA-N,CNC(=O)C1CC(COC2NNC(NC3CCC(CL)CC3)C3CCOC23)CCN1
TELAVANCIN,TELAVANCIN,CHEMBL507870,BRD:BRD-K00085355-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,ONUMZHGUFYIKPM-MXNFEBESSA-N,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](OC3C4CC5CC3OC3CCC(CC3CL)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C5CC(O)C(CNCP(=O)(O)O)C(O)C5-C5CC3CCC5O)[C@H](O)C3CCC(C(CL)C3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O
TELBIVUDINE,TELBIVUDINE,CHEMBL374731,BRD:BRD-BRD-K15976406-001-03-3;BRD:BRD-K15976406-001-03-3,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,TK2,HEPATITIS B,,LAUNCHED,,Small molecule,Approved,IQFYYKKMVGJFEH-CSMHCCOUSA-N,CC1CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)[NH]C1=O
TELCAGEPANT,TELCAGEPANT,CHEMBL236593,BRD:BRD-BRD-K91159026-001-01-7;BRD:BRD-K91159026-001-01-7,rep_primary;rep_single_dose,CALCITONIN ANTAGONIST,CALCRL;RAMP1,,,PHASE 3,,Small molecule,Phase 3,CGDZXLJGHVKVIE-DNVCBOLYSA-N,FC1CCCC([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)N3C4CCCNC4[NH]C3=O)C(=O)N(CC(F)(F)F)C2)C1F;O=C(N[C@@H]1CC[C@@H](C2CCCC(F)C2F)CN(CC(F)(F)F)C1=O)N1CCC(N2C(=O)[NH]C3NCCCC32)CC1
TELENZEPINE,TELENZEPINE,CHEMBL253978,BRD:BRD-BRD-K06147391-300-06-8;BRD:BRD-K06147391-300-06-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,,,PHASE 3,,Small molecule,Phase 1,VSWPGAIWKHPTKX-UHFFFAOYSA-N,CC1SCC2C1N(C(=O)CN1CCN(C)CC1)C1CCCCC1NC2=O;CN1CCN(CC(=O)N2C3C(C)SCC3C(=O)NC3CCCCC23)CC1
TELITHROMYCIN,TELITHROMYCIN,CHEMBL1136,BRD:BRD-A94008949-001-01-9;BRD:BRD-BRD-A94008949-001-01-9,rep_primary;rep_single_dose,"BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR, BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR",CYP1A2;CYP2D6;CYP3A4;CYP3A5;CYP3A7,PNEUMONIA,,LAUNCHED,,Small molecule,Approved,LJVAJPDWBABPEJ-PNUFFHFMSA-N,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3CNC(C3)-C3CCCNC3)C(=O)O[C@]12C)OC;CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCN3CNC(-C4CCCNC4)C3)C(=O)O[C@]12C;CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCN3CNC(C3)-C3CCCNC3)C(=O)O[C@]12C)OC
TELMESTEINE,TELMESTEINE,CHEMBL2107621,BRD:BRD-A05523972-001-01-5;BRD:BRD-BRD-A05523972-001-01-5,rep_primary;rep_single_dose,MUCOLYTIC AGENT,,,,LAUNCHED,,Small molecule,Unknown,XBJWOGLKABXFJE-YFKPBYRVSA-N,CCOC(=O)N1CSC[C@H]1C(=O)O;CCOC(=O)N1CSCC1C(O)=O
TELMISARTAN,TELMISARTAN,CHEMBL1017,BRD:BRD-BRD-K73999723-001-11-3;BRD:BRD-K73999723-001-11-3,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1;PPARG,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,RMMXLENWKUUMAY-UHFFFAOYSA-N,CCCC1NC2C(C)CC(-C3NC4CCCCC4N3C)CC2N1CC1CCC(-C2CCCCC2C(=O)O)CC1;CCCC1NC2C(C)CC(CC2N1CC1CCC(CC1)-C1CCCCC1C(O)=O)-C1NC2CCCCC2N1C
TELOMERASE INHIBITOR IX,TELOMERASE INHIBITOR IX,,GDSC2:1930,gdsc,,,,,,,,NA,,
TELOTRISTAT,TELOTRISTAT,CHEMBL2103855,BRD:BRD-BRD-K63178091-001-01-1;BRD:BRD-K63178091-001-01-1,rep_primary;rep_single_dose,TRYPTOPHAN HYDROXYLASE INHIBITOR,TPH1,,,LAUNCHED,,Small molecule,Approved,NCLGDOBQAWBXRA-PGRDOPGGSA-N,CC1CCN(-C2CC(CL)CCC2[C@@H](OC2CC(-C3CCC(C[C@H](N)C(=O)O)CC3)NC(N)N2)C(F)(F)F)N1;CC1CCN(N1)-C1CC(CL)CCC1[C@@H](OC1CC(NC(N)N1)-C1CCC(C[C@H](N)C(O)=O)CC1)C(F)(F)F
TELOTRISTAT-ETHYL,TELOTRISTAT-ETHYL,,BRD:BRD-BRD-K94559059-091-01-6;BRD:BRD-K94559059-091-01-6,rep_multi_dose;rep_primary;rep_single_dose,TRYPTOPHAN HYDROXYLASE INHIBITOR,TPH1,DIARRHEA,,LAUNCHED,,,NA,,CCOC(=O)[C@@H](N)CC1CCC(CC1)-C1CC(O[C@H](C2CCC(CL)CC2-N2CCC(C)N2)C(F)(F)F)NC(N)N1
TELRATOLIMOD,TELRATOLIMOD,CHEMBL4297631,BRD:BRD-K00004596-001-01-9,rep_single_dose,TOLL-LIKE RECEPTOR AGONIST,,,,,,Small molecule,Phase 1,RRTPWQXEERTRRK-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCC(=O)NCCCCON1C(CCCC)NC2C(N)NC3CCCCC3C21
TEMANOGREL,TEMANOGREL,CHEMBL1084617,BRD:BRD-K00003467-001-01-9,rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,ZEOQUKRCASTCFR-UHFFFAOYSA-N,COC1CCCC(C(=O)NC2CCC(OCCN3CCOCC3)C(-C3CCNN3C)C2)C1
TEMAZEPAM,TEMAZEPAM,CHEMBL967,BRD:BRD-A93093700-001-02-9;BRD:BRD-BRD-A93093700-001-02-9,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GABRR1;GABRR2;GABRR3;TSPO,,,WITHDRAWN,,Small molecule,Approved,SEQDDYPDSLOBDC-UHFFFAOYSA-N,CN1C(=O)C(O)N=C(C2CCCCC2)C2CC(CL)CCC21;CN1C2CCC(CL)CC2C(=NC(O)C1=O)C1CCCCC1
TEMEFOS,TEMEFOS,CHEMBL1355821,BRD:BRD-K51805276-001-10-9,rep_single_dose,CHOLINESTERASE INHIBITOR,,,,,,Small molecule,Unknown,WWJZWCUNLNYYAU-UHFFFAOYSA-N,COP(=S)(OC)OC1CCC(SC2CCC(OP(=S)(OC)OC)CC2)CC1
TEMOCAPRIL,TEMOCAPRIL,CHEMBL2110627,BRD:BRD-BRD-K10784860-003-02-3;BRD:BRD-K10784860-003-02-3,rep_multi_dose;rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, CONGESTIVE HEART FAILURE, DIABETIC NEPHROPATHY, CORONARY ARTERY DISEASE (CAD)",,LAUNCHED,,Small molecule,Unknown,FIQOFIRCTOWDOW-BJLQDIEVSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1CCCS1;CCOC(=O)[C@H](CCC1CCCCC1)N[C@H]1CS[C@H](C2CCCS2)CN(CC(=O)O)C1=O
TEMODAL,TEMODAL,CHEMBL810,GDSC1:1375;GDSC2:1375,gdsc,,,,,,,Small molecule,Approved,BPEGJWRSRHCHSN-UHFFFAOYSA-N,CN1NNC2C(C(N)=O)NCN2C1=O
TEMODAR,TEMODAR,CHEMBL810,GDSC1:1375;GDSC2:1375,gdsc,,,,,,,Small molecule,Approved,BPEGJWRSRHCHSN-UHFFFAOYSA-N,CN1NNC2C(C(N)=O)NCN2C1=O
TEMOPORFIN,TEMOPORFIN,CHEMBL383675,BRD:BRD-BRD-K63712959-001-01-8;BRD:BRD-K63712959-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,RADICAL FORMATION STIMULANT,,HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC),,LAUNCHED,,Small molecule,Approved,KSXLETNRCMCRAQ-LWQDQPMZSA-N,OC1CCCC(-C2C3NC(C(-C4CCCC(O)C4)C4CCC([NH]4)C(-C4CCCC(O)C4)C4CCC([NH]4)C(-C4CCCC(O)C4)C4NC2CC4)C=C3)C1;OC1CCCC(C1)-C1C2CCC(N2)C(-C2CCCC(O)C2)C2CCC([NH]2)C(-C2CCCC(O)C2)C2CCC(N2)C(-C2CCCC(O)C2)C2CCC1[NH]2
TEMOZOLOMIDE,TEMOZOLOMIDE,CHEMBL810,BRD:BRD-BRD-K32107296-001-16-9;BRD:BRD-K32107296-001-16-9;CTRP:351043;GDSC1:1375;GDSC2:1375,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,MGMT,"GLIOBLASTOMA, ASTROCYTOMA",,LAUNCHED,,Small molecule,Approved,BPEGJWRSRHCHSN-UHFFFAOYSA-N,CN1NNC2C(C(N)=O)NCN2C1=O;CN1NNC2C(NCN2C1=O)C(N)=O
TEMPOL,TEMPOL,CHEMBL607023,BRD:BRD-BRD-K95053546-001-01-9;BRD:BRD-BRD-K95053546-001-02-7;BRD:BRD-BRD-K95053546-001-03-5;BRD:BRD-K95053546-001-01-9;BRD:BRD-K95053546-001-02-7;BRD:BRD-K95053546-001-03-5,rep_primary;rep_single_dose,FREE RADICAL SCAVENGER,,,,PHASE 2,,Small molecule,Phase 2,UZFMOKQJFYMBGY-UHFFFAOYSA-N,CC1(C)CC(O)CC(C)(C)N1[O];CC1(C)CC(O)CC(C)(C)N1O
TEN-010,TEN-010,,BRD:BRD-K00005242-001-01-9,rep_single_dose,BROMODOMAIN INHIBITOR,,,,,,,NA,,
TENALISIB,TENALISIB,CHEMBL4297584,BRD:BRD-K00003263-001-01-9,rep_single_dose,PI3K INHIBITOR,,,,,,Small molecule,Phase 2,HDXDQPRPFRKGKZ-INIZCTEOSA-N,CC[C@H](NC1NCNC2[NH]CNC12)C1OC2CCCCC2C(=O)C1-C1CCCC(F)C1
TENAPANOR,TENAPANOR,CHEMBL3304485,BRD:BRD-K00003201-001-01-9,rep_single_dose,SODIUM/HYDROGEN EXCHANGER INHIBITOR,,,,,,Small molecule,Approved,DNHPDWGIXIMXSA-CXNSMIOJSA-N,CN1CC2C(CL)CC(CL)CC2[C@H](C2CCCC(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C3CCCC([C@@H]4CN(C)CC5C(CL)CC(CL)CC54)C3)C2)C1
TENATOPRAZOLE,TENATOPRAZOLE,CHEMBL1475252,BRD:BRD-A42270467-001-04-4;BRD:BRD-BRD-A42270467-001-04-4,rep_primary;rep_single_dose,ATPASE INHIBITOR,IDO1,,,PHASE 2,,Small molecule,Phase 2,ZBFDAUIVDSSISP-UHFFFAOYSA-N,COC1CCC2[NH]C([S+]([O-])CC3NCC(C)C(OC)C3C)NC2N1;COC1CCC2[NH]C(NC2N1)S(=O)CC1NCC(C)C(OC)C1C
TENELIGLIPTIN,TENELIGLIPTIN,CHEMBL2147777,BRD:BRD-BRD-K48068743-001-01-6;BRD:BRD-K48068743-001-01-6,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Phase 3,WGRQANOPCQRCME-PMACEKPBSA-N,CC1CC(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)N(-C2CCCCC2)N1;CC1CC(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)N(N1)-C1CCCCC1
TENIDAP,TENIDAP,CHEMBL1908355,BRD:BRD-A87479750-001-02-7;BRD:BRD-BRD-A87479750-001-02-7,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,KCNJ4;PTGS1,,,PHASE 3,,Small molecule,Unknown,LXIKEPCNDFVJKC-QXMHVHEDSA-N,NC(=O)N1C(=O)/C(=C(\O)C2CCCS2)C2CC(CL)CCC21;NC(=O)N1C(=O)C(C(=O)C2CCCS2)C2CC(CL)CCC12
TENIPOSIDE,TENIPOSIDE,CHEMBL452231,BRD:BRD-A35588707-001-05-5;BRD:BRD-BRD-A35588707-001-05-5;BRD:BRD-BRD-K10362825-001-03-4;BRD:BRD-K10362825-001-03-4;BRD:BRD-K10362825-001-04-2;CTRP:27871;GDSC2:1809,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A;TOP2B,ACUTE LYMPHOBLASTIC LEUKEMIA (ALL),,LAUNCHED,"Multiple values for structure_id: {'K10362825', 'A35588707'}, defaulting to None",Small molecule,Approved,NRUKOCRGYNPUPR-QBPJDGROSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C6CCCS6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1O;COC1CC(CC(OC)C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)C2CCCS2)C2CC3OCOC3CC12;COC1CC(CC(OC)C1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)C2CCCS2)C2CC3OCOC3CC12
TENOFOVIR,TENOFOVIR,CHEMBL1486;CHEMBL3989702;CHEMBL483,BRD:BRD-BRD-K15891719-001-05-1;BRD:BRD-K15891719-001-05-1,rep_primary;rep_single_dose,"HIV INTEGRASE INHIBITOR, NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR",,"HUMAN IMMUNODEFICIENCY VIRUS (HIV-1), HEPATITIS B",,LAUNCHED,,Small molecule,Approved,PINIEAOMWQJGBW-FYZOBXCZSA-N;SGOIRFVFHAKUTI-ZCFIWIBFSA-N;VCMJCVGFSROFHV-WZGZYPNHSA-N,C[C@H](CN1CNC2C(N)NCNC12)OCP(O)(O)=O;C[C@H](CN1CNC2C(N)NCNC21)OCP(=O)(O)O;C[C@H](CN1CNC2C(N)NCNC21)OCP(=O)(O)O.O;CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1CNC2C(N)NCNC21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O
TENOFOVIR-ALAFENAMIDE,TENOFOVIR-ALAFENAMIDE,,BRD:BRD-A25988899-001-01-6,rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,,,,,,NA,,
TENOFOVIR-DISOPROXIL,TENOFOVIR-DISOPROXIL,,BRD:BRD-BRD-K61868322-050-01-7;BRD:BRD-K61868322-050-01-7,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,CYP1A2,"HUMAN IMMUNODEFICIENCY VIRUS (HIV-1), HEPATITIS B",,LAUNCHED,,,NA,,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1CNC2C(N)NCNC12)OCOC(=O)OC(C)C
TENOVIN-1,TENOVIN-1,,BRD:BRD-BRD-K05977823-001-05-3;BRD:BRD-K05977823-001-05-3,rep_primary;rep_single_dose,"SIRT INHIBITOR, TP53 ACTIVATOR",SIRT1,,,PRECLINICAL,,,NA,,CC(=O)NC1CCC(NC(=S)NC(=O)C2CCC(CC2)C(C)(C)C)CC1
TENOVIN-6,TENOVIN-6,,BRD:BRD-BRD-K13949769-001-01-7;BRD:BRD-K13949769-001-01-7;GDSC1:342,gdsc;rep_multi_dose;rep_primary;rep_single_dose,SIRT INHIBITOR,SIRT1;SIRT2;SIRT3,,,PRECLINICAL,,,NA,,CN(C)CCCCC(=O)NC1CCC(NC(=S)NC(=O)C2CCC(CC2)C(C)(C)C)CC1
TENOXICAM,TENOXICAM,CHEMBL302795,BRD:BRD-A22844106-001-26-0;BRD:BRD-BRD-A22844106-001-26-0,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ANKYLOSING SPONDYLITIS, TENDINITIS, BURSITIS, PERIARTHRITIS",,LAUNCHED,,Small molecule,Approved,LZNWYQJJBLGYLT-UHFFFAOYSA-N,CN1C(C(=O)NC2CCCCN2)=C(O)C2SCCC2S1(=O)=O;CN1C(C(=O)NC2CCCCN2)C(=O)C2SCCC2S1(=O)=O
TEPILAMIDE FUMARATE,TEPILAMIDE FUMARATE,CHEMBL3989961,BRD:BRD-K00074843-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 2,AKUGRXRLHCCENI-VOTSOKGWSA-N,CCN(CC)C(=O)COC(=O)/C=C/C(=O)OC
TEPOXALIN,TEPOXALIN,CHEMBL316040,BRD:BRD-BRD-K89714990-001-01-5;BRD:BRD-K89714990-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, LIPOXYGENASE INHIBITOR",ALOX5,"RHEUMATOID ARTHRITIS, HIP DYSPLASIA",,LAUNCHED,,Small molecule,Unknown,XYKWNRUXCOIMFZ-UHFFFAOYSA-N,COC1CCC(-N2NC(CCC(=O)N(C)O)CC2-C2CCC(CL)CC2)CC1;COC1CCC(CC1)-N1NC(CCC(=O)N(C)O)CC1-C1CCC(CL)CC1
TEPP-46,TEPP-46,,BRD:BRD-K01826017-001-02-9,rep_single_dose,PYRUVATE KINASE ISOZYME ACTIVATOR,PKM,,,,,,NA,,
TEPRENONE,TEPRENONE,CHEMBL3989432;CHEMBL79686,BRD:BRD-BRD-K11510141-001-01-8;BRD:BRD-K11510141-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,MUCUS PROTECTING AGENT,,COSMETIC,,LAUNCHED,,Small molecule,Phase 3,DJAHKBBSJCDSOZ-AJLBTXRUSA-N;HUCXKZBETONXFO-NJFMWZAGSA-N,CC(=O)CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.CC(=O)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C;CC(=O)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C;CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C
TERAMEPROCOL,TERAMEPROCOL,CHEMBL90983,BRD:BRD-BRD-K76788410-001-01-6;BRD:BRD-K76788410-001-01-6,rep_primary;rep_single_dose,LIPOXYGENASE INHIBITOR,BIRC5;CDK1,,,PHASE 1/PHASE 2,,Small molecule,Phase 1,ORQFDHFZSMXRLM-IYBDPMFKSA-N,COC1CCC(C[C@@H](C)[C@@H](C)CC2CCC(OC)C(OC)C2)CC1OC;COC1CCC(C[C@H](C)[C@H](C)CC2CCC(OC)C(OC)C2)CC1OC
TERAZOSIN,TERAZOSIN,CHEMBL611,BRD:BRD-A22256192-003-22-7;BRD:BRD-BRD-A22256192-003-22-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;KCNH2;KCNH6;KCNH7,"BENIGN PROSTATIC HYPERPLASIA (BPH), HYPERTENSION",,LAUNCHED,,Small molecule,Approved,VCKUSRYTPJJLNI-UHFFFAOYSA-N,COC1CC2NC(N3CCN(C(=O)C4CCCO4)CC3)NC(N)C2CC1OC;COC1CC2NC(NC(N)C2CC1OC)N1CCN(CC1)C(=O)C1CCCO1
TERBINAFINE,TERBINAFINE,CHEMBL822,BRD:BRD-BRD-K68132782-003-13-8;BRD:BRD-K68132782-003-13-8,rep_primary;rep_single_dose,FUNGAL SQUALENE EPOXIDASE INHIBITOR,SQLE,"TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,CN(C/C=C/C#CC(C)(C)C)CC1CCCC2CCCCC12;CN(C\C=C\C#CC(C)(C)C)CC1CCCC2CCCCC12
TERBUTALINE,TERBUTALINE,CHEMBL1760,BRD:BRD-A50157456-065-20-6;BRD:BRD-BRD-A50157456-065-20-6,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,"BRONCHOSPASM, BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,XWTYSIMOBUGWOL-UHFFFAOYSA-N,CC(C)(C)NCC(O)C1CC(O)CC(O)C1
TERCIPRAZINE,TERCIPRAZINE,CHEMBL2107617,BRD:BRD-A11725667-001-01-8;BRD:BRD-BRD-A11725667-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Unknown,SDKXUWMRKYQIFU-UHFFFAOYSA-N,C#CC1(OCC(O)CN2CCN(C3CCCC(C(F)(F)F)C3)CC2)CCCCC1;OC(COC1(CCCCC1)C#C)CN1CCN(CC1)C1CCCC(C1)C(F)(F)F
TERCONAZOLE,TERCONAZOLE,CHEMBL1306,BRD:BRD-BRD-K86204871-001-16-2;BRD:BRD-K86204871-001-16-2,rep_multi_dose;rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,,VULVOVAGINAL CANDIDIASIS,,LAUNCHED,,Small molecule,Approved,BLSQLHNBWJLIBQ-OZXSUGGESA-N,CC(C)N1CCN(C2CCC(OC[C@H]3CO[C@](CN4CNCN4)(C4CCC(CL)CC4CL)O3)CC2)CC1;CC(C)N1CCN(CC1)C1CCC(OC[C@@H]2CO[C@](CN3CNCN3)(O2)C2CCC(CL)CC2CL)CC1;CC(C)N1CCN(CC1)C1CCC(OC[C@H]2CO[C@@](CN3CNCN3)(O2)C2CCC(CL)CC2CL)CC1
TERFENADINE,TERFENADINE,CHEMBL17157,BRD:BRD-A06352418-001-25-9;BRD:BRD-BRD-A06352418-001-25-9,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;HRH1;KCNH1;KCNH2,,,WITHDRAWN,,Small molecule,Approved,GUGOEEXESWIERI-UHFFFAOYSA-N,CC(C)(C)C1CCC(C(O)CCCN2CCC(C(O)(C3CCCCC3)C3CCCCC3)CC2)CC1;CC(C)(C)C1CCC(CC1)C(O)CCCN1CCC(CC1)C(O)(C1CCCCC1)C1CCCCC1
TERGURIDE,TERGURIDE,CHEMBL73151,BRD:BRD-A89207210-001-01-6;BRD:BRD-BRD-A89207210-001-01-6,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA2A;ADRA2B;ADRA2C;DRD2;DRD3;DRD4;HTR1A;HTR1B;HTR1D;HTR2A;HTR2B;HTR2C,,,LAUNCHED,,Small molecule,Unknown,JOAHPSVPXZTVEP-YXJHDRRASA-N,CCN(CC)C(=O)N[C@H]1C[C@@H]2C3CCCC4[NH]CC(C34)C[C@H]2N(C)C1;CCN(CC)C(=O)N[C@H]1CC2C(CC3C[NH]C4CCCC2C34)N(C)C1
TERIFLUNOMIDE,TERIFLUNOMIDE,CHEMBL973,BRD:BRD-A42699921-001-02-8;BRD:BRD-A42699921-001-03-6;BRD:BRD-BRD-A42699921-001-02-8;BRD:BRD-BRD-A42699921-001-03-6,rep_multi_dose;rep_primary;rep_single_dose,DIHYDROOROTATE DEHYDROGENASE INHIBITOR,DHODH,MULTIPLE SCLEROSIS,,LAUNCHED,,Small molecule,Approved,UTNUDOFZCWSZMS-YFHOEESVSA-N,C/C(O)=C(\C#N)C(=O)NC1CCC(C(F)(F)F)CC1;CC(=O)C(C#N)C(=O)NC1CCC(CC1)C(F)(F)F
TERLIPRESSIN,TERLIPRESSIN,CHEMBL2135460,BRD:BRD-BRD-K73451719-001-01-2;BRD:BRD-K73451719-001-01-2,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR AGONIST,AVPR1A;AVPR1B;AVPR2,HYPOTENSION,,LAUNCHED,,Protein,Approved,BENFXAYNYRLAIU-QSVFAHTRSA-N,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2CCC(O)CC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
TERODILINE,TERODILINE,CHEMBL363295,BRD:BRD-A33479817-003-03-7;BRD:BRD-BRD-A33479817-003-03-7,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,,,,PHASE 3,,Small molecule,Approved,UISARWKNNNHPGI-UHFFFAOYSA-N,CC(CC(C1CCCCC1)C1CCCCC1)NC(C)(C)C
TEROXIRONE,TEROXIRONE,CHEMBL453863,BRD:BRD-A39935389-001-05-9;BRD:BRD-BRD-A39935389-001-05-9,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,OUPZKGBUJRBPGC-UHFFFAOYSA-N,O=C1N(CC2CO2)C(=O)N(CC2CO2)C(=O)N1CC1CO1
TERUTROBAN,TERUTROBAN,CHEMBL2107786,BRD:BRD-BRD-K43975632-001-01-1;BRD:BRD-K43975632-001-01-1,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,TBXA2R,,,PHASE 3,,Small molecule,Phase 3,HWEOXFSBSQIWSY-MRXNPFEDSA-N,CC1CCC2C(C1CCC(=O)O)CC[C@@H](NS(=O)(=O)C1CCC(CL)CC1)C2;CC1CCC2C[C@@H](CCC2C1CCC(O)=O)NS(=O)(=O)C1CCC(CL)CC1
TESAGLITAZAR,TESAGLITAZAR,CHEMBL282686,BRD:BRD-BRD-K15507868-001-03-7;BRD:BRD-K15507868-001-03-7,rep_primary;rep_single_dose,"INSULIN SENSITIZER, PPAR RECEPTOR AGONIST",PPARA;PPARG,,,PHASE 3,,Small molecule,Phase 3,CXGTZJYQWSUFET-IBGZPJMESA-N,CCO[C@@H](CC1CCC(OCCC2CCC(OS(C)(=O)=O)CC2)CC1)C(=O)O;CCO[C@@H](CC1CCC(OCCC2CCC(OS(C)(=O)=O)CC2)CC1)C(O)=O
TESTOLACTONE,TESTOLACTONE,CHEMBL1571,BRD:BRD-BRD-K69636617-001-01-7;BRD:BRD-K69636617-001-01-7,rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP19A1,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,BPEWUONYVDABNZ-DZBHQSCQSA-N,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)OC(=O)CC[C@@H]12;C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2
TESTOSTERONE,TESTOSTERONE,CHEMBL1201101;CHEMBL2107067;CHEMBL386630,BRD:BRD-A55393291-001-09-9;BRD:BRD-BRD-A55393291-001-09-9,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,HYPOGONADISM,,LAUNCHED,,Small molecule,Approved,HPFVBGJFAYZEBE-ZLQWOROUSA-N;MUMGGOZAMZWBJJ-DYKIIFRCSA-N;UDSFVOAUHKGBEK-CNQKSJKFSA-N,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O;C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1;C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O;CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
TESTOSTERONE-ENANTHATE,TESTOSTERONE-ENANTHATE,CHEMBL1200335,BRD:BRD-BRD-K89657519-001-01-8;BRD:BRD-K89657519-001-01-8,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,HYPOGONADISM,,LAUNCHED,,Small molecule,Approved,VOCBWIIFXDYGNZ-IXKNJLPQSA-N,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
TESTOSTERONE-PROPIONATE,TESTOSTERONE-PROPIONATE,,BRD:BRD-A48720949-001-04-0;BRD:BRD-BRD-A48720949-001-04-0,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,,,LAUNCHED,,,NA,,CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C
TESTOSTERONE-UNDECANOATE,TESTOSTERONE-UNDECANOATE,CHEMBL2107067,BRD:BRD-BRD-K70650177-001-01-7;BRD:BRD-K70650177-001-01-7,rep_primary;rep_single_dose,ANDROGEN RECEPTOR AGONIST,AR,HYPOGONADISM,,LAUNCHED,,Small molecule,Approved,UDSFVOAUHKGBEK-CNQKSJKFSA-N,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
TETOMILAST,TETOMILAST,CHEMBL332750,BRD:BRD-K00004564-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4D,,,,,Small molecule,Phase 3,XDBHURGONHZNJF-UHFFFAOYSA-N,CCOC1CCC(-C2NC(-C3CCCC(C(=O)O)N3)CS2)CC1OCC
TETRABENAZINE,TETRABENAZINE,CHEMBL117785,BRD:BRD-BRD-K95739795-001-03-7;BRD:BRD-K95739795-001-03-7,rep_primary;rep_single_dose,VESICULAR MONOAMINE TRANSPORTER INHIBITOR,DRD2;SLC18A1;SLC18A2,"CHOLERA, HUNTINGTON'S DISEASE",,LAUNCHED,,Small molecule,Approved,MKJIEFSOBYUXJB-UHFFFAOYSA-N,COC1CC2C(CC1OC)C1CC(=O)C(CC(C)C)CN1CC2;COC1CC2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3C2CC1OC
TETRACAINE,TETRACAINE,CHEMBL698,BRD:BRD-BRD-K45071273-003-25-6;BRD:BRD-K45071273-003-25-6,rep_primary;rep_single_dose,MEMBRANE INTEGRITY INHIBITOR,SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,GKCBAIGFKIBETG-UHFFFAOYSA-N,CCCCNC1CCC(C(=O)OCCN(C)C)CC1;CCCCNC1CCC(CC1)C(=O)OCCN(C)C
TETRACYCLINE,TETRACYCLINE,CHEMBL1440,BRD:BRD-A34788695-003-10-2;BRD:BRD-BRD-A34788695-003-10-2;BRD:BRD-K00003352-003-01-9,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,PRNP,"RESPIRATORY TRACT INFECTIONS, PNEUMONIA, SKIN INFECTIONS, URINARY TRACT INFECTIONS, ACNE VULGARIS (AV), PLAGUE, PSITTACOSIS",,LAUNCHED,"Multiple values for structure_id: {'K00003352', 'A34788695'}, defaulting to None",Small molecule,Approved,OFVLGDICTFRJMM-WESIUVDSSA-N,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)C4C(O)CCCC4[C@@](C)(O)[C@H]3C[C@@H]12;CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4C(O)CCCC4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O
TETRADECYLTHIOACETIC-ACID,TETRADECYLTHIOACETIC-ACID,,BRD:BRD-BRD-K47539947-001-03-7;BRD:BRD-K47539947-001-03-7,rep_primary;rep_single_dose,LIPID PEROXIDASE INHIBITOR,,,,PHASE 2,,,NA,,CCCCCCCCCCCCCCSCC(O)=O
TETRAETHYLENEPENTAMINE,TETRAETHYLENEPENTAMINE,,BRD:BRD-BRD-K41298358-395-03-4;BRD:BRD-K41298358-395-03-4,rep_primary;rep_single_dose,SUPEROXIDE DISMUTASE INHIBITOR,SOD1;SOD2,,,PHASE 2/PHASE 3,,,NA,,NCCNCCNCCNCCN
TETRAHYDROPAPAVERINE,TETRAHYDROPAPAVERINE,CHEMBL160919,BRD:BRD-A91831168-003-02-5;BRD:BRD-BRD-A91831168-003-02-5,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,YXWQTVWJNHKSCC-UHFFFAOYSA-N,COC1CCC(CC2NCCC3CC(OC)C(OC)CC23)CC1OC;COC1CCC(CC2NCCC3CC(OC)C(OC)CC32)CC1OC
TETRAHYDROURIDINE,TETRAHYDROURIDINE,CHEMBL1236475,BRD:BRD-A86248581-001-01-4;BRD:BRD-BRD-A86248581-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,CYTIDINE DEAMINASE INHIBITOR,CDA,,,PHASE 2,,Small molecule,Phase 2,UCKYOOZPSJFJIZ-FMDGEEDCSA-N,O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O;OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O
TETRAHYDROZOLINE,TETRAHYDROZOLINE,CHEMBL1266,BRD:BRD-A28856712-003-26-0;BRD:BRD-BRD-A28856712-003-26-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,EYE IRRITATION,,LAUNCHED,,Small molecule,Approved,BYJAVTDNIXVSPW-UHFFFAOYSA-N,C1CCC2C(C1)CCCC2C1=NCCN1;C1CN=C(N1)C1CCCC2CCCCC12
TETRAMETHYLTHIURAM-MONOSULFIDE,TETRAMETHYLTHIURAM-MONOSULFIDE,CHEMBL571700,BRD:BRD-BRD-K36889451-001-01-1;BRD:BRD-K36889451-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,REQPQFUJGGOFQL-UHFFFAOYSA-N,CN(C)C(=S)SC(=S)N(C)C
TETRAMISOLE,TETRAMISOLE,CHEMBL1369896;CHEMBL1454;CHEMBL277775,BRD:BRD-A46393198-003-16-6;BRD:BRD-BRD-A46393198-003-16-6,rep_primary;rep_single_dose,IMMUNOSTIMULANT,ALPPL2;CHRNA3,GASTROINTESTINAL PARASITES,,LAUNCHED,,Small molecule,Approved,HLFSDGLLUJUHTE-JTQLQIEISA-N;HLFSDGLLUJUHTE-SNVBAGLBSA-N;HLFSDGLLUJUHTE-UHFFFAOYSA-N,C1CCC([C@@H]2CN3CCSC3=N2)CC1;C1CCC([C@H]2CN3CCSC3=N2)CC1;C1CCC(C2CN3CCSC3=N2)CC1;C1CN2CC(N=C2S1)C1CCCCC1
TETRANDRINE,TETRANDRINE,,BRD:BRD-BRD-K08078237-001-19-8;BRD:BRD-K08078237-001-19-8,rep_multi_dose;rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,SLC6A3,,,PRECLINICAL,,,NA,,COC1CCC2C[C@@H]3N(C)CCC4CC(OC)C(OC)C(OC5CC6[C@H](CC7CCC(OC1C2)CC7)N(C)CCC6CC5OC)C34
TETRAZOL-5-YL-GLYCINE-(RS),TETRAZOL-5-YL-GLYCINE-(RS),,BRD:BRD-A14757586-001-04-9,rep_single_dose,GLUTAMATE RECEPTOR AGONIST,GRIN1;GRIN2A;GRIN2B;GRIN2C;GRIN2D,,,,,,NA,,
TETRINDOLE,TETRINDOLE,,BRD:BRD-A52660433-066-02-1;BRD:BRD-BRD-A52660433-066-02-1,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA,,,PHASE 3,,,NA,,C1CCC(CC1)C1CCC2N3CCNC4CCCC(C34)C2C1
TEZACAFTOR,TEZACAFTOR,CHEMBL3544914,BRD:BRD-BRD-K97101532-001-02-8;BRD:BRD-K97101532-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,CFTR CHANNEL AGONIST,,CYSTIC FIBROSIS,,LAUNCHED,,Small molecule,Approved,MJUVRTYWUMPBTR-MRXNPFEDSA-N,CC(C)(CO)C1CC2CC(NC(=O)C3(C4CCC5C(C4)OC(F)(F)O5)CC3)C(F)CC2N1C[C@@H](O)CO;CC(C)(CO)C1CC2CC(NC(=O)C3(CC3)C3CCC4OC(F)(F)OC4C3)C(F)CC2N1C[C@@H](O)CO
TFC-007,TFC-007,,BRD:BRD-BRD-K57708067-001-01-3;BRD:BRD-K57708067-001-01-3,rep_primary;rep_single_dose,PROSTAGLANDIN INHIBITOR,HPGDS,,,PRECLINICAL,,,NA,,O=C(NC1CCC(CC1)N1CCC(CC1)C(=O)N1CCOCC1)C1CNC(OC2CCCCC2)NC1
TG-003,TG-003,,BRD:BRD-BRD-K97072811-001-11-4;BRD:BRD-K97072811-001-11-4,rep_primary;rep_single_dose,CLK INHIBITOR,CLK1;CLK4;DYRK1A;DYRK1B,,,PRECLINICAL,,,NA,,CCN1\C(SC2CCC(OC)CC12)=C\C(C)=O
TG-02,TG-02,CHEMBL1944698,BRD:BRD-BRD-K14560436-001-01-4;BRD:BRD-K14560436-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,"CDK INHIBITOR, FLT3 INHIBITOR, JAK INHIBITOR",CDK1;CDK2;CDK7;CDK9;FLT3;JAK2,,,PHASE 1,,Small molecule,Phase 1,VXBAJLGYBMTJCY-NSCUHMNNSA-N,CN1C/C=C/CCOC2CCCC(C2)-C2CCNC(N2)NC2CCCC(C2)C1;CN1C\C=C\CCOC2CCCC(C2)-C2CCNC(NC3CCCC(C1)C3)N2
TG-100-115,TG-100-115,,CTRP:606470,ctrp,,,,,,,,NA,,
TG-100572,TG-100572,,BRD:BRD-BRD-K18424115-003-01-3;BRD:BRD-K18424115-003-01-3,rep_multi_dose;rep_primary;rep_single_dose,"SRC INHIBITOR, VEGFR INHIBITOR",KDR;SRC,,,PRECLINICAL,,,NA,,CC1CC(CC2NNC(NC3CCC(OCCN4CCCC4)CC3)NC12)-C1CC(O)CCC1CL
TG-100713,TG-100713,,BRD:BRD-BRD-K46392623-001-02-5;BRD:BRD-K46392623-001-02-5,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,,,,PRECLINICAL,,,NA,,NC1NC(N)C2NC(CNC2N1)-C1CCCC(O)C1
TG-100801,TG-100801,,BRD:BRD-BRD-K12735121-001-01-4;BRD:BRD-K12735121-001-01-4,rep_primary;rep_single_dose,"SRC INHIBITOR, VEGFR INHIBITOR",CSK;FGFR1;FLT1;FLT4;KDR;SRC,,,PHASE 2,"Multiple values for repurposing_target: {'FGFR1;FLT1;KDR;SRC', 'CSK;FGFR1;FLT1;FLT4;KDR;SRC'}, taking the union",,NA,,CC1CC(CC2NNC(NC3CCC(OCCN4CCCC4)CC3)NC12)-C1CC(OC(=O)C2CCCCC2)CCC1CL
TG-101209,TG-101209,,BRD:BRD-BRD-K39841531-001-02-1;BRD:BRD-K39841531-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,JAK2;JAK3,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CCC(NC2NCC(C)C(NC3CCCC(C3)S(=O)(=O)NC(C)(C)C)N2)CC1
TG100-115,TG100-115,CHEMBL230011,BRD:BRD-BRD-K64785675-001-04-0;BRD:BRD-K64785675-001-04-0,rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CB;PIK3CD;PIK3CG,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,UJIAQDJKSXQLIT-UHFFFAOYSA-N,NC1NC(N)C2NC(-C3CCCC(O)C3)C(-C3CCCC(O)C3)NC2N1;NC1NC(N)C2NC(-C3CCCC(O)C3)C(NC2N1)-C1CCCC(O)C1
TGR-1202,TGR-1202,CHEMBL3989869,BRD:BRD-BRD-K52579889-001-01-9;BRD:BRD-K52579889-001-01-9,rep_primary;rep_single_dose,PI3K INHIBITOR,,,,PHASE 3,,Small molecule,Approved,KYJWUPZPSXZEPG-NTISSMGPSA-N,CC(C)OC1CCC(-C2NN([C@@H](C)C3OC4CCC(F)CC4C(=O)C3-C3CCCC(F)C3)C3NCNC(N)C23)CC1F.CC1CCC(S(=O)(=O)O)CC1;CC(C)OC1CCC(CC1F)-C1NN([C@@H](C)C2OC3CCC(F)CC3C(=O)C2-C2CCCC(F)C2)C2NCNC(N)C12
TGX 221,TGX 221,,GDSC1:94,gdsc,,,,,,,,NA,,
TGX-221,TGX-221,,BRD:BRD-A41692738-001-07-6;BRD:BRD-BRD-A41692738-001-07-6;CTRP:606356;GDSC1:94,ctrp;gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CB;PIK3CD,,,PRECLINICAL,,,NA,,CC(NC1CCCCC1)C1CC(C)CN2C1NC(CC2=O)N1CCOCC1
TGX221,TGX221,,GDSC1:94,gdsc,,,,,,,,NA,,
TH-302,TH-302,CHEMBL260046,BRD:BRD-BRD-K20958582-001-01-4;BRD:BRD-K20958582-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,DNA ALKYLATING AGENT,,,,PHASE 3,,Small molecule,Phase 3,UGJWRPJDTDGERK-UHFFFAOYSA-N,CN1C(COP(=O)(NCCBR)NCCBR)CNC1[N+]([O-])=O;CN1C(COP(=O)(NCCBR)NCCBR)CNC1[N+](=O)[O-]
TH588,TH-588;TH588,,BRD:BRD-BRD-K01054709-001-01-3;BRD:BRD-K01054709-001-01-3,rep_primary;rep_single_dose,MTH1 INHIBITOR,NUDT1,,,PRECLINICAL,,,NA,,NC1NC(NC2CC2)CC(N1)-C1CCCC(CL)C1CL
THAL-SNS-032,THAL-SNS-032,,BRD:BRD-U00115425-001-01-9,oncref_1,IMID-BASED DEGRADER OF CDK9,CDK9,,,,,,NA,,
THALIDOMIDE,THALIDOMIDE,CHEMBL468,BRD:BRD-A93255169-001-28-3;BRD:BRD-BRD-A93255169-001-28-3;CTRP:24197,ctrp;rep_primary;rep_single_dose,TUMOR NECROSIS FACTOR PRODUCTION INHIBITOR,CRBN;FGFR2;NFKB1;ORM1;ORM2;PTGS2;TNF,,,LAUNCHED,,Small molecule,Approved,UEJJHQNACJXSKW-UHFFFAOYSA-N,O=C1CCC(N2C(=O)C3CCCCC3C2=O)C(=O)N1;O=C1N(C2CCC(=O)NC2=O)C(=O)C2CCCCC12
THAPSIGARGIN,THAPSIGARGIN,CHEMBL96926,GDSC1:180,gdsc,,,,,,,Small molecule,NA,IXFPJGBNCFXKPI-FSIHEZPISA-N,C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@H]([C@@H]1OC(=O)CCCCCCC)[C@@](C)(OC(C)=O)C[C@H](OC(=O)CCC)[C@@]1(O)[C@H]2OC(=O)[C@@]1(C)O
THEAFLAVIN,THEAFLAVIN,CHEMBL346119,BRD:BRD-K60842365-001-03-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,NA,IPMYMEWFZKHGAX-ZKSIBHASSA-N,O=C1C(O)CC([C@H]2OC3CC(O)CC(O)C3C[C@H]2O)CC2C([C@H]3OC4CC(O)CC(O)C4C[C@H]3O)CC(O)C(O)C12
THELIATINIB,THELIATINIB,CHEMBL3545180,BRD:BRD-K00091285-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,,
THEOBROMINE,THEOBROMINE,CHEMBL1114,BRD:BRD-BRD-K34888156-213-01-4;BRD:BRD-K34888156-213-01-4,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,ADORA1;ADORA2A;PDE4B,,,LAUNCHED,,Small molecule,Phase 3,YAPQBXQYLJRXSA-UHFFFAOYSA-N,CN1CNC2C1C(=O)[NH]C(=O)N2C;CN1CNC2N(C)C(=O)[NH]C(=O)C12
THEOPHYLLINE,THEOPHYLLINE,CHEMBL190,BRD:BRD-BRD-K97799481-001-16-0,rep_primary,ADENOSINE RECEPTOR ANTAGONIST,,"ASTHMA, EMPHYSEMA, BRONCHITIS",,LAUNCHED,,Small molecule,Approved,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,CN1C(=O)C2[NH]CNC2N(C)C1=O;CN1C2NC[NH]C2C(=O)N(C)C1=O
THIAMET-G,THIAMET-G,,BRD:BRD-BRD-K38380126-001-01-4;BRD:BRD-K38380126-001-01-4,rep_primary;rep_single_dose,GLCNAC PHOSPHOTRANSFERASE INHIBITOR,MGEA5,,,PRECLINICAL,,,NA,,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1
THIAMINE,THIAMINE,CHEMBL1547;CHEMBL1588,BRD:BRD-BRD-K95785345-300-14-8;BRD:BRD-K95785345-300-14-8,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN B,SLC19A2;SLC19A3;TPK1,THIAMINE DEFICIENCY,,LAUNCHED,,Small molecule,Approved,JZRWCGZRTZMZEH-UHFFFAOYSA-N;MYVIATVLJGTBFV-UHFFFAOYSA-M,CC1C(CCO)SC[N+]1CC1CNC(C)NC1N;CC1NCC(C[N+]2CSC(CCO)C2C)C(N)N1;CC1NCC(C[N+]2CSC(CCO)C2C)C(N)N1.[CL-]
THIAMPHENICOL,THIAMPHENICOL,CHEMBL1236282,BRD:BRD-BRD-K79711234-001-18-3;BRD:BRD-K79711234-001-18-3,rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,PELVIC INFLAMMATORY DISEASE,,LAUNCHED,,Small molecule,Phase 1,OTVAEFIXJLOWRX-NXEZZACHSA-N,CS(=O)(=O)C1CCC([C@@H](O)[C@@H](CO)NC(=O)C(CL)CL)CC1;CS(=O)(=O)C1CCC(CC1)[C@@H](O)[C@@H](CO)NC(=O)C(CL)CL
THIAZOVIVIN,THIAZOVIVIN,,BRD:BRD-BRD-K03164761-001-02-1;BRD:BRD-K03164761-001-02-1,rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,,,,PRECLINICAL,,,NA,,O=C(NCC1CCCCC1)C1CSC(NC2CCNCN2)N1
THIETHYLPERAZINE,THIETHYLPERAZINE,CHEMBL1378,BRD:BRD-BRD-K69600043-328-05-5;BRD:BRD-K69600043-328-05-5,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;DRD4,NAUSEA,,LAUNCHED,,Small molecule,Approved,XCTYLCDETUVOIP-UHFFFAOYSA-N,CCSC1CCC2C(C1)N(CCCN1CCN(C)CC1)C1CCCCC1S2;CCSC1CCC2SC3CCCCC3N(CCCN3CCN(C)CC3)C2C1
THIOCOLCHICOSIDE,THIOCOLCHICOSIDE,CHEMBL1705373,BRD:BRD-BRD-K26619122-001-02-1;BRD:BRD-K26619122-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,GABA RECEPTOR ANTAGONIST,GABRA1;GABRB2;GABRG2;GLRA1;GLRB,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Phase 3,LEQAKWQJCITZNK-MSQQGMGVSA-N,COC1C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC2C(C1OC)-C1CCC(SC)C(=O)CC1C(NC(C)=O)CC2;COC1C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC2CC[C@H](NC(C)=O)C3CC(=O)C(SC)CCC3-C2C1OC
THIOCTIC-ACID,THIOCTIC-ACID,,BRD:BRD-A16347691-001-13-1;BRD:BRD-BRD-A16347691-001-13-1,rep_primary;rep_single_dose,REDUCING AGENT,ACHE;LIAS;LIPT1;PTGS2;SLC5A6,,,LAUNCHED,,,NA,,OC(=O)CCCCC1CCSS1
THIODIGLYCOL,THIODIGLYCOL,CHEMBL444480,BRD:BRD-BRD-K54521836-001-02-1;BRD:BRD-K54521836-001-02-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,YODZTKMDCQEPHD-UHFFFAOYSA-N,OCCSCCO
THIOGUANINE,THIOGUANINE,CHEMBL727,BRD:BRD-BRD-K49350383-001-13-7;BRD:BRD-K49350383-001-13-7;BRD:BRD-K49350383-001-14-5,rep_multi_dose;rep_primary;rep_single_dose,PURINE ANTAGONIST,IMPDH1;IMPDH2,ACUTE MYELOID LEUKEMIA (AML),,LAUNCHED,,Small molecule,Approved,WYWHKKSPHMUBEB-UHFFFAOYSA-N,NC1NC2[NH]CNC2C(=S)[NH]1;NC1NC2NC[NH]C2C(=S)[NH]1
THIOMERSAL,THIOMERSAL,CHEMBL508338,BRD:BRD-BRD-K61443650-236-13-1;BRD:BRD-K61443650-236-13-1,rep_multi_dose;rep_primary;rep_single_dose,OTHER ANTIBIOTIC,OXCT1,,,LAUNCHED,,Small molecule,Approved,,CC[HG]SC1CCCCC1C(O)=O
THIOPERAMIDE,THIOPERAMIDE,CHEMBL260374,BRD:BRD-BRD-K63874012-001-02-9;BRD:BRD-K63874012-001-02-9,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH3;HRH4,,,PRECLINICAL,,Small molecule,NA,QKDDJDBFONZGBW-UHFFFAOYSA-N,S=C(NC1CCCCC1)N1CCC(C2CNC[NH]2)CC1;S=C(NC1CCCCC1)N1CCC(CC1)C1C[NH]CN1
THIOPHANATE,THIOPHANATE,CHEMBL2103777,BRD:BRD-BRD-K90168339-001-08-6;BRD:BRD-K90168339-001-08-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,YFNCATAIYKQPOO-UHFFFAOYSA-N,CCOC(=O)NC(=S)NC1CCCCC1NC(=S)NC(=O)OCC;COC(=O)NC(=S)NC1CCCCC1NC(=S)NC(=O)OC
THIOPROPERAZINE,THIOPROPERAZINE,CHEMBL609109,BRD:BRD-BRD-K08619574-334-05-4;BRD:BRD-K08619574-334-05-4,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;DRD1;DRD2;HTR1A;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Unknown,VZYCZNZBPPHOFY-UHFFFAOYSA-N,CN(C)S(=O)(=O)C1CCC2SC3CCCCC3N(CCCN3CCN(C)CC3)C2C1;CN1CCN(CCCN2C3CCCCC3SC3CCC(S(=O)(=O)N(C)C)CC32)CC1
THIORIDAZINE,THIORIDAZINE,CHEMBL479,BRD:BRD-A84481105-003-31-3;BRD:BRD-BRD-A84481105-003-31-3,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HTR1A;HTR2A;HTR2C;HTR6;HTR7;KCNH2,,,WITHDRAWN,,Small molecule,Approved,KLBQZWRITKRQQV-UHFFFAOYSA-N,CSC1CCC2C(C1)N(CCC1CCCCN1C)C1CCCCC1S2;CSC1CCC2SC3CCCCC3N(CCC3CCCCN3C)C2C1
THIOSTREPTON,THIOSTREPTON,CHEMBL1236460;CHEMBL2303629;CHEMBL468719,BRD:BRD-BRD-K58049875-001-04-7;BRD:BRD-K58049875-001-04-7,rep_multi_dose;rep_primary;rep_single_dose,"FOXM1 INHIBITOR, PROTEIN SYNTHESIS INHIBITOR",FOXM1,MASTITIS,,LAUNCHED,,Small molecule;Unknown,Unknown,NSFFHOGKXHRQEW-AIHSUZKVSA-N;NSFFHOGKXHRQEW-BEEVBQKTSA-N;NSFFHOGKXHRQEW-WGQXSCKOSA-N,C=C(NC(=O)C(=C)NC(=O)C1CSC(C2=N[C@@H]3C4CSC(N4)[C@H]4NC(=O)C5CSC(N5)[C@H]([C@](C)(O)[C@@H](C)O)NC(=O)[C@H]5CSC(=N5)/C(=C/C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C5CSC(N5)[C@]3(CC2)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)N[C@@H]2C=CC3C([C@H](C)O)CC(NC3[C@H]2O)C(=O)O[C@@H]4C)N1)C(N)=O;C=C(NC(=O)C(=C)NC(=O)C1CSC(C2=N[C@@H]3C4CSC(N4)[C@H]4NC(=O)C5CSC(N5)[C@H]([C@](C)(O)[C@@H](C)O)NC(=O)C5CSC(=N5)/C(=C/C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C5CSC(N5)[C@]3(CC2)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC2C=CC3C([C@H](C)O)CC(NC3[C@H]2O)C(=O)O[C@@H]4C)N1)C(N)=O;C=C(NC(=O)C(=C)NC(=O)C1CSC(C2=N[C@@H]3C4CSC(N4)[C@H]4NC(=O)C5CSC(N5)[C@H]([C@@](C)(O)[C@@H](C)O)NC(=O)[C@H]5CSC(=N5)/C(=C/C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C5CSC(N5)[C@@]3(CC2)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)C(C)NC(=O)[C@H]([C@@H](C)CC)N[C@@H]2C=CC3C([C@H](C)O)CC(NC3[C@H]2O)C(=O)O[C@@H]4C)N1)C(N)=O;CC[C@H](C)[C@@H]1N[C@@H]2C=CC3C(CC(NC3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)C3CSC(N3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)C3CSC(N3)[C@]3(CCC(=N[C@@H]3C3CSC2N3)C2NC(CS2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O;CCC(C)C1NC2C=CC3C(CC(NC3C2O)C(=O)OC(C)C2NC(=O)C3CSC(N3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)C3CSC(N3)C3(CCC(=NC3C3CSC2N3)C2NC(CS2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O
THIOTEPA,THIOTEPA,CHEMBL671,BRD:BRD-K09631521-001-12-3,rep_multi_dose;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP2B6;CYP3A4,"BREAST CANCER, OVARIAN CANCER, BLADDER CANCER",,LAUNCHED,,Small molecule,Approved,FOCVUCIESVLUNU-UHFFFAOYSA-N,S=P(N1CC1)(N1CC1)N1CC1
THIOTHIXENE,THIOTHIXENE,CHEMBL1201,BRD:BRD-BRD-K97309399-001-09-4;BRD:BRD-K97309399-001-09-4,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD1;DRD2;HRH1;HTR2A,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,GFBKORZTTCHDGY-UWVJOHFNSA-N,CN(C)S(=O)(=O)C1CCC2SC3CCCCC3\C(=C/CCN3CCN(C)CC3)C2C1;CN1CCN(CC/C=C2/C3CCCCC3SC3CCC(S(=O)(=O)N(C)C)CC32)CC1
THIRAM,THIRAM,CHEMBL120563,BRD:BRD-BRD-K29254801-001-14-7;BRD:BRD-K29254801-001-14-7,rep_multi_dose;rep_primary;rep_single_dose,,JAK2,CONTACT DERMATITIS,,LAUNCHED,,Small molecule,Unknown,KUAZQDVKQLNFPE-UHFFFAOYSA-N,CN(C)C(=S)SSC(=S)N(C)C
THK5351,THK5351,,BRD:BRD-K00003401-001-01-9,rep_single_dose,PET RADIOTRACER,,,,,,,NA,,
THONZONIUM,THONZONIUM,CHEMBL1201322,BRD:BRD-BRD-K13387373-004-14-5;BRD:BRD-K13387373-004-14-5,rep_multi_dose;rep_primary;rep_single_dose,ATPASE INHIBITOR,,,,LAUNCHED,,Small molecule,Approved,IOYZYMQFUSNATM-UHFFFAOYSA-N,CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1CCC(OC)CC1)C1NCCCN1
THONZYLAMINE,THONZYLAMINE,CHEMBL1623738,BRD:BRD-BRD-K88405679-003-03-1;BRD:BRD-K88405679-003-03-1,rep_primary;rep_single_dose,ANTIHISTAMINE,,ITCHING,,LAUNCHED,,Small molecule,Unknown,GULNIHOSWFYMRN-UHFFFAOYSA-N,COC1CCC(CN(CCN(C)C)C2NCCCN2)CC1
THREO-2-METHYLISOCITRATE-(DL),THREO-2-METHYLISOCITRATE-(DL),,BRD:BRD-M01344114-348-01-0,rep_single_dose,ISOCITRATE LYASE SUBSTRATE,,,,,,,NA,,
THYMALFASIN,THYMALFASIN,CHEMBL2103979,BRD:BRD-K00004602-001-01-9,rep_single_dose,IMMUNE RESPONSE MODULATOR,,,,,,Protein,Phase 3,NZVYCXVTEHPMHE-ZSUJOUNUSA-N,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O
THYMOPENTIN,THYMOPENTIN,CHEMBL156025,BRD:BRD-K43977121-001-06-9,rep_single_dose,IMMUNE RESPONSE STIMULATOR,,,,,,Protein,Phase 3,PSWFFKRAVBDQEG-YGQNSOCVSA-N,CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](CC1CCC(O)CC1)C(=O)O
THZ-2-102-1,THZ-2-102-1,,GDSC1:346,gdsc,,,,,,,,NA,,
THZ-2-49,THZ-2-49,,GDSC1:344,gdsc,,,,,,,,NA,,
THZ1,THZ1,,BRD:BRD-BRD-K66401437-001-03-3;BRD:BRD-K66401437-001-03-3,rep_primary;rep_single_dose,CDK INHIBITOR,CDK7,,,PRECLINICAL,,,NA,,CN(C)C\C=C\C(=O)NC1CCC(CC1)C(=O)NC1CCCC(NC2NCC(CL)C(N2)-C2C[NH]C3CCCCC23)C1
THZ1-R,THZ1-R,,BRD:BRD-BRD-K02135007-001-01-8;BRD:BRD-K02135007-001-01-8,rep_primary;rep_single_dose,CDK INHIBITOR,CDK7,,,PRECLINICAL,,,NA,,CN(C)CCCC(=O)NC1CCC(CC1)C(=O)NC1CCCC(NC2NCC(CL)C(N2)-C2C[NH]C3CCCCC23)C1
THZ2,THZ2,,BRD:BRD-BRD-K95902121-001-01-0;BRD:BRD-K95902121-001-01-0,rep_primary;rep_single_dose,CDK INHIBITOR,CDK7,,,PRECLINICAL,,,NA,,CN(C)C\C=C\C(=O)NC1CCCC(C1)C(=O)NC1CCCC(NC2NCC(CL)C(N2)-C2C[NH]C3CCCCC23)C1
THZ531,THZ531,,BRD:BRD-K00104123-001-01-9,rep_single_dose,,,,,,,,NA,,
TIABENDAZOLE,TIABENDAZOLE,CHEMBL625,BRD:BRD-BRD-K77695569-001-30-0;BRD:BRD-K77695569-001-30-0,rep_primary;rep_single_dose,ANGIOGENESIS INHIBITOR,,"GASTROINTESTINAL ROUNDWORMS, HOOKWORM",,LAUNCHED,,Small molecule,Approved,WJCNZQLZVWNLKY-UHFFFAOYSA-N,C1CCC2[NH]C(-C3CSCN3)NC2C1;C1NC(CS1)-C1NC2CCCCC2[NH]1
TIAGABINE,TIAGABINE,CHEMBL1027,BRD:BRD-BRD-K60160658-003-11-2;BRD:BRD-K60160658-003-11-2,rep_multi_dose;rep_primary;rep_single_dose,GABA UPTAKE INHIBITOR,SLC6A1,SEIZURES,,LAUNCHED,,Small molecule,Approved,PBJUNZJWGZTSKL-MRXNPFEDSA-N,CC1CCSC1C(=CCCN1CCC[C@@H](C(=O)O)C1)C1SCCC1C;CC1CCSC1C(=CCCN1CCC[C@H](C1)C(O)=O)C1SCCC1C
TIANEPTINE,TIANEPTINE,CHEMBL1289110,BRD:BRD-A53077924-001-01-2;BRD:BRD-BRD-A53077924-001-01-2,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE ENHANCER (SSRE),OPRD1;OPRK1;OPRM1,"DEPRESSION, ASTHMA, IRRITABLE BOWEL SYNDROME",,LAUNCHED,,Small molecule,Phase 3,JICJBGPOMZQUBB-UHFFFAOYSA-N,CN1C2CCCCC2C(NCCCCCCC(=O)O)C2CCC(CL)CC2S1(=O)=O;CN1C2CCCCC2C(NCCCCCCC(O)=O)C2CCC(CL)CC2S1(=O)=O
TIAPRIDE,TIAPRIDE,CHEMBL84158,BRD:BRD-BRD-K57432881-003-21-8;BRD:BRD-K57432881-003-21-8,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3,"DYSKINESIA, ABSTINENCE FROM ALCOHOL, PSYCHOSIS",,LAUNCHED,,Small molecule,Phase 3,JTVPZMFULRWINT-UHFFFAOYSA-N,CCN(CC)CCNC(=O)C1CC(CCC1OC)S(C)(=O)=O;CCN(CC)CCNC(=O)C1CC(S(C)(=O)=O)CCC1OC
TIAPROFENIC-ACID,TIAPROFENIC-ACID,,BRD:BRD-A72988804-001-11-1;BRD:BRD-BRD-A72988804-001-11-1,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,RHEUMATOID ARTHRITIS,,LAUNCHED,,,NA,,CC(C(O)=O)C1CCC(S1)C(=O)C1CCCCC1
TIARAMIDE,TIARAMIDE,CHEMBL274239,BRD:BRD-BRD-K27293958-001-01-5;BRD:BRD-K27293958-001-01-5,rep_primary;rep_single_dose,ANTI-INFLAMMATORY AGENT,,ASTHMA,,LAUNCHED,,Small molecule,Unknown,HTJXMOGUGMSZOG-UHFFFAOYSA-N,O=C(CN1C(=O)SC2CCC(CL)CC21)N1CCN(CCO)CC1;OCCN1CCN(CC1)C(=O)CN1C2CC(CL)CCC2SC1=O
TIBOLONE,TIBOLONE,CHEMBL2103774,BRD:BRD-A82522119-001-01-7;BRD:BRD-BRD-A82522119-001-01-7,rep_primary;rep_single_dose,"ANDROGEN RECEPTOR AGONIST, ESTROGEN RECEPTOR AGONIST, PROGESTERONE RECEPTOR AGONIST",ESR1,ENDOMETRIOSIS,,LAUNCHED,,Small molecule,Approved,WZDGZWOAQTVYBX-XOINTXKNSA-N,C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)C12;C#C[C@]1(O)CC[C@H]2[C@@H]3[C@H](C)CC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C
TIC10,TIC10,CHEMBL4297310,BRD:BRD-BRD-K19939891-001-05-4;BRD:BRD-K19939891-001-05-4,rep_primary;rep_single_dose,"AKT INHIBITOR, TRAIL MODULATOR",AKT1;MAPK1,,,PHASE 2,,Small molecule,Phase 3,VLULRUCCHYVXOH-UHFFFAOYSA-N,CC1CCCCC1CN1C(=O)C2=C(CCN(CC3CCCCC3)C2)N2CCN=C12;CC1CCCCC1CN1C2=NCCN2C(=O)C2=C1CCN(CC1CCCCC1)C2;CC1CCCCC1CN1CC2=C(CCN(CC3CCCCC3)C2=O)N2CCN=C12
TICAGRELOR,TICAGRELOR,CHEMBL398435,BRD:BRD-BRD-K44974079-001-01-3;BRD:BRD-K44974079-001-01-3,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RY12,"ACUTE CORONARY SYNDROME (ACS), MYOCARDIAL INFARCTION",,LAUNCHED,,Small molecule,Approved,OEKWJQXRCDYSHL-FNOIDJSQSA-N,CCCSC1NC(N[C@@H]2C[C@@H]2C2CCC(F)C(F)C2)C2NNN([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)C2N1;CCCSC1NC(N[C@@H]2C[C@H]2C2CCC(F)C(F)C2)C2NNN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2N1
TICLOPIDINE,TICLOPIDINE,CHEMBL833,BRD:BRD-BRD-K00603606-003-24-0;BRD:BRD-K00603606-003-24-0,rep_primary;rep_single_dose,PURINERGIC RECEPTOR ANTAGONIST,P2RY12,"THROMBOSIS, STROKE",,LAUNCHED,,Small molecule,Approved,PHWBOXQYWZNQIN-UHFFFAOYSA-N,CLC1CCCCC1CN1CCC2SCCC2C1
TIDEGLUSIB,TIDEGLUSIB,CHEMBL3545157,BRD:BRD-BRD-K81330143-001-04-8;BRD:BRD-K81330143-001-04-8,rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3B,,,PHASE 2,,Small molecule,Phase 2,PMJIHLSCWIDGMD-UHFFFAOYSA-N,O=C1SN(-C2CCCC3CCCCC23)C(=O)N1CC1CCCCC1
TIE2-KINASE-INHIBITOR,TIE2-KINASE-INHIBITOR,,BRD:BRD-A92800748-001-05-5;BRD:BRD-BRD-A92800748-001-05-5,rep_primary;rep_single_dose,TIE TYROSINE KINASE INHIBITOR,KDR;MAPK14,,,PRECLINICAL,,,NA,,COC1CCC2CC(CCC2C1)-C1NC([NH]C1-C1CCNCC1)-C1CCC(CC1)S(C)=O
TIENILIC-ACID,TIENILIC-ACID,,BRD:BRD-BRD-K34098590-001-02-1;BRD:BRD-K34098590-001-02-1,rep_primary;rep_single_dose,"SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR, CYTOCHROME P450 INHIBITOR",CYP2C9;SLC12A1,,,WITHDRAWN,"Multiple values for MOA: {'CYTOCHROME P450 INHIBITOR, SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR', 'SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR, CYTOCHROME P450 INHIBITOR'}, defaulting to 'SODIUM/POTASSIUM/CHLORIDE TRANSPORTER INHIBITOR, CYTOCHROME P450 INHIBITOR'",,NA,,OC(=O)COC1CCC(C(=O)C2CCCS2)C(CL)C1CL
TIFENAZOXIDE,TIFENAZOXIDE,CHEMBL135191,BRD:BRD-BRD-K20568871-001-01-1;BRD:BRD-K20568871-001-01-1,rep_primary;rep_single_dose,ATP-SENSITIVE POTASSIUM CHANNEL AGONIST,ABCC8;KCNJ11,,,PHASE 1,,Small molecule,Unknown,KYSFUHHFTIGRJN-UHFFFAOYSA-N,CC1(CC1)NC1=NS(=O)(=O)C2SC(CL)CC2N1;CC1(NC2=NS(=O)(=O)C3SC(CL)CC3N2)CC1
TIGECYCLINE,TIGECYCLINE,CHEMBL376140,BRD:BRD-K00003349-001-01-9;CTRP:659993,ctrp;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,,,,,Small molecule,Approved,FPZLLRFZJZRHSY-HJYUBDRYSA-N,CN(C)C1CC(NC(=O)CNC(C)(C)C)C(O)C2C1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
TILDIPIROSIN,TILDIPIROSIN,CHEMBL3039509,BRD:BRD-K00073880-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,HNDXPZPJZGTJLJ-UEJFNEDBSA-N,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN2CCCCC2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CN1CCCCC1
TILETAMINE,TILETAMINE,CHEMBL2110703,BRD:BRD-A30582499-003-05-1;BRD:BRD-BRD-A30582499-003-05-1,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,ANESTHETIC,,LAUNCHED,,Small molecule,Unknown,QAXBVGVYDCAVLV-UHFFFAOYSA-N,CCNC1(C2CCCS2)CCCCC1=O;CCNC1(CCCCC1=O)C1CCCS1
TILMICOSIN,TILMICOSIN,CHEMBL1908333,BRD:BRD-BRD-K26634012-001-04-9;BRD:BRD-K26634012-001-04-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,BOVINE RESPIRATORY DISEASE (BRD),,LAUNCHED,,Small molecule,Unknown,JTSDBFGMPLKDCD-XVFHVFLVSA-N,CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC;CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
TILORONE,TILORONE,CHEMBL47298,BRD:BRD-BRD-K34568562-001-04-3;BRD:BRD-K34568562-001-04-3,rep_primary;rep_single_dose,INTERFERON INDUCER,,"INFLUENZA A VIRUS INFECTION, DIARRHEA, HEPATITIS B, MULTIPLE SCLEROSIS, URINARY TRACT INFECTIONS, VIRUS HERPES SIMPLEX (HSV), HEPATITIS C",,LAUNCHED,,Small molecule,Unknown,MPMFCABZENCRHV-UHFFFAOYSA-N,CCN(CC)CCOC1CCC2-C3CCC(OCCN(CC)CC)CC3C(=O)C2C1;CCN(CC)CCOC1CCC2C(C1)C(=O)C1CC(OCCN(CC)CC)CCC1-2
TILUDRONATE,TILUDRONATE,CHEMBL1350,BRD:BRD-BRD-K10845183-304-01-6;BRD:BRD-K10845183-304-01-6,rep_multi_dose;rep_primary;rep_single_dose,"BONE RESORPTION INHIBITOR, OSTEOCLAST INHIBITOR",ATP6V1A;MMP2;PTPN1,NAVICULAR SYNDROME,,LAUNCHED,,Small molecule,Approved,DKJJVAGXPKPDRL-UHFFFAOYSA-N,O=P(O)(O)C(SC1CCC(CL)CC1)P(=O)(O)O;OP(O)(=O)C(SC1CCC(CL)CC1)P(O)(O)=O
TIMOFIBRATE,TIMOFIBRATE,CHEMBL2106730,BRD:BRD-A64406146-001-01-2;BRD:BRD-BRD-A64406146-001-01-2,rep_primary;rep_single_dose,"CHOLESTEROL INHIBITOR, LIPASE CLEARING FACTOR INHIBITOR",LPL,,,PHASE 2,,Small molecule,Unknown,QSNOWCXXECLALL-UHFFFAOYSA-N,CC(C)(OC1CCC(CL)CC1)C(=O)N1CSCC1C(=O)O;CC(C)(OC1CCC(CL)CC1)C(=O)N1CSCC1C(O)=O
TIMOLOL,TIMOLOL,CHEMBL499,BRD:BRD-BRD-K30421593-050-04-9;BRD:BRD-K30421593-050-04-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2,"OCULAR HYPERTENSION, GLAUCOMA",,LAUNCHED,,Small molecule,Approved,BLJRIMJGRPQVNF-JTQLQIEISA-N,CC(C)(C)NC[C@@H](O)COC1NSNC1N1CCOCC1;CC(C)(C)NC[C@H](O)COC1NSNC1N1CCOCC1
TIMONACIC,TIMONACIC,CHEMBL358722,BRD:BRD-A38592941-001-02-7;BRD:BRD-BRD-A38592941-001-02-7,rep_primary;rep_single_dose,ANTIOXIDANT,ANXA5,,,LAUNCHED,,Small molecule,Unknown,DZLNHFMRPBPULJ-UHFFFAOYSA-N,O=C(O)C1CSCN1;OC(=O)C1CSCN1
TINAZOLINE,TINAZOLINE,CHEMBL2107015,BRD:BRD-K00004663-001-01-9,rep_single_dose,ADRENERGIC RECEPTOR AGONIST,,,,,,Small molecule,Unknown,JENBDJGHNIOHAJ-UHFFFAOYSA-N,C1CCC2C(SC3=NCCN3)C[NH]C2C1
TINIDAZOLE,TINIDAZOLE,CHEMBL1220,BRD:BRD-BRD-K89125793-001-26-0;BRD:BRD-K89125793-001-26-0,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,"GIARDIASIS, AMEBIASIS, BACTERIAL VAGINOSIS, TRICHOMONIASIS",,LAUNCHED,,Small molecule,Approved,HJLSLZFTEKNLFI-UHFFFAOYSA-N,CCS(=O)(=O)CCN1C([N+](=O)[O-])CNC1C;CCS(=O)(=O)CCN1C(C)NCC1[N+]([O-])=O
TINORIDINE,TINORIDINE,CHEMBL592943,BRD:BRD-K84313779-003-03-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,Small molecule,Phase 3,PFENFDGYVLAFBR-UHFFFAOYSA-N,CCOC(=O)C1C(N)SC2C1CCN(CC1CCCCC1)C2
TIOCONAZOLE,TIOCONAZOLE,CHEMBL1200438,BRD:BRD-A33084557-001-06-6;BRD:BRD-BRD-A33084557-001-06-6,rep_primary;rep_single_dose,STEROL DEMETHYLASE INHIBITOR,CYP51A1,YEAST INFECTION,,LAUNCHED,,Small molecule,Approved,QXHHHPZILQDDPS-UHFFFAOYSA-N,CLC1CCC(C(CN2CCNC2)OCC2CCSC2CL)C(CL)C1;CLC1SCCC1COC(CN1CCNC1)C1CCC(CL)CC1CL
TIOGUANINE,TIOGUANINE,CHEMBL727,BRD:BRD-BRD-K75649340-001-13-1;BRD:BRD-K75649340-001-13-1,rep_multi_dose;rep_primary;rep_single_dose,PURINE ANTAGONIST,,,,PHASE 2,,Small molecule,Approved,WYWHKKSPHMUBEB-UHFFFAOYSA-N,NC1NC(S)C2NCN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2N1;NC1NC2[NH]CNC2C(=S)[NH]1
TIOPRONIN,TIOPRONIN,CHEMBL1314;CHEMBL2106444,BRD:BRD-A85295731-001-06-4;BRD:BRD-BRD-A85295731-001-06-4,rep_primary;rep_single_dose,"CHELATING AGENT, REDUCING AGENT",,KIDNEY STONES,,LAUNCHED,,Small molecule,Approved,YTGJWQPHMWSCST-GSVOUGTGSA-N;YTGJWQPHMWSCST-UHFFFAOYSA-N,C[C@@H](S)C(=O)NCC(=O)O;CC(S)C(=O)NCC(=O)O;CC(S)C(=O)NCC(O)=O
TIOTIDINE,TIOTIDINE,CHEMBL269646,BRD:BRD-BRD-K15071410-001-01-1;BRD:BRD-K15071410-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,,,PHASE 2,,Small molecule,Unknown,YDDXVAXDYKBWDX-UHFFFAOYSA-N,C/N=C(/NC#N)NCCSCC1CSC(NC(=N)N)N1;CN\C(NCCSCC1CSC(N=C(N)N)N1)=N/C#N
TIOTROPIUM,TIOTROPIUM,CHEMBL1182657;CHEMBL1900528,BRD:BRD-BRD-K62782754-337-02-5;BRD:BRD-K62782754-337-02-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,LERNTVKEWCAPOY-DZZGSBJMSA-N;LERNTVKEWCAPOY-USXSHJJOSA-N,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(C3CCCS3)C3CCCS3)C[C@H]1[C@@H]1O[C@@H]12;C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(C3CCCS3)C3CCCS3)C[C@@H]1[C@H]1O[C@H]12;C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(C1CCCS1)C1CCCS1
TIOXOLONE,TIOXOLONE,CHEMBL442687,BRD:BRD-BRD-K41876534-001-13-7;BRD:BRD-K41876534-001-13-7,rep_multi_dose;rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA2,,,PRECLINICAL,,Small molecule,Unknown,SLYPOVJCSQHITR-UHFFFAOYSA-N,O=C1OC2CC(O)CCC2S1;OC1CCC2SC(=O)OC2C1
TIPELUKAST,TIPELUKAST,CHEMBL2104988,BRD:BRD-K00004627-001-01-9,rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,KPWYNAGOBXLMSE-UHFFFAOYSA-N,CCCC1C(SCCCOC2CCC(C(C)=O)C(OCCCC(=O)O)C2CCC)CCC(C(C)=O)C1O
TIPEPIDINE (HYDROCHLORIDE),TIPEPIDINE (HYDROCHLORIDE),,BRD:BRD-K00075727-003-02-9,rep_single_dose,,,,,,,,NA,,
TIPIFARNIB-P1,TIPIFARNIB-P1,,CTRP:417417,ctrp,,,,,,,,NA,,
TIPIFARNIB-P2,TIPIFARNIB-P2,,CTRP:417416,ctrp,,,,,,,,NA,,
TIPIRACIL,TIPIRACIL,CHEMBL235668,BRD:BRD-BRD-K11973162-003-01-8;BRD:BRD-K11973162-003-01-8,rep_multi_dose;rep_primary;rep_single_dose,THYMIDINE PHOSPHORYLASE INHIBITOR,TYMP,COLORECTAL CANCER,,LAUNCHED,,Small molecule,Approved,QQHMKNYGKVVGCZ-UHFFFAOYSA-N,CLC1C(CN2CCCC2=N)[NH]C(=O)[NH]C1=O;N=C1CCCN1CC1[NH]C(=O)[NH]C(=O)C1CL
TIPLAXTININ,TIPLAXTININ,,BRD:BRD-BRD-K30882994-001-01-6;BRD:BRD-K30882994-001-01-6,rep_primary;rep_single_dose,PLASMINOGEN ACTIVATOR INHIBITOR,SERPINE1,,,PHASE 1,,,NA,,OC(=O)C(=O)C1CN(CC2CCCCC2)C2CCC(CC12)-C1CCC(OC(F)(F)F)CC1
TIPRANAVIR,TIPRANAVIR,CHEMBL222559,BRD:BRD-A10039652-001-01-2;BRD:BRD-BRD-A10039652-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,HIV PROTEASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,SUJUHGSWHZTSEU-FYBSXPHGSA-N,CCC[C@@]1(CCC2CCCCC2)CC(=O)C([C@H](CC)C2CCCC(NS(=O)(=O)C3CCC(CN3)C(F)(F)F)C2)C(=O)O1;CCC[C@@]1(CCC2CCCCC2)CC(O)=C([C@H](CC)C2CCCC(NS(=O)(=O)C3CCC(C(F)(F)F)CN3)C2)C(=O)O1
TIPRENOLOL,TIPRENOLOL,CHEMBL2111163,BRD:BRD-A73566563-001-01-6;BRD:BRD-BRD-A73566563-001-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,,,PHASE 2,,Small molecule,Unknown,CSUNLSYSEQIDMO-UHFFFAOYSA-N,CSC1CCCCC1OCC(O)CNC(C)C
TIQUIZIUM,TIQUIZIUM,CHEMBL1872078;CHEMBL4301292,BRD:BRD-BRD-K77552740-004-01-0;BRD:BRD-K77552740-004-01-0,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,,SPASMS,,LAUNCHED,,Small molecule,Unknown,ZGSDGGRVFIYKKE-QRIPLOBPSA-N;ZGSDGGRVFIYKKE-UHFFFAOYSA-N,C[N@+]12CCCC[C@@H]1CCC(C2)=C(C1CCCS1)C1CCCS1;C[N+]12CCCC[C@@H]1CCC(=C(C1CCCS1)C1CCCS1)C2;C[N+]12CCCCC1CCC(=C(C1CCCS1)C1CCCS1)C2
TIRACIZINE,TIRACIZINE,CHEMBL1625260,BRD:BRD-BRD-K75250001-001-01-3;BRD:BRD-K75250001-001-01-3,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN5A,,,WITHDRAWN,,Small molecule,Unknown,KJAMZCVTJDTESW-UHFFFAOYSA-N,CCOC(=O)NC1CCC2C(C1)N(C(=O)CN(C)C)C1CCCCC1CC2;CCOC(=O)NC1CCC2CCC3CCCCC3N(C(=O)CN(C)C)C2C1
TIRAPAZAMINE,TIRAPAZAMINE,CHEMBL50882,BRD:BRD-BRD-K92968657-001-01-6;BRD:BRD-K92968657-001-01-6,rep_multi_dose;rep_primary;rep_single_dose,DNA INHIBITOR,,,,PHASE 3,,Small molecule,Phase 3,ORYDPOVDJJZGHQ-UHFFFAOYSA-N,NC1N[N+]([O-])C2CCCCC2[N+]1[O-]
TIRASEMTIV,TIRASEMTIV,CHEMBL3039529,BRD:BRD-BRD-K51087630-001-01-6;BRD:BRD-K51087630-001-01-6,rep_primary;rep_single_dose,TROPONIN ACTIVATOR,,,,PHASE 2,,Small molecule,Phase 3,RSQGZEAXODVTOL-UHFFFAOYSA-N,C#CC1CNC2NC(O)N(C(CC)CC)C2N1;CCC(CC)N1C2NC(CNC2[NH]C1=O)C#C
TIRATRICOL,TIRATRICOL,CHEMBL41632,BRD:BRD-BRD-K61236135-001-08-2;BRD:BRD-K61236135-001-08-2,rep_primary;rep_single_dose,THYROID HORMONE STIMULANT,THRA;THRB,REFETOFF SYNDROME,,LAUNCHED,,Small molecule,Phase 2,UOWZUVNAGUAEQC-UHFFFAOYSA-N,O=C(O)CC1CC(I)C(OC2CCC(O)C(I)C2)C(I)C1;OC(=O)CC1CC(I)C(OC2CCC(O)C(I)C2)C(I)C1
TIROFIBAN,TIROFIBAN,CHEMBL916,BRD:BRD-BRD-K37872686-003-01-9;BRD:BRD-K37872686-003-01-9,rep_primary;rep_single_dose,"PLATELET AGGREGATION INHIBITOR, STRUCTURAL GLYCOPROTEIN ANTAGONIST",ITGA2B;ITGB3,"MYOCARDIAL INFARCTION, REFACTORY ANGINA",,LAUNCHED,,Small molecule,Approved,COKMIXFXJJXBQG-NRFANRHFSA-N,CCCCS(=O)(=O)N[C@@H](CC1CCC(OCCCCC2CCNCC2)CC1)C(=O)O;CCCCS(=O)(=O)N[C@@H](CC1CCC(OCCCCC2CCNCC2)CC1)C(O)=O
TITANOCENE-DICHLORIDE,TITANOCENE-DICHLORIDE,,BRD:BRD-BRD-K60284353-001-01-3;BRD:BRD-K60284353-001-01-3,rep_primary;rep_single_dose,APOPTOSIS STIMULANT,,,,PHASE 2,,,NA,,CL[TI](CL)(C1C=CC=C1)C1C=CC=C1
TIVANTINIB,TIVANTINIB,CHEMBL2103882,BRD:BRD-BRD-K33379087-001-07-5;BRD:BRD-K33379087-001-07-5;CTRP:687406,ctrp;rep_multi_dose;rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,MET,,,PHASE 3,,Small molecule,Phase 3,UCEQXRCJXIVODC-PMACEKPBSA-N,O=C1NC(=O)[C@@H](C2CN3C4C(CCCC24)CCC3)[C@@H]1C1C[NH]C2CCCCC12;O=C1NC(=O)[C@H]([C@@H]1C1C[NH]C2CCCCC12)C1CN2CCCC3CCCC1C23
TIVOZANIB,TIVOZANIB,CHEMBL1289494,BRD:BRD-BRD-K53414658-001-08-2;BRD:BRD-K53414658-001-08-2;CTRP:418170;GDSC1:312,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,VEGFR INHIBITOR,FLT1;FLT4;KDR;KIT;PDGFRA;PDGFRB,,,PHASE 3,,Small molecule,Approved,SPMVMDHWKHCIDT-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)NC4CC(C)ON4)C(CL)C3)C2CC1OC
TIZANIDINE,TIZANIDINE,CHEMBL1079,BRD:BRD-BRD-K06335600-003-20-7;BRD:BRD-K06335600-003-20-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C;NISCH,SPASMS,,LAUNCHED,,Small molecule,Approved,XFYDIVBRZNQMJC-UHFFFAOYSA-N,CLC1CCC2NSNC2C1NC1=NCCN1
TK216,TK216,,BRD:BRD-K00090646-001-01-9,rep_single_dose,,,,,,,,NA,,
TL-1-85,TL-1-85,,GDSC1:261,gdsc,,,,,,,,NA,,
TL-2-105,TL-2-105,,GDSC1:211,gdsc,,,,,,,,NA,,
TMC-353121,TMC-353121,,BRD:BRD-BRD-K66097663-001-01-8;BRD:BRD-K66097663-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,RSV FUSION INHIBITOR,,,,PHASE 2,,,NA,,CC1CCC(CCCO)C(NCC2CCC3NC(NCCCN4CCOCC4)N(CC4NC(C)CCC4O)C3C2)C1
TMC647055,TMC647055,CHEMBL2043025,BRD:BRD-BRD-K49659468-436-01-2;BRD:BRD-K49659468-436-01-2,rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,UOBYJVFBFSLCTQ-UHFFFAOYSA-N,COC1CCC2-C3C(C4CCCCC4)C4CCC5CC4N3CC(=CC2C1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O;COC1CCC2C(C1)C=C1CN3C-2C(C2CCCCC2)C2CCC(CC23)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C1=O
TMN-355,TMN-355,,BRD:BRD-K24527118-001-02-9,rep_single_dose,CYCLOPHILIN INHIBITOR,PPIA,,,,,,NA,,
TMPH,TMPH,,BRD:BRD-BRD-K49119234-003-02-6;BRD:BRD-K49119234-003-02-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1
TMS,TMS,,BRD:BRD-BRD-K96233303-001-01-9;BRD:BRD-K96233303-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CCC(\C=C\C2CC(OC)CC(OC)C2)C(OC)C1
TMX-4116,TMX-4116,,BRD:BRD-K00093879-001-02-9,oncref_2,CK1A DEGRADER,CK1A;CRBN,,,,,,NA,,
TNP-470,TNP-470,CHEMBL424278,BRD:BRD-BRD-K53597484-001-02-7;BRD:BRD-K53597484-001-02-7,rep_primary;rep_single_dose,METHIONINE AMINOPEPTIDASE INHIBITOR,METAP2,,,PHASE 2,,Small molecule,Phase 2,MSHZHSPISPJWHW-PVDLLORBSA-N,CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCL;CO[C@@H]1[C@H](OC(=O)NC(=O)CCL)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C
TO-901317,TO-901317,,GDSC1:333,gdsc,,,,,,,,NA,,
TO901317,TO901317,,GDSC1:333,gdsc,,,,,,,,NA,,
TOBRAMYCIN,TOBRAMYCIN,CHEMBL1747,BRD:BRD-BRD-K05619559-001-12-7;BRD:BRD-K05619559-001-12-7,rep_primary;rep_single_dose,BACTERIAL 30S RIBOSOMAL SUBUNIT INHIBITOR,,"BACTERIAL SEPTICEMIA, RESPIRATORY TRACT INFECTIONS, MENINGITIS, SKIN INFECTIONS, URINARY TRACT INFECTIONS",,LAUNCHED,,Small molecule,Approved,NLVFBUXFDBBNBW-PBSUHMDJSA-N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O;NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](N)C[C@@H]1O
TOCAINIDE,TOCAINIDE,CHEMBL1762,BRD:BRD-A92670106-003-05-4;BRD:BRD-BRD-A92670106-003-05-4,rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCN5A,CARDIAC ARRYTHMIA,,LAUNCHED,,Small molecule,Approved,BUJAGSGYPOAWEI-UHFFFAOYSA-N,CC(N)C(=O)NC1C(C)CCCC1C;CC1CCCC(C)C1NC(=O)C(C)N
TOCERANIB,TOCERANIB,CHEMBL13608,BRD:BRD-BRD-K62040061-001-01-0;BRD:BRD-K62040061-001-01-0;BRD:BRD-K62040061-011-02-7,rep_multi_dose;rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,FLT1;FLT3;KDR;PDGFRA;PDGFRB,"CUTANEOUS MAST CELL TUMORS, CUTANEOUS MAST CELL TUMORS",,LAUNCHED,,Small molecule,Unknown,SRSGVKWWVXWSJT-ATVHPVEESA-N,CC1[NH]C(/C=C2\C(=O)NC3CCC(F)CC32)C(C)C1C(=O)NCCN1CCCC1;CC1[NH]C(\C=C2/C(=O)NC3CCC(F)CC23)C(C)C1C(=O)NCCN1CCCC1
TODRALAZINE,TODRALAZINE,CHEMBL1079787,BRD:BRD-BRD-K68553471-003-12-3;BRD:BRD-K68553471-003-12-3,rep_primary;rep_single_dose,ANTIHYPERTENSIVE AGENT,,,,LAUNCHED,,Small molecule,Unknown,WGZDBVOTUVNQFP-UHFFFAOYSA-N,CCOC(=O)NNC1NNCC2CCCCC12
TOFACITINIB,TOFACITINIB,CHEMBL221959,BRD:BRD-BRD-K31283835-048-04-4;BRD:BRD-K31283835-048-04-4,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3;TYK2,RHEUMATOID ARTHRITIS,,LAUNCHED,,Small molecule,Approved,UJLAWZDWDVHWOW-YPMHNXCESA-N,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1NCNC2[NH]CCC12;C[C@@H]1CCN(C[C@@H]1N(C)C1NCNC2[NH]CCC12)C(=O)CC#N
TOFISOPAM,TOFISOPAM,CHEMBL404216,BRD:BRD-BRD-K94830213-001-01-3;BRD:BRD-K94830213-001-01-3,rep_primary;rep_single_dose,"PHOSPHODIESTERASE INHIBITOR, CYTOCHROME P450 INHIBITOR",CYP3A4;PDE10A;PDE2A;PDE3A;PDE4A,"ANXIETY, ABSTINENCE FROM ALCOHOL",,LAUNCHED,"Multiple values for MOA: {'CYTOCHROME P450 INHIBITOR, PHOSPHODIESTERASE INHIBITOR', 'PHOSPHODIESTERASE INHIBITOR, CYTOCHROME P450 INHIBITOR'}, defaulting to 'PHOSPHODIESTERASE INHIBITOR, CYTOCHROME P450 INHIBITOR'",Small molecule,Unknown,RUJBDQSFYCKFAA-UHFFFAOYSA-N,CCC1=C(C)NN=C(C2CCC(OC)C(OC)C2)C2CC(OC)C(OC)CC12;CCC1C(C)=NN=C(C2CCC(OC)C(OC)C2)C2CC(OC)C(OC)CC21
TOFOGLIFLOZIN,TOFOGLIFLOZIN,CHEMBL2105711;CHEMBL2110731,BRD:BRD-BRD-K96344439-002-02-7;BRD:BRD-K96344439-002-02-7,rep_multi_dose;rep_primary;rep_single_dose,SODIUM/GLUCOSE COTRANSPORTER INHIBITOR,GCK,"DIABETES MELLITUS, DIABETES MELLITUS",,LAUNCHED,,Small molecule,Phase 3,VWVKUNOPTJGDOB-BDHVOXNPSA-N;ZXOCGDDVNPDRIW-NHFZGCSJSA-N,CCC1CCC(CC2CCC3C(C2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1;CCC1CCC(CC2CCC3C(C2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CC1.O;CCC1CCC(CC2CCC3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3C2)CC1
TOLAMOLOL,TOLAMOLOL,CHEMBL418192,BRD:BRD-A60498477-001-01-2;BRD:BRD-BRD-A60498477-001-01-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB1;ADRB2;ADRB3,,,PHASE 3,,Small molecule,Unknown,SKQDKFOTIPJUSV-UHFFFAOYSA-N,CC1CCCCC1OCC(O)CNCCOC1CCC(C(N)=O)CC1;CC1CCCCC1OCC(O)CNCCOC1CCC(CC1)C(N)=O
TOLAZAMIDE,TOLAZAMIDE,CHEMBL817,BRD:BRD-BRD-K32164935-001-30-8;BRD:BRD-K32164935-001-30-8,rep_primary;rep_single_dose,ATP CHANNEL BLOCKER,ABCC8;KCNJ1;KCNJ10;KCNJ11,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,OUDSBRTVNLOZBN-UHFFFAOYSA-N,CC1CCC(CC1)S(=O)(=O)NC(=O)NN1CCCCCC1;CC1CCC(S(=O)(=O)NC(=O)NN2CCCCCC2)CC1
TOLAZOLINE,TOLAZOLINE,CHEMBL770,BRD:BRD-BRD-K46211610-003-26-7;BRD:BRD-K46211610-003-26-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA2A;ADRA2B;ADRA2C;HRH1;HRH2,REVERSE SEDATIVE,,LAUNCHED,,Small molecule,Approved,JIVZKJJQOZQXQB-UHFFFAOYSA-N,C(C1=NCCN1)C1CCCCC1;C1CCC(CC2=NCCN2)CC1
TOLBUTAMIDE,TOLBUTAMIDE,CHEMBL782,BRD:BRD-BRD-K85119730-001-28-9;BRD:BRD-K85119730-001-28-9,rep_primary;rep_single_dose,ATP CHANNEL BLOCKER,ABCC8;KCNJ1;KCNJ11;KCNJ8,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,JLRGJRBPOGGCBT-UHFFFAOYSA-N,CCCCNC(=O)NS(=O)(=O)C1CCC(C)CC1
TOLCAPONE,TOLCAPONE,CHEMBL1324,BRD:BRD-BRD-K10852020-001-04-5;BRD:BRD-BRD-K10852020-001-05-2;BRD:BRD-K10852020-001-04-5;BRD:BRD-K10852020-001-05-2,rep_primary;rep_single_dose,CATECHOL O METHYLTRANSFERASE INHIBITOR,COMT,,,WITHDRAWN,,Small molecule,Approved,MIQPIUSUKVNLNT-UHFFFAOYSA-N,CC1CCC(C(=O)C2CC(O)C(O)C([N+](=O)[O-])C2)CC1;CC1CCC(CC1)C(=O)C1CC(O)C(O)C(C1)[N+]([O-])=O
TOLFENAMIC-ACID,TOLFENAMIC-ACID,,BRD:BRD-BRD-K50133271-001-18-7;BRD:BRD-K50133271-001-18-7,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PROSTANOID RECEPTOR ANTAGONIST",,MIGRAINE HEADACHE,,LAUNCHED,,,NA,,CC1C(CL)CCCC1NC1CCCCC1C(O)=O
TOLIMIDONE,TOLIMIDONE,CHEMBL8030,BRD:BRD-BRD-K41772907-001-01-2;BRD:BRD-K41772907-001-01-2,rep_primary;rep_single_dose,SRC ACTIVATOR,LYN;SRC,,,PHASE 2,,Small molecule,Phase 2,HJQILFPVRNHTIG-UHFFFAOYSA-N,CC1CCCC(OC2CNC(=O)[NH]C2)C1
TOLMETIN,TOLMETIN,CHEMBL1020,BRD:BRD-BRD-K82562631-236-04-6;BRD:BRD-K82562631-236-04-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"RHEUMATOID ARTHRITIS, OSTEOARTHRITIS",,LAUNCHED,,Small molecule,Approved,UPSPUYADGBWSHF-UHFFFAOYSA-N,CC1CCC(C(=O)C2CCC(CC(=O)O)N2C)CC1;CC1CCC(CC1)C(=O)C1CCC(CC(O)=O)N1C
TOLNAFTATE,TOLNAFTATE,CHEMBL83668,BRD:BRD-BRD-K44273375-001-25-0;BRD:BRD-K44273375-001-25-0,rep_primary;rep_single_dose,FUNGAL SQUALENE EPOXIDASE INHIBITOR,,"TINEA PEDIS, TINEA CORPORIS",,LAUNCHED,,Small molecule,Approved,FUSNMLFNXJSCDI-UHFFFAOYSA-N,CC1CCCC(N(C)C(=S)OC2CCC3CCCCC3C2)C1;CN(C(=S)OC1CCC2CCCCC2C1)C1CCCC(C)C1
TOLONIDINE,TOLONIDINE,CHEMBL304253,BRD:BRD-BRD-K82687598-001-01-6;BRD:BRD-K82687598-001-01-6,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A,,,LAUNCHED,,Small molecule,Unknown,KWBTZIFLQYYPTH-UHFFFAOYSA-N,CC1CCC(NC2=NCCN2)C(CL)C1
TOLONIUM,TOLONIUM,CHEMBL1197206;CHEMBL1622638,BRD:BRD-K94882685-003-10-0,rep_single_dose,,,,,,,Small molecule,Phase 1,KZEUBCUXBNEMSQ-UHFFFAOYSA-O;RQNADZJRELIICT-UHFFFAOYSA-N,CC1CC2NC3CCC(=[N+](C)C)CC-3SC2CC1N;CC1CC2NC3CCC(N(C)C)CC3[S+]C2CC1N
TOLOXATONE,TOLOXATONE,CHEMBL18116,BRD:BRD-A67182178-001-01-7;BRD:BRD-BRD-A67182178-001-01-7,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,MAOA;MAOB,DEPRESSION,,LAUNCHED,,Small molecule,Unknown,MXUNKHLAEDCYJL-UHFFFAOYSA-N,CC1CCCC(C1)N1CC(CO)OC1=O;CC1CCCC(N2CC(CO)OC2=O)C1
TOLPERISONE,TOLPERISONE,CHEMBL1076211,BRD:BRD-A27732521-003-08-3;BRD:BRD-BRD-A27732521-003-08-3,rep_primary;rep_single_dose,VOLTAGE-GATED SODIUM CHANNEL BLOCKER,CYP2C19;CYP2D6,"MUSCLE RELAXANT, MULTIPLE SCLEROSIS, ENCEPHALOMYELITIS, ANKYLOSING SPONDYLITIS, ATHEROSCLEROSIS, RAYNAUD'S DISEASE",,LAUNCHED,,Small molecule,Phase 3,FSKFPVLPFLJRQB-UHFFFAOYSA-N,CC(CN1CCCCC1)C(=O)C1CCC(C)CC1;CC1CCC(C(=O)C(C)CN2CCCCC2)CC1
TOLRESTAT,TOLRESTAT,CHEMBL436,BRD:BRD-BRD-K85693895-001-02-9;BRD:BRD-K85693895-001-02-9,rep_primary;rep_single_dose,ALDOSE REDUCTASE INHIBITOR,AKR1A1;AKR1B1;AKR1B10,,,WITHDRAWN,,Small molecule,Approved,LUBHDINQXIHVLS-UHFFFAOYSA-N,COC1CCC2C(C(=S)N(C)CC(=O)O)CCCC2C1C(F)(F)F;COC1CCC2C(CCCC2C1C(F)(F)F)C(=S)N(C)CC(O)=O
TOLTERODINE,TOLTERODINE,CHEMBL1382,BRD:BRD-BRD-K54316499-046-04-5;BRD:BRD-K54316499-046-04-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,"URINARY INCONTINENCE, URINARY FREQUENCY",,LAUNCHED,,Small molecule,Approved,OOGJQPCLVADCPB-HXUWFJFHSA-N,CC(C)N(CC[C@H](C1CCCCC1)C1CC(C)CCC1O)C(C)C;CC1CCC(O)C([C@H](CCN(C(C)C)C(C)C)C2CCCCC2)C1
TOLTRAZURIL,TOLTRAZURIL,CHEMBL2104931,BRD:BRD-BRD-K64514229-001-05-2;BRD:BRD-K64514229-001-05-2,rep_primary;rep_single_dose,ANTIPROTOZOAL AGENT,,COCCIDIOSIS,,LAUNCHED,,Small molecule,Unknown,OCINXEZVIIVXFU-UHFFFAOYSA-N,CC1CC(-N2C(=O)[NH]C(=O)N(C)C2=O)CCC1OC1CCC(SC(F)(F)F)CC1;CC1CC(CCC1OC1CCC(SC(F)(F)F)CC1)-N1C(=O)[NH]C(=O)N(C)C1=O
TOLVAPTAN,TOLVAPTAN,CHEMBL344159,BRD:BRD-A82035391-001-02-7;BRD:BRD-BRD-A82035391-001-02-7,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR ANTAGONIST,AVPR1A;AVPR2,"HYPONATREMIA, CONGESTIVE HEART FAILURE, HEPATIC CIRRHOSIS",,LAUNCHED,,Small molecule,Approved,GYHCTFXIZSNGJT-UHFFFAOYSA-N,CC1CCCCC1C(=O)NC1CCC(C(=O)N2CCCC(O)C3CC(CL)CCC23)C(C)C1;CC1CCCCC1C(=O)NC1CCC(C(=O)N2CCCC(O)C3CC(CL)CCC32)C(C)C1
TOMEGLOVIR,TOMEGLOVIR,CHEMBL1242035,BRD:BRD-K00003487-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Unknown,OSQAKHSYTKBSPB-UHFFFAOYSA-N,CN(C)C1CCCC2C(S(=O)(=O)NC3CCC(NC(=O)C(C)(C)CO)CC3)CCCC12
TOMELUKAST,TOMELUKAST,CHEMBL162358,BRD:BRD-BRD-K74765201-001-16-7;BRD:BRD-K74765201-001-16-7,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,CYSLTR1,,,PHASE 3,,Small molecule,Unknown,MWYHLEQJTQJHSS-UHFFFAOYSA-N,CCCC1C(OCCCCC2NNN[NH]2)CCC(C(C)=O)C1O
TOMIVOSERTIB,TOMIVOSERTIB,CHEMBL4073443,BRD:BRD-K00003361-001-01-9,rep_single_dose,MAPK-INTERACTING KINASE INHIBITOR,,,,,,Small molecule,Phase 2,HKTBYUWLRDZAJK-UHFFFAOYSA-N,CC1CC(NC2CC(N)NCN2)C(=O)N2C1C(=O)NC21CCCCC1
TONABERSAT,TONABERSAT,CHEMBL318191,BRD:BRD-BRD-K36970462-001-01-6;BRD:BRD-K36970462-001-01-6,rep_primary;rep_single_dose,"GAP JUNCTION MODULATOR, NITRIC OXIDE PRODUCTION INHIBITOR",,,,PHASE 2,,Small molecule,Phase 2,XLIIRNOPGJTBJD-ROUUACIJSA-N,CC(=O)C1CCC2C(C1)[C@H](NC(=O)C1CCC(F)C(CL)C1)[C@H](O)C(C)(C)O2;CC(=O)C1CCC2OC(C)(C)[C@@H](O)[C@@H](NC(=O)C3CCC(F)C(CL)C3)C2C1
TOPILUTAMIDE,TOPILUTAMIDE,CHEMBL2107790,BRD:BRD-K00003325-001-01-9,rep_single_dose,ANDROGEN RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,YCNCRLKXSLARFT-UHFFFAOYSA-N,CC(O)(CNC(=O)C(F)(F)F)C(=O)NC1CCC([N+](=O)[O-])C(C(F)(F)F)C1
TOPIRAMATE,TOPIRAMATE,CHEMBL220492,BRD:BRD-BRD-K29653726-001-13-4;BRD:BRD-K29653726-001-13-4,rep_primary;rep_single_dose,"CARBONIC ANHYDRASE INHIBITOR, GLUTAMATE RECEPTOR ANTAGONIST, KAINATE RECEPTOR ANTAGONIST",CA1;CA12;CA2;CA4;CA7;GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GRIA1;GRIA2;GRIA3;GRIA4;GRIK1;GRIK2;GRIK3;GRIK4;GRIK5;SCN10A;SCN11A;SCN1A;SCN2A;SCN3A;SCN4A;SCN5A;SCN7A;SCN8A;SCN9A,"EPILEPSY, MIGRAINE HEADACHE",,LAUNCHED,,Small molecule,Approved,KJADKKWYZYXHBB-XBWDGYHZSA-N,CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1;CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
TOPIROXOSTAT,TOPIROXOSTAT,CHEMBL1078685,BRD:BRD-BRD-K77561571-001-01-1;BRD:BRD-K77561571-001-01-1,rep_primary;rep_single_dose,XANTHINE OXIDASE INHIBITOR,XDH,"GOUT, HYPERURICEMIA",,LAUNCHED,,Small molecule,Phase 2,UBVZQGOVTLIHLH-UHFFFAOYSA-N,N#CC1CC(-C2N[NH]C(-C3CCNCC3)N2)CCN1;N#CC1CC(CCN1)-C1N[NH]C(N1)-C1CCNCC1
TOPOTECAN,TOPOTECAN,CHEMBL1607;CHEMBL84,BRD:BRD-BRD-K55696337-003-24-4;BRD:BRD-K55696337-003-24-4;CTRP:44580;GDSC2:1808,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP1;TOP1MT,"SMALL CELL LUNG CANCER, CERVICAL CANCER",,LAUNCHED,,Small molecule,Approved,DGHHQBMTXTWTJV-BQAIUKQQSA-N;UCFGDBYHRUNTLO-QHCPKHFHSA-N,CC[C@@]1(O)C(=O)OCC2C1CC1-C3NC4CCC(O)C(CN(C)C)C4CC3CN1C2=O;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3C(CN(C)C)C(O)CCC3NC2-1;CC[C@@]1(O)C(=O)OCC2C1CC1N(C2=O)CC2CC3C(CN(C)C)C(O)CCC3NC2-1.CL
TORASEMIDE,TORASEMIDE,CHEMBL1148,BRD:BRD-BRD-K30480208-001-18-5;BRD:BRD-K30480208-001-18-5,rep_multi_dose;rep_primary;rep_single_dose,"ELECTROLYTE REABSORPTION INHIBITOR, THROMBOXANE RECEPTOR ANTAGONIST",SLC12A1,"EDEMA, CONGESTIVE HEART FAILURE, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,NGBFQHCMQULJNZ-UHFFFAOYSA-N,CC(C)NC(=O)NS(=O)(=O)C1CNCCC1NC1CCCC(C)C1;CC1CCCC(NC2CCNCC2S(=O)(=O)NC(=O)NC(C)C)C1
TORCETRAPIB,TORCETRAPIB,CHEMBL479527,BRD:BRD-BRD-K55675242-001-03-0;BRD:BRD-K55675242-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR,CETP,,,PHASE 3,,Small molecule,Phase 3,CMSGWTNRGKRWGS-NQIIRXRSSA-N,CCOC(=O)N1[C@H](CC)C[C@H](N(CC2CC(CC(C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C2CC(CCC12)C(F)(F)F;CCOC(=O)N1C2CCC(C(F)(F)F)CC2[C@@H](N(CC2CC(C(F)(F)F)CC(C(F)(F)F)C2)C(=O)OC)C[C@H]1CC
TORCITABINE,TORCITABINE,CHEMBL554563,BRD:BRD-BRD-K91822704-003-07-2;BRD:BRD-K91822704-003-07-2,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,DCK;TK2,,,PHASE 2,,Small molecule,Unknown,CKTSBUTUHBMZGZ-CHKWXVPMSA-N,NC1CCN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)N1;NC1CCN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)N1
TOREMIFENE,TOREMIFENE,CHEMBL1655,BRD:BRD-BRD-K51350053-048-16-5;BRD:BRD-K51350053-048-16-5,rep_multi_dose;rep_primary;rep_single_dose,"ESTROGEN RECEPTOR ANTAGONIST, SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)",ESR1,BREAST CANCER,,LAUNCHED,,Small molecule,Approved,XFCLJVABOIYOMF-QPLCGJKRSA-N,CN(C)CCOC1CCC(/C(=C(/CCCL)C2CCCCC2)C2CCCCC2)CC1;CN(C)CCOC1CCC(CC1)C(\C1CCCCC1)=C(\CCCL)C1CCCCC1
TORIN 2,TORIN 2,,GDSC1:371,gdsc,,,,,,,,NA,,
TORIN-1,TORIN-1,,BRD:BRD-BRD-K40175214-001-11-6;BRD:BRD-K40175214-001-11-6,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,CCC(=O)N1CCN(CC1)C1CCC(CC1C(F)(F)F)-N1C2C(CCC1=O)CNC1CCC(CC21)-C1CNC2CCCCC2C1
TORIN-2,TORIN-2,,BRD:BRD-BRD-K68174511-001-06-6;BRD:BRD-K68174511-001-06-6,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,NC1CCC(CN1)-C1CCC2NCC3CCC(=O)N(-C4CCCC(C4)C(F)(F)F)C3C2C1
TORISEL,TORISEL,CHEMBL1201182,GDSC1:1016;GDSC1:3;GDSC2:1084,gdsc,,,,,,,Small molecule,Approved,CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
TOSEDOSTAT,TOSEDOSTAT,CHEMBL2103847,BRD:BRD-BRD-K92241597-001-06-0;BRD:BRD-K92241597-001-06-0;CTRP:417987,ctrp;rep_multi_dose;rep_primary;rep_single_dose,PEPTIDASE INHIBITOR,ANPEP;LAP3;NPEPPS,,,PHASE 2,,Small molecule,Phase 2,FWFGIHPGRQZWIW-SQNIBIBYSA-N,CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)C1CCCCC1)[C@H](O)C(=O)NO;CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)C1CCCCC1
TOSUFLOXACIN,TOSUFLOXACIN,CHEMBL273348,BRD:BRD-A41450521-075-10-8;BRD:BRD-BRD-A41450521-075-10-8,rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,,GRAM-NEGATIVE BACTERIAL INFECTIONS,,LAUNCHED,,Small molecule,Unknown,WUWFMDMBOJLQIV-UHFFFAOYSA-N,NC1CCN(C1)C1NC2N(CC(C(O)=O)C(=O)C2CC1F)-C1CCC(F)CC1F;NC1CCN(C2NC3C(CC2F)C(=O)C(C(=O)O)CN3-C2CCC(F)CC2F)C1
TOVOK,TOVOK,CHEMBL1173655,GDSC1:1032;GDSC1:1377;GDSC2:1032,gdsc,,,,,,,Small molecule,Approved,ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C/C=C/C(=O)NC1CC2C(NC3CCC(F)C(CL)C3)NCNC2CC1O[C@H]1CCOC1
TOYOCAMYCIN,TOYOCAMYCIN,CHEMBL99668,BRD:BRD-BRD-K26420709-001-01-7;BRD:BRD-K26420709-001-01-7,rep_primary;rep_single_dose,SERINE/THREONINE KINASE INHIBITOR,ERN1,,,PHASE 1,,Small molecule,NA,XOKJUSAYZUAMGJ-WOUKDFQISA-N,N#CC1CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C2NCNC(N)C12;NC1NCNC2N(CC(C#N)C12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
TOZADENANT,TOZADENANT,CHEMBL2105747,BRD:BRD-BRD-K93045741-001-01-0;BRD:BRD-K93045741-001-01-0,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA2A,,,PHASE 3,,Small molecule,Phase 3,XNBRWUQWSKXMPW-UHFFFAOYSA-N,COC1CCC(N2CCOCC2)C2SC(NC(=O)N3CCC(C)(O)CC3)NC12
TOZASERTIB,TOZASERTIB,CHEMBL572878,BRD:BRD-BRD-K59369769-001-20-3;BRD:BRD-K59369769-001-20-3;GDSC1:32;GDSC2:1096,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"AURORA KINASE INHIBITOR, BCR-ABL KINASE INHIBITOR, FLT3 INHIBITOR, JAK INHIBITOR",AURKA;AURKB;AURKC;LCK,,,PHASE 2,,Small molecule,Phase 2,GCIKSSRWRFVXBI-UHFFFAOYSA-N,CC1CC(NC2CC(N3CCN(C)CC3)NC(SC3CCC(NC(=O)C4CC4)CC3)N2)N[NH]1;CN1CCN(CC1)C1CC(NC2CC(C)[NH]N2)NC(SC2CCC(NC(=O)C3CC3)CC2)N1
TP-003,TP-003,,BRD:BRD-K87941707-001-02-9,rep_single_dose,GABA RECEPTOR INVERSE AGONIST,GABRA1;GABRA2;GABRA3;GABRA5,,,,,,NA,,
TP-0903,TP-0903,CHEMBL2022968,BRD:BRD-BRD-K84034737-001-01-1;BRD:BRD-K84034737-001-01-1,rep_primary;rep_single_dose,AXL KINASE INHIBITOR,AXL,,,PRECLINICAL,,Small molecule,Phase 1,YUAALFPUEOYPNX-UHFFFAOYSA-N,CN(C)S(=O)(=O)C1CCCCC1NC1NC(NC2CCC(CN3CCN(C)CC3)CC2)NCC1CL;CN1CCN(CC2CCC(NC3NCC(CL)C(NC4CCCCC4S(=O)(=O)N(C)C)N3)CC2)CC1
TP-3654,TP-3654,CHEMBL3975308,BRD:BRD-K00005239-001-01-9,rep_single_dose,"1,4,5-TRISPHOSPHATE INHIBITOR",,,,,,Small molecule,Phase 1,XRNVABDYQLHODA-JCNLHEQBSA-N,CC(C)(O)[C@H]1CC[C@H](NC2CCC3NCC(-C4CCCC(C(F)(F)F)C4)N3N2)CC1
TPCA-1,TPCA-1,,BRD:BRD-BRD-K51575138-001-13-2;BRD:BRD-K51575138-001-13-2;CTRP:375564;GDSC1:305,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,IKK INHIBITOR,IKBKB,,,PRECLINICAL,,,NA,,NC(=O)NC1SC(CC1C(N)=O)-C1CCC(F)CC1
TPPS4,TPPS4,,BRD:BRD-BRD-K39805756-001-01-6;BRD:BRD-K39805756-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,OS(=O)(=O)C1CCC(CC1)-C1C2CCC(N2)C(-C2CCC(CC2)S(O)(=O)=O)C2CCC([NH]2)C(-C2CCC(CC2)S(O)(=O)=O)C2CCC(N2)C(-C2CCC(CC2)S(O)(=O)=O)C2CCC1[NH]2
TRABECTEDIN,TRABECTEDIN,CHEMBL1224207;CHEMBL450449,BRD:BRD-K00003313-001-01-9,rep_single_dose,ANTITUMOR AGENT,,,,,,Small molecule,Approved,PKVRCIRHQMSYJX-AIFWHQITSA-N;PKVRCIRHQMSYJX-PYDRXBSSSA-N,COC1CC2C(CC1O)CCN[C@]21CS[C@@H]2C3C(OC(C)=O)C(C)C4C(C3[C@H](COC1=O)N1[C@@H]2[C@H]2C3C(CC(C)C(OC)C3O)C[C@@H]([C@@H]1O)N2C)OCO4;COC1CC2C(CC1O)CCN[C@]21CS[C@H]2C3C(OC(C)=O)C(C)C4C(C3[C@@H](COC1=O)N1[C@@H]2[C@H]2C3C(CC(C)C(OC)C3O)C[C@@H]([C@@H]1O)N2C)OCO4
TRABODENOSON,TRABODENOSON,CHEMBL3545407,BRD:BRD-K00004698-001-01-9,rep_single_dose,ADENOSINE RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,AQLVRTWKJDTWQQ-SDBHATRESA-N,O=[N+]([O-])OC[C@H]1O[C@@H](N2CNC3C(NC4CCCC4)NCNC32)[C@H](O)[C@@H]1O
TRACAZOLATE,TRACAZOLATE,CHEMBL84567,BRD:BRD-BRD-K34154330-003-06-4;BRD:BRD-K34154330-003-06-4,rep_primary;rep_single_dose,GABA RECEPTOR MODULATOR,GABRA1,,,PHASE 2,,Small molecule,Unknown,PCTRYMLLRKWXGF-UHFFFAOYSA-N,CCCCNC1C(C(=O)OCC)C(C)NC2C1CNN2CC;CCCCNC1C(C(=O)OCC)C(C)NC2N(CC)NCC12
TRADIPITANT,TRADIPITANT,CHEMBL3544984,BRD:BRD-K00003222-001-01-9,rep_single_dose,NEUROKININ RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,CAVRKWRKTNINFF-UHFFFAOYSA-N,O=C(C1CCCCC1CL)C1CCCNC1-C1NNN(CC2CC(C(F)(F)F)CC(C(F)(F)F)C2)C1-C1CCNCC1
TRAM-39,TRAM-39,,BRD:BRD-K81341251-001-02-9,rep_single_dose,CALCIUM-ACTIVATED POTASSIUM CHANNEL ACTIVATOR,KCNN4,,,,,,NA,,
TRAMADOL,TRAMADOL,CHEMBL1237044,BRD:BRD-BRD-K51033547-003-02-6;BRD:BRD-K51033547-003-02-6,rep_primary;rep_single_dose,"NOREPINEPHRINE REPUTAKE INHIBITOR, OPIOID RECEPTOR AGONIST, SEROTONIN REUPTAKE INHIBITOR",CHRFAM7A;CHRM3;GRIN3A;HTR2C;OPRD1;OPRK1;OPRM1;SLC6A2;SLC6A4,"ACUTE PAIN, CHRONIC PAIN",,LAUNCHED,,Small molecule,Approved,TVYLLZQTGLZFBW-UHFFFAOYSA-N,COC1CCCC(C1)[C@]1(O)CCCC[C@H]1CN(C)C;COC1CCCC(C2(O)CCCCC2CN(C)C)C1
TRAMIPROSATE,TRAMIPROSATE,CHEMBL149082,BRD:BRD-BRD-K82234479-001-09-4;BRD:BRD-K82234479-001-09-4,rep_primary;rep_single_dose,BETA AMYLOID PROTEIN NEUROTOXICITY INHIBITOR,APP,,,PHASE 3,,Small molecule,Phase 3,SNKZJIOFVMKAOJ-UHFFFAOYSA-N,NCCCS(=O)(=O)O;NCCCS(O)(=O)=O
TRANDOLAPRIL,TRANDOLAPRIL,CHEMBL1519,BRD:BRD-A32505112-001-04-4;BRD:BRD-BRD-A32505112-001-04-4,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,"HYPERTENSION, MYOCARDIAL INFARCTION",,LAUNCHED,,Small molecule,Approved,VXFJYXUZANRPDJ-WTNASJBWSA-N,CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21;CCOC(=O)[C@H](CCC1CCCCC1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O
TRANEXAMIC-ACID,TRANEXAMIC-ACID,,BRD:BRD-BRD-K15014948-001-10-3;BRD:BRD-K15014948-001-10-3,rep_primary;rep_single_dose,"ANTIFIBRINOLYTIC, PLASMINOGEN ACTIVATOR INHIBITOR",PLG,HEMOPHILIA,,LAUNCHED,,,NA,,NC[C@H]1CC[C@@H](CC1)C(O)=O
TRANILAST,TRANILAST,CHEMBL415324,BRD:BRD-BRD-K17849083-001-31-1;BRD:BRD-BRD-K17849083-001-32-9;BRD:BRD-K17849083-001-31-1;BRD:BRD-K17849083-001-32-9,rep_multi_dose;rep_primary;rep_single_dose,ANGIOGENESIS INHIBITOR,HPGDS;HRH1,ASTHMA,,LAUNCHED,,Small molecule,Phase 3,NZHGWWWHIYHZNX-CSKARUKUSA-N,COC1CCC(/C=C/C(=O)NC2CCCCC2C(=O)O)CC1OC;COC1CCC(\C=C\C(=O)NC2CCCCC2C(O)=O)CC1OC
"TRANS-10,CIS-12-CONJUGATED-LINOLEIC-ACID","TRANS-10,CIS-12-CONJUGATED-LINOLEIC-ACID",,BRD:BRD-BRD-K26222048-001-01-7;BRD:BRD-K26222048-001-01-7,rep_primary;rep_single_dose,,,,,LAUNCHED,,,NA,,CCCCC\C=C/C=C/CCCCCCCCC(O)=O
TRANS-2-UNDECENOIC-ACID,TRANS-2-UNDECENOIC-ACID,,BRD:BRD-BRD-K42959922-001-01-5;BRD:BRD-K42959922-001-01-5,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CCCCCCCC\C=C\C(O)=O
TRANS-4-HYDROXYCROTONIC-ACID,TRANS-4-HYDROXYCROTONIC-ACID,,BRD:BRD-BRD-K91614056-001-02-2;BRD:BRD-K91614056-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,GAMMA HYDROXYBUTYRIC ACID LIGAND,,,,PRECLINICAL,,,NA,,OC\C=C\C(O)=O
TRANS-4-METHOXYCINNAMIC-ACID,TRANS-4-METHOXYCINNAMIC-ACID,,BRD:BRD-BRD-K26273521-001-07-3;BRD:BRD-K26273521-001-07-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,COC1CCC(CC1)\C=C\C(O)=O
"TRANS-4-[8-(3-FLUOROPHENYL)-1,7-NAPHTHYRIDIN-6-YL]CYCLOHEXANECARBOXYLIC-ACID","TRANS-4-[8-(3-FLUOROPHENYL)-1,7-NAPHTHYRIDIN-6-YL]CYCLOHEXANECARBOXYLIC-ACID",,BRD:BRD-BRD-K75080769-001-01-6;BRD:BRD-K75080769-001-01-6,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC(=O)C1CCC(CC1)C1CC2CCCNC2C(N1)-C1CCCC(F)C1
TRANSCROCETINATE,TRANSCROCETINATE,CHEMBL464792,BRD:BRD-K00003217-304-01-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 3,PANKHBYNKQNAHN-MQQNZMFNSA-N,CC(/C=C/C=C(\C)C(=O)O)=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)O
TRANYLCYPROMINE,TRANYLCYPROMINE,CHEMBL313833;CHEMBL3989843,BRD:BRD-BRD-K47029922-003-10-9;BRD:BRD-K47029922-003-10-9,rep_primary;rep_single_dose,MONOAMINE OXIDASE INHIBITOR,KDM1A;MAOA;MAOB,DEPRESSION,,LAUNCHED,,Small molecule,Approved,AELCINSCMGFISI-UHFFFAOYSA-N;IGLYMJRIWWIQQE-QUOODJBBSA-N,N[C@@H]1C[C@H]1C1CCCCC1;N[C@@H]1C[C@H]1C1CCCCC1.N[C@H]1C[C@@H]1C1CCCCC1;N[C@H]1C[C@@H]1C1CCCCC1;NC1C[C@H]1C1CCCCC1;NC1CC1C1CCCCC1
TRAP-101,TRAP-101,,BRD:BRD-BRD-K69837166-003-02-0;BRD:BRD-K69837166-003-02-0,rep_primary;rep_single_dose,"NOCICEPTIN/ORPHANIN FQ RECEPTOR ANTAGONIST, OPIOID RECEPTOR ANTAGONIST",OPRL1,,,PRECLINICAL,,,NA,,CCN1C2CCCCC2N(C2=C(CO)CN(CC3CCCCCCC3)CC2)C1=O
TRAPIDIL,TRAPIDIL,CHEMBL132767,BRD:BRD-BRD-K95763993-001-19-3;BRD:BRD-K95763993-001-19-3,rep_multi_dose;rep_primary;rep_single_dose,PDGFR TYROSINE KINASE RECEPTOR INHIBITOR,PDGFRA,CORONARY ARTERY DISEASE (CAD),,LAUNCHED,,Small molecule,Unknown,GSNOZLZNQMLSKJ-UHFFFAOYSA-N,CCN(CC)C1CC(C)NC2NCNN12
TRAVOPROST,TRAVOPROST,CHEMBL1200799,BRD:BRD-BRD-K23976833-001-01-0;BRD:BRD-K23976833-001-01-0,rep_primary;rep_single_dose,PROSTANOID RECEPTOR AGONIST,PTGFR,"OCULAR HYPERTENSION, GLAUCOMA",,LAUNCHED,,Small molecule,Approved,MKPLKVHSHYCHOC-AHTXBMBWSA-N,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COC2CCCC(C(F)(F)F)C2)[C@H](O)C[C@@H]1O;CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1CCCC(C1)C(F)(F)F
TRAXOPRODIL,TRAXOPRODIL,CHEMBL17350,BRD:BRD-BRD-K38158531-001-02-1;BRD:BRD-K38158531-001-02-1,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIN2B,,,PHASE 2,,Small molecule,Phase 2,QEMSVZNTSXPFJA-HNAYVOBHSA-N,C[C@@H]([C@@H](O)C1CCC(O)CC1)N1CCC(O)(C2CCCCC2)CC1;C[C@@H]([C@@H](O)C1CCC(O)CC1)N1CCC(O)(CC1)C1CCCCC1
TRAZODONE,TRAZODONE,CHEMBL621,BRD:BRD-BRD-K70778732-003-26-7;BRD:BRD-K70778732-003-26-7,rep_primary;rep_single_dose,"ADRENERGIC RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST, SEROTONIN REUPTAKE INHIBITOR",ADRA1A;ADRA2A;HRH1;HTR1A;HTR2A;HTR2B;HTR2C;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,PHLBKPHSAVXXEF-UHFFFAOYSA-N,CLC1CCCC(C1)N1CCN(CCCN2NC3CCCCN3C2=O)CC1;O=C1N(CCCN2CCN(C3CCCC(CL)C3)CC2)NC2CCCCN12
TRELAGLIPTIN,TRELAGLIPTIN,CHEMBL1650443,BRD:BRD-A88369366-001-01-7;BRD:BRD-BRD-A88369366-001-01-7,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Phase 3,IWYJYHUNXVAVAA-OAHLLOKOSA-N,CN1C(=O)CC(N2CCC[C@@H](N)C2)N(CC2CC(F)CCC2C#N)C1=O;CN1C(=O)CC(N2CCCC(N)C2)N(CC2CC(F)CCC2C#N)C1=O
TREMORINE,TREMORINE,,BRD:BRD-BRD-K08619838-300-05-7;BRD:BRD-K08619838-300-05-7,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,,,,PRECLINICAL,,,NA,,C(C#CCN1CCCC1)N1CCCC1
TREPIBUTONE,TREPIBUTONE,CHEMBL1725880,BRD:BRD-BRD-K37543758-001-01-3;BRD:BRD-K37543758-001-01-3,rep_primary;rep_single_dose,CHOLINERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Unknown,YPTFHLJNWSJXKG-UHFFFAOYSA-N,CCOC1CC(OCC)C(C(=O)CCC(=O)O)CC1OCC;CCOC1CC(OCC)C(CC1OCC)C(=O)CCC(O)=O
TREPROSTINIL,TREPROSTINIL,CHEMBL1237119,BRD:BRD-K19706299-236-02-9,rep_single_dose,PROSTANOID RECEPTOR AGONIST,P2RY12;PPARD;PTGIR,,,,,Small molecule,Approved,PAJMKGZZBBTTOY-ZFORQUDYSA-N,CCCCC[C@H](O)CC[C@@H]1[C@H]2CC3CCCC(OCC(=O)O)C3C[C@H]2C[C@H]1O
TREQUINSIN,TREQUINSIN,CHEMBL285913,BRD:BRD-BRD-K84663978-003-02-9;BRD:BRD-K84663978-003-02-9,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A,,,PHASE 1,,Small molecule,Unknown,MCMSJVMUSBZUCN-YYDJUVGSSA-N,COC1CC2C(CC1OC)-C1C/C(=N\C3C(C)CC(C)CC3C)N(C)C(=O)N1CC2;COC1CC2CCN3C(C\C(=N/C4C(C)CC(C)CC4C)N(C)C3=O)-C2CC1OC
TRETAZICAR,TRETAZICAR,CHEMBL23330,BRD:BRD-BRD-K08748705-001-08-2;BRD:BRD-K08748705-001-08-2,rep_primary;rep_single_dose,DNA REPLICATION INHIBITOR,NQO2,,,PHASE 2,,Small molecule,Phase 2,WOCXQMCIOTUMJV-UHFFFAOYSA-N,NC(=O)C1CC(N2CC2)C([N+](=O)[O-])CC1[N+](=O)[O-];NC(=O)C1CC(N2CC2)C(CC1[N+]([O-])=O)[N+]([O-])=O
TRETIN-X,TRETIN-X,CHEMBL38,GDSC1:1009,gdsc,,,,,,,Small molecule,Approved,SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
TRETINOIN,TRETINOIN,CHEMBL38,BRD:BRD-K71879491-001-51-5;CTRP:23151;GDSC1:1009,ctrp;gdsc;rep_single_dose,"RETINOID RECEPTOR AGONIST, RETINOID RECEPTOR LIGAND",ALDH1A1;ALDH1A2;GPRC5A;NR0B1;NR2C2;PPARD;RARA;RARB;RARG;RARRES1;RORB;RORC;RXRB;RXRG,,,,,Small molecule,Approved,SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
TRETINOIN:CARBOPLATIN (2:1 MOL/MOL),TRETINOIN:CARBOPLATIN (2:1 MOL/MOL),,CTRP:660181,ctrp,,,,,,,,NA,,
TRETINOIN:NAVITOCLAX (4:1 MOL/MOL),TRETINOIN:NAVITOCLAX (4:1 MOL/MOL),,CTRP:660179,ctrp,,,,,,,,NA,,
TREXALL,TREXALL,CHEMBL3244648;CHEMBL34259,GDSC1:1008,gdsc,,,,,,,Small molecule,Approved,DASQOOZCTWOQPA-GXKRWWSZSA-L;FBOZXECLQNJBKD-ZDUSSCGKSA-N,CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])CC1.[NA+].[NA+];CN(CC1CNC2NC(N)NC(N)C2N1)C1CCC(C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC1
TRIACETIN,TRIACETIN,CHEMBL1489254,BRD:BRD-BRD-K92844263-001-09-8;BRD:BRD-K92844263-001-09-8,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Phase 2,URAYPUMNDPQOKB-UHFFFAOYSA-N,CC(=O)OCC(COC(C)=O)OC(C)=O
TRIAMCINOLONE,TRIAMCINOLONE,CHEMBL1451,BRD:BRD-BRD-K77554836-001-11-6;BRD:BRD-BRD-K77554836-001-14-0;BRD:BRD-K77554836-001-11-6;BRD:BRD-K77554836-001-14-0,rep_multi_dose;rep_primary;rep_single_dose,GLUCOCORTICOID RECEPTOR AGONIST,NR3C1;SERPINA6,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,Small molecule,Approved,GFNANZIMVAIWHM-OBYCQNJPSA-N,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO;C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F
TRIAMCINOLONE-ACETONIDE,TRIAMCINOLONE-ACETONIDE,,BRD:BRD-A92439610-001-05-7;BRD:BRD-BRD-A92439610-001-05-7,rep_multi_dose;rep_primary;rep_single_dose,"GLUCOCORTICOID RECEPTOR AGONIST, IMMUNOSUPPRESSANT",NR3C1,CORTICOSTEROID-RESPONSIVE DERMATOSES,,LAUNCHED,,,NA,,CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
TRIAMCINOLONE-HEXACETONIDE,TRIAMCINOLONE-HEXACETONIDE,,BRD:BRD-K00003338-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,,,,,,,NA,,
TRIAMTERENE,TRIAMTERENE,CHEMBL585,BRD:BRD-BRD-K92049597-001-20-8;BRD:BRD-K92049597-001-20-8,rep_multi_dose;rep_primary;rep_single_dose,SODIUM CHANNEL BLOCKER,SCNN1A;SCNN1B;SCNN1D;SCNN1G,"HYPOKALEMIA, HYPERTENSION, EDEMA",,LAUNCHED,,Small molecule,Approved,FNYLWPVRPXGIIP-UHFFFAOYSA-N,NC1NC(N)C2NC(-C3CCCCC3)C(N)NC2N1
TRIAPINE,TRIAPINE,CHEMBL231616,BRD:BRD-BRD-K01669786-001-02-2;BRD:BRD-K01669786-001-02-2,rep_multi_dose;rep_primary;rep_single_dose,RIBONUCLEOTIDE REDUCTASE INHIBITOR,RRM1;RRM2,,,PHASE 2,,Small molecule,Phase 3,XMYKNCNAZKMVQN-NYYWCZLTSA-N,NC(=S)N/N=C/C1NCCCC1N;NC(=S)N\N=C\C1NCCCC1N
TRIAZAVIRIN,TRIAZAVIRIN,,BRD:BRD-K00091130-325-01-9,rep_single_dose,,,,,,,,NA,,
TRIAZOLAM,TRIAZOLAM,CHEMBL646,BRD:BRD-BRD-K76890464-001-02-3;BRD:BRD-K76890464-001-02-3,rep_primary;rep_single_dose,GABA BENZODIAZEPINE SITE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA4;GABRA5;GABRA6;GABRB1;GABRB2;GABRB3;GABRD;GABRE;GABRG1;GABRG2;GABRG3;GABRP;GABRQ;GABRR1;GABRR2;GABRR3;TSPO,,,WITHDRAWN,,Small molecule,Approved,JOFWLTCLBGQGBO-UHFFFAOYSA-N,CC1NNC2CN=C(C3CCCCC3CL)C3CC(CL)CCC3-N12;CC1NNC2N1-C1CCC(CL)CC1C(C1CCCCC1CL)=NC2
TRIAZOLOTHIADIAZINE,TRIAZOLOTHIADIAZINE,,CTRP:385240,ctrp,,,,,,,,NA,,
TRIBOMSALAN,TRIBOMSALAN,,BRD:BRD-BRD-K09118247-001-03-3;BRD:BRD-K09118247-001-03-3,rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,OC1C(BR)CC(BR)CC1C(=O)NC1CCC(BR)CC1
TRIBROMOETHANOL,TRIBROMOETHANOL,CHEMBL1697852,BRD:BRD-K69632891-001-02-9,rep_single_dose,ANALGESIC AGENT,,,,,,Small molecule,Unknown,YFDSDPIBEUFTMI-UHFFFAOYSA-N,OCC(BR)(BR)BR
TRICAINE (METHANESULFONATE),TRICAINE (METHANESULFONATE),,BRD:BRD-K44518413-066-04-9,rep_single_dose,,,,,,,,NA,,
TRICAPRYLIN,TRICAPRYLIN,CHEMBL1406148,BRD:BRD-BRD-K24790130-001-07-1;BRD:BRD-K24790130-001-07-1,rep_primary;rep_single_dose,,,COSMETIC,,LAUNCHED,,Small molecule,Phase 3,VLPFTAMPNXLGLX-UHFFFAOYSA-N,CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
TRICHLORMETHIAZIDE,TRICHLORMETHIAZIDE,CHEMBL1054,BRD:BRD-A28940325-001-24-0;BRD:BRD-BRD-A28940325-001-24-0,rep_primary;rep_single_dose,CHLORIDE CHANNEL BLOCKER,ATP1A1;CA1;CA2;CA4;PTGS1;PTGS2;SLC12A1;SLC12A3,"HYPERTENSION, EDEMA",,LAUNCHED,"Multiple values for repurposing_target: {'ATP1A1;CA1;CA2;CA4;PTGS1;PTGS2;SLC12A1;SLC12A3', 'ATP1A1;CA1;CA2;CA4;SLC12A1;SLC12A3'}, taking the union",Small molecule,Approved,LMJSLTNSBFUCMU-UHFFFAOYSA-N,NS(=O)(=O)C1CC2C(CC1CL)NC(C(CL)CL)NS2(=O)=O;NS(=O)(=O)C1CC2C(NC(NS2(=O)=O)C(CL)CL)CC1CL
TRICHLOROACETIC-ACID,TRICHLOROACETIC-ACID,,BRD:BRD-BRD-K42090719-001-06-5;BRD:BRD-K42090719-001-06-5,rep_primary;rep_single_dose,,,WARTS,,LAUNCHED,,,NA,,OC(=O)C(CL)(CL)CL
TRICHLOROETHYLENE,TRICHLOROETHYLENE,CHEMBL279816,BRD:BRD-BRD-K46435528-001-04-4;BRD:BRD-K46435528-001-04-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Approved,XSTXAVWGXDQKEL-UHFFFAOYSA-N,CLC=C(CL)CL
TRICHOSTATIN A,TRICHOSTATIN A,,GDSC1:437,gdsc,,,,,,,,NA,,
TRICHOSTATIN-A,TRICHOSTATIN-A,,BRD:BRD-BRD-K68202742-001-16-5;BRD:BRD-K68202742-001-16-5,rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC10;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9,,,PRECLINICAL,,,NA,,C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)C1CCC(CC1)N(C)C
TRICIRIBINE,TRICIRIBINE,CHEMBL331237;CHEMBL462018,BRD:BRD-BRD-K80431395-001-07-3;BRD:BRD-BRD-K80431395-001-09-9;BRD:BRD-K80431395-001-07-3;BRD:BRD-K80431395-001-09-9,rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,AKT1;AKT2;AKT3,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,HOGVTUZUJGHKPL-HTVVRFAVSA-N;URLYINUFLXOMHP-HTVVRFAVSA-N,CN1N=C(N)C2CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C3NCNC1C23;CN1N=C(N)C2CN([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)C3NCNC1C23;CN1NC(N)C2CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C3NCNC1C23
TRICIRIBINE-PHOSPHATE,TRICIRIBINE-PHOSPHATE,,BRD:BRD-K00004666-001-01-9,rep_single_dose,AKT INHIBITOR,,,,,,,NA,,
TRICLABENDAZOLE,TRICLABENDAZOLE,CHEMBL1086440,BRD:BRD-BRD-K81916719-001-13-9;BRD:BRD-K81916719-001-13-9,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE INHIBITOR,DNMT1,TAPEWORM,,LAUNCHED,,Small molecule,Approved,NQPDXQQQCQDHHW-UHFFFAOYSA-N,CSC1NC2CC(CL)C(OC3CCCC(CL)C3CL)CC2[NH]1
TRICLOCARBAN,TRICLOCARBAN,CHEMBL1076347,BRD:BRD-BRD-K25029121-001-05-8;BRD:BRD-K25029121-001-05-8,rep_primary;rep_single_dose,OTHER ANTIBIOTIC,,,,LAUNCHED,,Small molecule,Approved,ICUTUKXCWQYESQ-UHFFFAOYSA-N,CLC1CCC(NC(=O)NC2CCC(CL)C(CL)C2)CC1;O=C(NC1CCC(CL)CC1)NC1CCC(CL)C(CL)C1
TRICLOSAN,TRICLOSAN,CHEMBL849,BRD:BRD-BRD-K41731458-001-15-1;BRD:BRD-K41731458-001-15-1,rep_primary;rep_single_dose,ANTIBACTERIAL AGENT,DNMT1,,,LAUNCHED,,Small molecule,Approved,XEFQLINVKFYRCS-UHFFFAOYSA-N,OC1CC(CL)CCC1OC1CCC(CL)CC1CL
TRIDIHEXETHYL,TRIDIHEXETHYL,CHEMBL1201354,BRD:BRD-A22152765-003-10-0;BRD:BRD-BRD-A22152765-003-10-0,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,"PEPTIC ULCER DISEASE (PUD), NYSTAGMUS",,LAUNCHED,,Small molecule,Approved,NPRHVSBSZMAEIN-UHFFFAOYSA-N,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1CCCCC1
TRIENTINE,TRIENTINE,CHEMBL609,BRD:BRD-BRD-K37111771-300-02-6;BRD:BRD-K37111771-300-02-6,rep_primary;rep_single_dose,CHELATING AGENT,CA14,WILSON'S DISEASE,,LAUNCHED,,Small molecule,Approved,VILCJCGEZXAXTO-UHFFFAOYSA-N,NCCNCCNCCN
TRIFAROTENE,TRIFAROTENE,CHEMBL3707313,BRD:BRD-K00077480-001-02-9,rep_single_dose,,,,,,,Small molecule,Approved,MFBCDACCJCDGBA-UHFFFAOYSA-N,CC(C)(C)C1CC(-C2CC(-C3CCC(C(=O)O)CC3)CCC2OCCO)CCC1N1CCCC1
TRIFLOXYSTROBIN,TRIFLOXYSTROBIN,CHEMBL1897483,BRD:BRD-K00005342-001-01-9,rep_single_dose,MITOCHONDRIAL ELECTRON TRANSPORT INHIBITOR,,,,,,Small molecule,NA,ONCZDRURRATYFI-TVJDWZFNSA-N,CO/N=C(/C(=O)OC)C1CCCCC1CO/N=C(\C)C1CCCC(C(F)(F)F)C1
TRIFLUOPERAZINE,TRIFLUOPERAZINE,CHEMBL422,BRD:BRD-BRD-K89732114-300-14-7;BRD:BRD-K89732114-300-14-7;CTRP:26914,ctrp;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;CALM1;CALY;DRD2;DRD4;HRH1;HTR2A;HTR2C;S100A4;TNNC1,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,ZEWQUBUPAILYHI-UHFFFAOYSA-N,CN1CCN(CCCN2C3CCCCC3SC3CCC(C(F)(F)F)CC32)CC1;CN1CCN(CCCN2C3CCCCC3SC3CCC(CC23)C(F)(F)F)CC1
TRIFLUPROMAZINE,TRIFLUPROMAZINE,CHEMBL570,BRD:BRD-BRD-K63675182-003-23-6;BRD:BRD-K63675182-003-23-6,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;DRD1;DRD2;HTR2B,"PSYCHOSIS, NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,XSCGXQMFQXDFCW-UHFFFAOYSA-N,CN(C)CCCN1C2CCCCC2SC2CCC(C(F)(F)F)CC21;CN(C)CCCN1C2CCCCC2SC2CCC(CC12)C(F)(F)F
TRIFLURIDINE,TRIFLURIDINE,CHEMBL1129,BRD:BRD-BRD-K03243820-001-23-8;BRD:BRD-BRD-K03243820-001-25-3;BRD:BRD-K03243820-001-23-8;BRD:BRD-K03243820-001-25-3,rep_multi_dose;rep_primary;rep_single_dose,"DNA DIRECTED DNA POLYMERASE INHIBITOR, THYMIDYLATE SYNTHASE INHIBITOR",TYMS,VIRUS HERPES SIMPLEX (HSV),,LAUNCHED,,Small molecule,Approved,VSQQQLOSPVPRAZ-RRKCRQDMSA-N,O=C1[NH]C(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CC1C(F)(F)F;OC[C@H]1O[C@H](C[C@@H]1O)N1CC(C(=O)[NH]C1=O)C(F)(F)F
TRIFLUSAL,TRIFLUSAL,CHEMBL1332032,BRD:BRD-BRD-K71696703-001-07-9;BRD:BRD-K71696703-001-07-9,rep_primary;rep_single_dose,"CYCLOOXYGENASE INHIBITOR, PLATELET AGGREGATION INHIBITOR, THROMBOXANE SYNTHASE INHIBITOR",NFKB1;NOS2;PDE10A;PTGS1,"STROKE, MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION (AF)",,LAUNCHED,,Small molecule,Phase 3,RMWVZGDJPAKBDE-UHFFFAOYSA-N,CC(=O)OC1CC(C(F)(F)F)CCC1C(=O)O;CC(=O)OC1CC(CCC1C(O)=O)C(F)(F)F
TRIGONELLINE,TRIGONELLINE,CHEMBL350675;CHEMBL489961,BRD:BRD-BRD-K69231085-003-05-7;BRD:BRD-K69231085-003-05-7,rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,NA,TZSYLWAXZMNUJB-UHFFFAOYSA-N;WWNNZCOKKKDOPX-UHFFFAOYSA-N,C[N+]1CCCC(C(=O)[O-])C1;C[N+]1CCCC(C(=O)[O-])C1.CL;C[N+]1CCCC(C1)C(O)=O
TRIHEXYPHENIDYL,TRIHEXYPHENIDYL,CHEMBL1490,BRD:BRD-A48180038-003-24-3;BRD:BRD-BRD-A48180038-003-24-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5,PARKINSONISM,,LAUNCHED,,Small molecule,Approved,HWHLPVGTWGOCJO-UHFFFAOYSA-N,OC(CCN1CCCCC1)(C1CCCCC1)C1CCCCC1
TRILACICLIB,TRILACICLIB,CHEMBL3894860,BRD:BRD-K00003412-300-01-9,rep_single_dose,CDK INHIBITOR,,,,,,Small molecule,Approved,PDGKHKMBHVFCMG-UHFFFAOYSA-N,CN1CCN(C2CCC(NC3NCC4CC5N(C4N3)C3(CCCCC3)CNC5=O)NC2)CC1
TRILOSTANE,TRILOSTANE,CHEMBL1200907,BRD:BRD-A04497688-001-04-2;BRD:BRD-BRD-A04497688-001-04-2,rep_primary;rep_single_dose,3BETA-HYDROXY-DELTA5-STEROID DEHYDROGENASE INHIBITOR,ESR1;ESR2;HSD3B1;HSD3B2,CUSHING'S SYNDROME,,LAUNCHED,,Small molecule,Approved,KVJXBPDAXMEYOA-CXANFOAXSA-N,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O;C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O
TRIMEBUTINE,TRIMEBUTINE,CHEMBL190044,BRD:BRD-A92630576-050-24-1;BRD:BRD-BRD-A92630576-050-24-1,rep_multi_dose;rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRD1;OPRK1;OPRM1,IRRITABLE BOWEL SYNDROME,,LAUNCHED,,Small molecule,Phase 3,LORDFXWUHHSAQU-UHFFFAOYSA-N,CCC(COC(=O)C1CC(OC)C(OC)C(OC)C1)(C1CCCCC1)N(C)C;CCC(COC(=O)C1CC(OC)C(OC)C(OC)C1)(N(C)C)C1CCCCC1
TRIMETAZIDINE,TRIMETAZIDINE,CHEMBL203266,BRD:BRD-BRD-K88366685-300-06-0;BRD:BRD-K88366685-300-06-0,rep_primary;rep_single_dose,3-KETOACYL COA THIOLASE INHIBITOR,ACAA2,ANGINA PECTORIS,,LAUNCHED,,Small molecule,Approved,UHWVSEOVJBQKBE-UHFFFAOYSA-N,COC1CCC(CN2CCNCC2)C(OC)C1OC
TRIMETHOBENZAMIDE,TRIMETHOBENZAMIDE,CHEMBL1201256,BRD:BRD-BRD-K34415467-003-13-0;BRD:BRD-K34415467-003-13-0,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,DRD2,"VOMITING, NAUSEA, GASTROENTERITIS",,LAUNCHED,,Small molecule,Approved,FEZBIKUBAYAZIU-UHFFFAOYSA-N,COC1CC(C(=O)NCC2CCC(OCCN(C)C)CC2)CC(OC)C1OC;COC1CC(CC(OC)C1OC)C(=O)NCC1CCC(OCCN(C)C)CC1
TRIMETHOPRIM,TRIMETHOPRIM,CHEMBL22,BRD:BRD-BRD-K07208025-001-29-7;BRD:BRD-K07208025-001-29-7,rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR;TYMS,"URINARY TRACT INFECTIONS, EAR INFECTIONS, DIARRHEA",,LAUNCHED,,Small molecule,Approved,IEDVJHCEMCRBQM-UHFFFAOYSA-N,COC1CC(CC2CNC(N)NC2N)CC(OC)C1OC
TRIMETHOQUINOL,TRIMETHOQUINOL,CHEMBL299175,BRD:BRD-A56241705-003-01-2;BRD:BRD-BRD-A56241705-003-01-2,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRB2;ADRB3,,,LAUNCHED,,Small molecule,Unknown,RGVPOXRFEPSFGH-UHFFFAOYSA-N,COC1CC(CC2NCCC3CC(O)C(O)CC23)CC(OC)C1OC;COC1CC(CC2NCCC3CC(O)C(O)CC32)CC(OC)C1OC
TRIMETOZINE,TRIMETOZINE,CHEMBL1697853,BRD:BRD-BRD-K53220666-001-02-6;BRD:BRD-K53220666-001-02-6,rep_primary;rep_single_dose,SEDATIVE,,SEDATIVE,,LAUNCHED,,Small molecule,Unknown,XWVOEFLBOSSYGM-UHFFFAOYSA-N,COC1CC(C(=O)N2CCOCC2)CC(OC)C1OC;COC1CC(CC(OC)C1OC)C(=O)N1CCOCC1
TRIMETREXATE,TRIMETREXATE,CHEMBL119,BRD:BRD-K13642819-001-02-9,rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,DHFR,,,,,Small molecule,Approved,NOYPYLRCIDNJJB-UHFFFAOYSA-N,COC1CC(NCC2CCC3NC(N)NC(N)C3C2C)CC(OC)C1OC
TRIMIPRAMINE,TRIMIPRAMINE,CHEMBL644,BRD:BRD-A19195498-050-14-1;BRD:BRD-BRD-A19195498-050-14-1,rep_primary;rep_single_dose,"NOREPINEPHRINE REPUTAKE INHIBITOR, TRICYCLIC ANTIDEPRESSANT",ADRA1A;ADRA1B;ADRA2A;ADRA2B;ADRB1;ADRB2;ADRB3;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD5;HRH1;HTR1A;HTR1D;HTR2A;HTR2C;HTR3A;SLC6A2;SLC6A3;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,ZSCDBOWYZJWBIY-UHFFFAOYSA-N,CC(CN(C)C)CN1C2CCCCC2CCC2CCCCC12;CC(CN(C)C)CN1C2CCCCC2CCC2CCCCC21
TRIOXSALEN,TRIOXSALEN,CHEMBL1475,BRD:BRD-BRD-K54790157-001-15-5;BRD:BRD-K54790157-001-15-5,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,"VITILIGO, ECZEMA",,LAUNCHED,,Small molecule,Approved,FMHHVULEAZTJMA-UHFFFAOYSA-N,CC1CC2CC3C(C)CC(=O)OC3C(C)C2O1
TRIPELENNAMINE,TRIPELENNAMINE,CHEMBL1241,BRD:BRD-BRD-K57033106-003-19-7;BRD:BRD-K57033106-003-19-7,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,"ASTHMA, ALLERGIC RHINITIS, URTICARIA",,LAUNCHED,,Small molecule,Approved,UFLGIAIHIAPJJC-UHFFFAOYSA-N,CN(C)CCN(CC1CCCCC1)C1CCCCN1
TRIPROLIDINE,TRIPROLIDINE,CHEMBL855,BRD:BRD-BRD-K11742128-003-23-4;BRD:BRD-K11742128-003-23-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH1,ALLERGIC RHINITIS,,LAUNCHED,,Small molecule,Approved,CBEQULMOCCWAQT-WOJGMQOQSA-N,CC1CCC(/C(=C\CN2CCCC2)C2CCCCN2)CC1;CC1CCC(CC1)C(=C/CN1CCCC1)\C1CCCCN1
TRIPTOLIDE,TRIPTOLIDE,CHEMBL463763,BRD:BRD-BRD-K39484304-001-16-5;BRD:BRD-K39484304-001-16-5;CTRP:411720,ctrp;rep_multi_dose;rep_primary;rep_single_dose,RNA POLYMERASE INHIBITOR,RELA,,,PHASE 3,,Small molecule,Phase 3,DFBIRQPKNDILPW-CIVMWXNOSA-N,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O;CC(C)[C@]12O[C@H]1[C@@H]1O[C@]13[C@]1(O[C@H]1C[C@H]1C4=C(CC[C@@]13C)C(=O)OC4)[C@@H]2O
TRIPTORELIN,TRIPTORELIN,CHEMBL1201334,BRD:BRD-BRD-K62685538-001-01-7;BRD:BRD-K62685538-001-01-7,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR AGONIST,GNRHR,"PROSTATE CANCER, BREAST CANCER, PRECOCIOUS PUBERTY, ENDOMETRIOSIS, MYOMA, GENDER DYSPHORIA",,LAUNCHED,,Protein,Approved,VXKHXGOKWPXYNA-PGBVPBMZSA-N,CC(C)C[C@H](NC(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O;CC(C)C[C@H](NC(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1C[NH]C2CCCCC12)NC(=O)[C@H](CC1C[NH]CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
TRITYLCYSTEINE,TRITYLCYSTEINE,,GDSC1:41,gdsc,,,,,,,,NA,,
TRODUSQUEMINE,TRODUSQUEMINE,CHEMBL2028167;CHEMBL508583,BRD:BRD-K00003124-389-01-9,rep_single_dose,TYROSINE PHOSPHATASE INHIBITOR,,,,,,Small molecule,Phase 1,WUJVPODXELZABP-FWJXURDUSA-N;ZWYIYHKVZSPZJQ-MVZYXQGASA-N,CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O;CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O.CL.CL.CL.CL
TROFOSFAMIDE,TROFOSFAMIDE,CHEMBL462019,BRD:BRD-A91386192-001-07-9,rep_single_dose,DNA ALKYLATING AGENT,,,,,,Small molecule,Phase 3,UMKFEPPTGMDVMI-UHFFFAOYSA-N,O=P1(N(CCCL)CCCL)OCCCN1CCCL
TROGLITAZONE,TROGLITAZONE,CHEMBL408,BRD:BRD-A13084692-001-17-3;BRD:BRD-BRD-A13084692-001-17-3,rep_primary;rep_single_dose,"INSULIN SENSITIZER, PPAR RECEPTOR AGONIST",ACSL4;CYP2C8;ESRRA;ESRRG;PPARG;SERPINE1;SLC29A1;TRPM3,,,WITHDRAWN,"Multiple values for repurposing_target: {'ACSL4;CYP2C8;ESRRA;ESRRG;PPARG;SERPINE1;SLC29A1;TRPM3', 'ACSL4;ESRRA;ESRRG;PPARG;SERPINE1;SLC29A1;TRPM3'}, taking the union",Small molecule,Approved,GXPHKUHSUJUWKP-UHFFFAOYSA-N,CC1C(C)C2C(C(C)C1O)CCC(C)(COC1CCC(CC3SC(=O)NC3=O)CC1)O2;CC1C(C)C2OC(C)(COC3CCC(CC4SC(=O)NC4=O)CC3)CCC2C(C)C1O
TROLEANDOMYCIN,TROLEANDOMYCIN,CHEMBL564085,BRD:BRD-A24297246-001-03-9;BRD:BRD-BRD-A24297246-001-03-9,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,"PNEUMONIA, BRONCHITIS, TONSILLITIS, SINUSITIS",,LAUNCHED,,Small molecule,Approved,LQCLVBQBTUVCEQ-QTFUVMRISA-N,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O;CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
TROLOX,TROLOX,CHEMBL153,BRD:BRD-A17846016-001-13-9;BRD:BRD-BRD-A17846016-001-13-9,rep_multi_dose;rep_primary;rep_single_dose,ANTIOXIDANT,,,,LAUNCHED,,Small molecule,NA,GLEVLJDDWXEYCO-UHFFFAOYSA-N,CC1C(C)C2C(C(C)C1O)CCC(C)(C(=O)O)O2;CC1C(C)C2OC(C)(CCC2C(C)C1O)C(O)=O
TROMARIL,TROMARIL,,BRD:BRD-BRD-K91422571-001-01-8;BRD:BRD-K91422571-001-01-8,rep_primary;rep_single_dose,PROSTANOID RECEPTOR ANTAGONIST,,,,LAUNCHED,,,NA,,OC(=O)C1CCCCC1NCCC1CCCCC1
TROMETAMOL,TROMETAMOL,CHEMBL1200391,BRD:BRD-BRD-K47978074-001-02-4;BRD:BRD-K47978074-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,,AMD1;CANT1;DCN;NEIL1;VEGFA,,,LAUNCHED,,Small molecule,Approved,LENZDBCJOHFCAS-UHFFFAOYSA-N,NC(CO)(CO)CO
"TROPANYL-3,5-DIMETHYLBENZOATE","TROPANYL-3,5-DIMETHYLBENZOATE",,BRD:BRD-A84389633-001-05-7;BRD:BRD-BRD-A84389633-001-05-7,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A;HTR3B,,,PRECLINICAL,,,NA,,CN1C2CCC1CC(C2)OC(=O)C1CC(C)CC(C)C1
TROPESIN,TROPESIN,,BRD:BRD-A34603619-001-01-9;BRD:BRD-BRD-A34603619-001-01-9,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,,,LAUNCHED,,,NA,,COC1CCC2N(C(=O)C3CCC(CL)CC3)C(C)C(CC(=O)OCC(C(O)=O)C3CCCCC3)C2C1
TROPICAMIDE,TROPICAMIDE,CHEMBL1200604,BRD:BRD-A79672927-001-20-7;BRD:BRD-BRD-A79672927-001-20-7,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,"MYDRIASIS DIAGNOSTIC, CYCLOPLEGIA DIAGNOSTIC",,LAUNCHED,,Small molecule,Approved,BGDKAVGWHJFAGW-UHFFFAOYSA-N,CCN(CC1CCNCC1)C(=O)C(CO)C1CCCCC1
TROPIFEXOR,TROPIFEXOR,CHEMBL4298169,BRD:BRD-K00003480-001-01-9,rep_single_dose,FXR AGONIST,,,,,,Small molecule,Phase 2,VYLOOGHLKSNNEK-PIIMJCKOSA-N,O=C(O)C1CC(F)C2NC(N3[C@@H]4CC[C@H]3C[C@@H](OCC3C(-C5CCCCC5OC(F)(F)F)NOC3C3CC3)C4)SC2C1
TROPISETRON,TROPISETRON,CHEMBL56564,BRD:BRD-BRD-K50866992-003-09-5;BRD:BRD-BRD-K50866992-003-10-3;BRD:BRD-K50866992-003-09-5;BRD:BRD-K50866992-003-10-3,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,GLRA1;GLRA2;GLRB;HTR3A;HTR4,"NAUSEA, VOMITING, NAUSEA, VOMITING",,LAUNCHED,,Small molecule,Approved,ZNRGQMMCGHDTEI-ITGUQSILSA-N,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C1C[NH]C3CCCCC13)C2;CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1C[NH]C2CCCCC12
TROSPIUM,TROSPIUM,CHEMBL1888176,BRD:BRD-BRD-K69469734-003-02-5;BRD:BRD-K69469734-003-02-5,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1,"URINARY INCONTINENCE, URINARY FREQUENCY",,LAUNCHED,,Small molecule,Approved,OYYDSUSKLWTMMQ-JKHIJQBDSA-N,O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(C1CCCCC1)C1CCCCC1;OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(C1CCCCC1)C1CCCCC1
TROVAFLOXACIN,TROVAFLOXACIN,CHEMBL428,BRD:BRD-BRD-K00494077-066-01-9;BRD:BRD-K00494077-066-01-9,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL DNA GYRASE INHIBITOR,TOP2A,,,WITHDRAWN,,Small molecule,Approved,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,N[C@@H]1[C@H]2CN(C3NC4C(CC3F)C(=O)C(C(=O)O)CN4-C3CCC(F)CC3F)C[C@@H]12;N[C@H]1[C@@H]2CN(C[C@H]12)C1NC2N(CC(C(O)=O)C(=O)C2CC1F)-C1CCC(F)CC1F
TROVENTOL,TROVENTOL,,BRD:BRD-A35868371-005-01-6;BRD:BRD-BRD-A35868371-005-01-6,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)C1CCCCC1
TROVIRDINE,TROVIRDINE,CHEMBL39999,BRD:BRD-BRD-K00989047-001-01-2;BRD:BRD-K00989047-001-01-2,rep_primary;rep_single_dose,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,,,PHASE 1,,Small molecule,Unknown,HOCFDYZWQYGULA-UHFFFAOYSA-N,BRC1CCC(NC(=S)NCCC2CCCCN2)NC1;S=C(NCCC1CCCCN1)NC1CCC(BR)CN1
TROXERUTIN,TROXERUTIN,CHEMBL3182320,BRD:BRD-BRD-K73529671-001-02-9;BRD:BRD-BRD-K73529671-001-04-5;BRD:BRD-K73529671-001-02-9;BRD:BRD-K73529671-001-04-5,rep_primary;rep_single_dose,ANTIOXIDANT,,,,LAUNCHED,,Small molecule,Phase 3,IYVFNTXFRYQLRP-VVSTWUKXSA-N,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3C(-C4CCC(OCCO)C(OCCO)C4)OC4CC(OCCO)CC(O)C4C3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O;C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3C(OC4CC(OCCO)CC(O)C4C3=O)-C3CCC(OCCO)C(OCCO)C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
TROXIPIDE,TROXIPIDE,CHEMBL1566956,BRD:BRD-A68589262-001-04-3;BRD:BRD-BRD-A68589262-001-04-3,rep_primary;rep_single_dose,GLUCOSAMINE SYNTHETASE STIMULANT,,GASTROESOPHAGEAL REFLUX DISEASE (GERD),,LAUNCHED,,Small molecule,Unknown,YSIITVVESCNIPR-UHFFFAOYSA-N,COC1CC(C(=O)NC2CCCNC2)CC(OC)C1OC;COC1CC(CC(OC)C1OC)C(=O)NC1CCCNC1
TRV130,TRV130,CHEMBL2443262,BRD:BRD-BRD-K35626314-003-01-1;BRD:BRD-K35626314-003-01-1,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRM1,,,PHASE 3,,Small molecule,Approved,DMNOVGJWPASQDL-OAQYLSRUSA-N,COC1CCSC1CNCC[C@]1(CCOC2(CCCC2)C1)C1CCCCN1;COC1CCSC1CNCC[C@@]1(C2CCCCN2)CCOC2(CCCC2)C1
TRYPTANTHRIN,TRYPTANTHRIN,CHEMBL306946,BRD:BRD-BRD-K76973696-001-12-6;BRD:BRD-K76973696-001-12-6,rep_multi_dose;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,IDO1,,,PRECLINICAL,,Small molecule,NA,VQQVWGVXDIPORV-UHFFFAOYSA-N,O=C1C2CCCCC2-N2C1NC1CCCCC1C2=O
TRYPTOPHAN,TRYPTOPHAN,CHEMBL350221;CHEMBL54976,BRD:BRD-BRD-K83776863-001-08-9;BRD:BRD-K83776863-001-08-9,rep_primary;rep_single_dose,SEROTONIN RECEPTOR PARTIAL AGONIST,CASR;IDO1;SLC36A1;WARS;WARS2,"ANXIETY, BLOATING, CONSTIPATION, FATIGUE, SLEEPLESSNESS",,LAUNCHED,,Small molecule,Approved,LDCYZAJDBXYCGN-VIFPVBQESA-N;QIVBCDIJIAJPQS-VIFPVBQESA-N,N[C@@H](CC1C[NH]C2CCC(O)CC12)C(=O)O;N[C@@H](CC1C[NH]C2CCCCC12)C(=O)O;N[C@@H](CC1C[NH]C2CCCCC12)C(O)=O
TS-011,TS-011,,BRD:BRD-K00004685-001-01-9,rep_single_dose,DELAYED VASOSPASM ANTAGONIST,,,,,,,NA,,
TTNPB,TTNPB,,BRD:BRD-BRD-K49685476-001-15-9;BRD:BRD-K49685476-001-15-9,rep_primary;rep_single_dose,RETINOID RECEPTOR AGONIST,RARA;RARB;RARG,,,PHASE 1,,,NA,,C\C(=C/C1CCC(CC1)C(O)=O)C1CCC2C(C1)C(C)(C)CCC2(C)C
TTP-22,TTP-22,,BRD:BRD-BRD-K64852730-001-01-7;BRD:BRD-K64852730-001-01-7,rep_primary;rep_single_dose,CASEIN KINASE INHIBITOR,CSNK2A1,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1CSC2NCNC(SCCC(O)=O)C12
TU-2100,TU-2100,,BRD:BRD-BRD-K44590731-001-01-7;BRD:BRD-K44590731-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 2,,,NA,,CCOC(=O)C1CCCCC1OC(=O)CCCCCCCC(=O)OC1CCCCC1C(=O)OCC
TUAMINOHEPTANE,TUAMINOHEPTANE,CHEMBL123693,BRD:BRD-A19958636-065-04-4;BRD:BRD-BRD-A19958636-065-04-4,rep_primary;rep_single_dose,,,NASAL CONGESTION,,LAUNCHED,,Small molecule,Unknown,VSRBKQFNFZQRBM-UHFFFAOYSA-N,CCCCCC(C)N
TUBASTATIN A,TUBASTATIN A,CHEMBL2018302,CTRP:411749;GDSC1:265,ctrp;gdsc,,,,,,,Small molecule,NA,GOVYBPLHWIEHEJ-UHFFFAOYSA-N,CN1CCC2C(C3CCCCC3N2CC2CCC(C(=O)NO)CC2)C1
TUBASTATIN-A,TUBASTATIN-A,,BRD:BRD-BRD-K00627859-003-03-7;BRD:BRD-K00627859-003-03-7,rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC6,,,PRECLINICAL,,,NA,,CN1CCC2C(C1)C1CCCCC1N2CC1CCC(CC1)C(=O)NO
TUBOCURARINE,TUBOCURARINE,CHEMBL339427,BRD:BRD-BRD-K99621550-300-01-8;BRD:BRD-K99621550-300-01-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,ACHE;CHRNA2;HTR3A;HTR3B;KCNN1;KCNN2;KCNN3;ZACN,ANESTHETIC,,LAUNCHED,,Small molecule,Approved,JFJZZMVDLULRGK-URLMMPGGSA-O,COC1CC2C3CC1OC1CC(CCC1O)C[C@@H]1C4C(CC(OC)C(O)C4OC4CCC(CC4)C[C@@H]3N(C)CC2)CC[N+]1(C)C;COC1CC2CCN(C)[C@H]3CC4CCC(OC5C(O)C(OC)CC6CC[N+](C)(C)[C@H](CC7CCC(O)C(OC1CC23)C7)C56)CC4
TUCIDINOSTAT,TUCIDINOSTAT,CHEMBL3621988,BRD:BRD-K95216408-001-02-9,rep_single_dose,HDAC INHIBITOR,,,,,,Small molecule,Phase 3,SZMJVTADHFNAIS-BJMVGYQFSA-N,NC1CC(F)CCC1NC(=O)C1CCC(CNC(=O)/C=C/C2CCCNC2)CC1
TUFTSIN,TUFTSIN,,BRD:BRD-K00003336-001-01-9,rep_single_dose,MACROPHAGE ACTIVATOR,,,,,,,NA,,
TUG-770,TUG-770,,BRD:BRD-BRD-K56086081-001-01-7;BRD:BRD-K56086081-001-01-7,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,FFAR1,,,PRECLINICAL,,,NA,,OC(=O)CCC1CCC(CC1F)C#CC1CCCCC1CC#N
TUG-891,TUG-891,,BRD:BRD-BRD-K24282351-001-01-4;BRD:BRD-K24282351-001-01-4,rep_primary;rep_single_dose,FREE FATTY ACID RECEPTOR AGONIST,FFAR4,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1CCC(F)CC1COC1CCC(CCC(O)=O)CC1
TULOBUTEROL,TULOBUTEROL,CHEMBL1159717,BRD:BRD-A37441042-003-04-8;BRD:BRD-BRD-A37441042-003-04-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,ASTHMA,,LAUNCHED,,Small molecule,Approved,YREYLAVBNPACJM-UHFFFAOYSA-N,CC(C)(C)NCC(O)C1CCCCC1CL
TULRAMPATOR,TULRAMPATOR,,BRD:BRD-K00005240-001-01-9,rep_single_dose,ANTIDEPRESSANT,,,,,,,NA,,
TW 37,TW 37,,GDSC1:1149,gdsc,,,,,,,,NA,,
TW-37,TW-37,,BRD:BRD-BRD-K28360340-001-08-3;BRD:BRD-K28360340-001-08-3;CTRP:609596;GDSC1:1149,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,BCL INHIBITOR,BCL2;BCL2L1;MCL1,,,PRECLINICAL,,,NA,,CC(C)C1CCCCC1CC1CC(C(=O)NC2CCC(CC2)S(=O)(=O)C2CCCCC2C(C)(C)C)C(O)C(O)C1O
TW37,TW37,,GDSC1:1149,gdsc,,,,,,,,NA,,
TWS-119,TWS-119,,BRD:BRD-BRD-K94176593-001-09-4;BRD:BRD-K94176593-001-09-4,rep_multi_dose;rep_primary;rep_single_dose,GLYCOGEN SYNTHASE KINASE INHIBITOR,GSK3B;JUN;MYC,,,PRECLINICAL,,,NA,,NC1CCCC(C1)-C1CC2C(OC3CCCC(O)C3)NCNC2[NH]1
TWS119,TWS119,,GDSC1:366,gdsc,,,,,,,,NA,,
TXA127,TXA127,CHEMBL3545347,BRD:BRD-BRD-K36040345-001-01-1;BRD:BRD-K36040345-001-01-1,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR AGONIST,,,,PHASE 2,,Protein,Phase 2,PVHLMTREZMEJCG-GDTLVBQBSA-N,CC[C@H](C)[C@H](NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](CC1CNC[NH]1)C(=O)N1CCC[C@H]1C(=O)O;CC[C@H](C)[C@H](NC(=O)[C@H](CC1CCC(O)CC1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1C[NH]CN1)C(=O)N1CCC[C@H]1C(O)=O
TY-52156,TY-52156,,BRD:BRD-K66584608-001-03-9,rep_single_dose,SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONIST,S1PR3,,,,,,NA,,
TYKERB,TYKERB,CHEMBL1201179,GDSC1:119;GDSC2:1558,gdsc,,,,,,,Small molecule,Approved,XNRVGTHNYCNCFF-UHFFFAOYSA-N,CS(=O)(=O)CCNCC1CCC(-C2CCC3NCNC(NC4CCC(OCC5CCCC(F)C5)C(CL)C4)C3C2)O1.CC1CCC(S(=O)(=O)O)CC1.CC1CCC(S(=O)(=O)O)CC1.O
TYLOSIN,TYLOSIN,CHEMBL42743,BRD:BRD-BRD-K37753391-046-03-2;BRD:BRD-K37753391-046-03-2,rep_primary;rep_single_dose,PROTEIN SYNTHESIS INHIBITOR,,"GRAM-POSITIVE BACTERIAL INFECTIONS, COLITIS",,LAUNCHED,,Small molecule,Unknown,WBPYTXDJUQJLPQ-VMXQISHHSA-N,CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC;CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
TYLOXAPOL,TYLOXAPOL,CHEMBL1201548,BRD:BRD-BRD-U25960968-000-01-9;BRD:BRD-BRD-U48018661-000-01-9;BRD:BRD-U25960968-000-01-9;BRD:BRD-U48018661-000-01-9,rep_multi_dose;rep_primary;rep_single_dose,NFKB PATHWAY INHIBITOR,LPL;NFKB2,,,LAUNCHED,"Multiple values for structure_id: {'U48018661', 'U25960968'}, defaulting to None",Unknown,Approved,,C=O.C1CO1.CC(C)(C)CC(C)(C)C1CCC(O)CC1
TYLVALOSIN,TYLVALOSIN,CHEMBL2103834,BRD:BRD-K00079560-001-02-9,rep_single_dose,,,,,,,Small molecule,Unknown,KCJJINQANFZSAM-HZDSEHBESA-N,CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
TYRPHOSTIN-A9,TYRPHOSTIN-A9,,BRD:BRD-BRD-K40255344-001-17-6;BRD:BRD-K40255344-001-17-6,rep_multi_dose;rep_primary;rep_single_dose,"PROTEIN TYROSINE KINASE INHIBITOR, TYROSINE KINASE INHIBITOR",,,,PRECLINICAL,,,NA,,CC(C)(C)C1CC(C=C(C#N)C#N)CC(C1O)C(C)(C)C
TYRPHOSTIN-AG-1296,TYRPHOSTIN-AG-1296,,BRD:BRD-BRD-K76064317-001-07-3;BRD:BRD-K76064317-001-07-3,rep_multi_dose;rep_primary;rep_single_dose,FLT3 INHIBITOR,FLT3,,,PRECLINICAL,,,NA,,COC1CC2NCC(NC2CC1OC)-C1CCCCC1
TYRPHOSTIN-AG-1478,TYRPHOSTIN-AG-1478,,BRD:BRD-BRD-K68336408-001-10-9;BRD:BRD-K68336408-001-10-9,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;MAPK14,,,PRECLINICAL,,,NA,,COC1CC2NCNC(NC3CCCC(CL)C3)C2CC1OC
TYRPHOSTIN-AG-18,TYRPHOSTIN-AG-18,,BRD:BRD-BRD-K49657628-001-14-8;BRD:BRD-K49657628-001-14-8,rep_primary;rep_single_dose,"EGFR INHIBITOR, TYROSINE KINASE INHIBITOR",EGFR,,,PRECLINICAL,,,NA,,OC1CCC(C=C(C#N)C#N)CC1O
TYRPHOSTIN-AG-494,TYRPHOSTIN-AG-494,,BRD:BRD-BRD-K34533029-001-08-5;BRD:BRD-K34533029-001-08-5,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,OC1CCC(CC1O)\C=C(/C#N)C(=O)NC1CCCCC1
TYRPHOSTIN-AG-825,TYRPHOSTIN-AG-825,,BRD:BRD-K87919739-001-08-9,rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,ERBB2,,,,,,NA,,
TYRPHOSTIN-AG-835,TYRPHOSTIN-AG-835,,BRD:BRD-BRD-K17415526-001-03-5;BRD:BRD-K17415526-001-03-5,rep_primary;rep_single_dose,PROTEIN TYROSINE KINASE INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,C[C@H](NC(=O)C(=C\C1CCC(O)C(O)C1)\C#N)C1CCCCC1
TYRPHOSTIN-AG-879,TYRPHOSTIN-AG-879,,BRD:BRD-BRD-K59469039-001-08-0;BRD:BRD-K59469039-001-08-0,rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,ERBB2;KDR;NTRK1,,,PRECLINICAL,,,NA,,CC(C)(C)C1CC(CC(C1O)C(C)(C)C)\C=C(/C#N)C(N)=S
TYRPHOSTIN-AG-99,TYRPHOSTIN-AG-99,,BRD:BRD-BRD-K60184833-001-05-6;BRD:BRD-K60184833-001-05-6,rep_multi_dose;rep_primary;rep_single_dose,TYROSINE KINASE INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,NC(=O)C(=C\C1CCC(O)C(O)C1)\C#N
TYVERB,TYVERB,CHEMBL554,GDSC1:119;GDSC2:1558,gdsc,,,,,,,Small molecule,Approved,BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCC1CCC(-C2CCC3NCNC(NC4CCC(OCC5CCCC(F)C5)C(CL)C4)C3C2)O1
U-0124,U-0124,,BRD:BRD-BRD-K63169195-001-01-5;BRD:BRD-K63169195-001-01-5,rep_primary;rep_single_dose,MEK INHIBITOR,,,,PRECLINICAL,,,NA,,CS\C(N)=C(C#N)\C(C#N)=C(/N)SC
U-0126,U-0126,CHEMBL100473,BRD:BRD-BRD-K18787491-001-08-6;BRD:BRD-BRD-K91701654-001-03-1;BRD:BRD-K18787491-001-08-6;BRD:BRD-K91701654-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,MEK INHIBITOR,AKT1;CHEK1;GSK3B;LCK;MAP2K1;MAP2K2;MAP2K7;MAPK1;MAPK11;MAPK12;MAPK14;MAPK8;PRKCA;RAF1;ROCK1;RPS6KB1;SGK1,,,PRECLINICAL,"Multiple values for structure_id: {'K91701654', 'K18787491'}, defaulting to None",Small molecule,NA,DVEXZJFMOKTQEZ-MJZABRMRSA-N,N\C(SC1CCCCC1N)=C(C#N)/C(C#N)=C(/N)SC1CCCCC1N;N\C(SC1CCCCC1N)=C(C#N)/C(C#N)=C(\N)SC1CCCCC1N;N#CC(=C(/N)SC1CCCCC1N)/C(C#N)=C(/N)SC1CCCCC1N
U-0521,U-0521,,BRD:BRD-BRD-K08953028-001-09-6;BRD:BRD-K08953028-001-09-6,rep_primary;rep_single_dose,CATECHOL O METHYLTRANSFERASE INHIBITOR,COMT,,,PRECLINICAL,,,NA,,CC(C)C(=O)C1CCC(O)C(O)C1
U-104,U-104,CHEMBL1615281,BRD:BRD-BRD-K77867004-001-02-7;BRD:BRD-K77867004-001-02-7,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,CA1;CA12;CA2;CA9,,,PRECLINICAL,,Small molecule,Phase 1,YJQZNWPYLCNRLP-UHFFFAOYSA-N,NS(=O)(=O)C1CCC(NC(=O)NC2CCC(F)CC2)CC1
U-18666A,U-18666A,,BRD:BRD-BRD-K22025381-003-01-9;BRD:BRD-K22025381-003-01-9,rep_multi_dose;rep_primary;rep_single_dose,OXIDOSQUALENE CYCLASE INHIBITOR,,,,PRECLINICAL,,,NA,,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1
U-19920,U-19920,CHEMBL803,GDSC1:1006;GDSC2:1006,gdsc,,,,,,,Small molecule,Approved,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,NC1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C(=O)N1
U-50488-(-),U-50488-(-),,BRD:BRD-BRD-K53532120-003-09-5;BRD:BRD-BRD-K53532120-003-11-1;BRD:BRD-K53532120-003-09-5;BRD:BRD-K53532120-003-11-1,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1,,,PRECLINICAL,,,NA,,CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)CC1CCC(CL)C(CL)C1
U-54494A,U-54494A,,BRD:BRD-BRD-K20995441-001-02-5;BRD:BRD-K20995441-001-02-5,rep_primary;rep_single_dose,OPIOID RECEPTOR AGONIST,OPRK1,,,PRECLINICAL,,,NA,,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)C1CCC(CL)C(CL)C1
U-75799E,U-75799E,,BRD:BRD-BRD-K77070363-001-01-5;BRD:BRD-K77070363-001-01-5,rep_primary;rep_single_dose,GROWTH HORMONE RELEASING FACTOR AGONIST,GHSR,,,PHASE 1,,,NA,,C[C@H](NC(=O)[C@@H](CC1C[NH]C2CCCCC12)NC(=O)[C@@H](N)CC1CNC[NH]1)C(=O)N[C@@H](CC1C[NH]C2CCCCC12)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@@H](CCCCN)C(N)=O
U-99194,U-99194,,BRD:BRD-BRD-K70281171-050-08-9;BRD:BRD-K70281171-050-08-9,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD3,,,PRECLINICAL,,,NA,,CCCN(CCC)C1CC2CC(OC)C(OC)CC2C1
UAMC-00039,UAMC-00039,,BRD:BRD-K38966689-300-02-9,rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4;DPP7,,,,,,NA,,
UB-165,UB-165,,BRD:BRD-A14574269-051-02-2;BRD:BRD-BRD-A14574269-051-02-2,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA3;CHRNA4;CHRNB2,,,PRECLINICAL,,,NA,,CLC1CCC(CN1)C1=CCCC2CCC1N2
UBENIMEX,UBENIMEX,CHEMBL29292,BRD:BRD-BRD-K59574735-001-11-8;BRD:BRD-K59574735-001-11-8,rep_multi_dose;rep_primary;rep_single_dose,LEUKOTRIENE SYNTHESIS INHIBITOR,LTA4H;RNPEP,ACUTE MYELOID LEUKEMIA (AML),,LAUNCHED,,Small molecule,Phase 2,VGGGPCQERPFHOB-RDBSUJKOSA-N,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1CCCCC1)C(=O)O;CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1CCCCC1)C(O)=O
UBP-296,UBP-296,,BRD:BRD-A45499626-001-04-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIK1,,,,,,NA,,
UBP-302,UBP-302,,BRD:BRD-BRD-K79753741-001-01-7;BRD:BRD-K79753741-001-01-7,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIK1,,,PRECLINICAL,,,NA,,N[C@@H](CN1CCC(=O)N(CC2CCCCC2C(O)=O)C1=O)C(O)=O
UBP-310,UBP-310,,BRD:BRD-K09597601-001-02-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRIK1;GRIK5,,,,,,NA,,
UBROGEPANT,UBROGEPANT,CHEMBL2364638,BRD:BRD-K00090624-001-01-9,rep_single_dose,,,,,,,Small molecule,Approved,DDOOFTLHJSMHLN-ZQHRPCGSSA-N,C[C@@H]1[C@H](C2CCCCC2)C[C@H](NC(=O)C2CNC3C(C2)C[C@@]2(C3)C(=O)NC3NCCCC32)C(=O)N1CC(F)(F)F
UC-112,UC-112,,BRD:BRD-K73610817-001-10-9,rep_single_dose,XIAP INHIBITOR,XIAP,,,,,,NA,,
UCL-2077,UCL-2077,,BRD:BRD-BRD-K50325075-001-02-1;BRD:BRD-K50325075-001-02-1,rep_primary;rep_single_dose,SLOW AFTERHYPERPOLARIZATION CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,C(NC(C1CCCCC1)(C1CCCCC1)C1CCCCC1)C1CCCNC1
UDENAFIL,UDENAFIL,CHEMBL2103849,BRD:BRD-K00003266-001-01-9,rep_single_dose,PHOSPHODIESTERASE INHIBITOR,,,,,,Small molecule,Phase 3,IYFNEFQTYQPVOC-UHFFFAOYSA-N,CCCOC1CCC(S(=O)(=O)NCCC2CCCN2C)CC1-C1NC2C(CCC)NN(C)C2C(=O)[NH]1
UF-010,UF-010,,BRD:BRD-K20480395-001-02-9,rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC2;HDAC3;HDAC8,,,,,,NA,,
UFENAMATE,UFENAMATE,CHEMBL2105605,BRD:BRD-BRD-K84173274-001-01-6;BRD:BRD-K84173274-001-01-6,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,PTGS1;PTGS2,"ECZEMA, DERMATITIS",,LAUNCHED,,Small molecule,Unknown,JDLSRXWHEBFHNC-UHFFFAOYSA-N,CCCCOC(=O)C1CCCCC1NC1CCCC(C(F)(F)F)C1;CCCCOC(=O)C1CCCCC1NC1CCCC(C1)C(F)(F)F
UH-232-(+),UH-232-(+),,BRD:BRD-BRD-K66715657-050-01-0;BRD:BRD-K66715657-050-01-0,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,DRD2;DRD3;DRD4;HTR1A,,,PRECLINICAL,,,NA,,CCCN(CCC)[C@@H]1CCC2C(OC)CCCC2[C@@H]1C
UK-356618,UK-356618,,BRD:BRD-K57011718-001-01-5,rep_single_dose,METALLOPROTEINASE INHIBITOR,MMP13;MMP14;MMP2;MMP3;MMP9,,,,,,NA,,
UK-383367,UK-383367,,BRD:BRD-BRD-K06294530-001-01-5;BRD:BRD-K06294530-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,"PROCOLLAGEN C-ENDOPEPTIDASE INHIBITOR, PROCOLLAGEN C-ENDOPEPTIDASE INHIBITORS",BMP1,,,PHASE 1,"Multiple values for MOA: {'PROCOLLAGEN C-ENDOPEPTIDASE INHIBITORS', 'PROCOLLAGEN C-ENDOPEPTIDASE INHIBITOR, PROCOLLAGEN C-ENDOPEPTIDASE INHIBITORS'}, defaulting to 'PROCOLLAGEN C-ENDOPEPTIDASE INHIBITOR, PROCOLLAGEN C-ENDOPEPTIDASE INHIBITORS'",,NA,,NC(=O)C1NOC(N1)[C@H](CCCC1CCCCC1)CC(=O)NO
UK-5099,UK-5099,,BRD:BRD-K19558579-001-02-9,rep_single_dose,MONOCARBOXYLATE TRANSPORTER INHIBITOR,SLC16A1,,,,,,NA,,
UKI-1,UKI-1,,BRD:BRD-K00003367-001-01-9,rep_single_dose,UROKINASE INHIBITOR,,,,,,,NA,,
ULIFLOXACIN,ULIFLOXACIN,CHEMBL345937,BRD:BRD-A61633223-001-02-8;BRD:BRD-BRD-A61633223-001-02-8,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Unknown,SUXQDLLXIBLQHW-UHFFFAOYSA-N,CC1SC2C(C(=O)O)C(=O)C3CC(F)C(N4CCNCC4)CC3N21;CC1SC2C(C(O)=O)C(=O)C3CC(F)C(CC3N12)N1CCNCC1
ULIPRISTAL,ULIPRISTAL,CHEMBL2103846,BRD:BRD-BRD-K64381438-001-03-8;BRD:BRD-K64381438-001-03-8,rep_multi_dose;rep_primary;rep_single_dose,PROGESTERONE RECEPTOR ANTAGONIST,PGR,CONTRACEPTIVE,,LAUNCHED,,Small molecule,Approved,HKDLNTKNLJPAIY-WKWWZUSTSA-N,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](C3CCC(N(C)C)CC3)C[C@@]21C;CN(C)C1CCC(CC1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12
ULIXERTINIB,ULIXERTINIB,CHEMBL3590106,GDSC2:1908;GDSC2:2047,gdsc,,,,,,,Small molecule,Phase 2,KSERXGMCDHOLSS-LJQANCHMSA-N,CC(C)NC1CC(-C2C[NH]C(C(=O)N[C@H](CO)C3CCCC(CL)C3)C2)C(CL)CN1
UMECLIDINIUM,UMECLIDINIUM,CHEMBL1187833,BRD:BRD-BRD-K46692793-004-01-8;BRD:BRD-K46692793-004-01-8,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3,"CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BRONCHITIS, EMPHYSEMA",,LAUNCHED,,Small molecule,Approved,FVTWTVQXNAJTQP-UHFFFAOYSA-N,OC(C1CCCCC1)(C1CCCCC1)C12CC[N+](CCOCC3CCCCC3)(CC1)CC2
UMI 77,UMI 77,,GDSC2:1939,gdsc,,,,,,,,NA,,
UMI-77,UMI-77,,GDSC2:1939,gdsc,,,,,,,,NA,,
UNBS-5162,UNBS-5162,,BRD:BRD-BRD-K30933884-001-01-0;BRD:BRD-K30933884-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,CN(C)CCN1C(=O)C2CCCC3CC(NC(N)=O)CC(C1=O)C23
UNC 0683,UNC 0683,,GDSC1:1236;GDSC1:245,gdsc,,,,,,,,NA,,
UNC-0638,UNC-0638,,GDSC1:1236;GDSC1:245,gdsc,,,,,,,,NA,,
UNC-1215,UNC-1215,,GDSC1:1262,gdsc,,,,,,,,NA,,
UNC2327,UNC-2327;UNC2327,,BRD:BRD-BRD-K60635008-001-01-5;BRD:BRD-K60635008-001-01-5,rep_primary;rep_single_dose,PROTEIN ARGININE N-METHYLTRANSFERASE INHIBITOR,PRMT3,,,PRECLINICAL,,,NA,,O=C(NCC(=O)N1CCCCC1)NC1CCC2NNSC2C1
UNC3230,UNC-3230;UNC3230,,BRD:BRD-BRD-K46344388-001-01-3;BRD:BRD-K46344388-001-01-3,rep_primary;rep_single_dose,PHOSPHATIDYL-INOSITOL ACTIVATOR,PIP5K1C,,,PRECLINICAL,,,NA,,NC(=O)C1NC(NC2CCCCC2)SC1NC(=O)C1CCCCC1
UNC926,UNC-926;UNC926,,BRD:BRD-BRD-K22229656-003-01-5;BRD:BRD-K22229656-003-01-5,rep_primary;rep_single_dose,MBT INHIBITOR,L3MBTL1,,,PRECLINICAL,,,NA,,BRC1CCCC(C1)C(=O)N1CCC(CC1)N1CCCC1
UNC0224,UNC0224,,BRD:BRD-BRD-K77428767-001-01-7;BRD:BRD-K77428767-001-01-7,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT1;EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCN(C)CC3)NC(NC2CC1OCCCN(C)C)N1CCCN(C)CC1
UNC0321,UNC0321,,BRD:BRD-BRD-K74236984-001-04-8;BRD:BRD-K74236984-001-04-8;CTRP:635576,ctrp;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCN(C)CC3)NC(NC2CC1OCCOCCN(C)C)N1CCCN(C)CC1
UNC0631,UNC0631,,BRD:BRD-BRD-K13060017-001-02-1;BRD:BRD-K13060017-001-01-3;BRD:BRD-K13060017-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCN(CC4CCCCC4)CC3)NC(NC2CC1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C
UNC0638,UNC0638,,BRD:BRD-BRD-K86856088-001-06-9;BRD:BRD-K86856088-001-06-9;CTRP:594665;GDSC1:1236;GDSC1:245,ctrp;gdsc;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT1;EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCN(CC3)C(C)C)NC(NC2CC1OCCCN1CCCC1)C1CCCCC1
UNC0638:NAVITOCLAX (1:1 MOL/MOL),UNC0638:NAVITOCLAX (1:1 MOL/MOL),,CTRP:660270,ctrp,,,,,,,,NA,,
UNC0642,UNC0642,,BRD:BRD-BRD-K60130390-001-02-1;BRD:BRD-K60130390-001-02-1;GDSC1:1263,gdsc;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT1;EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCN(CC3)C(C)C)NC(NC2CC1OCCCN1CCCC1)N1CCC(F)(F)CC1
UNC0646,UNC0646,,BRD:BRD-BRD-K87465484-001-02-7;BRD:BRD-K87465484-001-02-7,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCN(CC3)C3CCCCC3)NC(NC2CC1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C
UNC0737,UNC0737,,BRD:BRD-BRD-K02988401-001-01-2;BRD:BRD-K02988401-001-01-2,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EHMT1;EHMT2,,,PRECLINICAL,,,NA,,COC1CC2C(NC(NC2CC1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C
UNC1215,UNC1215,,BRD:BRD-BRD-K83189926-001-03-1;BRD:BRD-K83189926-001-03-1;GDSC1:1262,gdsc;rep_primary;rep_single_dose,L3MBTL ANTAGONIST,L3MBTL3,,,PRECLINICAL,,,NA,,O=C(N1CCC(CC1)N1CCCC1)C1CCC(C(=O)N2CCC(CC2)N2CCCC2)C(NC2CCCCC2)C1
UNC1999,UNC1999,,BRD:BRD-BRD-K26989966-001-03-5;BRD:BRD-K26989966-001-03-5;BRD:BRD-K26989966-001-07-9,oncref_1;rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,EZH2,,,PRECLINICAL,"Multiple values for MOA: {'INHIBITOR OF EZH2', 'HISTONE LYSINE METHYLTRANSFERASE INHIBITOR'}, defaulting to 'HISTONE LYSINE METHYLTRANSFERASE INHIBITOR'",,NA,,CCCC1CC(C)[NH]C(=O)C1CNC(=O)C1CC(CC2N(NCC12)C(C)C)-C1CCC(NC1)N1CCN(CC1)C(C)C
UNC2025,UNC2025,,BRD:BRD-BRD-K91283740-003-01-6;BRD:BRD-K91283740-003-01-6,rep_primary;rep_single_dose,"MER TYROSINE KINASE INHIBITOR, FLT3 INHIBITOR",FLT3;MERTK,,,PRECLINICAL,"Multiple values for MOA: {'FLT3 INHIBITOR, MER TYROSINE KINASE INHIBITOR', 'MER TYROSINE KINASE INHIBITOR, FLT3 INHIBITOR'}, defaulting to 'MER TYROSINE KINASE INHIBITOR, FLT3 INHIBITOR'",,NA,,CCCCNC1NCC2C(CN([C@H]3CC[C@H](O)CC3)C2N1)-C1CCC(CN2CCN(C)CC2)CC1
UNC2250,UNC2250,,BRD:BRD-BRD-K01773560-001-02-4;BRD:BRD-K01773560-001-02-4,rep_multi_dose;rep_primary;rep_single_dose,MER TYROSINE KINASE INHIBITOR,MERTK,,,PRECLINICAL,,,NA,,CCCCNC1NCC(-C2CCC(CN3CCOCC3)CN2)C(N[C@H]2CC[C@H](O)CC2)N1
UNC669,UNC669,,BRD:BRD-BRD-K21906513-001-04-0;BRD:BRD-K21906513-001-04-0,rep_primary;rep_single_dose,L3MBTL ANTAGONIST,L3MBTL1,,,PRECLINICAL,,,NA,,BRC1CNCC(C1)C(=O)N1CCC(CC1)N1CCCC1
UNDECYLENIC-ACID,UNDECYLENIC-ACID,,BRD:BRD-K19189338-001-03-2,rep_single_dose,OTHER ANTIFUNGAL,,,,,,,NA,,
UPADACITINIB,UPADACITINIB,CHEMBL3622821,BRD:BRD-K00003286-001-01-9,rep_single_dose,JAK INHIBITOR,,,,,,Small molecule,Approved,WYQFJHHDOKWSHR-MNOVXSKESA-N,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1CNC2CNC3[NH]CCC3N12
UPAMOSTAT,UPAMOSTAT,CHEMBL4206119,BRD:BRD-K00003218-001-01-9,rep_single_dose,SERINE PROTEASE INHIBITOR,,,,,,Small molecule,Phase 2,HUASEDVYRABWCV-NDEPHWFRSA-N,CCOC(=O)N1CCN(C(=O)[C@H](CC2CCCC(/C(N)=N\O)C2)NS(=O)(=O)C2C(C(C)C)CC(C(C)C)CC2C(C)C)CC1
UPF-1069,UPF-1069,,BRD:BRD-BRD-K77950083-001-03-3;BRD:BRD-K77950083-001-03-3,rep_primary;rep_single_dose,PARP INHIBITOR,PARP2,,,PRECLINICAL,,,NA,,O=C(COC1CCCC2C1CC[NH]C2=O)C1CCCCC1
UPRIFOSBUVIR,UPRIFOSBUVIR,CHEMBL3833371,BRD:BRD-K00003526-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 2,SFPFZQKYPOWCSI-KHFYHRBSSA-N,CC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](N2CCC(=O)[NH]C2=O)[C@](C)(CL)[C@@H]1O)OC1CCCCC1
UPROSERTIB,UPROSERTIB,CHEMBL3137336,BRD:BRD-BRD-K38332599-001-01-3;BRD:BRD-K38332599-001-01-3;GDSC2:1553;GDSC2:2106,gdsc;rep_multi_dose;rep_primary;rep_single_dose,AKT INHIBITOR,AKT1;AKT2;AKT3,,,PHASE 2,,Small molecule,Phase 2,AXTAPYRUEKNRBA-JTQLQIEISA-N,CN1NCC(CL)C1-C1CC(C(=O)N[C@H](CN)CC2CCC(F)C(F)C2)OC1CL;CN1NCC(CL)C1-C1CC(OC1CL)C(=O)N[C@H](CN)CC1CCC(F)C(F)C1
URACIL,URACIL,CHEMBL566,BRD:BRD-BRD-K80129304-001-08-1;BRD:BRD-K80129304-001-08-1,rep_multi_dose;rep_primary;rep_single_dose,,DPYD;UCKL1,,,LAUNCHED,,Small molecule,Phase 3,ISAKRJDGNUQOIC-UHFFFAOYSA-N,O=C1CC[NH]C(=O)[NH]1;OC1CCNC(O)N1
URAPIDIL,URAPIDIL,CHEMBL279229,BRD:BRD-BRD-K73196317-003-14-8;BRD:BRD-K73196317-003-14-8,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,HTR1A,HYPERTENSION,,LAUNCHED,,Small molecule,Phase 3,ICMGLRUYEQNHPF-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CCCNC2CC(=O)N(C)C(=O)N2C)CC1
URB597,URB597,CHEMBL184238,BRD:BRD-BRD-K92169341-001-11-2;BRD:BRD-K92169341-001-11-2,rep_primary;rep_single_dose,FAAH INHIBITOR,FAAH;FAAH2;TRPA1,,,PHASE 1,,Small molecule,Phase 1,ROFVXGGUISEHAM-UHFFFAOYSA-N,NC(=O)C1CCCC(-C2CCCC(OC(=O)NC3CCCCC3)C2)C1;NC(=O)C1CCCC(C1)-C1CCCC(OC(=O)NC2CCCCC2)C1
UREA,UREA,CHEMBL1908316;CHEMBL2096635;CHEMBL2096648;CHEMBL985,BRD:BRD-BRD-K88052444-001-08-8;BRD:BRD-K88052444-001-08-8,rep_primary;rep_single_dose,HYDROXY RADICAL FORMATION STIMULANT,ARG1;CA2;CTNNB1,"PSORIASIS, XEROSIS CUTIS, ICHTHYOSIS VULGARIS, ECZEMA, KERATOSIS, DERMATITIS",,LAUNCHED,,Small molecule,Approved,QCUPYFTWJOZAOB-HYXAFXHYSA-N;XSQUKJJJFZCRTK-NJFSPNSNSA-N;XSQUKJJJFZCRTK-OUBTZVSYSA-N;XSQUKJJJFZCRTK-UHFFFAOYSA-N,C/C=C(/CC)C(=O)NC(N)=O;N[13C](N)=O;N[14C](N)=O;NC(N)=O
URETHANE,URETHANE,CHEMBL462547,BRD:BRD-BRD-K24297741-001-05-2;BRD:BRD-K24297741-001-05-2,rep_primary;rep_single_dose,LOCAL ANESTHETIC,,,,PRECLINICAL,,Small molecule,Approved,JOYRKODLDBILNP-UHFFFAOYSA-N,CCOC(N)=O
URIC-ACID,URIC-ACID,,BRD:BRD-BRD-K01295354-001-02-8;BRD:BRD-K01295354-001-02-8,rep_multi_dose;rep_primary;rep_single_dose,,PYGL,,,PHASE 3,,,NA,,O=C1[NH]C2[NH]C(=O)[NH]C(=O)C2[NH]1
URIDINE,URIDINE,CHEMBL100259,BRD:BRD-BRD-K13050303-001-17-3;BRD:BRD-BRD-K13050303-001-18-1;BRD:BRD-K13050303-001-17-3;BRD:BRD-K13050303-001-18-1,rep_multi_dose;rep_primary;rep_single_dose,DOPAMINE RECEPTOR AGONIST,LSM6;TYMP,,,PHASE 2,,Small molecule,Phase 3,DRTQHJPVMGBUCF-XVFCMESISA-N,O=C1CCN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(=O)[NH]1;OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(=O)[NH]C1=O
URIDINE-TRIACETATE,URIDINE-TRIACETATE,,BRD:BRD-BRD-K18323388-001-01-1;BRD:BRD-K18323388-001-01-1,rep_primary;rep_single_dose,,,OROTIC ACIDURIA,,LAUNCHED,,,NA,,CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1CCC(=O)[NH]C1=O
URMC-099,URMC-099,,BRD:BRD-K66908976-001-01-8,rep_single_dose,MIXED LINEAGE KINASE INHIBITOR,CDKL2;DAPK3;FLT3;LRRK2;MAP3K10;MAP3K11;MAP3K2;MAP3K9;SRPK2,,,,,,NA,,
UROLITHIN-A,UROLITHIN-A,,BRD:BRD-K00003383-001-01-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
URSODEOXYCHOLYLTAURINE,URSODEOXYCHOLYLTAURINE,CHEMBL272427,BRD:BRD-BRD-K45245728-335-01-4;BRD:BRD-K45245728-335-01-4,rep_primary;rep_single_dose,CHOLESTEROL INHIBITOR,,,,PHASE 2,,Small molecule,Approved,BHTRKEVKTKCXOH-LBSADWJPSA-N,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C;C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
URSODIOL,URSODIOL,CHEMBL1551,BRD:BRD-BRD-K15697815-001-16-2;BRD:BRD-K15697815-001-16-2,rep_primary;rep_single_dose,"LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED",AKR1C2;NR1H4,GALLSTONES,,LAUNCHED,"Multiple values for MOA: {'NUCLEAR FACTOR ERYTHROID DERIVED, LIKE (NRF2) ACTIVATOR', 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'}, defaulting to 'LIKE (NRF2) ACTIVATOR, NUCLEAR FACTOR ERYTHROID DERIVED'
Multiple values for repurposing_target: {'AKR1C2;NR1H4', 'NR1H4'}, taking the union",Small molecule,Approved,RUDATBOHQWOJDD-UZVSRGJWSA-N,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C;C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
URSOLIC-ACID,URSOLIC-ACID,,BRD:BRD-BRD-K68185022-001-14-8;BRD:BRD-K68185022-001-14-8,rep_primary;rep_single_dose,"ATPASE INHIBITOR, NFKB PATHWAY INHIBITOR, STAT INHIBITOR",HSD11B1;PLA2G1B;PTPN1;PYGM,,,PHASE 1,,,NA,,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O
USL311,USL311,CHEMBL4297449,BRD:BRD-K00091126-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,XNUNVQKARNSSEO-UHFFFAOYSA-N,CC(C)N1CCC(N2CCCN(C3CCCC(C(=O)NC4CCNCC4)N3)CC2)CC1
USNIACIN-(+),USNIACIN-(+),,BRD:BRD-A12417644-001-07-6;BRD:BRD-BRD-A12417644-001-07-6,rep_multi_dose;rep_primary;rep_single_dose,MAP KINASE ACTIVATOR,PTPN1,,,PRECLINICAL,,,NA,,CC(=O)C1C(=O)C=C2OC3C(C(O)C(C)C(O)C3C(C)=O)[C@@]2(C)C1=O
V-51,V-51,,BRD:BRD-BRD-K75052463-001-01-4;BRD:BRD-K75052463-001-01-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,PHASE 1,,,NA,,COC1CC(CN2CCN(CC2)C2CCC(F)CC2)CC(OC)C1OC
VABORBACTAM,VABORBACTAM,CHEMBL3317857,BRD:BRD-K00003306-001-01-9,rep_single_dose,BETA LACTAMASE INHIBITOR,,,,,,Small molecule,Approved,IOOWNWLVCOUUEX-WPRPVWTQSA-N,O=C(O)C[C@@H]1CC[C@H](NC(=O)CC2CCCS2)B(O)O1
VADADUSTAT,VADADUSTAT,CHEMBL3646221,BRD:BRD-K00003407-001-01-9,rep_single_dose,HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR,,,,,,Small molecule,Phase 3,JGRXMPYUTJLTKT-UHFFFAOYSA-N,O=C(O)CNC(=O)C1NCC(-C2CCCC(CL)C2)CC1O
VAF-347,VAF-347,,CTRP:659226,ctrp,,,,,,,,NA,,
VAL,VAL,,BRD:BRD-BRD-K59424860-001-01-4,rep_primary,,BCAT1;PCCB;VARS,,,PHASE 2,,,NA,,CC(C)[C@@H](N)C(O)=O
VAL-TYR,VAL-TYR,,BRD:BRD-K00004630-001-01-9,rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,,,,,,,NA,,
VALACICLOVIR,VALACICLOVIR,CHEMBL1349,BRD:BRD-BRD-K46435977-003-11-1;BRD:BRD-K46435977-003-11-1,rep_primary;rep_single_dose,DNA POLYMERASE INHIBITOR,,"SHINGLES, VIRUS HERPES SIMPLEX (HSV)",,LAUNCHED,,Small molecule,Approved,HDOVUKNUBWVHOX-QMMMGPOBSA-N,CC(C)[C@H](N)C(=O)OCCOCN1CNC2C(=O)NC(N)[NH]C21;CC(C)[C@H](N)C(=O)OCCOCN1CNC2C1NC(N)[NH]C2=O
VALBENAZINE,VALBENAZINE,CHEMBL2364639,BRD:BRD-K00003233-001-01-9,rep_single_dose,VESICULAR MONOAMINE TRANSPORTER INHIBITOR,,,,,,Small molecule,Approved,GEJDGVNQKABXKG-CFKGEZKQSA-N,COC1CC2C(CC1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
VALDECOXIB,VALDECOXIB,CHEMBL865,BRD:BRD-BRD-K12994359-001-18-4;BRD:BRD-K12994359-001-18-4;CTRP:32372,ctrp;rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,CA12;PTGS2,,,WITHDRAWN,,Small molecule,Approved,LNPDTQAFDNKSHK-UHFFFAOYSA-N,CC1ONC(-C2CCCCC2)C1-C1CCC(S(N)(=O)=O)CC1;CC1ONC(C1-C1CCC(CC1)S(N)(=O)=O)-C1CCCCC1
VALETHAMATE,VALETHAMATE,CHEMBL2111176,BRD:BRD-A56613951-004-01-1;BRD:BRD-BRD-A56613951-004-01-1,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM1;CHRM4;CHRM5,LABOR INDUCTION,,LAUNCHED,,Small molecule,Unknown,UPPMZCXMQRVMME-UHFFFAOYSA-N,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1CCCCC1
VALGANCICLOVIR,VALGANCICLOVIR,CHEMBL1201314,BRD:BRD-A50922295-001-01-3;BRD:BRD-BRD-A50922295-001-01-3,rep_primary;rep_single_dose,DNA SYNTHESIS INHIBITOR,,CYTOMEGALOVIRUS (CMV),,LAUNCHED,,Small molecule,Approved,WPVFJKSGQUFQAP-GKAPJAKFSA-N,CC(C)[C@H](N)C(=O)OCC(CO)OCN1CNC2C(=O)[NH]C(N)NC21;CC(C)[C@H](N)C(=O)OCC(CO)OCN1CNC2C1NC(N)[NH]C2=O
VALNEMULIN,VALNEMULIN,CHEMBL1688852,BRD:BRD-BRD-K33813875-003-01-8;BRD:BRD-K33813875-003-01-8,rep_multi_dose;rep_primary;rep_single_dose,BACTERIAL 50S RIBOSOMAL SUBUNIT INHIBITOR,,"DYSENTRY, COLITIS, PNEUMONIA",,LAUNCHED,,Small molecule,Unknown,LLYYNOVSVPBRGV-MVNKZKPCSA-N,C=C[C@]1(C)C[C@@H](OC(=O)CSC(C)(C)CNC(=O)[C@H](N)C(C)C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O;CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3
VALNIVUDINE,VALNIVUDINE,CHEMBL4300944,BRD:BRD-K00091275-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,FJRRWJMFUNGZBJ-RBVMOCNTSA-N,CCCCCC1CCC(-C2CC3CN([C@H]4C[C@H](O)[C@@H](COC(=O)[C@@H](N)C(C)C)O4)C(=O)NC3O2)CC1
VALPROIC-ACID,VALPROIC-ACID,,BRD:BRD-BRD-K41260949-236-16-8;BRD:BRD-K41260949-236-16-8,rep_primary;rep_single_dose,"BENZODIAZEPINE RECEPTOR AGONIST, HDAC INHIBITOR",ABAT;ACADSB;ALDH5A1;HDAC1;HDAC2;HDAC9;OGDH;SCN10A;SCN11A;SCN1A;SCN1B;SCN2A;SCN2B;SCN3A;SCN3B;SCN4A;SCN4B;SCN5A;SCN7A;SCN8A;SCN9A,SEIZURES,,LAUNCHED,"Multiple values for MOA: {'BENZODIAZEPINE RECEPTOR AGONIST, HDAC INHIBITOR', 'HDAC INHIBITOR'}, defaulting to 'BENZODIAZEPINE RECEPTOR AGONIST, HDAC INHIBITOR'",,NA,,CCCC(CCC)C(O)=O
VALROCEMIDE,VALROCEMIDE,CHEMBL471638,BRD:BRD-BRD-K32804101-001-01-8;BRD:BRD-K32804101-001-01-8,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,RALGCAOVRLYSMA-UHFFFAOYSA-N,CCCC(CCC)C(=O)NCC(N)=O
VALRUBICIN,VALRUBICIN,CHEMBL1096885,BRD:BRD-BRD-K72951360-001-01-4;BRD:BRD-K72951360-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,"DNA INHIBITOR, TOPOISOMERASE INHIBITOR",TOP2A,BLADDER CANCER,,LAUNCHED,,Small molecule,Approved,ZOCKGBMQLCSHFP-KQRAQHLDSA-N,CCCCC(=O)OCC(=O)[C@]1(O)CC2C(O)C3C(C(O)C2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)C1C(OC)CCCC1C3=O;CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C2C(O)C3C(=O)C4C(OC)CCCC4C(=O)C3C(O)C2C1
VALSARTAN,VALSARTAN,CHEMBL1069,BRD:BRD-BRD-K45158365-001-11-4;BRD:BRD-K45158365-001-11-4,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,"HYPERTENSION, CONGESTIVE HEART FAILURE",,LAUNCHED,,Small molecule,Approved,ACWBQPMHZXGDFX-QFIPXVFZSA-N,CCCCC(=O)N(CC1CCC(-C2CCCCC2-C2NNN[NH]2)CC1)[C@H](C(=O)O)C(C)C;CCCCC(=O)N(CC1CCC(CC1)-C1CCCCC1-C1NN[NH]N1)[C@@H](C(C)C)C(O)=O
VANCOMYCIN,VANCOMYCIN,CHEMBL1200628;CHEMBL262777,BRD:BRD-BRD-K91065602-003-05-5;BRD:BRD-K91065602-003-05-5,rep_primary;rep_single_dose,BACTERIAL CELL WALL SYNTHESIS INHIBITOR,,ENDOCARDITIS,,LAUNCHED,,Small molecule,Approved,LCTORFDMHNKUSG-XTTLPDOESA-N;MYPYJXKWCTUITO-LYRMYLQWSA-N,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2CCC(OC3CC4CC(OC5CCC(CC5CL)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)C1CCC(O)C(C1)-C1C(O)CC(O)CC1[C@H](NC5=O)C(O)=O)C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)C(CL)C2;CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C4CC(O)CC(O)C4-C4CC3CCC4O)[C@H](O)C3CCC(C(CL)C3)OC3CC2CC(C3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)OC2CCC(CC2CL)[C@H]1O;CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C4CC(O)CC(O)C4-C4CC3CCC4O)[C@H](O)C3CCC(C(CL)C3)OC3CC2CC(C3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)OC2CCC(CC2CL)[C@H]1O.CL
VANDETANIB,VANDETANIB,CHEMBL24828,BRD:BRD-BRD-K77625799-001-07-7;BRD:BRD-K77625799-001-07-7;CTRP:349002,ctrp;rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, RET TYROSINE KINASE INHIBITOR, VEGFR INHIBITOR",EGFR;EPHA1;EPHA10;EPHA2;EPHA3;EPHA4;EPHA5;EPHA6;EPHA7;EPHA8;EPHB1;EPHB2;EPHB3;EPHB4;EPHB6;ERBB2;ERBB3;ERBB4;FLT1;FLT4;KDR;PTK6;RET;SRC;TEK;VEGFA,MEDULLARY THYROID CANCER (MTC),,LAUNCHED,,Small molecule,Approved,UHTHHESEBZOYNR-UHFFFAOYSA-N,COC1CC2/C(=N/C3CCC(BR)CC3F)NC[NH]C2CC1OCC1CCN(C)CC1;COC1CC2C(NC3CCC(BR)CC3F)NCNC2CC1OCC1CCN(C)CC1
VANILLIN,VANILLIN,CHEMBL13883,BRD:BRD-BRD-K24258499-001-05-8;BRD:BRD-K24258499-001-05-8,rep_primary;rep_single_dose,,ABAT;ALDH5A1,,,PRECLINICAL,,Small molecule,Unknown,MWOOGOJBHIARFG-UHFFFAOYSA-N,COC1CC(C=O)CCC1O
VANILLYLACETONE,VANILLYLACETONE,CHEMBL25894,BRD:BRD-BRD-K33510429-001-03-1;BRD:BRD-K33510429-001-03-1,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,OJYLAHXKWMRDGS-UHFFFAOYSA-N,COC1CC(CCC(C)=O)CCC1O
VANIPREVIR,VANIPREVIR,CHEMBL4525964,BRD:BRD-K00003445-001-01-9,rep_single_dose,SERINE PROTEASE INHIBITOR,,,,,,Small molecule,Phase 3,KUQWGLQLLVFLSM-ONAXAZCASA-N,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCC1CCCC3C1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1
VANITIOLIDE,VANITIOLIDE,CHEMBL1380480,BRD:BRD-BRD-K26502378-001-07-9;BRD:BRD-K26502378-001-07-9,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,Unknown,WQYRHRAZNNRDIA-UHFFFAOYSA-N,COC1CC(C(=S)N2CCOCC2)CCC1O;COC1CC(CCC1O)C(=S)N1CCOCC1
VANOXERINE,VANOXERINE,CHEMBL281594,BRD:BRD-BRD-K32501161-300-06-2;BRD:BRD-K32501161-300-06-2,rep_multi_dose;rep_primary;rep_single_dose,"DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR",SLC6A3,,,PHASE 3,"Multiple values for MOA: {'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR', 'DOPAMINE UPTAKE INHIBITOR'}, defaulting to 'DOPAMINE REUPTAKE INHIBITOR, DOPAMINE UPTAKE INHIBITOR'",Small molecule,Phase 3,NAUWTFJOPJWYOT-UHFFFAOYSA-N,FC1CCC(C(OCCN2CCN(CCCC3CCCCC3)CC2)C2CCC(F)CC2)CC1;FC1CCC(CC1)C(OCCN1CCN(CCCC2CCCCC2)CC1)C1CCC(F)CC1
VAPENDAVIR,VAPENDAVIR,CHEMBL2062774,BRD:BRD-K00004577-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Phase 2,DKSVBVKHUICELN-UHFFFAOYSA-N,CCOC1NOC2CC(OCCC3CCN(C4CCC(C)NN4)CC3)CCC12
VARDENAFIL,VARDENAFIL,CHEMBL1520,BRD:BRD-BRD-K13926615-003-03-3;BRD:BRD-K13926615-003-03-3,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE5A;PDE6G;PDE6H,ERECTILE DYSFUNCTION,,LAUNCHED,,Small molecule,Approved,SECKRCOLJRRGGV-UHFFFAOYSA-N,CCCC1NC(C)C2C(=O)NC(-C3CC(S(=O)(=O)N4CCN(CC)CC4)CCC3OCC)[NH]N12;CCCC1NC(C)C2N1NC([NH]C2=O)-C1CC(CCC1OCC)S(=O)(=O)N1CCN(CC)CC1
VARENICLINE,VARENICLINE,CHEMBL1396,BRD:BRD-A86216746-046-02-6;BRD:BRD-BRD-A86216746-046-02-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRNA3;CHRNA4;CHRNA6;CHRNA7,SMOKING CESSATION,,LAUNCHED,,Small molecule,Approved,JQSHBVHOMNKWFT-UHFFFAOYSA-N,C1C2CNCC1C1CC3NCCNC3CC21;C1CNC2CC3C(CC2N1)C1CNCC3C1
VARESPLADIB,VARESPLADIB,CHEMBL148674,BRD:BRD-BRD-K09711437-001-04-3;BRD:BRD-K09711437-001-04-3,rep_primary;rep_single_dose,SECRETORY PHOSPHOLIPASE INHIBITOR,PLA2G2A,,,PHASE 3,,Small molecule,Phase 2,BHLXTPHDSZUFHR-UHFFFAOYSA-N,CCC1C(C(=O)C(N)=O)C2C(OCC(=O)O)CCCC2N1CC1CCCCC1;CCC1C(C(=O)C(N)=O)C2C(OCC(O)=O)CCCC2N1CC1CCCCC1
VASOPRESSIN,VASOPRESSIN,CHEMBL1200690;CHEMBL373742,BRD:BRD-BRD-K73028949-001-02-8;BRD:BRD-K73028949-001-02-8,rep_primary;rep_single_dose,VASOPRESSIN RECEPTOR AGONIST,AVPR1A;AVPR1B;AVPR2;OXTR,ABDOMINAL DISTENSION,,LAUNCHED,,Protein,Approved,BJFIDCADFRDPIO-DZCXQCEKSA-N;KBZOIRJILGZLEJ-LGYYRGKSSA-N,N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC2CCC(O)CC2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O;N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2CCC(O)CC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O;NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2CCC(O)CC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
VATALANIB,VATALANIB,CHEMBL101253,BRD:BRD-BRD-K70163715-300-05-7;BRD:BRD-K70163715-300-05-7,rep_multi_dose;rep_primary;rep_single_dose,"KIT INHIBITOR, PDGFR TYROSINE KINASE RECEPTOR INHIBITOR, VEGFR INHIBITOR",EGFR;FLT1;FLT4;KDR;PDGFRB,,,PHASE 3,,Small molecule,Phase 3,YCOYDOIWSSHVCK-UHFFFAOYSA-N,CLC1CCC(NC2NNC(CC3CCNCC3)C3CCCCC23)CC1
VATINOXAN,VATINOXAN,CHEMBL4298165,BRD:BRD-K00003277-003-01-9,rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,,,Small molecule,Unknown,GTBKISRCRQUFNL-OXJNMPFZSA-N,CS(=O)(=O)NCCN1C(=O)NC[C@]12CCN1CCC3C(OC4CCCCC34)[C@@H]1C2
VBY-825,VBY-825,,BRD:BRD-K36338614-001-02-1,rep_single_dose,CATHEPSIN INHIBITOR,CTSB;CTSL;CTSS,,,,,,NA,,
VCH-916,VCH-916,,BRD:BRD-BRD-K75956464-237-01-5;BRD:BRD-K75956464-237-01-5,rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 1,,,NA,,CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)C1CC(SC1C(O)=O)C1=CCCCC1
VE 821,VE 821,,GDSC2:2111,gdsc,,,,,,,,NA,,
VE 822,VE 822,,GDSC2:1613,gdsc,,,,,,,,NA,,
VE-821,VE-821,,BRD:BRD-BRD-K26756394-001-02-2;BRD:BRD-K26756394-001-02-2;GDSC2:2111,gdsc;rep_multi_dose;rep_primary;rep_single_dose,ATR KINASE INHIBITOR,ATR,,,PRECLINICAL,,,NA,,CS(=O)(=O)C1CCC(CC1)-C1CNC(N)C(N1)C(=O)NC1CCCCC1
VE-822,VE-822,CHEMBL3989870,BRD:BRD-BRD-K04701033-001-04-7;BRD:BRD-K04701033-001-03-9;BRD:BRD-K04701033-001-04-7;GDSC2:1613,gdsc;rep_multi_dose;rep_primary;rep_single_dose,ATR KINASE INHIBITOR,ATM;ATR;MTOR;PIK3CG,,,PHASE 2,,Small molecule,Phase 2,JZCWLJDSIRUGIN-UHFFFAOYSA-N,CNCC1CCC(-C2CC(-C3NC(-C4CCC(S(=O)(=O)C(C)C)CC4)CNC3N)ON2)CC1;CNCC1CCC(CC1)-C1CC(ON1)-C1NC(CNC1N)-C1CCC(CC1)S(=O)(=O)C(C)C
VE821,VE821,,GDSC2:2111,gdsc,,,,,,,,NA,,
VE822,VE822,,GDSC2:1613,gdsc,,,,,,,,NA,,
VECABRUTINIB,VECABRUTINIB,CHEMBL4297640,BRD:BRD-K00003503-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Phase 1,QLRRJMOBVVGXEJ-XHSDSOJGSA-N,NC(=O)[C@H]1CCN(C2NCNC(N)C2F)C[C@@H]1N1CCC[C@@H](NC2CC(CL)CC(C(F)(F)F)C2)C1=O
VECURONIUM,VECURONIUM,CHEMBL1201219,BRD:BRD-BRD-K20168442-004-06-3;BRD:BRD-K20168442-004-06-3,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRNA2,MUSCLE RELAXANT,,LAUNCHED,,Small molecule,Approved,BGSZAXLLHYERSY-XQIGCQGXSA-N,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1;CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
VEDAPROFEN,VEDAPROFEN,CHEMBL2104464,BRD:BRD-K00004714-001-01-9,rep_single_dose,ANTI-INFLAMMATORY AGENT,PTGS2,,,,,Small molecule,Unknown,VZUGVMQFWFVFBX-UHFFFAOYSA-N,CC(C(=O)O)C1CCC(C2CCCCC2)C2CCCCC12
VELARESOL,VELARESOL,CHEMBL2107643,BRD:BRD-K00004580-001-01-9,rep_single_dose,,,,,,,Small molecule,Unknown,NSUDGNLOXMLAEB-UHFFFAOYSA-N,O=CC1C(O)CCCC1OCCCCC(=O)O
VELBAN,VELBAN,CHEMBL159;CHEMBL378544,GDSC1:1004;GDSC2:1004,gdsc,,,,,,,Small molecule,Approved,JXLYSJRDGCGARV-CFWMRBGOSA-N;KDQAABAKXDWYSZ-PNYVAJAMSA-N,CC[C@]1(O)C[C@@H]2CN(CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1;CC[C@]1(O)C[C@@H]2CN(CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
VELCADE,VELCADE,CHEMBL325041,GDSC1:104;GDSC2:1191,gdsc,,,,,,,Small molecule,Approved,GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C1CNCCN1)B(O)O
VELEDIMEX,VELEDIMEX,CHEMBL3039523,BRD:BRD-K00003235-001-01-9,rep_single_dose,CYTOCHROME P450 INHIBITOR,,,,,,Small molecule,Phase 2,LZWZPGLVHLSWQX-XMMPIXPASA-N,CCC[C@@H](N(NC(=O)C1CCCC(OC)C1CC)C(=O)C1CC(C)CC(C)C1)C(C)(C)C
VELIFLAPON,VELIFLAPON,CHEMBL88712,BRD:BRD-BRD-K12852738-001-01-2;BRD:BRD-K12852738-001-01-2,rep_primary;rep_single_dose,LEUKOTRIENE SYNTHESIS INHIBITOR,ALOX5AP,,,PHASE 3,,Small molecule,Phase 3,ZEYYDOLCHFETHQ-JOCHJYFZSA-N,O=C(O)[C@@H](C1CCC(OCC2CCC3CCCCC3N2)CC1)C1CCCC1;OC(=O)[C@H](C1CCCC1)C1CCC(OCC2CCC3CCCCC3N2)CC1
VELIPARIB,VELIPARIB,CHEMBL506871,BRD:BRD-BRD-K12737986-001-01-4;BRD:BRD-K12737986-001-01-4;CTRP:606034;GDSC1:1018,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,PARP INHIBITOR,PARP1;PARP2,,,PHASE 3,,Small molecule,Phase 3,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,C[C@]1(C2NC3C(C(N)=O)CCCC3[NH]2)CCCN1;C[C@]1(CCCN1)C1NC2C(CCCC2[NH]1)C(N)=O
VELNEPERIT,VELNEPERIT,CHEMBL2016681,BRD:BRD-BRD-K06357403-001-01-4;BRD:BRD-K06357403-001-01-4,rep_primary;rep_single_dose,NEUROPEPTIDE RECEPTOR ANTAGONIST,NPY5R,,,PHASE 2,,Small molecule,Phase 2,WGEWUYACXPEFPO-AULYBMBSSA-N,CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)NC1CCC(CN1)C(F)(F)F;CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)NC2CCC(C(F)(F)F)CN2)CC1
VELPATASVIR,VELPATASVIR,CHEMBL3545062,BRD:BRD-K00003133-001-01-9,rep_single_dose,ANTIVIRAL,,,,,,Small molecule,Approved,FHCUMDQMBHQXKK-CDIODLITSA-N,COC[C@H]1C[C@@H](C2NC(-C3CCC4C(C3)COC3CC5C(CCC6NC([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[NH]C65)CC3-4)C[NH]2)N(C(=O)[C@H](NC(=O)OC)C2CCCCC2)C1
VENECLEXTA,VENECLEXTA,,GDSC1:412;GDSC2:1909,gdsc,,,,,,,,NA,,
VENLAFAXINE,VENLAFAXINE,CHEMBL637,BRD:BRD-A51714012-003-13-6;BRD:BRD-BRD-A51714012-003-13-6,rep_primary;rep_single_dose,"ADRENERGIC INHIBITOR, NOREPINEPHRINE REUPTAKE INHIBITOR, SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)",SLC6A2;SLC6A3;SLC6A4,"DEPRESSION, GENERALIZED ANXIETY DISORDER (GAD), PANIC DISORDERS, SOCIAL ANXIETY DISORDER",,LAUNCHED,,Small molecule,Approved,PNVNVHUZROJLTJ-UHFFFAOYSA-N,COC1CCC(C(CN(C)C)C2(O)CCCCC2)CC1;COC1CCC(CC1)C(CN(C)C)C1(O)CCCCC1
VENOTOCLAX,VENOTOCLAX,,GDSC1:412,gdsc,,,,,,,,NA,,
VEPESID,VEPESID,CHEMBL44657,GDSC1:134,gdsc,,,,,,,Small molecule,Approved,VJJPUSNTGOMMGY-MRVIYFEKSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1O
VER-155008,VER-155008,,BRD:BRD-K32330832-001-01-0;CTRP:411815,ctrp;rep_single_dose,HSP INHIBITOR,HSPA1A,,,,,,NA,,
VER-49009,VER-49009,,BRD:BRD-BRD-K38548312-001-01-0;BRD:BRD-K38548312-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,HSP90AA1,,,PRECLINICAL,,,NA,,CCNC(=O)C1[NH]NC(C1-C1CCC(OC)CC1)-C1CC(CL)C(O)CC1O
VER-52296,VER-52296,CHEMBL252164,GDSC1:194;GDSC2:1559,gdsc,,,,,,,Small molecule,Phase 2,NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)C1NOC(-C2CC(C(C)C)C(O)CC2O)C1-C1CCC(CN2CCOCC2)CC1
VERALIPRIDE,VERALIPRIDE,CHEMBL2105581,BRD:BRD-K00003433-001-01-9,rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,,,,,,Small molecule,Approved,RYJXBGGBZJGVQF-UHFFFAOYSA-N,C=CCN1CCCC1CNC(=O)C1CC(S(N)(=O)=O)CC(OC)C1OC
VERAPAMIL,VERAPAMIL,CHEMBL197;CHEMBL6966,BRD:BRD-A09533288-003-31-2;BRD:BRD-BRD-A09533288-003-31-2,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,CACNA1A;CACNA1B;CACNA1C;CACNA1D;CACNA1F;CACNA1G;CACNA1I;CACNA1S;CACNB1;CACNB2;CACNB3;CACNB4;CYP3A4;KCNA10;KCNA7;KCNH2;KCNJ11;NALCN;SCN5A;SLC29A4;SLC6A4,HYPERTENSION,,LAUNCHED,,Small molecule,Approved,SGTNSNPWRIOYBX-HHHXNRCGSA-N;SGTNSNPWRIOYBX-UHFFFAOYSA-N,COC1CCC(CCN(C)CCC[C@](C#N)(C2CCC(OC)C(OC)C2)C(C)C)CC1OC;COC1CCC(CCN(C)CCCC(C#N)(C(C)C)C2CCC(OC)C(OC)C2)CC1OC;COC1CCC(CCN(C)CCCC(C#N)(C2CCC(OC)C(OC)C2)C(C)C)CC1OC
VERBASCOSIDE,VERBASCOSIDE,CHEMBL444478,BRD:BRD-BRD-K36201510-001-06-7;BRD:BRD-K36201510-001-06-7,rep_primary;rep_single_dose,"PKC INHIBITOR, NFKB PATHWAY INHIBITOR",,,,PHASE 2/PHASE 3,"Multiple values for MOA: {'NFKB PATHWAY INHIBITOR, PKC INHIBITOR', 'PKC INHIBITOR, NFKB PATHWAY INHIBITOR'}, defaulting to 'PKC INHIBITOR, NFKB PATHWAY INHIBITOR'",Oligosaccharide,Phase 2,FBSKJMQYURKNSU-ZLSOWSIRSA-N,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3CCC(O)C(O)C3)O[C@H](CO)[C@H]2OC(=O)/C=C/C2CCC(O)C(O)C2)[C@H](O)[C@H](O)[C@H]1O;C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3CCC(O)C(O)C3)O[C@H](CO)[C@H]2OC(=O)\C=C\C2CCC(O)C(O)C2)[C@H](O)[C@H](O)[C@H]1O
VERCIRNON,VERCIRNON,CHEMBL2178578,BRD:BRD-BRD-K47929404-001-01-0;BRD:BRD-K47929404-001-01-0,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR9,,,PHASE 3,,Small molecule,Phase 3,JRWROCIMSDXGOZ-UHFFFAOYSA-N,CC(C)(C)C1CCC(CC1)S(=O)(=O)NC1CCC(CL)CC1C(=O)C1CC[N+]([O-])CC1;CC(C)(C)C1CCC(S(=O)(=O)NC2CCC(CL)CC2C(=O)C2CC[N+]([O-])CC2)CC1
VERDINEXOR,VERDINEXOR,CHEMBL3545187,BRD:BRD-K00004674-001-01-9,rep_single_dose,EXPORTIN ANTAGONIST,,,,,,Small molecule,Phase 1,OPAKEJZFFCECPN-XQRVVYSFSA-N,O=C(/C=C\N1CNC(-C2CC(C(F)(F)F)CC(C(F)(F)F)C2)N1)NNC1CCCCN1
VERDIPERSTAT,VERDIPERSTAT,CHEMBL4297594,BRD:BRD-K00004612-001-01-9,rep_single_dose,MYELOPEROXIDASE INHIBITOR,,,,,,Small molecule,Phase 3,FVJCUZCRPIMVLB-UHFFFAOYSA-N,CC(C)OCCN1C(=S)[NH]C(=O)C2[NH]CCC21
VERICIGUAT,VERICIGUAT,CHEMBL4066936,BRD:BRD-K00003234-001-01-9,rep_single_dose,GUANYLATE CYCLASE STIMULANT,,,,,,Small molecule,Approved,QZFHIXARHDBPBY-UHFFFAOYSA-N,COC(=O)NC1C(N)NC(-C2NN(CC3CCCCC3F)C3NCC(F)CC23)NC1N
VERINURAD,VERINURAD,CHEMBL3707347,BRD:BRD-BRD-K36741660-001-01-1;BRD:BRD-K36741660-001-01-1,rep_primary;rep_single_dose,URATE TRANSPORTER INHIBITOR,SLC22A12,,,PHASE 2,,Small molecule,Phase 2,YYBOLPLTQDKXPM-UHFFFAOYSA-N,CC(C)(SC1CCNCC1-C1CCC(C#N)C2CCCCC12)C(=O)O;CC(C)(SC1CCNCC1-C1CCC(C#N)C2CCCCC12)C(O)=O
VERNAKALANT,VERNAKALANT,CHEMBL2111112,BRD:BRD-BRD-K19741547-003-01-7;BRD:BRD-K19741547-003-01-7,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNA5,ATRIAL FIBRILLATION (AF),,LAUNCHED,,Small molecule,Approved,VBHQKCBVWWUUKN-KZNAEPCWSA-N,COC1CCC(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)CC1OC
VERUBECESTAT,VERUBECESTAT,CHEMBL3301601,BRD:BRD-K00003229-001-01-9,rep_single_dose,BETA SECRETASE INHIBITOR,,,,,,Small molecule,Phase 3,YHYKUSGACIYRML-KRWDZBQOSA-N,CN1C(N)=N[C@](C)(C2CC(NC(=O)C3CCC(F)CN3)CCC2F)CS1(=O)=O
VERUBULIN,VERUBULIN,CHEMBL492399,BRD:BRD-BRD-K42673188-001-01-1;BRD:BRD-K42673188-001-01-1,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB,,,PHASE 2,,Small molecule,Phase 2,SNHCRNMVYDHVDT-UHFFFAOYSA-N,COC1CCC(CC1)N(C)C1NC(C)NC2CCCCC12;COC1CCC(N(C)C2NC(C)NC3CCCCC23)CC1
VERUCERFONT,VERUCERFONT,CHEMBL1287935,BRD:BRD-K00003180-001-01-9,rep_single_dose,CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONIST,,,,,,Small molecule,Phase 2,VKHVAUKFLBBZFJ-SFHVURJKSA-N,CC[C@H](NC1CC(C)NC2C(-C3CCC(OC)CC3C)C(C)NN12)C1NC(C)NO1
VESAMICOL,VESAMICOL,CHEMBL20730,BRD:BRD-BRD-K14765469-003-12-2;BRD:BRD-K14765469-003-12-2,rep_primary;rep_single_dose,ACETYLCHOLINESTERASE INHIBITOR,SLC18A3,,,PRECLINICAL,,Small molecule,NA,YSSBJODGIYRAMI-IAGOWNOFSA-N,O[C@@H]1CCCC[C@H]1N1CCC(C2CCCCC2)CC1;O[C@@H]1CCCC[C@H]1N1CCC(CC1)C1CCCCC1
VESANOID,VESANOID,CHEMBL38,GDSC1:1009,gdsc,,,,,,,Small molecule,Approved,SHGAZHPCJJPHSC-YCNIQYBTSA-N,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
VESNARINONE,VESNARINONE,CHEMBL17423,BRD:BRD-BRD-K13414800-001-01-3;BRD:BRD-K13414800-001-01-3,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,KCNH2;PDE3A,CONGESTIVE HEART FAILURE,,LAUNCHED,,Small molecule,Phase 2,ZVNYJIZDIRKMBF-UHFFFAOYSA-N,COC1CCC(C(=O)N2CCN(C3CCC4C(C3)CCC(=O)N4)CC2)CC1OC;COC1CCC(CC1OC)C(=O)N1CCN(CC1)C1CCC2NC(=O)CCC2C1
VGX-1027,VGX-1027,CHEMBL1320667,BRD:BRD-A32269193-001-01-5;BRD:BRD-BRD-A32269193-001-01-5,rep_primary;rep_single_dose,TUMOR NECROSIS FACTOR RECEPTOR ANTAGONIST,TLR4,,,PHASE 1,,Small molecule,Phase 2,MUFJHYRCIHHATF-UHFFFAOYSA-N,O=C(O)CC1CC(C2CCCCC2)=NO1;OC(=O)CC1CC(=NO1)C1CCCCC1
VICRIVIROC,VICRIVIROC,CHEMBL82301,BRD:BRD-BRD-K84748119-050-01-1;BRD:BRD-K84748119-050-01-1,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR5,,,PHASE 3,,Small molecule,Phase 3,CNPVJJQCETWNEU-CYFREDJKSA-N,COC[C@@H](C1CCC(C(F)(F)F)CC1)N1CCN(C2(C)CCN(C(=O)C3C(C)NCNC3C)CC2)C[C@@H]1C;COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1C(C)NCNC1C)C1CCC(CC1)C(F)(F)F
VIDARABINE,VIDARABINE,CHEMBL1090,BRD:BRD-BRD-K72093121-001-16-3;BRD:BRD-K72093121-001-16-3,rep_multi_dose;rep_primary;rep_single_dose,ANTIVIRAL,ADA,"VIRUS HERPES SIMPLEX (HSV), VARICELLA-ZOSTER VIRUS (VZV)",,LAUNCHED,,Small molecule,Approved,OIRDTQYFTABQOQ-UHTZMRCNSA-N,NC1NCNC2C1NCN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O;NC1NCNC2N(CNC12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
VIGABATRIN,VIGABATRIN,CHEMBL89598,BRD:BRD-A07893380-213-01-7;BRD:BRD-BRD-A07893380-213-01-7,rep_primary;rep_single_dose,GABA AMINOTRANSFERASE INHIBITOR,ABAT;GABBR1;SLC32A1,"SEIZURES, SPASMS",,LAUNCHED,,Small molecule,Approved,PJDFLNIOAUIZSL-UHFFFAOYSA-N,C=CC(N)CCC(=O)O;NC(CCC(O)=O)C=C
VILAZODONE,VILAZODONE,CHEMBL439849,BRD:BRD-BRD-K58010567-003-02-2;BRD:BRD-K58010567-003-02-2,rep_primary;rep_single_dose,SEROTONIN REUPTAKE INHIBITOR,DRD2;DRD3;HRH1;HTR1A;HTR4;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,SGEGOXDYSFKCPT-UHFFFAOYSA-N,N#CC1CCC2[NH]CC(CCCCN3CCN(C4CCC5OC(C(N)=O)CC5C4)CC3)C2C1;NC(=O)C1CC2CC(CCC2O1)N1CCN(CCCCC2C[NH]C3CCC(CC23)C#N)CC1
VILDAGLIPTIN,VILDAGLIPTIN,CHEMBL142703,BRD:BRD-A94993966-001-04-4;BRD:BRD-A94993966-001-05-1;BRD:BRD-BRD-A94993966-001-04-4;BRD:BRD-BRD-A94993966-001-05-1,rep_primary;rep_single_dose,DIPEPTIDYL PEPTIDASE INHIBITOR,DPP4,DIABETES MELLITUS,,LAUNCHED,,Small molecule,Approved,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2;OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
VILOXAZINE,VILOXAZINE,CHEMBL251072;CHEMBL306700,BRD:BRD-A59198242-003-02-9;BRD:BRD-BRD-A59198242-003-02-9,rep_primary;rep_single_dose,NOREPINEPHRINE REUPTAKE INHIBITOR,SLC6A2,DEPRESSION,,LAUNCHED,,Small molecule,Approved,YWPHCCPCQOJSGZ-NSHDSACASA-N;YWPHCCPCQOJSGZ-UHFFFAOYSA-N,CCOC1CCCCC1OC[C@@H]1CNCCO1;CCOC1CCCCC1OCC1CNCCO1
VINBLASTINE,VINBLASTINE,CHEMBL159,BRD:BRD-BRD-K06519765-001-01-1;BRD:BRD-K06519765-001-01-1;BRD:BRD-K06519765-065-01-6;GDSC1:1004;GDSC2:1004,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"MICROTUBULE INHIBITOR, TUBULIN POLYMERIZATION INHIBITOR",JUN;TUBA1A;TUBB;TUBD1;TUBE1;TUBG1,"HODGKIN'S LYMPHOMA, TRUE HISTIOCYTIC LYMPHOMA (THL), MYCOSIS, SMALL LYMPHOCYTIC LYMPHOMA (SLL), TESTICULAR CARCINOMA, KAPOSI SARCOMA",,LAUNCHED,,Small molecule,Approved,JXLYSJRDGCGARV-CFWMRBGOSA-N,CC[C@]1(O)C[C@@H]2C[N@](C1)CCC1C([NH]C3CCCCC13)[C@@](C2)(C(=O)OC)C1CC2C(CC1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC;CC[C@]1(O)C[C@@H]2CN(CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
VINBURNINE,VINBURNINE,CHEMBL1892145,BRD:BRD-BRD-K40227168-001-12-9;BRD:BRD-K40227168-001-12-9,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,STROKE,,LAUNCHED,,Small molecule,Unknown,WYJAPUKIYAZSEM-MOPGFXCFSA-N,CC[C@]12CCCN3CCC4C(N(C5CCCCC45)C(=O)C1)[C@@H]32;CC[C@@]12CCCN3CCC4C([C@H]13)N(C(=O)C2)C1CCCCC41
VINCAMINE,VINCAMINE,CHEMBL1165342,BRD:BRD-BRD-K89704198-001-12-3;BRD:BRD-K89704198-001-12-3,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,CHRM1;CHRM2;CHRM3;CHRM4,,,WITHDRAWN,,Small molecule,Approved,RXPRRQLKFXBCSJ-GIVPXCGWSA-N,CC[C@]12CCCN3CCC4C(N(C5CCCCC45)[C@@](O)(C(=O)OC)C1)[C@@H]32;CC[C@@]12CCCN3CCC4C([C@H]13)N(C1CCCCC41)[C@@](O)(C2)C(=O)OC
VINDESINE,VINDESINE,CHEMBL219146;CHEMBL238071,BRD:BRD-BRD-K59753975-001-02-6;BRD:BRD-K59753975-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBB;TUBB1,"BREAST CANCER, NON-SMALL CELL LUNG CANCER (NSCLC), MELANOMA",,LAUNCHED,,Small molecule,Approved,HHJUWIANJFBDHT-KOTLKJBCSA-N;HHJUWIANJFBDHT-ZVTSDNJWSA-N,CC[C@]1(O)C[C@@H]2CN(CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1;CC[C@]1(O)C[C@H]2C[N@](CCC3C([NH]C4CCCCC34)[C@@](C(=O)OC)(C3CC4C(CC3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1;CC[C@]1(O)C[C@H]2CN(C1)CCC1C([NH]C3CCCCC13)[C@@](C2)(C(=O)OC)C1CC2C(CC1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O
VINFLUNINE,VINFLUNINE,CHEMBL2110725,BRD:BRD-BRD-K64120610-001-01-4;BRD:BRD-BRD-K64120610-046-01-9;BRD:BRD-K64120610-001-01-4;BRD:BRD-K64120610-046-01-9,rep_multi_dose;rep_primary;rep_single_dose,MICROTUBULE INHIBITOR,,BLADDER CANCER,,LAUNCHED,,Small molecule,Approved,NMDYYWFGPIMTKO-KLCPSUAYSA-N,CC[C@]12C=CCN3CC[C@@]4(C5CC([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(CC8C6[NH]C6CCCCC86)C7)C(OC)CC5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32;CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1CC(OC)C(CC41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCC3C1[NH]C1CCCCC31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC
VINORELBINE,VINORELBINE,CHEMBL553025,BRD:BRD-BRD-K69280563-001-01-8;BRD:BRD-K69280563-001-01-8;GDSC1:140;GDSC2:2048,gdsc;rep_multi_dose;rep_primary;rep_single_dose,TUBULIN POLYMERIZATION INHIBITOR,TUBA1A;TUBA1B;TUBA1C;TUBA3C;TUBA3D;TUBA3E;TUBA4A;TUBB;TUBB1;TUBB2A;TUBB2B;TUBB3;TUBB4A;TUBB4B;TUBB6;TUBB8,NON-SMALL CELL LUNG CANCER (NSCLC),,LAUNCHED,,Small molecule,Approved,GBABOYUKABKIAF-IELIFDKJSA-N,CCC1=C[C@@H]2C[N@](C1)CC1C([NH]C3CCCCC13)[C@@](C2)(C(=O)OC)C1CC2C(CC1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC;CCC1=C[C@@H]2CN(C1)CC1C([NH]C3CCCCC13)[C@@](C(=O)OC)(C1CC3C(CC1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2;CCC1=C[C@@H]2CN(C1)CC1C([NH]C3CCCCC13)[C@@](C2)(C(=O)OC)C1CC2C(CC1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC
VINORELBINE TARTRATE,VINORELBINE TARTRATE,CHEMBL3039595;CHEMBL538943,GDSC1:140;GDSC2:2048,gdsc,,,,,,,Small molecule;Unknown,Approved,CILBMBUYJCWATM-UDRBCWGGSA-N;MVHREVCZLKPXGC-DSLGMBOJSA-N,CC[C@]12C=CCN3CC[C@@]4(C5CC([C@@]6(C(=O)OC)C[C@@H]7C=C(C)CN(C7)C7C6[NH]C6CCCCC76)C(OC)CC5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O;CCC1=C[C@@H]2CN(C1)CC1C([NH]C3CCCCC13)[C@@](C(=O)OC)(C1CC3C(CC1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O
VINPOCETINE,VINPOCETINE,CHEMBL71752,BRD:BRD-BRD-K53318339-001-24-9;BRD:BRD-K53318339-001-24-9,rep_primary;rep_single_dose,"PHOSPHODIESTERASE INHIBITOR, SODIUM CHANNEL BLOCKER",PDE1A;PDE1C,,,LAUNCHED,,Small molecule,Approved,DDNCQMVWWZOMLN-IRLDBZIGSA-N,CCOC(=O)C1=C[C@]2(CC)CCCN3CCC4C([C@H]23)N1C1CCCCC41;CCOC(=O)C1=C[C@]2(CC)CCCN3CCC4C(N1C1CCCCC41)[C@@H]32
VIPADENANT,VIPADENANT,CHEMBL447664,BRD:BRD-BRD-K56565215-001-01-9;BRD:BRD-K56565215-001-01-9,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PHASE 1,,Small molecule,Phase 2,HQSBCDPYXDGTCL-UHFFFAOYSA-N,CC1CC(CN2NNC3C(-C4CCCO4)NC(N)NC32)CCC1N;CC1CC(CN2NNC3C(NC(N)NC23)-C2CCCO2)CCC1N
VISOMITIN,VISOMITIN,,BRD:BRD-K00003375-004-01-9,rep_single_dose,ANTIOXIDANT,,,,,,,NA,,
VITAMIN-B12,VITAMIN-B12,,BRD:BRD-A75369945-001-01-2;BRD:BRD-BRD-A75369945-001-01-2,rep_primary;rep_single_dose,,,MEGALOBLASTIC ANEMIA,,LAUNCHED,,,NA,,C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[CO]31(C#N)N3C([C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]23C)=C(C)C2=[N+]1C(=C4)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1CNC2CC(C)C(C)CC12
VIXOTRIGINE,VIXOTRIGINE,CHEMBL3544913,BRD:BRD-K00003141-003-01-9,rep_single_dose,SODIUM CHANNEL BLOCKER,,,,,,Small molecule,Phase 3,JESCETIFNOFKEU-SJORKVTESA-N,NC(=O)[C@@H]1CC[C@H](C2CCC(OCC3CCCCC3F)CC2)N1
VL285,VL285,,BRD:BRD-K00005338-001-01-9,rep_single_dose,PROTAC,,,,,,,NA,,
VLX600,VLX-600;VLX600,CHEMBL2094620,BRD:BRD-BRD-K26122255-001-01-7;BRD:BRD-BRD-K89053832-001-01-0;BRD:BRD-K26122255-001-01-7;BRD:BRD-K89053832-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,"ANTITUMOR AGENT, UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR",TP53;USP14,,,PHASE 1,"Multiple values for MOA: {'ANTITUMOR AGENT, UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR', 'UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR', 'ANTITUMOR AGENT'}, defaulting to 'ANTITUMOR AGENT, UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR'
Multiple values for MOA: {'ANTITUMOR AGENT, UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR', 'UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR'}, defaulting to 'ANTITUMOR AGENT, UBIQUITIN C-TERMINAL HYDROLASE INHIBITOR'
Multiple values for SMILES: {'C\\C(=N\\NC1NNC2C(N1)[NH]C1C(C)CCCC21)C1CCCCN1', 'CC1CCCC2C1[NH]C1NC(NNC(=C)C3CCCCN3)NNC21'}, defaulting to 'C\\C(=N\\NC1NNC2C(N1)[NH]C1C(C)CCCC21)C1CCCCN1'
Multiple values for repurposing_target: {'TP53;USP14', 'TP53', 'USP14'}, taking the union
Multiple values for repurposing_target: {'TP53;USP14', 'USP14'}, taking the union
Multiple values for structure_id: {'K26122255', 'K89053832'}, defaulting to None",Small molecule,Phase 1,UQOSBPRTQFFUOA-NHDPSOOVSA-N,C/C(=N/NC1NNC2C(N1)[NH]C1C(C)CCCC12)C1CCCCN1;C\C(=N\NC1NNC2C(N1)[NH]C1C(C)CCCC21)C1CCCCN1
VLX1570,VLX1570,,BRD:BRD-K00003343-001-01-9,rep_single_dose,DEUBIQUITINASE INHIBITOR,,,,,,,NA,,
VNLG/124,VNLG/124,,GDSC1:271,gdsc,,,,,,,,NA,,
VOCLOSPORIN,VOCLOSPORIN,CHEMBL2218919,BRD:BRD-K00003472-001-01-9,rep_single_dose,CALCINEURIN INHIBITOR,,,,,,Protein,Approved,BICRTLVBTLFLRD-JDCIFRKPSA-N,C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
VOGLIBOSE,VOGLIBOSE,CHEMBL476960,BRD:BRD-BRD-K66850609-001-07-4;BRD:BRD-K66850609-001-07-4,rep_primary;rep_single_dose,GLUCOSIDASE INHIBITOR,MGAM,"DIABETES MELLITUS, HYPERGLYCEMIA",,LAUNCHED,,Small molecule,Phase 3,FZNCGRZWXLXZSZ-CIQUZCHMSA-N,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
VOLASERTIB,VOLASERTIB,CHEMBL1233528,BRD:BRD-BRD-K69776681-001-03-8;BRD:BRD-K69776681-001-03-8,rep_multi_dose;rep_primary;rep_single_dose,PLK INHIBITOR,PLK1,,,PHASE 3,,Small molecule,Phase 3,SXNJFOWDRLKDSF-STROYTFGSA-N,CC[C@@H]1C(=O)N(C)C2CNC(NC3CCC(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)CC3OC)NC2N1C(C)C;CC[C@H]1N(C(C)C)C2NC(NC3CCC(CC3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)NCC2N(C)C1=O
VOLINANSERIN,VOLINANSERIN,CHEMBL74355,BRD:BRD-BRD-K23647661-001-02-2;BRD:BRD-K23647661-001-02-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR2A;HTR2B;HTR2C;KCNH2,,,PHASE 3,,Small molecule,Phase 3,HXTGXYRHXAGCFP-OAQYLSRUSA-N,COC1CCCC([C@H](O)C2CCN(CCC3CCC(F)CC3)CC2)C1OC
VONOPRAZAN,VONOPRAZAN,CHEMBL2079130,BRD:BRD-BRD-K32768103-051-02-6;BRD:BRD-K32768103-051-02-6,rep_primary;rep_single_dose,POTASSIUM-COMPETITIVE ACID ANTAGONIST,ATP4A,PEPTIC ULCER DISEASE (PUD),,LAUNCHED,,Small molecule,Approved,BFDBKMOZYNOTPK-UHFFFAOYSA-N,CNCC1CC(-C2CCCCC2F)N(C1)S(=O)(=O)C1CCCNC1;CNCC1CC(-C2CCCCC2F)N(S(=O)(=O)C2CCCNC2)C1
VORAPAXAR,VORAPAXAR,CHEMBL493982,BRD:BRD-BRD-K93442924-001-03-4;BRD:BRD-K93442924-001-03-4;CTRP:660136,ctrp;rep_primary;rep_single_dose,"THROMBIN INHIBITOR, THROMBIN RECEPTOR ANTAGONIST",F2R,"MYOCARDIAL INFARCTION, PERIPHERAL ARTERY DISEASE (PAD)",,LAUNCHED,"Multiple values for MOA: {'THROMBIN RECEPTOR ANTAGONIST', 'THROMBIN INHIBITOR, THROMBIN RECEPTOR ANTAGONIST'}, defaulting to 'THROMBIN INHIBITOR, THROMBIN RECEPTOR ANTAGONIST'",Small molecule,Approved,ZBGXUVOIWDMMJE-QHNZEKIYSA-N,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/C1CCC(-C2CCCC(F)C2)CN1;CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\C2CCC(CN2)-C2CCCC(F)C2)C1
VORASIDENIB,VORASIDENIB,CHEMBL4279047,BRD:BRD-K00003460-001-01-9,rep_single_dose,ISOCITRATE DEHYDROGENASE INHIBITOR,,,,,,Small molecule,Phase 3,QCZAWDGAVJMPTA-RNFRBKRXSA-N,C[C@@H](NC1NC(N[C@H](C)C(F)(F)F)NC(-C2CCCC(CL)N2)N1)C(F)(F)F
VORELOXIN,VORELOXIN,CHEMBL68117,BRD:BRD-BRD-K23677682-003-01-2;BRD:BRD-K23677682-003-01-2,rep_multi_dose;rep_primary;rep_single_dose,TOPOISOMERASE INHIBITOR,TOP2A,,,PHASE 3,,Small molecule,Phase 3,XZAFZXJXZHRNAQ-STQMWFEESA-N,CN[C@H]1CN(C[C@@H]1OC)C1CCC2C(N1)N(CC(C(O)=O)C2=O)-C1NCCS1;CN[C@H]1CN(C2CCC3C(=O)C(C(=O)O)CN(-C4NCCS4)C3N2)C[C@@H]1OC
VORICONAZOLE,VORICONAZOLE,CHEMBL638,BRD:BRD-BRD-K06557128-001-07-0;BRD:BRD-K06557128-001-07-0,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP2C19;CYP2C9;CYP3A4;CYP3A5;PTGS1,"ESOPHAGEAL CANDIDIASIS, ASPERGILLOSIS, SKIN INFECTIONS",,LAUNCHED,,Small molecule,Approved,BCEHBSKCWLPMDN-MGPLVRAMSA-N,C[C@@H](C1NCNCC1F)[C@](O)(CN1CNCN1)C1CCC(F)CC1F
VORINOSTAT,VORINOSTAT,CHEMBL98,BRD:BRD-BRD-K81418486-001-47-5;BRD:BRD-K81418486-001-44-2;BRD:BRD-K81418486-001-47-5;CTRP:56554;GDSC1:1012;GDSC2:1012,ctrp;gdsc;rep_multi_dose;rep_primary;rep_single_dose,HDAC INHIBITOR,HDAC1;HDAC10;HDAC11;HDAC2;HDAC3;HDAC5;HDAC6;HDAC8;HDAC9,CUTANEOUS T-CELL LYMPHOMA (CTCL),,LAUNCHED,,Small molecule,Approved,WAEXFXRVDQXREF-UHFFFAOYSA-N,O=C(CCCCCCC(=O)NC1CCCCC1)NO;ONC(=O)CCCCCCC(=O)NC1CCCCC1
VORINOSTAT:CARBOPLATIN (1:1 MOL/MOL),VORINOSTAT:CARBOPLATIN (1:1 MOL/MOL),,CTRP:660131,ctrp,,,,,,,,NA,,
VORINOSTAT:NAVITOCLAX (4:1 MOL/MOL),VORINOSTAT:NAVITOCLAX (4:1 MOL/MOL),,CTRP:660301,ctrp,,,,,,,,NA,,
VORTIOXETINE,VORTIOXETINE,CHEMBL2104993,BRD:BRD-BRD-K53963539-004-02-0;BRD:BRD-K53963539-004-02-0,rep_primary;rep_single_dose,"SEROTONIN RECEPTOR AGONIST, SEROTONIN RECEPTOR ANTAGONIST",HTR1A;HTR1B;HTR2A;HTR2C;HTR3A;HTR5A;HTR6;HTR7;SLC6A4,DEPRESSION,,LAUNCHED,,Small molecule,Approved,YQNWZWMKLDQSAC-UHFFFAOYSA-N,CC1CCC(SC2CCCCC2N2CCNCC2)C(C)C1
VORUCICLIB,VORUCICLIB,CHEMBL3905910,BRD:BRD-K00004725-001-01-9,rep_single_dose,CDK9 INHIBITOR,,,,,,Small molecule,Phase 2,MRPGRAKIAJJGMM-OCCSQVGLSA-N,CN1CC[C@@H](C2C(O)CC(O)C3C(=O)CC(-C4CCC(C(F)(F)F)CC4CL)OC23)[C@@H]1CO
VOTRIENT,VOTRIENT,CHEMBL1201733;CHEMBL477772,GDSC1:199,gdsc,,,,,,,Small molecule,Approved,CUIHSIWYWATEQL-UHFFFAOYSA-N;MQHIQUBXFFAOMK-UHFFFAOYSA-N,CC1CCC(NC2NCCC(N(C)C3CCC4C(C)N(C)NC4C3)N2)CC1S(N)(=O)=O;CC1CCC(NC2NCCC(N(C)C3CCC4C(C)N(C)NC4C3)N2)CC1S(N)(=O)=O.CL
VOXTALISIB,VOXTALISIB,CHEMBL3545366,BRD:BRD-BRD-K56291712-001-01-0;BRD:BRD-K56291712-001-01-0;GDSC1:375,gdsc;rep_multi_dose;rep_primary;rep_single_dose,"MTOR INHIBITOR, PI3K INHIBITOR",MTOR;PIK3CA,,,PHASE 2,,Small molecule,Phase 2,RGHYDLZMTYDBDT-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC[NH]N2)CC2C(C)NC(N)NC21;CCN1C2NC(N)NC(C)C2CC(-C2CC[NH]N2)C1=O
VP-16,VP-16,CHEMBL1200645,GDSC1:134,gdsc,,,,,,,Small molecule,Approved,LIQODXNTTZAGID-OCBXBXKTSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1OP(=O)(O)O
VP-20629,VP-20629,,BRD:BRD-BRD-K21071223-001-02-8;BRD:BRD-K21071223-001-02-8,rep_primary;rep_single_dose,BETA AMYLOID ANTAGONIST,PLA2G2E;SLC36A1,,,PHASE 1,,,NA,,OC(=O)CCC1C[NH]C2CCCCC12
VRT752271,VRT752271,,GDSC2:1908;GDSC2:2047,gdsc,,,,,,,,NA,,
VS-4718,VS-4718,CHEMBL3040440,BRD:BRD-BRD-K09877029-001-01-2;BRD:BRD-K09877029-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,FOCAL ADHESION KINASE INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,IGUBBWJDMLCRIK-UHFFFAOYSA-N,CNC(=O)C1CCCCC1NC1CC(NC2CCC(CC2OC)N2CCOCC2)NCC1C(F)(F)F;CNC(=O)C1CCCCC1NC1CC(NC2CCC(N3CCOCC3)CC2OC)NCC1C(F)(F)F
VT-464,VT-464,CHEMBL3264610,BRD:BRD-BRD-K72005722-001-01-2;BRD:BRD-K72005722-001-01-2,rep_primary;rep_single_dose,CYTOCHROME P450 INHIBITOR,CYP17A1,,,PHASE 2,,Small molecule,Phase 2,ZBRAJOQFSNYJMF-SFHVURJKSA-N,CC(C)[C@](O)(C1CCC2CC(OC(F)F)C(OC(F)F)CC2C1)C1C[NH]NN1;CC(C)[C@@](O)(C1C[NH]NN1)C1CCC2CC(OC(F)F)C(OC(F)F)CC2C1
VTP-27999,VTP-27999,CHEMBL1276678,BRD:BRD-BRD-K81694556-003-01-9;BRD:BRD-K81694556-003-01-9,rep_multi_dose;rep_primary;rep_single_dose,RENIN INHIBITOR,REN,,,PHASE 1,,Small molecule,Phase 1,NXWASIVXQMMPLM-ZXMXYHOLSA-N,CN[C@H](CNC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)C2CCCC(CL)C2)C1)C[C@H]1CCCOC1;CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)C1CCCC(CL)C1)C[C@H]1CCCOC1
VU0240551,VU-0240551;VU0240551,,BRD:BRD-BRD-K27074404-001-08-4;BRD:BRD-K27074404-001-08-4,rep_primary;rep_single_dose,POTASSIUM/CHLORIDE COTRANSPORTER INHIBITOR,SLC12A5,,,PRECLINICAL,,,NA,,CC1CSC(NC(=O)CSC2CCC(NN2)-C2CCCCC2)N1
VU0364739,VU-0364739;VU0364739,,BRD:BRD-BRD-K93317811-003-02-2;BRD:BRD-K93317811-003-02-2,rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLD2,,,PRECLINICAL,,,NA,,FC1CCCC(C1)N1CNC(=O)C11CCN(CCNC(=O)C2CCC3CCCCC3C2)CC1
VU0422288,VU-0422288;VU0422288,,BRD:BRD-BRD-K68674163-001-01-7;BRD:BRD-K68674163-001-01-7,rep_primary;rep_single_dose,"GLUTAMATE RECEPTOR ALLOSTERIC MODULATOR, GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR",GRM3,,,PRECLINICAL,"Multiple values for MOA: {'GLUTAMATE RECEPTOR ALLOSTERIC MODULATOR', 'GLUTAMATE RECEPTOR ALLOSTERIC MODULATOR, GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR'}, defaulting to 'GLUTAMATE RECEPTOR ALLOSTERIC MODULATOR, GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR'",,NA,,CLC1CCC(OC2CCC(NC(=O)C3CCCCN3)CC2CL)NC1
VU0155056,VU0155056,,CTRP:660119,ctrp,,,,,,,,NA,,
VU0155069,VU0155069,,BRD:BRD-BRD-K48535733-003-01-2;BRD:BRD-K48535733-003-01-2,rep_primary;rep_single_dose,PHOSPHOLIPASE INHIBITOR,PLD1,,,PRECLINICAL,,,NA,,C[C@@H](CN1CCC(CC1)N1C2CCC(CL)CC2[NH]C1=O)NC(=O)C1CCC2CCCCC2C1
VU0238429,VU0238429,,BRD:BRD-BRD-K24187789-001-01-7;BRD:BRD-K24187789-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATOR,CHRM5,,,PRECLINICAL,,,NA,,COC1CCC(CN2C(=O)C(=O)C3CC(OC(F)(F)F)CCC23)CC1
VU0357121,VU0357121,,BRD:BRD-BRD-K86109159-001-02-6;BRD:BRD-K86109159-001-02-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM5,,,PRECLINICAL,,,NA,,CCCCOC1CCC(CC1)C(=O)NC1CCC(F)CC1F
VU0360172,VU0360172,,BRD:BRD-K83649660-003-04-9,rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM5,,,,,,NA,,
VU0361737,VU0361737,,BRD:BRD-BRD-K45462423-001-03-7;BRD:BRD-K45462423-001-03-7,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM4,,,PRECLINICAL,,,NA,,COC1CC(NC(=O)C2CCCCN2)CCC1CL
VU0364439,VU0364439,,BRD:BRD-BRD-K72687424-001-02-6;BRD:BRD-K72687424-001-02-6,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM4,,,PRECLINICAL,,,NA,,CLC1CCCCC1NS(=O)(=O)C1CCC(NC(=O)C2CCCCN2)CC1CL
VU0364770,VU0364770,,BRD:BRD-BRD-K66527818-001-02-6;BRD:BRD-K66527818-001-02-6,rep_multi_dose;rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM4,,,PRECLINICAL,,,NA,,CLC1CCCC(NC(=O)C2CCCCN2)C1
VU10010,VU10010,,BRD:BRD-K12483104-001-02-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATOR,CHRM4,,,,,,NA,,
VU152100,VU152100,,BRD:BRD-K87727457-001-02-9,rep_single_dose,ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATOR,CHRM4,,,,,,NA,,
VU1545,VU1545,,BRD:BRD-BRD-K48371964-001-06-5;BRD:BRD-K48371964-001-06-5,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR,GRM5,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCC(CC1)C(=O)NC1CC(NN1-C1CCCCC1F)-C1CCCCC1
VU29,VU29,,BRD:BRD-BRD-K54783522-001-01-8;BRD:BRD-K54783522-001-01-8,rep_primary;rep_single_dose,GLUTAMATE RECEPTOR POTENTIATOR,GRM5,,,PRECLINICAL,,,NA,,[O-][N+](=O)C1CCC(CC1)C(=O)NC1CC(NN1-C1CCCCC1)-C1CCCCC1
VU591,VU591,,BRD:BRD-K72063794-003-02-9,rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNJ1,,,,,,NA,,
VUBI1,VUBI1,,BRD:BRD-K00126786-001-01-9;BRD:BRD-U00115433-001-01-9,oncref_1;oncref_2,ACTIVATOR OF SOS1,SOS1,,,,"Multiple values for structure_id: {'U00115433', 'K00126786'}, defaulting to None",,NA,,
VUF10166,VUF10166,,BRD:BRD-BRD-K11046126-001-02-0;BRD:BRD-K11046126-001-02-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A;HTR3B,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1NC2CCCCC2NC1CL
VUF10460,VUF10460,,BRD:BRD-BRD-K90082312-001-01-5;BRD:BRD-K90082312-001-01-5,rep_primary;rep_single_dose,HISTAMINE RECEPTOR AGONIST,HRH4,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CC(NC(N)N1)-C1CCCCC1
VUF11207,VUF11207,,BRD:BRD-A93717708-051-01-2;BRD:BRD-BRD-A93717708-051-01-2,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR AGONIST,ACKR3,,,PRECLINICAL,,,NA,,COC1CC(CC(OC)C1OC)C(=O)N(CCC1CCCN1C)C\C(C)=C\C1CCCCC1F
VUMON,VUMON,CHEMBL452231,GDSC2:1809,gdsc,,,,,,,Small molecule,Approved,NRUKOCRGYNPUPR-QBPJDGROSA-N,COC1CC([C@@H]2C3CC4C(CC3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C6CCCS6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)CC(OC)C1O
VX 702,VX 702,,GDSC1:1028,gdsc,,,,,,,,NA,,
VX-11E,VX-11E,,BRD:BRD-BRD-K93725829-001-03-8;BRD:BRD-K93725829-001-03-8;GDSC1:262;GDSC2:2096,gdsc;rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK1,,,PRECLINICAL,,,NA,,CC1CNC(NC2CCC(F)CC2CL)NC1-C1C[NH]C(C1)C(=O)N[C@H](CO)C1CCCC(CL)C1
VX-222,VX-222,CHEMBL3039503,BRD:BRD-BRD-K70610771-001-02-9;BRD:BRD-K70610771-001-02-9,rep_primary;rep_single_dose,HCV INHIBITOR,,,,PHASE 2,,Small molecule,Phase 2,WPMJNLCLKAKMLA-VVPTUSLJSA-N,C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)C1CC(SC1C(O)=O)C#CC(C)(C)C;CC(C)(C)C#CC1CC(N(C(=O)[C@H]2CC[C@H](C)CC2)[C@H]2CC[C@H](O)CC2)C(C(=O)O)S1
VX-680,VX-680,CHEMBL2105657;CHEMBL572878,CTRP:340501,ctrp,,,,,,,Small molecule,Phase 2,GCIKSSRWRFVXBI-UHFFFAOYSA-N;MHFUWOIXNMZFIW-WNQIDUERSA-N,C[C@H](O)C(=O)O.CC1CC(NC2CC(N3CCN(C)CC3)NC(SC3CCC(NC(=O)C4CC4)CC3)N2)N[NH]1;CC1CC(NC2CC(N3CCN(C)CC3)NC(SC3CCC(NC(=O)C4CC4)CC3)N2)N[NH]1
VX-680 VX 680 VX-68,VX-680 VX 680 VX-68,,GDSC1:32;GDSC2:1096,gdsc,,,,,,,,NA,,
VX-702,VX-702,CHEMBL1090090,BRD:BRD-BRD-K07736136-001-04-6;BRD:BRD-K07736136-001-04-6;GDSC1:1028,gdsc;rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,IL1B;IL6;MAPK11;MAPK12;MAPK14;TNF,,,PHASE 2,"Multiple values for repurposing_target: {'IL1B;IL6;MAPK11;MAPK12;MAPK14;TNF', 'MAPK11;MAPK12;MAPK14'}, taking the union",Small molecule,Phase 2,FYSRKRZDBHOFAY-UHFFFAOYSA-N,NC(=O)C1CCC(N(C(N)=O)C2C(F)CCCC2F)NC1-C1CCC(F)CC1F;NC(=O)N(C1CCC(C(N)=O)C(N1)-C1CCC(F)CC1F)C1C(F)CCCC1F
VX-745,VX-745,CHEMBL119385,BRD:BRD-BRD-K91900765-001-07-6;BRD:BRD-K91900765-001-07-6,rep_multi_dose;rep_primary;rep_single_dose,P38 MAPK INHIBITOR,MAPK11;MAPK12;MAPK14,,,PHASE 2,,Small molecule,Phase 2,VEPKQEUBKLEPRA-UHFFFAOYSA-N,FC1CCC(SC2CCC3C(-C4C(CL)CCCC4CL)C(=O)NCN3N2)C(F)C1;O=C1NCN2NC(SC3CCC(F)CC3F)CCC2C1-C1C(CL)CCCC1CL
VX-765,VX-765,CHEMBL2107819,BRD:BRD-BRD-K26712974-001-01-5;BRD:BRD-K26712974-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,CASPASE INHIBITOR,CASP1,,,PHASE 2,,Small molecule,Phase 2,SJDDOCKBXFJEJB-MOKWFATOSA-N,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C1CCC(N)C(CL)C1)C(C)(C)C;CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)C1CCC(N)C(CL)C1)C(C)(C)C
VX-984,VX-984,,BRD:BRD-K00091070-001-01-9,rep_single_dose,,,,,,,,NA,,
VX11E,VX11E,,GDSC1:262;GDSC2:2096,gdsc,,,,,,,,NA,,
VX702,VX702,,GDSC1:1028,gdsc,,,,,,,,NA,,
W-54011,W-54011,,BRD:BRD-A00559310-003-01-1,rep_single_dose,ANAPHYLATOXIN CHEMOTACTIC RECEPTOR ANTAGONIST,C5AR1,,,,,,NA,,
WALRYCIN-B,WALRYCIN-B,,BRD:BRD-K01129913-001-01-5,rep_single_dose,TRANSCRIPTIONAL REGULATORY PROTEIN WALR,,,,,,,NA,,
WARFARIN,WARFARIN,CHEMBL1464,BRD:BRD-A24514565-001-09-7;BRD:BRD-BRD-A24514565-001-09-7,rep_multi_dose;rep_primary;rep_single_dose,VITAMIN K ANTAGONIST,VKORC1,"DEEP VEIN THROMBOSIS (DVT), PULMONARY EMBOLISM (PE), ATRIAL FIBRILLATION (AF), MYOCARDIAL INFARCTION",,LAUNCHED,,Small molecule,Approved,PJVWKTKQMONHTI-UHFFFAOYSA-N,CC(=O)CC(C1CCCCC1)C1C(O)C2CCCCC2OC1=O
WAY-100635,WAY-100635,CHEMBL31354,BRD:BRD-BRD-K69812556-305-02-0;BRD:BRD-K69812556-305-02-0,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR1A,,,PHASE 1,,Small molecule,NA,SBPRIAGPYFYCRT-UHFFFAOYSA-N,COC1CCCCC1N1CCN(CCN(C(=O)C2CCCCC2)C2CCCCN2)CC1
WAY-161503,WAY-161503,,BRD:BRD-A62021152-003-03-4;BRD:BRD-BRD-A62021152-003-03-4,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2C,,,PRECLINICAL,,,NA,,CLC1CC2NC(=O)C3CNCCN3C2CC1CL
WAY-170523,WAY-170523,,BRD:BRD-BRD-K36198571-001-02-0;BRD:BRD-K36198571-001-02-0,rep_multi_dose;rep_primary;rep_single_dose,METALLOPROTEINASE INHIBITOR,MMP13,,,PRECLINICAL,,,NA,,CC1CC(C)C(N(CC2CCCCC2)S(=O)(=O)C2CCC(OCCNC(=O)C3CC4CCCCC4O3)CC2)C(C1)C(=O)NO
WAY-181187,WAY-181187,,BRD:BRD-K00079493-001-02-9,rep_single_dose,,,,,,,,NA,,
WAY-200070,WAY-200070,,BRD:BRD-BRD-K08223200-001-01-1;BRD:BRD-K08223200-001-01-1,rep_primary;rep_single_dose,ESTROGEN RECEPTOR AGONIST,ERBB2;ERBB3;ERBB4;ESR2,,,PRECLINICAL,,,NA,,OC1CCC(CC1)-C1NC2CC(O)CC(BR)C2O1
WAY-207024,WAY-207024,,BRD:BRD-BRD-K08657056-300-01-1;BRD:BRD-K08657056-300-01-1,rep_primary;rep_single_dose,GONADOTROPIN RELEASING FACTOR HORMONE RECEPTOR ANTAGONIST,GNRHR;HRH2;TACR2,,,PRECLINICAL,,,NA,,CC(C)(C)C1CCC(CC1)-C1NC2CCCC(N3CCN(CC4CCC5NCCNC5C4)CC3)C2[NH]1
WAY-208466,WAY-208466,,BRD:BRD-BRD-K63483542-300-01-6;BRD:BRD-K63483542-300-01-6,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,DRD2;HTR2A;HTR2C;HTR6;HTR7,,,PRECLINICAL,,,NA,,CN(C)CCN1CC(C2CCCNC12)S(=O)(=O)C1CCCC(F)C1
WAY-213613,WAY-213613,,BRD:BRD-BRD-K96758128-001-01-8;BRD:BRD-K96758128-001-01-8,rep_primary;rep_single_dose,GLUTAMATE INHIBITOR,SLC1A2,,,PRECLINICAL,,,NA,,N[C@@H](CC(=O)NC1CCC(OC2CC(F)C(F)CC2BR)CC1)C(O)=O
WAY-255348,WAY-255348,,BRD:BRD-K00004556-001-01-9,rep_single_dose,PROGESTERONE RECEPTOR ANTAGONIST,,,,,,,NA,,
WAY-316606,WAY-316606,,BRD:BRD-K61871885-001-01-3,rep_single_dose,SECRETED FRIZZLED RELATED PROTEIN INHIBITOR,SFRP1,,,,,,NA,,
WAY-362450,WAY-362450,CHEMBL454138,BRD:BRD-BRD-K54640016-001-04-7;BRD:BRD-K54640016-001-04-7;CTRP:660821,ctrp;rep_primary;rep_single_dose,FXR AGONIST,NR1H4,,,PHASE 1,,Small molecule,Phase 1,INASOKQDNHHMRE-UHFFFAOYSA-N,CC(C)OC(=O)C1=CN(C(=O)C2CCC(F)C(F)C2)CC(C)(C)C2C1[NH]C1CCCCC21;CC(C)OC(=O)C1=CN(CC(C)(C)C2C1[NH]C1CCCCC21)C(=O)C1CCC(F)C(F)C1
WAY-600,WAY-600,,BRD:BRD-BRD-K85920262-001-02-1;BRD:BRD-K85920262-001-02-1,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,C(N1CCC(CC1)N1NCC2C(NC(NC12)-C1CCC2[NH]CCC2C1)N1CCOCC1)C1CCCNC1
WAY-629,WAY-629,,BRD:BRD-K55430733-003-03-9,rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR2C,,,,,,NA,,
WB-4101,WB-4101,,BRD:BRD-A01493904-003-12-1;BRD:BRD-BRD-A01493904-003-12-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C;HTR1A,,,PRECLINICAL,,,NA,,COC1CCCC(OC)C1OCCNCC1COC2CCCCC2O1
WDR5-0103,WDR5-0103,,BRD:BRD-BRD-K47726410-001-01-2;BRD:BRD-K47726410-001-01-2,rep_primary;rep_single_dose,HISTONE LYSINE METHYLTRANSFERASE INHIBITOR,WDR5,,,PRECLINICAL,,,NA,,COC(=O)C1CCC(N2CCN(C)CC2)C(NC(=O)C2CCCC(OC)C2)C1
WEE1 INHIBITOR,WEE1 INHIBITOR,,GDSC1:1046;GDSC2:1046,gdsc,,,,,,,,NA,,
WEHI-345-ANALOG,WEHI-345-ANALOG,,BRD:BRD-BRD-K55487946-001-01-3;BRD:BRD-K55487946-001-01-3,rep_primary;rep_single_dose,SRC INHIBITOR,,,,PRECLINICAL,,,NA,,CC1CCC(CC1)-C1NN(C2NCNC(N)C12)C(C)(C)CNC(=O)C1NCCCC1C
WEHI-539,WEHI-539,,GDSC2:1997,gdsc,,,,,,,,NA,,
WEHI539,WEHI539,,GDSC2:1997,gdsc,,,,,,,,NA,,
WH-4-023,WH-4-023,,BRD:BRD-K50199947-001-07-9;GDSC1:56,gdsc;rep_single_dose,SRC INHIBITOR,LCK;SRC,,,,,,NA,,
WHI-P154,WHI-P154,,BRD:BRD-BRD-K07487750-001-03-3;BRD:BRD-K07487750-001-03-3,rep_multi_dose;rep_primary;rep_single_dose,JAK INHIBITOR,EGFR;JAK1;JAK2;JAK3,,,PRECLINICAL,,,NA,,COC1CC2NCNC(NC3CCC(O)C(BR)C3)C2CC1OC
WHI-P97,WHI-P97,,GDSC1:288,gdsc,,,,,,,,NA,,
WIKI 4,WIKI 4,,GDSC2:1940,gdsc,,,,,,,,NA,,
WIKI-4,WIKI-4,,GDSC2:1940,gdsc,,,,,,,,NA,,
WIKI4,WIKI4,,BRD:BRD-BRD-K19316653-001-02-0;BRD:BRD-K19316653-001-02-0;GDSC2:1940,gdsc;rep_primary;rep_single_dose,"TANKYRASE INHIBITOR, WNT PATHWAY INHIBITOR",TNKS2,,,PRECLINICAL,"Multiple values for MOA: {'WNT PATHWAY INHIBITOR, TANKYRASE INHIBITOR', 'TANKYRASE INHIBITOR, WNT PATHWAY INHIBITOR'}, defaulting to 'TANKYRASE INHIBITOR, WNT PATHWAY INHIBITOR'",,NA,,COC1CCC(CC1)-N1C(SCCCN2C(=O)C3CCCC4CCCC(C2=O)C34)NNC1-C1CCNCC1
WIN-18446,WIN-18446,,BRD:BRD-BRD-K30930903-001-01-3;BRD:BRD-K30930903-001-01-3,rep_primary;rep_single_dose,ALDEHYDE DEHYDROGENASE INHIBITOR,ALDH1A2,,,PRECLINICAL,,,NA,,CLC(CL)C(=O)NCCCCCCCCNC(=O)C(CL)CL
WIN-64338,WIN-64338,,BRD:BRD-BRD-K22662557-300-01-7;BRD:BRD-K22662557-300-01-7,rep_primary;rep_single_dose,BRADYKININ RECEPTOR ANTAGONIST,BDKRB2,,,PRECLINICAL,,,NA,,CCCC[P+](CCCC)(CCCC)CC1CCC(NC(=O)[C@H](CC2CCC3CCCCC3C2)N\C(NC2CCCCC2)=N\C2CCCCC2)CC1
WISKOSTATIN,WISKOSTATIN,CHEMBL411084,BRD:BRD-A18579359-001-05-9,rep_single_dose,"ACTIN RELATED PROTEIN INHIBITOR, NEURAL WISKOTT-ALDRICH SYNDROME PROTEIN INHIBITOR",WASL,,,,,Small molecule,NA,XUBJEDZHBUPBKL-ZDUSSCGKSA-N,CN(C)C[C@H](O)CN1C2CCC(BR)CC2C2CC(BR)CCC21
WM-1119,WM-1119,CHEMBL4456585,BRD:BRD-U00115285-001-01-9,oncref_1,INHIBITOR OF KAT6A,KAT6A,,,,,Unknown,NA,QLXULUNLCRKWRD-UHFFFAOYSA-N,O=C(NNS(=O)(=O)C1CCCCC1F)C1CC(F)CC(-C2CCCCN2)C1
WM-8014,WM-8014,,BRD:BRD-U00115306-001-01-9,oncref_1,INHIBITOR OF KAT6A,KAT6A,,,,,,NA,,
WNT INHIBITOR IWP-2,WNT INHIBITOR IWP-2,,GDSC2:1576,gdsc,,,,,,,,NA,,
WORTMANNIN,WORTMANNIN,CHEMBL428496,BRD:BRD-K87343924-001-16-9,rep_single_dose,PI3K INHIBITOR,PI4KA;PI4KB;PIK3CA;PIK3CD;PIK3CG;PIK3R1;PLK1;PRKDC,,,,,Small molecule,NA,QDLHCMPXEPAAMD-QAIWCSMKSA-N,COC[C@H]1OC(=O)C2COC3C2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O
WP1066,WP1066,CHEMBL1923234,BRD:BRD-BRD-K05445342-001-05-3;BRD:BRD-K05445342-001-05-3,rep_multi_dose;rep_primary;rep_single_dose,STAT INHIBITOR,STAT3,,,PHASE 1,,Small molecule,Phase 1,VFUAJMPDXIRPKO-LQELWAHVSA-N,C[C@H](NC(=O)/C(C#N)=C/C1CCCC(BR)N1)C1CCCCC1;C[C@H](NC(=O)C(=C\C1CCCC(BR)N1)\C#N)C1CCCCC1
WP1130,WP1130,,BRD:BRD-BRD-K43644456-001-04-0;BRD:BRD-K43644456-001-04-0;CTRP:660432,ctrp;rep_multi_dose;rep_primary;rep_single_dose,DEUBIQUITINASE INHIBITOR,JAK2;UCHL5;USP14;USP9X,,,PRECLINICAL,,,NA,,CCC[C@H](NC(=O)C(=C\C1CCCC(BR)N1)\C#N)C1CCCCC1
WP921,WP921,,BRD:BRD-K00005248-001-01-9,rep_single_dose,,,,,,,,NA,,
WR99210,WR99210,,BRD:BRD-BRD-K45973863-001-01-4;BRD:BRD-K45973863-001-01-4,rep_primary;rep_single_dose,DIHYDROFOLATE REDUCTASE INHIBITOR,TYMS,MALARIA,,PRECLINICAL,,,NA,,CC1(C)N=C(N)N=C(N)N1OCCCOC1CC(CL)C(CL)CC1CL
WS6,WS6,,BRD:BRD-K00126472-001-01-9,oncref_2,INHIBITOR OF PA2G4,PA2G4,,,,,,NA,,
WWL-113,WWL-113,,BRD:BRD-BRD-K49389158-001-01-3;BRD:BRD-K49389158-001-01-3,rep_primary;rep_single_dose,CARBOXYLESTERASE INHIBITOR,CES3,,,PRECLINICAL,,,NA,,CCOC(=O)C1CCC(CC1)-C1CCC(OC(=O)N(C)CC2CCCC(C2)-C2CCNCC2)CC1
WWL-123,WWL-123,,BRD:BRD-BRD-K83176916-001-01-4;BRD:BRD-K83176916-001-01-4,rep_primary;rep_single_dose,MONOACYLGLYCEROL LIPASE INHIBITOR,ABHD6,,,PRECLINICAL,,,NA,,CN(CC1CCCC(C1)-C1CCCCC1)C(=O)OC1CCC(CC1)-C1CCC(CC1)C(N)=O
WY-16922,WY-16922,,BRD:BRD-BRD-K43419711-001-01-4;BRD:BRD-K43419711-001-01-4,rep_primary;rep_single_dose,HISTAMINE RELEASE INHIBITOR,,,,PHASE 1,,,NA,,CCOC(=O)C(=O)NC1CCCC(OC)C1C(N)=O
WYE-125132,WYE-125132,,BRD:BRD-A45498368-001-07-1;BRD:BRD-BRD-A45498368-001-07-1;GDSC1:317,gdsc;rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,CNC(=O)NC1CCC(CC1)-C1NC(N2CC3CCC(C2)O3)C2CNN(C3CCC4(CC3)OCCO4)C2N1
WYE-354,WYE-354,,BRD:BRD-BRD-K77008974-001-03-2;BRD:BRD-K77008974-001-03-2,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,COC(=O)NC1CCC(CC1)-C1NC(N2CCOCC2)C2CNN(C3CCN(CC3)C(=O)OC)C2N1
WYE-687,WYE-687,,BRD:BRD-K49900195-300-02-9,rep_single_dose,MTOR INHIBITOR,MTOR,,,,,,NA,,
WZ 4003,WZ 4003,,GDSC2:1614,gdsc,,,,,,,,NA,,
WZ-1-84,WZ-1-84,,GDSC1:59,gdsc,,,,,,,,NA,,
WZ-3146,WZ-3146,,BRD:BRD-BRD-K73293050-001-03-1;BRD:BRD-K73293050-001-03-1,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CCC(NC2NCC(CL)C(OC3CCCC(NC(=O)C=C)C3)N2)CC1
WZ-4002,WZ-4002,,BRD:BRD-BRD-K72420232-001-12-3;BRD:BRD-K72420232-001-12-3,rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR;ERBB2,,,PRECLINICAL,,,NA,,COC1CC(CCC1NC1NCC(CL)C(OC2CCCC(NC(=O)C=C)C2)N1)N1CCN(C)CC1
WZ3105,WZ3105,,GDSC1:252,gdsc,,,,,,,,NA,,
WZ4002,WZ4002,,CTRP:640366,ctrp,,,,,,,,NA,,
WZ4003,WZ4003,,BRD:BRD-BRD-K45909031-001-01-5;BRD:BRD-K45909031-001-01-5;GDSC2:1614,gdsc;rep_primary;rep_single_dose,AMPK INHIBITOR,NUAK1;NUAK2,,,PRECLINICAL,,,NA,,CCC(=O)NC1CCCC(OC2NC(NC3CCC(CC3OC)N3CCN(C)CC3)NCC2CL)C1
WZ8040,WZ8040,,BRD:BRD-BRD-K81728688-001-04-4;BRD:BRD-K81728688-001-04-4;CTRP:628614,ctrp;rep_multi_dose;rep_primary;rep_single_dose,EGFR INHIBITOR,EGFR,,,PRECLINICAL,,,NA,,CN1CCN(CC1)C1CCC(NC2NCC(CL)C(SC3CCCC(NC(=O)C=C)C3)N2)CC1
WZ811,WZ811,,BRD:BRD-BRD-K25359048-001-02-6;BRD:BRD-K25359048-001-02-6,rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CXCR4,,,PRECLINICAL,,,NA,,C(NC1CCCCN1)C1CCC(CNC2CCCCN2)CC1
XALIPRODEN,XALIPRODEN,CHEMBL1512580,BRD:BRD-BRD-K88358234-003-04-8;BRD:BRD-K88358234-003-04-8,rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A,,,PHASE 3,,Small molecule,Phase 3,WJJYZXPHLSLMGE-UHFFFAOYSA-N,FC(F)(F)C1CCCC(C1)C1=CCN(CCC2CCC3CCCCC3C2)CC1;FC(F)(F)C1CCCC(C2=CCN(CCC3CCC4CCCCC4C3)CC2)C1
XALKORI,XALKORI,CHEMBL601719,GDSC1:37;GDSC2:1083,gdsc,,,,,,,Small molecule,Approved,KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](OC1CC(-C2CNN(C3CCNCC3)C2)CNC1N)C1C(CL)CCC(F)C1CL
XAMOTEROL,XAMOTEROL,CHEMBL75753,BRD:BRD-A59337442-051-05-3;BRD:BRD-BRD-A59337442-051-05-3,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB1,,,PHASE 3,,Small molecule,Approved,DXPOSRCHIDYWHW-UHFFFAOYSA-N,O=C(NCCNCC(O)COC1CCC(O)CC1)N1CCOCC1;OC(CNCCNC(=O)N1CCOCC1)COC1CCC(O)CC1
XANOMELINE,XANOMELINE,CHEMBL21536,BRD:BRD-BRD-K72815923-034-01-2;BRD:BRD-K72815923-034-01-2,rep_multi_dose;rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR AGONIST,CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR6;HTR7,,,PHASE 3,,Small molecule,Phase 3,JOLJIIDDOBNFHW-UHFFFAOYSA-N,CCCCCCOC1NSNC1C1=CCCN(C)C1
XANTHONE,XANTHONE,CHEMBL186784,BRD:BRD-BRD-K27135764-001-08-7;BRD:BRD-K27135764-001-08-7,rep_primary;rep_single_dose,ANTIMALARIAL AGENT,,,,PRECLINICAL,,Small molecule,NA,JNELGWHKGNBSMD-UHFFFAOYSA-N,O=C1C2CCCCC2OC2CCCCC12
XAV 939,XAV 939,,GDSC1:1268;GDSC2:1268,gdsc,,,,,,,,NA,,
XAV-939,XAV-939,,BRD:BRD-BRD-K12762134-001-06-2;BRD:BRD-K12762134-001-06-2;GDSC1:1268;GDSC2:1268,gdsc;rep_primary;rep_single_dose,TANKYRASE INHIBITOR,TNKS;TNKS2,,,PRECLINICAL,,,NA,,OC1NC(NC2CCSCC12)-C1CCC(CC1)C(F)(F)F
XAV939,XAV939,,GDSC1:1268;GDSC2:1268,gdsc,,,,,,,,NA,,
XBD173,XBD173,CHEMBL513922,BRD:BRD-BRD-K45875383-001-01-2;BRD:BRD-K45875383-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR LIGAND,TSPO,,,PHASE 2,,Small molecule,Phase 2,NBMBIEOUVBHEBM-UHFFFAOYSA-N,CCN(CC1CCCCC1)C(=O)CN1C(=O)N(C)C2CNC(-C3CCCCC3)NC21;CCN(CC1CCCCC1)C(=O)CN1C2NC(NCC2N(C)C1=O)-C1CCCCC1
XD-14,XD-14,,BRD:BRD-K69211575-001-02-9,rep_single_dose,BROMODOMAIN INHIBITOR,BRD2;BRD3;BRD4;BRDT,,,,,,NA,,
XE-991,XE-991,,BRD:BRD-BRD-K42748308-300-02-0;BRD:BRD-K42748308-300-02-0,rep_primary;rep_single_dose,POTASSIUM CHANNEL BLOCKER,KCNQ1;KCNQ2;KCNQ3;KCNQ4;KCNQ5,,,PRECLINICAL,,,NA,,O=C1C2CCCCC2C(CC2CCNCC2)(CC2CCNCC2)C2CCCCC12
XENALIPIN,XENALIPIN,CHEMBL2104509,BRD:BRD-BRD-K99506538-001-03-8;BRD:BRD-K99506538-001-03-8,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,IQOMYCGTGFGDFN-UHFFFAOYSA-N,O=C(O)C1CCCCC1-C1CCC(C(F)(F)F)CC1;OC(=O)C1CCCCC1-C1CCC(CC1)C(F)(F)F
XI-006,XI-006,,GDSC1:269,gdsc,,,,,,,,NA,,
XIBENOLOL,XIBENOLOL,CHEMBL347795,BRD:BRD-A21446384-001-01-1;BRD:BRD-BRD-A21446384-001-01-1,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,,,,PHASE 3,,Small molecule,Unknown,RKUQLAPSGZJLGP-UHFFFAOYSA-N,CC1CCCC(OCC(O)CNC(C)(C)C)C1C
XILOBAM,XILOBAM,CHEMBL382769,BRD:BRD-BRD-K79633074-001-01-8;BRD:BRD-K79633074-001-01-8,rep_multi_dose;rep_primary;rep_single_dose,,,,,PHASE 1,,Small molecule,Unknown,PAXRPWSXCPTPCA-NTCAYCPXSA-N,CC1CCCC(C)C1NC(=O)/N=C1\CCCN1C;CN1CCC\C1=N\C(=O)NC1C(C)CCCC1C
XIPAMIDE,XIPAMIDE,CHEMBL517199,BRD:BRD-BRD-K27393415-001-01-0;BRD:BRD-K27393415-001-01-0,rep_primary;rep_single_dose,CARBONIC ANHYDRASE INHIBITOR,SLC12A3,"EDEMA, HYPERTENSION",,LAUNCHED,,Small molecule,Approved,MTZBBNMLMNBNJL-UHFFFAOYSA-N,CC1CCCC(C)C1NC(=O)C1CC(C(CL)CC1O)S(N)(=O)=O;CC1CCCC(C)C1NC(=O)C1CC(S(N)(=O)=O)C(CL)CC1O
XL147,XL-147;XL147,CHEMBL3218575;CHEMBL3360203,BRD:BRD-BRD-K95901403-001-04-5;BRD:BRD-K95901403-001-04-5;GDSC1:372,gdsc;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CA;PIK3CD;PIK3CG,,,PHASE 2,,Small molecule,Phase 2,MQMKRQLTIWPEDM-UHFFFAOYSA-N;QINPEPAQOBZPOF-UHFFFAOYSA-N,CC1CCC(CC1)S(=O)(=O)NC1NC2CCCCC2NC1NC1CCC2NSNC2C1;CC1CCC(S(=O)(=O)NC2NC3CCCCC3NC2NC2CCC3NSNC3C2)CC1;COC1CCC(CL)C(NC2NC3CCCCC3NC2NS(=O)(=O)C2CCCC(NC(=O)C(C)(C)N)C2)C1
XL-184,XL-184,CHEMBL2103868;CHEMBL2105717,GDSC1:249,gdsc,,,,,,,Small molecule,Approved,HFCFMRYTXDINDK-WNQIDUERSA-N;ONIQOQHATWINJY-UHFFFAOYSA-N,COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC;COC1CC2NCCC(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3)C2CC1OC.O=C(O)C[C@H](O)C(=O)O
XL647,XL-647;XL647,CHEMBL3544983,BRD:BRD-BRD-K03765900-001-01-9;BRD:BRD-K03765900-001-01-9,rep_multi_dose;rep_primary;rep_single_dose,"EGFR INHIBITOR, VEGFR INHIBITOR",EGFR;EPHB4;ERBB2;FLT4;KDR,,,PHASE 3,,Small molecule,Phase 3,HVXKQKFEHMGHSL-QKDCVEJESA-N,COC1CC2C(NC3CCC(CL)C(CL)C3F)NCNC2CC1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1;COC1CC2C(NC3CCC(CL)C(CL)C3F)NCNC2CC1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1
XL-765,XL-765,CHEMBL3545366,GDSC1:375,gdsc,,,,,,,Small molecule,Phase 2,RGHYDLZMTYDBDT-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC[NH]N2)CC2C(C)NC(N)NC21
XL-880,XL-880,CHEMBL1230609,GDSC1:308;GDSC2:2040,gdsc,,,,,,,Small molecule,Phase 2,CXQHYVUVSFXTMY-UHFFFAOYSA-N,COC1CC2C(OC3CCC(NC(=O)C4(C(=O)NC5CCC(F)CC5)CC4)CC3F)CCNC2CC1OCCCN1CCOCC1
XL019,XL019,CHEMBL3545328,BRD:BRD-BRD-K04266228-001-03-8;BRD:BRD-K04266228-001-03-8,rep_primary;rep_single_dose,JAK INHIBITOR,JAK1;JAK2;JAK3,,,PHASE 1,,Small molecule,Phase 1,ISOCDPQFIXDIMS-UHFFFAOYSA-N,O=C(NC1CCC(-C2CCNC(NC3CCC(N4CCOCC4)CC3)N2)CC1)C1CCCN1;O=C(NC1CCC(CC1)-C1CCNC(NC2CCC(CC2)N2CCOCC2)N1)[C@@H]1CCCN1
XL041,XL041,,BRD:BRD-K00003439-001-01-9,rep_single_dose,LXR AGONIST,,,,,,,NA,,
XL228,XL228,CHEMBL3545085,BRD:BRD-BRD-K14274271-001-02-8;BRD:BRD-K14274271-001-02-8,rep_primary;rep_single_dose,"ABL KINASE INHIBITOR, INSULIN GROWTH FACTOR RECEPTOR INHIBITOR, SRC INHIBITOR",IGF1R;SRC,,,PHASE 1,,Small molecule,Phase 1,ALKJNCZNEOTEMP-UHFFFAOYSA-N,CC(C)C1CC(CNC2NC(NC3CC([NH]N3)C3CC3)CC(N2)N2CCN(C)CC2)ON1;CC(C)C1CC(CNC2NC(NC3CC(C4CC4)[NH]N3)CC(N3CCN(C)CC3)N2)ON1
XL388,XL388,,BRD:BRD-BRD-K03549949-001-01-0;BRD:BRD-K03549949-001-01-0,rep_multi_dose;rep_primary;rep_single_dose,MTOR INHIBITOR,MTOR,,,PRECLINICAL,,,NA,,CC1C(F)C(CCC1C(=O)N1CCOC2CCC(CC2C1)-C1CCC(N)NC1)S(C)(=O)=O
XL765,XL765,CHEMBL3545366,CTRP:660304,ctrp,,,,,,,Small molecule,Phase 2,RGHYDLZMTYDBDT-UHFFFAOYSA-N,CCN1C(=O)C(-C2CC[NH]N2)CC2C(C)NC(N)NC21
XL888,XL888,CHEMBL4297451,BRD:BRD-A03506276-001-01-5;BRD:BRD-BRD-A03506276-001-01-5,rep_multi_dose;rep_primary;rep_single_dose,HSP INHIBITOR,,,,PHASE 1,,Small molecule,Phase 1,LHGWWAFKVCIILM-HLRQEUIKSA-N,CC[C@@H](C)NC1CC(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C2CCC(C(=O)C3CC3)CN2)C(C)CC1C(N)=O;CC[C@@H](C)NC1CC(C(=O)NC2CC3CCC(C2)N3C2CCC(CN2)C(=O)C2CC2)C(C)CC1C(N)=O
XMD 8-92,XMD 8-92,,GDSC1:1164,gdsc,,,,,,,,NA,,
XMD11-85H,XMD11-85H,,GDSC1:1158,gdsc,,,,,,,,NA,,
XMD13-2,XMD13-2,,GDSC1:330,gdsc,,,,,,,,NA,,
XMD14-99,XMD14-99,,GDSC1:253,gdsc,,,,,,,,NA,,
XMD15-27,XMD15-27,,GDSC1:332,gdsc,,,,,,,,NA,,
XMD17-109,XMD17-109,,BRD:BRD-BRD-K48449981-001-02-7;BRD:BRD-K48449981-001-02-7,rep_primary;rep_single_dose,MAP KINASE INHIBITOR,MAPK7,,,PRECLINICAL,,,NA,,CCOC1CC(CCC1NC1NCC2N(C)C(=O)C3CCCCC3N(C3CCCC3)C2N1)C(=O)N1CCC(CC1)N1CCN(C)CC1
XMD8-85,XMD8-85,,GDSC1:106,gdsc,,,,,,,,NA,,
XMD8-92,XMD8-92,,BRD:BRD-K50387473-001-11-0;GDSC1:1164,gdsc;rep_single_dose,MAP KINASE INHIBITOR,DCLK2;MAPK7;PLK4;TNK1,,,,,,NA,,
XYLAZINE,XYLAZINE,CHEMBL297362,BRD:BRD-BRD-K21565985-001-22-5;BRD:BRD-K21565985-001-22-5,rep_multi_dose;rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA2A;ADRA2B;ADRA2C,ANESTHETIC,,LAUNCHED,,Small molecule,Unknown,BPICBUSOMSTKRF-UHFFFAOYSA-N,CC1CCCC(C)C1NC1=NCCCS1
XYLOMETAZOLINE,XYLOMETAZOLINE,CHEMBL312448,BRD:BRD-BRD-K08356259-003-24-7;BRD:BRD-K08356259-003-24-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRA1A;ADRA1B;ADRA1D;ADRA2A;ADRA2B;ADRA2C,"NASAL CONGESTION, ALLERGIC RHINITIS",,LAUNCHED,,Small molecule,Approved,HUCJFAOMUPXHDK-UHFFFAOYSA-N,CC1CC(C(C)(C)C)CC(C)C1CC1=NCCN1;CC1CC(CC(C)C1CC1=NCCN1)C(C)(C)C
XYLOSE,XYLOSE,CHEMBL502135,BRD:BRD-BRD-K10759144-001-04-3;BRD:BRD-K10759144-001-04-3,rep_primary;rep_single_dose,,,,,LAUNCHED,,Small molecule,Approved,SRBFZHDQGSBBOR-IOVATXLUSA-N,OC[C@@H](O)[C@H](O)[C@@H](O)C=O;OC1OC[C@@H](O)[C@H](O)[C@H]1O
Y-11,Y-11,,BRD:BRD-BRD-K09317629-004-01-7;BRD:BRD-K09317629-004-01-7,rep_primary;rep_single_dose,FOCAL ADHESION KINASE INHIBITOR,PTK2,,,PRECLINICAL,,,NA,,OCC[N+]12CN3CN(CN(C3)C1)C2
Y-134,Y-134,,BRD:BRD-BRD-K94832621-001-02-3;BRD:BRD-K94832621-001-02-3,rep_primary;rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,ESR1;ESR2,,,PRECLINICAL,,,NA,,CC(C)N1CCN(CC1)C1CCC(CC1)C(=O)C1C(SC2CC(O)CCC12)-C1CCC(O)CC1
Y-26763,Y-26763,,BRD:BRD-BRD-K45117373-001-02-9;BRD:BRD-K45117373-001-02-9,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNJ8,,,PHASE 1,,,NA,,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)OC2CCC(CC12)C#N
Y-27152,Y-27152,,BRD:BRD-BRD-K42679050-001-02-1;BRD:BRD-K42679050-001-02-1,rep_primary;rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,KCNJ8,,,PHASE 1,,,NA,,CC(=O)N(OCC1CCCCC1)[C@H]1[C@H](O)C(C)(C)OC2CCC(CC12)C#N
Y-27632,Y-27632,CHEMBL559147,BRD:BRD-BRD-K44084986-300-08-4;BRD:BRD-K44084986-300-08-4,rep_multi_dose;rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,PKIA;PKN2;PRKACA;PRKCE;ROCK1;ROCK2,,,PRECLINICAL,,Small molecule,NA,IYOZTVGMEWJPKR-IJLUTSLNSA-N,C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)NC1CCNCC1;C[C@@H](N)[C@H]1CC[C@H](C(=O)NC2CCNCC2)CC1
Y-29794,Y-29794,,BRD:BRD-K48449073-034-03-9,rep_single_dose,PROLYL ENDOPEPTIDASE INHIBITOR,PREP,,,,,,NA,,
Y-320,Y-320,,BRD:BRD-BRD-K96259238-001-01-4;BRD:BRD-K96259238-001-01-4,rep_multi_dose;rep_primary;rep_single_dose,INTERLEUKIN INHIBITOR,IL17A,,,PRECLINICAL,,,NA,,CC1C(CNN1-C1CCC(CL)CC1)C(=O)NC1CCC(N2CCC(CC2)N2CCOCC2)C(C1)C#N
Y-39983,Y-39983,CHEMBL571948,BRD:BRD-BRD-K56751279-300-01-4;BRD:BRD-K56751279-300-01-4;GDSC1:309,gdsc;rep_multi_dose;rep_primary;rep_single_dose,RHO ASSOCIATED KINASE INHIBITOR,ROCK1;ROCK2,,,PHASE 2,,Small molecule,Phase 1,JTVBXQAYBIJXRP-SNVBAGLBSA-N,C[C@@H](N)C1CCC(C(=O)NC2CCNC3[NH]CCC23)CC1;C[C@@H](N)C1CCC(CC1)C(=O)NC1CCNC2[NH]CCC12
YC-1,YC-1,,BRD:BRD-K60476892-001-17-9,rep_single_dose,GUANYLYL CYCLASE ACTIVATOR,GUCY1A2;GUCY1A3;GUCY1B3;HIF1A,,,,,,NA,,
YIL-781,YIL-781,,BRD:BRD-K91403886-003-02-9,rep_single_dose,GHRELIN RECEPTOR ANTAGONIST,GHSR,,,,,,NA,,
YK 4-279,YK 4-279,,CTRP:632103;GDSC1:1239;GDSC2:1239,ctrp;gdsc,,,,,,,,NA,,
YK-4-279,YK-4-279,,BRD:BRD-A62182663-001-03-0;BRD:BRD-BRD-A62182663-001-03-0;GDSC1:1239;GDSC2:1239,gdsc;rep_primary;rep_single_dose,APOPTOSIS INHIBITOR,EWSR1;FLI1,,,PRECLINICAL,,,NA,,COC1CCC(CC1)C(=O)CC1(O)C(=O)NC2C1C(CL)CCC2CL
YL0919,YL0919,,BRD:BRD-K00003390-003-01-9,rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),,,,,,,NA,,
YL54,YL54,,CTRP:651298,ctrp,,,,,,,,NA,,
YM 155,YM 155,CHEMBL2105734,GDSC1:268;GDSC2:1941,gdsc,,,,,,,Small molecule,Phase 2,QBIYUDDJPRGKNJ-UHFFFAOYSA-M,COCC[N+]1C2C(N(CC3CNCCN3)C1C)C(=O)C1CCCCC1C2=O.[BR-]
YM 201636,YM 201636,,GDSC1:310,gdsc,,,,,,,,NA,,
YM022,YM-022;YM022,,BRD:BRD-BRD-K09436144-001-01-7;BRD:BRD-K09436144-001-01-7,rep_primary;rep_single_dose,CCK RECEPTOR ANTAGONIST,CCKBR,,,PHASE 2,,,NA,,CC1CCCC(NC(=O)N[C@@H]2N=C(C3CCCCC3)C3CCCCC3N(CC(=O)C3CCCCC3C)C2=O)C1
YM-201636,YM-201636,,BRD:BRD-BRD-K48488978-001-05-3;BRD:BRD-K48488978-001-05-3;GDSC1:310,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,,,,PRECLINICAL,,,NA,,NC1CCC(CN1)C(=O)NC1CCCC(C1)-C1NC(N2CCOCC2)C2OC3NCCCC3C2N1
YM-244769,YM-244769,,BRD:BRD-K52087522-300-02-9,rep_single_dose,SODIUM/CALCIUM EXCHANGE INHIBITOR,,,,,,,NA,,
YM-298198,YM-298198,,BRD:BRD-K59650319-003-04-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1,,,,,,NA,,
YM-298198-DESMETHYL,YM-298198-DESMETHYL,,BRD:BRD-K48059230-003-03-9,rep_single_dose,GLUTAMATE RECEPTOR ANTAGONIST,GRM1,,,,,,NA,,
YM-511,YM-511,,BRD:BRD-BRD-K38398115-001-01-9;BRD:BRD-K38398115-001-01-9,rep_primary;rep_single_dose,AROMATASE INHIBITOR,CYP19A1,,,PHASE 2,,,NA,,BRC1CCC(CN(C2CCC(CC2)C#N)N2CNNC2)CC1
YM-58483,YM-58483,,BRD:BRD-BRD-K42563464-001-01-9;BRD:BRD-K42563464-001-01-9,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,TRPC3;TRPC5;TRPM4,,,PRECLINICAL,,,NA,,CC1NNSC1C(=O)NC1CCC(CC1)-N1NC(CC1C(F)(F)F)C(F)(F)F
YM-750,YM-750,,BRD:BRD-BRD-K91716465-001-01-2;BRD:BRD-K91716465-001-01-2,rep_primary;rep_single_dose,ACAT INHIBITOR,SOAT1,,,PHASE 1,,,NA,,CC1CC(C)C(NC(=O)N(CC2CCC-3C(CC4CCCCC-34)C2)C2CCCCCC2)C(C)C1
YM-90709,YM-90709,,BRD:BRD-K06712146-001-04-9,rep_single_dose,IL5 INHIBITOR,CSF2RB;IL5RA,,,,,,NA,,
YM-976,YM-976,,BRD:BRD-BRD-K12932420-001-02-3;BRD:BRD-K12932420-001-02-3,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4A,,,PHASE 1,,,NA,,CCC1CCC2C(NC(=O)N(CC)C2N1)-C1CCCC(CL)C1
YM155,YM155,CHEMBL2105734,GDSC1:268;GDSC2:1941,gdsc,,,,,,,Small molecule,Phase 2,QBIYUDDJPRGKNJ-UHFFFAOYSA-M,COCC[N+]1C2C(N(CC3CNCCN3)C1C)C(=O)C1CCCCC1C2=O.[BR-]
YM201636,YM201636,,GDSC1:310,gdsc,,,,,,,,NA,,
YODA-1,YODA-1,,BRD:BRD-BRD-K88570498-001-01-9;BRD:BRD-K88570498-001-01-9,rep_primary;rep_single_dose,PIEZO CHANNEL ACTIVATOR,PIEZO1,,,PRECLINICAL,,,NA,,CLC1CCCC(CL)C1CSC1NNC(S1)-C1CNCCN1
YOHIMBINE,YOHIMBINE,CHEMBL15245,BRD:BRD-BRD-K35586044-003-15-4;BRD:BRD-K35586044-003-15-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR ANTAGONIST,ADRA2A;ADRA2B;ADRA2C;DRD2;DRD3;HTR1A;HTR1B;HTR1D;HTR1E;HTR1F;HTR2A;HTR2B;HTR2C;HTR5A;HTR7;KCNJ1;KCNJ10;KCNJ11;KCNJ12;KCNJ14;KCNJ15;KCNJ8,"CARDIAC ARRYTHMIA, BRADYCARDIA",,LAUNCHED,,Small molecule,Approved,BLGXFZZNTVWLAY-SCYLSFHTSA-N,COC(=O)[C@@H]1[C@H]2C[C@H]3C4[NH]C5CCCCC5C4CCN3C[C@@H]2CC[C@@H]1O;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4C([NH]C5CCCCC45)[C@@H]3C[C@H]12
YS-035,YS-035,,BRD:BRD-BRD-K06208435-003-08-2;BRD:BRD-K06208435-003-08-2,rep_primary;rep_single_dose,CALCIUM CHANNEL BLOCKER,,,,PRECLINICAL,,,NA,,COC1CCC(CCN(C)CCC2CCC(OC)C(OC)C2)CC1OC
YS-201,YS-201,,BRD:BRD-K00004746-001-01-9,rep_single_dose,CALCIUM RECEPTOR ANTAGONIST,,,,,,,NA,,
YZ9,YZ9,,BRD:BRD-BRD-K53438416-001-01-9;BRD:BRD-K53438416-001-01-9,rep_primary;rep_single_dose,PHOSPHOFRUCTOKINASE INHIBITOR,MIF;PFKFB3,,,PRECLINICAL,,,NA,,CCOC(=O)C1CC2CCC(O)CC2OC1=O
Z-L-NORLEUCINE-CHO,Z-L-NORLEUCINE-CHO,,GDSC1:45,gdsc,,,,,,,,NA,,
Z-LLNLE-CHO,Z-LLNLE-CHO,,GDSC1:45,gdsc,,,,,,,,NA,,
Z160,Z160,CHEMBL604710,BRD:BRD-BRD-K16037980-001-01-1;BRD:BRD-K16037980-001-01-1,rep_primary;rep_single_dose,N-TYPE CALCIUM CHANNEL BLOCKER,CACNA2D1,,,PHASE 2,,Small molecule,Phase 2,VCPMZDWBEWTGNW-UHFFFAOYSA-N,O=C(CC(C1CCCCC1)C1CCCCC1)N1CCN(C(C2CCCCC2)C2CCCCC2)CC1;O=C(CC(C1CCCCC1)C1CCCCC1)N1CCN(CC1)C(C1CCCCC1)C1CCCCC1
ZACOPRIDE,ZACOPRIDE,CHEMBL18041,BRD:BRD-A65615053-003-02-2;BRD:BRD-BRD-A65615053-003-02-2,rep_primary;rep_single_dose,SEROTONIN RECEPTOR ANTAGONIST,HTR3A;HTR3B;HTR4;HTR5A,,,PHASE 2,,Small molecule,Unknown,FEROPKNOYKURCJ-UHFFFAOYSA-N,COC1CC(N)C(CL)CC1C(=O)NC1CN2CCC1CC2
ZAFIRLUKAST,ZAFIRLUKAST,CHEMBL603,BRD:BRD-BRD-K71289571-001-11-4;BRD:BRD-K71289571-001-11-4,rep_primary;rep_single_dose,LEUKOTRIENE RECEPTOR ANTAGONIST,CYSLTR1;CYSLTR2,ASTHMA,,LAUNCHED,,Small molecule,Approved,YEEZWCHGZNKEEK-UHFFFAOYSA-N,COC1CC(C(=O)NS(=O)(=O)C2CCCCC2C)CCC1CC1CN(C)C2CCC(NC(=O)OC3CCCC3)CC12;COC1CC(CCC1CC1CN(C)C2CCC(NC(=O)OC3CCCC3)CC12)C(=O)NS(=O)(=O)C1CCCCC1C
ZALCITABINE,ZALCITABINE,CHEMBL853,BRD:BRD-BRD-K85925969-001-17-4;BRD:BRD-K85925969-001-17-4,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,,HUMAN IMMUNODEFICIENCY VIRUS (HIV-1),,LAUNCHED,,Small molecule,Approved,WREGKURFCTUGRC-POYBYMJQSA-N,NC1CCN([C@H]2CC[C@@H](CO)O2)C(=O)N1
ZALDARIDE,ZALDARIDE,CHEMBL1474352,BRD:BRD-A26032986-050-02-1;BRD:BRD-BRD-A26032986-050-02-1,rep_multi_dose;rep_primary;rep_single_dose,CALMODULIN ANTAGONIST,CALM1,,,PHASE 3,,Small molecule,Unknown,HTGCJAAPDHZCHL-UHFFFAOYSA-N,CC1(CN2CCC(CC2)N2C3CCCCC3[NH]C2=O)OCC2CCCCC2-N2CCCC12;CC1(CN2CCC(N3C(=O)[NH]C4CCCCC43)CC2)OCC2CCCCC2-N2CCCC21
ZALEPLON,ZALEPLON,CHEMBL1521,BRD:BRD-BRD-K92657060-001-05-7;BRD:BRD-K92657060-001-05-7,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRB1;GABRG2;TSPO,INSOMNIA,,LAUNCHED,,Small molecule,Approved,HUNXMJYCHXQEGX-UHFFFAOYSA-N,CCN(C(C)=O)C1CCCC(-C2CCNC3C(C#N)CNN23)C1;CCN(C(C)=O)C1CCCC(C1)-C1CCNC2C(CNN12)C#N
ZALTIDINE,ZALTIDINE,CHEMBL70209,BRD:BRD-BRD-K12261274-001-02-4;BRD:BRD-K12261274-001-02-4,rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,HRH2,,,PHASE 3,,Small molecule,Unknown,GIMNAEMRNXUAQP-UHFFFAOYSA-N,CC1NCC(-C2CSC(N=C(N)N)N2)[NH]1;CC1NCC([NH]1)-C1CSC(NC(N)=N)N1
ZALTOPROFEN,ZALTOPROFEN,CHEMBL1765291,BRD:BRD-A00578795-001-04-3;BRD:BRD-BRD-A00578795-001-04-3,rep_primary;rep_single_dose,CYCLOOXYGENASE INHIBITOR,,"FEVER, PAIN RELIEF",,LAUNCHED,,Small molecule,Unknown,MUXFZBHBYYYLTH-UHFFFAOYSA-N,CC(C(=O)O)C1CCC2C(C1)CC(=O)C1CCCCC1S2;CC(C(O)=O)C1CCC2SC3CCCCC3C(=O)CC2C1
ZAMI-633,ZAMI-633,,BRD:BRD-K11984358-001-01-3,rep_single_dose,UREASE INHIBITOR,,,,,,,NA,,
ZAMICASTAT,ZAMICASTAT,CHEMBL4594440,BRD:BRD-K00091086-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 2,ZSSLCFLHEFXANG-GOSISDBHSA-N,FC1CC(F)C2C(C1)C[C@@H](N1C(CCNCC3CCCCC3)C[NH]C1=S)CO2
ZAMIFENACIN,ZAMIFENACIN,CHEMBL27507,BRD:BRD-BRD-K80451230-051-02-6;BRD:BRD-K80451230-051-02-6,rep_primary;rep_single_dose,ACETYLCHOLINE RECEPTOR ANTAGONIST,CHRM3,,,PHASE 3,,Small molecule,Unknown,BDNFQGRSKSQXRI-XMMPIXPASA-N,C(CC1CCC2OCOC2C1)N1CCC[C@H](C1)OC(C1CCCCC1)C1CCCCC1;C1CCC(C(O[C@@H]2CCCN(CCC3CCC4C(C3)OCO4)C2)C2CCCCC2)CC1
ZANAMIVIR,ZANAMIVIR,CHEMBL1673195;CHEMBL222813,BRD:BRD-BRD-K23067689-001-02-1;BRD:BRD-K23067689-001-02-1,rep_primary;rep_single_dose,NEURAMINIDASE INHIBITOR,NEU2,INFLUENZA A VIRUS INFECTION,,LAUNCHED,,Small molecule,Approved,ARAIBEBZBOPLMB-DWQLSOMASA-N;ARAIBEBZBOPLMB-UFGQHTETSA-N,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O;CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1N[14C](=N)N;CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N
ZANDELISIB,ZANDELISIB,CHEMBL4650214,BRD:BRD-K00093440-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 3,WPFUFWIHMYZXSF-UHFFFAOYSA-N,CN1CCC(C2CCCCC2CC(C)(C)NC2NC(N3CCOCC3)NC(-N3C(C(F)F)NC4CCCCC43)N2)CC1
ZANUBRUTINIB,ZANUBRUTINIB,CHEMBL3936761,BRD:BRD-K00003413-001-01-9,rep_single_dose,BRUTON'S TYROSINE KINASE (BTK) INHIBITOR,,,,,,Small molecule,Approved,RNOAOAWBMHREKO-QFIPXVFZSA-N,C=CC(=O)N1CCC([C@@H]2CCNC3C(C(N)=O)C(-C4CCC(OC5CCCCC5)CC4)NN32)CC1
ZAPA,ZAPA,CHEMBL20562,BRD:BRD-BRD-K44825564-065-01-4;BRD:BRD-K44825564-065-01-4,rep_primary;rep_single_dose,,,,,PRECLINICAL,,Small molecule,NA,QEYNZJBVNYDZKZ-UPHRSURJSA-N,N=C(N)S/C=C\C(=O)O;NC(=N)S\C=C/C(O)=O
ZAPRINAST,ZAPRINAST,CHEMBL28079,BRD:BRD-BRD-K16542329-001-13-5;BRD:BRD-K16542329-001-13-5,rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,GPR35;PDE1A;PDE4D;PDE5A;PDE9A,,,PHASE 2,,Small molecule,Unknown,REZGGXNDEMKIQB-UHFFFAOYSA-N,CCCOC1CCCCC1-C1NC2[NH]NNC2C(=O)[NH]1
ZARDAVERINE,ZARDAVERINE,CHEMBL313842,BRD:BRD-BRD-K37561857-001-15-5;BRD:BRD-K37561857-001-15-5,rep_multi_dose;rep_primary;rep_single_dose,PHOSPHODIESTERASE INHIBITOR,PDE4D,,,PHASE 2,,Small molecule,Unknown,HJMQDJPMQIHLPB-UHFFFAOYSA-N,COC1CC(-C2CCC(=O)[NH]N2)CCC1OC(F)F;COC1CC(CCC1OC(F)F)-C1CCC(=O)[NH]N1
ZARNESTRA,ZARNESTRA,CHEMBL289228,GDSC1:204,gdsc,,,,,,,Small molecule,Phase 3,PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1CNCC1[C@@](N)(C1CCC(CL)CC1)C1CCC2C(C1)C(-C1CCCC(CL)C1)CC(=O)N2C
ZATEBRADINE,ZATEBRADINE,CHEMBL69679,BRD:BRD-BRD-K92446736-003-02-2;BRD:BRD-K92446736-003-02-2,rep_primary;rep_single_dose,HCN CHANNEL BLOCKER,HCN1;HCN2;HCN3;HCN4,,,PHASE 3,,Small molecule,Unknown,KEDQCFRVSHYKLR-UHFFFAOYSA-N,COC1CCC(CCN(C)CCCN2CCC3CC(OC)C(OC)CC3CC2=O)CC1OC
ZCL-278,ZCL-278,,BRD:BRD-BRD-K22829793-001-01-0;BRD:BRD-K22829793-001-01-0,rep_primary;rep_single_dose,CDC INHIBITOR,CDC42,,,PRECLINICAL,,,NA,,CC1CC(C)NC(NS(=O)(=O)C2CCC(NC(=S)NC(=O)COC3CCC(BR)CC3CL)CC2)N1
ZD-0947,ZD-0947,,BRD:BRD-K00004620-001-01-9,rep_single_dose,POTASSIUM CHANNEL ACTIVATOR,,,,,,,NA,,
ZD-1839,ZD-1839,CHEMBL939,GDSC1:1010;GDSC2:1010,gdsc,,,,,,,Small molecule,Approved,XGALLCVXEZPNRQ-UHFFFAOYSA-N,COC1CC2NCNC(NC3CCC(F)C(CL)C3)C2CC1OCCCN1CCOCC1
ZD-2079,ZD-2079,CHEMBL1354284,BRD:BRD-BRD-K64157027-003-02-7;BRD:BRD-K64157027-003-02-7,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB3,,,PHASE 2,,Small molecule,Unknown,KCEFVYIWOQSJCH-LMOVPXPDSA-N,CL.O=C(O)CC1CCC(OCCNC[C@H](O)C2CCCCC2)CC1;O[C@@H](CNCCOC1CCC(CC(O)=O)CC1)C1CCCCC1
ZD-4054,ZD-4054,CHEMBL1628688,GDSC1:266,gdsc,,,,,,,Small molecule,Phase 3,FJHHZXWJVIEFGJ-UHFFFAOYSA-N,COC1NC(C)CNC1NS(=O)(=O)C1CCCNC1-C1CCC(-C2NNCO2)CC1
ZD-4190,ZD-4190,CHEMBL281872;CHEMBL3544937,BRD:BRD-K00076465-001-02-9,rep_single_dose,,,,,,,Small molecule,Phase 1,IOFHDGSCWJNVRZ-UHFFFAOYSA-N;YBTGTVGEKMZEQX-UHFFFAOYSA-N,COC1CC2C(NC3CCC(BR)CC3F)NCNC2CC1OCCN1CCNN1;COC1CC2C(NC3CCC(BR)CC3F)NCNC2CC1OCCN1CCNN1.CL
ZD-7114,ZD-7114,,BRD:BRD-BRD-K28971625-003-01-4;BRD:BRD-K28971625-003-01-4,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB3,,,PHASE 1,,,NA,,COCCNC(=O)COC1CCC(OCCNC[C@H](O)COC2CCCCC2)CC1
ZD-7155,ZD-7155,,BRD:BRD-BRD-K11373525-003-02-1;BRD:BRD-K11373525-003-02-1,rep_primary;rep_single_dose,ANGIOTENSIN RECEPTOR ANTAGONIST,AGTR1,,,PRECLINICAL,,,NA,,CCC1CC2N(CC3CCC(CC3)-C3CCCCC3-C3NNN[NH]3)C(=O)CCC2C(CC)N1
ZD-7288,ZD-7288,,BRD:BRD-BRD-K18678457-003-02-8;BRD:BRD-K18678457-003-02-8,rep_primary;rep_single_dose,HCN CHANNEL BLOCKER,HCN1;HCN2;HCN3;HCN4,,,PHASE 2,,,NA,,CCN(C1CCCCC1)C1CC(NC)[N+](C)C(C)N1
ZD4054,ZD4054,CHEMBL1628688,GDSC1:266,gdsc,,,,,,,Small molecule,Phase 3,FJHHZXWJVIEFGJ-UHFFFAOYSA-N,COC1NC(C)CNC1NS(=O)(=O)C1CCCNC1-C1CCC(-C2NNCO2)CC1
ZEARALANOL,ZEARALANOL,,BRD:BRD-K11848003-001-17-9,rep_single_dose,,,,,,,,NA,,
ZEATIN,ZEATIN,,BRD:BRD-BRD-K90033078-001-08-7;BRD:BRD-K90033078-001-08-7,rep_primary;rep_single_dose,,,,,PHASE 1,,,NA,,C\C(CO)=C/CNC1[NH]CNC2NCNC12
ZEBULARINE,ZEBULARINE,CHEMBL504567,BRD:BRD-K87714311-001-05-9;CTRP:411739,ctrp;rep_single_dose,DNA METHYLTRANSFERASE INHIBITOR,CDA;DNMT1,,,,,Small molecule,NA,RPQZTTQVRYEKCR-WCTZXXKLSA-N,O=C1NCCCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
ZG-10,ZG-10,,GDSC1:1161,gdsc,,,,,,,,NA,,
ZIBOTENTAN,ZIBOTENTAN,CHEMBL1628688,BRD:BRD-BRD-K31553034-001-03-0;BRD:BRD-K31553034-001-03-0;GDSC1:266,gdsc;rep_multi_dose;rep_primary;rep_single_dose,ENDOTHELIN RECEPTOR ANTAGONIST,EDNRA,,,PHASE 3,,Small molecule,Phase 3,FJHHZXWJVIEFGJ-UHFFFAOYSA-N,COC1NC(C)CNC1NS(=O)(=O)C1CCCNC1-C1CCC(-C2NNCO2)CC1;COC1NC(C)CNC1NS(=O)(=O)C1CCCNC1-C1CCC(CC1)-C1NNCO1
ZIDOVUDINE,ZIDOVUDINE,CHEMBL129,BRD:BRD-A33692381-001-01-9;BRD:BRD-BRD-A33692381-001-01-9,rep_primary;rep_single_dose,NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR,TERT,"HUMAN IMMUNODEFICIENCY VIRUS (HIV-1), ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",,LAUNCHED,,Small molecule,Approved,HBOMLICNUCNMMY-XLPZGREQSA-N,CC1CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)[NH]C1=O;CC1CN(C2CC(N=[N+]=[N-])C(CO)O2)C(=O)[NH]C1=O
ZILEUTON,ZILEUTON,CHEMBL93,BRD:BRD-A56359832-001-11-1;BRD:BRD-A56359832-001-16-9;BRD:BRD-BRD-A56359832-001-11-1,rep_primary;rep_single_dose,"LEUKOTRIENE SYNTHESIS INHIBITOR, LIPOXYGENASE INHIBITOR",ALOX5,ASTHMA,,LAUNCHED,,Small molecule,Approved,MWLSOWXNZPKENC-UHFFFAOYSA-N,CC(C1CC2CCCCC2S1)N(O)C(N)=O;CC(N(O)C(N)=O)C1CC2CCCCC2S1
ZILPATEROL,ZILPATEROL,CHEMBL2218907,BRD:BRD-BRD-K42816473-001-01-0;BRD:BRD-K42816473-001-01-0,rep_primary;rep_single_dose,ADRENERGIC RECEPTOR AGONIST,ADRB2,WEIGHT-GAIN AID,,LAUNCHED,,Small molecule,Unknown,ZSTCZWJCLIRCOJ-UHFFFAOYSA-N,CC(C)N[C@H]1CCN2C(O)NC3CCCC([C@@H]1O)C23;CC(C)NC1CCN2C(=O)[NH]C3CCCC(C32)C1O
ZIMELIDINE,ZIMELIDINE,CHEMBL37744,BRD:BRD-BRD-K46914825-300-01-0;BRD:BRD-K46914825-300-01-0,rep_primary;rep_single_dose,SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI),MAOA;MAOB;SLC6A4,,,WITHDRAWN,,Small molecule,Approved,OYPPVKRFBIWMSX-SXGWCWSVSA-N,CN(C)C/C=C(/C1CCC(BR)CC1)C1CCCNC1;CN(C)C\C=C(\C1CCC(BR)CC1)C1CCCNC1
ZINC-UNDECYLENATE,ZINC-UNDECYLENATE,,BRD:BRD-K13330768-001-02-9,rep_single_dose,OTHER ANTIFUNGAL,,,,,,,NA,,
ZIPRASIDONE,ZIPRASIDONE,CHEMBL708,BRD:BRD-BRD-K29582115-066-01-2;BRD:BRD-K29582115-066-01-2,rep_multi_dose;rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA1A;ADRA1B;ADRA2A;ADRA2B;ADRA2C;CHRM1;CHRM2;CHRM3;CHRM4;CHRM5;DRD1;DRD2;DRD3;DRD4;DRD5;HRH1;HTR1A;HTR1B;HTR1D;HTR1E;HTR2A;HTR2C;HTR3A;HTR6;HTR7;SLC6A4,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Approved,MVWVFYHBGMAFLY-UHFFFAOYSA-N,CLC1CC2NC(=O)CC2CC1CCN1CCN(CC1)C1NSC2CCCCC12;O=C1CC2CC(CCN3CCN(C4NSC5CCCCC45)CC3)C(CL)CC2N1
ZIRITAXESTAT,ZIRITAXESTAT,CHEMBL3828074,BRD:BRD-K00003431-001-01-9,rep_single_dose,AUTOTAXIN INHIBITOR,,,,,,Small molecule,Phase 3,REQQVBGILUTQNN-UHFFFAOYSA-N,CCC1NC2C(C)CC(N3CCN(CC(=O)N4CC(O)C4)CC3)CN2C1N(C)C1NC(-C2CCC(F)CC2)C(C#N)S1
ZK-164015,ZK-164015,,BRD:BRD-BRD-K05151076-001-02-6;BRD:BRD-K05151076-001-02-6,rep_primary;rep_single_dose,ESTROGEN RECEPTOR ANTAGONIST,ESR1;ESR2,,,PRECLINICAL,,,NA,,CCCCCS(=O)(=O)CCCCCCCCCCN1C(C(C)C2CC(O)CCC12)-C1CCC(O)CC1
ZK-200775,ZK-200775,CHEMBL19892,BRD:BRD-BRD-K67525671-001-02-5;BRD:BRD-K67525671-001-02-5,rep_primary;rep_single_dose,KAINATE RECEPTOR ANTAGONIST,,,,PHASE 2,,Small molecule,Phase 1,WZMQMKNCWDCCMT-UHFFFAOYSA-N,O=C1[NH]C2CC(C(F)(F)F)C(N3CCOCC3)CC2N(CP(=O)(O)O)C1=O;OP(O)(=O)CN1C2CC(N3CCOCC3)C(CC2[NH]C(=O)C1=O)C(F)(F)F
ZK811752,ZK-811752;ZK811752,CHEMBL535607,BRD:BRD-BRD-K91825936-001-01-2;BRD:BRD-K91825936-001-01-2,rep_multi_dose;rep_primary;rep_single_dose,CC CHEMOKINE RECEPTOR ANTAGONIST,CCR1,,,PHASE 2,,Small molecule,Phase 2,FRUCNQBAWUHKLS-PFEQFJNWSA-N,C[C@@H]1CN(CC2CCC(F)CC2)CCN1C(=O)COC1CCC(CL)CC1NC(N)=O;C[C@@H]1CN(CC2CCC(F)CC2)CCN1C(=O)COC1CCC(CL)CC1NC(N)=O.CL
ZK-93423,ZK-93423,,BRD:BRD-BRD-K33882852-003-02-8;BRD:BRD-K33882852-003-02-8,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3;GABRA5;GABRB2;GABRG2,,,PHASE 3,,,NA,,CCOC(=O)C1NCC2[NH]C3CCC(OCC4CCCCC4)CC3C2C1COC
ZK-93426,ZK-93426,,BRD:BRD-BRD-K68392338-003-02-0;BRD:BRD-K68392338-003-02-0,rep_multi_dose;rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR ANTAGONIST,GABRA1;GABRA2;GABRA3;GABRA5,,,PHASE 1,,,NA,,CCOC(=O)C1NCC2[NH]C3CCCC(OC(C)C)C3C2C1C
ZLN005,ZLN005,,BRD:BRD-BRD-K73073971-001-01-7;BRD:BRD-K73073971-001-01-7,rep_multi_dose;rep_primary;rep_single_dose,,,,,PRECLINICAL,,,NA,,CC(C)(C)C1CCC(CC1)-C1NC2CCCCC2[NH]1
ZLN024,ZLN024,,BRD:BRD-K64103579-003-02-9,rep_single_dose,AMPK ACTIVATOR,PRKAA1;PRKAB1;PRKAG1,,,,,,NA,,
ZM 447439,ZM 447439,,GDSC1:1050;GDSC2:1050,gdsc,,,,,,,,NA,,
ZM-226600,ZM-226600,,BRD:BRD-A62209527-001-04-5;BRD:BRD-BRD-A62209527-001-04-5,rep_primary;rep_single_dose,KIR6 CHANNEL (KATP) ACTIVATOR,,,,PRECLINICAL,,,NA,,CC(O)(C(=O)NC1CCC(CC1)S(=O)(=O)C1CCCCC1)C(F)(F)F
ZM-241385,ZM-241385,CHEMBL113142,BRD:BRD-BRD-K19605405-001-02-7;BRD:BRD-K19605405-001-02-7,rep_primary;rep_single_dose,ADENOSINE RECEPTOR ANTAGONIST,ADORA1;ADORA2A;ADORA2B;ADORA3,,,PRECLINICAL,,Small molecule,NA,PWTBZOIUWZOPFT-UHFFFAOYSA-N,NC1NC(NCCC2CCC(O)CC2)NC2NC(-C3CCCO3)NN12;NC1NC(NCCC2CCC(O)CC2)NC2NC(NN12)-C1CCCO1
ZM-306416,ZM-306416,,BRD:BRD-BRD-K41337261-001-03-0;BRD:BRD-K41337261-001-03-0,rep_multi_dose;rep_primary;rep_single_dose,"ABL KINASE INHIBITOR, SRC INHIBITOR, VEGFR INHIBITOR",EGFR;FLT1;FLT4;KDR,,,PRECLINICAL,,,NA,,COC1CC2NCNC(NC3CCC(CL)CC3F)C2CC1OC
ZM-323881,ZM-323881,,BRD:BRD-BRD-K67831364-003-03-3;BRD:BRD-K67831364-003-03-3,rep_primary;rep_single_dose,VEGFR INHIBITOR,KDR,,,PRECLINICAL,,,NA,,CC1CC(F)C(NC2NCNC3CC(OCC4CCCCC4)CCC23)CC1O
ZM-336372,ZM-336372,,BRD:BRD-BRD-K73789395-001-10-7;BRD:BRD-K73789395-001-10-7,rep_primary;rep_single_dose,RAF INHIBITOR,BRAF;LCK;MAPK14;RAF1,,,PRECLINICAL,,,NA,,CN(C)C1CCCC(C1)C(=O)NC1CCC(C)C(NC(=O)C2CCC(O)CC2)C1
ZM-39923,ZM-39923,,BRD:BRD-K40624912-003-17-9,rep_single_dose,JAK INHIBITOR,JAK1;JAK3,,,,,,NA,,
ZM-447439,ZM-447439,,BRD:BRD-BRD-K72703948-001-10-1;BRD:BRD-K72703948-001-10-1;GDSC1:1050;GDSC2:1050,gdsc;rep_multi_dose;rep_primary;rep_single_dose,AURORA KINASE INHIBITOR,AURKA;AURKB,,,PRECLINICAL,,,NA,,COC1CC2C(NC3CCC(NC(=O)C4CCCCC4)CC3)NCNC2CC1OCCCN1CCOCC1
ZM447439,ZM447439,,GDSC1:1050;GDSC2:1050,gdsc,,,,,,,,NA,,
ZOFENOPRIL-CALCIUM,ZOFENOPRIL-CALCIUM,,BRD:BRD-BRD-K46654563-238-01-0;BRD:BRD-K46654563-238-01-0,rep_primary;rep_single_dose,ANGIOTENSIN CONVERTING ENZYME INHIBITOR,ACE,HYPERTENSION,,LAUNCHED,,,NA,,C[C@H](CSC(=O)C1CCCCC1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1CCCCC1
ZOLANTIDINE,ZOLANTIDINE,CHEMBL419296,BRD:BRD-BRD-K08996725-332-01-7;BRD:BRD-K08996725-332-01-7,rep_multi_dose;rep_primary;rep_single_dose,HISTAMINE RECEPTOR ANTAGONIST,,,,PRECLINICAL,,Small molecule,NA,KUBONGDXTUOOLM-UHFFFAOYSA-N,C(CNC1NC2CCCCC2S1)COC1CCCC(CN2CCCCC2)C1;C1CC(CN2CCCCC2)CC(OCCCNC2NC3CCCCC3S2)C1
ZOLEDRONATE,ZOLEDRONATE,CHEMBL924,GDSC2:1802,gdsc,,,,,,,Small molecule,Approved,XRASPMIURGNCCH-UHFFFAOYSA-N,O=P(O)(O)C(O)(CN1CCNC1)P(=O)(O)O
ZOLEDRONIC ACID,ZOLEDRONIC ACID,CHEMBL924,GDSC2:1802,gdsc,,,,,,,Small molecule,Approved,XRASPMIURGNCCH-UHFFFAOYSA-N,O=P(O)(O)C(O)(CN1CCNC1)P(=O)(O)O
ZOLEDRONIC-ACID,ZOLEDRONIC-ACID,,BRD:BRD-K84253429-001-06-9,rep_single_dose,BONE RESORPTION INHIBITOR,FDPS;GGPS1,,,,,,NA,,
ZOLIFLODACIN,ZOLIFLODACIN,CHEMBL3544978,BRD:BRD-K00003264-001-01-9,rep_single_dose,ANTIBACTERIAL,,,,,,Small molecule,Phase 3,ZSWMIFNWDQEXDT-ZESJGQACSA-N,C[C@@H]1CN2C3C(CC4C(N5C(=O)OC[C@@H]5C)NOC4C3F)CC3(C(=O)NC(=O)NC3=O)[C@H]2[C@H](C)O1
ZOLIMIDINE,ZOLIMIDINE,CHEMBL2105534,BRD:BRD-BRD-K45125084-001-01-4;BRD:BRD-K45125084-001-01-4,rep_primary;rep_single_dose,MUCUS PROTECTING AGENT,,,,LAUNCHED,,Small molecule,Unknown,VSLIUWLPFRVCDL-UHFFFAOYSA-N,CS(=O)(=O)C1CCC(-C2CN3CCCCC3N2)CC1;CS(=O)(=O)C1CCC(CC1)-C1CN2CCCCC2N1
ZOLINZA,ZOLINZA,CHEMBL98,GDSC1:1012;GDSC2:1012,gdsc,,,,,,,Small molecule,Approved,WAEXFXRVDQXREF-UHFFFAOYSA-N,O=C(CCCCCCC(=O)NC1CCCCC1)NO
ZOLMITRIPTAN,ZOLMITRIPTAN,CHEMBL1185,BRD:BRD-BRD-K54314721-001-10-2;BRD:BRD-K54314721-001-10-2,rep_multi_dose;rep_primary;rep_single_dose,SEROTONIN RECEPTOR AGONIST,HTR1A;HTR1B;HTR1D;HTR1E;HTR1F,MIGRAINE HEADACHE,,LAUNCHED,,Small molecule,Approved,ULSDMUVEXKOYBU-ZDUSSCGKSA-N,CN(C)CCC1C[NH]C2CCC(C[C@H]3COC(=O)N3)CC12
ZOLPIDEM,ZOLPIDEM,CHEMBL911,BRD:BRD-BRD-K44876623-001-03-7;BRD:BRD-K44876623-001-03-7,rep_primary;rep_single_dose,BENZODIAZEPINE RECEPTOR AGONIST,GABRA1;GABRA2;GABRA3,INSOMNIA,,LAUNCHED,,Small molecule,Approved,ZAFYATHCZYHLPB-UHFFFAOYSA-N,CC1CCC(-C2NC3CCC(C)CN3C2CC(=O)N(C)C)CC1;CN(C)C(=O)CC1C(NC2CCC(C)CN12)-C1CCC(C)CC1
ZOMEPIRAC,ZOMEPIRAC,CHEMBL19490,BRD:BRD-BRD-K81326768-001-04-0;BRD:BRD-K81326768-001-04-0,rep_primary;rep_single_dose,PROSTAGLANDIN SYNTHESIS INHIBITOR,PTGDR2,,,WITHDRAWN,,Small molecule,Approved,ZXVNMYWKKDOREA-UHFFFAOYSA-N,CC1CC(CC(=O)O)N(C)C1C(=O)C1CCC(CL)CC1;CC1CC(CC(O)=O)N(C)C1C(=O)C1CCC(CL)CC1
ZOMETA,ZOMETA,CHEMBL924,GDSC2:1802,gdsc,,,,,,,Small molecule,Approved,XRASPMIURGNCCH-UHFFFAOYSA-N,O=P(O)(O)C(O)(CN1CCNC1)P(=O)(O)O
ZOMETAPINE,ZOMETAPINE,CHEMBL174697,BRD:BRD-BRD-K14571191-001-01-6;BRD:BRD-K14571191-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,YCWROMXNZZIJDQ-UHFFFAOYSA-N,CC1NN(C)C2C1C(C1CCCC(CL)C1)=NCCN2;CC1NN(C)C2NCCN=C(C12)C1CCCC(CL)C1
ZONIPORIDE,ZONIPORIDE,CHEMBL355862,BRD:BRD-BRD-K43992824-300-01-0;BRD:BRD-K43992824-300-01-0,rep_primary;rep_single_dose,SODIUM/HYDROGEN EXCHANGER INHIBITOR,SLC9A1,,,PHASE 3,,Small molecule,Unknown,GDXBRVCQGGKXJY-UHFFFAOYSA-N,N=C(N)NC(=O)C1CNN(-C2CCCC3NCCCC23)C1C1CC1;NC(N)=NC(=O)C1CNN(C1C1CC1)-C1CCCC2NCCCC12
ZONISAMIDE,ZONISAMIDE,CHEMBL750,BRD:BRD-BRD-K48300629-001-14-5;BRD:BRD-K48300629-001-14-5,rep_primary;rep_single_dose,"SODIUM CHANNEL BLOCKER, T-TYPE CALCIUM CHANNEL BLOCKER",CA1;CA10;CA11;CA12;CA13;CA14;CA2;CA3;CA4;CA5A;CA5B;CA6;CA7;CA8;CA9;CACNA1G;CACNA1H;CACNA1I;MAOA;MAOB;SCN10A;SCN11A;SCN1A;SCN1B;SCN2A;SCN2B;SCN3A;SCN3B;SCN4A;SCN4B;SCN5A;SCN7A;SCN8A;SCN9A,"SEIZURES, EPILEPSY",,LAUNCHED,,Small molecule,Approved,UBQNRHZMVUUOMG-UHFFFAOYSA-N,NS(=O)(=O)CC1NOC2CCCCC12
ZOPOLRESTAT,ZOPOLRESTAT,CHEMBL10372,BRD:BRD-BRD-K84459715-001-01-6;BRD:BRD-K84459715-001-01-6,rep_primary;rep_single_dose,,,,,PHASE 2,,Small molecule,Unknown,BCSVCWVQNOXFGL-UHFFFAOYSA-N,O=C(O)CC1NN(CC2NC3CC(C(F)(F)F)CCC3S2)C(=O)C2CCCCC12;OC(=O)C=C1NN(CC2NC3CC(CCC3S2)C(F)(F)F)C(=O)C2CCCCC12
ZOSUQUIDAR,ZOSUQUIDAR,CHEMBL444172,BRD:BRD-BRD-K70557564-305-03-6;BRD:BRD-K70557564-305-03-6,rep_primary;rep_single_dose,P GLYCOPROTEIN INHIBITOR,ABCB1;ABCB4,,,PHASE 3,,Small molecule,Phase 3,IHOVFYSQUDPMCN-DBEBIPAYSA-N,O[C@@H](COC1CCCC2NCCCC12)CN1CCN([C@@H]2C3CCCCC3[C@@H]3[C@H](C4CCCCC42)C3(F)F)CC1;O[C@@H](COC1CCCC2NCCCC12)CN1CCN(CC1)[C@@H]1C2CCCCC2[C@@H]2[C@H](C3CCCCC13)C2(F)F
ZOTAROLIMUS,ZOTAROLIMUS,CHEMBL219410,BRD:BRD-BRD-K46843573-001-01-9;BRD:BRD-K46843573-001-01-9,rep_primary;rep_single_dose,MTOR INHIBITOR,FKBP1A,CORONARY ARTERY RESTENOSIS,,LAUNCHED,,Small molecule,Phase 3,CGTADGCBEXYWNE-JUKNQOCSSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1N1CNNN1;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](N3CNNN3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
ZOTATIFIN,ZOTATIFIN,CHEMBL4303782,BRD:BRD-K00090648-001-01-9,rep_single_dose,,,,,,,Small molecule,Phase 1,QYCXWOACFWMQFO-WZWZCULESA-N,COC1CC2C(C(OC)N1)[C@]1(O)[C@H](O)[C@H](CN(C)C)[C@@H](C3CCCCC3)[C@]1(C1CCC(C#N)CC1)O2
ZOTEPINE,ZOTEPINE,CHEMBL285802,BRD:BRD-BRD-K64557645-001-02-4;BRD:BRD-K64557645-001-02-4,rep_primary;rep_single_dose,"DOPAMINE RECEPTOR ANTAGONIST, SEROTONIN RECEPTOR ANTAGONIST",ADRA2B;DRD2;DRD3;DRD4;HRH1;HTR1A;HTR1B;HTR1D;HTR1E;HTR2A;HTR2C;HTR6;HTR7;SLC6A2;SLC6A4,SCHIZOPHRENIA,,LAUNCHED,,Small molecule,Approved,HDOZVRUNCMBHFH-UHFFFAOYSA-N,CN(C)CCOC1=CC2CCCCC2SC2CCC(CL)CC12;CN(C)CCOC1=CC2CCCCC2SC2CCC(CL)CC21
ZOXAZOLAMINE,ZOXAZOLAMINE,CHEMBL472566,BRD:BRD-BRD-K66353228-001-14-6;BRD:BRD-K66353228-001-14-6,rep_primary;rep_single_dose,MYORELAXANT,,,,PHASE 2,,Small molecule,Unknown,YGCODSQDUUUKIV-UHFFFAOYSA-N,NC1NC2CC(CL)CCC2O1
ZSET1446,ZSET1446,,BRD:BRD-K35984734-001-02-9,rep_single_dose,NICOTINIC RECEPTOR AGONIST,,,,,,,NA,,
ZSTK 474,ZSTK 474,,GDSC1:223,gdsc,,,,,,,,NA,,
ZSTK-474,ZSTK-474,CHEMBL586701;CHEMBL586702,BRD:BRD-BRD-K63068307-001-08-9;BRD:BRD-K63068307-001-08-9;GDSC1:223,gdsc;rep_multi_dose;rep_primary;rep_single_dose,PI3K INHIBITOR,PIK3CB;PIK3CD;PIK3CG,,,PHASE 1/PHASE 2,,Small molecule,Phase 2,HGVNLRPZOWWDKD-UHFFFAOYSA-N;SFUWDBKYNKBXQU-UHFFFAOYSA-N,CC1CCC(C2SC3CCCCC3N=C3C2=C(O)C2CCCCC23)CC1;FC(F)C1NC2CCCCC2N1-C1NC(N2CCOCC2)NC(N2CCOCC2)N1;FC(F)C1NC2CCCCC2N1-C1NC(NC(N1)N1CCOCC1)N1CCOCC1
ZSTK474,ZSTK474,CHEMBL586702,CTRP:606144;GDSC1:223,ctrp;gdsc,,,,,,,Small molecule,Phase 2,HGVNLRPZOWWDKD-UHFFFAOYSA-N,FC(F)C1NC2CCCCC2N1-C1NC(N2CCOCC2)NC(N2CCOCC2)N1
ZUCLOPENTHIXOL,ZUCLOPENTHIXOL,CHEMBL53904,BRD:BRD-BRD-K28761384-300-01-0;BRD:BRD-K28761384-300-01-0,rep_primary;rep_single_dose,DOPAMINE RECEPTOR ANTAGONIST,ADRA1A;ADRA2A;DRD1;DRD2;DRD5;HRH1;HTR2A,"SCHIZOPHRENIA, BIPOLAR DISORDER",,LAUNCHED,,Small molecule,Phase 3,WFPIAZLQTJBIFN-DVZOWYKESA-N,OCCN1CCN(CC/C=C2/C3CCCCC3SC3CCC(CL)CC32)CC1;OCCN1CCN(CC\C=C2\C3CCCCC3SC3CCC(CL)CC23)CC1
ZURANOLONE,ZURANOLONE,CHEMBL4105630,BRD:BRD-K00003448-001-01-9,rep_single_dose,GABA RECEPTOR AGONIST,,,,,,Small molecule,Phase 3,HARRKNSQXBRBGZ-GVKWWOCJSA-N,C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)CN4CC(C#N)CN4)CC[C@@H]32)C1
ZYDELIG,ZYDELIG,CHEMBL2216870,GDSC1:238,gdsc,,,,,,,Small molecule,Approved,IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](NC1NCNC2[NH]CNC12)C1NC2CCCC(F)C2C(=O)N1-C1CCCCC1
ZYNOPLEX,ZYNOPLEX,CHEMBL786,GDSC1:1199;GDSC2:1199,gdsc,,,,,,,Small molecule,Approved,FQZYTYWMLGAPFJ-OQKDUQJOSA-N,CC/C(=C(\C1CCCCC1)C1CCC(OCCN(C)C)CC1)C1CCCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
